article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,w2v_similarity_rank_chronic_lymphocytic_leukemia_(cll)
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.,Blood,Blood,2002-02-01,"Rituximab is a chimeric monoclonal antibody directed at CD20 with significant activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). A variety of pathways of tumor cytotoxicity different from cytotoxic chemotherapy have been proposed for this therapeutic antibody including antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. This report describes that a proportion of patients with CLL receiving rituximab treatment have in vivo activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP) cleavage in blood leukemia cells immediately following infusion of rituximab. This suggests that apoptosis using a pathway similar to fludarabine and other chemotherapeutic agents is intricately involved in the blood elimination of tumor cells after rituximab treatment. Patients having caspase-3 activation and PARP cleavage in vivo had a significantly lower blood leukemia cell count after treatment as compared to those without caspase activation. Significant down-modulation of the antiapoptotic proteins XIAP and Mcl-1 was also noted, possibly explaining in part how rituximab sensitizes CLL cells to the cytotoxic effect of chemotherapy in vivo. These findings suggest that the therapeutic benefit of antibody-based therapy in vivo for patients with CLL depends in part on induction of apoptosis and provides another area of focus for studying mechanisms of antibody-resistance in neoplastic cells.",Clinical Trial,6563.0,329.0,Rituximab is a chimeric monoclonal antibody directed at CD20 with significant activity in NHL and chronic lymphocytic CLL A variety of pathways of tumor cytotoxicity different from cytotoxic chemotherapy have been proposed for this therapeutic antibody including antibody-dependent cellular cytotoxicity and complement-mediated cell lysis This report describes that a proportion of patients with CLL receiving rituximab treatment have in vivo activation of caspase-9 caspase-3 and poly ADP-ribose polymerase PARP cleavage in blood cells immediately following infusion of rituximab This suggests that apoptosis using a pathway similar to fludarabine and other chemotherapeutic agents is intricately involved in the blood elimination of tumor cells after rituximab treatment Patients having caspase-3 activation and PARP cleavage in vivo had a significantly lower blood cell count after treatment as compared to those without caspase activation Significant down-modulation of the antiapoptotic proteins XIAP and Mcl-1 was also noted possibly explaining in part how rituximab sensitizes CLL cells to the cytotoxic effect of chemotherapy in vivo These findings suggest that the therapeutic benefit of antibody-based therapy in vivo for patients with CLL depends in part on induction of apoptosis and provides another area of focus for studying mechanisms of antibody-resistance in neoplastic cells,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[855, 16, 8, 2897, 848, 548, 1166, 28, 2198, 5, 93, 128, 4, 1176, 2, 442, 1193, 552, 8, 1362, 1, 460, 1, 30, 1408, 338, 29, 759, 56, 47, 85, 1587, 9, 26, 189, 548, 141, 548, 470, 763, 1408, 2, 3731, 517, 31, 4783, 26, 414, 2677, 17, 8, 920, 1, 7, 5, 552, 357, 855, 24, 47, 4, 386, 363, 1, 1469, 83, 1469, 27, 2, 2699, 3638, 3507, 1451, 2041, 3155, 4, 315, 37, 3467, 366, 904, 1, 855, 26, 844, 17, 351, 75, 8, 308, 288, 6, 2027, 2, 127, 1573, 183, 16, 52711, 646, 4, 3, 315, 3730, 1, 30, 37, 50, 855, 24, 7, 1041, 1469, 27, 363, 2, 2041, 3155, 4, 386, 42, 8, 97, 280, 315, 31, 1276, 50, 24, 22, 72, 6, 135, 187, 1469, 363, 93, 1328, 2356, 1, 3, 4176, 652, 5387, 2, 1308, 14, 10, 120, 1051, 2150, 8290, 4, 760, 832, 855, 6229, 552, 37, 6, 3, 759, 254, 1, 56, 4, 386, 46, 272, 309, 17, 3, 189, 247, 1, 548, 90, 36, 4, 386, 9, 7, 5, 552, 3828, 4, 760, 23, 504, 1, 351, 2, 777, 1809, 965, 1, 1222, 9, 4559, 483, 1, 548, 251, 4, 2000, 37]",1393.0,11807010,87
"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-02-01,"To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia. Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m(2)/d (40 mg/m(2) per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy. Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease. Troxacitabine has significant antileukemic activity in patients with AML and CML-BP.",Clinical Trial,6563.0,69.0,To investigate the activity of a novel dioxolane L-nucleoside analog troxacitabine L- -OddC BCH-4556 in patients with refractory Study participants were patients with refractory or relapsed acute myeloid AML or lymphocytic ALL syndromes MDS or chronic myelogenous in blastic phase CML-BP Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m 2 /d 40 mg/m 2 per course Courses were given every 3 to 4 weeks according to antileukemic efficacy Forty-two patients AML 18 patients MDS one patient ALL six patients CML-BP 17 patients were treated Median age was 51 years range 23 to 80 years 22 patients were male Stomatitis was the most significant adverse event with three patients 7 and two patients 5 respectively experiencing grade 3 or 4 toxicity Ten patients 24 had grade 3 hand-foot syndrome and two patients 5 had grade 3 rash One patient 2 had grade 3 fatigue and anorexia Marrow hypoplasia occurred between days 14 and 28 in 12 75 of 16 assessable patients with AML Two complete remissions and one partial remission 18 were observed in 16 assessable patients with AML None of six patients with ALL responded Six 37 of 16 assessable patients with CML-BP experienced a return to chronic-phase disease Troxacitabine has significant antileukemic activity in patients with AML and CML-BP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[6, 963, 3, 128, 1, 8, 229, 42835, 805, 4032, 3497, 10949, 805, 52719, 52720, 37077, 4, 7, 5, 430, 45, 776, 11, 7, 5, 430, 15, 591, 286, 533, 329, 15, 1193, 62, 2040, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 10949, 10, 1052, 22, 35, 1262, 904, 9, 80, 76, 201, 2511, 391, 9, 33, 162, 28, 8, 61, 1, 66, 13, 81, 188, 18, 427, 327, 81, 188, 18, 379, 906, 1993, 11, 447, 454, 27, 6, 39, 244, 768, 6, 4512, 209, 1213, 100, 7, 329, 203, 7, 1223, 104, 69, 62, 437, 7, 903, 3044, 269, 7, 11, 73, 52, 89, 10, 725, 60, 184, 382, 6, 493, 60, 350, 7, 11, 1045, 4486, 10, 3, 96, 93, 290, 774, 5, 169, 7, 67, 2, 100, 7, 33, 106, 2985, 88, 27, 15, 39, 155, 1618, 7, 259, 42, 88, 27, 2833, 4100, 681, 2, 100, 7, 33, 42, 88, 27, 1641, 104, 69, 18, 42, 88, 27, 613, 2, 3373, 581, 20991, 489, 59, 162, 213, 2, 339, 4, 133, 481, 1, 245, 3120, 7, 5, 329, 100, 236, 3166, 2, 104, 450, 734, 203, 11, 164, 4, 245, 3120, 7, 5, 329, 1292, 1, 437, 7, 5, 62, 2211, 437, 567, 1, 245, 3120, 7, 5, 903, 3044, 592, 8, 4656, 6, 442, 124, 34, 10949, 71, 93, 4512, 128, 4, 7, 5, 329, 2, 903, 3044]",1351.0,11821445,277
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2002-02-01,"Monoclonal antibody-based therapy has emerged as a novel approach in the treatment of hematologic malignancies. The safety and tolerability of monoclonal antibodies make these compounds attractive and easy to administer, even in elderly, heavily pretreated patients. Chronic lymphocytic leukemia is an incurable disease with few therapeutic options once patients fail purine analogue-based therapy. Two monoclonal antibodies have shown activity in this disease. The first is rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA), a chimeric human-mouse anti-CD20 antibody. The second is Campath-1H, a humanized form of a rat antibody active against CD52. We hypothesize that combining both antibodies in patients who have failed conventional therapies and express both CD20 and CD52 might have enhanced efficacy and therapeutic benefit. This concept is being explored at our institution in the context of a phase I/II clinical trial. The outcome and feasibility of this combination opens the way for future combination therapies using novel biologic agents.",Journal Article,6563.0,18.0,Monoclonal antibody-based therapy has emerged as a novel approach in the treatment of hematologic malignancies The safety and tolerability of monoclonal antibodies make these compounds attractive and easy to administer even in elderly heavily pretreated patients Chronic lymphocytic is an incurable disease with few therapeutic options once patients fail purine analogue-based therapy Two monoclonal antibodies have shown activity in this disease The first is rituximab Rituxan Genentech Inc South San Francisco CA and IDEC Pharmaceuticals San Diego CA a chimeric human-mouse anti-CD20 antibody The second is Campath-1H a humanized form of a rat antibody active against CD52 We hypothesize that combining both antibodies in patients who have failed conventional therapies and express both CD20 and CD52 might have enhanced efficacy and therapeutic benefit This concept is being explored at our institution in the context of a phase I/II clinical trial The outcome and feasibility of this combination opens the way for future combination therapies using novel biologic agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 548, 90, 36, 71, 2054, 22, 8, 229, 353, 4, 3, 24, 1, 813, 441, 3, 367, 2, 1543, 1, 848, 890, 2378, 46, 2411, 3059, 2, 6261, 6, 6888, 871, 4, 1216, 2447, 2193, 7, 442, 1193, 16, 35, 2641, 34, 5, 1021, 189, 838, 1059, 7, 4373, 5006, 4696, 90, 36, 100, 848, 890, 47, 443, 128, 4, 26, 34, 3, 157, 16, 855, 25976, 9010, 3479, 5452, 6889, 9732, 1568, 2, 21000, 5888, 6889, 12965, 1568, 8, 2897, 171, 830, 312, 2198, 548, 3, 419, 16, 16622, 10147, 8, 3619, 1297, 1, 8, 4008, 548, 544, 480, 7189, 21, 4919, 17, 1525, 110, 890, 4, 7, 54, 47, 1551, 809, 235, 2, 1669, 110, 2198, 2, 7189, 822, 47, 651, 209, 2, 189, 247, 26, 2545, 16, 486, 1443, 28, 114, 731, 4, 3, 1533, 1, 8, 124, 70, 215, 38, 160, 3, 228, 2, 1437, 1, 26, 150, 12701, 3, 2255, 9, 508, 150, 235, 75, 229, 1283, 183]",1074.0,11842392,443
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.,The New England journal of medicine,N. Engl. J. Med.,2002-02-01,"A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.",Journal Article,6563.0,1039.0,"A monoclonal gammopathy of undetermined significance MGUS occurs in up to 2 percent of persons 50 years of age or older Reliable predictors of progression have not been identified and information on prognosis is limited We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994 The primary end point was progression to multiple or another plasma-cell cancer During 11,009 person-years of follow-up MGUS progressed in 115 of the 1384 patients to multiple IgM primary amyloidosis macroglobulinemia chronic lymphocytic or plasmacytoma relative risk of progression 25.0 2.4 8.4 46.0 0.9 and 8.5 respectively The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance Epidemiology and End Results program In 32 additional patients the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the marrow increased to more than 10 percent smoldering multiple but without progression to overt or related disorders The cumulative probability of progression was 12 percent at 10 years 25 percent at 20 years and 30 percent at 25 years The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years The risk of progression of MGUS to multiple or related disorders is about 1 percent per year",0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 848, 5334, 1, 5206, 724, 3226, 1780, 4, 126, 6, 18, 714, 1, 4327, 212, 60, 1, 89, 15, 434, 2450, 674, 1, 91, 47, 44, 85, 108, 2, 487, 23, 356, 16, 383, 21, 108, 30203, 7, 8230, 4, 20167, 8297, 4, 953, 3226, 10, 265, 28, 3, 2486, 1188, 29, 10391, 298, 3023, 3, 86, 396, 741, 10, 91, 6, 232, 15, 1809, 554, 31, 12, 190, 175, 2376, 2719, 60, 1, 166, 126, 3226, 1839, 4, 3670, 1, 3, 30203, 7, 6, 232, 2852, 86, 3919, 3389, 442, 1193, 15, 9426, 580, 43, 1, 91, 243, 13, 18, 39, 66, 39, 641, 13, 13, 83, 2, 66, 33, 106, 3, 63, 580, 43, 1, 91, 10, 67, 27, 4, 46, 7, 22, 72, 5, 3, 886, 266, 1, 3, 8565, 617, 1284, 2, 396, 99, 1243, 4, 531, 402, 7, 3, 848, 178, 1227, 101, 6, 80, 76, 27, 499, 379, 21949, 15, 3, 1150, 1, 554, 37, 4, 3, 581, 101, 6, 80, 76, 79, 714, 7091, 232, 84, 187, 91, 6, 7192, 15, 139, 1997, 3, 967, 1320, 1, 91, 10, 133, 714, 28, 79, 60, 243, 714, 28, 179, 60, 2, 201, 714, 28, 243, 60, 3, 388, 1227, 1, 524, 848, 178, 10, 8, 93, 980, 1, 91, 28, 179, 60, 3, 43, 1, 91, 1, 3226, 6, 232, 15, 139, 1997, 16, 545, 14, 714, 379, 111]",1425.0,11856795,40
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",J. Immunother.,,"Clonotypic B cells circulating in patients with multiple myeloma (MM) express CD20, and it has been suggested that these cells may be clonogenic. Furthermore, 20% of patients with MM express CD20 on their bone marrow plasma cells (BMPCs). Therefore, the authors began a phase II clinical study to determine the activity of the anti-CD20 monoclonal antibody rituximab in MM patients. Nineteen previously treated MM patients received 375 mg/m2 rituximab per week for 4 weeks. Three months after initiation of treatment, patients were assessed for response and received a second course of therapy if their disease was stable (SD) or they achieved a partial response (PR). Six of 19 (32%) patients had either a PR (n = 1) or SD (n = 5), with a median time to treatment failure of 5.5 months (mean, 10.3 months; range, 3-27+ months). All six patients who had a PR or SD had CD20+ BMPC. Overall, rituximab therapy was well tolerated. Because most patients with MM poorly express CD20 on their BMPCs, the authors evaluated agents for their ability to induce CD20 expression and thereby facilitate rituximab binding on MM cells. These studies show that interferon-gamma (IFN-y) induced CD20 expression on MM BMPCs, MM B cells, and healthy donor BMPCs. In contrast, CD20 expression on chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, healthy donor B cells, and progenitor cells was unaffected by IFN-y. Rituximab binding to the BMPCs of MM patients was also increased after culture with pharmacologically attainable levels of IFN-gamma (1-100 U/mL). In conclusion, these studies suggest that MM patients with CD20+ BMPCs may benefit from rituximab therapy. Furthermore, IFN-gamma induces CD20 expression on MM BMPCs and B cells and facilitates rituximab binding to MM BMPCs, providing the rationale for clinical trials to examine its use with CD20-directed serotherapies in MM.",Clinical Trial,,126.0,Clonotypic B cells circulating in patients with multiple MM express CD20 and it has been suggested that these cells may be clonogenic Furthermore 20 of patients with MM express CD20 on their marrow plasma cells BMPCs Therefore the authors began a phase II clinical study to determine the activity of the anti-CD20 monoclonal antibody rituximab in MM patients Nineteen previously treated MM patients received 375 mg/m2 rituximab per week for 4 weeks Three months after initiation of treatment patients were assessed for response and received a second course of therapy if their disease was stable SD or they achieved a partial response PR Six of 19 32 patients had either a PR n 1 or SD n 5 with a median time to treatment failure of 5.5 months mean 10.3 months range 3-27+ months All six patients who had a PR or SD had CD20+ BMPC Overall rituximab therapy was well tolerated Because most patients with MM poorly express CD20 on their BMPCs the authors evaluated agents for their ability to induce CD20 expression and thereby facilitate rituximab binding on MM cells These studies show that interferon-gamma IFN-y induced CD20 expression on MM BMPCs MM B cells and healthy donor BMPCs In contrast CD20 expression on chronic lymphocytic follicular 's healthy donor B cells and progenitor cells was unaffected by IFN-y Rituximab binding to the BMPCs of MM patients was also increased after culture with pharmacologically attainable levels of IFN-gamma 1-100 U/mL In conclusion these studies suggest that MM patients with CD20+ BMPCs may benefit from rituximab therapy Furthermore IFN-gamma induces CD20 expression on MM BMPCs and B cells and facilitates rituximab binding to MM BMPCs providing the rationale for clinical trials to examine its use with CD20-directed serotherapies in MM,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[10959, 132, 37, 1033, 4, 7, 5, 232, 321, 1669, 2198, 2, 192, 71, 85, 1148, 17, 46, 37, 68, 40, 3798, 798, 179, 1, 7, 5, 321, 1669, 2198, 23, 136, 581, 554, 37, 17623, 673, 3, 738, 4603, 8, 124, 215, 38, 45, 6, 223, 3, 128, 1, 3, 312, 2198, 848, 548, 855, 4, 321, 7, 3498, 373, 73, 321, 7, 103, 4175, 81, 821, 855, 379, 647, 9, 39, 244, 169, 53, 50, 1118, 1, 24, 7, 11, 275, 9, 51, 2, 103, 8, 419, 906, 1, 36, 492, 136, 34, 10, 585, 1270, 15, 491, 513, 8, 450, 51, 998, 437, 1, 326, 531, 7, 42, 361, 8, 998, 78, 14, 15, 1270, 78, 33, 5, 8, 52, 98, 6, 24, 496, 1, 33, 33, 53, 313, 79, 27, 53, 184, 27, 428, 53, 62, 437, 7, 54, 42, 8, 998, 15, 1270, 42, 2198, 16202, 63, 855, 36, 10, 149, 421, 408, 96, 7, 5, 321, 1240, 1669, 2198, 23, 136, 17623, 3, 738, 194, 183, 9, 136, 801, 6, 1290, 2198, 55, 2, 2267, 1876, 855, 791, 23, 321, 37, 46, 94, 514, 17, 1688, 1705, 1256, 2055, 277, 2198, 55, 23, 321, 17623, 321, 132, 37, 2, 1331, 1488, 17623, 4, 748, 2198, 55, 23, 442, 1193, 1974, 292, 1331, 1488, 132, 37, 2, 2520, 37, 10, 4585, 20, 1256, 2055, 855, 791, 6, 3, 17623, 1, 321, 7, 10, 120, 101, 50, 2099, 5, 7854, 15100, 148, 1, 1256, 1705, 14, 394, 1767, 542, 4, 1221, 46, 94, 309, 17, 321, 7, 5, 2198, 17623, 68, 247, 29, 855, 36, 798, 1256, 1705, 1516, 2198, 55, 23, 321, 17623, 2, 132, 37, 2, 4936, 855, 791, 6, 321, 17623, 1736, 3, 1728, 9, 38, 143, 6, 1004, 211, 119, 5, 2198, 1166, 52806, 4, 321]",1783.0,11924912,65
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.,Cancer,Cancer,2002-04-01,"Treatments for fludarabine-refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are limited. Most new therapies being examined in fludarabine-refractory patients have shown a high frequency of serious infection. Little data exist regarding the frequency of infections in this population treated with noninvestigational best supportive care therapies. The infectious courses of 27 patients with fludarabine-refractory CLL/SLL were retrospectively reviewed. Fludarabine-refractoriness was defined as either relapse within six months of completion of or failure to respond to fludarabine treatment. Infections were documented after patients met National Cancer Institute criteria for further treatment. Serious infections were defined as infections mandating admission to the hospital for intravenous antibiotics. Patient characteristics included: median age 67 years (range, 40-83), median 3 chemotherapy treatments (range, 1-8), and hypogammaglobulinemia in 73% of patients. Pneumocystis carinii prophylaxis was given to 89% of patients. Serious infections developed in 24 out of 27 patients (89%). Patients had a median of 2 admissions (range, 0-11) for serious infection occurring at a median of 4 months (range, 0-21) from onset of fludarabine-refractoriness. The median frequency of admission for infection was 0.17 per month. Most common sites for infection in decreasing frequency were: respiratory tract, urinary tract, blood/sepsis, and soft tissues. Bacteria caused 69 out of 88 infections (78.4%); viruses (varicella-zoster and herpes simplex) caused 11 out of 88 (12.5%); fungi caused 4 out of 88 (4.5%); and opportunistic infections caused 4 out of 88 (4.5%). Median survival was 13.0 months (range, 1-44+). The frequency of serious infections in patients with fludarabine-refractory CLL/SLL is high. These findings are relevant to trials with new and highly effective agents for which the incidence of serious infections after treatment might otherwise appear to be prohibitively high.",Journal Article,6504.0,124.0,Treatments for fludarabine-refractory chronic lymphocytic CLL /small lymphocytic SLL are limited Most new therapies being examined in fludarabine-refractory patients have shown a high frequency of serious infection Little data exist regarding the frequency of infections in this population treated with noninvestigational best supportive care therapies The infectious courses of 27 patients with fludarabine-refractory CLL/SLL were retrospectively reviewed Fludarabine-refractoriness was defined as either relapse within six months of completion of or failure to respond to fludarabine treatment Infections were documented after patients met National Cancer Institute criteria for further treatment Serious infections were defined as infections mandating admission to the hospital for intravenous antibiotics Patient characteristics included median age 67 years range 40-83 median 3 chemotherapy treatments range 1-8 and hypogammaglobulinemia in 73 of patients Pneumocystis carinii prophylaxis was given to 89 of patients Serious infections developed in 24 out of 27 patients 89 Patients had a median of 2 admissions range 0-11 for serious infection occurring at a median of 4 months range 0-21 from onset of fludarabine-refractoriness The median frequency of admission for infection was 0.17 per month Most common sites for infection in decreasing frequency were respiratory tract urinary tract blood/sepsis and soft tissues Bacteria caused 69 out of 88 infections 78.4 viruses varicella-zoster and herpes simplex caused 11 out of 88 12.5 fungi caused 4 out of 88 4.5 and opportunistic infections caused 4 out of 88 4.5 Median survival was 13.0 months range 1-44+ The frequency of serious infections in patients with fludarabine-refractory CLL/SLL is high These findings are relevant to trials with new and highly effective agents for which the incidence of serious infections after treatment might otherwise appear to be prohibitively high,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[640, 9, 2027, 430, 442, 1193, 552, 302, 1193, 5302, 32, 383, 96, 217, 235, 486, 409, 4, 2027, 430, 7, 47, 443, 8, 64, 675, 1, 1762, 930, 1215, 74, 1923, 666, 3, 675, 1, 1875, 4, 26, 266, 73, 5, 37128, 824, 1877, 165, 235, 3, 3398, 1993, 1, 428, 7, 5, 2027, 430, 552, 5302, 11, 894, 446, 2027, 12483, 10, 395, 22, 361, 429, 262, 437, 53, 1, 1438, 1, 15, 496, 6, 1892, 6, 2027, 24, 1875, 11, 1405, 50, 7, 543, 657, 12, 1377, 371, 9, 195, 24, 1762, 1875, 11, 395, 22, 1875, 21014, 3411, 6, 3, 702, 9, 1262, 5214, 69, 374, 159, 52, 89, 598, 60, 184, 327, 852, 52, 27, 56, 640, 184, 14, 66, 2, 13242, 4, 803, 1, 7, 13243, 21967, 2049, 10, 447, 6, 887, 1, 7, 1762, 1875, 276, 4, 259, 1205, 1, 428, 7, 887, 7, 42, 8, 52, 1, 18, 5565, 184, 13, 175, 9, 1762, 930, 1821, 28, 8, 52, 1, 39, 53, 184, 13, 239, 29, 1707, 1, 2027, 12483, 3, 52, 675, 1, 3411, 9, 930, 10, 13, 269, 379, 811, 96, 186, 633, 9, 930, 4, 2777, 675, 11, 2718, 1696, 1660, 1696, 315, 4227, 2, 1214, 742, 8841, 1546, 790, 1205, 1, 889, 1875, 833, 39, 4405, 17098, 11398, 2, 4716, 7241, 1546, 175, 1205, 1, 889, 133, 33, 30222, 1546, 39, 1205, 1, 889, 39, 33, 2, 10026, 1875, 1546, 39, 1205, 1, 889, 39, 33, 52, 25, 10, 233, 13, 53, 184, 14, 584, 3, 675, 1, 1762, 1875, 4, 7, 5, 2027, 430, 552, 5302, 16, 64, 46, 272, 32, 867, 6, 143, 5, 217, 2, 561, 323, 183, 9, 92, 3, 287, 1, 1762, 1875, 50, 24, 822, 2632, 1322, 6, 40, 24436, 64]",1941.0,11932906,206
"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.",Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2002-04-27,"Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. We evaluated 192 patients with previously untreated B-cell CLL who were entered onto the fludarabine treatment arm (25 mg/m(2) daily for 5 days every 28 days) of CALGB study 9011, an intergroup study with participation from SWOG, CTG/NCI-C and ECOG. Patients were required to have serum creatinine within 1.5 times normal. Hematologic indices and infections were recorded during the first 28-day cycle of treatment. A time-to-toxicity endpoint was evaluated over the entire course of fludarabine treatment. Creatinine clearance (CrCl(est)) was estimated using serum creatinine, age and body mass index. The median age was 64 years (range 37-87 years) and median CrCl(est) was 62 ml/min (range 27-162 ml/min, interquartile range 52-79 ml/min). We found no association between age and incidence of hematologic toxicity or infection during the first cycle of treatment. There was a strong association between CrCl(est) and the time-to-toxicity endpoint. Patients with CrCl(est) below 80 ml/min had increased incidence of toxicity during their treatment course ( P<0.0001). Pretreatment anemia, thrombocytopenia and Rai stage were highly associated with the incidence of neutrophil toxicity and grade III/IV hematologic toxicities during the first cycle of treatment ( P<0.0001). Patient age was not an independent risk factor for fludarabine-related toxicity, but CrCl(est) was associated with time to toxicity.",Clinical Trial,6478.0,44.0,Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic CLL a disease predominantly of the elderly We sought to determine whether age function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL We evaluated 192 patients with previously untreated B-cell CLL who were entered onto the fludarabine treatment arm 25 mg/m 2 daily for 5 days every 28 days of CALGB study 9011 an intergroup study with participation from SWOG CTG/NCI-C and ECOG Patients were required to have serum creatinine within 1.5 times normal Hematologic indices and infections were recorded during the first 28-day cycle of treatment A time-to-toxicity endpoint was evaluated over the entire course of fludarabine treatment Creatinine clearance CrCl est was estimated using serum creatinine age and body mass index The median age was 64 years range 37-87 years and median CrCl est was 62 ml/min range 27-162 ml/min interquartile range 52-79 ml/min We found no association between age and incidence of hematologic toxicity or infection during the first cycle of treatment There was a strong association between CrCl est and the time-to-toxicity endpoint Patients with CrCl est below 80 ml/min had increased incidence of toxicity during their treatment course P 0.0001 Pretreatment anemia thrombocytopenia and Rai stage were highly associated with the incidence of neutrophil toxicity and grade III/IV hematologic toxicities during the first cycle of treatment P 0.0001 Patient age was not an independent risk factor for fludarabine-related toxicity but CrCl est was associated with time to toxicity,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 16, 8, 23124, 14119, 420, 17, 16, 35, 323, 24, 9, 442, 1193, 552, 8, 34, 2117, 1, 3, 1216, 21, 990, 6, 223, 317, 89, 343, 15, 1194, 813, 156, 783, 155, 1, 2027, 24, 9, 552, 21, 194, 5016, 7, 5, 373, 1278, 132, 31, 552, 54, 11, 2836, 3301, 3, 2027, 24, 475, 243, 81, 188, 18, 391, 9, 33, 162, 454, 339, 162, 1, 4077, 45, 33264, 35, 4839, 45, 5, 2599, 29, 5462, 16241, 2580, 256, 2, 2351, 7, 11, 616, 6, 47, 524, 3177, 262, 14, 33, 1072, 295, 813, 3824, 2, 1875, 11, 1872, 190, 3, 157, 339, 218, 417, 1, 24, 8, 98, 6, 155, 1138, 10, 194, 252, 3, 1797, 906, 1, 2027, 24, 3177, 1960, 7871, 13807, 10, 661, 75, 524, 3177, 89, 2, 642, 782, 558, 3, 52, 89, 10, 660, 60, 184, 567, 912, 60, 2, 52, 7871, 13807, 10, 744, 542, 1538, 184, 428, 5441, 542, 1538, 2899, 184, 653, 842, 542, 1538, 21, 204, 77, 248, 59, 89, 2, 287, 1, 813, 155, 15, 930, 190, 3, 157, 417, 1, 24, 125, 10, 8, 1082, 248, 59, 7871, 13807, 2, 3, 98, 6, 155, 1138, 7, 5, 7871, 13807, 2736, 493, 542, 1538, 42, 101, 287, 1, 155, 190, 136, 24, 906, 19, 13, 488, 1194, 1545, 1340, 2, 4121, 82, 11, 561, 41, 5, 3, 287, 1, 2595, 155, 2, 88, 316, 478, 813, 385, 190, 3, 157, 417, 1, 24, 19, 13, 488, 69, 89, 10, 44, 35, 306, 43, 161, 9, 2027, 139, 155, 84, 7871, 13807, 10, 41, 5, 98, 6, 155]",1640.0,12111110,37
"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-07-01,"DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies. DX-8951f is active in a human acute myeloid leukemia (AML) severe combined immunodeficient mouse model. In a leukemia Phase I study, we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blastic phase (CML-BP). DX-8951f was given as an i.v. infusion over 30 min daily for 5 or 7 days. The starting dose was 0.6 mg/m(2)/day for 5 days (3.0 mg/m(2)/course). Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty-five patients (AML, 21 patients; myelodysplastic syndrome, 1 patient; acute lymphocytic leukemia, 2 patients; CML-BP, 1 patient) were treated. Stomatitis was the dose-limiting toxicity, occurring in two of two patients treated at 1.35 mg/m(2)/day for 5 days, two of three treated at 1.2 mg/m(2)/day for 5 days, and one of six treated at 0.9 mg/m(2)/day for 7 days. The recommended Phase II dose was 0.9 mg/m(2)/day for 5 days. The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model. Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies.",Clinical Trial,6413.0,24.0,DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies DX-8951f is active in a human acute myeloid AML severe combined immunodeficient mouse model In a Phase I study we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic syndromes or chronic myelogenous in blastic phase CML-BP DX-8951f was given as an i.v infusion over 30 min daily for 5 or 7 days The starting dose was 0.6 mg/m 2 /day for 5 days 3.0 mg/m 2 /course Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy Twenty-five patients AML 21 patients syndrome 1 patient acute lymphocytic 2 patients CML-BP 1 patient were treated Stomatitis was the dose-limiting toxicity occurring in two of two patients treated at 1.35 mg/m 2 /day for 5 days two of three treated at 1.2 mg/m 2 /day for 5 days and one of six treated at 0.9 mg/m 2 /day for 7 days The recommended Phase II dose was 0.9 mg/m 2 /day for 5 days The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4946, 16242, 16, 8, 229, 37223, 6968, 4696, 3999, 70, 230, 5, 110, 4, 439, 4512, 128, 2, 2858, 22, 8, 61, 817, 155, 4, 537, 30, 124, 70, 94, 4946, 16242, 16, 544, 4, 8, 171, 286, 533, 329, 905, 397, 5031, 830, 202, 4, 8, 124, 70, 45, 21, 565, 3, 155, 800, 2, 1159, 1, 4946, 16242, 4, 7, 5, 86, 430, 15, 591, 329, 15, 286, 1193, 2040, 15, 442, 2194, 4, 6529, 124, 903, 3044, 4946, 16242, 10, 447, 22, 35, 70, 603, 904, 252, 201, 1538, 391, 9, 33, 15, 67, 162, 3, 1723, 61, 10, 13, 49, 81, 188, 18, 218, 9, 33, 162, 27, 13, 81, 188, 18, 906, 1993, 11, 447, 454, 27, 39, 244, 768, 6, 155, 2, 4512, 209, 737, 365, 7, 329, 239, 7, 681, 14, 69, 286, 1193, 18, 7, 903, 3044, 14, 69, 11, 73, 4486, 10, 3, 61, 817, 155, 1821, 4, 100, 1, 100, 7, 73, 28, 14, 465, 81, 188, 18, 218, 9, 33, 162, 100, 1, 169, 73, 28, 14, 18, 81, 188, 18, 218, 9, 33, 162, 2, 104, 1, 437, 73, 28, 13, 83, 81, 188, 18, 218, 9, 67, 162, 3, 793, 124, 215, 61, 10, 13, 83, 81, 188, 18, 218, 9, 33, 162, 3, 1159, 1, 4946, 24479, 10, 1646, 2, 149, 2975, 20, 8, 100, 3616, 202, 124, 215, 94, 32, 1197, 6, 195, 1107, 3, 128, 1, 4946, 16242, 4, 7, 5, 2890, 441]",1328.0,12114413,388
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.,Blood,Blood,2002-08-01,"Tumor necrosis factor-alpha (TNF-alpha), a cytokine possessing pleiotropic biological activities, is produced by leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL) and acts as an autocrine and paracrine growth factor in this disease. In this study, TNF-alpha levels were determined in 150 patients with CLL and correlated with disease characteristics, prognostic factors, and survival. The mean TNF-alpha plasma concentration in the patients with CLL was significantly higher than in the healthy control population (16.4 versus 8.7 pg/mL; P <.0001). Patients having an elevated TNF-alpha level had more advanced Rai and Binet stage disease, higher serum beta(2)-microglobulin (beta(2)M) levels, a greater percentage of cells expressing CD38, and lower hemoglobin and platelet levels. Patients having chromosomal abnormalities such as 11q deletion, trisomy 12, and chromosome 17 aberrations had a higher mean TNF-alpha level (27.5 pg/mL) than patients having a diploid karyotype or other miscellaneous cytogenetic abnormalities (14.2 pg/mL; P <.001). The TNF-alpha level was a predictor of survival when the Cox proportional hazards model was used with TNF-alpha entered as a continuous variable (P =.0001). Also, patients having a TNF-alpha level above the mean value of 14 pg/mL had significantly shorter survival duration (P =.00001). The TNF-alpha level remained predictive of survival in Cox multivariate analysis independent of Rai staging and beta(2)M, hemoglobin, prior therapy, white cell count, and platelet level (P =.005). We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance.",Journal Article,6382.0,131.0,Tumor necrosis factor-alpha TNF-alpha a cytokine possessing pleiotropic biological activities is produced by leukemic lymphocytes in patients with chronic lymphocytic CLL and acts as an autocrine and paracrine growth factor in this disease In this study TNF-alpha levels were determined in 150 patients with CLL and correlated with disease characteristics prognostic factors and survival The mean TNF-alpha plasma concentration in the patients with CLL was significantly higher than in the healthy control population 16.4 versus 8.7 pg/mL P .0001 Patients having an elevated TNF-alpha level had more advanced Rai and Binet stage disease higher serum beta 2 -microglobulin beta 2 M levels a greater percentage of cells expressing CD38 and lower hemoglobin and platelet levels Patients having chromosomal abnormalities such as 11q deletion trisomy 12 and chromosome 17 aberrations had a higher mean TNF-alpha level 27.5 pg/mL than patients having a diploid karyotype or other miscellaneous cytogenetic abnormalities 14.2 pg/mL P .001 The TNF-alpha level was a predictor of survival when the Cox proportional hazards model was used with TNF-alpha entered as a continuous variable P =.0001 Also patients having a TNF-alpha level above the mean value of 14 pg/mL had significantly shorter survival duration P =.00001 The TNF-alpha level remained predictive of survival in Cox multivariate analysis independent of Rai staging and beta 2 M hemoglobin prior therapy white cell count and platelet level P =.005 We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[30, 1523, 161, 950, 2254, 950, 8, 1675, 11228, 7872, 1037, 2042, 16, 1687, 20, 2015, 1594, 4, 7, 5, 442, 1193, 552, 2, 4459, 22, 35, 5297, 2, 6012, 129, 161, 4, 26, 34, 4, 26, 45, 2254, 950, 148, 11, 509, 4, 1577, 7, 5, 552, 2, 438, 5, 34, 374, 177, 130, 2, 25, 3, 313, 2254, 950, 554, 1227, 4, 3, 7, 5, 552, 10, 97, 142, 76, 4, 3, 1331, 182, 266, 245, 39, 185, 66, 67, 3234, 542, 19, 488, 7, 1041, 35, 804, 2254, 950, 301, 42, 80, 131, 4121, 2, 17129, 82, 34, 142, 524, 1090, 18, 5371, 1090, 18, 188, 148, 8, 378, 1150, 1, 37, 1046, 4469, 2, 280, 2222, 2, 1596, 148, 7, 1041, 1860, 1171, 225, 22, 7203, 1528, 6317, 133, 2, 1170, 269, 2152, 42, 8, 142, 313, 2254, 950, 301, 428, 33, 3234, 542, 76, 7, 1041, 8, 6815, 3385, 15, 127, 15106, 1266, 1171, 213, 18, 3234, 542, 19, 144, 3, 2254, 950, 301, 10, 8, 980, 1, 25, 198, 3, 418, 831, 1017, 202, 10, 95, 5, 2254, 950, 2836, 22, 8, 1314, 1347, 19, 488, 120, 7, 1041, 8, 2254, 950, 301, 2090, 3, 313, 549, 1, 213, 3234, 542, 42, 97, 985, 25, 654, 19, 7868, 3, 2254, 950, 301, 958, 464, 1, 25, 4, 418, 331, 65, 306, 1, 4121, 632, 2, 1090, 18, 188, 2222, 324, 36, 886, 31, 1276, 2, 1596, 301, 19, 1614, 21, 2060, 17, 3, 2254, 950, 301, 4711, 22, 8, 177, 161, 4, 7, 5, 552, 2, 17, 297, 1, 2254, 950, 4, 46, 7, 359, 47, 189, 1187]",1674.0,12149200,775
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.,Blood,Blood,2002-09-01,"Chronic lymphocytic leukemia (CLL) is associated with a variety of immunologic disturbances. Hypogammaglobulinemia and autoimmune phenomena are both often present in this disease. In contrast, humoral or cellular antitumor responses are rarely observed. It has been previously shown that antigens detected in patients with malignant diseases can provide information regarding intracellular molecules engaged in the transformation process and can identify tumor antigens that may be useful for development of immunotherapeutic strategies. Serologic identification by recombinant expression cloning (SEREX) has been demonstrated to be a useful method to detect tumor and tumor-associated antigens in a variety of malignancies. Although this approach is complicated in CLL, we used a modified SEREX approach and identified 14 antigens (KW-1 to KW-14) using this methodology. Several clones showed a restricted expression pattern in normal tissues. Moreover, distinctive expression of splice variants and aberrant gene expression in malignant tissue were detected. In this study, 6 antigens were detected exclusively in patients with CLL. Eight antigens were detected also in lymphoma patients. Healthy donors showed antibody responses against only 3 of the identified antigens. T cells with specific cytotoxicity against peptides derived from the 2 antigens tested could be generated from healthy donors. These findings demonstrate that humoral and cellular immune responses against CLL-associated antigens can be detected. Ongoing experiments investigate their potential for the development of immunotherapeutic strategies.",Journal Article,6351.0,103.0,Chronic lymphocytic CLL is associated with a variety of immunologic disturbances Hypogammaglobulinemia and autoimmune phenomena are both often present in this disease In contrast humoral or cellular antitumor responses are rarely observed It has been previously shown that antigens detected in patients with malignant diseases can provide information regarding intracellular molecules engaged in the transformation process and can identify tumor antigens that may be useful for development of immunotherapeutic strategies Serologic identification by recombinant expression cloning SEREX has been demonstrated to be a useful method to detect tumor and tumor-associated antigens in a variety of malignancies Although this approach is complicated in CLL we used a modified SEREX approach and identified 14 antigens KW-1 to KW-14 using this methodology Several clones showed a restricted expression pattern in normal tissues Moreover distinctive expression of splice variants and aberrant gene expression in malignant tissue were detected In this study 6 antigens were detected exclusively in patients with CLL Eight antigens were detected also in patients Healthy donors showed antibody responses against only 3 of the identified antigens T cells with specific cytotoxicity against peptides derived from the 2 antigens tested could be generated from healthy donors These findings demonstrate that humoral and cellular immune responses against CLL-associated antigens can be detected Ongoing experiments investigate their potential for the development of immunotherapeutic strategies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 41, 5, 8, 1362, 1, 3042, 6741, 13242, 2, 3445, 11549, 32, 110, 629, 364, 4, 26, 34, 4, 748, 5498, 15, 763, 579, 253, 32, 2416, 164, 192, 71, 85, 373, 443, 17, 1575, 530, 4, 7, 5, 393, 1342, 122, 377, 487, 666, 2087, 1598, 9173, 4, 3, 1392, 1129, 2, 122, 255, 30, 1575, 17, 68, 40, 999, 9, 193, 1, 3222, 422, 7850, 911, 20, 2835, 55, 11426, 30303, 71, 85, 264, 6, 40, 8, 999, 596, 6, 1426, 30, 2, 30, 41, 1575, 4, 8, 1362, 1, 441, 242, 26, 353, 16, 4286, 4, 552, 21, 95, 8, 1230, 30303, 353, 2, 108, 213, 1575, 10963, 14, 6, 10963, 213, 75, 26, 3209, 392, 2749, 224, 8, 2016, 55, 1177, 4, 295, 742, 1393, 5049, 55, 1, 4371, 839, 2, 1898, 145, 55, 4, 393, 246, 11, 530, 4, 26, 45, 49, 1575, 11, 530, 4437, 4, 7, 5, 552, 659, 1575, 11, 530, 120, 4, 7, 1331, 2344, 224, 548, 253, 480, 158, 27, 1, 3, 108, 1575, 102, 37, 5, 112, 1408, 480, 2491, 526, 29, 3, 18, 1575, 650, 359, 40, 1419, 29, 1331, 2344, 46, 272, 608, 17, 5498, 2, 763, 250, 253, 480, 552, 41, 1575, 122, 40, 530, 942, 2332, 963, 136, 174, 9, 3, 193, 1, 3222, 422]",1579.0,12200376,201
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2002-07-26,"Tumor necrosis factor-alpha (TNF-alpha) is an important effector and regulatory cytokine involved in the pathophysiology of hematologic malignancies, including hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), agnogenic myeloid metaplasia (AMM) and Philadelphia-negative myeloproliferative disorders (MPD). We conducted a pilot study to assess the safety of the soluble TNF receptor, etanercept (p75 TNFR:Fc; Enbrel) in patients with refractory hematologic malignancies. Patients were eligible if they had refractory HCL, CLL, AMM, or Philadelphia-negative MPD. Enbrel was administered twice weekly at a dose of 25 mg subcutaneously for a minimum of eight doses, and was continued in patients without overt progression. Among the 26 patients enrolled on study, 25 patients were evaluable. Nine patients had AMM, eight CLL, three HCL, and five Philadelphia-negative MPD. Their median age was 60 years (range 30-83 years). A total of 70 courses consisting of 486 doses of Enbrel were administered. Enbrel was well tolerated, without any overt increase in infectious episodes. Stable disease/no objective response was seen in 22 patients (88%) and progression in 3 patients (12%). Three patients with AMM improved (two showed hematologic improvement, and one showed a reduction in liver and spleen size), and two patients (one with CLL and one with Philadelphia-negative MPD) showed improvement in disease-related symptoms. Enbrel was well tolerated, but no responses were noted in these immunosuppressed patients with refractory hematologic malignancies.",Clinical Trial,6388.0,21.0,Tumor necrosis factor-alpha TNF-alpha is an important effector and regulatory cytokine involved in the pathophysiology of hematologic malignancies including hairy cell HCL chronic lymphocytic CLL agnogenic myeloid metaplasia AMM and Philadelphia-negative disorders MPD We conducted a pilot study to assess the safety of the soluble TNF receptor etanercept p75 TNFR Fc Enbrel in patients with refractory hematologic malignancies Patients were eligible if they had refractory HCL CLL AMM or Philadelphia-negative MPD Enbrel was administered twice weekly at a dose of 25 mg subcutaneously for a minimum of eight doses and was continued in patients without overt progression Among the 26 patients enrolled on study 25 patients were evaluable Nine patients had AMM eight CLL three HCL and five Philadelphia-negative MPD Their median age was 60 years range 30-83 years A total of 70 courses consisting of 486 doses of Enbrel were administered Enbrel was well tolerated without any overt increase in infectious episodes Stable disease/no objective response was seen in 22 patients 88 and progression in 3 patients 12 Three patients with AMM improved two showed hematologic improvement and one showed a reduction in and spleen size and two patients one with CLL and one with Philadelphia-negative MPD showed improvement in disease-related symptoms Enbrel was well tolerated but no responses were noted in these immunosuppressed patients with refractory hematologic malignancies,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[30, 1523, 161, 950, 2254, 950, 16, 35, 305, 2070, 2, 1253, 1675, 646, 4, 3, 4320, 1, 813, 441, 141, 7152, 31, 4623, 442, 1193, 552, 26059, 533, 6054, 18816, 2, 3006, 199, 1997, 7712, 21, 426, 8, 2281, 45, 6, 423, 3, 367, 1, 3, 2968, 2254, 153, 12527, 22004, 17669, 4127, 21065, 4, 7, 5, 430, 813, 441, 7, 11, 625, 492, 491, 42, 430, 4623, 552, 18816, 15, 3006, 199, 7712, 21065, 10, 468, 936, 709, 28, 8, 61, 1, 243, 81, 3928, 9, 8, 2499, 1, 659, 415, 2, 10, 1351, 4, 7, 187, 7192, 91, 107, 3, 432, 7, 346, 23, 45, 243, 7, 11, 859, 762, 7, 42, 18816, 659, 552, 169, 4623, 2, 365, 3006, 199, 7712, 136, 52, 89, 10, 335, 60, 184, 201, 852, 60, 8, 181, 1, 431, 1993, 2273, 1, 7582, 415, 1, 21065, 11, 468, 21065, 10, 149, 421, 187, 500, 7192, 344, 4, 3398, 3750, 585, 34, 77, 461, 51, 10, 527, 4, 350, 7, 889, 2, 91, 4, 27, 7, 133, 169, 7, 5, 18816, 231, 100, 224, 813, 767, 2, 104, 224, 8, 628, 4, 2, 4071, 444, 2, 100, 7, 104, 5, 552, 2, 104, 5, 3006, 199, 7712, 224, 767, 4, 34, 139, 507, 21065, 10, 149, 421, 84, 77, 253, 11, 1051, 4, 46, 12749, 7, 5, 430, 813, 441]",1469.0,12203106,378
Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.,Seminars in hematology,Semin. Hematol.,2002-07-01,"Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for treatment failure include high rates of relapse and treatment-related toxicities. Farnesyltransferase inhibitors (FTIs), a new class of agents that can interfere with intracellular signaling, are good therapeutic candidates for study in these diseases, given the relatively high levels of the target enzyme, farnesyltransferase, expressed in bone marrow and by peripheral circulating lymphocytes. ZARNESTRA (formerly R115777, Ortho Biotech Oncology, Raritan, NJ) is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro. In a phase I trial of Zarnestra in patients with high-risk leukemia (resistant or relapsed acute myeloid leukemia [AML] or acute lymphocytic leukemia [ALL], chronic myeloid leukemia [CML] in blast crisis, or AML in poor prognosis subgroups), patients experienced an overall response rate of 29%. Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily. Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily, and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the bone marrow in a dose-dependent fashion. These results suggest that Zarnestra should be studied further in patients with myeloid leukemia.",Journal Article,6413.0,26.0,Acute carries a poor prognosis especially in older patients emphasizing the need for novel therapies Reasons for treatment failure include high rates of relapse and treatment-related toxicities Farnesyltransferase inhibitors FTIs a new class of agents that can interfere with intracellular signaling are good therapeutic candidates for study in these diseases given the relatively high levels of the target enzyme farnesyltransferase expressed in marrow and by peripheral circulating lymphocytes ZARNESTRA formerly R115777 Ortho Biotech Oncology Raritan NJ is an FTI that has clinical activity in solid tumors and antileukemic activity in vitro In a phase I trial of Zarnestra in patients with high-risk resistant or relapsed acute myeloid AML or acute lymphocytic ALL chronic myeloid CML in blast crisis or AML in poor prognosis subgroups patients experienced an overall response rate of 29 Zarnestra was well tolerated with no dose-limiting toxicities through doses up to 900 mg twice daily Assays measuring inhibition of farnesyltransferase activity showed a reliable inhibition at doses greater than 300 mg twice daily and pharmacokinetic studies indicated that Zarnestra accumulated preferentially in the marrow in a dose-dependent fashion These results suggest that Zarnestra should be studied further in patients with myeloid,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[286, 4942, 8, 334, 356, 1093, 4, 434, 7, 6826, 3, 594, 9, 229, 235, 2325, 9, 24, 496, 643, 64, 151, 1, 429, 2, 24, 139, 385, 7480, 222, 8576, 8, 217, 1040, 1, 183, 17, 122, 6178, 5, 2087, 314, 32, 1178, 189, 1931, 9, 45, 4, 46, 1342, 447, 3, 1352, 64, 148, 1, 3, 283, 1644, 7480, 570, 4, 581, 2, 20, 672, 1033, 1594, 20218, 7350, 9645, 37266, 24505, 413, 33297, 12754, 16, 35, 10401, 17, 71, 38, 128, 4, 537, 57, 2, 4512, 128, 4, 439, 4, 8, 124, 70, 160, 1, 20218, 4, 7, 5, 64, 43, 436, 15, 591, 286, 533, 329, 15, 286, 1193, 62, 442, 533, 903, 4, 3112, 6540, 15, 329, 4, 334, 356, 1453, 7, 592, 35, 63, 51, 116, 1, 462, 20218, 10, 149, 421, 5, 77, 61, 817, 385, 298, 415, 126, 6, 5310, 81, 936, 391, 1013, 2978, 297, 1, 7480, 128, 224, 8, 2450, 297, 28, 415, 378, 76, 2036, 81, 936, 391, 2, 1456, 94, 1103, 17, 20218, 6664, 3509, 4, 3, 581, 4, 8, 61, 470, 3240, 46, 99, 309, 17, 20218, 257, 40, 656, 195, 4, 7, 5, 533]",1332.0,12214291,671
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.,Chest,Chest,2002-09-01,"Little is known about lung injury caused by fludarabine therapy. To establish a case definition, to describe management, and to identify risk factors for fludarabine-related pulmonary toxicity. Case-control study. Tertiary-care US Army teaching hospital. Individuals treated with fludarabine at our institution between January 1989 and June 2000. Cases of fludarabine-related pulmonary toxicity were defined as follows: dyspnea, fever, hypoxemia, and radiographic infiltrates seen in a patient treated with fludarabine; cases were excluded if there was evidence of pulmonary infection or progression of underlying lymphoproliferative disease affecting the lungs. For each case, demographic data, medical history, radiographic information, available bronchoscopy and pathology data, and details of treatment were reviewed. Cases were compared with fludarabine-treated control subjects to identify potential risk factors. Comparisons were made with regard to age, gender, history of underlying lung disease, lymphoproliferative diagnosis, prior chemotherapy, fludarabine treatment regimen, and pretreatment chest radiograph. During the study period, 105 patients were treated with fludarabine. The incidence of fludarabine-related pulmonary toxicity using our definition was 8.6% (95% confidence interval [CI], 3.2 to 13.9%). One patient died before this entity was suspected; the remainder of the patients underwent bronchoscopy to exclude infection. Patients were treated with corticosteroids with subjective and objective benefits. One patient later died of apparent infection during steroid therapy. One patient was retreated with fludarabine and symptoms of lung toxicity developed again. Patients (n = 9) were similar to control subjects (n = 96) with respect to age, gender, history of underlying lung disease, previous chemotherapy, and fludarabine regimen. Patients with chronic lymphocytic leukemia were 13.3 (95% CI, 1.6 to 300.6) times more likely to have toxicity develop than patients treated with fludarabine for other diagnoses. There was a trend toward an increased incidence in patients with interstitial infiltrates apparent on prefludarabine chest radiographs. A variety of lung conditions arise in patients treated with fludarabine; however, this agent seems to cause direct pulmonary toxicity. After performing an appropriate evaluation to exclude infection, corticosteroids are an effective therapy. The relative frequency of this condition and potential for mortality underscore the need for increased clinician awareness of fludarabine-related pulmonary toxicity and its risk factors.",Journal Article,6351.0,51.0,Little is known about injury caused by fludarabine therapy To establish a case definition to describe management and to identify risk factors for fludarabine-related pulmonary toxicity Case-control study Tertiary-care US Army teaching hospital Individuals treated with fludarabine at our institution between January 1989 and June 2000 Cases of fludarabine-related pulmonary toxicity were defined as follows dyspnea fever hypoxemia and radiographic infiltrates seen in a patient treated with fludarabine cases were excluded if there was evidence of pulmonary infection or progression of underlying lymphoproliferative disease affecting the lungs For each case demographic data medical history radiographic information available bronchoscopy and pathology data and details of treatment were reviewed Cases were compared with fludarabine-treated control subjects to identify potential risk factors Comparisons were made with regard to age gender history of underlying disease lymphoproliferative diagnosis prior chemotherapy fludarabine treatment regimen and pretreatment chest radiograph During the study period 105 patients were treated with fludarabine The incidence of fludarabine-related pulmonary toxicity using our definition was 8.6 95 confidence interval CI 3.2 to 13.9 One patient died before this entity was suspected the remainder of the patients underwent bronchoscopy to exclude infection Patients were treated with corticosteroids with subjective and objective benefits One patient later died of apparent infection during steroid therapy One patient was retreated with fludarabine and symptoms of toxicity developed again Patients n 9 were similar to control subjects n 96 with respect to age gender history of underlying disease previous chemotherapy and fludarabine regimen Patients with chronic lymphocytic were 13.3 95 CI 1.6 to 300.6 times more likely to have toxicity develop than patients treated with fludarabine for other diagnoses There was a trend toward an increased incidence in patients with interstitial infiltrates apparent on prefludarabine chest radiographs A variety of conditions arise in patients treated with fludarabine however this agent seems to cause direct pulmonary toxicity After performing an appropriate evaluation to exclude infection corticosteroids are an effective therapy The relative frequency of this condition and potential for mortality underscore the need for increased clinician awareness of fludarabine-related pulmonary toxicity and its risk factors,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 16, 440, 545, 2730, 1546, 20, 2027, 36, 6, 1811, 8, 473, 2470, 6, 897, 284, 2, 6, 255, 43, 130, 9, 2027, 139, 1087, 155, 473, 182, 45, 2557, 165, 843, 26062, 6292, 702, 869, 73, 5, 2027, 28, 114, 731, 59, 1024, 3965, 2, 1924, 1081, 140, 1, 2027, 139, 1087, 155, 11, 395, 22, 2962, 2923, 2775, 21069, 2, 1580, 5942, 527, 4, 8, 69, 73, 5, 2027, 140, 11, 1800, 492, 125, 10, 241, 1, 1087, 930, 15, 91, 1, 1181, 4192, 34, 2319, 3, 4465, 9, 296, 473, 1540, 74, 484, 532, 1580, 487, 390, 11570, 2, 1117, 74, 2, 3791, 1, 24, 11, 446, 140, 11, 72, 5, 2027, 73, 182, 976, 6, 255, 174, 43, 130, 2213, 11, 1229, 5, 2539, 6, 89, 1632, 532, 1, 1181, 34, 4192, 147, 324, 56, 2027, 24, 477, 2, 1194, 1662, 12295, 190, 3, 45, 727, 3263, 7, 11, 73, 5, 2027, 3, 287, 1, 2027, 139, 1087, 155, 75, 114, 2470, 10, 66, 49, 48, 307, 268, 58, 27, 18, 6, 233, 83, 104, 69, 1016, 348, 26, 2983, 10, 2768, 3, 7095, 1, 3, 7, 208, 11570, 6, 6262, 930, 7, 11, 73, 5, 3876, 5, 5571, 2, 461, 1141, 104, 69, 1559, 1016, 1, 2235, 930, 190, 3853, 36, 104, 69, 10, 11088, 5, 2027, 2, 507, 1, 155, 276, 5089, 7, 78, 83, 11, 288, 6, 182, 976, 78, 921, 5, 2184, 6, 89, 1632, 532, 1, 1181, 34, 698, 56, 2, 2027, 477, 7, 5, 442, 1193, 11, 233, 27, 48, 58, 14, 49, 6, 2036, 49, 1072, 80, 322, 6, 47, 155, 690, 76, 7, 73, 5, 2027, 9, 127, 2403, 125, 10, 8, 853, 1317, 35, 101, 287, 4, 7, 5, 4543, 5942, 2235, 23, 53118, 1662, 8921, 8, 1362, 1, 1298, 3043, 4, 7, 73, 5, 2027, 137, 26, 420, 2744, 6, 708, 1196, 1087, 155, 50, 3620, 35, 870, 451, 6, 6262, 930, 3876, 32, 35, 323, 36, 3, 580, 675, 1, 26, 2850, 2, 174, 9, 282, 5531, 3, 594, 9, 101, 3744, 3310, 1, 2027, 139, 1087, 155, 2, 211, 43, 130]",2505.0,12226014,478
"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-09-01,"Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual. A series of patients enrolled onto an intergroup CLL trial were examined for this complication. A total of 544 previously untreated B-cell CLL patients were enrolled onto a randomized intergroup study comparing treatment with chlorambucil, fludarabine, or fludarabine plus chlorambucil. Case report forms from 521 patients were reviewed for t-AML. With a median follow-up of 4.2 years, six patients (1.2%) to date have developed therapy-related myelodysplastic syndrome (t-MDS; n = 3), t-AML (n = 2), or t-MDS evolving to t-AML (n = 1), from 27 to 53 months (median, 34 months) after study entry. This included five (3.5%) of 142 patients treated with fludarabine plus chlorambucil and one (0.5%) of 188 receiving fludarabine; no chlorambucil-treated patients developed t-MDS or t-AML (P =.007). At study entry, the median age among these six patients was 56 years (range, 44 to 72 years); three were male; the CLL Rai stage was I/II (n = 4) or III/IV (n = 2). Response to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1). Marrow cytogenetics, obtained in three of six cases at diagnosis of t-MDS or t-AML, were complex, with abnormalities in either or both chromosomes 5 and 7. Other abnormalities involved chromosomes X, 1, 8, 12, 17, and 19. Median survival after diagnosis of t-MDS/AML was 3.5 months (range, 0.5 to 10.1 months). Our findings raise the possibility that alkylator-purine analog combination therapy may increase the risk of therapy-related myeloid malignancies, which is of particular relevance with regard to ongoing trials using these combination therapies.",Clinical Trial,6351.0,147.0,Patients with chronic lymphocytic CLL may have disease transformation to 's or prolymphocytic however development of therapy-related acute myeloid t-AML is unusual A series of patients enrolled onto an intergroup CLL trial were examined for this complication A total of 544 previously untreated B-cell CLL patients were enrolled onto a randomized intergroup study comparing treatment with chlorambucil fludarabine or fludarabine plus chlorambucil Case report forms from 521 patients were reviewed for t-AML With a median follow-up of 4.2 years six patients 1.2 to date have developed therapy-related syndrome t-MDS n 3 t-AML n 2 or t-MDS evolving to t-AML n 1 from 27 to 53 months median 34 months after study entry This included five 3.5 of 142 patients treated with fludarabine plus chlorambucil and one 0.5 of 188 receiving fludarabine no chlorambucil-treated patients developed t-MDS or t-AML P =.007 At study entry the median age among these six patients was 56 years range 44 to 72 years three were male the CLL Rai stage was I/II n 4 or III/IV n 2 Response to CLL therapy was complete n 4 or partial remission n 1 and stable disease n 1 Marrow cytogenetics obtained in three of six cases at diagnosis of t-MDS or t-AML were complex with abnormalities in either or both chromosomes 5 and 7 Other abnormalities involved chromosomes X 1 8 12 17 and 19 Median survival after diagnosis of t-MDS/AML was 3.5 months range 0.5 to 10.1 months Our findings raise the possibility that alkylator-purine analog combination therapy may increase the risk of therapy-related myeloid malignancies which is of particular relevance with regard to ongoing trials using these combination therapies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 68, 47, 34, 1392, 6, 292, 15, 14779, 137, 193, 1, 36, 139, 286, 533, 102, 329, 16, 4015, 8, 988, 1, 7, 346, 3301, 35, 4839, 552, 160, 11, 409, 9, 26, 1447, 8, 181, 1, 11770, 373, 1278, 132, 31, 552, 7, 11, 346, 3301, 8, 384, 4839, 45, 1430, 24, 5, 11585, 2027, 15, 2027, 349, 11585, 473, 414, 2377, 29, 11925, 7, 11, 446, 9, 102, 329, 5, 8, 52, 166, 126, 1, 39, 18, 60, 437, 7, 14, 18, 6, 1244, 47, 276, 36, 139, 681, 102, 1223, 78, 27, 102, 329, 78, 18, 15, 102, 1223, 3276, 6, 102, 329, 78, 14, 29, 428, 6, 699, 53, 52, 562, 53, 50, 45, 3001, 26, 159, 365, 27, 33, 1, 4785, 7, 73, 5, 2027, 349, 11585, 2, 104, 13, 33, 1, 5664, 357, 2027, 77, 11585, 73, 7, 276, 102, 1223, 15, 102, 329, 19, 1999, 28, 45, 3001, 3, 52, 89, 107, 46, 437, 7, 10, 664, 60, 184, 584, 6, 720, 60, 169, 11, 1045, 3, 552, 4121, 82, 10, 70, 215, 78, 39, 15, 316, 478, 78, 18, 51, 6, 552, 36, 10, 236, 78, 39, 15, 450, 734, 78, 14, 2, 585, 34, 78, 14, 581, 2510, 683, 4, 169, 1, 437, 140, 28, 147, 1, 102, 1223, 15, 102, 329, 11, 840, 5, 1171, 4, 361, 15, 110, 3560, 33, 2, 67, 127, 1171, 646, 3560, 1006, 14, 66, 133, 269, 2, 326, 52, 25, 50, 147, 1, 102, 1223, 329, 10, 27, 33, 53, 184, 13, 33, 6, 79, 14, 53, 114, 272, 5008, 3, 2526, 17, 9346, 5006, 3497, 150, 36, 68, 344, 3, 43, 1, 36, 139, 533, 441, 92, 16, 1, 1454, 2088, 5, 2539, 6, 942, 143, 75, 46, 150, 235]",1683.0,12228208,336
Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature.,Haematologia,Haematologia (Budap),2002-01-01,"Polycythemia vera and lymphoproliferative disorders can occur simultaneously. Lymphoproliferative disorders reported to occur simultaneously with polycythemia vera include chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute lymphoblastic leukemia (ALL). Different theories have attempted to explain this occurrence. Some implicate a common cell of origin to the two disorders, others include chance alone, yet others implicate an underlying humoral or immune mechanism caused by the first disorder leading to a second clonal expansion. We report the first case of polycythemia vera with a simultaneous diagnosis of Waldenstrom macroglobulinemia, and we review the literature trying to explain this unusual occurrence.",Case Reports,6594.0,4.0,Polycythemia vera and lymphoproliferative disorders can occur simultaneously Lymphoproliferative disorders reported to occur simultaneously with polycythemia vera include chronic lymphocytic CLL 's NHL and acute lymphoblastic ALL Different theories have attempted to explain this occurrence Some implicate a common cell of origin to the two disorders others include chance alone yet others implicate an underlying humoral or immune mechanism caused by the first disorder leading to a second clonal expansion We report the first case of polycythemia vera with a simultaneous diagnosis of Waldenstrom macroglobulinemia and we review the literature trying to explain this unusual occurrence,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[5755, 5756, 2, 4192, 1997, 122, 1271, 3074, 4192, 1997, 210, 6, 1271, 3074, 5, 5755, 5756, 643, 442, 1193, 552, 292, 1176, 2, 286, 1275, 62, 338, 18219, 47, 4098, 6, 2943, 26, 2291, 476, 5545, 8, 186, 31, 1, 1938, 6, 3, 100, 1997, 1749, 643, 3477, 279, 1145, 1749, 5545, 35, 1181, 5498, 15, 250, 670, 1546, 20, 3, 157, 2645, 1049, 6, 8, 419, 1946, 1422, 21, 414, 3, 157, 473, 1, 5755, 5756, 5, 8, 2824, 147, 1, 7933, 3389, 2, 21, 206, 3, 789, 14453, 6, 2943, 26, 4015, 2291]",687.0,12243551,506
"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).",Blood,Blood,2002-07-05,"Recent studies have suggested that rituximab has clinical activity and modulates antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia (CLL). We performed a randomized phase 2 study to determine the efficacy, safety, and optimal administration schedule of rituximab with fludarabine in previously untreated CLL patients. Patients were randomized to receive either 6 monthly courses of fludarabine concurrently with rituximab followed 2 months later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone followed 2 months later by rituximab consolidation therapy. A total of 104 patients were randomized to the concurrent (n = 51) and sequential (n = 53) regimens. During the induction portion of treatment, patients receiving the concurrent regimen experienced more grade 3 or 4 neutropenia (74% versus 41%) and grade 3 or 4 infusion-related toxicity (20% versus 0%) as compared with the sequential arm. The consolidation rituximab therapy was tolerated well in both arms. All other toxicities were similar in the 2 arms. The overall response rate with the concurrent regimen was 90% (47% complete response [CR], 43% partial response [PR]; 95% confidence interval [CI], 0.82-0.98) compared with 77% (28% CR, 49% PR; 95% CI, 0.66-0.99) with the sequential regimen. With a median follow-up time of 23 months, the median response duration and survival have not been reached for either regimen. Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted.",Clinical Trial,6409.0,503.0,Recent studies have suggested that rituximab has clinical activity and modulates antiapoptotic proteins associated with drug resistance in chronic lymphocytic CLL We performed a randomized phase 2 study to determine the efficacy safety and optimal administration schedule of rituximab with fludarabine in previously untreated CLL patients Patients were randomized to receive either 6 monthly courses of fludarabine concurrently with rituximab followed 2 months later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone followed 2 months later by rituximab consolidation therapy A total of 104 patients were randomized to the concurrent n 51 and sequential n 53 regimens During the induction portion of treatment patients receiving the concurrent regimen experienced more grade 3 or 4 neutropenia 74 versus 41 and grade 3 or 4 infusion-related toxicity 20 versus 0 as compared with the sequential arm The consolidation rituximab therapy was tolerated well in both arms All other toxicities were similar in the 2 arms The overall response rate with the concurrent regimen was 90 47 complete response CR 43 partial response PR 95 confidence interval CI 0.82-0.98 compared with 77 28 CR 49 PR 95 CI 0.66-0.99 with the sequential regimen With a median follow-up time of 23 months the median response duration and survival have not been reached for either regimen Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity Phase 3 studies using this combination approach for patients with CLL are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[435, 94, 47, 1148, 17, 855, 71, 38, 128, 2, 5259, 4176, 652, 41, 5, 234, 251, 4, 442, 1193, 552, 21, 173, 8, 384, 124, 18, 45, 6, 223, 3, 209, 367, 2, 665, 634, 1055, 1, 855, 5, 2027, 4, 373, 1278, 552, 7, 7, 11, 384, 6, 560, 361, 49, 3889, 1993, 1, 2027, 3294, 5, 855, 370, 18, 53, 1559, 20, 39, 709, 415, 1, 855, 9, 2173, 36, 15, 1787, 2027, 279, 370, 18, 53, 1559, 20, 855, 2173, 36, 8, 181, 1, 3407, 7, 11, 384, 6, 3, 750, 78, 725, 2, 1787, 78, 699, 472, 190, 3, 504, 3206, 1, 24, 7, 357, 3, 750, 477, 592, 80, 88, 27, 15, 39, 778, 794, 185, 605, 2, 88, 27, 15, 39, 904, 139, 155, 179, 185, 13, 22, 72, 5, 3, 1787, 475, 3, 2173, 855, 36, 10, 421, 149, 4, 110, 1335, 62, 127, 385, 11, 288, 4, 3, 18, 1335, 3, 63, 51, 116, 5, 3, 750, 477, 10, 424, 662, 236, 51, 684, 601, 450, 51, 998, 48, 307, 268, 58, 13, 878, 13, 1096, 72, 5, 849, 339, 684, 739, 998, 48, 58, 13, 700, 13, 1058, 5, 3, 1787, 477, 5, 8, 52, 166, 126, 98, 1, 382, 53, 3, 52, 51, 654, 2, 25, 47, 44, 85, 1300, 9, 361, 477, 855, 468, 3294, 5, 2027, 4, 373, 1278, 552, 7, 1902, 2003, 38, 209, 2, 1595, 155, 124, 27, 94, 75, 26, 150, 353, 9, 7, 5, 552, 32, 1197]",1630.0,12393429,199
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2002-11-01,"Our objective in this study was to evaluate whether the use of hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9-2.0) but not former (RR, 1.1; 95% CI, 0.8-1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RR(current), 1.5 (95% CI, 1.0-2.4); RR(former), 1.1 (95% CI, 0.8-1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RR(current), 3.3 (95% CI, 1.6-6.9); RR(former), 2.6 (95% CI, 1.4-4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8-8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.",Comparative Study,6290.0,43.0,"Our objective in this study was to evaluate whether the use of hormone replacement therapy HRT is associated with NHL or chronic lymphocytic CLL A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry Through 1998 13 years of follow-up 258 incident cases of NHL were identified including 135 cases of diffuse NHL 58 cases of follicular NHL and 31 cases of small lymphocytic NHL In addition 63 cases of CLL were identified Current and former use of HRT primarily estrogen and other cancer risk factors were self-reported on the baseline 1986 questionnaire Compared with never users of HRT at study baseline current multivariate relative risk RR 1.4 95 confidence intervals CIs 0.9-2.0 but not former RR 1.1 95 CI 0.8-1.4 users were at increased risk of NHL after adjustment for age and other confounding factors This association was seen only in nodal NHL RR current 1.5 95 CI 1.0-2.4 RR former 1.1 95 CI 0.8-1.6 and was not apparent for extra-nodal sites Of the common subtypes there was a strong positive association with follicular NHL RR current 3.3 95 CI 1.6-6.9 RR former 2.6 95 CI 1.4-4.7 and women who were current users for more than 5 years had the highest risk RR 3.9 95 CI 1.8-8.6 There was no association with diffuse or small lymphocytic NHL or with CLL Most of the follicular NHLs were nodal 88 and exclusion of extra-nodal sites slightly strengthened the association with HRT For diffuse NHL 64 of the cases were nodal and there was no association of HRT with either nodal or extra-nodal sites These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[114, 461, 4, 26, 45, 10, 6, 376, 317, 3, 119, 1, 785, 3892, 36, 5315, 16, 41, 5, 1176, 15, 442, 1193, 552, 8, 180, 1, 567, 6211, 8565, 117, 2165, 614, 6, 790, 60, 4, 3751, 5, 77, 532, 1, 324, 12, 10, 1199, 4226, 6, 8, 266, 90, 12, 1608, 298, 1850, 233, 60, 1, 166, 126, 8289, 2631, 140, 1, 1176, 11, 108, 141, 3978, 140, 1, 1388, 1176, 717, 140, 1, 1974, 1176, 2, 456, 140, 1, 302, 1193, 1176, 4, 352, 676, 140, 1, 552, 11, 108, 291, 2, 3623, 119, 1, 5315, 1561, 808, 2, 127, 12, 43, 130, 11, 1074, 210, 23, 3, 330, 3751, 1770, 72, 5, 1737, 2735, 1, 5315, 28, 45, 330, 291, 331, 580, 43, 861, 14, 39, 48, 307, 1582, 1927, 13, 83, 18, 13, 84, 44, 3623, 861, 14, 14, 48, 58, 13, 66, 14, 39, 2735, 11, 28, 101, 43, 1, 1176, 50, 1852, 9, 89, 2, 127, 4339, 130, 26, 248, 10, 527, 158, 4, 779, 1176, 861, 291, 14, 33, 48, 58, 14, 13, 18, 39, 861, 3623, 14, 14, 48, 58, 13, 66, 14, 49, 2, 10, 44, 2235, 9, 3420, 779, 633, 1, 3, 186, 814, 125, 10, 8, 1082, 109, 248, 5, 1974, 1176, 861, 291, 27, 27, 48, 58, 14, 49, 49, 83, 861, 3623, 18, 49, 48, 58, 14, 39, 39, 67, 2, 117, 54, 11, 291, 2735, 9, 80, 76, 33, 60, 42, 3, 1076, 43, 861, 27, 83, 48, 58, 14, 66, 66, 49, 125, 10, 77, 248, 5, 1388, 15, 302, 1193, 1176, 15, 5, 552, 96, 1, 3, 1974, 11440, 11, 779, 889, 2, 4721, 1, 3420, 779, 633, 3223, 12766, 3, 248, 5, 5315, 9, 1388, 1176, 660, 1, 3, 140, 11, 779, 2, 125, 10, 77, 248, 1, 5315, 5, 361, 779, 15, 3420, 779, 633, 46, 74, 309, 17, 5315, 16, 8, 43, 161, 9, 1974, 1176, 84, 44, 9, 1388, 15, 302, 1448, 1176, 15, 552]",1715.0,12433728,82
Chronic lymphocytic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2002-01-01,"This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whether there is a need for more aggressive management. In Section I, Dr. Terry Hamblin addresses the nature of the disease, accurate diagnostic procedures, evidence for an early ""preclinical"" phase, the use of newer prognostic features to distinguish who will be likely to progress or not, and whether it is best to watch or treat early stage disease. In Section II, Dr. Neil Kay and colleagues address the biologic aspects of the disease and how they may relate to disease progression. Review of the newer insights into gene expression, recurring genetic defects, role of cytokines/autocrine pathways, and the interaction of the CLL B cell with the microenvironment are emphasized. The relationship of these events to both trigger disease progression and as opportunities for future therapeutic intervention even in early stage disease is also considered. In Section III, Dr. John Byrd and colleagues review the historical and now current approaches to management of the previously untreated progressive B-CLL patient. They discuss what decision tree could be used in the initial decision to treat a given patient. The use of single agents versus newer combination approaches such as chemoimmunotherapy are discussed here. In addition, the place of marrow transplant and some of the newer antibodies available for treatment of B-CLL are considered. Finally, a challenge to utilize our growing knowledge of the biology of B-CLL in the early stage B-CLL is proffered.",Journal Article,6594.0,73.0,This update of early stage B-cell chronic lymphocytic B-CLL embraces current information on the diagnosis biology and intervention required to more fully develop algorithms for management of this disease Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whether there is a need for more aggressive management In Section I Dr. Terry Hamblin addresses the nature of the disease accurate diagnostic procedures evidence for an early `` preclinical '' phase the use of newer prognostic features to distinguish who will be likely to progress or not and whether it is best to watch or treat early stage disease In Section II Dr. Neil Kay and colleagues address the biologic aspects of the disease and how they may relate to disease progression Review of the newer insights into gene expression recurring genetic defects role of cytokines/autocrine pathways and the interaction of the CLL B cell with the microenvironment are emphasized The relationship of these events to both trigger disease progression and as opportunities for future therapeutic intervention even in early stage disease is also considered In Section III Dr. John Byrd and colleagues review the historical and now current approaches to management of the previously untreated progressive B-CLL patient They discuss what decision tree could be used in the initial decision to treat a given patient The use of single agents versus newer combination approaches such as chemoimmunotherapy are discussed here In addition the place of marrow transplant and some of the newer antibodies available for treatment of B-CLL are considered Finally a challenge to utilize our growing knowledge of the biology of B-CLL in the early stage B-CLL is proffered,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 2991, 1, 191, 82, 132, 31, 442, 1193, 132, 552, 53248, 291, 487, 23, 3, 147, 891, 2, 788, 616, 6, 80, 1910, 690, 3529, 9, 284, 1, 26, 34, 3136, 23, 191, 82, 16, 90, 23, 3, 1321, 7496, 4, 114, 612, 1, 3, 34, 1038, 2, 114, 602, 801, 6, 678, 9, 8, 447, 191, 82, 69, 317, 125, 16, 8, 594, 9, 80, 571, 284, 4, 2917, 70, 3436, 37330, 53249, 5437, 3, 2202, 1, 3, 34, 1481, 752, 1369, 241, 9, 35, 191, 693, 522, 124, 3, 119, 1, 2246, 177, 404, 6, 3081, 54, 303, 40, 322, 6, 1466, 15, 44, 2, 317, 192, 16, 824, 6, 16694, 15, 943, 191, 82, 34, 4, 2917, 215, 3436, 43088, 53250, 2, 6367, 1539, 3, 1283, 2695, 1, 3, 34, 2, 832, 491, 68, 6509, 6, 34, 91, 206, 1, 3, 2246, 1957, 237, 145, 55, 6385, 336, 2945, 200, 1, 1886, 5297, 460, 2, 3, 915, 1, 3, 552, 132, 31, 5, 3, 995, 32, 8585, 3, 858, 1, 46, 281, 6, 110, 5781, 34, 91, 2, 22, 2605, 9, 508, 189, 788, 871, 4, 191, 82, 34, 16, 120, 515, 4, 2917, 316, 3436, 9968, 33330, 2, 6367, 206, 3, 2252, 2, 1134, 291, 611, 6, 284, 1, 3, 373, 1278, 1014, 132, 552, 69, 491, 1139, 2067, 948, 4899, 359, 40, 95, 4, 3, 388, 948, 6, 943, 8, 447, 69, 3, 119, 1, 226, 183, 185, 2246, 150, 611, 225, 22, 4438, 32, 1588, 467, 4, 352, 3, 3536, 1, 581, 941, 2, 476, 1, 3, 2246, 890, 390, 9, 24, 1, 132, 552, 32, 515, 1368, 8, 1745, 6, 6391, 114, 1921, 922, 1, 3, 891, 1, 132, 552, 4, 3, 191, 82, 132, 552, 16, 43089]",1828.0,12446424,383
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.,Blood,Blood,2002-11-21,"CD20 is a 33- to 36-kDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B lymphocytes. The predicted amino acid sequence of the CD20 suggests 4 transmembrane-spanning regions with both N- and C-termini located in the cytoplasm. We demonstrate herein that significant levels of circulating CD20 (cCD20) can be detected in the plasma of patients with chronic lymphocytic leukemia (CLL) and that cCD20 interferes with the binding of rituximab, a humanized anti-CD20 monoclonal antibody, to CLL cells. An enzyme-linked immunosorbent assay (ELISA) was developed to measure circulating cCD20 levels in the plasma. We measured cCD20 levels in the plasma of 180 patients with CLL and correlated these levels with clinical characteristics and outcome. Circulating CD20 levels correlated positively with beta(2)-microglobulin level (p =.006) and percentage of CD38(+) cells (p =.03) and negatively with platelet count (p =.004) and hemoglobin level (p =.02). Patients with advanced Rai (III/IV) or Binet (C) stage disease had significantly higher levels of cCD20 than did patients with earlier-stage disease (P =.01 and P =.006, respectively). There was no correlation between cCD20 level and age, lymphocyte count, or white blood cell count. Using a recursive classification method, we found that patients with a cCD20 level more than 1875 nM/L had significantly shorter survival than those with cCD20 1875 nM/L or below (P =.01). The prognostic value of cCD20 was independent of Rai staging or hemoglobin level. Prospective evaluation is indicated to establish whether rituximab dosing should be adjusted according to cCD20 levels.",Journal Article,6270.0,169.0,CD20 is a 33- to 36-kDa transmembrane phosphoprotein involved in the activation proliferation and differentiation of B lymphocytes The predicted amino acid sequence of the CD20 suggests 4 transmembrane-spanning regions with both N- and C-termini located in the cytoplasm We demonstrate herein that significant levels of circulating CD20 cCD20 can be detected in the plasma of patients with chronic lymphocytic CLL and that cCD20 interferes with the binding of rituximab a humanized anti-CD20 monoclonal antibody to CLL cells An enzyme-linked immunosorbent assay ELISA was developed to measure circulating cCD20 levels in the plasma We measured cCD20 levels in the plasma of 180 patients with CLL and correlated these levels with clinical characteristics and outcome Circulating CD20 levels correlated positively with beta 2 -microglobulin level p =.006 and percentage of CD38 cells p =.03 and negatively with platelet count p =.004 and hemoglobin level p =.02 Patients with advanced Rai III/IV or Binet C stage disease had significantly higher levels of cCD20 than did patients with earlier-stage disease P =.01 and P =.006 respectively There was no correlation between cCD20 level and age lymphocyte count or white blood cell count Using a recursive classification method we found that patients with a cCD20 level more than 1875 nM/L had significantly shorter survival than those with cCD20 1875 nM/L or below P =.01 The prognostic value of cCD20 was independent of Rai staging or hemoglobin level Prospective evaluation is indicated to establish whether rituximab dosing should be adjusted according to cCD20 levels,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2198, 16, 8, 466, 6, 511, 6362, 5527, 12302, 646, 4, 3, 363, 457, 2, 910, 1, 132, 1594, 3, 783, 3078, 971, 1532, 1, 3, 2198, 844, 39, 5527, 7155, 1374, 5, 110, 78, 2, 256, 37333, 2308, 4, 3, 4558, 21, 608, 1986, 17, 93, 148, 1, 1033, 2198, 13837, 122, 40, 530, 4, 3, 554, 1, 7, 5, 442, 1193, 552, 2, 17, 13837, 12078, 5, 3, 791, 1, 855, 8, 3619, 312, 2198, 848, 548, 6, 552, 37, 35, 1644, 1199, 5339, 719, 3664, 10, 276, 6, 1463, 1033, 13837, 148, 4, 3, 554, 21, 644, 13837, 148, 4, 3, 554, 1, 3172, 7, 5, 552, 2, 438, 46, 148, 5, 38, 374, 2, 228, 1033, 2198, 148, 438, 2375, 5, 1090, 18, 5371, 301, 19, 1861, 2, 1150, 1, 4469, 37, 19, 680, 2, 2723, 5, 1596, 1276, 19, 1520, 2, 2222, 301, 19, 588, 7, 5, 131, 4121, 316, 478, 15, 17129, 256, 82, 34, 42, 97, 142, 148, 1, 13837, 76, 205, 7, 5, 1677, 82, 34, 19, 355, 2, 19, 1861, 106, 125, 10, 77, 816, 59, 13837, 301, 2, 89, 1448, 1276, 15, 886, 315, 31, 1276, 75, 8, 4493, 947, 596, 21, 204, 17, 7, 5, 8, 13837, 301, 80, 76, 37334, 2878, 805, 42, 97, 985, 25, 76, 135, 5, 13837, 37334, 2878, 805, 15, 2736, 19, 355, 3, 177, 549, 1, 13837, 10, 306, 1, 4121, 632, 15, 2222, 301, 482, 451, 16, 1103, 6, 1811, 317, 855, 1280, 257, 40, 586, 768, 6, 13837, 148]",1617.0,12446458,766
Advancing the treatment of hematologic malignancies through the development of targeted interventions.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Significant advances have been made in the development of targeted interventions for hematologic malignancies. Progress has been made in defining the molecular pathogenesis of human leukemias. Data indicate that nonrandom, somatically acquired translocations, inversions, and other abnormalities occur in many acute leukemias. In the treatment of acute promyelocytic leukemia (APL), targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy leads to dramatic improvements in disease-free survival. Imatinib mesylate, a signal transduction inhibitor that inhibits tyrosine kinase activity, the protein product of the ABL proto-oncogene, has remarkable activity in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). Farnesyltransferase inhibitors (FTIs), a promising class of agents that target multiple pathways including Ras proteins, are potential anticancer therapy for a wide range of malignancies, including leukemias and myelodysplastic syndromes (MDS). There also is evidence that recombinant human erythropoietin therapy (r-HuEPO) can benefit patients with chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. This supplement will discuss advances in our understanding of human leukemias, including the use of unconjugated monoclonal antibodies such as Campath-1H (Wellcome, Beckenham, UK, and Ilex Oncology, San Antonio, TX) and rituximab and immunoconjugates such as gemtuzumab ozogamicin and BL-22. Although these novel therapies are beginning to fulfill their promise, continued research efforts are needed to determine the optimal role of targeted therapy in acute and chronic leukemias.",Journal Article,6321.0,8.0,Significant advances have been made in the development of targeted interventions for hematologic malignancies Progress has been made in defining the molecular pathogenesis of human leukemias Data indicate that nonrandom somatically acquired translocations inversions and other abnormalities occur in many acute leukemias In the treatment of acute promyelocytic APL targeted therapy with all-trans retinoic acid ATRA and anthracycline-based chemotherapy leads to dramatic improvements in disease-free survival Imatinib mesylate a signal transduction inhibitor that inhibits tyrosine kinase activity the protein product of the ABL proto-oncogene has remarkable activity in patients with chronic myeloid CML and Philadelphia chromosome-positive Ph acute lymphoblastic ALL Farnesyltransferase inhibitors FTIs a promising class of agents that target multiple pathways including Ras proteins are potential anticancer therapy for a wide range of malignancies including leukemias and syndromes MDS There also is evidence that recombinant human erythropoietin therapy r-HuEPO can benefit patients with chronic lymphocytic CLL multiple and lymphomas This supplement will discuss advances in our understanding of human leukemias including the use of unconjugated monoclonal antibodies such as Campath-1H Wellcome Beckenham UK and Ilex Oncology San Antonio TX and rituximab and immunoconjugates such as gemtuzumab ozogamicin and BL-22 Although these novel therapies are beginning to fulfill their promise continued research efforts are needed to determine the optimal role of targeted therapy in acute and chronic leukemias,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[93, 954, 47, 85, 1229, 4, 3, 193, 1, 238, 1151, 9, 813, 441, 1466, 71, 85, 1229, 4, 2847, 3, 219, 1384, 1, 171, 2792, 74, 1008, 17, 12480, 12293, 1294, 3262, 24544, 2, 127, 1171, 1271, 4, 445, 286, 2792, 4, 3, 24, 1, 286, 4300, 2578, 238, 36, 5, 62, 3437, 3887, 971, 2822, 2, 2044, 90, 56, 1940, 6, 3079, 1474, 4, 34, 115, 25, 577, 2347, 8, 1235, 2761, 230, 17, 1576, 564, 216, 128, 3, 178, 2821, 1, 3, 1425, 4976, 1836, 71, 3813, 128, 4, 7, 5, 442, 533, 903, 2, 3006, 1170, 109, 2058, 286, 1275, 62, 7480, 222, 8576, 8, 721, 1040, 1, 183, 17, 283, 232, 460, 141, 1102, 652, 32, 174, 1475, 36, 9, 8, 1019, 184, 1, 441, 141, 2792, 2, 2040, 1223, 125, 120, 16, 241, 17, 2835, 171, 6266, 36, 668, 21090, 122, 247, 7, 5, 442, 1193, 552, 232, 2, 1557, 26, 5836, 303, 1139, 954, 4, 114, 612, 1, 171, 2792, 141, 3, 119, 1, 11116, 848, 890, 225, 22, 16622, 10147, 37335, 43091, 6975, 2, 43092, 413, 6889, 20244, 6614, 2, 855, 2, 15109, 225, 22, 7918, 5566, 2, 6331, 350, 242, 46, 229, 235, 32, 2948, 6, 11246, 136, 1783, 1351, 389, 1413, 32, 575, 6, 223, 3, 665, 200, 1, 238, 36, 4, 286, 2, 442, 2792]",1611.0,12447845,560
Monoclonal antibody therapies in leukemias.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Significant advances in the development of monoclonal antibodies (unconjugated) and monoclonal antibodies conjugated to potent toxins or cytotoxic agents (immunoconjugates) have enabled improved targeting of leukemic cells with acceptable toxicities. Gemtuzumab ozogamicin, a calicheamicin-conjugated anti-CD33 monoclonal antibody, has demonstrated substantial efficacy in patients with acute myeloid leukemia (AML) and has induced remissions in patients with favorable-, intermediate-, and poor-risk cytogenetics. The immunoconjugate BL-22, comprised of an anti-CD22 monoclonal antibody fused to a fragment of pseudomonas exotoxin PE38, has produced high response rates in patients with purine analog-resistant hairy cell leukemia. Campath-1H (Wellcome, Beckenham, UK, and Ilex Oncology, San Antonio, TX), an anti-CD52 monoclonal antibody, has demonstrated significant activity in patients with previously untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL), as well as in patients with T-cell prolymphocytic leukemia. The anti-CD20 monoclonal antibody rituximab also is effective in treating CLL and is being evaluated in combination with chemotherapeutic agents (cyclophosphamide) and fludarabine. Monoclonal antibodies may sensitize cells to chemotherapy. The optimal role of targeted therapy with monoclonal antibodies and immunoconjugates in acute and chronic leukemias has not yet been determined, but these novel therapies are beginning to fulfill their promise.",Journal Article,6321.0,28.0,Significant advances in the development of monoclonal antibodies unconjugated and monoclonal antibodies conjugated to potent toxins or cytotoxic agents immunoconjugates have enabled improved targeting of leukemic cells with acceptable toxicities Gemtuzumab ozogamicin a calicheamicin-conjugated anti-CD33 monoclonal antibody has demonstrated substantial efficacy in patients with acute myeloid AML and has induced remissions in patients with favorable- intermediate- and poor-risk cytogenetics The immunoconjugate BL-22 comprised of an anti-CD22 monoclonal antibody fused to a fragment of pseudomonas exotoxin PE38 has produced high response rates in patients with purine analog-resistant hairy cell Campath-1H Wellcome Beckenham UK and Ilex Oncology San Antonio TX an anti-CD52 monoclonal antibody has demonstrated significant activity in patients with previously untreated relapsed or refractory chronic lymphocytic CLL as well as in patients with T-cell prolymphocytic The anti-CD20 monoclonal antibody rituximab also is effective in treating CLL and is being evaluated in combination with chemotherapeutic agents cyclophosphamide and fludarabine Monoclonal antibodies may sensitize cells to chemotherapy The optimal role of targeted therapy with monoclonal antibodies and immunoconjugates in acute and chronic leukemias has not yet been determined but these novel therapies are beginning to fulfill their promise,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[93, 954, 4, 3, 193, 1, 848, 890, 11116, 2, 848, 890, 3868, 6, 1157, 13820, 15, 759, 183, 15109, 47, 4387, 231, 529, 1, 2015, 37, 5, 1595, 385, 7918, 5566, 8, 13499, 3868, 312, 6353, 848, 548, 71, 264, 1281, 209, 4, 7, 5, 286, 533, 329, 2, 71, 277, 3166, 4, 7, 5, 913, 919, 2, 334, 43, 2510, 3, 13498, 6331, 350, 2603, 1, 35, 312, 7599, 848, 548, 6263, 6, 8, 5245, 1, 13538, 19522, 14141, 71, 1687, 64, 51, 151, 4, 7, 5, 5006, 3497, 436, 7152, 31, 16622, 10147, 37335, 43091, 6975, 2, 43092, 413, 6889, 20244, 6614, 35, 312, 7189, 848, 548, 71, 264, 93, 128, 4, 7, 5, 373, 1278, 591, 15, 430, 442, 1193, 552, 22, 149, 22, 4, 7, 5, 102, 31, 14779, 3, 312, 2198, 848, 548, 855, 120, 16, 323, 4, 1367, 552, 2, 16, 486, 194, 4, 150, 5, 1573, 183, 1112, 2, 2027, 848, 890, 68, 5745, 37, 6, 56, 3, 665, 200, 1, 238, 36, 5, 848, 890, 2, 15109, 4, 286, 2, 442, 2792, 71, 44, 1145, 85, 509, 84, 46, 229, 235, 32, 2948, 6, 11246, 136, 1783]",1416.0,12447847,101
Epoetin alfa as a supportive measure in hematologic malignancies.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Anemia is prevalent among cancer patients with hematologic malignancies, with fatigue and weakness, major symptoms of anemia, contributing to diminished quality of life (QOL). Data from several randomized, placebo-controlled clinical trials and three large community-based studies in patients with hematologic malignancies indicate that recombinant human erythropoietin (r-HuEPO, epoetin alfa) can correct anemia, reduce transfusion requirements, and improve QOL. Moreover, a positive relationship has been found between increased hemoglobin (Hb) levels and improvements in QOL assessments, regardless of disease state, with the greatest incremental improvement occurring when Hb increases from 11 g/dL to 12 g/dL (range, 11 to 13 g/dL). This suggests that patients with mild-to-moderate anemia may achieve the greatest QOL benefit from epoetin alfa therapy. Evidence from community-based studies suggests that epoetin alfa administered once weekly has a similar safety and efficacy profile as three-times-weekly administration. Further research is ongoing with less frequent dosing regimens. The beneficial effects of epoetin alfa therapy have been reported in studies involving patients with chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. Evidence also exists that epoetin alfa can benefit patients with myelodysplastic syndromes (MDS), although these results have not been as impressive. Combining epoetin alfa with other cytokine growth factors may confer some additional benefit in these patients, but more rigorous investigation is required.",Journal Article,6321.0,9.0,Anemia is prevalent among cancer patients with hematologic malignancies with fatigue and weakness major symptoms of anemia contributing to diminished quality of life QOL Data from several randomized placebo-controlled clinical trials and three large community-based studies in patients with hematologic malignancies indicate that recombinant human erythropoietin r-HuEPO epoetin alfa can correct anemia reduce transfusion requirements and improve QOL Moreover a positive relationship has been found between increased hemoglobin Hb levels and improvements in QOL assessments regardless of disease state with the greatest incremental improvement occurring when Hb increases from 11 g/dL to 12 g/dL range 11 to 13 g/dL This suggests that patients with mild-to-moderate anemia may achieve the greatest QOL benefit from epoetin alfa therapy Evidence from community-based studies suggests that epoetin alfa administered once weekly has a similar safety and efficacy profile as three-times-weekly administration Further research is ongoing with less frequent dosing regimens The beneficial effects of epoetin alfa therapy have been reported in studies involving patients with chronic lymphocytic CLL multiple and lymphomas Evidence also exists that epoetin alfa can benefit patients with syndromes MDS although these results have not been as impressive Combining epoetin alfa with other cytokine growth factors may confer some additional benefit in these patients but more rigorous investigation is required,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1545, 16, 2485, 107, 12, 7, 5, 813, 441, 5, 613, 2, 6408, 458, 507, 1, 1545, 3156, 6, 2849, 372, 1, 358, 1001, 74, 29, 392, 384, 619, 1149, 38, 143, 2, 169, 375, 1714, 90, 94, 4, 7, 5, 813, 441, 1008, 17, 2835, 171, 6266, 668, 21090, 7305, 4443, 122, 4883, 1545, 969, 2785, 4230, 2, 401, 1001, 1393, 8, 109, 858, 71, 85, 204, 59, 101, 2222, 5753, 148, 2, 1474, 4, 1001, 2182, 1583, 1, 34, 1309, 5, 3, 2199, 3648, 767, 1821, 198, 5753, 1106, 29, 175, 499, 1826, 6, 133, 499, 1826, 184, 175, 6, 233, 499, 1826, 26, 844, 17, 7, 5, 1980, 6, 1163, 1545, 68, 1359, 3, 2199, 1001, 247, 29, 7305, 4443, 36, 241, 29, 1714, 90, 94, 844, 17, 7305, 4443, 468, 1059, 709, 71, 8, 288, 367, 2, 209, 800, 22, 169, 1072, 709, 634, 195, 389, 16, 942, 5, 299, 908, 1280, 472, 3, 2524, 176, 1, 7305, 4443, 36, 47, 85, 210, 4, 94, 1267, 7, 5, 442, 1193, 552, 232, 2, 1557, 241, 120, 2481, 17, 7305, 4443, 122, 247, 7, 5, 2040, 1223, 242, 46, 99, 47, 44, 85, 22, 5790, 1525, 7305, 4443, 5, 127, 1675, 129, 130, 68, 2913, 476, 402, 247, 4, 46, 7, 84, 80, 6496, 940, 16, 616]",1500.0,12447849,298
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.,Cancer investigation,Cancer Invest.,2002-01-01,"A significant number of chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma and Waldenstrm's macroglobulinemia patients, treated with fludarabine phosphate (fludarabine), are elderly with diminished renal function. Since the kidney eliminates approximately 60% of fludarabine's primary metabolite (F-ara-A), dose modification is necessary for all patients with impaired renal function including elderly patients. In this study, 22 patients with varying levels of renal function received a single intravenous dose of fludarabine (25 mg/m3), followed one week later by five (one per day) doses that were adjusted according to three predefined creatinine clearance (CLcr) levels. Relationships between renal function and F-ara-A clearance, F-ara-A exposure and F-ara-A--related toxicities were examined. The results demonstrate that total F-ara-A clearance correlated with CLcr and that F-ara-A exposure levels and patient toxicity profiles were similar across treatment groups. The CLcr-based fludarabine dose adjustments used in this study provided reasonably equivalent F-ara-A exposure with acceptable safety in patients with varying degrees of renal function.",Comparative Study,6594.0,42.0,A significant number of chronic lymphocytic follicular 's and Waldenstrm 's macroglobulinemia patients treated with fludarabine phosphate fludarabine are elderly with diminished function Since the eliminates approximately 60 of fludarabine 's primary metabolite F-ara-A dose modification is necessary for all patients with impaired function including elderly patients In this study 22 patients with varying levels of function received a single intravenous dose of fludarabine 25 mg/m3 followed one week later by five one per day doses that were adjusted according to three predefined creatinine clearance CLcr levels Relationships between function and F-ara-A clearance F-ara-A exposure and F-ara-A -- related toxicities were examined The results demonstrate that total F-ara-A clearance correlated with CLcr and that F-ara-A exposure levels and patient toxicity profiles were similar across treatment groups The CLcr-based fludarabine dose adjustments used in this study provided reasonably equivalent F-ara-A exposure with acceptable safety in patients with varying degrees of function,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 93, 207, 1, 442, 1193, 1974, 292, 2, 3700, 292, 3389, 7, 73, 5, 2027, 4849, 2027, 32, 1216, 5, 2849, 343, 1192, 3, 10794, 705, 335, 1, 2027, 292, 86, 3379, 1068, 3899, 8, 61, 2437, 16, 1493, 9, 62, 7, 5, 2364, 343, 141, 1216, 7, 4, 26, 45, 350, 7, 5, 2990, 148, 1, 343, 103, 8, 226, 1262, 61, 1, 2027, 243, 81, 9852, 370, 104, 647, 1559, 20, 365, 104, 379, 218, 415, 17, 11, 586, 768, 6, 169, 5944, 3177, 1960, 22018, 148, 2467, 59, 343, 2, 1068, 3899, 8, 1960, 1068, 3899, 8, 645, 2, 1068, 3899, 8, 139, 385, 11, 409, 3, 99, 608, 17, 181, 1068, 3899, 8, 1960, 438, 5, 22018, 2, 17, 1068, 3899, 8, 645, 148, 2, 69, 155, 1241, 11, 288, 716, 24, 271, 3, 22018, 90, 2027, 61, 6017, 95, 4, 26, 45, 1052, 6922, 2017, 1068, 3899, 8, 645, 5, 1595, 367, 4, 7, 5, 2990, 4133, 1, 343]",1088.0,12449721,366
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.,Cancer,Cancer,2003-01-01,"One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL). Twenty-nine patients with refractory or recurrent CLL or PLL received cladribine 4 mg/m(2)/day and cyclophosphamide 350 mg/m(2)/day (both administered intravenously) for 3 days every 4 weeks. Eleven patients (38%), nine with CLL and two with PLL, had a response. The median duration of response was 12 months. Severe extrahematologic toxicity (National Cancer Institute Grade 3-4) occurred in two patients, consisting of skin rash in one patient and progressive multifocal leukoencephalopathy in the other. The most common form of hematologic toxicity was severe neutropenia, which developed after 25% of the 84 courses was administered. Severe thrombocytopenia and anemia developed after 12% and 7% of the courses, respectively, and five episodes of anemia were immunomediated. In addition, three major infections resulted in the death of one patient. Although inferior to the combination fludarabine plus cyclophosphamide, this regimen showed interesting activity in patients with advanced CLL or PLL. Myelosuppression was the major dose-limiting toxic effect.",Clinical Trial,6229.0,69.0,One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation alkylating agents or other drugs To determine its antitumor activity in combination with cyclophosphamide we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic CLL or prolymphocytic PLL Twenty-nine patients with refractory or recurrent CLL or PLL received cladribine 4 mg/m 2 /day and cyclophosphamide 350 mg/m 2 /day both administered intravenously for 3 days every 4 weeks Eleven patients 38 nine with CLL and two with PLL had a response The median duration of response was 12 months Severe extrahematologic toxicity National Cancer Institute Grade 3-4 occurred in two patients consisting of rash in one patient and progressive multifocal leukoencephalopathy in the other The most common form of hematologic toxicity was severe neutropenia which developed after 25 of the 84 courses was administered Severe thrombocytopenia and anemia developed after 12 and 7 of the courses respectively and five episodes of anemia were immunomediated In addition three major infections resulted in the death of one patient Although inferior to the combination fludarabine plus cyclophosphamide this regimen showed interesting activity in patients with advanced CLL or PLL Myelosuppression was the major dose-limiting toxic effect,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[104, 1, 3, 483, 1, 1578, 1, 8251, 16, 3, 297, 1, 261, 972, 1, 1350, 1546, 20, 121, 3410, 183, 15, 127, 600, 6, 223, 211, 579, 128, 4, 150, 5, 1112, 21, 1917, 8, 124, 215, 160, 1, 3, 100, 183, 4, 7, 5, 131, 442, 1193, 552, 15, 14779, 10555, 737, 762, 7, 5, 430, 15, 387, 552, 15, 10555, 103, 8251, 39, 81, 188, 18, 218, 2, 1112, 5408, 81, 188, 18, 218, 110, 468, 1672, 9, 27, 162, 454, 39, 244, 2627, 7, 519, 762, 5, 552, 2, 100, 5, 10555, 42, 8, 51, 3, 52, 654, 1, 51, 10, 133, 53, 905, 43126, 155, 657, 12, 1377, 88, 27, 39, 489, 4, 100, 7, 2273, 1, 1641, 4, 104, 69, 2, 1014, 3492, 8744, 4, 3, 127, 3, 96, 186, 1297, 1, 813, 155, 10, 905, 778, 92, 276, 50, 243, 1, 3, 874, 1993, 10, 468, 905, 1340, 2, 1545, 276, 50, 133, 2, 67, 1, 3, 1993, 106, 2, 365, 3750, 1, 1545, 11, 53309, 4, 352, 169, 458, 1875, 627, 4, 3, 273, 1, 104, 69, 242, 1663, 6, 3, 150, 2027, 349, 1112, 26, 477, 224, 6597, 128, 4, 7, 5, 131, 552, 15, 10555, 2858, 10, 3, 458, 61, 817, 1812, 254]",1364.0,12491512,461
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.,Cancer research,Cancer Res.,2003-01-01,"Select cytogenetic abnormalities such as del(17)(p13.1) and del(11)(q22-q23)predict rapid disease progression and inferior survival in chronic lymphocytic leukemia (CLL). We sought to determine the impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to response to three-times-a-week rituximab therapy. Abnormalities were noted in 25 of the 28 patients to include del(13)(q14.3) [n = 16 (57%)], del(11)(q22.3) [n = 10 (36%)], +12 [n = 6 (21%)], del(17)(p13.1) [n = 5 (18%)], and normal [n = 3 (11%)]. Only a minority of each of these occurred as sole abnormalities. To categorize patients into one specific group, we used the hierarchical order del(17)(p13.1) > del(11)(q22.3) > trisomy 12 > del(13)(q14.3) to prioritize. Response to rituximab was noted to vary by cytogenetic group: del(17)(p13.1), 0% [n = 5]; del(11)(q22.3), 66% [n = 9]; del(13)(q14.3), 86% [n = 7]; +12, 25% [n = 4], and normal, 0% [n = 3]. Response was significantly lower (P = 0.05) in patients with del(17)(p13.1) as compared with those with other abnormalities. These data suggest that interphase cytogenetics in CLL may be predictive of a response to rituximab therapy and provide support for additional studies validating risk-adapted therapy in this disease.",Journal Article,6229.0,82.0,Select cytogenetic abnormalities such as del 17 p13.1 and del 11 q22-q23 predict rapid disease progression and inferior survival in chronic lymphocytic CLL We sought to determine the impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to response to three-times-a-week rituximab therapy Abnormalities were noted in 25 of the 28 patients to include del 13 q14.3 n 16 57 del 11 q22.3 n 10 36 +12 n 6 21 del 17 p13.1 n 5 18 and normal n 3 11 Only a minority of each of these occurred as sole abnormalities To categorize patients into one specific group we used the hierarchical order del 17 p13.1 del 11 q22.3 trisomy 12 del 13 q14.3 to prioritize Response to rituximab was noted to vary by cytogenetic group del 17 p13.1 0 n 5 del 11 q22.3 66 n 9 del 13 q14.3 86 n 7 +12 25 n 4 and normal 0 n 3 Response was significantly lower P 0.05 in patients with del 17 p13.1 as compared with those with other abnormalities These data suggest that interphase cytogenetics in CLL may be predictive of a response to rituximab therapy and provide support for additional studies validating risk-adapted therapy in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1717, 1266, 1171, 225, 22, 3084, 269, 7914, 14, 2, 3084, 175, 8026, 11423, 678, 1321, 34, 91, 2, 1663, 25, 4, 442, 1193, 552, 21, 990, 6, 223, 3, 345, 1, 3, 294, 96, 186, 8081, 1266, 1171, 4, 339, 552, 7, 580, 6, 51, 6, 169, 1072, 8, 647, 855, 36, 1171, 11, 1051, 4, 243, 1, 3, 339, 7, 6, 643, 3084, 233, 18847, 27, 78, 245, 696, 3084, 175, 8026, 27, 78, 79, 511, 133, 78, 49, 239, 3084, 269, 7914, 14, 78, 33, 203, 2, 295, 78, 27, 175, 158, 8, 2652, 1, 296, 1, 46, 489, 22, 4991, 1171, 6, 10440, 7, 237, 104, 112, 87, 21, 95, 3, 4466, 1732, 3084, 269, 7914, 14, 3084, 175, 8026, 27, 6317, 133, 3084, 233, 18847, 27, 6, 7716, 51, 6, 855, 10, 1051, 6, 2825, 20, 1266, 87, 3084, 269, 7914, 14, 13, 78, 33, 3084, 175, 8026, 27, 700, 78, 83, 3084, 233, 18847, 27, 868, 78, 67, 133, 243, 78, 39, 2, 295, 13, 78, 27, 51, 10, 97, 280, 19, 13, 474, 4, 7, 5, 3084, 269, 7914, 14, 22, 72, 5, 135, 5, 127, 1171, 46, 74, 309, 17, 8081, 2510, 4, 552, 68, 40, 464, 1, 8, 51, 6, 855, 36, 2, 377, 538, 9, 402, 94, 6897, 43, 3716, 36, 4, 26, 34]",1153.0,12517774,141
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.,Blood,Blood,2003-01-09,"We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11+ months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.",Clinical Trial,6221.0,226.0,We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies Forty-eight patients were treated and were assessable for response 32 with chronic lymphocytic CLL 9 with CLL/prolymphocytic PLL 1 with PLL 4 with mantle cell leukemia/lymphoma 2 with Richter transformation The overall response rate was 52 complete remission 8 nodular partial response 4 partial response 40 With a median follow-up of 6.5 months range 1-20 months the median time to progression was 6 months range 1-20 months median survival 11 months 11+ months for responders vs 6 months for nonresponders Most toxicities were grade 2 or lower and infusion-related Infections occurred in 52 of the patients Cytomegalovirus CMV antigenemia assays were positive in 27 of the patients but only 15 were symptomatic and required therapy The combination of rituximab and alemtuzumab is feasible has an acceptable safety profile and has clinical activity with a short course in a group of patients with poor prognoses,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 1443, 3, 367, 2, 209, 1, 855, 349, 3579, 4, 7, 5, 591, 15, 430, 2303, 441, 1213, 659, 7, 11, 73, 2, 11, 3120, 9, 51, 531, 5, 442, 1193, 552, 83, 5, 552, 14779, 10555, 14, 5, 10555, 39, 5, 2757, 31, 2647, 4763, 18, 5, 8452, 1392, 3, 63, 51, 116, 10, 653, 236, 734, 66, 4481, 450, 51, 39, 450, 51, 327, 5, 8, 52, 166, 126, 1, 49, 33, 53, 184, 14, 179, 53, 3, 52, 98, 6, 91, 10, 49, 53, 184, 14, 179, 53, 52, 25, 175, 53, 175, 53, 9, 1983, 105, 49, 53, 9, 4498, 96, 385, 11, 88, 18, 15, 280, 2, 904, 139, 1875, 489, 4, 653, 1, 3, 7, 7314, 3879, 21106, 1013, 11, 109, 4, 428, 1, 3, 7, 84, 158, 167, 11, 1704, 2, 616, 36, 3, 150, 1, 855, 2, 3579, 16, 1313, 71, 35, 1595, 367, 800, 2, 71, 38, 128, 5, 8, 978, 906, 4, 8, 87, 1, 7, 5, 334, 5362]",1040.0,12522009,140
Monoclonal antibody therapy for cancer.,Annual review of medicine,Annu. Rev. Med.,2001-12-03,"Monoclonal antibody therapy has emerged as an important therapeutic modality for cancer. Unconjugated antibodies show significant efficacy in the treatment of breast cancer, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. Promising new targets for unconjugated antibody therapy include cellular growth factor receptors, receptors or mediators of tumor-driven angiogenesis, and B cell surface antigens other than CD20. Immunoconjugates composed of antibodies conjugated to radionuclides or toxins show efficacy in non-Hodgkin's lymphoma. One immunoconjugate containing an antibody and a chemotherapy agent exhibits clinically meaningful antitumor activity in acute myeloid leukemia. Numerous efforts to exploit the ability of antibodies to focus the activities of toxic payloads at tumor sites are under way and show early promise. The ability to create essentially human antibody structures has reduced the likelihood of host-protective immune responses that otherwise limit the duration of therapy. Antibody structures now can be readily manipulated to facilitate selective interaction with host immune effectors. Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors.",Journal Article,6623.0,168.0,Monoclonal antibody therapy has emerged as an important therapeutic modality for cancer Unconjugated antibodies show significant efficacy in the treatment of cancer 's and chronic lymphocytic Promising new targets for unconjugated antibody therapy include cellular growth factor receptors receptors or mediators of tumor-driven angiogenesis and B cell surface antigens other than CD20 Immunoconjugates composed of antibodies conjugated to radionuclides or toxins show efficacy in 's One immunoconjugate containing an antibody and a chemotherapy agent exhibits clinically meaningful antitumor activity in acute myeloid Numerous efforts to exploit the ability of antibodies to focus the activities of toxic payloads at tumor sites are under way and show early promise The ability to create essentially human antibody structures has reduced the likelihood of host-protective immune responses that otherwise limit the duration of therapy Antibody structures now can be readily manipulated to facilitate selective interaction with host immune effectors Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments particularly for solid tumors,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 548, 36, 71, 2054, 22, 35, 305, 189, 1396, 9, 12, 11116, 890, 514, 93, 209, 4, 3, 24, 1, 12, 292, 2, 442, 1193, 721, 217, 637, 9, 11116, 548, 36, 643, 763, 129, 161, 1186, 1186, 15, 4425, 1, 30, 1621, 1056, 2, 132, 31, 1255, 1575, 127, 76, 2198, 15109, 3317, 1, 890, 3868, 6, 14396, 15, 13820, 514, 209, 4, 292, 104, 13498, 1101, 35, 548, 2, 8, 56, 420, 4273, 505, 2538, 579, 128, 4, 286, 533, 2331, 1413, 6, 6109, 3, 801, 1, 890, 6, 1222, 3, 2042, 1, 1812, 17704, 28, 30, 633, 32, 669, 2255, 2, 514, 191, 1783, 3, 801, 6, 3736, 7257, 171, 548, 2414, 71, 405, 3, 1420, 1, 1204, 2864, 250, 253, 17, 2632, 2385, 3, 654, 1, 36, 548, 2414, 1134, 122, 40, 3860, 13222, 6, 1876, 1094, 915, 5, 1204, 250, 4926, 127, 3281, 13775, 17, 401, 3, 1094, 529, 1571, 2, 1321, 403, 1960, 1, 15109, 257, 1122, 6, 3, 771, 1, 323, 217, 640, 823, 9, 537, 57]",1259.0,12525678,70
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.,Nature medicine,Nat. Med.,2003-02-10,"The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy.",Journal Article,6189.0,403.0,The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes However recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 IL-15 T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency SCID -Beige mice and eradicate disseminated intramedullary tumors Their anti-tumor activity is further enhanced by in vivo co-stimulation In addition transduced T cells from patients with chronic lymphocytic CLL effectively lyse autologous tumor cells These findings strongly support the clinical feasibility of this therapeutic strategy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 336, 2602, 1, 448, 1186, 777, 8, 2263, 6, 1755, 2562, 1028, 30, 2163, 102, 1594, 137, 2335, 1, 30, 1575, 20, 759, 102, 37, 16, 158, 104, 2458, 3113, 323, 12, 726, 127, 2653, 1037, 33371, 1642, 40, 9091, 6, 4082, 30, 2163, 102, 37, 17, 6630, 8, 583, 1005, 141, 4, 386, 6957, 128, 2, 3, 801, 6, 6793, 6, 30, 633, 187, 9771, 28013, 6, 351, 21, 514, 17, 46, 4230, 32, 543, 20, 4304, 672, 315, 102, 37, 2301, 238, 6, 3, 3158, 448, 4, 3, 463, 1, 9850, 2, 1603, 167, 501, 167, 102, 37, 2064, 4, 3, 463, 1, 501, 167, 7089, 5589, 4, 30, 1894, 905, 397, 5323, 4129, 16620, 399, 2, 5650, 3605, 8686, 57, 136, 312, 30, 128, 16, 195, 651, 20, 4, 386, 1269, 2503, 4, 352, 5042, 102, 37, 29, 7, 5, 442, 1193, 552, 1856, 11436, 1028, 30, 37, 46, 272, 1327, 538, 3, 38, 1437, 1, 26, 189, 692]",1095.0,12579196,585
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.,Blood,Blood,2003-02-13,"In chronic lymphocytic leukemia (CLL), analysis of immunoglobulin heavy chain variable regions for somatic hypermutation identifies 2 prognostic subsets, mutated and unmutated. Investigators have postulated that unmutated and mutated CLL arises from malignant transformation of pre- and post-germinal center (GC) B cells, respectively. Alternatively, unmutated cases may arise from B cells stimulated by T-cell-independent antigens or from GC B cells with inactive somatic hypermutation. Activation-induced cytidine deaminase (AID), a protein essential for somatic hypermutation, is expressed by GC B cells in which this process occurs. We investigated AID mRNA expression in 20 CLL cases. In 8 cases we detected high expression of wild-type AID mRNA and 2 splice variants; in 12 cases and 5 normal peripheral blood B-cell samples we detected no expression using standard conditions. Of 8 CLL cases that highly expressed AID, 7 were unmutated, suggesting that this subset may arise from GC-experienced B cells with inactive somatic hypermutation, and may predict prognosis.",Journal Article,6186.0,115.0,In chronic lymphocytic CLL analysis of immunoglobulin heavy chain variable regions for somatic hypermutation identifies 2 prognostic subsets mutated and unmutated Investigators have postulated that unmutated and mutated CLL arises from malignant transformation of pre- and post-germinal center GC B cells respectively Alternatively unmutated cases may arise from B cells stimulated by T-cell-independent antigens or from GC B cells with inactive somatic hypermutation Activation-induced cytidine deaminase AID a protein essential for somatic hypermutation is expressed by GC B cells in which this process occurs We investigated AID mRNA expression in 20 CLL cases In 8 cases we detected high expression of wild-type AID mRNA and 2 splice variants in 12 cases and 5 normal peripheral blood B-cell samples we detected no expression using standard conditions Of 8 CLL cases that highly expressed AID 7 were unmutated suggesting that this subset may arise from GC-experienced B cells with inactive somatic hypermutation and may predict prognosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 65, 1, 2593, 4013, 1260, 1347, 1374, 9, 1119, 13521, 2953, 18, 177, 1890, 1185, 2, 7216, 2394, 47, 6507, 17, 7216, 2, 1185, 552, 6053, 29, 393, 1392, 1, 671, 2, 539, 6312, 574, 1709, 132, 37, 106, 7133, 7216, 140, 68, 3043, 29, 132, 37, 2816, 20, 102, 31, 306, 1575, 15, 29, 1709, 132, 37, 5, 5002, 1119, 13521, 363, 277, 12783, 10197, 2427, 8, 178, 1452, 9, 1119, 13521, 16, 570, 20, 1709, 132, 37, 4, 92, 26, 1129, 1780, 21, 565, 2427, 956, 55, 4, 179, 552, 140, 4, 66, 140, 21, 530, 64, 55, 1, 955, 267, 2427, 956, 2, 18, 4371, 839, 4, 133, 140, 2, 33, 295, 672, 315, 132, 31, 347, 21, 530, 77, 55, 75, 260, 1298, 1, 66, 552, 140, 17, 561, 570, 2427, 67, 11, 7216, 802, 17, 26, 697, 68, 3043, 29, 1709, 592, 132, 37, 5, 5002, 1119, 13521, 2, 68, 678, 356]",1041.0,12586616,441
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.,Blood,Blood,2003-02-20,"Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new therapies for this disease. KRN5500 is a novel agent that has a unique sensitivity pattern in the National Cancer Institute cell line screening panel, suggesting a unique mechanism of action. To assess its in vitro activity in CLL, we exposed peripheral mononuclear cells from CLL patients (n = 11) to varying concentrations of this agent. Viability of the CLL cells was reduced by 50% (LC50) at 4 hours, 24 hours, and 4 days at KRN5500 concentrations of 2.50 microM, 0.276 microM, and 0.139 microM, respectively. KRN5500 induced cellular injury via caspase-dependent apoptosis involving the intrinsic mitochondrial (caspase-9) initiating caspase and caspase-3 effector caspase; however, expression of the antiapoptotic mitochondrial membrane protein Bcl-2 was unaffected. These data demonstrate KRN5500 has significant in vitro activity against human CLL cells, thus providing support for introduction of this agent into clinical trials for patients with CLL.",Journal Article,6179.0,18.0,Therapy of B-cell chronic lymphocytic CLL is currently palliative emphasizing the need for identification of new therapies for this disease KRN5500 is a novel agent that has a unique sensitivity pattern in the National Cancer Institute cell line screening panel suggesting a unique mechanism of action To assess its in vitro activity in CLL we exposed peripheral mononuclear cells from CLL patients n 11 to varying concentrations of this agent Viability of the CLL cells was reduced by 50 LC50 at 4 hours 24 hours and 4 days at KRN5500 concentrations of 2.50 microM 0.276 microM and 0.139 microM respectively KRN5500 induced cellular injury via caspase-dependent apoptosis involving the intrinsic mitochondrial caspase-9 initiating caspase and caspase-3 effector caspase however expression of the antiapoptotic mitochondrial membrane protein Bcl-2 was unaffected These data demonstrate KRN5500 has significant in vitro activity against human CLL cells thus providing support for introduction of this agent into clinical trials for patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[36, 1, 132, 31, 442, 1193, 552, 16, 694, 994, 6826, 3, 594, 9, 911, 1, 217, 235, 9, 26, 34, 20266, 16, 8, 229, 420, 17, 71, 8, 991, 485, 1177, 4, 3, 657, 12, 1377, 31, 328, 453, 993, 802, 8, 991, 670, 1, 1578, 6, 423, 211, 4, 439, 128, 4, 552, 21, 2234, 672, 3041, 37, 29, 552, 7, 78, 175, 6, 2990, 1003, 1, 26, 420, 2120, 1, 3, 552, 37, 10, 405, 20, 212, 33378, 28, 39, 1459, 259, 1459, 2, 39, 162, 28, 20266, 1003, 1, 18, 212, 3550, 13, 7976, 3550, 2, 13, 4929, 3550, 106, 20266, 277, 763, 2730, 847, 1469, 470, 351, 1267, 3, 2354, 2019, 1469, 83, 2637, 1469, 2, 1469, 27, 2070, 1469, 137, 55, 1, 3, 4176, 2019, 1905, 178, 1044, 18, 10, 4585, 46, 74, 608, 20266, 71, 93, 4, 439, 128, 480, 171, 552, 37, 631, 1736, 538, 9, 2456, 1, 26, 420, 237, 38, 143, 9, 7, 5, 552]",1048.0,12595316,99
"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.",Cancer,Cancer,2003-03-01,"Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Patients with high-risk acute myeloid leukemia (AML) (n = 12 patients); chronic myelomonocytic leukemia (CMML) (n = 1 patient); acute lymphocytic leukemia (ALL) (n = 1 patient); or late chronic phase, accelerated, or blastic phase chronic myelogenous leukemia (n = 9 patients) were eligible for the study. The treatment plan was comprised of busulfan, 12 mg/kg orally; cyclophosphamide, 100 mg/kg (n = 4 patients) or 120 mg/kg (n = 19 patients); and decitabine, intravenously at 3 dose levels: 400 mg/m(2) (n = 10 patients), 600 mg/m(2) (n = 8 patients), and 800 mg/m(2) (n = 5 patients). Donors were human leukocyte antigen-identical siblings in all cases, and all but one patient received peripheral blood stem cells. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus based in all but one patient. The median time to neutrophil and platelet engraftment was 12.5 days and 17.5 days, respectively. Twenty-one patients were engrafted and achieved disease remission. At a median of 3.3 years posttransplantation, 26% of patients (40% of patients with AML) were alive and disease free. The median survival for the group was 17.2 months, and the disease free survival for the group was 8.9 months. Causes of death were disease recurrence (nine patients), chronic GVHD (four patients), infections (three patients), and acute GVHD (one patient). The 100-day mortality rate was 9%. No decitabine dose-limiting toxicity was documented. The treatment-related mortality rate at 3 years was 35%. Responders were treated at all three decitabine dose levels, and no dose-response correlation was observed. There was a high response rate with low treatment-related mortality, with 26% of patients alive in remission 3.3 years after transplantation.",Clinical Trial,6170.0,35.0,Decitabine is a hypomethylating agent that has activity in patients with The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation Patients with high-risk acute myeloid AML n 12 patients chronic myelomonocytic CMML n 1 patient acute lymphocytic ALL n 1 patient or late chronic phase accelerated or blastic phase chronic myelogenous n 9 patients were eligible for the study The treatment plan was comprised of busulfan 12 mg/kg orally cyclophosphamide 100 mg/kg n 4 patients or 120 mg/kg n 19 patients and decitabine intravenously at 3 dose levels 400 mg/m 2 n 10 patients 600 mg/m 2 n 8 patients and 800 mg/m 2 n 5 patients Donors were human leukocyte antigen-identical siblings in all cases and all but one patient received peripheral blood stem cells Graft-versus-host disease GVHD prophylaxis was tacrolimus based in all but one patient The median time to neutrophil and platelet engraftment was 12.5 days and 17.5 days respectively Twenty-one patients were engrafted and achieved disease remission At a median of 3.3 years posttransplantation 26 of patients 40 of patients with AML were alive and disease free The median survival for the group was 17.2 months and the disease free survival for the group was 8.9 months Causes of death were disease recurrence nine patients chronic GVHD four patients infections three patients and acute GVHD one patient The 100-day mortality rate was 9 No decitabine dose-limiting toxicity was documented The treatment-related mortality rate at 3 years was 35 Responders were treated at all three decitabine dose levels and no dose-response correlation was observed There was a high response rate with low treatment-related mortality with 26 of patients alive in remission 3.3 years after transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3004, 16, 8, 4931, 420, 17, 71, 128, 4, 7, 5, 3, 738, 397, 3004, 5, 3906, 2, 1112, 22, 8, 1933, 477, 324, 6, 1063, 1007, 452, 31, 497, 7, 5, 64, 43, 286, 533, 329, 78, 133, 7, 442, 5451, 3382, 78, 14, 69, 286, 1193, 62, 78, 14, 69, 15, 807, 442, 124, 2241, 15, 6529, 124, 442, 2194, 78, 83, 7, 11, 625, 9, 3, 45, 3, 24, 2242, 10, 2603, 1, 3906, 133, 81, 503, 1428, 1112, 394, 81, 503, 78, 39, 7, 15, 2031, 81, 503, 78, 326, 7, 2, 3004, 1672, 28, 27, 61, 148, 1524, 81, 188, 18, 78, 79, 7, 2383, 81, 188, 18, 78, 66, 7, 2, 2796, 81, 188, 18, 78, 33, 7, 2344, 11, 171, 3627, 448, 3038, 2758, 4, 62, 140, 2, 62, 84, 104, 69, 103, 672, 315, 452, 37, 1599, 185, 1204, 34, 1562, 2049, 10, 5643, 90, 4, 62, 84, 104, 69, 3, 52, 98, 6, 2595, 2, 1596, 2881, 10, 133, 33, 162, 2, 269, 33, 162, 106, 737, 104, 7, 11, 6914, 2, 513, 34, 734, 28, 8, 52, 1, 27, 27, 60, 8046, 432, 1, 7, 327, 1, 7, 5, 329, 11, 1701, 2, 34, 115, 3, 52, 25, 9, 3, 87, 10, 269, 18, 53, 2, 3, 34, 115, 25, 9, 3, 87, 10, 66, 83, 53, 1626, 1, 273, 11, 34, 146, 762, 7, 442, 1562, 294, 7, 1875, 169, 7, 2, 286, 1562, 104, 69, 3, 394, 218, 282, 116, 10, 83, 77, 3004, 61, 817, 155, 10, 1405, 3, 24, 139, 282, 116, 28, 27, 60, 10, 465, 1983, 11, 73, 28, 62, 169, 3004, 61, 148, 2, 77, 61, 51, 816, 10, 164, 125, 10, 8, 64, 51, 116, 5, 154, 24, 139, 282, 5, 432, 1, 7, 1701, 4, 734, 27, 27, 60, 50, 497]",1836.0,12599231,344
Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2003-02-01,"Despite many therapeutic options for chronic lymphocytic leukemia (CLL), the disease remains incurable. Since monoclonal antibodies and recombinant toxins that bind surface antigens expressed on the malignant lymphocytes have been developed, targeted therapy has become a vital option in treating CLL. Rituximab (Rituxan), a chimeric human-mouse anti-CD20 antibody, and alemtuzumab (Campath), a humanized anti-CD52 monoclonal antibody, have both shown activity in CLL--as single agents and in combination with conventional chemotherapy. The possibility of combining antibodies has been explored as well, with some efficacy. In this review, we discuss the clinical data on the activity of commercially available antibodies in CLL, both as monotherapy and in combination with other agents.",Journal Article,6198.0,13.0,Despite many therapeutic options for chronic lymphocytic CLL the disease remains incurable Since monoclonal antibodies and recombinant toxins that bind surface antigens expressed on the malignant lymphocytes have been developed targeted therapy has become a vital option in treating CLL Rituximab Rituxan a chimeric human-mouse anti-CD20 antibody and alemtuzumab Campath a humanized anti-CD52 monoclonal antibody have both shown activity in CLL -- as single agents and in combination with conventional chemotherapy The possibility of combining antibodies has been explored as well with some efficacy In this review we discuss the clinical data on the activity of commercially available antibodies in CLL both as monotherapy and in combination with other agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 445, 189, 838, 9, 442, 1193, 552, 3, 34, 469, 2641, 1192, 848, 890, 2, 2835, 13820, 17, 4060, 1255, 1575, 570, 23, 3, 393, 1594, 47, 85, 276, 238, 36, 71, 1417, 8, 3511, 1501, 4, 1367, 552, 855, 25976, 8, 2897, 171, 830, 312, 2198, 548, 2, 3579, 16622, 8, 3619, 312, 7189, 848, 548, 47, 110, 443, 128, 4, 552, 22, 226, 183, 2, 4, 150, 5, 809, 56, 3, 2526, 1, 1525, 890, 71, 85, 1443, 22, 149, 5, 476, 209, 4, 26, 206, 21, 1139, 3, 38, 74, 23, 3, 128, 1, 5262, 390, 890, 4, 552, 110, 22, 1411, 2, 4, 150, 5, 127, 183]",760.0,12632866,515
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.,Blood,Blood,2003-03-20,"Depsipeptide is in clinical trials for chronic lymphocytic leukemia (CLL) on the basis of earlier observations demonstrating selective in vitro activity in CLL. We sought to determine the relationship of histone H3 and H4 acetylation, inhibition of histone deacetylase, and apoptosis observed in CLL cells to justify a pharmacodynamic end point in these clinical trials. We demonstrate that in vitro depsipeptide induces histone H3 and H4 acetylation and histone deacetylase enzyme inhibition at concentrations corresponding to the LC50 (concentration producing 50% cell death) for cultured CLL cells (0.038 microM depsipeptide). The changes in histone acetylation are lysine specific, involving H4 K5, H4 K12, and H3 K9, and to a lesser extent H4 K8, but not H4 K16 or H3 K14. Depsipeptide-induced apoptosis is caspase dependent, selectively involving the tumor necrosis factor (TNF) receptor (extrinsic pathway) initiating caspase 8 and effector caspase 3. Activation of caspase 8 was accompanied by the down-regulation of cellular FLICE-inhibitory protein (c-FLIP, I-FLICE) without evidence of Fas (CD95) up-regulation. Changes in other apoptotic proteins, including Bcl-2, Bax, Mcl-1, and X-linked inhibitor of apoptosis (XIAP), were not observed. Our results demonstrate a relationship between target enzyme inhibition of histone deacetylase, histone H3 and H4 acetylation, and apoptosis involving the TNF-receptor pathway of apoptosis that is not used by other therapeutic agents in CLL. These data suggest use of histone H3 and H4 acetylation, inhibition of histone deacetylase, and down-regulation of FLIP as pharmacodynamic end points for further evaluation of this drug in patients.",Journal Article,6151.0,147.0,Depsipeptide is in clinical trials for chronic lymphocytic CLL on the basis of earlier observations demonstrating selective in vitro activity in CLL We sought to determine the relationship of histone H3 and H4 acetylation inhibition of histone deacetylase and apoptosis observed in CLL cells to justify a pharmacodynamic end point in these clinical trials We demonstrate that in vitro depsipeptide induces histone H3 and H4 acetylation and histone deacetylase enzyme inhibition at concentrations corresponding to the LC50 concentration producing 50 cell death for cultured CLL cells 0.038 microM depsipeptide The changes in histone acetylation are lysine specific involving H4 K5 H4 K12 and H3 K9 and to a lesser extent H4 K8 but not H4 K16 or H3 K14 Depsipeptide-induced apoptosis is caspase dependent selectively involving the tumor necrosis factor TNF receptor extrinsic pathway initiating caspase 8 and effector caspase 3 Activation of caspase 8 was accompanied by the down-regulation of cellular FLICE-inhibitory protein c-FLIP I-FLICE without evidence of Fas CD95 up-regulation Changes in other apoptotic proteins including Bcl-2 Bax Mcl-1 and X-linked inhibitor of apoptosis XIAP were not observed Our results demonstrate a relationship between target enzyme inhibition of histone deacetylase histone H3 and H4 acetylation and apoptosis involving the TNF-receptor pathway of apoptosis that is not used by other therapeutic agents in CLL These data suggest use of histone H3 and H4 acetylation inhibition of histone deacetylase and down-regulation of FLIP as pharmacodynamic end points for further evaluation of this drug in patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[10072, 16, 4, 38, 143, 9, 442, 1193, 552, 23, 3, 877, 1, 1677, 2172, 2219, 1094, 4, 439, 128, 4, 552, 21, 990, 6, 223, 3, 858, 1, 1508, 3739, 2, 7812, 4145, 297, 1, 1508, 2732, 2, 351, 164, 4, 552, 37, 6, 6665, 8, 2424, 396, 741, 4, 46, 38, 143, 21, 608, 17, 4, 439, 10072, 1516, 1508, 3739, 2, 7812, 4145, 2, 1508, 2732, 1644, 297, 28, 1003, 1734, 6, 3, 33378, 1227, 3787, 212, 31, 273, 9, 3197, 552, 37, 13, 5215, 3550, 10072, 3, 400, 4, 1508, 4145, 32, 6041, 112, 1267, 7812, 37417, 7812, 28030, 2, 3739, 37418, 2, 6, 8, 5191, 1039, 7812, 43199, 84, 44, 7812, 43200, 15, 3739, 18259, 10072, 277, 351, 16, 1469, 470, 2382, 1267, 3, 30, 1523, 161, 2254, 153, 6539, 308, 2637, 1469, 66, 2, 2070, 1469, 27, 363, 1, 1469, 66, 10, 2756, 20, 3, 1328, 863, 1, 763, 19431, 1810, 178, 256, 9334, 70, 19431, 187, 241, 1, 3625, 6550, 126, 863, 400, 4, 127, 1631, 652, 141, 1044, 18, 3119, 1308, 14, 2, 1006, 1199, 230, 1, 351, 5387, 11, 44, 164, 114, 99, 608, 8, 858, 59, 283, 1644, 297, 1, 1508, 2732, 1508, 3739, 2, 7812, 4145, 2, 351, 1267, 3, 2254, 153, 308, 1, 351, 17, 16, 44, 95, 20, 127, 189, 183, 4, 552, 46, 74, 309, 119, 1, 1508, 3739, 2, 7812, 4145, 297, 1, 1508, 2732, 2, 1328, 863, 1, 9334, 22, 2424, 396, 862, 9, 195, 451, 1, 26, 234, 4, 7]",1639.0,12649137,378
"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.",Cancer,Cancer,2003-04-01,"Therapy for patients with Richter syndrome (RS) or fludarabine-refractory chronic lymphocytic leukemia (CLL) is unsatisfactory. A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients. Fludarabine-refractory CLL was defined as failure to respond to most recent prior fludarabine-containing regimen. Patients received up to six cycles of fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone (hyper-CVXD) plus rituximab and GM-CSF alternating with methotrexate and cytarabine plus rituximab and GM-CSF. Response, toxicity, and survival data were compared with data from prior therapy with hyper-CVXD alone in this patient group. Forty-nine patients with RS (n = 30 patients) or refractory CLL (n = 19 patients) were treated on study. Nine patients (18%) achieved a complete remission, and 11 patients achieved a partial remission (22%), for an overall objective response (OR) rate of 41%. With a median follow-up of 7.5 months and a maximum follow-up of 15.2 months, the 12-month failure free survival (FFS) rate was 27%, and the overall survival (OS) rate was 39%. Nine patients (18%) died during the first cycle of therapy, and two patients (4%) died during the second cycle. There were no significant differences between the rates of OR, OS, and FFS in the current study and those obtained with hyper-CVXD alone on a prior study. The study regimen had activity and significant toxicity in patients with RS or fludarabine-refractory CLL. It was not clearly better compared with hyper-CVXD alone in this patient population.",Journal Article,6139.0,73.0,Therapy for patients with Richter syndrome RS or fludarabine-refractory chronic lymphocytic CLL is unsatisfactory A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor GM-CSF in these patients Fludarabine-refractory CLL was defined as failure to respond to most recent prior fludarabine-containing regimen Patients received up to six cycles of fractionated cyclophosphamide vincristine liposomal daunorubicin and dexamethasone hyper-CVXD plus rituximab and GM-CSF alternating with methotrexate and cytarabine plus rituximab and GM-CSF Response toxicity and survival data were compared with data from prior therapy with hyper-CVXD alone in this patient group Forty-nine patients with RS n 30 patients or refractory CLL n 19 patients were treated on study Nine patients 18 achieved a complete remission and 11 patients achieved a partial remission 22 for an overall objective response OR rate of 41 With a median follow-up of 7.5 months and a maximum follow-up of 15.2 months the 12-month failure free survival FFS rate was 27 and the overall survival OS rate was 39 Nine patients 18 died during the first cycle of therapy and two patients 4 died during the second cycle There were no significant differences between the rates of OR OS and FFS in the current study and those obtained with hyper-CVXD alone on a prior study The study regimen had activity and significant toxicity in patients with RS or fludarabine-refractory CLL It was not clearly better compared with hyper-CVXD alone in this patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[36, 9, 7, 5, 8452, 681, 2250, 15, 2027, 430, 442, 1193, 552, 16, 9573, 8, 124, 215, 45, 10, 426, 6, 376, 35, 5181, 150, 759, 477, 447, 5, 855, 2, 2764, 2674, 1975, 2122, 161, 2147, 1211, 4, 46, 7, 2027, 430, 552, 10, 395, 22, 496, 6, 1892, 6, 96, 435, 324, 2027, 1101, 477, 7, 103, 126, 6, 437, 410, 1, 3950, 1112, 2132, 3275, 5247, 2, 1217, 4855, 33398, 349, 855, 2, 2147, 1211, 5181, 5, 2116, 2, 1855, 349, 855, 2, 2147, 1211, 51, 155, 2, 25, 74, 11, 72, 5, 74, 29, 324, 36, 5, 4855, 33398, 279, 4, 26, 69, 87, 1213, 762, 7, 5, 2250, 78, 201, 7, 15, 430, 552, 78, 326, 7, 11, 73, 23, 45, 762, 7, 203, 513, 8, 236, 734, 2, 175, 7, 513, 8, 450, 734, 350, 9, 35, 63, 461, 51, 15, 116, 1, 605, 5, 8, 52, 166, 126, 1, 67, 33, 53, 2, 8, 689, 166, 126, 1, 167, 18, 53, 3, 133, 811, 496, 115, 25, 5058, 116, 10, 428, 2, 3, 63, 25, 118, 116, 10, 587, 762, 7, 203, 1016, 190, 3, 157, 417, 1, 36, 2, 100, 7, 39, 1016, 190, 3, 419, 417, 125, 11, 77, 93, 362, 59, 3, 151, 1, 15, 118, 2, 5058, 4, 3, 291, 45, 2, 135, 683, 5, 4855, 33398, 279, 23, 8, 324, 45, 3, 45, 477, 42, 128, 2, 93, 155, 4, 7, 5, 2250, 15, 2027, 430, 552, 192, 10, 44, 2536, 380, 72, 5, 4855, 33398, 279, 4, 26, 69, 266]",1618.0,12655528,587
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL). Previously, combinations of fludarabine and chlorambucil were abandoned because of increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs. We studied 23 patients with previously treated CLL. All patients received pentostatin 4 mg/m(2). Seventeen patients received cyclophosphamide 600 mg/m(2), and six patients received cyclophosphamide 900 mg/m(2). Both drugs were administered on day 1 of each cycle, and cycles were repeated every 3 weeks for six treatments. Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylactically. The median number of prior treatment regimens was three (range, one to five) with 13 patients (57%) refractory to prior fludarabine therapy. The cyclophosphamide 900 mg/m(2) dose level was associated with moderate to severe nausea, and we chose cyclophosphamide 600 mg/m(2) as the dose for further study. There were 17 responses (74%; 95% confidence interval, 63% to 85%), including four complete responses. The response rate was 77% in fludarabine-refractory patients. Myelosuppression was acceptable with grade 3/4 neutropenia and thrombocytopenia, seen in 35% and 30% of patients, respectively. The relative sparing of thrombopoiesis can be seen in that only one patient (5%) with an initial platelet count of more than 20,000 required platelet transfusions while receiving therapy. Pentostatin 4 mg/m(2) with cyclophosphamide 600 mg/m(2) is safe and effective in previously treated patients with CLL. On the basis of these results, we are currently studying pentostatin, cyclophosphamide, and rituximab (PCR) therapy in patients with CLL.",Journal Article,6139.0,90.0,"Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic CLL Previously combinations of fludarabine and chlorambucil were abandoned because of increased toxicity from overlapping myelosuppression and immunosuppression Of the purine analogs active in CLL pentostatin may be least myelosuppressive We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs We studied 23 patients with previously treated CLL All patients received pentostatin 4 mg/m 2 Seventeen patients received cyclophosphamide 600 mg/m 2 and six patients received cyclophosphamide 900 mg/m 2 Both drugs were administered on day 1 of each cycle and cycles were repeated every 3 weeks for six treatments Filgrastim sulfamethoxazole/trimethoprim and acyclovir were administered prophylactically The median number of prior treatment regimens was three range one to five with 13 patients 57 refractory to prior fludarabine therapy The cyclophosphamide 900 mg/m 2 dose level was associated with moderate to severe nausea and we chose cyclophosphamide 600 mg/m 2 as the dose for further study There were 17 responses 74 95 confidence interval 63 to 85 including four complete responses The response rate was 77 in fludarabine-refractory patients Myelosuppression was acceptable with grade 3/4 neutropenia and thrombocytopenia seen in 35 and 30 of patients respectively The relative sparing of thrombopoiesis can be seen in that only one patient 5 with an initial platelet count of more than 20,000 required platelet transfusions while receiving therapy Pentostatin 4 mg/m 2 with cyclophosphamide 600 mg/m 2 is safe and effective in previously treated patients with CLL On the basis of these results we are currently studying pentostatin cyclophosphamide and rituximab PCR therapy in patients with CLL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5006, 4063, 2, 12777, 32, 305, 183, 4, 3, 24, 1, 442, 1193, 552, 373, 1247, 1, 2027, 2, 11585, 11, 13015, 408, 1, 101, 155, 29, 4551, 2858, 2, 3646, 1, 3, 5006, 4063, 544, 4, 552, 7596, 68, 40, 506, 11109, 21, 1237, 17, 1525, 7596, 5, 1112, 688, 47, 299, 17118, 76, 1247, 75, 127, 5006, 4063, 21, 656, 382, 7, 5, 373, 73, 552, 62, 7, 103, 7596, 39, 81, 188, 18, 3591, 7, 103, 1112, 2383, 81, 188, 18, 2, 437, 7, 103, 1112, 5310, 81, 188, 18, 110, 600, 11, 468, 23, 218, 14, 1, 296, 417, 2, 410, 11, 2113, 454, 27, 244, 9, 437, 640, 5552, 23152, 23151, 2, 17606, 11, 468, 21051, 3, 52, 207, 1, 324, 24, 472, 10, 169, 184, 104, 6, 365, 5, 233, 7, 696, 430, 6, 324, 2027, 36, 3, 1112, 5310, 81, 188, 18, 61, 301, 10, 41, 5, 1163, 6, 905, 1218, 2, 21, 6177, 1112, 2383, 81, 188, 18, 22, 3, 61, 9, 195, 45, 125, 11, 269, 253, 794, 48, 307, 268, 676, 6, 772, 141, 294, 236, 253, 3, 51, 116, 10, 849, 4, 2027, 430, 7, 2858, 10, 1595, 5, 88, 27, 39, 778, 2, 1340, 527, 4, 465, 2, 201, 1, 7, 106, 3, 580, 1851, 1, 33399, 122, 40, 527, 4, 17, 158, 104, 69, 33, 5, 35, 388, 1596, 1276, 1, 80, 76, 179, 984, 616, 1596, 4987, 369, 357, 36, 7596, 39, 81, 188, 18, 5, 1112, 2383, 81, 188, 18, 16, 1165, 2, 323, 4, 373, 73, 7, 5, 552, 23, 3, 877, 1, 46, 99, 21, 32, 694, 4559, 7596, 1112, 2, 855, 604, 36, 4, 7, 5, 552]",1875.0,12663715,354
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.,"Medical oncology (Northwood, London, England)",Med. Oncol.,2003-01-01,"Fludarabine is an active agent in low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Paclitaxel is also active in patients with refractory lymphoma, and preclinical data suggest an additive effect with fludarabine in vitro. We performed a phase I trial of fludarabine (25 mg/m(2) d 1-3) plus a 3-h infusion of paclitaxel (125, 150, or 175 mg/m(2)) on d 3 every 28 d in 13 patients with non-Hodgkin's lymphoma. The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema. Dose-limiting toxicity was defined as febrile neutropenia, platelet nadir less than 50,000/microL, or grade 3-4 nonhematologic toxicity. Thirteen patients were accrued to the study, 8 of these 13 patients (62%) had received prior chemotherapy. At the 125-, 150-, and 175-mg/m(2) dose levels of paclitaxel, dose-limiting toxicity occurred in 1/4, 0/4, and 0/4 patients, respectively. The single patient with dose-limiting toxicity had febrile neutropenia. Partial response occurred in two of eight patients with low-grade lymphoma and none of five patients with other types of lymphoma. A paclitaxel dose of 175 mg/m(2) given as a 3-h infusion on d 3 in conjunction with fludarabine (25 mg/m(2) d 1-3 every 4 wk) is a well-tolerated regimen for non-Hodgkin's lymphoma. Further study will be required in order to determine whether the fludarabine paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia",Clinical Trial,6229.0,2.0,"Fludarabine is an active agent in low-grade 's and chronic lymphocytic Paclitaxel is also active in patients with refractory and preclinical data suggest an additive effect with fludarabine in vitro We performed a phase I trial of fludarabine 25 mg/m 2 d 1-3 plus a 3-h infusion of paclitaxel 125 150 or 175 mg/m 2 on d 3 every 28 d in 13 patients with 's The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema Dose-limiting toxicity was defined as febrile neutropenia platelet nadir less than 50,000/microL or grade 3-4 nonhematologic toxicity Thirteen patients were accrued to the study 8 of these 13 patients 62 had received prior chemotherapy At the 125- 150- and 175-mg/m 2 dose levels of paclitaxel dose-limiting toxicity occurred in 1/4 0/4 and 0/4 patients respectively The single patient with dose-limiting toxicity had febrile neutropenia Partial response occurred in two of eight patients with low-grade and none of five patients with other types of A paclitaxel dose of 175 mg/m 2 given as a 3-h infusion on d 3 in conjunction with fludarabine 25 mg/m 2 d 1-3 every 4 wk is a well-tolerated regimen for 's Further study will be required in order to determine whether the fludarabine paclitaxel is more active than fludarabine alone in patients with low-grade and chronic lymphocytic",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 16, 35, 544, 420, 4, 154, 88, 292, 2, 442, 1193, 490, 16, 120, 544, 4, 7, 5, 430, 2, 693, 74, 309, 35, 3396, 254, 5, 2027, 4, 439, 21, 173, 8, 124, 70, 160, 1, 2027, 243, 81, 188, 18, 427, 14, 27, 349, 8, 27, 555, 904, 1, 490, 1731, 1577, 15, 3300, 81, 188, 18, 23, 427, 27, 454, 339, 427, 4, 233, 7, 5, 292, 3, 490, 61, 10, 2842, 4, 736, 1, 27, 39, 7, 75, 260, 124, 70, 771, 8371, 61, 817, 155, 10, 395, 22, 2498, 778, 1596, 3686, 299, 76, 212, 984, 5128, 15, 88, 27, 39, 3534, 155, 3170, 7, 11, 3198, 6, 3, 45, 66, 1, 46, 233, 7, 744, 42, 103, 324, 56, 28, 3, 1731, 1577, 2, 3300, 81, 188, 18, 61, 148, 1, 490, 61, 817, 155, 489, 4, 14, 39, 13, 39, 2, 13, 39, 7, 106, 3, 226, 69, 5, 61, 817, 155, 42, 2498, 778, 450, 51, 489, 4, 100, 1, 659, 7, 5, 154, 88, 2, 1292, 1, 365, 7, 5, 127, 630, 1, 8, 490, 61, 1, 3300, 81, 188, 18, 447, 22, 8, 27, 555, 904, 23, 427, 27, 4, 3357, 5, 2027, 243, 81, 188, 18, 427, 14, 27, 454, 39, 3293, 16, 8, 149, 421, 477, 9, 292, 195, 45, 303, 40, 616, 4, 1732, 6, 223, 317, 3, 2027, 490, 16, 80, 544, 76, 2027, 279, 4, 7, 5, 154, 88, 2, 442, 1193]",1337.0,12665685,292
Acquired von Willebrand's syndrome: a single institution experience.,American journal of hematology,Am. J. Hematol.,2003-04-01,"Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecular-weight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04%. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder.",Journal Article,6139.0,50.0,Acquired von Willebrand 's disease or syndrome AVWS is a rare bleeding disorder distinguished from congenital von Willebrand 's disease by age at presentation and absence of personal and family history of bleeding disorders We report on 22 patients with AVWS seen over 25 years Mean age at diagnosis was 61.3 years range 38-86 years most patients had a spontaneous or a post-operative hemorrhage at presentation bleeding and epistaxis were the most common spontaneous symptoms Bleeding time was prolonged in most patients associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity Plasma VWF multimer distribution was normal type 1 pattern in 5 patients indeterminate no multimers detectable in 6 patients type 3 pattern and abnormal decreased higher-molecular-weight multimers type 2 pattern in 11 patients None of 17 patients tested had an inhibitor of ristocetin cofactor activity An underlying malignant or benign hematologic disease was found in 18 patients and 1 patient had Crohn 's disease Desmopressin was effective in only half the patients so treated but all patients responded to treatment with VWF-containing concentrates Resolution of AVWS occurred with therapy of 1 patient and chronic lymphocytic 1 patient Sixteen patients were alive at last follow-up no deaths were related to bleeding AVWS may be more prevalent than has been appreciated we estimate up to 0.04 Awareness of the existence of AVWS is essential for diagnosis and appropriate management Therapy of associated diseases may improve the bleeding disorder,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1294, 6430, 16290, 292, 34, 15, 681, 26141, 16, 8, 622, 2294, 2645, 4735, 29, 6711, 6430, 16290, 292, 34, 20, 89, 28, 1031, 2, 1127, 1, 3008, 2, 607, 532, 1, 2294, 1997, 21, 414, 23, 350, 7, 5, 26141, 527, 252, 243, 60, 313, 89, 28, 147, 10, 713, 27, 60, 184, 519, 868, 60, 96, 7, 42, 8, 3280, 15, 8, 539, 1208, 3599, 28, 1031, 2294, 2, 12575, 11, 3, 96, 186, 3280, 507, 2294, 98, 10, 1069, 4, 96, 7, 41, 5, 2003, 2153, 4, 554, 6430, 16290, 161, 448, 2, 43210, 17137, 128, 554, 15914, 37421, 1395, 10, 295, 267, 14, 1177, 4, 33, 7, 5167, 77, 30388, 2083, 4, 49, 7, 267, 27, 1177, 2, 1668, 340, 142, 219, 924, 30388, 267, 18, 1177, 4, 175, 7, 1292, 1, 269, 7, 650, 42, 35, 230, 1, 43210, 17137, 128, 35, 1181, 393, 15, 1002, 813, 34, 10, 204, 4, 203, 7, 2, 14, 69, 42, 11612, 292, 34, 53459, 10, 323, 4, 158, 1303, 3, 7, 1743, 73, 84, 62, 7, 2211, 6, 24, 5, 15914, 1101, 37422, 2125, 1, 26141, 489, 5, 36, 1, 14, 69, 2, 442, 1193, 14, 69, 3228, 7, 11, 1701, 28, 1060, 166, 126, 77, 1043, 11, 139, 6, 2294, 26141, 68, 40, 80, 2485, 76, 71, 85, 7292, 21, 1191, 126, 6, 13, 755, 3310, 1, 3, 5335, 1, 26141, 16, 1452, 9, 147, 2, 870, 284, 36, 1, 41, 1342, 68, 401, 3, 2294, 2645]",1581.0,12666134,205
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"Rituximab has clinical activity in patients with chronic lymphocytic leukemia (CLL) and has a variety of proposed mechanisms, including apoptosis, complement-dependent cell lysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC). Here we examine pretreatment biologic features that promote resistance to apoptosis and CDC in CLL patients and correlate it with clinical outcome to rituximab-based therapy. Pretreatment samples from 21 CLL patients treated on a prospective, single-agent rituximab trial were examined for quantitative expression of apoptotic and CDC regulatory proteins, and the level of expression of these proteins was correlated with clinical outcome. Of the 21 patents for whom samples were available, 10 attained a partial response and 11 failed to respond to rituximab therapy. The mean pretreatment expression of Bcl-2, Mcl-1, XIAP, and the ratio of Bcl-2/Bax were higher but not statistically increased in nonresponding patients versus those responding to treatment. In contrast, the pretreatment Mcl-1/Bax ratio was significantly elevated (0.82 +/- 0.28 v 0.39 +/- 0.29, P <.016) in nonresponding patients compared with patients responding to rituximab therapy. Although pretreatment expression of CD55 and CD59 was not associated with response to rituximab therapy, significantly higher levels of CD59 were observed in the CLL cells that were not cleared from the blood at completion of therapy than the level observed at baseline levels (P =.02). These data indicate that baseline expression of the Mcl-1/Bax ratio, but not CD55 and CD59, predict for clinical response to rituximab therapy in CLL patients. Further study of disrupted apoptosis in CLL as a potential mechanism of resistance to rituximab appears warranted.",Journal Article,6139.0,152.0,Rituximab has clinical activity in patients with chronic lymphocytic CLL and has a variety of proposed mechanisms including apoptosis complement-dependent cell lysis CDC and antibody-dependent cellular cytotoxicity ADCC Here we examine pretreatment biologic features that promote resistance to apoptosis and CDC in CLL patients and correlate it with clinical outcome to rituximab-based therapy Pretreatment samples from 21 CLL patients treated on a prospective single-agent rituximab trial were examined for quantitative expression of apoptotic and CDC regulatory proteins and the level of expression of these proteins was correlated with clinical outcome Of the 21 patents for whom samples were available 10 attained a partial response and 11 failed to respond to rituximab therapy The mean pretreatment expression of Bcl-2 Mcl-1 XIAP and the ratio of Bcl-2/Bax were higher but not statistically increased in nonresponding patients versus those responding to treatment In contrast the pretreatment Mcl-1/Bax ratio was significantly elevated 0.82 +/- 0.28 v 0.39 +/- 0.29 P .016 in nonresponding patients compared with patients responding to rituximab therapy Although pretreatment expression of CD55 and CD59 was not associated with response to rituximab therapy significantly higher levels of CD59 were observed in the CLL cells that were not cleared from the blood at completion of therapy than the level observed at baseline levels P =.02 These data indicate that baseline expression of the Mcl-1/Bax ratio but not CD55 and CD59 predict for clinical response to rituximab therapy in CLL patients Further study of disrupted apoptosis in CLL as a potential mechanism of resistance to rituximab appears warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[855, 71, 38, 128, 4, 7, 5, 442, 1193, 552, 2, 71, 8, 1362, 1, 1587, 483, 141, 351, 3731, 470, 31, 4783, 9665, 2, 548, 470, 763, 1408, 5551, 467, 21, 1004, 1194, 1283, 404, 17, 1617, 251, 6, 351, 2, 9665, 4, 552, 7, 2, 1513, 192, 5, 38, 228, 6, 855, 90, 36, 1194, 347, 29, 239, 552, 7, 73, 23, 8, 482, 226, 420, 855, 160, 11, 409, 9, 1156, 55, 1, 1631, 2, 9665, 1253, 652, 2, 3, 301, 1, 55, 1, 46, 652, 10, 438, 5, 38, 228, 1, 3, 239, 17192, 9, 953, 347, 11, 390, 79, 5105, 8, 450, 51, 2, 175, 1551, 6, 1892, 6, 855, 36, 3, 313, 1194, 55, 1, 1044, 18, 1308, 14, 5387, 2, 3, 197, 1, 1044, 18, 3119, 11, 142, 84, 44, 712, 101, 4, 13488, 7, 185, 135, 3261, 6, 24, 4, 748, 3, 1194, 1308, 14, 3119, 197, 10, 97, 804, 13, 878, 13, 339, 603, 13, 587, 13, 462, 19, 3820, 4, 13488, 7, 72, 5, 7, 3261, 6, 855, 36, 242, 1194, 55, 1, 13554, 2, 19560, 10, 44, 41, 5, 51, 6, 855, 36, 97, 142, 148, 1, 19560, 11, 164, 4, 3, 552, 37, 17, 11, 44, 9266, 29, 3, 315, 28, 1438, 1, 36, 76, 3, 301, 164, 28, 330, 148, 19, 588, 46, 74, 1008, 17, 330, 55, 1, 3, 1308, 14, 3119, 197, 84, 44, 13554, 2, 19560, 678, 9, 38, 51, 6, 855, 36, 4, 552, 7, 195, 45, 1, 5576, 351, 4, 552, 22, 8, 174, 670, 1, 251, 6, 855, 1233, 1197]",1713.0,12697868,517
Expression of CD52 on plasma cells in plasma cell proliferative disorders.,Blood,Blood,2003-04-24,"Multiple myeloma (MM) and primary systemic amyloidosis (AL) remain incurable disorders, and new treatments targeted to the malignant plasma cells are needed. Alemtuzumab is a humanized monoclonal antibody to CD52 and has activity in chronic lymphocytic leukemia. We examined the CD52 expression on CD45+ and CD45- plasma cell populations to evaluate the potential for using alemtuzumab for these disorders. Bone marrows from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied using 3-color (CD38/45/52) flow cytometry. Among those with MGUS, MM, and AL, 67%, 52%, and 35%, respectively, were positive for CD52 expression. The CD52 expression was predominantly confined to the clonal CD38+/CD45+ plasma cell fraction with median expression of 68%, 88%, and 82% in MGUS, MM, and AL, respectively, compared with 18%, 6%, and 9% among the CD45- plasma cell population. Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy.",Journal Article,6116.0,41.0,Multiple MM and primary systemic amyloidosis AL remain incurable disorders and new treatments targeted to the malignant plasma cells are needed Alemtuzumab is a humanized monoclonal antibody to CD52 and has activity in chronic lymphocytic We examined the CD52 expression on CD45+ and CD45- plasma cell populations to evaluate the potential for using alemtuzumab for these disorders marrows from 61 patients 29 AL 23 MM and 9 MGUS monoclonal gammopathies of undetermined significance were studied using 3-color CD38/45/52 flow cytometry Among those with MGUS MM and AL 67 52 and 35 respectively were positive for CD52 expression The CD52 expression was predominantly confined to the clonal CD38+/CD45+ plasma cell fraction with median expression of 68 88 and 82 in MGUS MM and AL respectively compared with 18 6 and 9 among the CD45- plasma cell population Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[232, 321, 2, 86, 403, 3919, 2171, 918, 2641, 1997, 2, 217, 640, 238, 6, 3, 393, 554, 37, 32, 575, 3579, 16, 8, 3619, 848, 548, 6, 7189, 2, 71, 128, 4, 442, 1193, 21, 409, 3, 7189, 55, 23, 5280, 2, 5280, 554, 31, 1184, 6, 376, 3, 174, 9, 75, 3579, 9, 46, 1997, 13800, 29, 713, 7, 462, 2171, 382, 321, 2, 83, 3226, 848, 21139, 1, 5206, 724, 11, 656, 75, 27, 6052, 4469, 512, 653, 1412, 1914, 107, 135, 5, 3226, 321, 2, 2171, 598, 653, 2, 465, 106, 11, 109, 9, 7189, 55, 3, 7189, 55, 10, 2117, 2902, 6, 3, 1946, 4469, 5280, 554, 31, 1509, 5, 52, 55, 1, 806, 889, 2, 878, 4, 3226, 321, 2, 2171, 106, 72, 5, 203, 49, 2, 83, 107, 3, 5280, 554, 31, 266, 38, 143, 32, 1197, 4, 46, 1342, 6, 7586, 3, 189, 247, 1, 312, 7189, 726]",963.0,12714489,769
Palliative irradiation of the spleen.,American journal of clinical oncology,Am. J. Clin. Oncol.,2003-04-01,"We analyzed the efficacy of splenic irradiation in a population of patients with hematologic diseases. The records of the Radiation Oncology Division, Naval Medical Center San Diego were retrospectively reviewed for all patients treated with splenic irradiation (SI) between January 1, 1990 and March 1, 2001. The charts of 17 patients were identified: 5 patients had chronic myelogenous leukemia, 4 had chronic lymphocytic leukemia, 4 had idiopathic myelofibrosis, 2 had polycythemia vera, and 1 patient each had idiopathic thrombocytopenic purpura and acute myelogenous leukemia. Patient ages ranged from 37 to 88 years. Sixteen of 17 suffered from symptomatic splenomegaly. Twenty-six courses of splenic irradiation were delivered to these 17 patients. Treatment courses generally consisted of two fractions of 50 cGy in the first week, two fractions of 75 cGy the second week, and two fractions of 100 cGy the third week. Blood counts were checked prior to each treatment. Seven of the 17 patients died 1 month or less after SI due to the terminal nature of their disease. Twenty-two of 25 treatment courses for splenomegaly resulted in decreased pain and symptoms. Five patients required two treatment courses for splenomegaly, and one patient required five treatment courses. Three of four patients treated for thrombocytopenia demonstrated improvement, but only one was evaluable for more than 2 weeks due to disease-related mortality. Three of five patients treated for leukocytosis had significant improvement. In general, patients suffered few significant complications from this palliative intervention. Splenic irradiation can effectively palliate symptomatic splenomegaly in patients for whom splenectomy is not an option. Retreatment is possible. Splenic irradiation is less effective in the treatment of thrombocytopenia or leukocytosis.",Journal Article,6139.0,37.0,We analyzed the efficacy of splenic irradiation in a population of patients with hematologic diseases The records of the Radiation Oncology Division Naval Medical Center San Diego were retrospectively reviewed for all patients treated with splenic irradiation SI between January 1 1990 and March 1 2001 The charts of 17 patients were identified 5 patients had chronic myelogenous 4 had chronic lymphocytic 4 had idiopathic myelofibrosis 2 had polycythemia vera and 1 patient each had idiopathic thrombocytopenic purpura and acute myelogenous Patient ages ranged from 37 to 88 years Sixteen of 17 suffered from symptomatic splenomegaly Twenty-six courses of splenic irradiation were delivered to these 17 patients Treatment courses generally consisted of two fractions of 50 cGy in the first week two fractions of 75 cGy the second week and two fractions of 100 cGy the third week Blood counts were checked prior to each treatment Seven of the 17 patients died 1 month or less after SI due to the terminal nature of their disease Twenty-two of 25 treatment courses for splenomegaly resulted in decreased pain and symptoms Five patients required two treatment courses for splenomegaly and one patient required five treatment courses Three of four patients treated for thrombocytopenia demonstrated improvement but only one was evaluable for more than 2 weeks due to disease-related mortality Three of five patients treated for leukocytosis had significant improvement In general patients suffered few significant complications from this palliative intervention Splenic irradiation can effectively palliate symptomatic splenomegaly in patients for whom splenectomy is not an option Retreatment is possible Splenic irradiation is less effective in the treatment of thrombocytopenia or leukocytosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 311, 3, 209, 1, 5237, 1104, 4, 8, 266, 1, 7, 5, 813, 1342, 3, 1064, 1, 3, 121, 413, 5750, 53501, 484, 574, 6889, 12965, 11, 894, 446, 9, 62, 7, 73, 5, 5237, 1104, 5069, 59, 1024, 14, 2289, 2, 2363, 14, 1758, 3, 4413, 1, 269, 7, 11, 108, 33, 7, 42, 442, 2194, 39, 42, 442, 1193, 39, 42, 7540, 4637, 18, 42, 5755, 5756, 2, 14, 69, 296, 42, 7540, 11908, 14174, 2, 286, 2194, 69, 2165, 1869, 29, 567, 6, 889, 60, 3228, 1, 269, 6388, 29, 1704, 6364, 737, 437, 1993, 1, 5237, 1104, 11, 1623, 6, 46, 269, 7, 24, 1993, 1228, 1695, 1, 100, 1550, 1, 212, 3071, 4, 3, 157, 647, 100, 1550, 1, 481, 3071, 3, 419, 647, 2, 100, 1550, 1, 394, 3071, 3, 1282, 647, 315, 1911, 11, 14749, 324, 6, 296, 24, 648, 1, 3, 269, 7, 1016, 14, 811, 15, 299, 50, 5069, 520, 6, 3, 2158, 2202, 1, 136, 34, 737, 100, 1, 243, 24, 1993, 9, 6364, 627, 4, 340, 559, 2, 507, 365, 7, 616, 100, 24, 1993, 9, 6364, 2, 104, 69, 616, 365, 24, 1993, 169, 1, 294, 7, 73, 9, 1340, 264, 767, 84, 158, 104, 10, 859, 9, 80, 76, 18, 244, 520, 6, 34, 139, 282, 169, 1, 365, 7, 73, 9, 7463, 42, 93, 767, 4, 1083, 7, 6388, 1021, 93, 521, 29, 26, 994, 788, 5237, 1104, 122, 1856, 10982, 1704, 6364, 4, 7, 9, 953, 6569, 16, 44, 35, 1501, 6291, 16, 899, 5237, 1104, 16, 299, 323, 4, 3, 24, 1, 1340, 15, 7463]",1793.0,12714892,513
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.,Seminars in oncology,Semin. Oncol.,2003-04-01,"Waldenstrom's macroglobulinemia (WM) is a malignant disorder of lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM). Since the original description by Jan Waldenstrm of three patients with symptoms of hyperviscosity due to circulating monoclonal IgM, the definition of WM has been controversial. Standardized criteria for diagnosis have now been proposed, including the presence of any IgM monoclonal protein and marrow and/or nodal lymphoplasmacytic cells. Although previous response criteria have generally incorporated parameters for monoclonal protein reduction and/or improvement of marrow/nodal involvement, specific and uniform response criteria are needed to facilitate comparisons of response, remission duration, progression-free survival, and overall survival in clinical trials similar to those previously established for other diseases such as chronic lymphocytic leukemia, lymphoma, and myeloma. This is of particular importance as new agents are developed and evaluated. This presentation represents consensus recommendations for uniform response criteria for use in assessing responses to treatment for patients with WM, which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002.",Consensus Development Conference,6139.0,63.0,Waldenstrom 's macroglobulinemia WM is a malignant disorder of lymphoplasmacytic cells that produce a monoclonal immunoglobulin M IgM Since the original description by Jan Waldenstrm of three patients with symptoms of hyperviscosity due to circulating monoclonal IgM the definition of WM has been controversial Standardized criteria for diagnosis have now been proposed including the presence of any IgM monoclonal protein and marrow and/or nodal lymphoplasmacytic cells Although previous response criteria have generally incorporated parameters for monoclonal protein reduction and/or improvement of marrow/nodal involvement specific and uniform response criteria are needed to facilitate comparisons of response remission duration progression-free survival and overall survival in clinical trials similar to those previously established for other diseases such as chronic lymphocytic and This is of particular importance as new agents are developed and evaluated This presentation represents consensus recommendations for uniform response criteria for use in assessing responses to treatment for patients with WM which were prepared in conjunction with the Second International Workshop held in Athens Greece during September 2002,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7933, 292, 3389, 1518, 16, 8, 393, 2645, 1, 5325, 37, 17, 2410, 8, 848, 2593, 188, 2852, 1192, 3, 2279, 5263, 20, 7555, 3700, 1, 169, 7, 5, 507, 1, 8218, 520, 6, 1033, 848, 2852, 3, 2470, 1, 1518, 71, 85, 2010, 1670, 371, 9, 147, 47, 1134, 85, 1587, 141, 3, 463, 1, 500, 2852, 848, 178, 2, 581, 2, 15, 779, 5325, 37, 242, 698, 51, 371, 47, 1228, 2449, 1038, 9, 848, 178, 628, 2, 15, 767, 1, 581, 779, 799, 112, 2, 3490, 51, 371, 32, 575, 6, 1876, 2213, 1, 51, 734, 654, 91, 115, 25, 2, 63, 25, 4, 38, 143, 288, 6, 135, 373, 635, 9, 127, 1342, 225, 22, 442, 1193, 2, 26, 16, 1, 1454, 1187, 22, 217, 183, 32, 276, 2, 194, 26, 1031, 1449, 1391, 883, 9, 3490, 51, 371, 9, 119, 4, 1977, 253, 6, 24, 9, 7, 5, 1518, 92, 11, 4421, 4, 3357, 5, 3, 419, 944, 4014, 4033, 4, 30403, 23218, 190, 2636, 1544]",1233.0,12720121,355
Genetics and cytogenetics of Waldenstrom's macroglobulinemia.,Seminars in oncology,Semin. Oncol.,2003-04-01,"Waldenstrom's macroglobulinemia (WM) is a clonal B-cell disorder characterized by the production of a monoclonal paraprotein and lymphoplasmacytic clonal expansion. The genetic basis of this disorder is poorly understood. We have recently found that the genetic makeup of WM cells is different from that commonly reported for multiple myeloma (MM), follicular lymphoma, and B-cell chronic lymphocytic leukemia. Translocations involving the immunoglobulin heavy chain locus (IgH) translocations could not be detected in any case, and a molecular analysis showed that the IgH locus switch mu retained its germline configuration. Aneuploidy was not detected using chromosome enumeration probes. The only recurrent chromosome abnormality found was deletion of 6q21. The lack of legitimate of illegitimate rearrangements at the IgH locus suggests that other mechanisms are involved in the pathogenesis of the disorder. Given the clear evidence of a familial form of WM and the currently presumed genomic stability of the clonal cells, it is likely that a single gene defect may be responsible for disease pathogenesis. Having found deletions of the long arm of chromosome 6 as the only recurrent aberration, we speculate that a gene involved in B-cell maturation or survival at this locus may be inactivated as a cause of WM.",Journal Article,6139.0,18.0,Waldenstrom 's macroglobulinemia WM is a clonal B-cell disorder characterized by the production of a monoclonal paraprotein and lymphoplasmacytic clonal expansion The genetic basis of this disorder is poorly understood We have recently found that the genetic makeup of WM cells is different from that commonly reported for multiple MM follicular and B-cell chronic lymphocytic Translocations involving the immunoglobulin heavy chain locus IgH translocations could not be detected in any case and a molecular analysis showed that the IgH locus switch mu retained its germline configuration Aneuploidy was not detected using chromosome enumeration probes The only recurrent chromosome abnormality found was deletion of 6q21 The lack of legitimate of illegitimate rearrangements at the IgH locus suggests that other mechanisms are involved in the pathogenesis of the disorder Given the clear evidence of a familial form of WM and the currently presumed genomic stability of the clonal cells it is likely that a single gene defect may be responsible for disease pathogenesis Having found deletions of the long arm of chromosome 6 as the only recurrent aberration we speculate that a gene involved in B-cell maturation or survival at this locus may be inactivated as a cause of WM,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7933, 292, 3389, 1518, 16, 8, 1946, 132, 31, 2645, 765, 20, 3, 1529, 1, 8, 848, 10938, 2, 5325, 1946, 1422, 3, 336, 877, 1, 26, 2645, 16, 1240, 1784, 21, 47, 761, 204, 17, 3, 336, 14176, 1, 1518, 37, 16, 338, 29, 17, 841, 210, 9, 232, 321, 1974, 2, 132, 31, 442, 1193, 3262, 1267, 3, 2593, 4013, 1260, 2474, 5221, 3262, 359, 44, 40, 530, 4, 500, 473, 2, 8, 219, 65, 224, 17, 3, 5221, 2474, 5096, 6601, 3532, 211, 1009, 13796, 7437, 10, 44, 530, 75, 1170, 7014, 3701, 3, 158, 387, 1170, 3698, 204, 10, 1528, 1, 20225, 3, 926, 1, 23149, 1, 24513, 2072, 28, 3, 5221, 2474, 844, 17, 127, 483, 32, 646, 4, 3, 1384, 1, 3, 2645, 447, 3, 885, 241, 1, 8, 2200, 1297, 1, 1518, 2, 3, 694, 5472, 572, 2769, 1, 3, 1946, 37, 192, 16, 322, 17, 8, 226, 145, 5398, 68, 40, 2327, 9, 34, 1384, 1041, 204, 2439, 1, 3, 319, 475, 1, 1170, 49, 22, 3, 158, 387, 7794, 21, 11778, 17, 8, 145, 646, 4, 132, 31, 4537, 15, 25, 28, 26, 2474, 68, 40, 5458, 22, 8, 708, 1, 1518]",1275.0,12720124,320
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2003-06-03,"Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m(2) i.v. daily for 3 days, cyclophosphamide 300 mg/m(2) i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.",Clinical Trial,6076.0,3.0,Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy The combination of fludarabine and cyclophosphamide FC is highly active in patients with chronic lymphocytic CLL Infection is a serious toxicity of the FC regimen Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL Patients received FCA fludarabine 30 mg/m 2 i.v daily for 3 days cyclophosphamide 300 mg/m 2 i.v daily for 3 days and amifostine 500 mg i.v over 15 min daily for 3 days starting 30 min before cyclophosphamide at intervals of 4-6 weeks for a maximum of six courses Patients receiving FCA had equivalent rates of sepsis early death objective response and survival to those observed in a prior series of 78 patients treated with FC Amifostine-associated toxicities included nausea vomiting and hypotension The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5369, 16, 35, 9486, 53554, 17, 68, 2382, 4869, 295, 742, 29, 3, 385, 1, 56, 3, 150, 1, 2027, 2, 1112, 4127, 16, 561, 544, 4, 7, 5, 442, 1193, 552, 930, 16, 8, 1762, 155, 1, 3, 4127, 477, 5369, 10, 1953, 6, 3, 4127, 477, 4, 8, 124, 215, 45, 1, 641, 7, 5, 552, 7, 103, 43255, 2027, 201, 81, 188, 18, 70, 603, 391, 9, 27, 162, 1112, 2036, 81, 188, 18, 70, 603, 391, 9, 27, 162, 2, 5369, 1666, 81, 70, 603, 252, 167, 1538, 391, 9, 27, 162, 1723, 201, 1538, 348, 1112, 28, 1582, 1, 39, 49, 244, 9, 8, 689, 1, 437, 1993, 7, 357, 43255, 42, 2017, 151, 1, 4227, 191, 273, 461, 51, 2, 25, 6, 135, 164, 4, 8, 324, 988, 1, 833, 7, 73, 5, 4127, 5369, 41, 385, 159, 1218, 1966, 2, 6577, 3, 45, 5369, 477, 205, 44, 969, 3, 155, 15, 128, 1, 3, 4127, 477, 4, 7, 5, 552]",975.0,12783199,732
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.,Blood,Blood,2003-06-05,"In a phase 2 study, 62 patients with relapsed and refractory acute myeloid leukemia (AML; n = 31), myelodysplastic syndrome (MDS; n = 8), chronic myeloid leukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/m2 clofarabine intravenously over 1 hour daily for 5 days, every 3 to 6 weeks. Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 (15%) achieved CR but without platelet recovery (CRp), for an overall response rate of 48%. In AML, responses were noted in 2 (18%) of 11 patients in first salvage with short first CR (</= 12 months), in 7 (87%) of 8 patients with longer first CR, and in 8 (67%) of 12 patients in second or subsequent salvage. Responses were observed in 4 of 8 patients with high-risk MDS (50%), in 7 (64%) of 11 with CML-BP, and in 2 (17%) of 12 with ALL. Severe reversible liver dysfunction was noted in 15% to 25%. After the first clofarabine infusion, responders accumulated more clofarabine triphosphate in blasts compared with nonresponders (median 18 vs 10 microM; P =.03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance.",Clinical Trial,6074.0,255.0,In a phase 2 study 62 patients with relapsed and refractory acute myeloid AML n 31 syndrome MDS n 8 chronic myeloid in blastic phase CMLBP n 11 and acute lymphocytic ALL n 12 received 40 mg/m2 clofarabine intravenously over 1 hour daily for 5 days every 3 to 6 weeks Twenty patients 32 achieved complete response CR 1 had a partial response PR and 9 15 achieved CR but without platelet recovery CRp for an overall response rate of 48 In AML responses were noted in 2 18 of 11 patients in first salvage with short first CR /= 12 months in 7 87 of 8 patients with longer first CR and in 8 67 of 12 patients in second or subsequent salvage Responses were observed in 4 of 8 patients with high-risk MDS 50 in 7 64 of 11 with CML-BP and in 2 17 of 12 with ALL Severe reversible dysfunction was noted in 15 to 25 After the first clofarabine infusion responders accumulated more clofarabine triphosphate in blasts compared with nonresponders median 18 vs 10 microM P =.03 This increased only in responders median 1.8-fold P =.008 after the second clofarabine infusion In summary clofarabine is active in acute leukemias and MDS cellular pharmacokinetics may have prognostic significance,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 8, 124, 18, 45, 744, 7, 5, 591, 2, 430, 286, 533, 329, 78, 456, 681, 1223, 78, 66, 442, 533, 4, 6529, 124, 53560, 78, 175, 2, 286, 1193, 62, 78, 133, 103, 327, 81, 821, 4149, 1672, 252, 14, 2583, 391, 9, 33, 162, 454, 27, 6, 49, 244, 737, 7, 531, 513, 236, 51, 684, 14, 42, 8, 450, 51, 998, 2, 83, 167, 513, 684, 84, 187, 1596, 1602, 3162, 9, 35, 63, 51, 116, 1, 576, 4, 329, 253, 11, 1051, 4, 18, 203, 1, 175, 7, 4, 157, 992, 5, 978, 157, 684, 133, 53, 4, 67, 912, 1, 66, 7, 5, 589, 157, 684, 2, 4, 66, 598, 1, 133, 7, 4, 419, 15, 706, 992, 253, 11, 164, 4, 39, 1, 66, 7, 5, 64, 43, 1223, 212, 4, 67, 660, 1, 175, 5, 903, 3044, 2, 4, 18, 269, 1, 133, 5, 62, 905, 2786, 1527, 10, 1051, 4, 167, 6, 243, 50, 3, 157, 4149, 904, 1983, 6664, 80, 4149, 7345, 4, 2438, 72, 5, 4498, 52, 203, 105, 79, 3550, 19, 680, 26, 101, 158, 4, 1983, 52, 14, 66, 1116, 19, 2155, 50, 3, 419, 4149, 904, 4, 1962, 4149, 16, 544, 4, 286, 2792, 2, 1223, 763, 1159, 68, 47, 177, 724]",1179.0,12791647,634
In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-06-01,"Signal transducer and activator of transcription (STAT) proteins are important regulators of physiological stimuli in lymphocytes. Biological therapies directed at lymphocytic malignancies such as chronic lymphocytic leukemia (CLL) may be mediated by these transcription factors. One such approach, CD154 (CD40-ligand) gene therapy, involves expressing CD154 on malignant B cells from CLL patients by transduction with an adenovirus vector after which the cells are reinfused into the patients. To determine the intracellular signaling pathways that underlie the clinical and immunological responses observed in patients from a Phase I study of CD154 gene therapy, CLL cells from these patients were examined for changes in STAT signaling events. CLL cells from patients who underwent CD154 gene therapy were analyzed for changes in STAT signaling by Western blot analysis and electrophoretic mobility shift assay. Activation of STAT1 was correlated with patient response to therapy. Tyrosine phosphorylation of STAT1 was detected in the nontransduced CLL cells in 9 of 11 patients 24 h after infusion, but not before. Activation of STAT1 was associated with clinical response, as measured by decreased absolute lymphocyte count, and immunological response, as measured by elevated plasma levels of IFN-gamma. This study indicates that STAT signaling may be an important mediator of biological treatments, such as CD154 gene therapy, and that early STAT1 activation may predict response to this novel treatment.",Journal Article,6078.0,22.0,Signal transducer and activator of transcription STAT proteins are important regulators of physiological stimuli in lymphocytes Biological therapies directed at lymphocytic malignancies such as chronic lymphocytic CLL may be mediated by these transcription factors One such approach CD154 CD40-ligand gene therapy involves expressing CD154 on malignant B cells from CLL patients by transduction with an adenovirus vector after which the cells are reinfused into the patients To determine the intracellular signaling pathways that underlie the clinical and immunological responses observed in patients from a Phase I study of CD154 gene therapy CLL cells from these patients were examined for changes in STAT signaling events CLL cells from patients who underwent CD154 gene therapy were analyzed for changes in STAT signaling by Western blot analysis and electrophoretic mobility shift assay Activation of STAT1 was correlated with patient response to therapy Tyrosine phosphorylation of STAT1 was detected in the nontransduced CLL cells in 9 of 11 patients 24 h after infusion but not before Activation of STAT1 was associated with clinical response as measured by decreased absolute lymphocyte count and immunological response as measured by elevated plasma levels of IFN-gamma This study indicates that STAT signaling may be an important mediator of biological treatments such as CD154 gene therapy and that early STAT1 activation may predict response to this novel treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1235, 5182, 2, 3393, 1, 866, 4168, 652, 32, 305, 3196, 1, 4733, 7478, 4, 1594, 1037, 235, 1166, 28, 1193, 441, 225, 22, 442, 1193, 552, 68, 40, 517, 20, 46, 866, 130, 104, 225, 353, 18281, 5040, 1232, 145, 36, 2921, 1046, 18281, 23, 393, 132, 37, 29, 552, 7, 20, 2761, 5, 35, 4488, 3374, 50, 92, 3, 37, 32, 21154, 237, 3, 7, 6, 223, 3, 2087, 314, 460, 17, 5875, 3, 38, 2, 5073, 253, 164, 4, 7, 29, 8, 124, 70, 45, 1, 18281, 145, 36, 552, 37, 29, 46, 7, 11, 409, 9, 400, 4, 4168, 314, 281, 552, 37, 29, 7, 54, 208, 18281, 145, 36, 11, 311, 9, 400, 4, 4168, 314, 20, 1521, 2639, 65, 2, 10980, 5717, 3024, 719, 363, 1, 5793, 10, 438, 5, 69, 51, 6, 36, 564, 982, 1, 5793, 10, 530, 4, 3, 33450, 552, 37, 4, 83, 1, 175, 7, 259, 555, 50, 904, 84, 44, 348, 363, 1, 5793, 10, 41, 5, 38, 51, 22, 644, 20, 340, 1766, 1448, 1276, 2, 5073, 51, 22, 644, 20, 804, 554, 148, 1, 1256, 1705, 26, 45, 2640, 17, 4168, 314, 68, 40, 35, 305, 3810, 1, 1037, 640, 225, 22, 18281, 145, 36, 2, 17, 191, 5793, 363, 68, 678, 51, 6, 26, 229, 24]",1478.0,12796382,504
Advances in the therapy of chronic lymphocytic leukemia.,Current opinion in hematology,Curr. Opin. Hematol.,2003-07-01,"Chronic lymphocytic leukemia therapy has changed dramatically over the past decade, with recent studies supporting the use of fludarabine as the initial therapy for symptomatic disease. New findings relative to the use of fludarabine and complications arising from this therapy are reviewed. Exciting combination approaches using monoclonal antibodies such as rituximab or Campath-1H in combination with fludarabine offer the opportunity to improve the complete response rate further in chronic lymphocytic leukemia. Furthermore, the field of experimental therapeutics for chronic lymphocytic leukemia was advanced by the description of a new mouse model of human chronic lymphocytic leukemia and identification of several disrupted signal transduction pathways in this disease. The description of therapies that target AKT, protein kinase C, phosphodiesterase 4, mammalian target of rapamycin, histone deacetylase, and methyltransferase offer the opportunity to utilize molecularly targeted therapy for this disease. Such targeted approaches offer hope that we might be on the threshold to changing the natural history of chronic lymphocytic leukemia.",Journal Article,6048.0,6.0,Chronic lymphocytic therapy has changed dramatically over the past decade with recent studies supporting the use of fludarabine as the initial therapy for symptomatic disease New findings relative to the use of fludarabine and complications arising from this therapy are reviewed Exciting combination approaches using monoclonal antibodies such as rituximab or Campath-1H in combination with fludarabine offer the opportunity to improve the complete response rate further in chronic lymphocytic Furthermore the field of experimental therapeutics for chronic lymphocytic was advanced by the description of a new mouse model of human chronic lymphocytic and identification of several disrupted signal transduction pathways in this disease The description of therapies that target AKT protein kinase C phosphodiesterase 4 mammalian target of rapamycin histone deacetylase and methyltransferase offer the opportunity to utilize molecularly targeted therapy for this disease Such targeted approaches offer hope that we might be on the threshold to changing the natural history of chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 36, 71, 2368, 2729, 252, 3, 1219, 2025, 5, 435, 94, 1912, 3, 119, 1, 2027, 22, 3, 388, 36, 9, 1704, 34, 217, 272, 580, 6, 3, 119, 1, 2027, 2, 521, 2635, 29, 26, 36, 32, 446, 4963, 150, 611, 75, 848, 890, 225, 22, 855, 15, 16622, 10147, 4, 150, 5, 2027, 1918, 3, 2666, 6, 401, 3, 236, 51, 116, 195, 4, 442, 1193, 798, 3, 1067, 1, 1560, 1943, 9, 442, 1193, 10, 131, 20, 3, 5263, 1, 8, 217, 830, 202, 1, 171, 442, 1193, 2, 911, 1, 392, 5576, 1235, 2761, 460, 4, 26, 34, 3, 5263, 1, 235, 17, 283, 649, 178, 216, 256, 11624, 39, 2359, 283, 1, 1620, 1508, 2732, 2, 3747, 1918, 3, 2666, 6, 6391, 2372, 238, 36, 9, 26, 34, 225, 238, 611, 1918, 3045, 17, 21, 822, 40, 23, 3, 2390, 6, 3600, 3, 1504, 532, 1, 442, 1193]",1094.0,12799536,733
Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications.,Leukemia research,Leuk. Res.,2003-09-01,"Although chronic lymphocytic leukemia (CLL) is the most common leukemia in the west and over the past two decades the incidence of infection with the human immunodeficiency virus (HIV) has significantly increased, few reports of the coincidence of these diseases exist in the literature. Other lymphoid malignancies such as non-Hodgkin's lymphomas (NHL) and Hodgkin's disease (HD) occur frequently with HIV and indeed the former is an acquired immune deficiency syndrome (AIDS)-defining illness. It is not clear why HIV infected patients have a predisposition for some B-cell disorders and not others. This may be related to the different age ranges for patients with CLL and HIV infection although an overlap clearly does exist. Here, we describe our experience with a patient with co-existing HIV infection and CLL and explore possible implications.",Case Reports,5986.0,7.0,Although chronic lymphocytic CLL is the most common in the west and over the past two decades the incidence of infection with the human immunodeficiency virus HIV has significantly increased few reports of the coincidence of these diseases exist in the literature Other lymphoid malignancies such as 's lymphomas NHL and 's disease HD occur frequently with HIV and indeed the former is an acquired immune deficiency syndrome AIDS -defining illness It is not clear why HIV infected patients have a predisposition for some B-cell disorders and not others This may be related to the different age ranges for patients with CLL and HIV infection although an overlap clearly does exist Here we describe our experience with a patient with co-existing HIV infection and CLL and explore possible implications,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 442, 1193, 552, 16, 3, 96, 186, 4, 3, 7261, 2, 252, 3, 1219, 100, 1968, 3, 287, 1, 930, 5, 3, 171, 5323, 1450, 1942, 71, 97, 101, 1021, 1198, 1, 3, 26006, 1, 46, 1342, 1923, 4, 3, 789, 127, 2303, 441, 225, 22, 292, 1557, 1176, 2, 292, 34, 2701, 1271, 746, 5, 1942, 2, 4462, 3, 3623, 16, 35, 1294, 250, 2299, 681, 4174, 2847, 2973, 192, 16, 44, 885, 5283, 1942, 3369, 7, 47, 8, 2863, 9, 476, 132, 31, 1997, 2, 44, 1749, 26, 68, 40, 139, 6, 3, 338, 89, 5632, 9, 7, 5, 552, 2, 1942, 930, 242, 35, 4526, 2536, 1097, 1923, 467, 21, 897, 114, 730, 5, 8, 69, 5, 1269, 1692, 1942, 930, 2, 552, 2, 1645, 899, 1268]",799.0,12804644,398
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.,Blood,Blood,2003-07-24,"Little effort has been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS) of the immunoglobulin M (IgM) class, which progresses to lymphoma or Waldenstrm macroglobulinemia, whereas IgA and IgG MGUS progress to multiple myeloma, primary amyloidosis (AL), or a related plasma cell disorder. From 1960 to 1994, IgM MGUS was diagnosed in 213 patients in southeastern Minnesota. The end point was progression to lymphoma or a related disorder, as assessed with the Kaplan-Meier method. The 213 patients were followed up for 1567 person-years (median, 6.3 years per patient). Lymphoma developed in 17 patients (relative risk [RR], 14.8), Waldenstrm macroglobulinemia in 6 (RR, 262), primary amyloidosis in 3 (RR, 16.3), and chronic lymphocytic leukemia in 3 (RR, 5.7). The relative risk of progression was 16-fold higher in the patients with IgM MGUS than in the white population of the Iowa Surveillance, Epidemiology, and End Results Program. Cumulative incidence of progression was 10% at 5 years, 18% at 10 years, and 24% at 15 years. On multivariate analysis, the serum monoclonal protein and serum albumin concentrations at diagnosis were the only risk factors for progression to lymphoma or a related disorder. Risk for progression to lymphoma or a related disorder at 10 years after the diagnosis of MGUS was 14% with an initial monoclonal protein concentration of 0.5 g/dL or less, 26% with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL.",Journal Article,6025.0,227.0,Little effort has been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance MGUS of the immunoglobulin M IgM class which progresses to or Waldenstrm macroglobulinemia whereas IgA and IgG MGUS progress to multiple primary amyloidosis AL or a related plasma cell disorder From 1960 to 1994 IgM MGUS was diagnosed in 213 patients in southeastern Minnesota The end point was progression to or a related disorder as assessed with the Kaplan-Meier method The 213 patients were followed up for 1567 person-years median 6.3 years per patient developed in 17 patients relative risk RR 14.8 Waldenstrm macroglobulinemia in 6 RR 262 primary amyloidosis in 3 RR 16.3 and chronic lymphocytic in 3 RR 5.7 The relative risk of progression was 16-fold higher in the patients with IgM MGUS than in the white population of the Iowa Surveillance Epidemiology and End Results Program Cumulative incidence of progression was 10 at 5 years 18 at 10 years and 24 at 15 years On multivariate analysis the serum monoclonal protein and serum albumin concentrations at diagnosis were the only risk factors for progression to or a related disorder Risk for progression to or a related disorder at 10 years after the diagnosis of MGUS was 14 with an initial monoclonal protein concentration of 0.5 g/dL or less 26 with 1.5 g/dL 34 for 2.0 g/dL and 41 for more than 2.5 g/dL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 2919, 71, 85, 1229, 6, 13316, 290, 123, 1, 848, 5334, 1, 5206, 724, 3226, 1, 3, 2593, 188, 2852, 1040, 92, 6752, 6, 15, 3700, 3389, 547, 9368, 2, 3630, 3226, 1466, 6, 232, 86, 3919, 2171, 15, 8, 139, 554, 31, 2645, 29, 10391, 6, 3023, 2852, 3226, 10, 265, 4, 5833, 7, 4, 20167, 8297, 3, 396, 741, 10, 91, 6, 15, 8, 139, 2645, 22, 275, 5, 3, 876, 882, 596, 3, 5833, 7, 11, 370, 126, 9, 26194, 2719, 60, 52, 49, 27, 60, 379, 69, 276, 4, 269, 7, 580, 43, 861, 213, 66, 3700, 3389, 4, 49, 861, 7801, 86, 3919, 4, 27, 861, 245, 27, 2, 442, 1193, 4, 27, 861, 33, 67, 3, 580, 43, 1, 91, 10, 245, 1116, 142, 4, 3, 7, 5, 2852, 3226, 76, 4, 3, 886, 266, 1, 3, 8565, 617, 1284, 2, 396, 99, 1243, 967, 287, 1, 91, 10, 79, 28, 33, 60, 203, 28, 79, 60, 2, 259, 28, 167, 60, 23, 331, 65, 3, 524, 848, 178, 2, 524, 2799, 1003, 28, 147, 11, 3, 158, 43, 130, 9, 91, 6, 15, 8, 139, 2645, 43, 9, 91, 6, 15, 8, 139, 2645, 28, 79, 60, 50, 3, 147, 1, 3226, 10, 213, 5, 35, 388, 848, 178, 1227, 1, 13, 33, 499, 1826, 15, 299, 432, 5, 14, 33, 499, 1826, 562, 9, 18, 13, 499, 1826, 2, 605, 9, 80, 76, 18, 33, 499, 1826]",1383.0,12881316,17
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.,Blood,Blood,2003-07-31,"Lymphoid cells in most patients with chronic lymphocytic leukemia (CLL), when treated with rituximab, become CD20-. This is thought to be due to masking of CD20 by rituximab. We used specific antimouse immunoglobulin antibodies to detect rituximab on the surface of CLL lymphocytes and we demonstrate that rituximab is rarely detectable after therapy. Only 3 of 65 patients with CLL had rituximab detectable on their lymphocytes after rituximab therapy despite the fact that most had no detectable CD20 expression. In vitro mixing of CLL or Raji cells with rituximab demonstrated that rituximab was detectable on the surface of cells due to its binding to CD20. However, the addition of plasma led to the down-modulation of CD20 expression, and the rituximab became undetectable. This down-modulation of CD20 protein expression was associated with a down-modulation of CD20 mRNA. CLL cells that lost their CD20 expression regained CD20 expression after 24 hours in culture. These data suggest that rituximab therapy leads to a substantial but transient down-modulation of CD20 expression and that negativity for CD20 in cells from patients treated with rituximab is not necessarily due to CD20 masking. The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation.",Journal Article,6018.0,97.0,Lymphoid cells in most patients with chronic lymphocytic CLL when treated with rituximab become CD20- This is thought to be due to masking of CD20 by rituximab We used specific antimouse immunoglobulin antibodies to detect rituximab on the surface of CLL lymphocytes and we demonstrate that rituximab is rarely detectable after therapy Only 3 of 65 patients with CLL had rituximab detectable on their lymphocytes after rituximab therapy despite the fact that most had no detectable CD20 expression In vitro mixing of CLL or Raji cells with rituximab demonstrated that rituximab was detectable on the surface of cells due to its binding to CD20 However the addition of plasma led to the down-modulation of CD20 expression and the rituximab became undetectable This down-modulation of CD20 protein expression was associated with a down-modulation of CD20 mRNA CLL cells that lost their CD20 expression regained CD20 expression after 24 hours in culture These data suggest that rituximab therapy leads to a substantial but transient down-modulation of CD20 expression and that negativity for CD20 in cells from patients treated with rituximab is not necessarily due to CD20 masking The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2303, 37, 4, 96, 7, 5, 442, 1193, 552, 198, 73, 5, 855, 1417, 2198, 26, 16, 2739, 6, 40, 520, 6, 18896, 1, 2198, 20, 855, 21, 95, 112, 26198, 2593, 890, 6, 1426, 855, 23, 3, 1255, 1, 552, 1594, 2, 21, 608, 17, 855, 16, 2416, 2083, 50, 36, 158, 27, 1, 556, 7, 5, 552, 42, 855, 2083, 23, 136, 1594, 50, 855, 36, 550, 3, 1991, 17, 96, 42, 77, 2083, 2198, 55, 4, 439, 16296, 1, 552, 15, 9868, 37, 5, 855, 264, 17, 855, 10, 2083, 23, 3, 1255, 1, 37, 520, 6, 211, 791, 6, 2198, 137, 3, 352, 1, 554, 836, 6, 3, 1328, 2356, 1, 2198, 55, 2, 3, 855, 3451, 3920, 26, 1328, 2356, 1, 2198, 178, 55, 10, 41, 5, 8, 1328, 2356, 1, 2198, 956, 552, 37, 17, 3009, 136, 2198, 55, 17220, 2198, 55, 50, 259, 1459, 4, 2099, 46, 74, 309, 17, 855, 36, 1940, 6, 8, 1281, 84, 2473, 1328, 2356, 1, 2198, 55, 2, 17, 6014, 9, 2198, 4, 37, 29, 7, 73, 5, 855, 16, 44, 7766, 520, 6, 2198, 18896, 3, 1187, 1, 26, 1328, 2356, 4, 3, 209, 1, 291, 36, 5, 855, 1891, 195, 940]",1295.0,12893761,9
Immunologic monitoring in chronic lymphocytic leukemia.,Current oncology reports,Curr Oncol Rep,2003-09-01,"Chronic lymphocytic leukemia (CLL) is characterized by progressive defects in humoral- and cell-mediated immunity. These defects are manifested as a propensity to develop infections with encapsulated bacteria, and less frequently, with gram-negative enterics. In addition, reactivation of viruses such as herpesvirus is not uncommon. Treatment of the disease further exacerbates immunosuppression by depleting immune effectors and broadening the spectrum of potentially offending pathogens. Risk of infection can potentially be reduced by administration of intravenous immunoglobulin and use of prophylactic antibiotics for individuals who are at high risk. Current work focuses on development of cellular and cytokine therapy to facilitate immune reconstitution in patients with CLL, thereby reducing morbidity and mortality and potentially improving survival.",Journal Article,5986.0,2.0,Chronic lymphocytic CLL is characterized by progressive defects in humoral- and cell-mediated immunity These defects are manifested as a propensity to develop infections with encapsulated bacteria and less frequently with gram-negative enterics In addition reactivation of viruses such as herpesvirus is not uncommon Treatment of the disease further exacerbates immunosuppression by depleting immune effectors and broadening the spectrum of potentially offending pathogens Risk of infection can potentially be reduced by administration of intravenous immunoglobulin and use of prophylactic antibiotics for individuals who are at high risk Current work focuses on development of cellular and cytokine therapy to facilitate immune reconstitution in patients with CLL thereby reducing morbidity and mortality and potentially improving survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 765, 20, 1014, 2945, 4, 5498, 2, 31, 517, 1604, 46, 2945, 32, 6023, 22, 8, 1925, 6, 690, 1875, 5, 7431, 8841, 2, 299, 746, 5, 6653, 199, 53668, 4, 352, 3834, 1, 4405, 225, 22, 9329, 16, 44, 2052, 24, 1, 3, 34, 195, 24628, 3646, 20, 9438, 250, 4926, 2, 17221, 3, 1873, 1, 751, 28093, 9275, 43, 1, 930, 122, 751, 40, 405, 20, 634, 1, 1262, 2593, 2, 119, 1, 1862, 5214, 9, 869, 54, 32, 28, 64, 43, 291, 1357, 3026, 23, 193, 1, 763, 2, 1675, 36, 6, 1876, 250, 5616, 4, 7, 5, 552, 2267, 1818, 787, 2, 282, 2, 751, 1673, 25]",840.0,12895395,584
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.,Cancer,Cancer,2003-08-01,"Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4-12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir. The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of patients and resolution of bone marrow involvement was observed in 49% of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46%) experienced at least one episode of fever or infection. Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders.",Clinical Trial,6017.0,117.0,Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders Seventy-eight patients were enrolled The most common diagnoses were chronic lymphocytic n 42 patients and T-cell prolymphocytic n 18 patients Before entering the study the patients had received multiple therapies median three therapies and the median time from diagnosis was 7 years Alemtuzumab was given intravenously at doses of 3 mg 10 mg and 30 mg on 3 consecutive days after which 30 mg was administered 3 times a week Patients were treated for 4-12 weeks depending on disease response All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir The overall response rate was 35 the complete response CR rate was 13 and the partial response PR rate was 22 The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR The median duration of survival was 25 months for patients who had a response and 12 months for the entire population Normalization of the lymphocyte count was observed in 84 of patients and resolution of marrow involvement was observed in 49 of patients The most common infusion-related adverse events were fever rigors rash nausea and dyspnea These were most common during the first week of therapy Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia Thirty-six patients 46 experienced at least one episode of fever or infection Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[2281, 94, 224, 17, 3579, 16, 544, 4, 4192, 1997, 3, 738, 426, 8, 124, 215, 160, 6, 376, 3, 209, 2, 367, 1, 3579, 4, 131, 15, 430, 442, 4192, 1997, 2073, 659, 7, 11, 346, 3, 96, 186, 2403, 11, 442, 1193, 78, 595, 7, 2, 102, 31, 14779, 78, 203, 7, 348, 7653, 3, 45, 3, 7, 42, 103, 232, 235, 52, 169, 235, 2, 3, 52, 98, 29, 147, 10, 67, 60, 3579, 10, 447, 1672, 28, 415, 1, 27, 81, 79, 81, 2, 201, 81, 23, 27, 935, 162, 50, 92, 201, 81, 10, 468, 27, 1072, 8, 647, 7, 11, 73, 9, 39, 133, 244, 3221, 23, 34, 51, 62, 7, 103, 1862, 23151, 23152, 2, 26204, 3, 63, 51, 116, 10, 465, 3, 236, 51, 684, 116, 10, 233, 2, 3, 450, 51, 998, 116, 10, 350, 3, 52, 654, 1, 51, 10, 203, 53, 9, 7, 1785, 8, 684, 2, 67, 53, 9, 7, 1785, 8, 998, 3, 52, 654, 1, 25, 10, 243, 53, 9, 7, 54, 42, 8, 51, 2, 133, 53, 9, 3, 1797, 266, 5924, 1, 3, 1448, 1276, 10, 164, 4, 874, 1, 7, 2, 2125, 1, 581, 799, 10, 164, 4, 739, 1, 7, 3, 96, 186, 904, 139, 290, 281, 11, 2775, 16755, 1641, 1218, 2, 2923, 46, 11, 96, 186, 190, 3, 157, 647, 1, 36, 813, 155, 10, 2603, 1, 319, 3443, 18790, 2, 2473, 778, 2, 1340, 977, 437, 7, 641, 592, 28, 506, 104, 6934, 1, 2775, 15, 930, 3579, 71, 8, 64, 51, 116, 4, 7, 5, 442, 4192, 1997]",1717.0,12910522,45
Rituximab in B-cell chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2003-08-01,"The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms, including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic leukemia (B-CLL). Phase II clinical studies demonstrated that rituximab, given weekly as a single agent, exhibits significantly less activity in B-CLL than in indolent B-cell lymphomas. Dose escalation, achieved by a thrice-weekly dosing schedule, is necessary for rituximab to effect significant clinical activity as a single agent. A multicenter, prospective, randomized trial demonstrated that concurrent administration with fludarabine improves the complete response (CR) rate. Ongoing clinical studies are examining the use of rituximab in other combination regimens, including FCR (fludarabine, cyclophosphamide, and rituximab), which has shown great promise in a single-center phase II trial. B-CLL patients may experience more infusion toxicity, including tumor lysis syndrome, to rituximab than patients with lymphoma. However, such infusion toxicity is minimized with appropriate premedication and a stepped up dosing schedule, allowing safe and effective use of rituximab in this disease.",Journal Article,6017.0,46.0,The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic B-CLL Phase II clinical studies demonstrated that rituximab given weekly as a single agent exhibits significantly less activity in B-CLL than in indolent B-cell lymphomas Dose escalation achieved by a thrice-weekly dosing schedule is necessary for rituximab to effect significant clinical activity as a single agent A multicenter prospective randomized trial demonstrated that concurrent administration with fludarabine improves the complete response CR rate Ongoing clinical studies are examining the use of rituximab in other combination regimens including FCR fludarabine cyclophosphamide and rituximab which has shown great promise in a single-center phase II trial B-CLL patients may experience more infusion toxicity including tumor lysis syndrome to rituximab than patients with However such infusion toxicity is minimized with appropriate premedication and a stepped up dosing schedule allowing safe and effective use of rituximab in this disease,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 848, 312, 2198, 548, 855, 5685, 211, 579, 128, 298, 8, 1362, 1, 483, 141, 5375, 480, 3, 763, 2945, 4, 351, 17, 4978, 3693, 6, 132, 442, 1193, 132, 552, 124, 215, 38, 94, 264, 17, 855, 447, 709, 22, 8, 226, 420, 4273, 97, 299, 128, 4, 132, 552, 76, 4, 2316, 132, 31, 1557, 61, 1125, 513, 20, 8, 10058, 709, 1280, 1055, 16, 1493, 9, 855, 6, 254, 93, 38, 128, 22, 8, 226, 420, 8, 1570, 482, 384, 160, 264, 17, 750, 634, 5, 2027, 1804, 3, 236, 51, 684, 116, 942, 38, 94, 32, 3282, 3, 119, 1, 855, 4, 127, 150, 472, 141, 4953, 2027, 1112, 2, 855, 92, 71, 443, 2797, 1783, 4, 8, 226, 574, 124, 215, 160, 132, 552, 7, 68, 730, 80, 904, 155, 141, 30, 4783, 681, 6, 855, 76, 7, 5, 137, 225, 904, 155, 16, 9243, 5, 870, 8656, 2, 8, 33497, 126, 1280, 1055, 2952, 1165, 2, 323, 119, 1, 855, 4, 26, 34]",1159.0,12939717,282
Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.,Current treatment options in oncology,Curr Treat Options Oncol,2003-08-01,"Natural killer (NK) cell leukemia and lymphoma represent rare conditions with heterogeneity of biologic behavior, prognosis, and responsiveness to therapy. The initial diagnosis of NK-cell malignancies can be difficult because of the lack of immunophenotypic clonality markers, morphologic heterogeneity, and a poor correlation between cytomorphology and prognosis. Therapeutic recommendations for NK-cell malignancies are derived from retrospective studies or case reports. Immature NK-cell malignancies often have aggressive behavior with poor prognosis, despite administration of acute myeloid leukemia or acute lymphocytic leukemia induction chemotherapy. The use of high-dose chemotherapy with stem cell rescue resulted in a prolonged survival in a small series of patients. NK-cell malignancies originating from cells with mature phenotypes form a spectrum of diseases with distinct prognosis. Patients with aggressive NK-cell leukemia invariably die within several months. Nasal and nasal-like NK/T-cell lymphomas with limited stage disease often respond to radiation therapy alone or combination with chemotherapy and radiation therapy, with 5-year disease-free survival rates ranging from 30% to 75%. Patients with T-cell large granular lymphocyte leukemia or chronic NK-cell lymphoproliferative disease of granular lymphocytes can have an indolent clinical course with long survival without therapy. However, approximately 66% of patients with T-cell large granular lymphocyte leukemia require low-dose chemotherapy with methotrexate or cyclophosphamide or immunosuppressive therapy with glucocorticosteroids or cyclosporine A for symptomatic cytopenias during the course of their disease.",Journal Article,6017.0,9.0,Natural killer NK cell and represent rare conditions with heterogeneity of biologic behavior prognosis and responsiveness to therapy The initial diagnosis of NK-cell malignancies can be difficult because of the lack of immunophenotypic clonality markers morphologic heterogeneity and a poor correlation between cytomorphology and prognosis Therapeutic recommendations for NK-cell malignancies are derived from retrospective studies or case reports Immature NK-cell malignancies often have aggressive behavior with poor prognosis despite administration of acute myeloid or acute lymphocytic induction chemotherapy The use of high-dose chemotherapy with stem cell rescue resulted in a prolonged survival in a small series of patients NK-cell malignancies originating from cells with mature phenotypes form a spectrum of diseases with distinct prognosis Patients with aggressive NK-cell invariably die within several months Nasal and nasal-like NK/T-cell lymphomas with limited stage disease often respond to radiation therapy alone or combination with chemotherapy and radiation therapy with 5-year disease-free survival rates ranging from 30 to 75 Patients with T-cell large granular lymphocyte or chronic NK-cell lymphoproliferative disease of granular lymphocytes can have an indolent clinical course with long survival without therapy However approximately 66 of patients with T-cell large granular lymphocyte require low-dose chemotherapy with methotrexate or cyclophosphamide or immunosuppressive therapy with glucocorticosteroids or cyclosporine A for symptomatic cytopenias during the course of their disease,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1504, 3458, 1765, 31, 2, 1231, 622, 1298, 5, 1144, 1, 1283, 1710, 356, 2, 3642, 6, 36, 3, 388, 147, 1, 1765, 31, 441, 122, 40, 1740, 408, 1, 3, 926, 1, 6599, 8905, 525, 2815, 1144, 2, 8, 334, 816, 59, 14729, 2, 356, 189, 883, 9, 1765, 31, 441, 32, 526, 29, 459, 94, 15, 473, 1198, 5733, 1765, 31, 441, 629, 47, 571, 1710, 5, 334, 356, 550, 634, 1, 286, 533, 15, 286, 1193, 504, 56, 3, 119, 1, 64, 61, 56, 5, 452, 31, 4256, 627, 4, 8, 1069, 25, 4, 8, 302, 988, 1, 7, 1765, 31, 441, 6794, 29, 37, 5, 2908, 2618, 1297, 8, 1873, 1, 1342, 5, 834, 356, 7, 5, 571, 1765, 31, 6912, 3384, 262, 392, 53, 6743, 2, 6743, 733, 1765, 102, 31, 1557, 5, 383, 82, 34, 629, 1892, 6, 121, 36, 279, 15, 150, 5, 56, 2, 121, 36, 5, 33, 111, 34, 115, 25, 151, 2223, 29, 201, 6, 481, 7, 5, 102, 31, 375, 7694, 1448, 15, 442, 1765, 31, 4192, 34, 1, 7694, 1594, 122, 47, 35, 2316, 38, 906, 5, 319, 25, 187, 36, 137, 705, 700, 1, 7, 5, 102, 31, 375, 7694, 1448, 1353, 154, 61, 56, 5, 2116, 15, 1112, 15, 2989, 36, 5, 43360, 15, 9112, 8, 9, 1704, 5635, 190, 3, 906, 1, 136, 34]",1614.0,12943609,438
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.,European journal of haematology,Eur. J. Haematol.,2003-10-01,"The genetic events involved in the transformation of chronic lymphocytic leukemia (CLL) to Richter's syndrome (RS) are poorly understood. Frequently large cells are seen in the bone marrows of patients with CLL and evidence of RS. Using a laser-capture microdissection we analyzed small and large leukemic bone marrow cells from 19 patients with RS for loss of heterozygosity (LOH) on chromosome 11 (D11S2179 at the ATM gene), 17 (D17S938 and D17S1852 at the TP53 site), and 20 (Plc1, D20S96, D20S110, and D20S119). Megakaryocytes were also isolated and used as a control for normal cells. Four of 15 (27.7%) informative cases showed LOH in small cells in the ATM gene while seven (46.7%) showed LOH in large cells. Six of 15 (40%) informative cases had LOH in chromosome 17 in small cells, and eight (53%) showed LOH in large cells. Eleven of 19 informative cases (61.1%) showed LOH in chromosome 20 in large cells, and eight (42.1%) showed LOH in small cells. RS cases with LOH at chromosome 20 were associated with marginally shorter survival rates (P = 0.08). Our data suggest that there are significant molecular differences between large and small cells in patients with CLL. Further analysis of the genes on these chromosomes may provide new insight into our understanding of the transformation of small CLL cells to large (Richter) cells.",Journal Article,5956.0,11.0,The genetic events involved in the transformation of chronic lymphocytic CLL to Richter 's syndrome RS are poorly understood Frequently large cells are seen in the marrows of patients with CLL and evidence of RS Using a laser-capture microdissection we analyzed small and large leukemic marrow cells from 19 patients with RS for loss of heterozygosity LOH on chromosome 11 D11S2179 at the ATM gene 17 D17S938 and D17S1852 at the TP53 site and 20 Plc1 D20S96 D20S110 and D20S119 Megakaryocytes were also isolated and used as a control for normal cells Four of 15 27.7 informative cases showed LOH in small cells in the ATM gene while seven 46.7 showed LOH in large cells Six of 15 40 informative cases had LOH in chromosome 17 in small cells and eight 53 showed LOH in large cells Eleven of 19 informative cases 61.1 showed LOH in chromosome 20 in large cells and eight 42.1 showed LOH in small cells RS cases with LOH at chromosome 20 were associated with marginally shorter survival rates P 0.08 Our data suggest that there are significant molecular differences between large and small cells in patients with CLL Further analysis of the genes on these chromosomes may provide new insight into our understanding of the transformation of small CLL cells to large Richter cells,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 336, 281, 646, 4, 3, 1392, 1, 442, 1193, 552, 6, 8452, 292, 681, 2250, 32, 1240, 1784, 746, 375, 37, 32, 527, 4, 3, 13800, 1, 7, 5, 552, 2, 241, 1, 2250, 75, 8, 3555, 2891, 8338, 21, 311, 302, 2, 375, 2015, 581, 37, 29, 326, 7, 5, 2250, 9, 407, 1, 3963, 2594, 23, 1170, 175, 37525, 28, 3, 3552, 145, 269, 53729, 2, 53730, 28, 3, 1206, 606, 2, 179, 53731, 53732, 53733, 2, 53734, 15110, 11, 120, 1355, 2, 95, 22, 8, 182, 9, 295, 37, 294, 1, 167, 428, 67, 4189, 140, 224, 2594, 4, 302, 37, 4, 3, 3552, 145, 369, 648, 641, 67, 224, 2594, 4, 375, 37, 437, 1, 167, 327, 4189, 140, 42, 2594, 4, 1170, 269, 4, 302, 37, 2, 659, 699, 224, 2594, 4, 375, 37, 2627, 1, 326, 4189, 140, 713, 14, 224, 2594, 4, 1170, 179, 4, 375, 37, 2, 659, 595, 14, 224, 2594, 4, 302, 37, 2250, 140, 5, 2594, 28, 1170, 179, 11, 41, 5, 5007, 985, 25, 151, 19, 13, 1592, 114, 74, 309, 17, 125, 32, 93, 219, 362, 59, 375, 2, 302, 37, 4, 7, 5, 552, 195, 65, 1, 3, 214, 23, 46, 3560, 68, 377, 217, 2670, 237, 114, 612, 1, 3, 1392, 1, 302, 552, 37, 6, 375, 8452, 37]",1275.0,12950231,292
Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.,Clinical lymphoma,Clin Lymphoma,2003-08-01,"Anemia has been reported in approximately 40%-70% of patients with hematologic malignancies, with severity depending on the type and stage of disease and whether the patient has received myelosuppressive chemotherapy. Growing evidence supports the role of epoetin alfa in correcting anemia and improving quality of life (QOL) in patients with hematologic malignancies. Clinical practice guidelines recommend the use of epoetin alfa in patients with cancer-related anemia (including patients with hematologic malignancies) and hemoglobin levels < or =10 g/dL. Epoetin alfa treatment is optional for patients with cancer-related anemia and hemoglobin levels>10 g/dL and <12 g/dL, depending on clinical circumstances. A prospective, open-label, randomized trial evaluating hematologic response, transfusion use, and QOL after immediate or delayed epoetin alfa treatment in mildly anemic patients (hemoglobin< or =12 g/dL) undergoing chemotherapy for chronic lymphocytic leukemia, multiple myeloma, or lymphoma was recently completed. Study objectives included determining any correlation between changes in hemoglobin level and QOL and assessing any correlation between QOL measures and health care resource use. Interim results suggest that epoetin alfa treatment in patients with hematologic cancers and hemoglobin< or =12 g/dL who are receiving chemotherapy increases hemoglobin, functional capacity, well-being, work and productivity, and health resource use. Further evaluation of alternative epoetin alfa dosing schedules and use of epoetin alfa in treating anemia in patients with specific hematologic malignancies is ongoing.",Clinical Trial,6017.0,7.0,Anemia has been reported in approximately 40 -70 of patients with hematologic malignancies with severity depending on the type and stage of disease and whether the patient has received myelosuppressive chemotherapy Growing evidence supports the role of epoetin alfa in correcting anemia and improving quality of life QOL in patients with hematologic malignancies Clinical practice guidelines recommend the use of epoetin alfa in patients with cancer-related anemia including patients with hematologic malignancies and hemoglobin levels or =10 g/dL Epoetin alfa treatment is optional for patients with cancer-related anemia and hemoglobin levels 10 g/dL and 12 g/dL depending on clinical circumstances A prospective open-label randomized trial evaluating hematologic response transfusion use and QOL after immediate or delayed epoetin alfa treatment in mildly anemic patients hemoglobin or =12 g/dL undergoing chemotherapy for chronic lymphocytic multiple or was recently completed Study objectives included determining any correlation between changes in hemoglobin level and QOL and assessing any correlation between QOL measures and health care resource use Interim results suggest that epoetin alfa treatment in patients with hematologic cancers and hemoglobin or =12 g/dL who are receiving chemotherapy increases hemoglobin functional capacity well-being work and productivity and health resource use Further evaluation of alternative epoetin alfa dosing schedules and use of epoetin alfa in treating anemia in patients with specific hematologic malignancies is ongoing,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1545, 71, 85, 210, 4, 705, 327, 431, 1, 7, 5, 813, 441, 5, 1702, 3221, 23, 3, 267, 2, 82, 1, 34, 2, 317, 3, 69, 71, 103, 11109, 56, 1921, 241, 2304, 3, 200, 1, 7305, 4443, 4, 11154, 1545, 2, 1673, 372, 1, 358, 1001, 4, 7, 5, 813, 441, 38, 758, 677, 2237, 3, 119, 1, 7305, 4443, 4, 7, 5, 12, 139, 1545, 141, 7, 5, 813, 441, 2, 2222, 148, 15, 79, 499, 1826, 7305, 4443, 24, 16, 9281, 9, 7, 5, 12, 139, 1545, 2, 2222, 148, 79, 499, 1826, 2, 133, 499, 1826, 3221, 23, 38, 7684, 8, 482, 1020, 1756, 384, 160, 1435, 813, 51, 2785, 119, 2, 1001, 50, 2181, 15, 1612, 7305, 4443, 24, 4, 9443, 16224, 7, 2222, 15, 133, 499, 1826, 479, 56, 9, 442, 1193, 232, 15, 10, 761, 781, 45, 2409, 159, 2196, 500, 816, 59, 400, 4, 2222, 301, 2, 1001, 2, 1977, 500, 816, 59, 1001, 1018, 2, 341, 165, 3069, 119, 2914, 99, 309, 17, 7305, 4443, 24, 4, 7, 5, 813, 163, 2, 2222, 15, 133, 499, 1826, 54, 32, 357, 56, 1106, 2222, 583, 2162, 149, 486, 1357, 2, 10321, 2, 341, 3069, 119, 195, 451, 1, 1091, 7305, 4443, 1280, 2314, 2, 119, 1, 7305, 4443, 4, 1367, 1545, 4, 7, 5, 112, 813, 441, 16, 942]",1572.0,14556671,257
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.,Blood,Blood,2003-10-23,"Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL) makes it difficult for physicians to accurately identify which patients may benefit from an early or more aggressive treatment strategy and to provide patients with relevant prognostic information. Given the potential efficacy of newer therapies and the desire to treat patients at ""optimum"" times, it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis. The evolution of risk stratification models has advanced from clinical staging and use of basic laboratory parameters to include relevant biologic and genetic features. This article will review the dramatic progress in prognostication for CLL and will propose statistical modeling techniques to evaluate the utility of these new measures in predictive models to help determine the optimal combination of markers to improve prognostication for individual patients. This discussion will also elaborate which markers and tools should be used in current clinical practice and evaluated in ongoing clinical trials.",Journal Article,5934.0,201.0,Heterogeneity in the clinical behavior of patients with chronic lymphocytic CLL makes it difficult for physicians to accurately identify which patients may benefit from an early or more aggressive treatment strategy and to provide patients with relevant prognostic information Given the potential efficacy of newer therapies and the desire to treat patients at `` optimum '' times it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis The evolution of risk stratification models has advanced from clinical staging and use of basic laboratory parameters to include relevant biologic and genetic features This article will review the dramatic progress in prognostication for CLL and will propose statistical modeling techniques to evaluate the utility of these new measures in predictive models to help determine the optimal combination of markers to improve prognostication for individual patients This discussion will also elaborate which markers and tools should be used in current clinical practice and evaluated in ongoing clinical trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1144, 4, 3, 38, 1710, 1, 7, 5, 442, 1193, 552, 4677, 192, 1740, 9, 1261, 6, 2141, 255, 92, 7, 68, 247, 29, 35, 191, 15, 80, 571, 24, 692, 2, 6, 377, 7, 5, 867, 177, 487, 447, 3, 174, 209, 1, 2246, 235, 2, 3, 5278, 6, 943, 7, 28, 6357, 522, 1072, 192, 16, 80, 305, 76, 3353, 6, 690, 745, 1541, 1038, 6, 255, 7, 5, 334, 356, 3, 2554, 1, 43, 1541, 274, 71, 131, 29, 38, 632, 2, 119, 1, 2795, 1624, 1038, 6, 643, 867, 1283, 2, 336, 404, 26, 946, 303, 206, 3, 3079, 1466, 4, 4260, 9, 552, 2, 303, 2548, 1050, 2057, 1092, 6, 376, 3, 1207, 1, 46, 217, 1018, 4, 464, 274, 6, 987, 223, 3, 665, 150, 1, 525, 6, 401, 4260, 9, 797, 7, 26, 2488, 303, 120, 16764, 92, 525, 2, 1896, 257, 40, 95, 4, 291, 38, 758, 2, 194, 4, 942, 38, 143]",1106.0,14576043,695
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.,Blood,Blood,2003-11-06,"Decitabine (5-aza-2'-deoxycytidine) inhibits DNA methylation and has dual effects on neoplastic cells, including the reactivation of silenced genes and differentiation at low doses and cytotoxicity at high doses. We evaluated, in a phase 1 study, low-dose prolonged exposure schedules of decitabine in relapsed/refractory leukemias. Patient cohorts received decitabine at 5, 10, 15, or 20 mg/m2 intravenously over one hour daily, 5 days a week for 2 consecutive weeks, doses 5- to approximately 30-fold lower than the maximum tolerated dose (MTD). There were 2 groups that also received 15 mg/m2 daily for 15 or 20 days. A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect. Responses were seen at all dose levels. However, the dose of 15 mg/m2 for 10 days appeared to induce the most responses (11 of 17 or 65%), with fewer responses seen when the dose was escalated or prolonged (2 of 19 or 11%). There was no correlation between P15 methylation at baseline or after therapy and response to decitabine. We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.",Clinical Trial,5920.0,643.0,Decitabine 5-aza-2'-deoxycytidine inhibits DNA methylation and has dual effects on neoplastic cells including the reactivation of silenced genes and differentiation at low doses and cytotoxicity at high doses We evaluated in a phase 1 study low-dose prolonged exposure schedules of decitabine in relapsed/refractory leukemias Patient cohorts received decitabine at 5 10 15 or 20 mg/m2 intravenously over one hour daily 5 days a week for 2 consecutive weeks doses 5- to approximately 30-fold lower than the maximum tolerated dose MTD There were 2 groups that also received 15 mg/m2 daily for 15 or 20 days A total of 50 patients were treated 44 with acute myelogenous AML /myelodysplasia MDS 5 with chronic myelogenous CML and 1 with acute lymphocytic ALL and the drug was well tolerated at all dose levels with myelosuppression being the major side effect Responses were seen at all dose levels However the dose of 15 mg/m2 for 10 days appeared to induce the most responses 11 of 17 or 65 with fewer responses seen when the dose was escalated or prolonged 2 of 19 or 11 There was no correlation between P15 methylation at baseline or after therapy and response to decitabine We conclude that decitabine is effective in myeloid malignancies and low doses are as or more effective than higher doses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3004, 33, 3924, 6135, 6750, 1576, 261, 569, 2, 71, 1828, 176, 23, 2000, 37, 141, 3, 3834, 1, 5442, 214, 2, 910, 28, 154, 415, 2, 1408, 28, 64, 415, 21, 194, 4, 8, 124, 14, 45, 154, 61, 1069, 645, 2314, 1, 3004, 4, 591, 430, 2792, 69, 736, 103, 3004, 28, 33, 79, 167, 15, 179, 81, 821, 1672, 252, 104, 2583, 391, 33, 162, 8, 647, 9, 18, 935, 244, 415, 33, 6, 705, 201, 1116, 280, 76, 3, 689, 421, 61, 961, 125, 11, 18, 271, 17, 120, 103, 167, 81, 821, 391, 9, 167, 15, 179, 162, 8, 181, 1, 212, 7, 11, 73, 584, 5, 286, 2194, 329, 6128, 1223, 33, 5, 442, 2194, 903, 2, 14, 5, 286, 1193, 62, 2, 3, 234, 10, 149, 421, 28, 62, 61, 148, 5, 2858, 486, 3, 458, 1152, 254, 253, 11, 527, 28, 62, 61, 148, 137, 3, 61, 1, 167, 81, 821, 9, 79, 162, 2121, 6, 1290, 3, 96, 253, 175, 1, 269, 15, 556, 5, 1497, 253, 527, 198, 3, 61, 10, 2842, 15, 1069, 18, 1, 326, 15, 175, 125, 10, 77, 816, 59, 8840, 569, 28, 330, 15, 50, 36, 2, 51, 6, 3004, 21, 2060, 17, 3004, 16, 323, 4, 533, 441, 2, 154, 415, 32, 22, 15, 80, 323, 76, 142, 415]",1296.0,14604977,272
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.,Blood,Blood,2003-11-20,"The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR beta-chain-specific antibody that is currently in clinical trials for hematologic malignancies. We demonstrate that Hu1D10 induces caspase-independent apoptosis following secondary cross-linking in primary chronic lymphocytic leukemia (CLL) cells. Generation of reactive oxygen species (ROS) and signal transduction, as evidenced by phosphorylation of Syk and AKT, were noted. The source of the Hu1D10-induced ROS was examined using the Raji lymphoblastic cell line with engineered defects in the mitochondrial respiratory chain. Hu1D10 treatment of clones with deficient mitochondrial respiration produced ROS suggesting a cytoplasmic source. Administration of ROS scavengers to primary CLL cells prior to Hu1D10 treatment diminished AKT activation. Treatment with Hu1D10 and the phosphatidylinositol 3-kinase inhibitor LY294002 demonstrated in vitro synergy with enhanced apoptosis. In conjunction with an ongoing clinical trial, blood samples were collected following intravenous infusion of Hu1D10 and analyzed for phosphorylation of AKT. Two of 3 patient samples showed a sustained increase in AKT phosphorylation following Hu1D10 administration. These data suggest that Hu1D10 ligation in CLL cells induces death and survival signals for which combination therapies may be designed to greatly enhance efficiency of both Hu1D10 and other class II antibodies in development.",Journal Article,5906.0,54.0,The 1D10 antigen is the target for Hu1D10 apolizumab a humanized HLA-DR beta-chain-specific antibody that is currently in clinical trials for hematologic malignancies We demonstrate that Hu1D10 induces caspase-independent apoptosis following secondary cross-linking in primary chronic lymphocytic CLL cells Generation of reactive oxygen species ROS and signal transduction as evidenced by phosphorylation of Syk and AKT were noted The source of the Hu1D10-induced ROS was examined using the Raji lymphoblastic cell line with engineered defects in the mitochondrial respiratory chain Hu1D10 treatment of clones with deficient mitochondrial respiration produced ROS suggesting a cytoplasmic source Administration of ROS scavengers to primary CLL cells prior to Hu1D10 treatment diminished AKT activation Treatment with Hu1D10 and the phosphatidylinositol 3-kinase inhibitor LY294002 demonstrated in vitro synergy with enhanced apoptosis In conjunction with an ongoing clinical trial blood samples were collected following intravenous infusion of Hu1D10 and analyzed for phosphorylation of AKT Two of 3 patient samples showed a sustained increase in AKT phosphorylation following Hu1D10 administration These data suggest that Hu1D10 ligation in CLL cells induces death and survival signals for which combination therapies may be designed to greatly enhance efficiency of both Hu1D10 and other class II antibodies in development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 33429, 448, 16, 3, 283, 9, 19610, 33555, 8, 3619, 1160, 3436, 1090, 1260, 112, 548, 17, 16, 694, 4, 38, 143, 9, 813, 441, 21, 608, 17, 19610, 1516, 1469, 306, 351, 366, 568, 1383, 5806, 4, 86, 442, 1193, 552, 37, 914, 1, 2163, 2848, 2915, 2609, 2, 1235, 2761, 22, 4728, 20, 982, 1, 6792, 2, 649, 11, 1051, 3, 2353, 1, 3, 19610, 277, 2609, 10, 409, 75, 3, 9868, 1275, 31, 328, 5, 2794, 2945, 4, 3, 2019, 2718, 1260, 19610, 24, 1, 2749, 5, 1971, 2019, 7725, 1687, 2609, 802, 8, 2828, 2353, 634, 1, 2609, 26237, 6, 86, 552, 37, 324, 6, 19610, 24, 2849, 649, 363, 24, 5, 19610, 2, 3, 3415, 27, 216, 230, 7527, 264, 4, 439, 3439, 5, 651, 351, 4, 3357, 5, 35, 942, 38, 160, 315, 347, 11, 786, 366, 1262, 904, 1, 19610, 2, 311, 9, 982, 1, 649, 100, 1, 27, 69, 347, 224, 8, 2275, 344, 4, 649, 982, 366, 19610, 634, 46, 74, 309, 17, 19610, 5307, 4, 552, 37, 1516, 273, 2, 25, 2312, 9, 92, 150, 235, 68, 40, 1114, 6, 3510, 1304, 2904, 1, 110, 19610, 2, 127, 1040, 215, 890, 4, 193]",1424.0,14630799,692
"Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.",Leukemia research,Leuk. Res.,2004-02-01,"Fifteen patients with previously untreated chronic lymphocytic leukemia (CLL) were treated with oral fludarabine. Toxicities were mainly hematologic, and the response rate was 80%. To assess the effect of fludarabine on the transcription factor STAT1, blood samples obtained on study entry were treated in vitro with fludarabine for 24 h, and the majority of samples displayed an expected decrease in STAT1. To determine whether similar changes occurred in vivo, we developed a flow cytometric assay to quantitate STAT1 levels. On completion of fludarabine cycle 1, CLL cells showed increased STAT1 in the majority of patients, in contrast to the in vitro findings. This may reflect a survival advantage for cells that express high levels of STAT1. In conclusion, oral fludarabine is highly active and merits further investigation in previously untreated patients with CLL. Larger studies are indicated to determine optimal timing of STAT1 assessment, and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy.",Clinical Trial,5833.0,18.0,Fifteen patients with previously untreated chronic lymphocytic CLL were treated with oral fludarabine Toxicities were mainly hematologic and the response rate was 80 To assess the effect of fludarabine on the transcription factor STAT1 blood samples obtained on study entry were treated in vitro with fludarabine for 24 h and the majority of samples displayed an expected decrease in STAT1 To determine whether similar changes occurred in vivo we developed a flow cytometric assay to quantitate STAT1 levels On completion of fludarabine cycle 1 CLL cells showed increased STAT1 in the majority of patients in contrast to the in vitro findings This may reflect a survival advantage for cells that express high levels of STAT1 In conclusion oral fludarabine is highly active and merits further investigation in previously untreated patients with CLL Larger studies are indicated to determine optimal timing of STAT1 assessment and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3057, 7, 5, 373, 1278, 442, 1193, 552, 11, 73, 5, 518, 2027, 385, 11, 2615, 813, 2, 3, 51, 116, 10, 493, 6, 423, 3, 254, 1, 2027, 23, 3, 866, 161, 5793, 315, 347, 683, 23, 45, 3001, 11, 73, 4, 439, 5, 2027, 9, 259, 555, 2, 3, 686, 1, 347, 2507, 35, 1336, 775, 4, 5793, 6, 223, 317, 288, 400, 489, 4, 386, 21, 276, 8, 1412, 6226, 719, 6, 13316, 5793, 148, 23, 1438, 1, 2027, 417, 14, 552, 37, 224, 101, 5793, 4, 3, 686, 1, 7, 4, 748, 6, 3, 4, 439, 272, 26, 68, 2694, 8, 25, 1874, 9, 37, 17, 1669, 64, 148, 1, 5793, 4, 1221, 518, 2027, 16, 561, 544, 2, 4986, 195, 940, 4, 373, 1278, 7, 5, 552, 1077, 94, 32, 1103, 6, 223, 665, 1972, 1, 5793, 455, 2, 492, 400, 4, 5793, 1231, 35, 4, 386, 3287, 1, 51, 6, 5006, 3497, 36]",1016.0,14654078,80
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2003-12-01,"The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti-CD52 monoclonal antibody, in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy. Forty-one patients received alemtuzumab 3 times weekly for 4 weeks. The first 24 patients received 10 mg per dose, and the next 17 patients received 30 mg. All patients received infection prophylaxis during therapy and for 2 months after treatment. The overall response rate was 46%, including 39% of patients who received the 10 mg dose and responded versus 56% of the patients who received the 30 mg dose. The major reason for failure to respond was the presence of adenopathy. Residual bone marrow disease cleared in most patients, and 11 of 29 patients (38%) achieved a molecular disease remission. The median time to disease progression had not been reached in responders with a median follow-up of 18 months. Six patients remained in disease remission between 24-38 months after therapy. Infusion-related events were common with the initial doses, but all such events were NCI Common Toxicity Criteria Grade 1-2. Infections were reported to occur in 15 patients (37%), and 9 of these infections were reactivation of cytomegalovirus. Three patients developed Epstein-Barr virus positive, large cell lymphoma. Two patients had spontaneous resolution of the lymphoma and, in one patient, the lymphoma resolved after treatment with cidofovir and immunoglobulin. Alemtuzumab produced significant responses in patients with residual disease after chemotherapy. Bone marrow disease was eradicated more frequently than lymph node disease, and molecular disease remissions were achieved. A randomized trial comparing alemtuzumab with observation after chemotherapy is indicated.",Clinical Trial,5895.0,202.0,The objective of this study was to investigate the efficacy and safety of alemtuzumab the humanized anti-CD52 monoclonal antibody in patients with B-cell chronic lymphocytic and residual disease after chemotherapy Forty-one patients received alemtuzumab 3 times weekly for 4 weeks The first 24 patients received 10 mg per dose and the next 17 patients received 30 mg. All patients received infection prophylaxis during therapy and for 2 months after treatment The overall response rate was 46 including 39 of patients who received the 10 mg dose and responded versus 56 of the patients who received the 30 mg dose The major reason for failure to respond was the presence of adenopathy Residual marrow disease cleared in most patients and 11 of 29 patients 38 achieved a molecular disease remission The median time to disease progression had not been reached in responders with a median follow-up of 18 months Six patients remained in disease remission between 24-38 months after therapy Infusion-related events were common with the initial doses but all such events were NCI Common Toxicity Criteria Grade 1-2 Infections were reported to occur in 15 patients 37 and 9 of these infections were reactivation of cytomegalovirus Three patients developed Epstein-Barr virus positive large cell Two patients had spontaneous resolution of the and in one patient the resolved after treatment with cidofovir and immunoglobulin Alemtuzumab produced significant responses in patients with residual disease after chemotherapy marrow disease was eradicated more frequently than lymph node disease and molecular disease remissions were achieved A randomized trial comparing alemtuzumab with observation after chemotherapy is indicated,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 963, 3, 209, 2, 367, 1, 3579, 3, 3619, 312, 7189, 848, 548, 4, 7, 5, 132, 31, 442, 1193, 2, 753, 34, 50, 56, 1213, 104, 7, 103, 3579, 27, 1072, 709, 9, 39, 244, 3, 157, 259, 7, 103, 79, 81, 379, 61, 2, 3, 1305, 269, 7, 103, 201, 81, 62, 7, 103, 930, 2049, 190, 36, 2, 9, 18, 53, 50, 24, 3, 63, 51, 116, 10, 641, 141, 587, 1, 7, 54, 103, 3, 79, 81, 61, 2, 2211, 185, 664, 1, 3, 7, 54, 103, 3, 201, 81, 61, 3, 458, 3852, 9, 496, 6, 1892, 10, 3, 463, 1, 7741, 753, 581, 34, 9266, 4, 96, 7, 2, 175, 1, 462, 7, 519, 513, 8, 219, 34, 734, 3, 52, 98, 6, 34, 91, 42, 44, 85, 1300, 4, 1983, 5, 8, 52, 166, 126, 1, 203, 53, 437, 7, 958, 4, 34, 734, 59, 259, 519, 53, 50, 36, 904, 139, 281, 11, 186, 5, 3, 388, 415, 84, 62, 225, 281, 11, 2580, 186, 155, 371, 88, 14, 18, 1875, 11, 210, 6, 1271, 4, 167, 7, 567, 2, 83, 1, 46, 1875, 11, 3834, 1, 7314, 169, 7, 276, 5212, 5190, 1450, 109, 375, 31, 100, 7, 42, 3280, 2125, 1, 3, 2, 4, 104, 69, 3, 3862, 50, 24, 5, 26247, 2, 2593, 3579, 1687, 93, 253, 4, 7, 5, 753, 34, 50, 56, 581, 34, 10, 14124, 80, 746, 76, 263, 289, 34, 2, 219, 34, 3166, 11, 513, 8, 384, 160, 1430, 3579, 5, 1664, 50, 56, 16, 1103]",1720.0,14669286,465
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.,Leukemia & lymphoma,Leuk. Lymphoma,2003-10-01,"Anti-B4-blocked ricin is an immunotoxin consisting of anti-B4 murine monoclonal antibody and ""blocked ricin"" toxin. The anti-B4 monoclonal antibody is directed against the CD19 antigen, which is expressed on B-lymphocytes. A phase II study of anti-B4 blocked ricin toxin in patients with B-cell chronic lymphocytic leukemia (CLL) with residual disease after chemotherapy was conducted. Eleven patients received anti-B4 blocked ricin at 30 microg/kg lean body mass (LBM) daily by continuous infusion for 7 days followed with repeat infusion administered at 14-day intervals. No patient achieved an objective response. The major reasons for failure to respond were the presence of adenopathy and residual marrow disease. Three patients achieved immunophenotypic response in marrow and peripheral blood. Three of 6 patients with rearranged IgH and/or Ig kappa were germline after anti-B4 blocked ricin. The median follow-up of surviving patients is 8.6 years. The median survival is 5.8 years (range, 0.0-8.8). All patients have progressed. The median time to progression was 0.8 years (range, 0.3-3.0). Infusion-related toxicities were all grade 1-2. The most common toxicity was transaminitis. Human antimouse antibody (HAMA) and/or human antiricin antibody (HARA) development was documented in 2 patients. Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy.",Clinical Trial,5956.0,12.0,Anti-B4-blocked ricin is an immunotoxin consisting of anti-B4 murine monoclonal antibody and `` blocked ricin '' toxin The anti-B4 monoclonal antibody is directed against the CD19 antigen which is expressed on B-lymphocytes A phase II study of anti-B4 blocked ricin toxin in patients with B-cell chronic lymphocytic CLL with residual disease after chemotherapy was conducted Eleven patients received anti-B4 blocked ricin at 30 microg/kg lean body mass LBM daily by continuous infusion for 7 days followed with repeat infusion administered at 14-day intervals No patient achieved an objective response The major reasons for failure to respond were the presence of adenopathy and residual marrow disease Three patients achieved immunophenotypic response in marrow and peripheral blood Three of 6 patients with rearranged IgH and/or Ig kappa were germline after anti-B4 blocked ricin The median follow-up of surviving patients is 8.6 years The median survival is 5.8 years range 0.0-8.8 All patients have progressed The median time to progression was 0.8 years range 0.3-3.0 Infusion-related toxicities were all grade 1-2 The most common toxicity was transaminitis Human antimouse antibody HAMA and/or human antiricin antibody HARA development was documented in 2 patients Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[312, 14476, 2582, 18255, 16, 35, 14464, 2273, 1, 312, 14476, 1471, 848, 548, 2, 2582, 18255, 522, 8848, 3, 312, 14476, 848, 548, 16, 1166, 480, 3, 3158, 448, 92, 16, 570, 23, 132, 1594, 8, 124, 215, 45, 1, 312, 14476, 2582, 18255, 8848, 4, 7, 5, 132, 31, 442, 1193, 552, 5, 753, 34, 50, 56, 10, 426, 2627, 7, 103, 312, 14476, 2582, 18255, 28, 201, 2440, 503, 6949, 642, 782, 18941, 391, 20, 1314, 904, 9, 67, 162, 370, 5, 2334, 904, 468, 28, 213, 218, 1582, 77, 69, 513, 35, 461, 51, 3, 458, 2325, 9, 496, 6, 1892, 11, 3, 463, 1, 7741, 2, 753, 581, 34, 169, 7, 513, 6599, 51, 4, 581, 2, 672, 315, 169, 1, 49, 7, 5, 3201, 5221, 2, 15, 4200, 3096, 11, 1009, 50, 312, 14476, 2582, 18255, 3, 52, 166, 126, 1, 3050, 7, 16, 66, 49, 60, 3, 52, 25, 16, 33, 66, 60, 184, 13, 13, 66, 66, 62, 7, 47, 1839, 3, 52, 98, 6, 91, 10, 13, 66, 60, 184, 13, 27, 27, 13, 904, 139, 385, 11, 62, 88, 14, 18, 3, 96, 186, 155, 10, 8181, 171, 26198, 548, 22176, 2, 15, 171, 53930, 548, 53931, 193, 10, 1405, 4, 18, 7, 312, 14476, 2582, 18255, 10, 149, 421, 84, 42, 383, 128, 4, 7, 5, 753, 552, 50, 56]",1385.0,14692524,326
Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.,Journal of the American Society for Mass Spectrometry,J. Am. Soc. Mass Spectrom.,2004-01-01,"The post-translational modification of the core histones is critical to the regulation of chromatin structure. Traditional methods for the determination of histone modification utilize immunoassay techniques to determine the extent and site of post-translational modification. These methods, though sensitive, require site-specific antibodies. This manuscript describes the application of reverse-phase high-pressure liquid chromatography and mass spectrometry (LC-MS) to analyze global modification levels of core histones. The method is fast, sensitive, and easily automated. Furthermore, the technique gives the global patterns of modification for all four core histones in a single experiment. The LC-MS method was optimized using histones extracted from bovine thymus. These methods were then applied to the characterization of changes in histone modification in acute myeloid leukemia (AML) cell lines treated with histone deacetylase (HDAC) inhibitors. Dose-dependent changes in the distribution of modified core histones were observed. These results were validated in primary leukemia cells from patients with refractory or relapsed AML or chronic lymphocytic leukemia (CLL) treated on a Phase I clinical trial of the HDAC inhibitor depsipeptide. An increase in the relative abundance of specific acetylated forms of histone H4 was readily observable in these patients at intervals of 4 and 24 h after treatment.",Journal Article,5864.0,,The post-translational modification of the core histones is critical to the regulation of chromatin structure Traditional methods for the determination of histone modification utilize immunoassay techniques to determine the extent and site of post-translational modification These methods though sensitive require site-specific antibodies This manuscript describes the application of reverse-phase high-pressure liquid chromatography and mass spectrometry LC-MS to analyze global modification levels of core histones The method is fast sensitive and easily automated Furthermore the technique gives the global patterns of modification for all four core histones in a single experiment The LC-MS method was optimized using histones extracted from bovine thymus These methods were then applied to the characterization of changes in histone modification in acute myeloid AML cell lines treated with histone deacetylase HDAC inhibitors Dose-dependent changes in the distribution of modified core histones were observed These results were validated in primary cells from patients with refractory or relapsed AML or chronic lymphocytic CLL treated on a Phase I clinical trial of the HDAC inhibitor depsipeptide An increase in the relative abundance of specific acetylated forms of histone H4 was readily observable in these patients at intervals of 4 and 24 h after treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 539, 2460, 2437, 1, 3, 1793, 8457, 16, 740, 6, 3, 863, 1, 2287, 2772, 1847, 636, 9, 3, 3104, 1, 1508, 2437, 6391, 9006, 1092, 6, 223, 3, 1039, 2, 606, 1, 539, 2460, 2437, 46, 636, 2471, 745, 1353, 606, 112, 890, 26, 5825, 2677, 3, 1581, 1, 1772, 124, 64, 3738, 3165, 5140, 2, 782, 3680, 1837, 2307, 6, 1992, 1648, 2437, 148, 1, 1793, 8457, 3, 596, 16, 5830, 745, 2, 4697, 3235, 798, 3, 1312, 7989, 3, 1648, 764, 1, 2437, 9, 62, 294, 1793, 8457, 4, 8, 226, 8722, 3, 1837, 2307, 596, 10, 4039, 75, 8457, 2484, 29, 14218, 9468, 46, 636, 11, 818, 1498, 6, 3, 2136, 1, 400, 4, 1508, 2437, 4, 286, 533, 329, 31, 285, 73, 5, 1508, 2732, 2654, 222, 61, 470, 400, 4, 3, 1395, 1, 1230, 1793, 8457, 11, 164, 46, 99, 11, 938, 4, 86, 37, 29, 7, 5, 430, 15, 591, 329, 15, 442, 1193, 552, 73, 23, 8, 124, 70, 38, 160, 1, 3, 2654, 230, 10072, 35, 344, 4, 3, 580, 4778, 1, 112, 11941, 2377, 1, 1508, 7812, 10, 3860, 13793, 4, 46, 7, 28, 1582, 1, 39, 2, 259, 555, 50, 24]",1369.0,14698558,170
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.,Experimental hematology,Exp. Hematol.,2004-01-01,"To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia. Patients were eligible to treatment if they were refractory or recurred after a prior response to fludarabine. Seventeen patients were treated. All patients received a preparative regimen of fludarabine (30 mg/m(2) daily for 3 days) and intravenous cyclophosphamide (750 mg/m(2) daily for 3 days). Ten patients received rituximab in addition to chemotherapy. The median time from diagnosis to transplant was 67 months. Nine of 17 patients had refractory disease. All patients had engraftment of donor cells. Eleven (65%) did not require platelet transfusions. Ten patients with persistent disease underwent immunomanipulation to augment GVL effects including immunosuppression withdrawal and donor lymphocyte infusion with or without rituximab treatment. Seven of these 10 patients had a complete response and 2 had a partial response; 8 of these 9 responders had received rituximab with their immunomanipulation process. The final response was complete remission in 12 and partial remission in 4 patients for an overall response rate of 94%. Overall survival was 100% for patients who received the combined chemo-rituximab conditioning regimen, vs 14% for those who received chemotherapy alone (p=0.03). Our results indicate that a pronounced GVL effect occurs after nonmyeloablative allogeneic hematopoietic transplantation for advanced CLL. This activity might be facilitated by rituximab. Prospective controlled trials are needed to define the role of nonablative allogeneic hematopoietic transplantation for treatment of this disease.",Journal Article,5864.0,114.0,To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic Patients were eligible to treatment if they were refractory or recurred after a prior response to fludarabine Seventeen patients were treated All patients received a preparative regimen of fludarabine 30 mg/m 2 daily for 3 days and intravenous cyclophosphamide 750 mg/m 2 daily for 3 days Ten patients received rituximab in addition to chemotherapy The median time from diagnosis to transplant was 67 months Nine of 17 patients had refractory disease All patients had engraftment of donor cells Eleven 65 did not require platelet transfusions Ten patients with persistent disease underwent immunomanipulation to augment GVL effects including immunosuppression withdrawal and donor lymphocyte infusion with or without rituximab treatment Seven of these 10 patients had a complete response and 2 had a partial response 8 of these 9 responders had received rituximab with their immunomanipulation process The final response was complete remission in 12 and partial remission in 4 patients for an overall response rate of 94 Overall survival was 100 for patients who received the combined chemo-rituximab conditioning regimen vs 14 for those who received chemotherapy alone p=0.03 Our results indicate that a pronounced GVL effect occurs after nonmyeloablative allogeneic hematopoietic transplantation for advanced CLL This activity might be facilitated by rituximab Prospective controlled trials are needed to define the role of nonablative allogeneic hematopoietic transplantation for treatment of this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 963, 3, 1599, 105, 2647, 254, 1, 1063, 452, 31, 497, 50, 8, 24659, 1933, 477, 22, 24, 9, 7, 5, 442, 1193, 7, 11, 625, 6, 24, 492, 491, 11, 430, 15, 3363, 50, 8, 324, 51, 6, 2027, 3591, 7, 11, 73, 62, 7, 103, 8, 6085, 477, 1, 2027, 201, 81, 188, 18, 391, 9, 27, 162, 2, 1262, 1112, 4506, 81, 188, 18, 391, 9, 27, 162, 1618, 7, 103, 855, 4, 352, 6, 56, 3, 52, 98, 29, 147, 6, 941, 10, 598, 53, 762, 1, 269, 7, 42, 430, 34, 62, 7, 42, 2881, 1, 1488, 37, 2627, 556, 205, 44, 1353, 1596, 4987, 1618, 7, 5, 1882, 34, 208, 28175, 6, 4369, 8149, 176, 141, 3646, 3683, 2, 1488, 1448, 904, 5, 15, 187, 855, 24, 648, 1, 46, 79, 7, 42, 8, 236, 51, 2, 18, 42, 8, 450, 51, 66, 1, 46, 83, 1983, 42, 103, 855, 5, 136, 28175, 1129, 3, 1457, 51, 10, 236, 734, 4, 133, 2, 450, 734, 4, 39, 7, 9, 35, 63, 51, 116, 1, 960, 63, 25, 10, 394, 9, 7, 54, 103, 3, 397, 3341, 855, 1933, 477, 105, 213, 9, 135, 54, 103, 56, 279, 19, 13, 680, 114, 99, 1008, 17, 8, 3517, 8149, 254, 1780, 50, 6094, 1063, 1007, 497, 9, 131, 552, 26, 128, 822, 40, 4667, 20, 855, 482, 1149, 143, 32, 575, 6, 1107, 3, 200, 1, 24659, 1063, 1007, 497, 9, 24, 1, 26, 34]",1684.0,14725898,170
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.,Blood,Blood,2004-01-15,"The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions. Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.",Journal Article,5850.0,354.0,The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic CLL We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab 15 42 of whom had p53 mutations or deletions Clinical responses in patients with p53 mutations deletions or both were noted in 6 40 of 15 versus 4 19 of 21 of patients without The median response duration for this subset of patients was 8 months range 3-17 months These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 463, 1, 624, 258, 15, 1528, 2623, 9, 334, 51, 6, 809, 36, 4, 442, 1193, 552, 21, 990, 6, 223, 317, 3, 3619, 312, 7189, 548, 3579, 10, 323, 4, 26, 69, 87, 977, 437, 7, 5, 2027, 430, 552, 11, 73, 5, 3579, 167, 595, 1, 953, 42, 624, 138, 15, 2439, 38, 253, 4, 7, 5, 624, 138, 2439, 15, 110, 11, 1051, 4, 49, 327, 1, 167, 185, 39, 326, 1, 239, 1, 7, 187, 3, 52, 51, 654, 9, 26, 697, 1, 7, 10, 66, 53, 184, 27, 269, 53, 46, 74, 309, 17, 3579, 68, 40, 35, 323, 36, 9, 7, 5, 552, 5, 624, 138, 15, 2439]",694.0,14726385,674
Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).,American journal of hematology,Am. J. Hematol.,2004-02-01,"We report a unique case of 83-year-old Caucasian male with the initial simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). The patient presented with absolute lymphocytosis in the blood, asymptomatic generalized lymphadenopathy, and mild splenomegaly. The diagnosis of CLL was suggested from the blood film, but subsequent flow cytometric (FC) analysis on peripheral blood mononuclear cells (PBMNC) revealed two distinct abnormal clones of mature B cells. A small subpopulation (7%) of lymphoid cells expressed CD20, CD11c, FMC-7, CD103, CD25, and kappa surface light chain, consistent with HCL. The larger subpopulation (75%) of lymphoid cells expressed CD19, CD20, CD23, CD5, and lambda light chain, consistent with CLL. The expression of different immunoglobulin light chains on the circulating CLL (lambda) and HCL (kappa) cells suggested two, independent, malignant B-cell clones. Interestingly, FC analysis of bone marrow (BM) cells done 6 months later revealed bright lambda light chain expression on the HCL cells. Despite administration of several different courses of chemotherapy, the HCL subpopulation was not eliminated from the BM but remained stable between 7% and 10% of total BM lymphoid cells. The CLL, responsible for most of clinical symptoms in our patient, responded to combination chemotherapy with fludarabine and cytoxan, and later to monotherapy with rituximab.",Case Reports,5833.0,21.0,We report a unique case of 83-year-old Caucasian male with the initial simultaneous manifestation of chronic lymphocytic CLL and hairy cell HCL The patient presented with absolute lymphocytosis in the blood asymptomatic generalized lymphadenopathy and mild splenomegaly The diagnosis of CLL was suggested from the blood film but subsequent flow cytometric FC analysis on peripheral blood mononuclear cells PBMNC revealed two distinct abnormal clones of mature B cells A small subpopulation 7 of lymphoid cells expressed CD20 CD11c FMC-7 CD103 CD25 and kappa surface light chain consistent with HCL The larger subpopulation 75 of lymphoid cells expressed CD19 CD20 CD23 CD5 and lambda light chain consistent with CLL The expression of different immunoglobulin light chains on the circulating CLL lambda and HCL kappa cells suggested two independent malignant B-cell clones Interestingly FC analysis of marrow BM cells done 6 months later revealed bright lambda light chain expression on the HCL cells Despite administration of several different courses of chemotherapy the HCL subpopulation was not eliminated from the BM but remained stable between 7 and 10 of total BM lymphoid cells The CLL responsible for most of clinical symptoms in our patient responded to combination chemotherapy with fludarabine and cytoxan and later to monotherapy with rituximab,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 414, 8, 991, 473, 1, 852, 111, 1095, 3229, 1045, 5, 3, 388, 2824, 6746, 1, 442, 1193, 552, 2, 7152, 31, 4623, 3, 69, 917, 5, 1766, 8125, 4, 3, 315, 2100, 4169, 4962, 2, 1980, 6364, 3, 147, 1, 552, 10, 1148, 29, 3, 315, 9414, 84, 706, 1412, 6226, 4127, 65, 23, 672, 315, 3041, 37, 53985, 553, 100, 834, 1668, 2749, 1, 2908, 132, 37, 8, 302, 5518, 67, 1, 2303, 37, 570, 2198, 12513, 28184, 67, 13856, 4531, 2, 3096, 1255, 1691, 1260, 925, 5, 4623, 3, 1077, 5518, 481, 1, 2303, 37, 570, 3158, 2198, 9937, 6349, 2, 8561, 1691, 1260, 925, 5, 552, 3, 55, 1, 338, 2593, 1691, 7802, 23, 3, 1033, 552, 8561, 2, 4623, 3096, 37, 1148, 100, 306, 393, 132, 31, 2749, 2873, 4127, 65, 1, 581, 1246, 37, 1822, 49, 53, 1559, 553, 9676, 8561, 1691, 1260, 55, 23, 3, 4623, 37, 550, 634, 1, 392, 338, 1993, 1, 56, 3, 4623, 5518, 10, 44, 6173, 29, 3, 1246, 84, 958, 585, 59, 67, 2, 79, 1, 181, 1246, 2303, 37, 3, 552, 2327, 9, 96, 1, 38, 507, 4, 114, 69, 2211, 6, 150, 56, 5, 2027, 2, 26029, 2, 1559, 6, 1411, 5, 855]",1356.0,14755378,4
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2004-03-01,"Complement plays an important role in the immunotherapeutic action of the anti-CD20 mAb rituximab, and therefore we investigated whether complement might be the limiting factor in rituximab therapy. Our in vitro studies indicate that at high cell densities, binding of rituximab to human CD20(+) cells leads to loss of complement activity and consumption of component C2. Infusion of rituximab in chronic lymphocytic leukemia patients also depletes complement; sera of treated patients have reduced capacity to C3b opsonize and kill CD20(+) cells unless supplemented with normal serum or component C2. Initiation of rituximab infusion in chronic lymphocytic leukemia patients leads to rapid clearance of CD20(+) cells. However, substantial numbers of B cells, with significantly reduced levels of CD20, return to the bloodstream immediately after rituximab infusion. In addition, a mAb specific for the Fc region of rituximab does not bind to these recirculating cells, suggesting that the rituximab-opsonized cells were temporarily sequestered by the mononuclear phagocytic system, and then released back into the circulation after the rituximab-CD20 complexes were removed by phagocytic cells. Western blots provide additional evidence for this escape mechanism that appears to occur as a consequence of CD20 loss. Treatment paradigms to prevent this escape, such as use of engineered or alternative anti-CD20 mAbs, may allow for more effective immunotherapy of chronic lymphocytic leukemia.",Journal Article,5804.0,253.0,Complement plays an important role in the immunotherapeutic action of the anti-CD20 mAb rituximab and therefore we investigated whether complement might be the limiting factor in rituximab therapy Our in vitro studies indicate that at high cell densities binding of rituximab to human CD20 cells leads to loss of complement activity and consumption of component C2 Infusion of rituximab in chronic lymphocytic patients also depletes complement sera of treated patients have reduced capacity to C3b opsonize and kill CD20 cells unless supplemented with normal serum or component C2 Initiation of rituximab infusion in chronic lymphocytic patients leads to rapid clearance of CD20 cells However substantial numbers of B cells with significantly reduced levels of CD20 return to the bloodstream immediately after rituximab infusion In addition a mAb specific for the Fc region of rituximab does not bind to these recirculating cells suggesting that the rituximab-opsonized cells were temporarily sequestered by the mononuclear phagocytic system and then released back into the circulation after the rituximab-CD20 complexes were removed by phagocytic cells Western blots provide additional evidence for this escape mechanism that appears to occur as a consequence of CD20 loss Treatment paradigms to prevent this escape such as use of engineered or alternative anti-CD20 mAbs may allow for more effective immunotherapy of chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3731, 1698, 35, 305, 200, 4, 3, 3222, 1578, 1, 3, 312, 2198, 2780, 855, 2, 673, 21, 565, 317, 3731, 822, 40, 3, 817, 161, 4, 855, 36, 114, 4, 439, 94, 1008, 17, 28, 64, 31, 6908, 791, 1, 855, 6, 171, 2198, 37, 1940, 6, 407, 1, 3731, 128, 2, 2421, 1, 1249, 6706, 904, 1, 855, 4, 442, 1193, 7, 120, 15243, 3731, 4210, 1, 73, 7, 47, 405, 2162, 6, 37636, 43520, 2, 5097, 2198, 37, 6179, 7687, 5, 295, 524, 15, 1249, 6706, 1118, 1, 855, 904, 4, 442, 1193, 7, 1940, 6, 1321, 1960, 1, 2198, 37, 137, 1281, 1870, 1, 132, 37, 5, 97, 405, 148, 1, 2198, 4656, 6, 3, 10210, 3467, 50, 855, 904, 4, 352, 8, 2780, 112, 9, 3, 4127, 1053, 1, 855, 1097, 44, 4060, 6, 46, 43521, 37, 802, 17, 3, 855, 22192, 37, 11, 17734, 19627, 20, 3, 3041, 19415, 398, 2, 818, 5394, 4636, 237, 3, 4984, 50, 3, 855, 2198, 3817, 11, 2264, 20, 19415, 37, 1521, 13483, 377, 402, 241, 9, 26, 3776, 670, 17, 1233, 6, 1271, 22, 8, 4177, 1, 2198, 407, 24, 4887, 6, 1682, 26, 3776, 225, 22, 119, 1, 2794, 15, 1091, 312, 2198, 5207, 68, 1700, 9, 80, 323, 726, 1, 442, 1193]",1438.0,14978136,171
"VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.",Blood,Blood,2004-03-02,"We recently reported that chronic lymphocytic leukemia (CLL) cells synthesize and release vascular endothelial growth factor (VEGF) under normoxic and hypoxic conditions. CLL B cells also express VEGF membrane receptors (VEGF-R1 and VEGF-R2), suggesting that they use VEGF as a survival factor. To assess the mechanism of apoptosis resistance related to VEGF, we determined the impact of VEGF on CLL B cells, and we studied the impact of epigallocatechin-3-gallate (EGCG), a known receptor tyrosine kinase (RTK) inhibitor, on VEGF receptor status and viability of CLL B cells. VEGF165 significantly increased apoptotic resistance of CLL B cells, and immunoblotting revealed that VEGF-R1 and VEGF-R2 are spontaneously phosphorylated on CLL B cells. EGCG significantly increased apoptosis/cell death in 8 of 10 CLL samples measured by annexin V/propidium iodide (PI) staining. The increase in annexin V/PI staining was accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase (PARP) cleavage at low concentrations of EGCG (3 microg/mL). Moreover, EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein (Bcl-2), X-linked inhibitor of apoptosis protein (XIAP), and myeloid cell leukemia-1 (Mcl-1) in CLL B cells. Finally, EGCG (3-25 microg/mL) suppressed VEGF-R1 and VEGF-R2 phosphorylation, albeit incompletely. Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death.",Comparative Study,5803.0,176.0,We recently reported that chronic lymphocytic CLL cells synthesize and release vascular endothelial growth factor VEGF under normoxic and hypoxic conditions CLL B cells also express VEGF membrane receptors VEGF-R1 and VEGF-R2 suggesting that they use VEGF as a survival factor To assess the mechanism of apoptosis resistance related to VEGF we determined the impact of VEGF on CLL B cells and we studied the impact of epigallocatechin-3-gallate EGCG a known receptor tyrosine kinase RTK inhibitor on VEGF receptor status and viability of CLL B cells VEGF165 significantly increased apoptotic resistance of CLL B cells and immunoblotting revealed that VEGF-R1 and VEGF-R2 are spontaneously phosphorylated on CLL B cells EGCG significantly increased apoptosis/cell death in 8 of 10 CLL samples measured by annexin V/propidium iodide PI staining The increase in annexin V/PI staining was accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase PARP cleavage at low concentrations of EGCG 3 microg/mL Moreover EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein Bcl-2 X-linked inhibitor of apoptosis protein XIAP and myeloid cell leukemia-1 Mcl-1 in CLL B cells Finally EGCG 3-25 microg/mL suppressed VEGF-R1 and VEGF-R2 phosphorylation albeit incompletely Thus these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 761, 210, 17, 442, 1193, 552, 37, 11254, 2, 2008, 756, 845, 129, 161, 618, 669, 15964, 2, 4744, 1298, 552, 132, 37, 120, 1669, 618, 1905, 1186, 618, 3239, 2, 618, 4332, 802, 17, 491, 119, 618, 22, 8, 25, 161, 6, 423, 3, 670, 1, 351, 251, 139, 6, 618, 21, 509, 3, 345, 1, 618, 23, 552, 132, 37, 2, 21, 656, 3, 345, 1, 15613, 27, 15965, 7729, 8, 440, 153, 564, 216, 5261, 230, 23, 618, 153, 156, 2, 2120, 1, 552, 132, 37, 43527, 97, 101, 1631, 251, 1, 552, 132, 37, 2, 5293, 553, 17, 618, 3239, 2, 618, 4332, 32, 6459, 2365, 23, 552, 132, 37, 7729, 97, 101, 351, 31, 273, 4, 66, 1, 79, 552, 347, 644, 20, 4850, 603, 10839, 8456, 2928, 1029, 3, 344, 4, 4850, 603, 2928, 1029, 10, 2756, 20, 1469, 27, 363, 2, 2699, 4938, 8762, 3507, 1451, 2041, 3155, 28, 154, 1003, 1, 7729, 27, 2440, 542, 1393, 7729, 1908, 3, 652, 132, 31, 2647, 4763, 18, 178, 1044, 18, 1006, 1199, 230, 1, 351, 178, 5387, 2, 533, 31, 2647, 14, 1308, 14, 4, 552, 132, 37, 1368, 7729, 27, 243, 2440, 542, 1908, 618, 3239, 2, 618, 4332, 982, 5993, 5252, 631, 46, 99, 309, 17, 618, 314, 2468, 25, 2312, 4, 552, 37, 2, 17, 4823, 1, 26, 5297, 308, 99, 4, 1469, 363, 2, 706, 2015, 31, 273]",1493.0,14996703,760
Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.,Mayo Clinic proceedings,Mayo Clin. Proc.,2004-03-01,"To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic leukemia (B-CLL). Peripheral blood mononuclear cells from 45 patients with B-CLL were purified and compared with lymph node samples collected from 17 of these patients. Also compared were B cells obtained from peripheral blood samples from 5 healthy controls and B cells from reactive lymph nodes from 3 otherwise healthy persons. The patients were treated at the Mayo Clinic in Rochester, Minn, between January 15,1991, and February 7, 2003. Mononuclear cells were stained by a 2-color (fluorescein isothiocyanate/phycoerythrin) flow cytometric assay using antibodies to the chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CCR2, CCR4, CCR5, CCR6, and CCR7) and also to CD19. Of the 45 patients in this study, 20 had Rai stage 0 disease, 12 had stage I disease, 3 had stage II disease, 2 had stage III disease, and 8 had stage IV disease. The mean fluorescent intensity (MFI) of the chemokine receptor expression on B-CLL cells was compared with normal controls and was not significantly different, except for an increase in the median expression of CXCR3 (P = .003) and CCR7 (P = .001) on B-CLL cells. We also found a significant increase in the expression of CXCR4 and CCR7 in B-CLL cells from patients with stage IV compared with stage 0 disease (P = .001 and P = .02, respectively). Furthermore, circulating B-CLL cells showed significantly higher expression of CXCR4 and CCR7 when compared with B lymphocytes in lymph nodes (P = .003 and P < .001, respectively). The expression of CXCR4 and CCR7 on B-CLL cells correlates with Rai stage. Also, these chemokine receptors may be down-regulated once malignant B cells enter the lymph nodes. To our knowledge, this is the first published report that shows the strong association of Rai stage with CXCR4 and CCR7 expression levels in B-CLL cells.",Journal Article,5804.0,,"To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic B-CLL Peripheral blood mononuclear cells from 45 patients with B-CLL were purified and compared with lymph node samples collected from 17 of these patients Also compared were B cells obtained from peripheral blood samples from 5 healthy controls and B cells from reactive lymph nodes from 3 otherwise healthy persons The patients were treated at the Mayo Clinic in Rochester Minn between January 15,1991 and February 7 2003 Mononuclear cells were stained by a 2-color fluorescein isothiocyanate/phycoerythrin flow cytometric assay using antibodies to the chemokine receptors CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CCR2 CCR4 CCR5 CCR6 and CCR7 and also to CD19 Of the 45 patients in this study 20 had Rai stage 0 disease 12 had stage I disease 3 had stage II disease 2 had stage III disease and 8 had stage IV disease The mean fluorescent intensity MFI of the chemokine receptor expression on B-CLL cells was compared with normal controls and was not significantly different except for an increase in the median expression of CXCR3 P .003 and CCR7 P .001 on B-CLL cells We also found a significant increase in the expression of CXCR4 and CCR7 in B-CLL cells from patients with stage IV compared with stage 0 disease P .001 and P .02 respectively Furthermore circulating B-CLL cells showed significantly higher expression of CXCR4 and CCR7 when compared with B lymphocytes in lymph nodes P .003 and P .001 respectively The expression of CXCR4 and CCR7 on B-CLL cells correlates with Rai stage Also these chemokine receptors may be down-regulated once malignant B cells enter the lymph nodes To our knowledge this is the first published report that shows the strong association of Rai stage with CXCR4 and CCR7 expression levels in B-CLL cells",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 423, 3, 38, 2088, 1, 3596, 153, 55, 23, 3, 91, 1, 132, 31, 442, 1193, 132, 552, 672, 315, 3041, 37, 29, 512, 7, 5, 132, 552, 11, 5963, 2, 72, 5, 263, 289, 347, 786, 29, 269, 1, 46, 7, 120, 72, 11, 132, 37, 683, 29, 672, 315, 347, 29, 33, 1331, 535, 2, 132, 37, 29, 2163, 263, 502, 29, 27, 2632, 1331, 4327, 3, 7, 11, 73, 28, 3, 2486, 1188, 4, 5801, 23080, 59, 1024, 167, 3372, 2, 3010, 67, 1522, 3041, 37, 11, 3386, 20, 8, 18, 6052, 14425, 13790, 43532, 1412, 6226, 719, 75, 890, 6, 3, 3596, 1186, 21231, 8201, 8198, 2318, 13280, 12167, 20357, 12602, 37650, 2, 10874, 2, 120, 6, 3158, 1, 3, 512, 7, 4, 26, 45, 179, 42, 4121, 82, 13, 34, 133, 42, 82, 70, 34, 27, 42, 82, 215, 34, 18, 42, 82, 316, 34, 2, 66, 42, 82, 478, 34, 3, 313, 2910, 837, 11162, 1, 3, 3596, 153, 55, 23, 132, 552, 37, 10, 72, 5, 295, 535, 2, 10, 44, 97, 338, 2187, 9, 35, 344, 4, 3, 52, 55, 1, 8198, 19, 1421, 2, 10874, 19, 144, 23, 132, 552, 37, 21, 120, 204, 8, 93, 344, 4, 3, 55, 1, 2318, 2, 10874, 4, 132, 552, 37, 29, 7, 5, 82, 478, 72, 5, 82, 13, 34, 19, 144, 2, 19, 588, 106, 798, 1033, 132, 552, 37, 224, 97, 142, 55, 1, 2318, 2, 10874, 198, 72, 5, 132, 1594, 4, 263, 502, 19, 1421, 2, 19, 144, 106, 3, 55, 1, 2318, 2, 10874, 23, 132, 552, 37, 1871, 5, 4121, 82, 120, 46, 3596, 1186, 68, 40, 1328, 1065, 1059, 393, 132, 37, 7058, 3, 263, 502, 6, 114, 922, 26, 16, 3, 157, 983, 414, 17, 1949, 3, 1082, 248, 1, 4121, 82, 5, 2318, 2, 10874, 55, 148, 4, 132, 552, 37]",1846.0,15008605,32
Current approach to diagnosis and management of chronic lymphocytic leukemia.,Mayo Clinic proceedings,Mayo Clin. Proc.,2004-03-01,"The care of patients with chronic lymphocytic leukemia (CLL) has changed dramatically during the past decade. This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL. Although clinical staging (Rai and Binet) remains the foundation for determining prognosis, 50% of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL. New laboratory techniques (CD38, fluorescence in situ hybridization [FISH]) can identify some patients with early-stage CLL at high risk of rapid disease progression. The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents, which have culminated in dramatically improved response rates. Supportive care guidelines now include vaccination strategies, surveillance for secondary malignancies, and aggressive management of infectious complications. An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial.",Journal Article,5804.0,,The care of patients with chronic lymphocytic CLL has changed dramatically during the past decade This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL Although clinical staging Rai and Binet remains the foundation for determining prognosis 50 of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL New laboratory techniques CD38 fluorescence in situ hybridization FISH can identify some patients with early-stage CLL at high risk of rapid disease progression The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents which have culminated in dramatically improved response rates Supportive care guidelines now include vaccination strategies surveillance for secondary malignancies and aggressive management of infectious complications An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 165, 1, 7, 5, 442, 1193, 552, 71, 2368, 2729, 190, 3, 1219, 2025, 26, 206, 2869, 3, 1357, 126, 1, 8125, 2, 3, 291, 752, 371, 2, 284, 1, 552, 242, 38, 632, 4121, 2, 17129, 469, 3, 3247, 9, 2196, 356, 212, 1, 7, 5, 191, 82, 34, 28, 147, 303, 730, 35, 571, 906, 1, 34, 5, 191, 91, 2, 5682, 273, 520, 6, 552, 217, 1624, 1092, 4469, 1591, 4, 957, 1554, 1277, 122, 255, 476, 7, 5, 191, 82, 552, 28, 64, 43, 1, 1321, 34, 91, 3, 1926, 1, 24, 838, 71, 2064, 4, 435, 60, 2, 1134, 1920, 848, 890, 95, 279, 15, 4, 150, 5, 5006, 4032, 4768, 2, 3410, 183, 92, 47, 17736, 4, 2729, 231, 51, 151, 1877, 165, 677, 1134, 643, 1915, 422, 617, 9, 568, 441, 2, 571, 284, 1, 3398, 521, 35, 191, 6216, 2981, 16, 793, 9, 62, 7, 28, 147, 6, 255, 2, 9892, 64, 43, 7, 5, 191, 82, 34, 54, 68, 247, 29, 80, 908, 166, 126, 15, 191, 24, 22, 760, 1, 8, 38, 160]",1251.0,15008611,105
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.,Cancer research,Cancer Res.,2004-04-01,"CpG island methylation is an epigenetic alteration that contributes to tumorigenesis by transcriptional inactivation of genes. Little is known about the overall levels of CpG island methylation in chronic lymphocytic leukemia (CLL). To provide a baseline estimate of global aberrant methylation and identify target sequences for additional investigation, we performed Restriction Landmark Genomic Scanning on 10 CLL samples. Two methylation-sensitive landmark enzymes were used (NotI and AscI), allowing assessment of over 3000 CpG islands in each sample. Tumor-derived Restriction Landmark Genomic Scanning profiles were compared with profiles from CD19-selected B cells from normal volunteers and matched normal neutrophils from 4 CLL patients. We found 2.5-8.1% (mean 4.8%) of the CpG islands in CLL samples were aberrantly methylated compared with controls, and the methylation events had a nonrandom distribution (P < 0.0001). Furthermore, we identified 193 aberrantly methylated sequences, of which 93% have CpG island characteristics and 90% have homology to genes or expressed sequences. One such gene, the G protein-coupled metabotropic glutamate receptor 7 (GRM7), possibly inhibits cyclic AMP signaling in the induction of apoptosis. Bisulfite sequencing of GRM7 confirmed extensive CpG island methylation, and treatment with 5-aza-2'-deoxycytidine (decitabine) resulted in up-regulated expression of several genes in vitro with concurrent cellular depletion of DNMT1 protein. Our dual-enzyme global methylation study shows that CLL is characterized by widespread nonrandom CpG island methylation similar to other tumors and provides a panel of novel methylation targets that can be used in larger studies designed to assess impact on disease progression and survival.",Journal Article,5773.0,118.0,CpG island methylation is an epigenetic alteration that contributes to tumorigenesis by transcriptional inactivation of genes Little is known about the overall levels of CpG island methylation in chronic lymphocytic CLL To provide a baseline estimate of global aberrant methylation and identify target sequences for additional investigation we performed Restriction Landmark Genomic Scanning on 10 CLL samples Two methylation-sensitive landmark enzymes were used NotI and AscI allowing assessment of over 3000 CpG islands in each sample Tumor-derived Restriction Landmark Genomic Scanning profiles were compared with profiles from CD19-selected B cells from normal volunteers and matched normal neutrophils from 4 CLL patients We found 2.5-8.1 mean 4.8 of the CpG islands in CLL samples were aberrantly methylated compared with controls and the methylation events had a nonrandom distribution P 0.0001 Furthermore we identified 193 aberrantly methylated sequences of which 93 have CpG island characteristics and 90 have homology to genes or expressed sequences One such gene the G protein-coupled metabotropic glutamate receptor 7 GRM7 possibly inhibits cyclic AMP signaling in the induction of apoptosis Bisulfite sequencing of GRM7 confirmed extensive CpG island methylation and treatment with 5-aza-2'-deoxycytidine decitabine resulted in up-regulated expression of several genes in vitro with concurrent cellular depletion of DNMT1 protein Our dual-enzyme global methylation study shows that CLL is characterized by widespread nonrandom CpG island methylation similar to other tumors and provides a panel of novel methylation targets that can be used in larger studies designed to assess impact on disease progression and survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2075, 3454, 569, 16, 35, 1418, 2611, 17, 2444, 6, 1565, 20, 1431, 2297, 1, 214, 1215, 16, 440, 545, 3, 63, 148, 1, 2075, 3454, 569, 4, 442, 1193, 552, 6, 377, 8, 330, 1191, 1, 1648, 1898, 569, 2, 255, 283, 2866, 9, 402, 940, 21, 173, 4575, 3829, 572, 3702, 23, 79, 552, 347, 100, 569, 745, 3829, 3039, 11, 95, 54094, 2, 54095, 2952, 455, 1, 252, 11264, 2075, 6046, 4, 296, 1000, 30, 526, 4575, 3829, 572, 3702, 1241, 11, 72, 5, 1241, 29, 3158, 715, 132, 37, 29, 295, 5495, 2, 655, 295, 5700, 29, 39, 552, 7, 21, 204, 18, 33, 66, 14, 313, 39, 66, 1, 3, 2075, 6046, 4, 552, 347, 11, 5619, 2963, 72, 5, 535, 2, 3, 569, 281, 42, 8, 12480, 1395, 19, 13, 488, 798, 21, 108, 5744, 5619, 2963, 2866, 1, 92, 966, 47, 2075, 3454, 374, 2, 424, 47, 7984, 6, 214, 15, 570, 2866, 104, 225, 145, 3, 499, 178, 3332, 30577, 8334, 153, 67, 43567, 2150, 1576, 8644, 7793, 314, 4, 3, 504, 1, 351, 6181, 615, 1, 43567, 557, 1344, 2075, 3454, 569, 2, 24, 5, 33, 3924, 6135, 6750, 3004, 627, 4, 126, 1065, 55, 1, 392, 214, 4, 439, 5, 750, 763, 2286, 1, 7328, 178, 114, 1828, 1644, 1648, 569, 45, 1949, 17, 552, 16, 765, 20, 3029, 12480, 2075, 3454, 569, 288, 6, 127, 57, 2, 777, 8, 993, 1, 229, 569, 637, 17, 122, 40, 95, 4, 1077, 94, 1114, 6, 423, 345, 23, 34, 91, 2, 25]",1734.0,15059895,406
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.,Leukemia research,Leuk. Res.,2004-05-01,"Purine nucleoside analogues are unique drugs that are effective in a variety of hematologic malignancies. Fludarabine and 2-chlorodeoxyadenosine (2-CdA) are active in chronic lymphocytic leukemia (CLL) both as salvage therapy and in newly diagnosed patients. These agents have revolutionized therapeutic strategies for patients with CLL that had remained unchanged for many years and included alkylating agents-based therapy with no potential for long-term remission or cure. Purine analogues have also been successfully combined with a variety of other chemotherapeutic drugs such as mitoxantrone, cyclophosphamide, corticosteroids, and monoclonal antibodies, specifically Rituximab and CAMPATH-1H. These agents are immunosuppressive and have been associated with opportunistic infections, the incidence of which can be significantly reduced by early recognition and administration of prophylactic antibiotics. In this review, the activity and toxicity of 2-CdA, fludarabine, and pentostatin in CLL as single agents and in combination with conventional chemotherapy are discussed. These drugs are increasingly used as initial therapy in CLL. Such strategies are associated with higher remission rates than have been previously achieved and in some cases, molecular remission, suggesting an important step towards cure.",Journal Article,5743.0,54.0,Purine nucleoside analogues are unique drugs that are effective in a variety of hematologic malignancies Fludarabine and 2-chlorodeoxyadenosine 2-CdA are active in chronic lymphocytic CLL both as salvage therapy and in newly diagnosed patients These agents have revolutionized therapeutic strategies for patients with CLL that had remained unchanged for many years and included alkylating agents-based therapy with no potential for long-term remission or cure Purine analogues have also been successfully combined with a variety of other chemotherapeutic drugs such as mitoxantrone cyclophosphamide corticosteroids and monoclonal antibodies specifically Rituximab and CAMPATH-1H These agents are immunosuppressive and have been associated with opportunistic infections the incidence of which can be significantly reduced by early recognition and administration of prophylactic antibiotics In this review the activity and toxicity of 2-CdA fludarabine and pentostatin in CLL as single agents and in combination with conventional chemotherapy are discussed These drugs are increasingly used as initial therapy in CLL Such strategies are associated with higher remission rates than have been previously achieved and in some cases molecular remission suggesting an important step towards cure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5006, 4032, 4768, 32, 991, 600, 17, 32, 323, 4, 8, 1362, 1, 813, 441, 2027, 2, 18, 23121, 18, 8174, 32, 544, 4, 442, 1193, 552, 110, 22, 992, 36, 2, 4, 732, 265, 7, 46, 183, 47, 5746, 189, 422, 9, 7, 5, 552, 17, 42, 958, 4639, 9, 445, 60, 2, 159, 3410, 183, 90, 36, 5, 77, 174, 9, 319, 337, 734, 15, 1722, 5006, 4768, 47, 120, 85, 1878, 397, 5, 8, 1362, 1, 127, 1573, 600, 225, 22, 4419, 1112, 3876, 2, 848, 890, 1225, 855, 2, 16622, 10147, 46, 183, 32, 2989, 2, 47, 85, 41, 5, 10026, 1875, 3, 287, 1, 92, 122, 40, 97, 405, 20, 191, 2335, 2, 634, 1, 1862, 5214, 4, 26, 206, 3, 128, 2, 155, 1, 18, 8174, 2027, 2, 7596, 4, 552, 22, 226, 183, 2, 4, 150, 5, 809, 56, 32, 1588, 46, 600, 32, 1635, 95, 22, 388, 36, 4, 552, 225, 422, 32, 41, 5, 142, 734, 151, 76, 47, 85, 373, 513, 2, 4, 476, 140, 219, 734, 802, 35, 305, 2458, 3113, 1722]",1288.0,15068894,563
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.,Clinical lymphoma,Clin Lymphoma,2004-03-01,"An expert opinion roundtable held August 8-9, 2002, brought together clinicians with the most extensive experience with the use of alemtuzumab to pool knowledge and develop treatment goals and guidelines for optimal therapy. By sharing our collective experience, we have been able to formulate recommendations for current clinical practice, which are included in this report, and have emphasized results that have implications for future practice. Guidelines for the management of acute ""first-dose"" events, prophylaxis for infection, detection and treatment of cytomegalovirus reactivation, and hematologic support are presented, with emphasis on allowing patients to proceed smoothly through therapy while maximizing therapeutic benefit. Management of adverse events is facilitated by the predictable timing of their appearance. In general, hematologic adverse events are transient, manageable, and reversible. Clinicians should be cautious of prematurely terminating treatment at 4-6 weeks in patients whose disease responds to treatment. Although resolution of peripheral blood lymphocytosis occurs early in most patients, bone marrow is unlikely to be clear of disease. In particular, grade 4 neutropenia at this time is common and, because it is manageable, it is not an indication to discontinue treatment. The eradication of minimal residual disease from blood and bone marrow observed with alemtuzumab therapy is a major step forward in the treatment of B-cell chronic lymphocytic leukemia. Combination therapies such as alemtuzumab/fludarabine with the potential to maximize eradication at all disease sites should be systematically investigated. Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients.",Journal Article,5804.0,86.0,An expert opinion roundtable held August 8-9 2002 brought together clinicians with the most extensive experience with the use of alemtuzumab to pool knowledge and develop treatment goals and guidelines for optimal therapy By sharing our collective experience we have been able to formulate recommendations for current clinical practice which are included in this report and have emphasized results that have implications for future practice Guidelines for the management of acute `` first-dose '' events prophylaxis for infection detection and treatment of cytomegalovirus reactivation and hematologic support are presented with emphasis on allowing patients to proceed smoothly through therapy while maximizing therapeutic benefit Management of adverse events is facilitated by the predictable timing of their appearance In general hematologic adverse events are transient manageable and reversible Clinicians should be cautious of prematurely terminating treatment at 4-6 weeks in patients whose disease responds to treatment Although resolution of peripheral blood lymphocytosis occurs early in most patients marrow is unlikely to be clear of disease In particular grade 4 neutropenia at this time is common and because it is manageable it is not an indication to discontinue treatment The eradication of minimal residual disease from blood and marrow observed with alemtuzumab therapy is a major step forward in the treatment of B-cell chronic lymphocytic Combination therapies such as alemtuzumab/fludarabine with the potential to maximize eradication at all disease sites should be systematically investigated Because high response rates and few complications are observed in previously untreated patients the use of alemtuzumab earlier in therapy may provide optimum benefit to patients,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[35, 2005, 3564, 14446, 4033, 2480, 66, 83, 1544, 6681, 1162, 1490, 5, 3, 96, 1344, 730, 5, 3, 119, 1, 3579, 6, 6545, 922, 2, 690, 24, 2802, 2, 677, 9, 665, 36, 20, 7436, 114, 9549, 730, 21, 47, 85, 1665, 6, 10992, 883, 9, 291, 38, 758, 92, 32, 159, 4, 26, 414, 2, 47, 8585, 99, 17, 47, 1268, 9, 508, 758, 677, 9, 3, 284, 1, 286, 157, 61, 522, 281, 2049, 9, 930, 638, 2, 24, 1, 7314, 3834, 2, 813, 538, 32, 917, 5, 3136, 23, 2952, 7, 6, 6174, 43575, 298, 36, 369, 8260, 189, 247, 284, 1, 290, 281, 16, 4667, 20, 3, 7639, 1972, 1, 136, 3592, 4, 1083, 813, 290, 281, 32, 2473, 2808, 2, 2786, 1490, 257, 40, 17741, 1, 9771, 30580, 24, 28, 39, 49, 244, 4, 7, 1310, 34, 7920, 6, 24, 242, 2125, 1, 672, 315, 8125, 1780, 191, 4, 96, 7, 581, 16, 3568, 6, 40, 885, 1, 34, 4, 1454, 88, 39, 778, 28, 26, 98, 16, 186, 2, 408, 192, 16, 2808, 192, 16, 44, 35, 3607, 6, 7934, 24, 3, 5173, 1, 1048, 753, 34, 29, 315, 2, 581, 164, 5, 3579, 36, 16, 8, 458, 2458, 4674, 4, 3, 24, 1, 132, 31, 442, 1193, 150, 235, 225, 22, 3579, 2027, 5, 3, 174, 6, 4116, 5173, 28, 62, 34, 633, 257, 40, 3390, 565, 408, 64, 51, 151, 2, 1021, 521, 32, 164, 4, 373, 1278, 7, 3, 119, 1, 3579, 1677, 4, 36, 68, 377, 6357, 247, 6, 7]",1793.0,15072613,313
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2004-04-01,"Humoral immunotherapy using the monoclonal anti-CD20 antibody rituximab induces remissions in approximately 60% of patients with relapsed follicular lymphoma; however, most patients eventually relapse despite continued expression of CD20 on lymphoma cells. We have hypothesized that cellular immunotherapy targeting CD20(+) cells might provide a more effective mechanism for eliminating lymphoma cells than anti-CD20 antibodies and are therefore investigating the utility of cytotoxic T lymphocytes (CTL) genetically modified to target the CD20 antigen. Peripheral blood mononuclear cells were activated with anti-CD3 antibody (OKT3) and recombinant human interleukin-2 and electroporated with a plasmid containing a CD20-specific scFvFc:zeta chimeric T cell receptor gene and a neomycin phosphotransferase gene (neo(R)). Transfected cells were selected using the antibiotic G418 and cloned by limiting dilution. Using this approach, we have generated CD8(+) CTL clones with CD20-specific cytotoxicity, which specifically lysed CD20(+) target cells, including actual tumor cells from patients with follicular lymphoma, small lymphocytic lymphoma, splenic marginal zone lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia. The CTL clones have been expanded to numbers sufficient for therapy ( approximately 10(9) cells). Our data indicate the feasibility of generating and expanding CD20-specific CTL and, for the first time, demonstrate that such CTL exhibit specific cytotoxicity against actual tumor cells isolated from patients with a variety of B lymphoid malignancies. In view of these promising findings, a Phase I clinical trial for relapsed follicular lymphoma is being initiated.",Journal Article,5773.0,64.0,Humoral immunotherapy using the monoclonal anti-CD20 antibody rituximab induces remissions in approximately 60 of patients with relapsed follicular however most patients eventually relapse despite continued expression of CD20 on cells We have hypothesized that cellular immunotherapy targeting CD20 cells might provide a more effective mechanism for eliminating cells than anti-CD20 antibodies and are therefore investigating the utility of cytotoxic T lymphocytes CTL genetically modified to target the CD20 antigen Peripheral blood mononuclear cells were activated with anti-CD3 antibody OKT3 and recombinant human interleukin-2 and electroporated with a plasmid containing a CD20-specific scFvFc zeta chimeric T cell receptor gene and a neomycin phosphotransferase gene neo R Transfected cells were selected using the antibiotic G418 and cloned by limiting dilution Using this approach we have generated CD8 CTL clones with CD20-specific cytotoxicity which specifically lysed CD20 target cells including actual tumor cells from patients with follicular small lymphocytic splenic marginal zone diffuse large B cell and chronic lymphocytic The CTL clones have been expanded to numbers sufficient for therapy approximately 10 9 cells Our data indicate the feasibility of generating and expanding CD20-specific CTL and for the first time demonstrate that such CTL exhibit specific cytotoxicity against actual tumor cells isolated from patients with a variety of B lymphoid malignancies In view of these promising findings a Phase I clinical trial for relapsed follicular is being initiated,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5498, 726, 75, 3, 848, 312, 2198, 548, 855, 1516, 3166, 4, 705, 335, 1, 7, 5, 591, 1974, 137, 96, 7, 3124, 429, 550, 1351, 55, 1, 2198, 23, 37, 21, 47, 1237, 17, 763, 726, 529, 2198, 37, 822, 377, 8, 80, 323, 670, 9, 6923, 37, 76, 312, 2198, 890, 2, 32, 673, 3103, 3, 1207, 1, 759, 102, 1594, 3872, 2301, 1230, 6, 283, 3, 2198, 448, 672, 315, 3041, 37, 11, 735, 5, 312, 3117, 548, 17791, 2, 2835, 171, 1603, 18, 2, 28214, 5, 8, 6007, 1101, 8, 2198, 112, 43583, 12105, 2897, 102, 31, 153, 145, 2, 8, 30411, 43584, 145, 5357, 668, 3245, 37, 11, 715, 75, 3, 5210, 33211, 2, 8560, 20, 817, 10446, 75, 26, 353, 21, 47, 1419, 968, 3872, 2749, 5, 2198, 112, 1408, 92, 1225, 14098, 2198, 283, 37, 141, 3480, 30, 37, 29, 7, 5, 1974, 302, 1193, 5237, 3450, 3614, 1388, 375, 132, 31, 2, 442, 1193, 3, 3872, 2749, 47, 85, 2064, 6, 1870, 1952, 9, 36, 705, 79, 83, 37, 114, 74, 1008, 3, 1437, 1, 3997, 2, 4304, 2198, 112, 3872, 2, 9, 3, 157, 98, 608, 17, 225, 3872, 2239, 112, 1408, 480, 3480, 30, 37, 1355, 29, 7, 5, 8, 1362, 1, 132, 2303, 441, 4, 3811, 1, 46, 721, 272, 8, 124, 70, 38, 160, 9, 591, 1974, 16, 486, 1917]",1588.0,15093188,134
Treatment of chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2004-04-01,"Treatment options for patients with chronic lymphocytic leukemia have changed over the past two decades. This article reviews the experience accumulated with the use of alkylating agents alone and in combination; purine analogues alone and in combination and monoclonal antibodies such as rituximab, and alemtuzumab alone and in combination. The results obtained with different treatment strategies are summarized, compared, and reviewed.",Journal Article,5773.0,15.0,Treatment options for patients with chronic lymphocytic have changed over the past two decades This article reviews the experience accumulated with the use of alkylating agents alone and in combination purine analogues alone and in combination and monoclonal antibodies such as rituximab and alemtuzumab alone and in combination The results obtained with different treatment strategies are summarized compared and reviewed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[24, 838, 9, 7, 5, 442, 1193, 47, 2368, 252, 3, 1219, 100, 1968, 26, 946, 2004, 3, 730, 6664, 5, 3, 119, 1, 3410, 183, 279, 2, 4, 150, 5006, 4768, 279, 2, 4, 150, 2, 848, 890, 225, 22, 855, 2, 3579, 279, 2, 4, 150, 3, 99, 683, 5, 338, 24, 422, 32, 3989, 72, 2, 446]",422.0,15124136,236
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.,Blood,Blood,2004-05-11,"Fludarabine and rituximab combination therapies in chronic lymphocytic leukemia (CLL) have yielded promising early results, but no comparative efficacy data relative to standard fludarabine treatment regimens have been reported. To assess the effect of the addition of rituximab to fludarabine therapy, we retrospectively compared the treatment outcome of patients with similar clinical characteristics enrolled on 2 multicenter clinical trials performed by the Cancer and Leukemia Group B and the US Intergroup that used fludarabine and rituximab (CALGB 9712, n = 104) or fludarabine (CALGB 9011, n = 178). In multivariate analyses controlling for pretreatment characteristics, the patients receiving fludarabine and rituximab had a significantly better progression-free survival (PFS; P < .0001) and overall survival (OS; P = .0006) than patients receiving fludarabine therapy. Two-year PFS probabilities were 0.67 versus 0.45, and 2-year OS probabilities were 0.93 versus 0.81. Infectious toxicity was similar between the 2 treatment approaches. These comparative data are retrospective and could be confounded by differences in supportive care or dissimilar enrollment of genetic subsets on each trial. Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine.",Comparative Study,5733.0,360.0,Fludarabine and rituximab combination therapies in chronic lymphocytic CLL have yielded promising early results but no comparative efficacy data relative to standard fludarabine treatment regimens have been reported To assess the effect of the addition of rituximab to fludarabine therapy we retrospectively compared the treatment outcome of patients with similar clinical characteristics enrolled on 2 multicenter clinical trials performed by the Cancer and Group B and the US Intergroup that used fludarabine and rituximab CALGB 9712 n 104 or fludarabine CALGB 9011 n 178 In multivariate analyses controlling for pretreatment characteristics the patients receiving fludarabine and rituximab had a significantly better progression-free survival PFS P .0001 and overall survival OS P .0006 than patients receiving fludarabine therapy Two-year PFS probabilities were 0.67 versus 0.45 and 2-year OS probabilities were 0.93 versus 0.81 Infectious toxicity was similar between the 2 treatment approaches These comparative data are retrospective and could be confounded by differences in supportive care or dissimilar enrollment of genetic subsets on each trial Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 2, 855, 150, 235, 4, 442, 1193, 552, 47, 2178, 721, 191, 99, 84, 77, 2352, 209, 74, 580, 6, 260, 2027, 24, 472, 47, 85, 210, 6, 423, 3, 254, 1, 3, 352, 1, 855, 6, 2027, 36, 21, 894, 72, 3, 24, 228, 1, 7, 5, 288, 38, 374, 346, 23, 18, 1570, 38, 143, 173, 20, 3, 12, 2, 87, 132, 2, 3, 843, 4839, 17, 95, 2027, 2, 855, 4077, 30595, 78, 3407, 15, 2027, 4077, 33264, 78, 7046, 4, 331, 318, 1893, 9, 1194, 374, 3, 7, 357, 2027, 2, 855, 42, 8, 97, 380, 91, 115, 25, 300, 19, 488, 2, 63, 25, 118, 19, 6013, 76, 7, 357, 2027, 36, 100, 111, 300, 3518, 11, 13, 598, 185, 13, 512, 2, 18, 111, 118, 3518, 11, 13, 966, 185, 13, 865, 3398, 155, 10, 288, 59, 3, 18, 24, 611, 46, 2352, 74, 32, 459, 2, 359, 40, 8927, 20, 362, 4, 1877, 165, 15, 16773, 1798, 1, 336, 1890, 23, 296, 160, 3551, 1, 46, 272, 303, 1353, 8, 482, 384, 160, 1430, 2027, 2, 855, 6, 2027]",1282.0,15138165,97
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.,Cancer,Cancer,2004-05-01,"Although central nervous system (CNS) prophylaxis in patients with leukemia has reduced the incidence of CNS disease recurrence, it still is reported to occur in approximately 5-10% of cases, resulting in a median survival of 6 months. Craniospinal irradiation (CSI) has been shown to improve survival in children who develop a CNS recurrence of acute lymphocytic leukemia (ALL). However, to the authors' knowledge, the role of CSI in adults with a CNS recurrence of leukemia is unknown. A retrospective review of adult patients treated with CSI for a CNS recurrence of leukemia identified 16 patients treated between 1986 and 2001. The median age of the patients was 34 years (range, 16-58 years). The diagnoses included seven patients with acute myelogenous leukemia (AML), eight patients with ALL, and one patient with chronic myelogenous leukemia in blast crisis. All patients had achieved a complete disease remission prior to the CNS recurrence. Eleven patients had an isolated CNS recurrence and 5 patients had concurrent disease identified in the blood/bone marrow. The median dose of radiation was 24 grays (Gy) (range, 18-34.5 Gy) to the cranium and 18 Gy (range, 15-30 Gy) to the spine. The median fraction size was 1.8 Gy (range, 1.5-2.0 Gy) to the cranium and 1.5 Gy (range, 1.5-2.0 Gy) to the spine. Fifteen patients were also treated with intrathecal chemotherapy. One patient failed to complete radiation treatment because of disease progression. Thirteen patients achieved a complete response in the cerebrospinal fluid (CSF). The median time to disease progression was 3 months from the first day of CSI and 7 months from CNS recurrence. The median survival was 4 months and 9 months, respectively. No CNS recurrences occurred, but there were 11 bone marrow failures, 2 patients without recurrence at > 5 years, and 3 deaths without a documented site of failure. Thirteen patients had no evidence of disease in the CSF until their death or the time of last follow-up. CSI with or without intrathecal chemotherapy appears to be effective at eliminating leukemia in the craniospinal axis. However, the eradication of disease in the CNS was not found to be effective at preventing disease recurrence in the bone marrow, and despite improved control of disease in the CNS, adult patients with a CNS recurrence still had a poor prognosis. Furthermore, the rapidly fatal course of disease prevented an assessment of the durability of CNS response to irradiation.",Journal Article,5743.0,26.0,Although central nervous system CNS prophylaxis in patients with has reduced the incidence of CNS disease recurrence it still is reported to occur in approximately 5-10 of cases resulting in a median survival of 6 months Craniospinal irradiation CSI has been shown to improve survival in children who develop a CNS recurrence of acute lymphocytic ALL However to the authors knowledge the role of CSI in adults with a CNS recurrence of is unknown A retrospective review of adult patients treated with CSI for a CNS recurrence of identified 16 patients treated between 1986 and 2001 The median age of the patients was 34 years range 16-58 years The diagnoses included seven patients with acute myelogenous AML eight patients with ALL and one patient with chronic myelogenous in blast crisis All patients had achieved a complete disease remission prior to the CNS recurrence Eleven patients had an isolated CNS recurrence and 5 patients had concurrent disease identified in the blood/bone marrow The median dose of radiation was 24 grays Gy range 18-34.5 Gy to the cranium and 18 Gy range 15-30 Gy to the spine The median fraction size was 1.8 Gy range 1.5-2.0 Gy to the cranium and 1.5 Gy range 1.5-2.0 Gy to the spine Fifteen patients were also treated with intrathecal chemotherapy One patient failed to complete radiation treatment because of disease progression Thirteen patients achieved a complete response in the cerebrospinal fluid CSF The median time to disease progression was 3 months from the first day of CSI and 7 months from CNS recurrence The median survival was 4 months and 9 months respectively No CNS recurrences occurred but there were 11 marrow failures 2 patients without recurrence at 5 years and 3 deaths without a documented site of failure Thirteen patients had no evidence of disease in the CSF until their death or the time of last follow-up CSI with or without intrathecal chemotherapy appears to be effective at eliminating in the craniospinal axis However the eradication of disease in the CNS was not found to be effective at preventing disease recurrence in the marrow and despite improved control of disease in the CNS adult patients with a CNS recurrence still had a poor prognosis Furthermore the rapidly fatal course of disease prevented an assessment of the durability of CNS response to irradiation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 854, 1880, 398, 1025, 2049, 4, 7, 5, 71, 405, 3, 287, 1, 1025, 34, 146, 192, 1234, 16, 210, 6, 1271, 4, 705, 33, 79, 1, 140, 1113, 4, 8, 52, 25, 1, 49, 53, 5748, 1104, 4293, 71, 85, 443, 6, 401, 25, 4, 541, 54, 690, 8, 1025, 146, 1, 286, 1193, 62, 137, 6, 3, 738, 922, 3, 200, 1, 4293, 4, 857, 5, 8, 1025, 146, 1, 16, 860, 8, 459, 206, 1, 780, 7, 73, 5, 4293, 9, 8, 1025, 146, 1, 108, 245, 7, 73, 59, 3751, 2, 1758, 3, 52, 89, 1, 3, 7, 10, 562, 60, 184, 245, 717, 60, 3, 2403, 159, 648, 7, 5, 286, 2194, 329, 659, 7, 5, 62, 2, 104, 69, 5, 442, 2194, 4, 3112, 6540, 62, 7, 42, 513, 8, 236, 34, 734, 324, 6, 3, 1025, 146, 2627, 7, 42, 35, 1355, 1025, 146, 2, 33, 7, 42, 750, 34, 108, 4, 3, 315, 3417, 581, 3, 52, 61, 1, 121, 10, 259, 9864, 381, 184, 203, 562, 33, 381, 6, 3, 37683, 2, 203, 381, 184, 167, 201, 381, 6, 3, 2342, 3, 52, 1509, 444, 10, 14, 66, 381, 184, 14, 33, 18, 13, 381, 6, 3, 37683, 2, 14, 33, 381, 184, 14, 33, 18, 13, 381, 6, 3, 2342, 3057, 7, 11, 120, 73, 5, 5126, 56, 104, 69, 1551, 6, 236, 121, 24, 408, 1, 34, 91, 3170, 7, 513, 8, 236, 51, 4, 3, 5156, 2357, 1211, 3, 52, 98, 6, 34, 91, 10, 27, 53, 29, 3, 157, 218, 1, 4293, 2, 67, 53, 29, 1025, 146, 3, 52, 25, 10, 39, 53, 2, 83, 53, 106, 77, 1025, 1593, 489, 84, 125, 11, 175, 581, 3368, 18, 7, 187, 146, 28, 33, 60, 2, 27, 1043, 187, 8, 1405, 606, 1, 496, 3170, 7, 42, 77, 241, 1, 34, 4, 3, 1211, 1100, 136, 273, 15, 3, 98, 1, 1060, 166, 126, 4293, 5, 15, 187, 5126, 56, 1233, 6, 40, 323, 28, 6923, 4, 3, 5748, 2310, 137, 3, 5173, 1, 34, 4, 3, 1025, 10, 44, 204, 6, 40, 323, 28, 3017, 34, 146, 4, 3, 581, 2, 550, 231, 182, 1, 34, 4, 3, 1025, 780, 7, 5, 8, 1025, 146, 1234, 42, 8, 334, 356, 798, 3, 1755, 3034, 906, 1, 34, 3902, 35, 455, 1, 3, 6867, 1, 1025, 51, 6, 1104]",2336.0,15139061,144
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.,Cancer,Cancer,2004-05-01,"(90)Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. The aim of the current analysis was to evaluate retrospectively the efficacy and safety of (90)Y ibritumomab tiuxetan in patients with Richter syndrome (RS). Patients with histologically proven CD20-positive RS and < 25% lymphoma and/or chronic lymphocytic leukemia in the bone marrow were treated. Patients received an imaging dose of (111)In-labeled ibritumomab tiuxetan of 1.6 mg (5.0 mCi of (111)In) intravenously. One week later, they received 0.3 or 0.4 mCi/kg of (90)Y ibritumomab tiuxetan. Rituximab, at a dose of 250 mg/m(2) intravenously, was given immediately before ibritumomab tiuxetan on Days 1 and 8. Seven patients were treated. Their median age was 56 years (range, 44-70 years). The median time to transformation was 7.9 years (range, 0.7-28.4 years). The median number of previous therapies received was five (range, one to seven previous therapies). The median number of previous therapies received for RS was one (range, none to three previous therapies). Six patients were treated previously with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytosine arabinoside. No patient responded to (90)Y ibritumomab tiuxetan therapy. All patients developed disease progression. The median time to disease progression was 41 days (range, 39-89 days). Side effects included hematologic toxicity. Grade 3-4 (according to the second version of the National Cancer Institute Common Toxicity Criteria) thrombocytopenia and neutropenia occurred in 5 patients (71%) and 2 patients (29%), respectively. There was one episode of septic shock in a patient with Grade 4 neutropenia. (90)Y ibritumomab tiuxetan had no significant antitumor activity and hematologic toxicity was severe in these heavily pretreated patients with RS.",Journal Article,5743.0,32.0,90 Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with The aim of the current analysis was to evaluate retrospectively the efficacy and safety of 90 Y ibritumomab tiuxetan in patients with Richter syndrome RS Patients with histologically proven CD20-positive RS and 25 and/or chronic lymphocytic in the marrow were treated Patients received an imaging dose of 111 In-labeled ibritumomab tiuxetan of 1.6 mg 5.0 mCi of 111 In intravenously One week later they received 0.3 or 0.4 mCi/kg of 90 Y ibritumomab tiuxetan Rituximab at a dose of 250 mg/m 2 intravenously was given immediately before ibritumomab tiuxetan on Days 1 and 8 Seven patients were treated Their median age was 56 years range 44-70 years The median time to transformation was 7.9 years range 0.7-28.4 years The median number of previous therapies received was five range one to seven previous therapies The median number of previous therapies received for RS was one range none to three previous therapies Six patients were treated previously with hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with methotrexate and cytosine arabinoside No patient responded to 90 Y ibritumomab tiuxetan therapy All patients developed disease progression The median time to disease progression was 41 days range 39-89 days Side effects included hematologic toxicity Grade 3-4 according to the second version of the National Cancer Institute Common Toxicity Criteria thrombocytopenia and neutropenia occurred in 5 patients 71 and 2 patients 29 respectively There was one episode of septic shock in a patient with Grade 4 neutropenia 90 Y ibritumomab tiuxetan had no significant antitumor activity and hematologic toxicity was severe in these heavily pretreated patients with RS,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[424, 2055, 5251, 5294, 16, 8, 43610, 3883, 17, 16, 210, 6, 40, 35, 323, 24, 9, 7, 5, 3, 1130, 1, 3, 291, 65, 10, 6, 376, 894, 3, 209, 2, 367, 1, 424, 2055, 5251, 5294, 4, 7, 5, 8452, 681, 2250, 7, 5, 2161, 1930, 2198, 109, 2250, 2, 243, 2, 15, 442, 1193, 4, 3, 581, 11, 73, 7, 103, 35, 270, 61, 1, 3167, 4, 2841, 5251, 5294, 1, 14, 49, 81, 33, 13, 4076, 1, 3167, 4, 1672, 104, 647, 1559, 491, 103, 13, 27, 15, 13, 39, 4076, 503, 1, 424, 2055, 5251, 5294, 855, 28, 8, 61, 1, 2039, 81, 188, 18, 1672, 10, 447, 3467, 348, 5251, 5294, 23, 162, 14, 2, 66, 648, 7, 11, 73, 136, 52, 89, 10, 664, 60, 184, 584, 431, 60, 3, 52, 98, 6, 1392, 10, 67, 83, 60, 184, 13, 67, 339, 39, 60, 3, 52, 207, 1, 698, 235, 103, 10, 365, 184, 104, 6, 648, 698, 235, 3, 52, 207, 1, 698, 235, 103, 9, 2250, 10, 104, 184, 1292, 6, 169, 698, 235, 437, 7, 11, 73, 373, 5, 6201, 1112, 2132, 856, 2, 1217, 5181, 5, 2116, 2, 6903, 11563, 77, 69, 2211, 6, 424, 2055, 5251, 5294, 36, 62, 7, 276, 34, 91, 3, 52, 98, 6, 34, 91, 10, 605, 162, 184, 587, 887, 162, 1152, 176, 159, 813, 155, 88, 27, 39, 768, 6, 3, 419, 2256, 1, 3, 657, 12, 1377, 186, 155, 371, 1340, 2, 778, 489, 4, 33, 7, 792, 2, 18, 7, 462, 106, 125, 10, 104, 6934, 1, 12526, 3971, 4, 8, 69, 5, 88, 39, 778, 424, 2055, 5251, 5294, 42, 77, 93, 579, 128, 2, 813, 155, 10, 905, 4, 46, 2447, 2193, 7, 5, 2250]",1841.0,15139064,642
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.,Cancer,Cancer,2004-06-01,"The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B-cell chronic lymphocytic leukemia (CLL). Eighty-eight patients were treated with fludarabine 30 mg/m(2) intravenously daily for 3 days and mitoxantrone 10 mg/m(2) on Day 1 (FN). Patients were divided into four groups based on expected response to single-agent fludarabine. These four groups included previously untreated patients, patients who previously were treated with alkylating agents, patients who were successfully treated with alkylating agents and fludarabine but who developed recurrent disease, and patients whose disease was refractory to fludarabine with or without alkylating agents. The overall response rate was 66%. The response rates were 83% in previously untreated patients, 87% in patients previously treated with alkylating agents, 50% in patients whose disease was not refractory to fludarabine at the start of therapy, and 25% in patients whose disease was refractory to fludarabine. The complete remission (CR) rate was 20% for previously untreated patients, which was not significantly different from the CR rate for a group of historical control patients who were treated with single-agent fludarabine. The median follow-up was 8 years for surviving patients. The median progression free survival was 24 months for all patients and 34 months for previously untreated patients. The median overall survival was 40 months, and the median survival of previously untreated patients was 88 months. The most common toxicities were myelosuppression and infection. Eleven patients (12.5%) developed a second malignancy after a median of 62 months. The FN regimen did not have a significant advantage over fludarabine alone in the treatment of patients with CLL.",Clinical Trial,5712.0,35.0,The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B-cell chronic lymphocytic CLL Eighty-eight patients were treated with fludarabine 30 mg/m 2 intravenously daily for 3 days and mitoxantrone 10 mg/m 2 on Day 1 FN Patients were divided into four groups based on expected response to single-agent fludarabine These four groups included previously untreated patients patients who previously were treated with alkylating agents patients who were successfully treated with alkylating agents and fludarabine but who developed recurrent disease and patients whose disease was refractory to fludarabine with or without alkylating agents The overall response rate was 66 The response rates were 83 in previously untreated patients 87 in patients previously treated with alkylating agents 50 in patients whose disease was not refractory to fludarabine at the start of therapy and 25 in patients whose disease was refractory to fludarabine The complete remission CR rate was 20 for previously untreated patients which was not significantly different from the CR rate for a group of historical control patients who were treated with single-agent fludarabine The median follow-up was 8 years for surviving patients The median progression free survival was 24 months for all patients and 34 months for previously untreated patients The median overall survival was 40 months and the median survival of previously untreated patients was 88 months The most common toxicities were myelosuppression and infection Eleven patients 12.5 developed a second malignancy after a median of 62 months The FN regimen did not have a significant advantage over fludarabine alone in the treatment of patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 461, 1, 3, 291, 45, 10, 6, 423, 3, 209, 1, 150, 36, 5, 2027, 2, 4419, 4, 7, 5, 132, 31, 442, 1193, 552, 2207, 659, 7, 11, 73, 5, 2027, 201, 81, 188, 18, 1672, 391, 9, 27, 162, 2, 4419, 79, 81, 188, 18, 23, 218, 14, 5165, 7, 11, 2176, 237, 294, 271, 90, 23, 1336, 51, 6, 226, 420, 2027, 46, 294, 271, 159, 373, 1278, 7, 7, 54, 373, 11, 73, 5, 3410, 183, 7, 54, 11, 1878, 73, 5, 3410, 183, 2, 2027, 84, 54, 276, 387, 34, 2, 7, 1310, 34, 10, 430, 6, 2027, 5, 15, 187, 3410, 183, 3, 63, 51, 116, 10, 700, 3, 51, 151, 11, 852, 4, 373, 1278, 7, 912, 4, 7, 373, 73, 5, 3410, 183, 212, 4, 7, 1310, 34, 10, 44, 430, 6, 2027, 28, 3, 2435, 1, 36, 2, 243, 4, 7, 1310, 34, 10, 430, 6, 2027, 3, 236, 734, 684, 116, 10, 179, 9, 373, 1278, 7, 92, 10, 44, 97, 338, 29, 3, 684, 116, 9, 8, 87, 1, 2252, 182, 7, 54, 11, 73, 5, 226, 420, 2027, 3, 52, 166, 126, 10, 66, 60, 9, 3050, 7, 3, 52, 91, 115, 25, 10, 259, 53, 9, 62, 7, 2, 562, 53, 9, 373, 1278, 7, 3, 52, 63, 25, 10, 327, 53, 2, 3, 52, 25, 1, 373, 1278, 7, 10, 889, 53, 3, 96, 186, 385, 11, 2858, 2, 930, 2627, 7, 133, 33, 276, 8, 419, 710, 50, 8, 52, 1, 744, 53, 3, 5165, 477, 205, 44, 47, 8, 93, 1874, 252, 2027, 279, 4, 3, 24, 1, 7, 5, 552]",1771.0,15197800,704
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group.,Leukemia research,Leuk. Res.,2004-08-01,"The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.",Clinical Trial,5651.0,11.0,The role of multidrug resistance MDR was investigated in patients with relapsed chronic lymphocytic CLL PSC-833 was added to modified VAD a 4-day infusion of vincristine doxorubicin with oral dexamethasone every 3 weeks in an attempt to improve the response rate 21 in a prior study Laboratory tests to determine MDR and apoptosis proteins were correlated with response Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response no significant difference No significant correlation with response was found in any of the laboratory tests for apoptosis VAD plus PSC-833 had the same 21 partial response rate as a prior ECOG study without PSC-833 No correlation of response with MDR or apoptosis testing was found Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 200, 1, 4814, 251, 4186, 10, 565, 4, 7, 5, 591, 442, 1193, 552, 5417, 11422, 10, 1953, 6, 1230, 10167, 8, 39, 218, 904, 1, 2132, 856, 5, 518, 1217, 454, 27, 244, 4, 35, 3448, 6, 401, 3, 51, 116, 239, 4, 8, 324, 45, 1624, 895, 6, 223, 4186, 2, 351, 652, 11, 438, 5, 51, 100, 1, 3, 648, 4186, 109, 140, 2, 104, 1, 3, 294, 4186, 199, 7, 513, 8, 450, 51, 77, 93, 523, 77, 93, 816, 5, 51, 10, 204, 4, 500, 1, 3, 1624, 895, 9, 351, 10167, 349, 5417, 11422, 42, 3, 827, 239, 450, 51, 116, 22, 8, 324, 2351, 45, 187, 5417, 11422, 77, 816, 1, 51, 5, 4186, 15, 351, 471, 10, 204, 127, 234, 251, 130, 1642, 1343, 8, 93, 200, 4, 2196, 3, 51, 1, 591, 7, 5, 552]",874.0,15203279,373
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.,Blood,Blood,2004-06-24,"We examined the immunoglobulin (Ig) heavy chain variable region genes (V(H) genes) used by leukemia cells of 1220 unrelated patients with chronic lymphocytic leukemia (CLL). We found 1188 (97%) expressed Ig encoded by a single Ig V(H) subgroup, the most common of which was V(H)3 (571 or 48.1%), followed by V(H)1 (319 or 26.8%) and V(H)4 (241 or 20.2%). Using allele-specific primers, we found 13.8% of all samples (n = 164) used one major V(H)1-69 allele, designated 51p1, 163 of which were not somatically mutated. For these cases, there was marked restriction in the structure of the Ig third complementarity determining regions (CDR3s), which were encoded by a small number of unmutated D and J(H) gene segments. Strikingly, 15 of the 163 cases had virtually identical CDR3s encoded by the second reading frame of D3-16 and J(H)3. Further analysis revealed that each of these 15 samples used the same unmutated Ig kappa light-chain gene, namely A27. These data reveal that approximately 1.3% (15/1220) of all patients had leukemia cells that expressed virtually identical Ig. This finding provides compelling evidence that the Ig expressed by CLL B cells are highly selected and not representative of the Ig expressed by naive B cells.",Journal Article,5689.0,180.0,We examined the immunoglobulin Ig heavy chain variable region genes V H genes used by cells of 1220 unrelated patients with chronic lymphocytic CLL We found 1188 97 expressed Ig encoded by a single Ig V H subgroup the most common of which was V H 3 571 or 48.1 followed by V H 1 319 or 26.8 and V H 4 241 or 20.2 Using allele-specific primers we found 13.8 of all samples n 164 used one major V H 1-69 allele designated 51p1 163 of which were not somatically mutated For these cases there was marked restriction in the structure of the Ig third complementarity determining regions CDR3s which were encoded by a small number of unmutated D and J H gene segments Strikingly 15 of the 163 cases had virtually identical CDR3s encoded by the second reading frame of D3-16 and J H 3 Further analysis revealed that each of these 15 samples used the same unmutated Ig kappa light-chain gene namely A27 These data reveal that approximately 1.3 15/1220 of all patients had cells that expressed virtually identical Ig This finding provides compelling evidence that the Ig expressed by CLL B cells are highly selected and not representative of the Ig expressed by naive B cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 409, 3, 2593, 4200, 4013, 1260, 1347, 1053, 214, 603, 555, 214, 95, 20, 37, 1, 37718, 2092, 7, 5, 442, 1193, 552, 21, 204, 43644, 1015, 570, 4200, 4587, 20, 8, 226, 4200, 603, 555, 1363, 3, 96, 186, 1, 92, 10, 603, 555, 27, 7846, 15, 576, 14, 370, 20, 603, 555, 14, 9052, 15, 432, 66, 2, 603, 555, 39, 7086, 15, 179, 18, 75, 1254, 112, 10031, 21, 204, 233, 66, 1, 62, 347, 78, 5279, 95, 104, 458, 603, 555, 14, 790, 1254, 4107, 43645, 5409, 1, 92, 11, 44, 12293, 1185, 9, 46, 140, 125, 10, 2003, 4575, 4, 3, 2772, 1, 3, 4200, 1282, 17673, 2196, 1374, 37719, 92, 11, 4587, 20, 8, 302, 207, 1, 7216, 427, 2, 3543, 555, 145, 5138, 6787, 167, 1, 3, 5409, 140, 42, 5860, 3038, 37719, 4587, 20, 3, 419, 7299, 5331, 1, 6037, 245, 2, 3543, 555, 27, 195, 65, 553, 17, 296, 1, 46, 167, 347, 95, 3, 827, 7216, 4200, 3096, 1691, 1260, 145, 5046, 54241, 46, 74, 2396, 17, 705, 14, 27, 167, 37718, 1, 62, 7, 42, 37, 17, 570, 5860, 3038, 4200, 26, 1567, 777, 6051, 241, 17, 3, 4200, 570, 20, 552, 132, 37, 32, 561, 715, 2, 44, 3724, 1, 3, 4200, 570, 20, 2462, 132, 37]",1165.0,15217828,310
Current guidelines in defining therapeutic strategies.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2004-08-01,"The past three decades have brought major changes in the approach toward chronic lymphocytic leukemia (CLL). This disease was considered a simple form of leukemia for which the only goal of treatment was control of the leukocytosis and of the symptoms related to disease expansion. Many biologic discoveries have increased our understanding of the disease process. New prognostic markers have been identified and are being incorporated into clinical practice. Now, CLL is considered a complex and challenging leukemia for which multiple treatment options are emerging, from chemotherapy to monoclonal antibodies, from vaccines to immunomodulatory strategies. The evaluation of treatment results also has been revolutionized: clones carrying genetic aberrations are monitored, and patients who have had a response are assessed for the presence of minimal residual disease.",Journal Article,5651.0,2.0,The past three decades have brought major changes in the approach toward chronic lymphocytic CLL This disease was considered a simple form of for which the only goal of treatment was control of the leukocytosis and of the symptoms related to disease expansion Many biologic discoveries have increased our understanding of the disease process New prognostic markers have been identified and are being incorporated into clinical practice Now CLL is considered a complex and challenging for which multiple treatment options are emerging from chemotherapy to monoclonal antibodies from vaccines to immunomodulatory strategies The evaluation of treatment results also has been revolutionized clones carrying genetic aberrations are monitored and patients who have had a response are assessed for the presence of minimal residual disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1219, 169, 1968, 47, 6681, 458, 400, 4, 3, 353, 1317, 442, 1193, 552, 26, 34, 10, 515, 8, 2763, 1297, 1, 9, 92, 3, 158, 1326, 1, 24, 10, 182, 1, 3, 7463, 2, 1, 3, 507, 139, 6, 34, 1422, 445, 1283, 5012, 47, 101, 114, 612, 1, 3, 34, 1129, 217, 177, 525, 47, 85, 108, 2, 32, 486, 2449, 237, 38, 758, 1134, 552, 16, 515, 8, 840, 2, 1950, 9, 92, 232, 24, 838, 32, 1478, 29, 56, 6, 848, 890, 29, 1842, 6, 2555, 422, 3, 451, 1, 24, 99, 120, 71, 85, 5746, 2749, 2934, 336, 2152, 32, 2909, 2, 7, 54, 47, 42, 8, 51, 32, 275, 9, 3, 463, 1, 1048, 753, 34]",831.0,15325704,242
Antibody therapy for chronic lymphocytic leukemia: a promising new modality.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2004-08-01,"Therapeutic options for chronic lymphocytic leukemia (CLL) have been limited, with low complete response rates (CR) and no treatments demonstrating a survival advantage. The recent introduction of the monoclonal antibodies rituximab and alemtuzumab into clinical trials for patients with CLL has generated promising results. Rituximab targets the CD20 antigen and demonstrates varied single-agent activity that is highly dependent upon the dosing schedule and treatment status of the patient. More importantly, when rituximab is combined with fludarabine or fludarabine and cyclophosphamide, a high frequency of CR and prolonged progression-free survival are observed without an appreciable increase in significant toxicity. Alemtuzumab targets the more ubiquitously expressed CD52 antigen and is therefore associated with a higher frequency of toxicity, particularly immunosuppression, but has appreciable activity in fludarabine refractory CLL. Additionally, alemtuzumab is effective against CLL clones that have p53 mutations or deletions. Future efforts in developing combination strategies with rituximab, alemtuzumab, and potentially other new antibodies offer great promise for the future treatment of CLL.",Journal Article,5651.0,13.0,Therapeutic options for chronic lymphocytic CLL have been limited with low complete response rates CR and no treatments demonstrating a survival advantage The recent introduction of the monoclonal antibodies rituximab and alemtuzumab into clinical trials for patients with CLL has generated promising results Rituximab targets the CD20 antigen and demonstrates varied single-agent activity that is highly dependent upon the dosing schedule and treatment status of the patient More importantly when rituximab is combined with fludarabine or fludarabine and cyclophosphamide a high frequency of CR and prolonged progression-free survival are observed without an appreciable increase in significant toxicity Alemtuzumab targets the more ubiquitously expressed CD52 antigen and is therefore associated with a higher frequency of toxicity particularly immunosuppression but has appreciable activity in fludarabine refractory CLL Additionally alemtuzumab is effective against CLL clones that have p53 mutations or deletions Future efforts in developing combination strategies with rituximab alemtuzumab and potentially other new antibodies offer great promise for the future treatment of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[189, 838, 9, 442, 1193, 552, 47, 85, 383, 5, 154, 236, 51, 151, 684, 2, 77, 640, 2219, 8, 25, 1874, 3, 435, 2456, 1, 3, 848, 890, 855, 2, 3579, 237, 38, 143, 9, 7, 5, 552, 71, 1419, 721, 99, 855, 637, 3, 2198, 448, 2, 1902, 2051, 226, 420, 128, 17, 16, 561, 470, 1548, 3, 1280, 1055, 2, 24, 156, 1, 3, 69, 80, 1859, 198, 855, 16, 397, 5, 2027, 15, 2027, 2, 1112, 8, 64, 675, 1, 684, 2, 1069, 91, 115, 25, 32, 164, 187, 35, 9371, 344, 4, 93, 155, 3579, 637, 3, 80, 11156, 570, 7189, 448, 2, 16, 673, 41, 5, 8, 142, 675, 1, 155, 823, 3646, 84, 71, 9371, 128, 4, 2027, 430, 552, 1724, 3579, 16, 323, 480, 552, 2749, 17, 47, 624, 138, 15, 2439, 508, 1413, 4, 931, 150, 422, 5, 855, 3579, 2, 751, 127, 217, 890, 1918, 2797, 1783, 9, 3, 508, 24, 1, 552]",1185.0,15325705,458
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2004-08-01,"The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV(H)) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV(H) but lack expression of ZAP-70. We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV(H) gene. We then investigated the association between the results and the time from diagnosis to initial therapy. We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV(H) gene (71 percent), but in only 24 of the 143 patients with a mutated IgV(H) gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV(H) gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV(H) gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV(H) genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV(H) gene and 7.1 years in those with an unmutated IgV(H) gene (P<0.001). Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.",Journal Article,5651.0,758.0,The course of chronic lymphocytic CLL is variable In aggressive disease the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene IgV H and the 70-kD zeta-associated protein ZAP-70 whereas in indolent disease the CLL cells usually express mutated IgV H but lack expression of ZAP-70 We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV H gene We then investigated the association between the results and the time from diagnosis to initial therapy We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV H gene 71 percent but in only 24 of the 143 patients with a mutated IgV H gene 17 percent P 0.001 Among the patients with ZAP-70-positive CLL cells the median time from diagnosis to initial therapy in those who had an unmutated IgV H gene 2.8 years was not significantly different from the median time in those who had a mutated IgV H gene 4.2 years P=0.07 However the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV H genes P 0.001 The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV H gene and 7.1 years in those with an unmutated IgV H gene P 0.001 Although the presence of an unmutated IgV H gene is strongly associated with the expression of ZAP-70 ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 906, 1, 442, 1193, 552, 16, 1347, 4, 571, 34, 3, 552, 37, 2082, 1669, 35, 7216, 2593, 4013, 1260, 1347, 1053, 145, 12179, 555, 2, 3, 431, 6271, 12105, 41, 178, 6251, 431, 547, 4, 2316, 34, 3, 552, 37, 2082, 1669, 1185, 12179, 555, 84, 926, 55, 1, 6251, 431, 21, 194, 3, 552, 132, 37, 29, 9682, 7, 5, 552, 9, 6251, 431, 2, 138, 4, 3, 3201, 12179, 555, 145, 21, 818, 565, 3, 248, 59, 3, 99, 2, 3, 98, 29, 147, 6, 388, 36, 21, 204, 17, 6251, 431, 10, 570, 2090, 8, 395, 2390, 301, 4, 3843, 1, 3, 5279, 7, 5, 35, 7216, 12179, 555, 145, 792, 714, 84, 4, 158, 259, 1, 3, 4400, 7, 5, 8, 1185, 12179, 555, 145, 269, 714, 19, 13, 144, 107, 3, 7, 5, 6251, 431, 109, 552, 37, 3, 52, 98, 29, 147, 6, 388, 36, 4, 135, 54, 42, 35, 7216, 12179, 555, 145, 18, 66, 60, 10, 44, 97, 338, 29, 3, 52, 98, 4, 135, 54, 42, 8, 1185, 12179, 555, 145, 39, 18, 60, 19, 13, 1615, 137, 3, 52, 98, 29, 147, 6, 388, 24, 4, 296, 1, 46, 271, 10, 97, 985, 76, 3, 98, 4, 7, 5, 6251, 431, 199, 552, 37, 54, 42, 361, 1185, 15, 7216, 12179, 555, 214, 19, 13, 144, 3, 52, 98, 29, 147, 6, 388, 36, 107, 7, 54, 205, 44, 47, 6251, 431, 10, 175, 13, 60, 4, 135, 5, 8, 1185, 12179, 555, 145, 2, 67, 14, 60, 4, 135, 5, 35, 7216, 12179, 555, 145, 19, 13, 144, 242, 3, 463, 1, 35, 7216, 12179, 555, 145, 16, 1327, 41, 5, 3, 55, 1, 6251, 431, 6251, 431, 16, 8, 3355, 980, 1, 3, 594, 9, 24, 4, 132, 31, 552]",1597.0,15329427,713
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.,Cancer,Cancer,2004-09-01,"The CD52 antigen is a glycoprotein anchored on the cell membrane of mature B and T lymphocytes, monocytes, and eosinophils. Alemtuzumab (CAMPATH-1H; anti-CD52) is currently approved for the treatment of patients with refractory chronic lymphocytic leukemia (CLL). The authors investigated the possibility that CD52 may be shed from cells and, once soluble, may bind to injected alemtuzumab, forming immune complexes. The authors used Western blot analysis, immunoprecipitation, and enzyme-linked immunoadsorbent assay to investigate the presence of soluble CD52 (sCD52) in the plasma specimens of 117 patients with CLL. They also used in vitro mixing experiments to examine the ability of sCD52 to compete with cells and sequester therapeutic alemtuzumab. The authors detected high levels of sCD52 in the plasma specimens of patients with CLL. sCD52 can compete with cells in vitro for binding to alemtuzumab, and can form complexes in patients receiving alemtuzumab. Plasma levels of sCD52 were found to be correlated (r)with Rai stage (P = 0.0001), beta-2-microglobulin (beta-2M) levels (P = 0.00002), soluble CD23 levels (r = 0.42, P < 0.001), and immunoglobulin mutation status (P = 0.003). In the multivariate analysis adjusted for beta-2M level, patients with sCD52 levels > 2336 nM/L had a nearly 4-fold increase in risk of death. Higher levels of plasma alemtuzumab were achieved when levels of sCD52 were lower. These data not only demonstrated that sCD52 was detectable and useful in the staging and monitoring of patients with CLL, but also showed that sCD52 formed immune complexes with alemtuzumab and may influence the efficacy and toxicity of alemtuzumab therapy.",Journal Article,5620.0,55.0,The CD52 antigen is a glycoprotein anchored on the cell membrane of mature B and T lymphocytes monocytes and eosinophils Alemtuzumab CAMPATH-1H anti-CD52 is currently approved for the treatment of patients with refractory chronic lymphocytic CLL The authors investigated the possibility that CD52 may be shed from cells and once soluble may bind to injected alemtuzumab forming immune complexes The authors used Western blot analysis immunoprecipitation and enzyme-linked immunoadsorbent assay to investigate the presence of soluble CD52 sCD52 in the plasma specimens of 117 patients with CLL They also used in vitro mixing experiments to examine the ability of sCD52 to compete with cells and sequester therapeutic alemtuzumab The authors detected high levels of sCD52 in the plasma specimens of patients with CLL sCD52 can compete with cells in vitro for binding to alemtuzumab and can form complexes in patients receiving alemtuzumab Plasma levels of sCD52 were found to be correlated r with Rai stage P 0.0001 beta-2-microglobulin beta-2M levels P 0.00002 soluble CD23 levels r 0.42 P 0.001 and immunoglobulin mutation status P 0.003 In the multivariate analysis adjusted for beta-2M level patients with sCD52 levels 2336 nM/L had a nearly 4-fold increase in risk of death Higher levels of plasma alemtuzumab were achieved when levels of sCD52 were lower These data not only demonstrated that sCD52 was detectable and useful in the staging and monitoring of patients with CLL but also showed that sCD52 formed immune complexes with alemtuzumab and may influence the efficacy and toxicity of alemtuzumab therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 7189, 448, 16, 8, 4455, 15268, 23, 3, 31, 1905, 1, 2908, 132, 2, 102, 1594, 5078, 2, 14880, 3579, 16622, 10147, 312, 7189, 16, 694, 850, 9, 3, 24, 1, 7, 5, 430, 442, 1193, 552, 3, 738, 565, 3, 2526, 17, 7189, 68, 40, 5816, 29, 37, 2, 1059, 2968, 68, 4060, 6, 2651, 3579, 4525, 250, 3817, 3, 738, 95, 1521, 2639, 65, 4857, 2, 1644, 1199, 33728, 719, 6, 963, 3, 463, 1, 2968, 7189, 23359, 4, 3, 554, 623, 1, 3843, 7, 5, 552, 491, 120, 95, 4, 439, 16296, 2332, 6, 1004, 3, 801, 1, 23359, 6, 17094, 5, 37, 2, 24741, 189, 3579, 3, 738, 530, 64, 148, 1, 23359, 4, 3, 554, 623, 1, 7, 5, 552, 23359, 122, 17094, 5, 37, 4, 439, 9, 791, 6, 3579, 2, 122, 1297, 3817, 4, 7, 357, 3579, 554, 148, 1, 23359, 11, 204, 6, 40, 438, 668, 5, 4121, 82, 19, 13, 488, 1090, 18, 5371, 1090, 14237, 148, 19, 13, 20389, 2968, 9937, 148, 668, 13, 595, 19, 13, 144, 2, 2593, 258, 156, 19, 13, 1421, 4, 3, 331, 65, 586, 9, 1090, 14237, 301, 7, 5, 23359, 148, 37754, 2878, 805, 42, 8, 1857, 39, 1116, 344, 4, 43, 1, 273, 142, 148, 1, 554, 3579, 11, 513, 198, 148, 1, 23359, 11, 280, 46, 74, 44, 158, 264, 17, 23359, 10, 2083, 2, 999, 4, 3, 632, 2, 1315, 1, 7, 5, 552, 84, 120, 224, 17, 23359, 3516, 250, 3817, 5, 3579, 2, 68, 1054, 3, 209, 2, 155, 1, 3579, 36]",1614.0,15329909,348
"Use of the World Health Organization (WHO) classification of non-Hodgkin's lymphoma in Mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists.",Leukemia & lymphoma,Leuk. Lymphoma,2004-08-01,"This study aims to answer the question whether the World Health Organization (WHO) classification of non-Hodgkin's lymphoma (NHL) can be practised to international standards at the Lymphoma Registry (LR) established at the Tata Memorial Hospital, Mumbai, India. Furthermore, the study aims to identify differences in the distribution of NHL subtypes at this LR (likely to be representative of India) as compared to the rest of the world. A panel of 5 expert hematopathologists from the NHL Classification Project reviewed 200 consecutive NHL cases at the LR in January of 2001. These cases were accrued during August and September, 2000. On all cases, hematoxylin and eosin stains and appropriate immunostains were available for review. The diagnosis made by the host pathologist at the LR (KNN) and the initial diagnosis made by each of the expert hematopathologists was compared with the consensus diagnosis. A consensus diagnosis was made by the 5 experts in 197 cases. The agreement of the host pathologist with the consensus diagnosis was 82% and the agreement of the individual experts with the consensus diagnosis varied from 76-88% (mean 82%). According to the consensus diagnosis, 80% of NHLs were of B-cell type, 18% were of T-cell type, and the immunophenotype could not be determined in the remaining 2% of cases. In conclusion, the WHO classification of NHL was properly utilized at the Lymphoma Registry, Mumbai, India, and geographic differences were noted in the distribution of NHL subtypes at the LR as compared to the rest of the world. Precursor T lymphoblastic leukemia/lymphoma was more common in India (7%) than the rest of the world (1-4%), and indolent B-cell NHLs (29%) were less common than in the West. As compared to China and Japan, peripheral T-cell lymphoma (4.6%), extranodal NK/T cell lymphoma, nasal type (0.5%) and extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) (2.6%) were less common, but follicular lymphoma (15%) and chronic lymphocytic leukemia/small lymphocytic lymphoma (5%) were more common. This suggests that the distribution of the B-cell and T-cell lymphomas in the Indian population, except for lymphoblastic lymphoma, lies in between the Western world (mainly Caucasian) and the Orientals.",Journal Article,5651.0,38.0,This study aims to answer the question whether the World Health Organization WHO classification of 's NHL can be practised to international standards at the Registry LR established at the Tata Memorial Hospital Mumbai India Furthermore the study aims to identify differences in the distribution of NHL subtypes at this LR likely to be representative of India as compared to the rest of the world A panel of 5 expert hematopathologists from the NHL Classification Project reviewed 200 consecutive NHL cases at the LR in January of 2001 These cases were accrued during August and September 2000 On all cases hematoxylin and eosin stains and appropriate immunostains were available for review The diagnosis made by the host pathologist at the LR KNN and the initial diagnosis made by each of the expert hematopathologists was compared with the consensus diagnosis A consensus diagnosis was made by the 5 experts in 197 cases The agreement of the host pathologist with the consensus diagnosis was 82 and the agreement of the individual experts with the consensus diagnosis varied from 76-88 mean 82 According to the consensus diagnosis 80 of NHLs were of B-cell type 18 were of T-cell type and the immunophenotype could not be determined in the remaining 2 of cases In conclusion the WHO classification of NHL was properly utilized at the Registry Mumbai India and geographic differences were noted in the distribution of NHL subtypes at the LR as compared to the rest of the world Precursor T lymphoblastic leukemia/lymphoma was more common in India 7 than the rest of the world 1-4 and indolent B-cell NHLs 29 were less common than in the West As compared to China and Japan peripheral T-cell 4.6 extranodal NK/T cell nasal type 0.5 and extranodal marginal zone B-cell of mucosa-associated lymphoid tissue MALT-lymphoma 2.6 were less common but follicular 15 and chronic lymphocytic leukemia/small lymphocytic 5 were more common This suggests that the distribution of the B-cell and T-cell lymphomas in the Indian population except for lymphoblastic lies in between the Western world mainly Caucasian and the Orientals,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 45, 2970, 6, 6634, 3, 2840, 317, 3, 1956, 341, 2533, 54, 947, 1, 292, 1176, 122, 40, 54361, 6, 944, 3371, 28, 3, 1608, 2030, 635, 28, 3, 23096, 2563, 702, 33733, 7776, 798, 3, 45, 2970, 6, 255, 362, 4, 3, 1395, 1, 1176, 814, 28, 26, 2030, 322, 6, 40, 3724, 1, 7776, 22, 72, 6, 3, 3677, 1, 3, 1956, 8, 993, 1, 33, 2005, 18169, 29, 3, 1176, 947, 3105, 446, 1250, 935, 1176, 140, 28, 3, 2030, 4, 1024, 1, 1758, 46, 140, 11, 3198, 190, 2480, 2, 2636, 1081, 23, 62, 140, 6209, 2, 5975, 7742, 2, 870, 14889, 11, 390, 9, 206, 3, 147, 1229, 20, 3, 1204, 5093, 28, 3, 2030, 43718, 2, 3, 388, 147, 1229, 20, 296, 1, 3, 2005, 18169, 10, 72, 5, 3, 1391, 147, 8, 1391, 147, 10, 1229, 20, 3, 33, 3186, 4, 6114, 140, 3, 2024, 1, 3, 1204, 5093, 5, 3, 1391, 147, 10, 878, 2, 3, 2024, 1, 3, 797, 3186, 5, 3, 1391, 147, 2051, 29, 846, 889, 313, 878, 768, 6, 3, 1391, 147, 493, 1, 11440, 11, 1, 132, 31, 267, 203, 11, 1, 102, 31, 267, 2, 3, 5496, 359, 44, 40, 509, 4, 3, 1844, 18, 1, 140, 4, 1221, 3, 54, 947, 1, 1176, 10, 6785, 2080, 28, 3, 1608, 33733, 7776, 2, 3466, 362, 11, 1051, 4, 3, 1395, 1, 1176, 814, 28, 3, 2030, 22, 72, 6, 3, 3677, 1, 3, 1956, 2765, 102, 1275, 2647, 4763, 10, 80, 186, 4, 7776, 67, 76, 3, 3677, 1, 3, 1956, 14, 39, 2, 2316, 132, 31, 11440, 462, 11, 299, 186, 76, 4, 3, 7261, 22, 72, 6, 5055, 2, 6157, 672, 102, 31, 39, 49, 4093, 1765, 102, 31, 6743, 267, 13, 33, 2, 4093, 3450, 3614, 132, 31, 1, 2713, 41, 2303, 246, 8273, 4763, 18, 49, 11, 299, 186, 84, 1974, 167, 2, 442, 1193, 2647, 302, 1193, 33, 11, 80, 186, 26, 844, 17, 3, 1395, 1, 3, 132, 31, 2, 102, 31, 1557, 4, 3, 7968, 266, 2187, 9, 1275, 9247, 4, 59, 3, 1521, 1956, 2615, 3229, 2, 3, 54362]",2116.0,15370208,790
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.,Blood,Blood,2004-09-23,"B-cell chronic lymphocytic leukemia (CLL) is characterized by accumulation of clonal lymphocytes resistant to apoptosis. We evaluated the ability of the investigational antileukemic agent adaphostin to induce apoptosis in CLL B cells and synergize with fludarabine in vitro. Analysis by annexin V/propidium iodide (PI) staining revealed that the concentration of adaphostin required to induce 50% cell death (IC50) at 24 hours was 4.2 microM (range, 1.10-11.25 microM; median, 4.25 microM; n=29) for CLL isolates and more than 10 microM for B and T cells from healthy donors. Immunoblots demonstrated adaphostin induced poly(adenosine diphosphate-ribose) polymerase (PARP) cleavage and cleavage of caspase-3 substrates, suggesting that adaphostin induces apoptosis. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells, and the antioxidant N-acetylcysteine blocked both adaphostin-induced ROS generation and apoptosis. Adaphostin also caused a decrease in the level of the antiapoptotic protein Bcl-2. When adaphostin was combined with fludarabine (F-ARA-AMP), a synergistic effect on cell death was observed in all 10 CLL samples. These findings not only indicate that adaphostin induces apoptosis selectively in CLL B cells through a mechanism that involves ROS generation but also demonstrate its ability to augment the effects of fludarabine. Further preclinical development of adaphostin as a novel agent for the treatment of CLL appears warranted.",Journal Article,5598.0,38.0,B-cell chronic lymphocytic CLL is characterized by accumulation of clonal lymphocytes resistant to apoptosis We evaluated the ability of the investigational antileukemic agent adaphostin to induce apoptosis in CLL B cells and synergize with fludarabine in vitro Analysis by annexin V/propidium iodide PI staining revealed that the concentration of adaphostin required to induce 50 cell death IC50 at 24 hours was 4.2 microM range 1.10-11.25 microM median 4.25 microM n=29 for CLL isolates and more than 10 microM for B and T cells from healthy donors Immunoblots demonstrated adaphostin induced poly adenosine diphosphate-ribose polymerase PARP cleavage and cleavage of caspase-3 substrates suggesting that adaphostin induces apoptosis Adaphostin increased the level of reactive oxygen species ROS within CLL B cells and the antioxidant N-acetylcysteine blocked both adaphostin-induced ROS generation and apoptosis Adaphostin also caused a decrease in the level of the antiapoptotic protein Bcl-2 When adaphostin was combined with fludarabine F-ARA-AMP a synergistic effect on cell death was observed in all 10 CLL samples These findings not only indicate that adaphostin induces apoptosis selectively in CLL B cells through a mechanism that involves ROS generation but also demonstrate its ability to augment the effects of fludarabine Further preclinical development of adaphostin as a novel agent for the treatment of CLL appears warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 765, 20, 1835, 1, 1946, 1594, 436, 6, 351, 21, 194, 3, 801, 1, 3, 3093, 4512, 420, 10028, 6, 1290, 351, 4, 552, 132, 37, 2, 8717, 5, 2027, 4, 439, 65, 20, 4850, 603, 10839, 8456, 2928, 1029, 553, 17, 3, 1227, 1, 10028, 616, 6, 1290, 212, 31, 273, 5211, 28, 259, 1459, 10, 39, 18, 3550, 184, 14, 79, 175, 243, 3550, 52, 39, 243, 3550, 78, 462, 9, 552, 9274, 2, 80, 76, 79, 3550, 9, 132, 2, 102, 37, 29, 1331, 2344, 13867, 264, 10028, 277, 2699, 4938, 8762, 3507, 1451, 2041, 3155, 2, 3155, 1, 1469, 27, 6063, 802, 17, 10028, 1516, 351, 10028, 101, 3, 301, 1, 2163, 2848, 2915, 2609, 262, 552, 132, 37, 2, 3, 5536, 78, 11729, 2582, 110, 10028, 277, 2609, 914, 2, 351, 10028, 120, 1546, 8, 775, 4, 3, 301, 1, 3, 4176, 178, 1044, 18, 198, 10028, 10, 397, 5, 2027, 1068, 3899, 7793, 8, 1806, 254, 23, 31, 273, 10, 164, 4, 62, 79, 552, 347, 46, 272, 44, 158, 1008, 17, 10028, 1516, 351, 2382, 4, 552, 132, 37, 298, 8, 670, 17, 2921, 2609, 914, 84, 120, 608, 211, 801, 6, 4369, 3, 176, 1, 2027, 195, 693, 193, 1, 10028, 22, 8, 229, 420, 9, 3, 24, 1, 552, 1233, 1197]",1442.0,15388586,48
"A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.",Blood,Blood,2004-09-28,"Chronic lymphocytic leukemia (CLL) is an incurable adult leukemia characterized by disrupted apoptosis. OSU03012 is a bioavailable third-generation celecoxib derivative devoid of cyclooxygenase-2 inhibitory activity that potently induces apoptosis in prostate cancer cell lines and is being developed as an anticancer therapy in the National Cancer Institute (NCI) Rapid Access to Intervention Development (RAID) program. We assessed the ability of OSU03012 to induce apoptosis in primary CLL cells and the mechanism by which this occurs. The LC50 (lethal concentration 50%) of OSU03012 at 24 hours was 7.1 microM, and this decreased to 5.5 microM at 72 hours. Additionally, we have demonstrated that OSU03012 mediates apoptosis by activation of the intrinsic, mitochondrial pathway of apoptosis but also activates alternative cell death pathways that are caspase independent. The early activation of both caspase-dependent and -independent pathways of apoptosis is novel to OSU03012 and suggests it has great potential promise for the treatment of CLL. Moreover, unlike the great majority of therapeutic agents used to treat leukemia or other forms of cancer, OSU03012 induces cell death entirely independent of bcl-2 expression. Overall, these data provide justification for further preclinical development of OSU03012 as a potential therapeutic agent for CLL.",Journal Article,5593.0,64.0,Chronic lymphocytic CLL is an incurable adult characterized by disrupted apoptosis OSU03012 is a bioavailable third-generation celecoxib derivative devoid of cyclooxygenase-2 inhibitory activity that potently induces apoptosis in cancer cell lines and is being developed as an anticancer therapy in the National Cancer Institute NCI Rapid Access to Intervention Development RAID program We assessed the ability of OSU03012 to induce apoptosis in primary CLL cells and the mechanism by which this occurs The LC50 lethal concentration 50 of OSU03012 at 24 hours was 7.1 microM and this decreased to 5.5 microM at 72 hours Additionally we have demonstrated that OSU03012 mediates apoptosis by activation of the intrinsic mitochondrial pathway of apoptosis but also activates alternative cell death pathways that are caspase independent The early activation of both caspase-dependent and -independent pathways of apoptosis is novel to OSU03012 and suggests it has great potential promise for the treatment of CLL Moreover unlike the great majority of therapeutic agents used to treat or other forms of cancer OSU03012 induces cell death entirely independent of bcl-2 expression Overall these data provide justification for further preclinical development of OSU03012 as a potential therapeutic agent for CLL,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 35, 2641, 780, 765, 20, 5576, 351, 23373, 16, 8, 6582, 1282, 914, 2673, 4819, 15126, 1, 4043, 18, 1810, 128, 17, 4684, 1516, 351, 4, 12, 31, 285, 2, 16, 486, 276, 22, 35, 1475, 36, 4, 3, 657, 12, 1377, 2580, 1321, 1655, 6, 788, 193, 54378, 1243, 21, 275, 3, 801, 1, 23373, 6, 1290, 351, 4, 86, 552, 37, 2, 3, 670, 20, 92, 26, 1780, 3, 33378, 2266, 1227, 212, 1, 23373, 28, 259, 1459, 10, 67, 14, 3550, 2, 26, 340, 6, 33, 33, 3550, 28, 720, 1459, 1724, 21, 47, 264, 17, 23373, 3961, 351, 20, 363, 1, 3, 2354, 2019, 308, 1, 351, 84, 120, 3932, 1091, 31, 273, 460, 17, 32, 1469, 306, 3, 191, 363, 1, 110, 1469, 470, 2, 306, 460, 1, 351, 16, 229, 6, 23373, 2, 844, 192, 71, 2797, 174, 1783, 9, 3, 24, 1, 552, 1393, 4246, 3, 2797, 686, 1, 189, 183, 95, 6, 943, 15, 127, 2377, 1, 12, 23373, 1516, 31, 273, 6848, 306, 1, 1044, 18, 55, 63, 46, 74, 377, 12611, 9, 195, 693, 193, 1, 23373, 22, 8, 174, 189, 420, 9, 552]",1303.0,15454489,191
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.,Blood,Blood,2004-10-05,"Preclinical studies with the histone deacetylase (HDAC) inhibitor depsipeptide (FK228) in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) have demonstrated that it effectively induces apoptosis at concentrations at which HDAC inhibition occurs. We initiated a minimum effective pharmacologic dose study of depsipeptide, targeting an in vivo dose at which acetylation of histone proteins H3 and H4 increased by 100% or more in vitro. Ten patients with CLL and 10 patients with AML were treated with 13 mg/m(2) depsipeptide intravenously days 1, 8, and 15 of therapy. Neither life-threatening toxicities nor cardiac toxicities were noted, although the majority of patients experienced progressive fatigue, nausea, and other constitutional symptoms that prevented repeated dosing. Several patients had evidence of antitumor activity following treatment, but no partial or complete responses were noted by National Cancer Institute criteria. HDAC inhibition and histone acetylation increases of at least 100% were noted, as well as increases in p21 promoter H4 acetylation, p21 protein, and 1D10 antigen expression. We conclude that depsipeptide effectively inhibits HDAC in vivo in patients with CLL and AML, but its use in the current schedule of administration is limited by progressive constitutional symptoms. Future studies with depsipeptide should examine alternative administration schedules.",Clinical Trial,5586.0,358.0,Preclinical studies with the histone deacetylase HDAC inhibitor depsipeptide FK228 in chronic lymphocytic CLL and acute myeloid AML have demonstrated that it effectively induces apoptosis at concentrations at which HDAC inhibition occurs We initiated a minimum effective pharmacologic dose study of depsipeptide targeting an in vivo dose at which acetylation of histone proteins H3 and H4 increased by 100 or more in vitro Ten patients with CLL and 10 patients with AML were treated with 13 mg/m 2 depsipeptide intravenously days 1 8 and 15 of therapy Neither life-threatening toxicities nor toxicities were noted although the majority of patients experienced progressive fatigue nausea and other constitutional symptoms that prevented repeated dosing Several patients had evidence of antitumor activity following treatment but no partial or complete responses were noted by National Cancer Institute criteria HDAC inhibition and histone acetylation increases of at least 100 were noted as well as increases in p21 promoter H4 acetylation p21 protein and 1D10 antigen expression We conclude that depsipeptide effectively inhibits HDAC in vivo in patients with CLL and AML but its use in the current schedule of administration is limited by progressive constitutional symptoms Future studies with depsipeptide should examine alternative administration schedules,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"[693, 94, 5, 3, 1508, 2732, 2654, 230, 10072, 12372, 4, 442, 1193, 552, 2, 286, 533, 329, 47, 264, 17, 192, 1856, 1516, 351, 28, 1003, 28, 92, 2654, 297, 1780, 21, 1917, 8, 2499, 323, 2788, 61, 45, 1, 10072, 529, 35, 4, 386, 61, 28, 92, 4145, 1, 1508, 652, 3739, 2, 7812, 101, 20, 394, 15, 80, 4, 439, 1618, 7, 5, 552, 2, 79, 7, 5, 329, 11, 73, 5, 233, 81, 188, 18, 10072, 1672, 162, 14, 66, 2, 167, 1, 36, 2174, 358, 3691, 385, 2110, 385, 11, 1051, 242, 3, 686, 1, 7, 592, 1014, 613, 1218, 2, 127, 5962, 507, 17, 3902, 2113, 1280, 392, 7, 42, 241, 1, 579, 128, 366, 24, 84, 77, 450, 15, 236, 253, 11, 1051, 20, 657, 12, 1377, 371, 2654, 297, 2, 1508, 4145, 1106, 1, 28, 506, 394, 11, 1051, 22, 149, 22, 1106, 4, 2657, 973, 7812, 4145, 2657, 178, 2, 33429, 448, 55, 21, 2060, 17, 10072, 1856, 1576, 2654, 4, 386, 4, 7, 5, 552, 2, 329, 84, 211, 119, 4, 3, 291, 1055, 1, 634, 16, 383, 20, 1014, 5962, 507, 508, 94, 5, 10072, 257, 1004, 1091, 634, 2314]",1360.0,15466934,566
Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.,Cancer,Cancer,2004-11-01,"Hematopoietic stem cell transplantation (HSCT) is an effective but expensive medical procedure to which some ethnic minorities, the elderly, and those without insurance have been shown to have limited access. The purpose of the current study was to determine whether socioeconomic factors were associated with HSCT usage rates in patients with leukemia. The authors identified 6574 patients with acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, or other leukemias from the 1999 Texas Hospital Inpatient Discharge Public Use Data File. Of these patients, 1604 received an autologous or allogeneic HSCT. The authors assessed patients' ethnicity, payer status, age, gender, and comorbid medical conditions. Logistic regression was used to control for patient characteristics and to evaluate associations among payer status, ethnicity, and HSCT use. P < or = 0.05 indicated statistical significance. Patients who self-paid had the highest rate of HSCT use in all age groups (32%; P < or = 0.01) and in the adult group (36%; P = 0.11). Elderly patients with Medicare had a low rate of HSCT use (17%; P = 0.13). Logistic regression showed no statistically significant associations between payer status or ethnicity and HSCT use. However, elderly women were significantly less likely to undergo HSCT than elderly men (odds ratio, 0.34; P < or = 0.01). The lack of statistically significant differences in HSCT use among adult patients with leukemia was surprising because previous studies had shown differences in HSCT by ethnicity and insurance.",Comparative Study,5559.0,12.0,Hematopoietic stem cell transplantation HSCT is an effective but expensive medical procedure to which some ethnic minorities the elderly and those without insurance have been shown to have limited access The purpose of the current study was to determine whether socioeconomic factors were associated with HSCT usage rates in patients with The authors identified 6574 patients with acute lymphocytic chronic lymphocytic acute myelogenous chronic myelogenous or other leukemias from the 1999 Texas Hospital Inpatient Discharge Public Use Data File Of these patients 1604 received an autologous or allogeneic HSCT The authors assessed patients ethnicity payer status age gender and comorbid medical conditions Logistic regression was used to control for patient characteristics and to evaluate associations among payer status ethnicity and HSCT use P or 0.05 indicated statistical significance Patients who self-paid had the highest rate of HSCT use in all age groups 32 P or 0.01 and in the adult group 36 P 0.11 Elderly patients with Medicare had a low rate of HSCT use 17 P 0.13 Logistic regression showed no statistically significant associations between payer status or ethnicity and HSCT use However elderly women were significantly less likely to undergo HSCT than elderly men odds ratio 0.34 P or 0.01 The lack of statistically significant differences in HSCT use among adult patients with was surprising because previous studies had shown differences in HSCT by ethnicity and insurance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1007, 452, 31, 497, 1703, 16, 35, 323, 84, 6038, 484, 1299, 6, 92, 476, 2871, 6727, 3, 1216, 2, 135, 187, 1935, 47, 85, 443, 6, 47, 383, 1655, 3, 743, 1, 3, 291, 45, 10, 6, 223, 317, 3331, 130, 11, 41, 5, 1703, 5015, 151, 4, 7, 5, 3, 738, 108, 54405, 7, 5, 286, 1193, 442, 1193, 286, 2194, 442, 2194, 15, 127, 2792, 29, 3, 2043, 2738, 702, 2420, 2993, 3067, 119, 74, 12339, 1, 46, 7, 54406, 103, 35, 1028, 15, 1063, 1703, 3, 738, 275, 7, 2091, 7433, 156, 89, 1632, 2, 3952, 484, 1298, 812, 320, 10, 95, 6, 182, 9, 69, 374, 2, 6, 376, 685, 107, 7433, 156, 2091, 2, 1703, 119, 19, 15, 13, 474, 1103, 1050, 724, 7, 54, 1074, 8328, 42, 3, 1076, 116, 1, 1703, 119, 4, 62, 89, 271, 531, 19, 15, 13, 355, 2, 4, 3, 780, 87, 511, 19, 13, 175, 1216, 7, 5, 1378, 42, 8, 154, 116, 1, 1703, 119, 269, 19, 13, 233, 812, 320, 224, 77, 712, 93, 685, 59, 7433, 156, 15, 2091, 2, 1703, 119, 137, 1216, 117, 11, 97, 299, 322, 6, 1251, 1703, 76, 1216, 325, 610, 197, 13, 562, 19, 15, 13, 355, 3, 926, 1, 712, 93, 362, 4, 1703, 119, 107, 780, 7, 5, 10, 14157, 408, 698, 94, 42, 443, 362, 4, 1703, 20, 2091, 2, 1935]",1491.0,15484218,64
Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.,Molecular cancer therapeutics,Mol. Cancer Ther.,2004-10-01,"The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear receptor family that forms heterodimers with retinoid X receptor. These heterodimers bind to DNA and activate the transcription of target genes. Here, we report that the PPAR gamma receptor protein is expressed in primary myeloid and lymphoid leukemias and in lymphoma and myeloma cell lines. In this study, we compared the activity of several PPAR gamma ligands including BRL49653 (rosiglitazone), 15-deoxy-Delta 12,14-prostaglandin J(2), and the novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid on leukemia cells. Exposure to these PPAR gamma ligands induced apoptosis in myeloid (U937 and HL-60) and lymphoid (Su-DHL, Sup-M2, Ramos, Raji, Hodgkin's cell lines, and primary chronic lymphocytic leukemia) cells. A similar exposure to these PPAR gamma ligands induced the differentiation of myeloid leukemic cells. A combination of PPAR gamma ligands with a retinoid X receptor agonist (i.e., LG100268) or a retinoic acid receptor agonist (i.e., all trans-retinoic acid) enhanced differentiating and growth-inhibitory effects. 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced differentiation and apoptosis with much greater potency than the other PPAR gamma ligands in established cell lines and primary chronic lymphocytic leukemia samples. Exposure to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced mitochondrial depolarization and caspase activation, which was associated with apoptosis induction. In Bcl-2-overexpressing chronic lymphocytic leukemia cells, the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-induced apoptosis. These results suggest that PPAR gamma ligation alone and in combination with retinoids holds promise as novel therapy for leukemias by activating the transcriptional activity of target genes that control apoptosis and differentiation in leukemias.",Journal Article,5590.0,85.0,"The peroxisome proliferator-activated receptor gamma PPAR gamma is a member of the nuclear receptor family that forms heterodimers with retinoid X receptor These heterodimers bind to DNA and activate the transcription of target genes Here we report that the PPAR gamma receptor protein is expressed in primary myeloid and lymphoid leukemias and in and cell lines In this study we compared the activity of several PPAR gamma ligands including BRL49653 rosiglitazone 15-deoxy-Delta 12,14-prostaglandin J 2 and the novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid on cells Exposure to these PPAR gamma ligands induced apoptosis in myeloid U937 and HL-60 and lymphoid Su-DHL Sup-M2 Ramos Raji 's cell lines and primary chronic lymphocytic cells A similar exposure to these PPAR gamma ligands induced the differentiation of myeloid leukemic cells A combination of PPAR gamma ligands with a retinoid X receptor agonist i.e. LG100268 or a retinoic acid receptor agonist i.e. all trans-retinoic acid enhanced differentiating and growth-inhibitory effects 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced differentiation and apoptosis with much greater potency than the other PPAR gamma ligands in established cell lines and primary chronic lymphocytic samples Exposure to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced mitochondrial depolarization and caspase activation which was associated with apoptosis induction In Bcl-2-overexpressing chronic lymphocytic cells the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-induced apoptosis These results suggest that PPAR gamma ligation alone and in combination with retinoids holds promise as novel therapy for leukemias by activating the transcriptional activity of target genes that control apoptosis and differentiation in leukemias",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 8659, 8660, 735, 153, 1705, 5649, 1705, 16, 8, 2693, 1, 3, 928, 153, 607, 17, 2377, 15468, 5, 6709, 1006, 153, 46, 15468, 4060, 6, 261, 2, 2977, 3, 866, 1, 283, 214, 467, 21, 414, 17, 3, 5649, 1705, 153, 178, 16, 570, 4, 86, 533, 2, 2303, 2792, 2, 4, 2, 31, 285, 4, 26, 45, 21, 72, 3, 128, 1, 392, 5649, 1705, 3123, 141, 54409, 9046, 167, 6149, 4305, 133, 213, 6068, 3543, 18, 2, 3, 229, 15818, 18, 11777, 27, 133, 15540, 14, 83, 13030, 339, 14817, 971, 23, 37, 645, 6, 46, 5649, 1705, 3123, 277, 351, 4, 533, 7000, 2, 1718, 335, 2, 2303, 6449, 7384, 172, 821, 30674, 9868, 292, 31, 285, 2, 86, 442, 1193, 37, 8, 288, 645, 6, 46, 5649, 1705, 3123, 277, 3, 910, 1, 533, 2015, 37, 8, 150, 1, 5649, 1705, 3123, 5, 8, 6709, 1006, 153, 3821, 70, 563, 17599, 15, 8, 3887, 971, 153, 3821, 70, 563, 62, 3437, 3887, 971, 651, 5209, 2, 129, 1810, 176, 18, 11777, 27, 133, 15540, 14, 83, 13030, 339, 14817, 971, 277, 910, 2, 351, 5, 1802, 378, 3593, 76, 3, 127, 5649, 1705, 3123, 4, 635, 31, 285, 2, 86, 442, 1193, 347, 645, 6, 18, 11777, 27, 133, 15540, 14, 83, 13030, 339, 14817, 971, 277, 2019, 14809, 2, 1469, 363, 92, 10, 41, 5, 351, 504, 4, 1044, 18, 2810, 442, 1193, 37, 3, 302, 1354, 1044, 18, 230, 15104, 14, 4242, 46, 37, 6, 18, 11777, 27, 133, 15540, 14, 83, 13030, 339, 14817, 971, 277, 351, 46, 99, 309, 17, 5649, 1705, 5307, 279, 2, 4, 150, 5, 7358, 5253, 1783, 22, 229, 36, 9, 2792, 20, 1616, 3, 1431, 128, 1, 283, 214, 17, 182, 351, 2, 910, 4, 2792]",1865.0,15486192,76
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).,Leukemia & lymphoma,Leuk. Lymphoma,2004-11-01,"The treatment of patients with chronic lymphocytic leukemia (CLL) who fail purine analogues is sub optimal. CLL lymphocytes express two antigens, namely CD 20 and CD 52, for which monoclonal antibodies are readily available. Rituximab is a chimeric monoclonal antibody targeted against CD 20, which has some activity in refractory CLL, with primary effect on nodal disease. Alemtuzumab is a humanized anti-CD 52 antibody that is approved for the treatment of CLL in patients who fail alkylating agents and purine analogues. Alemtuzumab has better activity in the peripheral blood and the bone marrow compared to nodal disease. We investigated whether combining both antibodies is safe in refractory CLL. Both antibodies were given to a total of 12 patients divided into 3 cohorts with escalating alemtuzumab doses (3 mg, 10 mg, and 30 mg). The combination was proven to be safe, not toxic, feasible, and active. One patient attained PR by NCI criteria while all other patients had stable disease lasting a median of 101.5 days. All patients normalized their peripheral lymphocytosis within a median of 23.5 days. No treatment-related mortality was identified. No CMV reactivation occurred. Additional studies are needed to investigate the clinical significance of such a combination in this patient population, and whether this combination can be administered safely with systemic chemotherapy. These studies are currently underway.",Clinical Trial,5559.0,58.0,The treatment of patients with chronic lymphocytic CLL who fail purine analogues is sub optimal CLL lymphocytes express two antigens namely CD 20 and CD 52 for which monoclonal antibodies are readily available Rituximab is a chimeric monoclonal antibody targeted against CD 20 which has some activity in refractory CLL with primary effect on nodal disease Alemtuzumab is a humanized anti-CD 52 antibody that is approved for the treatment of CLL in patients who fail alkylating agents and purine analogues Alemtuzumab has better activity in the peripheral blood and the marrow compared to nodal disease We investigated whether combining both antibodies is safe in refractory CLL Both antibodies were given to a total of 12 patients divided into 3 cohorts with escalating alemtuzumab doses 3 mg 10 mg and 30 mg The combination was proven to be safe not toxic feasible and active One patient attained PR by NCI criteria while all other patients had stable disease lasting a median of 101.5 days All patients normalized their peripheral lymphocytosis within a median of 23.5 days No treatment-related mortality was identified No CMV reactivation occurred Additional studies are needed to investigate the clinical significance of such a combination in this patient population and whether this combination can be administered safely with systemic chemotherapy These studies are currently underway,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 24, 1, 7, 5, 442, 1193, 552, 54, 4373, 5006, 4768, 16, 551, 665, 552, 1594, 1669, 100, 1575, 5046, 4420, 179, 2, 4420, 653, 9, 92, 848, 890, 32, 3860, 390, 855, 16, 8, 2897, 848, 548, 238, 480, 4420, 179, 92, 71, 476, 128, 4, 430, 552, 5, 86, 254, 23, 779, 34, 3579, 16, 8, 3619, 312, 4420, 653, 548, 17, 16, 850, 9, 3, 24, 1, 552, 4, 7, 54, 4373, 3410, 183, 2, 5006, 4768, 3579, 71, 380, 128, 4, 3, 672, 315, 2, 3, 581, 72, 6, 779, 34, 21, 565, 317, 1525, 110, 890, 16, 1165, 4, 430, 552, 110, 890, 11, 447, 6, 8, 181, 1, 133, 7, 2176, 237, 27, 736, 5, 2922, 3579, 415, 27, 81, 79, 81, 2, 201, 81, 3, 150, 10, 1930, 6, 40, 1165, 44, 1812, 1313, 2, 544, 104, 69, 5105, 998, 20, 2580, 371, 369, 62, 127, 7, 42, 585, 34, 3443, 8, 52, 1, 2338, 33, 162, 62, 7, 4207, 136, 672, 8125, 262, 8, 52, 1, 382, 33, 162, 77, 24, 139, 282, 10, 108, 77, 3879, 3834, 489, 402, 94, 32, 575, 6, 963, 3, 38, 724, 1, 225, 8, 150, 4, 26, 69, 266, 2, 317, 26, 150, 122, 40, 468, 2268, 5, 403, 56, 46, 94, 32, 694, 3948]",1390.0,15512816,300
Chronic lymphocytic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2004-01-01,"Chronic lymphocytic leukemia (CLL) is one of the most commonly diagnosed leukemias managed by practicing hematologists. For many years patients with CLL have been viewed as similar, with a long natural history and only marginally effective therapies that rarely yielded complete responses. Recently, several important observations related to the biologic significance of V(H) mutational status and associated ZAP-70 overexpression, disrupted p53 function, and chromosomal aberrations have led to the ability to identify patients at high risk for early disease progression and inferior survival. Concurrent with these investigations, several treatments including the nucleoside analogues, monoclonal antibodies rituximab and alemtuzumab have been introduced. Combination of these therapies in clinical trials has led to high complete and overall response rates when applied as initial therapy for symptomatic CLL. Thus, the complexity of initial risk stratification of CLL and treatment has increased significantly. Furthermore, when these initial therapies do not work, approach of the CLL patient with fludarabine-refractory disease can be quite challenging. This session will describe the natural history of a CLL patient with emphasis on important decision junctures at different time points in the disease. In Section I, Dr. Stephan Stilgenbauer focuses on the discussion that occurs with CLL patients at their initial evaluation. This includes a review of the diagnostic criteria for CLL and prognostic factors utilized to predict the natural history of the disease. The later discussion of risk stratification focuses on molecular and genomic aberrations that predict rapid progression, poor response to therapy, and inferior survival. Ongoing and future efforts examining early intervention strategies in high risk CLL are reviewed. In Section II, Drs. Ian Flinn and Jesus G. Berdeja focus on the discussion of CLL patients when symptomatic disease has developed. This includes an updated review of monotherapy trials with nucleoside analogs and recent trials that have combined these with monoclonal antibodies and/or alternative chemotherapy agents. Appropriate application of more aggressive therapies such as autologous and allogeneic immunotherapy and less aggressive treatments for appropriate CLL patient candidates are discussed. In Section III, Dr. John Byrd focuses on the discussion that occurs with CLL patients whose disease is refractory to fludarabine. The application of genetic risk stratification in choosing therapy for this subset of patients is reviewed. Available data with conventional combination based therapies and monoclonal antibodies are discussed. Finally, alternative promising investigational therapies including new antibodies, kinase inhibitors (CDK, PDK1/AKT, PKC) and alternative targeted therapies (DNA methyltransferase inhibitors, histone deacetylase inhibitors, etc.) are reviewed with an emphasis on the most promising agents for this patient population.",Journal Article,5864.0,140.0,Chronic lymphocytic CLL is one of the most commonly diagnosed leukemias managed by practicing hematologists For many years patients with CLL have been viewed as similar with a long natural history and only marginally effective therapies that rarely yielded complete responses Recently several important observations related to the biologic significance of V H mutational status and associated ZAP-70 overexpression disrupted p53 function and chromosomal aberrations have led to the ability to identify patients at high risk for early disease progression and inferior survival Concurrent with these investigations several treatments including the nucleoside analogues monoclonal antibodies rituximab and alemtuzumab have been introduced Combination of these therapies in clinical trials has led to high complete and overall response rates when applied as initial therapy for symptomatic CLL Thus the complexity of initial risk stratification of CLL and treatment has increased significantly Furthermore when these initial therapies do not work approach of the CLL patient with fludarabine-refractory disease can be quite challenging This session will describe the natural history of a CLL patient with emphasis on important decision junctures at different time points in the disease In Section I Dr. Stephan Stilgenbauer focuses on the discussion that occurs with CLL patients at their initial evaluation This includes a review of the diagnostic criteria for CLL and prognostic factors utilized to predict the natural history of the disease The later discussion of risk stratification focuses on molecular and genomic aberrations that predict rapid progression poor response to therapy and inferior survival Ongoing and future efforts examining early intervention strategies in high risk CLL are reviewed In Section II Drs Ian Flinn and Jesus G. Berdeja focus on the discussion of CLL patients when symptomatic disease has developed This includes an updated review of monotherapy trials with nucleoside analogs and recent trials that have combined these with monoclonal antibodies and/or alternative chemotherapy agents Appropriate application of more aggressive therapies such as autologous and allogeneic immunotherapy and less aggressive treatments for appropriate CLL patient candidates are discussed In Section III Dr. John Byrd focuses on the discussion that occurs with CLL patients whose disease is refractory to fludarabine The application of genetic risk stratification in choosing therapy for this subset of patients is reviewed Available data with conventional combination based therapies and monoclonal antibodies are discussed Finally alternative promising investigational therapies including new antibodies kinase inhibitors CDK PDK1/AKT PKC and alternative targeted therapies DNA methyltransferase inhibitors histone deacetylase inhibitors etc are reviewed with an emphasis on the most promising agents for this patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 104, 1, 3, 96, 841, 265, 2792, 2231, 20, 6734, 11474, 9, 445, 60, 7, 5, 552, 47, 85, 7879, 22, 288, 5, 8, 319, 1504, 532, 2, 158, 5007, 323, 235, 17, 2416, 2178, 236, 253, 761, 392, 305, 2172, 139, 6, 3, 1283, 724, 1, 603, 555, 1619, 156, 2, 41, 6251, 431, 851, 5576, 624, 343, 2, 1860, 2152, 47, 836, 6, 3, 801, 6, 255, 7, 28, 64, 43, 9, 191, 34, 91, 2, 1663, 25, 750, 5, 46, 2492, 392, 640, 141, 3, 4032, 4768, 848, 890, 855, 2, 3579, 47, 85, 3955, 150, 1, 46, 235, 4, 38, 143, 71, 836, 6, 64, 236, 2, 63, 51, 151, 198, 1498, 22, 388, 36, 9, 1704, 552, 631, 3, 3082, 1, 388, 43, 1541, 1, 552, 2, 24, 71, 101, 97, 798, 198, 46, 388, 235, 1022, 44, 1357, 353, 1, 3, 552, 69, 5, 2027, 430, 34, 122, 40, 6223, 1950, 26, 5510, 303, 897, 3, 1504, 532, 1, 8, 552, 69, 5, 3136, 23, 305, 948, 54494, 28, 338, 98, 862, 4, 3, 34, 4, 2917, 70, 3436, 54495, 54496, 3026, 23, 3, 2488, 17, 1780, 5, 552, 7, 28, 136, 388, 451, 26, 1920, 8, 206, 1, 3, 752, 371, 9, 552, 2, 177, 130, 2080, 6, 678, 3, 1504, 532, 1, 3, 34, 3, 1559, 2488, 1, 43, 1541, 3026, 23, 219, 2, 572, 2152, 17, 678, 1321, 91, 334, 51, 6, 36, 2, 1663, 25, 942, 2, 508, 1413, 3282, 191, 788, 422, 4, 64, 43, 552, 32, 446, 4, 2917, 215, 9227, 43793, 54497, 2, 54498, 499, 54499, 1222, 23, 3, 2488, 1, 552, 7, 198, 1704, 34, 71, 276, 26, 1920, 35, 2939, 206, 1, 1411, 143, 5, 4032, 4063, 2, 435, 143, 17, 47, 397, 46, 5, 848, 890, 2, 15, 1091, 56, 183, 870, 1581, 1, 80, 571, 235, 225, 22, 1028, 2, 1063, 726, 2, 299, 571, 640, 9, 870, 552, 69, 1931, 32, 1588, 4, 2917, 316, 3436, 9968, 33330, 3026, 23, 3, 2488, 17, 1780, 5, 552, 7, 1310, 34, 16, 430, 6, 2027, 3, 1581, 1, 336, 43, 1541, 4, 5065, 36, 9, 26, 697, 1, 7, 16, 446, 390, 74, 5, 809, 150, 90, 235, 2, 848, 890, 32, 1588, 1368, 1091, 721, 3093, 235, 141, 217, 890, 216, 222, 3954, 16384, 649, 4644, 2, 1091, 238, 235, 261, 3747, 222, 1508, 2732, 222, 9188, 32, 446, 5, 35, 3136, 23, 3, 96, 721, 183, 9, 26, 69, 266]",2945.0,15561682,503
"Richter syndrome: biology, incidence, and therapeutic strategies.",Cancer,Cancer,2005-01-01,"Richter's transformation denotes the development of high-grade non-Hodgkin lymphoma, prolymphocytic leukemia, Hodgkin disease, or acute leukemia in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. A search of published articles in Medline (PubMed) and abstracts from professional meetings was performed. An electronic database search of patients with CLL at The University of Texas M. D. Anderson Cancer Center (Houston, TX) determined the incidence of Richter syndrome (RS) in patients with CLL between 1992 and 2002. RS occurs in approximately 5% of patients with CLL. The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm. RS may be triggered by viral infections, such as Epstein-Barr virus. Trisomy 12 and chromosome 11 abnormalities are more frequent in patients with RS than in the overall population of patients with CLL. Multiple genetic defects, such as mutations of the p53 tumor suppressor gene, p16INK4A, and p21, loss of p27 expression, deletion of retinoblastoma, increased copy number of C-MYC, and decreased expression of the A-MYB gene, have been described. These abnormalities may cause CLL cells to proliferate and-by facilitating the acquisition of new genetic abnormalities-to transform into RS cells. Therapeutic strategies include intensive chemotherapy, monoclonal antibodies, and stem cell transplantation. The response rates range from 5% to 43% (complete response, 5-38%), and the median survival duration ranges from 5 months to 8 months. In conclusion, RS may be triggered by viral infections or by genetic defects. Current treatments are aggressive, but prognosis is poor. Novel curative treatment strategies are needed.",Comparative Study,5498.0,201.0,Richter 's transformation denotes the development of high-grade prolymphocytic disease or acute in patients with chronic lymphocytic CLL /small lymphocytic A search of published articles in Medline PubMed and abstracts from professional meetings was performed An electronic database search of patients with CLL at The University of Texas M. D. Anderson Cancer Center Houston TX determined the incidence of Richter syndrome RS in patients with CLL between 1992 and 2002 RS occurs in approximately 5 of patients with CLL The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm RS may be triggered by viral infections such as Epstein-Barr virus Trisomy 12 and chromosome 11 abnormalities are more frequent in patients with RS than in the overall population of patients with CLL Multiple genetic defects such as mutations of the p53 tumor suppressor gene p16INK4A and p21 loss of p27 expression deletion of increased copy number of C-MYC and decreased expression of the A-MYB gene have been described These abnormalities may cause CLL cells to proliferate and-by facilitating the acquisition of new genetic abnormalities-to transform into RS cells Therapeutic strategies include intensive chemotherapy monoclonal antibodies and stem cell transplantation The response rates range from 5 to 43 complete response 5-38 and the median survival duration ranges from 5 months to 8 months In conclusion RS may be triggered by viral infections or by genetic defects Current treatments are aggressive but prognosis is poor Novel curative treatment strategies are needed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 292, 1392, 19535, 3, 193, 1, 64, 88, 14779, 34, 15, 286, 4, 7, 5, 442, 1193, 552, 302, 1193, 8, 1901, 1, 983, 2384, 4, 3388, 3161, 2, 5159, 29, 5341, 6941, 10, 173, 35, 3098, 609, 1901, 1, 7, 5, 552, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 6212, 6614, 509, 3, 287, 1, 8452, 681, 2250, 4, 7, 5, 552, 59, 2846, 2, 1544, 2250, 1780, 4, 705, 33, 1, 7, 5, 552, 3, 375, 37, 1, 2250, 68, 3043, 298, 1392, 1, 3, 2279, 552, 3910, 15, 1231, 8, 217, 2131, 2250, 68, 40, 4173, 20, 1667, 1875, 225, 22, 5212, 5190, 1450, 6317, 133, 2, 1170, 175, 1171, 32, 80, 908, 4, 7, 5, 2250, 76, 4, 3, 63, 266, 1, 7, 5, 552, 232, 336, 2945, 225, 22, 138, 1, 3, 624, 30, 1245, 145, 13747, 2, 2657, 407, 1, 2804, 55, 1528, 1, 101, 1337, 207, 1, 256, 1371, 2, 340, 55, 1, 3, 8, 6929, 145, 47, 85, 1027, 46, 1171, 68, 708, 552, 37, 6, 9554, 2, 20, 5379, 3, 3405, 1, 217, 336, 1171, 6, 7136, 237, 2250, 37, 189, 422, 643, 1686, 56, 848, 890, 2, 452, 31, 497, 3, 51, 151, 184, 29, 33, 6, 601, 236, 51, 33, 519, 2, 3, 52, 25, 654, 5632, 29, 33, 53, 6, 66, 53, 4, 1221, 2250, 68, 40, 4173, 20, 1667, 1875, 15, 20, 336, 2945, 291, 640, 32, 571, 84, 356, 16, 334, 229, 1075, 24, 422, 32, 575]",1608.0,15578683,148
"Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.","Hematology (Amsterdam, Netherlands)",Hematology,2004-08-01,"B-cell chronic lymphocytic leukemia (CLL) has been traditionally described as a disease characterized by an accumulation of quiescent small lymphocytes with decreased susceptibility to apoptotic cell death. However, small numbers of ""atypical"" lymphocytes and prolymphocytes (PL) are frequently observed in the bone marrow (BM) of patients with CLL. In this study, we examined BM biopsy and aspirate specimens obtained from seven patients with atypical CLL. Using a double labeling (Ki-67+/CD20+) immunohistochemical method, we found that an appreciable number of the atypical CLL cells expressed the proliferation-associated protein Ki-67. Because CLL is characterized by a slow change in the peripheral blood (PB) lymphocyte count, we reasoned that a subpopulation of CLL cells probably undergoes spontaneous apoptosis. Using Western blot analysis, we observed expression of procaspase-9, procaspase-10, and poly(ADP-ribose) polymerase by the neoplastic cells in all seven cases of CLL, and procaspase-3 and procaspase-8 expression in six neoplasms. We also detected cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase in four and five CLL cases, respectively. To determine whether CLL cells undergo spontaneous apoptosis, we performed the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay using BM biopsy specimens. We found TUNEL-positive lymphocytes in areas infiltrated by CLL. In summary, our data show that subpopulations of B-lymphocytes are proliferating or undergoing spontaneous apoptotic cell death in patients with atypical CLL.",Journal Article,5651.0,21.0,B-cell chronic lymphocytic CLL has been traditionally described as a disease characterized by an accumulation of quiescent small lymphocytes with decreased susceptibility to apoptotic cell death However small numbers of `` atypical '' lymphocytes and prolymphocytes PL are frequently observed in the marrow BM of patients with CLL In this study we examined BM biopsy and aspirate specimens obtained from seven patients with atypical CLL Using a double labeling Ki-67+/CD20+ immunohistochemical method we found that an appreciable number of the atypical CLL cells expressed the proliferation-associated protein Ki-67 Because CLL is characterized by a slow change in the peripheral blood PB lymphocyte count we reasoned that a subpopulation of CLL cells probably undergoes spontaneous apoptosis Using Western blot analysis we observed expression of procaspase-9 procaspase-10 and poly ADP-ribose polymerase by the neoplastic cells in all seven cases of CLL and procaspase-3 and procaspase-8 expression in six neoplasms We also detected cleaved caspase-3 and cleaved poly ADP-ribose polymerase in four and five CLL cases respectively To determine whether CLL cells undergo spontaneous apoptosis we performed the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling TUNEL assay using BM biopsy specimens We found TUNEL-positive lymphocytes in areas infiltrated by CLL In summary our data show that subpopulations of B-lymphocytes are proliferating or undergoing spontaneous apoptotic cell death in patients with atypical CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 71, 85, 4206, 1027, 22, 8, 34, 765, 20, 35, 1835, 1, 6735, 302, 1594, 5, 340, 1432, 6, 1631, 31, 273, 137, 302, 1870, 1, 1973, 522, 1594, 2, 33784, 7774, 32, 746, 164, 4, 3, 581, 1246, 1, 7, 5, 552, 4, 26, 45, 21, 409, 1246, 411, 2, 8022, 623, 683, 29, 648, 7, 5, 1973, 552, 75, 8, 1627, 3383, 2311, 598, 2198, 1382, 596, 21, 204, 17, 35, 9371, 207, 1, 3, 1973, 552, 37, 570, 3, 457, 41, 178, 2311, 598, 408, 552, 16, 765, 20, 8, 3645, 707, 4, 3, 672, 315, 3767, 1448, 1276, 21, 15577, 17, 8, 5518, 1, 552, 37, 4061, 9776, 3280, 351, 75, 1521, 2639, 65, 21, 164, 55, 1, 10153, 83, 10153, 79, 2, 2699, 3638, 3507, 1451, 20, 3, 2000, 37, 4, 62, 648, 140, 1, 552, 2, 10153, 27, 2, 10153, 66, 55, 4, 437, 1179, 21, 120, 530, 5885, 1469, 27, 2, 5885, 2699, 3638, 3507, 1451, 4, 294, 2, 365, 552, 140, 106, 6, 223, 317, 552, 37, 1251, 3280, 351, 21, 173, 3, 2158, 10655, 4402, 517, 12716, 9547, 396, 3383, 8159, 719, 75, 1246, 411, 623, 21, 204, 8159, 109, 1594, 4, 1361, 8652, 20, 552, 4, 1962, 114, 74, 514, 17, 4847, 1, 132, 1594, 32, 5639, 15, 479, 3280, 1631, 31, 273, 4, 7, 5, 1973, 552]",1537.0,15621735,97
Cat scratch disease mimicking Richter's Syndrome in a patient with chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2005-03-01,"Richter's Syndrome is a highly refractory and usually fatal condition. It occurs as a result of transformation of chronic lymphocytic leukemia (CLL) or low grade lymphoma into highly aggressive lymphoma. Patients usually present with rapidly enlarging lymph nodes and systemic symptoms like night sweats, fever and weight loss. We are reporting a case of CLL presenting with similar symptoms. Initial suspicion of Richter's Syndrome proved wrong when lymph node biopsy did not reveal evidence of high grade lymphoma. Instead it showed findings consistent with cat scratch disease (CSD), later confirmed by serology. To our knowledge this is the first reported case of CSD in a patient with CLL.",Case Reports,5439.0,2.0,Richter 's Syndrome is a highly refractory and usually fatal condition It occurs as a result of transformation of chronic lymphocytic CLL or low grade into highly aggressive Patients usually present with rapidly enlarging lymph nodes and systemic symptoms like night sweats fever and weight loss We are reporting a case of CLL presenting with similar symptoms Initial suspicion of Richter 's Syndrome proved wrong when lymph node biopsy did not reveal evidence of high grade Instead it showed findings consistent with cat scratch disease CSD later confirmed by serology To our knowledge this is the first reported case of CSD in a patient with CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 292, 681, 16, 8, 561, 430, 2, 2082, 3034, 2850, 192, 1780, 22, 8, 757, 1, 1392, 1, 442, 1193, 552, 15, 154, 88, 237, 561, 571, 7, 2082, 364, 5, 1755, 11961, 263, 502, 2, 403, 507, 733, 8955, 13298, 2775, 2, 924, 407, 21, 32, 1760, 8, 473, 1, 552, 1656, 5, 288, 507, 388, 5782, 1, 8452, 292, 681, 4328, 28325, 198, 263, 289, 411, 205, 44, 2396, 241, 1, 64, 88, 3496, 192, 224, 272, 925, 5, 14190, 18385, 34, 18386, 1559, 557, 20, 10654, 6, 114, 922, 26, 16, 3, 157, 210, 473, 1, 18386, 4, 8, 69, 5, 552]",647.0,15621836,105
Clinical significance of monoclonal B cells in cerebrospinal fluid.,"Cytometry. Part B, Clinical cytometry",Cytometry B Clin Cytom,2005-01-01,"Morphologically malignant lymphocytes in the cerebrospinal fluid (CSF) are highly suggestive of central nervous system involvement by lymphoid malignancy. Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF, the significance of this finding in the absence of morphologically identifiable malignant cells is unknown. We reviewed CSF flow cytometric results in 32 patients studied at a single institution over 5 years and identified patients who had monoclonal B-cells in the CSF. Clinical presentation and course were reviewed. Twelve patients had a monoclonal B-cell population in the CSF, but only three had clinical evidence of malignant CNS disease. Of the other nine patients, 4 had nonmalignant neurologic disease and five had a lymphoproliferative disorder: chronic lymphocytic leukemia (n = 4) and mantle cell lymphoma (n = 1). In patients who had chronic lymphocytic leukemia and mantle cell lymphoma, the monoclonal B-cell population was small and had an immunophenotype identical to that of circulating malignant B cells. None of these nine patients developed clinical evidence of malignant CNS involvement during follow-up. In patients who have indolent B-cell malignancies, the presence of monoclonal B cells in the CSF may not be diagnostic of clinically significant CNS involvement by a lymphoid malignancy.",Journal Article,5498.0,27.0,Morphologically malignant lymphocytes in the cerebrospinal fluid CSF are highly suggestive of central nervous system involvement by lymphoid malignancy Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF the significance of this finding in the absence of morphologically identifiable malignant cells is unknown We reviewed CSF flow cytometric results in 32 patients studied at a single institution over 5 years and identified patients who had monoclonal B-cells in the CSF Clinical presentation and course were reviewed Twelve patients had a monoclonal B-cell population in the CSF but only three had clinical evidence of malignant CNS disease Of the other nine patients 4 had nonmalignant neurologic disease and five had a lymphoproliferative disorder chronic lymphocytic n 4 and mantle cell n 1 In patients who had chronic lymphocytic and mantle cell the monoclonal B-cell population was small and had an immunophenotype identical to that of circulating malignant B cells None of these nine patients developed clinical evidence of malignant CNS involvement during follow-up In patients who have indolent B-cell malignancies the presence of monoclonal B cells in the CSF may not be diagnostic of clinically significant CNS involvement by a lymphoid malignancy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6204, 393, 1594, 4, 3, 5156, 2357, 1211, 32, 561, 3832, 1, 854, 1880, 398, 799, 20, 2303, 710, 242, 1412, 1914, 16, 1635, 95, 6, 1426, 8, 848, 132, 31, 266, 4, 3, 1211, 3, 724, 1, 26, 1567, 4, 3, 1127, 1, 6204, 6237, 393, 37, 16, 860, 21, 446, 1211, 1412, 6226, 99, 4, 531, 7, 656, 28, 8, 226, 731, 252, 33, 60, 2, 108, 7, 54, 42, 848, 132, 37, 4, 3, 1211, 38, 1031, 2, 906, 11, 446, 2544, 7, 42, 8, 848, 132, 31, 266, 4, 3, 1211, 84, 158, 169, 42, 38, 241, 1, 393, 1025, 34, 1, 3, 127, 762, 7, 39, 42, 5967, 2543, 34, 2, 365, 42, 8, 4192, 2645, 442, 1193, 78, 39, 2, 2757, 31, 78, 14, 4, 7, 54, 42, 442, 1193, 2, 2757, 31, 3, 848, 132, 31, 266, 10, 302, 2, 42, 35, 5496, 3038, 6, 17, 1, 1033, 393, 132, 37, 1292, 1, 46, 762, 7, 276, 38, 241, 1, 393, 1025, 799, 190, 166, 126, 4, 7, 54, 47, 2316, 132, 31, 441, 3, 463, 1, 848, 132, 37, 4, 3, 1211, 68, 44, 40, 752, 1, 505, 93, 1025, 799, 20, 8, 2303, 710]",1305.0,15624205,596
Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.,Leukemia research,Leuk. Res.,2005-03-01,"Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q. Compared to stable disease, more patients with progressive disease had > or =2 anomalies and a high percentage of neoplastic nuclei. Anomalies of genes for basic fibroblast growth factor, interleukin 4, vascular endothelial growth factor or TCL1 were not detected. Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21.",Comparative Study,5439.0,26.0,Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic B-CLL patients for 1 disease progression 2 angiogenesis genes 3 T-cell 1 gene TCL1 4 immunoglobulin heavy chain variable region IGHv and 5 chromosome 6q Compared to stable disease more patients with progressive disease had or =2 anomalies and a high percentage of neoplastic nuclei Anomalies of genes for basic fibroblast growth factor interleukin 4 vascular endothelial growth factor or TCL1 were not detected Deletions in IGHv occurred in 25 of patients and correlated with IGHv gene expression Probes for 6q23 detected more deletions in 6q than probes for 6q21,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2910, 2841, 261, 3701, 11, 95, 6, 45, 653, 442, 1193, 132, 552, 7, 9, 14, 34, 91, 18, 1056, 214, 27, 102, 31, 14, 145, 8979, 39, 2593, 4013, 1260, 1347, 1053, 6220, 2, 33, 1170, 10961, 72, 6, 585, 34, 80, 7, 5, 1014, 34, 42, 15, 18, 7623, 2, 8, 64, 1150, 1, 2000, 4725, 7623, 1, 214, 9, 2795, 3758, 129, 161, 1603, 39, 756, 845, 129, 161, 15, 8979, 11, 44, 530, 2439, 4, 6220, 489, 4, 243, 1, 7, 2, 438, 5, 6220, 145, 55, 3701, 9, 23401, 530, 80, 2439, 4, 10961, 76, 3701, 9, 20225]",636.0,15661260,8
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.,Blood,Blood,2005-02-17,"Myeloid cell leukemia-1 (MCL-1) acts as a key survival factor for chronic lymphocytic leukemia (CLL) cells. In addition, dissipation of cellular bioenergy may impose a lethal effect on these quiescent cells. Previously, in multiple myeloma cell lines we demonstrated that halogenated adenosine (8-Cl-Ado) was phosphorylated to triphosphate (8-Cl-adenosine triphosphate [ATP]), which preferentially incorporated into mRNA and inhibited RNA synthesis by premature transcription termination. Furthermore, 8-Cl-ATP accumulation was associated with a decline in cellular bioenergy. Based on these actions, we hypothesized that 8-Cl-Ado would be ideal to target CLL lymphocytes. In the present study we demonstrate that leukemic lymphocytes incubated with 8-Cl-Ado display time- and dose-dependent increase in the accumulation of 8-Cl-ATP, with a parallel depletion of the endogenous ATP pool. Inhibition of global RNA synthesis resulted in a significant decline in the expression of transcripts with a short half-life such as MCL1. Consistent to this, protein expression of MCL-1 but not B-cell lymphoma-2 (BCL-2) was decreased. Furthermore, 8-Cl-ATP induced programmed cell death, as suggested by caspases activation, cleavage of caspase 3, and PARP (poly-adenosine diphosphate [ADP]-ribose polymerase), and increased DNA fragmentation. In conclusion, 8-Cl-Ado induces apoptosis in CLL lymphocytes by targeting cellular bioenergy as well as RNA transcription and translation of key survival genes such as MCL1.",Journal Article,5451.0,31.0,Myeloid cell leukemia-1 MCL-1 acts as a key survival factor for chronic lymphocytic CLL cells In addition dissipation of cellular bioenergy may impose a lethal effect on these quiescent cells Previously in multiple cell lines we demonstrated that halogenated adenosine 8-Cl-Ado was phosphorylated to triphosphate 8-Cl-adenosine triphosphate ATP which preferentially incorporated into mRNA and inhibited RNA synthesis by premature transcription termination Furthermore 8-Cl-ATP accumulation was associated with a decline in cellular bioenergy Based on these actions we hypothesized that 8-Cl-Ado would be ideal to target CLL lymphocytes In the present study we demonstrate that leukemic lymphocytes incubated with 8-Cl-Ado display time- and dose-dependent increase in the accumulation of 8-Cl-ATP with a parallel depletion of the endogenous ATP pool Inhibition of global RNA synthesis resulted in a significant decline in the expression of transcripts with a short half-life such as MCL1 Consistent to this protein expression of MCL-1 but not B-cell lymphoma-2 BCL-2 was decreased Furthermore 8-Cl-ATP induced programmed cell death as suggested by caspases activation cleavage of caspase 3 and PARP poly-adenosine diphosphate ADP -ribose polymerase and increased DNA fragmentation In conclusion 8-Cl-Ado induces apoptosis in CLL lymphocytes by targeting cellular bioenergy as well as RNA transcription and translation of key survival genes such as MCL1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[533, 31, 2647, 14, 1308, 14, 4459, 22, 8, 825, 25, 161, 9, 442, 1193, 552, 37, 4, 352, 30734, 1, 763, 28358, 68, 15099, 8, 2266, 254, 23, 46, 6735, 37, 373, 4, 232, 31, 285, 21, 264, 17, 37855, 4938, 66, 5192, 8614, 10, 2365, 6, 7345, 66, 5192, 4938, 7345, 3918, 92, 3509, 2449, 237, 956, 2, 879, 893, 2525, 20, 5682, 866, 7202, 798, 66, 5192, 3918, 1835, 10, 41, 5, 8, 1858, 4, 763, 28358, 90, 23, 46, 5592, 21, 1237, 17, 66, 5192, 8614, 688, 40, 3662, 6, 283, 552, 1594, 4, 3, 364, 45, 21, 608, 17, 2015, 1594, 8303, 5, 66, 5192, 8614, 3640, 98, 2, 61, 470, 344, 4, 3, 1835, 1, 66, 5192, 3918, 5, 8, 2755, 2286, 1, 3, 2682, 3918, 6545, 297, 1, 1648, 893, 2525, 627, 4, 8, 93, 1858, 4, 3, 55, 1, 2680, 5, 8, 978, 1303, 358, 225, 22, 8132, 925, 6, 26, 178, 55, 1, 1308, 14, 84, 44, 132, 31, 4763, 18, 1044, 18, 10, 340, 798, 66, 5192, 3918, 277, 1846, 31, 273, 22, 1148, 20, 7629, 363, 3155, 1, 1469, 27, 2, 2041, 2699, 4938, 8762, 3638, 3507, 1451, 2, 101, 261, 7678, 4, 1221, 66, 5192, 8614, 1516, 351, 4, 552, 1594, 20, 529, 763, 28358, 22, 149, 22, 893, 866, 2, 2691, 1, 825, 25, 214, 225, 22, 8132]",1451.0,15718423,29
Alemtuzumab.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2005-02-01,"Alemtuzumab is a humanized monoclonal antibody against CD52, a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes, and on a large proportion of malignant lymphoid cells, but not on hematopoietic progenitor cells. Over the past several years, a number of clinical trials have demonstrated the clinical activity of alemtuzumab in treating patients with chronic lymphocytic leukemia, T-cell malignancies such as T-prolymphocytic leukemia and cutaneous T-cell lymphoma, as well as in the prevention and therapy of graft-versus-host disease in the setting of allogeneic stem cell transplantation. Its application in a number of autoimmune disorders is currently under investigation. The most significant side effect of alemtuzumab is predisposition to infections related to the associated profound lymphopenia. Despite this, and with appropriate and more effective antibiotic prophylaxis, it is likely that we will witness an expansion of the role of alemtuzumab in the future.",Journal Article,5467.0,52.0,Alemtuzumab is a humanized monoclonal antibody against CD52 a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of malignant lymphoid cells but not on hematopoietic progenitor cells Over the past several years a number of clinical trials have demonstrated the clinical activity of alemtuzumab in treating patients with chronic lymphocytic T-cell malignancies such as T-prolymphocytic and cutaneous T-cell as well as in the prevention and therapy of graft-versus-host disease in the setting of allogeneic stem cell transplantation Its application in a number of autoimmune disorders is currently under investigation The most significant side effect of alemtuzumab is predisposition to infections related to the associated profound lymphopenia Despite this and with appropriate and more effective antibiotic prophylaxis it is likely that we will witness an expansion of the role of alemtuzumab in the future,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3579, 16, 8, 3619, 848, 548, 480, 7189, 8, 302, 37352, 15268, 4455, 17, 16, 561, 570, 23, 295, 102, 2, 132, 1594, 2, 23, 8, 375, 920, 1, 393, 2303, 37, 84, 44, 23, 1007, 2520, 37, 252, 3, 1219, 392, 60, 8, 207, 1, 38, 143, 47, 264, 3, 38, 128, 1, 3579, 4, 1367, 7, 5, 442, 1193, 102, 31, 441, 225, 22, 102, 14779, 2, 1486, 102, 31, 22, 149, 22, 4, 3, 1070, 2, 36, 1, 1599, 185, 1204, 34, 4, 3, 546, 1, 1063, 452, 31, 497, 211, 1581, 4, 8, 207, 1, 3445, 1997, 16, 694, 669, 940, 3, 96, 93, 1152, 254, 1, 3579, 16, 2863, 6, 1875, 139, 6, 3, 41, 4399, 3655, 550, 26, 2, 5, 870, 2, 80, 323, 5210, 2049, 192, 16, 322, 17, 21, 303, 20209, 35, 1422, 1, 3, 200, 1, 3579, 4, 3, 508]",994.0,15757437,96
"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-03-14,"The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m(2) day 1 of course 1 and 500 mg/m(2) day 1 of courses 2 to 6; fludarabine 25 mg/m(2)/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m(2)/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. CR was achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patients, respectively; the overall response rate was 73%. Twelve (32%) of 37 complete responders tested achieved molecular remission in bone marrow. Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission, longer time to progression, and overall survival. The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL. Myelosuppression was the most common toxicity. FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL. Furthermore, molecular remissions were achieved in a third of patients achieving CR.",Journal Article,5426.0,475.0,The efficacy toxicity and tolerability of chemoimmunotherapy with the combination of fludarabine cyclophosphamide and rituximab FCR were evaluated in previously treated patients with chronic lymphocytic CLL The purpose of this study was to improve the complete remission CR rate for previously treated patients and evaluate the quality of marrow response One hundred seventy-seven previously treated patients with CLL were evaluated Treatment consisted of rituximab 375 mg/m 2 day 1 of course 1 and 500 mg/m 2 day 1 of courses 2 to 6 fludarabine 25 mg/m 2 /d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6 and cyclophosphamide 250 mg/m 2 /d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6 Courses were repeated every 4 weeks CR was achieved in 25 of 177 patients and nodular partial remission and partial remission were achieved in 16 and 32 of patients respectively the overall response rate was 73 Twelve 32 of 37 complete responders tested achieved molecular remission in marrow Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission longer time to progression and overall survival The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL Myelosuppression was the most common toxicity FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL Furthermore molecular remissions were achieved in a third of patients achieving CR,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 209, 155, 2, 1543, 1, 4438, 5, 3, 150, 1, 2027, 1112, 2, 855, 4953, 11, 194, 4, 373, 73, 7, 5, 442, 1193, 552, 3, 743, 1, 26, 45, 10, 6, 401, 3, 236, 734, 684, 116, 9, 373, 73, 7, 2, 376, 3, 372, 1, 581, 51, 104, 1128, 2073, 648, 373, 73, 7, 5, 552, 11, 194, 24, 1695, 1, 855, 4175, 81, 188, 18, 218, 14, 1, 906, 14, 2, 1666, 81, 188, 18, 218, 14, 1, 1993, 18, 6, 49, 2027, 243, 81, 188, 18, 427, 162, 18, 6, 39, 1, 906, 14, 2, 162, 14, 6, 27, 1, 1993, 18, 6, 49, 2, 1112, 2039, 81, 188, 18, 427, 162, 18, 6, 39, 1, 906, 14, 2, 162, 14, 6, 27, 1, 1993, 18, 6, 49, 1993, 11, 2113, 454, 39, 244, 684, 10, 513, 4, 243, 1, 4699, 7, 2, 4481, 450, 734, 2, 450, 734, 11, 513, 4, 245, 2, 531, 1, 7, 106, 3, 63, 51, 116, 10, 803, 2544, 531, 1, 567, 236, 1983, 650, 513, 219, 734, 4, 581, 880, 2, 331, 318, 11, 95, 6, 255, 1194, 69, 374, 41, 5, 684, 2, 63, 734, 589, 98, 6, 91, 2, 63, 25, 3, 4953, 477, 10, 35, 544, 2, 149, 421, 24, 9, 373, 73, 7, 5, 552, 2858, 10, 3, 96, 186, 155, 4953, 277, 3, 1076, 684, 116, 210, 4, 8, 38, 160, 1, 373, 73, 7, 5, 552, 798, 219, 3166, 11, 513, 4, 8, 1282, 1, 7, 1785, 684]",1517.0,15767647,737
Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance.,Clinical lymphoma,Clin Lymphoma,2005-03-01,"Monoclonal gammopathy of undetermined significance (MGUS) of the immunoglobulin M (IgM) class was diagnosed at our institution in 213 patients who resided in the 11 counties of southeastern Minnesota from 1960 to 1994. The median age at diagnosis was 74 years and the median concentration of serum M-protein was 1.2 g/dL. The 213 patients were monitored for 1567 person-years (median, 6.3 years), during which 71% died. During follow-up, non-Hodgkin's lymphoma (n = 17), Waldenstrom's macroglobulinemia (n = 6), primary amyloidosis (n = 3), and chronic lymphocytic leukemia (n = 3) developed in 29 patients (14%). The number of patients with progression to lymphoid neoplasms was 15.9 times that expected in the general population. The cumulative probabilities of progression to one of these disorders were 10% at 5 years, 18% at 10 years, and 24% at 15 years. The overall average risks for progression were approximately 1.5% per year. Rates of death resulting from other diseases (cardiovascular, cerebrovascular, etc.) were 31% at 5 years, 52% at 10 years, and 65% at 15 years. Multivariate analysis revealed that only the concentration of serum M-protein at diagnosis and the serum albumin value were independent predictors of progression. It was concluded that the patients with IgM MGUS should be followed indefinitely.",Journal Article,5439.0,19.0,Monoclonal gammopathy of undetermined significance MGUS of the immunoglobulin M IgM class was diagnosed at our institution in 213 patients who resided in the 11 counties of southeastern Minnesota from 1960 to 1994 The median age at diagnosis was 74 years and the median concentration of serum M-protein was 1.2 g/dL The 213 patients were monitored for 1567 person-years median 6.3 years during which 71 died During follow-up 's n 17 Waldenstrom 's macroglobulinemia n 6 primary amyloidosis n 3 and chronic lymphocytic n 3 developed in 29 patients 14 The number of patients with progression to lymphoid neoplasms was 15.9 times that expected in the general population The cumulative probabilities of progression to one of these disorders were 10 at 5 years 18 at 10 years and 24 at 15 years The overall average risks for progression were approximately 1.5 per year Rates of death resulting from other diseases cardiovascular cerebrovascular etc were 31 at 5 years 52 at 10 years and 65 at 15 years Multivariate analysis revealed that only the concentration of serum M-protein at diagnosis and the serum albumin value were independent predictors of progression It was concluded that the patients with IgM MGUS should be followed indefinitely,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 5334, 1, 5206, 724, 3226, 1, 3, 2593, 188, 2852, 1040, 10, 265, 28, 114, 731, 4, 5833, 7, 54, 13472, 4, 3, 175, 8257, 1, 20167, 8297, 29, 10391, 6, 3023, 3, 52, 89, 28, 147, 10, 794, 60, 2, 3, 52, 1227, 1, 524, 188, 178, 10, 14, 18, 499, 1826, 3, 5833, 7, 11, 2909, 9, 26194, 2719, 60, 52, 49, 27, 60, 190, 92, 792, 1016, 190, 166, 126, 292, 78, 269, 7933, 292, 3389, 78, 49, 86, 3919, 78, 27, 2, 442, 1193, 78, 27, 276, 4, 462, 7, 213, 3, 207, 1, 7, 5, 91, 6, 2303, 1179, 10, 167, 83, 1072, 17, 1336, 4, 3, 1083, 266, 3, 967, 3518, 1, 91, 6, 104, 1, 46, 1997, 11, 79, 28, 33, 60, 203, 28, 79, 60, 2, 259, 28, 167, 60, 3, 63, 1011, 1098, 9, 91, 11, 705, 14, 33, 379, 111, 151, 1, 273, 1113, 29, 127, 1342, 2179, 9261, 9188, 11, 456, 28, 33, 60, 653, 28, 79, 60, 2, 556, 28, 167, 60, 331, 65, 553, 17, 158, 3, 1227, 1, 524, 188, 178, 28, 147, 2, 3, 524, 2799, 549, 11, 306, 674, 1, 91, 192, 10, 4724, 17, 3, 7, 5, 2852, 3226, 257, 40, 370, 13931]",1239.0,15794860,113
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-04-04,"Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease for which natural history can be predicted based on the presence or absence of immunoglobulin (Ig) variable heavy chain (V(H)) gene mutations. Herein we report selective epigenetic silencing of the transcription factor TWIST2 (DERMO1) in Ig V(H) mutated CLL and describe a semiquantitative assay to study promoter methylation of this gene in primary tumor cells. TWIST2 promoter methylation was identified by restriction landmark genome scanning. Southern blot (SB), bisulfite sequencing, and combined bisulfite restriction analysis (COBRA), and quantitative SB-COBRA was performed to study methylation of the TWIST2 promoter. Reverse transcription polymerase chain reaction assays were used to study TWIST2 expression in CLL cells. Following identification and confirmation of TWIST2 methylation in CLL patients, we demonstrated that expression of this transcription factor is related to the degree of promoter methylation. Expression of TWIST2 in a CLL cell line in which the promoter is methylated was increased following decitabine treatment. We next studied 53 patients by COBRA and demonstrated that 72% of patient samples with mutated Ig V(H) show TWIST2 methylation, while only 16% of patient samples with unmutated Ig V(H) were methylated (P < .001). In a subset of patients, methylation of TWIST2 correlated with mRNA expression. TWIST2 is differentially methylated in CLL cells relative to Ig V(H) mutational status and can be quantitatively monitored by SB-COBRA. Based on the known role of TWIST2 in silencing p53 function in other malignancies, future studies should focus on the role of TWIST2 in CLL and related lymphoproliferative diseases.",Journal Article,5405.0,76.0,Chronic lymphocytic CLL is a clinically heterogeneous disease for which natural history can be predicted based on the presence or absence of immunoglobulin Ig variable heavy chain V H gene mutations Herein we report selective epigenetic silencing of the transcription factor TWIST2 DERMO1 in Ig V H mutated CLL and describe a semiquantitative assay to study promoter methylation of this gene in primary tumor cells TWIST2 promoter methylation was identified by restriction landmark genome scanning Southern blot SB bisulfite sequencing and combined bisulfite restriction analysis COBRA and quantitative SB-COBRA was performed to study methylation of the TWIST2 promoter Reverse transcription polymerase chain reaction assays were used to study TWIST2 expression in CLL cells Following identification and confirmation of TWIST2 methylation in CLL patients we demonstrated that expression of this transcription factor is related to the degree of promoter methylation Expression of TWIST2 in a CLL cell line in which the promoter is methylated was increased following decitabine treatment We next studied 53 patients by COBRA and demonstrated that 72 of patient samples with mutated Ig V H show TWIST2 methylation while only 16 of patient samples with unmutated Ig V H were methylated P .001 In a subset of patients methylation of TWIST2 correlated with mRNA expression TWIST2 is differentially methylated in CLL cells relative to Ig V H mutational status and can be quantitatively monitored by SB-COBRA Based on the known role of TWIST2 in silencing p53 function in other malignancies future studies should focus on the role of TWIST2 in CLL and related lymphoproliferative diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 505, 1564, 34, 9, 92, 1504, 532, 122, 40, 783, 90, 23, 3, 463, 15, 1127, 1, 2593, 4200, 1347, 4013, 1260, 603, 555, 145, 138, 1986, 21, 414, 1094, 1418, 2077, 1, 3, 866, 161, 21319, 54719, 4, 4200, 603, 555, 1185, 552, 2, 897, 8, 8942, 719, 6, 45, 973, 569, 1, 26, 145, 4, 86, 30, 37, 21319, 973, 569, 10, 108, 20, 4575, 3829, 898, 3702, 7525, 2639, 5343, 6181, 615, 2, 397, 6181, 4575, 65, 19473, 2, 1156, 5343, 19473, 10, 173, 6, 45, 569, 1, 3, 21319, 973, 1772, 866, 1451, 1260, 1329, 1013, 11, 95, 6, 45, 21319, 55, 4, 552, 37, 366, 911, 2, 3551, 1, 21319, 569, 4, 552, 7, 21, 264, 17, 55, 1, 26, 866, 161, 16, 139, 6, 3, 1444, 1, 973, 569, 55, 1, 21319, 4, 8, 552, 31, 328, 4, 92, 3, 973, 16, 2963, 10, 101, 366, 3004, 24, 21, 1305, 656, 699, 7, 20, 19473, 2, 264, 17, 720, 1, 69, 347, 5, 1185, 4200, 603, 555, 514, 21319, 569, 369, 158, 245, 1, 69, 347, 5, 7216, 4200, 603, 555, 11, 2963, 19, 144, 4, 8, 697, 1, 7, 569, 1, 21319, 438, 5, 956, 55, 21319, 16, 2478, 2963, 4, 552, 37, 580, 6, 4200, 603, 555, 1619, 156, 2, 122, 40, 5889, 2909, 20, 5343, 19473, 90, 23, 3, 440, 200, 1, 21319, 4, 2077, 624, 343, 4, 127, 441, 508, 94, 257, 1222, 23, 3, 200, 1, 21319, 4, 552, 2, 139, 4192, 1342]",1680.0,15809452,539
Genetics and molecular biology of chronic lymphocytic leukemia.,Current treatment options in oncology,Curr Treat Options Oncol,2005-05-01,"B cell chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by accumulation of malignant CD5+ B cells. Multiple molecular events likely contribute to malignant transformation; no single genetic abnormality or event has been shown to be responsible for development of the disease. Significant advances have recently been made towards understanding the genetic and molecular basis for the etiology and clinical course of CLL. Our current understanding is only now bringing us to the point where we can use this information in management and in developing new therapies for patients with CLL. Familial clustering of CLL cases is not uncommon and implicates a genetic basis for the development of the disease in some individuals. Potential interventions in this instance could employ strategies of gene transfer or gene therapy to correct genetic defects or strategies of chemoprevention, none of which is currently under investigation. Greater potential for therapeutic intervention rests with targeting molecular aberrations and altered gene expression in leukemia cells, for example, over expression of the anti-apoptotic proteins of the Bcl-2 family. CLL follows a variable clinical course, with some patients not needing treatment for many years and responding to therapy completely and repeatedly. Other patients have rapidly progressive disease that is refractory to currently available agents and they quickly succumb to their disease. One major recent advance has been the identification of molecular and genetic prognostic factors that can be used in early-stage patients to identify those likely to rapidly progress. This affords the opportunity to tailor management for patients based on the predictable aggressiveness of their disease. Molecular and genetic findings are increasingly influencing management decisions in CLL. Bone marrow transplantation may be considered for a patient with unfavorable prognostic features earlier than for a patient with favorable features and same clinical stage of disease. It is likely that these genetic and molecular-based factors will be targets of new treatment modalities that fundamentally change the management of this disease. In this review we detail the current understanding of the genetics and molecular biology of CLL and introduce potentials for therapeutic intervention.",Journal Article,5378.0,13.0,B cell chronic lymphocytic CLL is a clinically heterogeneous disease characterized by accumulation of malignant CD5+ B cells Multiple molecular events likely contribute to malignant transformation no single genetic abnormality or event has been shown to be responsible for development of the disease Significant advances have recently been made towards understanding the genetic and molecular basis for the etiology and clinical course of CLL Our current understanding is only now bringing us to the point where we can use this information in management and in developing new therapies for patients with CLL Familial clustering of CLL cases is not uncommon and implicates a genetic basis for the development of the disease in some individuals Potential interventions in this instance could employ strategies of gene transfer or gene therapy to correct genetic defects or strategies of chemoprevention none of which is currently under investigation Greater potential for therapeutic intervention rests with targeting molecular aberrations and altered gene expression in cells for example over expression of the anti-apoptotic proteins of the Bcl-2 family CLL follows a variable clinical course with some patients not needing treatment for many years and responding to therapy completely and repeatedly Other patients have rapidly progressive disease that is refractory to currently available agents and they quickly succumb to their disease One major recent advance has been the identification of molecular and genetic prognostic factors that can be used in early-stage patients to identify those likely to rapidly progress This affords the opportunity to tailor management for patients based on the predictable aggressiveness of their disease Molecular and genetic findings are increasingly influencing management decisions in CLL marrow transplantation may be considered for a patient with unfavorable prognostic features earlier than for a patient with favorable features and same clinical stage of disease It is likely that these genetic and molecular-based factors will be targets of new treatment modalities that fundamentally change the management of this disease In this review we detail the current understanding of the genetics and molecular biology of CLL and introduce potentials for therapeutic intervention,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 8, 505, 1564, 34, 765, 20, 1835, 1, 393, 6349, 132, 37, 232, 219, 281, 322, 1248, 6, 393, 1392, 77, 226, 336, 3698, 15, 774, 71, 85, 443, 6, 40, 2327, 9, 193, 1, 3, 34, 93, 954, 47, 761, 85, 1229, 3113, 612, 3, 336, 2, 219, 877, 9, 3, 2855, 2, 38, 906, 1, 552, 114, 291, 612, 16, 158, 1134, 12548, 843, 6, 3, 741, 1257, 21, 122, 119, 26, 487, 4, 284, 2, 4, 931, 217, 235, 9, 7, 5, 552, 2200, 3147, 1, 552, 140, 16, 44, 2052, 2, 11255, 8, 336, 877, 9, 3, 193, 1, 3, 34, 4, 476, 869, 174, 1151, 4, 26, 10642, 359, 9431, 422, 1, 145, 2602, 15, 145, 36, 6, 4883, 336, 2945, 15, 422, 1, 2886, 1292, 1, 92, 16, 694, 669, 940, 378, 174, 9, 189, 788, 14405, 5, 529, 219, 2152, 2, 1495, 145, 55, 4, 37, 9, 2685, 252, 55, 1, 3, 312, 1631, 652, 1, 3, 1044, 18, 607, 552, 2962, 8, 1347, 38, 906, 5, 476, 7, 44, 12864, 24, 9, 445, 60, 2, 3261, 6, 36, 2500, 2, 11132, 127, 7, 47, 1755, 1014, 34, 17, 16, 430, 6, 694, 390, 183, 2, 491, 7325, 9025, 6, 136, 34, 104, 458, 435, 3148, 71, 85, 3, 911, 1, 219, 2, 336, 177, 130, 17, 122, 40, 95, 4, 191, 82, 7, 6, 255, 135, 322, 6, 1755, 1466, 26, 13485, 3, 2666, 6, 6585, 284, 9, 7, 90, 23, 3, 7639, 3908, 1, 136, 34, 219, 2, 336, 272, 32, 1635, 4743, 284, 1526, 4, 552, 581, 497, 68, 40, 515, 9, 8, 69, 5, 2483, 177, 404, 1677, 76, 9, 8, 69, 5, 913, 404, 2, 827, 38, 82, 1, 34, 192, 16, 322, 17, 46, 336, 2, 219, 90, 130, 303, 40, 637, 1, 217, 24, 1558, 17, 13933, 707, 3, 284, 1, 26, 34, 4, 26, 206, 21, 5000, 3, 291, 612, 1, 3, 2894, 2, 219, 891, 1, 552, 2, 7630, 13328, 9, 189, 788]",2319.0,15869733,353
Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.,American journal of clinical pathology,Am. J. Clin. Pathol.,2005-06-01,"The diagnosis of B-cell chronic lymphoproliferative disorders is a great challenge when made in a background of polyclonal B cells. We studied the diagnostic usefulness of aberrant CD22 expression for differentiating neoplastic from benign B cells by 4-color flow cytometry. Of 56 cases of B-cell chronic lymphoproliferative disorders, we found that neoplastic cells showed aberrant CD22 expression in 39 (70%) of 56 cases, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, hairy cell leukemia, and follicular lymphoma. In 4 cases, monoclonality was detected definitively only by evaluating the immunoglobulin light chain restriction in B cells with aberrant CD22 expression because numerous polyclonal B cells were present. Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells.",Journal Article,5347.0,,The diagnosis of B-cell chronic lymphoproliferative disorders is a great challenge when made in a background of polyclonal B cells We studied the diagnostic usefulness of aberrant CD22 expression for differentiating neoplastic from benign B cells by 4-color flow cytometry Of 56 cases of B-cell chronic lymphoproliferative disorders we found that neoplastic cells showed aberrant CD22 expression in 39 70 of 56 cases including chronic lymphocytic mantle cell marginal zone hairy cell and follicular In 4 cases monoclonality was detected definitively only by evaluating the immunoglobulin light chain restriction in B cells with aberrant CD22 expression because numerous polyclonal B cells were present Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 147, 1, 132, 31, 442, 4192, 1997, 16, 8, 2797, 1745, 198, 1229, 4, 8, 2426, 1, 6350, 132, 37, 21, 656, 3, 752, 5235, 1, 1898, 7599, 55, 9, 5209, 2000, 29, 1002, 132, 37, 20, 39, 6052, 1412, 1914, 1, 664, 140, 1, 132, 31, 442, 4192, 1997, 21, 204, 17, 2000, 37, 224, 1898, 7599, 55, 4, 587, 431, 1, 664, 140, 141, 442, 1193, 2757, 31, 3450, 3614, 7152, 31, 2, 1974, 4, 39, 140, 43969, 10, 530, 6008, 158, 20, 1435, 3, 2593, 1691, 1260, 4575, 4, 132, 37, 5, 1898, 7599, 55, 408, 2331, 6350, 132, 37, 11, 364, 1898, 7599, 55, 16, 8, 999, 952, 9, 638, 1, 848, 132, 37, 14861, 5, 2331, 1002, 6350, 132, 37]",829.0,15899772,14
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.,Leukemia research,Leuk. Res.,2005-11-01,": Studies with flavopiridol have demonstrated that this agent has in vitro activity in chronic lymphocytic leukemia (CLL) and promotes apoptosis independent of p53 function or prior fludarabine exposure. Based upon this pre-clinical data, a phase I/II study of 24h flavopiridol was performed. : Patients with previously treated CLL patients were enrolled on two sequentially performed cohorts of 13 patients. Patients in the first cohort received flavopiridol (80 mg/m(2) as a 24-h continuous infusion [24h CI]) every 2 weeks. Patients in the second cohort received flavopiridol (80 mg/m(2) as a 24h CI) for week 1 and then were dose escalated by 20mg/m(2) every 2 weeks to a maximal dose of 140 mg/m(2) in the absence of symptoms. Patients received up to 12 doses of therapy. : Thirteen patients with fludarabine-refractory or intolerant CLL enrolled in each cohort. Patients received a median of five treatments in each cohort with only two patients completing all 12 courses of therapy. There were no partial or complete responses noted. Toxicity was manageable in most patients and included anemia, thrombocytopenia, infections, diarrhea, and fatigue. : Flavopiridol as a 24-h continuous infusion has no clinical activity in relapsed, fludarabine-refractory CLL.",Clinical Trial,5194.0,85.0,Studies with flavopiridol have demonstrated that this agent has in vitro activity in chronic lymphocytic CLL and promotes apoptosis independent of p53 function or prior fludarabine exposure Based upon this pre-clinical data a phase I/II study of 24h flavopiridol was performed Patients with previously treated CLL patients were enrolled on two sequentially performed cohorts of 13 patients Patients in the first cohort received flavopiridol 80 mg/m 2 as a 24-h continuous infusion 24h CI every 2 weeks Patients in the second cohort received flavopiridol 80 mg/m 2 as a 24h CI for week 1 and then were dose escalated by 20mg/m 2 every 2 weeks to a maximal dose of 140 mg/m 2 in the absence of symptoms Patients received up to 12 doses of therapy Thirteen patients with fludarabine-refractory or intolerant CLL enrolled in each cohort Patients received a median of five treatments in each cohort with only two patients completing all 12 courses of therapy There were no partial or complete responses noted Toxicity was manageable in most patients and included anemia thrombocytopenia infections diarrhea and fatigue Flavopiridol as a 24-h continuous infusion has no clinical activity in relapsed fludarabine-refractory CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[94, 5, 3030, 47, 264, 17, 26, 420, 71, 4, 439, 128, 4, 442, 1193, 552, 2, 2148, 351, 306, 1, 624, 343, 15, 324, 2027, 645, 90, 1548, 26, 671, 38, 74, 8, 124, 70, 215, 45, 1, 12551, 3030, 10, 173, 7, 5, 373, 73, 552, 7, 11, 346, 23, 100, 5455, 173, 736, 1, 233, 7, 7, 4, 3, 157, 180, 103, 3030, 493, 81, 188, 18, 22, 8, 259, 555, 1314, 904, 12551, 58, 454, 18, 244, 7, 4, 3, 419, 180, 103, 3030, 493, 81, 188, 18, 22, 8, 12551, 58, 9, 647, 14, 2, 818, 11, 61, 2842, 20, 16403, 188, 18, 454, 18, 244, 6, 8, 2725, 61, 1, 3304, 81, 188, 18, 4, 3, 1127, 1, 507, 7, 103, 126, 6, 133, 415, 1, 36, 3170, 7, 5, 2027, 430, 15, 4944, 552, 346, 4, 296, 180, 7, 103, 8, 52, 1, 365, 640, 4, 296, 180, 5, 158, 100, 7, 4144, 62, 133, 1993, 1, 36, 125, 11, 77, 450, 15, 236, 253, 1051, 155, 10, 2808, 4, 96, 7, 2, 159, 1545, 1340, 1875, 1172, 2, 613, 3030, 22, 8, 259, 555, 1314, 904, 71, 77, 38, 128, 4, 591, 2027, 430, 552]",1220.0,15916806,161
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-06-01,"Flavopiridol has in vitro activity in chronic lymphocytic leukemia (CLL) and promotes apoptosis independent of p53 function or prior fludarabine exposure. We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration. Patients with previously treated CLL were enrolled in two sequentially done phase II studies. Patients in the first trial received flavopiridol (50 mg/m(2)/d) as a continuous infusion (CI) for 72 hours every 2 weeks. Patients in the second trial received flavopiridol 50 mg/m(2) as a 1-hour bolus (IVB) daily for 3 days repeated every 3 weeks. Patients received up to 12 (CI cohort) or 8 (IVB cohort) cycles of therapy. Fifteen patients were enrolled in the 72-hour CI phase II trial; 6 (40%) had intermediate-risk (Rai stage I or II) and 9 (60%) had high-risk (Rai stage III and IV) stages. No responses were noted in this group; 27% had stable disease and 73% had progressive disease. Thirty-six patients were enrolled in the second IVB trial, with 13 (36%) having intermediate and 23 (64%) having high-risk disease. Four patients (11%) had partial responses, 19 (53%) had stable disease, and 13 (36%) had progressive disease. The progression-free survival for responders in the IVB trial was 3, 3, 9, and 19 months. The median progression-free survival was 2 months [95% confidence interval (95% CI), 1.8-3.8] for patients in the CI trial and 3 months (95% CI, 2.5-7.4) for the IVB trial. The median overall survival was 27 months (95% CI, 20-42) for the CI trial and 24 months (95% CI, 18-31) for the IVB trial. Toxicity was manageable and included mainly myelosuppression, infections, diarrhea, and fatigue. Flavopiridol has modest, schedule-dependent clinical activity in relapsed CLL and warrants future investigation utilizing alternative schedules of administration.",Clinical Trial,5347.0,114.0,Flavopiridol has in vitro activity in chronic lymphocytic CLL and promotes apoptosis independent of p53 function or prior fludarabine exposure We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration Patients with previously treated CLL were enrolled in two sequentially done phase II studies Patients in the first trial received flavopiridol 50 mg/m 2 /d as a continuous infusion CI for 72 hours every 2 weeks Patients in the second trial received flavopiridol 50 mg/m 2 as a 1-hour bolus IVB daily for 3 days repeated every 3 weeks Patients received up to 12 CI cohort or 8 IVB cohort cycles of therapy Fifteen patients were enrolled in the 72-hour CI phase II trial 6 40 had intermediate-risk Rai stage I or II and 9 60 had high-risk Rai stage III and IV stages No responses were noted in this group 27 had stable disease and 73 had progressive disease Thirty-six patients were enrolled in the second IVB trial with 13 36 having intermediate and 23 64 having high-risk disease Four patients 11 had partial responses 19 53 had stable disease and 13 36 had progressive disease The progression-free survival for responders in the IVB trial was 3 3 9 and 19 months The median progression-free survival was 2 months 95 confidence interval 95 CI 1.8-3.8 for patients in the CI trial and 3 months 95 CI 2.5-7.4 for the IVB trial The median overall survival was 27 months 95 CI 20-42 for the CI trial and 24 months 95 CI 18-31 for the IVB trial Toxicity was manageable and included mainly myelosuppression infections diarrhea and fatigue Flavopiridol has modest schedule-dependent clinical activity in relapsed CLL and warrants future investigation utilizing alternative schedules of administration,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 71, 4, 439, 128, 4, 442, 1193, 552, 2, 2148, 351, 306, 1, 624, 343, 15, 324, 2027, 645, 21, 990, 6, 223, 492, 3030, 71, 128, 4, 373, 73, 552, 75, 100, 2314, 1, 634, 7, 5, 373, 73, 552, 11, 346, 4, 100, 5455, 1822, 124, 215, 94, 7, 4, 3, 157, 160, 103, 3030, 212, 81, 188, 18, 427, 22, 8, 1314, 904, 58, 9, 720, 1459, 454, 18, 244, 7, 4, 3, 419, 160, 103, 3030, 212, 81, 188, 18, 22, 8, 14, 2583, 3604, 7042, 391, 9, 27, 162, 2113, 454, 27, 244, 7, 103, 126, 6, 133, 58, 180, 15, 66, 7042, 180, 410, 1, 36, 3057, 7, 11, 346, 4, 3, 720, 2583, 58, 124, 215, 160, 49, 327, 42, 919, 43, 4121, 82, 70, 15, 215, 2, 83, 335, 42, 64, 43, 4121, 82, 316, 2, 478, 1153, 77, 253, 11, 1051, 4, 26, 87, 428, 42, 585, 34, 2, 803, 42, 1014, 34, 977, 437, 7, 11, 346, 4, 3, 419, 7042, 160, 5, 233, 511, 1041, 919, 2, 382, 660, 1041, 64, 43, 34, 294, 7, 175, 42, 450, 253, 326, 699, 42, 585, 34, 2, 233, 511, 42, 1014, 34, 3, 91, 115, 25, 9, 1983, 4, 3, 7042, 160, 10, 27, 27, 83, 2, 326, 53, 3, 52, 91, 115, 25, 10, 18, 53, 48, 307, 268, 48, 58, 14, 66, 27, 66, 9, 7, 4, 3, 58, 160, 2, 27, 53, 48, 58, 18, 33, 67, 39, 9, 3, 7042, 160, 3, 52, 63, 25, 10, 428, 53, 48, 58, 179, 595, 9, 3, 58, 160, 2, 259, 53, 48, 58, 203, 456, 9, 3, 7042, 160, 155, 10, 2808, 2, 159, 2615, 2858, 1875, 1172, 2, 613, 3030, 71, 1721, 1055, 470, 38, 128, 4, 591, 552, 2, 2782, 508, 940, 2600, 1091, 2314, 1, 634]",1752.0,15930354,798
Decitabine in chronic leukemias.,Seminars in hematology,Semin. Hematol.,2005-07-01,"5-Aza-2'-deoxycitidine (decitabine, Dacogen, Bloomington, MN) is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies. Indeed, promising clinical results have been observed in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). Aberrant methylation has also been found in chronic leukemias, providing a rationale for investigating the use of decitabine in these diseases. There is clear evidence of molecular (hypomethylation) as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous leukemia of all phases, including in patients resistant to imatinib mesylate. Clinical trials of decitabine in chronic lymphocytic leukemia are ongoing. There are many unanswered questions regarding optimizing this treatment for chronic leukemias, but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes.",Journal Article,5317.0,15.0,5-Aza-2'-deoxycitidine decitabine Dacogen Bloomington MN is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies Indeed promising clinical results have been observed in acute myeloid AML and the syndromes MDS Aberrant methylation has also been found in chronic leukemias providing a rationale for investigating the use of decitabine in these diseases There is clear evidence of molecular hypomethylation as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous of all phases including in patients resistant to imatinib mesylate Clinical trials of decitabine in chronic lymphocytic are ongoing There are many unanswered questions regarding optimizing this treatment for chronic leukemias but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[33, 3924, 6135, 44028, 3004, 33559, 37971, 4691, 16, 8, 6903, 4696, 17, 2148, 4441, 1, 261, 2, 71, 1405, 209, 4, 533, 441, 4462, 721, 38, 99, 47, 85, 164, 4, 286, 533, 329, 2, 3, 2040, 1223, 1898, 569, 71, 120, 85, 204, 4, 442, 2792, 1736, 8, 1728, 9, 3103, 3, 119, 1, 3004, 4, 46, 1342, 125, 16, 885, 241, 1, 219, 4441, 22, 149, 22, 813, 2, 1266, 253, 6, 3004, 4, 442, 2194, 1, 62, 3523, 141, 4, 7, 436, 6, 577, 2347, 38, 143, 1, 3004, 4, 442, 1193, 32, 942, 125, 32, 445, 7550, 1937, 666, 4336, 26, 24, 9, 442, 2792, 84, 1401, 3840, 1, 2545, 94, 9, 4931, 183, 6759, 843, 6576, 6, 611, 17, 68, 47, 8, 93, 345, 23, 69, 123]",922.0,16015505,113
Immune defects in patients with chronic lymphocytic leukemia.,"Cancer immunology, immunotherapy : CII",Cancer Immunol. Immunother.,2005-07-16,"Over the past decade, the introduction of nucleoside analogs and monoclonal antibodies into the treatment of patients with chronic lymphocytic leukemia (CLL) has resulted in higher rates and longer duration of response. This is a significant step towards achieving the ultimate goal of disease-eradication and improved survival. A continuing problem, however, is the susceptibility of these patients to infections. Profound dysregulation of the host immune system in patients with CLL and its impact on the clinical course of the disease are well established. A number of investigators have sought to identify the mechanisms underlying this innate immune dysfunction, which is further exacerbated by the actions of the potent therapeutic agents. The early recognition of infections as well as prophylactic administration of appropriate antibiotics has been the mainstay of managing infections in patients with CLL. Hopefully, increasing understanding of the molecular events underlying the neoplastic change in CLL will lead to more targeted and less immunosuppressive therapeutic modalities. Furthermore, the understanding of the mechanisms of immune dysfunction in CLL is of pivotal importance in the novel immune-based therapeutic strategies currently under development.",Journal Article,5302.0,86.0,Over the past decade the introduction of nucleoside analogs and monoclonal antibodies into the treatment of patients with chronic lymphocytic CLL has resulted in higher rates and longer duration of response This is a significant step towards achieving the ultimate goal of disease-eradication and improved survival A continuing problem however is the susceptibility of these patients to infections Profound dysregulation of the host immune system in patients with CLL and its impact on the clinical course of the disease are well established A number of investigators have sought to identify the mechanisms underlying this innate immune dysfunction which is further exacerbated by the actions of the potent therapeutic agents The early recognition of infections as well as prophylactic administration of appropriate antibiotics has been the mainstay of managing infections in patients with CLL Hopefully increasing understanding of the molecular events underlying the neoplastic change in CLL will lead to more targeted and less immunosuppressive therapeutic modalities Furthermore the understanding of the mechanisms of immune dysfunction in CLL is of pivotal importance in the novel immune-based therapeutic strategies currently under development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 2025, 3, 2456, 1, 4032, 4063, 2, 848, 890, 237, 3, 24, 1, 7, 5, 442, 1193, 552, 71, 627, 4, 142, 151, 2, 589, 654, 1, 51, 26, 16, 8, 93, 2458, 3113, 1785, 3, 5768, 1326, 1, 34, 5173, 2, 231, 25, 8, 4346, 2497, 137, 16, 3, 1432, 1, 46, 7, 6, 1875, 4399, 3935, 1, 3, 1204, 250, 398, 4, 7, 5, 552, 2, 211, 345, 23, 3, 38, 906, 1, 3, 34, 32, 149, 635, 8, 207, 1, 2394, 47, 990, 6, 255, 3, 483, 1181, 26, 3939, 250, 1527, 92, 16, 195, 10545, 20, 3, 5592, 1, 3, 1157, 189, 183, 3, 191, 2335, 1, 1875, 22, 149, 22, 1862, 634, 1, 870, 5214, 71, 85, 3, 4041, 1, 3969, 1875, 4, 7, 5, 552, 7464, 602, 612, 1, 3, 219, 281, 1181, 3, 2000, 707, 4, 552, 303, 1122, 6, 80, 238, 2, 299, 2989, 189, 1558, 798, 3, 612, 1, 3, 483, 1, 250, 1527, 4, 552, 16, 1, 3754, 1187, 4, 3, 229, 250, 90, 189, 422, 694, 669, 193]",1248.0,16025268,363
Genomic analysis in lymphoid leukemias.,Reviews in clinical and experimental hematology,Rev Clin Exp Hematol,2005-06-01,"The introduction of microarray analysis represents a revolution in the scientific field, allowing to investigate thousand of genes in a single experiment. Important biological insights have been revealed by this technique in several tumors: in acute lymphoblastic leukemia (ALL), these studies have allowed to identify specific patterns associated with known molecular abnormalities, as well as with phenotypic characteristics and with different prognostic features. In chronic lymphocytic leukemia (CLL), this approach has helped to dissect that this disease is a single entity with distinct variants that are characterized by a diverse IgVH mutational status, that can be discriminated by a small set of genes, has allowed to define a similarity between this disease and memory B cells and has also led to hypothesize that CLL cells from IgVH unmutated patients may be continuously stimulated in vivo, thus showing a gene profile that is reminiscent of the B cell receptor. In multiple myeloma (MM), gene expression profiles has provided insights into the disease and has offered the opportunity of stratifying patients according to the degree of aggressiveness of the disease. Current efforts are directed to the identification of patterns that may distinguish patients with a different outcome, thus providing useful prognostic information and to design experiments that may allow the identification of new therapeutic targets.",Journal Article,5347.0,1.0,The introduction of microarray analysis represents a revolution in the scientific field allowing to investigate thousand of genes in a single experiment Important biological insights have been revealed by this technique in several tumors in acute lymphoblastic ALL these studies have allowed to identify specific patterns associated with known molecular abnormalities as well as with phenotypic characteristics and with different prognostic features In chronic lymphocytic CLL this approach has helped to dissect that this disease is a single entity with distinct variants that are characterized by a diverse IgVH mutational status that can be discriminated by a small set of genes has allowed to define a similarity between this disease and memory B cells and has also led to hypothesize that CLL cells from IgVH unmutated patients may be continuously stimulated in vivo thus showing a gene profile that is reminiscent of the B cell receptor In multiple MM gene expression profiles has provided insights into the disease and has offered the opportunity of stratifying patients according to the degree of aggressiveness of the disease Current efforts are directed to the identification of patterns that may distinguish patients with a different outcome thus providing useful prognostic information and to design experiments that may allow the identification of new therapeutic targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 2456, 1, 1727, 65, 1449, 8, 11030, 4, 3, 3138, 1067, 2952, 6, 963, 6161, 1, 214, 4, 8, 226, 8722, 305, 1037, 1957, 47, 85, 553, 20, 26, 1312, 4, 392, 57, 4, 286, 1275, 62, 46, 94, 47, 2313, 6, 255, 112, 764, 41, 5, 440, 219, 1171, 22, 149, 22, 5, 3290, 374, 2, 5, 338, 177, 404, 4, 442, 1193, 552, 26, 353, 71, 6156, 6, 10830, 17, 26, 34, 16, 8, 226, 2983, 5, 834, 839, 17, 32, 765, 20, 8, 1867, 14484, 1619, 156, 17, 122, 40, 8752, 20, 8, 302, 916, 1, 214, 71, 2313, 6, 1107, 8, 6700, 59, 26, 34, 2, 2407, 132, 37, 2, 71, 120, 836, 6, 4919, 17, 552, 37, 29, 14484, 7216, 7, 68, 40, 4285, 2816, 4, 386, 631, 2069, 8, 145, 800, 17, 16, 17726, 1, 3, 132, 31, 153, 4, 232, 321, 145, 55, 1241, 71, 1052, 1957, 237, 3, 34, 2, 71, 2216, 3, 2666, 1, 5035, 7, 768, 6, 3, 1444, 1, 3908, 1, 3, 34, 291, 1413, 32, 1166, 6, 3, 911, 1, 764, 17, 68, 3081, 7, 5, 8, 338, 228, 631, 1736, 999, 177, 487, 2, 6, 771, 2332, 17, 68, 1700, 3, 911, 1, 217, 189, 637]",1384.0,16027105,454
Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature.,Leukemia research,Leuk. Res.,2005-07-25,"Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.",Case Reports,5293.0,33.0,Pure red cell aplasia PRCA is an unusual cause of anemia in patients with chronic lymphoproliferative disorders Here we present two cases of PRCA one associated with chronic lymphocytic CLL and the other with splenic marginal zone in which the PRCA responded dramatically to treatment with rituximab We then review the literature on PRCA in and response to rituximab PRCA associated with CLL or may be another indication for rituximab therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3092, 3422, 31, 12307, 7861, 16, 35, 4015, 708, 1, 1545, 4, 7, 5, 442, 4192, 1997, 467, 21, 364, 100, 140, 1, 7861, 104, 41, 5, 442, 1193, 552, 2, 3, 127, 5, 5237, 3450, 3614, 4, 92, 3, 7861, 2211, 2729, 6, 24, 5, 855, 21, 818, 206, 3, 789, 23, 7861, 4, 2, 51, 6, 855, 7861, 41, 5, 552, 15, 68, 40, 1809, 3607, 9, 855, 36]",442.0,16043218,768
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-07-25,"To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL). A total of 38 CLL patients received a matched URD transplant using bone marrow procured by the National Marrow Donor Program. The median age was 45 years (range, 26 to 57 years), the median time from diagnosis was 51 months, and the median number of prior chemotherapy regimens was three. Fifty-five percent of patients were chemotherapy refractory and 89% had received fludarabine. Conditioning included total-body irradiation in 92% of patients. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82% of patients. Twenty-one patients (58%) achieved complete response and six (17%) achieved partial response. Incidences of grades 2 to 4 acute GVHD were 45% at 100 days and incidences of chronic GVHD were 85% at 5 years. Eleven patients are alive and disease free at a median of 6 years (range, 3.0 to 9.0 years). Five-year overall survival, failure-free survival, disease progression rates, and treatment-related mortality (TRM) were 33%, 30%, 32%, and 38% respectively. These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL. High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols, and it is mandatory to investigate transplant strategies with a lower morbidity and mortality, including the use of nonmyeloablative regimens.",Journal Article,5293.0,82.0,To determine the role of myeloablative conditioning and unrelated donor URD marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic CLL A total of 38 CLL patients received a matched URD transplant using marrow procured by the National Marrow Donor Program The median age was 45 years range 26 to 57 years the median time from diagnosis was 51 months and the median number of prior chemotherapy regimens was three Fifty-five percent of patients were chemotherapy refractory and 89 had received fludarabine Conditioning included total-body irradiation in 92 of patients Graft-versus-host disease GVHD prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82 of patients Twenty-one patients 58 achieved complete response and six 17 achieved partial response Incidences of grades 2 to 4 acute GVHD were 45 at 100 days and incidences of chronic GVHD were 85 at 5 years Eleven patients are alive and disease free at a median of 6 years range 3.0 to 9.0 years Five-year overall survival failure-free survival disease progression rates and treatment-related mortality TRM were 33 30 32 and 38 respectively These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols and it is mandatory to investigate transplant strategies with a lower morbidity and mortality including the use of nonmyeloablative regimens,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 223, 3, 200, 1, 3246, 1933, 2, 2092, 1488, 5847, 581, 497, 4, 3, 24, 1, 7, 5, 131, 132, 31, 442, 1193, 552, 8, 181, 1, 519, 552, 7, 103, 8, 655, 5847, 941, 75, 581, 19722, 20, 3, 657, 581, 1488, 1243, 3, 52, 89, 10, 512, 60, 184, 432, 6, 696, 60, 3, 52, 98, 29, 147, 10, 725, 53, 2, 3, 52, 207, 1, 324, 56, 472, 10, 169, 1461, 365, 714, 1, 7, 11, 56, 430, 2, 887, 42, 103, 2027, 1933, 159, 181, 642, 1104, 4, 937, 1, 7, 1599, 185, 1204, 34, 1562, 2049, 1695, 1, 2116, 5, 9112, 15, 5643, 9, 878, 1, 7, 737, 104, 7, 717, 513, 236, 51, 2, 437, 269, 513, 450, 51, 3981, 1, 2276, 18, 6, 39, 286, 1562, 11, 512, 28, 394, 162, 2, 3981, 1, 442, 1562, 11, 772, 28, 33, 60, 2627, 7, 32, 1701, 2, 34, 115, 28, 8, 52, 1, 49, 60, 184, 27, 13, 6, 83, 13, 60, 365, 111, 63, 25, 496, 115, 25, 34, 91, 151, 2, 24, 139, 282, 5064, 11, 466, 201, 531, 2, 519, 106, 46, 74, 608, 17, 3443, 3166, 122, 40, 513, 50, 5847, 497, 4, 7, 5, 131, 552, 64, 5064, 309, 17, 3246, 1933, 2, 1160, 5095, 2344, 257, 40, 5617, 4, 508, 2189, 2, 192, 16, 7322, 6, 963, 941, 422, 5, 8, 280, 787, 2, 282, 141, 3, 119, 1, 6094, 472]",1527.0,16043827,727
Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2005-10-01,"Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas. Using immunohistochemical methods, we assessed for HSP90 expression in 412 cases of non-Hodgkin's lymphoma. In B-cell lymphomas, HSP90 was moderately to strongly expressed in all cases of Burkitt's lymphoma (5/5, 100%), and in subsets of follicular lymphoma (17/28, 61%), diffuse large B-cell lymphoma (27/46, 59%), nodal marginal zone B-cell lymphoma (6/16, 38%), plasma cell neoplasms (14/39, 36%), small lymphocytic lymphoma/chronic lymphocytic leukemia (3/9, 33%), mantle cell lymphoma (12/38, 32%) and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (3/10, 30%). HSP90 was weakly expressed in six of 14 (43%) cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. In T-cell lymphomas, HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell lymphoma (14/24, 58%; 9/12 ALK+ and 5/12 ALK-), precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%), unspecified peripheral T-cell lymphoma (8/43, 23%) and angioimmunoblastic T-cell lymphoma (2/17, 12%). HSP90 was weakly expressed in seven of 58 (12%) cases of mycosis fungoides. We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell lymphoma. These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients.",Journal Article,5225.0,36.0,Heat-shock protein-90 HSP90 inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas Using immunohistochemical methods we assessed for HSP90 expression in 412 cases of 's In B-cell lymphomas HSP90 was moderately to strongly expressed in all cases of 's 5/5 100 and in subsets of follicular 17/28 61 diffuse large B-cell 27/46 59 nodal marginal zone B-cell 6/16 38 plasma cell neoplasms 14/39 36 small lymphocytic lymphoma/chronic lymphocytic 3/9 33 mantle cell 12/38 32 and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia 3/10 30 HSP90 was weakly expressed in six of 14 43 cases of extranodal marginal zone B-cell of mucosa-associated lymphoid tissue In T-cell lymphomas HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell 14/24 58 9/12 ALK+ and 5/12 ALK- precursor-T-cell lymphoblastic leukemia/lymphoma 20/65 31 unspecified peripheral T-cell 8/43 23 and angioimmunoblastic T-cell 2/17 12 HSP90 was weakly expressed in seven of 58 12 cases of mycosis fungoides We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell These data suggest that many types are suitable targets for modulation of HSP90 activity and that HSP90 inhibitors are a potential investigational therapy for patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3545, 3971, 178, 424, 2515, 222, 32, 694, 486, 95, 4, 124, 70, 38, 143, 9, 1367, 7, 5, 8, 1362, 1, 1179, 141, 1557, 75, 1382, 636, 21, 275, 9, 2515, 55, 4, 9963, 140, 1, 292, 4, 132, 31, 1557, 2515, 10, 3508, 6, 1327, 570, 4, 62, 140, 1, 292, 33, 33, 394, 2, 4, 1890, 1, 1974, 269, 339, 713, 1388, 375, 132, 31, 428, 641, 728, 779, 3450, 3614, 132, 31, 49, 245, 519, 554, 31, 1179, 213, 587, 511, 302, 1193, 4763, 442, 1193, 27, 83, 466, 2757, 31, 133, 519, 531, 2, 5325, 4763, 7933, 3389, 27, 79, 201, 2515, 10, 7348, 570, 4, 437, 1, 213, 601, 140, 1, 4093, 3450, 3614, 132, 31, 1, 2713, 41, 2303, 246, 4, 102, 31, 1557, 2515, 10, 3508, 6, 1327, 570, 4, 1890, 1, 1841, 375, 31, 213, 259, 717, 83, 133, 1023, 2, 33, 133, 1023, 2765, 102, 31, 1275, 2647, 4763, 179, 556, 456, 12288, 672, 102, 31, 66, 601, 382, 2, 10722, 102, 31, 18, 269, 133, 2515, 10, 7348, 570, 4, 648, 1, 717, 133, 140, 1, 6789, 6744, 21, 2060, 17, 2515, 16, 841, 570, 4, 8, 697, 1, 445, 630, 1, 132, 2, 102, 31, 46, 74, 309, 17, 445, 630, 32, 2884, 637, 9, 2356, 1, 2515, 128, 2, 17, 2515, 222, 32, 8, 174, 3093, 36, 9, 7]",1329.0,16056252,16
"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.",Blood,Blood,2005-08-04,"Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.",Clinical Trial,5283.0,292.0,Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies Recently we and others identified a single recurrent somatic activating mutation JAK2V617F in the Janus kinase 2 JAK2 tyrosine kinase in the disorders MPDs polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid AML chronic myelomonocytic CMML /atypical chronic myelogenous aCML syndrome MDS B-lineage acute lymphoblastic ALL T-cell ALL and chronic lymphocytic CLL Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML 3 of whom had a preceding MPD JAK2V617F mutations were identified in 9 7.8 of 116 CMML/a CML samples and in 2 4.2 of 48 MDS samples We did not identify the JAK2V617F disease allele in B-lineage ALL n 83 T-cell ALL n 93 or CLL n 45 These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1616, 138, 4, 564, 1549, 47, 85, 108, 4, 1007, 2, 19463, 441, 761, 21, 2, 1749, 108, 8, 226, 387, 1119, 1616, 258, 9061, 4, 3, 6191, 216, 18, 2509, 564, 216, 4, 3, 1997, 24840, 5755, 5756, 1452, 8962, 2, 533, 6054, 5, 4637, 21, 95, 1196, 1532, 65, 6, 223, 492, 3, 9061, 258, 10, 364, 4, 286, 533, 329, 442, 5451, 3382, 1973, 442, 2194, 21345, 681, 1223, 132, 2542, 286, 1275, 62, 102, 31, 62, 2, 442, 1193, 552, 65, 1, 5647, 7, 5, 329, 108, 9061, 138, 4, 39, 7, 5, 329, 27, 1, 953, 42, 8, 5892, 7712, 9061, 138, 11, 108, 4, 83, 67, 66, 1, 3790, 3382, 8, 903, 347, 2, 4, 18, 39, 18, 1, 576, 1223, 347, 21, 205, 44, 255, 3, 9061, 34, 1254, 4, 132, 2542, 62, 78, 852, 102, 31, 62, 78, 966, 15, 552, 78, 512, 46, 74, 1008, 17, 3, 9061, 1254, 16, 364, 4, 286, 2, 442, 533, 441, 84, 44, 4, 2303, 441]",1059.0,16081687,8
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.,Blood,Blood,2005-08-30,"We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens.",Clinical Trial,5257.0,183.0,We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic CLL who have undergone hematopoietic stem cell transplantation SCT at a single center from 1989 to 1999 Twenty-five patients with human leukocyte antigen HLA -matched sibling donors underwent T-cell-depleted allogeneic SCT and 137 patients without HLA-matched sibling donors underwent autologous SCT The 100-day mortality was 4 for both groups but later morbidity and mortality were negatively affected on outcome Progression-free survival was significantly longer following autologous than allogeneic SCT but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival The majority of patients treated with donor lymphocyte infusions after relapse responded demonstrating a significant graft-versus-leukemia effect in CLL From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 414, 467, 23, 3, 319, 337, 166, 126, 23, 5441, 7, 5, 64, 43, 442, 1193, 552, 54, 47, 1989, 1007, 452, 31, 497, 1988, 28, 8, 226, 574, 29, 3965, 6, 2043, 737, 365, 7, 5, 171, 3627, 448, 1160, 655, 3684, 2344, 208, 102, 31, 4358, 1063, 1988, 2, 4352, 7, 187, 1160, 655, 3684, 2344, 208, 1028, 1988, 3, 394, 218, 282, 10, 39, 9, 110, 271, 84, 1559, 787, 2, 282, 11, 2723, 1424, 23, 228, 91, 115, 25, 10, 97, 589, 366, 1028, 76, 1063, 1988, 84, 125, 10, 77, 523, 4, 63, 25, 2, 77, 523, 4, 3, 967, 287, 1, 34, 146, 15, 1043, 187, 146, 59, 3, 18, 271, 28, 8, 52, 166, 126, 1, 49, 33, 60, 125, 16, 77, 241, 1, 8, 6133, 1, 91, 115, 25, 3, 686, 1, 7, 73, 5, 1488, 1448, 3435, 50, 429, 2211, 2219, 8, 93, 1599, 185, 2647, 254, 4, 552, 29, 46, 272, 21, 47, 1495, 114, 353, 9, 7, 5, 64, 43, 552, 2, 32, 694, 4378, 3, 200, 1, 139, 2, 2092, 1063, 1988, 366, 405, 837, 1933, 472]",1223.0,16131571,509
Novel immune-based treatment strategies for chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-09-01,"Immune-based treatments represent a new group of therapeutic strategies for patients with cancer, including chronic lymphocytic leukemia (CLL), that employ immune effector mechanisms. Among these strategies is passive immunotherapy with monoclonal antibody, alone or in combination with chemotherapy. Active immunotherapy strategies currently under development include vaccines, administration of expanded and activated T cells, and allogeneic stem cell transplantation. These immune-based strategies represent new treatments with potentially complementary mechanisms of action to standard therapies and signify major advances in treatments for patients with CLL.",Comparative Study,5255.0,57.0,Immune-based treatments represent a new group of therapeutic strategies for patients with cancer including chronic lymphocytic CLL that employ immune effector mechanisms Among these strategies is passive immunotherapy with monoclonal antibody alone or in combination with chemotherapy Active immunotherapy strategies currently under development include vaccines administration of expanded and activated T cells and allogeneic stem cell transplantation These immune-based strategies represent new treatments with potentially complementary mechanisms of action to standard therapies and signify major advances in treatments for patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[250, 90, 640, 1231, 8, 217, 87, 1, 189, 422, 9, 7, 5, 12, 141, 442, 1193, 552, 17, 9431, 250, 2070, 483, 107, 46, 422, 16, 6422, 726, 5, 848, 548, 279, 15, 4, 150, 5, 56, 544, 726, 422, 694, 669, 193, 643, 1842, 634, 1, 2064, 2, 735, 102, 37, 2, 1063, 452, 31, 497, 46, 250, 90, 422, 1231, 217, 640, 5, 751, 3380, 483, 1, 1578, 6, 260, 235, 2, 19016, 458, 954, 4, 640, 9, 7, 5, 552]",643.0,16155015,87
"Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-09-01,"To determine if RNA-directed nucleoside analogue, 8-NH(2)-adenosine, induces cell death and if that is accompanied with transcription inhibition of the key survival factors of chronic lymphocytic leukemia (CLL) cells. Primary lymphocytes from CLL patients were incubated with 10 micromol/L 8-NH(2)-adenosine for 2, 4, and 6 or 8 hours. The accumulation of analogue triphosphate and the decline in endogenous ATP pool were analyzed by high-performance liquid chromatography. Inhibition of global RNA and protein synthesis was measured and correlated with specific decline in transcript and protein levels of MCL-1, XIAP, and BCL-2, the key survival factors of CLL. These biochemical and molecular end points were related to cell death of these quiescent lymphocytes. In vitro incubations of CLL lymphocytes with 8-NH(2)-adenosine resulted in rapid but heterogeneous accumulation of 8-NH(2)-ATP (390-680 micromol/L), with a concomitant decline in endogenous ATP (median, >50% by 4 hour). Global RNA synthesis was decreased in all samples and was associated with a decline in MCL-1, XIAP, and BCL-2 transcripts. There was a parallel decrease in the protein level of MCL-1 and XIAP but not BCL-2. These biochemical changes were accompanied by apoptosis. The evidence of CLL cell death with complementary changes in the expression of survival proteins provides a molecular rationale for using 8-NH(2)-adenosine as a therapeutic agent for this indolent leukemia.",Journal Article,5255.0,15.0,To determine if RNA-directed nucleoside analogue 8-NH 2 -adenosine induces cell death and if that is accompanied with transcription inhibition of the key survival factors of chronic lymphocytic CLL cells Primary lymphocytes from CLL patients were incubated with 10 micromol/L 8-NH 2 -adenosine for 2 4 and 6 or 8 hours The accumulation of analogue triphosphate and the decline in endogenous ATP pool were analyzed by high-performance liquid chromatography Inhibition of global RNA and protein synthesis was measured and correlated with specific decline in transcript and protein levels of MCL-1 XIAP and BCL-2 the key survival factors of CLL These biochemical and molecular end points were related to cell death of these quiescent lymphocytes In vitro incubations of CLL lymphocytes with 8-NH 2 -adenosine resulted in rapid but heterogeneous accumulation of 8-NH 2 -ATP 390-680 micromol/L with a concomitant decline in endogenous ATP median 50 by 4 hour Global RNA synthesis was decreased in all samples and was associated with a decline in MCL-1 XIAP and BCL-2 transcripts There was a parallel decrease in the protein level of MCL-1 and XIAP but not BCL-2 These biochemical changes were accompanied by apoptosis The evidence of CLL cell death with complementary changes in the expression of survival proteins provides a molecular rationale for using 8-NH 2 -adenosine as a therapeutic agent for this indolent,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 223, 492, 893, 1166, 4032, 4696, 66, 6260, 18, 4938, 1516, 31, 273, 2, 492, 17, 16, 2756, 5, 866, 297, 1, 3, 825, 25, 130, 1, 442, 1193, 552, 37, 86, 1594, 29, 552, 7, 11, 8303, 5, 79, 6297, 805, 66, 6260, 18, 4938, 9, 18, 39, 2, 49, 15, 66, 1459, 3, 1835, 1, 4696, 7345, 2, 3, 1858, 4, 2682, 3918, 6545, 11, 311, 20, 64, 528, 3165, 5140, 297, 1, 1648, 893, 2, 178, 2525, 10, 644, 2, 438, 5, 112, 1858, 4, 3268, 2, 178, 148, 1, 1308, 14, 5387, 2, 1044, 18, 3, 825, 25, 130, 1, 552, 46, 1487, 2, 219, 396, 862, 11, 139, 6, 31, 273, 1, 46, 6735, 1594, 4, 439, 30844, 1, 552, 1594, 5, 66, 6260, 18, 4938, 627, 4, 1321, 84, 1564, 1835, 1, 66, 6260, 18, 3918, 7992, 9297, 6297, 805, 5, 8, 1781, 1858, 4, 2682, 3918, 52, 212, 20, 39, 2583, 1648, 893, 2525, 10, 340, 4, 62, 347, 2, 10, 41, 5, 8, 1858, 4, 1308, 14, 5387, 2, 1044, 18, 2680, 125, 10, 8, 2755, 775, 4, 3, 178, 301, 1, 1308, 14, 2, 5387, 84, 44, 1044, 18, 46, 1487, 400, 11, 2756, 20, 351, 3, 241, 1, 552, 31, 273, 5, 3380, 400, 4, 3, 55, 1, 25, 652, 777, 8, 219, 1728, 9, 75, 66, 6260, 18, 4938, 22, 8, 189, 420, 9, 26, 2316]",1409.0,16166456,223
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2005-08-01,"Over the past few decades, the management of chronic lymphocytic leukemia (CLL) has evolved considerably. This advancement is due in part to increasing awareness of prognostic factors and molecular heterogeneity of the disease which has helped to identify distinct risk groups of CLL. In addition, novel treatment regimens have demonstrated much higher complete and overall response rates than previously seen with conventional CLL therapy. Indeed, as complete response rates exceed 50%, curative therapy for CLL is within reach. Ongoing clinical research may define the optimal treatment strategies and improve outcomes for patients with CLL.",Journal Article,5286.0,2.0,Over the past few decades the management of chronic lymphocytic CLL has evolved considerably This advancement is due in part to increasing awareness of prognostic factors and molecular heterogeneity of the disease which has helped to identify distinct risk groups of CLL In addition novel treatment regimens have demonstrated much higher complete and overall response rates than previously seen with conventional CLL therapy Indeed as complete response rates exceed 50 curative therapy for CLL is within reach Ongoing clinical research may define the optimal treatment strategies and improve outcomes for patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 1021, 1968, 3, 284, 1, 442, 1193, 552, 71, 3937, 5597, 26, 7496, 16, 520, 4, 760, 6, 602, 3310, 1, 177, 130, 2, 219, 1144, 1, 3, 34, 92, 71, 6156, 6, 255, 834, 43, 271, 1, 552, 4, 352, 229, 24, 472, 47, 264, 1802, 142, 236, 2, 63, 51, 151, 76, 373, 527, 5, 809, 552, 36, 4462, 22, 236, 51, 151, 6818, 212, 1075, 36, 9, 552, 16, 262, 3690, 942, 38, 389, 68, 1107, 3, 665, 24, 422, 2, 401, 123, 9, 7, 5, 552]",622.0,16201050,74
Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2005-10-01,"Since the advent of hematopoietic stem cell transplantation more than 40 years ago, numerous methods of transplantation have been developed, modified and improved upon. Although hematopoietic stem cell transplantation has been used in a variety of malignant diseases since then, its use in the treatment of chronic lymphocytic leukemia has recently started to gain interest. Patients with chronic lymphocytic leukemia are generally elderly, and because of its relatively benign course, they were not considered suitable candidates for hematopoietic stem cell transplantation. Nonetheless, there have been marked improvements in transplantation techniques, including better conditioning regimens that have decreased treatment-related morbidity and mortality. In this article, the authors review the most recent data on hematopoietic stem cell transplantation in chronic lymphocytic leukemia as well as the change in risk stratification based on newer prognostic factors and its impact on treatment decisions in chronic lymphocytic leukemia.",Journal Article,5225.0,0.0,Since the advent of hematopoietic stem cell transplantation more than 40 years ago numerous methods of transplantation have been developed modified and improved upon Although hematopoietic stem cell transplantation has been used in a variety of malignant diseases since then its use in the treatment of chronic lymphocytic has recently started to gain interest Patients with chronic lymphocytic are generally elderly and because of its relatively benign course they were not considered suitable candidates for hematopoietic stem cell transplantation Nonetheless there have been marked improvements in transplantation techniques including better conditioning regimens that have decreased treatment-related morbidity and mortality In this article the authors review the most recent data on hematopoietic stem cell transplantation in chronic lymphocytic as well as the change in risk stratification based on newer prognostic factors and its impact on treatment decisions in chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1192, 3, 4114, 1, 1007, 452, 31, 497, 80, 76, 327, 60, 5028, 2331, 636, 1, 497, 47, 85, 276, 1230, 2, 231, 1548, 242, 1007, 452, 31, 497, 71, 85, 95, 4, 8, 1362, 1, 393, 1342, 1192, 818, 211, 119, 4, 3, 24, 1, 442, 1193, 71, 761, 3461, 6, 1803, 1333, 7, 5, 442, 1193, 32, 1228, 1216, 2, 408, 1, 211, 1352, 1002, 906, 491, 11, 44, 515, 2884, 1931, 9, 1007, 452, 31, 497, 4648, 125, 47, 85, 2003, 1474, 4, 497, 1092, 141, 380, 1933, 472, 17, 47, 340, 24, 139, 787, 2, 282, 4, 26, 946, 3, 738, 206, 3, 96, 435, 74, 23, 1007, 452, 31, 497, 4, 442, 1193, 22, 149, 22, 3, 707, 4, 43, 1541, 90, 23, 2246, 177, 130, 2, 211, 345, 23, 24, 1526, 4, 442, 1193]",990.0,16221057,143
"Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-12-01,"Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts. In an attempt to preserve CD4 counts, we conducted a phase I, double-blind, placebo-controlled trial of recombinant interleukin-2 (IL-2) added to fludarabine and cyclophosphamide in patients with treatment-naive indolent lymphomas or chronic lymphocytic leukemia. Subcutaneous IL-2 (days 1-21 of each 28-day cycle) was combined with cyclophosphamide (600 mg/m2, day 8) and fludarabine (20 mg/m2, days 8-12) at four dose levels: 0.8, 1.0, 1.2, and 1.4 x 10(6) IU/m2/d. IL-2 dose was escalated in cohorts of four to six patients, with one patient per cohort receiving placebo. Twenty-three patients, median age 50, were enrolled, of whom 30% had chronic lymphocytic leukemia/small lymphocytic lymphoma and 52% had follicular lymphomas. The combination was generally well tolerated, with mainly hematologic toxicities. CD4 counts typically declined substantially during the early weeks of treatment and remained suppressed for months afterward. In the 18 evaluable patients who received IL-2, the mean absolute CD4 count was 999 cells/microL (range, 97-3,776) pretreatment, 379 cells/microL (range, 54-2,599) at day 14, and 98 cells/microL (range, 17-291) at end of treatment. In longitudinal linear models, the changes in CD4 counts were not significantly different across IL-2 dose levels. The addition of low-dose IL-2 to fludarabine and cyclophosphamide does not seem immunoprotective. New approaches are needed to reduce the cellular immunosuppression and infectious complications associated with purine analogues.","Clinical Trial, Phase I",5164.0,6.0,"Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts In an attempt to preserve CD4 counts we conducted a phase I double-blind placebo-controlled trial of recombinant interleukin-2 IL-2 added to fludarabine and cyclophosphamide in patients with treatment-naive indolent lymphomas or chronic lymphocytic Subcutaneous IL-2 days 1-21 of each 28-day cycle was combined with cyclophosphamide 600 mg/m2 day 8 and fludarabine 20 mg/m2 days 8-12 at four dose levels 0.8 1.0 1.2 and 1.4 x 10 6 IU/m2/d IL-2 dose was escalated in cohorts of four to six patients with one patient per cohort receiving placebo Twenty-three patients median age 50 were enrolled of whom 30 had chronic lymphocytic leukemia/small lymphocytic and 52 had follicular lymphomas The combination was generally well tolerated with mainly hematologic toxicities CD4 counts typically declined substantially during the early weeks of treatment and remained suppressed for months afterward In the 18 evaluable patients who received IL-2 the mean absolute CD4 count was 999 cells/microL range 97-3,776 pretreatment 379 cells/microL range 54-2,599 at day 14 and 98 cells/microL range 17-291 at end of treatment In longitudinal linear models the changes in CD4 counts were not significantly different across IL-2 dose levels The addition of low-dose IL-2 to fludarabine and cyclophosphamide does not seem immunoprotective New approaches are needed to reduce the cellular immunosuppression and infectious complications associated with purine analogues",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 2, 1112, 16, 35, 323, 150, 84, 1106, 3, 43, 1, 10026, 1875, 520, 6, 9233, 1448, 1911, 4, 35, 3448, 6, 6783, 1440, 1911, 21, 426, 8, 124, 70, 1627, 3142, 619, 1149, 160, 1, 2835, 1603, 18, 501, 18, 1953, 6, 2027, 2, 1112, 4, 7, 5, 24, 2462, 2316, 1557, 15, 442, 1193, 2529, 501, 18, 162, 14, 239, 1, 296, 339, 218, 417, 10, 397, 5, 1112, 2383, 81, 821, 218, 66, 2, 2027, 179, 81, 821, 162, 66, 133, 28, 294, 61, 148, 13, 66, 14, 13, 14, 18, 2, 14, 39, 1006, 79, 49, 4588, 821, 427, 501, 18, 61, 10, 2842, 4, 736, 1, 294, 6, 437, 7, 5, 104, 69, 379, 180, 357, 619, 737, 169, 7, 52, 89, 212, 11, 346, 1, 953, 201, 42, 442, 1193, 2647, 302, 1193, 2, 653, 42, 1974, 1557, 3, 150, 10, 1228, 149, 421, 5, 2615, 813, 385, 1440, 1911, 1969, 3054, 2109, 190, 3, 191, 244, 1, 24, 2, 958, 1908, 9, 53, 14752, 4, 3, 203, 859, 7, 54, 103, 501, 18, 3, 313, 1766, 1440, 1276, 10, 10323, 37, 5128, 184, 1015, 27, 14414, 1194, 9799, 37, 5128, 184, 667, 18, 13029, 28, 218, 213, 2, 1096, 37, 5128, 184, 269, 8253, 28, 396, 1, 24, 4, 2380, 1646, 274, 3, 400, 4, 1440, 1911, 11, 44, 97, 338, 716, 501, 18, 61, 148, 3, 352, 1, 154, 61, 501, 18, 6, 2027, 2, 1112, 1097, 44, 3233, 55186, 217, 611, 32, 575, 6, 969, 3, 763, 3646, 2, 3398, 521, 41, 5, 5006, 4768]",1597.0,16322303,56
Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.,Leukemia research,Leuk. Res.,2005-12-05,"Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported. We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively. BCR-ABL transcripts were not detected after completion of primary therapy in two cases. All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation. All three patients have ongoing favorable responses to CML therapy.",Case Reports,5160.0,22.0,Recent improved treatments for lymphoid malignancies produce more long-term survivors yet increase the risk for secondary malignancies Therapy-related myelodysplasia and acute myeloid are well described but secondary chronic myeloid CML has only rarely been reported We report three patients with CML diagnosed 8 10 and 2.5 years following 's disease 's and chronic lymphocytic therapy respectively BCR-ABL transcripts were not detected after completion of primary therapy in two cases All three patients received imatinib therapy with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation All three patients have ongoing favorable responses to CML therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[435, 231, 640, 9, 2303, 441, 2410, 80, 319, 337, 332, 1145, 344, 3, 43, 9, 568, 441, 36, 139, 6128, 2, 286, 533, 32, 149, 1027, 84, 568, 442, 533, 903, 71, 158, 2416, 85, 210, 21, 414, 169, 7, 5, 903, 265, 66, 79, 2, 18, 33, 60, 366, 292, 34, 292, 2, 442, 1193, 36, 106, 1062, 1425, 2680, 11, 44, 530, 50, 1438, 1, 86, 36, 4, 100, 140, 62, 169, 7, 103, 577, 36, 5, 104, 69, 1611, 479, 1063, 1007, 452, 31, 497, 62, 169, 7, 47, 942, 913, 253, 6, 903, 36]",689.0,16330096,159
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).,"Cytometry. Part B, Clinical cytometry",Cytometry B Clin Cytom,2006-07-01,"Since Zap-70 expression in chronic lymphocytic leukemia (CLL) cells correlates with a lack of somatic mutation of the immunoglobulin variable heavy chain (IgVH) genes, it has been proposed as a surrogate marker for disease prognosis. However, published studies of Zap-70 expression have used different commercial antibodies and analytic strategies. This study was undertaken to determine if any strategy was broadly applicable in a clinical flow cytometry laboratory. Expression of Zap-70 was determined in 37 CLL patients using four different commercial antibodies. T, NK, and CLL cells were identified by immunophenotyping along with Zap-70 expression. Data was analyzed in terms of both percent of CLL cells expressing Zap-70 and the ratio of Zap-70 expression in CLL cells compared to that in T + NK cells. Three Zap-70 antibodies showed wide ranges of Zap-70 expression as a percentage of tumor cells, while a fourth gave consistently elevated results. Comparing the percent Zap-70 expression with any two antibodies gave poor correlations (r(2) = 0.45-0.63). Our results indicated that the previous analytical strategies were not reproducible. A ratio metric is proposed, which gave better correlations (r(2) as high as 0.95) and would allow separation of CLL patients with elevated or decreased Zap-70 expression.",Journal Article,4952.0,30.0,Since Zap-70 expression in chronic lymphocytic CLL cells correlates with a lack of somatic mutation of the immunoglobulin variable heavy chain IgVH genes it has been proposed as a surrogate marker for disease prognosis However published studies of Zap-70 expression have used different commercial antibodies and analytic strategies This study was undertaken to determine if any strategy was broadly applicable in a clinical flow cytometry laboratory Expression of Zap-70 was determined in 37 CLL patients using four different commercial antibodies T NK and CLL cells were identified by immunophenotyping along with Zap-70 expression Data was analyzed in terms of both percent of CLL cells expressing Zap-70 and the ratio of Zap-70 expression in CLL cells compared to that in T NK cells Three Zap-70 antibodies showed wide ranges of Zap-70 expression as a percentage of tumor cells while a fourth gave consistently elevated results Comparing the percent Zap-70 expression with any two antibodies gave poor correlations r 2 0.45-0.63 Our results indicated that the previous analytical strategies were not reproducible A ratio metric is proposed which gave better correlations r 2 as high as 0.95 and would allow separation of CLL patients with elevated or decreased Zap-70 expression,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1192, 6251, 431, 55, 4, 442, 1193, 552, 37, 1871, 5, 8, 926, 1, 1119, 258, 1, 3, 2593, 1347, 4013, 1260, 14484, 214, 192, 71, 85, 1587, 22, 8, 2592, 952, 9, 34, 356, 137, 983, 94, 1, 6251, 431, 55, 47, 95, 338, 4860, 890, 2, 5146, 422, 26, 45, 10, 2789, 6, 223, 492, 500, 692, 10, 5482, 3801, 4, 8, 38, 1412, 1914, 1624, 55, 1, 6251, 431, 10, 509, 4, 567, 552, 7, 75, 294, 338, 4860, 890, 102, 1765, 2, 552, 37, 11, 108, 20, 9416, 1510, 5, 6251, 431, 55, 74, 10, 311, 4, 1794, 1, 110, 714, 1, 552, 37, 1046, 6251, 431, 2, 3, 197, 1, 6251, 431, 55, 4, 552, 37, 72, 6, 17, 4, 102, 1765, 37, 169, 6251, 431, 890, 224, 1019, 5632, 1, 6251, 431, 55, 22, 8, 1150, 1, 30, 37, 369, 8, 3608, 6421, 2433, 804, 99, 1430, 3, 714, 6251, 431, 55, 5, 500, 100, 890, 6421, 334, 2553, 668, 18, 13, 512, 13, 676, 114, 99, 1103, 17, 3, 698, 5625, 422, 11, 44, 4172, 8, 197, 6515, 16, 1587, 92, 6421, 380, 2553, 668, 18, 22, 64, 22, 13, 48, 2, 688, 1700, 5422, 1, 552, 7, 5, 804, 15, 340, 6251, 431, 55]",1281.0,16342060,338
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-12-12,"Several new prognostic factors predicting rapid disease progression in chronic lymphocytic leukemia (CLL) have been identified, including unmutated Ig V(H) mutational status, del(11)(q23), del(17)(p13.1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy. We examined the impact of these new prognostic factors on predicting treatment outcome in symptomatic, untreated CLL patients who received chemoimmunotherapy with fludarabine and rituximab as part of a completed, randomized phase II study, Cancer and Leukemia Group B (CALGB) 9712. Eighty-eight patients treated as part of CALGB 9712 had detailed prognostic factor assessment performed. Using Ig V(H) mutational status to classify risk, there was no association between complete response rate with either unmutated Ig V(H) mutational status or high-risk interphase cytogenetics. However, the median progression-free survival (PFS; P = .048) and overall survival (OS; P = .01) were shorter among the Ig V(H) unmutated patients as compared with the Ig V(H) mutated patients. Using the hierarchical classification of Dhner, PFS (P = .005) and OS (P = .004) were significantly longer as the classification moved from high risk [del (11)(q22.3) or del (17)(p13.1)] to low risk. These data demonstrate that high-risk CLL patients characterized by Ig V(H) unmutated (> or = 98%) or high-risk interphase cytogenetics, including either del(17p) or del(11q), appear to have a shorter PFS and OS with chemoimmunotherapy. Larger prospective studies will be required to determine the independent influence of Ig V(H) mutational status and interphase cytogenetics on treatment outcome.",Journal Article,5153.0,200.0,Several new prognostic factors predicting rapid disease progression in chronic lymphocytic CLL have been identified including unmutated Ig V H mutational status del 11 q23 del 17 p13.1 and p53 mutations To date the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy We examined the impact of these new prognostic factors on predicting treatment outcome in symptomatic untreated CLL patients who received chemoimmunotherapy with fludarabine and rituximab as part of a completed randomized phase II study Cancer and Group B CALGB 9712 Eighty-eight patients treated as part of CALGB 9712 had detailed prognostic factor assessment performed Using Ig V H mutational status to classify risk there was no association between complete response rate with either unmutated Ig V H mutational status or high-risk interphase cytogenetics However the median progression-free survival PFS P .048 and overall survival OS P .01 were shorter among the Ig V H unmutated patients as compared with the Ig V H mutated patients Using the hierarchical classification of Dhner PFS P .005 and OS P .004 were significantly longer as the classification moved from high risk del 11 q22.3 or del 17 p13.1 to low risk These data demonstrate that high-risk CLL patients characterized by Ig V H unmutated or 98 or high-risk interphase cytogenetics including either del 17p or del 11q appear to have a shorter PFS and OS with chemoimmunotherapy Larger prospective studies will be required to determine the independent influence of Ig V H mutational status and interphase cytogenetics on treatment outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[392, 217, 177, 130, 1434, 1321, 34, 91, 4, 442, 1193, 552, 47, 85, 108, 141, 7216, 4200, 603, 555, 1619, 156, 3084, 175, 11423, 3084, 269, 7914, 14, 2, 624, 138, 6, 1244, 3, 345, 1, 46, 827, 177, 130, 47, 44, 85, 409, 580, 6, 24, 228, 5, 4438, 21, 409, 3, 345, 1, 46, 217, 177, 130, 23, 1434, 24, 228, 4, 1704, 1278, 552, 7, 54, 103, 4438, 5, 2027, 2, 855, 22, 760, 1, 8, 781, 384, 124, 215, 45, 12, 2, 87, 132, 4077, 30595, 2207, 659, 7, 73, 22, 760, 1, 4077, 30595, 42, 2455, 177, 161, 455, 173, 75, 4200, 603, 555, 1619, 156, 6, 4896, 43, 125, 10, 77, 248, 59, 236, 51, 116, 5, 361, 7216, 4200, 603, 555, 1619, 156, 15, 64, 43, 8081, 2510, 137, 3, 52, 91, 115, 25, 300, 19, 4969, 2, 63, 25, 118, 19, 355, 11, 985, 107, 3, 4200, 603, 555, 7216, 7, 22, 72, 5, 3, 4200, 603, 555, 1185, 7, 75, 3, 4466, 947, 1, 55199, 300, 19, 1614, 2, 118, 19, 1520, 11, 97, 589, 22, 3, 947, 13329, 29, 64, 43, 3084, 175, 8026, 27, 15, 3084, 269, 7914, 14, 6, 154, 43, 46, 74, 608, 17, 64, 43, 552, 7, 765, 20, 4200, 603, 555, 7216, 15, 1096, 15, 64, 43, 8081, 2510, 141, 361, 3084, 4135, 15, 3084, 7203, 1322, 6, 47, 8, 985, 300, 2, 118, 5, 4438, 1077, 482, 94, 303, 40, 616, 6, 223, 3, 306, 1054, 1, 4200, 603, 555, 1619, 156, 2, 8081, 2510, 23, 24, 228]",1637.0,16344317,547
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.,Cancer,Cancer,2006-01-01,"Combining therapeutics with single-agent activity has improved treatment for patients with many malignancies. Debate continues about the impact of treatment on survival in patients with chronic lymphocytic leukemia (CLL). Purine analogues are the most active agents for treatment of patients with CLL. Recently, it was shown that a chemoimmunotherapy regimen combining fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) was very effective in treating patients with recurrent and/or refractory CLL. The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL. Three nonoverlapping, sequential groups of patients enrolled on Phase II studies who received treatment with F (n = 251 patients), FC (n = 111 patients), or FCR (n = 143 patients) were analyzed. Pretreatment characteristics, responses to treatment, and overall survival were compared. Patients who were treated with FCR had a higher complete remission rate compared with patients who were treated with combined F and C or with F alone. Statistically significantly longer estimated median survival was noted for patients who received FCR. A Cox proportional hazards, multivariable model for overall survival that included all patients (n = 505) showed that patients who received FCR had longer survival (P < 0.0001) after adjusting for other significant (P < 0.05) pretreatment characteristics, including age, hemoglobin, beta-2 microglobulin, and the number of prior treatments. The results of this retrospective comparison of patients with recurrent and refractory CLL indicated a higher complete remission rate and the longest estimated survival for patients who were treated with FCR, providing the basis for randomized clinical trials of this regimen.",Comparative Study,5133.0,66.0,Combining therapeutics with single-agent activity has improved treatment for patients with many malignancies Debate continues about the impact of treatment on survival in patients with chronic lymphocytic CLL Purine analogues are the most active agents for treatment of patients with CLL Recently it was shown that a chemoimmunotherapy regimen combining fludarabine F cyclophosphamide C and rituximab R FCR was very effective in treating patients with recurrent and/or refractory CLL The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL Three nonoverlapping sequential groups of patients enrolled on Phase II studies who received treatment with F n 251 patients FC n 111 patients or FCR n 143 patients were analyzed Pretreatment characteristics responses to treatment and overall survival were compared Patients who were treated with FCR had a higher complete remission rate compared with patients who were treated with combined F and C or with F alone Statistically significantly longer estimated median survival was noted for patients who received FCR A Cox proportional hazards multivariable model for overall survival that included all patients n 505 showed that patients who received FCR had longer survival P 0.0001 after adjusting for other significant P 0.05 pretreatment characteristics including age hemoglobin beta-2 microglobulin and the number of prior treatments The results of this retrospective comparison of patients with recurrent and refractory CLL indicated a higher complete remission rate and the longest estimated survival for patients who were treated with FCR providing the basis for randomized clinical trials of this regimen,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1525, 1943, 5, 226, 420, 128, 71, 231, 24, 9, 7, 5, 445, 441, 5220, 2274, 545, 3, 345, 1, 24, 23, 25, 4, 7, 5, 442, 1193, 552, 5006, 4768, 32, 3, 96, 544, 183, 9, 24, 1, 7, 5, 552, 761, 192, 10, 443, 17, 8, 4438, 477, 1525, 2027, 1068, 1112, 256, 2, 855, 668, 4953, 10, 923, 323, 4, 1367, 7, 5, 387, 2, 15, 430, 552, 3, 461, 1, 3, 291, 65, 10, 6, 223, 317, 1474, 4, 24, 47, 42, 35, 345, 23, 25, 9, 7, 5, 552, 169, 10142, 1787, 271, 1, 7, 346, 23, 124, 215, 94, 54, 103, 24, 5, 1068, 78, 7288, 7, 4127, 78, 3167, 7, 15, 4953, 78, 4400, 7, 11, 311, 1194, 374, 253, 6, 24, 2, 63, 25, 11, 72, 7, 54, 11, 73, 5, 4953, 42, 8, 142, 236, 734, 116, 72, 5, 7, 54, 11, 73, 5, 397, 1068, 2, 256, 15, 5, 1068, 279, 712, 97, 589, 661, 52, 25, 10, 1051, 9, 7, 54, 103, 4953, 8, 418, 831, 1017, 658, 202, 9, 63, 25, 17, 159, 62, 7, 78, 9766, 224, 17, 7, 54, 103, 4953, 42, 589, 25, 19, 13, 488, 50, 1358, 9, 127, 93, 19, 13, 474, 1194, 374, 141, 89, 2222, 1090, 18, 5371, 2, 3, 207, 1, 324, 640, 3, 99, 1, 26, 459, 1155, 1, 7, 5, 387, 2, 430, 552, 1103, 8, 142, 236, 734, 116, 2, 3, 5683, 661, 25, 9, 7, 54, 11, 73, 5, 4953, 1736, 3, 877, 9, 384, 38, 143, 1, 26, 477]",1740.0,16353201,747
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia.,Cancer research,Cancer Res.,2006-01-01,"B-cell chronic lymphocytic leukemia (CLL) is characterized by a clonal accumulation of mature neoplastic B cells indicating disruption of apoptosis. Restriction Landmark Genome Scanning was done to identify novel target genes silenced by CpG island methylation in CLL. Secreted frizzled-related protein 4 (SFRP4), a negative regulator of the Wnt signaling pathway, was found to be frequently methylated in CLL samples. Wnt signaling has been shown to control normal apoptotic behavior and is required for normal B-cell development whereas aberrant activation of this pathway has been observed in CLL. We show aberrant DNA methylation and silencing of SFRP4, as well as of additional SFRP family members, in primary CLL samples. Induction of their expression in a dose-dependent manner following treatment with a demethylating agent, 5-aza-2'-deoxycytidine, was shown. Of the five SFRP family members studied in detail, SFRP1 was hypermethylated and down-regulated in all CLL patient samples studied, suggesting that this epigenetic event is a critical step during leukemogenesis. Our results suggest that silencing of SFRPs by CpG island methylation is one possible mechanism contributing to aberrant activation of Wnt signaling pathway in CLL.",Journal Article,5133.0,100.0,B-cell chronic lymphocytic CLL is characterized by a clonal accumulation of mature neoplastic B cells indicating disruption of apoptosis Restriction Landmark Genome Scanning was done to identify novel target genes silenced by CpG island methylation in CLL Secreted frizzled-related protein 4 SFRP4 a negative regulator of the Wnt signaling pathway was found to be frequently methylated in CLL samples Wnt signaling has been shown to control normal apoptotic behavior and is required for normal B-cell development whereas aberrant activation of this pathway has been observed in CLL We show aberrant DNA methylation and silencing of SFRP4 as well as of additional SFRP family members in primary CLL samples Induction of their expression in a dose-dependent manner following treatment with a demethylating agent 5-aza-2'-deoxycytidine was shown Of the five SFRP family members studied in detail SFRP1 was hypermethylated and down-regulated in all CLL patient samples studied suggesting that this epigenetic event is a critical step during leukemogenesis Our results suggest that silencing of SFRPs by CpG island methylation is one possible mechanism contributing to aberrant activation of Wnt signaling pathway in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 765, 20, 8, 1946, 1835, 1, 2908, 2000, 132, 37, 1716, 3220, 1, 351, 4575, 3829, 898, 3702, 10, 1822, 6, 255, 229, 283, 214, 5442, 20, 2075, 3454, 569, 4, 552, 3613, 12845, 139, 178, 39, 20486, 8, 199, 2452, 1, 3, 2112, 314, 308, 10, 204, 6, 40, 746, 2963, 4, 552, 347, 2112, 314, 71, 85, 443, 6, 182, 295, 1631, 1710, 2, 16, 616, 9, 295, 132, 31, 193, 547, 1898, 363, 1, 26, 308, 71, 85, 164, 4, 552, 21, 514, 1898, 261, 569, 2, 2077, 1, 20486, 22, 149, 22, 1, 402, 17345, 607, 1684, 4, 86, 552, 347, 504, 1, 136, 55, 4, 8, 61, 470, 1708, 366, 24, 5, 8, 8399, 420, 33, 3924, 6135, 6750, 10, 443, 1, 3, 365, 17345, 607, 1684, 656, 4, 5000, 9396, 10, 6936, 2, 1328, 1065, 4, 62, 552, 69, 347, 656, 802, 17, 26, 1418, 774, 16, 8, 740, 2458, 190, 5661, 114, 99, 309, 17, 2077, 1, 26470, 20, 2075, 3454, 569, 16, 104, 899, 670, 3156, 6, 1898, 363, 1, 2112, 314, 308, 4, 552]",1215.0,16423993,158
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-01-23,"Serum B-lymphocyte stimulator (BLyS) levels have been found to be elevated in a number of immune disease models. Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease. Specimens were collected from the peripheral blood of individuals diagnosed with B-cell chronic lymphocytic leukemia (B-CLL; n = 70) or from age- and sex-matched patients seen at the same institution (n = 41). Serum BLyS levels were determined by enzyme-linked immunosorbent assay, and sequencing of the BLyS promoter was performed by conventional methods and confirmed by restriction fragment length polymorphism analysis. We found that elevated BLyS levels were more common in patients with familial B-CLL than individuals with sporadic B-CLL or normal controls. Because of this association, we sequenced the BLyS promoter in patients with B-CLL and normal controls and identified a polymorphic site, -871 C/T. We found that the wild-type sequence was significantly underrepresented in patients with familial B-CLL (4%) compared with patients with sporadic B-CLL (30%; P = .01) or controls (24%; P = .04). Furthermore, using a luciferase reporter under control of the BLyS promoter containing either a C or a T at position -871, we found that the reporter construct containing a T at -871 had a 2.6-fold increase in activity (P = .004). Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter.",Journal Article,5111.0,69.0,Serum B-lymphocyte stimulator BLyS levels have been found to be elevated in a number of immune disease models Therefore we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease Specimens were collected from the peripheral blood of individuals diagnosed with B-cell chronic lymphocytic B-CLL n 70 or from age- and sex-matched patients seen at the same institution n 41 Serum BLyS levels were determined by enzyme-linked immunosorbent assay and sequencing of the BLyS promoter was performed by conventional methods and confirmed by restriction fragment length polymorphism analysis We found that elevated BLyS levels were more common in patients with familial B-CLL than individuals with sporadic B-CLL or normal controls Because of this association we sequenced the BLyS promoter in patients with B-CLL and normal controls and identified a polymorphic site -871 C/T We found that the wild-type sequence was significantly underrepresented in patients with familial B-CLL 4 compared with patients with sporadic B-CLL 30 P .01 or controls 24 P .04 Furthermore using a luciferase reporter under control of the BLyS promoter containing either a C or a T at position -871 we found that the reporter construct containing a T at -871 had a 2.6-fold increase in activity P .004 Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[524, 132, 1448, 11091, 9291, 148, 47, 85, 204, 6, 40, 804, 4, 8, 207, 1, 250, 34, 274, 673, 21, 990, 6, 1811, 317, 9291, 148, 11, 804, 4, 7, 5, 132, 31, 4192, 1997, 2, 6, 223, 317, 804, 9291, 148, 438, 5, 38, 374, 1, 3, 34, 623, 11, 786, 29, 3, 672, 315, 1, 869, 265, 5, 132, 31, 442, 1193, 132, 552, 78, 431, 15, 29, 89, 2, 1035, 655, 7, 527, 28, 3, 827, 731, 78, 605, 524, 9291, 148, 11, 509, 20, 1644, 1199, 5339, 719, 2, 615, 1, 3, 9291, 973, 10, 173, 20, 809, 636, 2, 557, 20, 4575, 5245, 1318, 1907, 65, 21, 204, 17, 804, 9291, 148, 11, 80, 186, 4, 7, 5, 2200, 132, 552, 76, 869, 5, 1928, 132, 552, 15, 295, 535, 408, 1, 26, 248, 21, 4040, 3, 9291, 973, 4, 7, 5, 132, 552, 2, 295, 535, 2, 108, 8, 7087, 606, 10621, 256, 102, 21, 204, 17, 3, 955, 267, 1532, 10, 97, 9900, 4, 7, 5, 2200, 132, 552, 39, 72, 5, 7, 5, 1928, 132, 552, 201, 19, 355, 15, 535, 259, 19, 755, 798, 75, 8, 3864, 3674, 669, 182, 1, 3, 9291, 973, 1101, 361, 8, 256, 15, 8, 102, 28, 3559, 10621, 21, 204, 17, 3, 3674, 3883, 1101, 8, 102, 28, 10621, 42, 8, 18, 49, 1116, 344, 4, 128, 19, 1520, 114, 74, 309, 524, 9291, 148, 32, 804, 4, 7, 5, 2200, 132, 552, 2, 17, 804, 9291, 148, 1513, 5, 3, 463, 1, 8, 102, 28, 10621, 4, 3, 9291, 973]",1597.0,16432079,292
The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2006-02-01,"Clinical investigations have revealed that infusion of immunotherapeutic mAbs directed to normal or tumor cells can lead to loss of targeted epitopes, a phenomenon called antigenic modulation. Recently, we reported that rituximab treatment of chronic lymphocytic leukemia patients induced substantial loss of CD20 on B cells found in the circulation after rituximab infusion, when rituximab plasma concentrations were high. Such antigenic modulation can severely compromise therapeutic efficacy, and we postulated that B cells had been stripped (shaved) of the rituximab/CD20 complex by monocytes or macrophages in a reaction mediated by FcgammaR. We developed an in vitro model to replicate this in vivo shaving process, based on reacting rituximab-opsonized CD20(+) cells with acceptor THP-1 monocytes. After 45 min at 37 degrees C, rituximab and CD20 are removed from opsonized cells, and both are demonstrable on acceptor THP-1 cells. The reaction occurs equally well in the presence and absence of normal human serum, and monocytes isolated from peripheral blood also promote shaving of CD20 from rituximab-opsonized cells. Tests with inhibitors and use of F(ab')(2) of rituximab indicate transfer of rituximab/CD20 complexes to THP-1 cells is mediated by FcgammaR. Antigenic modulation described in previous reports may have been mediated by such shaving, and our findings may have profound implications for the use of mAbs in the immunotherapy of cancer.",Journal Article,5102.0,154.0,Clinical investigations have revealed that infusion of immunotherapeutic mAbs directed to normal or tumor cells can lead to loss of targeted epitopes a phenomenon called antigenic modulation Recently we reported that rituximab treatment of chronic lymphocytic patients induced substantial loss of CD20 on B cells found in the circulation after rituximab infusion when rituximab plasma concentrations were high Such antigenic modulation can severely compromise therapeutic efficacy and we postulated that B cells had been stripped shaved of the rituximab/CD20 complex by monocytes or macrophages in a reaction mediated by FcgammaR We developed an in vitro model to replicate this in vivo shaving process based on reacting rituximab-opsonized CD20 cells with acceptor THP-1 monocytes After 45 min at 37 degrees C rituximab and CD20 are removed from opsonized cells and both are demonstrable on acceptor THP-1 cells The reaction occurs equally well in the presence and absence of normal human serum and monocytes isolated from peripheral blood also promote shaving of CD20 from rituximab-opsonized cells Tests with inhibitors and use of F ab 2 of rituximab indicate transfer of rituximab/CD20 complexes to THP-1 cells is mediated by FcgammaR Antigenic modulation described in previous reports may have been mediated by such shaving and our findings may have profound implications for the use of mAbs in the immunotherapy of cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[38, 2492, 47, 553, 17, 904, 1, 3222, 5207, 1166, 6, 295, 15, 30, 37, 122, 1122, 6, 407, 1, 238, 4915, 8, 3936, 3472, 8357, 2356, 761, 21, 210, 17, 855, 24, 1, 442, 1193, 7, 277, 1281, 407, 1, 2198, 23, 132, 37, 204, 4, 3, 4984, 50, 855, 904, 198, 855, 554, 1003, 11, 64, 225, 8357, 2356, 122, 7207, 4665, 189, 209, 2, 21, 6507, 17, 132, 37, 42, 85, 37376, 17349, 1, 3, 855, 2198, 840, 20, 5078, 15, 2748, 4, 8, 1329, 517, 20, 18892, 21, 276, 35, 4, 439, 202, 6, 6423, 26, 4, 386, 17331, 1129, 90, 23, 34040, 855, 22192, 2198, 37, 5, 19680, 10186, 14, 5078, 50, 512, 1538, 28, 567, 4133, 256, 855, 2, 2198, 32, 2264, 29, 22192, 37, 2, 110, 32, 11411, 23, 19680, 10186, 14, 37, 3, 1329, 1780, 4142, 149, 4, 3, 463, 2, 1127, 1, 295, 171, 524, 2, 5078, 1355, 29, 672, 315, 120, 1617, 17331, 1, 2198, 29, 855, 22192, 37, 895, 5, 222, 2, 119, 1, 1068, 5094, 18, 1, 855, 1008, 2602, 1, 855, 2198, 3817, 6, 10186, 14, 37, 16, 517, 20, 18892, 8357, 2356, 1027, 4, 698, 1198, 68, 47, 85, 517, 20, 225, 17331, 2, 114, 272, 68, 47, 4399, 1268, 9, 3, 119, 1, 5207, 4, 3, 726, 1, 12]",1427.0,16456022,103
"A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.",Annals of hematology,Ann. Hematol.,2006-03-04,"In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), we combined theophylline, pentostatin, and chlorambucil at two dose levels (cohort I: 30 mg/m(2); cohort II: 20 mg/m(2)) on a 21-day cycle for up to six courses. We employed a phase I/II design to determine feasibility, define the maximum tolerated dose (MTD), and explore the impact of biologic modulation on response and time to progression (TTP) in 20 patients with relapsed or refractory CLL and NHL. Eight patients were enrolled in cohort I. They demonstrated a response rate (RR) of 28% and a 16.5-month TTP after receiving a median of two cycles. A 50% RR was observed in this cohort when patients with adverse histologies were excluded. Because of myelotoxicity, this dose level defined the MTD, and de-escalation occurred. All 12 patients in cohort II received 20 mg/m(2) chlorambucil. A 50% RR and an 18-month TTP were observed after a median of 5.5 cycles. An RR of 47% and a complete remission (CR) of 5% were observed for the entire group, although responses and TTP varied greatly by histology. Significant activity was observed in patients with B-cell CLL and follicular lymphoma (FL). RR and TTP for fludarabine-sensitive/nave and fludarabine-refractory (FR) B-cell CLL patients were 66 vs 25% and 20 vs 8.5 months, respectively. Both FL patients responded (one with partial remission and one with CR), with a 22.5-monthly median TTP. For responding patients, median TTP and overall survival (OS) was 21 and 69 months, respectively, compared to a median TTP of 2 months and an OS of 13.5 months for nonresponders. The combination of pentostatin, chlorambucil, and theophylline is the active regimen in patients with FL and B-cell CLL.","Clinical Trial, Phase II",5071.0,9.0,In an attempt to exploit bcl-2 overexpression and aberrant p53 function two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic CLL and 's NHL we combined theophylline pentostatin and chlorambucil at two dose levels cohort I 30 mg/m 2 cohort II 20 mg/m 2 on a 21-day cycle for up to six courses We employed a phase I/II design to determine feasibility define the maximum tolerated dose MTD and explore the impact of biologic modulation on response and time to progression TTP in 20 patients with relapsed or refractory CLL and NHL Eight patients were enrolled in cohort I They demonstrated a response rate RR of 28 and a 16.5-month TTP after receiving a median of two cycles A 50 RR was observed in this cohort when patients with adverse histologies were excluded Because of myelotoxicity this dose level defined the MTD and de-escalation occurred All 12 patients in cohort II received 20 mg/m 2 chlorambucil A 50 RR and an 18-month TTP were observed after a median of 5.5 cycles An RR of 47 and a complete remission CR of 5 were observed for the entire group although responses and TTP varied greatly by histology Significant activity was observed in patients with B-cell CLL and follicular FL RR and TTP for fludarabine-sensitive/nave and fludarabine-refractory FR B-cell CLL patients were 66 vs 25 and 20 vs 8.5 months respectively Both FL patients responded one with partial remission and one with CR with a 22.5-monthly median TTP For responding patients median TTP and overall survival OS was 21 and 69 months respectively compared to a median TTP of 2 months and an OS of 13.5 months for nonresponders The combination of pentostatin chlorambucil and theophylline is the active regimen in patients with FL and B-cell CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 35, 3448, 6, 6109, 1044, 18, 851, 2, 1898, 624, 343, 100, 746, 3903, 2152, 17, 678, 2003, 24, 251, 2, 639, 356, 4, 7, 5, 442, 1193, 552, 2, 292, 1176, 21, 397, 38124, 7596, 2, 11585, 28, 100, 61, 148, 180, 70, 201, 81, 188, 18, 180, 215, 179, 81, 188, 18, 23, 8, 239, 218, 417, 9, 126, 6, 437, 1993, 21, 2516, 8, 124, 70, 215, 771, 6, 223, 1437, 1107, 3, 689, 421, 61, 961, 2, 1645, 3, 345, 1, 1283, 2356, 23, 51, 2, 98, 6, 91, 2422, 4, 179, 7, 5, 591, 15, 430, 552, 2, 1176, 659, 7, 11, 346, 4, 180, 70, 491, 264, 8, 51, 116, 861, 1, 339, 2, 8, 245, 33, 811, 2422, 50, 357, 8, 52, 1, 100, 410, 8, 212, 861, 10, 164, 4, 26, 180, 198, 7, 5, 290, 3489, 11, 1800, 408, 1, 17118, 26, 61, 301, 395, 3, 961, 2, 1566, 1125, 489, 62, 133, 7, 4, 180, 215, 103, 179, 81, 188, 18, 11585, 8, 212, 861, 2, 35, 203, 811, 2422, 11, 164, 50, 8, 52, 1, 33, 33, 410, 35, 861, 1, 662, 2, 8, 236, 734, 684, 1, 33, 11, 164, 9, 3, 1797, 87, 242, 253, 2, 2422, 2051, 3510, 20, 784, 93, 128, 10, 164, 4, 7, 5, 132, 31, 552, 2, 1974, 2633, 861, 2, 2422, 9, 2027, 745, 2809, 2, 2027, 430, 6413, 132, 31, 552, 7, 11, 700, 105, 243, 2, 179, 105, 66, 33, 53, 106, 110, 2633, 7, 2211, 104, 5, 450, 734, 2, 104, 5, 684, 5, 8, 350, 33, 3889, 52, 2422, 9, 3261, 7, 52, 2422, 2, 63, 25, 118, 10, 239, 2, 790, 53, 106, 72, 6, 8, 52, 2422, 1, 18, 53, 2, 35, 118, 1, 233, 33, 53, 9, 4498, 3, 150, 1, 7596, 11585, 2, 38124, 16, 3, 544, 477, 4, 7, 5, 2633, 2, 132, 31, 552]",1808.0,16518606,496
"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-03-06,"Purine analogs and alkylators are important agents for treating chronic lymphocytic leukemia (CLL). Early studies combining fludarabine and chlorambucil were abandoned owing to increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin appears to be the least myelosuppressive. We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination. We treated 46 patients with either previously treated CLL (32 patients) or other low-grade B-cell neoplasms (14 patients). Patients received pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2 (PCR). All drugs were administered on the same day (rituximab omitted from cycle 1), and patients received six cycles at 3-week intervals. Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylactically. The median age was 62 years (range, 30 to 80 years). The median number of prior regimens was two (range, one to seven). For CLL patients, there were 24 responses (75%), including eight complete responses (25%). In fludarabine-refractory patients, 75% responded. Toxicity was acceptable, with grade 3/4 infections (including fever of unknown origin) in 28%. The regimen was well tolerated, with 72% of patients receiving the planned treatment at full dose. PCR is safe and effective in previously treated patients with CLL. In comparison with our prior two-drug regimen, we find that rituximab did not seem to add significantly to the toxicity, but did appear to confer a survival advantage. Based on these results, we are currently studying PCR as initial therapy for patients with CLL.",Journal Article,5069.0,140.0,Purine analogs and alkylators are important agents for treating chronic lymphocytic CLL Early studies combining fludarabine and chlorambucil were abandoned owing to increased toxicity from overlapping myelosuppression and immunosuppression Of the purine analogs active in CLL pentostatin appears to be the least myelosuppressive We previously reported that pentostatin and cyclophosphamide PC is active and well-tolerated in patients with relapsed or refractory CLL Subsequently we added rituximab and now report on this three-drug combination We treated 46 patients with either previously treated CLL 32 patients or other low-grade B-cell neoplasms 14 patients Patients received pentostatin 4 mg/m2 cyclophosphamide 600 mg/m2 and rituximab 375 mg/m2 PCR All drugs were administered on the same day rituximab omitted from cycle 1 and patients received six cycles at 3-week intervals Filgrastim sulfamethoxazole/trimethoprim and acyclovir were administered prophylactically The median age was 62 years range 30 to 80 years The median number of prior regimens was two range one to seven For CLL patients there were 24 responses 75 including eight complete responses 25 In fludarabine-refractory patients 75 responded Toxicity was acceptable with grade 3/4 infections including fever of unknown origin in 28 The regimen was well tolerated with 72 of patients receiving the planned treatment at full dose PCR is safe and effective in previously treated patients with CLL In comparison with our prior two-drug regimen we find that rituximab did not seem to add significantly to the toxicity but did appear to confer a survival advantage Based on these results we are currently studying PCR as initial therapy for patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5006, 4063, 2, 12777, 32, 305, 183, 9, 1367, 442, 1193, 552, 191, 94, 1525, 2027, 2, 11585, 11, 13015, 3421, 6, 101, 155, 29, 4551, 2858, 2, 3646, 1, 3, 5006, 4063, 544, 4, 552, 7596, 1233, 6, 40, 3, 506, 11109, 21, 373, 210, 17, 7596, 2, 1112, 1341, 16, 544, 2, 149, 421, 4, 7, 5, 591, 15, 430, 552, 1611, 21, 1953, 855, 2, 1134, 414, 23, 26, 169, 234, 150, 21, 73, 641, 7, 5, 361, 373, 73, 552, 531, 7, 15, 127, 154, 88, 132, 31, 1179, 213, 7, 7, 103, 7596, 39, 81, 821, 1112, 2383, 81, 821, 2, 855, 4175, 81, 821, 604, 62, 600, 11, 468, 23, 3, 827, 218, 855, 7138, 29, 417, 14, 2, 7, 103, 437, 410, 28, 27, 647, 1582, 5552, 23152, 23151, 2, 17606, 11, 468, 21051, 3, 52, 89, 10, 744, 60, 184, 201, 6, 493, 60, 3, 52, 207, 1, 324, 472, 10, 100, 184, 104, 6, 648, 9, 552, 7, 125, 11, 259, 253, 481, 141, 659, 236, 253, 243, 4, 2027, 430, 7, 481, 2211, 155, 10, 1595, 5, 88, 27, 39, 1875, 141, 2775, 1, 860, 1938, 4, 339, 3, 477, 10, 149, 421, 5, 720, 1, 7, 357, 3, 1465, 24, 28, 1647, 61, 604, 16, 1165, 2, 323, 4, 373, 73, 7, 5, 552, 4, 1155, 5, 114, 324, 100, 234, 477, 21, 2469, 17, 855, 205, 44, 3233, 6, 4178, 97, 6, 3, 155, 84, 205, 1322, 6, 2913, 8, 25, 1874, 90, 23, 46, 99, 21, 32, 694, 4559, 604, 22, 388, 36, 9, 7, 5, 552]",1725.0,16520464,378
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.,Blood,Blood,2006-03-16,"Although TP53 mutations are rare in B-cell chronic lymphocytic leukemia (CLL), Mdm2 overexpression has been reported as an alternative cause of p53 dysfunction. We investigated the potential therapeutic use of nongenotoxic p53 activation by a small-molecule antagonist of Mdm2, Nutlin-3a, in CLL. Nutlin-3a induced significant apoptosis in 30 (91%) of 33 samples from previously untreated patients with CLL; all resistant samples had TP53 mutations. Low levels of Atm (ataxia telangiectasia mutated) or high levels of Mdm2 (murine double minute 2) did not prevent Nutlin-3a from inducing apoptosis. Nutlin-3a used transcription-dependent and transcription-independent pathways to induce p53-mediated apoptosis. Predominant activation of the transcription-independent pathway induced more pronounced apoptosis than that of the transcription-dependent pathway, suggesting that activation of the transcription-independent pathway is sufficient to initiate p53-mediated apoptosis in CLL. Combination treatment of Nutlin-3a and fludarabine synergistically increased p53 levels, and induced conformational change of Bax and apoptosis in wild-type p53 cells but not in cells with mutant p53. The synergistic apoptotic effect was maintained in samples with low Atm that were fludarabine resistant. Results suggest that the nongenotoxic activation of p53 by targeting the Mdm2-p53 interaction provides a novel therapeutic strategy for CLL.",Journal Article,5059.0,183.0,Although TP53 mutations are rare in B-cell chronic lymphocytic CLL Mdm2 overexpression has been reported as an alternative cause of p53 dysfunction We investigated the potential therapeutic use of nongenotoxic p53 activation by a small-molecule antagonist of Mdm2 Nutlin-3a in CLL Nutlin-3a induced significant apoptosis in 30 91 of 33 samples from previously untreated patients with CLL all resistant samples had TP53 mutations Low levels of Atm ataxia telangiectasia mutated or high levels of Mdm2 murine double minute 2 did not prevent Nutlin-3a from inducing apoptosis Nutlin-3a used transcription-dependent and transcription-independent pathways to induce p53-mediated apoptosis Predominant activation of the transcription-independent pathway induced more pronounced apoptosis than that of the transcription-dependent pathway suggesting that activation of the transcription-independent pathway is sufficient to initiate p53-mediated apoptosis in CLL Combination treatment of Nutlin-3a and fludarabine synergistically increased p53 levels and induced conformational change of Bax and apoptosis in wild-type p53 cells but not in cells with mutant p53 The synergistic apoptotic effect was maintained in samples with low Atm that were fludarabine resistant Results suggest that the nongenotoxic activation of p53 by targeting the Mdm2-p53 interaction provides a novel therapeutic strategy for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 1206, 138, 32, 622, 4, 132, 31, 442, 1193, 552, 3277, 851, 71, 85, 210, 22, 35, 1091, 708, 1, 624, 1527, 21, 565, 3, 174, 189, 119, 1, 34056, 624, 363, 20, 8, 302, 1354, 3137, 1, 3277, 7449, 6981, 4, 552, 7449, 6981, 277, 93, 351, 4, 201, 970, 1, 466, 347, 29, 373, 1278, 7, 5, 552, 62, 436, 347, 42, 1206, 138, 154, 148, 1, 3552, 8299, 8524, 1185, 15, 64, 148, 1, 3277, 1471, 1627, 3949, 18, 205, 44, 1682, 7449, 6981, 29, 1958, 351, 7449, 6981, 95, 866, 470, 2, 866, 306, 460, 6, 1290, 624, 517, 351, 2750, 363, 1, 3, 866, 306, 308, 277, 80, 3517, 351, 76, 17, 1, 3, 866, 470, 308, 802, 17, 363, 1, 3, 866, 306, 308, 16, 1952, 6, 4565, 624, 517, 351, 4, 552, 150, 24, 1, 7449, 6981, 2, 2027, 4240, 101, 624, 148, 2, 277, 9011, 707, 1, 3119, 2, 351, 4, 955, 267, 624, 37, 84, 44, 4, 37, 5, 620, 624, 3, 1806, 1631, 254, 10, 1955, 4, 347, 5, 154, 3552, 17, 11, 2027, 436, 99, 309, 17, 3, 34056, 363, 1, 624, 20, 529, 3, 3277, 624, 915, 777, 8, 229, 189, 692, 9, 552]",1397.0,16543464,360
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.,Blood,Blood,2006-03-21,"We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patients with previously treated and previously untreated chronic lymphocytic leukemia (CLL). Higher levels of TPO were associated with advanced Rai stage (P < .001), higher levels of beta(2)-microglobulin (beta2-M) (P < .001), and the absence of mutation in the immunoglobulin heavy chain variable region (IgV(H)) (P < .001), and were inversely correlated with platelet count (P = .002). We found that TPO correlated strongly in a continuous manner with overall survival in both previously treated and untreated patients. The univariate Cox proportional hazard model demonstrated that high TPO levels were associated with shorter survival (P < .001), and multiple variable Cox proportional hazards regression analysis demonstrated that this was independent of the IgV(H) mutation status, beta2-M, and Rai stage. Recursive partitioning showed that a cutoff point of 639 pg/mL separated the CLL patients into 2 major survival groups (P < .001). The effects of beta2-M were masked by the effects of TPO in the patients with TPO levels higher than 639 pg/mL, but in the remainder, patients with beta2-M level higher than 4.95 mg/L had significantly shorter survival than those with lower values. Plasma TPO and beta2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgV(H) mutation status.",Journal Article,5054.0,17.0,We investigated the association of plasma thrombopoietin TPO and overall survival in 127 patients with previously treated and previously untreated chronic lymphocytic CLL Higher levels of TPO were associated with advanced Rai stage P .001 higher levels of beta 2 -microglobulin beta2-M P .001 and the absence of mutation in the immunoglobulin heavy chain variable region IgV H P .001 and were inversely correlated with platelet count P .002 We found that TPO correlated strongly in a continuous manner with overall survival in both previously treated and untreated patients The univariate Cox proportional hazard model demonstrated that high TPO levels were associated with shorter survival P .001 and multiple variable Cox proportional hazards regression analysis demonstrated that this was independent of the IgV H mutation status beta2-M and Rai stage Recursive partitioning showed that a cutoff point of 639 pg/mL separated the CLL patients into 2 major survival groups P .001 The effects of beta2-M were masked by the effects of TPO in the patients with TPO levels higher than 639 pg/mL but in the remainder patients with beta2-M level higher than 4.95 mg/L had significantly shorter survival than those with lower values Plasma TPO and beta2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgV H mutation status,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 565, 3, 248, 1, 554, 15494, 14110, 2, 63, 25, 4, 4080, 7, 5, 373, 73, 2, 373, 1278, 442, 1193, 552, 142, 148, 1, 14110, 11, 41, 5, 131, 4121, 82, 19, 144, 142, 148, 1, 1090, 18, 5371, 8911, 188, 19, 144, 2, 3, 1127, 1, 258, 4, 3, 2593, 4013, 1260, 1347, 1053, 12179, 555, 19, 144, 2, 11, 2659, 438, 5, 1596, 1276, 19, 1111, 21, 204, 17, 14110, 438, 1327, 4, 8, 1314, 1708, 5, 63, 25, 4, 110, 373, 73, 2, 1278, 7, 3, 880, 418, 831, 360, 202, 264, 17, 64, 14110, 148, 11, 41, 5, 985, 25, 19, 144, 2, 232, 1347, 418, 831, 1017, 320, 65, 264, 17, 26, 10, 306, 1, 3, 12179, 555, 258, 156, 8911, 188, 2, 4121, 82, 4493, 4515, 224, 17, 8, 2779, 741, 1, 14553, 3234, 542, 4910, 3, 552, 7, 237, 18, 458, 25, 271, 19, 144, 3, 176, 1, 8911, 188, 11, 7415, 20, 3, 176, 1, 14110, 4, 3, 7, 5, 14110, 148, 142, 76, 14553, 3234, 542, 84, 4, 3, 7095, 7, 5, 8911, 188, 301, 142, 76, 39, 48, 81, 805, 42, 97, 985, 25, 76, 135, 5, 280, 1030, 554, 14110, 2, 8911, 188, 68, 40, 999, 9, 3, 1590, 1, 38, 1710, 4, 552, 2, 68, 7195, 3, 594, 9, 3, 3104, 1, 12179, 555, 258, 156]",1382.0,16551975,68
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.,Blood,Blood,2006-04-06,"Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain. Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown. Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL). Patients harbored 9 different protein kinase mutations (T315I mutation, n = 2). Preparative regimens were ablative (n = 7) and nonablative (n = 3). All patients engrafted; there were no treatment-related deaths. Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1). Three patients (mutations Q252H, E255K, and T315I) died of relapse after Allo-SCT. Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations.",Journal Article,5038.0,75.0,Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid CML often associated with point mutations in the Bcr-Abl kinase domain Outcome of patients with such mutations after allogeneic stem cell transplantation Allo-SCT is unknown Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant 9 had CML 3 in chronic phase 4 in accelerated phase and 2 in blast phase and 1 had Philadelphia-positive acute lymphocytic ALL Patients harbored 9 different protein kinase mutations T315I mutation n 2 Preparative regimens were ablative n 7 and nonablative n 3 All patients engrafted there were no treatment-related deaths Disease response was complete molecular CMR n 7 major molecular n 2 and no response n 1 Three patients mutations Q252H E255K and T315I died of relapse after Allo-SCT Seven patients are alive 6 in CMR for a median of 19 months Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[251, 6, 577, 2347, 16, 35, 1478, 2497, 4, 3, 24, 1, 442, 533, 903, 629, 41, 5, 741, 138, 4, 3, 1062, 1425, 216, 1398, 228, 1, 7, 5, 225, 138, 50, 1063, 452, 31, 497, 2564, 1988, 16, 860, 1618, 577, 436, 7, 5, 1062, 1425, 216, 138, 103, 8, 941, 83, 42, 903, 27, 4, 442, 124, 39, 4, 2241, 124, 2, 18, 4, 3112, 124, 2, 14, 42, 3006, 109, 286, 1193, 62, 7, 3253, 83, 338, 178, 216, 138, 6184, 258, 78, 18, 6085, 472, 11, 4504, 78, 67, 2, 24659, 78, 27, 62, 7, 6914, 125, 11, 77, 24, 139, 1043, 34, 51, 10, 236, 219, 7334, 78, 67, 458, 219, 78, 18, 2, 77, 51, 78, 14, 169, 7, 138, 55398, 16677, 2, 6184, 1016, 1, 429, 50, 2564, 1988, 648, 7, 32, 1701, 49, 4, 7334, 9, 8, 52, 1, 326, 53, 2564, 1988, 469, 35, 305, 992, 1501, 9, 7, 54, 690, 251, 6, 577, 298, 1062, 1425, 138]",1015.0,16601247,208
Epigenetics in chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Enormous evidence has accumulated in the past decades that establishes the importance of epigenetic modifications in cancer and has resulted in shifting the focus from entirely genetic-based studies to integrated studies involving both genetic and epigenetic alterations. Chronic lymphocytic leukemia (CLL) is one such example where studies involving epigenetic aberrations have accelerated the search for affected genes, which was initially restricted to commonly deleted chromosomal regions. Many novel genes that are epigenetically silenced in CLL have been identified. Advances in the understanding of post-translational histone modifications and DNA methylation in normal and in CLL cells have proven to be extremely beneficial in finding powerful diagnostic markers, as well as in exploring novel therapies. At present, the field of epigenetics is at an evolving stage, but there is no doubt that further unraveling of its cause and effects in transformed cells will bring a new revolution in cancer therapeutics.",Journal Article,5043.0,30.0,Enormous evidence has accumulated in the past decades that establishes the importance of epigenetic modifications in cancer and has resulted in shifting the focus from entirely genetic-based studies to integrated studies involving both genetic and epigenetic alterations Chronic lymphocytic CLL is one such example where studies involving epigenetic aberrations have accelerated the search for affected genes which was initially restricted to commonly deleted chromosomal regions Many novel genes that are epigenetically silenced in CLL have been identified Advances in the understanding of post-translational histone modifications and DNA methylation in normal and in CLL cells have proven to be extremely beneficial in finding powerful diagnostic markers as well as in exploring novel therapies At present the field of epigenetics is at an evolving stage but there is no doubt that further unraveling of its cause and effects in transformed cells will bring a new revolution in cancer therapeutics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8790, 241, 71, 6664, 4, 3, 1219, 1968, 17, 7410, 3, 1187, 1, 1418, 2916, 4, 12, 2, 71, 627, 4, 8964, 3, 1222, 29, 6848, 336, 90, 94, 6, 2102, 94, 1267, 110, 336, 2, 1418, 593, 442, 1193, 552, 16, 104, 225, 2685, 1257, 94, 1267, 1418, 2152, 47, 2241, 3, 1901, 9, 1424, 214, 92, 10, 1625, 2016, 6, 841, 4389, 1860, 1374, 445, 229, 214, 17, 32, 8976, 5442, 4, 552, 47, 85, 108, 954, 4, 3, 612, 1, 539, 2460, 1508, 2916, 2, 261, 569, 4, 295, 2, 4, 552, 37, 47, 1930, 6, 40, 2938, 2524, 4, 1567, 3757, 752, 525, 22, 149, 22, 4, 4378, 229, 235, 28, 364, 3, 1067, 1, 9706, 16, 28, 35, 3276, 82, 84, 125, 16, 77, 19436, 17, 195, 21376, 1, 211, 708, 2, 176, 4, 2423, 37, 303, 8798, 8, 217, 11030, 4, 12, 1943]",999.0,16616062,722
The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Angiogenesis has been found to be an important regulator in the growth and metastasis of solid tumors. More recent studies have also demonstrated the importance of this biologic process in normal hematopoietic cell development and the pathophysiology of several hematologic malignancies. This review provides an overview of the clinical and biologic importance of angiogenesis in chronic lymphocytic leukemia (CLL). Patients with CLL have detectable levels of both plasma and cellular pro- and anti-angiogenic cytokines, as well as abnormal neovascularization in the marrow and lymph nodes. Recent evidence suggests a vascular endothelial growth factor (VEGF)-based autocrine pathway promotes the survival of CLL B cells in part through upregulation of anti-apoptotic proteins. Additionally, interactions between CLL B cells and their microenvironment generate alterations in the secretion of angiogenic factors that result in enhanced leukemic B-cell resistance to apoptotic cell death. From a clinical standpoint, interpatient variation is observed in markers of angiogenesis and appears to have prognostic implications. Several clinical trials evaluating the efficacy of anti-angiogenic agents for treatment of patients with CLL are underway with promising preliminary results. Additional research is needed to identify the regulation of aberrant and critical angiogenic pathways in CLL B cells, to determine how angiogenic markers can be used to improve prognostication for CLL patients, and to explore how the angiogenic characteristics of CLL B cells can best be manipulated for therapeutic benefit.",Journal Article,5043.0,48.0,Angiogenesis has been found to be an important regulator in the growth and metastasis of solid tumors More recent studies have also demonstrated the importance of this biologic process in normal hematopoietic cell development and the pathophysiology of several hematologic malignancies This review provides an overview of the clinical and biologic importance of angiogenesis in chronic lymphocytic CLL Patients with CLL have detectable levels of both plasma and cellular pro- and anti-angiogenic cytokines as well as abnormal neovascularization in the marrow and lymph nodes Recent evidence suggests a vascular endothelial growth factor VEGF -based autocrine pathway promotes the survival of CLL B cells in part through upregulation of anti-apoptotic proteins Additionally interactions between CLL B cells and their microenvironment generate alterations in the secretion of angiogenic factors that result in enhanced leukemic B-cell resistance to apoptotic cell death From a clinical standpoint interpatient variation is observed in markers of angiogenesis and appears to have prognostic implications Several clinical trials evaluating the efficacy of anti-angiogenic agents for treatment of patients with CLL are underway with promising preliminary results Additional research is needed to identify the regulation of aberrant and critical angiogenic pathways in CLL B cells to determine how angiogenic markers can be used to improve prognostication for CLL patients and to explore how the angiogenic characteristics of CLL B cells can best be manipulated for therapeutic benefit,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1056, 71, 85, 204, 6, 40, 35, 305, 2452, 4, 3, 129, 2, 278, 1, 537, 57, 80, 435, 94, 47, 120, 264, 3, 1187, 1, 26, 1283, 1129, 4, 295, 1007, 31, 193, 2, 3, 4320, 1, 392, 813, 441, 26, 206, 777, 35, 2901, 1, 3, 38, 2, 1283, 1187, 1, 1056, 4, 442, 1193, 552, 7, 5, 552, 47, 2083, 148, 1, 110, 554, 2, 763, 1805, 2, 312, 2068, 1886, 22, 149, 22, 1668, 10551, 4, 3, 581, 2, 263, 502, 435, 241, 844, 8, 756, 845, 129, 161, 618, 90, 5297, 308, 2148, 3, 25, 1, 552, 132, 37, 4, 760, 298, 2218, 1, 312, 1631, 652, 1724, 1286, 59, 552, 132, 37, 2, 136, 995, 2562, 593, 4, 3, 2935, 1, 2068, 130, 17, 757, 4, 651, 2015, 132, 31, 251, 6, 1631, 31, 273, 29, 8, 38, 13941, 7423, 1380, 16, 164, 4, 525, 1, 1056, 2, 1233, 6, 47, 177, 1268, 392, 38, 143, 1435, 3, 209, 1, 312, 2068, 183, 9, 24, 1, 7, 5, 552, 32, 3948, 5, 721, 1676, 99, 402, 389, 16, 575, 6, 255, 3, 863, 1, 1898, 2, 740, 2068, 460, 4, 552, 132, 37, 6, 223, 832, 2068, 525, 122, 40, 95, 6, 401, 4260, 9, 552, 7, 2, 6, 1645, 832, 3, 2068, 374, 1, 552, 132, 37, 122, 824, 40, 13222, 9, 189, 247]",1579.0,16616064,392
Initial therapy for patients with chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Evolution of frontline treatment for patients with chronic lymphocytic leukemia (CLL) has been driven by the objective of increasing complete remission (CR) rates and achieving maximum elimination of leukemia. As a result, effective combination regimens incorporating new agents such as monoclonal antibodies have been developed. Beyond morphologic CR, evaluation for residual disease by multicolor flow cytometry or molecular techniques may provide a tool to assess potentially more effective therapies. Although new prognostic factors correlate with time to treatment and survival have been identified, the utility of these factors in predicting response rates or response duration has not been established. Clearly, strides have been made in developing effective treatments that are improving remission duration with the ultimate goal of improving survival for patients with CLL. Herein, we review the recent progress in frontline therapies for patients with CLL.",Journal Article,5043.0,13.0,Evolution of frontline treatment for patients with chronic lymphocytic CLL has been driven by the objective of increasing complete remission CR rates and achieving maximum elimination of As a result effective combination regimens incorporating new agents such as monoclonal antibodies have been developed Beyond morphologic CR evaluation for residual disease by multicolor flow cytometry or molecular techniques may provide a tool to assess potentially more effective therapies Although new prognostic factors correlate with time to treatment and survival have been identified the utility of these factors in predicting response rates or response duration has not been established Clearly strides have been made in developing effective treatments that are improving remission duration with the ultimate goal of improving survival for patients with CLL Herein we review the recent progress in frontline therapies for patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2554, 1, 3171, 24, 9, 7, 5, 442, 1193, 552, 71, 85, 1621, 20, 3, 461, 1, 602, 236, 734, 684, 151, 2, 1785, 689, 3730, 1, 22, 8, 757, 323, 150, 472, 2570, 217, 183, 225, 22, 848, 890, 47, 85, 276, 1654, 2815, 684, 451, 9, 753, 34, 20, 11920, 1412, 1914, 15, 219, 1092, 68, 377, 8, 1515, 6, 423, 751, 80, 323, 235, 242, 217, 177, 130, 1513, 5, 98, 6, 24, 2, 25, 47, 85, 108, 3, 1207, 1, 46, 130, 4, 1434, 51, 151, 15, 51, 654, 71, 44, 85, 635, 2536, 10698, 47, 85, 1229, 4, 931, 323, 640, 17, 32, 1673, 734, 654, 5, 3, 5768, 1326, 1, 1673, 25, 9, 7, 5, 552, 1986, 21, 206, 3, 435, 1466, 4, 3171, 235, 9, 7, 5, 552]",933.0,16616067,786
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.,Seminars in oncology,Semin. Oncol.,2006-04-01,"There are several initial therapies available for chronic lymphocytic leukemia (CLL) that offer extended disease-free or treatment-free survival time. However, once patients relapse, particularly after fludarabine-based therapy, treatment choices have remained limited. Newer therapies have now become available, including alemtuzumab, fludarabine-based combinations, rituximab, methylprednisolone, alternative nucleoside analogs, flavopirodol, lenalidomide, signal transduction inhibitors/small molecules, and new monoclonal antibodies. We discuss selection of therapy for the relapsed patient using risk stratification and the role of clinical research in continuing to pursue therapeutic advances against CLL.",Journal Article,5043.0,28.0,There are several initial therapies available for chronic lymphocytic CLL that offer extended disease-free or treatment-free survival time However once patients relapse particularly after fludarabine-based therapy treatment choices have remained limited Newer therapies have now become available including alemtuzumab fludarabine-based combinations rituximab methylprednisolone alternative nucleoside analogs flavopirodol lenalidomide signal transduction inhibitors/small molecules and new monoclonal antibodies We discuss selection of therapy for the relapsed patient using risk stratification and the role of clinical research in continuing to pursue therapeutic advances against CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[125, 32, 392, 388, 235, 390, 9, 442, 1193, 552, 17, 1918, 1747, 34, 115, 15, 24, 115, 25, 98, 137, 1059, 7, 429, 823, 50, 2027, 90, 36, 24, 5218, 47, 958, 383, 2246, 235, 47, 1134, 1417, 390, 141, 3579, 2027, 90, 1247, 855, 10787, 1091, 4032, 4063, 55414, 1288, 1235, 2761, 222, 302, 1598, 2, 217, 848, 890, 21, 1139, 881, 1, 36, 9, 3, 591, 69, 75, 43, 1541, 2, 3, 200, 1, 38, 389, 4, 4346, 6, 7874, 189, 954, 480, 552]",685.0,16616068,699
Richter's transformation in chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Richter's syndrome (RS) is characterized by the development of high-grade non-Hodgkin's lymphoma (NHL) in a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. At The University of Texas M.D. Anderson Cancer Center the incidence of RS is 3.9%. The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm. RS may be triggered by viral infections, such as Epstein-Barr virus (EBV). Trisomy 12 and chromosome 11 abnormalities, as well as multiple genetic defects, have been described in patients with RS. These abnormalities may cause CLL cells to proliferate and, by facilitating the acquisition of new genetic abnormalities, to transform into RS cells. The therapeutic strategies for RS typically include therapies developed for NHL or acute lymphoblastic leukemia. The reported response rates with these therapies are 5% to 43%, and the median survival duration ranges from 5 to 8 months. The median overall survival duration at our institution of patients with RS is 9.1 months (95% confidence interval, 7.8 to 11 months), and the median failure-free survival duration is 7.1 months (95% confidence interval, 5.1 to 10.4 months). Patients appear to benefit from cytoreductive therapy consisting of chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation, as postremission therapy. As part of a program aiming to cure RS, we are currently conducting a clinical trial of oxaliplatin, fludarabine, and cytarabine in combination with rituximab and recommend postremission therapy, including allogeneic stem cell transplantation in patients with available donors.",Journal Article,5043.0,52.0,Richter 's syndrome RS is characterized by the development of high-grade 's NHL in a patient with chronic lymphocytic CLL or small lymphocytic At The University of Texas M.D Anderson Cancer Center the incidence of RS is 3.9 The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm RS may be triggered by viral infections such as Epstein-Barr virus EBV Trisomy 12 and chromosome 11 abnormalities as well as multiple genetic defects have been described in patients with RS These abnormalities may cause CLL cells to proliferate and by facilitating the acquisition of new genetic abnormalities to transform into RS cells The therapeutic strategies for RS typically include therapies developed for NHL or acute lymphoblastic The reported response rates with these therapies are 5 to 43 and the median survival duration ranges from 5 to 8 months The median overall survival duration at our institution of patients with RS is 9.1 months 95 confidence interval 7.8 to 11 months and the median failure-free survival duration is 7.1 months 95 confidence interval 5.1 to 10.4 months Patients appear to benefit from cytoreductive therapy consisting of chemotherapy and immunotherapy followed by allogeneic stem cell transplantation as postremission therapy As part of a program aiming to cure RS we are currently conducting a clinical trial of oxaliplatin fludarabine and cytarabine in combination with rituximab and recommend postremission therapy including allogeneic stem cell transplantation in patients with available donors,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[8452, 292, 681, 2250, 16, 765, 20, 3, 193, 1, 64, 88, 292, 1176, 4, 8, 69, 5, 442, 1193, 552, 15, 302, 1193, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 3, 287, 1, 2250, 16, 27, 83, 3, 375, 37, 1, 2250, 68, 3043, 298, 1392, 1, 3, 2279, 552, 3910, 15, 1231, 8, 217, 2131, 2250, 68, 40, 4173, 20, 1667, 1875, 225, 22, 5212, 5190, 1450, 2672, 6317, 133, 2, 1170, 175, 1171, 22, 149, 22, 232, 336, 2945, 47, 85, 1027, 4, 7, 5, 2250, 46, 1171, 68, 708, 552, 37, 6, 9554, 2, 20, 5379, 3, 3405, 1, 217, 336, 1171, 6, 7136, 237, 2250, 37, 3, 189, 422, 9, 2250, 1969, 643, 235, 276, 9, 1176, 15, 286, 1275, 3, 210, 51, 151, 5, 46, 235, 32, 33, 6, 601, 2, 3, 52, 25, 654, 5632, 29, 33, 6, 66, 53, 3, 52, 63, 25, 654, 28, 114, 731, 1, 7, 5, 2250, 16, 83, 14, 53, 48, 307, 268, 67, 66, 6, 175, 53, 2, 3, 52, 496, 115, 25, 654, 16, 67, 14, 53, 48, 307, 268, 33, 14, 6, 79, 39, 53, 7, 1322, 6, 247, 29, 2604, 36, 2273, 1, 56, 2, 726, 370, 20, 1063, 452, 31, 497, 22, 8635, 36, 22, 760, 1, 8, 1243, 10279, 6, 1722, 2250, 21, 32, 694, 6018, 8, 38, 160, 1, 1476, 2027, 2, 1855, 4, 150, 5, 855, 2, 2237, 8635, 36, 141, 1063, 452, 31, 497, 4, 7, 5, 390, 2344]",1570.0,16616072,425
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2006-04-01,"Interphase fluorescence in situ hybridization (FISH) studies with D13S319 show that deletions of 13q14 are common in B-cell chronic lymphocytic leukemia (B-CLL). In contrast, conventional cytogenetic studies in B-CLL seldom reveal abnormalities of chromosome 13. We hypothesized that chromosome 13 anomalies might not be detected because they are caused by cryptic deletions rather than by the absence of dividing B-CLL cells. To investigate this possibility, we used FISH with D13S319 to study metaphases from 12 patients known to have 13q- by interphase FISH. These same patients had normal chromosomes by conventional cytogenetic studies. As a result of this study, we report evidence that B-CLL metaphases with 13q- are not detected because these deletions are often cryptic and not visible by standard G-banding.",Journal Article,5043.0,13.0,Interphase fluorescence in situ hybridization FISH studies with D13S319 show that deletions of 13q14 are common in B-cell chronic lymphocytic B-CLL In contrast conventional cytogenetic studies in B-CLL seldom reveal abnormalities of chromosome 13 We hypothesized that chromosome 13 anomalies might not be detected because they are caused by cryptic deletions rather than by the absence of dividing B-CLL cells To investigate this possibility we used FISH with D13S319 to study metaphases from 12 patients known to have 13q- by interphase FISH These same patients had normal chromosomes by conventional cytogenetic studies As a result of this study we report evidence that B-CLL metaphases with 13q- are not detected because these deletions are often cryptic and not visible by standard G-banding,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8081, 1591, 4, 957, 1554, 1277, 94, 5, 24413, 514, 17, 2439, 1, 13221, 32, 186, 4, 132, 31, 442, 1193, 132, 552, 4, 748, 809, 1266, 94, 4, 132, 552, 10805, 2396, 1171, 1, 1170, 233, 21, 1237, 17, 1170, 233, 7623, 822, 44, 40, 530, 408, 491, 32, 1546, 20, 10294, 2439, 1832, 76, 20, 3, 1127, 1, 9515, 132, 552, 37, 6, 963, 26, 2526, 21, 95, 1277, 5, 24413, 6, 45, 10653, 29, 133, 7, 440, 6, 47, 8453, 20, 8081, 1277, 46, 827, 7, 42, 295, 3560, 20, 809, 1266, 94, 22, 8, 757, 1, 26, 45, 21, 414, 241, 17, 132, 552, 10653, 5, 8453, 32, 44, 530, 408, 46, 2439, 32, 629, 10294, 2, 44, 4822, 20, 260, 499, 24410]",795.0,16631472,394
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.,Blood,Blood,2006-05-02,"Drug development in human chronic lymphocytic leukemia (CLL) has been limited by lack of a suitable animal model to adequately assess pharmacologic properties relevant to clinical application. A recently described TCL-1 transgenic mouse develops a chronic B-cell CD5(+) leukemia that might be useful for such studies. Following confirmation of the natural history of this leukemia in the transgenic mice, we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets (Bcl-2, Mcl-1, AKT, PDK1, and DNMT1), wild-type p53 status, and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL. We then demonstrated the in vivo clinical activity of low-dose fludarabine in transgenic TCL-1 mice with active leukemia. These studies demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of survival (P = .046) compared with control mice. Similar to human CLL, an emergence of resistance was noted with fludarabine treatment in vivo. Overall, these studies suggest that the TCL-1 transgenic leukemia mouse model has similar clinical and therapeutic response properties to human CLL and may therefore serve as a useful in vivo tool to screen new drugs for subsequent development in CLL.",Comparative Study,5012.0,83.0,Drug development in human chronic lymphocytic CLL has been limited by lack of a suitable animal model to adequately assess pharmacologic properties relevant to clinical application A recently described TCL-1 transgenic mouse develops a chronic B-cell CD5 that might be useful for such studies Following confirmation of the natural history of this in the transgenic mice we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets Bcl-2 Mcl-1 AKT PDK1 and DNMT1 wild-type p53 status and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL We then demonstrated the in vivo clinical activity of low-dose fludarabine in transgenic TCL-1 mice with active These studies demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of survival P .046 compared with control mice Similar to human CLL an emergence of resistance was noted with fludarabine treatment in vivo Overall these studies suggest that the TCL-1 transgenic mouse model has similar clinical and therapeutic response properties to human CLL and may therefore serve as a useful in vivo tool to screen new drugs for subsequent development in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[234, 193, 4, 171, 442, 1193, 552, 71, 85, 383, 20, 926, 1, 8, 2884, 2026, 202, 6, 4215, 423, 2788, 1571, 867, 6, 38, 1581, 8, 761, 1027, 8885, 14, 2862, 830, 4734, 8, 442, 132, 31, 6349, 17, 822, 40, 999, 9, 225, 94, 366, 3551, 1, 3, 1504, 532, 1, 26, 4, 3, 2862, 399, 21, 264, 17, 3, 2423, 1471, 1594, 1669, 867, 189, 637, 1044, 18, 1308, 14, 649, 16384, 2, 7328, 955, 267, 624, 156, 2, 4, 439, 485, 6, 189, 183, 867, 6, 3, 24, 1, 171, 552, 21, 818, 264, 3, 4, 386, 38, 128, 1, 154, 61, 2027, 4, 2862, 8885, 14, 399, 5, 544, 46, 94, 264, 110, 191, 628, 4, 315, 1448, 1276, 2, 4071, 444, 2, 4464, 1, 25, 19, 4902, 72, 5, 182, 399, 288, 6, 171, 552, 35, 3397, 1, 251, 10, 1051, 5, 2027, 24, 4, 386, 63, 46, 94, 309, 17, 3, 8885, 14, 2862, 830, 202, 71, 288, 38, 2, 189, 51, 1571, 6, 171, 552, 2, 68, 673, 1833, 22, 8, 999, 4, 386, 1515, 6, 2413, 217, 600, 9, 706, 193, 4, 552]",1199.0,16670263,659
Activity of alemtuzumab in patients with CD52-positive acute leukemia.,Cancer,Cancer,2006-06-01,"Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic leukemia and other CD52-positive lymphoproliferative disorders. Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Fifteen patients with CD52-positive (> or = 20%), recurrent or refractory acute leukemia (9 patients with AML and 6 patients with ALL) received alemtuzumab at a dose of 30 mg intravenously given 3 times a week (dose escalation during Week 1) for a total of 4 to 12 weeks. The median age of the patients was 39 years (range, 18-71 years). Patients had received a median of 3 prior therapies (range, 1-5 prior therapies). Two patients (13%) achieved a bone marrow complete response and 1 patient achieved a substantial reduction in bone marrow blasts. No complete remissions were observed. Ten patients developed disease progression while on study. Alemtuzumab was myelosuppressive in nearly all patients. Infusion-related toxicities were common, but usually did not exceed Grade 2 (according to the National Cancer Institute Common Toxicity Criteria). Infectious episodes occurred in 13 patients (87%) and included pneumonia (6 patients), bacteremia (11 patients), fungemia (2 patients), and cytomegalovirus reactivation (2 patients). Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute leukemia. An evaluation in patients with a better prognosis, in combination with other agents or as part of consolidation therapy, is warranted.",Clinical Trial,4982.0,74.0,Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic and other CD52-positive lymphoproliferative disorders Because CD52 also is expressed on acute leukemic blasts the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid AML and acute lymphoblastic ALL Fifteen patients with CD52-positive or 20 recurrent or refractory acute 9 patients with AML and 6 patients with ALL received alemtuzumab at a dose of 30 mg intravenously given 3 times a week dose escalation during Week 1 for a total of 4 to 12 weeks The median age of the patients was 39 years range 18-71 years Patients had received a median of 3 prior therapies range 1-5 prior therapies Two patients 13 achieved a marrow complete response and 1 patient achieved a substantial reduction in marrow blasts No complete remissions were observed Ten patients developed disease progression while on study Alemtuzumab was myelosuppressive in nearly all patients Infusion-related toxicities were common but usually did not exceed Grade 2 according to the National Cancer Institute Common Toxicity Criteria Infectious episodes occurred in 13 patients 87 and included pneumonia 6 patients bacteremia 11 patients fungemia 2 patients and cytomegalovirus reactivation 2 patients Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute An evaluation in patients with a better prognosis in combination with other agents or as part of consolidation therapy is warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3579, 16, 8, 3619, 848, 548, 1166, 480, 3, 31, 1255, 448, 7189, 2, 71, 264, 128, 4, 442, 1193, 2, 127, 7189, 109, 4192, 1997, 408, 7189, 120, 16, 570, 23, 286, 2015, 2438, 3, 738, 565, 3, 367, 2, 209, 1, 3579, 4, 7, 5, 286, 533, 329, 2, 286, 1275, 62, 3057, 7, 5, 7189, 109, 15, 179, 387, 15, 430, 286, 83, 7, 5, 329, 2, 49, 7, 5, 62, 103, 3579, 28, 8, 61, 1, 201, 81, 1672, 447, 27, 1072, 8, 647, 61, 1125, 190, 647, 14, 9, 8, 181, 1, 39, 6, 133, 244, 3, 52, 89, 1, 3, 7, 10, 587, 60, 184, 203, 792, 60, 7, 42, 103, 8, 52, 1, 27, 324, 235, 184, 14, 33, 324, 235, 100, 7, 233, 513, 8, 581, 236, 51, 2, 14, 69, 513, 8, 1281, 628, 4, 581, 2438, 77, 236, 3166, 11, 164, 1618, 7, 276, 34, 91, 369, 23, 45, 3579, 10, 11109, 4, 1857, 62, 7, 904, 139, 385, 11, 186, 84, 2082, 205, 44, 6818, 88, 18, 768, 6, 3, 657, 12, 1377, 186, 155, 371, 3398, 3750, 489, 4, 233, 7, 912, 2, 159, 3485, 49, 7, 7085, 175, 7, 34088, 18, 7, 2, 7314, 3834, 18, 7, 226, 420, 3579, 10, 204, 6, 47, 383, 128, 4, 387, 15, 430, 286, 35, 451, 4, 7, 5, 8, 380, 356, 4, 150, 5, 127, 183, 15, 22, 760, 1, 2173, 36, 16, 1197]",1576.0,16688777,284
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.,Cancer,Cancer,2006-07-01,"The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone. The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004. The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia. SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 x 10(3). Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3-year survival rates were 95%, 100%, and 55%, respectively. The 3-year failure-free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS. Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.",Comparative Study,4952.0,82.0,The optimal management of patients with splenic marginal zone lymphoma/marginal zone SMZL is controversial The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab rituximab plus chemotherapy or chemotherapy alone The Service database was searched for patients with splenic who were registered between May 1995 and October 2004 The indications for treatment were the same as those used for patients with chronic lymphocytic SMZL was confirmed in 70 patients The median age was 64 years The median number of CD20 molecules per cell was 69 x 10 3 Forty-three patients required systemic therapy rituximab in 26 patients chemotherapy plus rituximab in 6 patients and chemotherapy alone in 11 patients Ten additional patients underwent splenectomy and 17 patients were in the observation group The overall response rates were 88 with rituximab 83 with rituximab plus chemotherapy and 55 with chemotherapy alone the 3-year survival rates were 95 100 and 55 respectively The 3-year failure-free survival FFS rates were 86 100 and 45 in the rituximab rituximab plus chemotherapy and chemotherapy alone groups respectively Rituximab treatments resulted in longer survival and FFS compared with chemotherapy Rituximab alone resulted in disappearance of splenomegaly in 92 of patients and normalization of absolute lymphocyte counts In univariate analysis younger age and rituximab-based therapy were predictive of longer FFS Rituximab with or without chemotherapy was found to have major activity in patients with SMZL These results may be associated with high levels of cellular CD20 antigen sites Rituximab should be the treatment of choice at least in older patients with SMZL who have comorbid diseases,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 665, 284, 1, 7, 5, 5237, 3450, 3614, 4763, 3450, 3614, 19764, 16, 2010, 3, 461, 1, 26, 459, 45, 10, 6, 932, 3, 123, 1, 7, 5, 19764, 54, 103, 24, 5, 855, 855, 349, 56, 15, 56, 279, 3, 3086, 609, 10, 3080, 9, 7, 5, 5237, 54, 11, 1653, 59, 68, 2323, 2, 2551, 1131, 3, 2406, 9, 24, 11, 3, 827, 22, 135, 95, 9, 7, 5, 442, 1193, 19764, 10, 557, 4, 431, 7, 3, 52, 89, 10, 660, 60, 3, 52, 207, 1, 2198, 1598, 379, 31, 10, 790, 1006, 79, 27, 1213, 169, 7, 616, 403, 36, 855, 4, 432, 7, 56, 349, 855, 4, 49, 7, 2, 56, 279, 4, 175, 7, 1618, 402, 7, 208, 6569, 2, 269, 7, 11, 4, 3, 1664, 87, 3, 63, 51, 151, 11, 889, 5, 855, 852, 5, 855, 349, 56, 2, 614, 5, 56, 279, 3, 27, 111, 25, 151, 11, 48, 394, 2, 614, 106, 3, 27, 111, 496, 115, 25, 5058, 151, 11, 868, 394, 2, 512, 4, 3, 855, 855, 349, 56, 2, 56, 279, 271, 106, 855, 640, 627, 4, 589, 25, 2, 5058, 72, 5, 56, 855, 279, 627, 4, 13528, 1, 6364, 4, 937, 1, 7, 2, 5924, 1, 1766, 1448, 1911, 4, 880, 65, 773, 89, 2, 855, 90, 36, 11, 464, 1, 589, 5058, 855, 5, 15, 187, 56, 10, 204, 6, 47, 458, 128, 4, 7, 5, 19764, 46, 99, 68, 40, 41, 5, 64, 148, 1, 763, 2198, 448, 633, 855, 257, 40, 3, 24, 1, 1866, 28, 506, 4, 434, 7, 5, 19764, 54, 47, 3952, 1342]",1769.0,16700034,456
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-05-01,"The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival. An electronic database search of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The University of Texas M.D. Anderson Cancer Center (Houston, TX) between January 1975 and June 2005 was performed, and patient medical records were reviewed. Of the 3,986 patients with CLL/SLL, 204 patients (5.1%) had possible RS, and 148 patients (3.7%) had biopsy- or fine-needle aspiration-proven RS. Treatment included chemotherapy alone and chemoimmunotherapy with rituximab. The overall response rate for the 130 assessable patients was 39% (chemotherapy, 34%; chemoimmunotherapy, 47%; P = .2). In multivariate analysis, factors predicting prolonged survival were Zubrod performance status 0-1 (P = .006), lactate dehydrogenase < or = 1.5x the upper limit of normal (P = .003), platelet count > or = 100,000 (P = .01), tumor size < or = 5 cm (P = .02), and fewer than two prior therapies (P = .02). The five adverse factors predicting shorter survival were used to design a model to predict an individual patient's risk of death: the RS score. A total of 20 patients underwent stem-cell transplantation (SCT). Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients who achieved remission and received no additional therapy or patients who underwent allogeneic or autologous SCT as salvage therapy (P = .019). A score to predict an individual patient's risk of death is proposed. Chemotherapy and rituximab combinations are effective in RS. Patients with available donors may be considered for allogeneic SCT as postremission therapy.",Journal Article,5013.0,157.0,"The purpose of this study was to assess the incidence presenting characteristics and treatment outcomes of Richter 's syndrome RS and factors predicting response and survival An electronic database search of patients with chronic lymphocytic CLL /small lymphocytic SLL who presented at The University of Texas M.D Anderson Cancer Center Houston TX between January 1975 and June 2005 was performed and patient medical records were reviewed Of the 3,986 patients with CLL/SLL 204 patients 5.1 had possible RS and 148 patients 3.7 had biopsy- or fine-needle aspiration-proven RS Treatment included chemotherapy alone and chemoimmunotherapy with rituximab The overall response rate for the 130 assessable patients was 39 chemotherapy 34 chemoimmunotherapy 47 P .2 In multivariate analysis factors predicting prolonged survival were Zubrod performance status 0-1 P .006 lactate dehydrogenase or 1.5x the upper limit of normal P .003 platelet count or 100,000 P .01 tumor size or 5 cm P .02 and fewer than two prior therapies P .02 The five adverse factors predicting shorter survival were used to design a model to predict an individual patient 's risk of death the RS score A total of 20 patients underwent stem-cell transplantation SCT Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients who achieved remission and received no additional therapy or patients who underwent allogeneic or autologous SCT as salvage therapy P .019 A score to predict an individual patient 's risk of death is proposed Chemotherapy and rituximab combinations are effective in RS Patients with available donors may be considered for allogeneic SCT as postremission therapy",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 423, 3, 287, 1656, 374, 2, 24, 123, 1, 8452, 292, 681, 2250, 2, 130, 1434, 51, 2, 25, 35, 3098, 609, 1901, 1, 7, 5, 442, 1193, 552, 302, 1193, 5302, 54, 917, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 6212, 6614, 59, 1024, 7585, 2, 1924, 1242, 10, 173, 2, 69, 484, 1064, 11, 446, 1, 3, 27, 16032, 7, 5, 552, 5302, 5996, 7, 33, 14, 42, 899, 2250, 2, 4647, 7, 27, 67, 42, 411, 15, 2924, 2177, 3256, 1930, 2250, 24, 159, 56, 279, 2, 4438, 5, 855, 3, 63, 51, 116, 9, 3, 3431, 3120, 7, 10, 587, 56, 562, 4438, 662, 19, 18, 4, 331, 65, 130, 1434, 1069, 25, 11, 10672, 528, 156, 13, 14, 19, 1861, 3330, 2374, 15, 14, 26510, 3, 1726, 2385, 1, 295, 19, 1421, 1596, 1276, 15, 394, 984, 19, 355, 30, 444, 15, 33, 494, 19, 588, 2, 1497, 76, 100, 324, 235, 19, 588, 3, 365, 290, 130, 1434, 985, 25, 11, 95, 6, 771, 8, 202, 6, 678, 35, 797, 69, 292, 43, 1, 273, 3, 2250, 368, 8, 181, 1, 179, 7, 208, 452, 31, 497, 1988, 7, 54, 208, 1063, 1988, 22, 8635, 36, 42, 589, 25, 76, 7, 54, 513, 734, 2, 103, 77, 402, 36, 15, 7, 54, 208, 1063, 15, 1028, 1988, 22, 992, 36, 19, 4049, 8, 368, 6, 678, 35, 797, 69, 292, 43, 1, 273, 16, 1587, 56, 2, 855, 1247, 32, 323, 4, 2250, 7, 5, 390, 2344, 68, 40, 515, 9, 1063, 1988, 22, 8635, 36]",1691.0,16710033,552
The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Nonmyeloablative stem cell transplants provide a viable therapeutic option for older patients or patients with comorbid conditions, who were previously deemed to be ineligible for transplantation. Despite improvements in clinical outcomes, graft-versus-host disease (GVHD) remains a significant and potentially lethal complication. One approach by which GVHD has been managed is through introduction of new agents, such as alemtuzumab, into the conditioning regimen. Alemtuzumab is a humanized monoclonal antibody that targets the CD52 antigen, which is highly expressed on both B and T lymphocytes. By depleting T cells in both the donor and the recipient, alemtuzumab has been shown to prevent development of both acute and chronic GVHD, without inhibiting the benefits associated with the graft-versus-leukemia effect. Clinical trials have shown that alemtuzumab is able to decrease the incidence of acute and chronic GVHD without impairing engraftment. Furthermore, in chronic lymphocytic leukemia therapy, alemtuzumab has been shown to purge malignant cells from the host to allow for harvesting for the purpose of autologous transplantation. Despite results showing that alemtuzumab can play an important role in managing GVHD, little information is available regarding a standardized dosing schedule. Greater insight into alemtuzumab's pharmacokinetic activity would assist in developing a schedule that can optimize alemtuzumab-mediated T-cell depletion to prevent GVHD, while retaining sufficient host T-cell activity to encourage the graft-versus-leukemia effect and prevent relapse.",Journal Article,5043.0,16.0,Nonmyeloablative stem cell transplants provide a viable therapeutic option for older patients or patients with comorbid conditions who were previously deemed to be ineligible for transplantation Despite improvements in clinical outcomes graft-versus-host disease GVHD remains a significant and potentially lethal complication One approach by which GVHD has been managed is through introduction of new agents such as alemtuzumab into the conditioning regimen Alemtuzumab is a humanized monoclonal antibody that targets the CD52 antigen which is highly expressed on both B and T lymphocytes By depleting T cells in both the donor and the recipient alemtuzumab has been shown to prevent development of both acute and chronic GVHD without inhibiting the benefits associated with the graft-versus-leukemia effect Clinical trials have shown that alemtuzumab is able to decrease the incidence of acute and chronic GVHD without impairing engraftment Furthermore in chronic lymphocytic therapy alemtuzumab has been shown to purge malignant cells from the host to allow for harvesting for the purpose of autologous transplantation Despite results showing that alemtuzumab can play an important role in managing GVHD little information is available regarding a standardized dosing schedule Greater insight into alemtuzumab 's pharmacokinetic activity would assist in developing a schedule that can optimize alemtuzumab-mediated T-cell depletion to prevent GVHD while retaining sufficient host T-cell activity to encourage the graft-versus-leukemia effect and prevent relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6094, 452, 31, 4016, 377, 8, 2663, 189, 1501, 9, 434, 7, 15, 7, 5, 3952, 1298, 54, 11, 373, 3779, 6, 40, 3773, 9, 497, 550, 1474, 4, 38, 123, 1599, 185, 1204, 34, 1562, 469, 8, 93, 2, 751, 2266, 1447, 104, 353, 20, 92, 1562, 71, 85, 2231, 16, 298, 2456, 1, 217, 183, 225, 22, 3579, 237, 3, 1933, 477, 3579, 16, 8, 3619, 848, 548, 17, 637, 3, 7189, 448, 92, 16, 561, 570, 23, 110, 132, 2, 102, 1594, 20, 9438, 102, 37, 4, 110, 3, 1488, 2, 3, 5783, 3579, 71, 85, 443, 6, 1682, 193, 1, 110, 286, 2, 442, 1562, 187, 2062, 3, 1141, 41, 5, 3, 1599, 185, 2647, 254, 38, 143, 47, 443, 17, 3579, 16, 1665, 6, 775, 3, 287, 1, 286, 2, 442, 1562, 187, 12880, 2881, 798, 4, 442, 1193, 36, 3579, 71, 85, 443, 6, 33265, 393, 37, 29, 3, 1204, 6, 1700, 9, 17700, 9, 3, 743, 1, 1028, 497, 550, 99, 2069, 17, 3579, 122, 1343, 35, 305, 200, 4, 3969, 1562, 1215, 487, 16, 390, 666, 8, 1670, 1280, 1055, 378, 2670, 237, 3579, 292, 1456, 128, 688, 3425, 4, 931, 8, 1055, 17, 122, 2465, 3579, 517, 102, 31, 2286, 6, 1682, 1562, 369, 14171, 1952, 1204, 102, 31, 128, 6, 7113, 3, 1599, 185, 2647, 254, 2, 1682, 429]",1563.0,16720202,101
Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2006-06-01,"Loss of tumor protein 53 (TP53) has been associated with aggressive disease and poor response to therapy in B-cell chronic lymphocytic leukemia (B-CLL). TP53 is located at chromosome band 17p13 and its absence can be detected by fluorescence in situ hybridization (FISH) in the interphase nuclei of 8-10% patients with B-CLL. To study the cytogenetic mechanism for loss of TP53, metaphase and interphase FISH studies were conducted on 16 B-CLL patients to investigate 17p10 to 17p12, a chromosome region known to be rich in low-copy DNA repeats. Loss of TP53 was caused by an isochromosome with breakpoints between 17p10 and 17p11.2 in four patients, an unbalanced translocation involving 17p10 to 17p11.2 in nine patients, and an unbalanced translocation involving 17p11.2 to 17p12 in three patients. These findings indicate that loss of TP53 results from the absence of nearly the entire chromosome 17 p-arm rather than to monosomy 17 or deletions of TP53. Translocations or isochromosome formations at sites of low-copy DNA repeats in 17p10 to 17p12 appear to be the mechanism for the loss of TP53 in B-CLL.",Journal Article,4982.0,29.0,Loss of tumor protein 53 TP53 has been associated with aggressive disease and poor response to therapy in B-cell chronic lymphocytic B-CLL TP53 is located at chromosome band 17p13 and its absence can be detected by fluorescence in situ hybridization FISH in the interphase nuclei of 8-10 patients with B-CLL To study the cytogenetic mechanism for loss of TP53 metaphase and interphase FISH studies were conducted on 16 B-CLL patients to investigate 17p10 to 17p12 a chromosome region known to be rich in low-copy DNA repeats Loss of TP53 was caused by an isochromosome with breakpoints between 17p10 and 17p11.2 in four patients an unbalanced translocation involving 17p10 to 17p11.2 in nine patients and an unbalanced translocation involving 17p11.2 to 17p12 in three patients These findings indicate that loss of TP53 results from the absence of nearly the entire chromosome 17 p-arm rather than to monosomy 17 or deletions of TP53 Translocations or isochromosome formations at sites of low-copy DNA repeats in 17p10 to 17p12 appear to be the mechanism for the loss of TP53 in B-CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[407, 1, 30, 178, 699, 1206, 71, 85, 41, 5, 571, 34, 2, 334, 51, 6, 36, 4, 132, 31, 442, 1193, 132, 552, 1206, 16, 2308, 28, 1170, 7679, 7526, 2, 211, 1127, 122, 40, 530, 20, 1591, 4, 957, 1554, 1277, 4, 3, 8081, 4725, 1, 66, 79, 7, 5, 132, 552, 6, 45, 3, 1266, 670, 9, 407, 1, 1206, 10569, 2, 8081, 1277, 94, 11, 426, 23, 245, 132, 552, 7, 6, 963, 34095, 6, 34096, 8, 1170, 1053, 440, 6, 40, 3697, 4, 154, 1337, 261, 7197, 407, 1, 1206, 10, 1546, 20, 35, 22366, 5, 7843, 59, 34095, 2, 17751, 18, 4, 294, 7, 35, 11947, 2006, 1267, 34095, 6, 17751, 18, 4, 762, 7, 2, 35, 11947, 2006, 1267, 17751, 18, 6, 34096, 4, 169, 7, 46, 272, 1008, 17, 407, 1, 1206, 99, 29, 3, 1127, 1, 1857, 3, 1797, 1170, 269, 19, 475, 1832, 76, 6, 7521, 269, 15, 2439, 1, 1206, 3262, 15, 22366, 24462, 28, 633, 1, 154, 1337, 261, 7197, 4, 34095, 6, 34096, 1322, 6, 40, 3, 670, 9, 3, 407, 1, 1206, 4, 132, 552]",1084.0,16737921,741
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study.,Leukemia & lymphoma,Leuk. Lymphoma,2006-05-01,"The objective of this study was to assess the incidence and the clinical significance of Epstein-Barr virus (EBV) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients with CLL/SLL who presented at The University of Texas M. D. Anderson Cancer Center over a 2-year period and had available marrow paraffin blocks were studied for evidence of EBV infection using a highly specific in-situ hybridization assay for detection of EBV encoded RNA (EBERs). Results were analysed in relation to other presenting characteristics and outcome. Thirty-two patients were examined. EBERs were detected in the bone marrow of 12 of 32 (38%) CLL/SLL marrows vs 0 of 20 normal marrows (p = 0.002). EBERs were observed in sporadic granulocytes alone or in addition to its presence in lymphocytes in nine of the 12 EBV-positive patients. EBERs were detected less frequently in patients with Rai stage 0 - 1 disease (20%) compared with Rai stage 2 - 4 (66%; p = 0.008). EBER-positive patients tended to have higher lactate dehydrogenase levels (p = 0.053). The 10-year survival rate was 22% vs 58% for patients with and without discernible EBERs (log-rank, p = 0.08). Evidence of EBV infection was found in 38% of patients with CLL/SLL. Despite the small number of patients tested, discernable EBERs were significantly more common in individuals with more advanced Rai stage and there was a trend toward shorter survival in patients in whom EBV EBERs were discerned. Larger studies are needed to determine the prognostic value and role of EBV infection in patients with CLL/SLL.",Journal Article,5013.0,30.0,The objective of this study was to assess the incidence and the clinical significance of Epstein-Barr virus EBV in patients with chronic lymphocytic CLL /small lymphocytic SLL Patients with CLL/SLL who presented at The University of Texas M. D. Anderson Cancer Center over a 2-year period and had available marrow paraffin blocks were studied for evidence of EBV infection using a highly specific in-situ hybridization assay for detection of EBV encoded RNA EBERs Results were analysed in relation to other presenting characteristics and outcome Thirty-two patients were examined EBERs were detected in the marrow of 12 of 32 38 CLL/SLL marrows vs 0 of 20 normal marrows p 0.002 EBERs were observed in sporadic granulocytes alone or in addition to its presence in lymphocytes in nine of the 12 EBV-positive patients EBERs were detected less frequently in patients with Rai stage 0 1 disease 20 compared with Rai stage 2 4 66 p 0.008 EBER-positive patients tended to have higher lactate dehydrogenase levels p 0.053 The 10-year survival rate was 22 vs 58 for patients with and without discernible EBERs log-rank p 0.08 Evidence of EBV infection was found in 38 of patients with CLL/SLL Despite the small number of patients tested discernable EBERs were significantly more common in individuals with more advanced Rai stage and there was a trend toward shorter survival in patients in whom EBV EBERs were discerned Larger studies are needed to determine the prognostic value and role of EBV infection in patients with CLL/SLL,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 423, 3, 287, 2, 3, 38, 724, 1, 5212, 5190, 1450, 2672, 4, 7, 5, 442, 1193, 552, 302, 1193, 5302, 7, 5, 552, 5302, 54, 917, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 252, 8, 18, 111, 727, 2, 42, 390, 581, 2487, 2860, 11, 656, 9, 241, 1, 2672, 930, 75, 8, 561, 112, 4, 957, 1554, 719, 9, 638, 1, 2672, 4587, 893, 24933, 99, 11, 3141, 4, 2191, 6, 127, 1656, 374, 2, 228, 977, 100, 7, 11, 409, 24933, 11, 530, 4, 3, 581, 1, 133, 1, 531, 519, 552, 5302, 13800, 105, 13, 1, 179, 295, 13800, 19, 13, 1111, 24933, 11, 164, 4, 1928, 12695, 279, 15, 4, 352, 6, 211, 463, 4, 1594, 4, 762, 1, 3, 133, 2672, 109, 7, 24933, 11, 530, 299, 746, 4, 7, 5, 4121, 82, 13, 14, 34, 179, 72, 5, 4121, 82, 18, 39, 700, 19, 13, 2155, 12345, 109, 7, 3886, 6, 47, 142, 3330, 2374, 148, 19, 13, 9948, 3, 79, 111, 25, 116, 10, 350, 105, 717, 9, 7, 5, 2, 187, 19070, 24933, 1066, 1026, 19, 13, 1592, 241, 1, 2672, 930, 10, 204, 4, 519, 1, 7, 5, 552, 5302, 550, 3, 302, 207, 1, 7, 650, 24830, 24933, 11, 97, 80, 186, 4, 869, 5, 80, 131, 4121, 82, 2, 125, 10, 8, 853, 1317, 985, 25, 4, 7, 4, 953, 2672, 24933, 11, 19767, 1077, 94, 32, 575, 6, 223, 3, 177, 549, 2, 200, 1, 2672, 930, 4, 7, 5, 552, 5302]",1523.0,16753866,335
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.,Current opinion in hematology,Curr. Opin. Hematol.,2006-07-01,"To review risk stratification strategies used in chronic lymphocytic leukemia at diagnosis to predict aggressiveness of disease and, at time of treatment, to predict duration of response. Several new prognostic factors can better assist clinicians in predicting the aggressiveness of chronic lymphocytic leukemia at diagnosis and the likelihood of maintaining a prolonged remission with treatment. This article reviews older prognostic factors such as beta2-microglobulin and thymidine kinase activity that have been partially validated by recently completed large studies. New prognostic factors such as interphase cytogenetics, immunoglobulin heavy-chain gene mutational analysis, and relevant secondary surrogate markers of immunoglobulin heavy-chain gene, including methylation of the zeta-associated protein gene, lipoprotein lipase overexpression, telomere length, and telomerase activity are reviewed. Some prognostic factors (interphase cytogenetics) but not others (immunoglobulin heavy-chain gene mutational status, zeta-associated protein expression) predict the duration of response to fludarabine-based combination strategies. Recent advances in risk stratification provide clinicians with tools to better predict outcome of chronic lymphocytic leukemia at the time of treatment and response to treatment at the time of developing symptomatic disease.",Journal Article,4952.0,19.0,To review risk stratification strategies used in chronic lymphocytic at diagnosis to predict aggressiveness of disease and at time of treatment to predict duration of response Several new prognostic factors can better assist clinicians in predicting the aggressiveness of chronic lymphocytic at diagnosis and the likelihood of maintaining a prolonged remission with treatment This article reviews older prognostic factors such as beta2-microglobulin and thymidine kinase activity that have been partially validated by recently completed large studies New prognostic factors such as interphase cytogenetics immunoglobulin heavy-chain gene mutational analysis and relevant secondary surrogate markers of immunoglobulin heavy-chain gene including methylation of the zeta-associated protein gene lipoprotein lipase overexpression telomere length and telomerase activity are reviewed Some prognostic factors interphase cytogenetics but not others immunoglobulin heavy-chain gene mutational status zeta-associated protein expression predict the duration of response to fludarabine-based combination strategies Recent advances in risk stratification provide clinicians with tools to better predict outcome of chronic lymphocytic at the time of treatment and response to treatment at the time of developing symptomatic disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 206, 43, 1541, 422, 95, 4, 442, 1193, 28, 147, 6, 678, 3908, 1, 34, 2, 28, 98, 1, 24, 6, 678, 654, 1, 51, 392, 217, 177, 130, 122, 380, 3425, 1490, 4, 1434, 3, 3908, 1, 442, 1193, 28, 147, 2, 3, 1420, 1, 3284, 8, 1069, 734, 5, 24, 26, 946, 2004, 434, 177, 130, 225, 22, 8911, 5371, 2, 6403, 216, 128, 17, 47, 85, 2995, 938, 20, 761, 781, 375, 94, 217, 177, 130, 225, 22, 8081, 2510, 2593, 4013, 1260, 145, 1619, 65, 2, 867, 568, 2592, 525, 1, 2593, 4013, 1260, 145, 141, 569, 1, 3, 12105, 41, 178, 145, 8984, 7272, 851, 4136, 1318, 2, 3916, 128, 32, 446, 476, 177, 130, 8081, 2510, 84, 44, 1749, 2593, 4013, 1260, 145, 1619, 156, 12105, 41, 178, 55, 678, 3, 654, 1, 51, 6, 2027, 90, 150, 422, 435, 954, 4, 43, 1541, 377, 1490, 5, 1896, 6, 380, 678, 228, 1, 442, 1193, 28, 3, 98, 1, 24, 2, 51, 6, 24, 28, 3, 98, 1, 931, 1704, 34]",1318.0,16755224,517
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,Clin. Infect. Dis.,2006-05-17,"Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders. The associated long-term risks of infection remain poorly defined. From July 2001 through December 2003, all patients who received alemtuzumab for the treatment of lymphoproliferative disorders at 1 institution underwent a retrospective evaluation to document infectious complications until death or end of follow-up in October 2004. Alemtuzumab recipients who underwent allogeneic hematopoietic stem cell transplantation were compared with a concurrent cohort who also underwent allogeneic hematopoietic stem cell transplantation but did not receive alemtuzumab. Twenty-seven patients were identified (21 with chronic lymphocytic leukemia and 6 with plasma cell disorders). The overall mortality was 37%, with 7 of 10 deaths being related to infection. Significant opportunistic infections occurred in 9 patients (43%) with chronic lymphocytic leukemia, including cytomegalovirus, progressive multifocal leukoencephalopathy, adenovirus, toxoplasmosis, and acanthamaebiasis. Thirty nonopportunistic infections in 22 patients (82%) were also identified. The 3 deaths related to nonopportunistic infections all involved Enterococcus species bacteremia. When compared with a concurrent chronic lymphocytic leukemia cohort that underwent allogeneic hematopoietic stem cell transplantation, alemtuzumab recipients had an incidence of cytomegalovirus reactivation of 66.7% (6 of 9 patients), compared with 37% in the non-alemtuzumab group (10 of 27 patients; P = .15), and an incidence of post-transplant opportunistic infections (excluding herpesviruses) of 44.4% (compared with 29.6% in the non-alemtuzumab group; P = .41). Despite the use of herpesvirus and Pneumocystis pneumonia prophylaxis, serious infectious complications occur in patients receiving alemtuzumab for lymphoproliferative disorders. Infectious complications are more varied and diverse in patients receiving alemtuzumab than has been reported in trials to date.",Comparative Study,4997.0,204.0,Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders The associated long-term risks of infection remain poorly defined From July 2001 through December 2003 all patients who received alemtuzumab for the treatment of lymphoproliferative disorders at 1 institution underwent a retrospective evaluation to document infectious complications until death or end of follow-up in October 2004 Alemtuzumab recipients who underwent allogeneic hematopoietic stem cell transplantation were compared with a concurrent cohort who also underwent allogeneic hematopoietic stem cell transplantation but did not receive alemtuzumab Twenty-seven patients were identified 21 with chronic lymphocytic and 6 with plasma cell disorders The overall mortality was 37 with 7 of 10 deaths being related to infection Significant opportunistic infections occurred in 9 patients 43 with chronic lymphocytic including cytomegalovirus progressive multifocal leukoencephalopathy adenovirus toxoplasmosis and acanthamaebiasis Thirty nonopportunistic infections in 22 patients 82 were also identified The 3 deaths related to nonopportunistic infections all involved Enterococcus species bacteremia When compared with a concurrent chronic lymphocytic cohort that underwent allogeneic hematopoietic stem cell transplantation alemtuzumab recipients had an incidence of cytomegalovirus reactivation of 66.7 6 of 9 patients compared with 37 in the non-alemtuzumab group 10 of 27 patients P .15 and an incidence of post-transplant opportunistic infections excluding herpesviruses of 44.4 compared with 29.6 in the non-alemtuzumab group P .41 Despite the use of herpesvirus and Pneumocystis pneumonia prophylaxis serious infectious complications occur in patients receiving alemtuzumab for lymphoproliferative disorders Infectious complications are more varied and diverse in patients receiving alemtuzumab than has been reported in trials to date,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3579, 16, 35, 1478, 36, 9, 430, 4192, 1997, 3, 41, 319, 337, 1098, 1, 930, 918, 1240, 395, 29, 2066, 1758, 298, 1397, 1522, 62, 7, 54, 103, 3579, 9, 3, 24, 1, 4192, 1997, 28, 14, 731, 208, 8, 459, 451, 6, 4753, 3398, 521, 1100, 273, 15, 396, 1, 166, 126, 4, 2551, 1131, 3579, 2190, 54, 208, 1063, 1007, 452, 31, 497, 11, 72, 5, 8, 750, 180, 54, 120, 208, 1063, 1007, 452, 31, 497, 84, 205, 44, 560, 3579, 737, 648, 7, 11, 108, 239, 5, 442, 1193, 2, 49, 5, 554, 31, 1997, 3, 63, 282, 10, 567, 5, 67, 1, 79, 1043, 486, 139, 6, 930, 93, 10026, 1875, 489, 4, 83, 7, 601, 5, 442, 1193, 141, 7314, 1014, 3492, 8744, 4488, 43453, 2, 55553, 977, 37812, 1875, 4, 350, 7, 878, 11, 120, 108, 3, 27, 1043, 139, 6, 37812, 1875, 62, 646, 19485, 2915, 7085, 198, 72, 5, 8, 750, 442, 1193, 180, 17, 208, 1063, 1007, 452, 31, 497, 3579, 2190, 42, 35, 287, 1, 7314, 3834, 1, 700, 67, 49, 1, 83, 7, 72, 5, 567, 4, 3, 220, 3579, 87, 79, 1, 428, 7, 19, 167, 2, 35, 287, 1, 539, 941, 10026, 1875, 3207, 26036, 1, 584, 39, 72, 5, 462, 49, 4, 3, 220, 3579, 87, 19, 605, 550, 3, 119, 1, 9329, 2, 13243, 3485, 2049, 1762, 3398, 521, 1271, 4, 7, 357, 3579, 9, 4192, 1997, 3398, 521, 32, 80, 2051, 2, 1867, 4, 7, 357, 3579, 76, 71, 85, 210, 4, 143, 6, 1244]",1931.0,16758413,107
"Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.",Blood,Blood,2006-06-15,"Purine nucleoside phosphorylase (PNP) deficiency in humans results in T lymphocytopenia. Forodesine, a potent inhibitor of PNP, was designed based on the transition-state structure stabilized by the enzyme. Previous studies established that forodesine in the presence of deoxyguanosine (dGuo) inhibits the proliferation of T lymphocytes. A phase 1 clinical trial of forodesine in T-cell malignancies demonstrated significant antileukemic activity with an increase in intracellular dGuo triphosphate (dGTP). High accumulation of dGTP in T cells may be dependent on the levels of deoxynucleoside kinases. Because B-cell chronic lymphocytic leukemia (B-CLL) cells have high activity of deoxycytidine kinase (dCK), we hypothesized that these lymphocytes would respond to forodesine. This postulate was tested in primary lymphocytes during in vitro investigations. Lymphocytes from 12 patients with CLL were incubated with forodesine and dGuo. These CLL cells showed a wide variation in the accumulation of intracellular dGTP without any effect on other deoxynucleotides. This was associated with DNA damage-induced p53 stabilization, phosphorylation of p53 at Ser15, and activation of p21. The dGTP accumulation was related to induction of apoptosis measured by caspase activation, changes in mitochondrial membrane potential, and PARP cleavage. Based on these data, a phase 2 clinical trial of forodesine has been initiated for CLL patients.",Journal Article,4968.0,65.0,Purine nucleoside phosphorylase PNP deficiency in humans results in T lymphocytopenia Forodesine a potent inhibitor of PNP was designed based on the transition-state structure stabilized by the enzyme Previous studies established that forodesine in the presence of deoxyguanosine dGuo inhibits the proliferation of T lymphocytes A phase 1 clinical trial of forodesine in T-cell malignancies demonstrated significant antileukemic activity with an increase in intracellular dGuo triphosphate dGTP High accumulation of dGTP in T cells may be dependent on the levels of deoxynucleoside kinases Because B-cell chronic lymphocytic B-CLL cells have high activity of deoxycytidine kinase dCK we hypothesized that these lymphocytes would respond to forodesine This postulate was tested in primary lymphocytes during in vitro investigations Lymphocytes from 12 patients with CLL were incubated with forodesine and dGuo These CLL cells showed a wide variation in the accumulation of intracellular dGTP without any effect on other deoxynucleotides This was associated with DNA damage-induced p53 stabilization phosphorylation of p53 at Ser15 and activation of p21 The dGTP accumulation was related to induction of apoptosis measured by caspase activation changes in mitochondrial membrane potential and PARP cleavage Based on these data a phase 2 clinical trial of forodesine has been initiated for CLL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5006, 4032, 10658, 13133, 2299, 4, 3218, 99, 4, 102, 18790, 10483, 8, 1157, 230, 1, 13133, 10, 1114, 90, 23, 3, 1970, 1309, 2772, 7368, 20, 3, 1644, 698, 94, 635, 17, 10483, 4, 3, 463, 1, 17863, 17864, 1576, 3, 457, 1, 102, 1594, 8, 124, 14, 38, 160, 1, 10483, 4, 102, 31, 441, 264, 93, 4512, 128, 5, 35, 344, 4, 2087, 17864, 7345, 16319, 64, 1835, 1, 16319, 4, 102, 37, 68, 40, 470, 23, 3, 148, 1, 30959, 1549, 408, 132, 31, 442, 1193, 132, 552, 37, 47, 64, 128, 1, 6750, 216, 16320, 21, 1237, 17, 46, 1594, 688, 1892, 6, 10483, 26, 12071, 10, 650, 4, 86, 1594, 190, 4, 439, 2492, 1594, 29, 133, 7, 5, 552, 11, 8303, 5, 10483, 2, 17864, 46, 552, 37, 224, 8, 1019, 1380, 4, 3, 1835, 1, 2087, 16319, 187, 500, 254, 23, 127, 55569, 26, 10, 41, 5, 261, 1350, 277, 624, 3184, 982, 1, 624, 28, 26518, 2, 363, 1, 2657, 3, 16319, 1835, 10, 139, 6, 504, 1, 351, 644, 20, 1469, 363, 400, 4, 2019, 1905, 174, 2, 2041, 3155, 90, 23, 46, 74, 8, 124, 18, 38, 160, 1, 10483, 71, 85, 1917, 9, 552, 7]",1399.0,16778146,199
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.,Blood,Blood,2006-06-27,"Waldenstrm macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.",Comparative Study,4956.0,125.0,Waldenstrm macroglobulinemia WM is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells Although the clinical syndrome and the pathologic characteristics are well defined little is known about its biology and controversy still exists regarding its cell of origin In this gene-expression study we compared the transcription profiles of WM with those of other malignant B cells including chronic lymphocytic CLL and multiple MM as well as normal cells peripheral-blood B cells and marrow plasma cells We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles Only a small gene set has expression profiles unique to WM compared to CLL and MM The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling Thus IL6 and its downstream signaling may be of biologic importance in WM Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3700, 3389, 1518, 16, 8, 132, 31, 710, 765, 20, 3, 801, 1, 3, 132, 31, 3910, 6, 3723, 237, 554, 37, 242, 3, 38, 681, 2, 3, 510, 374, 32, 149, 395, 1215, 16, 440, 545, 211, 891, 2, 4089, 1234, 2481, 666, 211, 31, 1, 1938, 4, 26, 145, 55, 45, 21, 72, 3, 866, 1241, 1, 1518, 5, 135, 1, 127, 393, 132, 37, 141, 442, 1193, 552, 2, 232, 321, 22, 149, 22, 295, 37, 672, 315, 132, 37, 2, 581, 554, 37, 21, 204, 17, 1518, 71, 8, 10408, 145, 55, 1583, 1, 10961, 1528, 156, 2, 3780, 5, 552, 2, 295, 132, 37, 23, 6512, 3147, 5, 923, 288, 55, 1241, 158, 8, 302, 145, 916, 71, 55, 1241, 991, 6, 1518, 72, 6, 552, 2, 321, 3, 96, 97, 126, 1065, 145, 16, 6772, 2, 3, 96, 97, 41, 308, 9, 26, 916, 1, 214, 16, 1748, 314, 631, 6772, 2, 211, 1489, 314, 68, 40, 1, 1283, 1187, 4, 1518, 195, 7481, 1, 3, 200, 1, 501, 49, 4, 1518, 16, 1197, 22, 26, 68, 1918, 8, 174, 189, 10537]",1137.0,16804116,106
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.,The Journal of urology,J. Urol.,2006-08-01,"We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. We retrospectively reviewed the charts of 697 patients treated with bacillus Calmette-Guerin instillations at our institution from 1991 to 2004. In 24 patients (3.5%) an underlying comorbidity directly affecting the immune system was diagnosed before bacillus Calmette-Guerin administration or steroids were administered at least 6 weeks before and at the time of bacillus Calmette-Guerin instillations. The immunosuppressive effect of steroids was assessed by the percent of lymphocytes. End points were the bacillus Calmette-Guerin response at 6 months, defined as normal cystoscopy, cytology and biopsy when available, and treatment related toxicity. Four patients (17%) had active lymphoma or chronic lymphocytic leukemia during bacillus Calmette-Guerin administration and 21 (88%) had a concurrent condition for which oral steroids (11), inhaled steroids (14) or oral and inhaled steroids (4) were administered. Patients treated with oral steroids had a lower percent of lymphocytes than patients treated with inhaled steroids and 15 age matched patients with high risk superficial bladder cancer and no steroid treatment (12.3% vs 17.5% and 18.6%, respectively). The overall bacillus Calmette-Guerin response rate at 6 months was 58%. Ten of the 24 patients had disease recurrence and 3 had disease progression at a median followup of 63.5 months (IQR 19.5, 89). One patient treated with oral steroids had self-limited febrile disease and worsening of myalgia 48 hours after his third bacillus Calmette-Guerin cycle. No other systemic adverse event following bacillus Calmette-Guerin therapy was recorded and all patients completed scheduled treatments. Intravesical bacillus Calmette-Guerin is a viable therapeutic option in patients with high risk superficial bladder cancer and concomitant lymphoma or chronic lymphocytic leukemia, treatment with low dose oral steroids or treatment with inhaled steroids. The bacillus Calmette-Guerin response rate at 6 months and the side effects profile associated with bacillus Calmette-Guerin therapy in these patients were comparable to those in patients with no evidence of immunosuppression. Further studies are warranted to assess the safety and efficacy of bacillus Calmette-Guerin instillations in critically immunocompromised patients.",Journal Article,4921.0,34.0,We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients We retrospectively reviewed the charts of 697 patients treated with bacillus Calmette-Guerin instillations at our institution from 1991 to 2004 In 24 patients 3.5 an underlying comorbidity directly affecting the immune system was diagnosed before bacillus Calmette-Guerin administration or steroids were administered at least 6 weeks before and at the time of bacillus Calmette-Guerin instillations The immunosuppressive effect of steroids was assessed by the percent of lymphocytes End points were the bacillus Calmette-Guerin response at 6 months defined as normal cystoscopy cytology and biopsy when available and treatment related toxicity Four patients 17 had active or chronic lymphocytic during bacillus Calmette-Guerin administration and 21 88 had a concurrent condition for which oral steroids 11 inhaled steroids 14 or oral and inhaled steroids 4 were administered Patients treated with oral steroids had a lower percent of lymphocytes than patients treated with inhaled steroids and 15 age matched patients with high risk superficial cancer and no steroid treatment 12.3 vs 17.5 and 18.6 respectively The overall bacillus Calmette-Guerin response rate at 6 months was 58 Ten of the 24 patients had disease recurrence and 3 had disease progression at a median followup of 63.5 months IQR 19.5 89 One patient treated with oral steroids had self-limited febrile disease and worsening of myalgia 48 hours after his third bacillus Calmette-Guerin cycle No other systemic adverse event following bacillus Calmette-Guerin therapy was recorded and all patients completed scheduled treatments Intravesical bacillus Calmette-Guerin is a viable therapeutic option in patients with high risk superficial cancer and concomitant or chronic lymphocytic treatment with low dose oral steroids or treatment with inhaled steroids The bacillus Calmette-Guerin response rate at 6 months and the side effects profile associated with bacillus Calmette-Guerin therapy in these patients were comparable to those in patients with no evidence of immunosuppression Further studies are warranted to assess the safety and efficacy of bacillus Calmette-Guerin instillations in critically immunocompromised patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,"[21, 275, 3, 367, 2, 209, 1, 4284, 4947, 4803, 8337, 22117, 4, 3853, 73, 2, 7796, 7, 21, 894, 446, 3, 4413, 1, 11989, 7, 73, 5, 4947, 4803, 8337, 22117, 28, 114, 731, 29, 3372, 6, 1131, 4, 259, 7, 27, 33, 35, 1181, 1879, 1606, 2319, 3, 250, 398, 10, 265, 348, 4947, 4803, 8337, 634, 15, 4580, 11, 468, 28, 506, 49, 244, 348, 2, 28, 3, 98, 1, 4947, 4803, 8337, 22117, 3, 2989, 254, 1, 4580, 10, 275, 20, 3, 714, 1, 1594, 396, 862, 11, 3, 4947, 4803, 8337, 51, 28, 49, 53, 395, 22, 295, 4362, 2045, 2, 411, 198, 390, 2, 24, 139, 155, 294, 7, 269, 42, 544, 15, 442, 1193, 190, 4947, 4803, 8337, 634, 2, 239, 889, 42, 8, 750, 2850, 9, 92, 518, 4580, 175, 18374, 4580, 213, 15, 518, 2, 18374, 4580, 39, 11, 468, 7, 73, 5, 518, 4580, 42, 8, 280, 714, 1, 1594, 76, 7, 73, 5, 18374, 4580, 2, 167, 89, 655, 7, 5, 64, 43, 3562, 12, 2, 77, 3853, 24, 133, 27, 105, 269, 33, 2, 203, 49, 106, 3, 63, 4947, 4803, 8337, 51, 116, 28, 49, 53, 10, 717, 1618, 1, 3, 259, 7, 42, 34, 146, 2, 27, 42, 34, 91, 28, 8, 52, 3569, 1, 676, 33, 53, 2245, 326, 33, 887, 104, 69, 73, 5, 518, 4580, 42, 1074, 383, 2498, 34, 2, 4323, 1, 8490, 576, 1459, 50, 3224, 1282, 4947, 4803, 8337, 417, 77, 127, 403, 290, 774, 366, 4947, 4803, 8337, 36, 10, 1872, 2, 62, 7, 781, 4394, 640, 4284, 4947, 4803, 8337, 16, 8, 2663, 189, 1501, 4, 7, 5, 64, 43, 3562, 12, 2, 1781, 15, 442, 1193, 24, 5, 154, 61, 518, 4580, 15, 24, 5, 18374, 4580, 3, 4947, 4803, 8337, 51, 116, 28, 49, 53, 2, 3, 1152, 176, 800, 41, 5, 4947, 4803, 8337, 36, 4, 46, 7, 11, 1279, 6, 135, 4, 7, 5, 77, 241, 1, 3646, 195, 94, 32, 1197, 6, 423, 3, 367, 2, 209, 1, 4947, 4803, 8337, 22117, 4, 4331, 7796, 7]",2335.0,16813873,277
Role of angiogenesis in chronic lymphocytic leukemia.,Cancer,Cancer,2006-09-01,"Angiogenesis is a physiologic process of new blood vessels formation mediated by various cytokines called angiogenic and angiostatic factors. Although its potential pathophysiologic role in solid tumors has been extensively studied for more than 3 decades, enhancement of angiogenesis in chronic lymphocytic leukemia (CLL) and other malignant hematological disorders has been recognized more recently. An increased level of angiogenesis has been documented by various experimental methods both in bone marrow and lymph nodes of patients with CLL. Although the role of angiogenesis in the pathophysiology of this disease remains to be fully elucidated, experimental data suggest that several angiogenic factors play a role in the disease progression. Biologic markers of angiogenesis were also shown to be of prognostic relevance in CLL. The current findings provide the rationale for investigating antiangiogenic agents in CLL. In the current review angiogenesis in CLL is discussed and its potential diagnostic and therapeutic applications.",Journal Article,4890.0,43.0,Angiogenesis is a physiologic process of new blood vessels formation mediated by various cytokines called angiogenic and angiostatic factors Although its potential pathophysiologic role in solid tumors has been extensively studied for more than 3 decades enhancement of angiogenesis in chronic lymphocytic CLL and other malignant hematological disorders has been recognized more recently An increased level of angiogenesis has been documented by various experimental methods both in marrow and lymph nodes of patients with CLL Although the role of angiogenesis in the pathophysiology of this disease remains to be fully elucidated experimental data suggest that several angiogenic factors play a role in the disease progression Biologic markers of angiogenesis were also shown to be of prognostic relevance in CLL The current findings provide the rationale for investigating antiangiogenic agents in CLL In the current review angiogenesis in CLL is discussed and its potential diagnostic and therapeutic applications,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1056, 16, 8, 4628, 1129, 1, 217, 315, 3102, 1264, 517, 20, 747, 1886, 3472, 2068, 2, 28559, 130, 242, 211, 174, 11575, 200, 4, 537, 57, 71, 85, 3576, 656, 9, 80, 76, 27, 1968, 2461, 1, 1056, 4, 442, 1193, 552, 2, 127, 393, 2890, 1997, 71, 85, 1904, 80, 761, 35, 101, 301, 1, 1056, 71, 85, 1405, 20, 747, 1560, 636, 110, 4, 581, 2, 263, 502, 1, 7, 5, 552, 242, 3, 200, 1, 1056, 4, 3, 4320, 1, 26, 34, 469, 6, 40, 1910, 3901, 1560, 74, 309, 17, 392, 2068, 130, 1343, 8, 200, 4, 3, 34, 91, 1283, 525, 1, 1056, 11, 120, 443, 6, 40, 1, 177, 2088, 4, 552, 3, 291, 272, 377, 3, 1728, 9, 3103, 2168, 183, 4, 552, 4, 3, 291, 206, 1056, 4, 552, 16, 1588, 2, 211, 174, 752, 2, 189, 2911]",1016.0,16832815,308
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.,Cancer,Cancer,2006-09-01,"Therapeutic options are limited and the prognosis is poor for patients with fludarabine-refractory B-cell chronic lymphocytic leukemia (CLL). Bortezomib induces apoptosis in vitro in CLL cells, both alone and in combination, including in cells resistant to fludarabine or other agents. The aim of the current randomized, open-label, Phase II study was to investigate the clinical activity of bortezomib in patients with fludarabine-refractory B-cell CLL. Twenty-two patients with histologically confirmed B-cell CLL were treated with bortezomib at doses of 1.0 mg/m2, 1.3 mg/m2, or 1.5 mg/m2 on Days 1, 4, 8, and 11 of a 21-day treatment cycle for a maximum of 9 cycles. None of 19 patients evaluable for response achieved complete remission or partial response; however, signs of biologic activity based on disease site responses (e.g., reduction in lymphocytosis, splenomegaly, and lymphadenopathy) were observed. In the 1.5 mg/m2 dose group, a higher proportion of patients had stable disease, and a lower proportion had progressive disease compared with the 2 lower-dose groups. Eleven patients, all in the 2 higher dose groups, experienced Grade 3/4 adverse events (AEs) (according to National Cancer Institute Common Toxicity Criteria [version 2.0]); 2 patients experienced Grade 4 neutropenia. Grade 3 hematologic AEs included anemia, neutropenia, thrombocytopenia, and hemolytic anemia; Grade 3 nervous system AEs included aphasia; peripheral neuropathy, not otherwise specified; and peripheral sensory neuropathy. Although no objective responses were achieved in patients with fludarabine-refractory B-cell CLL, single-agent bortezomib demonstrated biologic activity. In view of the evidence for its activity, further exploration of bortezomib in combination with other agents is warranted.","Clinical Trial, Phase II",4890.0,72.0,Therapeutic options are limited and the prognosis is poor for patients with fludarabine-refractory B-cell chronic lymphocytic CLL Bortezomib induces apoptosis in vitro in CLL cells both alone and in combination including in cells resistant to fludarabine or other agents The aim of the current randomized open-label Phase II study was to investigate the clinical activity of bortezomib in patients with fludarabine-refractory B-cell CLL Twenty-two patients with histologically confirmed B-cell CLL were treated with bortezomib at doses of 1.0 mg/m2 1.3 mg/m2 or 1.5 mg/m2 on Days 1 4 8 and 11 of a 21-day treatment cycle for a maximum of 9 cycles None of 19 patients evaluable for response achieved complete remission or partial response however signs of biologic activity based on disease site responses e.g. reduction in lymphocytosis splenomegaly and lymphadenopathy were observed In the 1.5 mg/m2 dose group a higher proportion of patients had stable disease and a lower proportion had progressive disease compared with the 2 lower-dose groups Eleven patients all in the 2 higher dose groups experienced Grade 3/4 adverse events AEs according to National Cancer Institute Common Toxicity Criteria version 2.0 2 patients experienced Grade 4 neutropenia Grade 3 hematologic AEs included anemia neutropenia thrombocytopenia and hemolytic anemia Grade 3 nervous system AEs included aphasia peripheral neuropathy not otherwise specified and peripheral sensory neuropathy Although no objective responses were achieved in patients with fludarabine-refractory B-cell CLL single-agent bortezomib demonstrated biologic activity In view of the evidence for its activity further exploration of bortezomib in combination with other agents is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[189, 838, 32, 383, 2, 3, 356, 16, 334, 9, 7, 5, 2027, 430, 132, 31, 442, 1193, 552, 819, 1516, 351, 4, 439, 4, 552, 37, 110, 279, 2, 4, 150, 141, 4, 37, 436, 6, 2027, 15, 127, 183, 3, 1130, 1, 3, 291, 384, 1020, 1756, 124, 215, 45, 10, 6, 963, 3, 38, 128, 1, 819, 4, 7, 5, 2027, 430, 132, 31, 552, 737, 100, 7, 5, 2161, 557, 132, 31, 552, 11, 73, 5, 819, 28, 415, 1, 14, 13, 81, 821, 14, 27, 81, 821, 15, 14, 33, 81, 821, 23, 162, 14, 39, 66, 2, 175, 1, 8, 239, 218, 24, 417, 9, 8, 689, 1, 83, 410, 1292, 1, 326, 7, 859, 9, 51, 513, 236, 734, 15, 450, 51, 137, 3408, 1, 1283, 128, 90, 23, 34, 606, 253, 563, 499, 628, 4, 8125, 6364, 2, 4962, 11, 164, 4, 3, 14, 33, 81, 821, 61, 87, 8, 142, 920, 1, 7, 42, 585, 34, 2, 8, 280, 920, 42, 1014, 34, 72, 5, 3, 18, 280, 61, 271, 2627, 7, 62, 4, 3, 18, 142, 61, 271, 592, 88, 27, 39, 290, 281, 1477, 768, 6, 657, 12, 1377, 186, 155, 371, 2256, 18, 13, 18, 7, 592, 88, 39, 778, 88, 27, 813, 1477, 159, 1545, 778, 1340, 2, 10425, 1545, 88, 27, 1880, 398, 1477, 159, 23075, 672, 1751, 44, 2632, 3575, 2, 672, 4148, 1751, 242, 77, 461, 253, 11, 513, 4, 7, 5, 2027, 430, 132, 31, 552, 226, 420, 819, 264, 1283, 128, 4, 3811, 1, 3, 241, 9, 211, 128, 195, 3370, 1, 819, 4, 150, 5, 127, 183, 16, 1197]",1742.0,16832816,449
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.,Cancer,Cancer,2006-09-01,"Hodgkin transformation is a rare complication of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL/SLL who developed Hodgkin lymphoma (HL). An electronic database search of patients with CLL/SLL who presented at The University of Texas M. D. Anderson Cancer Center Department of Leukemia between 1975 and 2005 was performed. Among 4121 patients with CLL/SLL, 18 patients (0.4%) developed HL. Presenting features included B-symptoms (67%), lymph node enlargement (79%), splenomegaly (43%), hepatomegaly (29%), hypercalcemia (6%), infection (6%), and mental status changes (6%). The median age was 72 years (range, 49-81 years), and there was a male preponderance (78%). The median time from CLL to HL diagnosis was 4.6 years (range, 0-12.9 years). Fourteen patients (78%) had been previously treated for CLL/SLL. Ten patients (56%) had received >1 prior therapy. The median beta2-microglobulin level was 4.5 mg/L, and the median lactate dehydrogenase level was 610 IU/L. Epstein-Barr virus (EBV) was positive by in situ hybridization for EBV-encoded RNA in 3 of 4 tested patients. Fourteen patients (78%) received chemotherapy. The overall response rate was 44% (complete response rate, 19%). The median overall survival duration was 0.8 years (range, 0.03 years-6.7+ years). The median failure-free survival (FFS) duration was 0.4 years. The rates of response, survival, and FFS in patients with Hodgkin transformation of CLL/SLL were inferior to those reported in patients with de novo HL and were similar to those in patients with Richter syndrome.",Journal Article,4890.0,93.0,transformation is a rare complication of chronic lymphocytic leukemia/small lymphocytic CLL/SLL In this study the authors assessed the incidence presenting characteristics and outcomes of patients with CLL/SLL who developed HL An electronic database search of patients with CLL/SLL who presented at The University of Texas M. D. Anderson Cancer Center Department of between 1975 and 2005 was performed Among 4121 patients with CLL/SLL 18 patients 0.4 developed HL Presenting features included B-symptoms 67 lymph node enlargement 79 splenomegaly 43 hepatomegaly 29 hypercalcemia 6 infection 6 and mental status changes 6 The median age was 72 years range 49-81 years and there was a male preponderance 78 The median time from CLL to HL diagnosis was 4.6 years range 0-12.9 years Fourteen patients 78 had been previously treated for CLL/SLL Ten patients 56 had received 1 prior therapy The median beta2-microglobulin level was 4.5 mg/L and the median lactate dehydrogenase level was 610 IU/L Epstein-Barr virus EBV was positive by in situ hybridization for EBV-encoded RNA in 3 of 4 tested patients Fourteen patients 78 received chemotherapy The overall response rate was 44 complete response rate 19 The median overall survival duration was 0.8 years range 0.03 years-6.7+ years The median failure-free survival FFS duration was 0.4 years The rates of response survival and FFS in patients with transformation of CLL/SLL were inferior to those reported in patients with de novo HL and were similar to those in patients with Richter syndrome,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1392, 16, 8, 622, 1447, 1, 442, 1193, 2647, 302, 1193, 552, 5302, 4, 26, 45, 3, 738, 275, 3, 287, 1656, 374, 2, 123, 1, 7, 5, 552, 5302, 54, 276, 1718, 35, 3098, 609, 1901, 1, 7, 5, 552, 5302, 54, 917, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 4271, 1, 59, 7585, 2, 1242, 10, 173, 107, 44436, 7, 5, 552, 5302, 203, 7, 13, 39, 276, 1718, 1656, 404, 159, 132, 507, 598, 263, 289, 9738, 842, 6364, 601, 16840, 462, 6210, 49, 930, 49, 2, 3031, 156, 400, 49, 3, 52, 89, 10, 720, 60, 184, 739, 865, 60, 2, 125, 10, 8, 1045, 12531, 833, 3, 52, 98, 29, 552, 6, 1718, 147, 10, 39, 49, 60, 184, 13, 133, 83, 60, 3225, 7, 833, 42, 85, 373, 73, 9, 552, 5302, 1618, 7, 664, 42, 103, 14, 324, 36, 3, 52, 8911, 5371, 301, 10, 39, 33, 81, 805, 2, 3, 52, 3330, 2374, 301, 10, 11302, 4588, 805, 5212, 5190, 1450, 2672, 10, 109, 20, 4, 957, 1554, 9, 2672, 4587, 893, 4, 27, 1, 39, 650, 7, 3225, 7, 833, 103, 56, 3, 63, 51, 116, 10, 584, 236, 51, 116, 326, 3, 52, 63, 25, 654, 10, 13, 66, 60, 184, 13, 680, 60, 49, 67, 60, 3, 52, 496, 115, 25, 5058, 654, 10, 13, 39, 60, 3, 151, 1, 51, 25, 2, 5058, 4, 7, 5, 1392, 1, 552, 5302, 11, 1663, 6, 135, 210, 4, 7, 5, 1566, 2018, 1718, 2, 11, 288, 6, 135, 4, 7, 5, 8452, 681]",1540.0,16902984,607
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-09-01,"Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division. A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study. Twenty-seven patients (9 acute myelogenous leukemia, 5 myelodysplastic syndrome, 6 B-chronic lymphocytic leukemia, 4 mantle cell lymphoma, 1 myelofibrosis, 1 natural killer cell/T-cell leukemia, and 1 T-cell prolymphocytic leukemia) received everolimus. No dose-limiting toxicities were observed. Grade 3 potentially drug-related toxicities included hyperglycemia (22%), hypophosphatemia (7%), fatigue (7%), anorexia (4%), and diarrhea (4%). One patient developed a cutaneous leukocytoclastic vasculitis requiring a skin graft. One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration. A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration. Phosphorylation of downstream targets of mTOR, eukaryotic initiation factor 4E-binding protein 1, and/or, p70 S6 kinase, was inhibited in six of nine patient samples, including those from the patient with a major platelet response. Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with myelodysplastic syndrome. Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted.","Clinical Trial, Phase I",4890.0,262.0,Everolimus RAD001 Novartis an oral derivative of rapamycin inhibits the mammalian target of rapamycin mTOR which regulates many aspects of cell growth and division A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies Two dose levels 5 and 10 mg orally once daily continuously were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study Twenty-seven patients 9 acute myelogenous 5 syndrome 6 B-chronic lymphocytic 4 mantle cell 1 myelofibrosis 1 natural killer cell/T-cell and 1 T-cell prolymphocytic received everolimus No dose-limiting toxicities were observed Grade 3 potentially drug-related toxicities included hyperglycemia 22 hypophosphatemia 7 fatigue 7 anorexia 4 and diarrhea 4 One patient developed a cutaneous leukocytoclastic vasculitis requiring a graft One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration Phosphorylation of downstream targets of mTOR eukaryotic initiation factor 4E-binding protein 1 and/or p70 S6 kinase was inhibited in six of nine patient samples including those from the patient with a major platelet response Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with syndrome Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[1400, 7027, 7855, 35, 518, 4819, 1, 1620, 1576, 3, 2359, 283, 1, 1620, 873, 92, 2468, 445, 2695, 1, 31, 129, 2, 5750, 8, 124, 70, 215, 45, 10, 1822, 6, 223, 367, 2, 209, 1, 1400, 4, 7, 5, 591, 15, 430, 813, 441, 100, 61, 148, 33, 2, 79, 81, 1428, 1059, 391, 4285, 11, 194, 4, 3, 124, 70, 3206, 1, 26, 45, 6, 223, 3, 689, 421, 61, 1, 1400, 6, 40, 95, 4, 3, 124, 215, 45, 737, 648, 7, 83, 286, 2194, 33, 681, 49, 132, 442, 1193, 39, 2757, 31, 14, 4637, 14, 1504, 3458, 31, 102, 31, 2, 14, 102, 31, 14779, 103, 1400, 77, 61, 817, 385, 11, 164, 88, 27, 751, 234, 139, 385, 159, 3992, 350, 8021, 67, 613, 67, 3373, 39, 2, 1172, 39, 104, 69, 276, 8, 1486, 38242, 18850, 1888, 8, 1599, 104, 69, 5, 430, 1545, 5, 2612, 2438, 513, 8, 458, 1596, 51, 1, 252, 27, 811, 654, 8, 419, 69, 5, 430, 1545, 5, 2612, 2438, 224, 8, 2278, 1596, 51, 1, 243, 218, 654, 982, 1, 1489, 637, 1, 873, 8374, 1118, 161, 6726, 791, 178, 14, 2, 15, 9036, 4977, 216, 10, 879, 4, 437, 1, 762, 69, 347, 141, 135, 29, 3, 69, 5, 8, 458, 1596, 51, 1400, 16, 149, 421, 28, 8, 391, 61, 1, 79, 81, 391, 2, 68, 47, 128, 4, 7, 5, 681, 94, 1, 1400, 4, 150, 5, 189, 183, 1166, 480, 127, 1628, 1, 3, 3415, 27, 216, 649, 873, 308, 32, 1197]",1654.0,16951235,344
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.,Cancer,Cancer,2006-10-01,"Chemotherapy-related anemia is prevalent among patients with hematologic malignancies. A randomized, open-label, multicenter trial of early versus late epoetin alfa in this population was conducted, focusing on quality of life (QOL). Patients with non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, or multiple myeloma and baseline hemoglobin of 10 to 12 g/dL who were scheduled for > or = 4 months of myelosuppressive chemotherapy were randomized to receive < or = 16 weeks of epoetin alfa at a dose of 40,000 U once weekly immediately (early) or to wait and only receive epoetin alfa if hemoglobin decreased to < 9 g/dL (late). Those patients with a hemoglobin level > 12 g/dL after 3 chemotherapy cycles were not randomized. The primary endpoint was a mean change in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) total. In all, 269 patients with a hemoglobin level < or = 12 g/dL were randomized. The mean total FACT-An increased 3.84 (95% confidence interval [95% CI], 0.21-7.46) in early patients and decreased 4.37 (95% CI, -7.99 to -0.74) in late patients (P = .003). Early patients had significantly (P < .05) higher mean scores for total FACT-General; FACT-General physical and functional well-being subscales, total anemia scale, and fatigue subscale; and daily activity, energy, and important activity Linear Analog Scale Assessment scales, as well as reduced bedrest days and restricted activity days. The mean hemoglobin increased 1.2 g/dL (95% CI, 0.98-1.46) in early patients but decreased 0.2 g/dL (95% CI, -0.32-0.12) in late patients (P < .0001). Adverse events were similar between groups (with fatigue being the most prevalent); clinically relevant thromboembolic events were more common in early patients. Treating mild anemia immediately with epoetin alfa during chemotherapy for hematologic malignancy significantly improved QOL, productivity, and hemoglobin compared with delaying treatment until the hemoglobin level decreases to < 9.0 g/dL.",Journal Article,4860.0,53.0,"Chemotherapy-related anemia is prevalent among patients with hematologic malignancies A randomized open-label multicenter trial of early versus late epoetin alfa in this population was conducted focusing on quality of life QOL Patients with chronic lymphocytic or multiple and baseline hemoglobin of 10 to 12 g/dL who were scheduled for or 4 months of myelosuppressive chemotherapy were randomized to receive or 16 weeks of epoetin alfa at a dose of 40,000 U once weekly immediately early or to wait and only receive epoetin alfa if hemoglobin decreased to 9 g/dL late Those patients with a hemoglobin level 12 g/dL after 3 chemotherapy cycles were not randomized The primary endpoint was a mean change in the Functional Assessment of Cancer Therapy-Anemia FACT-An total In all 269 patients with a hemoglobin level or 12 g/dL were randomized The mean total FACT-An increased 3.84 95 confidence interval 95 CI 0.21-7.46 in early patients and decreased 4.37 95 CI -7.99 to -0.74 in late patients P .003 Early patients had significantly P .05 higher mean scores for total FACT-General FACT-General physical and functional well-being subscales total anemia scale and fatigue subscale and daily activity energy and important activity Linear Analog Scale Assessment scales as well as reduced bedrest days and restricted activity days The mean hemoglobin increased 1.2 g/dL 95 CI 0.98-1.46 in early patients but decreased 0.2 g/dL 95 CI -0.32-0.12 in late patients P .0001 Adverse events were similar between groups with fatigue being the most prevalent clinically relevant thromboembolic events were more common in early patients Treating mild anemia immediately with epoetin alfa during chemotherapy for hematologic malignancy significantly improved QOL productivity and hemoglobin compared with delaying treatment until the hemoglobin level decreases to 9.0 g/dL",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[56, 139, 1545, 16, 2485, 107, 7, 5, 813, 441, 8, 384, 1020, 1756, 1570, 160, 1, 191, 185, 807, 7305, 4443, 4, 26, 266, 10, 426, 3312, 23, 372, 1, 358, 1001, 7, 5, 442, 1193, 15, 232, 2, 330, 2222, 1, 79, 6, 133, 499, 1826, 54, 11, 4394, 9, 15, 39, 53, 1, 11109, 56, 11, 384, 6, 560, 15, 245, 244, 1, 7305, 4443, 28, 8, 61, 1, 327, 984, 1767, 1059, 709, 3467, 191, 15, 6, 7554, 2, 158, 560, 7305, 4443, 492, 2222, 340, 6, 83, 499, 1826, 807, 135, 7, 5, 8, 2222, 301, 133, 499, 1826, 50, 27, 56, 410, 11, 44, 384, 3, 86, 1138, 10, 8, 313, 707, 4, 3, 583, 455, 1, 12, 36, 1545, 1991, 35, 181, 4, 62, 8639, 7, 5, 8, 2222, 301, 15, 133, 499, 1826, 11, 384, 3, 313, 181, 1991, 35, 101, 27, 874, 48, 307, 268, 48, 58, 13, 239, 67, 641, 4, 191, 7, 2, 340, 39, 567, 48, 58, 67, 1058, 6, 13, 794, 4, 807, 7, 19, 1421, 191, 7, 42, 97, 19, 474, 142, 313, 703, 9, 181, 1991, 1083, 1991, 1083, 900, 2, 583, 149, 486, 6472, 181, 1545, 1124, 2, 613, 5593, 2, 391, 128, 2803, 2, 305, 128, 1646, 3497, 1124, 455, 5083, 22, 149, 22, 405, 55759, 162, 2, 2016, 128, 162, 3, 313, 2222, 101, 14, 18, 499, 1826, 48, 58, 13, 1096, 14, 641, 4, 191, 7, 84, 340, 13, 18, 499, 1826, 48, 58, 13, 531, 13, 133, 4, 807, 7, 19, 488, 290, 281, 11, 288, 59, 271, 5, 613, 486, 3, 96, 2485, 505, 867, 4703, 281, 11, 80, 186, 4, 191, 7, 1367, 1980, 1545, 3467, 5, 7305, 4443, 190, 56, 9, 813, 710, 97, 231, 1001, 10321, 2, 2222, 72, 5, 7151, 24, 1100, 3, 2222, 301, 2140, 6, 83, 13, 499, 1826]",1858.0,16977654,194
"Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.",Annals of internal medicine,Ann. Intern. Med.,2006-09-01,"Chronic lymphocytic leukemia is one of the most common malignant lymphoid diseases in the western world and is frequently diagnosed by internists. There have been clinically significant changes in method of diagnosis, prognostic tools, supportive care, and treatment over the past 2 decades. Most patients with chronic lymphocytic leukemia now have Rai stage 0 or I disease at diagnosis. Patients with early-stage disease are a heterogeneous group: Approximately 30% to 50% will have accelerated disease progression, and the remainder may live for decades and possibly never require therapy. Recent insights into the biological characteristics of leukemic B cells have led to the discovery of new prognostic tools (immunoglobulin variable-region heavy chain gene mutation status, cytogenetic abnormalities assessed by fluorescent in situ hybridization, and Z-chain-associated protein kinase-70 protein expression) that can identify patients with early-stage disease who are at high risk for early disease progression. These tools allow physicians to individualize counseling, follow-up, and management on the basis of disease risk. In addition, new treatments developed over the past 2 decades (purine nucleoside analogues, monoclonal antibodies, and combination chemoimmunotherapy regimens) have dramatically improved response rates and appear to prolong survival. In this review, the authors discuss the current work-up of lymphocytosis and highlight how to use recently identified prognostic tools to stratify risk in patients with newly diagnosed, early-stage chronic lymphocytic leukemia. Recommendations for patient counseling, follow-up, supportive care, and initial treatment are presented for each risk category.",Journal Article,4890.0,49.0,Chronic lymphocytic is one of the most common malignant lymphoid diseases in the western world and is frequently diagnosed by internists There have been clinically significant changes in method of diagnosis prognostic tools supportive care and treatment over the past 2 decades Most patients with chronic lymphocytic now have Rai stage 0 or I disease at diagnosis Patients with early-stage disease are a heterogeneous group Approximately 30 to 50 will have accelerated disease progression and the remainder may live for decades and possibly never require therapy Recent insights into the biological characteristics of leukemic B cells have led to the discovery of new prognostic tools immunoglobulin variable-region heavy chain gene mutation status cytogenetic abnormalities assessed by fluorescent in situ hybridization and Z-chain-associated protein kinase-70 protein expression that can identify patients with early-stage disease who are at high risk for early disease progression These tools allow physicians to individualize counseling follow-up and management on the basis of disease risk In addition new treatments developed over the past 2 decades purine nucleoside analogues monoclonal antibodies and combination chemoimmunotherapy regimens have dramatically improved response rates and appear to prolong survival In this review the authors discuss the current work-up of lymphocytosis and highlight how to use recently identified prognostic tools to stratify risk in patients with newly diagnosed early-stage chronic lymphocytic Recommendations for patient counseling follow-up supportive care and initial treatment are presented for each risk category,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 16, 104, 1, 3, 96, 186, 393, 2303, 1342, 4, 3, 1521, 1956, 2, 16, 746, 265, 20, 22383, 125, 47, 85, 505, 93, 400, 4, 596, 1, 147, 177, 1896, 1877, 165, 2, 24, 252, 3, 1219, 18, 1968, 96, 7, 5, 442, 1193, 1134, 47, 4121, 82, 13, 15, 70, 34, 28, 147, 7, 5, 191, 82, 34, 32, 8, 1564, 87, 705, 201, 6, 212, 303, 47, 2241, 34, 91, 2, 3, 7095, 68, 3812, 9, 1968, 2, 2150, 1737, 1353, 36, 435, 1957, 237, 3, 1037, 374, 1, 2015, 132, 37, 47, 836, 6, 3, 1574, 1, 217, 177, 1896, 2593, 1347, 1053, 4013, 1260, 145, 258, 156, 1266, 1171, 275, 20, 2910, 4, 957, 1554, 2, 3905, 1260, 41, 178, 216, 431, 178, 55, 17, 122, 255, 7, 5, 191, 82, 34, 54, 32, 28, 64, 43, 9, 191, 34, 91, 46, 1896, 1700, 1261, 6, 7177, 2011, 166, 126, 2, 284, 23, 3, 877, 1, 34, 43, 4, 352, 217, 640, 276, 252, 3, 1219, 18, 1968, 5006, 4032, 4768, 848, 890, 2, 150, 4438, 472, 47, 2729, 231, 51, 151, 2, 1322, 6, 3615, 25, 4, 26, 206, 3, 738, 1139, 3, 291, 1357, 126, 1, 8125, 2, 1817, 832, 6, 119, 761, 108, 177, 1896, 6, 3570, 43, 4, 7, 5, 732, 265, 191, 82, 442, 1193, 883, 9, 69, 2011, 166, 126, 1877, 165, 2, 388, 24, 32, 917, 9, 296, 43, 2169]",1662.0,16983131,358
"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.",Blood,Blood,2006-09-26,"Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic-derived schedule of administration of this agent. On the basis of pharmacokinetic modeling using our in vitro results and data from a previous trial, we initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administered weekly for 4 of 6 weeks in patients with refractory CLL. A group of 42 patients were enrolled on 3 cohorts (cohort 1, 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion; cohort 2, 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion; and cohort 3, cohort 1 dose for treatments 1 to 4, then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion). The dose-limiting toxicity using this novel schedule was hyperacute tumor lysis syndrome. Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200x10(9)/L have made this drug safe to administer at the cohort 3 dose. Of the 42 patients treated, 19 (45%) achieved a partial response with a median response duration that exceeds 12 months. Responses were noted in patients with genetically high-risk disease, including 5 (42%) of 12 patients with del(17p13.1) and 13 (72%) of 18 patients with del(11q22.3). Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL. Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases.","Clinical Trial, Phase I",4865.0,312.0,Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic CLL and other diseases previous clinical trials with this agent have been disappointing The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic-derived schedule of administration of this agent On the basis of pharmacokinetic modeling using our in vitro results and data from a previous trial we initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administered weekly for 4 of 6 weeks in patients with refractory CLL A group of 42 patients were enrolled on 3 cohorts cohort 1 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion cohort 2 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion and cohort 3 cohort 1 dose for treatments 1 to 4 then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion The dose-limiting toxicity using this novel schedule was hyperacute tumor lysis syndrome Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200x10 9 /L have made this drug safe to administer at the cohort 3 dose Of the 42 patients treated 19 45 achieved a partial response with a median response duration that exceeds 12 months Responses were noted in patients with genetically high-risk disease including 5 42 of 12 patients with del 17p13.1 and 13 72 of 18 patients with del 11q22.3 Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL Patients with bulky disease and high-risk genetic features have achieved durable responses thereby justifying further study of flavopiridol in CLL and other diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 721, 693, 94, 5, 3, 1226, 470, 216, 230, 3030, 4, 442, 1193, 552, 2, 127, 1342, 698, 38, 143, 5, 26, 420, 47, 85, 5964, 3, 1574, 1, 1777, 178, 791, 1, 3030, 4, 171, 2, 14218, 524, 3447, 6, 35, 323, 1456, 526, 1055, 1, 634, 1, 26, 420, 23, 3, 877, 1, 1456, 2057, 75, 114, 4, 439, 99, 2, 74, 29, 8, 698, 160, 21, 1917, 8, 124, 14, 45, 75, 8, 201, 3949, 4717, 61, 370, 20, 39, 1459, 1, 904, 468, 709, 9, 39, 1, 49, 244, 4, 7, 5, 430, 552, 8, 87, 1, 595, 7, 11, 346, 23, 27, 736, 180, 14, 201, 81, 821, 4717, 61, 370, 20, 201, 81, 821, 39, 2583, 904, 180, 18, 327, 81, 821, 4717, 61, 370, 20, 327, 81, 821, 39, 2583, 904, 2, 180, 27, 180, 14, 61, 9, 640, 14, 6, 39, 818, 8, 201, 81, 821, 4717, 61, 370, 20, 8, 212, 81, 821, 39, 2583, 904, 3, 61, 817, 155, 75, 26, 229, 1055, 10, 44487, 30, 4783, 681, 571, 2049, 2, 4721, 1, 7, 5, 3627, 1911, 378, 76, 55793, 83, 805, 47, 1229, 26, 234, 1165, 6, 6888, 28, 3, 180, 27, 61, 1, 3, 595, 7, 73, 326, 512, 513, 8, 450, 51, 5, 8, 52, 51, 654, 17, 9956, 133, 53, 253, 11, 1051, 4, 7, 5, 2301, 64, 43, 34, 141, 33, 595, 1, 133, 7, 5, 3084, 7526, 14, 2, 233, 720, 1, 203, 7, 5, 3084, 12647, 27, 3030, 468, 75, 26, 229, 1055, 71, 93, 38, 128, 4, 430, 552, 7, 5, 4112, 34, 2, 64, 43, 336, 404, 47, 513, 1480, 253, 2267, 13579, 195, 45, 1, 3030, 4, 552, 2, 127, 1342]",1736.0,17003373,196
"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.",Blood,Blood,2006-09-28,"Building on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and rituximab (375 mg/m2) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were high Rai risk, 71% were nonmutated for the immunoglobulin heavy-chain variable region gene, 34% were CD38+, and 34% were ZAP-70+. Thirty patients (52%) had one anomaly detected by fluorescence in situ (FISH) hybridization, and 21 (36%) had complex FISH defects. Thirty-eight patients (58%) had grade 3+ hematologic toxicity but minimal transfusion needs and no major infections. Responses occurred in 58 patients (91%), with 26 (41%) complete responses (CRs), 14 (22%) nodular partial responses (nodular PRs), and 18 (28%) partial responses (PRs). Many patients with a CR also lacked evidence of minimal residual disease by 2-color flow cytometry. Examination of prognostic factors demonstrated poor response in the 3 patients with del(17p). In contrast, we found this regimen was equally effective in young versus older (>70 years) patients and in del(11q22.3) versus other favorable prognostic factors. Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previously untreated patients with CLL demonstrated significant clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in some, and modest toxicity.","Clinical Trial, Phase II",4863.0,252.0,Building on the prior work of use of pentostatin in chronic lymphocytic CLL we initiated a trial of combined pentostatin 2 mg/m2 cyclophosphamide 600 mg/m2 and rituximab 375 mg/m2 for 65 symptomatic previously untreated patients Of 64 evaluable patients 34 53 were high Rai risk 71 were nonmutated for the immunoglobulin heavy-chain variable region gene 34 were CD38+ and 34 were ZAP-70+ Thirty patients 52 had one anomaly detected by fluorescence in situ FISH hybridization and 21 36 had complex FISH defects Thirty-eight patients 58 had grade 3+ hematologic toxicity but minimal transfusion needs and no major infections Responses occurred in 58 patients 91 with 26 41 complete responses CRs 14 22 nodular partial responses nodular PRs and 18 28 partial responses PRs Many patients with a CR also lacked evidence of minimal residual disease by 2-color flow cytometry Examination of prognostic factors demonstrated poor response in the 3 patients with del 17p In contrast we found this regimen was equally effective in young versus older 70 years patients and in del 11q22.3 versus other favorable prognostic factors Thus this novel regimen of pentostatin cyclophosphamide and rituximab for previously untreated patients with CLL demonstrated significant clinical activity despite poor risk-based prognoses achievement of minimal residual disease in some and modest toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5808, 23, 3, 324, 1357, 1, 119, 1, 7596, 4, 442, 1193, 552, 21, 1917, 8, 160, 1, 397, 7596, 18, 81, 821, 1112, 2383, 81, 821, 2, 855, 4175, 81, 821, 9, 556, 1704, 373, 1278, 7, 1, 660, 859, 7, 562, 699, 11, 64, 4121, 43, 792, 11, 17210, 9, 3, 2593, 4013, 1260, 1347, 1053, 145, 562, 11, 4469, 2, 562, 11, 6251, 431, 977, 7, 653, 42, 104, 17085, 530, 20, 1591, 4, 957, 1277, 1554, 2, 239, 511, 42, 840, 1277, 2945, 977, 659, 7, 717, 42, 88, 27, 813, 155, 84, 1048, 2785, 1891, 2, 77, 458, 1875, 253, 489, 4, 717, 7, 970, 5, 432, 605, 236, 253, 3115, 213, 350, 4481, 450, 253, 4481, 4018, 2, 203, 339, 450, 253, 4018, 445, 7, 5, 8, 684, 120, 5005, 241, 1, 1048, 753, 34, 20, 18, 6052, 1412, 1914, 1385, 1, 177, 130, 264, 334, 51, 4, 3, 27, 7, 5, 3084, 4135, 4, 748, 21, 204, 26, 477, 10, 4142, 323, 4, 1169, 185, 434, 431, 60, 7, 2, 4, 3084, 12647, 27, 185, 127, 913, 177, 130, 631, 26, 229, 477, 1, 7596, 1112, 2, 855, 9, 373, 1278, 7, 5, 552, 264, 93, 38, 128, 550, 334, 43, 90, 5362, 5088, 1, 1048, 753, 34, 4, 476, 2, 1721, 155]",1375.0,17008537,99
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-10-01,"Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease. There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH. Between 1994 and 2002, we enrolled 159 patients with previously untreated CLL (83% Rai stage 0/I) on a prospective trial evaluating clonal evolution by FISH. Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years. Chromosomal abnormalities detected by FISH at study entry predicted overall survival. Eighteen patients experienced clonal evolution during follow-up. The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years (n = 71; 1.4%) but 17 occurrences (n = 63; 27%) among patients tested after 5+ years. Clonal evolution occurred among 10% of ZAP-70-negative and 42% of ZAP-70-positive patients at 5+ years (P = .008). This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease. Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution. These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL.",Journal Article,4860.0,196.0,Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization FISH can identify patients with chronic lymphocytic CLL who will experience a more aggressive disease course Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH Between 1994 and 2002 we enrolled 159 patients with previously untreated CLL 83 Rai stage 0/I on a prospective trial evaluating clonal evolution by FISH Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years Chromosomal abnormalities detected by FISH at study entry predicted overall survival Eighteen patients experienced clonal evolution during follow-up The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years n 71 1.4 but 17 occurrences n 63 27 among patients tested after 5+ years Clonal evolution occurred among 10 of ZAP-70-negative and 42 of ZAP-70-positive patients at 5+ years P .008 This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis but also suggests that many patients acquire new abnormalities during the course of their disease Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution These findings have important implications for both clinical management and trials of early treatment for patients with high-risk early-stage CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[459, 94, 309, 1266, 1171, 530, 20, 8081, 2910, 4, 957, 1554, 1277, 122, 255, 7, 5, 442, 1193, 552, 54, 303, 730, 8, 80, 571, 34, 906, 127, 94, 309, 17, 7, 68, 6206, 1170, 1171, 190, 3, 906, 1, 136, 34, 125, 32, 1048, 482, 74, 23, 3, 38, 1207, 1, 3, 1792, 95, 4466, 1277, 177, 1996, 4, 7, 5, 732, 265, 191, 82, 552, 15, 3, 675, 1, 1946, 2554, 22, 509, 20, 8081, 1277, 59, 3023, 2, 1544, 21, 346, 5917, 7, 5, 373, 1278, 552, 852, 4121, 82, 13, 70, 23, 8, 482, 160, 1435, 1946, 2554, 20, 1277, 7, 1052, 330, 2, 166, 126, 623, 9, 1277, 471, 190, 18, 6, 133, 60, 1860, 1171, 530, 20, 1277, 28, 45, 3001, 783, 63, 25, 3195, 7, 592, 1946, 2554, 190, 166, 126, 3, 116, 1, 1946, 2554, 101, 5, 654, 1, 166, 126, 5, 158, 104, 2291, 4, 3, 157, 18, 60, 78, 792, 14, 39, 84, 269, 8781, 78, 676, 428, 107, 7, 650, 50, 33, 60, 1946, 2554, 489, 107, 79, 1, 6251, 431, 199, 2, 595, 1, 6251, 431, 109, 7, 28, 33, 60, 19, 2155, 26, 38, 160, 5120, 1143, 17, 1266, 1171, 530, 20, 1277, 122, 678, 63, 25, 9, 552, 7, 28, 3, 98, 1, 147, 84, 120, 844, 17, 445, 7, 6206, 217, 1171, 190, 3, 906, 1, 136, 34, 7, 5, 142, 6251, 431, 55, 68, 40, 80, 322, 6, 730, 225, 1946, 2554, 46, 272, 47, 305, 1268, 9, 110, 38, 284, 2, 143, 1, 191, 24, 9, 7, 5, 64, 43, 191, 82, 552]",1750.0,17008705,151
Monoclonal antibodies in chronic lymphocytic leukemia.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2006-09-01,"Multiple options are now available for the treatment of chronic lymphocytic leukemia. Over the last 10 years, monoclonal antibodies have become an integral part of the management of this disease. Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic leukemia. Rituximab has been investigated extensively in chronic lymphocytic leukemia both as a single agent and in combination with chemotherapy and other monoclonal antibodies. Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development. This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic leukemia, the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy, and other biological agents and newer compounds undergoing clinical trials.",Journal Article,4890.0,4.0,Multiple options are now available for the treatment of chronic lymphocytic Over the last 10 years monoclonal antibodies have become an integral part of the management of this disease Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic Rituximab has been investigated extensively in chronic lymphocytic both as a single agent and in combination with chemotherapy and other monoclonal antibodies Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy and other biological agents and newer compounds undergoing clinical trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[232, 838, 32, 1134, 390, 9, 3, 24, 1, 442, 1193, 252, 3, 1060, 79, 60, 848, 890, 47, 1417, 35, 4450, 760, 1, 3, 284, 1, 26, 34, 3579, 71, 103, 1814, 9, 119, 4, 7, 5, 2027, 430, 442, 1193, 855, 71, 85, 565, 3576, 4, 442, 1193, 110, 22, 8, 226, 420, 2, 4, 150, 5, 56, 2, 127, 848, 890, 14801, 2, 16443, 32, 2246, 848, 890, 4, 3, 191, 124, 1, 38, 193, 26, 946, 303, 206, 3, 848, 890, 80, 841, 95, 6, 943, 442, 1193, 3, 99, 683, 5, 848, 890, 22, 226, 183, 2, 4, 150, 5, 56, 2, 127, 1037, 183, 2, 2246, 2411, 479, 38, 143]",823.0,17020457,309
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-10-01,"Preclinical studies suggested that bryostatin 1 might potentiate the therapeutic effects of fludarabine in the treatment of hematologic malignancies. We undertook a phase I study to identify appropriate schedules and doses of bryostatin 1 and fludarabine to be used in phase II studies. Patients with chronic lymphocytic leukemia (CLL) or indolent lymphoma received fludarabine daily for 5 days and a single dose of bryostatin 1 via a 24-hour continuous infusion either before or after the fludarabine course. Doses were escalated in successive patients until recommended phase II doses for each sequence were identified on the basis of dose-limiting toxic events. Bryostatin 1 can be administered safely and tolerably with full dose fludarabine (25 mg/m(2)/d x 5). The recommended bryostatin 1 phase II dose is 50 microg/m(2) for both sequences, bryostatin 1 --> fludarabine and fludarabine --> bryostatin 1. The combination is active against both CLL and indolent lymphomas with responses seen in patients who had been previously treated with fludarabine. Correlative studies do not support the hypothesis that bryostatin 1 potentiates fludarabine activity through down-regulation of protein kinase C in target cells. Bryostatin 1 can be administered with full dose fludarabine, and the combination is moderately active in patients with persistent disease following prior treatment. In view of the activity of monoclonal antibodies such as the anti-CD20 monoclonal antibody rituximab in the treatment of CLL and indolent lymphomas, the concept of combining bryostatin 1 and fludarabine with rituximab warrants future consideration.","Clinical Trial, Phase I",4860.0,40.0,Preclinical studies suggested that bryostatin 1 might potentiate the therapeutic effects of fludarabine in the treatment of hematologic malignancies We undertook a phase I study to identify appropriate schedules and doses of bryostatin 1 and fludarabine to be used in phase II studies Patients with chronic lymphocytic CLL or indolent received fludarabine daily for 5 days and a single dose of bryostatin 1 via a 24-hour continuous infusion either before or after the fludarabine course Doses were escalated in successive patients until recommended phase II doses for each sequence were identified on the basis of dose-limiting toxic events Bryostatin 1 can be administered safely and tolerably with full dose fludarabine 25 mg/m 2 /d x 5 The recommended bryostatin 1 phase II dose is 50 microg/m 2 for both sequences bryostatin 1 -- fludarabine and fludarabine -- bryostatin 1 The combination is active against both CLL and indolent lymphomas with responses seen in patients who had been previously treated with fludarabine Correlative studies do not support the hypothesis that bryostatin 1 potentiates fludarabine activity through down-regulation of protein kinase C in target cells Bryostatin 1 can be administered with full dose fludarabine and the combination is moderately active in patients with persistent disease following prior treatment In view of the activity of monoclonal antibodies such as the anti-CD20 monoclonal antibody rituximab in the treatment of CLL and indolent lymphomas the concept of combining bryostatin 1 and fludarabine with rituximab warrants future consideration,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[693, 94, 1148, 17, 6574, 14, 822, 6428, 3, 189, 176, 1, 2027, 4, 3, 24, 1, 813, 441, 21, 5418, 8, 124, 70, 45, 6, 255, 870, 2314, 2, 415, 1, 6574, 14, 2, 2027, 6, 40, 95, 4, 124, 215, 94, 7, 5, 442, 1193, 552, 15, 2316, 103, 2027, 391, 9, 33, 162, 2, 8, 226, 61, 1, 6574, 14, 847, 8, 259, 2583, 1314, 904, 361, 348, 15, 50, 3, 2027, 906, 415, 11, 2842, 4, 6808, 7, 1100, 793, 124, 215, 415, 9, 296, 1532, 11, 108, 23, 3, 877, 1, 61, 817, 1812, 281, 6574, 14, 122, 40, 468, 2268, 2, 44494, 5, 1647, 61, 2027, 243, 81, 188, 18, 427, 1006, 33, 3, 793, 6574, 14, 124, 215, 61, 16, 212, 2440, 188, 18, 9, 110, 2866, 6574, 14, 2027, 2, 2027, 6574, 14, 3, 150, 16, 544, 480, 110, 552, 2, 2316, 1557, 5, 253, 527, 4, 7, 54, 42, 85, 373, 73, 5, 2027, 3679, 94, 1022, 44, 538, 3, 1492, 17, 6574, 14, 8091, 2027, 128, 298, 1328, 863, 1, 178, 216, 256, 4, 283, 37, 6574, 14, 122, 40, 468, 5, 1647, 61, 2027, 2, 3, 150, 16, 3508, 544, 4, 7, 5, 1882, 34, 366, 324, 24, 4, 3811, 1, 3, 128, 1, 848, 890, 225, 22, 3, 312, 2198, 848, 548, 855, 4, 3, 24, 1, 552, 2, 2316, 1557, 3, 2545, 1, 1525, 6574, 14, 2, 2027, 5, 855, 2782, 508, 2415]",1595.0,17020988,145
Update on risk-stratified management for chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2006-09-01,"Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions. CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis. Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy. Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative. The treatment of relapsed and refractory CLL is less successful. However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients. Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy. The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research.",Journal Article,4890.0,22.0,Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic CLL have improved clinical evaluation and influenced treatment decisions CLL can be diagnosed early and accurately and biological measurements can be used to predict a prognosis at diagnosis Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative The treatment of relapsed and refractory CLL is less successful However recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways and active and passive immunotherapy The management of CLL is in a dynamic phase of rapid evolution Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[458, 435, 954, 4, 612, 3, 891, 1, 442, 1193, 2647, 302, 1193, 552, 47, 231, 38, 451, 2, 2574, 24, 1526, 552, 122, 40, 265, 191, 2, 2141, 2, 1037, 1685, 122, 40, 95, 6, 678, 8, 356, 28, 147, 797, 69, 165, 122, 40, 43, 1173, 6, 2465, 247, 2, 3241, 521, 1, 36, 5006, 4063, 2, 848, 890, 47, 2195, 231, 3, 209, 1, 388, 36, 84, 32, 44, 1075, 3, 24, 1, 591, 2, 430, 552, 16, 299, 1401, 137, 435, 3703, 309, 17, 1063, 452, 31, 941, 359, 47, 8, 1077, 200, 4, 8, 715, 87, 1, 46, 7, 174, 217, 24, 1558, 643, 238, 1598, 17, 15870, 825, 1628, 1, 552, 31, 25, 460, 2, 544, 2, 6422, 726, 3, 284, 1, 552, 16, 4, 8, 2540, 124, 1, 1321, 2554, 43, 1541, 75, 1037, 177, 525, 122, 401, 291, 69, 165, 2, 1196, 508, 38, 389]",1060.0,17064983,687
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2006-11-01,"Treatment of chronic lymphocytic leukemia (CLL) patients with standard dose infusion of rituximab (RTX), 375 mg/m2, induces clearance of malignant cells from peripheral blood after infusion of 30 mg of RTX. After completion of the full RTX infusion, substantial recrudescence of CLL cells occurs, and these cells have lost > 90% of CD20. To gain insight into mechanism(s) of CD20 loss, we investigated the hypothesis that thrice-weekly low-dose RTX (20 or 60 mg/m2) treatment for CLL over 4 wk would preserve CD20 and enhance leukemic cell clearance. During initial infusions in all 12 patients, the first 30 mg of RTX promoted clearance of > 75% leukemic cells. Four of six patients receiving 20 mg/m2 RTX retained > or = 50% CD20, and additional RTX infusions promoted further cell clearance. However, four of six patients receiving 60 mg/m2 had CD20 levels < 20% baseline 2 days after initial infusions, and additional RTX infusions were less effective, presumably due to epitope loss. Our results suggest that when a threshold RTX dose is exceeded, recrudesced RTX-opsonized cells are not cleared, due to saturation of the mononuclear phagocytic system, but instead are shaved of RTX-CD20 complexes by acceptor cells. Thrice-weekly low-dose RTX may promote enhanced clearance of circulating CLL cells by preserving CD20.",Journal Article,4829.0,106.0,Treatment of chronic lymphocytic CLL patients with standard dose infusion of rituximab RTX 375 mg/m2 induces clearance of malignant cells from peripheral blood after infusion of 30 mg of RTX After completion of the full RTX infusion substantial recrudescence of CLL cells occurs and these cells have lost 90 of CD20 To gain insight into mechanism s of CD20 loss we investigated the hypothesis that thrice-weekly low-dose RTX 20 or 60 mg/m2 treatment for CLL over 4 wk would preserve CD20 and enhance leukemic cell clearance During initial infusions in all 12 patients the first 30 mg of RTX promoted clearance of 75 leukemic cells Four of six patients receiving 20 mg/m2 RTX retained or 50 CD20 and additional RTX infusions promoted further cell clearance However four of six patients receiving 60 mg/m2 had CD20 levels 20 baseline 2 days after initial infusions and additional RTX infusions were less effective presumably due to epitope loss Our results suggest that when a threshold RTX dose is exceeded recrudesced RTX-opsonized cells are not cleared due to saturation of the mononuclear phagocytic system but instead are shaved of RTX-CD20 complexes by acceptor cells Thrice-weekly low-dose RTX may promote enhanced clearance of circulating CLL cells by preserving CD20,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[24, 1, 442, 1193, 552, 7, 5, 260, 61, 904, 1, 855, 10916, 4175, 81, 821, 1516, 1960, 1, 393, 37, 29, 672, 315, 50, 904, 1, 201, 81, 1, 10916, 50, 1438, 1, 3, 1647, 10916, 904, 1281, 44527, 1, 552, 37, 1780, 2, 46, 37, 47, 3009, 424, 1, 2198, 6, 1803, 2670, 237, 670, 695, 1, 2198, 407, 21, 565, 3, 1492, 17, 10058, 709, 154, 61, 10916, 179, 15, 335, 81, 821, 24, 9, 552, 252, 39, 3293, 688, 6783, 2198, 2, 1304, 2015, 31, 1960, 190, 388, 3435, 4, 62, 133, 7, 3, 157, 201, 81, 1, 10916, 2992, 1960, 1, 481, 2015, 37, 294, 1, 437, 7, 357, 179, 81, 821, 10916, 3532, 15, 212, 2198, 2, 402, 10916, 3435, 2992, 195, 31, 1960, 137, 294, 1, 437, 7, 357, 335, 81, 821, 42, 2198, 148, 179, 330, 18, 162, 50, 388, 3435, 2, 402, 10916, 3435, 11, 299, 323, 8682, 520, 6, 4430, 407, 114, 99, 309, 17, 198, 8, 2390, 10916, 61, 16, 4726, 55875, 10916, 22192, 37, 32, 44, 9266, 520, 6, 7506, 1, 3, 3041, 19415, 398, 84, 3496, 32, 17349, 1, 10916, 2198, 3817, 20, 19680, 37, 10058, 709, 154, 61, 10916, 68, 1617, 651, 1960, 1, 1033, 552, 37, 20, 4972, 2198]",1273.0,17082663,83
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2006-10-01,"Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear. In this analysis, we report the outcomes of 46 patients with advanced CLL who underwent nonmyeloablative stem cell transplantation (NST) from HLA-matched unrelated (67%) or related (33%) donors. Fludarabine (30 mg/m2 x 4) and low-dose intravenous busulfan (0.8 mg/kg/day x 4) were used for conditioning. The 2-year overall survival (OS) and progression-free survival (PFS) rates in this refractory patient population were 54% and 34%, respectively, with a median follow-up of 20 months. The primary cause of treatment failure was relapse, with a 2-year cumulative incidence of 48%. High hematopoietic donor chimerism > or = 75% at day +30 was a significant predictor of 2-year PFS (47% vs 11%; P = .03). In multivariate analysis, chemotherapy-refractory disease at transplantation was associated with a 3.2-fold risk of progression (P = .01) and a 4.6-fold risk of death (P = .02). Increasing number of previous therapies and increasing bone marrow involvement were also associated with decreased PFS and OS. These results suggest that NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients.",Journal Article,4860.0,92.0,Although chronic lymphocytic CLL remains an incurable disease with standard chemotherapy the appropriate role and timing of transplantation are unclear In this analysis we report the outcomes of 46 patients with advanced CLL who underwent nonmyeloablative stem cell transplantation NST from HLA-matched unrelated 67 or related 33 donors Fludarabine 30 mg/m2 x 4 and low-dose intravenous busulfan 0.8 mg/kg/day x 4 were used for conditioning The 2-year overall survival OS and progression-free survival PFS rates in this refractory patient population were 54 and 34 respectively with a median follow-up of 20 months The primary cause of treatment failure was relapse with a 2-year cumulative incidence of 48 High hematopoietic donor chimerism or 75 at day +30 was a significant predictor of 2-year PFS 47 vs 11 P .03 In multivariate analysis chemotherapy-refractory disease at transplantation was associated with a 3.2-fold risk of progression P .01 and a 4.6-fold risk of death P .02 Increasing number of previous therapies and increasing marrow involvement were also associated with decreased PFS and OS These results suggest that NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 442, 1193, 552, 469, 35, 2641, 34, 5, 260, 56, 3, 870, 200, 2, 1972, 1, 497, 32, 1200, 4, 26, 65, 21, 414, 3, 123, 1, 641, 7, 5, 131, 552, 54, 208, 6094, 452, 31, 497, 5976, 29, 1160, 655, 2092, 598, 15, 139, 466, 2344, 2027, 201, 81, 821, 1006, 39, 2, 154, 61, 1262, 3906, 13, 66, 81, 503, 218, 1006, 39, 11, 95, 9, 1933, 3, 18, 111, 63, 25, 118, 2, 91, 115, 25, 300, 151, 4, 26, 430, 69, 266, 11, 667, 2, 562, 106, 5, 8, 52, 166, 126, 1, 179, 53, 3, 86, 708, 1, 24, 496, 10, 429, 5, 8, 18, 111, 967, 287, 1, 576, 64, 1007, 1488, 6047, 15, 481, 28, 218, 201, 10, 8, 93, 980, 1, 18, 111, 300, 662, 105, 175, 19, 680, 4, 331, 65, 56, 430, 34, 28, 497, 10, 41, 5, 8, 27, 18, 1116, 43, 1, 91, 19, 355, 2, 8, 39, 49, 1116, 43, 1, 273, 19, 588, 602, 207, 1, 698, 235, 2, 602, 581, 799, 11, 120, 41, 5, 340, 300, 2, 118, 46, 99, 309, 17, 5976, 75, 2027, 2, 154, 61, 1262, 3906, 16, 8, 3203, 24, 1501, 9, 7, 5, 131, 552, 84, 17, 5976, 1677, 4, 3, 34, 906, 303, 322, 40, 575, 6, 1359, 319, 337, 34, 182, 4, 8, 64, 920, 1, 7]",1386.0,17084369,230
Alemtuzumab in CLL and other lymphoid neoplasms.,Cancer investigation,Cancer Invest.,2006-11-01,"The recent success of monoclonal antibodies in the treatment of various hematological and nonhematological cancers is the result of several decades of research in immune therapy of cancer. The identification of cancer-specific surface markers has led to the development of numerous monoclonal antibodies directed at these antigens, which have been associated with variable success in treating patients with different malignancies. Alemtuzumab, one such monoclonal antibody, is a humanized antibody directed against CD52. The target antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of malignant lymphoid cells, but not on hematopoietic progenitor cells. A number of clinical trials have demonstrated the clinical activity of alemtuzumab in chronic lymphocytic leukemia (CLL), T-cell malignancies such as T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma (CTCL), and have examined its role as an immunosuppressive agent in transplantation and for the treatment of autoimmune disorders. Effective antibiotic prophylaxis can limit the incidence of infections, which are the major side effect associated with the profound lymphopenia occurring as a result of treatment with this agent.",Journal Article,4829.0,24.0,The recent success of monoclonal antibodies in the treatment of various hematological and nonhematological cancers is the result of several decades of research in immune therapy of cancer The identification of cancer-specific surface markers has led to the development of numerous monoclonal antibodies directed at these antigens which have been associated with variable success in treating patients with different malignancies Alemtuzumab one such monoclonal antibody is a humanized antibody directed against CD52 The target antigen is a small glycosylphosphatidylinositol GPI -anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of malignant lymphoid cells but not on hematopoietic progenitor cells A number of clinical trials have demonstrated the clinical activity of alemtuzumab in chronic lymphocytic CLL T-cell malignancies such as T-prolymphocytic T-PLL and cutaneous T-cell CTCL and have examined its role as an immunosuppressive agent in transplantation and for the treatment of autoimmune disorders Effective antibiotic prophylaxis can limit the incidence of infections which are the major side effect associated with the profound lymphopenia occurring as a result of treatment with this agent,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 435, 1825, 1, 848, 890, 4, 3, 24, 1, 747, 2890, 2, 12494, 163, 16, 3, 757, 1, 392, 1968, 1, 389, 4, 250, 36, 1, 12, 3, 911, 1, 12, 112, 1255, 525, 71, 836, 6, 3, 193, 1, 2331, 848, 890, 1166, 28, 46, 1575, 92, 47, 85, 41, 5, 1347, 1825, 4, 1367, 7, 5, 338, 441, 3579, 104, 225, 848, 548, 16, 8, 3619, 548, 1166, 480, 7189, 3, 283, 448, 16, 8, 302, 37352, 10344, 15268, 4455, 17, 16, 561, 570, 23, 295, 102, 2, 132, 1594, 2, 23, 8, 375, 920, 1, 393, 2303, 37, 84, 44, 23, 1007, 2520, 37, 8, 207, 1, 38, 143, 47, 264, 3, 38, 128, 1, 3579, 4, 442, 1193, 552, 102, 31, 441, 225, 22, 102, 14779, 102, 10555, 2, 1486, 102, 31, 4742, 2, 47, 409, 211, 200, 22, 35, 2989, 420, 4, 497, 2, 9, 3, 24, 1, 3445, 1997, 323, 5210, 2049, 122, 2385, 3, 287, 1, 1875, 92, 32, 3, 458, 1152, 254, 41, 5, 3, 4399, 3655, 1821, 22, 8, 757, 1, 24, 5, 26, 420]",1256.0,17118783,116
Current and investigational therapies for patients with CLL.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2006-01-01,Clinical and laboratory investigations are driving the rapid change in treatments for patients with chronic lymphocytic leukemia (CLL). Randomized trials have demonstrated superior activity for fludarabine combined with cyclophosphamide versus single-agent fludarabine or chlorambucil as initial treatment. Chemoimmunotherapy holds promise for further improvement and is being tested in randomized trials. New combinations and agents are being identified and tested. Eliminating minimal residual disease is a therapeutic endpoint that may prove to prolong survival and is also under investigation in prospective clinical trials. Work continues toward improving survival and potentially curing patients of this disease.,Journal Article,5133.0,12.0,Clinical and laboratory investigations are driving the rapid change in treatments for patients with chronic lymphocytic CLL Randomized trials have demonstrated superior activity for fludarabine combined with cyclophosphamide versus single-agent fludarabine or chlorambucil as initial treatment Chemoimmunotherapy holds promise for further improvement and is being tested in randomized trials New combinations and agents are being identified and tested Eliminating minimal residual disease is a therapeutic endpoint that may prove to prolong survival and is also under investigation in prospective clinical trials Work continues toward improving survival and potentially curing patients of this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[38, 2, 1624, 2492, 32, 4057, 3, 1321, 707, 4, 640, 9, 7, 5, 442, 1193, 552, 384, 143, 47, 264, 1123, 128, 9, 2027, 397, 5, 1112, 185, 226, 420, 2027, 15, 11585, 22, 388, 24, 4438, 5253, 1783, 9, 195, 767, 2, 16, 486, 650, 4, 384, 143, 217, 1247, 2, 183, 32, 486, 108, 2, 650, 6923, 1048, 753, 34, 16, 8, 189, 1138, 17, 68, 4361, 6, 3615, 25, 2, 16, 120, 669, 940, 4, 482, 38, 143, 1357, 2274, 1317, 1673, 25, 2, 751, 12775, 7, 1, 26, 34]",701.0,17124074,51
Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2006-01-01,"Autologous stem-cell transplantation is widely accepted as effective therapy for patients with relapsed aggressive B-cell non-Hodgkin lymphomas. Although 40-60% of younger patients with diffuse large cell lymphoma can expect to be cured, substantial numbers will experience a relapse. In addition, certain histologic subtypes are associated with particularly poor prognoses with combination chemotherapy alone (e.g., mantle cell lymphoma). Relatively few of these patients will experience long-term responses. Although other NHL subtypes are associated with more favorable prognoses in terms of overall survival, they are rarely cured (e.g., follicular lymphoma, chronic lymphocytic leukemia). Allogeneic transplantation has been increasingly utilized in patients with lymphoid malignancies but is associated with high toxicity. Recently, reduced-intensity conditioning regimens have shown encouraging results, attributed to graft-versus-lymphoma effects. This article discusses changes in the way autologous and allogeneic transplants may be carried out in the future to treat patients with lymphoid malignancies.",Journal Article,5133.0,47.0,Autologous stem-cell transplantation is widely accepted as effective therapy for patients with relapsed aggressive B-cell lymphomas Although 40-60 of younger patients with diffuse large cell can expect to be cured substantial numbers will experience a relapse In addition certain histologic subtypes are associated with particularly poor prognoses with combination chemotherapy alone e.g. mantle cell Relatively few of these patients will experience long-term responses Although other NHL subtypes are associated with more favorable prognoses in terms of overall survival they are rarely cured e.g. follicular chronic lymphocytic Allogeneic transplantation has been increasingly utilized in patients with lymphoid malignancies but is associated with high toxicity Recently reduced-intensity conditioning regimens have shown encouraging results attributed to graft-versus-lymphoma effects This article discusses changes in the way autologous and allogeneic transplants may be carried out in the future to treat patients with lymphoid malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1028, 452, 31, 497, 16, 1792, 3058, 22, 323, 36, 9, 7, 5, 591, 571, 132, 31, 1557, 242, 327, 335, 1, 773, 7, 5, 1388, 375, 31, 122, 8439, 6, 40, 3733, 1281, 1870, 303, 730, 8, 429, 4, 352, 1840, 884, 814, 32, 41, 5, 823, 334, 5362, 5, 150, 56, 279, 563, 499, 2757, 31, 1352, 1021, 1, 46, 7, 303, 730, 319, 337, 253, 242, 127, 1176, 814, 32, 41, 5, 80, 913, 5362, 4, 1794, 1, 63, 25, 491, 32, 2416, 3733, 563, 499, 1974, 442, 1193, 1063, 497, 71, 85, 1635, 2080, 4, 7, 5, 2303, 441, 84, 16, 41, 5, 64, 155, 761, 405, 837, 1933, 472, 47, 443, 2269, 99, 3073, 6, 1599, 185, 4763, 176, 26, 946, 2759, 400, 4, 3, 2255, 1028, 2, 1063, 4016, 68, 40, 2629, 1205, 4, 3, 508, 6, 943, 7, 5, 2303, 441]",1045.0,17124088,249
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-12-01,"CD52 is a GPI-linked glycoprotein expressed by B cells, T cells, monocytes, and macrophages. The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed. We evaluated 294 hematologic neoplasms for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin, B-Plus, Zenker's acetic acid, or B5-formalin. The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52. In addition, we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen. In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52. In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified. Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression. In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.",Journal Article,4799.0,102.0,CD52 is a GPI-linked glycoprotein expressed by B cells T cells monocytes and macrophages The humanized monoclonal antibody alemtuzumab CAMPATH-1H is specific for CD52 and is Food and Drug Administration approved for the treatment of relapsed or refractory chronic lymphocytic CLL The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored however a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed We evaluated 294 hematologic neoplasms for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin B-Plus Zenker 's acetic acid or B5-formalin The vast majority of low-grade B cell lymphoproliferative disorders CLL/small lymphocytic follicular lymphoplasmacytic hairy cell and mucosa-associated lymphoid tissue lymphomas express CD52 In addition we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen In contrast there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas with 25 of cases of diffuse large B cell and demonstrating no detectable CD52 In addition the majority of neoplasms of the T cell lineage are negative for the antigen including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma anaplastic large cell and peripheral T cell not otherwise specified Finally the vast majority of cases of acute myeloid and multiple are negative for CD52 expression In contrast with CLL the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[7189, 16, 8, 10344, 1199, 4455, 570, 20, 132, 37, 102, 37, 5078, 2, 2748, 3, 3619, 848, 548, 3579, 16622, 10147, 16, 112, 9, 7189, 2, 16, 1773, 2, 234, 634, 850, 9, 3, 24, 1, 591, 15, 430, 442, 1193, 552, 3, 1207, 1, 16622, 4, 3, 24, 1, 127, 813, 1179, 71, 85, 1443, 137, 8, 949, 1407, 1, 7189, 55, 107, 8, 2094, 1873, 1, 54, 395, 30, 630, 71, 44, 85, 781, 21, 194, 8375, 813, 1179, 9, 3, 463, 1, 7189, 75, 260, 1382, 1092, 23, 2487, 2505, 411, 623, 1959, 5, 3265, 132, 349, 55915, 292, 16812, 971, 15, 28617, 3265, 3, 4337, 686, 1, 154, 88, 132, 31, 4192, 1997, 552, 302, 1193, 1974, 5325, 7152, 31, 2, 2713, 41, 2303, 246, 1557, 1669, 7189, 4, 352, 21, 204, 17, 3, 686, 1, 2765, 132, 31, 286, 1275, 2647, 1557, 1669, 26, 448, 4, 748, 125, 16, 14157, 1144, 4, 7189, 55, 107, 80, 571, 132, 31, 1557, 5, 243, 1, 140, 1, 1388, 375, 132, 31, 2, 2219, 77, 2083, 7189, 4, 352, 3, 686, 1, 1179, 1, 3, 102, 31, 2542, 32, 199, 9, 3, 448, 141, 96, 140, 1, 2765, 102, 31, 286, 1275, 2647, 4763, 1841, 375, 31, 2, 672, 102, 31, 44, 2632, 3575, 1368, 3, 4337, 686, 1, 140, 1, 286, 533, 2, 232, 32, 199, 9, 7189, 55, 4, 748, 5, 552, 3, 1347, 55, 1, 7189, 107, 127, 813, 441, 844, 17, 283, 929, 23, 8, 473, 20, 473, 877, 303, 322, 40, 1493, 6, 1597, 3, 2696, 65, 1, 16622, 36]",1750.0,17145843,61
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.,Molecular cancer therapeutics,Mol. Cancer Ther.,2006-12-01,"The chemokine receptor CXCR4 mediates the migration of hematopoietic cells to the stroma-derived factor 1alpha (SDF-1alpha)-producing bone marrow microenvironment. Using peptide-based CXCR4 inhibitors derived from the chemokine viral macrophage inflammatory protein II, we tested the hypothesis that the inhibition of CXCR4 increases sensitivity to chemotherapy by interfering with stromal/leukemia cell interactions. First, leukemic cells expressing varying amounts of surface CXCR4 were examined for their chemotactic response to SDF-1alpha or stromal cells, alone or in the presence of different CXCR4 inhibitors. Results showed that the polypeptide RCP168 had the strongest antagonistic effect on the SDF-1alpha- or stromal cell-induced chemotaxis of leukemic cells. Furthermore, RCP168 blocked the binding of anti-CXCR4 monoclonal antibody 12G5 to surface CXCR4 in a concentration-dependent manner and inhibited SDF-1alpha-induced AKT and extracellular signal-regulated kinase phosphorylation. Finally, RCP168 significantly enhanced chemotherapy-induced apoptosis in stroma-cocultured Jurkat, primary chronic lymphocytic leukemia, and in a subset of acute myelogenous leukemia cells harboring Flt3 mutation. Equivalent results were obtained with the small-molecule CXCR4 inhibitor AMD3465. Our data therefore suggest that the SDF-1alpha/CXCR4 interaction contributes to the resistance of leukemia cells to chemotherapy-induced apoptosis. Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the bone marrow microenvironment.",Journal Article,4799.0,141.0,The chemokine receptor CXCR4 mediates the migration of hematopoietic cells to the stroma-derived factor 1alpha SDF-1alpha -producing marrow microenvironment Using peptide-based CXCR4 inhibitors derived from the chemokine viral macrophage inflammatory protein II we tested the hypothesis that the inhibition of CXCR4 increases sensitivity to chemotherapy by interfering with stromal/leukemia cell interactions First leukemic cells expressing varying amounts of surface CXCR4 were examined for their chemotactic response to SDF-1alpha or stromal cells alone or in the presence of different CXCR4 inhibitors Results showed that the polypeptide RCP168 had the strongest antagonistic effect on the SDF-1alpha- or stromal cell-induced chemotaxis of leukemic cells Furthermore RCP168 blocked the binding of anti-CXCR4 monoclonal antibody 12G5 to surface CXCR4 in a concentration-dependent manner and inhibited SDF-1alpha-induced AKT and extracellular signal-regulated kinase phosphorylation Finally RCP168 significantly enhanced chemotherapy-induced apoptosis in stroma-cocultured Jurkat primary chronic lymphocytic and in a subset of acute myelogenous cells harboring Flt3 mutation Equivalent results were obtained with the small-molecule CXCR4 inhibitor AMD3465 Our data therefore suggest that the SDF-1alpha/CXCR4 interaction contributes to the resistance of cells to chemotherapy-induced apoptosis Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the marrow microenvironment,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[3, 3596, 153, 2318, 3961, 3, 1381, 1, 1007, 37, 6, 3, 2477, 526, 161, 5018, 5524, 5018, 3787, 581, 995, 75, 1389, 90, 2318, 222, 526, 29, 3, 3596, 1667, 2674, 1291, 178, 215, 21, 650, 3, 1492, 17, 3, 297, 1, 2318, 1106, 485, 6, 56, 20, 3449, 5, 1126, 2647, 31, 1286, 157, 2015, 37, 1046, 2990, 4939, 1, 1255, 2318, 11, 409, 9, 136, 15279, 51, 6, 5524, 5018, 15, 1126, 37, 279, 15, 4, 3, 463, 1, 338, 2318, 222, 99, 224, 17, 3, 8720, 34192, 42, 3, 3311, 9863, 254, 23, 3, 5524, 5018, 15, 1126, 31, 277, 12561, 1, 2015, 37, 798, 34192, 2582, 3, 791, 1, 312, 2318, 848, 548, 55947, 6, 1255, 2318, 4, 8, 1227, 470, 1708, 2, 879, 5524, 5018, 277, 649, 2, 1976, 1235, 1065, 216, 982, 1368, 34192, 97, 651, 56, 277, 351, 4, 2477, 11444, 8433, 86, 442, 1193, 2, 4, 8, 697, 1, 286, 2194, 37, 2105, 1224, 258, 2017, 99, 11, 683, 5, 3, 302, 1354, 2318, 230, 20532, 114, 74, 673, 309, 17, 3, 5524, 5018, 2318, 915, 2444, 6, 3, 251, 1, 37, 6, 56, 277, 351, 3220, 1, 46, 1286, 20, 3, 1389, 2318, 230, 34192, 1449, 8, 229, 692, 9, 529, 2015, 37, 262, 3, 581, 995]",1557.0,17172414,729
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.,"Cytometry. Part B, Clinical cytometry",Cytometry B Clin Cytom,2007-05-01,"Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments. It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals. We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine, chlorambucil, cladribine, or prednisolone. We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity. In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53, a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically. In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL. Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay.",Evaluation Study,4648.0,7.0,Patients with B-cell chronic lymphocytic B-CLL often demonstrate variable responses to similar treatments It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine chlorambucil cladribine or prednisolone We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53 a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 132, 31, 442, 1193, 132, 552, 629, 608, 1347, 253, 6, 288, 640, 192, 688, 40, 561, 7365, 6, 690, 8, 2175, 189, 692, 9, 881, 1, 870, 600, 15, 472, 90, 23, 3, 234, 485, 1241, 1, 2015, 37, 29, 869, 21, 1498, 8, 10757, 1412, 6226, 234, 1408, 719, 6, 376, 234, 176, 1225, 23, 132, 552, 37, 29, 601, 869, 50, 2015, 37, 11, 8303, 4, 439, 5, 2027, 11585, 8251, 15, 11253, 21, 264, 17, 338, 132, 552, 31, 1184, 29, 601, 869, 224, 8, 2003, 1982, 4, 234, 485, 4, 439, 251, 6, 2027, 10, 2199, 4, 132, 552, 37, 5, 2439, 1, 624, 8, 1266, 3698, 17, 16, 2214, 6912, 41, 5, 8, 334, 189, 51, 505, 4, 439, 234, 485, 1241, 311, 20, 8, 10757, 1412, 6226, 1408, 719, 68, 1833, 22, 8, 1515, 6, 1876, 2596, 881, 1, 870, 600, 9, 24, 4, 132, 552, 482, 143, 303, 40, 575, 6, 2183, 3, 38, 1207, 1, 26, 1412, 6226, 1408, 719]",1171.0,17226861,32
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-02-05,"Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome. We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients. Complete response (CR) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P = .00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL; P < .0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P = .0002) or del(11q22.3) (hazard ratio, 1.904; P = .006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgVH mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS. These results support the use of interphase cytogenetic analysis, but not IgVH, CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies.","Clinical Trial, Phase III",4733.0,272.0,Genomic features including unmutated immunoglobulin variable region heavy chain IgVH genes del 11q22.3 del 17p13.1 and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic CLL In addition ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival PFS using samples and data from 235 patients enrolled onto a therapeutic trial Patients received either fludarabine FL n 113 or fludarabine plus cyclophosphamide FC n 122 as part of a US Intergroup randomized trial for previously untreated CLL patients Complete response CR rates were 24.6 for patients receiving FC and 5.3 for patients receiving FL P .00004 PFS was statistically significantly longer in patients receiving FC median 33.5 months for patients receiving FC and 19.9 months for patients receiving FL P .0001 The occurrence of del 17p13.1 hazard ratio 3.428 P .0002 or del 11q22.3 hazard ratio 1.904 P .006 was associated with reduced PFS CR and overall response rates were not significantly different based on cytogenetics IgVH mutational status CD38 expression or p53 mutational status Expression of ZAP-70 Bcl-2 Bax Mcl-1 XIAP Caspase-3 and Traf-1 was not associated with either clinical response or PFS These results support the use of interphase cytogenetic analysis but not IgVH CD38 expression or ZAP-70 status to predict outcome of FL-based chemotherapy Patients with high-risk cytogenetic features should be considered for alternative therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[572, 404, 141, 7216, 2593, 1347, 1053, 4013, 1260, 14484, 214, 3084, 12647, 27, 3084, 7526, 14, 2, 624, 138, 47, 85, 210, 6, 678, 3, 38, 906, 2, 63, 25, 1, 7, 5, 442, 1193, 552, 4, 352, 6251, 431, 2, 1044, 18, 607, 652, 47, 85, 1443, 22, 674, 1, 228, 21, 1143, 194, 3, 177, 724, 1, 8, 949, 993, 1, 1624, 130, 23, 110, 51, 2, 91, 115, 25, 300, 75, 347, 2, 74, 29, 6465, 7, 346, 3301, 8, 189, 160, 7, 103, 361, 2027, 2633, 78, 4259, 15, 2027, 349, 1112, 4127, 78, 3285, 22, 760, 1, 8, 843, 4839, 384, 160, 9, 373, 1278, 552, 7, 236, 51, 684, 151, 11, 259, 49, 9, 7, 357, 4127, 2, 33, 27, 9, 7, 357, 2633, 19, 30815, 300, 10, 712, 97, 589, 4, 7, 357, 4127, 52, 466, 33, 53, 9, 7, 357, 4127, 2, 326, 83, 53, 9, 7, 357, 2633, 19, 488, 3, 2291, 1, 3084, 7526, 14, 360, 197, 27, 10222, 19, 3531, 15, 3084, 12647, 27, 360, 197, 14, 13145, 19, 1861, 10, 41, 5, 405, 300, 684, 2, 63, 51, 151, 11, 44, 97, 338, 90, 23, 2510, 14484, 1619, 156, 4469, 55, 15, 624, 1619, 156, 55, 1, 6251, 431, 1044, 18, 3119, 1308, 14, 5387, 1469, 27, 2, 34214, 14, 10, 44, 41, 5, 361, 38, 51, 15, 300, 46, 99, 538, 3, 119, 1, 8081, 1266, 65, 84, 44, 14484, 4469, 55, 15, 6251, 431, 156, 6, 678, 228, 1, 2633, 90, 56, 7, 5, 64, 43, 1266, 404, 257, 40, 515, 9, 1091, 235]",1649.0,17283363,701
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-02-05,"The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%; P < .001) and a higher overall response (OR) rate (74.3% v 59.5%, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.","Clinical Trial, Phase III",4733.0,344.0,The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic CLL However it may be accompanied by increased toxicity compared with fludarabine alone E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide FC arm versus fludarabine F arm alone in patients receiving their first chemotherapy regimen for CLL Symptomatic previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously IV days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m2 IV days 1 through 5 These cycles were repeated every 28 days for a maximum of six cycles A total of 278 patients were randomly assigned in this Intergroup study Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response CR rate 23.4 v 4.6 P .001 and a higher overall response OR rate 74.3 v 59.5 P .013 than treatment with fludarabine as a single agent Progression-free survival PFS was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine 31.6 v 19.2 months P .0001 Fludarabine and cyclophosphamide caused additional hematologic toxicity including more severe thrombocytopenia P .046 but it did not increase the number of severe infections P .812 Fludarabine and cyclophosphamide produced an increase in OR and CR and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 150, 1, 2027, 2, 1112, 16, 35, 323, 477, 9, 7, 5, 442, 1193, 552, 137, 192, 68, 40, 2756, 20, 101, 155, 72, 5, 2027, 279, 23577, 16, 8, 124, 316, 384, 4839, 160, 1430, 2027, 2, 1112, 4127, 475, 185, 2027, 1068, 475, 279, 4, 7, 357, 136, 157, 56, 477, 9, 552, 1704, 373, 1278, 7, 5, 552, 11, 1108, 896, 6, 560, 361, 2027, 243, 81, 821, 1672, 478, 162, 14, 298, 33, 15, 1112, 2383, 81, 821, 478, 218, 14, 2, 2027, 179, 81, 821, 478, 162, 14, 298, 33, 46, 410, 11, 2113, 454, 339, 162, 9, 8, 689, 1, 437, 410, 8, 181, 1, 9128, 7, 11, 1108, 896, 4, 26, 4839, 45, 24, 5, 2027, 2, 1112, 10, 41, 5, 8, 97, 142, 236, 51, 684, 116, 382, 39, 603, 39, 49, 19, 144, 2, 8, 142, 63, 51, 15, 116, 794, 27, 603, 728, 33, 19, 3612, 76, 24, 5, 2027, 22, 8, 226, 420, 91, 115, 25, 300, 10, 120, 1123, 4, 7, 73, 5, 2027, 2, 1112, 76, 135, 73, 5, 2027, 456, 49, 603, 326, 18, 53, 19, 488, 2027, 2, 1112, 1546, 402, 813, 155, 141, 80, 905, 1340, 19, 4902, 84, 192, 205, 44, 344, 3, 207, 1, 905, 1875, 19, 14162, 2027, 2, 1112, 1687, 35, 344, 4, 15, 2, 684, 2, 192, 231, 300, 4, 7, 5, 373, 1278, 552, 72, 5, 2027, 279, 2, 10, 44, 41, 5, 35, 344, 4, 3398, 155]",1582.0,17283364,591
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.,Blood,Blood,2007-02-13,"The clinical course for patients with chronic lymphocytic leukemia is extremely heterogeneous. The Rai and Binet staging systems have been used to risk-stratify patients; most patients present with early-stage disease. We evaluated a group of previously untreated patients with chronic lymphocytic leukemia (CLL) at initial presentation to University of Texas M. D. Anderson Cancer Center to identify independent characteristics that predict for overall survival. Clinical and routine laboratory characteristics for 1674 previously untreated patients who presented for evaluation of CLL from 1981 to 2004 were included. Univariate and multivariate analyses identified several patient characteristics at presentation that predicted for overall survival in previously untreated patients with CLL. A multivariate Cox proportional hazards model was developed, including the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups. Inclusion of patients from a single institution and the proportion of patients younger than 65 years may limit this model. A weighted prognostic model, or nomogram, predictive for overall survival was constructed using these 6 characteristics for 5- and 10-year survival probability and estimated median survival time. This prognostic model may help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design.",Journal Article,4725.0,221.0,The clinical course for patients with chronic lymphocytic is extremely heterogeneous The Rai and Binet staging systems have been used to risk-stratify patients most patients present with early-stage disease We evaluated a group of previously untreated patients with chronic lymphocytic CLL at initial presentation to University of Texas M. D. Anderson Cancer Center to identify independent characteristics that predict for overall survival Clinical and routine laboratory characteristics for 1674 previously untreated patients who presented for evaluation of CLL from 1981 to 2004 were included Univariate and multivariate analyses identified several patient characteristics at presentation that predicted for overall survival in previously untreated patients with CLL A multivariate Cox proportional hazards model was developed including the following independent characteristics age beta-2 microglobulin absolute lymphocyte count sex Rai stage and number of involved lymph node groups Inclusion of patients from a single institution and the proportion of patients younger than 65 years may limit this model A weighted prognostic model or nomogram predictive for overall survival was constructed using these 6 characteristics for 5- and 10-year survival probability and estimated median survival time This prognostic model may help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 906, 9, 7, 5, 442, 1193, 16, 2938, 1564, 3, 4121, 2, 17129, 632, 1530, 47, 85, 95, 6, 43, 3570, 7, 96, 7, 364, 5, 191, 82, 34, 21, 194, 8, 87, 1, 373, 1278, 7, 5, 442, 1193, 552, 28, 388, 1031, 6, 1652, 1, 2738, 188, 427, 1929, 12, 574, 6, 255, 306, 374, 17, 678, 9, 63, 25, 38, 2, 1311, 1624, 374, 9, 44624, 373, 1278, 7, 54, 917, 9, 451, 1, 552, 29, 10264, 6, 1131, 11, 159, 880, 2, 331, 318, 108, 392, 69, 374, 28, 1031, 17, 783, 9, 63, 25, 4, 373, 1278, 7, 5, 552, 8, 331, 418, 831, 1017, 202, 10, 276, 141, 3, 366, 306, 374, 89, 1090, 18, 5371, 1766, 1448, 1276, 1035, 4121, 82, 2, 207, 1, 646, 263, 289, 271, 1680, 1, 7, 29, 8, 226, 731, 2, 3, 920, 1, 7, 773, 76, 556, 60, 68, 2385, 26, 202, 8, 2337, 177, 202, 15, 1981, 464, 9, 63, 25, 10, 2776, 75, 46, 49, 374, 9, 33, 2, 79, 111, 25, 1320, 2, 661, 52, 25, 98, 26, 177, 202, 68, 987, 7, 2, 1490, 4, 38, 948, 1079, 22, 149, 22, 4, 38, 389, 2, 38, 160, 771]",1442.0,17299097,20
Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.,Translational research : the journal of laboratory and clinical medicine,Transl Res,2007-04-01,"New nephelometric immunoassays specific for free immunoglobulin light chains (FLCs) improve detection of monoclonal proteins (M-protein). Initial studies with FLC have focused on multiple myeloma and amyloidosis. The goal of this study was to evaluate the frequency of monoclonal serum FLC in patients with other B-cell malignancies. Frozen sera from 226 patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) were tested for M-protein by the serum FLC assay and compared with standard protein electrophoresis (PEL) and immunofixation (IF). Overall, 24% (54/226) of samples had a detectable M-protein with 63% of these (34/54) FLC-positive. In 35% (19/54), the M-protein was only detectable by FLC analysis. Of the 208 NHL patients, 22% (46/208) had a detectable M-protein. Also, 13% (27/208) were positive for FLC and 16% (33/208) had a detectable M-protein by PEL/IF. Twenty-eighty percent (13/46) of NHL patients with M-proteins were detectable only by FLC analysis. Within NHL, the highest incidences of FLC presence were in patients with mantle cell (36%) and small lymphocytic (24%). Among CLL patients, 44% had an M-protein with 39% detected by FLC and 11% detected by PEL/IF. Notably, in 6 of 8 CLL patients, the M-protein was only detectable by the FLC method. Serum FLC can be detected in a substantial fraction of patients with NHL/CLL, and the FLC technique improves detection of M-proteins when combined with standard PEL/IF. Future studies are warranted to elucidate the role of serum FLC as biomarkers of disease, for monitoring of minimal residual disease, and as a prognostic factor for response and survival.",Comparative Study,4678.0,52.0,New nephelometric immunoassays specific for free immunoglobulin light chains FLCs improve detection of monoclonal proteins M-protein Initial studies with FLC have focused on multiple and amyloidosis The goal of this study was to evaluate the frequency of monoclonal serum FLC in patients with other B-cell malignancies Frozen sera from 226 patients with NHL or chronic lymphocytic CLL were tested for M-protein by the serum FLC assay and compared with standard protein electrophoresis PEL and immunofixation IF Overall 24 54/226 of samples had a detectable M-protein with 63 of these 34/54 FLC-positive In 35 19/54 the M-protein was only detectable by FLC analysis Of the 208 NHL patients 22 46/208 had a detectable M-protein Also 13 27/208 were positive for FLC and 16 33/208 had a detectable M-protein by PEL/IF Twenty-eighty percent 13/46 of NHL patients with M-proteins were detectable only by FLC analysis Within NHL the highest incidences of FLC presence were in patients with mantle cell 36 and small lymphocytic 24 Among CLL patients 44 had an M-protein with 39 detected by FLC and 11 detected by PEL/IF Notably in 6 of 8 CLL patients the M-protein was only detectable by the FLC method Serum FLC can be detected in a substantial fraction of patients with NHL/CLL and the FLC technique improves detection of M-proteins when combined with standard PEL/IF Future studies are warranted to elucidate the role of serum FLC as biomarkers of disease for monitoring of minimal residual disease and as a prognostic factor for response and survival,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[217, 38402, 14785, 112, 9, 115, 2593, 1691, 7802, 17307, 401, 638, 1, 848, 652, 188, 178, 388, 94, 5, 4266, 47, 1649, 23, 232, 2, 3919, 3, 1326, 1, 26, 45, 10, 6, 376, 3, 675, 1, 848, 524, 4266, 4, 7, 5, 127, 132, 31, 441, 3015, 4210, 29, 7400, 7, 5, 1176, 15, 442, 1193, 552, 11, 650, 9, 188, 178, 20, 3, 524, 4266, 719, 2, 72, 5, 260, 178, 6777, 9204, 2, 11892, 492, 63, 259, 667, 7400, 1, 347, 42, 8, 2083, 188, 178, 5, 676, 1, 46, 562, 667, 4266, 109, 4, 465, 326, 667, 3, 188, 178, 10, 158, 2083, 20, 4266, 65, 1, 3, 5920, 1176, 7, 350, 641, 5920, 42, 8, 2083, 188, 178, 120, 233, 428, 5920, 11, 109, 9, 4266, 2, 245, 466, 5920, 42, 8, 2083, 188, 178, 20, 9204, 492, 737, 2207, 714, 233, 641, 1, 1176, 7, 5, 188, 652, 11, 2083, 158, 20, 4266, 65, 262, 1176, 3, 1076, 3981, 1, 4266, 463, 11, 4, 7, 5, 2757, 31, 511, 2, 302, 1193, 259, 107, 552, 7, 584, 42, 35, 188, 178, 5, 587, 530, 20, 4266, 2, 175, 530, 20, 9204, 492, 2552, 4, 49, 1, 66, 552, 7, 3, 188, 178, 10, 158, 2083, 20, 3, 4266, 596, 524, 4266, 122, 40, 530, 4, 8, 1281, 1509, 1, 7, 5, 1176, 552, 2, 3, 4266, 1312, 1804, 638, 1, 188, 652, 198, 397, 5, 260, 9204, 492, 508, 94, 32, 1197, 6, 3061, 3, 200, 1, 524, 4266, 22, 582, 1, 34, 9, 1315, 1, 1048, 753, 34, 2, 22, 8, 177, 161, 9, 51, 2, 25]",1546.0,17383597,70
Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test.,Mayo Clinic proceedings,Mayo Clin. Proc.,2007-04-01,"Recently developed prognostic tests in early Rai and Binet stage chronic lymphocytic leukemia (CLL) require considerable technologic expertise and are not available worldwide. Smudge cells are CLL cells ruptured during smear preparation. We hypothesized that smudge cell formation is inversely correlated with expression of vimentin, a cytoskeletal protein and prognostic marker, and that the percentage of smudge cells would predict prognosis in CLL. We reviewed the blood smears of 75 patients with previously untreated early and intermediate-stage CLL (Rai stage 0-II) who were seen at the Mayo Clinic in Rochester, Minn, between September 1989 and December 2000. A total of 200 lymphocytes and smudge cells were counted on each slide and the results expressed as a percentage of the total lymphocytes (intact and smudged). The median percentage of smudge cells was 27% (range, 4%-72%). The percentage of smudge cells inversely correlated with vimentin expression (r=-0.57; P=.007). The median percentage of smudge cells was higher in patients with the mutated immunoglobulin heavy chain gene than in those with the unmutated immunoglobulin heavy chain gene (31% vs 13%; P=.02). Patients with less than 30% smudge cells had a median time from diagnosis to initial treatment of 72.7 months, whereas the median time from diagnosis to initial treatment in patients with 30% or more smudge cells was not reached (P=.001). The percentage of smudge cells as a continuous variable correlated with overall survival (P=.04). The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL.",Journal Article,4678.0,,Recently developed prognostic tests in early Rai and Binet stage chronic lymphocytic CLL require considerable technologic expertise and are not available worldwide Smudge cells are CLL cells ruptured during smear preparation We hypothesized that smudge cell formation is inversely correlated with expression of vimentin a cytoskeletal protein and prognostic marker and that the percentage of smudge cells would predict prognosis in CLL We reviewed the blood smears of 75 patients with previously untreated early and intermediate-stage CLL Rai stage 0-II who were seen at the Mayo Clinic in Rochester Minn between September 1989 and December 2000 A total of 200 lymphocytes and smudge cells were counted on each slide and the results expressed as a percentage of the total lymphocytes intact and smudged The median percentage of smudge cells was 27 range 4 -72 The percentage of smudge cells inversely correlated with vimentin expression r=-0.57 P=.007 The median percentage of smudge cells was higher in patients with the mutated immunoglobulin heavy chain gene than in those with the unmutated immunoglobulin heavy chain gene 31 vs 13 P=.02 Patients with less than 30 smudge cells had a median time from diagnosis to initial treatment of 72.7 months whereas the median time from diagnosis to initial treatment in patients with 30 or more smudge cells was not reached P=.001 The percentage of smudge cells as a continuous variable correlated with overall survival P=.04 The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[761, 276, 177, 895, 4, 191, 4121, 2, 17129, 82, 442, 1193, 552, 1353, 2658, 15579, 4935, 2, 32, 44, 390, 2358, 14969, 37, 32, 552, 37, 18937, 190, 8379, 4824, 21, 1237, 17, 14969, 31, 1264, 16, 2659, 438, 5, 55, 1, 4840, 8, 10055, 178, 2, 177, 952, 2, 17, 3, 1150, 1, 14969, 37, 688, 678, 356, 4, 552, 21, 446, 3, 315, 8916, 1, 481, 7, 5, 373, 1278, 191, 2, 919, 82, 552, 4121, 82, 13, 215, 54, 11, 527, 28, 3, 2486, 1188, 4, 5801, 23080, 59, 2636, 3965, 2, 1397, 1081, 8, 181, 1, 1250, 1594, 2, 14969, 37, 11, 12252, 23, 296, 7911, 2, 3, 99, 570, 22, 8, 1150, 1, 3, 181, 1594, 2964, 2, 38420, 3, 52, 1150, 1, 14969, 37, 10, 428, 184, 39, 720, 3, 1150, 1, 14969, 37, 2659, 438, 5, 4840, 55, 668, 13, 696, 19, 1999, 3, 52, 1150, 1, 14969, 37, 10, 142, 4, 7, 5, 3, 1185, 2593, 4013, 1260, 145, 76, 4, 135, 5, 3, 7216, 2593, 4013, 1260, 145, 456, 105, 233, 19, 588, 7, 5, 299, 76, 201, 14969, 37, 42, 8, 52, 98, 29, 147, 6, 388, 24, 1, 720, 67, 53, 547, 3, 52, 98, 29, 147, 6, 388, 24, 4, 7, 5, 201, 15, 80, 14969, 37, 10, 44, 1300, 19, 144, 3, 1150, 1, 14969, 37, 22, 8, 1314, 1347, 438, 5, 63, 25, 19, 755, 3, 4470, 1, 14969, 37, 23, 8, 315, 8379, 359, 40, 8, 6813, 390, 177, 412, 4, 191, 82, 552]",1585.0,17418074,370
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.,Blood,Blood,2007-04-17,"CD37 is a lineage-specific B-cell antigen that to date has been neglected as an attractive therapeutic target. To exploit this, novel CD37-specific small modular immunopharmaceuticals (CD37-SMIP) that include variable regions linked to modified human IgG(1) hinge, CH(2), and CH(3) domains were designed. The lead CD37-SMIP molecule induces potent apoptosis in the presence of a cross-linker, and antibody-dependent cellular cytotoxicity against B-cell leukemia/lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) cells superior to therapeutic antibodies used in these diseases. The CD37-SMIP-dependent ADCC function in vitro was mediated by natural killer (NK) cells but not naive or activated monocytes. Significant in vivo therapeutic efficacy was demonstrated in a SCID mouse xenograft leukemia/lymphoma model. Depletion of NK cells in this mouse model resulted in diminished efficacy further supported the in vivo importance of NK cells in SMIP therapy. These findings provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies.",Journal Article,4662.0,107.0,CD37 is a lineage-specific B-cell antigen that to date has been neglected as an attractive therapeutic target To exploit this novel CD37-specific small modular immunopharmaceuticals CD37-SMIP that include variable regions linked to modified human IgG 1 hinge CH 2 and CH 3 domains were designed The lead CD37-SMIP molecule induces potent apoptosis in the presence of a cross-linker and antibody-dependent cellular cytotoxicity against B-cell leukemia/lymphoma cell lines and primary chronic lymphocytic CLL cells superior to therapeutic antibodies used in these diseases The CD37-SMIP-dependent ADCC function in vitro was mediated by natural killer NK cells but not naive or activated monocytes Significant in vivo therapeutic efficacy was demonstrated in a SCID mouse xenograft leukemia/lymphoma model Depletion of NK cells in this mouse model resulted in diminished efficacy further supported the in vivo importance of NK cells in SMIP therapy These findings provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[10006, 16, 8, 2542, 112, 132, 31, 448, 17, 6, 1244, 71, 85, 18450, 22, 35, 3059, 189, 283, 6, 6109, 26, 229, 10006, 112, 302, 14236, 44698, 10006, 18502, 17, 643, 1347, 1374, 1199, 6, 1230, 171, 3630, 14, 18339, 6557, 18, 2, 6557, 27, 2703, 11, 1114, 3, 1122, 10006, 18502, 1354, 1516, 1157, 351, 4, 3, 463, 1, 8, 1383, 8437, 2, 548, 470, 763, 1408, 480, 132, 31, 2647, 4763, 31, 285, 2, 86, 442, 1193, 552, 37, 1123, 6, 189, 890, 95, 4, 46, 1342, 3, 10006, 18502, 470, 5551, 343, 4, 439, 10, 517, 20, 1504, 3458, 1765, 37, 84, 44, 2462, 15, 735, 5078, 93, 4, 386, 189, 209, 10, 264, 4, 8, 4129, 830, 1330, 2647, 4763, 202, 2286, 1, 1765, 37, 4, 26, 830, 202, 627, 4, 2849, 209, 195, 2708, 3, 4, 386, 1187, 1, 1765, 37, 4, 18502, 36, 46, 272, 377, 1082, 12611, 9, 10006, 22, 8, 189, 283, 2, 7630, 302, 14236, 44698, 22, 8, 229, 1040, 1, 238, 235, 9, 132, 31, 441]",1135.0,17440052,314
"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.",Cancer,Cancer,2007-06-01,"The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients >or=70 years of age. Sixty-four previously untreated patients with CLL and serum creatinine <1.5 times the upper limit of normal who met National Cancer Institute (NCI) 96-WG criteria for treatment received pentostatin (2 mg/m(2)), cyclophosphamide (600 mg/m(2)), and rituximab (375 mg/m(2)). The authors measured performance status at study entry and used age, weight, and baseline creatinine to calculate creatinine clearance (CrCl). Eighteen of 64 (28%) patients were ages >or=70 years. Although individuals ages >or=70 years were more likely to have delayed treatment cycles (28% vs 7%; P=.03), there were no significant differences in the number of cycles administered, need for dose reductions, or grade 3-4 hematologic, infectious, or other toxicities. No significant differences in overall response rate, complete response rate, or progression-free survival were observed by age. Twenty-five (39%) patients had a CrCl < 70 mL/min (range, 34-67). Although individuals with CrCl < 70 were more likely to require dose reduction (24% vs 5%; P=.05), there were no significant differences in the number of cycles administered or grade 3-4 hematologic, infectious, or other toxicities. No significant difference in overall response rate, complete response rate, or progression-free survival were observed between patients with CrCl >or= 70 mL/min and those with CrCl < 70 mL/min. In this clinical trial, the PCR regimen was well tolerated by older patients and individuals with CrCl <or= 70. The efficacy of PCR was not significantly affected by age or renal function. These findings suggest PCR may be a good therapeutic option for older patients and those with modestly decreased renal function.",Journal Article,4617.0,128.0,The prevalence of chronic lymphocytic CLL increases with age Although chemoimmunotherapy CIT has dramatically improved response rates in patients with CLL some CIT regimens are not well tolerated by many patients or=70 years of age Sixty-four previously untreated patients with CLL and serum creatinine 1.5 times the upper limit of normal who met National Cancer Institute NCI 96-WG criteria for treatment received pentostatin 2 mg/m 2 cyclophosphamide 600 mg/m 2 and rituximab 375 mg/m 2 The authors measured performance status at study entry and used age weight and baseline creatinine to calculate creatinine clearance CrCl Eighteen of 64 28 patients were ages or=70 years Although individuals ages or=70 years were more likely to have delayed treatment cycles 28 vs 7 P=.03 there were no significant differences in the number of cycles administered need for dose reductions or grade 3-4 hematologic infectious or other toxicities No significant differences in overall response rate complete response rate or progression-free survival were observed by age Twenty-five 39 patients had a CrCl 70 mL/min range 34-67 Although individuals with CrCl 70 were more likely to require dose reduction 24 vs 5 P=.05 there were no significant differences in the number of cycles administered or grade 3-4 hematologic infectious or other toxicities No significant difference in overall response rate complete response rate or progression-free survival were observed between patients with CrCl or= 70 mL/min and those with CrCl 70 mL/min In this clinical trial the PCR regimen was well tolerated by older patients and individuals with CrCl or= 70 The efficacy of PCR was not significantly affected by age or function These findings suggest PCR may be a good therapeutic option for older patients and those with modestly decreased function,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1078, 1, 442, 1193, 552, 1106, 5, 89, 242, 4438, 9192, 71, 2729, 231, 51, 151, 4, 7, 5, 552, 476, 9192, 472, 32, 44, 149, 421, 20, 445, 7, 15, 431, 60, 1, 89, 1746, 294, 373, 1278, 7, 5, 552, 2, 524, 3177, 14, 33, 1072, 3, 1726, 2385, 1, 295, 54, 543, 657, 12, 1377, 2580, 921, 12906, 371, 9, 24, 103, 7596, 18, 81, 188, 18, 1112, 2383, 81, 188, 18, 2, 855, 4175, 81, 188, 18, 3, 738, 644, 528, 156, 28, 45, 3001, 2, 95, 89, 924, 2, 330, 3177, 6, 3232, 3177, 1960, 7871, 3195, 1, 660, 339, 7, 11, 2165, 15, 431, 60, 242, 869, 2165, 15, 431, 60, 11, 80, 322, 6, 47, 1612, 24, 410, 339, 105, 67, 19, 680, 125, 11, 77, 93, 362, 4, 3, 207, 1, 410, 468, 594, 9, 61, 2153, 15, 88, 27, 39, 813, 3398, 15, 127, 385, 77, 93, 362, 4, 63, 51, 116, 236, 51, 116, 15, 91, 115, 25, 11, 164, 20, 89, 737, 365, 587, 7, 42, 8, 7871, 431, 542, 1538, 184, 562, 598, 242, 869, 5, 7871, 431, 11, 80, 322, 6, 1353, 61, 628, 259, 105, 33, 19, 474, 125, 11, 77, 93, 362, 4, 3, 207, 1, 410, 468, 15, 88, 27, 39, 813, 3398, 15, 127, 385, 77, 93, 523, 4, 63, 51, 116, 236, 51, 116, 15, 91, 115, 25, 11, 164, 59, 7, 5, 7871, 15, 431, 542, 1538, 2, 135, 5, 7871, 431, 542, 1538, 4, 26, 38, 160, 3, 604, 477, 10, 149, 421, 20, 434, 7, 2, 869, 5, 7871, 15, 431, 3, 209, 1, 604, 10, 44, 97, 1424, 20, 89, 15, 343, 46, 272, 309, 604, 68, 40, 8, 1178, 189, 1501, 9, 434, 7, 2, 135, 5, 5588, 340, 343]",1826.0,17514743,420
Genomics and proteomics in multiple myeloma and Waldenstrm macroglobulinemia.,Current opinion in hematology,Curr. Opin. Hematol.,2007-07-01,"Multiple myeloma and Waldenstrm macroglobulinemia are incurable hematologic malignancies with similar clinical phenotypes characterized by over-production of monoclonal immunoglobulins. Translocations into the immunoglobulin heavy chain locus and aneuploidy are nearly universal in multiple myeloma, whereas Waldenstrm macroglobulinemia generally does not harbor translocations. Deletion of 6q is identified in 50% of patients with Waldenstrm macroglobulinemia, however. The genetic abnormalities in multiple myeloma and Waldenstrm macroglobulinemia have implications for disease progression, and the subsequent proteomic expression associated with each disease influences therapeutic decisions. Gene expression profiling in these hematologic malignancies demonstrated distinct differences in mRNA expression patterns. Following profiling, Waldenstrm macroglobulinemia samples clustered with chronic lymphocytic leukemia and normal B-cell samples. Profiling performed after separation of Waldenstrm macroglobulinemia samples into populations with plasma cell or B-cell morphology revealed that plasma cell Waldenstrm macroglobulinemia samples most closely resembled multiple myeloma samples rather than chronic lymphocytic leukemia or normal control samples. Diverse genetic abnormalities have been identified in these hematologic malignancies, although they have similar clinical features. Gene expression profiling has elucidated the impact of genetic abnormalities. Furthermore, it may be used to identify a specific pathway for therapeutic targeting, such as interleukin-6 in Waldenstrm macroglobulinemia.",Journal Article,4587.0,5.0,Multiple and Waldenstrm macroglobulinemia are incurable hematologic malignancies with similar clinical phenotypes characterized by over-production of monoclonal immunoglobulins Translocations into the immunoglobulin heavy chain locus and aneuploidy are nearly universal in multiple whereas Waldenstrm macroglobulinemia generally does not harbor translocations Deletion of 6q is identified in 50 of patients with Waldenstrm macroglobulinemia however The genetic abnormalities in multiple and Waldenstrm macroglobulinemia have implications for disease progression and the subsequent proteomic expression associated with each disease influences therapeutic decisions Gene expression profiling in these hematologic malignancies demonstrated distinct differences in mRNA expression patterns Following profiling Waldenstrm macroglobulinemia samples clustered with chronic lymphocytic and normal B-cell samples Profiling performed after separation of Waldenstrm macroglobulinemia samples into populations with plasma cell or B-cell morphology revealed that plasma cell Waldenstrm macroglobulinemia samples most closely resembled multiple samples rather than chronic lymphocytic or normal control samples Diverse genetic abnormalities have been identified in these hematologic malignancies although they have similar clinical features Gene expression profiling has elucidated the impact of genetic abnormalities Furthermore it may be used to identify a specific pathway for therapeutic targeting such as interleukin-6 in Waldenstrm macroglobulinemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[232, 2, 3700, 3389, 32, 2641, 813, 441, 5, 288, 38, 2618, 765, 20, 252, 1529, 1, 848, 13373, 3262, 237, 3, 2593, 4013, 1260, 2474, 2, 7437, 32, 1857, 4967, 4, 232, 547, 3700, 3389, 1228, 1097, 44, 2760, 3262, 1528, 1, 10961, 16, 108, 4, 212, 1, 7, 5, 3700, 3389, 137, 3, 336, 1171, 4, 232, 2, 3700, 3389, 47, 1268, 9, 34, 91, 2, 3, 706, 3784, 55, 41, 5, 296, 34, 3859, 189, 1526, 145, 55, 1080, 4, 46, 813, 441, 264, 834, 362, 4, 956, 55, 764, 366, 1080, 3700, 3389, 347, 6464, 5, 442, 1193, 2, 295, 132, 31, 347, 1080, 173, 50, 5422, 1, 3700, 3389, 347, 237, 1184, 5, 554, 31, 15, 132, 31, 2567, 553, 17, 554, 31, 3700, 3389, 347, 96, 3210, 11311, 232, 347, 1832, 76, 442, 1193, 15, 295, 182, 347, 1867, 336, 1171, 47, 85, 108, 4, 46, 813, 441, 242, 491, 47, 288, 38, 404, 145, 55, 1080, 71, 3901, 3, 345, 1, 336, 1171, 798, 192, 68, 40, 95, 6, 255, 8, 112, 308, 9, 189, 529, 225, 22, 1603, 49, 4, 3700, 3389]",1549.0,17534163,10
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.,Cell,Cell,2007-06-01,"The heritability of B cell chronic lymphocytic leukemia (CLL) is relatively high; however, no predisposing mutation has been convincingly identified. We show that loss or reduced expression of death-associated protein kinase 1 (DAPK1) underlies cases of heritable predisposition to CLL and the majority of sporadic CLL. Epigenetic silencing of DAPK1 by promoter methylation occurs in almost all sporadic CLL cases. Furthermore, we defined a disease haplotype, which segregates with the CLL phenotype in a large family. DAPK1 expression of the CLL allele is downregulated by 75% in germline cells due to increased HOXB7 binding. In the blood cells from affected family members, promoter methylation results in additional loss of DAPK1 expression. Thus, reduced expression of DAPK1 can result from germline predisposition, as well as epigenetic or somatic events causing or contributing to the CLL phenotype.",Journal Article,4617.0,273.0,The heritability of B cell chronic lymphocytic CLL is relatively high however no predisposing mutation has been convincingly identified We show that loss or reduced expression of death-associated protein kinase 1 DAPK1 underlies cases of heritable predisposition to CLL and the majority of sporadic CLL Epigenetic silencing of DAPK1 by promoter methylation occurs in almost all sporadic CLL cases Furthermore we defined a disease haplotype which segregates with the CLL phenotype in a large family DAPK1 expression of the CLL allele is downregulated by 75 in germline cells due to increased HOXB7 binding In the blood cells from affected family members promoter methylation results in additional loss of DAPK1 expression Thus reduced expression of DAPK1 can result from germline predisposition as well as epigenetic or somatic events causing or contributing to the CLL phenotype,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 13160, 1, 132, 31, 442, 1193, 552, 16, 1352, 64, 137, 77, 6885, 258, 71, 85, 16274, 108, 21, 514, 17, 407, 15, 405, 55, 1, 273, 41, 178, 216, 14, 11503, 10702, 140, 1, 6874, 2863, 6, 552, 2, 3, 686, 1, 1928, 552, 1418, 2077, 1, 11503, 20, 973, 569, 1780, 4, 2214, 62, 1928, 552, 140, 798, 21, 395, 8, 34, 4179, 92, 23175, 5, 3, 552, 1005, 4, 8, 375, 607, 11503, 55, 1, 3, 552, 1254, 16, 3315, 20, 481, 4, 1009, 37, 520, 6, 101, 56304, 791, 4, 3, 315, 37, 29, 1424, 607, 1684, 973, 569, 99, 4, 402, 407, 1, 11503, 55, 631, 405, 55, 1, 11503, 122, 757, 29, 1009, 2863, 22, 149, 22, 1418, 15, 1119, 281, 3440, 15, 3156, 6, 3, 552, 1005]",878.0,17540169,21
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-06-01,"Previous studies in our laboratory have shown the progressive methylation and suppression of the gene encoding protein tyrosine phosphatase, PTPRO, in the livers of rats fed a methyl-deficient diet that induces hepatocarcinogenesis. Subsequently, we observed the methylation of PTPRO in primary human lung tumors and also showed its potential tumor suppressor characteristics. The present study was undertaken to investigate whether the truncated form of PTPRO (PTPROt), specifically expressed in nave B lymphocytes, was also methylated and suppressed in chronic lymphocytic leukemia (CLL), a disease generally affecting B lymphocytes. Initial screening showed that 60% of the 52 CLL samples analyzed using methylation-specific PCR assay were methylated compared with B lymphocytes from normal individuals, which were not methylated. The expression of PTPROt, as measured by semiquantitative reverse transcription-PCR, inversely correlated with methylation in the few samples tested. Analysis of additional samples (n = 50) by combined bisulfite restriction analysis showed that the PTPRO CpG island was methylated in 82% of patients with CLL compared with B lymphocytes from normal individuals. Furthermore, overall expression of PTPRO was reduced in CLL relative to normal lymphocytes. The PTPRO gene was also suppressed by methylation in the CLL cell line WaC3CD5, where it could be reactivated upon treatment with the DNA hypomethylating agent 5-AzaC. Ectopic expression of PTPROt in a nonexpressing cell line increased growth inhibition with fludarabine treatment, a therapy commonly used for CLL. This study reveals the potential role of PTPRO methylation and silencing in CLL tumorigenesis and also provides a novel molecular target in the epigenetic therapy.",Journal Article,4617.0,52.0,Previous studies in our laboratory have shown the progressive methylation and suppression of the gene encoding protein tyrosine phosphatase PTPRO in the livers of rats fed a methyl-deficient diet that induces hepatocarcinogenesis Subsequently we observed the methylation of PTPRO in primary human tumors and also showed its potential tumor suppressor characteristics The present study was undertaken to investigate whether the truncated form of PTPRO PTPROt specifically expressed in nave B lymphocytes was also methylated and suppressed in chronic lymphocytic CLL a disease generally affecting B lymphocytes Initial screening showed that 60 of the 52 CLL samples analyzed using methylation-specific PCR assay were methylated compared with B lymphocytes from normal individuals which were not methylated The expression of PTPROt as measured by semiquantitative reverse transcription-PCR inversely correlated with methylation in the few samples tested Analysis of additional samples n 50 by combined bisulfite restriction analysis showed that the PTPRO CpG island was methylated in 82 of patients with CLL compared with B lymphocytes from normal individuals Furthermore overall expression of PTPRO was reduced in CLL relative to normal lymphocytes The PTPRO gene was also suppressed by methylation in the CLL cell line WaC3CD5 where it could be reactivated upon treatment with the DNA hypomethylating agent 5-AzaC Ectopic expression of PTPROt in a nonexpressing cell line increased growth inhibition with fludarabine treatment a therapy commonly used for CLL This study reveals the potential role of PTPRO methylation and silencing in CLL tumorigenesis and also provides a novel molecular target in the epigenetic therapy,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[698, 94, 4, 114, 1624, 47, 443, 3, 1014, 569, 2, 1332, 1, 3, 145, 2362, 178, 564, 2577, 16460, 4, 3, 8868, 1, 3765, 6994, 8, 5228, 1971, 2453, 17, 1516, 9858, 1611, 21, 164, 3, 569, 1, 16460, 4, 86, 171, 57, 2, 120, 224, 211, 174, 30, 1245, 374, 3, 364, 45, 10, 2789, 6, 963, 317, 3, 6502, 1297, 1, 16460, 18508, 1225, 570, 4, 2809, 132, 1594, 10, 120, 2963, 2, 1908, 4, 442, 1193, 552, 8, 34, 1228, 2319, 132, 1594, 388, 453, 224, 17, 335, 1, 3, 653, 552, 347, 311, 75, 569, 112, 604, 719, 11, 2963, 72, 5, 132, 1594, 29, 295, 869, 92, 11, 44, 2963, 3, 55, 1, 18508, 22, 644, 20, 8942, 1772, 866, 604, 2659, 438, 5, 569, 4, 3, 1021, 347, 650, 65, 1, 402, 347, 78, 212, 20, 397, 6181, 4575, 65, 224, 17, 3, 16460, 2075, 3454, 10, 2963, 4, 878, 1, 7, 5, 552, 72, 5, 132, 1594, 29, 295, 869, 798, 63, 55, 1, 16460, 10, 405, 4, 552, 580, 6, 295, 1594, 3, 16460, 145, 10, 120, 1908, 20, 569, 4, 3, 552, 31, 328, 44738, 1257, 192, 359, 40, 13566, 1548, 24, 5, 3, 261, 4931, 420, 33, 34280, 3647, 55, 1, 18508, 4, 8, 26604, 31, 328, 101, 129, 297, 5, 2027, 24, 8, 36, 841, 95, 9, 552, 26, 45, 4054, 3, 174, 200, 1, 16460, 569, 2, 2077, 4, 552, 1565, 2, 120, 777, 8, 229, 219, 283, 4, 3, 1418, 36]",1721.0,17545520,336
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.,PloS one,PLoS ONE,2007-06-27,"The synthetic triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid (CDDO) and derivatives display anti-tumor activity against a variety of cultured tumor cell lines and in mouse xenografts. In this report, we have studied the effects of CDDO and its imidazolide derivative (CDDO-Im) on chronic lymphocytic leukemia (CLL), using patients' CLL cells and a mouse model of CLL and small B cell lymphoma (SBL). CDDO and CDDO-Im efficiently induced apoptosis of malignant human and mouse B-cells ex vivo, although CDDO-Im was over 10-fold more potent than CDDO. Treating mice with CLL/SBL with liposome-formulated CDDO or CDDO-Im resulted in significant reductions of B cells in blood, spleen and lung. CDDO-Im was shown to be more potent than CDDO, while treatment with empty liposomes had no impact on disease. CDDO-Im treatment initially resulted in an increase of circulating B cells, which correlates with a reduction in resident lymphocytes in spleen, and lungs, suggesting that CDDO-Im induces mobilization of tumor cells from lymphoid organs and infiltrated tissues into the circulation. Analysis of blood cells recovered from treated mice also showed that CDDO-Im is a potent inducer of tumor cells death in vivo. Furthermore, CDDO-Im efficiently eradicated mouse CLL/SBL cells but had little effect on the viability of normal B and T cells in vivo. The presented data demonstrate that triterpenoids CDDO and CDDO-Im reduce leukemia and lymphoma burden in vivo in a transgenic mouse model of CLL/SBL, and support the clinical testing of CDDO-based synthetic triterpenoids in patients with CLL.",Journal Article,4591.0,22.0,"The synthetic triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid CDDO and derivatives display anti-tumor activity against a variety of cultured tumor cell lines and in mouse xenografts In this report we have studied the effects of CDDO and its imidazolide derivative CDDO-Im on chronic lymphocytic CLL using patients CLL cells and a mouse model of CLL and small B cell SBL CDDO and CDDO-Im efficiently induced apoptosis of malignant human and mouse B-cells ex vivo although CDDO-Im was over 10-fold more potent than CDDO Treating mice with CLL/SBL with liposome-formulated CDDO or CDDO-Im resulted in significant reductions of B cells in blood spleen and CDDO-Im was shown to be more potent than CDDO while treatment with empty liposomes had no impact on disease CDDO-Im treatment initially resulted in an increase of circulating B cells which correlates with a reduction in resident lymphocytes in spleen and lungs suggesting that CDDO-Im induces mobilization of tumor cells from lymphoid organs and infiltrated tissues into the circulation Analysis of blood cells recovered from treated mice also showed that CDDO-Im is a potent inducer of tumor cells death in vivo Furthermore CDDO-Im efficiently eradicated mouse CLL/SBL cells but had little effect on the viability of normal B and T cells in vivo The presented data demonstrate that triterpenoids CDDO and CDDO-Im reduce and burden in vivo in a transgenic mouse model of CLL/SBL and support the clinical testing of CDDO-based synthetic triterpenoids in patients with CLL",0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 3273, 15818, 18, 11777, 27, 133, 15540, 14, 83, 13030, 339, 14817, 971, 4111, 2, 6490, 3640, 312, 30, 128, 480, 8, 1362, 1, 3197, 30, 31, 285, 2, 4, 830, 1348, 4, 26, 414, 21, 47, 656, 3, 176, 1, 4111, 2, 211, 38006, 4819, 4111, 2820, 23, 442, 1193, 552, 75, 7, 552, 37, 2, 8, 830, 202, 1, 552, 2, 302, 132, 31, 21452, 4111, 2, 4111, 2820, 4143, 277, 351, 1, 393, 171, 2, 830, 132, 37, 2581, 386, 242, 4111, 2820, 10, 252, 79, 1116, 80, 1157, 76, 4111, 1367, 399, 5, 552, 21452, 5, 8645, 7495, 4111, 15, 4111, 2820, 627, 4, 93, 2153, 1, 132, 37, 4, 315, 4071, 2, 4111, 2820, 10, 443, 6, 40, 80, 1157, 76, 4111, 369, 24, 5, 9436, 7438, 42, 77, 345, 23, 34, 4111, 2820, 24, 1625, 627, 4, 35, 344, 1, 1033, 132, 37, 92, 1871, 5, 8, 628, 4, 8185, 1594, 4, 4071, 2, 4465, 802, 17, 4111, 2820, 1516, 4030, 1, 30, 37, 29, 2303, 2285, 2, 8652, 742, 237, 3, 4984, 65, 1, 315, 37, 5784, 29, 73, 399, 120, 224, 17, 4111, 2820, 16, 8, 1157, 9567, 1, 30, 37, 273, 4, 386, 798, 4111, 2820, 4143, 14124, 830, 552, 21452, 37, 84, 42, 1215, 254, 23, 3, 2120, 1, 295, 132, 2, 102, 37, 4, 386, 3, 917, 74, 608, 17, 21985, 4111, 2, 4111, 2820, 969, 2, 892, 4, 386, 4, 8, 2862, 830, 202, 1, 552, 21452, 2, 538, 3, 38, 471, 1, 4111, 90, 3273, 21985, 4, 7, 5, 552]",1533.0,17593960,302
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.,Blood,Blood,2007-06-26,"Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for eradication of cancer. Here, we estimated relapse risks according to disease characteristics. Between 1997 and 2006, 834 consecutive patients (median age, 55 years; range, 5-74 years) received related (n = 498) or unrelated (n = 336) HCT after 2 Gy total body irradiation alone (n = 171) or combined with fludarabine (90 mg/m(2); n = 663). Relapse rates per patient year (PY) at risk, corrected for follow-up and competing nonrelapse mortality, were calculated for 29 different diseases and stages. The overall relapse rate per PY was 0.36. Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) in remission (CR), low-grade or mantle cell non-Hodgkin lymphoma (NHL) (CR + partial remission [PR]), and high-grade NHL-CR had the lowest rates (0.00-0.24; low risk). In contrast, patients with advanced myeloid and lymphoid malignancies had rates of more than 0.52 (high risk). Patients with lymphoproliferative diseases not in CR (except Hodgkin lymphoma and high-grade NHL) and myeloid malignancies in CR had rates of 0.26-0.37 (standard risk). In conclusion, patients with low-grade lymphoproliferative disorders experienced the lowest relapse rates, whereas patients with advanced myeloid and lymphoid malignancies had high relapse rates after nonmyeloablative HCT. The latter might benefit from cytoreductive treatment before HCT.",Journal Article,4592.0,133.0,Allogeneic hematopoietic cell transplantation HCT after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for eradication of cancer Here we estimated relapse risks according to disease characteristics Between 1997 and 2006 834 consecutive patients median age 55 years range 5-74 years received related n 498 or unrelated n 336 HCT after 2 Gy total body irradiation alone n 171 or combined with fludarabine 90 mg/m 2 n 663 Relapse rates per patient year PY at risk corrected for follow-up and competing nonrelapse mortality were calculated for 29 different diseases and stages The overall relapse rate per PY was 0.36 Patients with chronic lymphocytic CLL and multiple MM in remission CR low-grade or mantle cell NHL CR partial remission PR and high-grade NHL-CR had the lowest rates 0.00-0.24 low risk In contrast patients with advanced myeloid and lymphoid malignancies had rates of more than 0.52 high risk Patients with lymphoproliferative diseases not in CR except and high-grade NHL and myeloid malignancies in CR had rates of 0.26-0.37 standard risk In conclusion patients with low-grade lymphoproliferative disorders experienced the lowest relapse rates whereas patients with advanced myeloid and lymphoid malignancies had high relapse rates after nonmyeloablative HCT The latter might benefit from cytoreductive treatment before HCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 50, 6094, 1933, 9, 813, 441, 3828, 23, 1599, 185, 30, 176, 9, 5173, 1, 12, 467, 21, 661, 429, 1098, 768, 6, 34, 374, 59, 2341, 2, 1324, 13896, 935, 7, 52, 89, 614, 60, 184, 33, 794, 60, 103, 139, 78, 8928, 15, 2092, 78, 10047, 1085, 50, 18, 381, 181, 642, 1104, 279, 78, 5702, 15, 397, 5, 2027, 424, 81, 188, 18, 78, 10693, 429, 151, 379, 69, 111, 16898, 28, 43, 3848, 9, 166, 126, 2, 2573, 4640, 282, 11, 981, 9, 462, 338, 1342, 2, 1153, 3, 63, 429, 116, 379, 16898, 10, 13, 511, 7, 5, 442, 1193, 552, 2, 232, 321, 4, 734, 684, 154, 88, 15, 2757, 31, 1176, 684, 450, 734, 998, 2, 64, 88, 1176, 684, 42, 3, 2101, 151, 13, 2038, 13, 259, 154, 43, 4, 748, 7, 5, 131, 533, 2, 2303, 441, 42, 151, 1, 80, 76, 13, 653, 64, 43, 7, 5, 4192, 1342, 44, 4, 684, 2187, 2, 64, 88, 1176, 2, 533, 441, 4, 684, 42, 151, 1, 13, 432, 13, 567, 260, 43, 4, 1221, 7, 5, 154, 88, 4192, 1997, 592, 3, 2101, 429, 151, 547, 7, 5, 131, 533, 2, 2303, 441, 42, 64, 429, 151, 50, 6094, 1085, 3, 3286, 822, 247, 29, 2604, 24, 348, 1085]",1387.0,17595333,602
Chronic lymphocytic leukemia FISH panel: impact on diagnosis.,American journal of clinical pathology,Am. J. Clin. Pathol.,2007-08-01,"Interphase fluorescence in situ hybridization (FISH) is an alternative to conventional chromosome analysis of chronic lymphocytic leukemia (CLL) cells. We analyzed 172 samples from 136 possible CLL cases using a FISH panel. Reflex testing with probes to CCND1, BCL2, BCL3, BCL11A, c-MYC, MALT1, and a break-apart immunoglobulin heavy chain (IGH) probe was done if more than 2 signals for 14q32 occurred. For 111 cases, there were sufficient data for analysis. Of 111 cases, 81 (72.9%) had 1 or more genetic abnormalities. The most frequent abnormality was 13q-, followed by trisomy 12, 11q-, and 17p-. In 13 cases, there were IGH abnormalities. Two cases with CCND1/IGH fusion were reclassified as mantle cell lymphoma. Four CLL cases had IGH fusion with BCL2, BCL3 (2 cases), and BCL11A; no fusion partner was detected in 7 cases. Morphologic features were atypical for CLL in 2 cases with IGH fusion (BCL11A and BCL3). The FISH CLL panel is useful to identify prognostic aberrations and to clarify diagnosis in cases with unusual morphologic features.",Journal Article,4556.0,33.0,Interphase fluorescence in situ hybridization FISH is an alternative to conventional chromosome analysis of chronic lymphocytic CLL cells We analyzed 172 samples from 136 possible CLL cases using a FISH panel Reflex testing with probes to CCND1 BCL2 BCL3 BCL11A c-MYC MALT1 and a break-apart immunoglobulin heavy chain IGH probe was done if more than 2 signals for 14q32 occurred For 111 cases there were sufficient data for analysis Of 111 cases 81 72.9 had 1 or more genetic abnormalities The most frequent abnormality was 13q- followed by trisomy 12 11q- and 17p- In 13 cases there were IGH abnormalities Two cases with CCND1/IGH fusion were reclassified as mantle cell Four CLL cases had IGH fusion with BCL2 BCL3 2 cases and BCL11A no fusion partner was detected in 7 cases Morphologic features were atypical for CLL in 2 cases with IGH fusion BCL11A and BCL3 The FISH CLL panel is useful to identify prognostic aberrations and to clarify diagnosis in cases with unusual morphologic features,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8081, 1591, 4, 957, 1554, 1277, 16, 35, 1091, 6, 809, 1170, 65, 1, 442, 1193, 552, 37, 21, 311, 5312, 347, 29, 4829, 899, 552, 140, 75, 8, 1277, 993, 10265, 471, 5, 3701, 6, 5737, 3214, 17938, 31137, 256, 1371, 31138, 2, 8, 4338, 5461, 2593, 4013, 1260, 5221, 2888, 10, 1822, 492, 80, 76, 18, 2312, 9, 12077, 489, 9, 3167, 140, 125, 11, 1952, 74, 9, 65, 1, 3167, 140, 865, 720, 83, 42, 14, 15, 80, 336, 1171, 3, 96, 908, 3698, 10, 8453, 370, 20, 6317, 133, 7203, 2, 4135, 4, 233, 140, 125, 11, 5221, 1171, 100, 140, 5, 5737, 5221, 1212, 11, 7864, 22, 2757, 31, 294, 552, 140, 42, 5221, 1212, 5, 3214, 17938, 18, 140, 2, 31137, 77, 1212, 4852, 10, 530, 4, 67, 140, 2815, 404, 11, 1973, 9, 552, 4, 18, 140, 5, 5221, 1212, 31137, 2, 17938, 3, 1277, 552, 993, 16, 999, 6, 255, 177, 2152, 2, 6, 3968, 147, 4, 140, 5, 4015, 2815, 404]",996.0,17638669,14
"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.",Blood,Blood,2007-07-25,"CXCL13 is a homeostatic chemokine for lymphocyte homing and positioning within follicles of secondary lymphoid tissues, acting through its cognate receptor, CXCR5. Moreover, the CXCR5-CXCL13 axis plays a unique role in trafficking and homing of B1 cells. Here, we report that chronic lymphocytic leukemia (CLL) B cells express high levels of functional CXCR5. CXCR5 expression levels were similar on CLL B cells and normal CD5+ B cells, and higher compared with normal CD5- B cells, follicular B-helper T cells (T(FH) cells), or neoplastic B cells from other B-cell neoplasias. Stimulation of CLL cells with CXCL13 induces actin polymerization, CXCR5 endocytosis, chemotaxis, and prolonged activation of p44/42 mitogen-activated protein kinases. Anti-CXCR5 antibodies, pertussis toxin, and wortmannin inhibited chemotaxis to CXCL13, demonstrating the importance of Gi proteins and PI3 kinases for CXCR5 signaling. Moreover, CLL patients had significantly higher CXCL13 serum levels than volunteers, and CXCL13 levels correlated with beta2 microglobulin. We detected CXCL13 mRNA expression by nurselike cells, and high levels of CXCL13 protein in supernatants of CLL nurselike cell cultures. By immunohistochemistry, we detected CXCL13+ expression by CD68+ macrophages in situ within CLL lymph nodes. These data suggest that CXCR5 plays a role in CLL cell positioning and cognate interactions between CLL and CXCL13-secreting CD68+ accessory cells in lymphoid tissues.",Journal Article,4563.0,143.0,CXCL13 is a homeostatic chemokine for lymphocyte homing and positioning within follicles of secondary lymphoid tissues acting through its cognate receptor CXCR5 Moreover the CXCR5-CXCL13 axis plays a unique role in trafficking and homing of B1 cells Here we report that chronic lymphocytic CLL B cells express high levels of functional CXCR5 CXCR5 expression levels were similar on CLL B cells and normal CD5+ B cells and higher compared with normal CD5- B cells follicular B-helper T cells T FH cells or neoplastic B cells from other B-cell neoplasias Stimulation of CLL cells with CXCL13 induces actin polymerization CXCR5 endocytosis chemotaxis and prolonged activation of p44/42 mitogen-activated protein kinases Anti-CXCR5 antibodies pertussis toxin and wortmannin inhibited chemotaxis to CXCL13 demonstrating the importance of Gi proteins and PI3 kinases for CXCR5 signaling Moreover CLL patients had significantly higher CXCL13 serum levels than volunteers and CXCL13 levels correlated with beta2 microglobulin We detected CXCL13 mRNA expression by nurselike cells and high levels of CXCL13 protein in supernatants of CLL nurselike cell cultures By immunohistochemistry we detected CXCL13+ expression by CD68+ macrophages in situ within CLL lymph nodes These data suggest that CXCR5 plays a role in CLL cell positioning and cognate interactions between CLL and CXCL13-secreting CD68+ accessory cells in lymphoid tissues,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[9462, 16, 8, 11334, 3596, 9, 1448, 5515, 2, 7172, 262, 17600, 1, 568, 2303, 742, 5375, 298, 211, 8903, 153, 13280, 1393, 3, 13280, 9462, 2310, 1698, 8, 991, 200, 4, 6105, 2, 5515, 1, 7018, 37, 467, 21, 414, 17, 442, 1193, 552, 132, 37, 1669, 64, 148, 1, 583, 13280, 13280, 55, 148, 11, 288, 23, 552, 132, 37, 2, 295, 6349, 132, 37, 2, 142, 72, 5, 295, 6349, 132, 37, 1974, 132, 5539, 102, 37, 102, 5348, 37, 15, 2000, 132, 37, 29, 127, 132, 31, 8235, 2503, 1, 552, 37, 5, 9462, 1516, 5525, 12273, 13280, 11504, 12561, 2, 1069, 363, 1, 12996, 595, 2625, 735, 178, 1549, 312, 13280, 890, 21457, 8848, 2, 16726, 879, 12561, 6, 9462, 2219, 3, 1187, 1, 2104, 652, 2, 6892, 1549, 9, 13280, 314, 1393, 552, 7, 42, 97, 142, 9462, 524, 148, 76, 5495, 2, 9462, 148, 438, 5, 8911, 5371, 21, 530, 9462, 956, 55, 20, 28698, 37, 2, 64, 148, 1, 9462, 178, 4, 12142, 1, 552, 28698, 31, 3231, 20, 888, 21, 530, 9462, 55, 20, 6439, 2748, 4, 957, 262, 552, 263, 502, 46, 74, 309, 17, 13280, 1698, 8, 200, 4, 552, 31, 7172, 2, 8903, 1286, 59, 552, 2, 9462, 5052, 6439, 12082, 37, 4, 2303, 742]",1426.0,17652619,441
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-08-01,"Therapeutic antibodies have improved the outcome for patients with chronic lymphocytic leukemia (CLL). We conducted a phase 1, dose escalation and schedule optimization study of the primatized anti-CD23 antibody, lumiliximab, in patients with previously treated and refractory CLL. Forty-six patients were assigned sequentially to cohorts 1 through 6 and received lumiliximab at 125, 250, or 375 mg/m(2) weekly for 4 weeks; 500 mg/m(2) weekly for 4 weeks [500(A)]; 500 mg/m(2) thrice during week 1 then 500 mg/m(2) weekly for the next 3 weeks [500(B)]; or 500 mg/m(2) thrice a week for 4 weeks [500(C)], respectively. The median age was 62 years (range, 47-80), and the median number of prior regimens was four (range, 1-13). No partial or complete responses were observed. Toxicity was limited and unrelated to dose. The pharmacokinetics of lumiliximab was similar to other IgG(1) monoclonal antibodies with accumulation at doses > or =250 mg/m(2) and a median terminal half-life of 7 days. Pharmacodynamic studies showed dose-dependent increases in soluble CD23, but no down-regulation of CD23 antigen. Saturation of CD23 receptors occurred at 250 mg/m(2) and was maintained for > or =1 week following completion of therapy at > or =375 mg/m(2). Treatment with lumiliximab seemed to be well tolerated and to have clinical activity in patients with relapsed or refractory CLL.","Clinical Trial, Phase I",4556.0,92.0,Therapeutic antibodies have improved the outcome for patients with chronic lymphocytic CLL We conducted a phase 1 dose escalation and schedule optimization study of the primatized anti-CD23 antibody lumiliximab in patients with previously treated and refractory CLL Forty-six patients were assigned sequentially to cohorts 1 through 6 and received lumiliximab at 125 250 or 375 mg/m 2 weekly for 4 weeks 500 mg/m 2 weekly for 4 weeks 500 A 500 mg/m 2 thrice during week 1 then 500 mg/m 2 weekly for the next 3 weeks 500 B or 500 mg/m 2 thrice a week for 4 weeks 500 C respectively The median age was 62 years range 47-80 and the median number of prior regimens was four range 1-13 No partial or complete responses were observed Toxicity was limited and unrelated to dose The pharmacokinetics of lumiliximab was similar to other IgG 1 monoclonal antibodies with accumulation at doses or =250 mg/m 2 and a median terminal half-life of 7 days Pharmacodynamic studies showed dose-dependent increases in soluble CD23 but no down-regulation of CD23 antigen Saturation of CD23 receptors occurred at 250 mg/m 2 and was maintained for or =1 week following completion of therapy at or =375 mg/m 2 Treatment with lumiliximab seemed to be well tolerated and to have clinical activity in patients with relapsed or refractory CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[189, 890, 47, 231, 3, 228, 9, 7, 5, 442, 1193, 552, 21, 426, 8, 124, 14, 61, 1125, 2, 1055, 3980, 45, 1, 3, 38502, 312, 9937, 548, 16443, 4, 7, 5, 373, 73, 2, 430, 552, 1213, 437, 7, 11, 896, 5455, 6, 736, 14, 298, 49, 2, 103, 16443, 28, 1731, 2039, 15, 4175, 81, 188, 18, 709, 9, 39, 244, 1666, 81, 188, 18, 709, 9, 39, 244, 1666, 8, 1666, 81, 188, 18, 10058, 190, 647, 14, 818, 1666, 81, 188, 18, 709, 9, 3, 1305, 27, 244, 1666, 132, 15, 1666, 81, 188, 18, 10058, 8, 647, 9, 39, 244, 1666, 256, 106, 3, 52, 89, 10, 744, 60, 184, 662, 493, 2, 3, 52, 207, 1, 324, 472, 10, 294, 184, 14, 233, 77, 450, 15, 236, 253, 11, 164, 155, 10, 383, 2, 2092, 6, 61, 3, 1159, 1, 16443, 10, 288, 6, 127, 3630, 14, 848, 890, 5, 1835, 28, 415, 15, 2039, 81, 188, 18, 2, 8, 52, 2158, 1303, 358, 1, 67, 162, 2424, 94, 224, 61, 470, 1106, 4, 2968, 9937, 84, 77, 1328, 863, 1, 9937, 448, 7506, 1, 9937, 1186, 489, 28, 2039, 81, 188, 18, 2, 10, 1955, 9, 15, 14, 647, 366, 1438, 1, 36, 28, 15, 4175, 81, 188, 18, 24, 5, 16443, 5025, 6, 40, 149, 421, 2, 6, 47, 38, 128, 4, 7, 5, 591, 15, 430, 552]",1315.0,17671129,84
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.,Blood,Blood,2007-08-03,"We analyzed the immunoglobulin (Ig) variable heavy (IGHV) and variable light chain genes used by leukemia cells of 258 unrelated patients with chronic lymphocytic leukemia (CLL) found to express unmutated Ig heavy chains (IgH) encoded by a 51p1 allele of IGHV1-69 among 1846 CLL patients examined. We found each had at least 98% homology to an identified germline IGKV or IGLV gene. Within the 258 IgH, we identified heavy chain CDR3 (HCDR3) motifs encoded by certain unmutated IGHD and IGHJ genes with restricted reading frames. Frequent and restricted use of particular IGKV and IGLV genes revealed nonstochastic pairing of disparate Ig light chains (IgL) with IgH that had restricted HCDR3 motifs designated CLL69A, -B, -C, and -D. Eighty-six percent (19/22) of CLL cases that expressed motif CLL69B encoded by IGHD2-2/IGHJ6 had distinctive IgL encoded by IGKV1-39. Similarly, 83% (5/6) of samples with motif CLL69D encoded by IGHD2-2/IGHJ6 expressed IGKV3-11, 100% (25/25) with motif CLL69A encoded by IGHD3-16/IGHJ3 used IGKV3-20, and 77% (10/13) with motif CLL69C encoded by IGHD3-3/IGHJ6 expressed IGLV3-9. This study reveals nonstochastic pairing of IgH with particular IgL that is predicated upon Ig HCDR3 structure, providing compelling evidence for selection of antibodies expressed in CLL by conventional antigens.",Journal Article,4554.0,34.0,We analyzed the immunoglobulin Ig variable heavy IGHV and variable light chain genes used by cells of 258 unrelated patients with chronic lymphocytic CLL found to express unmutated Ig heavy chains IgH encoded by a 51p1 allele of IGHV1-69 among 1846 CLL patients examined We found each had at least 98 homology to an identified germline IGKV or IGLV gene Within the 258 IgH we identified heavy chain CDR3 HCDR3 motifs encoded by certain unmutated IGHD and IGHJ genes with restricted reading frames Frequent and restricted use of particular IGKV and IGLV genes revealed nonstochastic pairing of disparate Ig light chains IgL with IgH that had restricted HCDR3 motifs designated CLL69A -B -C and -D. Eighty-six percent 19/22 of CLL cases that expressed motif CLL69B encoded by IGHD2-2/IGHJ6 had distinctive IgL encoded by IGKV1-39 Similarly 83 5/6 of samples with motif CLL69D encoded by IGHD2-2/IGHJ6 expressed IGKV3-11 100 25/25 with motif CLL69A encoded by IGHD3-16/IGHJ3 used IGKV3-20 and 77 10/13 with motif CLL69C encoded by IGHD3-3/IGHJ6 expressed IGLV3-9 This study reveals nonstochastic pairing of IgH with particular IgL that is predicated upon Ig HCDR3 structure providing compelling evidence for selection of antibodies expressed in CLL by conventional antigens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 311, 3, 2593, 4200, 1347, 4013, 6220, 2, 1347, 1691, 1260, 214, 95, 20, 37, 1, 8289, 2092, 7, 5, 442, 1193, 552, 204, 6, 1669, 7216, 4200, 4013, 7802, 5221, 4587, 20, 8, 43645, 1254, 1, 56442, 790, 107, 43726, 552, 7, 409, 21, 204, 296, 42, 28, 506, 1096, 7984, 6, 35, 108, 1009, 38509, 15, 38510, 145, 262, 3, 8289, 5221, 21, 108, 4013, 1260, 14485, 23615, 8578, 4587, 20, 1840, 7216, 31151, 2, 44799, 214, 5, 2016, 7299, 13302, 908, 2, 2016, 119, 1, 1454, 38509, 2, 38510, 214, 553, 44800, 19737, 1, 7985, 4200, 1691, 7802, 17659, 5, 5221, 17, 42, 2016, 23615, 8578, 4107, 44801, 132, 256, 2, 427, 2207, 437, 714, 326, 350, 1, 552, 140, 17, 570, 5298, 56443, 4587, 20, 44802, 18, 38511, 42, 5049, 17659, 4587, 20, 56444, 587, 1813, 852, 33, 49, 1, 347, 5, 5298, 56445, 4587, 20, 44802, 18, 38511, 570, 34306, 175, 394, 243, 243, 5, 5298, 44801, 4587, 20, 34307, 245, 56446, 95, 34306, 179, 2, 849, 79, 233, 5, 5298, 56447, 4587, 20, 34307, 27, 38511, 570, 34308, 83, 26, 45, 4054, 44800, 19737, 1, 5221, 5, 1454, 17659, 17, 16, 20212, 1548, 4200, 23615, 2772, 1736, 6051, 241, 9, 881, 1, 890, 570, 4, 552, 20, 809, 1575]",1270.0,17675554,243
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.,Blood,Blood,2007-08-08,"Chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders display familial aggregation. To identify a susceptibility gene for CLL, we assembled families from the major European (ICLLC) and American (GEC) consortia to conduct a genome-wide linkage analysis of 101 new CLL pedigrees using a high-density single nucleotide polymorphism (SNP) array and combined the results with data from our previously reported analysis of 105 families. Here, we report on the combined analysis of the 206 families. Multipoint linkage analyses were undertaken using both nonparametric (model-free) and parametric (model-based) methods. After the removal of high linkage disequilibrium SNPs, we obtained a maximum nonparametric linkage (NPL) score of 3.02 (P = .001) on chromosome 2q21.2. The same genomic position also yielded the highest multipoint heterogeneity LOD (HLOD) score under a common recessive model of disease susceptibility (HLOD = 3.11; P = 7.7 x 10(-5)), which was significant at the genome-wide level. In addition, 2 other chromosomal positions, 6p22.1 (corresponding to the major histocompatibility locus) and 18q21.1, displayed HLOD scores higher than 2.1 (P < .002). None of the regions coincided with areas of common chromosomal abnormalities frequently observed in CLL. These findings provide direct evidence for Mendelian predisposition to CLL and evidence for the location of disease loci.",Journal Article,4549.0,59.0,Chronic lymphocytic CLL and other B-cell lymphoproliferative disorders display familial aggregation To identify a susceptibility gene for CLL we assembled families from the major European ICLLC and American GEC consortia to conduct a genome-wide linkage analysis of 101 new CLL pedigrees using a high-density single nucleotide polymorphism SNP array and combined the results with data from our previously reported analysis of 105 families Here we report on the combined analysis of the 206 families Multipoint linkage analyses were undertaken using both nonparametric model-free and parametric model-based methods After the removal of high linkage disequilibrium SNPs we obtained a maximum nonparametric linkage NPL score of 3.02 P .001 on chromosome 2q21.2 The same genomic position also yielded the highest multipoint heterogeneity LOD HLOD score under a common recessive model of disease susceptibility HLOD 3.11 P 7.7 x 10 -5 which was significant at the genome-wide level In addition 2 other chromosomal positions 6p22.1 corresponding to the major histocompatibility locus and 18q21.1 displayed HLOD scores higher than 2.1 P .002 None of the regions coincided with areas of common chromosomal abnormalities frequently observed in CLL These findings provide direct evidence for Mendelian predisposition to CLL and evidence for the location of disease loci,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 127, 132, 31, 4192, 1997, 3640, 2200, 6598, 6, 255, 8, 1432, 145, 9, 552, 21, 6154, 1954, 29, 3, 458, 1865, 56456, 2, 597, 10759, 14303, 6, 4073, 8, 898, 1019, 4820, 65, 1, 2338, 217, 552, 14111, 75, 8, 64, 1263, 226, 1579, 1907, 1845, 1926, 2, 397, 3, 99, 5, 74, 29, 114, 373, 210, 65, 1, 3263, 1954, 467, 21, 414, 23, 3, 397, 65, 1, 3, 5956, 1954, 44808, 4820, 318, 11, 2789, 75, 110, 8310, 202, 115, 2, 7590, 202, 90, 636, 50, 3, 2829, 1, 64, 4820, 8459, 1109, 21, 683, 8, 689, 8310, 4820, 56457, 368, 1, 27, 588, 19, 144, 23, 1170, 56458, 18, 3, 827, 572, 3559, 120, 2178, 3, 1076, 44808, 1144, 13024, 33164, 368, 669, 8, 186, 9724, 202, 1, 34, 1432, 33164, 27, 175, 19, 67, 67, 1006, 79, 33, 92, 10, 93, 28, 3, 898, 1019, 301, 4, 352, 18, 127, 1860, 7134, 17940, 14, 1734, 6, 3, 458, 6537, 2474, 2, 17605, 14, 2507, 33164, 703, 142, 76, 18, 14, 19, 1111, 1292, 1, 3, 1374, 13050, 5, 1361, 1, 186, 1860, 1171, 746, 164, 4, 552, 46, 272, 377, 1196, 241, 9, 12728, 2863, 6, 552, 2, 241, 9, 3, 1147, 1, 34, 2012]",1359.0,17687107,81
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.,The Journal of molecular diagnostics : JMD,J Mol Diagn,2007-08-09,"To develop a model incorporating relevant prognostic biomarkers for untreated chronic lymphocytic leukemia patients, we re-analyzed the raw data from four published gene expression profiling studies. We selected 88 candidate biomarkers linked to immunoglobulin heavy-chain variable region gene (IgV(H)) mutation status and produced a reliable and reproducible microfluidics quantitative real-time polymerase chain reaction array. We applied this array to a training set of 29 purified samples from previously untreated patients. In an unsupervised analysis, the samples clustered into two groups. Using a cutoff point of 2% homology to the germline IgV(H) sequence, one group contained all 14 IgV(H)-unmutated samples; the other contained all 15 mutated samples. We confirmed the differential expression of 37 of the candidate biomarkers using two-sample t-tests. Next, we constructed 16 different models to predict IgV(H) mutation status and evaluated their performance on an independent test set of 20 new samples. Nine models correctly classified 11 of 11 IgV(H)-mutated cases and eight of nine IgV(H)-unmutated cases, with some models using three to seven genes. Thus, we can classify cases with 95% accuracy based on the expression of as few as three genes.",Journal Article,4548.0,21.0,To develop a model incorporating relevant prognostic biomarkers for untreated chronic lymphocytic patients we re-analyzed the raw data from four published gene expression profiling studies We selected 88 candidate biomarkers linked to immunoglobulin heavy-chain variable region gene IgV H mutation status and produced a reliable and reproducible microfluidics quantitative real-time polymerase chain reaction array We applied this array to a training set of 29 purified samples from previously untreated patients In an unsupervised analysis the samples clustered into two groups Using a cutoff point of 2 homology to the germline IgV H sequence one group contained all 14 IgV H -unmutated samples the other contained all 15 mutated samples We confirmed the differential expression of 37 of the candidate biomarkers using two-sample t-tests Next we constructed 16 different models to predict IgV H mutation status and evaluated their performance on an independent test set of 20 new samples Nine models correctly classified 11 of 11 IgV H -mutated cases and eight of nine IgV H -unmutated cases with some models using three to seven genes Thus we can classify cases with 95 accuracy based on the expression of as few as three genes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 690, 8, 202, 2570, 867, 177, 582, 9, 1278, 442, 1193, 7, 21, 1491, 311, 3, 10170, 74, 29, 294, 983, 145, 55, 1080, 94, 21, 715, 889, 1609, 582, 1199, 6, 2593, 4013, 1260, 1347, 1053, 145, 12179, 555, 258, 156, 2, 1687, 8, 2450, 2, 4172, 34314, 1156, 1589, 98, 1451, 1260, 1329, 1926, 21, 1498, 26, 1926, 6, 8, 1741, 916, 1, 462, 5963, 347, 29, 373, 1278, 7, 4, 35, 6512, 65, 3, 347, 6464, 237, 100, 271, 75, 8, 2779, 741, 1, 18, 7984, 6, 3, 1009, 12179, 555, 1532, 104, 87, 3070, 62, 213, 12179, 555, 7216, 347, 3, 127, 3070, 62, 167, 1185, 347, 21, 557, 3, 1777, 55, 1, 567, 1, 3, 1609, 582, 75, 100, 1000, 102, 895, 1305, 21, 2776, 245, 338, 274, 6, 678, 12179, 555, 258, 156, 2, 194, 136, 528, 23, 35, 306, 412, 916, 1, 179, 217, 347, 762, 274, 4911, 1373, 175, 1, 175, 12179, 555, 1185, 140, 2, 659, 1, 762, 12179, 555, 7216, 140, 5, 476, 274, 75, 169, 6, 648, 214, 631, 21, 122, 4896, 140, 5, 48, 1190, 90, 23, 3, 55, 1, 22, 1021, 22, 169, 214]",1230.0,17690214,312
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2007-09-01,"Chronic lymphocytic leukemia (CLL) is a common leukemia with a highly variable natural history. A subset of patients with high-risk CLL rapidly progress to develop symptomatic disease requiring treatment. Over-represented in this group are those who have a deletion of 17p13.1, the chromosomal location of the tumor suppressor gene P53. Of all prognostic factors examined in CLL, del(17p13.1) has a superior predictive value for poor response to conventional therapy. In this article we review the current published data on prognostic factors relevant to treatment in CLL. We next provide therapeutic recommendations for patients with del(17p13.1) that are available to oncologists in general practice. Chemoimmunotherapy, alemtuzumab, or high-dose corticosteroids are all effective as initial therapy for these patients, but progression is generally rapid. If allogeneic immune therapy is to be considered, it should be approached as part of initial or first salvage therapy. The investigational agent flavopiridol has also demonstrated clinical activity in this subset of patients. Identification of small molecules and new treatment approaches for patients with del(17p13.1) is a major focus of several investigators. Selection of therapy based on high-risk genomic features represents an appropriate treatment approach supported by currently available published data.",Journal Article,4525.0,28.0,Chronic lymphocytic CLL is a common with a highly variable natural history A subset of patients with high-risk CLL rapidly progress to develop symptomatic disease requiring treatment Over-represented in this group are those who have a deletion of 17p13.1 the chromosomal location of the tumor suppressor gene P53 Of all prognostic factors examined in CLL del 17p13.1 has a superior predictive value for poor response to conventional therapy In this article we review the current published data on prognostic factors relevant to treatment in CLL We next provide therapeutic recommendations for patients with del 17p13.1 that are available to oncologists in general practice Chemoimmunotherapy alemtuzumab or high-dose corticosteroids are all effective as initial therapy for these patients but progression is generally rapid If allogeneic immune therapy is to be considered it should be approached as part of initial or first salvage therapy The investigational agent flavopiridol has also demonstrated clinical activity in this subset of patients Identification of small molecules and new treatment approaches for patients with del 17p13.1 is a major focus of several investigators Selection of therapy based on high-risk genomic features represents an appropriate treatment approach supported by currently available published data,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 186, 5, 8, 561, 1347, 1504, 532, 8, 697, 1, 7, 5, 64, 43, 552, 1755, 1466, 6, 690, 1704, 34, 1888, 24, 252, 3324, 4, 26, 87, 32, 135, 54, 47, 8, 1528, 1, 7526, 14, 3, 1860, 1147, 1, 3, 30, 1245, 145, 624, 1, 62, 177, 130, 409, 4, 552, 3084, 7526, 14, 71, 8, 1123, 464, 549, 9, 334, 51, 6, 809, 36, 4, 26, 946, 21, 206, 3, 291, 983, 74, 23, 177, 130, 867, 6, 24, 4, 552, 21, 1305, 377, 189, 883, 9, 7, 5, 3084, 7526, 14, 17, 32, 390, 6, 1339, 4, 1083, 758, 4438, 3579, 15, 64, 61, 3876, 32, 62, 323, 22, 388, 36, 9, 46, 7, 84, 91, 16, 1228, 1321, 492, 1063, 250, 36, 16, 6, 40, 515, 192, 257, 40, 5738, 22, 760, 1, 388, 15, 157, 992, 36, 3, 3093, 420, 3030, 71, 120, 264, 38, 128, 4, 26, 697, 1, 7, 911, 1, 302, 1598, 2, 217, 24, 611, 9, 7, 5, 3084, 7526, 14, 16, 8, 458, 1222, 1, 392, 2394, 881, 1, 36, 90, 23, 64, 43, 572, 404, 1449, 35, 870, 24, 353, 2708, 20, 694, 390, 983, 74]",1331.0,17707839,179
Gene therapy and active immune therapy of hematologic malignancies.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2007-09-01,"Gene therapy for patients with hematologic malignancies, particularly chronic lymphocytic leukemia (CLL), have focused on transducing primary leukemia cells with a virus vector to express immune-stimulating genes which can induce and propagate a productive and clinically significant immune response against the malignant cells. A variety of replication-defective vectors has been studied to transduce genes for cytokines and function-associated surface molecules. Active vaccines have been developed in vitro, and their activity has been confirmed in clinical trials. Ongoing work aims to optimize this strategy and to identify the appropriate and optimal patient groups in which to apply vaccine therapy. Clinical trials also have provided insight into unexpected alternative mechanisms through which these strategies might provide a clinical benefit.",Journal Article,4525.0,11.0,Gene therapy for patients with hematologic malignancies particularly chronic lymphocytic CLL have focused on transducing primary cells with a virus vector to express immune-stimulating genes which can induce and propagate a productive and clinically significant immune response against the malignant cells A variety of replication-defective vectors has been studied to transduce genes for cytokines and function-associated surface molecules Active vaccines have been developed in vitro and their activity has been confirmed in clinical trials Ongoing work aims to optimize this strategy and to identify the appropriate and optimal patient groups in which to apply vaccine therapy Clinical trials also have provided insight into unexpected alternative mechanisms through which these strategies might provide a clinical benefit,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[145, 36, 9, 7, 5, 813, 441, 823, 442, 1193, 552, 47, 1649, 23, 18795, 86, 37, 5, 8, 1450, 3374, 6, 1669, 250, 2122, 214, 92, 122, 1290, 2, 13985, 8, 10110, 2, 505, 93, 250, 51, 480, 3, 393, 37, 8, 1362, 1, 2079, 4552, 5453, 71, 85, 656, 6, 22219, 214, 9, 1886, 2, 343, 41, 1255, 1598, 544, 1842, 47, 85, 276, 4, 439, 2, 136, 128, 71, 85, 557, 4, 38, 143, 942, 1357, 2970, 6, 2465, 26, 692, 2, 6, 255, 3, 870, 2, 665, 69, 271, 4, 92, 6, 4930, 1274, 36, 38, 143, 120, 47, 1052, 2670, 237, 3792, 1091, 483, 298, 92, 46, 422, 822, 377, 8, 38, 247]",825.0,17707840,367
"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.",The Journal of clinical investigation,J. Clin. Invest.,2007-09-01,"Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.",Journal Article,4525.0,271.0,"Blast crisis chronic myelogenous CML-BC and Philadelphia chromosome-positive Ph1-positive acute lymphocytic ALL are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response We recently reported that functional loss of protein phosphatase 2A PP2A activity is important for CML blastic transformation We assessed the therapeutic potential of the PP2A activator FTY720 2-amino-2- 2- 4-octylphenyl ethyl -1,3-propanediol hydrochloride an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190 BCR/ABL myeloid and lymphoid cell lines and CML-BC CD34+ and Ph1 ALL CD34+/CD19+ progenitors but not of normal CD34+ and CD34+/CD19+ marrow cells Furthermore pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190 BCR/ABL -driven including p210/p190 BCR/ABL T315I leukemogenesis without exerting any toxicity Altogether these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3112, 6540, 442, 2194, 903, 1402, 2, 3006, 1170, 109, 21381, 109, 286, 1193, 62, 32, 18, 3034, 1062, 1425, 1621, 2792, 480, 92, 1425, 216, 222, 4373, 6, 1290, 8, 319, 337, 51, 21, 761, 210, 17, 583, 407, 1, 178, 2577, 4707, 7890, 128, 16, 305, 9, 903, 6529, 1392, 21, 275, 3, 189, 174, 1, 3, 7890, 3393, 6340, 18, 3078, 18, 18, 39, 56484, 10559, 14, 27, 56485, 12268, 35, 21196, 4, 124, 316, 143, 9, 7, 5, 232, 7426, 15, 479, 1259, 497, 4, 903, 1402, 2, 21381, 62, 69, 37, 2, 4, 4, 439, 2, 4, 386, 274, 1, 46, 1062, 1425, 2792, 114, 74, 1008, 17, 6340, 1516, 351, 2, 8312, 9880, 1, 577, 1674, 745, 2, 436, 11538, 18813, 1062, 1425, 533, 2, 2303, 31, 285, 2, 903, 1402, 2215, 2, 21381, 62, 2215, 3158, 4321, 84, 44, 1, 295, 2215, 2, 2215, 3158, 581, 37, 798, 2788, 415, 1, 6340, 4856, 3134, 4, 386, 11538, 18813, 1062, 1425, 1621, 141, 11538, 18813, 1062, 1425, 6184, 5661, 187, 17648, 500, 155, 6767, 46, 99, 1817, 3, 189, 2088, 1, 31159, 7890, 30, 1245, 128, 4, 21381, 2792, 2, 1327, 538, 3, 2456, 1, 3, 7890, 3393, 6340, 4, 3, 24, 1, 903, 1402, 2, 21381, 62, 7]",1377.0,17717597,215
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.,Journal of pharmaceutical sciences,J Pharm Sci,2008-04-01,"Fludarabine (FLU)-based combination therapies are commonly used to treat low-grade lymphoma and chronic lymphocytic leukemia (CLL) patients. In vitro and clinical studies have indicated advantages when FLU and mitoxantrone (MTO) are applied in combination. To further enhance this effect, these two agents were coencapsulated in liposomes. FLU was passively encapsulated during liposome formation, and MTO was loaded with a transmembrane pH gradient. Entrapment efficiency, particle size, stability, and drug release kinetics were characterized. In vitro cytotoxicity study was carried out in two representative B-cell lines: Wac3CD5 and Raji. Synergism as measured by combination index (CI) was observed in cells treated with liposomes coencapsulating FLU and MTO. Annexin V/propidium iodide (PI) analysis further confirmed that coencapsulated FLU and MTO improved the percentage of apoptosis among primary CLL cells. These data suggest that adopting liposomes containing coencapsulated drug combinations constitutes a potential strategy to promote drug synergism and may have utility in the treatment of leukemia and lymphoma.",Journal Article,4312.0,17.0,Fludarabine FLU -based combination therapies are commonly used to treat low-grade and chronic lymphocytic CLL patients In vitro and clinical studies have indicated advantages when FLU and mitoxantrone MTO are applied in combination To further enhance this effect these two agents were coencapsulated in liposomes FLU was passively encapsulated during liposome formation and MTO was loaded with a transmembrane pH gradient Entrapment efficiency particle size stability and drug release kinetics were characterized In vitro cytotoxicity study was carried out in two representative B-cell lines Wac3CD5 and Raji Synergism as measured by combination index CI was observed in cells treated with liposomes coencapsulating FLU and MTO Annexin V/propidium iodide PI analysis further confirmed that coencapsulated FLU and MTO improved the percentage of apoptosis among primary CLL cells These data suggest that adopting liposomes containing coencapsulated drug combinations constitutes a potential strategy to promote drug synergism and may have utility in the treatment of and,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 5119, 90, 150, 235, 32, 841, 95, 6, 943, 154, 88, 2, 442, 1193, 552, 7, 4, 439, 2, 38, 94, 47, 1103, 3126, 198, 5119, 2, 4419, 34326, 32, 1498, 4, 150, 6, 195, 1304, 26, 254, 46, 100, 183, 11, 24800, 4, 7438, 5119, 10, 16075, 7431, 190, 8645, 1264, 2, 34326, 10, 4805, 5, 8, 5527, 2058, 7099, 15670, 2904, 5997, 444, 2769, 2, 234, 2008, 3839, 11, 765, 4, 439, 1408, 45, 10, 2629, 1205, 4, 100, 3724, 132, 31, 285, 44738, 2, 9868, 6494, 22, 644, 20, 150, 558, 58, 10, 164, 4, 37, 73, 5, 7438, 38534, 5119, 2, 34326, 4850, 603, 10839, 8456, 2928, 65, 195, 557, 17, 24800, 5119, 2, 34326, 231, 3, 1150, 1, 351, 107, 86, 552, 37, 46, 74, 309, 17, 10096, 7438, 1101, 24800, 234, 1247, 6788, 8, 174, 692, 6, 1617, 234, 6494, 2, 68, 47, 1207, 4, 3, 24, 1, 2]",1068.0,17722102,9
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.,Blood,Blood,2007-08-29,"FTY720 is an immunosuppressant developed to prevent organ transplant rejection. Recent studies indicate an additional role for FTY720 in inducing cell apoptosis. We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chronic lymphocytic leukemia (CLL). In contrast to previous reports in T-cell lines, FTY720-induced toxicity in the Raji cell line and primary CLL B cells is independent of activation of caspases or poly(ADP-ribose) polymerase processing. Further, pancaspase inhibitor Z-VAD-fmk failed to rescue these cells from apoptosis mediated by FTY720. FTY720 induced down-regulation of Mcl-1 but not Bcl-2 in CLL B cells. Overexpression of Bcl-2 failed to protect transformed B cells from FTY720-induced apoptosis, suggesting a Bcl-2-independent mechanism. Interestingly, FTY720 induced protein phosphatase 2a (PP2a) activation and downstream dephosphorylation of ERK1/2, whereas okadaic acid at concentrations that inhibited the FTY720-induced PP2a activation also resulted in inhibition of FTY720-mediated apoptosis and restoration of baseline ERK1/2 phosphorylation in primary CLL cells, indicating a role for PP2a activation in FTY720-induced cytotoxicity. Further, FTY720 treatment resulted in significant prolonged survival in a xenograft severe combined immunodeficiency (SCID) mouse model of disseminated B-cell lymphoma/leukemia. These results provide the first evidence for the potential use of FTY720 as a therapeutic agent in a variety of B-cell malignancies, including CLL.",Journal Article,4528.0,126.0,FTY720 is an immunosuppressant developed to prevent organ transplant rejection Recent studies indicate an additional role for FTY720 in inducing cell apoptosis We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chronic lymphocytic CLL In contrast to previous reports in T-cell lines FTY720-induced toxicity in the Raji cell line and primary CLL B cells is independent of activation of caspases or poly ADP-ribose polymerase processing Further pancaspase inhibitor Z-VAD-fmk failed to rescue these cells from apoptosis mediated by FTY720 FTY720 induced down-regulation of Mcl-1 but not Bcl-2 in CLL B cells Overexpression of Bcl-2 failed to protect transformed B cells from FTY720-induced apoptosis suggesting a Bcl-2-independent mechanism Interestingly FTY720 induced protein phosphatase 2a PP2a activation and downstream dephosphorylation of ERK1/2 whereas okadaic acid at concentrations that inhibited the FTY720-induced PP2a activation also resulted in inhibition of FTY720-mediated apoptosis and restoration of baseline ERK1/2 phosphorylation in primary CLL cells indicating a role for PP2a activation in FTY720-induced cytotoxicity Further FTY720 treatment resulted in significant prolonged survival in a xenograft severe combined immunodeficiency SCID mouse model of disseminated B-cell lymphoma/leukemia These results provide the first evidence for the potential use of FTY720 as a therapeutic agent in a variety of B-cell malignancies including CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6340, 16, 35, 20343, 276, 6, 1682, 1259, 941, 4772, 435, 94, 1008, 35, 402, 200, 9, 6340, 4, 1958, 31, 351, 21, 608, 467, 17, 6340, 3961, 1812, 176, 4, 31, 285, 2861, 338, 132, 31, 441, 2, 86, 132, 37, 29, 7, 5, 442, 1193, 552, 4, 748, 6, 698, 1198, 4, 102, 31, 285, 6340, 277, 155, 4, 3, 9868, 31, 328, 2, 86, 552, 132, 37, 16, 306, 1, 363, 1, 7629, 15, 2699, 3638, 3507, 1451, 3325, 195, 44837, 230, 3905, 10167, 10281, 1551, 6, 4256, 46, 37, 29, 351, 517, 20, 6340, 6340, 277, 1328, 863, 1, 1308, 14, 84, 44, 1044, 18, 4, 552, 132, 37, 851, 1, 1044, 18, 1551, 6, 4869, 2423, 132, 37, 29, 6340, 277, 351, 802, 8, 1044, 18, 306, 670, 2873, 6340, 277, 178, 2577, 4707, 7890, 363, 2, 1489, 7849, 1, 3533, 18, 547, 28519, 971, 28, 1003, 17, 879, 3, 6340, 277, 7890, 363, 120, 627, 4, 297, 1, 6340, 517, 351, 2, 5194, 1, 330, 3533, 18, 982, 4, 86, 552, 37, 1716, 8, 200, 9, 7890, 363, 4, 6340, 277, 1408, 195, 6340, 24, 627, 4, 93, 1069, 25, 4, 8, 1330, 905, 397, 5323, 4129, 830, 202, 1, 3605, 132, 31, 4763, 2647, 46, 99, 377, 3, 157, 241, 9, 3, 174, 119, 1, 6340, 22, 8, 189, 420, 4, 8, 1362, 1, 132, 31, 441, 141, 552]",1556.0,17761520,334
Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2007-09-01,"Infusion of standard-dose rituximab (RTX) in chronic lymphocytic leukemia (CLL) patients promotes rapid complement activation and deposition of C3 fragments on CLL B cells. However, immediately after RTX infusions, there is substantial loss (shaving) of CD20 from circulating malignant cells. Because shaving can compromise efficacies of anticancer immunotherapeutic mAbs, we investigated whether shaving occurs in SCID mouse models. Z138 cells, a B cell line derived from human mantle cell lymphoma, were infused i.v. or s.c. The i.v. model recapitulates findings we previously reported for therapeutic RTX in CLL: i.v. infused RTX rapidly binds to Z138 cells in lungs, and binding is accompanied by deposition of C3 fragments. However, within 1 h targeted cells lose bound RTX and CD20, and these shaved cells are still demonstrable 40 h after RTX infusion. Z138 cells grow in tumors at s.c. injection sites, and infusion of large amounts of RTX (0.50 mg on each of 4 days) leads to considerable loss of CD20 from these cells. Human i.v. Ig blocked shaving, suggesting that FcgammaRI on cells of the mononuclear phagocytic system promote shaving. Examination of frozen tumor sections from treated mice by immunofluorescence revealed large areas of B cells devoid of CD20, with CD20 intact in adjacent areas; it is likely that RTX had opsonized Z138 cells closest to capillaries, and these cells were shaved by monocyte/macrophages. The shaving reaction occurs in neoplastic B cells in tissue and in peripheral blood, and strategies to enhance therapeutic targeting and block shaving are under development.",Journal Article,4525.0,49.0,Infusion of standard-dose rituximab RTX in chronic lymphocytic CLL patients promotes rapid complement activation and deposition of C3 fragments on CLL B cells However immediately after RTX infusions there is substantial loss shaving of CD20 from circulating malignant cells Because shaving can compromise efficacies of anticancer immunotherapeutic mAbs we investigated whether shaving occurs in SCID mouse models Z138 cells a B cell line derived from human mantle cell were infused i.v or s.c The i.v model recapitulates findings we previously reported for therapeutic RTX in CLL i.v infused RTX rapidly binds to Z138 cells in lungs and binding is accompanied by deposition of C3 fragments However within 1 h targeted cells lose bound RTX and CD20 and these shaved cells are still demonstrable 40 h after RTX infusion Z138 cells grow in tumors at s.c. injection sites and infusion of large amounts of RTX 0.50 mg on each of 4 days leads to considerable loss of CD20 from these cells Human i.v Ig blocked shaving suggesting that FcgammaRI on cells of the mononuclear phagocytic system promote shaving Examination of frozen tumor sections from treated mice by immunofluorescence revealed large areas of B cells devoid of CD20 with CD20 intact in adjacent areas it is likely that RTX had opsonized Z138 cells closest to capillaries and these cells were shaved by monocyte/macrophages The shaving reaction occurs in neoplastic B cells in tissue and in peripheral blood and strategies to enhance therapeutic targeting and block shaving are under development,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[904, 1, 260, 61, 855, 10916, 4, 442, 1193, 552, 7, 2148, 1321, 3731, 363, 2, 6686, 1, 8732, 5843, 23, 552, 132, 37, 137, 3467, 50, 10916, 3435, 125, 16, 1281, 407, 17331, 1, 2198, 29, 1033, 393, 37, 408, 17331, 122, 4665, 14198, 1, 1475, 3222, 5207, 21, 565, 317, 17331, 1780, 4, 4129, 830, 274, 31164, 37, 8, 132, 31, 328, 526, 29, 171, 2757, 31, 11, 4524, 70, 603, 15, 695, 256, 3, 70, 603, 202, 11076, 272, 21, 373, 210, 9, 189, 10916, 4, 552, 70, 603, 4524, 10916, 1755, 3333, 6, 31164, 37, 4, 4465, 2, 791, 16, 2756, 20, 6686, 1, 8732, 5843, 137, 262, 14, 555, 238, 37, 11027, 2951, 10916, 2, 2198, 2, 46, 17349, 37, 32, 1234, 11411, 327, 555, 50, 10916, 904, 31164, 37, 6265, 4, 57, 28, 695, 256, 1754, 633, 2, 904, 1, 375, 4939, 1, 10916, 13, 212, 81, 23, 296, 1, 39, 162, 1940, 6, 2658, 407, 1, 2198, 29, 46, 37, 171, 70, 603, 4200, 2582, 17331, 802, 17, 33570, 23, 37, 1, 3, 3041, 19415, 398, 1617, 17331, 1385, 1, 3015, 30, 3013, 29, 73, 399, 20, 4130, 553, 375, 1361, 1, 132, 37, 15126, 1, 2198, 5, 2198, 2964, 4, 2086, 1361, 192, 16, 322, 17, 10916, 42, 22192, 31164, 37, 12197, 6, 26442, 2, 46, 37, 11, 17349, 20, 5231, 2748, 3, 17331, 1329, 1780, 4, 2000, 132, 37, 4, 246, 2, 4, 672, 315, 2, 422, 6, 1304, 189, 529, 2, 2381, 17331, 32, 669, 193]",1552.0,17785867,24
Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients.,British journal of haematology,Br. J. Haematol.,2007-10-01,"Although a diagnosis of chronic lymphocytic leukemia (CLL) can have a profound effect on the quality of life (QOL), few studies have objectively measured the QOL of CLL patients or compared it to the general population. We conducted an international, web-based survey of patients with CLL using standardized instruments with published population norms to evaluate fatigue and QOL. Co-morbid health conditions were assessed using the Charlson Co-Morbidity Index. Between June and October 2006, 1482 patients with CLL responded to the survey. The physical, social/family, functional, and overall QOL scores of CLL patients were similar to or better than published population norms. In contrast, the emotional well-being scores of CLL patients were dramatically lower than that of both the general population (P < 0.001) and patients with other types of cancer (P < 0.001). QOL scores were lower among individuals with advanced stage disease (all P < 0.05). Factors associated with lower overall QOL on multivariate analysis included older age, greater fatigue, severity of co-morbid health conditions, and current treatment. CLL has a profound impact on QOL at all disease stages. The effects of CLL on QOL appear to differ from that of other malignancies with a more marked impact on emotional QOL. Research identifying efficacious psycho-oncologic support interventions for patients with CLL is needed.",Comparative Study,4495.0,69.0,Although a diagnosis of chronic lymphocytic CLL can have a profound effect on the quality of life QOL few studies have objectively measured the QOL of CLL patients or compared it to the general population We conducted an international web-based survey of patients with CLL using standardized instruments with published population norms to evaluate fatigue and QOL Co-morbid health conditions were assessed using the Charlson Co-Morbidity Index Between June and October 2006 1482 patients with CLL responded to the survey The physical social/family functional and overall QOL scores of CLL patients were similar to or better than published population norms In contrast the emotional well-being scores of CLL patients were dramatically lower than that of both the general population P 0.001 and patients with other types of cancer P 0.001 QOL scores were lower among individuals with advanced stage disease all P 0.05 Factors associated with lower overall QOL on multivariate analysis included older age greater fatigue severity of co-morbid health conditions and current treatment CLL has a profound impact on QOL at all disease stages The effects of CLL on QOL appear to differ from that of other malignancies with a more marked impact on emotional QOL Research identifying efficacious psycho-oncologic support interventions for patients with CLL is needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 8, 147, 1, 442, 1193, 552, 122, 47, 8, 4399, 254, 23, 3, 372, 1, 358, 1001, 1021, 94, 47, 8731, 644, 3, 1001, 1, 552, 7, 15, 72, 192, 6, 3, 1083, 266, 21, 426, 35, 944, 3469, 90, 1407, 1, 7, 5, 552, 75, 1670, 4730, 5, 983, 266, 9875, 6, 376, 613, 2, 1001, 1269, 8188, 341, 1298, 11, 275, 75, 3, 4670, 1269, 787, 558, 59, 1924, 2, 2551, 1324, 38563, 7, 5, 552, 2211, 6, 3, 1407, 3, 900, 2032, 607, 583, 2, 63, 1001, 703, 1, 552, 7, 11, 288, 6, 15, 380, 76, 983, 266, 9875, 4, 748, 3, 2671, 149, 486, 703, 1, 552, 7, 11, 2729, 280, 76, 17, 1, 110, 3, 1083, 266, 19, 13, 144, 2, 7, 5, 127, 630, 1, 12, 19, 13, 144, 1001, 703, 11, 280, 107, 869, 5, 131, 82, 34, 62, 19, 13, 474, 130, 41, 5, 280, 63, 1001, 23, 331, 65, 159, 434, 89, 378, 613, 1702, 1, 1269, 8188, 341, 1298, 2, 291, 24, 552, 71, 8, 4399, 345, 23, 1001, 28, 62, 34, 1153, 3, 176, 1, 552, 23, 1001, 1322, 6, 1505, 29, 17, 1, 127, 441, 5, 8, 80, 2003, 345, 23, 2671, 1001, 389, 1386, 3289, 18464, 1998, 538, 1151, 9, 7, 5, 552, 16, 575]",1356.0,17897301,444
Flavopiridol in the treatment of chronic lymphocytic leukemia.,Current opinion in oncology,Curr Opin Oncol,2007-11-01,"The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic leukemia cells in vitro; however, initial studies administering flavopiridol by a 24- to 72-h continuous intravenous infusion demonstrated no clinical activity. This review focuses on a novel dosing regimen that has achieved significant clinical activity in relapsed, poor-risk chronic lymphocytic leukemia. Binding to human plasma proteins reduces free flavopiridol concentration and makes continuous intravenous infusion dosing ineffective. Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion would achieve serum concentrations necessary to induce in-vivo apoptosis. Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia. Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia. Careful monitoring and aggressive intervention for hyperkalemia, including hemodialysis if necessary, allowed flavopiridol to be given safely. Nineteen of 42 patients responded (45%), including five of 12 patients (42%) with del(17p13) and 13 of 18 patients (72%) with del(11q22). Flavopiridol, when administered by a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion, is active in high-risk, refractory chronic lymphocytic leukemia. Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration. Further studies to optimize the dose and schedule of administration, and to study this drug in other hematologic malignancies, are ongoing.",Journal Article,4464.0,45.0,The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic cells in vitro however initial studies administering flavopiridol by a 24- to 72-h continuous intravenous infusion demonstrated no clinical activity This review focuses on a novel dosing regimen that has achieved significant clinical activity in relapsed poor-risk chronic lymphocytic Binding to human plasma proteins reduces free flavopiridol concentration and makes continuous intravenous infusion dosing ineffective Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion would achieve serum concentrations necessary to induce in-vivo apoptosis Our institution conducted a phase I study in relapsed chronic lymphocytic Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia Careful monitoring and aggressive intervention for hyperkalemia including hemodialysis if necessary allowed flavopiridol to be given safely Nineteen of 42 patients responded 45 including five of 12 patients 42 with del 17p13 and 13 of 18 patients 72 with del 11q22 Flavopiridol when administered by a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion is active in high-risk refractory chronic lymphocytic Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration Further studies to optimize the dose and schedule of administration and to study this drug in other hematologic malignancies are ongoing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 3273, 30341, 3030, 1516, 351, 1, 442, 1193, 37, 4, 439, 137, 388, 94, 5776, 3030, 20, 8, 259, 6, 720, 555, 1314, 1262, 904, 264, 77, 38, 128, 26, 206, 3026, 23, 8, 229, 1280, 477, 17, 71, 513, 93, 38, 128, 4, 591, 334, 43, 442, 1193, 791, 6, 171, 554, 652, 2389, 115, 3030, 1227, 2, 4677, 1314, 1262, 904, 1280, 3957, 1456, 2057, 1103, 17, 5776, 3030, 20, 8, 201, 1538, 1262, 3604, 370, 20, 8, 39, 555, 1314, 1262, 904, 688, 1359, 524, 1003, 1493, 6, 1290, 4, 386, 351, 114, 731, 426, 8, 124, 70, 45, 4, 591, 442, 1193, 61, 817, 155, 10, 286, 30, 4783, 681, 1113, 4, 3034, 26635, 3465, 1315, 2, 571, 788, 9, 26635, 141, 11170, 492, 1493, 2313, 3030, 6, 40, 447, 2268, 3498, 1, 595, 7, 2211, 512, 141, 365, 1, 133, 7, 595, 5, 3084, 7526, 2, 233, 1, 203, 7, 720, 5, 3084, 12647, 3030, 198, 468, 20, 8, 201, 1538, 1262, 3604, 370, 20, 8, 39, 555, 1314, 1262, 904, 16, 544, 4, 64, 43, 430, 442, 1193, 3465, 1315, 2, 571, 788, 9, 30, 4783, 681, 2, 26635, 16, 1493, 9, 1165, 234, 634, 195, 94, 6, 2465, 3, 61, 2, 1055, 1, 634, 2, 6, 45, 26, 234, 4, 127, 813, 441, 32, 942]",1572.0,17906454,33
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.,Leukemia & lymphoma,Leuk. Lymphoma,2007-10-01,"The natural history and outcome of salvage treatment for patients with fludarabine-refractory chronic lymphocytic leukemia who are either refractory to alemtuzumab (""double-refractory"") or ineligible for alemtuzumab due to bulky lymphadenopathy (""bulky fludarabine-refractory"") have not been described. We present the outcomes of 99 such patients (double-refractory n = 58, bulky fludarabine-refractory n = 41) undergoing their first salvage treatment at our center. Patients received a variety of salvage regimens including monoclonal antibodies (n = 15), single-agent cytotoxic drugs (n = 14), purine analogue combination regimens (n = 21), intensive combination chemotherapy (n = 36), allogeneic stem cell transplantation (SCT; n = 4), or other therapies (n = 9). Overall response to first salvage therapy other than SCT was 23%, with no complete responses. All four patients who underwent SCT as first salvage achieved complete remission. Early death (within 8 weeks of commencing first salvage) occurred in 13% of patients, and 54% of patients experienced a major infection during therapy. Overall survival was 9 months, with hemoglobin < 11 g/dL (hazard ratio 2.3), hepatomegaly (hazard ratio 2.4), and performance status > or = 2 (hazard ratio 1.9) being significant independent predictors of inferior survival.",Journal Article,4495.0,78.0,The natural history and outcome of salvage treatment for patients with fludarabine-refractory chronic lymphocytic who are either refractory to alemtuzumab `` double-refractory '' or ineligible for alemtuzumab due to bulky lymphadenopathy `` bulky fludarabine-refractory '' have not been described We present the outcomes of 99 such patients double-refractory n 58 bulky fludarabine-refractory n 41 undergoing their first salvage treatment at our center Patients received a variety of salvage regimens including monoclonal antibodies n 15 single-agent cytotoxic drugs n 14 purine analogue combination regimens n 21 intensive combination chemotherapy n 36 allogeneic stem cell transplantation SCT n 4 or other therapies n 9 Overall response to first salvage therapy other than SCT was 23 with no complete responses All four patients who underwent SCT as first salvage achieved complete remission Early death within 8 weeks of commencing first salvage occurred in 13 of patients and 54 of patients experienced a major infection during therapy Overall survival was 9 months with hemoglobin 11 g/dL hazard ratio 2.3 hepatomegaly hazard ratio 2.4 and performance status or 2 hazard ratio 1.9 being significant independent predictors of inferior survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1504, 532, 2, 228, 1, 992, 24, 9, 7, 5, 2027, 430, 442, 1193, 54, 32, 361, 430, 6, 3579, 1627, 430, 522, 15, 3773, 9, 3579, 520, 6, 4112, 4962, 4112, 2027, 430, 522, 47, 44, 85, 1027, 21, 364, 3, 123, 1, 1058, 225, 7, 1627, 430, 78, 717, 4112, 2027, 430, 78, 605, 479, 136, 157, 992, 24, 28, 114, 574, 7, 103, 8, 1362, 1, 992, 472, 141, 848, 890, 78, 167, 226, 420, 759, 600, 78, 213, 5006, 4696, 150, 472, 78, 239, 1686, 150, 56, 78, 511, 1063, 452, 31, 497, 1988, 78, 39, 15, 127, 235, 78, 83, 63, 51, 6, 157, 992, 36, 127, 76, 1988, 10, 382, 5, 77, 236, 253, 62, 294, 7, 54, 208, 1988, 22, 157, 992, 513, 236, 734, 191, 273, 262, 66, 244, 1, 16385, 157, 992, 489, 4, 233, 1, 7, 2, 667, 1, 7, 592, 8, 458, 930, 190, 36, 63, 25, 10, 83, 53, 5, 2222, 175, 499, 1826, 360, 197, 18, 27, 16840, 360, 197, 18, 39, 2, 528, 156, 15, 18, 360, 197, 14, 83, 486, 93, 306, 674, 1, 1663, 25]",1247.0,17917961,640
"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-10-01,"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly. We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors. We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anderson Cancer Center (Houston, TX) between 1985 and 2005. We reviewed patient records to determine presenting characteristics, treatment, and clinical outcomes. Cox models using training and validation sets of patients and resampling methods were used to develop a model predicting survival. Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less than 5 x 10(9)/L. Patients with ALC less than 5 x 10(9)/L had lower rates of cytogenetic abnormalities (P = .0002) and higher rates of CD38-positive results (P = .0002) and had mutated immunoglobulin heavy-chain variable region gene status (P = .034). Rates of response, survival, and failure-free survival (FFS) were not different among ALC groups. Regimens that included rituximab and a nucleoside analog were associated with superior rates of response and FFS compared with other therapies, irrespective of ALC. Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, beta2-microglobulin at least 2 mg/L, albumin less than 3.5 g/dL, and creatinine at least 1.6 mg/dL were each found to independently predict shorter survival and formed the basis of a scoring system. Patients with CLL or SLL can be treated similarly. A new prognostic score is proposed.",Journal Article,4495.0,57.0,"Chronic lymphocytic CLL and small lymphocytic SLL are currently considered the same entity but controversy remains over whether CLL and SLL should be treated similarly We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count ALC and evaluated treatment outcomes and prognostic factors We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D Anderson Cancer Center Houston TX between 1985 and 2005 We reviewed patient records to determine presenting characteristics treatment and clinical outcomes Cox models using training and validation sets of patients and resampling methods were used to develop a model predicting survival Among 2,126 consecutive CLL/SLL patients 312 15 had ALC less than 5 x 10 9 /L Patients with ALC less than 5 x 10 9 /L had lower rates of cytogenetic abnormalities P .0002 and higher rates of CD38-positive results P .0002 and had mutated immunoglobulin heavy-chain variable region gene status P .034 Rates of response survival and failure-free survival FFS were not different among ALC groups Regimens that included rituximab and a nucleoside analog were associated with superior rates of response and FFS compared with other therapies irrespective of ALC Deletion 17p or 6q with or without other cytogenetic abnormalities age at least 60 years beta2-microglobulin at least 2 mg/L albumin less than 3.5 g/dL and creatinine at least 1.6 mg/dL were each found to independently predict shorter survival and formed the basis of a scoring system Patients with CLL or SLL can be treated similarly A new prognostic score is proposed",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 302, 1193, 5302, 32, 694, 515, 3, 827, 2983, 84, 4089, 469, 252, 317, 552, 2, 5302, 257, 40, 73, 1813, 21, 275, 317, 374, 1, 7, 5, 552, 2, 5302, 1505, 4, 4245, 127, 76, 3, 1766, 1448, 1276, 3749, 2, 194, 24, 123, 2, 177, 130, 21, 3080, 3, 3098, 609, 9, 7, 5, 552, 15, 5302, 54, 917, 6, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 6212, 6614, 59, 4675, 2, 1242, 21, 446, 69, 1064, 6, 223, 1656, 374, 24, 2, 38, 123, 418, 274, 75, 1741, 2, 929, 2270, 1, 7, 2, 12703, 636, 11, 95, 6, 690, 8, 202, 1434, 25, 107, 18, 3927, 935, 552, 5302, 7, 8187, 167, 42, 3749, 299, 76, 33, 1006, 79, 83, 805, 7, 5, 3749, 299, 76, 33, 1006, 79, 83, 805, 42, 280, 151, 1, 1266, 1171, 19, 3531, 2, 142, 151, 1, 4469, 109, 99, 19, 3531, 2, 42, 1185, 2593, 4013, 1260, 1347, 1053, 145, 156, 19, 5337, 151, 1, 51, 25, 2, 496, 115, 25, 5058, 11, 44, 338, 107, 3749, 271, 472, 17, 159, 855, 2, 8, 4032, 3497, 11, 41, 5, 1123, 151, 1, 51, 2, 5058, 72, 5, 127, 235, 3500, 1, 3749, 1528, 4135, 15, 10961, 5, 15, 187, 127, 1266, 1171, 89, 28, 506, 335, 60, 8911, 5371, 28, 506, 18, 81, 805, 2799, 299, 76, 27, 33, 499, 1826, 2, 3177, 28, 506, 14, 49, 81, 1826, 11, 296, 204, 6, 1042, 678, 985, 25, 2, 3516, 3, 877, 1, 8, 2504, 398, 7, 5, 552, 15, 5302, 122, 40, 73, 1813, 8, 217, 177, 368, 16, 1587]",1669.0,17925562,532
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.,Blood,Blood,2007-10-25,"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest. Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible. Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia. The maximum tolerated dose (MTD) was 200 mg twice daily or 250 mg thrice daily. Dose-limiting toxicities were fatigue, nausea, vomiting, and diarrhea. Common drug-related adverse experiences were diarrhea, nausea, fatigue, and anorexia and were mild/moderate in severity. Grade 3/4 drug-related adverse experiences included fatigue (27%), thrombocytopenia (12%), and diarrhea (10%). There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD). Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted.","Clinical Trial, Phase I",4471.0,367.0,Vorinostat suberoylanilide hydroxamic acid SAHA is a histone deacetylase inhibitor active clinically in cutaneous T-cell and preclinically in A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest Patients with relapsed or refractory leukemias or syndromes MDS and untreated patients who were not candidates for chemotherapy were eligible Of 41 patients 31 had acute myeloid AML 4 chronic lymphocytic 3 MDS 2 acute lymphoblastic and 1 chronic myelocytic The maximum tolerated dose MTD was 200 mg twice daily or 250 mg thrice daily Dose-limiting toxicities were fatigue nausea vomiting and diarrhea Common drug-related adverse experiences were diarrhea nausea fatigue and anorexia and were mild/moderate in severity Grade 3/4 drug-related adverse experiences included fatigue 27 thrombocytopenia 12 and diarrhea 10 There were no drug-related deaths 7 patients had hematologic improvement response including 2 complete responses and 2 complete responses with incomplete blood count recovery all with AML treated at/below MTD Increased histone acetylation was observed at all doses Antioxidant gene expression may confer vorinostat resistance Further evaluation of vorinostat in AML/MDS is warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[2371, 9258, 8856, 971, 5484, 16, 8, 1508, 2732, 230, 544, 505, 4, 1486, 102, 31, 2, 10838, 4, 8, 124, 14, 45, 10, 426, 6, 376, 3, 367, 2, 128, 1, 518, 2371, 394, 6, 2036, 81, 936, 15, 10058, 391, 9, 213, 162, 370, 20, 14, 647, 3677, 7, 5, 591, 15, 430, 2792, 15, 2040, 1223, 2, 1278, 7, 54, 11, 44, 1931, 9, 56, 11, 625, 1, 605, 7, 456, 42, 286, 533, 329, 39, 442, 1193, 27, 1223, 18, 286, 1275, 2, 14, 442, 19446, 3, 689, 421, 61, 961, 10, 1250, 81, 936, 391, 15, 2039, 81, 10058, 391, 61, 817, 385, 11, 613, 1218, 1966, 2, 1172, 186, 234, 139, 290, 4031, 11, 1172, 1218, 613, 2, 3373, 2, 11, 1980, 1163, 4, 1702, 88, 27, 39, 234, 139, 290, 4031, 159, 613, 428, 1340, 133, 2, 1172, 79, 125, 11, 77, 234, 139, 1043, 67, 7, 42, 813, 767, 51, 141, 18, 236, 253, 2, 18, 236, 253, 5, 2610, 315, 1276, 1602, 62, 5, 329, 73, 28, 2736, 961, 101, 1508, 4145, 10, 164, 28, 62, 415, 5536, 145, 55, 68, 2913, 2371, 251, 195, 451, 1, 2371, 4, 329, 1223, 16, 1197]",1298.0,17962510,211
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-11-05,"National Cancer Institute-sponsored Working Group (NCI-WG) response criteria for chronic lymphocytic leukemia (CLL) rely on physical examination, blood, and bone marrow evaluations. The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria. In a retrospective review of 82 CLL patients treated at the Ohio State University (Columbus, OH), we compared CT assessed response using non-Hodgkin's lymphoma (NHL) response definitions with NCI-WG response. Responses by NCI-WG criteria included five complete responses (CRs), 32 partial responses (PRs), 21 patients with stable disease (SD), 17 patients with progressive disease (PD), and seven patients not assessable (NA). Responses by NHL-CT criteria included three CRs, 12 unconfirmed CRs (CRus), 16 PRs, 26 with SD, four with PD, and 21 NA. Using NCI-WG criteria, progression-free survival (PFS) was 27.3 months for CR and 11.4 months for PR. With NHL-CT criteria, PFS was 18.4 months for CR, 11.7 months for CRu, and 14.5 months for PR. In multivariate analysis, both NCI-WG and NHL-CT response correlated with PFS (P = .009 and .001, respectively). Current NCI-WG CLL response criteria are a significant predictor of PFS in previously treated CLL patients, with no additional benefit from the inclusion of CT scans. Although retrospective, these results highlight the importance of prospective validation of CT scans before routine inclusion in CLL response criteria.",Journal Article,4460.0,20.0,National Cancer Institute-sponsored Working Group NCI-WG response criteria for chronic lymphocytic CLL rely on physical examination blood and marrow evaluations The widespread use of computed tomography CT scans has prompted many to advocate for the incorporation of this test into CLL response criteria In a retrospective review of 82 CLL patients treated at the Ohio State University Columbus OH we compared CT assessed response using 's NHL response definitions with NCI-WG response Responses by NCI-WG criteria included five complete responses CRs 32 partial responses PRs 21 patients with stable disease SD 17 patients with progressive disease PD and seven patients not assessable NA Responses by NHL-CT criteria included three CRs 12 unconfirmed CRs CRus 16 PRs 26 with SD four with PD and 21 NA Using NCI-WG criteria progression-free survival PFS was 27.3 months for CR and 11.4 months for PR With NHL-CT criteria PFS was 18.4 months for CR 11.7 months for CRu and 14.5 months for PR In multivariate analysis both NCI-WG and NHL-CT response correlated with PFS P .009 and .001 respectively Current NCI-WG CLL response criteria are a significant predictor of PFS in previously treated CLL patients with no additional benefit from the inclusion of CT scans Although retrospective these results highlight the importance of prospective validation of CT scans before routine inclusion in CLL response criteria,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[657, 12, 1377, 5537, 2644, 87, 2580, 12906, 51, 371, 9, 442, 1193, 552, 5533, 23, 900, 1385, 315, 2, 581, 3816, 3, 3029, 119, 1, 1220, 872, 425, 1441, 71, 4140, 445, 6, 8912, 9, 3, 2838, 1, 26, 412, 237, 552, 51, 371, 4, 8, 459, 206, 1, 878, 552, 7, 73, 28, 3, 10009, 1309, 1652, 31186, 2912, 21, 72, 425, 275, 51, 75, 292, 1176, 51, 3833, 5, 2580, 12906, 51, 253, 20, 2580, 12906, 371, 159, 365, 236, 253, 3115, 531, 450, 253, 4018, 239, 7, 5, 585, 34, 1270, 269, 7, 5, 1014, 34, 333, 2, 648, 7, 44, 3120, 5328, 253, 20, 1176, 425, 371, 159, 169, 3115, 133, 5971, 3115, 34366, 245, 4018, 432, 5, 1270, 294, 5, 333, 2, 239, 5328, 75, 2580, 12906, 371, 91, 115, 25, 300, 10, 428, 27, 53, 9, 684, 2, 175, 39, 53, 9, 998, 5, 1176, 425, 371, 300, 10, 203, 39, 53, 9, 684, 175, 67, 53, 9, 12624, 2, 213, 33, 53, 9, 998, 4, 331, 65, 110, 2580, 12906, 2, 1176, 425, 51, 438, 5, 300, 19, 2376, 2, 144, 106, 291, 2580, 12906, 552, 51, 371, 32, 8, 93, 980, 1, 300, 4, 373, 73, 552, 7, 5, 77, 402, 247, 29, 3, 1680, 1, 425, 1441, 242, 459, 46, 99, 1817, 3, 1187, 1, 482, 929, 1, 425, 1441, 348, 1311, 1680, 4, 552, 51, 371]",1411.0,17984187,40
Comprehensive management of the CLL patient: a holistic approach.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2007-01-01,"The current management of B-chronic lymphocytic leukemia (CLL) is no longer straightforward for the practicing hematologist. Rapid advances in diagnostic precision, methods of predicting prognosis, understanding of natural history of CLL, recognition of clinical complications, clarification of the quality of life (QOL) issues facing the CLL patient, and the exciting array of novel treatment approaches have made the care of the CLL patient more demanding. This review is focused on summarizing these advances in order to provide a framework for integrating this knowledge into routine hematologic practice.",Journal Article,4768.0,16.0,The current management of B-chronic lymphocytic CLL is no longer straightforward for the practicing hematologist Rapid advances in diagnostic precision methods of predicting prognosis understanding of natural history of CLL recognition of clinical complications clarification of the quality of life QOL issues facing the CLL patient and the exciting array of novel treatment approaches have made the care of the CLL patient more demanding This review is focused on summarizing these advances in order to provide a framework for integrating this knowledge into routine hematologic practice,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 291, 284, 1, 132, 442, 1193, 552, 16, 77, 589, 12753, 9, 3, 6734, 15278, 1321, 954, 4, 752, 2720, 636, 1, 1434, 356, 612, 1, 1504, 532, 1, 552, 2335, 1, 38, 521, 11621, 1, 3, 372, 1, 358, 1001, 1553, 7917, 3, 552, 69, 2, 3, 4963, 1926, 1, 229, 24, 611, 47, 1229, 3, 165, 1, 3, 552, 69, 80, 14562, 26, 206, 16, 1649, 23, 15693, 46, 954, 4, 1732, 6, 377, 8, 2586, 9, 4568, 26, 922, 237, 1311, 813, 758]",588.0,18024647,430
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.,Blood,Blood,2007-11-26,"Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells. Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent. Approximately 20% to 25% of patients will experience cytomegalovirus (CMV) reactivation. We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily. The study design planned to enroll 128 patients, but stopping rules for early termination were met. Forty patients were evaluable. Median age was 58 years (range, 25-83 years); median number of prior therapies was 2 (range, 0-10). Diagnoses included chronic lymphocytic leukemia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma (ATLL) (1), marginal zone leukemia (1), large granular lymphocyte leukemia (2), acute lymphoblastic leukemia (1), and T-cell lymphoma (2). Patients received various alemtuzumab-containing regimens, including single agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and rituximab (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (hyper-CVAD) (4). Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770.",Journal Article,4439.0,70.0,Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent Approximately 20 to 25 of patients will experience cytomegalovirus CMV reactivation We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily The study design planned to enroll 128 patients but stopping rules for early termination were met Forty patients were evaluable Median age was 58 years range 25-83 years median number of prior therapies was 2 range 0-10 Diagnoses included chronic lymphocytic 29 T-cell prolymphocytic 3 hairy cell 1 adult T-cell leukemia/lymphoma ATLL 1 marginal zone 1 large granular lymphocyte 2 acute lymphoblastic 1 and T-cell 2 Patients received various alemtuzumab-containing regimens including single agent 5 or combined with rituximab 2 pentostatin 6 fludarabine cyclophosphamide and rituximab 23 or fractionated cyclophosphamide vincristine adriamycin and dexamethasone hyper-CVAD 4 Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation None of the 20 patients randomized to valganciclovir experienced CMV reactivation P .004 In conclusion this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab This trial was registered at www.ClinicalTrials.gov as NCT00562770,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3579, 16, 35, 2989, 548, 17, 15243, 295, 102, 37, 2, 132, 37, 2049, 9, 4716, 1450, 2, 13243, 21967, 16, 260, 5, 26, 420, 705, 179, 6, 243, 1, 7, 303, 730, 7314, 3879, 3834, 21, 426, 8, 384, 160, 7893, 7, 486, 73, 5, 35, 3579, 1101, 477, 103, 2049, 5, 361, 44949, 1666, 81, 1428, 391, 15, 44950, 5669, 81, 1428, 936, 391, 3, 45, 771, 1465, 6, 6559, 3990, 7, 84, 6811, 8679, 9, 191, 7202, 11, 543, 1213, 7, 11, 859, 52, 89, 10, 717, 60, 184, 243, 852, 60, 52, 207, 1, 324, 235, 10, 18, 184, 13, 79, 2403, 159, 442, 1193, 462, 102, 31, 14779, 27, 7152, 31, 14, 780, 102, 31, 2647, 4763, 12416, 14, 3450, 3614, 14, 375, 7694, 1448, 18, 286, 1275, 14, 2, 102, 31, 18, 7, 103, 747, 3579, 1101, 472, 141, 226, 420, 33, 15, 397, 5, 855, 18, 7596, 49, 2027, 1112, 2, 855, 382, 15, 3950, 1112, 2132, 7700, 2, 1217, 4855, 5574, 39, 648, 1, 179, 7, 346, 23, 3, 44949, 475, 592, 3879, 3834, 1292, 1, 3, 179, 7, 384, 6, 44950, 592, 3879, 3834, 19, 1520, 4, 1221, 26, 420, 10, 561, 323, 9, 2049, 1, 3879, 3834, 4, 7, 357, 3579, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 56693]",1493.0,18039954,26
Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.,The Journal of clinical investigation,J. Clin. Invest.,2008-01-01,"Survival of patients with B cell chronic lymphocytic leukemia (B-CLL) can be predicted by analysis of mutations in the immunoglobulin heavy chain variable gene (IGHV). Patients without mutations (unmutated [UM]) are at greater risk for disease progression and death than patients with mutations (M). Despite this broad prognostic difference, there remains wide intragroup variation in the clinical outcome of UM patients, especially those with low/intermediate Rai risk disease. We evaluated UM B-CLL patients with low/intermediate Rai risk to determine the relationship between IGHV, IGH diversity (IGHD), and IGH joining (IGHJ) gene usage and time to treatment (TTT). Irrespective of IGHV usage, UM patients whose B-CLL cells expressed the IGHD3-3 gene had a significantly shorter TTT than other UM B-CLL patients, and specifically, use of the IGHD3-3 gene in reading frame 2 (RF2) predicted shorter TTT. As expected, Rai risk was the best single prognostic factor for TTT; however, IGHD usage was also a significant variable for TTT. Therefore, both IGHD gene and IGHD RF usage have prognostic relevance in UM B-CLL patients with low/intermediate Rai risk disease. In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL.",Journal Article,4403.0,20.0,Survival of patients with B cell chronic lymphocytic B-CLL can be predicted by analysis of mutations in the immunoglobulin heavy chain variable gene IGHV Patients without mutations unmutated UM are at greater risk for disease progression and death than patients with mutations M Despite this broad prognostic difference there remains wide intragroup variation in the clinical outcome of UM patients especially those with low/intermediate Rai risk disease We evaluated UM B-CLL patients with low/intermediate Rai risk to determine the relationship between IGHV IGH diversity IGHD and IGH joining IGHJ gene usage and time to treatment TTT Irrespective of IGHV usage UM patients whose B-CLL cells expressed the IGHD3-3 gene had a significantly shorter TTT than other UM B-CLL patients and specifically use of the IGHD3-3 gene in reading frame 2 RF2 predicted shorter TTT As expected Rai risk was the best single prognostic factor for TTT however IGHD usage was also a significant variable for TTT Therefore both IGHD gene and IGHD RF usage have prognostic relevance in UM B-CLL patients with low/intermediate Rai risk disease In addition these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[25, 1, 7, 5, 132, 31, 442, 1193, 132, 552, 122, 40, 783, 20, 65, 1, 138, 4, 3, 2593, 4013, 1260, 1347, 145, 6220, 7, 187, 138, 7216, 5878, 32, 28, 378, 43, 9, 34, 91, 2, 273, 76, 7, 5, 138, 188, 550, 26, 2094, 177, 523, 125, 469, 1019, 56744, 1380, 4, 3, 38, 228, 1, 5878, 7, 1093, 135, 5, 154, 919, 4121, 43, 34, 21, 194, 5878, 132, 552, 7, 5, 154, 919, 4121, 43, 6, 223, 3, 858, 59, 6220, 5221, 3653, 31151, 2, 5221, 10690, 44799, 145, 5015, 2, 98, 6, 24, 10630, 3500, 1, 6220, 5015, 5878, 7, 1310, 132, 552, 37, 570, 3, 34307, 27, 145, 42, 8, 97, 985, 10630, 76, 127, 5878, 132, 552, 7, 2, 1225, 119, 1, 3, 34307, 27, 145, 4, 7299, 5331, 18, 56745, 783, 985, 10630, 22, 1336, 4121, 43, 10, 3, 824, 226, 177, 161, 9, 10630, 137, 31151, 5015, 10, 120, 8, 93, 1347, 9, 10630, 673, 110, 31151, 145, 2, 31151, 7279, 5015, 47, 177, 2088, 4, 5878, 132, 552, 7, 5, 154, 919, 4121, 43, 34, 4, 352, 46, 74, 538, 3, 2545, 17, 448, 1621, 881, 1, 112, 4200, 1186, 1698, 8, 200, 4, 3, 38, 906, 1, 132, 552]",1265.0,18064298,201
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.,Leukemia & lymphoma,Leuk. Lymphoma,2007-12-01,"Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26 - 66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.",Journal Article,4434.0,85.0,Chronic lymphocytic CLL patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival Studies suggest that high-dose methylprednisolone HDMP has activity in such patients and combining HDMP with rituximab may enhance efficacy We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic Nine of 27 33 had deletion of 17p13.1 and six of 27 22 had deletion of 11q22.3 After a median of one cycle of HDMP-rituximab 29 78 patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1 Eight 22 patients had a complete clinical response Although well tolerated 11 29 patients developed infectious complications before completing one month of therapy Three-year survival was 41 95 CI 26 66 HDMP-rituximab is an active regimen in patients with relapsed refractory and cytogenetically high-risk CLL Further evaluation of this regimen in controlled trials appears warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 7, 5, 571, 219, 374, 225, 22, 1528, 1, 7526, 14, 1022, 44, 1892, 6, 809, 640, 2, 47, 8, 985, 25, 94, 309, 17, 64, 61, 10787, 31199, 71, 128, 4, 225, 7, 2, 1525, 31199, 5, 855, 68, 1304, 209, 21, 108, 567, 7, 5, 552, 73, 5, 3, 31199, 855, 54, 42, 166, 126, 28, 2486, 1188, 762, 1, 428, 466, 42, 1528, 1, 7526, 14, 2, 437, 1, 428, 350, 42, 1528, 1, 12647, 27, 50, 8, 52, 1, 104, 417, 1, 31199, 855, 462, 833, 7, 42, 35, 461, 51, 768, 6, 3, 657, 12, 1377, 552, 2644, 87, 371, 141, 365, 1, 762, 7, 5, 1528, 1, 7526, 14, 659, 350, 7, 42, 8, 236, 38, 51, 242, 149, 421, 175, 462, 7, 276, 3398, 521, 348, 4144, 104, 811, 1, 36, 169, 111, 25, 10, 605, 48, 58, 432, 700, 31199, 855, 16, 35, 544, 477, 4, 7, 5, 591, 430, 2, 7809, 64, 43, 552, 195, 451, 1, 26, 477, 4, 1149, 143, 1233, 1197]",1089.0,18067017,194
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?,Leukemia research,Leuk. Res.,2008-01-07,"To eliminate overlap with monoclonal B-cell lymphocytosis (MBL), some have proposed basing the diagnosis of chronic lymphocytic leukemia (CLL) on B lymphocyte count rather than absolute lymphocyte count (ALC). Such criteria should be based, in part, on patient outcomes. We evaluated the clinical implications of the proposed re-classification in 112 consecutive, newly diagnosed, Rai stage 0 patients. The new criteria would have changed the diagnosis from CLL to MBL in 47/112 (42%) patients. There was no difference in time to treatment (TTT) between those classified as MBL and CLL under the new criteria. In contrast, CD38 predicted TTT (p=0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold.",Journal Article,4397.0,38.0,To eliminate overlap with monoclonal B-cell lymphocytosis MBL some have proposed basing the diagnosis of chronic lymphocytic CLL on B lymphocyte count rather than absolute lymphocyte count ALC Such criteria should be based in part on patient outcomes We evaluated the clinical implications of the proposed re-classification in 112 consecutive newly diagnosed Rai stage 0 patients The new criteria would have changed the diagnosis from CLL to MBL in 47/112 42 patients There was no difference in time to treatment TTT between those classified as MBL and CLL under the new criteria In contrast CD38 predicted TTT p=0.02 regardless of the proposed new classification Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 4964, 4526, 5, 848, 132, 31, 8125, 8992, 476, 47, 1587, 25974, 3, 147, 1, 442, 1193, 552, 23, 132, 1448, 1276, 1832, 76, 1766, 1448, 1276, 3749, 225, 371, 257, 40, 90, 4, 760, 23, 69, 123, 21, 194, 3, 38, 1268, 1, 3, 1587, 1491, 947, 4, 3726, 935, 732, 265, 4121, 82, 13, 7, 3, 217, 371, 688, 47, 2368, 3, 147, 29, 552, 6, 8992, 4, 662, 3726, 595, 7, 125, 10, 77, 523, 4, 98, 6, 24, 10630, 59, 135, 1373, 22, 8992, 2, 552, 669, 3, 217, 371, 4, 748, 4469, 783, 10630, 19, 13, 588, 1583, 1, 3, 1587, 217, 947, 219, 374, 1, 3, 2015, 3910, 32, 8, 380, 980, 1, 91, 76, 35, 16183, 3749, 15, 132, 1448, 1276, 2390]",803.0,18179821,91
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.,European journal of haematology,Eur. J. Haematol.,2007-12-21,We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population.,Clinical Trial,4414.0,7.0,We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic The continuous infusion of alemtuzumab was well tolerated The typical infusion reaction seen with intravenous alemtuzumab was abolished Two patients achieved a partial response with an overall response rate of 20 Alemtuzumab levels were measured in four patients and detectable levels were obtained in three Clinical activity needs to be confirmed in a larger patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 3, 128, 2, 1543, 1, 3579, 447, 22, 8, 1314, 904, 9, 67, 427, 370, 20, 2529, 634, 9, 175, 3293, 22, 992, 36, 9, 79, 7, 5, 2027, 430, 442, 1193, 3, 1314, 904, 1, 3579, 10, 149, 421, 3, 3476, 904, 1329, 527, 5, 1262, 3579, 10, 6020, 100, 7, 513, 8, 450, 51, 5, 35, 63, 51, 116, 1, 179, 3579, 148, 11, 644, 4, 294, 7, 2, 2083, 148, 11, 683, 4, 169, 38, 128, 1891, 6, 40, 557, 4, 8, 1077, 69, 266]",608.0,18182081,742
"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-01-01,"Richter's syndrome (RS) and fludarabine-refractory chronic lymphocytic leukemia (CLL) are associated with poor clinical outcomes. We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases. The OFAR regimen consisted of increasing doses of oxaliplatin (17.5, 20, or 25 mg/m(2)/d) on days 1 to 4 (phase I), fludarabine 30 mg/m(2) on days 2 to 3, cytarabine 1 g/m(2) on days 2 to 3, rituximab 375 mg/m(2) on day 3 of cycle 1 and day 1 of subsequent cycles, and pegfilgrastim 6 mg on day 6, every 4 weeks for a maximum of six courses. Dose-limiting toxicity (DLT) was defined as any nonhematologic, treatment-related toxicity >/= grade 3. Fifty patients were treated (20 patients had RS, and 30 had CLL). The highest tolerated oxaliplatin dose was 25 mg/m(2), which was the highest dose tested. DLT was not observed. Pharmacodynamic analyses demonstrated enhanced leukemia cell killing by oxaliplatin in the presence of fludarabine and cytarabine. The overall response rates were 50% in RS and 33% in fludarabine-refractory CLL. The overall response rate in 14 patients with age >/= 70 years was 50%. Responses were achieved in seven (35%) of 20 patients with 17p deletion, two (29%) of seven patients with 11q deletion, all four patients with trisomy 12, and two (40%) of five patients with 13q deletion. The median response duration was 10 months. Toxicities were mainly hematologic; prolonged myelosuppression was not observed. The OFAR regimen is highly active in RS and has activity in fludarabine-refractory patients with CLL. This regimen warrants further investigation in the treatment of these disorders.","Clinical Trial, Phase I",4403.0,106.0,Richter 's syndrome RS and fludarabine-refractory chronic lymphocytic CLL are associated with poor clinical outcomes We conducted a phase I-II trial of oxaliplatin fludarabine cytarabine and rituximab OFAR in these diseases The OFAR regimen consisted of increasing doses of oxaliplatin 17.5 20 or 25 mg/m 2 /d on days 1 to 4 phase I fludarabine 30 mg/m 2 on days 2 to 3 cytarabine 1 g/m 2 on days 2 to 3 rituximab 375 mg/m 2 on day 3 of cycle 1 and day 1 of subsequent cycles and pegfilgrastim 6 mg on day 6 every 4 weeks for a maximum of six courses Dose-limiting toxicity DLT was defined as any nonhematologic treatment-related toxicity /= grade 3 Fifty patients were treated 20 patients had RS and 30 had CLL The highest tolerated oxaliplatin dose was 25 mg/m 2 which was the highest dose tested DLT was not observed Pharmacodynamic analyses demonstrated enhanced cell killing by oxaliplatin in the presence of fludarabine and cytarabine The overall response rates were 50 in RS and 33 in fludarabine-refractory CLL The overall response rate in 14 patients with age /= 70 years was 50 Responses were achieved in seven 35 of 20 patients with 17p deletion two 29 of seven patients with 11q deletion all four patients with trisomy 12 and two 40 of five patients with 13q deletion The median response duration was 10 months Toxicities were mainly hematologic prolonged myelosuppression was not observed The OFAR regimen is highly active in RS and has activity in fludarabine-refractory patients with CLL This regimen warrants further investigation in the treatment of these disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 292, 681, 2250, 2, 2027, 430, 442, 1193, 552, 32, 41, 5, 334, 38, 123, 21, 426, 8, 124, 70, 215, 160, 1, 1476, 2027, 1855, 2, 855, 38635, 4, 46, 1342, 3, 38635, 477, 1695, 1, 602, 415, 1, 1476, 269, 33, 179, 15, 243, 81, 188, 18, 427, 23, 162, 14, 6, 39, 124, 70, 2027, 201, 81, 188, 18, 23, 162, 18, 6, 27, 1855, 14, 499, 188, 18, 23, 162, 18, 6, 27, 855, 4175, 81, 188, 18, 23, 218, 27, 1, 417, 14, 2, 218, 14, 1, 706, 410, 2, 6005, 49, 81, 23, 218, 49, 454, 39, 244, 9, 8, 689, 1, 437, 1993, 61, 817, 155, 2059, 10, 395, 22, 500, 3534, 24, 139, 155, 88, 27, 1461, 7, 11, 73, 179, 7, 42, 2250, 2, 201, 42, 552, 3, 1076, 421, 1476, 61, 10, 243, 81, 188, 18, 92, 10, 3, 1076, 61, 650, 2059, 10, 44, 164, 2424, 318, 264, 651, 31, 3003, 20, 1476, 4, 3, 463, 1, 2027, 2, 1855, 3, 63, 51, 151, 11, 212, 4, 2250, 2, 466, 4, 2027, 430, 552, 3, 63, 51, 116, 4, 213, 7, 5, 89, 431, 60, 10, 212, 253, 11, 513, 4, 648, 465, 1, 179, 7, 5, 4135, 1528, 100, 462, 1, 648, 7, 5, 7203, 1528, 62, 294, 7, 5, 6317, 133, 2, 100, 327, 1, 365, 7, 5, 8453, 1528, 3, 52, 51, 654, 10, 79, 53, 385, 11, 2615, 813, 1069, 2858, 10, 44, 164, 3, 38635, 477, 16, 561, 544, 4, 2250, 2, 71, 128, 4, 2027, 430, 7, 5, 552, 26, 477, 2782, 195, 940, 4, 3, 24, 1, 46, 1997]",1582.0,18182662,216
Controversies in the front-line management of chronic lymphocytic leukemia.,Leukemia research,Leuk. Res.,2008-01-11,"Once considered a simple homogeneous disease, chronic lymphocytic leukemia (CLL) is now recognized to be a heterogeneous lymphoid malignancy with patients classified into low, intermediate, and high-risk categories based on traditional and novel prognostic factors. Purine nucleoside analogues have been the standard first-line approach for over a decade. The recognition of synergistic activity between purine analogues, alkylating agents, and monoclonal antibodies has allowed the introduction of many new active combination therapies for treatment of this disease. The paucity of randomized studies determining the efficacy and tolerability of these new regimens, however, has made therapy selection for individual patients complex and cumbersome. At the present time, it remains unclear whether patients with aggressive disease based on molecular features should receive early or alternative treatment strategies. In this review, we summarize the data on combination chemotherapy and chemoimmunotherapy in CLL and propose several key factors that should be taken into consideration when deciding on an initial treatment strategy. The review is intended to discuss and simplify first-line therapy selection for patients with CLL in the era of new prognostic indicators and the better understanding of disease biology.",Journal Article,4393.0,6.0,Once considered a simple homogeneous disease chronic lymphocytic CLL is now recognized to be a heterogeneous lymphoid malignancy with patients classified into low intermediate and high-risk categories based on traditional and novel prognostic factors Purine nucleoside analogues have been the standard first-line approach for over a decade The recognition of synergistic activity between purine analogues alkylating agents and monoclonal antibodies has allowed the introduction of many new active combination therapies for treatment of this disease The paucity of randomized studies determining the efficacy and tolerability of these new regimens however has made therapy selection for individual patients complex and cumbersome At the present time it remains unclear whether patients with aggressive disease based on molecular features should receive early or alternative treatment strategies In this review we summarize the data on combination chemotherapy and chemoimmunotherapy in CLL and propose several key factors that should be taken into consideration when deciding on an initial treatment strategy The review is intended to discuss and simplify first-line therapy selection for patients with CLL in the era of new prognostic indicators and the better understanding of disease biology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1059, 515, 8, 2763, 5642, 34, 442, 1193, 552, 16, 1134, 1904, 6, 40, 8, 1564, 2303, 710, 5, 7, 1373, 237, 154, 919, 2, 64, 43, 1996, 90, 23, 1847, 2, 229, 177, 130, 5006, 4032, 4768, 47, 85, 3, 260, 157, 328, 353, 9, 252, 8, 2025, 3, 2335, 1, 1806, 128, 59, 5006, 4768, 3410, 183, 2, 848, 890, 71, 2313, 3, 2456, 1, 445, 217, 544, 150, 235, 9, 24, 1, 26, 34, 3, 4832, 1, 384, 94, 2196, 3, 209, 2, 1543, 1, 46, 217, 472, 137, 71, 1229, 36, 881, 9, 797, 7, 840, 2, 20214, 28, 3, 364, 98, 192, 469, 1200, 317, 7, 5, 571, 34, 90, 23, 219, 404, 257, 560, 191, 15, 1091, 24, 422, 4, 26, 206, 21, 2479, 3, 74, 23, 150, 56, 2, 4438, 4, 552, 2, 2548, 392, 825, 130, 17, 257, 40, 1633, 237, 2415, 198, 10160, 23, 35, 388, 24, 692, 3, 206, 16, 4081, 6, 1139, 2, 16084, 157, 328, 36, 881, 9, 7, 5, 552, 4, 3, 1713, 1, 217, 177, 3539, 2, 3, 380, 612, 1, 34, 891]",1293.0,18191201,368
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.,Blood,Blood,2008-01-11,"Effective administration of flavopiridol in advanced-stage chronic lymphocytic leukemia (CLL) is often associated with early biochemical evidence of tumor cell lysis. Previous work using other cell types showed that flavopiridol impacts mitochondria, and in CLL cells flavopiridol down-regulates the mitochondrial protein Mcl-1. We therefore investigated mitochondrial structure and function in flavopiridol-treated CLL patient cells and in the lymphoblastic cell line 697 using concentrations and times at which tumor lysis is observed in treated patients. Mitochondrial membrane depolarization was detected in flavopiridol-treated CLL cells by 6 hours, well before the onset of cell death. Flavopiridol-induced mitochondrial depolarization was not blocked by caspase inhibitors or by the calcium chelator EGTA, but was reduced by Bcl-2 overexpression. Intracellular calcium mobilization was noted at early time points using fluorescence microscopy. Furthermore, electron paramagnetic resonance oximetry showed a gradual but significant reduction in cellular oxygen consumption rate by 6 hours, corresponding with ultrastructural mitochondrial damage detected by electron microscopy. These observations suggest that in CLL and 697 cells, flavopiridol mediates its cytotoxic effects via induction of the mitochondrial permeability transition and changes in intracellular calcium.",Journal Article,4393.0,47.0,Effective administration of flavopiridol in advanced-stage chronic lymphocytic CLL is often associated with early biochemical evidence of tumor cell lysis Previous work using other cell types showed that flavopiridol impacts mitochondria and in CLL cells flavopiridol down-regulates the mitochondrial protein Mcl-1 We therefore investigated mitochondrial structure and function in flavopiridol-treated CLL patient cells and in the lymphoblastic cell line 697 using concentrations and times at which tumor lysis is observed in treated patients Mitochondrial membrane depolarization was detected in flavopiridol-treated CLL cells by 6 hours well before the onset of cell death Flavopiridol-induced mitochondrial depolarization was not blocked by caspase inhibitors or by the calcium chelator EGTA but was reduced by Bcl-2 overexpression Intracellular calcium mobilization was noted at early time points using fluorescence microscopy Furthermore electron paramagnetic resonance oximetry showed a gradual but significant reduction in cellular oxygen consumption rate by 6 hours corresponding with ultrastructural mitochondrial damage detected by electron microscopy These observations suggest that in CLL and 697 cells flavopiridol mediates its cytotoxic effects via induction of the mitochondrial permeability transition and changes in intracellular calcium,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[323, 634, 1, 3030, 4, 131, 82, 442, 1193, 552, 16, 629, 41, 5, 191, 1487, 241, 1, 30, 31, 4783, 698, 1357, 75, 127, 31, 630, 224, 17, 3030, 4719, 5443, 2, 4, 552, 37, 3030, 1328, 2468, 3, 2019, 178, 1308, 14, 21, 673, 565, 2019, 2772, 2, 343, 4, 3030, 73, 552, 69, 37, 2, 4, 3, 1275, 31, 328, 11989, 75, 1003, 2, 1072, 28, 92, 30, 4783, 16, 164, 4, 73, 7, 2019, 1905, 14809, 10, 530, 4, 3030, 73, 552, 37, 20, 49, 1459, 149, 348, 3, 1707, 1, 31, 273, 3030, 277, 2019, 14809, 10, 44, 2582, 20, 1469, 222, 15, 20, 3, 3299, 17613, 42956, 84, 10, 405, 20, 1044, 18, 851, 2087, 3299, 4030, 10, 1051, 28, 191, 98, 862, 75, 1591, 3804, 798, 4560, 20995, 1535, 22167, 224, 8, 11268, 84, 93, 628, 4, 763, 2848, 2421, 116, 20, 49, 1459, 1734, 5, 13755, 2019, 1350, 530, 20, 4560, 3804, 46, 2172, 309, 17, 4, 552, 2, 11989, 37, 3030, 3961, 211, 759, 176, 847, 504, 1, 3, 2019, 4757, 1970, 2, 400, 4, 2087, 3299]",1354.0,18192508,488
Circulating endothelial cells in patients with chronic lymphocytic leukemia.,Annals of hematology,Ann. Hematol.,2008-01-12,"Angiogenesis is increased in B-cell chronic lymphocytic leukemia (B-CLL). We wanted to quantify and characterize the circulating endothelial cells (CECs) in patients with B-CLL and correlate with plasma angiogenesis-related factors. Using a four-color flow cytometry, we prospectively analyzed the CEC in the whole blood of 20 healthy controls and 20 patients with B-CLL. We quantified (CD45-/CD31+/CD146+) and characterized the CECs according to whether they were apoptotic (annexin stain) or activated (CD106+). We also measured plasma levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and thrombospondin-1 (TSP-1). Most patients (90%) had Rai stages 0-2 at the time of diagnosis. As a group, B-CLL patients had higher number of CECs (median of 26.5 cells/ml) compared (P = 0.04) to healthy controls (18.5 cells/ml). However, only four (20%) patients had elevated CEC counts, defined as >/=2 SD of the control mean (>/=53 cells/ml). The proportions of apoptotic (P = 0.83) and activated (P = 0.12) CECs were similar in both groups. B-CLL patients had higher FGF-2 (P < 0.001), lower TSP-1 (P = 0.004), and similar VEGF (P = 0.27) plasma levels. The number of CECs was not associated with Rai stage, absolute lymphocyte count, or levels of angiogenesis-related factors. CECs are increased in only a small fraction of B-CLL patients in our cohort with low rates of apoptosis and activation. While no correlation was found between CECs and clinical features, more studies in a larger patient sample size and advanced disease are necessary.",Journal Article,4392.0,13.0,Angiogenesis is increased in B-cell chronic lymphocytic B-CLL We wanted to quantify and characterize the circulating endothelial cells CECs in patients with B-CLL and correlate with plasma angiogenesis-related factors Using a four-color flow cytometry we prospectively analyzed the CEC in the whole blood of 20 healthy controls and 20 patients with B-CLL We quantified CD45-/CD31+/CD146+ and characterized the CECs according to whether they were apoptotic annexin stain or activated CD106+ We also measured plasma levels of vascular endothelial growth factor VEGF fibroblast growth factor-2 FGF-2 and thrombospondin-1 TSP-1 Most patients 90 had Rai stages 0-2 at the time of diagnosis As a group B-CLL patients had higher number of CECs median of 26.5 cells/ml compared P 0.04 to healthy controls 18.5 cells/ml However only four 20 patients had elevated CEC counts defined as /=2 SD of the control mean /=53 cells/ml The proportions of apoptotic P 0.83 and activated P 0.12 CECs were similar in both groups B-CLL patients had higher FGF-2 P 0.001 lower TSP-1 P 0.004 and similar VEGF P 0.27 plasma levels The number of CECs was not associated with Rai stage absolute lymphocyte count or levels of angiogenesis-related factors CECs are increased in only a small fraction of B-CLL patients in our cohort with low rates of apoptosis and activation While no correlation was found between CECs and clinical features more studies in a larger patient sample size and advanced disease are necessary,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1056, 16, 101, 4, 132, 31, 442, 1193, 132, 552, 21, 7931, 6, 3091, 2, 1507, 3, 1033, 845, 37, 7361, 4, 7, 5, 132, 552, 2, 1513, 5, 554, 1056, 139, 130, 75, 8, 294, 6052, 1412, 1914, 21, 1143, 311, 3, 14569, 4, 3, 902, 315, 1, 179, 1331, 535, 2, 179, 7, 5, 132, 552, 21, 2790, 5280, 6019, 13647, 2, 765, 3, 7361, 768, 6, 317, 491, 11, 1631, 4850, 8763, 15, 735, 44999, 21, 120, 644, 554, 148, 1, 756, 845, 129, 161, 618, 3758, 129, 161, 18, 6517, 18, 2, 12596, 14, 9545, 14, 96, 7, 424, 42, 4121, 1153, 13, 18, 28, 3, 98, 1, 147, 22, 8, 87, 132, 552, 7, 42, 142, 207, 1, 7361, 52, 1, 432, 33, 37, 542, 72, 19, 13, 755, 6, 1331, 535, 203, 33, 37, 542, 137, 158, 294, 179, 7, 42, 804, 14569, 1911, 395, 22, 18, 1270, 1, 3, 182, 313, 699, 37, 542, 3, 4117, 1, 1631, 19, 13, 852, 2, 735, 19, 13, 133, 7361, 11, 288, 4, 110, 271, 132, 552, 7, 42, 142, 6517, 18, 19, 13, 144, 280, 9545, 14, 19, 13, 1520, 2, 288, 618, 19, 13, 428, 554, 148, 3, 207, 1, 7361, 10, 44, 41, 5, 4121, 82, 1766, 1448, 1276, 15, 148, 1, 1056, 139, 130, 7361, 32, 101, 4, 158, 8, 302, 1509, 1, 132, 552, 7, 4, 114, 180, 5, 154, 151, 1, 351, 2, 363, 369, 77, 816, 10, 204, 59, 7361, 2, 38, 404, 80, 94, 4, 8, 1077, 69, 1000, 444, 2, 131, 34, 32, 1493]",1490.0,18193423,348
"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.",Leukemia & lymphoma,Leuk. Lymphoma,2008-01-01,"Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL. Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review. Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006, 373 (31%) were local/non-referred. At diagnosis, 89% of these patients had one or more comorbidities, and 46% had at least one major comorbidity. Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial. On multi-factor analysis, Rai risk category (1.39 per each risk category increase; p < 0.0001) and age (1.056 per year increase; p < 0.0001) were the only factors associated with overall survival. We conclude that, although common, comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL. Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed.",Journal Article,4403.0,124.0,Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic CLL We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006 373 31 were local/non-referred At diagnosis 89 of these patients had one or more comorbidities and 46 had at least one major comorbidity Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial On multi-factor analysis Rai risk category 1.39 per each risk category increase p 0.0001 and age 1.056 per year increase p 0.0001 were the only factors associated with overall survival We conclude that although common comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 16, 440, 545, 3, 1873, 15, 675, 1, 1909, 4, 7, 5, 442, 1193, 552, 21, 565, 3, 1078, 2, 177, 1268, 1, 1909, 4, 7, 5, 732, 265, 552, 293, 220, 1995, 7, 5, 552, 194, 20, 8, 15278, 28, 2486, 1188, 262, 14, 111, 1, 147, 11, 625, 9, 26, 459, 206, 1, 19146, 869, 194, 9, 732, 265, 552, 59, 2323, 2, 1324, 9342, 456, 11, 293, 220, 1995, 28, 147, 887, 1, 46, 7, 42, 104, 15, 80, 1909, 2, 641, 42, 28, 506, 104, 458, 1879, 737, 437, 714, 1, 7, 1551, 6, 3362, 2580, 2644, 87, 677, 6, 3506, 4, 8, 38, 160, 23, 1414, 161, 65, 4121, 43, 2169, 14, 587, 379, 296, 43, 2169, 344, 19, 13, 488, 2, 89, 14, 9556, 379, 111, 344, 19, 13, 488, 11, 3, 158, 130, 41, 5, 63, 25, 21, 2060, 17, 242, 186, 3952, 1298, 32, 299, 305, 76, 89, 2, 82, 4, 1434, 356, 4, 732, 265, 7, 5, 552, 38, 143, 1435, 640, 17, 32, 1114, 6, 40, 421, 20, 7, 54, 1022, 44, 3362, 1847, 38, 160, 2317, 371, 32, 575]",1188.0,18203011,455
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-01-01,"The goal of this study was to characterize interactions between the proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors (HDACI) romidepsin or belinostat in chronic lymphocytic leukemia (CLL) cells. Primary and cultured (JVM-3 and MEC-2) CLL cells were exposed to agents alone or in combination, after which cell death was determined by 7-aminoactinomycin D staining/flow cytometry. Acetylation of target proteins, activation of caspase cascades, and expression of apoptosis-regulatory proteins were monitored by Western blot analysis. Nuclear factor-kappaB (NF-kappaB) activity was determined by luciferase reporter assay. Cells were transiently transfected with wild-type and acetylation site-mutated (inactive) RelA(p65) (e.g., K221R, K310R, or K281/221/310R) and assessed for HDACI sensitivity. Combined exposure to very low concentrations of romidepsin or belinostat (i.e., low nanomolar and submicromolar, respectively) in combination with low nanomolar concentrations of bortezomib synergistically induced cell death in primary and cultured CLL cells. These events were likely associated with prevention of HDACI-mediated RelA acetylation and NF-kappaB activation by bortezomib, down-regulation of antiapoptotic proteins (i.e., Bcl-xL, Mcl-1, and XIAP), as well as up-regulation of the proapoptotic protein Bim, resulting in activation of caspase cascade. Finally, CLL cells transfected with inactive RelA displayed a significant increase in HDACI lethality. Coadministration of the clinically relevant HDACIs romidepsin or belinostat with bortezomib synergistically induces cell death in CLL cells, likely through mechanisms involving, among other factors, NF-kappaB inactivation and perturbation in the expression of proapoptotic and antiapoptotic proteins. A strategy combining HDAC with proteasome inhibition warrants further attention in CLL.",Journal Article,4403.0,76.0,The goal of this study was to characterize interactions between the proteasome inhibitor bortezomib and the histone deacetylase HDAC inhibitors HDACI romidepsin or belinostat in chronic lymphocytic CLL cells Primary and cultured JVM-3 and MEC-2 CLL cells were exposed to agents alone or in combination after which cell death was determined by 7-aminoactinomycin D staining/flow cytometry Acetylation of target proteins activation of caspase cascades and expression of apoptosis-regulatory proteins were monitored by Western blot analysis Nuclear factor-kappaB NF-kappaB activity was determined by luciferase reporter assay Cells were transiently transfected with wild-type and acetylation site-mutated inactive RelA p65 e.g. K221R K310R or K281/221/310R and assessed for HDACI sensitivity Combined exposure to very low concentrations of romidepsin or belinostat i.e. low nanomolar and submicromolar respectively in combination with low nanomolar concentrations of bortezomib synergistically induced cell death in primary and cultured CLL cells These events were likely associated with prevention of HDACI-mediated RelA acetylation and NF-kappaB activation by bortezomib down-regulation of antiapoptotic proteins i.e. Bcl-xL Mcl-1 and XIAP as well as up-regulation of the proapoptotic protein Bim resulting in activation of caspase cascade Finally CLL cells transfected with inactive RelA displayed a significant increase in HDACI lethality Coadministration of the clinically relevant HDACIs romidepsin or belinostat with bortezomib synergistically induces cell death in CLL cells likely through mechanisms involving among other factors NF-kappaB inactivation and perturbation in the expression of proapoptotic and antiapoptotic proteins A strategy combining HDAC with proteasome inhibition warrants further attention in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1326, 1, 26, 45, 10, 6, 1507, 1286, 59, 3, 1694, 230, 819, 2, 3, 1508, 2732, 2654, 222, 4265, 6256, 15, 6842, 4, 442, 1193, 552, 37, 86, 2, 3197, 33969, 27, 2, 7391, 18, 552, 37, 11, 2234, 6, 183, 279, 15, 4, 150, 50, 92, 31, 273, 10, 509, 20, 67, 56824, 427, 1029, 1412, 1914, 4145, 1, 283, 652, 363, 1, 1469, 8036, 2, 55, 1, 351, 1253, 652, 11, 2909, 20, 1521, 2639, 65, 928, 161, 2119, 1365, 2119, 128, 10, 509, 20, 3864, 3674, 719, 37, 11, 9235, 3245, 5, 955, 267, 2, 4145, 606, 1185, 5002, 8672, 6781, 563, 499, 56825, 56826, 15, 56827, 5600, 56828, 2, 275, 9, 4265, 485, 397, 645, 6, 923, 154, 1003, 1, 6256, 15, 6842, 70, 563, 154, 7927, 2, 23066, 106, 4, 150, 5, 154, 7927, 1003, 1, 819, 4240, 277, 31, 273, 4, 86, 2, 3197, 552, 37, 46, 281, 11, 322, 41, 5, 1070, 1, 4265, 517, 8672, 4145, 2, 1365, 2119, 363, 20, 819, 1328, 863, 1, 4176, 652, 70, 563, 1044, 3870, 1308, 14, 2, 5387, 22, 149, 22, 126, 863, 1, 3, 4118, 178, 3595, 1113, 4, 363, 1, 1469, 4678, 1368, 552, 37, 3245, 5, 5002, 8672, 2507, 8, 93, 344, 4, 4265, 3266, 5777, 1, 3, 505, 867, 6250, 6256, 15, 6842, 5, 819, 4240, 1516, 31, 273, 4, 552, 37, 322, 298, 483, 1267, 107, 127, 130, 1365, 2119, 2297, 2, 10564, 4, 3, 55, 1, 4118, 2, 4176, 652, 8, 692, 1525, 2654, 5, 1694, 297, 2782, 195, 2111, 4, 552]",1823.0,18223231,300
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-01-01,"To date, efforts to study CD52-targeted therapies, such as alemtuzumab, have been limited due to the lack of stable CD52 expressing transformed B-cell lines and animal models. We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo. By limiting dilution, we have established several clones of Raji-Burkitt's lymphoma cell line that express surface CD52. Immunophenotype and cytogenetic characterization of these clones was done. In vivo usefulness of the CD52(high) cell line to evaluate the therapeutic efficacy of CD52-directed antibody was investigated using a SCID mouse xenograft model. Stable expression of CD52 was confirmed in cells cultured in vitro up to 52 weeks of continuous growth. The functional integrity of the expressed CD52 molecule was shown using alemtuzumab, which induced cytotoxic effects in vitro in the CD52(high) but not the CD52(low) clone. Compared with control antibody, alemtuzumab treatment in CD52(high) inoculated mice resulted in significantly increased median survival. Comparable levels of CD52-targeted direct cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity and anti-CD52 immunoliposome-mediated delivery of synthetic oligodeoxyribo nucleotides in CD52(high) clone and primary B-chronic lymphocytic leukemia cells implicated potential in vivo application of this model for evaluation of CD52-targeted antibody and immunoliposomes encapsulating therapeutic agents. These results show the in vitro utility of the cloned Raji cell lines that stably express high levels CD52. The disseminated leukemia-lymphoma mouse model described herein using these stable cell lines can serve as an excellent system for in vivo therapeutic and mechanistic evaluation of existing and novel antibodies directed against CD52 molecule.",Journal Article,4403.0,23.0,To date efforts to study CD52-targeted therapies such as alemtuzumab have been limited due to the lack of stable CD52 expressing transformed B-cell lines and animal models We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo By limiting dilution we have established several clones of Raji-Burkitt 's cell line that express surface CD52 Immunophenotype and cytogenetic characterization of these clones was done In vivo usefulness of the CD52 high cell line to evaluate the therapeutic efficacy of CD52-directed antibody was investigated using a SCID mouse xenograft model Stable expression of CD52 was confirmed in cells cultured in vitro up to 52 weeks of continuous growth The functional integrity of the expressed CD52 molecule was shown using alemtuzumab which induced cytotoxic effects in vitro in the CD52 high but not the CD52 low clone Compared with control antibody alemtuzumab treatment in CD52 high inoculated mice resulted in significantly increased median survival Comparable levels of CD52-targeted direct cytotoxicity complement-dependent cytotoxicity and antibody-dependent cytotoxicity and anti-CD52 immunoliposome-mediated delivery of synthetic oligodeoxyribo nucleotides in CD52 high clone and primary B-chronic lymphocytic cells implicated potential in vivo application of this model for evaluation of CD52-targeted antibody and immunoliposomes encapsulating therapeutic agents These results show the in vitro utility of the cloned Raji cell lines that stably express high levels CD52 The disseminated leukemia-lymphoma mouse model described herein using these stable cell lines can serve as an excellent system for in vivo therapeutic and mechanistic evaluation of existing and novel antibodies directed against CD52 molecule,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 1244, 1413, 6, 45, 7189, 238, 235, 225, 22, 3579, 47, 85, 383, 520, 6, 3, 926, 1, 585, 7189, 1046, 2423, 132, 31, 285, 2, 2026, 274, 21, 897, 914, 2, 1961, 1, 31, 285, 17, 5834, 1669, 7189, 110, 4, 439, 2, 4, 386, 20, 817, 10446, 21, 47, 635, 392, 2749, 1, 9868, 14387, 292, 31, 328, 17, 1669, 1255, 7189, 5496, 2, 1266, 2136, 1, 46, 2749, 10, 1822, 4, 386, 5235, 1, 3, 7189, 64, 31, 328, 6, 376, 3, 189, 209, 1, 7189, 1166, 548, 10, 565, 75, 8, 4129, 830, 1330, 202, 585, 55, 1, 7189, 10, 557, 4, 37, 3197, 4, 439, 126, 6, 653, 244, 1, 1314, 129, 3, 583, 4797, 1, 3, 570, 7189, 1354, 10, 443, 75, 3579, 92, 277, 759, 176, 4, 439, 4, 3, 7189, 64, 84, 44, 3, 7189, 154, 3910, 72, 5, 182, 548, 3579, 24, 4, 7189, 64, 8669, 399, 627, 4, 97, 101, 52, 25, 1279, 148, 1, 7189, 238, 1196, 1408, 3731, 470, 1408, 2, 548, 470, 1408, 2, 312, 7189, 38641, 517, 989, 1, 3273, 56829, 11381, 4, 7189, 64, 3910, 2, 86, 132, 442, 1193, 37, 1771, 174, 4, 386, 1581, 1, 26, 202, 9, 451, 1, 7189, 238, 548, 2, 31220, 19114, 189, 183, 46, 99, 514, 3, 4, 439, 1207, 1, 3, 8560, 9868, 31, 285, 17, 5834, 1669, 64, 148, 7189, 3, 3605, 2647, 4763, 830, 202, 1027, 1986, 75, 46, 585, 31, 285, 122, 1833, 22, 35, 1503, 398, 9, 4, 386, 189, 2, 2716, 451, 1, 1692, 2, 229, 890, 1166, 480, 7189, 1354]",1796.0,18223233,57
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2008-03-01,"The ubiquitin-proteasome pathway has been implicated in the pathogenesis of many hematologic malignancies. The authors measured proteasome peptidase activity levels in plasma samples from 225 patients with chronic lymphocytic leukemia (CLL) and correlated the results with clinical behavior. By using fluorogenic kinetic assays, the enzymatic activity levels of 3 proteasomes were measured: chymotrypsin-like (Ch-L), trypsin-like (Tr-L), and caspase-like (Cas-L). All activity levels were significantly higher in patients who had CLL compared with the levels in a control group of healthy volunteers (P<.001). Rai stage was correlated with Ch-L activity (P<.001) but not with Cas-L or Tr-L activity. Levels of beta2 microglobulin (B2M) were correlated with Ch-L activity (correlation coefficient [R]=0.4; P<.001) and with Cas-L activity (R=0.25; P=.001) but not with Tr-L activity. Cas-L activity as a continuous variable was a strong predictor of survival. Ch-L and Cas-L activity levels as categorical variables both were strong predictors of survival; Cas-L activity was independent of B2M level but not of immunoglobulin variable heavy chain gene (IgVH) mutation status. However, the combination of elevated B2M levels (>3.2 mg/L) and Cas-L activity (>1.32 pmoL/second/mL plasma) was associated with significantly shorter survival independent of IgVH mutation status. The current results indicated that measuring plasma proteasome activity has prognostic value in CLL that, when combined with B2M, can be independent of IgVH mutation status.",Comparative Study,4343.0,25.0,The ubiquitin-proteasome pathway has been implicated in the pathogenesis of many hematologic malignancies The authors measured proteasome peptidase activity levels in plasma samples from 225 patients with chronic lymphocytic CLL and correlated the results with clinical behavior By using fluorogenic kinetic assays the enzymatic activity levels of 3 proteasomes were measured chymotrypsin-like Ch-L trypsin-like Tr-L and caspase-like Cas-L All activity levels were significantly higher in patients who had CLL compared with the levels in a control group of healthy volunteers P .001 Rai stage was correlated with Ch-L activity P .001 but not with Cas-L or Tr-L activity Levels of beta2 microglobulin B2M were correlated with Ch-L activity correlation coefficient R =0.4 P .001 and with Cas-L activity R=0.25 P=.001 but not with Tr-L activity Cas-L activity as a continuous variable was a strong predictor of survival Ch-L and Cas-L activity levels as categorical variables both were strong predictors of survival Cas-L activity was independent of B2M level but not of immunoglobulin variable heavy chain gene IgVH mutation status However the combination of elevated B2M levels 3.2 mg/L and Cas-L activity 1.32 pmoL/second/mL plasma was associated with significantly shorter survival independent of IgVH mutation status The current results indicated that measuring plasma proteasome activity has prognostic value in CLL that when combined with B2M can be independent of IgVH mutation status,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4213, 1694, 308, 71, 85, 1771, 4, 3, 1384, 1, 445, 813, 441, 3, 738, 644, 1694, 14312, 128, 148, 4, 554, 347, 29, 4011, 7, 5, 442, 1193, 552, 2, 438, 3, 99, 5, 38, 1710, 20, 75, 33176, 7009, 1013, 3, 5226, 128, 148, 1, 27, 24715, 11, 644, 19118, 733, 6557, 805, 15990, 733, 7161, 805, 2, 1469, 733, 10205, 805, 62, 128, 148, 11, 97, 142, 4, 7, 54, 42, 552, 72, 5, 3, 148, 4, 8, 182, 87, 1, 1331, 5495, 19, 144, 4121, 82, 10, 438, 5, 6557, 805, 128, 19, 144, 84, 44, 5, 10205, 805, 15, 7161, 805, 128, 148, 1, 8911, 5371, 10918, 11, 438, 5, 6557, 805, 128, 816, 3200, 668, 13, 39, 19, 144, 2, 5, 10205, 805, 128, 668, 13, 243, 19, 144, 84, 44, 5, 7161, 805, 128, 10205, 805, 128, 22, 8, 1314, 1347, 10, 8, 1082, 980, 1, 25, 6557, 805, 2, 10205, 805, 128, 148, 22, 5982, 682, 110, 11, 1082, 674, 1, 25, 10205, 805, 128, 10, 306, 1, 10918, 301, 84, 44, 1, 2593, 1347, 4013, 1260, 145, 14484, 258, 156, 137, 3, 150, 1, 804, 10918, 148, 27, 18, 81, 805, 2, 10205, 805, 128, 14, 531, 9835, 419, 542, 554, 10, 41, 5, 97, 985, 25, 306, 1, 14484, 258, 156, 3, 291, 99, 1103, 17, 2978, 554, 1694, 128, 71, 177, 549, 4, 552, 17, 198, 397, 5, 10918, 122, 40, 306, 1, 14484, 258, 156]",1489.0,18224667,198
Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS).,Sleep,Sleep,2008-02-01,"To examine the prevalence of and risk factors for fatigue and sleep disturbance among adult survivors of childhood cancer. Retrospective cohort of childhood cancer survivors. Twenty-six academic institutions treating childhood cancer. Two thousand six hundred forty-five survivors of childhood acute lymphocytic leukemia, central nervous system tumors, Hodgkin lymphoma, soft-tissue sarcomas, or bone tumors diagnosed before age 21, surviving at least 5 years from diagnosis, and a 500-sibling comparison group. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale. Significant differences were found between survivors and siblings on the Functional Assessment of Chronic Illness Therapy-Fatigue (40.8 vs 42.0, P < 0.02), Pittsburgh Sleep Quality Index (6.1 vs 5.5, P < 0.004), and Epworth Sleepiness Scale (6.2 vs 5.4, P < 0.001). Nineteen percent of survivors were in the most fatigued range, 16.7% reported disrupted sleep, and 14% increased daytime sleepiness. Survivors with a history of radiation therapy were more likely to be fatigued (odds ratio 1.7, 95% confidence interval 1.3-2.3), yet without significantly different mean scores. Female sex, congestive heart failure, pulmonary fibrosis, depression, and being unmarried significantly predicted more fatigue, whereas obesity and an infant in the house predicted more daytime sleepiness. Similar sociodemographic predictors were also identified among the siblings. Because of the large sample size, we detected more objectively reported fatigue, sleep disturbance, and daytime sleepiness among adult survivors of childhood cancer. However, the clinical significance of these differences is questionable. Predictors of fatigue and poor sleep were similar in both survivors and the siblings.",Journal Article,4372.0,119.0,To examine the prevalence of and risk factors for fatigue and sleep disturbance among adult survivors of childhood cancer Retrospective cohort of childhood cancer survivors Twenty-six academic institutions treating childhood cancer Two thousand six hundred forty-five survivors of childhood acute lymphocytic central nervous system tumors soft-tissue sarcomas or tumors diagnosed before age 21 surviving at least 5 years from diagnosis and a 500-sibling comparison group Functional Assessment of Chronic Illness Therapy-Fatigue FACIT-Fatigue Pittsburgh Sleep Quality Index Epworth Sleepiness Scale Significant differences were found between survivors and siblings on the Functional Assessment of Chronic Illness Therapy-Fatigue 40.8 vs 42.0 P 0.02 Pittsburgh Sleep Quality Index 6.1 vs 5.5 P 0.004 and Epworth Sleepiness Scale 6.2 vs 5.4 P 0.001 Nineteen percent of survivors were in the most fatigued range 16.7 reported disrupted sleep and 14 increased daytime sleepiness Survivors with a history of radiation therapy were more likely to be fatigued odds ratio 1.7 95 confidence interval 1.3-2.3 yet without significantly different mean scores Female sex congestive failure pulmonary fibrosis depression and being unmarried significantly predicted more fatigue whereas obesity and an infant in the house predicted more daytime sleepiness Similar sociodemographic predictors were also identified among the siblings Because of the large sample size we detected more objectively reported fatigue sleep disturbance and daytime sleepiness among adult survivors of childhood cancer However the clinical significance of these differences is questionable Predictors of fatigue and poor sleep were similar in both survivors and the siblings,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,"[6, 1004, 3, 1078, 1, 2, 43, 130, 9, 613, 2, 2494, 6663, 107, 780, 332, 1, 864, 12, 459, 180, 1, 864, 12, 332, 737, 437, 1916, 1764, 1367, 864, 12, 100, 6161, 437, 1128, 1213, 365, 332, 1, 864, 286, 1193, 854, 1880, 398, 57, 1214, 246, 1479, 15, 57, 265, 348, 89, 239, 3050, 28, 506, 33, 60, 29, 147, 2, 8, 1666, 3684, 1155, 87, 583, 455, 1, 442, 2973, 36, 613, 7230, 613, 12030, 2494, 372, 558, 24851, 13136, 1124, 93, 362, 11, 204, 59, 332, 2, 2758, 23, 3, 583, 455, 1, 442, 2973, 36, 613, 327, 66, 105, 595, 13, 19, 13, 588, 12030, 2494, 372, 558, 49, 14, 105, 33, 33, 19, 13, 1520, 2, 24851, 13136, 1124, 49, 18, 105, 33, 39, 19, 13, 144, 3498, 714, 1, 332, 11, 4, 3, 96, 20434, 184, 245, 67, 210, 5576, 2494, 2, 213, 101, 12010, 13136, 332, 5, 8, 532, 1, 121, 36, 11, 80, 322, 6, 40, 20434, 610, 197, 14, 67, 48, 307, 268, 14, 27, 18, 27, 1145, 187, 97, 338, 313, 703, 1061, 1035, 6395, 496, 1087, 3000, 1774, 2, 486, 8491, 97, 783, 80, 613, 547, 1661, 2, 35, 8027, 4, 3, 10087, 783, 80, 12010, 13136, 288, 4221, 674, 11, 120, 108, 107, 3, 2758, 408, 1, 3, 375, 1000, 444, 21, 530, 80, 8731, 210, 613, 2494, 6663, 2, 12010, 13136, 107, 780, 332, 1, 864, 12, 137, 3, 38, 724, 1, 46, 362, 16, 14853, 674, 1, 613, 2, 334, 2494, 11, 288, 4, 110, 332, 2, 3, 2758]",1733.0,18274275,94
"Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.",Blood,Blood,2008-03-07,"We examined the chronic lymphocytic leukemia (CLL) cells of 2457 patients evaluated by the CLL Research Consortium (CRC) and found that 63 (2.6%) expressed immunoglobulin (Ig) encoded by the Ig heavy-chain-variable-region gene (IGHV), IGHV3-21. We identified the amino acid sequence DANGMDV (motif-1) or DPSFYSSSWTLFDY (motif-2) in the Ig heavy-chain (IgH) third complementarity-determining region (HCDR3) of IgH, respectively, used by 25 or 3 cases. The IgH with HCDR3 motif-1 or motif-2, respectively, was paired with Ig light chains (IgL) encoded by IGLV3-21 or IGKV3-20, suggesting that these Ig had been selected for binding to conventional antigen(s). Cases that had HCDR3 motif-1 had a median time from diagnosis to initial therapy comparable with that of cases without a defined HCDR3 motif, as did cases that used mutated IGHV3-21 (n = 27) versus unmutated IGHV3-21 (n = 30). Of 7 examined cases that used Ig encoded by IGHV3-21/IGLV3-21, we found that 5 had a functionally rearranged IGKV allele that apparently had incurred antigendriven somatic mutations and subsequent rearrangement with KDE. This study reveals that CLL cells expressing IGHV3-21/IGLV3-21 most likely were derived from B cells that had experienced somatic mutation and germinal-center maturation in an apparent antigen-driven immune response before undergoing Ig-receptor editing and after germinal-center leukemogenic selection.",Journal Article,4337.0,50.0,We examined the chronic lymphocytic CLL cells of 2457 patients evaluated by the CLL Research Consortium CRC and found that 63 2.6 expressed immunoglobulin Ig encoded by the Ig heavy-chain-variable-region gene IGHV IGHV3-21 We identified the amino acid sequence DANGMDV motif-1 or DPSFYSSSWTLFDY motif-2 in the Ig heavy-chain IgH third complementarity-determining region HCDR3 of IgH respectively used by 25 or 3 cases The IgH with HCDR3 motif-1 or motif-2 respectively was paired with Ig light chains IgL encoded by IGLV3-21 or IGKV3-20 suggesting that these Ig had been selected for binding to conventional antigen s Cases that had HCDR3 motif-1 had a median time from diagnosis to initial therapy comparable with that of cases without a defined HCDR3 motif as did cases that used mutated IGHV3-21 n 27 versus unmutated IGHV3-21 n 30 Of 7 examined cases that used Ig encoded by IGHV3-21/IGLV3-21 we found that 5 had a functionally rearranged IGKV allele that apparently had incurred antigendriven somatic mutations and subsequent rearrangement with KDE This study reveals that CLL cells expressing IGHV3-21/IGLV3-21 most likely were derived from B cells that had experienced somatic mutation and germinal-center maturation in an apparent antigen-driven immune response before undergoing Ig-receptor editing and after germinal-center leukemogenic selection,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 409, 3, 442, 1193, 552, 37, 1, 56915, 7, 194, 20, 3, 552, 389, 2404, 590, 2, 204, 17, 676, 18, 49, 570, 2593, 4200, 4587, 20, 3, 4200, 4013, 1260, 1347, 1053, 145, 6220, 31242, 239, 21, 108, 3, 3078, 971, 1532, 56916, 5298, 14, 15, 56917, 5298, 18, 4, 3, 4200, 4013, 1260, 5221, 1282, 17673, 2196, 1053, 23615, 1, 5221, 106, 95, 20, 243, 15, 27, 140, 3, 5221, 5, 23615, 5298, 14, 15, 5298, 18, 106, 10, 2355, 5, 4200, 1691, 7802, 17659, 4587, 20, 34308, 239, 15, 34306, 179, 802, 17, 46, 4200, 42, 85, 715, 9, 791, 6, 809, 448, 695, 140, 17, 42, 23615, 5298, 14, 42, 8, 52, 98, 29, 147, 6, 388, 36, 1279, 5, 17, 1, 140, 187, 8, 395, 23615, 5298, 22, 205, 140, 17, 95, 1185, 31242, 239, 78, 428, 185, 7216, 31242, 239, 78, 201, 1, 67, 409, 140, 17, 95, 4200, 4587, 20, 31242, 239, 34308, 239, 21, 204, 17, 33, 42, 8, 3772, 3201, 38509, 1254, 17, 6343, 42, 11172, 56918, 1119, 138, 2, 706, 2675, 5, 45049, 26, 45, 4054, 17, 552, 37, 1046, 31242, 239, 34308, 239, 96, 322, 11, 526, 29, 132, 37, 17, 42, 592, 1119, 258, 2, 6312, 574, 4537, 4, 35, 2235, 448, 1621, 250, 51, 348, 479, 4200, 153, 6120, 2, 50, 6312, 574, 13519, 881]",1356.0,18326815,487
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.,Blood,Blood,2008-03-11,"This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated V(H), and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL.",Clinical Trial,4333.0,351.0,This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic CLL Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily Three patients 7 achieved a complete response CR one a nodular partial remission and 10 patients a partial remission PR for an overall response OR rate of 32 Treatment with lenalidomide was associated with an OR rate of 31 in patients with 11q or 17p deletion of 24 in patients with unmutated V H and of 25 in patients with fludarabine-refractory disease The most common toxicity was myelosuppression and the median daily dose of lenalidomide tolerated was 10 mg Plasma levels of angiogenic factors inflammatory cytokines and cytokine receptors were measured at baseline day 7 and day 28 There was a dramatic increase in median interleukin IL -6 IL-10 IL-2 and tumor necrosis factor receptor-1 levels on day 7 whereas no changes were observed in median vascular endothelial growth factor levels 20 patients studied According to our experience lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 45, 565, 3, 128, 1, 1288, 4, 7, 5, 591, 430, 442, 1193, 552, 1288, 10, 447, 28, 79, 81, 391, 5, 61, 1125, 126, 6, 243, 81, 391, 169, 7, 67, 513, 8, 236, 51, 684, 104, 8, 4481, 450, 734, 2, 79, 7, 8, 450, 734, 998, 9, 35, 63, 51, 15, 116, 1, 531, 24, 5, 1288, 10, 41, 5, 35, 15, 116, 1, 456, 4, 7, 5, 7203, 15, 4135, 1528, 1, 259, 4, 7, 5, 7216, 603, 555, 2, 1, 243, 4, 7, 5, 2027, 430, 34, 3, 96, 186, 155, 10, 2858, 2, 3, 52, 391, 61, 1, 1288, 421, 10, 79, 81, 554, 148, 1, 2068, 130, 1291, 1886, 2, 1675, 1186, 11, 644, 28, 330, 218, 67, 2, 218, 339, 125, 10, 8, 3079, 344, 4, 52, 1603, 501, 49, 501, 79, 501, 18, 2, 30, 1523, 161, 153, 14, 148, 23, 218, 67, 547, 77, 400, 11, 164, 4, 52, 756, 845, 129, 161, 148, 179, 7, 656, 768, 6, 114, 730, 1288, 447, 22, 8, 1314, 24, 71, 579, 128, 4, 2447, 2193, 7, 5, 552]",1141.0,18334676,532
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.,Leukemia & lymphoma,Leuk. Lymphoma,2008-04-01,"Chronic lymphocytic leukemia (CLL) cells rapidly undergo apoptosis when cultured in vitro, which contrasts with their prolonged survival in vivo. Multiple cytokines and cytokine receptors are believed to work together to regulate the survival of CLL cells. The aim of the current study was to measure the endogenous expression and secretion of cytokines and cytokine receptors in CLL cells when exogenous cytokines are minimized. We demonstrated that the intracellular and secreted levels of 174 cytokines and cytokine receptors of purified CLL B-cells were not significantly different from those of normal B-cells except for the secreted levels of IL-6 and eotaxin. IL-6 was 3.0 times lower (p = 0.038) whereas eotaxin was 2.2 times higher (p = 0.027) in CLL conditioned medium than in normal B-cell conditioned medium. Our results suggest that, except for IL-6 and eotaxin, CLL B-cells and their normal counterparts produce and secrete similar amounts of cytokines and cytokine receptors in vitro.",Journal Article,4312.0,9.0,Chronic lymphocytic CLL cells rapidly undergo apoptosis when cultured in vitro which contrasts with their prolonged survival in vivo Multiple cytokines and cytokine receptors are believed to work together to regulate the survival of CLL cells The aim of the current study was to measure the endogenous expression and secretion of cytokines and cytokine receptors in CLL cells when exogenous cytokines are minimized We demonstrated that the intracellular and secreted levels of 174 cytokines and cytokine receptors of purified CLL B-cells were not significantly different from those of normal B-cells except for the secreted levels of IL-6 and eotaxin IL-6 was 3.0 times lower p 0.038 whereas eotaxin was 2.2 times higher p 0.027 in CLL conditioned medium than in normal B-cell conditioned medium Our results suggest that except for IL-6 and eotaxin CLL B-cells and their normal counterparts produce and secrete similar amounts of cytokines and cytokine receptors in vitro,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 37, 1755, 1251, 351, 198, 3197, 4, 439, 92, 18485, 5, 136, 1069, 25, 4, 386, 232, 1886, 2, 1675, 1186, 32, 3979, 6, 1357, 1162, 6, 2288, 3, 25, 1, 552, 37, 3, 1130, 1, 3, 291, 45, 10, 6, 1463, 3, 2682, 55, 2, 2935, 1, 1886, 2, 1675, 1186, 4, 552, 37, 198, 4181, 1886, 32, 9243, 21, 264, 17, 3, 2087, 2, 3613, 148, 1, 5811, 1886, 2, 1675, 1186, 1, 5963, 552, 132, 37, 11, 44, 97, 338, 29, 135, 1, 295, 132, 37, 2187, 9, 3, 3613, 148, 1, 501, 49, 2, 21511, 501, 49, 10, 27, 13, 1072, 280, 19, 13, 5215, 547, 21511, 10, 18, 18, 1072, 142, 19, 13, 4523, 4, 552, 5636, 3759, 76, 4, 295, 132, 31, 5636, 3759, 114, 99, 309, 17, 2187, 9, 501, 49, 2, 21511, 552, 132, 37, 2, 136, 295, 3953, 2410, 2, 6401, 288, 4939, 1, 1886, 2, 1675, 1186, 4, 439]",971.0,18398743,360
"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.",Blood,Blood,2008-04-14,"Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia. In this report, we present the final results of all 300 study patients at a median follow up of 6 years. The overall response rate was 95%, with complete remission in 72%, nodular partial remission in 10%, partial remission due to cytopenia in 7%, and partial remission due to residual disease in 6%. Two patients (< 1%) died within 3 months of starting therapy. Six-year overall and failure-free survival were 77% and 51%, respectively. Median time to progression was 80 months. Pretreatment characteristics independently associated with inferior response were age 70 years or older, beta2-microglobulin twice the upper limit of normal (2N) or more, white cell count 150 x 10(9)/L or more, abnormal chromosome 17, and lactate dehydrogenase 2N or more. No pretreatment characteristic was independently associated with decreased complete remission duration. The risk of late infection was 10% and 4% for the first and second years of remission, respectively, and less than 1.5% per year for the third year onward. In a multivariate analysis of patients receiving fludarabine-based therapy at our center, FCR therapy emerged as the strongest independent determinant of survival.","Clinical Trial, Phase II",4299.0,543.0,Early results of the fludarabine cyclophosphamide and rituximab FCR regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic In this report we present the final results of all 300 study patients at a median follow up of 6 years The overall response rate was 95 with complete remission in 72 nodular partial remission in 10 partial remission due to cytopenia in 7 and partial remission due to residual disease in 6 Two patients 1 died within 3 months of starting therapy Six-year overall and failure-free survival were 77 and 51 respectively Median time to progression was 80 months Pretreatment characteristics independently associated with inferior response were age 70 years or older beta2-microglobulin twice the upper limit of normal 2N or more white cell count 150 x 10 9 /L or more abnormal chromosome 17 and lactate dehydrogenase 2N or more No pretreatment characteristic was independently associated with decreased complete remission duration The risk of late infection was 10 and 4 for the first and second years of remission respectively and less than 1.5 per year for the third year onward In a multivariate analysis of patients receiving fludarabine-based therapy at our center FCR therapy emerged as the strongest independent determinant of survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[191, 99, 1, 3, 2027, 1112, 2, 855, 4953, 477, 4, 5908, 7, 224, 17, 192, 10, 561, 544, 22, 388, 36, 1, 442, 1193, 4, 26, 414, 21, 364, 3, 1457, 99, 1, 62, 2036, 45, 7, 28, 8, 52, 166, 126, 1, 49, 60, 3, 63, 51, 116, 10, 48, 5, 236, 734, 4, 720, 4481, 450, 734, 4, 79, 450, 734, 520, 6, 8165, 4, 67, 2, 450, 734, 520, 6, 753, 34, 4, 49, 100, 7, 14, 1016, 262, 27, 53, 1, 1723, 36, 437, 111, 63, 2, 496, 115, 25, 11, 849, 2, 725, 106, 52, 98, 6, 91, 10, 493, 53, 1194, 374, 1042, 41, 5, 1663, 51, 11, 89, 431, 60, 15, 434, 8911, 5371, 936, 3, 1726, 2385, 1, 295, 24955, 15, 80, 886, 31, 1276, 1577, 1006, 79, 83, 805, 15, 80, 1668, 1170, 269, 2, 3330, 2374, 24955, 15, 80, 77, 1194, 2037, 10, 1042, 41, 5, 340, 236, 734, 654, 3, 43, 1, 807, 930, 10, 79, 2, 39, 9, 3, 157, 2, 419, 60, 1, 734, 106, 2, 299, 76, 14, 33, 379, 111, 9, 3, 1282, 111, 15088, 4, 8, 331, 65, 1, 7, 357, 2027, 90, 36, 28, 114, 574, 4953, 36, 2054, 22, 3, 3311, 306, 4372, 1, 25]",1304.0,18411418,229
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,Clin. Infect. Dis.,2008-04-01,"The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.",Case Reports,4312.0,4.0,The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies However its potential role in augmenting immune reactions against opportunistic infections has not been explored We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2555, 234, 1288, 16, 694, 486, 194, 9, 211, 3940, 1571, 4, 1367, 813, 441, 137, 211, 174, 200, 4, 9015, 250, 2428, 480, 10026, 1875, 71, 44, 85, 1443, 21, 414, 3, 1321, 2125, 1, 442, 28789, 57036, 930, 4, 8, 69, 366, 1118, 1, 1288, 36, 9, 442, 1193]",407.0,18444808,26
"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-05-01,"Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. Eligible patients were assigned to one of five disease-specific, parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks. A Simon two-stage design was used for each cohort. Safety, pharmacokinetics, pharmacodynamics, and antitumor response were assessed. Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma. Most patients were heavily pretreated. Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma. Hematologic improvement/stable disease was observed in 21 (40%). Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia. Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus. Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.","Clinical Trial, Phase II",4282.0,192.0,Deforolimus AP23573 a novel non-prodrug rapamycin analogue inhibits the mammalian target of rapamycin a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies Eligible patients were assigned to one of five disease-specific parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks A Simon two-stage design was used for each cohort Safety pharmacokinetics pharmacodynamics and antitumor response were assessed Fifty-five patients received deforolimus as follows cohort 1 23 acute myelogenous two syndrome and one chronic myelogenous in nonlymphoid blast phase cohort 2 one acute lymphocytic cohort 3 nine agnogenic myeloid metaplasia cohort 4 eight chronic lymphocytic cohort 5 nine mantle cell and two T-cell leukemia/lymphoma Most patients were heavily pretreated Of the 52 evaluable patients partial responses were noted in five 10 two of seven agnogenic myeloid metaplasia and three of nine mantle cell Hematologic improvement/stable disease was observed in 21 40 Common treatment-related adverse events which were generally mild and reversible were mouth sores fatigue nausea and thrombocytopenia Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies and antitumor activity was observed Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[19848, 24680, 8, 229, 220, 5227, 1620, 4696, 1576, 3, 2359, 283, 1, 1620, 8, 1489, 2070, 1, 3, 3415, 27, 216, 649, 2, 8749, 8350, 460, 8, 124, 18, 160, 10, 426, 6, 223, 3, 209, 2, 367, 1, 226, 420, 19848, 4, 7, 5, 591, 15, 430, 813, 441, 625, 7, 11, 896, 6, 104, 1, 365, 34, 112, 2755, 736, 2, 447, 133, 33, 81, 19848, 22, 8, 201, 3949, 904, 1059, 391, 9, 33, 162, 454, 18, 244, 8, 7385, 100, 82, 771, 10, 95, 9, 296, 180, 367, 1159, 3587, 2, 579, 51, 11, 275, 1461, 365, 7, 103, 19848, 22, 2962, 180, 14, 382, 286, 2194, 100, 681, 2, 104, 442, 2194, 4, 20180, 3112, 124, 180, 18, 104, 286, 1193, 180, 27, 762, 26059, 533, 6054, 180, 39, 659, 442, 1193, 180, 33, 762, 2757, 31, 2, 100, 102, 31, 2647, 4763, 96, 7, 11, 2447, 2193, 1, 3, 653, 859, 7, 450, 253, 11, 1051, 4, 365, 79, 100, 1, 648, 26059, 533, 6054, 2, 169, 1, 762, 2757, 31, 813, 767, 585, 34, 10, 164, 4, 239, 327, 186, 24, 139, 290, 281, 92, 11, 1228, 1980, 2, 2786, 11, 5831, 45115, 613, 1218, 2, 1340, 340, 148, 1, 2365, 6726, 7949, 4, 83, 1, 175, 286, 2194, 2647, 10589, 681, 7, 50, 36, 224, 2359, 283, 1, 1620, 297, 20, 19848, 19848, 10, 149, 421, 4, 7, 5, 2447, 2193, 813, 441, 2, 579, 128, 10, 164, 195, 940, 1, 19848, 279, 2, 4, 150, 5, 127, 189, 183, 16, 1197, 4, 7, 5, 715, 813, 441]",1820.0,18451242,93
"Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.",Cancer,Cancer,2008-07-01,"For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 microg) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV. They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF. A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 6B, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. In patients with CLL, the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF. In all patients, reactogenicity was minor.",Journal Article,4221.0,32.0,For the current study the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor GM-CSF could improve response to standard 23-valent polysaccharide pneumococcal vaccine PPV in patients with chronic lymphocytic CLL Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF 250 microg given before or after vaccination Serum was obtained before 4 weeks after and 12 weeks after vaccination for antibody determination Thirty-two patients with CLL were given PPV They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF A 4-fold rise in immunoglobulin G IgG to capsular polysaccharides from Streptococcus pneumoniae types 4 6B 9V 14 19F and 23F occurred in 10 of patients in each of the 3 groups There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination In patients with CLL the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF In all patients reactogenicity was minor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[9, 3, 291, 45, 3, 738, 990, 6, 223, 317, 634, 1, 232, 61, 2764, 2674, 1975, 2122, 161, 2147, 1211, 359, 401, 51, 6, 260, 382, 34395, 26702, 15708, 1274, 4998, 4, 7, 5, 442, 1193, 552, 7, 11, 6682, 1108, 6, 560, 4998, 361, 279, 15, 5, 27, 415, 1, 2147, 1211, 2039, 2440, 447, 348, 15, 50, 1915, 524, 10, 683, 348, 39, 244, 50, 2, 133, 244, 50, 1915, 9, 548, 3104, 977, 100, 7, 5, 552, 11, 447, 4998, 491, 11, 384, 6, 560, 27, 415, 1, 2147, 1211, 361, 348, 15, 50, 1915, 15, 6, 560, 77, 2147, 1211, 8, 39, 1116, 3693, 4, 2593, 499, 3630, 6, 13548, 57048, 29, 16037, 13590, 630, 39, 27840, 30873, 213, 24456, 2, 45121, 489, 4, 79, 1, 7, 4, 296, 1, 3, 27, 271, 125, 11, 77, 362, 4, 8570, 313, 3630, 148, 4, 500, 1, 3, 27, 271, 39, 244, 15, 133, 244, 50, 1915, 4, 7, 5, 552, 3, 51, 6, 3092, 26702, 15708, 1274, 10, 154, 550, 250, 2461, 5, 232, 415, 1, 2147, 1211, 4, 62, 7, 38717, 10, 2278]",1134.0,18470901,116
"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.",Blood,Blood,2008-05-22,"B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder characterized by the surface expression of CD20, CD5 antigens, as well as the receptor CD40. Activation of CD40 by its ligand (CD40L) induces proliferation and rescues the cells from spontaneous and chemotherapy-induced apoptosis. CD40 activation also induces secretion of cytokines, such as IL-6, IL-10, TNF-alpha, IL-8, and GM-CSF, which are involved in tumor cell survival, migration, and interaction with cells in the tumor microenvironment. Here we demonstrate that in primary B-CLL tumor cells, the novel antagonist anti-CD40 monoclonal antibody, HCD122, inhibits CD40L-induced activation of signaling pathways, proliferation and survival, and secretion of cytokines. Furthermore, HCD122 is also a potent mediator of antibody-dependent cellular cytotoxicity (ADCC), lysing B-CLL cells more efficiently than rituximab in vitro, despite a significantly higher number of cell surface CD20 binding sites compared with CD40. Unlike rituximab, however, HCD122 (formerly CHIR-12.12) does not internalize upon binding to the cells. Our data suggest that HCD122 may inhibit B-CLL growth by blocking CD40 signaling and by ADCC-mediated cell lysis.",Journal Article,4261.0,76.0,B-cell chronic lymphocytic B-CLL is a lymphoproliferative disorder characterized by the surface expression of CD20 CD5 antigens as well as the receptor CD40 Activation of CD40 by its ligand CD40L induces proliferation and rescues the cells from spontaneous and chemotherapy-induced apoptosis CD40 activation also induces secretion of cytokines such as IL-6 IL-10 TNF-alpha IL-8 and GM-CSF which are involved in tumor cell survival migration and interaction with cells in the tumor microenvironment Here we demonstrate that in primary B-CLL tumor cells the novel antagonist anti-CD40 monoclonal antibody HCD122 inhibits CD40L-induced activation of signaling pathways proliferation and survival and secretion of cytokines Furthermore HCD122 is also a potent mediator of antibody-dependent cellular cytotoxicity ADCC lysing B-CLL cells more efficiently than rituximab in vitro despite a significantly higher number of cell surface CD20 binding sites compared with CD40 Unlike rituximab however HCD122 formerly CHIR-12.12 does not internalize upon binding to the cells Our data suggest that HCD122 may inhibit B-CLL growth by blocking CD40 signaling and by ADCC-mediated cell lysis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 132, 552, 16, 8, 4192, 2645, 765, 20, 3, 1255, 55, 1, 2198, 6349, 1575, 22, 149, 22, 3, 153, 5040, 363, 1, 5040, 20, 211, 1232, 8285, 1516, 457, 2, 17156, 3, 37, 29, 3280, 2, 56, 277, 351, 5040, 363, 120, 1516, 2935, 1, 1886, 225, 22, 501, 49, 501, 79, 2254, 950, 501, 66, 2, 2147, 1211, 92, 32, 646, 4, 30, 31, 25, 1381, 2, 915, 5, 37, 4, 3, 30, 995, 467, 21, 608, 17, 4, 86, 132, 552, 30, 37, 3, 229, 3137, 312, 5040, 848, 548, 31290, 1576, 8285, 277, 363, 1, 314, 460, 457, 2, 25, 2, 2935, 1, 1886, 798, 31290, 16, 120, 8, 1157, 3810, 1, 548, 470, 763, 1408, 5551, 24779, 132, 552, 37, 80, 4143, 76, 855, 4, 439, 550, 8, 97, 142, 207, 1, 31, 1255, 2198, 791, 633, 72, 5, 5040, 4246, 855, 137, 31290, 7350, 57085, 133, 133, 1097, 44, 28510, 1548, 791, 6, 3, 37, 114, 74, 309, 17, 31290, 68, 1433, 132, 552, 129, 20, 2521, 5040, 314, 2, 20, 5551, 517, 31, 4783]",1177.0,18497318,180
Autoimmune pancreatitis and concurrent small lymphocytic lymphoma: not just a coincidence?,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2008-05-28,"A 76-year-old gentleman presented with painless jaundice, weight loss, and anorexia. Computed tomography imaging revealed fullness of the pancreatic head and multiple enlarged retroperitoneal lymph nodes. Cholangiogram revealed a distal common bile duct stricture. Due to concerns of malignancy, the patient underwent operative exploration. Several enlarged lymph nodes in the aortocaval region and a firm hard mass in the pancreatic head were found. Frozen section from one of the lymph nodes was suspicious for low-grade lymphoma. A pancreaticoduodenectomy was performed. Histologic analysis of the pancreatic head revealed a lymphoplasmacytic infiltrate with stromal fibrosis consistent with autoimmune pancreatitis. The retroperitoneal lymph nodes were involved by small lymphocytic lymphoma. Autoimmune pancreatitis is the most common benign diagnosis after pancreatic resection for presumed malignancy. It has a well-documented association with autoimmune conditions, such as Sjgren's syndrome, inflammatory bowel disease, and sclerosing cholangitis. Additionally, chronic lymphocytic leukemia-small lymphocytic lymphoma is often associated with autoimmune phenomena, most notably autoimmune hemolytic anemia. However, an association between autoimmune pancreatitis and small lymphocytic lymphoma has not been previously described. To our knowledge, this is the first reported case of a patient with concurrent autoimmune pancreatitis and small lymphocytic lymphoma.",Case Reports,4255.0,20.0,A 76-year-old gentleman presented with painless jaundice weight loss and anorexia Computed tomography imaging revealed fullness of the head and multiple enlarged retroperitoneal lymph nodes Cholangiogram revealed a distal common duct stricture Due to concerns of malignancy the patient underwent operative exploration Several enlarged lymph nodes in the aortocaval region and a firm hard mass in the head were found Frozen section from one of the lymph nodes was suspicious for low-grade A pancreaticoduodenectomy was performed Histologic analysis of the head revealed a lymphoplasmacytic infiltrate with stromal fibrosis consistent with autoimmune pancreatitis The retroperitoneal lymph nodes were involved by small lymphocytic Autoimmune pancreatitis is the most common benign diagnosis after resection for presumed malignancy It has a well-documented association with autoimmune conditions such as Sjgren 's syndrome inflammatory bowel disease and sclerosing cholangitis Additionally chronic lymphocytic leukemia-small lymphocytic is often associated with autoimmune phenomena most notably autoimmune hemolytic anemia However an association between autoimmune pancreatitis and small lymphocytic has not been previously described To our knowledge this is the first reported case of a patient with concurrent autoimmune pancreatitis and small lymphocytic,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[8, 846, 111, 1095, 28444, 917, 5, 14963, 7655, 924, 407, 2, 3373, 1220, 872, 270, 553, 30803, 1, 3, 718, 2, 232, 7547, 2591, 263, 502, 28026, 553, 8, 2107, 186, 2920, 6673, 520, 6, 2061, 1, 710, 3, 69, 208, 1208, 3370, 392, 7547, 263, 502, 4, 3, 17414, 1053, 2, 8, 10851, 9327, 782, 4, 3, 718, 11, 204, 3015, 2917, 29, 104, 1, 3, 263, 502, 10, 3230, 9, 154, 88, 8, 4104, 10, 173, 884, 65, 1, 3, 718, 553, 8, 5325, 5172, 5, 1126, 3000, 925, 5, 3445, 4535, 3, 2591, 263, 502, 11, 646, 20, 302, 1193, 3445, 4535, 16, 3, 96, 186, 1002, 147, 50, 170, 9, 5472, 710, 192, 71, 8, 149, 1405, 248, 5, 3445, 1298, 225, 22, 26707, 292, 681, 1291, 1659, 34, 2, 6782, 8541, 1724, 442, 1193, 2647, 302, 1193, 16, 629, 41, 5, 3445, 11549, 96, 2552, 3445, 10425, 1545, 137, 35, 248, 59, 3445, 4535, 2, 302, 1193, 71, 44, 85, 373, 1027, 6, 114, 922, 26, 16, 3, 157, 210, 473, 1, 8, 69, 5, 750, 3445, 4535, 2, 302, 1193]",1356.0,18506547,34
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.,The Journal of clinical investigation,J. Clin. Invest.,2008-07-01,"Cancer is associated with immune deficiency, but the biologic basis of this is poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation with APCs. Although this synapse dysfunction was in part a result of the CLL cells having poor APC function, defective actin polymerization was also identified in T cells from patients with CLL. We further demonstrate that, following contact with CLL cells, defects in immune synapse formation were induced in healthy allogeneic T cells. This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells. In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells, recruitment of key regulatory proteins to the immune synapse was inhibited. Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation. These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches.",Journal Article,4221.0,385.0,Cancer is associated with immune deficiency but the biologic basis of this is poorly defined Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic CLL exhibiting defective immunological synapse formation with APCs Although this synapse dysfunction was in part a result of the CLL cells having poor APC function defective actin polymerization was also identified in T cells from patients with CLL We further demonstrate that following contact with CLL cells defects in immune synapse formation were induced in healthy allogeneic T cells This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells recruitment of key regulatory proteins to the immune synapse was inhibited Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[12, 16, 41, 5, 250, 2299, 84, 3, 1283, 877, 1, 26, 16, 1240, 395, 467, 21, 608, 17, 2364, 5525, 12273, 99, 4, 1440, 2, 968, 102, 37, 29, 7, 5, 442, 1193, 552, 4801, 4552, 5073, 15533, 1264, 5, 6966, 242, 26, 15533, 1527, 10, 4, 760, 8, 757, 1, 3, 552, 37, 1041, 334, 2528, 343, 4552, 5525, 12273, 10, 120, 108, 4, 102, 37, 29, 7, 5, 552, 21, 195, 608, 17, 366, 4393, 5, 552, 37, 2945, 4, 250, 15533, 1264, 11, 277, 4, 1331, 1063, 102, 37, 26, 616, 1196, 4393, 2, 10, 879, 20, 2521, 2128, 1598, 23, 552, 132, 37, 4, 102, 37, 29, 7, 5, 552, 2, 4, 102, 37, 29, 1331, 869, 17, 42, 85, 4, 4393, 5, 552, 37, 3202, 1, 825, 1253, 652, 6, 3, 250, 15533, 10, 879, 24, 1, 1028, 102, 37, 2, 552, 37, 5, 3, 13861, 234, 1288, 627, 4, 231, 15533, 1264, 46, 99, 1107, 2067, 21, 4629, 6, 40, 8, 229, 250, 1527, 4, 102, 37, 29, 7, 5, 552, 17, 71, 1268, 9, 110, 1028, 2, 1063, 726, 611, 2, 2953, 972, 1, 250, 15533, 2945, 22, 35, 1452, 2458, 4, 1673, 12, 726, 611]",1319.0,18551193,60
"Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.",Blood,Blood,2008-06-19,"Gossypol, a cottonseed extract derivative, acts as a BH3-mimetic, binding to the BH3 pocket of antiapoptotic proteins and displacing pro-death partners to induce apoptosis. However, knowledge on the molecular underpinnings of its downstream effects is limited. Since chronic lymphocytic leukemia (CLL) cells express high levels of antiapoptotic proteins that act as a survival mechanism for these replicationally quiescent lymphocytes, we investigated whether gossypol induces apoptosis in these cells and what mechanism underlies gossypol-mediated cytotoxicity. Gossypol induced cell death in a concentration- and time-dependent manner; 24-hour incubation with 30 microM gossypol resulted in 50% cell death (median; range, 10%-80%; n = 47) that was not abrogated by pan-specific caspase inhibitor. Starting at 4 hours, the mitochondrial outer membrane was significantly permeabilized (median, 77%; range, 54%-93%; n = 15). Mitochondrial outer membrane permeabiliztaion (MOMP) was concurrent with increased production of reactive oxygen species (ROS); however, antioxidants did not abrogate gossypol-induced cell death. Mitochondrial membrane permeabilization was also associated with loss of intracellular adenosine triphosphate (ATP), activation of BAX, and release of cytochrome c and apoptosis-inducing factor (AIF), which was translocated to the nucleus. Blocking AIF translocation resulted in a decreased apoptosis, suggesting that AIF contributes to gossypol-mediated cytotoxicity in CLL lymphocytes.",Journal Article,4233.0,107.0,Gossypol a cottonseed extract derivative acts as a BH3-mimetic binding to the BH3 pocket of antiapoptotic proteins and displacing pro-death partners to induce apoptosis However knowledge on the molecular underpinnings of its downstream effects is limited Since chronic lymphocytic CLL cells express high levels of antiapoptotic proteins that act as a survival mechanism for these replicationally quiescent lymphocytes we investigated whether gossypol induces apoptosis in these cells and what mechanism underlies gossypol-mediated cytotoxicity Gossypol induced cell death in a concentration- and time-dependent manner 24-hour incubation with 30 microM gossypol resulted in 50 cell death median range 10 -80 n 47 that was not abrogated by pan-specific caspase inhibitor Starting at 4 hours the mitochondrial outer membrane was significantly permeabilized median 77 range 54 -93 n 15 Mitochondrial outer membrane permeabiliztaion MOMP was concurrent with increased production of reactive oxygen species ROS however antioxidants did not abrogate gossypol-induced cell death Mitochondrial membrane permeabilization was also associated with loss of intracellular adenosine triphosphate ATP activation of BAX and release of cytochrome c and apoptosis-inducing factor AIF which was translocated to the nucleus Blocking AIF translocation resulted in a decreased apoptosis suggesting that AIF contributes to gossypol-mediated cytotoxicity in CLL lymphocytes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[16912, 8, 45173, 7164, 4819, 4459, 22, 8, 5486, 7343, 791, 6, 3, 5486, 6575, 1, 4176, 652, 2, 34493, 1805, 273, 4005, 6, 1290, 351, 137, 922, 23, 3, 219, 8807, 1, 211, 1489, 176, 16, 383, 1192, 442, 1193, 552, 37, 1669, 64, 148, 1, 4176, 652, 17, 2559, 22, 8, 25, 670, 9, 46, 38754, 6735, 1594, 21, 565, 317, 16912, 1516, 351, 4, 46, 37, 2, 2067, 670, 10702, 16912, 517, 1408, 16912, 277, 31, 273, 4, 8, 1227, 2, 98, 470, 1708, 259, 2583, 7797, 5, 201, 3550, 16912, 627, 4, 212, 31, 273, 52, 184, 79, 493, 78, 662, 17, 10, 44, 3728, 20, 3055, 112, 1469, 230, 1723, 28, 39, 1459, 3, 2019, 7808, 1905, 10, 97, 45174, 52, 849, 184, 667, 966, 78, 167, 2019, 7808, 1905, 57181, 57182, 10, 750, 5, 101, 1529, 1, 2163, 2848, 2915, 2609, 137, 10721, 205, 44, 8581, 16912, 277, 31, 273, 2019, 1905, 19717, 10, 120, 41, 5, 407, 1, 2087, 4938, 7345, 3918, 363, 1, 3119, 2, 2008, 1, 4155, 256, 2, 351, 1958, 161, 10092, 92, 10, 12475, 6, 3, 4262, 2521, 10092, 2006, 627, 4, 8, 340, 351, 802, 17, 10092, 2444, 6, 16912, 517, 1408, 4, 552, 1594]",1448.0,18566329,118
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.,Blood,Blood,2008-06-23,"Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, and resistance to fludarabine-based therapies is a major challenge in CLL treatment. Because CLL cells are known to have elevated levels of reactive oxygen species (ROS), we aimed to test a novel ROS-mediated strategy to eliminate fludarabine-resistant CLL cells based on this redox alteration. Using primary CLL cells and normal lymphocytes from patients (n = 58) and healthy subjects (n = 12), we showed that both fludarabine-resistant and -sensitive CLL cells were highly sensitive to beta-phenylethyl isothiocyanate (PEITC) with mean IC(50) values of 5.4 microM and 5.1 microM, respectively. Normal lymphocytes were significantly less sensitive to PEITC (IC(50) = 27 microM, P < .001). CLL cells exhibited intrinsically higher ROS level and lower cellular glutathione, which were shown to be the critical determinants of CLL sensitivity to PEITC. Exposure of CLL cells to PEITC induced severe glutathione depletion, ROS accumulation, and oxidation of mitochondrial cardiolipin leading to massive cell death. Such ROS stress also caused deglutathionylation of MCL1, followed by a rapid degradation of this cell survival molecule. Our study demonstrated that the natural compound PEITC is effective in eliminating fludarabine-resistant CLL cells through a redox-mediated mechanism with low toxicity to normal lymphocytes, and warrants further clinical evaluation.",Journal Article,4229.0,139.0,Chronic lymphocytic CLL is the most common adult and resistance to fludarabine-based therapies is a major challenge in CLL treatment Because CLL cells are known to have elevated levels of reactive oxygen species ROS we aimed to test a novel ROS-mediated strategy to eliminate fludarabine-resistant CLL cells based on this redox alteration Using primary CLL cells and normal lymphocytes from patients n 58 and healthy subjects n 12 we showed that both fludarabine-resistant and -sensitive CLL cells were highly sensitive to beta-phenylethyl isothiocyanate PEITC with mean IC 50 values of 5.4 microM and 5.1 microM respectively Normal lymphocytes were significantly less sensitive to PEITC IC 50 27 microM P .001 CLL cells exhibited intrinsically higher ROS level and lower cellular glutathione which were shown to be the critical determinants of CLL sensitivity to PEITC Exposure of CLL cells to PEITC induced severe glutathione depletion ROS accumulation and oxidation of mitochondrial cardiolipin leading to massive cell death Such ROS stress also caused deglutathionylation of MCL1 followed by a rapid degradation of this cell survival molecule Our study demonstrated that the natural compound PEITC is effective in eliminating fludarabine-resistant CLL cells through a redox-mediated mechanism with low toxicity to normal lymphocytes and warrants further clinical evaluation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 780, 2, 251, 6, 2027, 90, 235, 16, 8, 458, 1745, 4, 552, 24, 408, 552, 37, 32, 440, 6, 47, 804, 148, 1, 2163, 2848, 2915, 2609, 21, 1295, 6, 412, 8, 229, 2609, 517, 692, 6, 4964, 2027, 436, 552, 37, 90, 23, 26, 7237, 2611, 75, 86, 552, 37, 2, 295, 1594, 29, 7, 78, 717, 2, 1331, 976, 78, 133, 21, 224, 17, 110, 2027, 436, 2, 745, 552, 37, 11, 561, 745, 6, 1090, 28738, 13790, 14318, 5, 313, 2340, 212, 1030, 1, 33, 39, 3550, 2, 33, 14, 3550, 106, 295, 1594, 11, 97, 299, 745, 6, 14318, 2340, 212, 428, 3550, 19, 144, 552, 37, 1416, 9759, 142, 2609, 301, 2, 280, 763, 4571, 92, 11, 443, 6, 40, 3, 740, 3403, 1, 552, 485, 6, 14318, 645, 1, 552, 37, 6, 14318, 277, 905, 4571, 2286, 2609, 1835, 2, 8740, 1, 2019, 44193, 1049, 6, 7929, 31, 273, 225, 2609, 1531, 120, 1546, 57199, 1, 8132, 370, 20, 8, 1321, 2373, 1, 26, 31, 25, 1354, 114, 45, 264, 17, 3, 1504, 2823, 14318, 16, 323, 4, 6923, 2027, 436, 552, 37, 298, 8, 7237, 517, 670, 5, 154, 155, 6, 295, 1594, 2, 2782, 195, 38, 451]",1377.0,18574029,156
"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.",Blood,Blood,2008-06-24,"Leukemia-cell expression of ZAP-70, CD38, or unmutated immunoglobulin heavy chain variable region genes (U-IGHV) each is associated with aggressive disease in patients with chronic lymphocytic leukemia (CLL). To assess the relative strength of each marker, we defined thresholds for designating a case as positive for CD38 or ZAP-70 in a test cohort of 307 patients and used these data-defined criteria to stratify patients in an independent cohort of 705 patients. Multivariable analysis revealed that ZAP-70 was the strongest risk factor. Knowledge of the IGHV mutation status or CD38 did not improve our ability to predict the time to first treatment except for ZAP-70-negative cases, which could be segregated into 2 groups of intermediate-risk or low-risk disease based on whether they expressed unmutated or mutated IGHV. ZAP-70 maintained its high relative prognostic value for the subset of patients with early-stage, asymptomatic disease, including patients evaluated within 1 year of diagnosis. Although it is premature to recommend therapy based on these risk factors, patients with ZAP-70-positive CLL cells should be monitored closely for disease progression as they have a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3 years.",Journal Article,4228.0,236.0,Leukemia-cell expression of ZAP-70 CD38 or unmutated immunoglobulin heavy chain variable region genes U-IGHV each is associated with aggressive disease in patients with chronic lymphocytic CLL To assess the relative strength of each marker we defined thresholds for designating a case as positive for CD38 or ZAP-70 in a test cohort of 307 patients and used these data-defined criteria to stratify patients in an independent cohort of 705 patients Multivariable analysis revealed that ZAP-70 was the strongest risk factor Knowledge of the IGHV mutation status or CD38 did not improve our ability to predict the time to first treatment except for ZAP-70-negative cases which could be segregated into 2 groups of intermediate-risk or low-risk disease based on whether they expressed unmutated or mutated IGHV ZAP-70 maintained its high relative prognostic value for the subset of patients with early-stage asymptomatic disease including patients evaluated within 1 year of diagnosis Although it is premature to recommend therapy based on these risk factors patients with ZAP-70-positive CLL cells should be monitored closely for disease progression as they have a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3 years,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2647, 31, 55, 1, 6251, 431, 4469, 15, 7216, 2593, 4013, 1260, 1347, 1053, 214, 1767, 6220, 296, 16, 41, 5, 571, 34, 4, 7, 5, 442, 1193, 552, 6, 423, 3, 580, 3671, 1, 296, 952, 21, 395, 4634, 9, 27906, 8, 473, 22, 109, 9, 4469, 15, 6251, 431, 4, 8, 412, 180, 1, 9682, 7, 2, 95, 46, 74, 395, 371, 6, 3570, 7, 4, 35, 306, 180, 1, 11303, 7, 658, 65, 553, 17, 6251, 431, 10, 3, 3311, 43, 161, 922, 1, 3, 6220, 258, 156, 15, 4469, 205, 44, 401, 114, 801, 6, 678, 3, 98, 6, 157, 24, 2187, 9, 6251, 431, 199, 140, 92, 359, 40, 11324, 237, 18, 271, 1, 919, 43, 15, 154, 43, 34, 90, 23, 317, 491, 570, 7216, 15, 1185, 6220, 6251, 431, 1955, 211, 64, 580, 177, 549, 9, 3, 697, 1, 7, 5, 191, 82, 2100, 34, 141, 7, 194, 262, 14, 111, 1, 147, 242, 192, 16, 5682, 6, 2237, 36, 90, 23, 46, 43, 130, 7, 5, 6251, 431, 109, 552, 37, 257, 40, 2909, 3210, 9, 34, 91, 22, 491, 47, 8, 52, 98, 29, 147, 6, 1888, 388, 36, 20, 260, 371, 1, 705, 27, 60]",1263.0,18577710,177
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.,Leukemia research,Leuk. Res.,2008-06-27,The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity (CDC) although a subpopulation of CLL cells had intrinsic resistance. Rituximab had no direct cytotoxicity and caused minimal CDC in cells from most patients. These data suggest that CDC has a therapeutic role in patients treated with alemtuzumab and that measures to decrease resistance to CDC could increase efficacy.,Clinical Trial,4225.0,60.0,The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic CLL is not well understood We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity CDC although a subpopulation of CLL cells had intrinsic resistance Rituximab had no direct cytotoxicity and caused minimal CDC in cells from most patients These data suggest that CDC has a therapeutic role in patients treated with alemtuzumab and that measures to decrease resistance to CDC could increase efficacy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 670, 1, 1408, 1, 3579, 2, 855, 4, 442, 1193, 552, 16, 44, 149, 1784, 21, 683, 4329, 552, 37, 29, 191, 919, 82, 64, 43, 7, 4673, 324, 6, 24, 5, 3579, 2, 855, 6, 45, 483, 1, 1578, 2, 251, 3579, 42, 1048, 1196, 1408, 84, 1546, 93, 3731, 470, 1408, 9665, 242, 8, 5518, 1, 552, 37, 42, 2354, 251, 855, 42, 77, 1196, 1408, 2, 1546, 1048, 9665, 4, 37, 29, 96, 7, 46, 74, 309, 17, 9665, 71, 8, 189, 200, 4, 7, 73, 5, 3579, 2, 17, 1018, 6, 775, 251, 6, 9665, 359, 344, 209]",701.0,18584865,0
Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.,Mayo Clinic proceedings,Mayo Clin. Proc.,2008-07-01,"To study the effectiveness of peripheral blood (PB) and bone marrow flow cytometric immunophenotyping (FCIP) in predicting the histologic B-cell lymphoma type. We studied the FCIP results and tissue histopathology from 252 patients with B-cell lymphoma seen at Mayo Clinic's site in Rochester, MN, between January 1, 1997, and January 1, 2004, who had positive results on PB, bone marrow, or body fluid FCIP and a corresponding diagnostic tissue biopsy specimen. Most of the B-cell lymphomas studied were low grade, with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma being most common. Flow cytometric immunophenotyping histogram analysis was more informative than tabulated percentage antigen positivity; surface immunoglobulin and CD20 staining intensity, CD5 and CD23 positivity, CD10 positivity, and the coexpression of CD11c/CD22 and CD103 were the most pertinent markers. Using these FCIP parameters and strict immunophenotypic definitions for CLL, mantle cell lymphoma (MCL), and hairy cell leukemia, we obtained greater than 95% specificity for each diagnosis. However, we encountered the following exceptions to standard paradigms of B-cell lymphoma-associated FCIP: (1) CD5 expression by disorders distinct from CLL and MCL, (2) lack of uniform CD5 positivity in some CLL and MCL cases, (3) absence of CD10 in approximately 50% of follicular lymphomas, and (4) expression of CD103 by occasional marginal zone lymphomas. Stringent interpretation of PB and bone marrow FCIP results enables identification of certain B-cell lymphoma types. However, the observed exceptions to accepted immunophenotypic paradigms highlight the occasional phenotypic overlap among diseases and emphasize that a systematic approach to FCIP interpretations is key to providing clinically useful diagnostic information.",Comparative Study,4221.0,,To study the effectiveness of peripheral blood PB and marrow flow cytometric immunophenotyping FCIP in predicting the histologic B-cell type We studied the FCIP results and tissue histopathology from 252 patients with B-cell seen at Mayo Clinic 's site in Rochester MN between January 1 1997 and January 1 2004 who had positive results on PB marrow or body fluid FCIP and a corresponding diagnostic tissue biopsy specimen Most of the B-cell lymphomas studied were low grade with chronic lymphocytic CLL /small lymphocytic being most common Flow cytometric immunophenotyping histogram analysis was more informative than tabulated percentage antigen positivity surface immunoglobulin and CD20 staining intensity CD5 and CD23 positivity CD10 positivity and the coexpression of CD11c/CD22 and CD103 were the most pertinent markers Using these FCIP parameters and strict immunophenotypic definitions for CLL mantle cell MCL and hairy cell we obtained greater than 95 specificity for each diagnosis However we encountered the following exceptions to standard paradigms of B-cell lymphoma-associated FCIP 1 CD5 expression by disorders distinct from CLL and MCL 2 lack of uniform CD5 positivity in some CLL and MCL cases 3 absence of CD10 in approximately 50 of follicular lymphomas and 4 expression of CD103 by occasional marginal zone lymphomas Stringent interpretation of PB and marrow FCIP results enables identification of certain B-cell types However the observed exceptions to accepted immunophenotypic paradigms highlight the occasional phenotypic overlap among diseases and emphasize that a systematic approach to FCIP interpretations is key to providing clinically useful diagnostic information,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 45, 3, 1236, 1, 672, 315, 3767, 2, 581, 1412, 6226, 9416, 22492, 4, 1434, 3, 884, 132, 31, 267, 21, 656, 3, 22492, 99, 2, 246, 3831, 29, 6951, 7, 5, 132, 31, 527, 28, 2486, 1188, 292, 606, 4, 5801, 4691, 59, 1024, 14, 2341, 2, 1024, 14, 1131, 54, 42, 109, 99, 23, 3767, 581, 15, 642, 2357, 22492, 2, 8, 1734, 752, 246, 411, 2360, 96, 1, 3, 132, 31, 1557, 656, 11, 154, 88, 5, 442, 1193, 552, 302, 1193, 486, 96, 186, 1412, 6226, 9416, 8261, 65, 10, 80, 4189, 76, 9903, 1150, 448, 1887, 1255, 2593, 2, 2198, 1029, 837, 6349, 2, 9937, 1887, 6289, 1887, 2, 3, 7588, 1, 12513, 7599, 2, 13856, 11, 3, 96, 5799, 525, 75, 46, 22492, 1038, 2, 8043, 6599, 3833, 9, 552, 2757, 31, 1308, 2, 7152, 31, 21, 683, 378, 76, 48, 1121, 9, 296, 147, 137, 21, 3903, 3, 366, 11084, 6, 260, 4887, 1, 132, 31, 4763, 41, 22492, 14, 6349, 55, 20, 1997, 834, 29, 552, 2, 1308, 18, 926, 1, 3490, 6349, 1887, 4, 476, 552, 2, 1308, 140, 27, 1127, 1, 6289, 4, 705, 212, 1, 1974, 1557, 2, 39, 55, 1, 13856, 20, 9753, 3450, 3614, 1557, 6763, 3037, 1, 3767, 2, 581, 22492, 99, 4843, 911, 1, 1840, 132, 31, 630, 137, 3, 164, 11084, 6, 3058, 6599, 4887, 1817, 3, 9753, 3290, 4526, 107, 1342, 2, 5560, 17, 8, 1556, 353, 6, 22492, 11158, 16, 825, 6, 1736, 505, 999, 752, 487]",1696.0,18613994,668
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia.,Leukemia research,Leuk. Res.,2008-07-25,"We evaluated patients' satisfaction with the physician caring for them as part of an international web-based survey of quality of life (QOL) in patients with chronic lymphocytic leukemia (CLL; n=1482). Over half (55.9%) of patients thought about their diagnosis daily. Although >90% felt their doctor understood how their disease was progressing (i.e., stage, blood counts, nodes), <70% felt their physician understood how CLL affected their QOL (anxiety, worry, fatigue). Reported satisfaction with their physician in a variety of areas strongly related to patients' measured emotional and overall QOL (all p<0.001). Physician use of specific euphemistic phrases to characterize CLL (e.g., ""CLL is the 'good' leukemia"") was also associated with lower emotional QOL among patients (p<0.001). These effects on QOL remained (p<0.001) after adjustment for age, co-morbid health conditions, fatigue, and treatment status. The effectiveness with which physicians help patients adjust to the physical, intellectual, and emotional challenges of CLL appears to impact patient QOL.",Journal Article,4197.0,19.0,We evaluated patients satisfaction with the physician caring for them as part of an international web-based survey of quality of life QOL in patients with chronic lymphocytic CLL n=1482 Over half 55.9 of patients thought about their diagnosis daily Although 90 felt their doctor understood how their disease was progressing i.e. stage blood counts nodes 70 felt their physician understood how CLL affected their QOL anxiety worry fatigue Reported satisfaction with their physician in a variety of areas strongly related to patients measured emotional and overall QOL all p 0.001 Physician use of specific euphemistic phrases to characterize CLL e.g. `` CLL is the 'good '' was also associated with lower emotional QOL among patients p 0.001 These effects on QOL remained p 0.001 after adjustment for age co-morbid health conditions fatigue and treatment status The effectiveness with which physicians help patients adjust to the physical intellectual and emotional challenges of CLL appears to impact patient QOL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 7, 2885, 5, 3, 1473, 6571, 9, 1370, 22, 760, 1, 35, 944, 3469, 90, 1407, 1, 372, 1, 358, 1001, 4, 7, 5, 442, 1193, 552, 78, 38563, 252, 1303, 614, 83, 1, 7, 2739, 545, 136, 147, 391, 242, 424, 5284, 136, 9350, 1784, 832, 136, 34, 10, 4527, 70, 563, 82, 315, 1911, 502, 431, 5284, 136, 1473, 1784, 832, 552, 1424, 136, 1001, 2021, 6309, 613, 210, 2885, 5, 136, 1473, 4, 8, 1362, 1, 1361, 1327, 139, 6, 7, 644, 2671, 2, 63, 1001, 62, 19, 13, 144, 1473, 119, 1, 112, 57259, 34516, 6, 1507, 552, 563, 499, 552, 16, 3, 38783, 522, 10, 120, 41, 5, 280, 2671, 1001, 107, 7, 19, 13, 144, 46, 176, 23, 1001, 958, 19, 13, 144, 50, 1852, 9, 89, 1269, 8188, 341, 1298, 613, 2, 24, 156, 3, 1236, 5, 92, 1261, 987, 7, 6611, 6, 3, 900, 12346, 2, 2671, 1427, 1, 552, 1233, 6, 345, 69, 1001]",1012.0,18656259,125
Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells.,Blood,Blood,2008-08-06,"The mutagenic enzyme activation-induced cytidine deaminase (AID) is required for immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM) in germinal center (GC) B cells. Deregulated expression of AID is associated with various B-cell malignancies and, currently, it remains unclear how AID activity is extinguished to avoid illegitimate mutations. AID has also been shown to be alternatively spliced in malignant B cells, and there is limited evidence that this also occurs in normal blood B cells. The functional significance of these splice variants remains unknown. Here we show that normal GC human B cells and blood memory B cells similarly express AID splice variants and show for the first time that AID splicing variants are singly expressed in individual normal B cells as well as malignant B cells from chronic lymphocytic leukemia patients. We further demonstrate that the alternative AID splice variants display different activities ranging from inactivation of CSR to inactivation or heightened SHM activity. Our data therefore suggest that CSR and SHM are differentially switched off by varying the expression of splicing products of AID at the individual cell level. Most importantly, our findings suggest a novel tumor suppression mechanism by which unnecessary AID mutagenic activities are promptly contained for GC B cells.",Journal Article,4185.0,33.0,The mutagenic enzyme activation-induced cytidine deaminase AID is required for immunoglobulin class switch recombination CSR and somatic hypermutation SHM in germinal center GC B cells Deregulated expression of AID is associated with various B-cell malignancies and currently it remains unclear how AID activity is extinguished to avoid illegitimate mutations AID has also been shown to be alternatively spliced in malignant B cells and there is limited evidence that this also occurs in normal blood B cells The functional significance of these splice variants remains unknown Here we show that normal GC human B cells and blood memory B cells similarly express AID splice variants and show for the first time that AID splicing variants are singly expressed in individual normal B cells as well as malignant B cells from chronic lymphocytic patients We further demonstrate that the alternative AID splice variants display different activities ranging from inactivation of CSR to inactivation or heightened SHM activity Our data therefore suggest that CSR and SHM are differentially switched off by varying the expression of splicing products of AID at the individual cell level Most importantly our findings suggest a novel tumor suppression mechanism by which unnecessary AID mutagenic activities are promptly contained for GC B cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 14578, 1644, 363, 277, 12783, 10197, 2427, 16, 616, 9, 2593, 1040, 5096, 4017, 28827, 2, 1119, 13521, 31331, 4, 6312, 574, 1709, 132, 37, 5415, 55, 1, 2427, 16, 41, 5, 747, 132, 31, 441, 2, 694, 192, 469, 1200, 832, 2427, 128, 16, 28697, 6, 3085, 24513, 138, 2427, 71, 120, 85, 443, 6, 40, 7133, 10945, 4, 393, 132, 37, 2, 125, 16, 383, 241, 17, 26, 120, 1780, 4, 295, 315, 132, 37, 3, 583, 724, 1, 46, 4371, 839, 469, 860, 467, 21, 514, 17, 295, 1709, 171, 132, 37, 2, 315, 2407, 132, 37, 1813, 1669, 2427, 4371, 839, 2, 514, 9, 3, 157, 98, 17, 2427, 3895, 839, 32, 16659, 570, 4, 797, 295, 132, 37, 22, 149, 22, 393, 132, 37, 29, 442, 1193, 7, 21, 195, 608, 17, 3, 1091, 2427, 4371, 839, 3640, 338, 2042, 2223, 29, 2297, 1, 28827, 6, 2297, 15, 7145, 31331, 128, 114, 74, 673, 309, 17, 28827, 2, 31331, 32, 2478, 7883, 1889, 20, 2990, 3, 55, 1, 3895, 2766, 1, 2427, 28, 3, 797, 31, 301, 96, 1859, 114, 272, 309, 8, 229, 30, 1332, 670, 20, 92, 4224, 2427, 14578, 2042, 32, 11396, 3070, 9, 1709, 132, 37]",1336.0,18684869,63
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.,Therapeutic drug monitoring,Ther Drug Monit,2008-10-01,"Lenalidomide, an immunomodulatory agent, and flavopiridol, a broad cyclin-dependent kinase inhibitor, are active therapies for clinical use in genomic high-risk chronic lymphocytic leukemia. A high-performance liquid chromatographic assay with tandem mass spectrometric detection has been developed to simultaneously quantify lenalidomide and flavopiridol in human and mouse plasma to facilitate their combined clinical development. Samples were prepared by liquid-liquid extraction with acetonitrile (ACN)-containing internal standard, genistein, followed by evaporation of solvent and reconstitution in 95/5 H2O/ACN. Lenalidomide and internal standard were separated by reversed-phase liquid chromatography on a C-18 column using a gradient of H2O and ACN, each with 0.1% formic acid. Atmospheric pressure chemical ionization in positive ion mode with single reaction monitoring on a triple quadrupole mass spectrometer was applied to detect transitions of lenalidomide (260.06 > 149.10) and flavopiridol (402.09 > 341.02). Lower limits of quantification of lenalidomide and flavopiridol were 1 and 0.3 nM, respectively. Recoveries of lenalidomide and flavopiridol from human plasma ranged from 99% to 116% throughout their linear ranges. Within- and between-run precision and accuracy of replicate samples were all less than 15%. This is the most sensitive analytical method reported to date for both lenalidomide and flavopiridol. This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic leukemia.",Clinical Trial,4129.0,24.0,Lenalidomide an immunomodulatory agent and flavopiridol a broad cyclin-dependent kinase inhibitor are active therapies for clinical use in genomic high-risk chronic lymphocytic A high-performance liquid chromatographic assay with tandem mass spectrometric detection has been developed to simultaneously quantify lenalidomide and flavopiridol in human and mouse plasma to facilitate their combined clinical development Samples were prepared by liquid-liquid extraction with acetonitrile ACN -containing internal standard genistein followed by evaporation of solvent and reconstitution in 95/5 H2O/ACN Lenalidomide and internal standard were separated by reversed-phase liquid chromatography on a C-18 column using a gradient of H2O and ACN each with 0.1 formic acid Atmospheric pressure chemical ionization in positive ion mode with single reaction monitoring on a triple quadrupole mass spectrometer was applied to detect transitions of lenalidomide 260.06 149.10 and flavopiridol 402.09 341.02 Lower limits of quantification of lenalidomide and flavopiridol were 1 and 0.3 nM respectively Recoveries of lenalidomide and flavopiridol from human plasma ranged from 99 to 116 throughout their linear ranges Within- and between-run precision and accuracy of replicate samples were all less than 15 This is the most sensitive analytical method reported to date for both lenalidomide and flavopiridol This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 35, 2555, 420, 2, 3030, 8, 2094, 1226, 470, 216, 230, 32, 544, 235, 9, 38, 119, 4, 572, 64, 43, 442, 1193, 8, 64, 528, 3165, 23063, 719, 5, 2905, 782, 14506, 638, 71, 85, 276, 6, 3074, 3091, 1288, 2, 3030, 4, 171, 2, 830, 554, 6, 1876, 136, 397, 38, 193, 347, 11, 4421, 20, 3165, 3165, 5763, 5, 21530, 38799, 1101, 2329, 260, 7395, 370, 20, 26737, 1, 10614, 2, 5616, 4, 48, 33, 38800, 38799, 1288, 2, 2329, 260, 11, 4910, 20, 3682, 124, 3165, 5140, 23, 8, 256, 203, 9004, 75, 8, 7099, 1, 38800, 2, 38799, 296, 5, 13, 14, 20616, 971, 31338, 3738, 3743, 9012, 4, 109, 7714, 4530, 5, 226, 1329, 1315, 23, 8, 1500, 34526, 782, 23638, 10, 1498, 6, 1426, 7738, 1, 1288, 6398, 1460, 4928, 79, 2, 3030, 9422, 1730, 4065, 588, 280, 3526, 1, 4752, 1, 1288, 2, 3030, 11, 14, 2, 13, 27, 2878, 106, 24778, 1, 1288, 2, 3030, 29, 171, 554, 1869, 29, 1058, 6, 3790, 2432, 136, 1646, 5632, 262, 2, 59, 7726, 2720, 2, 1190, 1, 6423, 347, 11, 62, 299, 76, 167, 26, 16, 3, 96, 745, 5625, 596, 210, 6, 1244, 9, 110, 1288, 2, 3030, 26, 485, 303, 3047, 807, 2158, 124, 1227, 1685, 2, 1481, 1456, 4219, 4470, 4, 8, 1465, 38, 160, 5, 1288, 2, 3030, 4, 7, 5, 442, 1193]",1621.0,18708993,364
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.,Cancer,Cancer,2008-10-01,"Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors of a high risk of disease progression, together with the development of newer, more targeted therapies, could change this paradigm. In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab. Patients were eligible for treatment if they were 1) previously untreated, 2) had no National Cancer Institute-Working Group 1996 criteria for treatment, and 3) had at least 1 marker of high-risk disease 17p13-, 11q22-, or a combination of unmutated IgVH and CD38+/ZAP70+). Treatment consisted of subcutaneous alemtuzumab (initial dose escalation followed by 30 mg on Monday, Wednesday, and Friday for 4 weeks) and intravenous rituximab (375 mg/m(2) per week x4 doses). All patients received Pneumocystis pneumonia and herpes virus prophylaxis and were monitored for cytomegalovirus reactivation. Twenty-seven of 30 patients (90%) responded to therapy with 11 (37%) complete responses (CRs). Five patients (17%) patients who had a CR had no detectable minimal residual disease. The median response duration was 14.4 months, and only 9 patients required retreatment for progressive disease at the time of the current report (median follow-up, 17.6 months). Study patients had a significantly longer time from diagnosis to first treatment for CLL according to conventional indications than a comparison cohort with similar biologic risk profiles. The therapy regimen used was safe and effective for early treatment of patients with high-risk CLL. Further studies will be required to determine whether this early treatment strategy decreases morbidity and mortality for high-risk CLL.","Clinical Trial, Phase II",4129.0,70.0,Patients with chronic lymphocytic CLL usually are treated only for progressive disease However the discovery of biologic predictors of a high risk of disease progression together with the development of newer more targeted therapies could change this paradigm In this phase 2 study the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab Patients were eligible for treatment if they were 1 previously untreated 2 had no National Cancer Institute-Working Group 1996 criteria for treatment and 3 had at least 1 marker of high-risk disease 17p13- 11q22- or a combination of unmutated IgVH and CD38+/ZAP70+ Treatment consisted of subcutaneous alemtuzumab initial dose escalation followed by 30 mg on Monday Wednesday and Friday for 4 weeks and intravenous rituximab 375 mg/m 2 per week x4 doses All patients received Pneumocystis pneumonia and herpes virus prophylaxis and were monitored for cytomegalovirus reactivation Twenty-seven of 30 patients 90 responded to therapy with 11 37 complete responses CRs Five patients 17 patients who had a CR had no detectable minimal residual disease The median response duration was 14.4 months and only 9 patients required retreatment for progressive disease at the time of the current report median follow-up 17.6 months Study patients had a significantly longer time from diagnosis to first treatment for CLL according to conventional indications than a comparison cohort with similar biologic risk profiles The therapy regimen used was safe and effective for early treatment of patients with high-risk CLL Further studies will be required to determine whether this early treatment strategy decreases morbidity and mortality for high-risk CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 2082, 32, 73, 158, 9, 1014, 34, 137, 3, 1574, 1, 1283, 674, 1, 8, 64, 43, 1, 34, 91, 1162, 5, 3, 193, 1, 2246, 80, 238, 235, 359, 707, 26, 2431, 4, 26, 124, 18, 45, 3, 738, 650, 3, 367, 2, 209, 1, 191, 24, 9, 7, 5, 64, 43, 552, 75, 3579, 2, 855, 7, 11, 625, 9, 24, 492, 491, 11, 14, 373, 1278, 18, 42, 77, 657, 12, 1377, 2644, 87, 2648, 371, 9, 24, 2, 27, 42, 28, 506, 14, 952, 1, 64, 43, 34, 7526, 12647, 15, 8, 150, 1, 7216, 14484, 2, 4469, 12921, 24, 1695, 1, 2529, 3579, 388, 61, 1125, 370, 20, 201, 81, 23, 9339, 14412, 2, 9872, 9, 39, 244, 2, 1262, 855, 4175, 81, 188, 18, 379, 647, 45249, 415, 62, 7, 103, 13243, 3485, 2, 4716, 1450, 2049, 2, 11, 2909, 9, 7314, 3834, 737, 648, 1, 201, 7, 424, 2211, 6, 36, 5, 175, 567, 236, 253, 3115, 365, 7, 269, 7, 54, 42, 8, 684, 42, 77, 2083, 1048, 753, 34, 3, 52, 51, 654, 10, 213, 39, 53, 2, 158, 83, 7, 616, 6291, 9, 1014, 34, 28, 3, 98, 1, 3, 291, 414, 52, 166, 126, 269, 49, 53, 45, 7, 42, 8, 97, 589, 98, 29, 147, 6, 157, 24, 9, 552, 768, 6, 809, 2406, 76, 8, 1155, 180, 5, 288, 1283, 43, 1241, 3, 36, 477, 95, 10, 1165, 2, 323, 9, 191, 24, 1, 7, 5, 64, 43, 552, 195, 94, 303, 40, 616, 6, 223, 317, 26, 191, 24, 692, 2140, 787, 2, 282, 9, 64, 43, 552]",1750.0,18759253,279
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.,Blood,Blood,2008-09-04,"Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL). The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide. We therefore examined whether lenalidomide combined with rituximab enhances direct apoptosis and ADCC in CLL cells. In contrast to previous reports using CD20-positive lymphoma cell lines, lenalidomide down-regulated CD20 surface antigen expression in CLL patient cells via enhanced internalization, without influencing transcription. The CD20 surface antigen internalization enhanced delivery of an oligonucleotide incorporated into anti-CD20 immunoliposomes. In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC. These observations suggest a need for alternative sequencing strategies to avoid antagonism between lenalidomide and rituximab therapy in CLL. In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies.",Journal Article,4156.0,97.0,Lenalidomide an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity ADCC is currently being investigated as a therapy for chronic lymphocytic CLL The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide We therefore examined whether lenalidomide combined with rituximab enhances direct apoptosis and ADCC in CLL cells In contrast to previous reports using CD20-positive cell lines lenalidomide down-regulated CD20 surface antigen expression in CLL patient cells via enhanced internalization without influencing transcription The CD20 surface antigen internalization enhanced delivery of an oligonucleotide incorporated into anti-CD20 immunoliposomes In addition CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC These observations suggest a need for alternative sequencing strategies to avoid antagonism between lenalidomide and rituximab therapy in CLL In addition they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 35, 2555, 420, 17, 2519, 548, 470, 763, 1408, 5551, 16, 694, 486, 565, 22, 8, 36, 9, 442, 1193, 552, 3, 312, 2198, 548, 855, 16, 544, 4, 552, 2, 1449, 8, 2696, 420, 6, 4680, 5, 1288, 21, 673, 409, 317, 1288, 397, 5, 855, 2519, 1196, 351, 2, 5551, 4, 552, 37, 4, 748, 6, 698, 1198, 75, 2198, 109, 31, 285, 1288, 1328, 1065, 2198, 1255, 448, 55, 4, 552, 69, 37, 847, 651, 7520, 187, 4743, 866, 3, 2198, 1255, 448, 7520, 651, 989, 1, 35, 4727, 2449, 237, 312, 2198, 31220, 4, 352, 2198, 1255, 448, 1328, 2356, 20, 1288, 4, 552, 10, 2756, 20, 2849, 855, 517, 351, 2, 5551, 46, 2172, 309, 8, 594, 9, 1091, 615, 422, 6, 3085, 7537, 59, 1288, 2, 855, 36, 4, 552, 4, 352, 491, 309, 17, 1288, 36, 822, 40, 999, 6, 1304, 238, 989, 1, 5881, 90, 235, 75, 2198, 31220, 4, 132, 31, 441]",1181.0,18772452,207
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years.,Leukemia & lymphoma,Leuk. Lymphoma,2008-09-01,"In order to evaluate the long-term results of allogeneic stem cell transplantation (ASCT) in B-cell chronic lymphocytic leukemia (CLL), we reviewed the outcome of 12 consecutive CLL patients, who underwent ASCT at the Mayo Clinic prior to July, 2004. Median age was 44 years (range 18-55) and median time from diagnosis to transplant 58.5 months. All patients had failed prior fludarabine-based chemotherapy and all but two patients had chemo-resistant refractory disease at time of transplant. A 'myeloablative' conditioning regimen was used in 11 patients and 'reduced intensity' in one. Bone marrow was the source of hematopoietic stem cells in 10 patients and peripheral blood in two. Donors were matched sibling in nine patients, unrelated in two and partial phenotypic match father in one. Grade II-IV acute and chronic graft versus host disease was documented in five and four patients, respectively. To date, six patients (50%) have died including four early deaths from infection. Complete remission (CR) was documented in eight patients (66.7%) post-transplant; six are currently alive whereas one died at 7 months from infection while still in CR and one relapsed 7 months post-transplant and died later. One CR patient relapsed after 4.5 years but was successfully re-transplanted and remains in second CR for 6.5+ years. Another patient recently relapsed after 10.5 years of CR. Duration of ASCT-induced CR in the remaining four patients was 6.5+, 8.5+, 9+ and 10+ years. All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur.",Journal Article,4159.0,17.0,In order to evaluate the long-term results of allogeneic stem cell transplantation ASCT in B-cell chronic lymphocytic CLL we reviewed the outcome of 12 consecutive CLL patients who underwent ASCT at the Mayo Clinic prior to July 2004 Median age was 44 years range 18-55 and median time from diagnosis to transplant 58.5 months All patients had failed prior fludarabine-based chemotherapy and all but two patients had chemo-resistant refractory disease at time of transplant A 'myeloablative conditioning regimen was used in 11 patients and 'reduced intensity in one marrow was the source of hematopoietic stem cells in 10 patients and peripheral blood in two Donors were matched sibling in nine patients unrelated in two and partial phenotypic match father in one Grade II-IV acute and chronic graft versus host disease was documented in five and four patients respectively To date six patients 50 have died including four early deaths from infection Complete remission CR was documented in eight patients 66.7 post-transplant six are currently alive whereas one died at 7 months from infection while still in CR and one relapsed 7 months post-transplant and died later One CR patient relapsed after 4.5 years but was successfully re-transplanted and remains in second CR for 6.5+ years Another patient recently relapsed after 10.5 years of CR Duration of ASCT-induced CR in the remaining four patients was 6.5+ 8.5+ 9+ and 10+ years All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 1732, 6, 376, 3, 319, 337, 99, 1, 1063, 452, 31, 497, 1584, 4, 132, 31, 442, 1193, 552, 21, 446, 3, 228, 1, 133, 935, 552, 7, 54, 208, 1584, 28, 3, 2486, 1188, 324, 6, 2066, 1131, 52, 89, 10, 584, 60, 184, 203, 614, 2, 52, 98, 29, 147, 6, 941, 717, 33, 53, 62, 7, 42, 1551, 324, 2027, 90, 56, 2, 62, 84, 100, 7, 42, 3341, 436, 430, 34, 28, 98, 1, 941, 8, 57366, 1933, 477, 10, 95, 4, 175, 7, 2, 57367, 837, 4, 104, 581, 10, 3, 2353, 1, 1007, 452, 37, 4, 79, 7, 2, 672, 315, 4, 100, 2344, 11, 655, 3684, 4, 762, 7, 2092, 4, 100, 2, 450, 3290, 5364, 17610, 4, 104, 88, 215, 478, 286, 2, 442, 1599, 185, 1204, 34, 10, 1405, 4, 365, 2, 294, 7, 106, 6, 1244, 437, 7, 212, 47, 1016, 141, 294, 191, 1043, 29, 930, 236, 734, 684, 10, 1405, 4, 659, 7, 700, 67, 539, 941, 437, 32, 694, 1701, 547, 104, 1016, 28, 67, 53, 29, 930, 369, 1234, 4, 684, 2, 104, 591, 67, 53, 539, 941, 2, 1016, 1559, 104, 684, 69, 591, 50, 39, 33, 60, 84, 10, 1878, 1491, 4600, 2, 469, 4, 419, 684, 9, 49, 33, 60, 1809, 69, 761, 591, 50, 79, 33, 60, 1, 684, 654, 1, 1584, 277, 684, 4, 3, 1844, 294, 7, 10, 49, 33, 66, 33, 83, 2, 79, 60, 62, 3050, 7, 2507, 1503, 528, 156, 187, 942, 442, 1599, 185, 1204, 34, 21, 2060, 17, 1584, 16, 35, 323, 992, 36, 9, 2027, 430, 552, 84, 807, 3713, 122, 1271]",1658.0,18798106,355
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.,Cancer,Cancer,2008-10-01,"Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85% to 90%. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.",Journal Article,4129.0,74.0,Major therapeutic progress has been accomplished in and syndrome MDS over the past 40 years which may not be fully appreciated by the larger medical community The objective of this review was to briefly highlight the treatment breakthroughs in and MDS Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents like imatinib mesylate in chronic myeloid CML and through astute empirical discoveries in the clinic like all-trans retinoic acid and arsenic trioxide in acute promyelocytic APL and chlorodeoxyadenosine in hairy cell HCL Today the 5- to 10-year survival rates in patients with APL and HCL exceed 80 In patients with CML imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85 to 90 In patients with adult acute lymphocytic modern intensive regimens have improved the 5-year survival rates from 20 up to 40 In patients with chronic lymphocytic chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome In younger patients with acute myeloid AML the 5-year survival rates range from 40 to 50 although elderly AML remains a therapeutic challenge In patients with MDS it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival Much therapeutic progress has been witnessed in and MDS and much more is expected to occur soon,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[458, 189, 1466, 71, 85, 5741, 4, 2, 681, 1223, 252, 3, 1219, 327, 60, 92, 68, 44, 40, 1910, 7292, 20, 3, 1077, 484, 1714, 3, 461, 1, 26, 206, 10, 6, 6277, 1817, 3, 24, 9985, 4, 2, 1223, 189, 1466, 20566, 298, 380, 612, 1, 34, 44576, 2, 2696, 193, 1, 238, 183, 733, 577, 2347, 4, 442, 533, 903, 2, 298, 38816, 7273, 5012, 4, 3, 1188, 733, 62, 3437, 3887, 971, 2, 3217, 4574, 4, 286, 4300, 2578, 2, 23121, 4, 7152, 31, 4623, 5665, 3, 33, 6, 79, 111, 25, 151, 4, 7, 5, 2578, 2, 4623, 6818, 493, 4, 7, 5, 903, 577, 36, 71, 85, 41, 5, 661, 33, 6, 67, 111, 25, 151, 29, 772, 6, 424, 4, 7, 5, 780, 286, 1193, 2366, 1686, 472, 47, 231, 3, 33, 111, 25, 151, 29, 179, 126, 6, 327, 4, 7, 5, 442, 1193, 4438, 761, 1687, 64, 151, 1, 372, 253, 2, 231, 319, 337, 228, 4, 773, 7, 5, 286, 533, 329, 3, 33, 111, 25, 151, 184, 29, 327, 6, 212, 242, 1216, 329, 469, 8, 189, 1745, 4, 7, 5, 1223, 192, 10, 761, 264, 17, 1418, 36, 5, 4931, 183, 231, 25, 1802, 189, 1466, 71, 85, 10606, 4, 2, 1223, 2, 1802, 80, 16, 1336, 6, 1271, 6176]",1416.0,18798533,0
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.,Blood,Blood,2008-09-24,"To characterize genetic contributions toward aberrant splicing of the hyaluronan synthase 1 (HAS1) gene in multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM), we sequenced 3616 bp in HAS1 exons and introns involved in aberrant splicing, from 17 patients. We identified a total of 197 HAS1 genetic variations (GVs), a range of 3 to 24 GVs/patient, including 87 somatic GVs acquired in splicing regions of HAS1. Nearly all newly identified inherited and somatic GVs in MM and/or WM were absent from B chronic lymphocytic leukemia, nonmalignant disease, and healthy donors. Somatic HAS1 GVs recurred in all hematopoietic cells tested, including normal CD34(+) hematopoietic progenitor cells and T cells, or as tumor-specific GVs restricted to malignant B and plasma cells. An in vitro splicing assay confirmed that HAS1 GVs direct aberrant HAS1 intronic splicing. Recurrent somatic GVs may be enriched by strong mutational selection leading to MM and/or WM.",Journal Article,4136.0,21.0,To characterize genetic contributions toward aberrant splicing of the hyaluronan synthase 1 HAS1 gene in multiple MM and Waldenstrom macroglobulinemia WM we sequenced 3616 bp in HAS1 exons and introns involved in aberrant splicing from 17 patients We identified a total of 197 HAS1 genetic variations GVs a range of 3 to 24 GVs/patient including 87 somatic GVs acquired in splicing regions of HAS1 Nearly all newly identified inherited and somatic GVs in MM and/or WM were absent from B chronic lymphocytic nonmalignant disease and healthy donors Somatic HAS1 GVs recurred in all hematopoietic cells tested including normal CD34 hematopoietic progenitor cells and T cells or as tumor-specific GVs restricted to malignant B and plasma cells An in vitro splicing assay confirmed that HAS1 GVs direct aberrant HAS1 intronic splicing Recurrent somatic GVs may be enriched by strong mutational selection leading to MM and/or WM,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 1507, 336, 5621, 1317, 1898, 3895, 1, 3, 15712, 3522, 14, 17420, 145, 4, 232, 321, 2, 7933, 3389, 1518, 21, 4040, 37119, 3044, 4, 17420, 3885, 2, 12491, 646, 4, 1898, 3895, 29, 269, 7, 21, 108, 8, 181, 1, 6114, 17420, 336, 2293, 25113, 8, 184, 1, 27, 6, 259, 25113, 69, 141, 912, 1119, 25113, 1294, 4, 3895, 1374, 1, 17420, 1857, 62, 732, 108, 2986, 2, 1119, 25113, 4, 321, 2, 15, 1518, 11, 3269, 29, 132, 442, 1193, 5967, 34, 2, 1331, 2344, 1119, 17420, 25113, 3363, 4, 62, 1007, 37, 650, 141, 295, 2215, 1007, 2520, 37, 2, 102, 37, 15, 22, 30, 112, 25113, 2016, 6, 393, 132, 2, 554, 37, 35, 4, 439, 3895, 719, 557, 17, 17420, 25113, 1196, 1898, 17420, 7998, 3895, 387, 1119, 25113, 68, 40, 2220, 20, 1082, 1619, 881, 1049, 6, 321, 2, 15, 1518]",922.0,18815290,494
Genetic counseling for DAPK1 mutation in a chronic lymphocytic leukemia family.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2008-10-01,"Genetic counseling has become the clinical bedrock of hereditary cancer management. Countless advances in molecular genetics contributing to the identification of cancer-causing germline mutations have increased its importance. We report a unique genetic counseling experience involving a family with hereditary chronic lymphocytic leukemia and the cancer-causing mutation in the death-associated protein kinase 1 gene (DAPK1). This hereditary disorder currently lacks any preventive or curative interventions for mutation carriers. This family has been under our investigation for a decade, during which time genealogy, cancer of all anatomic sites, medical and pathology records, and, whenever possible, slides and tissue blocks were reviewed. Family attendance at three group-oriented family information service sessions provided intensive education about this disease. Blood and skin fibroblasts were obtained for molecular genetic studies of DNA leading to the discovery of the DAPK1 mutation in the family. Their intellectual and emotional reaction to its presence or absence in them was assessed. This family serves as a model for genetic counseling in disorders for which lifesaving intervention is not yet possible.",Journal Article,4129.0,1.0,Genetic counseling has become the clinical bedrock of hereditary cancer management Countless advances in molecular genetics contributing to the identification of cancer-causing germline mutations have increased its importance We report a unique genetic counseling experience involving a family with hereditary chronic lymphocytic and the cancer-causing mutation in the death-associated protein kinase 1 gene DAPK1 This hereditary disorder currently lacks any preventive or curative interventions for mutation carriers This family has been under our investigation for a decade during which time genealogy cancer of all anatomic sites medical and pathology records and whenever possible slides and tissue blocks were reviewed Family attendance at three group-oriented family information service sessions provided intensive education about this disease Blood and fibroblasts were obtained for molecular genetic studies of DNA leading to the discovery of the DAPK1 mutation in the family Their intellectual and emotional reaction to its presence or absence in them was assessed This family serves as a model for genetic counseling in disorders for which lifesaving intervention is not yet possible,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[336, 2011, 71, 1417, 3, 38, 45296, 1, 2305, 12, 284, 26289, 954, 4, 219, 2894, 3156, 6, 3, 911, 1, 12, 3440, 1009, 138, 47, 101, 211, 1187, 21, 414, 8, 991, 336, 2011, 730, 1267, 8, 607, 5, 2305, 442, 1193, 2, 3, 12, 3440, 258, 4, 3, 273, 41, 178, 216, 14, 145, 11503, 26, 2305, 2645, 694, 6856, 500, 3494, 15, 1075, 1151, 9, 258, 1316, 26, 607, 71, 85, 669, 114, 940, 9, 8, 2025, 190, 92, 98, 26755, 12, 1, 62, 2745, 633, 484, 2, 1117, 1064, 2, 8395, 899, 3830, 2, 246, 2860, 11, 446, 607, 12349, 28, 169, 87, 8095, 607, 487, 3086, 4390, 1052, 1686, 1848, 545, 26, 34, 315, 2, 3921, 11, 683, 9, 219, 336, 94, 1, 261, 1049, 6, 3, 1574, 1, 3, 11503, 258, 4, 3, 607, 136, 12346, 2, 2671, 1329, 6, 211, 463, 15, 1127, 4, 1370, 10, 275, 26, 607, 4711, 22, 8, 202, 9, 336, 2011, 4, 1997, 9, 92, 27944, 788, 16, 44, 1145, 899]",1193.0,18940472,627
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.,Blood,Blood,2008-11-03,"We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic leukemia (CLL) whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion. We now report full pharmacokinetic (PK) data, correlations of PK with clinical outcomes, and final response and progression-free survival (PFS). Twenty-one (40%) of 52 patients with relapsed CLL achieved a partial response (PR) with a median PFS of 12 months. Responders included 17 (40%) of 43 fludarabine refractory patients, 7 (39%) of 18 patients with del(17p13), and 14 (74%) of 19 patients with del(11q22). Six responders received repeat therapy at relapse, and 5 responded again with a second median PFS of 10 months. Noncompartmental analysis and nonlinear mixed effects modeling was used to estimate PK parameters and evaluate covariates. Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively. Flavopiridol area under the plasma concentration-time curve (AUC) correlated with clinical response and cytokine release syndrome, and glucuronide metabolite AUC correlated with tumor lysis syndrome. These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity.","Clinical Trial, Phase I",4096.0,123.0,We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic CLL whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion We now report full pharmacokinetic PK data correlations of PK with clinical outcomes and final response and progression-free survival PFS Twenty-one 40 of 52 patients with relapsed CLL achieved a partial response PR with a median PFS of 12 months Responders included 17 40 of 43 fludarabine refractory patients 7 39 of 18 patients with del 17p13 and 14 74 of 19 patients with del 11q22 Six responders received repeat therapy at relapse and 5 responded again with a second median PFS of 10 months Noncompartmental analysis and nonlinear mixed effects modeling was used to estimate PK parameters and evaluate covariates Two-compartment population parameter estimates were 31.4 L/h 65.8 L 8.49 L/h and 157 L for CL V1 Q and V2 respectively Flavopiridol area under the plasma concentration-time curve AUC correlated with clinical response and cytokine release syndrome and glucuronide metabolite AUC correlated with tumor lysis syndrome These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed genetically high-risk CLL Furthermore PK describes some but not all variability in response and toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 373, 210, 2914, 99, 1, 8, 124, 14, 160, 4, 7, 5, 442, 1193, 552, 6131, 3030, 10, 468, 1672, 22, 8, 201, 3949, 3604, 370, 20, 39, 2583, 904, 21, 1134, 414, 1647, 1456, 2395, 74, 2553, 1, 2395, 5, 38, 123, 2, 1457, 51, 2, 91, 115, 25, 300, 737, 104, 327, 1, 653, 7, 5, 591, 552, 513, 8, 450, 51, 998, 5, 8, 52, 300, 1, 133, 53, 1983, 159, 269, 327, 1, 601, 2027, 430, 7, 67, 587, 1, 203, 7, 5, 3084, 7526, 2, 213, 794, 1, 326, 7, 5, 3084, 12647, 437, 1983, 103, 2334, 36, 28, 429, 2, 33, 2211, 5089, 5, 8, 419, 52, 300, 1, 79, 53, 31368, 65, 2, 7488, 1739, 176, 2057, 10, 95, 6, 1191, 2395, 1038, 2, 376, 2489, 100, 3616, 266, 4219, 1423, 11, 456, 39, 805, 555, 556, 66, 805, 66, 739, 805, 555, 2, 5311, 805, 9, 5192, 7673, 4170, 2, 15333, 106, 3030, 965, 669, 3, 554, 1227, 98, 1496, 1376, 438, 5, 38, 51, 2, 1675, 2008, 681, 2, 11435, 3379, 1376, 438, 5, 30, 4783, 681, 46, 3308, 99, 1843, 64, 128, 1, 26, 14920, 526, 1055, 4, 591, 2301, 64, 43, 552, 798, 2395, 2677, 476, 84, 44, 62, 1982, 4, 51, 2, 155]",1340.0,18981292,171
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-11-03,"Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved. Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk. Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL. This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.",Journal Article,4096.0,116.0,"Acute graft-versus-host disease GVHD causes substantial morbidity and mortality after human leukocyte antigen HLA -identical sibling transplants No large registry studies of acute GVHD risk factors have been reported in two decades Risk factors may have changed in this interval as transplant-related techniques have evolved Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid AML acute lymphocytic ALL or chronic myeloid CML reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002 Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD with death without acute GVHD as a competing risk Cumulative incidence of grade 2 to 4 acute GVHD was 35 95 CI 33 to 37 In multivariable analyses factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide total-body irradiation versus busulfan cyclophosphamide relative risk RR 1.4 P .0001 blood cell versus marrow grafts in patients age 18 to 39 years RR 1.43 P .0023 recipient age 40 and older versus age 18 to 39 years receiving marrow grafts RR 1.44 P .0005 CML versus AML/ALL RR 1.35 P .0003 white/Black versus Asian/Hispanic race RR 1.54 P .0003 Karnofsky performance score less than 90 versus 90 to 100 RR 1.27 P .014 and recipient/donor cytomegalovirus-seronegative versus either positive RR 1.20 P .04 Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML however KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD However several new factors were identified whereas others are no longer significant These new data may facilitate individualized risk estimates and raise several interesting biologic questions",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[286, 1599, 185, 1204, 34, 1562, 1626, 1281, 787, 2, 282, 50, 171, 3627, 448, 1160, 3038, 3684, 4016, 77, 375, 1608, 94, 1, 286, 1562, 43, 130, 47, 85, 210, 4, 100, 1968, 43, 130, 68, 47, 2368, 4, 26, 268, 22, 941, 139, 1092, 47, 3937, 286, 1562, 43, 130, 11, 311, 4, 14, 8809, 857, 50, 1160, 3038, 3684, 3246, 941, 9, 286, 533, 329, 286, 1193, 62, 15, 442, 533, 903, 210, 20, 7400, 1168, 2358, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 29, 2323, 6, 1544, 228, 10, 644, 22, 98, 29, 941, 6, 1707, 1, 88, 18, 6, 39, 286, 1562, 5, 273, 187, 286, 1562, 22, 8, 2573, 43, 967, 287, 1, 88, 18, 6, 39, 286, 1562, 10, 465, 48, 58, 466, 6, 567, 4, 658, 318, 130, 97, 41, 5, 88, 18, 6, 39, 286, 1562, 11, 1112, 181, 642, 1104, 185, 3906, 1112, 580, 43, 861, 14, 39, 19, 488, 315, 31, 185, 581, 4713, 4, 7, 89, 203, 6, 587, 60, 861, 14, 601, 19, 15555, 5783, 89, 327, 2, 434, 185, 89, 203, 6, 587, 60, 357, 581, 4713, 861, 14, 584, 19, 4252, 903, 185, 329, 62, 861, 14, 465, 19, 4418, 886, 1445, 185, 2399, 1776, 1047, 861, 14, 667, 19, 4418, 2857, 528, 368, 299, 76, 424, 185, 424, 6, 394, 861, 14, 428, 19, 3618, 2, 5783, 1488, 7314, 14924, 185, 361, 109, 861, 14, 179, 19, 755, 1541, 20, 34, 224, 3, 827, 93, 674, 1, 88, 18, 6, 39, 286, 1562, 9, 903, 137, 2988, 2, 7314, 20631, 11, 44, 93, 674, 9, 329, 62, 26, 65, 557, 392, 373, 210, 43, 130, 9, 88, 18, 6, 39, 286, 1562, 137, 392, 217, 130, 11, 108, 547, 1749, 32, 77, 589, 93, 46, 217, 74, 68, 1876, 2596, 43, 1423, 2, 5008, 392, 6597, 1283, 1937]",1910.0,18981462,779
"Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.",Blood,Blood,2008-11-13,"Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs 19%, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.).","Clinical Trial, Phase II",4086.0,48.0,Myeloid cell leukemia-1 Mcl-1 is an antiapoptotic member of the Bcl-2 protein family Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic CLL However the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin cyclophosphamide and rituximab in patients with untreated CLL No significant difference by Mcl-1 expression was noted in pretreatment or response parameters However in patients with higher Mcl-1 expression both minimal residual disease-negative status and progression-free survival was found to be significantly reduced 57 vs 19 P .01 50.8 vs 18.7 months P .02 respectively Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy These findings further support pursuing treatment strategies targeting this important antiapoptotic protein Because the trials described were conducted before the requirement to register them was implemented they are not registered in a clinical trial database,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[533, 31, 2647, 14, 1308, 14, 16, 35, 4176, 2693, 1, 3, 1044, 18, 178, 607, 101, 1308, 14, 55, 16, 41, 5, 496, 6, 1359, 734, 50, 24, 5, 2027, 2, 11585, 4, 7, 5, 442, 1193, 552, 137, 3, 1054, 1, 1308, 14, 55, 71, 44, 85, 409, 4, 552, 143, 75, 4438, 21, 565, 1308, 14, 178, 55, 1143, 22, 760, 1, 8, 124, 18, 45, 1435, 3, 209, 1, 7596, 1112, 2, 855, 4, 7, 5, 1278, 552, 77, 93, 523, 20, 1308, 14, 55, 10, 1051, 4, 1194, 15, 51, 1038, 137, 4, 7, 5, 142, 1308, 14, 55, 110, 1048, 753, 34, 199, 156, 2, 91, 115, 25, 10, 204, 6, 40, 97, 405, 696, 105, 326, 19, 355, 212, 66, 105, 203, 67, 53, 19, 588, 106, 1308, 14, 55, 68, 673, 40, 999, 4, 1434, 334, 51, 6, 4438, 46, 272, 195, 538, 10692, 24, 422, 529, 26, 305, 4176, 178, 408, 3, 143, 1027, 11, 426, 348, 3, 4701, 6, 11861, 1370, 10, 3426, 491, 32, 44, 1653, 4, 8, 38, 160, 609]",1200.0,19008456,314
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.,Blood,Blood,2008-11-17,"The diagnosis of chronic lymphocytic leukemia (CLL) in asymptomatic patients has historically been based on documenting a characteristic lymphocyte clone and the presence of lymphocytosis. There are minimal data regarding which lymphocyte parameter (absolute lymphocyte count [ALC] or B-cell count) and what threshold should be used for diagnosis. We analyzed the relationship of ALC and B-cell count with clinical outcome in 459 patients with a clonal population of CLL phenotype to determine (1) whether the CLL diagnosis should be based on ALC or B-cell count, (2) what lymphocyte threshold should be used for diagnosis, and (3) whether any lymphocyte count has independent prognostic value after accounting for biologic/molecular prognostic markers. B-cell count and ALC had similar value for predicting treatment-free survival (TFS) and overall survival as continuous variables, but as binary factors, a B-cell threshold of 11 x 10(9)/L best predicted survival. B-cell count remained an independent predictor of TFS after controlling for ZAP-70, IGHV, CD38, or fluorescence in situ hybridization (FISH) results (all P < .001). These analyses support basing the diagnosis of CLL on B-cell count and retaining the size of the B-cell count in the diagnostic criteria. Using clinically relevant criteria to distinguish between monoclonal B-cell lymphocytosis (MBL) and CLL could minimize patient distress caused by labeling asymptomatic people at low risk for adverse clinical consequences as having CLL.",Journal Article,4082.0,90.0,The diagnosis of chronic lymphocytic CLL in asymptomatic patients has historically been based on documenting a characteristic lymphocyte clone and the presence of lymphocytosis There are minimal data regarding which lymphocyte parameter absolute lymphocyte count ALC or B-cell count and what threshold should be used for diagnosis We analyzed the relationship of ALC and B-cell count with clinical outcome in 459 patients with a clonal population of CLL phenotype to determine 1 whether the CLL diagnosis should be based on ALC or B-cell count 2 what lymphocyte threshold should be used for diagnosis and 3 whether any lymphocyte count has independent prognostic value after accounting for biologic/molecular prognostic markers B-cell count and ALC had similar value for predicting treatment-free survival TFS and overall survival as continuous variables but as binary factors a B-cell threshold of 11 x 10 9 /L best predicted survival B-cell count remained an independent predictor of TFS after controlling for ZAP-70 IGHV CD38 or fluorescence in situ hybridization FISH results all P .001 These analyses support basing the diagnosis of CLL on B-cell count and retaining the size of the B-cell count in the diagnostic criteria Using clinically relevant criteria to distinguish between monoclonal B-cell lymphocytosis MBL and CLL could minimize patient distress caused by labeling asymptomatic people at low risk for adverse clinical consequences as having CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 147, 1, 442, 1193, 552, 4, 2100, 7, 71, 3578, 85, 90, 23, 9255, 8, 2037, 1448, 3910, 2, 3, 463, 1, 8125, 125, 32, 1048, 74, 666, 92, 1448, 4219, 1766, 1448, 1276, 3749, 15, 132, 31, 1276, 2, 2067, 2390, 257, 40, 95, 9, 147, 21, 311, 3, 858, 1, 3749, 2, 132, 31, 1276, 5, 38, 228, 4, 10986, 7, 5, 8, 1946, 266, 1, 552, 1005, 6, 223, 14, 317, 3, 552, 147, 257, 40, 90, 23, 3749, 15, 132, 31, 1276, 18, 2067, 1448, 2390, 257, 40, 95, 9, 147, 2, 27, 317, 500, 1448, 1276, 71, 306, 177, 549, 50, 3116, 9, 1283, 219, 177, 525, 132, 31, 1276, 2, 3749, 42, 288, 549, 9, 1434, 24, 115, 25, 7335, 2, 63, 25, 22, 1314, 682, 84, 22, 6405, 130, 8, 132, 31, 2390, 1, 175, 1006, 79, 83, 805, 824, 783, 25, 132, 31, 1276, 958, 35, 306, 980, 1, 7335, 50, 1893, 9, 6251, 431, 6220, 4469, 15, 1591, 4, 957, 1554, 1277, 99, 62, 19, 144, 46, 318, 538, 25974, 3, 147, 1, 552, 23, 132, 31, 1276, 2, 14171, 3, 444, 1, 3, 132, 31, 1276, 4, 3, 752, 371, 75, 505, 867, 371, 6, 3081, 59, 848, 132, 31, 8125, 8992, 2, 552, 359, 3241, 69, 1462, 1546, 20, 3383, 2100, 3788, 28, 154, 43, 9, 290, 38, 3255, 22, 1041, 552]",1460.0,19015397,435
"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.",Blood,Blood,2008-12-02,"Although immunoglobulin V(H) mutation status (IgV(H) MS) is prognostic in patients with chronic lymphocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its significance in the era of chemoimmunotherapy is not known. We determined the IgV(H) somatic mutation status (MS) in 177 patients enrolled in a phase 2 study of fludarabine, cyclophosphamide, and rituximab (FCR) and in 127 patients treated with subsequent chemoimmunotherapy protocols. IgV(H) MS did not impact significantly on the complete remission (CR) rate of patients receiving FCR or related regimens. However, CR duration was significantly shorter in patients with CLL that used unmutated IgV(H) than those whose CLL used mutated IgV(H) (TTP 47% vs 82% at 6 years, P < .001). In a multivariate model considering all baseline characteristics, IgV(H) MS emerged as the only determinant of remission duration (hazard ratio 3.8, P < .001). Our results suggest that postremission interventions should be targeted toward patients with unmutated IgV(H) status.","Clinical Trial, Phase II",4067.0,63.0,Although immunoglobulin V H mutation status IgV H MS is prognostic in patients with chronic lymphocytic CLL who are treated with alkylating agents or single-agent fludarabine its significance in the era of chemoimmunotherapy is not known We determined the IgV H somatic mutation status MS in 177 patients enrolled in a phase 2 study of fludarabine cyclophosphamide and rituximab FCR and in 127 patients treated with subsequent chemoimmunotherapy protocols IgV H MS did not impact significantly on the complete remission CR rate of patients receiving FCR or related regimens However CR duration was significantly shorter in patients with CLL that used unmutated IgV H than those whose CLL used mutated IgV H TTP 47 vs 82 at 6 years P .001 In a multivariate model considering all baseline characteristics IgV H MS emerged as the only determinant of remission duration hazard ratio 3.8 P .001 Our results suggest that postremission interventions should be targeted toward patients with unmutated IgV H status,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 2593, 603, 555, 258, 156, 12179, 555, 2307, 16, 177, 4, 7, 5, 442, 1193, 552, 54, 32, 73, 5, 3410, 183, 15, 226, 420, 2027, 211, 724, 4, 3, 1713, 1, 4438, 16, 44, 440, 21, 509, 3, 12179, 555, 1119, 258, 156, 2307, 4, 4699, 7, 346, 4, 8, 124, 18, 45, 1, 2027, 1112, 2, 855, 4953, 2, 4, 4080, 7, 73, 5, 706, 4438, 2189, 12179, 555, 2307, 205, 44, 345, 97, 23, 3, 236, 734, 684, 116, 1, 7, 357, 4953, 15, 139, 472, 137, 684, 654, 10, 97, 985, 4, 7, 5, 552, 17, 95, 7216, 12179, 555, 76, 135, 1310, 552, 95, 1185, 12179, 555, 2422, 662, 105, 878, 28, 49, 60, 19, 144, 4, 8, 331, 202, 3075, 62, 330, 374, 12179, 555, 2307, 2054, 22, 3, 158, 4372, 1, 734, 654, 360, 197, 27, 66, 19, 144, 114, 99, 309, 17, 8635, 1151, 257, 40, 238, 1317, 7, 5, 7216, 12179, 555, 156]",1005.0,19050308,112
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.,The Journal of molecular diagnostics : JMD,J Mol Diagn,2008-12-12,"Chromosome gains and losses used for risk stratification in chronic lymphocytic leukemia (CLL) are commonly assessed by multiprobe fluorescence in situ hybridization (FISH) studies. We designed and validated a customized array-comparative genomic hybridization (aCGH) platform as a clinical assay for CLL genomic profiling. A 60-mer, 44,000-probe oligonucleotide array with a 50-kb average spatial resolution was augmented with high-density probe tiling at loci that are frequently aberrant in CLL. Aberrations identified by aCGH were compared with those identified by a FISH panel, including locus-specific probes to ATM (11q22.3), the centromeric region of chromosome 12 (12p11.1-q11), D13S319 (13q14.3), LAMP1 (13q34), and TP53 (17p13.1). In 100 CLL samples, aCGH/FISH concordance was seen for 89% of FISH-called aberrations at the ATM (n=18), D13S319 (n=42), LAMP (n=12), and TP53 (n=22) loci and for chromosome 12 (n=14). Eighty-four percentage of FISH/aCGH discordant calls were in samples either at or below the limit of aCGH sensitivity (10% to 25% FISH aberration-containing cells). Therefore, aCGH profiling is a feasible routine clinical test with comparable results to multiprobe FISH studies; however, it may be less sensitive than FISH in cases with low-level aberrations. Further, a customized array design can provide comprehensive genomic profiling with additional accuracy in both identifying and defining the extent of small aberrations at target loci.",Journal Article,4057.0,32.0,"Chromosome gains and losses used for risk stratification in chronic lymphocytic CLL are commonly assessed by multiprobe fluorescence in situ hybridization FISH studies We designed and validated a customized array-comparative genomic hybridization aCGH platform as a clinical assay for CLL genomic profiling A 60-mer 44,000-probe oligonucleotide array with a 50-kb average spatial resolution was augmented with high-density probe tiling at loci that are frequently aberrant in CLL Aberrations identified by aCGH were compared with those identified by a FISH panel including locus-specific probes to ATM 11q22.3 the centromeric region of chromosome 12 12p11.1-q11 D13S319 13q14.3 LAMP1 13q34 and TP53 17p13.1 In 100 CLL samples aCGH/FISH concordance was seen for 89 of FISH-called aberrations at the ATM n=18 D13S319 n=42 LAMP n=12 and TP53 n=22 loci and for chromosome 12 n=14 Eighty-four percentage of FISH/aCGH discordant calls were in samples either at or below the limit of aCGH sensitivity 10 to 25 FISH aberration-containing cells Therefore aCGH profiling is a feasible routine clinical test with comparable results to multiprobe FISH studies however it may be less sensitive than FISH in cases with low-level aberrations Further a customized array design can provide comprehensive genomic profiling with additional accuracy in both identifying and defining the extent of small aberrations at target loci",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1170, 3849, 2, 5324, 95, 9, 43, 1541, 4, 442, 1193, 552, 32, 841, 275, 20, 38875, 1591, 4, 957, 1554, 1277, 94, 21, 1114, 2, 938, 8, 8959, 1926, 2352, 572, 1554, 8879, 2243, 22, 8, 38, 719, 9, 552, 572, 1080, 8, 335, 10068, 584, 984, 2888, 4727, 1926, 5, 8, 212, 5116, 1011, 5104, 2125, 10, 4277, 5, 64, 1263, 2888, 26435, 28, 2012, 17, 32, 746, 1898, 4, 552, 2152, 108, 20, 8879, 11, 72, 5, 135, 108, 20, 8, 1277, 993, 141, 2474, 112, 3701, 6, 3552, 12647, 27, 3, 15531, 1053, 1, 1170, 133, 19024, 14, 11532, 24413, 13221, 27, 34602, 34603, 2, 1206, 7526, 14, 4, 394, 552, 347, 8879, 1277, 1827, 10, 527, 9, 887, 1, 1277, 3472, 2152, 28, 3, 3552, 78, 203, 24413, 78, 595, 30219, 78, 133, 2, 1206, 78, 350, 2012, 2, 9, 1170, 133, 78, 213, 2207, 294, 1150, 1, 1277, 8879, 4570, 6467, 11, 4, 347, 361, 28, 15, 2736, 3, 2385, 1, 8879, 485, 79, 6, 243, 1277, 7794, 1101, 37, 673, 8879, 1080, 16, 8, 1313, 1311, 38, 412, 5, 1279, 99, 6, 38875, 1277, 94, 137, 192, 68, 40, 299, 745, 76, 1277, 4, 140, 5, 154, 301, 2152, 195, 8, 8959, 1926, 771, 122, 377, 949, 572, 1080, 5, 402, 1190, 4, 110, 1386, 2, 2847, 3, 1039, 1, 302, 2152, 28, 283, 2012]",1409.0,19074592,65
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.,Blood,Blood,2008-12-12,"In lymphatic tissues, chronic lymphocytic leukemia (CLL) cells are interspersed with CD68(+) nurselike cells (NLCs), T cells, and other stromal cells that constitute the leukemia microenvironment. However, the mechanism regulating colocalization of CLL and these accessory cells are largely unknown. To dissect the molecular cross talk between CLL and NLCs, we profiled the gene expression of CD19-purified CLL cells before and after coculture with NLCs. NLC coculture induced high-level expression of B-cell maturation antigen and 2 chemoattractants (CCL3, CCL4) by CLL cells. CCL3/CCL4 induction in NLC cocultures correlated with ZAP-70 expression by CLL cells. High CCL3/CCL4 protein levels were found in CLL cocultures with NLCs, and CCL3/CCL4 induction was abrogated by R406, a Syk inhibitor, suggesting that NLCs induce these chemokines via B-cell receptor (BCR) activation. BCR triggering also caused robust CCL3/CCL4 protein secretion by CLL cells. High CCL3 and CCL4 plasma levels in CLL patients suggest that this pathway plays a role in vivo. These studies reveal a novel mechanism of cross talk between CLL cells and their microenvironment, namely, the secretion of 2 T-cell chemokines in response to NLC coculture and BCR stimulation. Through these chemokines, CLL cells can recruit accessory cells and thereby actively create a supportive microenvironment.",Journal Article,4057.0,191.0,In lymphatic tissues chronic lymphocytic CLL cells are interspersed with CD68 nurselike cells NLCs T cells and other stromal cells that constitute the microenvironment However the mechanism regulating colocalization of CLL and these accessory cells are largely unknown To dissect the molecular cross talk between CLL and NLCs we profiled the gene expression of CD19-purified CLL cells before and after coculture with NLCs NLC coculture induced high-level expression of B-cell maturation antigen and 2 chemoattractants CCL3 CCL4 by CLL cells CCL3/CCL4 induction in NLC cocultures correlated with ZAP-70 expression by CLL cells High CCL3/CCL4 protein levels were found in CLL cocultures with NLCs and CCL3/CCL4 induction was abrogated by R406 a Syk inhibitor suggesting that NLCs induce these chemokines via B-cell receptor BCR activation BCR triggering also caused robust CCL3/CCL4 protein secretion by CLL cells High CCL3 and CCL4 plasma levels in CLL patients suggest that this pathway plays a role in vivo These studies reveal a novel mechanism of cross talk between CLL cells and their microenvironment namely the secretion of 2 T-cell chemokines in response to NLC coculture and BCR stimulation Through these chemokines CLL cells can recruit accessory cells and thereby actively create a supportive microenvironment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[4, 2936, 742, 442, 1193, 552, 37, 32, 11038, 5, 6439, 28698, 37, 17425, 102, 37, 2, 127, 1126, 37, 17, 4999, 3, 995, 137, 3, 670, 2681, 15872, 1, 552, 2, 46, 12082, 37, 32, 1733, 860, 6, 10830, 3, 219, 1383, 6522, 59, 552, 2, 17425, 21, 5490, 3, 145, 55, 1, 3158, 5963, 552, 37, 348, 2, 50, 7604, 5, 17425, 31383, 7604, 277, 64, 301, 55, 1, 132, 31, 4537, 448, 2, 18, 37377, 9711, 12660, 20, 552, 37, 9711, 12660, 504, 4, 31383, 16398, 438, 5, 6251, 431, 55, 20, 552, 37, 64, 9711, 12660, 178, 148, 11, 204, 4, 552, 16398, 5, 17425, 2, 9711, 12660, 504, 10, 3728, 20, 18529, 8, 6792, 230, 802, 17, 17425, 1290, 46, 4906, 847, 132, 31, 153, 1062, 363, 1062, 8867, 120, 1546, 1922, 9711, 12660, 178, 2935, 20, 552, 37, 64, 9711, 2, 12660, 554, 148, 4, 552, 7, 309, 17, 26, 308, 1698, 8, 200, 4, 386, 46, 94, 2396, 8, 229, 670, 1, 1383, 6522, 59, 552, 37, 2, 136, 995, 5046, 3, 2935, 1, 18, 102, 31, 4906, 4, 51, 6, 31383, 7604, 2, 1062, 2503, 298, 46, 4906, 552, 37, 122, 8973, 12082, 37, 2, 2267, 4489, 3736, 8, 1877, 995]",1319.0,19074730,457
"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-12-15,"Modern combination strategies are active in chronic lymphocytic leukemia (CLL) but can have significant myelosuppression and immunosuppression that may require dose attenuation for safety. We explored a sequential treatment strategy to allow safe delivery of active agents at full doses. Previously, we studied sequential therapy with fludarabine followed by cyclophosphamide (F-->C). In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R). Thirty-six previously untreated CLL patients received therapy with fludarabine 25 mg/m(2) on days 1 through 5 every 4 weeks for six cycles, followed by consolidation with cyclophosphamide 3,000 mg/m(2) administered every 3 weeks for three cycles, followed by consolidation with weekly rituximab 375 mg/m(2) for four cycles. Evaluation for minimal residual disease included flow cytometry and a highly sensitive clonotypic polymerase chain reaction (PCR). The median age was 59 years (range, 37 to 71 years), 61% of patients had high-risk disease, and 58% had unmutated IgV(H) genes. There were 32 responses (89%), including 22 CRs (61%). Consolidation with cyclophosphamide improved responses in 13 patients (36%); nine patients (25%) further improved their response with rituximab. Twenty patients (56%) achieved flow cytometric CRs, and 12 patients (33%) achieved a molecular CR (PCR negative). Patients achieving molecular CRs had an excellent prognosis with a plateau in the response duration curve, and 90% remain in clinical CR at 5 years. For the entire group, 5-year survival rate is 71% compared with a rate of 48% with our prior F-->C regimen (P = .10). Sequential therapy with F-->C-->R yields improvement in quality of response, with many patients achieving a PCR-negative state.",Comparative Study,4054.0,59.0,"Modern combination strategies are active in chronic lymphocytic CLL but can have significant myelosuppression and immunosuppression that may require dose attenuation for safety We explored a sequential treatment strategy to allow safe delivery of active agents at full doses Previously we studied sequential therapy with fludarabine followed by cyclophosphamide F -- C In that study cyclophosphamide consolidation improved the frequency of complete response CR four-fold Subsequently rituximab was added to this regimen F -- C -- R Thirty-six previously untreated CLL patients received therapy with fludarabine 25 mg/m 2 on days 1 through 5 every 4 weeks for six cycles followed by consolidation with cyclophosphamide 3,000 mg/m 2 administered every 3 weeks for three cycles followed by consolidation with weekly rituximab 375 mg/m 2 for four cycles Evaluation for minimal residual disease included flow cytometry and a highly sensitive clonotypic polymerase chain reaction PCR The median age was 59 years range 37 to 71 years 61 of patients had high-risk disease and 58 had unmutated IgV H genes There were 32 responses 89 including 22 CRs 61 Consolidation with cyclophosphamide improved responses in 13 patients 36 nine patients 25 further improved their response with rituximab Twenty patients 56 achieved flow cytometric CRs and 12 patients 33 achieved a molecular CR PCR negative Patients achieving molecular CRs had an excellent prognosis with a plateau in the response duration curve and 90 remain in clinical CR at 5 years For the entire group 5-year survival rate is 71 compared with a rate of 48 with our prior F -- C regimen P .10 Sequential therapy with F -- C -- R yields improvement in quality of response with many patients achieving a PCR-negative state",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2366, 150, 422, 32, 544, 4, 442, 1193, 552, 84, 122, 47, 93, 2858, 2, 3646, 17, 68, 1353, 61, 5349, 9, 367, 21, 1443, 8, 1787, 24, 692, 6, 1700, 1165, 989, 1, 544, 183, 28, 1647, 415, 373, 21, 656, 1787, 36, 5, 2027, 370, 20, 1112, 1068, 256, 4, 17, 45, 1112, 2173, 231, 3, 675, 1, 236, 51, 684, 294, 1116, 1611, 855, 10, 1953, 6, 26, 477, 1068, 256, 668, 977, 437, 373, 1278, 552, 7, 103, 36, 5, 2027, 243, 81, 188, 18, 23, 162, 14, 298, 33, 454, 39, 244, 9, 437, 410, 370, 20, 2173, 5, 1112, 27, 984, 81, 188, 18, 468, 454, 27, 244, 9, 169, 410, 370, 20, 2173, 5, 709, 855, 4175, 81, 188, 18, 9, 294, 410, 451, 9, 1048, 753, 34, 159, 1412, 1914, 2, 8, 561, 745, 10959, 1451, 1260, 1329, 604, 3, 52, 89, 10, 728, 60, 184, 567, 6, 792, 60, 713, 1, 7, 42, 64, 43, 34, 2, 717, 42, 7216, 12179, 555, 214, 125, 11, 531, 253, 887, 141, 350, 3115, 713, 2173, 5, 1112, 231, 253, 4, 233, 7, 511, 762, 7, 243, 195, 231, 136, 51, 5, 855, 737, 7, 664, 513, 1412, 6226, 3115, 2, 133, 7, 466, 513, 8, 219, 684, 604, 199, 7, 1785, 219, 3115, 42, 35, 1503, 356, 5, 8, 6133, 4, 3, 51, 654, 1496, 2, 424, 918, 4, 38, 684, 28, 33, 60, 9, 3, 1797, 87, 33, 111, 25, 116, 16, 792, 72, 5, 8, 116, 1, 576, 5, 114, 324, 1068, 256, 477, 19, 79, 1787, 36, 5, 1068, 256, 668, 4788, 767, 4, 372, 1, 51, 5, 445, 7, 1785, 8, 604, 199, 1309]",1769.0,19075280,664
Validation of a new prognostic index for patients with chronic lymphocytic leukemia.,Cancer,Cancer,2009-01-01,"The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. A prognostic index based on widely available clinical and laboratory features was recently developed to predict survival among patients with previously untreated CLL. This index requires validation in an independent series of patients before widespread use can be recommended. The Mayo Clinic CLL database was used to evaluate the validity and reproducibility of the new prognostic index. A total of 440 patients with newly diagnosed CLL who were seen at the Mayo Clinic within 12 months of diagnosis and for whom data were available with which to calculate index score were identified. Patients were classified as low, intermediate, or high risk using the prognostic index. The estimated median survival times were: not reached for low risk, 10.1 years for intermediate risk, and 7.2 years for high risk. The estimated median and 5-year survival by prognostic index risk category were similar to those originally reported. The prognostic index risk category added predictive value beyond that of Rai risk alone (P=.004). The prognostic index risk category remained a predictor of survival when analysis was limited to Rai stage 0 (P=.03) and nonreferred patients (P<.0001) and also predicted time to treatment (P<.0001). The results of the current study confirm the ability of a newly developed prognostic index to predict survival among patients with previously untreated CLL. The study also extended the utility of the index by demonstrating that it is useful at diagnosis, retains prognostic value when applied exclusively to Rai stage 0 patients, is effective in nonreferred patients, and predicts time to treatment.",Journal Article,4037.0,57.0,The clinical course of chronic lymphocytic CLL is highly variable A prognostic index based on widely available clinical and laboratory features was recently developed to predict survival among patients with previously untreated CLL This index requires validation in an independent series of patients before widespread use can be recommended The Mayo Clinic CLL database was used to evaluate the validity and reproducibility of the new prognostic index A total of 440 patients with newly diagnosed CLL who were seen at the Mayo Clinic within 12 months of diagnosis and for whom data were available with which to calculate index score were identified Patients were classified as low intermediate or high risk using the prognostic index The estimated median survival times were not reached for low risk 10.1 years for intermediate risk and 7.2 years for high risk The estimated median and 5-year survival by prognostic index risk category were similar to those originally reported The prognostic index risk category added predictive value beyond that of Rai risk alone P=.004 The prognostic index risk category remained a predictor of survival when analysis was limited to Rai stage 0 P=.03 and nonreferred patients P .0001 and also predicted time to treatment P .0001 The results of the current study confirm the ability of a newly developed prognostic index to predict survival among patients with previously untreated CLL The study also extended the utility of the index by demonstrating that it is useful at diagnosis retains prognostic value when applied exclusively to Rai stage 0 patients is effective in nonreferred patients and predicts time to treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 906, 1, 442, 1193, 552, 16, 561, 1347, 8, 177, 558, 90, 23, 1792, 390, 38, 2, 1624, 404, 10, 761, 276, 6, 678, 25, 107, 7, 5, 373, 1278, 552, 26, 558, 1706, 929, 4, 35, 306, 988, 1, 7, 348, 3029, 119, 122, 40, 793, 3, 2486, 1188, 552, 609, 10, 95, 6, 376, 3, 3099, 2, 4688, 1, 3, 217, 177, 558, 8, 181, 1, 9596, 7, 5, 732, 265, 552, 54, 11, 527, 28, 3, 2486, 1188, 262, 133, 53, 1, 147, 2, 9, 953, 74, 11, 390, 5, 92, 6, 3232, 558, 368, 11, 108, 7, 11, 1373, 22, 154, 919, 15, 64, 43, 75, 3, 177, 558, 3, 661, 52, 25, 1072, 11, 44, 1300, 9, 154, 43, 79, 14, 60, 9, 919, 43, 2, 67, 18, 60, 9, 64, 43, 3, 661, 52, 2, 33, 111, 25, 20, 177, 558, 43, 2169, 11, 288, 6, 135, 5045, 210, 3, 177, 558, 43, 2169, 1953, 464, 549, 1654, 17, 1, 4121, 43, 279, 19, 1520, 3, 177, 558, 43, 2169, 958, 8, 980, 1, 25, 198, 65, 10, 383, 6, 4121, 82, 13, 19, 680, 2, 45373, 7, 19, 488, 2, 120, 783, 98, 6, 24, 19, 488, 3, 99, 1, 3, 291, 45, 1843, 3, 801, 1, 8, 732, 276, 177, 558, 6, 678, 25, 107, 7, 5, 373, 1278, 552, 3, 45, 120, 1747, 3, 1207, 1, 3, 558, 20, 2219, 17, 192, 16, 999, 28, 147, 10785, 177, 549, 198, 1498, 4437, 6, 4121, 82, 13, 7, 16, 323, 4, 45373, 7, 2, 2623, 98, 6, 24]",1660.0,19090008,213
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.,Blood,Blood,2008-12-18,"Chronic lymphocytic leukemia (CLL) is characterized by cells that exhibit dysfunctional apoptosis. Here, we show that deacetylase inhibition led to the E2F1- and myc-mediated transcriptional activation of the microRNA miR106b in primary CLL cells. Induction of miR106b was associated with a down-regulation in the levels of the E3-ubiquitin ligase Itch. Decreases in Itch protein levels were associated with a reciprocal accumulation of its proapoptotic substrate, TAp73 (p73), and induction of p53 up-regulated modulator of apoptosis (PUMA) mRNA and protein. This event was accompanied by mitochondrial dysfunction, processing of caspase-9, and apoptosis of CLL cells. Ectopic expression of miR106b in CLL cells demonstrated that Itch was a direct target of miR106b such that miR106b-induced decreases in Itch resulted in an accumulation of p73. Thus, our results identify a novel regulatory mechanism wherein microRNA regulate cell survival by mediating the posttranscriptional down-regulation of an ubiquitin ligase, leading to the induction of a proapoptotic regulator in malignant cells. Silencing of miRNA expression in CLL may selectively suppress proapoptotic pathways, providing such tumors with a survival advantage. Consequently, chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells.",Journal Article,4051.0,65.0,Chronic lymphocytic CLL is characterized by cells that exhibit dysfunctional apoptosis Here we show that deacetylase inhibition led to the E2F1- and myc-mediated transcriptional activation of the microRNA miR106b in primary CLL cells Induction of miR106b was associated with a down-regulation in the levels of the E3-ubiquitin ligase Itch Decreases in Itch protein levels were associated with a reciprocal accumulation of its proapoptotic substrate TAp73 p73 and induction of p53 up-regulated modulator of apoptosis PUMA mRNA and protein This event was accompanied by mitochondrial dysfunction processing of caspase-9 and apoptosis of CLL cells Ectopic expression of miR106b in CLL cells demonstrated that Itch was a direct target of miR106b such that miR106b-induced decreases in Itch resulted in an accumulation of p73 Thus our results identify a novel regulatory mechanism wherein microRNA regulate cell survival by mediating the posttranscriptional down-regulation of an ubiquitin ligase leading to the induction of a proapoptotic regulator in malignant cells Silencing of miRNA expression in CLL may selectively suppress proapoptotic pathways providing such tumors with a survival advantage Consequently chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 765, 20, 37, 17, 2239, 9666, 351, 467, 21, 514, 17, 2732, 297, 836, 6, 3, 6112, 2, 1371, 517, 1431, 363, 1, 3, 3213, 26778, 4, 86, 552, 37, 504, 1, 26778, 10, 41, 5, 8, 1328, 863, 4, 3, 148, 1, 3, 7193, 4213, 5839, 17977, 2140, 4, 17977, 178, 148, 11, 41, 5, 8, 8020, 1835, 1, 211, 4118, 4235, 28869, 8242, 2, 504, 1, 624, 126, 1065, 6318, 1, 351, 8691, 956, 2, 178, 26, 774, 10, 2756, 20, 2019, 1527, 3325, 1, 1469, 83, 2, 351, 1, 552, 37, 3647, 55, 1, 26778, 4, 552, 37, 264, 17, 17977, 10, 8, 1196, 283, 1, 26778, 225, 17, 26778, 277, 2140, 4, 17977, 627, 4, 35, 1835, 1, 8242, 631, 114, 99, 255, 8, 229, 1253, 670, 7893, 3213, 2288, 31, 25, 20, 3941, 3, 14386, 1328, 863, 1, 35, 4213, 5839, 1049, 6, 3, 504, 1, 8, 4118, 2452, 4, 393, 37, 2077, 1, 2053, 55, 4, 552, 68, 2382, 3134, 4118, 460, 1736, 225, 57, 5, 8, 25, 1874, 3244, 1573, 600, 17, 2977, 26778, 359, 4565, 8, 624, 306, 670, 17, 637, 552, 37]",1319.0,19096009,222
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-12-29,"Other malignancies have been reported to occur with increased frequency in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The aim of this study was to determine the frequency, outcomes, and factors associated with other cancers in patients with CLL/SLL. We reviewed the records of consecutive patients with previously untreated CLL/SLL seen at The University of Texas M. D. Anderson Cancer Center from 1985 to 2005. The number of second cancers observed was compared with the number expected from the Surveillance, Epidemiology, and End Results database. Among 2,028 patients, 324 (16%) had a history of other cancers and 227 (11.2%) developed other malignancies during the follow-up period. Overall, 625 cancers were observed in 551 patients, including skin (30%), prostate (13%), breast (9%), melanoma (8%), lymphoma (8%), gastrointestinal (9%), lung (6%), and other cancers (17%). The risk of a second cancer was 2.2 times higher than the expected risk. The response rates in patients with and without a history of other cancers were 86% and 92%, respectively (P = .04), and the 5-year survival rates were 70% and 82%, respectively (P < .001). In Cox analysis, independent factors predicting development of new cancers were older age, male sex, and elevated levels of beta2-microglobulin, lactate dehydrogenase, and creatinine. In patients who were treated for CLL/SLL, the treatment regimen did not affect the risk of subsequent cancer (P = .49). Patients with CLL/SLL have more than twice the risk of developing a second cancer and an increased frequency of certain cancer types. Awareness of risk factors could permit early detection.",Journal Article,4040.0,142.0,"Other malignancies have been reported to occur with increased frequency in chronic lymphocytic leukemia/small lymphocytic CLL/SLL The aim of this study was to determine the frequency outcomes and factors associated with other cancers in patients with CLL/SLL We reviewed the records of consecutive patients with previously untreated CLL/SLL seen at The University of Texas M. D. Anderson Cancer Center from 1985 to 2005 The number of second cancers observed was compared with the number expected from the Surveillance Epidemiology and End Results database Among 2,028 patients 324 16 had a history of other cancers and 227 11.2 developed other malignancies during the follow-up period Overall 625 cancers were observed in 551 patients including 30 13 9 8 8 9 6 and other cancers 17 The risk of a second cancer was 2.2 times higher than the expected risk The response rates in patients with and without a history of other cancers were 86 and 92 respectively P .04 and the 5-year survival rates were 70 and 82 respectively P .001 In Cox analysis independent factors predicting development of new cancers were older age male sex and elevated levels of beta2-microglobulin lactate dehydrogenase and creatinine In patients who were treated for CLL/SLL the treatment regimen did not affect the risk of subsequent cancer P .49 Patients with CLL/SLL have more than twice the risk of developing a second cancer and an increased frequency of certain cancer types Awareness of risk factors could permit early detection",1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[127, 441, 47, 85, 210, 6, 1271, 5, 101, 675, 4, 442, 1193, 2647, 302, 1193, 552, 5302, 3, 1130, 1, 26, 45, 10, 6, 223, 3, 675, 123, 2, 130, 41, 5, 127, 163, 4, 7, 5, 552, 5302, 21, 446, 3, 1064, 1, 935, 7, 5, 373, 1278, 552, 5302, 527, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 29, 4675, 6, 1242, 3, 207, 1, 419, 163, 164, 10, 72, 5, 3, 207, 1336, 29, 3, 617, 1284, 2, 396, 99, 609, 107, 18, 4836, 7, 8393, 245, 42, 8, 532, 1, 127, 163, 2, 7132, 175, 18, 276, 127, 441, 190, 3, 166, 126, 727, 63, 9629, 163, 11, 164, 4, 11248, 7, 141, 201, 233, 83, 66, 66, 83, 49, 2, 127, 163, 269, 3, 43, 1, 8, 419, 12, 10, 18, 18, 1072, 142, 76, 3, 1336, 43, 3, 51, 151, 4, 7, 5, 2, 187, 8, 532, 1, 127, 163, 11, 868, 2, 937, 106, 19, 755, 2, 3, 33, 111, 25, 151, 11, 431, 2, 878, 106, 19, 144, 4, 418, 65, 306, 130, 1434, 193, 1, 217, 163, 11, 434, 89, 1045, 1035, 2, 804, 148, 1, 8911, 5371, 3330, 2374, 2, 3177, 4, 7, 54, 11, 73, 9, 552, 5302, 3, 24, 477, 205, 44, 1158, 3, 43, 1, 706, 12, 19, 739, 7, 5, 552, 5302, 47, 80, 76, 936, 3, 43, 1, 931, 8, 419, 12, 2, 35, 101, 675, 1, 1840, 12, 630, 3310, 1, 43, 130, 359, 5634, 191, 638]",1507.0,19114699,610
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.,Cancer,Cancer,2009-01-01,"An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL). We searched the electronic CLL database for consecutive patients who presented to the M. D. Anderson Cancer Center Department of Leukemia from October 2003 to April 2007 with untreated CLL and who had an 11q22 deletion, detected by fluorescence in situ hybridization (FISH) analysis of bone marrow samples. FISH analysis was performed using the following probes: trisomy 12 (12p11.1-q11), TP53 (17p13.1), ATM (11q22.3), LAMP1 (13q34), and D13S319 loci (13q14.3). Sixty-nine patients with untreated CLL with an 11q22 deletion were identified. The median patient age was 59 years (range, 26-81 years); 80% were men, 53% had Zubrod performance status>0, and 13% had Rai stage III to IV disease. Lymphadenopathy (massive), splenomegaly, anemia, and thrombocytopenia were present in 96% (12%), 19%, 9%, and 4%, respectively. In addition, 62% of patients had deletions in 13q, and 3% had trisomy 12. Forty patients required therapy for progressive disease. The overall response rates for FCR (fludarabine, cyclophosphamide, and rituximab), CFAR (FCR plus alemtuzumab), and rituximab plus granulocyte-macrophage colony-stimulating factor were 100%, 100%, and 33%, respectively. The 11q22 deletion was undetectable in 25 of 27 patients monitored after treatment using FISH analysis. The median follow-up was 17 months. At 1 and 3 years, the survival rates were 97% and 91%, respectively, and the relapse-free survival rates were 100% and 77%, respectively. CLL with an 11q22 deletion was associated with high rates of response, survival, and relapse-free survival when treated with chemoimmunotherapy.",Journal Article,4037.0,93.0,An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic CLL We searched the electronic CLL database for consecutive patients who presented to the M. D. Anderson Cancer Center Department of from October 2003 to April 2007 with untreated CLL and who had an 11q22 deletion detected by fluorescence in situ hybridization FISH analysis of marrow samples FISH analysis was performed using the following probes trisomy 12 12p11.1-q11 TP53 17p13.1 ATM 11q22.3 LAMP1 13q34 and D13S319 loci 13q14.3 Sixty-nine patients with untreated CLL with an 11q22 deletion were identified The median patient age was 59 years range 26-81 years 80 were men 53 had Zubrod performance status 0 and 13 had Rai stage III to IV disease Lymphadenopathy massive splenomegaly anemia and thrombocytopenia were present in 96 12 19 9 and 4 respectively In addition 62 of patients had deletions in 13q and 3 had trisomy 12 Forty patients required therapy for progressive disease The overall response rates for FCR fludarabine cyclophosphamide and rituximab CFAR FCR plus alemtuzumab and rituximab plus granulocyte-macrophage colony-stimulating factor were 100 100 and 33 respectively The 11q22 deletion was undetectable in 25 of 27 patients monitored after treatment using FISH analysis The median follow-up was 17 months At 1 and 3 years the survival rates were 97 and 91 respectively and the relapse-free survival rates were 100 and 77 respectively CLL with an 11q22 deletion was associated with high rates of response survival and relapse-free survival when treated with chemoimmunotherapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[35, 12647, 1528, 16, 515, 35, 306, 161, 1434, 334, 25, 4, 442, 1193, 552, 21, 3080, 3, 3098, 552, 609, 9, 935, 7, 54, 917, 6, 3, 188, 427, 1929, 12, 574, 4271, 1, 29, 2551, 1522, 6, 2292, 1307, 5, 1278, 552, 2, 54, 42, 35, 12647, 1528, 530, 20, 1591, 4, 957, 1554, 1277, 65, 1, 581, 347, 1277, 65, 10, 173, 75, 3, 366, 3701, 6317, 133, 19024, 14, 11532, 1206, 7526, 14, 3552, 12647, 27, 34602, 34603, 2, 24413, 2012, 13221, 27, 1746, 762, 7, 5, 1278, 552, 5, 35, 12647, 1528, 11, 108, 3, 52, 69, 89, 10, 728, 60, 184, 432, 865, 60, 493, 11, 325, 699, 42, 10672, 528, 156, 13, 2, 233, 42, 4121, 82, 316, 6, 478, 34, 4962, 7929, 6364, 1545, 2, 1340, 11, 364, 4, 921, 133, 326, 83, 2, 39, 106, 4, 352, 744, 1, 7, 42, 2439, 4, 8453, 2, 27, 42, 6317, 133, 1213, 7, 616, 36, 9, 1014, 34, 3, 63, 51, 151, 9, 4953, 2027, 1112, 2, 855, 25141, 4953, 349, 3579, 2, 855, 349, 2764, 2674, 1975, 2122, 161, 11, 394, 394, 2, 466, 106, 3, 12647, 1528, 10, 3920, 4, 243, 1, 428, 7, 2909, 50, 24, 75, 1277, 65, 3, 52, 166, 126, 10, 269, 53, 28, 14, 2, 27, 60, 3, 25, 151, 11, 1015, 2, 970, 106, 2, 3, 429, 115, 25, 151, 11, 394, 2, 849, 106, 552, 5, 35, 12647, 1528, 10, 41, 5, 64, 151, 1, 51, 25, 2, 429, 115, 25, 198, 73, 5, 4438]",1602.0,19117034,274
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Haematologica,Haematologica,2009-01-14,"Because hepatitis C virus infection causes hepatic and immunological dysfunction, we hypothesized that seropositivity for this virus could be associated with increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. We performed a case-control study of the outcomes of patients who were hepatitis C virus seropositive at the time of allogeneic hematopoietic stem cell transplantation (N=31). Patients positive for hepatitis C virus were considered candidates for stem cell transplantation only if they had no significant evidence of hepatic dysfunction. Matched controls (N=31) were seronegative for viral hepatitides and were paired according to age, diagnosis, disease stage, conditioning regimen and donor type. We also compared the hepatitis C virus seropositive patients to all seronegative patients (all controls, N=1800) transplanted during the same period, to adjust for other confounding effects. The median age of the seropositive patients was 49 (range 26-72); 15 had acute myeloid leukemia/myelodysplastic syndrome, 6 had chronic myeloid leukemia/myeloproliferative disease, 6 non-Hodgkin's lymphoma, 2 myeloma, 1 acute lymphocytic leukemia and 1 Hodgkin's lymphoma; 61% had poor risk disease; 68% had related donors; 68% received reduced intensity conditioning; 7 patients had mildly abnormal alanine transaminase levels (all less than three times the upper limit of normal) and 1 patient had minimally elevated bilirubin. These characteristics were similar to those of the matched control group. Median overall survival was 3, 18 and 20 months, and 1-year survival was 29%, 56% and 56%, in the hepatitis C virus, matched and all controls groups, respectively (hazard ratio for death 3.1, 95% confidence interval 1.9-5.6, p<0.001 in multivariate analysis). Non-relapse mortality at 1 year was 43%, 24% and 23%, respectively (hazard ratio 3.3, 95% confidence interval 1.8-7.1, p<0.01). Disease progression and graft-versus-host disease rates were comparable. Hepatitis C virus seropositivity is a significant risk factor for non-relapse mortality after allogeneic hematopoietic stem cell transplantation even in patients with normal or minimally abnormal liver function tests.",Journal Article,4024.0,35.0,Because hepatitis C virus infection causes hepatic and immunological dysfunction we hypothesized that seropositivity for this virus could be associated with increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation We performed a case-control study of the outcomes of patients who were hepatitis C virus seropositive at the time of allogeneic hematopoietic stem cell transplantation N=31 Patients positive for hepatitis C virus were considered candidates for stem cell transplantation only if they had no significant evidence of hepatic dysfunction Matched controls N=31 were seronegative for viral hepatitides and were paired according to age diagnosis disease stage conditioning regimen and donor type We also compared the hepatitis C virus seropositive patients to all seronegative patients all controls N=1800 transplanted during the same period to adjust for other confounding effects The median age of the seropositive patients was 49 range 26-72 15 had acute myeloid leukemia/myelodysplastic syndrome 6 had chronic myeloid leukemia/myeloproliferative disease 6 's 2 1 acute lymphocytic and 1 's 61 had poor risk disease 68 had related donors 68 received reduced intensity conditioning 7 patients had mildly abnormal alanine transaminase levels all less than three times the upper limit of normal and 1 patient had minimally elevated bilirubin These characteristics were similar to those of the matched control group Median overall survival was 3 18 and 20 months and 1-year survival was 29 56 and 56 in the hepatitis C virus matched and all controls groups respectively hazard ratio for death 3.1 95 confidence interval 1.9-5.6 p 0.001 in multivariate analysis Non-relapse mortality at 1 year was 43 24 and 23 respectively hazard ratio 3.3 95 confidence interval 1.8-7.1 p 0.01 Disease progression and graft-versus-host disease rates were comparable Hepatitis C virus seropositivity is a significant risk factor for non-relapse mortality after allogeneic hematopoietic stem cell transplantation even in patients with normal or minimally abnormal function tests,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[408, 3002, 256, 1450, 930, 1626, 939, 2, 5073, 1527, 21, 1237, 17, 9525, 9, 26, 1450, 359, 40, 41, 5, 101, 220, 429, 282, 50, 1063, 1007, 452, 31, 497, 21, 173, 8, 473, 182, 45, 1, 3, 123, 1, 7, 54, 11, 3002, 256, 1450, 9909, 28, 3, 98, 1, 1063, 1007, 452, 31, 497, 78, 456, 7, 109, 9, 3002, 256, 1450, 11, 515, 1931, 9, 452, 31, 497, 158, 492, 491, 42, 77, 93, 241, 1, 939, 1527, 655, 535, 78, 456, 11, 14924, 9, 1667, 45397, 2, 11, 2355, 768, 6, 89, 147, 34, 82, 1933, 477, 2, 1488, 267, 21, 120, 72, 3, 3002, 256, 1450, 9909, 7, 6, 62, 14924, 7, 62, 535, 78, 13507, 4600, 190, 3, 827, 727, 6, 6611, 9, 127, 4339, 176, 3, 52, 89, 1, 3, 9909, 7, 10, 739, 184, 432, 720, 167, 42, 286, 533, 2647, 10589, 681, 49, 42, 442, 533, 2647, 10857, 34, 49, 292, 18, 14, 286, 1193, 2, 14, 292, 713, 42, 334, 43, 34, 806, 42, 139, 2344, 806, 103, 405, 837, 1933, 67, 7, 42, 9443, 1668, 5411, 6997, 148, 62, 299, 76, 169, 1072, 3, 1726, 2385, 1, 295, 2, 14, 69, 42, 2144, 804, 5009, 46, 374, 11, 288, 6, 135, 1, 3, 655, 182, 87, 52, 63, 25, 10, 27, 203, 2, 179, 53, 2, 14, 111, 25, 10, 462, 664, 2, 664, 4, 3, 3002, 256, 1450, 655, 2, 62, 535, 271, 106, 360, 197, 9, 273, 27, 14, 48, 307, 268, 14, 83, 33, 49, 19, 13, 144, 4, 331, 65, 220, 429, 282, 28, 14, 111, 10, 601, 259, 2, 382, 106, 360, 197, 27, 27, 48, 307, 268, 14, 66, 67, 14, 19, 13, 355, 34, 91, 2, 1599, 185, 1204, 34, 151, 11, 1279, 3002, 256, 1450, 9525, 16, 8, 93, 43, 161, 9, 220, 429, 282, 50, 1063, 1007, 452, 31, 497, 871, 4, 7, 5, 295, 15, 2144, 1668, 343, 895]",2098.0,19144658,95
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.,Blood,Blood,2009-02-03,"Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited. Available treatments can also deplete T lymphocytes, leaving patients at risk of life-threatening infections. In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells. We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models. In CLL cells, silvestrol LC(50) (concentration lethal to 50%) is 6.9 nM at 72 hours. At this concentration, there is no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality. In isolated cells and whole blood, silvestrol is more cytotoxic toward B cells than T cells. Silvestrol causes early reduction in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage, as evidenced by reactive oxygen species generation and membrane depolarization. In vivo, silvestrol causes significant B-cell reduction in Emu-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without discernible toxicity. These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias.",Journal Article,4004.0,118.0,Therapeutic options for advanced B-cell acute lymphoblastic ALL and chronic lymphocytic CLL are limited Available treatments can also deplete T lymphocytes leaving patients at risk of life-threatening infections In the National Cancer Institute cell line screen the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in and selectivity for B cells We investigated silvestrol efficacy using primary human B-leukemia cells established B-leukemia cell lines and animal models In CLL cells silvestrol LC 50 concentration lethal to 50 is 6.9 nM at 72 hours At this concentration there is no difference in sensitivity of cells from patients with or without the del 17p13.1 abnormality In isolated cells and whole blood silvestrol is more cytotoxic toward B cells than T cells Silvestrol causes early reduction in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage as evidenced by reactive oxygen species generation and membrane depolarization In vivo silvestrol causes significant B-cell reduction in Emu-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient SCID mice without discernible toxicity These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[189, 838, 9, 131, 132, 31, 286, 1275, 62, 2, 442, 1193, 552, 32, 383, 390, 640, 122, 120, 9450, 102, 1594, 7806, 7, 28, 43, 1, 358, 3691, 1875, 4, 3, 657, 12, 1377, 31, 328, 2413, 3, 8533, 991, 1504, 2821, 10015, 4042, 35, 4015, 1177, 1, 1408, 17, 844, 128, 4, 2, 6072, 9, 132, 37, 21, 565, 10015, 209, 75, 86, 171, 132, 2647, 37, 635, 132, 2647, 31, 285, 2, 2026, 274, 4, 552, 37, 10015, 1837, 212, 1227, 2266, 6, 212, 16, 49, 83, 2878, 28, 720, 1459, 28, 26, 1227, 125, 16, 77, 523, 4, 485, 1, 37, 29, 7, 5, 15, 187, 3, 3084, 7526, 14, 3698, 4, 1355, 37, 2, 902, 315, 10015, 16, 80, 759, 1317, 132, 37, 76, 102, 37, 10015, 1626, 191, 628, 4, 1308, 14, 55, 520, 6, 2460, 297, 5, 706, 2019, 1350, 22, 4728, 20, 2163, 2848, 2915, 914, 2, 1905, 14809, 4, 386, 10015, 1626, 93, 132, 31, 628, 4, 28315, 8885, 14, 2862, 399, 2, 97, 8464, 25, 1, 11989, 1330, 905, 397, 5031, 4129, 399, 187, 19070, 155, 46, 74, 1008, 10015, 71, 209, 480, 132, 37, 4, 439, 2, 4, 386, 2, 255, 2460, 297, 22, 8, 174, 189, 283, 4, 132, 31, 2792]",1414.0,19190247,43
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-02-17,"Response to front-line treatment and subsequent clinical course for patients with chronic lymphocytic leukemia (CLL) are heterogeneous. Identifying pretreatment patient characteristics or prognostic factors associated with clinical outcomes is important for counseling patients, conducting clinical research, and evaluating trial results. We evaluated the pretreatment characteristics of 595 previously untreated patients who had National Cancer Institute Working Group indications to initiate front-line therapy for predictors of complete response (CR), time to treatment failure (TTF), and overall survival (OS). Multivariable models were developed for all three end points. CR is an important treatment end point correlated with longer TTF and OS. In this retrospective analysis, front-line treatment regimen was a significant independent predictive factor for all three end points; chemoimmunotherapy was the superior treatment regimen. Considering front-line treatment regimen, other independent patient characteristics associated with CR included age and beta(2)-microglobulin (beta-2M). TTF was independently associated with age, beta-2M, percent lymphocytes in bone marrow, and treatment regimen. Improved OS was independently associated with younger age, lower beta-2M, and treatment regimen. Two weighted prognostic models or nomograms, one including and one excluding treatment regimen, were constructed using significant characteristics to predict 5- and 10-year survival probability and estimate median survival time. Identifying pretreatment patient characteristics associated with CR, TTF, and OS establishes a baseline to compare and incorporate new prognostic factors. Treatment had an impact on the significance of these factors. Prognostic models may help patients and clinicians in decision making as well as facilitate clinical research through design and analyses of clinical trials.",Journal Article,3990.0,60.0,Response to front-line treatment and subsequent clinical course for patients with chronic lymphocytic CLL are heterogeneous Identifying pretreatment patient characteristics or prognostic factors associated with clinical outcomes is important for counseling patients conducting clinical research and evaluating trial results We evaluated the pretreatment characteristics of 595 previously untreated patients who had National Cancer Institute Working Group indications to initiate front-line therapy for predictors of complete response CR time to treatment failure TTF and overall survival OS Multivariable models were developed for all three end points CR is an important treatment end point correlated with longer TTF and OS In this retrospective analysis front-line treatment regimen was a significant independent predictive factor for all three end points chemoimmunotherapy was the superior treatment regimen Considering front-line treatment regimen other independent patient characteristics associated with CR included age and beta 2 -microglobulin beta-2M TTF was independently associated with age beta-2M percent lymphocytes in marrow and treatment regimen Improved OS was independently associated with younger age lower beta-2M and treatment regimen Two weighted prognostic models or nomograms one including and one excluding treatment regimen were constructed using significant characteristics to predict 5- and 10-year survival probability and estimate median survival time Identifying pretreatment patient characteristics associated with CR TTF and OS establishes a baseline to compare and incorporate new prognostic factors Treatment had an impact on the significance of these factors Prognostic models may help patients and clinicians in decision making as well as facilitate clinical research through design and analyses of clinical trials,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[51, 6, 3007, 328, 24, 2, 706, 38, 906, 9, 7, 5, 442, 1193, 552, 32, 1564, 1386, 1194, 69, 374, 15, 177, 130, 41, 5, 38, 123, 16, 305, 9, 2011, 7, 6018, 38, 389, 2, 1435, 160, 99, 21, 194, 3, 1194, 374, 1, 11442, 373, 1278, 7, 54, 42, 657, 12, 1377, 2644, 87, 2406, 6, 4565, 3007, 328, 36, 9, 674, 1, 236, 51, 684, 98, 6, 24, 496, 4583, 2, 63, 25, 118, 658, 274, 11, 276, 9, 62, 169, 396, 862, 684, 16, 35, 305, 24, 396, 741, 438, 5, 589, 4583, 2, 118, 4, 26, 459, 65, 3007, 328, 24, 477, 10, 8, 93, 306, 464, 161, 9, 62, 169, 396, 862, 4438, 10, 3, 1123, 24, 477, 3075, 3007, 328, 24, 477, 127, 306, 69, 374, 41, 5, 684, 159, 89, 2, 1090, 18, 5371, 1090, 14237, 4583, 10, 1042, 41, 5, 89, 1090, 14237, 714, 1594, 4, 581, 2, 24, 477, 231, 118, 10, 1042, 41, 5, 773, 89, 280, 1090, 14237, 2, 24, 477, 100, 2337, 177, 274, 15, 4620, 104, 141, 2, 104, 3207, 24, 477, 11, 2776, 75, 93, 374, 6, 678, 33, 2, 79, 111, 25, 1320, 2, 1191, 52, 25, 98, 1386, 1194, 69, 374, 41, 5, 684, 4583, 2, 118, 7410, 8, 330, 6, 932, 2, 3360, 217, 177, 130, 24, 42, 35, 345, 23, 3, 724, 1, 46, 130, 177, 274, 68, 987, 7, 2, 1490, 4, 948, 1079, 22, 149, 22, 1876, 38, 389, 298, 771, 2, 318, 1, 38, 143]",1852.0,19224852,187
Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2009-02-01,"Chronic lymphocytic leukemia (CLL) is incurable with current chemotherapy treatments. Curcumin (diferuloylmethane), an active ingredient in the spice turmeric, inhibits tumor metastasis, invasion, and angiogenesis in tumor cell lines. We evaluated the effects of curcumin on the viability of primary CLL B cells and its ability to overcome stromal mediated protection. The in vitro effect of curcumin on primary CLL B cells was evaluated using fluorescence activated cell sorter analysis and Western blotting. For some experiments, CLL B cells were cocultured with human stromal cells to evaluate the effects of curcumin on leukemia cells cultured in their microenvironment. Finally, the effect of curcumin in combination with the green tea extract epigallocatechin-3 gallate (EGCG) was evaluated. Curcumin induced apoptosis in CLL B cells in a dose-dependent (5-20 micromol/L) manner and inhibited constitutively active prosurvival pathways, including signal transducers and activators of transcription 3 (STAT3), AKT, and nuclear factor kappaB. Moreover, curcumin suppressed expression of the anti-apoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), and up-regulated the pro-apoptotic protein BIM. Coculture of CLL B cells with stromal cells resulted in elevated levels of STAT3, increased expression of Mcl-1 and XIAP, and decreased sensitivity to curcumin. When curcumin was administered simultaneously with EGCG, antagonism was observed for most patient samples. In contrast, sequential administration of these agents led to substantial increases in CLL B-cell death and could overcome stromal protection. Curcumin treatment was able to overcome stromal protection of CLL B cells on in vitro testing and to synergize with EGCG when administered in a sequential fashion. Additional evaluation of curcumin as a potential therapeutic agent for treatment of CLL seems warranted.",Journal Article,4006.0,82.0,Chronic lymphocytic CLL is incurable with current chemotherapy treatments Curcumin diferuloylmethane an active ingredient in the spice turmeric inhibits tumor metastasis invasion and angiogenesis in tumor cell lines We evaluated the effects of curcumin on the viability of primary CLL B cells and its ability to overcome stromal mediated protection The in vitro effect of curcumin on primary CLL B cells was evaluated using fluorescence activated cell sorter analysis and Western blotting For some experiments CLL B cells were cocultured with human stromal cells to evaluate the effects of curcumin on cells cultured in their microenvironment Finally the effect of curcumin in combination with the green tea extract epigallocatechin-3 gallate EGCG was evaluated Curcumin induced apoptosis in CLL B cells in a dose-dependent 5-20 micromol/L manner and inhibited constitutively active prosurvival pathways including signal transducers and activators of transcription 3 STAT3 AKT and nuclear factor kappaB Moreover curcumin suppressed expression of the anti-apoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis protein XIAP and up-regulated the pro-apoptotic protein BIM Coculture of CLL B cells with stromal cells resulted in elevated levels of STAT3 increased expression of Mcl-1 and XIAP and decreased sensitivity to curcumin When curcumin was administered simultaneously with EGCG antagonism was observed for most patient samples In contrast sequential administration of these agents led to substantial increases in CLL B-cell death and could overcome stromal protection Curcumin treatment was able to overcome stromal protection of CLL B cells on in vitro testing and to synergize with EGCG when administered in a sequential fashion Additional evaluation of curcumin as a potential therapeutic agent for treatment of CLL seems warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 2641, 5, 291, 56, 640, 3775, 24733, 35, 544, 26729, 4, 3, 26028, 19471, 1576, 30, 278, 578, 2, 1056, 4, 30, 31, 285, 21, 194, 3, 176, 1, 3775, 23, 3, 2120, 1, 86, 552, 132, 37, 2, 211, 801, 6, 1768, 1126, 517, 3525, 3, 4, 439, 254, 1, 3775, 23, 86, 552, 132, 37, 10, 194, 75, 1591, 735, 31, 20221, 65, 2, 1521, 3661, 9, 476, 2332, 552, 132, 37, 11, 11444, 5, 171, 1126, 37, 6, 376, 3, 176, 1, 3775, 23, 37, 3197, 4, 136, 995, 1368, 3, 254, 1, 3775, 4, 150, 5, 3, 4658, 8854, 7164, 15613, 27, 15965, 7729, 10, 194, 3775, 277, 351, 4, 552, 132, 37, 4, 8, 61, 470, 33, 179, 6297, 805, 1708, 2, 879, 2818, 544, 7331, 460, 141, 1235, 11439, 2, 7751, 1, 866, 27, 1439, 649, 2, 928, 161, 2119, 1393, 3775, 1908, 55, 1, 3, 312, 1631, 652, 1308, 14, 2, 1006, 1199, 230, 1, 351, 178, 5387, 2, 126, 1065, 3, 1805, 1631, 178, 3595, 7604, 1, 552, 132, 37, 5, 1126, 37, 627, 4, 804, 148, 1, 1439, 101, 55, 1, 1308, 14, 2, 5387, 2, 340, 485, 6, 3775, 198, 3775, 10, 468, 3074, 5, 7729, 7537, 10, 164, 9, 96, 69, 347, 4, 748, 1787, 634, 1, 46, 183, 836, 6, 1281, 1106, 4, 552, 132, 31, 273, 2, 359, 1768, 1126, 3525, 3775, 24, 10, 1665, 6, 1768, 1126, 3525, 1, 552, 132, 37, 23, 4, 439, 471, 2, 6, 8717, 5, 7729, 198, 468, 4, 8, 1787, 3240, 402, 451, 1, 3775, 22, 8, 174, 189, 420, 9, 24, 1, 552, 2744, 1197]",1846.0,19228728,185
"Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.",Blood,Blood,2009-02-20,"Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription. Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9. We hypothesized that transient inhibition of transcription by SNS-032 would decrease antiapoptotic proteins, resulting in cell death. SNS-032 effectively killed chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history. This was associated with inhibition of phosphorylation of RNA polymerase II and inhibition of RNA synthesis. Consistent with the intrinsic turnover rates of their transcripts and proteins, antiapoptotic proteins, such as Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), were rapidly reduced on exposure to SNS-032, whereas Bcl-2 protein was not affected. The initial decrease of Mcl-1 protein was the result of transcriptional inhibition rather than cleavage by caspase. Compared with flavopiridol and roscovitine, SNS-032 was more potent, both in inhibition of RNA synthesis and at induction of apoptosis. SNS-032 activity was readily reversible; removal of SNS-032 reactivated RNA polymerase II, which led to resynthesis of Mcl-1 and cell survival. Thus, these data support the clinical development of SNS-032 in diseases that require short-lived oncoproteins for survival.",Journal Article,3987.0,105.0,Inhibitors of cyclin-dependent kinases Cdks have been reported to have activities in chronic lymphocytic cells by inhibiting Cdk7 and Cdk9 which control transcription Here we studied the novel Cdk inhibitor SNS-032 which exhibits potent and selective inhibitory activity against Cdk2 Cdk7 and Cdk9 We hypothesized that transient inhibition of transcription by SNS-032 would decrease antiapoptotic proteins resulting in cell death SNS-032 effectively killed chronic lymphocytic cells in vitro regardless of prognostic indicators and treatment history This was associated with inhibition of phosphorylation of RNA polymerase II and inhibition of RNA synthesis Consistent with the intrinsic turnover rates of their transcripts and proteins antiapoptotic proteins such as Mcl-1 and X-linked inhibitor of apoptosis protein XIAP were rapidly reduced on exposure to SNS-032 whereas Bcl-2 protein was not affected The initial decrease of Mcl-1 protein was the result of transcriptional inhibition rather than cleavage by caspase Compared with flavopiridol and roscovitine SNS-032 was more potent both in inhibition of RNA synthesis and at induction of apoptosis SNS-032 activity was readily reversible removal of SNS-032 reactivated RNA polymerase II which led to resynthesis of Mcl-1 and cell survival Thus these data support the clinical development of SNS-032 in diseases that require short-lived oncoproteins for survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[222, 1, 1226, 470, 1549, 9336, 47, 85, 210, 6, 47, 2042, 4, 442, 1193, 37, 20, 2062, 19055, 2, 11333, 92, 182, 866, 467, 21, 656, 3, 229, 3954, 230, 7323, 4708, 92, 4273, 1157, 2, 1094, 1810, 128, 480, 4547, 19055, 2, 11333, 21, 1237, 17, 2473, 297, 1, 866, 20, 7323, 4708, 688, 775, 4176, 652, 1113, 4, 31, 273, 7323, 4708, 1856, 8239, 442, 1193, 37, 4, 439, 1583, 1, 177, 3539, 2, 24, 532, 26, 10, 41, 5, 297, 1, 982, 1, 893, 1451, 215, 2, 297, 1, 893, 2525, 925, 5, 3, 2354, 5445, 151, 1, 136, 2680, 2, 652, 4176, 652, 225, 22, 1308, 14, 2, 1006, 1199, 230, 1, 351, 178, 5387, 11, 1755, 405, 23, 645, 6, 7323, 4708, 547, 1044, 18, 178, 10, 44, 1424, 3, 388, 775, 1, 1308, 14, 178, 10, 3, 757, 1, 1431, 297, 1832, 76, 3155, 20, 1469, 72, 5, 3030, 2, 11617, 7323, 4708, 10, 80, 1157, 110, 4, 297, 1, 893, 2525, 2, 28, 504, 1, 351, 7323, 4708, 128, 10, 3860, 2786, 2829, 1, 7323, 4708, 13566, 893, 1451, 215, 92, 836, 6, 57700, 1, 1308, 14, 2, 31, 25, 631, 46, 74, 538, 3, 38, 193, 1, 7323, 4708, 4, 1342, 17, 1353, 978, 4813, 8241, 9, 25]",1417.0,19234140,707
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",J. Immunother.,,"On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL. We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28. This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor. These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors. The validation requirements in terms of T-cell expansion, T-cell transduction with the 1928z CAR, biologic activity, quality control testing, and release criteria were met for all 4 validation runs using apheresis products from patients with CLL. Additionally, after expansion of the T cells, the diversity of the skewed Vbeta T-cell receptor repertoire was significantly restored. This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic leukemia. It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor.",Journal Article,,159.0,On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models we are launching phase I clinical trials in patients with chronic lymphocytic CLL and acute lymphoblastic We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine virus encoding a chimeric antigen receptor CAR targeted to CD19 1928z can be expanded with Dynabeads CD3/CD28 This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors The validation requirements in terms of T-cell expansion T-cell transduction with the 1928z CAR biologic activity quality control testing and release criteria were met for all 4 validation runs using apheresis products from patients with CLL Additionally after expansion of the T cells the diversity of the skewed Vbeta T-cell receptor repertoire was significantly restored This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[23, 3, 877, 1, 721, 693, 74, 2219, 3, 5173, 1, 403, 132, 31, 441, 20, 3158, 238, 102, 1594, 4, 386, 4, 905, 397, 5031, 16620, 830, 274, 21, 32, 28241, 124, 70, 38, 143, 4, 7, 5, 442, 1193, 552, 2, 286, 1275, 21, 364, 467, 3, 929, 1, 3, 34641, 92, 21, 276, 9, 3, 1529, 2, 1422, 1, 38, 88, 1028, 102, 37, 526, 29, 7, 5, 552, 21, 608, 17, 102, 37, 2301, 1230, 5, 8, 2079, 4552, 45448, 3374, 526, 29, 3, 33793, 1471, 1450, 2362, 8, 2897, 448, 153, 1881, 238, 6, 3158, 34642, 122, 40, 2064, 5, 57705, 3117, 5603, 26, 34641, 2333, 843, 6, 2562, 38, 415, 1, 34642, 102, 37, 4, 705, 18, 6, 27, 244, 4, 8, 375, 1124, 57706, 2099, 398, 75, 3, 10320, 38493, 46, 34642, 102, 37, 918, 2665, 583, 44, 158, 4, 439, 84, 120, 4, 905, 397, 5031, 16620, 399, 1894, 3605, 57, 3, 929, 4230, 4, 1794, 1, 102, 31, 1422, 102, 31, 2761, 5, 3, 34642, 1881, 1283, 128, 372, 182, 471, 2, 2008, 371, 11, 543, 9, 62, 39, 929, 31027, 75, 9456, 2766, 29, 7, 5, 552, 1724, 50, 1422, 1, 3, 102, 37, 3, 3653, 1, 3, 16082, 18819, 102, 31, 153, 5306, 10, 97, 4138, 26, 938, 1129, 303, 40, 95, 4, 124, 70, 38, 143, 4, 7, 5, 8923, 552, 2, 4, 7, 5, 591, 286, 1275, 192, 122, 120, 40, 3716, 9, 127, 38, 143, 1267, 3, 1422, 2, 2761, 1, 69, 15, 1488, 102, 37, 75, 500, 1881, 15, 102, 31, 153]",1713.0,19238016,206
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.,Proteomics,Proteomics,2009-03-01,"The in vitro evaluation of histones and their PTMs has drawn substantial interest in the development of epigenetic therapies. The differential expression of histone isoforms may serve as a potential marker in the classification of diseases affected by chromatin abnormalities. In this study, protein profiling by LC and MS was used to explore differences in histone composition in primary chronic lymphocytic leukemia (CLL) cells. Extensive method validations were performed to determine the experimental variances that would impact histone relative abundance. The resulting data demonstrated that the proposed methodology was suitable for the analysis of histone profiles. In 4 normal individuals and 40 CLL patients, a significant decrease in the relative abundance of histone H2A variants (H2AFL and H2AFA/M*) was observed in primary CLL cells as compared to normal B cells. Protein identities were determined using high mass accuracy MS and shotgun proteomics.",Journal Article,3978.0,20.0,The in vitro evaluation of histones and their PTMs has drawn substantial interest in the development of epigenetic therapies The differential expression of histone isoforms may serve as a potential marker in the classification of diseases affected by chromatin abnormalities In this study protein profiling by LC and MS was used to explore differences in histone composition in primary chronic lymphocytic CLL cells Extensive method validations were performed to determine the experimental variances that would impact histone relative abundance The resulting data demonstrated that the proposed methodology was suitable for the analysis of histone profiles In 4 normal individuals and 40 CLL patients a significant decrease in the relative abundance of histone H2A variants H2AFL and H2AFA/M* was observed in primary CLL cells as compared to normal B cells Protein identities were determined using high mass accuracy MS and shotgun proteomics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4, 439, 451, 1, 8457, 2, 136, 33402, 71, 5694, 1281, 1333, 4, 3, 193, 1, 1418, 235, 3, 1777, 55, 1, 1508, 3913, 68, 1833, 22, 8, 174, 952, 4, 3, 947, 1, 1342, 1424, 20, 2287, 1171, 4, 26, 45, 178, 1080, 20, 1837, 2, 2307, 10, 95, 6, 1645, 362, 4, 1508, 3761, 4, 86, 442, 1193, 552, 37, 1344, 596, 23553, 11, 173, 6, 223, 3, 1560, 24607, 17, 688, 345, 1508, 580, 4778, 3, 1113, 74, 264, 17, 3, 1587, 3209, 10, 2884, 9, 3, 65, 1, 1508, 1241, 4, 39, 295, 869, 2, 327, 552, 7, 8, 93, 775, 4, 3, 580, 4778, 1, 1508, 19741, 839, 57716, 2, 57717, 188, 10, 164, 4, 86, 552, 37, 22, 72, 6, 295, 132, 37, 178, 31415, 11, 509, 75, 64, 782, 1190, 2307, 2, 26798, 6478]",942.0,19253275,49
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2008-03-01,"Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), a genetic aberration that codes for bcrabl, which plays a key role in disease pathophysiology. The first oral inhibitor of Brc-Abl was imatinib, which also targets KIT and platelet-derived growth factor receptor kinase and has demonstrated improved outcomes when compared with interferon, the previous standard of care. Imatinib resistance and intolerance have been an issue for patients, and as a result, new therapeutic approaches have been evaluated. Dose-escalated imatinib (800 mg daily) has shown some limited activity in patients with imatinib-resistant CML, but the development of second-generation tyrosine kinase inhibitors has broadened the treatment options. Dasatinib is also an oral kinase inhibitor, but it has increased potency for Brc-Abl compared with imatinib. Dasatinib has demonstrated activity in all phases of CML and Ph+ acute lymphocytic leukemia and is approved for the treatment of adults in this setting. Recent phase III data have demonstrated that, in patients with chronic-phase CML, dasatinib 100 mg once daily is equally effective, with improved tolerability, compared with the previously approved 70-mg twice-daily dose. Nilotinib, which has been recently approved, has increased potency for Brc-Abl compared with imatinib and has demonstrated activity in patients with imatinib-resistant and -intolerant chronic- and accelerated-phase CML. As experience with these agents continues to mature, we might optimize the treatment efficacy and safety profiles by altering dose regimens.",Journal Article,4343.0,3.0,Chronic myeloid CML is characterized by the presence of the Philadelphia chromosome Ph a genetic aberration that codes for bcrabl which plays a key role in disease pathophysiology The first oral inhibitor of Brc-Abl was imatinib which also targets KIT and platelet-derived growth factor receptor kinase and has demonstrated improved outcomes when compared with interferon the previous standard of care Imatinib resistance and intolerance have been an issue for patients and as a result new therapeutic approaches have been evaluated Dose-escalated imatinib 800 mg daily has shown some limited activity in patients with imatinib-resistant CML but the development of second-generation tyrosine kinase inhibitors has broadened the treatment options Dasatinib is also an oral kinase inhibitor but it has increased potency for Brc-Abl compared with imatinib Dasatinib has demonstrated activity in all phases of CML and Ph+ acute lymphocytic and is approved for the treatment of adults in this setting Recent phase III data have demonstrated that in patients with chronic-phase CML dasatinib 100 mg once daily is equally effective with improved tolerability compared with the previously approved 70-mg twice-daily dose Nilotinib which has been recently approved has increased potency for Brc-Abl compared with imatinib and has demonstrated activity in patients with imatinib-resistant and -intolerant chronic- and accelerated-phase CML As experience with these agents continues to mature we might optimize the treatment efficacy and safety profiles by altering dose regimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 533, 903, 16, 765, 20, 3, 463, 1, 3, 3006, 1170, 2058, 8, 336, 7794, 17, 5271, 9, 57718, 92, 1698, 8, 825, 200, 4, 34, 4320, 3, 157, 518, 230, 1, 19184, 1425, 10, 577, 92, 120, 637, 1164, 2, 1596, 526, 129, 161, 153, 216, 2, 71, 264, 231, 123, 198, 72, 5, 1688, 3, 698, 260, 1, 165, 577, 251, 2, 5266, 47, 85, 35, 2537, 9, 7, 2, 22, 8, 757, 217, 189, 611, 47, 85, 194, 61, 2842, 577, 2796, 81, 391, 71, 443, 476, 383, 128, 4, 7, 5, 577, 436, 903, 84, 3, 193, 1, 419, 914, 564, 216, 222, 71, 16626, 3, 24, 838, 1674, 16, 120, 35, 518, 216, 230, 84, 192, 71, 101, 3593, 9, 19184, 1425, 72, 5, 577, 1674, 71, 264, 128, 4, 62, 3523, 1, 903, 2, 2058, 286, 1193, 2, 16, 850, 9, 3, 24, 1, 857, 4, 26, 546, 435, 124, 316, 74, 47, 264, 17, 4, 7, 5, 442, 124, 903, 1674, 394, 81, 1059, 391, 16, 4142, 323, 5, 231, 1543, 72, 5, 3, 373, 850, 431, 81, 936, 391, 61, 2638, 92, 71, 85, 761, 850, 71, 101, 3593, 9, 19184, 1425, 72, 5, 577, 2, 71, 264, 128, 4, 7, 5, 577, 436, 2, 4944, 442, 2, 2241, 124, 903, 22, 730, 5, 46, 183, 2274, 6, 2908, 21, 822, 2465, 3, 24, 209, 2, 367, 1241, 20, 4831, 61, 472]",1568.0,19254884,440
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-03-02,"Smudge cells are ruptured chronic lymphocytic leukemia (CLL) cells appearing on the blood smears of CLL patients. Our recent findings suggest that the number of smudge cells may have important biologic correlations rather than being only an artifact of slide preparation. In this study, we evaluated whether the smudge cell percentage on a blood smear predicted survival of CLL patients. We calculated smudge cell percentages (ratio of smudged to intact cells plus smudged lymphocytes) on archived blood smears from a cohort of previously untreated patients with predominantly early-stage CLL enrolled onto a prospective observational study. The relationship between percentage of smudge cells, patient survival, and other prognostic factors was explored. Between 1994 and 2002, 108 patients were enrolled onto the study and had archived blood smears available for review; 80% of patients had Rai stage 0 or I disease. The median smudge cell percentage was 28% (range, 1% to 75%). The percentage of smudge cells was lower in CD38(+) versus CD38(-) patients (P = .019) and in Zap70-positive versus Zap70-negative patients (P = .028). Smudge cell percentage as a continuous variable was associated with prolonged survival (P = .042). The 10-year survival rate was 50% for patients with 30% or less smudge cells compared with 80% for patients with more than 30% of smudge cells (P = .015). In multivariate analysis, the percentage of smudge cells was an independent predictor of overall survival. Percentage of smudge cells on blood smear is readily available and an independent factor predicting overall survival in CLL.",Journal Article,3977.0,50.0,Smudge cells are ruptured chronic lymphocytic CLL cells appearing on the blood smears of CLL patients Our recent findings suggest that the number of smudge cells may have important biologic correlations rather than being only an artifact of slide preparation In this study we evaluated whether the smudge cell percentage on a blood smear predicted survival of CLL patients We calculated smudge cell percentages ratio of smudged to intact cells plus smudged lymphocytes on archived blood smears from a cohort of previously untreated patients with predominantly early-stage CLL enrolled onto a prospective observational study The relationship between percentage of smudge cells patient survival and other prognostic factors was explored Between 1994 and 2002 108 patients were enrolled onto the study and had archived blood smears available for review 80 of patients had Rai stage 0 or I disease The median smudge cell percentage was 28 range 1 to 75 The percentage of smudge cells was lower in CD38 versus CD38 patients P .019 and in Zap70-positive versus Zap70-negative patients P .028 Smudge cell percentage as a continuous variable was associated with prolonged survival P .042 The 10-year survival rate was 50 for patients with 30 or less smudge cells compared with 80 for patients with more than 30 of smudge cells P .015 In multivariate analysis the percentage of smudge cells was an independent predictor of overall survival Percentage of smudge cells on blood smear is readily available and an independent factor predicting overall survival in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[14969, 37, 32, 18937, 442, 1193, 552, 37, 6536, 23, 3, 315, 8916, 1, 552, 7, 114, 435, 272, 309, 17, 3, 207, 1, 14969, 37, 68, 47, 305, 1283, 2553, 1832, 76, 486, 158, 35, 14759, 1, 7911, 4824, 4, 26, 45, 21, 194, 317, 3, 14969, 31, 1150, 23, 8, 315, 8379, 783, 25, 1, 552, 7, 21, 981, 14969, 31, 5504, 197, 1, 38420, 6, 2964, 37, 349, 38420, 1594, 23, 6282, 315, 8916, 29, 8, 180, 1, 373, 1278, 7, 5, 2117, 191, 82, 552, 346, 3301, 8, 482, 2495, 45, 3, 858, 59, 1150, 1, 14969, 37, 69, 25, 2, 127, 177, 130, 10, 1443, 59, 3023, 2, 1544, 3590, 7, 11, 346, 3301, 3, 45, 2, 42, 6282, 315, 8916, 390, 9, 206, 493, 1, 7, 42, 4121, 82, 13, 15, 70, 34, 3, 52, 14969, 31, 1150, 10, 339, 184, 14, 6, 481, 3, 1150, 1, 14969, 37, 10, 280, 4, 4469, 185, 4469, 7, 19, 4049, 2, 4, 12921, 109, 185, 12921, 199, 7, 19, 4836, 14969, 31, 1150, 22, 8, 1314, 1347, 10, 41, 5, 1069, 25, 19, 5606, 3, 79, 111, 25, 116, 10, 212, 9, 7, 5, 201, 15, 299, 14969, 37, 72, 5, 493, 9, 7, 5, 80, 76, 201, 1, 14969, 37, 19, 3433, 4, 331, 65, 3, 1150, 1, 14969, 37, 10, 35, 306, 980, 1, 63, 25, 1150, 1, 14969, 37, 23, 315, 8379, 16, 3860, 390, 2, 35, 306, 161, 1434, 63, 25, 4, 552]",1554.0,19255329,42
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.,Blood,Blood,2009-03-24,"Phosphoinositide 3-kinases (PI3Ks) are among the most frequently activated signaling pathways in cancer. In chronic lymphocytic leukemia (CLL), signals from the microenvironment are critical for expansion of the malignant B cells, and cause constitutive activation of PI3Ks. CXCR4 is a key receptor for CLL cell migration and adhesion to marrow stromal cells (MSCs). Because of the importance of CXCR4 and PI3Ks for CLL-microenvironment cross-talk, we investigated the activity of novel, isoform-selective PI3K inhibitors that target different isoforms of the p110-kDa subunit. Inhibition with p110alpha inhibitors (PIK-90 and PI-103) resulted in a significant reduction of chemotaxis and actin polymerization to CXCL12 and reduced migration beneath MSC (pseudoemperipolesis). Western blot and reverse phase protein array analyses consistently demonstrated that PIK-90 and PI-103 inhibited phosphorylation of Akt and S6, whereas p110delta or p110beta/p110delta inhibitors were less effective. In suspension and MSC cocultures, PI-103 and PIK-90 were potent inducers of CLL cell apoptosis. Moreover, these p110alpha inhibitors enhanced the cytotoxicity of fludarabine and reversed the protective effect of MSC on fludarabine-induced apoptosis. Collectively, our data demonstrate that p110alpha inhibitors antagonize stromal cell-derived migration, survival, and drug-resistance signals and therefore provide a rational to explore the therapeutic activity of these promising agents in CLL.",Journal Article,3955.0,111.0,Phosphoinositide 3-kinases PI3Ks are among the most frequently activated signaling pathways in cancer In chronic lymphocytic CLL signals from the microenvironment are critical for expansion of the malignant B cells and cause constitutive activation of PI3Ks CXCR4 is a key receptor for CLL cell migration and adhesion to marrow stromal cells MSCs Because of the importance of CXCR4 and PI3Ks for CLL-microenvironment cross-talk we investigated the activity of novel isoform-selective PI3K inhibitors that target different isoforms of the p110-kDa subunit Inhibition with p110alpha inhibitors PIK-90 and PI-103 resulted in a significant reduction of chemotaxis and actin polymerization to CXCL12 and reduced migration beneath MSC pseudoemperipolesis Western blot and reverse phase protein array analyses consistently demonstrated that PIK-90 and PI-103 inhibited phosphorylation of Akt and S6 whereas p110delta or p110beta/p110delta inhibitors were less effective In suspension and MSC cocultures PI-103 and PIK-90 were potent inducers of CLL cell apoptosis Moreover these p110alpha inhibitors enhanced the cytotoxicity of fludarabine and reversed the protective effect of MSC on fludarabine-induced apoptosis Collectively our data demonstrate that p110alpha inhibitors antagonize stromal cell-derived migration survival and drug-resistance signals and therefore provide a rational to explore the therapeutic activity of these promising agents in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[4497, 27, 1549, 38948, 32, 107, 3, 96, 746, 735, 314, 460, 4, 12, 4, 442, 1193, 552, 2312, 29, 3, 995, 32, 740, 9, 1422, 1, 3, 393, 132, 37, 2, 708, 3178, 363, 1, 38948, 2318, 16, 8, 825, 153, 9, 552, 31, 1381, 2, 2128, 6, 581, 1126, 37, 4460, 408, 1, 3, 1187, 1, 2318, 2, 38948, 9, 552, 995, 1383, 6522, 21, 565, 3, 128, 1, 229, 3995, 1094, 974, 222, 17, 283, 338, 3913, 1, 3, 23068, 6362, 3350, 297, 5, 18183, 222, 38949, 424, 2, 2928, 3283, 627, 4, 8, 93, 628, 1, 12561, 2, 5525, 12273, 6, 5807, 2, 405, 1381, 17080, 4150, 38950, 1521, 2639, 2, 1772, 124, 178, 1926, 318, 2433, 264, 17, 38949, 424, 2, 2928, 3283, 879, 982, 1, 649, 2, 4977, 547, 25154, 15, 45472, 25154, 222, 11, 299, 323, 4, 9348, 2, 4150, 16398, 2928, 3283, 2, 38949, 424, 11, 1157, 12780, 1, 552, 31, 351, 1393, 46, 18183, 222, 651, 3, 1408, 1, 2027, 2, 3682, 3, 2864, 254, 1, 4150, 23, 2027, 277, 351, 2535, 114, 74, 608, 17, 18183, 222, 12718, 1126, 31, 526, 1381, 25, 2, 234, 251, 2312, 2, 673, 377, 8, 2696, 6, 1645, 3, 189, 128, 1, 46, 721, 183, 4, 552]",1449.0,19318683,76
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.,Blood,Blood,2009-03-31,"The molecular mechanism of autocrine regulation of vascular endothelial growth factor (VEGF) in chronic lymphocytic leukemia (CLL) B cells is unknown. Here, we report that CLL B cells express constitutive levels of HIF-1alpha under normoxia. We have examined the status of the von Hippel-Lindau gene product (pVHL) that is responsible for HIF-1alpha degradation and found it to be at a notably low level in CLL B cells compared with normal B cells. We demonstrate that the microRNA, miR-92-1, overexpressed in CLL B cells, can target the VHL transcript to repress its expression. We found that the stabilized HIF-1alpha can form an active complex with the transcriptional coactivator p300 and phosphorylated-STAT3 at the VEGF promoter and recruit RNA polymerase II. This is initial evidence that pVHL, without any genetic alteration, can be regulated by microRNA and explains the aberrant autocrine VEGF secretion in CLL.",Journal Article,3948.0,93.0,The molecular mechanism of autocrine regulation of vascular endothelial growth factor VEGF in chronic lymphocytic CLL B cells is unknown Here we report that CLL B cells express constitutive levels of HIF-1alpha under normoxia We have examined the status of the von Hippel-Lindau gene product pVHL that is responsible for HIF-1alpha degradation and found it to be at a notably low level in CLL B cells compared with normal B cells We demonstrate that the microRNA miR-92-1 overexpressed in CLL B cells can target the VHL transcript to repress its expression We found that the stabilized HIF-1alpha can form an active complex with the transcriptional coactivator p300 and phosphorylated-STAT3 at the VEGF promoter and recruit RNA polymerase II This is initial evidence that pVHL without any genetic alteration can be regulated by microRNA and explains the aberrant autocrine VEGF secretion in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 219, 670, 1, 5297, 863, 1, 756, 845, 129, 161, 618, 4, 442, 1193, 552, 132, 37, 16, 860, 467, 21, 414, 17, 552, 132, 37, 1669, 3178, 148, 1, 2940, 5018, 669, 20448, 21, 47, 409, 3, 156, 1, 3, 6430, 7703, 7704, 145, 2821, 13253, 17, 16, 2327, 9, 2940, 5018, 2373, 2, 204, 192, 6, 40, 28, 8, 2552, 154, 301, 4, 552, 132, 37, 72, 5, 295, 132, 37, 21, 608, 17, 3, 3213, 722, 937, 14, 1711, 4, 552, 132, 37, 122, 283, 3, 3808, 3268, 6, 11385, 211, 55, 21, 204, 17, 3, 7368, 2940, 5018, 122, 1297, 35, 544, 840, 5, 3, 1431, 8777, 10685, 2, 2365, 1439, 28, 3, 618, 973, 2, 8973, 893, 1451, 215, 26, 16, 388, 241, 17, 13253, 187, 500, 336, 2611, 122, 40, 1065, 20, 3213, 2, 10558, 3, 1898, 5297, 618, 2935, 4, 552]",894.0,19336759,31
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2009-03-01,"We evaluated the clinical activity of GM-CSF in combination with standard dose rituximab in patients with chronic lymphocytic leukemia (CLL). The rationale for exploring this combination is provided by the ability of GM-CSF to increase surface expression of CD20 in CLL cells and potentially render them a better target for rituximab. GM-CSF also enhances antibody-dependent cellular cytotoxicity against CLL cells. The combination of GM-CSF and rituximab was evaluated as initial treatment in elderly patients with indication for treatment and in patients at high risk for progression identified by elevated beta(2) microglobulin. This combination was also evaluated in patients with recurrent CLL. On the basis of the results of 118 patients, we observed an overall response rate of 65 and 9% complete remission and these results compare favourably with the results obtained with rituximab single agent. This combination was well tolerated with the most common toxicity consisting in mild GM-CSF injection site erythema. On the basis of this experience, we are currently evaluating the use of GM-CSF in combination with the chemoimmunotherapy regimen fludarabine, cyclophosphamide and rituximab.","Clinical Trial, Phase II",3978.0,15.0,We evaluated the clinical activity of GM-CSF in combination with standard dose rituximab in patients with chronic lymphocytic CLL The rationale for exploring this combination is provided by the ability of GM-CSF to increase surface expression of CD20 in CLL cells and potentially render them a better target for rituximab GM-CSF also enhances antibody-dependent cellular cytotoxicity against CLL cells The combination of GM-CSF and rituximab was evaluated as initial treatment in elderly patients with indication for treatment and in patients at high risk for progression identified by elevated beta 2 microglobulin This combination was also evaluated in patients with recurrent CLL On the basis of the results of 118 patients we observed an overall response rate of 65 and 9 complete remission and these results compare favourably with the results obtained with rituximab single agent This combination was well tolerated with the most common toxicity consisting in mild GM-CSF injection site erythema On the basis of this experience we are currently evaluating the use of GM-CSF in combination with the chemoimmunotherapy regimen fludarabine cyclophosphamide and rituximab,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 3, 38, 128, 1, 2147, 1211, 4, 150, 5, 260, 61, 855, 4, 7, 5, 442, 1193, 552, 3, 1728, 9, 4378, 26, 150, 16, 1052, 20, 3, 801, 1, 2147, 1211, 6, 344, 1255, 55, 1, 2198, 4, 552, 37, 2, 751, 7873, 1370, 8, 380, 283, 9, 855, 2147, 1211, 120, 2519, 548, 470, 763, 1408, 480, 552, 37, 3, 150, 1, 2147, 1211, 2, 855, 10, 194, 22, 388, 24, 4, 1216, 7, 5, 3607, 9, 24, 2, 4, 7, 28, 64, 43, 9, 91, 108, 20, 804, 1090, 18, 5371, 26, 150, 10, 120, 194, 4, 7, 5, 387, 552, 23, 3, 877, 1, 3, 99, 1, 4002, 7, 21, 164, 35, 63, 51, 116, 1, 556, 2, 83, 236, 734, 2, 46, 99, 932, 20557, 5, 3, 99, 683, 5, 855, 226, 420, 26, 150, 10, 149, 421, 5, 3, 96, 186, 155, 2273, 4, 1980, 2147, 1211, 1754, 606, 9167, 23, 3, 877, 1, 26, 730, 21, 32, 694, 1435, 3, 119, 1, 2147, 1211, 4, 150, 5, 3, 4438, 477, 2027, 1112, 2, 855]",1173.0,19347738,224
IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrm's macroglobulinemia.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-03-01,"Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14%) developed non-Hodgkin lymphoma (n = 17), Waldenstrm's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years.",Journal Article,3978.0,30.0,Immunoglobulin M monoclonal gammopathy of undetermined significance IgM-MUS was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994 During long-term follow-up 29 14 developed n 17 Waldenstrm 's macroglobulinemia WM n 6 chronic lymphocytic n 3 and AL amyloidosis n 3 with relative risks of 15- 262- 6- and 16-fold respectively The cumulative probability of progression to one of these disorders was 10 at 5 years 18 at 10 years and 24 at 15 years approximately 1.5 per year Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995 During follow-up 33 of the 48 patients progressed to symptomatic WM The median time to progression was 4.6 years The risk of progression to WM was 6 at 1 year 39 at 3 years and 55 at 5 years,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2593, 188, 848, 5334, 1, 5206, 724, 2852, 23614, 10, 265, 4, 5833, 2486, 1188, 7, 54, 11, 5662, 1, 175, 8257, 4, 20167, 8297, 29, 10391, 6, 3023, 190, 319, 337, 166, 126, 462, 213, 276, 78, 269, 3700, 292, 3389, 1518, 78, 49, 442, 1193, 78, 27, 2, 2171, 3919, 78, 27, 5, 580, 1098, 1, 167, 7801, 49, 2, 245, 1116, 106, 3, 967, 1320, 1, 91, 6, 104, 1, 46, 1997, 10, 79, 28, 33, 60, 203, 28, 79, 60, 2, 259, 28, 167, 60, 705, 14, 33, 379, 111, 7091, 1518, 10, 108, 4, 576, 7, 28, 2486, 1188, 29, 10201, 6, 2323, 190, 166, 126, 466, 1, 3, 576, 7, 1839, 6, 1704, 1518, 3, 52, 98, 6, 91, 10, 39, 49, 60, 3, 43, 1, 91, 6, 1518, 10, 49, 28, 14, 111, 587, 28, 27, 60, 2, 614, 28, 33, 60]",805.0,19362962,16
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2009-04-01,"We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days). The median age was 66 years and 71% were males. Study participants received a median of 2 (range 1-7) prior treatment regimens and 61% had Rai stage 3-4 disease at enrollment. Grade 3 or higher hematologic toxicity was observed in 13 (46%) and 16 (57%) had grade 3 or higher non-hematologic toxicity. Grade 3-4 tumor flare was observed in five (18%) patients. The overall response rate was 11% (3 of 28) with one (4%) complete remission and two (7%) partial remissions. Duration of response for these three responders was 3, 14 and 15 months. Fourteen (50%) patients had stabilisation of disease for a median duration of 8 months (95% CI: 7-16 months). Median time to progression for all 28 patients was 7.3 months. Although thalidomide appears to have modest clinical activity in pretreated/relapsed CLL primarily based on reduction of the absolute lymphocyte count, in our opinion the toxicity profile precludes it from more active investigation in CLL.","Clinical Trial, Phase II",3947.0,14.0,We enrolled 28 eligible patients with relapsed chronic lymphocytic CLL to a phase II study of single agent thalidomide 200 mg/d with dose escalation up to 1000 mg/d over 60 days The median age was 66 years and 71 were males Study participants received a median of 2 range 1-7 prior treatment regimens and 61 had Rai stage 3-4 disease at enrollment Grade 3 or higher hematologic toxicity was observed in 13 46 and 16 57 had grade 3 or higher non-hematologic toxicity Grade 3-4 tumor flare was observed in five 18 patients The overall response rate was 11 3 of 28 with one 4 complete remission and two 7 partial remissions Duration of response for these three responders was 3 14 and 15 months Fourteen 50 patients had stabilisation of disease for a median duration of 8 months 95 CI 7-16 months Median time to progression for all 28 patients was 7.3 months Although thalidomide appears to have modest clinical activity in pretreated/relapsed CLL primarily based on reduction of the absolute lymphocyte count in our opinion the toxicity profile precludes it from more active investigation in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 346, 339, 625, 7, 5, 591, 442, 1193, 552, 6, 8, 124, 215, 45, 1, 226, 420, 2159, 1250, 81, 427, 5, 61, 1125, 126, 6, 2345, 81, 427, 252, 335, 162, 3, 52, 89, 10, 700, 60, 2, 792, 11, 2296, 45, 776, 103, 8, 52, 1, 18, 184, 14, 67, 324, 24, 472, 2, 713, 42, 4121, 82, 27, 39, 34, 28, 1798, 88, 27, 15, 142, 813, 155, 10, 164, 4, 233, 641, 2, 245, 696, 42, 88, 27, 15, 142, 220, 813, 155, 88, 27, 39, 30, 6915, 10, 164, 4, 365, 203, 7, 3, 63, 51, 116, 10, 175, 27, 1, 339, 5, 104, 39, 236, 734, 2, 100, 67, 450, 3166, 654, 1, 51, 9, 46, 169, 1983, 10, 27, 213, 2, 167, 53, 3225, 212, 7, 42, 24742, 1, 34, 9, 8, 52, 654, 1, 66, 53, 48, 58, 67, 245, 53, 52, 98, 6, 91, 9, 62, 339, 7, 10, 67, 27, 53, 242, 2159, 1233, 6, 47, 1721, 38, 128, 4, 2193, 591, 552, 1561, 90, 23, 628, 1, 3, 1766, 1448, 1276, 4, 114, 3564, 3, 155, 800, 11593, 192, 29, 80, 544, 940, 4, 552]",1093.0,19373657,300
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.,Cancer research,Cancer Res.,2009-04-21,"Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been found in patients with B-cell malignancies and autoimmune diseases, suggesting that it may play a pathogenic role. We previously found that a single nucleotide polymorphism (SNP) in the TNFSF13B promoter resulted in increased transcription, suggesting that genetic variation in TNFSF13B may influence its expression. We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non-Hogkin lymphoma (NHL) risk. We genotyped 9 tagSNPs within TNFSF13B in a clinic-based study of 441 NHL cases and 475 matched controls and evaluated the association of individual SNPs with risk of NHL; 3 tagSNPs were significant (P < 0.05). When categorized into low-, moderate-, and high-risk groups based on risk alleles, we found the permutation-corrected odds ratio for the trend to be 1.43 (P = 0.0019) for risk of B-cell NHL, 1.69 (P = 0.0093) for diffuse large B-cell lymphoma, 1.43 (P = 0.029) for follicular lymphoma, and 1.06 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma. The mean serum BAFF level in those who carried the low-risk alleles was 2 ng/mL compared with 4.3 ng/mL in those with the high-risk alleles (P = 0.02). Taken together, our data suggest that genetic variation in the TNFSF13B gene is significantly associated with NHL risk and elevated serum BAFF levels.",Journal Article,3927.0,48.0,Elevated B-cell-activating factor BAFF TNFSF13B levels have been found in patients with B-cell malignancies and autoimmune diseases suggesting that it may play a pathogenic role We previously found that a single nucleotide polymorphism SNP in the TNFSF13B promoter resulted in increased transcription suggesting that genetic variation in TNFSF13B may influence its expression We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non-Hogkin NHL risk We genotyped 9 tagSNPs within TNFSF13B in a clinic-based study of 441 NHL cases and 475 matched controls and evaluated the association of individual SNPs with risk of NHL 3 tagSNPs were significant P 0.05 When categorized into low- moderate- and high-risk groups based on risk alleles we found the permutation-corrected odds ratio for the trend to be 1.43 P 0.0019 for risk of B-cell NHL 1.69 P 0.0093 for diffuse large B-cell 1.43 P 0.029 for follicular and 1.06 P 0.21 for chronic lymphocytic leukemia/small lymphocytic The mean serum BAFF level in those who carried the low-risk alleles was 2 ng/mL compared with 4.3 ng/mL in those with the high-risk alleles P 0.02 Taken together our data suggest that genetic variation in the TNFSF13B gene is significantly associated with NHL risk and elevated serum BAFF levels,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[804, 132, 31, 1616, 161, 6587, 26812, 148, 47, 85, 204, 4, 7, 5, 132, 31, 441, 2, 3445, 1342, 802, 17, 192, 68, 1343, 8, 2806, 200, 21, 373, 204, 17, 8, 226, 1579, 1907, 1845, 4, 3, 26812, 973, 627, 4, 101, 866, 802, 17, 336, 1380, 4, 26812, 68, 1054, 211, 55, 21, 673, 7931, 6, 223, 492, 336, 1380, 4, 26812, 16, 41, 5, 64, 6587, 148, 2, 220, 57834, 1176, 43, 21, 3053, 83, 14954, 262, 26812, 4, 8, 1188, 90, 45, 1, 10258, 1176, 140, 2, 9201, 655, 535, 2, 194, 3, 248, 1, 797, 1109, 5, 43, 1, 1176, 27, 14954, 11, 93, 19, 13, 474, 198, 2320, 237, 154, 1163, 2, 64, 43, 271, 90, 23, 43, 2558, 21, 204, 3, 10479, 3848, 610, 197, 9, 3, 853, 6, 40, 14, 601, 19, 13, 12960, 9, 43, 1, 132, 31, 1176, 14, 790, 19, 13, 26813, 9, 1388, 375, 132, 31, 14, 601, 19, 13, 4770, 9, 1974, 2, 14, 1460, 19, 13, 239, 9, 442, 1193, 2647, 302, 1193, 3, 313, 524, 6587, 301, 4, 135, 54, 2629, 3, 154, 43, 2558, 10, 18, 997, 542, 72, 5, 39, 27, 997, 542, 4, 135, 5, 3, 64, 43, 2558, 19, 13, 588, 1633, 1162, 114, 74, 309, 17, 336, 1380, 4, 3, 26812, 145, 16, 97, 41, 5, 1176, 43, 2, 804, 524, 6587, 148]",1319.0,19383901,323
Treatment of fludarabine-refractory chronic lymphocytic leukemia.,Cancer,Cancer,2009-07-01,"The development of resistance to purine analogs defines a poor-risk subset of patients with chronic lymphocytic leukemia (CLL). Although in recent years chemoimmunotherapeutic combinations such as fludarabine, cyclophosphamide, and rituximab have induced response rates of 95% in previously untreated patients and increased the rates of failure-free survival, CLL remains incurable for many patients because of a lack of disease response or the development of refractoriness to fludarabine. Fludarabine-refractory disease is defined as CLL that does not respond to fludarabine or that recurs within 6 months of treatment with a fludarabine-containing regimen. The natural course of the disease is associated with poor survival. Salvage therapeutic strategies include alemtuzumab-containing regimens, targeted agents, and allogeneic stem cell transplantation. Single-agent alemtuzumab induces response in up to 40% of patients with fludarabine-refractory CLL, but responses are not durable, and the median survival is approximately 1 to 2 years. Alemtuzumab is also combined with fludarabine, cyclophosphamide, and/or rituximab, and other agents such as lenalidomide and flavopiridol, as well as targeted agents, and used in fludarabine-refractory CLL. Cumulative evidence suggests that allogeneic stem cell transplantation is an efficacious therapeutic strategy for patients who do not respond to fludarabine or who develop disease recurrence within 12 months after purine analog treatment. In conclusion, chemoimmunotherapy regimens that include alemtuzumab and/or rituximab and allogeneic stem cell transplantation improve the prognosis of this disease, but there is a continued need for novel, more effective therapies.",Journal Article,3856.0,51.0,The development of resistance to purine analogs defines a poor-risk subset of patients with chronic lymphocytic CLL Although in recent years chemoimmunotherapeutic combinations such as fludarabine cyclophosphamide and rituximab have induced response rates of 95 in previously untreated patients and increased the rates of failure-free survival CLL remains incurable for many patients because of a lack of disease response or the development of refractoriness to fludarabine Fludarabine-refractory disease is defined as CLL that does not respond to fludarabine or that recurs within 6 months of treatment with a fludarabine-containing regimen The natural course of the disease is associated with poor survival Salvage therapeutic strategies include alemtuzumab-containing regimens targeted agents and allogeneic stem cell transplantation Single-agent alemtuzumab induces response in up to 40 of patients with fludarabine-refractory CLL but responses are not durable and the median survival is approximately 1 to 2 years Alemtuzumab is also combined with fludarabine cyclophosphamide and/or rituximab and other agents such as lenalidomide and flavopiridol as well as targeted agents and used in fludarabine-refractory CLL Cumulative evidence suggests that allogeneic stem cell transplantation is an efficacious therapeutic strategy for patients who do not respond to fludarabine or who develop disease recurrence within 12 months after purine analog treatment In conclusion chemoimmunotherapy regimens that include alemtuzumab and/or rituximab and allogeneic stem cell transplantation improve the prognosis of this disease but there is a continued need for novel more effective therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 193, 1, 251, 6, 5006, 4063, 5849, 8, 334, 43, 697, 1, 7, 5, 442, 1193, 552, 242, 4, 435, 60, 45519, 1247, 225, 22, 2027, 1112, 2, 855, 47, 277, 51, 151, 1, 48, 4, 373, 1278, 7, 2, 101, 3, 151, 1, 496, 115, 25, 552, 469, 2641, 9, 445, 7, 408, 1, 8, 926, 1, 34, 51, 15, 3, 193, 1, 12483, 6, 2027, 2027, 430, 34, 16, 395, 22, 552, 17, 1097, 44, 1892, 6, 2027, 15, 17, 12172, 262, 49, 53, 1, 24, 5, 8, 2027, 1101, 477, 3, 1504, 906, 1, 3, 34, 16, 41, 5, 334, 25, 992, 189, 422, 643, 3579, 1101, 472, 238, 183, 2, 1063, 452, 31, 497, 226, 420, 3579, 1516, 51, 4, 126, 6, 327, 1, 7, 5, 2027, 430, 552, 84, 253, 32, 44, 1480, 2, 3, 52, 25, 16, 705, 14, 6, 18, 60, 3579, 16, 120, 397, 5, 2027, 1112, 2, 15, 855, 2, 127, 183, 225, 22, 1288, 2, 3030, 22, 149, 22, 238, 183, 2, 95, 4, 2027, 430, 552, 967, 241, 844, 17, 1063, 452, 31, 497, 16, 35, 3289, 189, 692, 9, 7, 54, 1022, 44, 1892, 6, 2027, 15, 54, 690, 34, 146, 262, 133, 53, 50, 5006, 3497, 24, 4, 1221, 4438, 472, 17, 643, 3579, 2, 15, 855, 2, 1063, 452, 31, 497, 401, 3, 356, 1, 26, 34, 84, 125, 16, 8, 1351, 594, 9, 229, 80, 323, 235]",1685.0,19402170,374
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.,Blood,Blood,2009-05-04,"To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p- CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.",Journal Article,3914.0,130.0,To determine the clinical fate of patients with de novo deletion 17p13.1 17p- chronic lymphocytic CLL we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center n 64 and the Mayo Clinic n 35 Among 67 asymptomatic patients followed for progression 53 developed CLL requiring treatment over 3 years Patients who had not progressed by 18 months subsequently had stable disease with 3 of 19 patients progressing after follow-up of up to 70 months Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain IgVH The overall survival rate was 65 at 3 years Rai stage 1 or higher unmutated IgVH and 17p- in 25 or more of nuclei were adverse factors for survival The 3-year survival rates of patients with 1 or fewer 2 and 3 of these factors were 95 74 and 22 respectively P .001 Response rates to therapy with rituximab n 6 purine analogues and rituximab n 25 and purine analogues rituximab and alemtuzumab n 16 combinations were 50 72 and 81 respectively Patients with 17p- CLL exhibit clinical heterogeneity with some patients experiencing an indolent course Survival can be predicted using clinical and biologic characteristics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 223, 3, 38, 7878, 1, 7, 5, 1566, 2018, 1528, 7526, 14, 4135, 442, 1193, 552, 21, 894, 656, 3, 228, 1, 1058, 24, 2462, 4135, 552, 7, 29, 3, 188, 427, 1929, 12, 574, 78, 660, 2, 3, 2486, 1188, 78, 465, 107, 598, 2100, 7, 370, 9, 91, 699, 276, 552, 1888, 24, 252, 27, 60, 7, 54, 42, 44, 1839, 20, 203, 53, 1611, 42, 585, 34, 5, 27, 1, 326, 7, 4527, 50, 166, 126, 1, 126, 6, 431, 53, 43, 130, 9, 1014, 34, 11, 4121, 82, 1, 14, 15, 142, 2, 7216, 2593, 1347, 1053, 4013, 1260, 14484, 3, 63, 25, 116, 10, 556, 28, 27, 60, 4121, 82, 14, 15, 142, 7216, 14484, 2, 4135, 4, 243, 15, 80, 1, 4725, 11, 290, 130, 9, 25, 3, 27, 111, 25, 151, 1, 7, 5, 14, 15, 1497, 18, 2, 27, 1, 46, 130, 11, 48, 794, 2, 350, 106, 19, 144, 51, 151, 6, 36, 5, 855, 78, 49, 5006, 4768, 2, 855, 78, 243, 2, 5006, 4768, 855, 2, 3579, 78, 245, 1247, 11, 212, 720, 2, 865, 106, 7, 5, 4135, 552, 2239, 38, 1144, 5, 476, 7, 2985, 35, 2316, 906, 25, 122, 40, 783, 75, 38, 2, 1283, 374]",1246.0,19414856,764
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-05-26,"To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic leukemia (CLL). Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation. Polyphenon E with a standardized dose of epigallocatechin-3-gallate (EGCG) was administered using the standard phase I design with three to six patients per dose level (range, 400 to 2,000 mg by mouth twice a day). Trough plasma EGCG levels were measured 1 month after initiation of therapy. Response was classified using the National Cancer Institute (NCI) Working Group (WG) Criteria. Thirty-three eligible patients were accrued to dose levels 1 to 8. The maximum-tolerated dose was not reached. The most common adverse effects included transaminitis (33%, all grade 1), abdominal pain (30% grade 1, 0% grade 2, and 3% grade 3), and nausea (39% grade 1 and 9% grade 2). One patient experienced an NCI WG partial remission. Other signs of clinical activity were also observed, with 11 patients (33%) having a sustained > or = 20% reduction in absolute lymphocyte count (ALC) and 11 (92%) of 12 patients with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all nodal areas during treatment. Trough plasma EGCG levels after 1 month of treatment ranged from 2.9 to 3,974 ng/mL (median, 40.4 ng/mL). Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase I trial. Declines in ALC and/or lymphadenopathy were observed in the majority of patients. A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.","Clinical Trial, Phase I",3892.0,114.0,"To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic CLL Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation Polyphenon E with a standardized dose of epigallocatechin-3-gallate EGCG was administered using the standard phase I design with three to six patients per dose level range 400 to 2,000 mg by mouth twice a day Trough plasma EGCG levels were measured 1 month after initiation of therapy Response was classified using the National Cancer Institute NCI Working Group WG Criteria Thirty-three eligible patients were accrued to dose levels 1 to 8 The maximum-tolerated dose was not reached The most common adverse effects included transaminitis 33 all grade 1 abdominal pain 30 grade 1 0 grade 2 and 3 grade 3 and nausea 39 grade 1 and 9 grade 2 One patient experienced an NCI WG partial remission Other signs of clinical activity were also observed with 11 patients 33 having a sustained or 20 reduction in absolute lymphocyte count ALC and 11 92 of 12 patients with palpable adenopathy experiencing at least a 50 reduction in the sum of the products of all nodal areas during treatment Trough plasma EGCG levels after 1 month of treatment ranged from 2.9 to 3,974 ng/mL median 40.4 ng/mL Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase I trial Declines in ALC and/or lymphadenopathy were observed in the majority of patients A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 1107, 3, 665, 61, 1, 22545, 563, 9, 442, 391, 634, 2, 1543, 4, 7, 5, 442, 1193, 552, 373, 1278, 7, 5, 2100, 4121, 82, 13, 6, 215, 552, 11, 625, 9, 2599, 22545, 563, 5, 8, 1670, 61, 1, 15613, 27, 15965, 7729, 10, 468, 75, 3, 260, 124, 70, 771, 5, 169, 6, 437, 7, 379, 61, 301, 184, 1524, 6, 18, 984, 81, 20, 5831, 936, 8, 218, 6000, 554, 7729, 148, 11, 644, 14, 811, 50, 1118, 1, 36, 51, 10, 1373, 75, 3, 657, 12, 1377, 2580, 2644, 87, 12906, 371, 977, 169, 625, 7, 11, 3198, 6, 61, 148, 14, 6, 66, 3, 689, 421, 61, 10, 44, 1300, 3, 96, 186, 290, 176, 159, 8181, 466, 62, 88, 14, 1467, 559, 201, 88, 14, 13, 88, 18, 2, 27, 88, 27, 2, 1218, 587, 88, 14, 2, 83, 88, 18, 104, 69, 592, 35, 2580, 12906, 450, 734, 127, 3408, 1, 38, 128, 11, 120, 164, 5, 175, 7, 466, 1041, 8, 2275, 15, 179, 628, 4, 1766, 1448, 1276, 3749, 2, 175, 937, 1, 133, 7, 5, 4880, 7741, 2985, 28, 506, 8, 212, 628, 4, 3, 3216, 1, 3, 2766, 1, 62, 779, 1361, 190, 24, 6000, 554, 7729, 148, 50, 14, 811, 1, 24, 1869, 29, 18, 83, 6, 27, 17847, 997, 542, 52, 327, 39, 997, 542, 391, 518, 7729, 4, 3, 22545, 563, 4824, 10, 149, 421, 20, 552, 7, 4, 26, 124, 70, 160, 4264, 4, 3749, 2, 15, 4962, 11, 164, 4, 3, 686, 1, 7, 8, 124, 215, 160, 6, 376, 209, 75, 18, 984, 81, 936, 8, 218, 4603, 4, 2868, 1307]",1593.0,19470922,226
"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.",Blood,Blood,2009-06-02,"Antigenic stimulation through the B-cell antigen receptor (BCR) is considered to promote the expansion of chronic lymphocytic leukemia (CLL) B cells. The spleen tyrosine kinase (Syk), a key component of BCR signaling, can be blocked by R406, a small-molecule Syk inhibitor, that displayed activity in CLL patients in a first clinical trial. In this study, we investigated the effects of BCR stimulation and R406 on CLL cell survival and migration. The prosurvival effects promoted by anti-IgM stimulation and nurselike cells were abrogated by R406. BCR triggering up-regulated adhesion molecules, and increased CLL cell migration toward the chemokines CXCL12 and CXCL13. BCR activation also enhanced CLL cell migration beneath marrow stromal cells. These responses were blocked by R406, which furthermore abrogated BCR-dependent secretion of T-cell chemokines (CCL3 and CCL4) by CLL cells. Finally, R406 inhibited constitutive and BCR-induced activation of Syk, extracellular signal-regulated kinases, and AKT, and blocked BCR-induced calcium mobilization. These findings suggest that BCR activation favors CLL cell homing, retention, and survival in tissue microenvironments. R406 effectively blocks these BCR-dependent responses in CLL cells, providing an explanation for the activity of R406 in patients with CLL.",Journal Article,3885.0,185.0,Antigenic stimulation through the B-cell antigen receptor BCR is considered to promote the expansion of chronic lymphocytic CLL B cells The spleen tyrosine kinase Syk a key component of BCR signaling can be blocked by R406 a small-molecule Syk inhibitor that displayed activity in CLL patients in a first clinical trial In this study we investigated the effects of BCR stimulation and R406 on CLL cell survival and migration The prosurvival effects promoted by anti-IgM stimulation and nurselike cells were abrogated by R406 BCR triggering up-regulated adhesion molecules and increased CLL cell migration toward the chemokines CXCL12 and CXCL13 BCR activation also enhanced CLL cell migration beneath marrow stromal cells These responses were blocked by R406 which furthermore abrogated BCR-dependent secretion of T-cell chemokines CCL3 and CCL4 by CLL cells Finally R406 inhibited constitutive and BCR-induced activation of Syk extracellular signal-regulated kinases and AKT and blocked BCR-induced calcium mobilization These findings suggest that BCR activation favors CLL cell homing retention and survival in tissue microenvironments R406 effectively blocks these BCR-dependent responses in CLL cells providing an explanation for the activity of R406 in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[8357, 2503, 298, 3, 132, 31, 448, 153, 1062, 16, 515, 6, 1617, 3, 1422, 1, 442, 1193, 552, 132, 37, 3, 4071, 564, 216, 6792, 8, 825, 1249, 1, 1062, 314, 122, 40, 2582, 20, 18529, 8, 302, 1354, 6792, 230, 17, 2507, 128, 4, 552, 7, 4, 8, 157, 38, 160, 4, 26, 45, 21, 565, 3, 176, 1, 1062, 2503, 2, 18529, 23, 552, 31, 25, 2, 1381, 3, 7331, 176, 2992, 20, 312, 2852, 2503, 2, 28698, 37, 11, 3728, 20, 18529, 1062, 8867, 126, 1065, 2128, 1598, 2, 101, 552, 31, 1381, 1317, 3, 4906, 5807, 2, 9462, 1062, 363, 120, 651, 552, 31, 1381, 17080, 581, 1126, 37, 46, 253, 11, 2582, 20, 18529, 92, 798, 3728, 1062, 470, 2935, 1, 102, 31, 4906, 9711, 2, 12660, 20, 552, 37, 1368, 18529, 879, 3178, 2, 1062, 277, 363, 1, 6792, 1976, 1235, 1065, 1549, 2, 649, 2, 2582, 1062, 277, 3299, 4030, 46, 272, 309, 17, 1062, 363, 13054, 552, 31, 5515, 3947, 2, 25, 4, 246, 9912, 18529, 1856, 2860, 46, 1062, 470, 253, 4, 552, 37, 1736, 35, 6603, 9, 3, 128, 1, 18529, 4, 7, 5, 552]",1275.0,19491390,120
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.,Cancer,Cancer,2009-09-01,"Patients with purine analogue-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. Defining the best salvage strategies for this population is challenging, because limited data are available from clinical trials, and because studies have enrolled mixed populations (patients with recurrent and refractory disease or patients with refractory disease and Richter transformation). Moreover, patients with refractory CLL have a high incidence of unfavorable molecular and clinical features, such as high-risk genomic profiles, unmutated immunoglobulin heavy-chain genes, expression of zeta-chain-associated protein kinase 70, and bulky lymphadenopathies. These patients are also severely immunosuppressed because of the underlying disease and the treatments received, and experience a high rate of infectious complications that pose an additional difficulty in selecting treatment. Despite these challenges, in parallel with better characterizations of the biologic features of refractory CLL, the number of available treatment modalities for this population has increased. Several chemoimmunotherapy combinations have been developed, and novel agents with a different mechanism of action are being investigated in clinical trials. Furthermore, allogeneic stem cell transplantation with nonmyeloablative conditioning regimens is a therapeutic strategy that is increasingly offered to patients with refractory CLL.",Journal Article,3794.0,11.0,Patients with purine analogue-refractory chronic lymphocytic CLL have short survival and limited treatment options Defining the best salvage strategies for this population is challenging because limited data are available from clinical trials and because studies have enrolled mixed populations patients with recurrent and refractory disease or patients with refractory disease and Richter transformation Moreover patients with refractory CLL have a high incidence of unfavorable molecular and clinical features such as high-risk genomic profiles unmutated immunoglobulin heavy-chain genes expression of zeta-chain-associated protein kinase 70 and bulky lymphadenopathies These patients are also severely immunosuppressed because of the underlying disease and the treatments received and experience a high rate of infectious complications that pose an additional difficulty in selecting treatment Despite these challenges in parallel with better characterizations of the biologic features of refractory CLL the number of available treatment modalities for this population has increased Several chemoimmunotherapy combinations have been developed and novel agents with a different mechanism of action are being investigated in clinical trials Furthermore allogeneic stem cell transplantation with nonmyeloablative conditioning regimens is a therapeutic strategy that is increasingly offered to patients with refractory CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 5006, 4696, 430, 442, 1193, 552, 47, 978, 25, 2, 383, 24, 838, 2847, 3, 824, 992, 422, 9, 26, 266, 16, 1950, 408, 383, 74, 32, 390, 29, 38, 143, 2, 408, 94, 47, 346, 1739, 1184, 7, 5, 387, 2, 430, 34, 15, 7, 5, 430, 34, 2, 8452, 1392, 1393, 7, 5, 430, 552, 47, 8, 64, 287, 1, 2483, 219, 2, 38, 404, 225, 22, 64, 43, 572, 1241, 7216, 2593, 4013, 1260, 214, 55, 1, 12105, 1260, 41, 178, 216, 431, 2, 4112, 39022, 46, 7, 32, 120, 7207, 12749, 408, 1, 3, 1181, 34, 2, 3, 640, 103, 2, 730, 8, 64, 116, 1, 3398, 521, 17, 6015, 35, 402, 4035, 4, 3675, 24, 550, 46, 1427, 4, 2755, 5, 380, 19668, 1, 3, 1283, 404, 1, 430, 552, 3, 207, 1, 390, 24, 1558, 9, 26, 266, 71, 101, 392, 4438, 1247, 47, 85, 276, 2, 229, 183, 5, 8, 338, 670, 1, 1578, 32, 486, 565, 4, 38, 143, 798, 1063, 452, 31, 497, 5, 6094, 1933, 472, 16, 8, 189, 692, 17, 16, 1635, 2216, 6, 7, 5, 430, 552]",1421.0,19536902,609
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2009-07-10,"Dysregulation of the sonic hedgehog (SHH) signaling pathway has been shown in several cancer types, but has not been explored in diffuse large B-cell lymphoma. We assessed 67 cases of diffuse large B-cell lymphoma for expression of SHH (ligand), GLI1, GLI2 and GLI3 (transcriptional effectors of SHH signaling), and the ATP-binding cassette (ABC)G2 (a downstream target of SHH signaling), using immunohistochemistry. For comparison, we assessed the expression levels of these proteins in 28 cases of follicular lymphoma, 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, and 5 reactive lymph nodes. In diffuse large B-cell lymphoma, SHH was expressed in 61 of 67 (91%) cases, GLI1 in 62 of 67 (93%), GLI2 in 41 of 56 (73%), and GLI3 in 22 of 56 (39%). Expression of ABCG2 was detected in 52 of 55 (95%) cases and was high in 15 (27%) cases. SHH expression positively correlated with expression levels of ABCG2 (P=0.05). Patients with diffuse large B-cell lymphoma with high ABCG2 expression showed significantly shorter overall survival (P=0.031) and failure-free survival (P=0.029) compared with patients with tumors with low or no expression of ABCG2. Diffuse large B-cell lymphomas expressed SHH, and GLI1, GLI2, and GLI3 more frequently and more intensely than cases of follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. In conclusion, our data show that SHH signaling proteins and ABCG2 are aberrantly expressed in diffuse large B-cell lymphoma and that ABCG2 expression has prognostic implications. These findings also provide evidence that dysregulation of the SHH pathway may be involved in the pathogenesis of diffuse large B-cell lymphoma.",Comparative Study,3847.0,67.0,Dysregulation of the sonic hedgehog SHH signaling pathway has been shown in several cancer types but has not been explored in diffuse large B-cell We assessed 67 cases of diffuse large B-cell for expression of SHH ligand GLI1 GLI2 and GLI3 transcriptional effectors of SHH signaling and the ATP-binding cassette ABC G2 a downstream target of SHH signaling using immunohistochemistry For comparison we assessed the expression levels of these proteins in 28 cases of follicular 5 chronic lymphocytic leukemia/small lymphocytic and 5 reactive lymph nodes In diffuse large B-cell SHH was expressed in 61 of 67 91 cases GLI1 in 62 of 67 93 GLI2 in 41 of 56 73 and GLI3 in 22 of 56 39 Expression of ABCG2 was detected in 52 of 55 95 cases and was high in 15 27 cases SHH expression positively correlated with expression levels of ABCG2 P=0.05 Patients with diffuse large B-cell with high ABCG2 expression showed significantly shorter overall survival P=0.031 and failure-free survival P=0.029 compared with patients with tumors with low or no expression of ABCG2 Diffuse large B-cell lymphomas expressed SHH and GLI1 GLI2 and GLI3 more frequently and more intensely than cases of follicular or chronic lymphocytic leukemia/small lymphocytic In conclusion our data show that SHH signaling proteins and ABCG2 are aberrantly expressed in diffuse large B-cell and that ABCG2 expression has prognostic implications These findings also provide evidence that dysregulation of the SHH pathway may be involved in the pathogenesis of diffuse large B-cell,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3935, 1, 3, 10025, 4097, 5170, 314, 308, 71, 85, 443, 4, 392, 12, 630, 84, 71, 44, 85, 1443, 4, 1388, 375, 132, 31, 21, 275, 598, 140, 1, 1388, 375, 132, 31, 9, 55, 1, 5170, 1232, 5124, 14637, 2, 25181, 1431, 4926, 1, 5170, 314, 2, 3, 3918, 791, 10548, 5106, 3774, 8, 1489, 283, 1, 5170, 314, 75, 888, 9, 1155, 21, 275, 3, 55, 148, 1, 46, 652, 4, 339, 140, 1, 1974, 33, 442, 1193, 2647, 302, 1193, 2, 33, 2163, 263, 502, 4, 1388, 375, 132, 31, 5170, 10, 570, 4, 713, 1, 598, 970, 140, 5124, 4, 744, 1, 598, 966, 14637, 4, 605, 1, 664, 803, 2, 25181, 4, 350, 1, 664, 587, 55, 1, 6447, 10, 530, 4, 653, 1, 614, 48, 140, 2, 10, 64, 4, 167, 428, 140, 5170, 55, 2375, 438, 5, 55, 148, 1, 6447, 19, 13, 474, 7, 5, 1388, 375, 132, 31, 5, 64, 6447, 55, 224, 97, 985, 63, 25, 19, 13, 5304, 2, 496, 115, 25, 19, 13, 4770, 72, 5, 7, 5, 57, 5, 154, 15, 77, 55, 1, 6447, 1388, 375, 132, 31, 1557, 570, 5170, 2, 5124, 14637, 2, 25181, 80, 746, 2, 80, 20549, 76, 140, 1, 1974, 15, 442, 1193, 2647, 302, 1193, 4, 1221, 114, 74, 514, 17, 5170, 314, 652, 2, 6447, 32, 5619, 570, 4, 1388, 375, 132, 31, 2, 17, 6447, 55, 71, 177, 1268, 46, 272, 120, 377, 241, 17, 3935, 1, 3, 5170, 308, 68, 40, 646, 4, 3, 1384, 1, 1388, 375, 132, 31]",1538.0,19593328,280
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-07-20,"The diagnosis of monoclonal B-cell lymphocytosis (MBL) is used to characterize patients with a circulating population of clonal B cells, a total B-cell count of less than 5 x 10(9)/L, and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/organomegaly. The natural history of clinically identified MBL is unclear. The goal of this study was to explore the outcome of patients with MBL relative to that of individuals with Rai stage 0 chronic lymphocytic leukemia (CLL). We used hematopathology records to identify a cohort of 631 patients with newly diagnosed MBL or Rai stage 0 CLL. Within this cohort, 302 patients had MBL (B-cell counts of 0.02 to 4.99 x 10(9)/L); 94 patients had Rai stage 0 CLL with an absolute lymphocyte count (ALC) < or = 10 x 10(9)/L; and 219 patients had Rai stage 0 CLL with an ALC more than 10 x 10(9)/L. Data on clinical outcome were abstracted from medical records. The percentage of MBL patients free of treatment at 1, 2, and 5 years was 99%, 98%, and 93%, respectively. B-cell count as a continuous variable (hazard ratio [HR] = 2.9, P = .04) and CD38 status (HR = 10.8, P = .006) predicted time to treatment (TTT) among MBL patients. The likelihood of treatment for MBL patients was lower (HR = 0.32, P = .04) than that of both Rai stage 0 CLL patients with an ALC less than 10 x 10(9)/L (n = 94) and Rai stage 0 CLL patients with an ALC more than 10 x 10(9)/L (n = 219; P = .0003). Individuals with MBL identified in clinical practice have a low risk for progression at 5 years. Because B-cell count seems to relate to TTT as a continuous variable, additional studies are needed to determine what B-cell count should be used to distinguish between MBL and CLL.",Comparative Study,3837.0,100.0,The diagnosis of monoclonal B-cell lymphocytosis MBL is used to characterize patients with a circulating population of clonal B cells a total B-cell count of less than 5 x 10 9 /L and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/organomegaly The natural history of clinically identified MBL is unclear The goal of this study was to explore the outcome of patients with MBL relative to that of individuals with Rai stage 0 chronic lymphocytic CLL We used hematopathology records to identify a cohort of 631 patients with newly diagnosed MBL or Rai stage 0 CLL Within this cohort 302 patients had MBL B-cell counts of 0.02 to 4.99 x 10 9 /L 94 patients had Rai stage 0 CLL with an absolute lymphocyte count ALC or 10 x 10 9 /L and 219 patients had Rai stage 0 CLL with an ALC more than 10 x 10 9 /L Data on clinical outcome were abstracted from medical records The percentage of MBL patients free of treatment at 1 2 and 5 years was 99 98 and 93 respectively B-cell count as a continuous variable hazard ratio HR 2.9 P .04 and CD38 status HR 10.8 P .006 predicted time to treatment TTT among MBL patients The likelihood of treatment for MBL patients was lower HR 0.32 P .04 than that of both Rai stage 0 CLL patients with an ALC less than 10 x 10 9 /L n 94 and Rai stage 0 CLL patients with an ALC more than 10 x 10 9 /L n 219 P .0003 Individuals with MBL identified in clinical practice have a low risk for progression at 5 years Because B-cell count seems to relate to TTT as a continuous variable additional studies are needed to determine what B-cell count should be used to distinguish between MBL and CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 147, 1, 848, 132, 31, 8125, 8992, 16, 95, 6, 1507, 7, 5, 8, 1033, 266, 1, 1946, 132, 37, 8, 181, 132, 31, 1276, 1, 299, 76, 33, 1006, 79, 83, 805, 2, 77, 127, 404, 1, 8, 132, 31, 4192, 2645, 141, 4962, 16738, 3, 1504, 532, 1, 505, 108, 8992, 16, 1200, 3, 1326, 1, 26, 45, 10, 6, 1645, 3, 228, 1, 7, 5, 8992, 580, 6, 17, 1, 869, 5, 4121, 82, 13, 442, 1193, 552, 21, 95, 30197, 1064, 6, 255, 8, 180, 1, 14576, 7, 5, 732, 265, 8992, 15, 4121, 82, 13, 552, 262, 26, 180, 4952, 7, 42, 8992, 132, 31, 1911, 1, 13, 588, 6, 39, 1058, 1006, 79, 83, 805, 960, 7, 42, 4121, 82, 13, 552, 5, 35, 1766, 1448, 1276, 3749, 15, 79, 1006, 79, 83, 805, 2, 6679, 7, 42, 4121, 82, 13, 552, 5, 35, 3749, 80, 76, 79, 1006, 79, 83, 805, 74, 23, 38, 228, 11, 4106, 29, 484, 1064, 3, 1150, 1, 8992, 7, 115, 1, 24, 28, 14, 18, 2, 33, 60, 10, 1058, 1096, 2, 966, 106, 132, 31, 1276, 22, 8, 1314, 1347, 360, 197, 168, 18, 83, 19, 755, 2, 4469, 156, 168, 79, 66, 19, 1861, 783, 98, 6, 24, 10630, 107, 8992, 7, 3, 1420, 1, 24, 9, 8992, 7, 10, 280, 168, 13, 531, 19, 755, 76, 17, 1, 110, 4121, 82, 13, 552, 7, 5, 35, 3749, 299, 76, 79, 1006, 79, 83, 805, 78, 960, 2, 4121, 82, 13, 552, 7, 5, 35, 3749, 80, 76, 79, 1006, 79, 83, 805, 78, 6679, 19, 4418, 869, 5, 8992, 108, 4, 38, 758, 47, 8, 154, 43, 9, 91, 28, 33, 60, 408, 132, 31, 1276, 2744, 6, 6509, 6, 10630, 22, 8, 1314, 1347, 402, 94, 32, 575, 6, 223, 2067, 132, 31, 1276, 257, 40, 95, 6, 3081, 59, 8992, 2, 552]",1648.0,19620484,66
JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).,Leukemia research,Leuk. Res.,2009-07-22,"JAK2 mutation has not been described in patients with chronic lymphocytic leukemia (CLL). We found JAK2 mutation in a patient with CLL and coexisting myeloproliferative neoplasm (MPN). In this patient, we demonstrated the presence of the JAK2 mutation in CD34(+) progenitor cells, myeloid lineage cells, megakaryocytes, B lymphocytes but not in T lymphocytes. This case represents the first case report of JAK2 mutation in CLL and may also suggest that, JAK2 mutation most likely represents a secondary event from primary gene mutations involving the primitive stem cells which give rise to MPN and CLL. Furthermore, in this case, we believe that we are the first to demonstrate that JAK2 mutation in myeloid and B lymphoid cells but not T lymphocytes in a case of coexisting CLL and MPN.",Case Reports,3835.0,19.0,JAK2 mutation has not been described in patients with chronic lymphocytic CLL We found JAK2 mutation in a patient with CLL and coexisting neoplasm MPN In this patient we demonstrated the presence of the JAK2 mutation in CD34 progenitor cells myeloid lineage cells megakaryocytes B lymphocytes but not in T lymphocytes This case represents the first case report of JAK2 mutation in CLL and may also suggest that JAK2 mutation most likely represents a secondary event from primary gene mutations involving the primitive stem cells which give rise to MPN and CLL Furthermore in this case we believe that we are the first to demonstrate that JAK2 mutation in myeloid and B lymphoid cells but not T lymphocytes in a case of coexisting CLL and MPN,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2509, 258, 71, 44, 85, 1027, 4, 7, 5, 442, 1193, 552, 21, 204, 2509, 258, 4, 8, 69, 5, 552, 2, 8859, 2131, 4125, 4, 26, 69, 21, 264, 3, 463, 1, 3, 2509, 258, 4, 2215, 2520, 37, 533, 2542, 37, 15110, 132, 1594, 84, 44, 4, 102, 1594, 26, 473, 1449, 3, 157, 473, 414, 1, 2509, 258, 4, 552, 2, 68, 120, 309, 17, 2509, 258, 96, 322, 1449, 8, 568, 774, 29, 86, 145, 138, 1267, 3, 5594, 452, 37, 92, 4978, 3693, 6, 4125, 2, 552, 798, 4, 26, 473, 21, 4629, 17, 21, 32, 3, 157, 6, 608, 17, 2509, 258, 4, 533, 2, 132, 2303, 37, 84, 44, 102, 1594, 4, 8, 473, 1, 8859, 552, 2, 4125]",741.0,19625083,81
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2009-10-01,"Radioimmunotherapy (RIT) with radio-labeled monoclonal antibodies to CD20 produce a high response rate in patients with relapsed lymphoma. Use of this modality in patients with chronic lymphocytic leukemia (CLL) has been hampered by the extensive marrow involvement seen in patients with CLL, which would produce a high risk for marrow aplasia after treatment with RIT. Patients with lymphoma and marrow involvement have been treated with RIT if involved marrow was less than 25% of the total marrow. Thus, we adapted this approach as consolidation therapy in patients with CLL responding to chemoimmunotherapy. Fourteen patients with relapsed CLL either in partial remission or in complete remission but with disease documented by flow cytometry were treated with (90)Y ibritumomab tiuxetan. One patient responded and achieved a complete remission but with residual disease detected by flow cytometry. Of note was that grade 3 or 4 hematologic toxicity was seen in 12 of the 13 (92%) evaluable patients, with grade 3 or 4 thrombocytopenia noted in 11 (85%) of the patients. In addition, myelosuppression was prolonged with a median duration of grade 3 or 4 thrombocytopenia of 37 days. Five patients had persistent thrombocytopenia 3 months post-therapy. Even in patients with CLL and limited marrow involvement, the use of RIT results in unacceptable hematologic toxicity.","Clinical Trial, Phase II",3764.0,14.0,Radioimmunotherapy RIT with radio-labeled monoclonal antibodies to CD20 produce a high response rate in patients with relapsed Use of this modality in patients with chronic lymphocytic CLL has been hampered by the extensive marrow involvement seen in patients with CLL which would produce a high risk for marrow aplasia after treatment with RIT Patients with and marrow involvement have been treated with RIT if involved marrow was less than 25 of the total marrow Thus we adapted this approach as consolidation therapy in patients with CLL responding to chemoimmunotherapy Fourteen patients with relapsed CLL either in partial remission or in complete remission but with disease documented by flow cytometry were treated with 90 Y ibritumomab tiuxetan One patient responded and achieved a complete remission but with residual disease detected by flow cytometry Of note was that grade 3 or 4 hematologic toxicity was seen in 12 of the 13 92 evaluable patients with grade 3 or 4 thrombocytopenia noted in 11 85 of the patients In addition myelosuppression was prolonged with a median duration of grade 3 or 4 thrombocytopenia of 37 days Five patients had persistent thrombocytopenia 3 months post-therapy Even in patients with CLL and limited marrow involvement the use of RIT results in unacceptable hematologic toxicity,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5862, 6313, 5, 6477, 2841, 848, 890, 6, 2198, 2410, 8, 64, 51, 116, 4, 7, 5, 591, 119, 1, 26, 1396, 4, 7, 5, 442, 1193, 552, 71, 85, 6786, 20, 3, 1344, 581, 799, 527, 4, 7, 5, 552, 92, 688, 2410, 8, 64, 43, 9, 581, 12307, 50, 24, 5, 6313, 7, 5, 2, 581, 799, 47, 85, 73, 5, 6313, 492, 646, 581, 10, 299, 76, 243, 1, 3, 181, 581, 631, 21, 3716, 26, 353, 22, 2173, 36, 4, 7, 5, 552, 3261, 6, 4438, 3225, 7, 5, 591, 552, 361, 4, 450, 734, 15, 4, 236, 734, 84, 5, 34, 1405, 20, 1412, 1914, 11, 73, 5, 424, 2055, 5251, 5294, 104, 69, 2211, 2, 513, 8, 236, 734, 84, 5, 753, 34, 530, 20, 1412, 1914, 1, 5739, 10, 17, 88, 27, 15, 39, 813, 155, 10, 527, 4, 133, 1, 3, 233, 937, 859, 7, 5, 88, 27, 15, 39, 1340, 1051, 4, 175, 772, 1, 3, 7, 4, 352, 2858, 10, 1069, 5, 8, 52, 654, 1, 88, 27, 15, 39, 1340, 1, 567, 162, 365, 7, 42, 1882, 1340, 27, 53, 539, 36, 871, 4, 7, 5, 552, 2, 383, 581, 799, 3, 119, 1, 6313, 99, 4, 3215, 813, 155]",1320.0,19637351,106
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2009-07-28,"Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the Emu-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from Emu-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-kappaB p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-kappaB components in CLL and potentially other B-cell malignancies.",Journal Article,3829.0,68.0,Epigenetic alterations including gain or loss of DNA methylation are a hallmark of nearly every malignancy Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors Because such epigenetic changes are reversible they are being aggressively investigated as potential therapeutic targets Here we use the Emu-TCL1 transgenic mouse model of chronic lymphocytic CLL to determine the timing and patterns of aberrant DNA methylation and to investigate the mechanisms that lead to aberrant DNA methylation We show that CLL cells from Emu-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals well before disease onset Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3 We show that loss of Foxd3 expression due to an NF-kappaB p50/p50 HDAC1 repressor complex occurs in TCL1-positive B cells before methylation Therefore specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL These results provide strong rationale for the development of strategies to target NF-kappaB components in CLL and potentially other B-cell malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1418, 593, 141, 1803, 15, 407, 1, 261, 569, 32, 8, 4683, 1, 1857, 454, 710, 400, 4, 261, 569, 122, 345, 55, 1, 12, 139, 214, 141, 351, 3196, 2, 30, 5704, 408, 225, 1418, 400, 32, 2786, 491, 32, 486, 8503, 565, 22, 174, 189, 637, 467, 21, 119, 3, 28315, 8979, 2862, 830, 202, 1, 442, 1193, 552, 6, 223, 3, 1972, 2, 764, 1, 1898, 261, 569, 2, 6, 963, 3, 483, 17, 1122, 6, 1898, 261, 569, 21, 514, 17, 552, 37, 29, 28315, 8979, 399, 28, 747, 1153, 7746, 1418, 593, 527, 4, 171, 552, 1898, 569, 1, 973, 2866, 16, 164, 22, 191, 22, 27, 53, 1, 89, 4, 46, 2258, 149, 348, 34, 1707, 11749, 2963, 973, 1374, 643, 791, 633, 9, 3, 866, 161, 18573, 21, 514, 17, 407, 1, 18573, 55, 520, 6, 35, 1365, 2119, 16197, 16197, 14241, 7434, 840, 1780, 4, 8979, 109, 132, 37, 348, 569, 673, 112, 1431, 5255, 16, 35, 191, 774, 1049, 6, 1418, 2077, 1, 283, 214, 4, 1471, 2, 171, 552, 46, 99, 377, 1082, 1728, 9, 3, 193, 1, 422, 6, 283, 1365, 2119, 1628, 4, 552, 2, 751, 127, 132, 31, 441]",1331.0,19666576,188
Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.,Current oncology reports,Curr Oncol Rep,2009-09-01,"Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored, this review focuses on the newer and most clinically relevant markers: cytogenetic aberrations, zeta-associated protein 70, immunoglobulin mutational status, and CD38 expression. Although these markers have been shown to predict outcomes for groups of patients, individual patients may have a variable course; therefore, the outcome for any one patient remains hard to predict. To date, no study has shown a benefit from early cytotoxic therapy for any subgroup of patients with chronic lymphocytic leukemia.",Journal Article,3794.0,1.0,Most patients with chronic lymphocytic are diagnosed at an early stage when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis This failure underscores the need for better prognostic markers Although many markers have been explored this review focuses on the newer and most clinically relevant markers cytogenetic aberrations zeta-associated protein 70 immunoglobulin mutational status and CD38 expression Although these markers have been shown to predict outcomes for groups of patients individual patients may have a variable course therefore the outcome for any one patient remains hard to predict To date no study has shown a benefit from early cytotoxic therapy for any subgroup of patients with chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[96, 7, 5, 442, 1193, 32, 265, 28, 35, 191, 82, 198, 1847, 632, 1530, 4373, 6, 3081, 135, 5, 35, 571, 34, 906, 29, 135, 5, 35, 1503, 356, 26, 496, 6926, 3, 594, 9, 380, 177, 525, 242, 445, 525, 47, 85, 1443, 26, 206, 3026, 23, 3, 2246, 2, 96, 505, 867, 525, 1266, 2152, 12105, 41, 178, 431, 2593, 1619, 156, 2, 4469, 55, 242, 46, 525, 47, 85, 443, 6, 678, 123, 9, 271, 1, 7, 797, 7, 68, 47, 8, 1347, 906, 673, 3, 228, 9, 500, 104, 69, 469, 9327, 6, 678, 6, 1244, 77, 45, 71, 443, 8, 247, 29, 191, 759, 36, 9, 500, 1363, 1, 7, 5, 442, 1193]",796.0,19679010,311
"Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.",Blood,Blood,2009-09-04,"Pim kinases are involved in B-cell development and are overexpressed in B-cell chronic lymphocytic leukemia (CLL). We hypothesized that Pim kinase inhibition would affect B-cell survival. Identified from a screen of imidazo[1,2-b]pyridazine compounds, SGI-1776 inhibits Pim-1, Pim-2, and Pim-3. Treatment of CLL cells with SGI-1776 results in a concentration-dependent induction of apoptosis. To elucidate its mechanism of action, we evaluated the effect of SGI-1776 on Pim kinase function. Unlike in replicating cells, phosphorylation of traditional Pim-1 kinase targets, phospho-Bad (Ser112) and histone H3 (Ser10), and cell-cycle proteins were unaffected by SGI-1776, suggesting an alternative mechanism in CLL. Protein levels of total c-Myc as well as phospho-c-Myc(Ser62), a Pim-1 target site, were decreased after SGI-1776 treatment. Levels of antiapoptotic proteins Bcl-2, Bcl-X(L), XIAP, and proapoptotic Bak and Bax were unchanged; however, a significant reduction in Mcl-1 was observed that was not caused by caspase-mediated cleavage of Mcl-1 protein. The mechanism of decline in Mcl-1 was at the RNA level and was correlated with inhibition of global RNA synthesis. Consistent with a decline in new RNA synthesis, MCL-1 transcript levels were decreased after treatment with SGI-1776. These data suggest that SGI-1776 induces apoptosis in CLL and that the mechanism involves Mcl-1 reduction.",Journal Article,3791.0,142.0,"Pim kinases are involved in B-cell development and are overexpressed in B-cell chronic lymphocytic CLL We hypothesized that Pim kinase inhibition would affect B-cell survival Identified from a screen of imidazo 1,2-b pyridazine compounds SGI-1776 inhibits Pim-1 Pim-2 and Pim-3 Treatment of CLL cells with SGI-1776 results in a concentration-dependent induction of apoptosis To elucidate its mechanism of action we evaluated the effect of SGI-1776 on Pim kinase function Unlike in replicating cells phosphorylation of traditional Pim-1 kinase targets phospho-Bad Ser112 and histone H3 Ser10 and cell-cycle proteins were unaffected by SGI-1776 suggesting an alternative mechanism in CLL Protein levels of total c-Myc as well as phospho-c-Myc Ser62 a Pim-1 target site were decreased after SGI-1776 treatment Levels of antiapoptotic proteins Bcl-2 Bcl-X L XIAP and proapoptotic Bak and Bax were unchanged however a significant reduction in Mcl-1 was observed that was not caused by caspase-mediated cleavage of Mcl-1 protein The mechanism of decline in Mcl-1 was at the RNA level and was correlated with inhibition of global RNA synthesis Consistent with a decline in new RNA synthesis MCL-1 transcript levels were decreased after treatment with SGI-1776 These data suggest that SGI-1776 induces apoptosis in CLL and that the mechanism involves Mcl-1 reduction",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7606, 1549, 32, 646, 4, 132, 31, 193, 2, 32, 1711, 4, 132, 31, 442, 1193, 552, 21, 1237, 17, 7606, 216, 297, 688, 1158, 132, 31, 25, 108, 29, 8, 2413, 1, 30480, 14, 18, 132, 58222, 2411, 10768, 18578, 1576, 7606, 14, 7606, 18, 2, 7606, 27, 24, 1, 552, 37, 5, 10768, 18578, 99, 4, 8, 1227, 470, 504, 1, 351, 6, 3061, 211, 670, 1, 1578, 21, 194, 3, 254, 1, 10768, 18578, 23, 7606, 216, 343, 4246, 4, 13012, 37, 982, 1, 1847, 7606, 14, 216, 637, 3125, 5618, 58223, 2, 1508, 3739, 37828, 2, 31, 417, 652, 11, 4585, 20, 10768, 18578, 802, 35, 1091, 670, 4, 552, 178, 148, 1, 181, 256, 1371, 22, 149, 22, 3125, 256, 1371, 58224, 8, 7606, 14, 283, 606, 11, 340, 50, 10768, 18578, 24, 148, 1, 4176, 652, 1044, 18, 1044, 1006, 805, 5387, 2, 4118, 5599, 2, 3119, 11, 4639, 137, 8, 93, 628, 4, 1308, 14, 10, 164, 17, 10, 44, 1546, 20, 1469, 517, 3155, 1, 1308, 14, 178, 3, 670, 1, 1858, 4, 1308, 14, 10, 28, 3, 893, 301, 2, 10, 438, 5, 297, 1, 1648, 893, 2525, 925, 5, 8, 1858, 4, 217, 893, 2525, 1308, 14, 3268, 148, 11, 340, 50, 24, 5, 10768, 18578, 46, 74, 309, 17, 10768, 18578, 1516, 351, 4, 552, 2, 17, 3, 670, 2921, 1308, 14, 628]",1358.0,19734450,564
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.,Blood,Blood,2009-09-17,"Marrow stromal cells (MSCs) provide important survival and drug resistance signals to chronic lymphocytic leukemia (CLL) cells, but current models to analyze CLL-MSC interactions are heterogeneous. Therefore, we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis. Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis. This protective effect was sustained over a wide range of CLL-MSC ratios (5:1 to 100:1), and the levels of protection were reproducible in 4 different laboratories. Human and murine MSCs also protected CLL cells from dexamethasone- and cyclophosphamide-induced apoptosis. This protection required cell-cell contact and was virtually absent when CLL cells were separated from the MSCs by micropore filters. Furthermore, MSCs maintained Mcl-1 and protected CLL cells from spontaneous and fludarabine-induced Mcl-1 and PARP cleavage. Collectively, these studies define common denominators for CLL cocultures with MSCs. They also provide a reliable, validated tool for future investigations into the mechanism of MSC-CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures.",Journal Article,3778.0,211.0,Marrow stromal cells MSCs provide important survival and drug resistance signals to chronic lymphocytic CLL cells but current models to analyze CLL-MSC interactions are heterogeneous Therefore we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis This protective effect was sustained over a wide range of CLL-MSC ratios 5:1 to 100:1 and the levels of protection were reproducible in 4 different laboratories Human and murine MSCs also protected CLL cells from dexamethasone- and cyclophosphamide-induced apoptosis This protection required cell-cell contact and was virtually absent when CLL cells were separated from the MSCs by micropore filters Furthermore MSCs maintained Mcl-1 and protected CLL cells from spontaneous and fludarabine-induced Mcl-1 and PARP cleavage Collectively these studies define common denominators for CLL cocultures with MSCs They also provide a reliable validated tool for future investigations into the mechanism of MSC-CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[581, 1126, 37, 4460, 377, 305, 25, 2, 234, 251, 2312, 6, 442, 1193, 552, 37, 84, 291, 274, 6, 1992, 552, 4150, 1286, 32, 1564, 673, 21, 650, 338, 171, 2, 1471, 4150, 285, 2, 86, 171, 4460, 9, 136, 801, 6, 4869, 552, 37, 29, 3280, 2, 234, 277, 351, 114, 99, 514, 17, 110, 171, 2, 1471, 4460, 32, 4142, 323, 4, 11638, 552, 37, 29, 2027, 277, 351, 26, 2864, 254, 10, 2275, 252, 8, 1019, 184, 1, 552, 4150, 1137, 33, 14, 6, 394, 14, 2, 3, 148, 1, 3525, 11, 4172, 4, 39, 338, 4884, 171, 2, 1471, 4460, 120, 5541, 552, 37, 29, 1217, 2, 1112, 277, 351, 26, 3525, 616, 31, 31, 4393, 2, 10, 5860, 3269, 198, 552, 37, 11, 4910, 29, 3, 4460, 20, 58254, 10788, 798, 4460, 1955, 1308, 14, 2, 5541, 552, 37, 29, 3280, 2, 2027, 277, 1308, 14, 2, 2041, 3155, 2535, 46, 94, 1107, 186, 31514, 9, 552, 16398, 5, 4460, 491, 120, 377, 8, 2450, 938, 1515, 9, 508, 2492, 237, 3, 670, 1, 4150, 552, 1383, 6522, 2, 9, 234, 471, 4, 8, 80, 867, 3240, 76, 3, 841, 95, 9348, 3231]",1283.0,19762485,37
Flavopiridol in chronic lymphocytic leukemia: a concise review.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-01-01,"Patients with chronic lymphocytic leukemia (CLL) with high-risk cytogenetic features such as del(17p13) have limited treatment options and decreased overall survival. Dysfunction of p53 leads to resistance to fludarabine-based therapies. Cyclin-dependent kinase inhibitors (CDKi) are a novel class of agents that induce apoptosis in CLL cells independent of p53 mutational status. The synthetic flavone flavopiridol demonstrated promising in vitro activity in CLL. In initial phase I studies using a continuous infusion dosing schedule in a variety of malignancies, no clinical activity was observed. Detailed pharmacokinetic modeling led to the development of a novel dosing schedule designed to achieve target drug concentrations in vivo. In phase I testing, this dosing schedule resulted in acute tumor lysis syndrome (TLS) as the dose-limiting toxicity. With the implementation of a standardized protocol to prevent severe TLS, flavopiridol was administered safely, and responses were observed in heavily pretreated, fludarabine-refractory patients, cytogenetically high-risk patients, and patients with bulky lymphadenopathy. In a pharmacokinetic analysis, flavopiridol area under the plasma concentration-time curve (AUC) correlated with clinical response and cytokine release syndrome. Phase II studies are under way with encouraging preliminary results. Flavopiridol is currently under active investigation in combination with other agents and as a means to eradicate minimal residual disease in patients following cytoreductive chemotherapy. Several other investigational CDKi in preclinical and early clinical development are briefly discussed in this review.",Journal Article,4037.0,38.0,Patients with chronic lymphocytic CLL with high-risk cytogenetic features such as del 17p13 have limited treatment options and decreased overall survival Dysfunction of p53 leads to resistance to fludarabine-based therapies Cyclin-dependent kinase inhibitors CDKi are a novel class of agents that induce apoptosis in CLL cells independent of p53 mutational status The synthetic flavone flavopiridol demonstrated promising in vitro activity in CLL In initial phase I studies using a continuous infusion dosing schedule in a variety of malignancies no clinical activity was observed Detailed pharmacokinetic modeling led to the development of a novel dosing schedule designed to achieve target drug concentrations in vivo In phase I testing this dosing schedule resulted in acute tumor lysis syndrome TLS as the dose-limiting toxicity With the implementation of a standardized protocol to prevent severe TLS flavopiridol was administered safely and responses were observed in heavily pretreated fludarabine-refractory patients cytogenetically high-risk patients and patients with bulky lymphadenopathy In a pharmacokinetic analysis flavopiridol area under the plasma concentration-time curve AUC correlated with clinical response and cytokine release syndrome Phase II studies are under way with encouraging preliminary results Flavopiridol is currently under active investigation in combination with other agents and as a means to eradicate minimal residual disease in patients following cytoreductive chemotherapy Several other investigational CDKi in preclinical and early clinical development are briefly discussed in this review,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 5, 64, 43, 1266, 404, 225, 22, 3084, 7526, 47, 383, 24, 838, 2, 340, 63, 25, 1527, 1, 624, 1940, 6, 251, 6, 2027, 90, 235, 1226, 470, 216, 222, 28287, 32, 8, 229, 1040, 1, 183, 17, 1290, 351, 4, 552, 37, 306, 1, 624, 1619, 156, 3, 3273, 30341, 3030, 264, 721, 4, 439, 128, 4, 552, 4, 388, 124, 70, 94, 75, 8, 1314, 904, 1280, 1055, 4, 8, 1362, 1, 441, 77, 38, 128, 10, 164, 2455, 1456, 2057, 836, 6, 3, 193, 1, 8, 229, 1280, 1055, 1114, 6, 1359, 283, 234, 1003, 4, 386, 4, 124, 70, 471, 26, 1280, 1055, 627, 4, 286, 30, 4783, 681, 8778, 22, 3, 61, 817, 155, 5, 3, 2393, 1, 8, 1670, 1182, 6, 1682, 905, 8778, 3030, 10, 468, 2268, 2, 253, 11, 164, 4, 2447, 2193, 2027, 430, 7, 7809, 64, 43, 7, 2, 7, 5, 4112, 4962, 4, 8, 1456, 65, 3030, 965, 669, 3, 554, 1227, 98, 1496, 1376, 438, 5, 38, 51, 2, 1675, 2008, 681, 124, 215, 94, 32, 669, 2255, 5, 2269, 1676, 99, 3030, 16, 694, 669, 544, 940, 4, 150, 5, 127, 183, 2, 22, 8, 2263, 6, 5650, 1048, 753, 34, 4, 7, 366, 2604, 56, 392, 127, 3093, 28287, 4, 693, 2, 191, 38, 193, 32, 6277, 1588, 4, 26, 206]",1631.0,19778838,25
Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.,Leukemia & lymphoma,Leuk. Lymphoma,2009-08-01,"Improved medical care could have altered the clinical presentation and survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) complicated by autoimmune disease cytopenia (AID cytopenia). We reviewed the clinical characteristics, treatment, and outcome of AID cytopenia that was diagnosed in 75 (4.3%) of 1750 patients with CLL seen at a single institution over 10 years. When compared with the historical reported data, our study shows a lower rate of autoimmune hemolytic anemia (2.3%), and similar rates of immune thrombocytopenia (2.0%), and pure red blood cell aplasia (0.5%). AID cytopenia occurred at all stages of CLL, responded well to treatment, did not alter overall survival, and contributed to death in only 6 (12%) patients. We propose that more sensitive and accurate diagnostic methods for CLL have decreased the perceived prevalence of AID cytopenia and that improvements in management could have increased the survival of these patients.",Journal Article,3825.0,51.0,Improved medical care could have altered the clinical presentation and survival of patients with chronic lymphocytic leukemia/small lymphocytic CLL/SLL complicated by autoimmune disease cytopenia AID cytopenia We reviewed the clinical characteristics treatment and outcome of AID cytopenia that was diagnosed in 75 4.3 of 1750 patients with CLL seen at a single institution over 10 years When compared with the historical reported data our study shows a lower rate of autoimmune hemolytic anemia 2.3 and similar rates of immune thrombocytopenia 2.0 and pure red blood cell aplasia 0.5 AID cytopenia occurred at all stages of CLL responded well to treatment did not alter overall survival and contributed to death in only 6 12 patients We propose that more sensitive and accurate diagnostic methods for CLL have decreased the perceived prevalence of AID cytopenia and that improvements in management could have increased the survival of these patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[231, 484, 165, 359, 47, 1495, 3, 38, 1031, 2, 25, 1, 7, 5, 442, 1193, 2647, 302, 1193, 552, 5302, 4286, 20, 3445, 34, 8165, 2427, 8165, 21, 446, 3, 38, 374, 24, 2, 228, 1, 2427, 8165, 17, 10, 265, 4, 481, 39, 27, 1, 34443, 7, 5, 552, 527, 28, 8, 226, 731, 252, 79, 60, 198, 72, 5, 3, 2252, 210, 74, 114, 45, 1949, 8, 280, 116, 1, 3445, 10425, 1545, 18, 27, 2, 288, 151, 1, 250, 1340, 18, 13, 2, 3092, 3422, 315, 31, 12307, 13, 33, 2427, 8165, 489, 28, 62, 1153, 1, 552, 2211, 149, 6, 24, 205, 44, 2688, 63, 25, 2, 3447, 6, 273, 4, 158, 49, 133, 7, 21, 2548, 17, 80, 745, 2, 1481, 752, 636, 9, 552, 47, 340, 3, 2588, 1078, 1, 2427, 8165, 2, 17, 1474, 4, 284, 359, 47, 101, 3, 25, 1, 46, 7]",950.0,19811329,743
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-10-13,"Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated. Patients with relapsed CLL were treated with single-agent flavopiridol, with subsequent addition of dexamethasone to suppress cytokine release syndrome (CRS). High-risk genomic features were prospectively assessed for response to therapy. Sixty-four patients were enrolled. Median age was 60 years, median number of prior therapies was four, and all patients had received prior purine analog therapy. If patients tolerated treatment during week 1, dose escalation occurred during week 2. Dose escalation did not occur in four patients, as a result of severe tumor lysis syndrome; three of these patients required hemodialysis. Thirty-four patients (53%) achieved response, including 30 partial responses (PRs; 47%), three nodular PRs (5%), and one complete response (1.6%). A majority of high-risk patients responded; 12 (57%) of 21 patients with del(17p13.1) and 14 (50%) of 28 patients with del(11q22.3) responded irrespective of lymph node size. Median progression-free survival among responders was 10 to 12 months across all cytogenetic risk groups. Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P < or = .01), resulted in improved tolerability and treatment delivery. Flavopiridol achieves significant clinical activity in patients with relapsed CLL, including those with high-risk genomic features and bulky lymphadenopathy. Subsequent clinical trials should use the amended treatment schedule developed herein and prophylactic corticosteroids.","Clinical Trial, Phase II",3752.0,172.0,Patients with chronic lymphocytic CLL with high-risk genomic features achieve poor outcomes with traditional therapies A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL irrespective of high-risk features Given the relevance of these findings to treating genetically high-risk CLL a prospective confirmatory study was initiated Patients with relapsed CLL were treated with single-agent flavopiridol with subsequent addition of dexamethasone to suppress cytokine release syndrome CRS High-risk genomic features were prospectively assessed for response to therapy Sixty-four patients were enrolled Median age was 60 years median number of prior therapies was four and all patients had received prior purine analog therapy If patients tolerated treatment during week 1 dose escalation occurred during week 2 Dose escalation did not occur in four patients as a result of severe tumor lysis syndrome three of these patients required hemodialysis Thirty-four patients 53 achieved response including 30 partial responses PRs 47 three nodular PRs 5 and one complete response 1.6 A majority of high-risk patients responded 12 57 of 21 patients with del 17p13.1 and 14 50 of 28 patients with del 11q22.3 responded irrespective of lymph node size Median progression-free survival among responders was 10 to 12 months across all cytogenetic risk groups Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone which abrogated interleukin-6 release and CRS P or .01 resulted in improved tolerability and treatment delivery Flavopiridol achieves significant clinical activity in patients with relapsed CLL including those with high-risk genomic features and bulky lymphadenopathy Subsequent clinical trials should use the amended treatment schedule developed herein and prophylactic corticosteroids,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 5, 64, 43, 572, 404, 1359, 334, 123, 5, 1847, 235, 8, 124, 70, 45, 1, 8, 14920, 526, 1055, 1, 3030, 1148, 721, 128, 4, 552, 3500, 1, 64, 43, 404, 447, 3, 2088, 1, 46, 272, 6, 1367, 2301, 64, 43, 552, 8, 482, 5697, 45, 10, 1917, 7, 5, 591, 552, 11, 73, 5, 226, 420, 3030, 5, 706, 352, 1, 1217, 6, 3134, 1675, 2008, 681, 3115, 64, 43, 572, 404, 11, 1143, 275, 9, 51, 6, 36, 1746, 294, 7, 11, 346, 52, 89, 10, 335, 60, 52, 207, 1, 324, 235, 10, 294, 2, 62, 7, 42, 103, 324, 5006, 3497, 36, 492, 7, 421, 24, 190, 647, 14, 61, 1125, 489, 190, 647, 18, 61, 1125, 205, 44, 1271, 4, 294, 7, 22, 8, 757, 1, 905, 30, 4783, 681, 169, 1, 46, 7, 616, 11170, 977, 294, 7, 699, 513, 51, 141, 201, 450, 253, 4018, 662, 169, 4481, 4018, 33, 2, 104, 236, 51, 14, 49, 8, 686, 1, 64, 43, 7, 2211, 133, 696, 1, 239, 7, 5, 3084, 7526, 14, 2, 213, 212, 1, 339, 7, 5, 3084, 12647, 27, 2211, 3500, 1, 263, 289, 444, 52, 91, 115, 25, 107, 1983, 10, 79, 6, 133, 53, 716, 62, 1266, 43, 271, 1818, 3, 207, 1, 709, 640, 379, 417, 29, 294, 6, 169, 2, 2726, 1862, 1217, 92, 3728, 1603, 49, 2008, 2, 3115, 19, 15, 355, 627, 4, 231, 1543, 2, 24, 989, 3030, 6358, 93, 38, 128, 4, 7, 5, 591, 552, 141, 135, 5, 64, 43, 572, 404, 2, 4112, 4962, 706, 38, 143, 257, 119, 3, 7595, 24, 1055, 276, 1986, 2, 1862, 3876]",1894.0,19826119,438
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.,Blood,Blood,2009-10-14,"Immune-related deficiencies are well-known complications of chronic lymphocytic leukemia (CLL). Although recent data indicate that almost all CLL patients are preceded by a monoclonal B-cell lymphocytosis precursor state, patterns of immune defects preceding CLL diagnosis are unclear. We identified 109 persons who developed CLL from the prospective and nationwide Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial with 77 469 participants, with serially collected prediagnostic serum samples. We assayed monoclonal (M)-proteins, kappa/lambda free light chains (FLCs) in prediagnostic obtained up to 9.8 years before CLL diagnosis. The prevalence of an abnormal FLC ratio, M-protein, and hypogamma-globulinemia before CLL diagnosis was 38% (95% confidence interval, 29%-47%), 13% (7%-21%), and 3% (1%-8%), respectively. M-proteins and abnormal FLC ratios were detected up to 9.8 years before CLL diagnosis in a total of 48 persons (44%). Hypogammaglobulinemia was not present until 3 years before the diagnosis of CLL. Among 37 patients with information on tumor cell immunophenotype, an association between immunophenotype and involved FLC (P = .024, Fisher exact test) was observed. Among 61 persons with a normal FLC ratio and without an M-protein, 17 had elevated kappa and/or lambda FLC levels, indicating polyclonal B-cell activation in 17 of 109 (16%) patients. These findings support a role for chronic immune stimulation in CLL genesis.",Journal Article,3751.0,52.0,Immune-related deficiencies are well-known complications of chronic lymphocytic CLL Although recent data indicate that almost all CLL patients are preceded by a monoclonal B-cell lymphocytosis precursor state patterns of immune defects preceding CLL diagnosis are unclear We identified 109 persons who developed CLL from the prospective and nationwide and Cancer Screening Trial with 77 469 participants with serially collected prediagnostic serum samples We assayed monoclonal M -proteins kappa/lambda free light chains FLCs in prediagnostic obtained up to 9.8 years before CLL diagnosis The prevalence of an abnormal FLC ratio M-protein and hypogamma-globulinemia before CLL diagnosis was 38 95 confidence interval 29 -47 13 7 -21 and 3 1 -8 respectively M-proteins and abnormal FLC ratios were detected up to 9.8 years before CLL diagnosis in a total of 48 persons 44 Hypogammaglobulinemia was not present until 3 years before the diagnosis of CLL Among 37 patients with information on tumor cell immunophenotype an association between immunophenotype and involved FLC P .024 Fisher exact test was observed Among 61 persons with a normal FLC ratio and without an M-protein 17 had elevated kappa and/or lambda FLC levels indicating polyclonal B-cell activation in 17 of 109 16 patients These findings support a role for chronic immune stimulation in CLL genesis,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[250, 139, 7159, 32, 149, 440, 521, 1, 442, 1193, 552, 242, 435, 74, 1008, 17, 2214, 62, 552, 7, 32, 6083, 20, 8, 848, 132, 31, 8125, 2765, 1309, 764, 1, 250, 2945, 5892, 552, 147, 32, 1200, 21, 108, 3486, 4327, 54, 276, 552, 29, 3, 482, 2, 5405, 2, 12, 453, 160, 5, 849, 9747, 776, 5, 6754, 786, 7366, 524, 347, 21, 4499, 848, 188, 652, 3096, 8561, 115, 1691, 7802, 17307, 4, 7366, 683, 126, 6, 83, 66, 60, 348, 552, 147, 3, 1078, 1, 35, 1668, 4266, 197, 188, 178, 2, 58330, 58331, 348, 552, 147, 10, 519, 48, 307, 268, 462, 662, 233, 67, 239, 2, 27, 14, 66, 106, 188, 652, 2, 1668, 4266, 1137, 11, 530, 126, 6, 83, 66, 60, 348, 552, 147, 4, 8, 181, 1, 576, 4327, 584, 13242, 10, 44, 364, 1100, 27, 60, 348, 3, 147, 1, 552, 107, 567, 7, 5, 487, 23, 30, 31, 5496, 35, 248, 59, 5496, 2, 646, 4266, 19, 4247, 3135, 2472, 412, 10, 164, 107, 713, 4327, 5, 8, 295, 4266, 197, 2, 187, 35, 188, 178, 269, 42, 804, 3096, 2, 15, 8561, 4266, 148, 1716, 6350, 132, 31, 363, 4, 269, 1, 3486, 245, 7, 46, 272, 538, 8, 200, 9, 442, 250, 2503, 4, 552, 9110]",1363.0,19828698,540
"Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.",Blood,Blood,2009-10-20,"Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients. Thirty-one patients received either 375 mg/m(2) (n = 3) or 500 mg/m(2) (n = 28) of lumiliximab in combination with FCR for 6 cycles. The toxicity profile was similar to that previously reported for FCR in treatment of relapsed CLL. The overall response rate was 65%, with 52% of patients achieving a complete response (CR), which compares favorably with the CR rate previously reported for the FCR regimen alone in relapsed CLL. The estimated median progression-free survival for all responders was 28.7 months. The addition of lumiliximab to FCR therapy is feasible, achieves a high CR rate, and does not appear to enhance toxicity in previously treated patients with CLL. A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL. This trial was registered at clinicaltrials.gov as NCT00103558.","Clinical Trial, Phase I",3745.0,80.0,Preclinical data demonstrate enhanced antitumor effect when lumiliximab an anti-CD23 monoclonal antibody is combined with fludarabine or rituximab Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic CLL We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine cyclophosphamide and rituximab FCR in previously treated CLL patients Thirty-one patients received either 375 mg/m 2 n 3 or 500 mg/m 2 n 28 of lumiliximab in combination with FCR for 6 cycles The toxicity profile was similar to that previously reported for FCR in treatment of relapsed CLL The overall response rate was 65 with 52 of patients achieving a complete response CR which compares favorably with the CR rate previously reported for the FCR regimen alone in relapsed CLL The estimated median progression-free survival for all responders was 28.7 months The addition of lumiliximab to FCR therapy is feasible achieves a high CR rate and does not appear to enhance toxicity in previously treated patients with CLL A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL This trial was registered at clinicaltrials.gov as NCT00103558,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[693, 74, 608, 651, 579, 254, 198, 16443, 35, 312, 9937, 848, 548, 16, 397, 5, 2027, 15, 855, 38, 74, 29, 8, 124, 14, 160, 5, 16443, 264, 35, 1595, 155, 800, 4, 7, 5, 591, 15, 430, 442, 1193, 552, 21, 673, 5299, 8, 124, 14, 18, 61, 1125, 45, 1, 16443, 1953, 6, 2027, 1112, 2, 855, 4953, 4, 373, 73, 552, 7, 977, 104, 7, 103, 361, 4175, 81, 188, 18, 78, 27, 15, 1666, 81, 188, 18, 78, 339, 1, 16443, 4, 150, 5, 4953, 9, 49, 410, 3, 155, 800, 10, 288, 6, 17, 373, 210, 9, 4953, 4, 24, 1, 591, 552, 3, 63, 51, 116, 10, 556, 5, 653, 1, 7, 1785, 8, 236, 51, 684, 92, 5815, 5001, 5, 3, 684, 116, 373, 210, 9, 3, 4953, 477, 279, 4, 591, 552, 3, 661, 52, 91, 115, 25, 9, 62, 1983, 10, 339, 67, 53, 3, 352, 1, 16443, 6, 4953, 36, 16, 1313, 6358, 8, 64, 684, 116, 2, 1097, 44, 1322, 6, 1304, 155, 4, 373, 73, 7, 5, 552, 8, 384, 160, 1430, 16443, 349, 4953, 5, 4953, 279, 16, 3948, 6, 1107, 3, 247, 1, 26, 150, 4, 591, 552, 26, 160, 10, 1653, 28, 1252, 1239, 22, 58345]",1316.0,19843887,312
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2009-12-01,"Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR beta-chain antibody, mediates apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro. We conducted a phase I/II dose-escalation study of thrice-weekly apolizumab (1.5, 3.0, 5.0 mg/kg/dose) for 4 weeks in relapsed CLL. Two of six patients at 5.0 mg/kg/dose developed treatment-related dose-limiting toxicity (aseptic meningitis, hemolytic uremia). Other toxicities included infusion toxicity, urticaria, and headache. Eleven patients were enrolled in a phase I/II expansion to evaluate the maximum tolerated dose (MTD) of 3.0 mg/kg/dose. In total, 23 patients were enrolled (22 CLL, 1 ALL). Nineteen patients with CLL were treated at or above the MTD. One partial response was observed, and three patients had stable disease exceeding 6 months. Pharmacokinetic analysis demonstrated a dose-dependent C(max) increase and serum antibody accumulation after week 1 of therapy. Given the toxicity and lack of efficacy in this and other trials in lymphoma and solid tumors, further development of apolizumab was discontinued.","Clinical Trial, Phase I",3703.0,24.0,Apolizumab Hu1D10 a humanized monoclonal anti- Human leukocyte antigen -DR beta-chain antibody mediates apoptosis of chronic lymphocytic CLL cells in vitro We conducted a phase I/II dose-escalation study of thrice-weekly apolizumab 1.5 3.0 5.0 mg/kg/dose for 4 weeks in relapsed CLL Two of six patients at 5.0 mg/kg/dose developed treatment-related dose-limiting toxicity aseptic meningitis hemolytic uremia Other toxicities included infusion toxicity urticaria and headache Eleven patients were enrolled in a phase I/II expansion to evaluate the maximum tolerated dose MTD of 3.0 mg/kg/dose In total 23 patients were enrolled 22 CLL 1 ALL Nineteen patients with CLL were treated at or above the MTD One partial response was observed and three patients had stable disease exceeding 6 months Pharmacokinetic analysis demonstrated a dose-dependent C max increase and serum antibody accumulation after week 1 of therapy Given the toxicity and lack of efficacy in this and other trials in and solid tumors further development of apolizumab was discontinued,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[33555, 19610, 8, 3619, 848, 312, 171, 3627, 448, 3436, 1090, 1260, 548, 3961, 351, 1, 442, 1193, 552, 37, 4, 439, 21, 426, 8, 124, 70, 215, 61, 1125, 45, 1, 10058, 709, 33555, 14, 33, 27, 13, 33, 13, 81, 503, 61, 9, 39, 244, 4, 591, 552, 100, 1, 437, 7, 28, 33, 13, 81, 503, 61, 276, 24, 139, 61, 817, 155, 34786, 10792, 10425, 44039, 127, 385, 159, 904, 155, 18802, 2, 4538, 2627, 7, 11, 346, 4, 8, 124, 70, 215, 1422, 6, 376, 3, 689, 421, 61, 961, 1, 27, 13, 81, 503, 61, 4, 181, 382, 7, 11, 346, 350, 552, 14, 62, 3498, 7, 5, 552, 11, 73, 28, 15, 2090, 3, 961, 104, 450, 51, 10, 164, 2, 169, 7, 42, 585, 34, 5178, 49, 53, 1456, 65, 264, 8, 61, 470, 256, 2649, 344, 2, 524, 548, 1835, 50, 647, 14, 1, 36, 447, 3, 155, 2, 926, 1, 209, 4, 26, 2, 127, 143, 4, 2, 537, 57, 195, 193, 1, 33555, 10, 2402]",1052.0,19860603,159
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2009-12-01,"Chronic lymphocytic leukemia (CLL) cells are susceptible to oxidative stress. The expanded porphyrin, motexafin gadolinium (MGd), reacts with intracellular reducing metabolites and protein thiols to generate reactive oxygen species (ROS). A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and small lymphocytic lymphoma. Thirteen patients (median age 66 years) with a median of four prior therapies (range 2-9) were enrolled. Modest anti-tumor activity was seen in three patients, with improvement in lymphocytosis, lymphadenopathy and/or splenomegaly, but no patient achieved a partial or complete response by NCI 96 criteria. Flow cytometry confirmed tumor uptake of MGd. Serial increase in AKT phosphorylation in patient samples following MGd treatment was not observed, suggesting intracellular generation of ROS was not optimal. Therefore, this schedule of administration achieved MGd uptake into primary tumor cells in vivo, but clinical activity was modest.","Clinical Trial, Phase II",3703.0,15.0,Chronic lymphocytic CLL cells are susceptible to oxidative stress The expanded porphyrin motexafin gadolinium MGd reacts with intracellular reducing metabolites and protein thiols to generate reactive oxygen species ROS A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and small lymphocytic Thirteen patients median age 66 years with a median of four prior therapies range 2-9 were enrolled Modest anti-tumor activity was seen in three patients with improvement in lymphocytosis lymphadenopathy and/or splenomegaly but no patient achieved a partial or complete response by NCI 96 criteria Flow cytometry confirmed tumor uptake of MGd Serial increase in AKT phosphorylation in patient samples following MGd treatment was not observed suggesting intracellular generation of ROS was not optimal Therefore this schedule of administration achieved MGd uptake into primary tumor cells in vivo but clinical activity was modest,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 37, 32, 4012, 6, 3495, 1531, 3, 2064, 20627, 12300, 7295, 11809, 23374, 5, 2087, 1818, 3406, 2, 178, 20356, 6, 2562, 2163, 2848, 2915, 2609, 8, 124, 215, 160, 468, 11809, 33, 81, 503, 218, 478, 9, 33, 162, 454, 27, 244, 1100, 34, 91, 6, 7, 5, 373, 73, 552, 2, 302, 1193, 3170, 7, 52, 89, 700, 60, 5, 8, 52, 1, 294, 324, 235, 184, 18, 83, 11, 346, 1721, 312, 30, 128, 10, 527, 4, 169, 7, 5, 767, 4, 8125, 4962, 2, 15, 6364, 84, 77, 69, 513, 8, 450, 15, 236, 51, 20, 2580, 921, 371, 1412, 1914, 557, 30, 1135, 1, 11809, 2108, 344, 4, 649, 982, 4, 69, 347, 366, 11809, 24, 10, 44, 164, 802, 2087, 914, 1, 2609, 10, 44, 665, 673, 26, 1055, 1, 634, 513, 11809, 1135, 237, 86, 30, 37, 4, 386, 84, 38, 128, 10, 1721]",1010.0,19860624,486
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.,Leukemia & lymphoma,Leuk. Lymphoma,2009-10-01,"The humanized anti-CD52 monoclonal antibody alemtuzumab is an effective therapy for chronic lymphocytic leukemia (CLL). We examined the impact of alemtuzumab treatment after initial fludarabine treatment for feasibility and safety. Patients (N = 85) with previously untreated symptomatic CLL received fludarabine (25 mg/m(2)/day) for 5 days every 4 weeks for four cycles followed by 2 months of observation. Patients with stable disease or better response then received alemtuzumab 30 mg three times weekly for 6 weeks either intravenously (IV; cohort 1; N = 39) or subcutaneously (SC; cohort 2; N = 20). Of the 85 evaluable patients enrolled on our study, four (5%) attained a complete response (CR) and 43 (51%) attained a partial response after fludarabine induction for an overall response rate (ORR) of 55%. Thirty-nine patients received IV alemtuzumab for consolidation with improvement in CR to 27% and ORR to 73%. Twenty patients received SC alemtuzumab consolidation with improvement in CR to 17% and ORR to 69%. Toxicity from IV alemtuzumab included infusion-related reactions and infection. Mild local inflammation was common from SC alemtuzumab but there were virtually no systemic side effects. Nine of 59 (15%) patients had cytomegalovirus (CMV) infections; one patient died. The administration of alemtuzumab as consolidation therapy following an abbreviated fludarabine induction is feasible but requires close monitoring for CMV infection and other infectious events.","Clinical Trial, Phase II",3764.0,27.0,The humanized anti-CD52 monoclonal antibody alemtuzumab is an effective therapy for chronic lymphocytic CLL We examined the impact of alemtuzumab treatment after initial fludarabine treatment for feasibility and safety Patients N 85 with previously untreated symptomatic CLL received fludarabine 25 mg/m 2 /day for 5 days every 4 weeks for four cycles followed by 2 months of observation Patients with stable disease or better response then received alemtuzumab 30 mg three times weekly for 6 weeks either intravenously IV cohort 1 N 39 or subcutaneously SC cohort 2 N 20 Of the 85 evaluable patients enrolled on our study four 5 attained a complete response CR and 43 51 attained a partial response after fludarabine induction for an overall response rate ORR of 55 Thirty-nine patients received IV alemtuzumab for consolidation with improvement in CR to 27 and ORR to 73 Twenty patients received SC alemtuzumab consolidation with improvement in CR to 17 and ORR to 69 Toxicity from IV alemtuzumab included infusion-related reactions and infection Mild local inflammation was common from SC alemtuzumab but there were virtually no systemic side effects Nine of 59 15 patients had cytomegalovirus CMV infections one patient died The administration of alemtuzumab as consolidation therapy following an abbreviated fludarabine induction is feasible but requires close monitoring for CMV infection and other infectious events,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 3619, 312, 7189, 848, 548, 3579, 16, 35, 323, 36, 9, 442, 1193, 552, 21, 409, 3, 345, 1, 3579, 24, 50, 388, 2027, 24, 9, 1437, 2, 367, 7, 78, 772, 5, 373, 1278, 1704, 552, 103, 2027, 243, 81, 188, 18, 218, 9, 33, 162, 454, 39, 244, 9, 294, 410, 370, 20, 18, 53, 1, 1664, 7, 5, 585, 34, 15, 380, 51, 818, 103, 3579, 201, 81, 169, 1072, 709, 9, 49, 244, 361, 1672, 478, 180, 14, 78, 587, 15, 3928, 2969, 180, 18, 78, 179, 1, 3, 772, 859, 7, 346, 23, 114, 45, 294, 33, 5105, 8, 236, 51, 684, 2, 601, 725, 5105, 8, 450, 51, 50, 2027, 504, 9, 35, 63, 51, 116, 1735, 1, 614, 977, 762, 7, 103, 478, 3579, 9, 2173, 5, 767, 4, 684, 6, 428, 2, 1735, 6, 803, 737, 7, 103, 2969, 3579, 2173, 5, 767, 4, 684, 6, 269, 2, 1735, 6, 790, 155, 29, 478, 3579, 159, 904, 139, 2428, 2, 930, 1980, 293, 1815, 10, 186, 29, 2969, 3579, 84, 125, 11, 5860, 77, 403, 1152, 176, 762, 1, 728, 167, 7, 42, 7314, 3879, 1875, 104, 69, 1016, 3, 634, 1, 3579, 22, 2173, 36, 366, 35, 9786, 2027, 504, 16, 1313, 84, 1706, 2336, 1315, 9, 3879, 930, 2, 127, 3398, 281]",1422.0,19863336,670
Epigenetic alterations in a murine model for chronic lymphocytic leukemia.,"Cell cycle (Georgetown, Tex.)",Cell Cycle,2009-11-01,"Early stages in the development of chronic lymphocytic leukemia (CLL) have not been explored mainly due to the inability to study normal B-cells en route to transformation. In order to determine such early events of leukemogenesis, we have used a well established mouse model for CLL. Over-expression of human TCL1, a known CLL oncogene in murine B-cells leads to the development of mature CD19+/CD5+/IgM+ clonal leukemia with a disease phenotype similar to that seen in human CLL. Herein, we review our recent study using this TCL1-driven mouse model for CLL and corresponding human CLL samples in a cross-species epigenomics approach to address the timing and relevance of epigenetic events occurring during leukemogenesis. We demonstrated that the mouse model recapitulates the epigenetic events that have been reported for human CLL, affirming the power and validity of this mouse model to study early epigenetic events in cancer progression. Epigenetic alterations are detected as early as three months after birth, far before disease manifests at about 11 months of age. These mice undergo NFkappaB repressor complex mediated inactivation of the transcription factor Foxd3, whose targets become aberrantly methylated and silenced in mouse and human CLL. Overall, our data suggest the accumulated epigenetic alterations during CLL pathogenesis as a consequence of gene silencing through TCL1 and NFkappaB repressor complex, suggesting the relevance for NFkappaB as a therapeutic target in CLL.",Journal Article,3733.0,16.0,Early stages in the development of chronic lymphocytic CLL have not been explored mainly due to the inability to study normal B-cells en route to transformation In order to determine such early events of leukemogenesis we have used a well established mouse model for CLL Over-expression of human TCL1 a known CLL oncogene in murine B-cells leads to the development of mature CD19+/CD5+/IgM+ clonal with a disease phenotype similar to that seen in human CLL Herein we review our recent study using this TCL1-driven mouse model for CLL and corresponding human CLL samples in a cross-species epigenomics approach to address the timing and relevance of epigenetic events occurring during leukemogenesis We demonstrated that the mouse model recapitulates the epigenetic events that have been reported for human CLL affirming the power and validity of this mouse model to study early epigenetic events in cancer progression Epigenetic alterations are detected as early as three months after birth far before disease manifests at about 11 months of age These mice undergo NFkappaB repressor complex mediated inactivation of the transcription factor Foxd3 whose targets become aberrantly methylated and silenced in mouse and human CLL Overall our data suggest the accumulated epigenetic alterations during CLL pathogenesis as a consequence of gene silencing through TCL1 and NFkappaB repressor complex suggesting the relevance for NFkappaB as a therapeutic target in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[191, 1153, 4, 3, 193, 1, 442, 1193, 552, 47, 44, 85, 1443, 2615, 520, 6, 3, 4985, 6, 45, 295, 132, 37, 4375, 5841, 6, 1392, 4, 1732, 6, 223, 225, 191, 281, 1, 5661, 21, 47, 95, 8, 149, 635, 830, 202, 9, 552, 252, 55, 1, 171, 8979, 8, 440, 552, 1836, 4, 1471, 132, 37, 1940, 6, 3, 193, 1, 2908, 3158, 6349, 2852, 1946, 5, 8, 34, 1005, 288, 6, 17, 527, 4, 171, 552, 1986, 21, 206, 114, 435, 45, 75, 26, 8979, 1621, 830, 202, 9, 552, 2, 1734, 171, 552, 347, 4, 8, 1383, 2915, 25048, 353, 6, 1539, 3, 1972, 2, 2088, 1, 1418, 281, 1821, 190, 5661, 21, 264, 17, 3, 830, 202, 11076, 3, 1418, 281, 17, 47, 85, 210, 9, 171, 552, 31541, 3, 2349, 2, 3099, 1, 26, 830, 202, 6, 45, 191, 1418, 281, 4, 12, 91, 1418, 593, 32, 530, 22, 191, 22, 169, 53, 50, 3809, 3272, 348, 34, 15096, 28, 545, 175, 53, 1, 89, 46, 399, 1251, 6469, 7434, 840, 517, 2297, 1, 3, 866, 161, 18573, 1310, 637, 1417, 5619, 2963, 2, 5442, 4, 830, 2, 171, 552, 63, 114, 74, 309, 3, 6664, 1418, 593, 190, 552, 1384, 22, 8, 4177, 1, 145, 2077, 298, 8979, 2, 6469, 7434, 840, 802, 3, 2088, 9, 6469, 22, 8, 189, 283, 4, 552]",1462.0,19901553,379
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.,Blood,Blood,2009-11-24,"Chronic lymphocytic leukemia (CLL) involves a profound humoral immune defect and tumor-specific humoral tolerance that directly contribute to disease morbidity and mortality. CD154 gene therapy can reverse this immune defect, but attempts to do this pharmacologically have been unsuccessful. The immune-modulatory agent lenalidomide shows clinical activity in CLL, but its mechanism is poorly understood. Here, we demonstrate that lenalidomide induces expression of functional CD154 antigen on CLL cells both in vitro and in vivo. This occurs via enhanced CD154 transcription mediated by a Nuclear Factor of Activated T cells c1 (NFATc1)/Nuclear Factor-kappaB (NF-kappaB) complex and also through phosphoinositide-3 (PI3)-kinase pathway-dependent stabilization of CD154 mRNA. Importantly, CD154-positive CLL cells up-regulate BID, DR5, and p73, become sensitized to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, and promote costimulatory activation of normal B cells to produce antibodies. In CLL patients receiving lenalidomide, similar evidence of CD154 activation is observed including BID, DR5, and p73 induction and also development of anti-ROR1 tumor-directed antibodies. Our data demonstrate that lenalidomide promotes CD154 expression on CLL cells with subsequent activation phenotype, and may therefore reverse the humoral immune defect observed in this disease. This study is registered at http://clinicaltrials.gov as NCT00466895.",Case Reports,3710.0,101.0,Chronic lymphocytic CLL involves a profound humoral immune defect and tumor-specific humoral tolerance that directly contribute to disease morbidity and mortality CD154 gene therapy can reverse this immune defect but attempts to do this pharmacologically have been unsuccessful The immune-modulatory agent lenalidomide shows clinical activity in CLL but its mechanism is poorly understood Here we demonstrate that lenalidomide induces expression of functional CD154 antigen on CLL cells both in vitro and in vivo This occurs via enhanced CD154 transcription mediated by a Nuclear Factor of Activated T cells c1 NFATc1 /Nuclear Factor-kappaB NF-kappaB complex and also through phosphoinositide-3 PI3 -kinase pathway-dependent stabilization of CD154 mRNA Importantly CD154-positive CLL cells up-regulate BID DR5 and p73 become sensitized to tumor necrosis factor-related apoptosis-inducing ligand TRAIL -mediated apoptosis and promote costimulatory activation of normal B cells to produce antibodies In CLL patients receiving lenalidomide similar evidence of CD154 activation is observed including BID DR5 and p73 induction and also development of anti-ROR1 tumor-directed antibodies Our data demonstrate that lenalidomide promotes CD154 expression on CLL cells with subsequent activation phenotype and may therefore reverse the humoral immune defect observed in this disease This study is registered at http //clinicaltrials.gov as NCT00466895,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2921, 8, 4399, 5498, 250, 5398, 2, 30, 112, 5498, 2614, 17, 1606, 1248, 6, 34, 787, 2, 282, 18281, 145, 36, 122, 1772, 26, 250, 5398, 84, 4374, 6, 1022, 26, 7854, 47, 85, 7581, 3, 250, 11424, 420, 1288, 1949, 38, 128, 4, 552, 84, 211, 670, 16, 1240, 1784, 467, 21, 608, 17, 1288, 1516, 55, 1, 583, 18281, 448, 23, 552, 37, 110, 4, 439, 2, 4, 386, 26, 1780, 847, 651, 18281, 866, 517, 20, 8, 928, 161, 1, 735, 102, 37, 6801, 34335, 928, 161, 2119, 1365, 2119, 840, 2, 120, 298, 4497, 27, 6892, 216, 308, 470, 3184, 1, 18281, 956, 1859, 18281, 109, 552, 37, 126, 2288, 2793, 10351, 2, 8242, 1417, 4242, 6, 30, 1523, 161, 139, 351, 1958, 1232, 2585, 517, 351, 2, 1617, 5555, 363, 1, 295, 132, 37, 6, 2410, 890, 4, 552, 7, 357, 1288, 288, 241, 1, 18281, 363, 16, 164, 141, 2793, 10351, 2, 8242, 504, 2, 120, 193, 1, 312, 9826, 30, 1166, 890, 114, 74, 608, 17, 1288, 2148, 18281, 55, 23, 552, 37, 5, 706, 363, 1005, 2, 68, 673, 1772, 3, 5498, 250, 5398, 164, 4, 26, 34, 26, 45, 16, 1653, 28, 5196, 1252, 1239, 22, 45273]",1442.0,19965642,645
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.,Blood,Blood,2009-12-02,"CD19 is a B cell-specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified constant fragment (Fc)-domain designed to enhance binding of FcgammaRIIIa. Herein, we demonstrate that XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest direct cytotoxicity, and antibody-dependent cellular phagocytosis but not complement-mediated cytotoxicity against CLL cells. Interestingly, XmAb5574 mediates significantly higher ADCC compared with both the humanized anti-CD19 nonengineered antibody it is derived from and also rituximab, a therapeutic antibody widely used in the treatment of CLL. The XmAb5574-dependent ADCC is mediated by natural killer (NK) cells through a granzyme B-dependent mechanism. The NK cell-mediated cytolytic and secretory function with XmAb5574 compared with the nonengineered antibody is associated with enhanced NK-cell activation, interferon production, extracellular signal-regulated kinase phosphorylation downstream of Fcgamma receptor, and no increased NK-cell apoptosis. Notably, enhanced NK cell-mediated ADCC with XmAb5574 was enhanced further by lenalidomide. These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies.",Journal Article,3702.0,63.0,CD19 is a B cell-specific antigen expressed on chronic lymphocytic CLL cells but to date has not been effectively targeted with therapeutic monoclonal antibodies XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified constant fragment Fc -domain designed to enhance binding of FcgammaRIIIa Herein we demonstrate that XmAb5574 mediates potent antibody-dependent cellular cytotoxicity ADCC modest direct cytotoxicity and antibody-dependent cellular phagocytosis but not complement-mediated cytotoxicity against CLL cells Interestingly XmAb5574 mediates significantly higher ADCC compared with both the humanized anti-CD19 nonengineered antibody it is derived from and also rituximab a therapeutic antibody widely used in the treatment of CLL The XmAb5574-dependent ADCC is mediated by natural killer NK cells through a granzyme B-dependent mechanism The NK cell-mediated cytolytic and secretory function with XmAb5574 compared with the nonengineered antibody is associated with enhanced NK-cell activation interferon production extracellular signal-regulated kinase phosphorylation downstream of Fcgamma receptor and no increased NK-cell apoptosis Notably enhanced NK cell-mediated ADCC with XmAb5574 was enhanced further by lenalidomide These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19 B-cell malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3158, 16, 8, 132, 31, 112, 448, 570, 23, 442, 1193, 552, 37, 84, 6, 1244, 71, 44, 85, 1856, 238, 5, 189, 848, 890, 20682, 16, 8, 229, 2794, 312, 3158, 848, 548, 5, 8, 1230, 4982, 5245, 4127, 1398, 1114, 6, 1304, 791, 1, 13662, 1986, 21, 608, 17, 20682, 3961, 1157, 548, 470, 763, 1408, 5551, 1721, 1196, 1408, 2, 548, 470, 763, 11788, 84, 44, 3731, 517, 1408, 480, 552, 37, 2873, 20682, 3961, 97, 142, 5551, 72, 5, 110, 3, 3619, 312, 3158, 45789, 548, 192, 16, 526, 29, 2, 120, 855, 8, 189, 548, 1792, 95, 4, 3, 24, 1, 552, 3, 20682, 470, 5551, 16, 517, 20, 1504, 3458, 1765, 37, 298, 8, 9965, 132, 470, 670, 3, 1765, 31, 517, 6957, 2, 7106, 343, 5, 20682, 72, 5, 3, 45789, 548, 16, 41, 5, 651, 1765, 31, 363, 1688, 1529, 1976, 1235, 1065, 216, 982, 1489, 1, 39185, 153, 2, 77, 101, 1765, 31, 351, 2552, 651, 1765, 31, 517, 5551, 5, 20682, 10, 651, 195, 20, 1288, 46, 272, 377, 1082, 538, 9, 195, 38, 193, 1, 20682, 22, 110, 8, 1411, 2, 4, 150, 5, 1288, 9, 3, 36, 1, 552, 2, 139, 3158, 132, 31, 441]",1459.0,19965644,714
Milatuzumab - a promising new immunotherapeutic agent.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2010-01-01,"Milatuzumab is a new immunotherapeutic agent targeting CD74, a membrane protein preferentially expressed in hematopoietic cancers and some solid tumors. Broad expression and fast internalization makes CD74 an ideal target for cancer therapy. We reviewed published articles about CD74 and milatuzumab. We present a comprehensive review of CD74 functions and provide explanation of milatuzumab antitumor effects. This review describes CD74 protein biology with the emphasis on the role of CD74 in tumor survival and its new role in regulation of the Fas death receptor. The development of CD74 targeting therapies to induce tumor regression and cancer cell apoptosis is described and results of clinical trials are discussed. Milatuzumab shows selective binding and rapid internalization into CD74-positive cancer cells. Milatuzumab with and without conjugated toxins synergizes with other chemotherapeutic agents and elicits significant antitumor effects in mice. In a Phase I trial, milatuzumab showed no severe adverse effects in patients with relapsed/refractory multiple myeloma and it stabilized the disease in some patients for up to 12 weeks. Ongoing trials testing different treatment schedules of milatuzumab in chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma indicate that milatuzumab shows no severe adverse effects in humans.",Journal Article,3672.0,35.0,Milatuzumab is a new immunotherapeutic agent targeting CD74 a membrane protein preferentially expressed in hematopoietic cancers and some solid tumors Broad expression and fast internalization makes CD74 an ideal target for cancer therapy We reviewed published articles about CD74 and milatuzumab We present a comprehensive review of CD74 functions and provide explanation of milatuzumab antitumor effects This review describes CD74 protein biology with the emphasis on the role of CD74 in tumor survival and its new role in regulation of the Fas death receptor The development of CD74 targeting therapies to induce tumor regression and cancer cell apoptosis is described and results of clinical trials are discussed Milatuzumab shows selective binding and rapid internalization into CD74-positive cancer cells Milatuzumab with and without conjugated toxins synergizes with other chemotherapeutic agents and elicits significant antitumor effects in mice In a Phase I trial milatuzumab showed no severe adverse effects in patients with relapsed/refractory multiple and it stabilized the disease in some patients for up to 12 weeks Ongoing trials testing different treatment schedules of milatuzumab in chronic lymphocytic 's and multiple indicate that milatuzumab shows no severe adverse effects in humans,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[12038, 16, 8, 217, 3222, 420, 529, 7780, 8, 1905, 178, 3509, 570, 4, 1007, 163, 2, 476, 537, 57, 2094, 55, 2, 5830, 7520, 4677, 7780, 35, 3662, 283, 9, 12, 36, 21, 446, 983, 2384, 545, 7780, 2, 12038, 21, 364, 8, 949, 206, 1, 7780, 1681, 2, 377, 6603, 1, 12038, 579, 176, 26, 206, 2677, 7780, 178, 891, 5, 3, 3136, 23, 3, 200, 1, 7780, 4, 30, 25, 2, 211, 217, 200, 4, 863, 1, 3, 3625, 273, 153, 3, 193, 1, 7780, 529, 235, 6, 1290, 30, 320, 2, 12, 31, 351, 16, 1027, 2, 99, 1, 38, 143, 32, 1588, 12038, 1949, 1094, 791, 2, 1321, 7520, 237, 7780, 109, 12, 37, 12038, 5, 2, 187, 3868, 13820, 10824, 5, 127, 1573, 183, 2, 8748, 93, 579, 176, 4, 399, 4, 8, 124, 70, 160, 12038, 224, 77, 905, 290, 176, 4, 7, 5, 591, 430, 232, 2, 192, 7368, 3, 34, 4, 476, 7, 9, 126, 6, 133, 244, 942, 143, 471, 338, 24, 2314, 1, 12038, 4, 442, 1193, 292, 2, 232, 1008, 17, 12038, 1949, 77, 905, 290, 176, 4, 3218]",1304.0,19968579,299
Predicting clinical outcome in CLL: how and why.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2009-01-01,"The clinical course of patients with chronic lymphocytic leukemia (CLL) is heterogeneous, with some patients experiencing rapid disease progression and others living for decades without requiring treatment. Clinical features and molecular/biologic factors such as ZAP-70, immunoglobulin heavy chain (IGHV) gene mutation status, and cytogenetic abnormalities on fluorescent in situ hybridization (FISH) have been found to be robust predictors of treatment-free survival and overall survival among newly diagnosed patients. Beyond their widely recognized value for providing insight into disease biology and utility for stratifying patient risk in clinical trials, these prognostic tools play an important role in the current counseling and management of patients with CLL. Recent studies have focused on how to combine the results of multiple prognostic assays into an integrated risk stratification system and explored how these characteristics influence response to treatment. This chapter reviews the available tools to stratify patient risk and discusses how these tools can be used in routine clinical practice to individualize patient counseling, guide the frequency of follow-up, and inform treatment selection.",Journal Article,4037.0,48.0,The clinical course of patients with chronic lymphocytic CLL is heterogeneous with some patients experiencing rapid disease progression and others living for decades without requiring treatment Clinical features and molecular/biologic factors such as ZAP-70 immunoglobulin heavy chain IGHV gene mutation status and cytogenetic abnormalities on fluorescent in situ hybridization FISH have been found to be robust predictors of treatment-free survival and overall survival among newly diagnosed patients Beyond their widely recognized value for providing insight into disease biology and utility for stratifying patient risk in clinical trials these prognostic tools play an important role in the current counseling and management of patients with CLL Recent studies have focused on how to combine the results of multiple prognostic assays into an integrated risk stratification system and explored how these characteristics influence response to treatment This chapter reviews the available tools to stratify patient risk and discusses how these tools can be used in routine clinical practice to individualize patient counseling guide the frequency of follow-up and inform treatment selection,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 906, 1, 7, 5, 442, 1193, 552, 16, 1564, 5, 476, 7, 2985, 1321, 34, 91, 2, 1749, 2798, 9, 1968, 187, 1888, 24, 38, 404, 2, 219, 1283, 130, 225, 22, 6251, 431, 2593, 4013, 1260, 6220, 145, 258, 156, 2, 1266, 1171, 23, 2910, 4, 957, 1554, 1277, 47, 85, 204, 6, 40, 1922, 674, 1, 24, 115, 25, 2, 63, 25, 107, 732, 265, 7, 1654, 136, 1792, 1904, 549, 9, 1736, 2670, 237, 34, 891, 2, 1207, 9, 5035, 69, 43, 4, 38, 143, 46, 177, 1896, 1343, 35, 305, 200, 4, 3, 291, 2011, 2, 284, 1, 7, 5, 552, 435, 94, 47, 1649, 23, 832, 6, 4680, 3, 99, 1, 232, 177, 1013, 237, 35, 2102, 43, 1541, 398, 2, 1443, 832, 46, 374, 1054, 51, 6, 24, 26, 6366, 2004, 3, 390, 1896, 6, 3570, 69, 43, 2, 2759, 832, 46, 1896, 122, 40, 95, 4, 1311, 38, 758, 6, 7177, 69, 2011, 1597, 3, 675, 1, 166, 126, 2, 2295, 24, 881]",1191.0,20008228,567
"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-12-14,"Flavopiridol downmodulates antiapoptotic proteins associated with resistance to fludarabine and rituximab and is effective against p53-mutated chronic lymphocytic leukemia (CLL). We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR. Therapy included fludarabine 25 mg/m(2) intravenously (IV) days 1 to 5 and rituximab 375 mg/m(2) day 1 every 28 days for 6 cycles. We administered flavopiridol 50 mg/m(2) by 1-hour IV bolus (IVB) day 1 (n = 15); day 1 to 2 (n = 6); 20 mg/m(2) 30-minute IVB + 20 mg/m(2) 4-hour IV infusion (n = 3); or 30 mg/m(2) + 30 mg/m(2) (n = 14). Thirty-eight patients (median age, 62 years) with MCL (n = 10); indolent B-NHL including follicular (n = 9), marginal zone (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), were enrolled. Twenty-two patients were previously untreated; 16 had received one to two prior therapies. Two patients in cohort 2 developed grade 3 dose-limiting toxicity (seizures, renal insufficiency). The median number of treatment cycles was 4, with cytopenias (n = 10) and fatigue (n = 3) the most common reasons for early discontinuation. Overall response rate was 82% (complete response, 50%; unconfirmed complete response, 5%; partial response, 26%), including 80% of patients with MCL (median age, 68; seven complete responses, one partial response). Median progression-free survival (PFS) was 25.6 months. Median PFS of patients with nonblastoid variant MCL (n = 8) was 35.9 months. FFR was active in MCL, indolent B-NHL, and CLL and should be studied for older patients with MCL who are not candidates for aggressive chemotherapy.","Clinical Trial, Phase I",3690.0,72.0,Flavopiridol downmodulates antiapoptotic proteins associated with resistance to fludarabine and rituximab and is effective against p53-mutated chronic lymphocytic CLL We conducted a phase I study of flavopiridol fludarabine and rituximab FFR in patients with mantle-cell MCL indolent B-cell 's lymphomas B-NHL and CLL to determine the activity of FFR Therapy included fludarabine 25 mg/m 2 intravenously IV days 1 to 5 and rituximab 375 mg/m 2 day 1 every 28 days for 6 cycles We administered flavopiridol 50 mg/m 2 by 1-hour IV bolus IVB day 1 n 15 day 1 to 2 n 6 20 mg/m 2 30-minute IVB 20 mg/m 2 4-hour IV infusion n 3 or 30 mg/m 2 30 mg/m 2 n 14 Thirty-eight patients median age 62 years with MCL n 10 indolent B-NHL including follicular n 9 marginal zone n 4 lymphoplasmacytic n 1 or small lymphocytic n 3 and CLL n 11 were enrolled Twenty-two patients were previously untreated 16 had received one to two prior therapies Two patients in cohort 2 developed grade 3 dose-limiting toxicity seizures insufficiency The median number of treatment cycles was 4 with cytopenias n 10 and fatigue n 3 the most common reasons for early discontinuation Overall response rate was 82 complete response 50 unconfirmed complete response 5 partial response 26 including 80 of patients with MCL median age 68 seven complete responses one partial response Median progression-free survival PFS was 25.6 months Median PFS of patients with nonblastoid variant MCL n 8 was 35.9 months FFR was active in MCL indolent B-NHL and CLL and should be studied for older patients with MCL who are not candidates for aggressive chemotherapy,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 39188, 4176, 652, 41, 5, 251, 6, 2027, 2, 855, 2, 16, 323, 480, 624, 1185, 442, 1193, 552, 21, 426, 8, 124, 70, 45, 1, 3030, 2027, 2, 855, 15974, 4, 7, 5, 2757, 31, 1308, 2316, 132, 31, 292, 1557, 132, 1176, 2, 552, 6, 223, 3, 128, 1, 15974, 36, 159, 2027, 243, 81, 188, 18, 1672, 478, 162, 14, 6, 33, 2, 855, 4175, 81, 188, 18, 218, 14, 454, 339, 162, 9, 49, 410, 21, 468, 3030, 212, 81, 188, 18, 20, 14, 2583, 478, 3604, 7042, 218, 14, 78, 167, 218, 14, 6, 18, 78, 49, 179, 81, 188, 18, 201, 3949, 7042, 179, 81, 188, 18, 39, 2583, 478, 904, 78, 27, 15, 201, 81, 188, 18, 201, 81, 188, 18, 78, 213, 977, 659, 7, 52, 89, 744, 60, 5, 1308, 78, 79, 2316, 132, 1176, 141, 1974, 78, 83, 3450, 3614, 78, 39, 5325, 78, 14, 15, 302, 1193, 78, 27, 2, 552, 78, 175, 11, 346, 737, 100, 7, 11, 373, 1278, 245, 42, 103, 104, 6, 100, 324, 235, 100, 7, 4, 180, 18, 276, 88, 27, 61, 817, 155, 4448, 4360, 3, 52, 207, 1, 24, 410, 10, 39, 5, 5635, 78, 79, 2, 613, 78, 27, 3, 96, 186, 2325, 9, 191, 2007, 63, 51, 116, 10, 878, 236, 51, 212, 5971, 236, 51, 33, 450, 51, 432, 141, 493, 1, 7, 5, 1308, 52, 89, 806, 648, 236, 253, 104, 450, 51, 52, 91, 115, 25, 300, 10, 243, 49, 53, 52, 300, 1, 7, 5, 58477, 1142, 1308, 78, 66, 10, 465, 83, 53, 15974, 10, 544, 4, 1308, 2316, 132, 1176, 2, 552, 2, 257, 40, 656, 9, 434, 7, 5, 1308, 54, 32, 44, 1931, 9, 571, 56]",1613.0,20008633,115
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.,British journal of haematology,Br. J. Haematol.,2009-12-16,"Interphase cytogenetics are commonly used to identify clonal abnormalities in chronic lymphocytic leukemia (CLL) patients but fail to identify recurrent translocations that ultimately can direct more focused molecular characterization. Given the importance of del(17p13.1) in CLL outcome, we performed an extensive review of 1213 patients undergoing metaphase cytogenetics at our institution and identified 16 (1.3%) with a recurrent unbalanced translocation between the p arms of chromosomes 17 and 18 that results in a dicentric chromosome with loss of much of 17p and 18p. The dic(17;18)(p11.2;p11.2) was associated with a complex (three or more unrelated cytogenetic abnormalities) karyotype in 12 patients (75%) at the time that the abnormality was first identified, and eventually associated with a complex karyotype in 94% of patients. IGHV mutational analysis was un-mutated in 88% of cases where evaluation was possible. Except for one patient who was diagnosed with CLL incidentally during a workup for metastatic tonsillar cancer, all patients identified with dic(17;18)(p11.2;p11.2) met criteria for disease treatment, with a median time from diagnosis to first treatment of 15 months. Our data demonstrate that dic(17;18)(p11.2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing.",Journal Article,3688.0,13.0,Interphase cytogenetics are commonly used to identify clonal abnormalities in chronic lymphocytic CLL patients but fail to identify recurrent translocations that ultimately can direct more focused molecular characterization Given the importance of del 17p13.1 in CLL outcome we performed an extensive review of 1213 patients undergoing metaphase cytogenetics at our institution and identified 16 1.3 with a recurrent unbalanced translocation between the p arms of chromosomes 17 and 18 that results in a dicentric chromosome with loss of much of 17p and 18p The dic 17 18 p11.2 p11.2 was associated with a complex three or more unrelated cytogenetic abnormalities karyotype in 12 patients 75 at the time that the abnormality was first identified and eventually associated with a complex karyotype in 94 of patients IGHV mutational analysis was un-mutated in 88 of cases where evaluation was possible Except for one patient who was diagnosed with CLL incidentally during a workup for metastatic tonsillar cancer all patients identified with dic 17 18 p11.2 p11.2 met criteria for disease treatment with a median time from diagnosis to first treatment of 15 months Our data demonstrate that dic 17 18 p11.2 p11.2 is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression Future efforts to identify genes disrupted by this translocation are warranted and ongoing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8081, 2510, 32, 841, 95, 6, 255, 1946, 1171, 4, 442, 1193, 552, 7, 84, 4373, 6, 255, 387, 3262, 17, 2050, 122, 1196, 80, 1649, 219, 2136, 447, 3, 1187, 1, 3084, 7526, 14, 4, 552, 228, 21, 173, 35, 1344, 206, 1, 26075, 7, 479, 10569, 2510, 28, 114, 731, 2, 108, 245, 14, 27, 5, 8, 387, 11947, 2006, 59, 3, 19, 1335, 1, 3560, 269, 2, 203, 17, 99, 4, 8, 33550, 1170, 5, 407, 1, 1802, 1, 4135, 2, 45584, 3, 19893, 269, 203, 11230, 18, 11230, 18, 10, 41, 5, 8, 840, 169, 15, 80, 2092, 1266, 1171, 3385, 4, 133, 7, 481, 28, 3, 98, 17, 3, 3698, 10, 157, 108, 2, 3124, 41, 5, 8, 840, 3385, 4, 960, 1, 7, 6220, 1619, 65, 10, 17157, 1185, 4, 889, 1, 140, 1257, 451, 10, 899, 2187, 9, 104, 69, 54, 10, 265, 5, 552, 5925, 190, 8, 4755, 9, 113, 13411, 12, 62, 7, 108, 5, 19893, 269, 203, 11230, 18, 11230, 18, 543, 371, 9, 34, 24, 5, 8, 52, 98, 29, 147, 6, 157, 24, 1, 167, 53, 114, 74, 608, 17, 19893, 269, 203, 11230, 18, 11230, 18, 16, 8, 229, 387, 1266, 3698, 4, 552, 41, 5, 191, 89, 28, 147, 2, 2241, 34, 91, 508, 1413, 6, 255, 214, 5576, 20, 26, 2006, 32, 1197, 2, 942]",1428.0,20015097,690
Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.,American journal of hematology,Am. J. Hematol.,2010-01-01,"Metabolic pathway enzymes, such as Cytochrome P450 (CYP), glutathione S-transferase (GST), and N-acetyltransferases (NAT) are involved in activation and detoxification of environmental carcinogens as well as drug metabolism. We hypothesized that the genetic variations in such metabolic pathways may affect NHL prognosis and survival. Follow-up information of 496 female NHL incident cases diagnosed during 1996-2000 in Connecticut were abstracted from the Connecticut Tumor Registry in 2008; survival analyses were conducted by comparing the Kaplan-Meier curves, and hazard ratios (HR) were computed from the Cox Proportional Hazard models adjusting for demographic and tumor characteristics which were suggested by previous studies to be determinants of NHL survival. We identified six SNPs from four metabolism genes (CYP2E1, GSTP1, GSTT1, and NAT1) that were associated with NHL survival. Specifically, polymorphisms in GSTT1 were associated with follicular lymphoma survival; and polymorphisms in CYP2E1, GSTP1, and NAT1 were associated with survival of chronic lymphocytic leukemia/small lymphocytic lymphoma. Our study suggests that genetic polymorphisms in metabolic pathways may help improve the prediction of NHL survival and prognosis.",Journal Article,3672.0,19.0,Metabolic pathway enzymes such as Cytochrome P450 CYP glutathione S-transferase GST and N-acetyltransferases NAT are involved in activation and detoxification of environmental carcinogens as well as drug metabolism We hypothesized that the genetic variations in such metabolic pathways may affect NHL prognosis and survival Follow-up information of 496 female NHL incident cases diagnosed during 1996-2000 in Connecticut were abstracted from the Connecticut Tumor Registry in 2008 survival analyses were conducted by comparing the Kaplan-Meier curves and hazard ratios HR were computed from the Cox Proportional Hazard models adjusting for demographic and tumor characteristics which were suggested by previous studies to be determinants of NHL survival We identified six SNPs from four metabolism genes CYP2E1 GSTP1 GSTT1 and NAT1 that were associated with NHL survival Specifically polymorphisms in GSTT1 were associated with follicular survival and polymorphisms in CYP2E1 GSTP1 and NAT1 were associated with survival of chronic lymphocytic leukemia/small lymphocytic Our study suggests that genetic polymorphisms in metabolic pathways may help improve the prediction of NHL survival and prognosis,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1436, 308, 3039, 225, 22, 4155, 6965, 9495, 4571, 695, 4402, 5645, 2, 78, 18849, 11145, 32, 646, 4, 363, 2, 13817, 1, 3766, 8850, 22, 149, 22, 234, 1600, 21, 1237, 17, 3, 336, 2293, 4, 225, 1436, 460, 68, 1158, 1176, 356, 2, 25, 166, 126, 487, 1, 11291, 1061, 1176, 2631, 140, 265, 190, 2648, 1081, 4, 26273, 11, 4106, 29, 3, 26273, 30, 1608, 4, 1375, 25, 318, 11, 426, 20, 1430, 3, 876, 882, 2400, 2, 360, 1137, 168, 11, 1220, 29, 3, 418, 831, 360, 274, 1358, 9, 1540, 2, 30, 374, 92, 11, 1148, 20, 698, 94, 6, 40, 3403, 1, 1176, 25, 21, 108, 437, 1109, 29, 294, 1600, 214, 20987, 5689, 10790, 2, 12247, 17, 11, 41, 5, 1176, 25, 1225, 1203, 4, 10790, 11, 41, 5, 1974, 25, 2, 1203, 4, 20987, 5689, 2, 12247, 11, 41, 5, 25, 1, 442, 1193, 2647, 302, 1193, 114, 45, 844, 17, 336, 1203, 4, 1436, 460, 68, 987, 401, 3, 1590, 1, 1176, 25, 2, 356]",1200.0,20029944,6
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2010-01-01,"The use of nucleoside analog-based chemo-immunotherapeutic regimens over the last decade has significantly improved outcomes in patients with chronic lymphocytic leukemia (CLL). Nonetheless, virtually all patients with CLL relapse from chemoimmmunotherapy and current available therapies are not curative. Identifying therapies that effectively eliminate CLL cells and lack immunesuppression represent an exciting new therapeutic approach. IMiDs are a class of immunomodulating drugs that increase T-cell and NK-cell directed killing of tumor cells. The first generation molecule is thalidomide followed by a second generation molecule lenalidomide that lacks neurotoxicity and is being explored more extensively in clinical trials. Lenalidomide has been shown to benefit patients with multiple myeloma, myelodysplastic syndromes, and lymphoma. Initial reports in patients with relapsed and refractory CLL have shown promising responses. In a subset of patients with CLL complete responses have been noted. Subsequent studies, however, have suggested that this class of drug can also have serious and potentially life-threatening side effects including myelosuppression, tumor flare reaction and in a small subset of patients tumor lysis syndrome. Tumor flare with both thalidomide and lenalidomide appear to be disease specific to CLL and may reflect clinical manifestation of CLL tumor cell activation. As a consequence of these disease specific effects, the optimal safe dose of lenalidomide in CLL remains to be determined but appears to be lower than that tolerated in other B-cell malignancies. To date, biomarkers for response remain poorly defined and the relationship of clinical benefit to tumor flare is uncertain. This review examines the existing literature on the use of IMiDs in patients with CLL and provides suggestions for future research in this area.",Journal Article,3672.0,26.0,The use of nucleoside analog-based chemo-immunotherapeutic regimens over the last decade has significantly improved outcomes in patients with chronic lymphocytic CLL Nonetheless virtually all patients with CLL relapse from chemoimmmunotherapy and current available therapies are not curative Identifying therapies that effectively eliminate CLL cells and lack immunesuppression represent an exciting new therapeutic approach IMiDs are a class of immunomodulating drugs that increase T-cell and NK-cell directed killing of tumor cells The first generation molecule is thalidomide followed by a second generation molecule lenalidomide that lacks neurotoxicity and is being explored more extensively in clinical trials Lenalidomide has been shown to benefit patients with multiple syndromes and Initial reports in patients with relapsed and refractory CLL have shown promising responses In a subset of patients with CLL complete responses have been noted Subsequent studies however have suggested that this class of drug can also have serious and potentially life-threatening side effects including myelosuppression tumor flare reaction and in a small subset of patients tumor lysis syndrome Tumor flare with both thalidomide and lenalidomide appear to be disease specific to CLL and may reflect clinical manifestation of CLL tumor cell activation As a consequence of these disease specific effects the optimal safe dose of lenalidomide in CLL remains to be determined but appears to be lower than that tolerated in other B-cell malignancies To date biomarkers for response remain poorly defined and the relationship of clinical benefit to tumor flare is uncertain This review examines the existing literature on the use of IMiDs in patients with CLL and provides suggestions for future research in this area,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 119, 1, 4032, 3497, 90, 3341, 3222, 472, 252, 3, 1060, 2025, 71, 97, 231, 123, 4, 7, 5, 442, 1193, 552, 4648, 5860, 62, 7, 5, 552, 429, 29, 58535, 2, 291, 390, 235, 32, 44, 1075, 1386, 235, 17, 1856, 4964, 552, 37, 2, 926, 58536, 1231, 35, 4963, 217, 189, 353, 7587, 32, 8, 1040, 1, 13861, 600, 17, 344, 102, 31, 2, 1765, 31, 1166, 3003, 1, 30, 37, 3, 157, 914, 1354, 16, 2159, 370, 20, 8, 419, 914, 1354, 1288, 17, 6856, 3561, 2, 16, 486, 1443, 80, 3576, 4, 38, 143, 1288, 71, 85, 443, 6, 247, 7, 5, 232, 2040, 2, 388, 1198, 4, 7, 5, 591, 2, 430, 552, 47, 443, 721, 253, 4, 8, 697, 1, 7, 5, 552, 236, 253, 47, 85, 1051, 706, 94, 137, 47, 1148, 17, 26, 1040, 1, 234, 122, 120, 47, 1762, 2, 751, 358, 3691, 1152, 176, 141, 2858, 30, 6915, 1329, 2, 4, 8, 302, 697, 1, 7, 30, 4783, 681, 30, 6915, 5, 110, 2159, 2, 1288, 1322, 6, 40, 34, 112, 6, 552, 2, 68, 2694, 38, 6746, 1, 552, 30, 31, 363, 22, 8, 4177, 1, 46, 34, 112, 176, 3, 665, 1165, 61, 1, 1288, 4, 552, 469, 6, 40, 509, 84, 1233, 6, 40, 280, 76, 17, 421, 4, 127, 132, 31, 441, 6, 1244, 582, 9, 51, 918, 1240, 395, 2, 3, 858, 1, 38, 247, 6, 30, 6915, 16, 2717, 26, 206, 4468, 3, 1692, 789, 23, 3, 119, 1, 7587, 4, 7, 5, 552, 2, 777, 9796, 9, 508, 389, 4, 26, 965]",1805.0,20055657,160
Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.,mAbs,MAbs,2010-01-08,"CD4(+) CD25(+) regulatory T cells are expanded in solid and hematological malignancies including chronic lymphocytic leukemia (CLL). Several cytokines and co-stimulatory molecules are required for generation, survival and maintenance of their suppressive effect. We and others have shown direct cytotoxic effect of the novel common gamma chain cytokine interleukin (IL)-21 on primary B cells from CLL patients. Since members of this family of cytokines are known to exhibit their effects on diverse immune cells, we have examined the effects of IL-21 on CLL patient derived regulatory T cell (Treg) induction, expansion and the inhibitory effect on natural killer cells in vitro. We demonstrate here the expression of IL-21 receptor in CD4(+)CD25(High) regulatory cells from CLL patients. In contrast to IL-2, the IL-21 cytokine failed to mediate expansion of regulatory T cells or induced expression of Foxp3 in CD4(+)CD25(Intermediate) or CD4(+)CD25(Dim/-) T cells in whole blood derived from CLL patients. Interestingly, in contrast to their differential effects on expansion of the CD4(+)CD25(+)Foxp3(+)T cells, IL-2 and IL-21 exhibited a redundant role in Treg mediated suppression of NK cell mediated antibody dependent cytotoxicity function. Given the infusion related toxicities and pro-survival effect of IL-2 in CLL, these studies provide a rationale to explore IL-21 as an alternate gamma chain cytokine in CLL therapy.",Journal Article,3665.0,23.0,CD4 CD25 regulatory T cells are expanded in solid and hematological malignancies including chronic lymphocytic CLL Several cytokines and co-stimulatory molecules are required for generation survival and maintenance of their suppressive effect We and others have shown direct cytotoxic effect of the novel common gamma chain cytokine interleukin IL -21 on primary B cells from CLL patients Since members of this family of cytokines are known to exhibit their effects on diverse immune cells we have examined the effects of IL-21 on CLL patient derived regulatory T cell Treg induction expansion and the inhibitory effect on natural killer cells in vitro We demonstrate here the expression of IL-21 receptor in CD4 CD25 High regulatory cells from CLL patients In contrast to IL-2 the IL-21 cytokine failed to mediate expansion of regulatory T cells or induced expression of Foxp3 in CD4 CD25 Intermediate or CD4 CD25 Dim/- T cells in whole blood derived from CLL patients Interestingly in contrast to their differential effects on expansion of the CD4 CD25 Foxp3 T cells IL-2 and IL-21 exhibited a redundant role in Treg mediated suppression of NK cell mediated antibody dependent cytotoxicity function Given the infusion related toxicities and pro-survival effect of IL-2 in CLL these studies provide a rationale to explore IL-21 as an alternate gamma chain cytokine in CLL therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1440, 4531, 1253, 102, 37, 32, 2064, 4, 537, 2, 2890, 441, 141, 442, 1193, 552, 392, 1886, 2, 1269, 6708, 1598, 32, 616, 9, 914, 25, 2, 1146, 1, 136, 3707, 254, 21, 2, 1749, 47, 443, 1196, 759, 254, 1, 3, 229, 186, 1705, 1260, 1675, 1603, 501, 239, 23, 86, 132, 37, 29, 552, 7, 1192, 1684, 1, 26, 607, 1, 1886, 32, 440, 6, 2239, 136, 176, 23, 1867, 250, 37, 21, 47, 409, 3, 176, 1, 501, 239, 23, 552, 69, 526, 1253, 102, 31, 3960, 504, 1422, 2, 3, 1810, 254, 23, 1504, 3458, 37, 4, 439, 21, 608, 467, 3, 55, 1, 501, 239, 153, 4, 1440, 4531, 64, 1253, 37, 29, 552, 7, 4, 748, 6, 501, 18, 3, 501, 239, 1675, 1551, 6, 3367, 1422, 1, 1253, 102, 37, 15, 277, 55, 1, 3548, 4, 1440, 4531, 919, 15, 1440, 4531, 8657, 102, 37, 4, 902, 315, 526, 29, 552, 7, 2873, 4, 748, 6, 136, 1777, 176, 23, 1422, 1, 3, 1440, 4531, 3548, 102, 37, 501, 18, 2, 501, 239, 1416, 8, 10716, 200, 4, 3960, 517, 1332, 1, 1765, 31, 517, 548, 470, 1408, 343, 447, 3, 904, 139, 385, 2, 1805, 25, 254, 1, 501, 18, 4, 552, 46, 94, 377, 8, 1728, 6, 1645, 501, 239, 22, 35, 4689, 1705, 1260, 1675, 4, 552, 36]",1380.0,20081380,438
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.,Cancer research,Cancer Res.,2010-02-02,"Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease. By probing high-density protein microarrays with patient plasma, we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma. Three antigens-C6orf130, MDS032, and ZFYVE19-were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells. DAPK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences are identical in both donor and tumor. Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens. Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.",Journal Article,3640.0,25.0,Patients with chronic lymphocytic CLL who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion DLI showing the potency of donor-derived immunity in eradicating tumors We sought to elucidate the antigenic basis of the effective graft-versus-leukemia GvL responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease By probing high-density protein microarrays with patient plasma we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma Three antigens-C6orf130 MDS032 and ZFYVE19-were identified by both patients Along with additional candidate antigens DAPK3 SERBP1 and OGFOD1 these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells DAPK3 and the shared antigens do not represent minor histocompatibility antigens as their sequences are identical in both donor and tumor Although ZFYVE19 DAPK3 and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens Moreover antibody reactivity against these antigens was temporally correlated with clinical disease regression These B-cell antigens represent promising biomarkers of effective anti-CLL immunity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 54, 429, 50, 1063, 941, 68, 1359, 1480, 734, 366, 1488, 1448, 904, 4676, 2069, 3, 3593, 1, 1488, 526, 1604, 4, 11001, 57, 21, 990, 6, 3061, 3, 8357, 877, 1, 3, 323, 1599, 185, 2647, 8149, 253, 41, 5, 4676, 9, 3, 24, 1, 552, 20, 4449, 3, 1121, 1, 554, 548, 253, 931, 4, 100, 4676, 73, 7, 54, 513, 319, 337, 734, 187, 1599, 185, 1204, 34, 20, 15492, 64, 1263, 178, 2774, 5, 69, 554, 21, 2747, 465, 2117, 2087, 1575, 17, 5179, 64, 8444, 548, 4601, 378, 4, 539, 4676, 76, 4, 671, 4676, 554, 169, 1575, 58612, 58613, 2, 45865, 11, 108, 20, 110, 7, 1510, 5, 402, 1609, 1575, 39225, 58614, 2, 45866, 46, 652, 224, 142, 3268, 2, 178, 55, 4, 132, 37, 2, 552, 37, 72, 5, 295, 672, 315, 3041, 37, 39225, 2, 3, 2664, 1575, 1022, 44, 1231, 2278, 6537, 1575, 22, 136, 2866, 32, 3038, 4, 110, 1488, 2, 30, 242, 45865, 39225, 2, 45866, 5179, 1048, 548, 4601, 4, 133, 295, 976, 2, 133, 56, 73, 552, 7, 33, 1, 133, 552, 7, 5, 38, 8149, 253, 11, 34050, 2163, 6, 46, 1575, 1393, 548, 4601, 480, 46, 1575, 10, 11114, 438, 5, 38, 34, 320, 46, 132, 31, 1575, 1231, 721, 582, 1, 323, 312, 552, 1604]",1573.0,20124481,431
"STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.",Blood,Blood,2010-02-12,"Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western hemisphere, but its pathogenesis is still poorly understood. Constitutive tyrosine phosphorylation (p) of signal transducer and activator of transcription (STAT) 3 occurs in several solid tumors and hematologic malignancies. In CLL, however, STAT3 is constitutively phosphorylated on serine 727, not tyrosine 705, residues. Because the biologic significance of serine pSTAT3 in CLL is not known, we studied peripheral blood cells of 106 patients with CLL and found that, although tyrosine pSTAT3 was inducible, serine pSTAT3 was constitutive in all patients studied, regardless of blood count, disease stage, or treatment status. In addition, we demonstrated that constitutive serine pSTAT3 translocates to the nucleus by the karyopherin-beta nucleocytoplasmic system and binds DNA. Dephosphorylation of inducible tyrosine pSTAT3 did not affect STAT3-DNA binding, suggesting that constitutive serine pSTAT3 binds DNA. Furthermore, infection of CLL cells with lentiviral STAT3-small hairpin RNA reduced the expression of several STAT3-regulated survival and proliferation genes and induced apoptosis, suggesting that constitutive serine pSTAT3 initiates transcription in CLL cells. Taken together, our data suggest that constitutive phosphorylation of STAT3 on serine 727 residues is a hallmark of CLL and that STAT3 be considered a therapeutic target in this disease.",Journal Article,3630.0,,Chronic lymphocytic CLL is the most common in the Western hemisphere but its pathogenesis is still poorly understood Constitutive tyrosine phosphorylation p of signal transducer and activator of transcription STAT 3 occurs in several solid tumors and hematologic malignancies In CLL however STAT3 is constitutively phosphorylated on serine 727 not tyrosine 705 residues Because the biologic significance of serine pSTAT3 in CLL is not known we studied peripheral blood cells of 106 patients with CLL and found that although tyrosine pSTAT3 was inducible serine pSTAT3 was constitutive in all patients studied regardless of blood count disease stage or treatment status In addition we demonstrated that constitutive serine pSTAT3 translocates to the nucleus by the karyopherin-beta nucleocytoplasmic system and binds DNA Dephosphorylation of inducible tyrosine pSTAT3 did not affect STAT3-DNA binding suggesting that constitutive serine pSTAT3 binds DNA Furthermore infection of CLL cells with lentiviral STAT3-small hairpin RNA reduced the expression of several STAT3-regulated survival and proliferation genes and induced apoptosis suggesting that constitutive serine pSTAT3 initiates transcription in CLL cells Taken together our data suggest that constitutive phosphorylation of STAT3 on serine 727 residues is a hallmark of CLL and that STAT3 be considered a therapeutic target in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 4, 3, 1521, 12741, 84, 211, 1384, 16, 1234, 1240, 1784, 3178, 564, 982, 19, 1, 1235, 5182, 2, 3393, 1, 866, 4168, 27, 1780, 4, 392, 537, 57, 2, 813, 441, 4, 552, 137, 1439, 16, 2818, 2365, 23, 3734, 14093, 44, 564, 11303, 6418, 408, 3, 1283, 724, 1, 3734, 6480, 4, 552, 16, 44, 440, 21, 656, 672, 315, 37, 1, 3251, 7, 5, 552, 2, 204, 17, 242, 564, 6480, 10, 2877, 3734, 6480, 10, 3178, 4, 62, 7, 656, 1583, 1, 315, 1276, 34, 82, 15, 24, 156, 4, 352, 21, 264, 17, 3178, 3734, 6480, 22560, 6, 3, 4262, 20, 3, 34838, 1090, 26914, 398, 2, 3333, 261, 7849, 1, 2877, 564, 6480, 205, 44, 1158, 1439, 261, 791, 802, 17, 3178, 3734, 6480, 3333, 261, 798, 930, 1, 552, 37, 5, 7823, 1439, 302, 5957, 893, 405, 3, 55, 1, 392, 1439, 1065, 25, 2, 457, 214, 2, 277, 351, 802, 17, 3178, 3734, 6480, 11935, 866, 4, 552, 37, 1633, 1162, 114, 74, 309, 17, 3178, 982, 1, 1439, 23, 3734, 14093, 6418, 16, 8, 4683, 1, 552, 2, 17, 1439, 40, 515, 8, 189, 283, 4, 26, 34]",1397.0,20154216,407
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.,Cancer,Cancer,2010-05-01,"Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) often have chemotherapy-resistant disease, resulting in poor prognosis. The aim of this study was to learn if inhibition of the mammalian target of rapamycin (mTOR) would produce tumor responses. This was a phase 2 study of oral single-agent everolimus (10 mg/day) for recurrent/refractory indolent lymphoid malignancies including CLL. Four of 22 patients with CLL (18%; 95% confidence interval, 5%-40%) achieved a partial remission to therapy. An unanticipated finding in this study was an increase in absolute lymphocyte count (ALC) associated with a decrease in lymphadenopathy in 8 (36%) patients. ALC increased a median of 4.8-fold (range, 1.9- to 25.1-fold), and the clinically measurable lymphadenopathy decreased a median of 75.5% (range, 38%-93%) compared with baseline measurements. Everolimus has modest antitumor activity against CLL and can mobilize malignant cells from nodal masses into the peripheral circulation in a subset of CLL patients. Because CLL cells in lymphatic tissue and bone marrow can be more resistant to therapy than circulating CLL cells, the ability of everolimus to mobilize CLL cells into the circulation could be used in combination therapeutic regimens.","Clinical Trial, Phase II",3552.0,86.0,Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphocytic CLL often have chemotherapy-resistant disease resulting in poor prognosis The aim of this study was to learn if inhibition of the mammalian target of rapamycin mTOR would produce tumor responses This was a phase 2 study of oral single-agent everolimus 10 mg/day for recurrent/refractory indolent lymphoid malignancies including CLL Four of 22 patients with CLL 18 95 confidence interval 5 -40 achieved a partial remission to therapy An unanticipated finding in this study was an increase in absolute lymphocyte count ALC associated with a decrease in lymphadenopathy in 8 36 patients ALC increased a median of 4.8-fold range 1.9- to 25.1-fold and the clinically measurable lymphadenopathy decreased a median of 75.5 range 38 -93 compared with baseline measurements Everolimus has modest antitumor activity against CLL and can mobilize malignant cells from nodal masses into the peripheral circulation in a subset of CLL patients Because CLL cells in lymphatic tissue and marrow can be more resistant to therapy than circulating CLL cells the ability of everolimus to mobilize CLL cells into the circulation could be used in combination therapeutic regimens,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 387, 430, 442, 1193, 2647, 302, 1193, 552, 629, 47, 56, 436, 34, 1113, 4, 334, 356, 3, 1130, 1, 26, 45, 10, 6, 7586, 492, 297, 1, 3, 2359, 283, 1, 1620, 873, 688, 2410, 30, 253, 26, 10, 8, 124, 18, 45, 1, 518, 226, 420, 1400, 79, 81, 218, 9, 387, 430, 2316, 2303, 441, 141, 552, 294, 1, 350, 7, 5, 552, 203, 48, 307, 268, 33, 327, 513, 8, 450, 734, 6, 36, 35, 12580, 1567, 4, 26, 45, 10, 35, 344, 4, 1766, 1448, 1276, 3749, 41, 5, 8, 775, 4, 4962, 4, 66, 511, 7, 3749, 101, 8, 52, 1, 39, 66, 1116, 184, 14, 83, 6, 243, 14, 1116, 2, 3, 505, 1884, 4962, 340, 8, 52, 1, 481, 33, 184, 519, 966, 72, 5, 330, 1685, 1400, 71, 1721, 579, 128, 480, 552, 2, 122, 13788, 393, 37, 29, 779, 2692, 237, 3, 672, 4984, 4, 8, 697, 1, 552, 7, 408, 552, 37, 4, 2936, 246, 2, 581, 122, 40, 80, 436, 6, 36, 76, 1033, 552, 37, 3, 801, 1, 1400, 6, 13788, 552, 37, 237, 3, 4984, 359, 40, 95, 4, 150, 189, 472]",1238.0,20166206,10
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.,Leukemia research,Leuk. Res.,2010-02-19,"The compromised antioxidant defense system in chronic lymphocytic leukemia (CLL) suggested a potential use for reactive oxygen species (ROS) generating arsenic trioxide (ATO) and ascorbic acid. While both ATO and ascorbic acid mediate cytotoxicity in CLL B cells as single agents, the efficacy of ATO is enhanced by ascorbic acid. This effect is dependent on increased ROS accumulation, as pretreatment of B-CLL cells with a glutathione reducing buthionine sulfoximine or catalase inhibiting aminotriazole, enhanced ATO/ascorbic acid-mediated cytotoxicity. Pretreatment with reducing agents such as catalase, or thiol antioxidant, N-acetyl cysteine or GSH also abrogated ATO/ascorbic acid-mediated cytotoxicity. Furthermore, Hu1D10-mediated cell death was enhanced with ATO and ascorbic acid, thus justifying potential combination of ATO/arsenic trioxide therapy with antibodies such as Hu1D10 that also cause accumulation of ROS.",Journal Article,3623.0,17.0,The compromised antioxidant defense system in chronic lymphocytic CLL suggested a potential use for reactive oxygen species ROS generating arsenic trioxide ATO and ascorbic acid While both ATO and ascorbic acid mediate cytotoxicity in CLL B cells as single agents the efficacy of ATO is enhanced by ascorbic acid This effect is dependent on increased ROS accumulation as pretreatment of B-CLL cells with a glutathione reducing buthionine sulfoximine or catalase inhibiting aminotriazole enhanced ATO/ascorbic acid-mediated cytotoxicity Pretreatment with reducing agents such as catalase or thiol antioxidant N-acetyl cysteine or GSH also abrogated ATO/ascorbic acid-mediated cytotoxicity Furthermore Hu1D10-mediated cell death was enhanced with ATO and ascorbic acid thus justifying potential combination of ATO/arsenic trioxide therapy with antibodies such as Hu1D10 that also cause accumulation of ROS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4867, 5536, 9539, 398, 4, 442, 1193, 552, 1148, 8, 174, 119, 9, 2163, 2848, 2915, 2609, 3997, 3217, 4574, 4021, 2, 18841, 971, 369, 110, 4021, 2, 18841, 971, 3367, 1408, 4, 552, 132, 37, 22, 226, 183, 3, 209, 1, 4021, 16, 651, 20, 18841, 971, 26, 254, 16, 470, 23, 101, 2609, 1835, 22, 1194, 1, 132, 552, 37, 5, 8, 4571, 1818, 24554, 24555, 15, 12336, 2062, 58676, 651, 4021, 18841, 971, 517, 1408, 1194, 5, 1818, 183, 225, 22, 12336, 15, 17076, 5536, 78, 7055, 6943, 15, 9077, 120, 3728, 4021, 18841, 971, 517, 1408, 798, 19610, 517, 31, 273, 10, 651, 5, 4021, 2, 18841, 971, 631, 13579, 174, 150, 1, 4021, 3217, 4574, 36, 5, 890, 225, 22, 19610, 17, 120, 708, 1835, 1, 2609]",903.0,20171736,801
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.,Cancer,Cancer,2010-05-01,"The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m(2)). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged >or=70 years), and 64% were classified as having Rai stage III to IV disease. The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL.","Clinical Trial, Phase II",3552.0,31.0,The combination of pentostatin P cyclophosphamide C and rituximab R achieved an overall response OR rate 90 with 40 complete responses CRs in patients with untreated chronic lymphocytic CLL To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy a phase 2 trial was conducted of P and R without C using a higher P dose 4 mg/m 2 Among the 33 patients enrolled 82 were male the median age was 65 years 9 patients were aged or=70 years and 64 were classified as having Rai stage III to IV disease The OR rate was 76 with 9 CRs 27 5 nodular partial responses and 11 partial responses PRs reported At the time of last follow-up 29 of 33 patients were still alive at a median follow-up of 14 months range 1-34.8 months Four 12 patients experienced grade 3 or higher hematologic toxicity and 5 15 experienced grade 3 or higher nonhematologic toxicity Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate 91 vs 76 and CR rate 41 vs 27 compared with patients treated with PR The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR 30 months vs 16 months The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 150, 1, 7596, 19, 1112, 256, 2, 855, 668, 513, 35, 63, 51, 15, 116, 424, 5, 327, 236, 253, 3115, 4, 7, 5, 1278, 442, 1193, 552, 6, 376, 317, 3, 1543, 1, 26, 477, 359, 40, 651, 187, 14886, 209, 8, 124, 18, 160, 10, 426, 1, 19, 2, 668, 187, 256, 75, 8, 142, 19, 61, 39, 81, 188, 18, 107, 3, 466, 7, 346, 878, 11, 1045, 3, 52, 89, 10, 556, 60, 83, 7, 11, 1032, 15, 431, 60, 2, 660, 11, 1373, 22, 1041, 4121, 82, 316, 6, 478, 34, 3, 15, 116, 10, 846, 5, 83, 3115, 428, 33, 4481, 450, 253, 2, 175, 450, 253, 4018, 210, 28, 3, 98, 1, 1060, 166, 126, 462, 1, 466, 7, 11, 1234, 1701, 28, 8, 52, 166, 126, 1, 213, 53, 184, 14, 562, 66, 53, 294, 133, 7, 592, 88, 27, 15, 142, 813, 155, 2, 33, 167, 592, 88, 27, 15, 142, 3534, 155, 1155, 1, 26, 160, 5, 3, 698, 604, 160, 264, 17, 7, 73, 5, 604, 42, 8, 142, 15, 116, 970, 105, 846, 2, 684, 116, 605, 105, 428, 72, 5, 7, 73, 5, 998, 3, 52, 24, 115, 25, 9, 62, 3198, 7, 10, 2552, 589, 4, 7, 73, 5, 604, 72, 5, 998, 201, 53, 105, 245, 53, 3, 272, 1, 3, 291, 45, 309, 17, 602, 3, 61, 1, 3, 5006, 4032, 4696, 1097, 44, 4964, 3, 594, 9, 1112, 4, 4438, 9, 3, 24, 1, 552]",1419.0,20187101,203
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-03-01,"New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor outcomes with available salvage regimens. Ofatumumab (HuMax-CD20) is a human monoclonal antibody targeting a distinct small-loop epitope on the CD20 molecule. We conducted an international clinical study to evaluate the efficacy and safety of ofatumumab in patients with FA-ref and BF-ref CLL. Patients received eight weekly infusions of ofatumumab followed by four monthly infusions during a 24-week period (dose 1 = 300 mg; doses 2 to 12 = 2,000 mg); response by an independent review committee (1996 National Cancer Institute Working Group criteria) was assessed every 4 weeks until week 24 and then every 3 months until month 24. This planned interim analysis included 138 treated patients with FA-ref (n = 59) and BF-ref (n = 79) CLL. The overall response rates (primary end point) were 58% [corrected] and 47% in the FA-ref and BF-ref groups, respectively. Complete resolution of constitutional symptoms and improved performance status occurred in 57% and 48% of patients, respectively. Median progression-free survival and overall survival times were 5.7 and 13.7 months in the FA-ref group, respectively, and 5.9 and 15.4 months in the BF-ref group, respectively. The most common adverse events during treatment were infusion reactions and infections, which were primarily grade 1 or 2 events. Hematologic events during treatment included anemia and neutropenia. Ofatumumab is an active, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patients with very poor-prognosis CLL.",Clinical Trial,3613.0,461.0,"New treatments are needed for patients with fludarabine- and alemtuzumab-refractory FA-ref chronic lymphocytic CLL or patients with fludarabine-refractory CLL with bulky 5 cm lymphadenopathy BF-ref who are less suitable for alemtuzumab treatment these groups have poor outcomes with available salvage regimens Ofatumumab HuMax-CD20 is a human monoclonal antibody targeting a distinct small-loop epitope on the CD20 molecule We conducted an international clinical study to evaluate the efficacy and safety of ofatumumab in patients with FA-ref and BF-ref CLL Patients received eight weekly infusions of ofatumumab followed by four monthly infusions during a 24-week period dose 1 300 mg doses 2 to 12 2,000 mg response by an independent review committee 1996 National Cancer Institute Working Group criteria was assessed every 4 weeks until week 24 and then every 3 months until month 24 This planned interim analysis included 138 treated patients with FA-ref n 59 and BF-ref n 79 CLL The overall response rates primary end point were 58 corrected and 47 in the FA-ref and BF-ref groups respectively Complete resolution of constitutional symptoms and improved performance status occurred in 57 and 48 of patients respectively Median progression-free survival and overall survival times were 5.7 and 13.7 months in the FA-ref group respectively and 5.9 and 15.4 months in the BF-ref group respectively The most common adverse events during treatment were infusion reactions and infections which were primarily grade 1 or 2 events Hematologic events during treatment included anemia and neutropenia Ofatumumab is an active well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patients with very poor-prognosis CLL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[217, 640, 32, 575, 9, 7, 5, 2027, 2, 3579, 430, 4307, 7357, 442, 1193, 552, 15, 7, 5, 2027, 430, 552, 5, 4112, 33, 494, 4962, 6139, 7357, 54, 32, 299, 2884, 9, 3579, 24, 46, 271, 47, 334, 123, 5, 390, 992, 472, 5732, 58698, 2198, 16, 8, 171, 848, 548, 529, 8, 834, 302, 4432, 4430, 23, 3, 2198, 1354, 21, 426, 35, 944, 38, 45, 6, 376, 3, 209, 2, 367, 1, 5732, 4, 7, 5, 4307, 7357, 2, 6139, 7357, 552, 7, 103, 659, 709, 3435, 1, 5732, 370, 20, 294, 3889, 3435, 190, 8, 259, 647, 727, 61, 14, 2036, 81, 415, 18, 6, 133, 18, 984, 81, 51, 20, 35, 306, 206, 2002, 2648, 657, 12, 1377, 2644, 87, 371, 10, 275, 454, 39, 244, 1100, 647, 259, 2, 818, 454, 27, 53, 1100, 811, 259, 26, 1465, 2914, 65, 159, 4478, 73, 7, 5, 4307, 7357, 78, 728, 2, 6139, 7357, 78, 842, 552, 3, 63, 51, 151, 86, 396, 741, 11, 717, 3848, 2, 662, 4, 3, 4307, 7357, 2, 6139, 7357, 271, 106, 236, 2125, 1, 5962, 507, 2, 231, 528, 156, 489, 4, 696, 2, 576, 1, 7, 106, 52, 91, 115, 25, 2, 63, 25, 1072, 11, 33, 67, 2, 233, 67, 53, 4, 3, 4307, 7357, 87, 106, 2, 33, 83, 2, 167, 39, 53, 4, 3, 6139, 7357, 87, 106, 3, 96, 186, 290, 281, 190, 24, 11, 904, 2428, 2, 1875, 92, 11, 1561, 88, 14, 15, 18, 281, 813, 281, 190, 24, 159, 1545, 2, 778, 5732, 16, 35, 544, 149, 421, 24, 1736, 885, 38, 1474, 9, 2027, 430, 7, 5, 923, 334, 356, 552]",1747.0,20194866,672
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.,Cancer,Cancer,2010-05-01,"Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. To optimize dose, schedule, and route of alemtuzumab, a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients with previously treated CLL. Data from 40 patients with a median age of 59 years, and a median of 3 prior regimens (range, 1-8 regimens) were evaluable. Approximately 64% of patients were fludarabine-refractory. Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%. Of 11 major responses (CR, nPR), 8 occurred after cycle 1. Response rates were highest in blood (94%), followed by liver/spleen (82%), bone marrow (68%), and lymph nodes (51%). The combination did not generate unexpected toxicities. Cytomegalovirus (CMV) reactivations occurred in 6 patients (15%) and responded well to anti-CMV therapy. High titers of anti-idiotype antibodies after sc alemtuzumab were demonstrated in 1 patient, but remained without clinical sequelae. The combination of civ/sc alemtuzumab plus rituximab has activity in some patients with recurrent/refractory CLL and maximum response is achieved after 1 cycle (4 weeks) in 73% of patients. Further exploration in other settings of CLL together with accompanying pharmacokinetic studies is recommended.",Clinical Trial,3552.0,38.0,Monoclonal antibodies may be used more effectively in combination A previous study of intravenous iv bolus alemtuzumab plus rituximab in patients with chronic lymphocytic CLL recurrence produced a response rate of 54 after a 4-week treatment period To optimize dose schedule and route of alemtuzumab a study was designed exploring continuous intravenous infusion civ followed by subcutaneous sc alemtuzumab together with weekly iv rituximab in patients with previously treated CLL Data from 40 patients with a median age of 59 years and a median of 3 prior regimens range 1-8 regimens were evaluable Approximately 64 of patients were fludarabine-refractory Seven patients 18 achieved a complete response CR 4 10 a nodular partial response nPR and 10 25 a partial response for an overall response rate of 53 Of 11 major responses CR nPR 8 occurred after cycle 1 Response rates were highest in blood 94 followed by liver/spleen 82 marrow 68 and lymph nodes 51 The combination did not generate unexpected toxicities Cytomegalovirus CMV reactivations occurred in 6 patients 15 and responded well to anti-CMV therapy High titers of anti-idiotype antibodies after sc alemtuzumab were demonstrated in 1 patient but remained without clinical sequelae The combination of civ/sc alemtuzumab plus rituximab has activity in some patients with recurrent/refractory CLL and maximum response is achieved after 1 cycle 4 weeks in 73 of patients Further exploration in other settings of CLL together with accompanying pharmacokinetic studies is recommended,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 890, 68, 40, 95, 80, 1856, 4, 150, 8, 698, 45, 1, 1262, 478, 3604, 3579, 349, 855, 4, 7, 5, 442, 1193, 552, 146, 1687, 8, 51, 116, 1, 667, 50, 8, 39, 647, 24, 727, 6, 2465, 61, 1055, 2, 5841, 1, 3579, 8, 45, 10, 1114, 4378, 1314, 1262, 904, 17086, 370, 20, 2529, 2969, 3579, 1162, 5, 709, 478, 855, 4, 7, 5, 373, 73, 552, 74, 29, 327, 7, 5, 8, 52, 89, 1, 728, 60, 2, 8, 52, 1, 27, 324, 472, 184, 14, 66, 472, 11, 859, 705, 660, 1, 7, 11, 2027, 430, 648, 7, 203, 513, 8, 236, 51, 684, 39, 79, 8, 4481, 450, 51, 23816, 2, 79, 243, 8, 450, 51, 9, 35, 63, 51, 116, 1, 699, 1, 175, 458, 253, 684, 23816, 66, 489, 50, 417, 14, 51, 151, 11, 1076, 4, 315, 960, 370, 20, 4094, 4071, 878, 581, 806, 2, 263, 502, 725, 3, 150, 205, 44, 2562, 3792, 385, 7314, 3879, 39271, 489, 4, 49, 7, 167, 2, 2211, 149, 6, 312, 3879, 36, 64, 6671, 1, 312, 17615, 890, 50, 2969, 3579, 11, 264, 4, 14, 69, 84, 958, 187, 38, 4156, 3, 150, 1, 17086, 2969, 3579, 349, 855, 71, 128, 4, 476, 7, 5, 387, 430, 552, 2, 689, 51, 16, 513, 50, 14, 417, 39, 244, 4, 803, 1, 7, 195, 3370, 4, 127, 1947, 1, 552, 1162, 5, 9503, 1456, 94, 16, 793]",1539.0,20225334,534
"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.",Leukemia & lymphoma,Leuk. Lymphoma,2010-04-01,"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia (CLL) is constrained by intolerance of myelosuppression and the risk of exacerbation of autoimmune cytopenia by purine analogs particularly when used as single agents. We report on 20 such patients treated with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). Autoimmune cytopenia responded in 19 patients (14 complete remissions (CR), five partial remissions (PR)) with a median time to next treatment (TTT) for autoimmune cytopenia of 21.7 months. Progressive CLL responded in 17 patients (nine CR/complete clinical response, eight PR) with a median TTT of 27.7 months. Five patients have not required any re-treatment at 15-30 months. Grade 3-4 toxicities were infections (n = 3) and drug-induced pneumonitis (n = 1). No patient required blood cell transfusions after cycle 1 of therapy. We conclude that R-CVP is effective and tolerable therapy for autoimmune cytopenia complicating progressive CLL, but the duration of response is suboptimal.",Evaluation Study,3582.0,39.0,Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic CLL is constrained by intolerance of myelosuppression and the risk of exacerbation of autoimmune cytopenia by purine analogs particularly when used as single agents We report on 20 such patients treated with rituximab cyclophosphamide vincristine and prednisone R-CVP Autoimmune cytopenia responded in 19 patients 14 complete remissions CR five partial remissions PR with a median time to next treatment TTT for autoimmune cytopenia of 21.7 months Progressive CLL responded in 17 patients nine CR/complete clinical response eight PR with a median TTT of 27.7 months Five patients have not required any re-treatment at 15-30 months Grade 3-4 toxicities were infections n 3 and drug-induced pneumonitis n 1 No patient required blood cell transfusions after cycle 1 of therapy We conclude that R-CVP is effective and tolerable therapy for autoimmune cytopenia complicating progressive CLL but the duration of response is suboptimal,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[24, 1, 3445, 8165, 13630, 1014, 442, 1193, 552, 16, 9133, 20, 5266, 1, 2858, 2, 3, 43, 1, 12195, 1, 3445, 8165, 20, 5006, 4063, 823, 198, 95, 22, 226, 183, 21, 414, 23, 179, 225, 7, 73, 5, 855, 1112, 2132, 2, 1979, 668, 17692, 3445, 8165, 2211, 4, 326, 7, 213, 236, 3166, 684, 365, 450, 3166, 998, 5, 8, 52, 98, 6, 1305, 24, 10630, 9, 3445, 8165, 1, 239, 67, 53, 1014, 552, 2211, 4, 269, 7, 762, 684, 236, 38, 51, 659, 998, 5, 8, 52, 10630, 1, 428, 67, 53, 365, 7, 47, 44, 616, 500, 1491, 24, 28, 167, 201, 53, 88, 27, 39, 385, 11, 1875, 78, 27, 2, 234, 277, 2949, 78, 14, 77, 69, 616, 315, 31, 4987, 50, 417, 14, 1, 36, 21, 2060, 17, 668, 17692, 16, 323, 2, 2668, 36, 9, 3445, 8165, 13630, 1014, 552, 84, 3, 654, 1, 51, 16, 3291]",1007.0,20302386,103
Genetic susceptibility variants for chronic lymphocytic leukemia.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2010-03-23,"There is strong and consistent evidence that a genetic component contributes to the etiology of chronic lymphocytic leukemia (CLL). A recent genome-wide association study of CLL identified seven genetic variants that increased the risk of CLL within a European population. We evaluated the association of these variants, or variants in linkage disequilibrium with these variants, with CLL risk in an independent sample of 438 CLL cases and 328 controls. Of these seven single nucleotide polymorphisms (SNP), six had P trend < 0.05 and had estimated odds ratios (OR) that were strikingly comparable to those of the previous study. Associations were seen for rs9378805 [OR, 1.47; 95% confidence intervals (CI), 1.19-1.80; P trend = 0.0003] near IRF4 and rs735665 near GRAMD1B (OR, 1.47; 95% CI, 1.14-1.89; P trend = 0.003). However, no associations (P > 0.05) were found for rs11083846, nor were any found for any SNP in linkage disequilibrium with rs11083846. Our results confirm the previous findings and further support the role of a genetic basis in the etiology of CLL; however, more research is needed to elucidate the causal SNP(s) and the potential manner in which these SNPs or linked SNPs function in CLL pathogenesis.",Journal Article,3591.0,27.0,There is strong and consistent evidence that a genetic component contributes to the etiology of chronic lymphocytic CLL A recent genome-wide association study of CLL identified seven genetic variants that increased the risk of CLL within a European population We evaluated the association of these variants or variants in linkage disequilibrium with these variants with CLL risk in an independent sample of 438 CLL cases and 328 controls Of these seven single nucleotide polymorphisms SNP six had P trend 0.05 and had estimated odds ratios OR that were strikingly comparable to those of the previous study Associations were seen for rs9378805 OR 1.47 95 confidence intervals CI 1.19-1.80 P trend 0.0003 near IRF4 and rs735665 near GRAMD1B OR 1.47 95 CI 1.14-1.89 P trend 0.003 However no associations P 0.05 were found for rs11083846 nor were any found for any SNP in linkage disequilibrium with rs11083846 Our results confirm the previous findings and further support the role of a genetic basis in the etiology of CLL however more research is needed to elucidate the causal SNP s and the potential manner in which these SNPs or linked SNPs function in CLL pathogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[125, 16, 1082, 2, 925, 241, 17, 8, 336, 1249, 2444, 6, 3, 2855, 1, 442, 1193, 552, 8, 435, 898, 1019, 248, 45, 1, 552, 108, 648, 336, 839, 17, 101, 3, 43, 1, 552, 262, 8, 1865, 266, 21, 194, 3, 248, 1, 46, 839, 15, 839, 4, 4820, 8459, 5, 46, 839, 5, 552, 43, 4, 35, 306, 1000, 1, 11003, 552, 140, 2, 8584, 535, 1, 46, 648, 226, 1579, 1203, 1845, 437, 42, 19, 853, 13, 474, 2, 42, 661, 610, 1137, 15, 17, 11, 6787, 1279, 6, 135, 1, 3, 698, 45, 685, 11, 527, 9, 58774, 15, 14, 662, 48, 307, 1582, 58, 14, 326, 14, 493, 19, 853, 13, 4418, 1829, 10018, 2, 45942, 1829, 58775, 15, 14, 662, 48, 58, 14, 213, 14, 887, 19, 853, 13, 1421, 137, 77, 685, 19, 13, 474, 11, 204, 9, 45943, 2110, 11, 500, 204, 9, 500, 1845, 4, 4820, 8459, 5, 45943, 114, 99, 1843, 3, 698, 272, 2, 195, 538, 3, 200, 1, 8, 336, 877, 4, 3, 2855, 1, 552, 137, 80, 389, 16, 575, 6, 3061, 3, 5163, 1845, 695, 2, 3, 174, 1708, 4, 92, 46, 1109, 15, 1199, 1109, 343, 4, 552, 1384]",1170.0,20332261,393
Rituximab in chronic lymphocytic leukemia.,Seminars in hematology,Semin. Hematol.,2010-04-01,"Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic lymphocytic leukemia (CLL), both as a single agent and in combination with traditional chemotherapies. The modest activity demonstrated in early studies evaluating rituximab in relapsed CLL was improved with higher doses or more dose-intensive regimens that overcame the unfavorable pharmacokinetic features commonly found in CLL. These studies led to a variety of combination trials of rituximab with chemotherapy, where both phase II and later phase III studies have shown great promise for the advancement of CLL therapy. Despite the therapeutic success of rituximab in CLL, studies demonstrating the definitive relative mechanism of tumor clearance are still lacking and this requires further investigation. In addition to being used as a therapy for CLL, rituximab is an effective treatment for autoimmune CLL complications such as hemolytic anemia and immune thrombocytopenia (ITP). Patients with CLL may experience early infusion-related side effects that can be diminished with corticosteroid pretreatment and stepped-up dosing. Risk factors for infusion-related toxicity may relate to atypical CLL expressing bright CD20 antigen expression, although several different studies have not clearly implicated elevated white blood cell count as a risk factor. Other adverse events, including delayed cytopenias, reactivation of hepatitis B, and development of progressive multifocal leukoencephalopathy, are rare. Future efforts focusing on novel combination-based strategies will be required to fully appreciate the benefit of this therapy in CLL.",Journal Article,3582.0,23.0,Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic lymphocytic CLL both as a single agent and in combination with traditional chemotherapies The modest activity demonstrated in early studies evaluating rituximab in relapsed CLL was improved with higher doses or more dose-intensive regimens that overcame the unfavorable pharmacokinetic features commonly found in CLL These studies led to a variety of combination trials of rituximab with chemotherapy where both phase II and later phase III studies have shown great promise for the advancement of CLL therapy Despite the therapeutic success of rituximab in CLL studies demonstrating the definitive relative mechanism of tumor clearance are still lacking and this requires further investigation In addition to being used as a therapy for CLL rituximab is an effective treatment for autoimmune CLL complications such as hemolytic anemia and immune thrombocytopenia ITP Patients with CLL may experience early infusion-related side effects that can be diminished with corticosteroid pretreatment and stepped-up dosing Risk factors for infusion-related toxicity may relate to atypical CLL expressing bright CD20 antigen expression although several different studies have not clearly implicated elevated white blood cell count as a risk factor Other adverse events including delayed cytopenias reactivation of hepatitis B and development of progressive multifocal leukoencephalopathy are rare Future efforts focusing on novel combination-based strategies will be required to fully appreciate the benefit of this therapy in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[855, 16, 8, 1040, 70, 2897, 312, 2198, 548, 17, 71, 443, 209, 4, 442, 1193, 552, 110, 22, 8, 226, 420, 2, 4, 150, 5, 1847, 4203, 3, 1721, 128, 264, 4, 191, 94, 1435, 855, 4, 591, 552, 10, 231, 5, 142, 415, 15, 80, 61, 1686, 472, 17, 11097, 3, 2483, 1456, 404, 841, 204, 4, 552, 46, 94, 836, 6, 8, 1362, 1, 150, 143, 1, 855, 5, 56, 1257, 110, 124, 215, 2, 1559, 124, 316, 94, 47, 443, 2797, 1783, 9, 3, 7496, 1, 552, 36, 550, 3, 189, 1825, 1, 855, 4, 552, 94, 2219, 3, 1057, 580, 670, 1, 30, 1960, 32, 1234, 1941, 2, 26, 1706, 195, 940, 4, 352, 6, 486, 95, 22, 8, 36, 9, 552, 855, 16, 35, 323, 24, 9, 3445, 552, 521, 225, 22, 10425, 1545, 2, 250, 1340, 14094, 7, 5, 552, 68, 730, 191, 904, 139, 1152, 176, 17, 122, 40, 2849, 5, 5654, 1194, 2, 33497, 126, 1280, 43, 130, 9, 904, 139, 155, 68, 6509, 6, 1973, 552, 1046, 9676, 2198, 448, 55, 242, 392, 338, 94, 47, 44, 2536, 1771, 804, 886, 315, 31, 1276, 22, 8, 43, 161, 127, 290, 281, 141, 1612, 5635, 3834, 1, 3002, 132, 2, 193, 1, 1014, 3492, 8744, 32, 622, 508, 1413, 3312, 23, 229, 150, 90, 422, 303, 40, 616, 6, 1910, 19754, 3, 247, 1, 26, 36, 4, 552]",1606.0,20350663,617
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.,Blood,Blood,2010-03-29,"The HSP90 client chaperone interaction stabilizes several important enzymes and antiapoptotic proteins, and pharmacologic inhibition of HSP90 results in rapid client protein degradation. Therefore, HSP90 inhibition is an attractive therapeutic approach when this protein is active, a phenotype commonly observed in transformed but not normal cells. However, preclinical studies with HSP90 inhibitors such as 17-AAG demonstrated depletion of only a subset of client proteins and very modest tumor cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Herein, we describe another HSP90 inhibitor, 17-DMAG, which is cytotoxic to CLL but not normal lymphocytes. Treatment with 17-DMAG leads to depletion of the HSP90 client protein IKK, resulting in diminished NF-kappaB p50/p65 DNA binding, decreased NF-kappaB target gene transcription, and caspase-dependent apoptosis. Furthermore, treatment with 17-DMAG significantly decreased the white blood cell count and prolonged the survival in a TCL1-SCID transplant mouse model. The ability of 17-DMAG to function as an NF-kappaB inhibitor is of great interest clinically, as few currently available CLL drugs target this transcription factor. Therefore, the effect of 17-DMAG on NF-kappaB signaling pathways represents a novel therapy warranting further clinical pursuit in this and other B-cell lymphoproliferative disorders.",Journal Article,3585.0,82.0,The HSP90 client chaperone interaction stabilizes several important enzymes and antiapoptotic proteins and pharmacologic inhibition of HSP90 results in rapid client protein degradation Therefore HSP90 inhibition is an attractive therapeutic approach when this protein is active a phenotype commonly observed in transformed but not normal cells However preclinical studies with HSP90 inhibitors such as 17-AAG demonstrated depletion of only a subset of client proteins and very modest tumor cytotoxicity in chronic lymphocytic CLL cells Herein we describe another HSP90 inhibitor 17-DMAG which is cytotoxic to CLL but not normal lymphocytes Treatment with 17-DMAG leads to depletion of the HSP90 client protein IKK resulting in diminished NF-kappaB p50/p65 DNA binding decreased NF-kappaB target gene transcription and caspase-dependent apoptosis Furthermore treatment with 17-DMAG significantly decreased the white blood cell count and prolonged the survival in a TCL1-SCID transplant mouse model The ability of 17-DMAG to function as an NF-kappaB inhibitor is of great interest clinically as few currently available CLL drugs target this transcription factor Therefore the effect of 17-DMAG on NF-kappaB signaling pathways represents a novel therapy warranting further clinical pursuit in this and other B-cell lymphoproliferative disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2515, 7304, 7255, 915, 11019, 392, 305, 3039, 2, 4176, 652, 2, 2788, 297, 1, 2515, 99, 4, 1321, 7304, 178, 2373, 673, 2515, 297, 16, 35, 3059, 189, 353, 198, 26, 178, 16, 544, 8, 1005, 841, 164, 4, 2423, 84, 44, 295, 37, 137, 693, 94, 5, 2515, 222, 225, 22, 269, 4513, 264, 2286, 1, 158, 8, 697, 1, 7304, 652, 2, 923, 1721, 30, 1408, 4, 442, 1193, 552, 37, 1986, 21, 897, 1809, 2515, 230, 269, 15323, 92, 16, 759, 6, 552, 84, 44, 295, 1594, 24, 5, 269, 15323, 1940, 6, 2286, 1, 3, 2515, 7304, 178, 13581, 1113, 4, 2849, 1365, 2119, 16197, 6781, 261, 791, 340, 1365, 2119, 283, 145, 866, 2, 1469, 470, 351, 798, 24, 5, 269, 15323, 97, 340, 3, 886, 315, 31, 1276, 2, 1069, 3, 25, 4, 8, 8979, 4129, 941, 830, 202, 3, 801, 1, 269, 15323, 6, 343, 22, 35, 1365, 2119, 230, 16, 1, 2797, 1333, 505, 22, 1021, 694, 390, 552, 600, 283, 26, 866, 161, 673, 3, 254, 1, 269, 15323, 23, 1365, 2119, 314, 460, 1449, 8, 229, 36, 7643, 195, 38, 13649, 4, 26, 2, 127, 132, 31, 4192, 1997]",1341.0,20351313,237
Potential of plant-derived natural products in the treatment of leukemia and lymphoma.,Current drug targets,Curr Drug Targets,2010-07-01,"Hematologic malignancies account for a substantial percentage of cancers worldwide, and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challenges. Although treatment options exist for most of these diseases, many types remain incurable and the emergence of drug resistance is pervasive. Thus, novel treatment approaches are essential to improve outcome. Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products. The enormous chemical diversity in nature, coupled with millennia of biological selection, has generated a vast and underexplored reservoir of unique chemical structures with biologic activity. This review will describe the investigation and application of natural products derived from higher plants in the treatment of leukemia and lymphoma and the rationale behind these efforts. In addition to the approved vinca alkaloids and the epipodophyllotoxin derivatives, a number of other plant compounds have shown promise in clinical trials and in preclinical investigations. In particular, we will focus on the discovery and biological evaluation of the plant-derived agent silvestrol, which shows potential for additional development as a new therapeutic agent for B-cell malignancies including chronic lymphocytic leukemia.",Journal Article,3491.0,56.0,Hematologic malignancies account for a substantial percentage of cancers worldwide and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challenges Although treatment options exist for most of these diseases many types remain incurable and the emergence of drug resistance is pervasive Thus novel treatment approaches are essential to improve outcome Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products The enormous chemical diversity in nature coupled with millennia of biological selection has generated a vast and underexplored reservoir of unique chemical structures with biologic activity This review will describe the investigation and application of natural products derived from higher plants in the treatment of and and the rationale behind these efforts In addition to the approved vinca alkaloids and the epipodophyllotoxin derivatives a number of other plant compounds have shown promise in clinical trials and in preclinical investigations In particular we will focus on the discovery and biological evaluation of the plant-derived agent silvestrol which shows potential for additional development as a new therapeutic agent for B-cell malignancies including chronic lymphocytic,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[813, 441, 1967, 9, 8, 1281, 1150, 1, 163, 2358, 2, 3, 1144, 2, 1037, 374, 1, 2792, 2, 1557, 364, 991, 189, 1427, 242, 24, 838, 1923, 9, 96, 1, 46, 1342, 445, 630, 918, 2641, 2, 3, 3397, 1, 234, 251, 16, 15130, 631, 229, 24, 611, 32, 1452, 6, 401, 228, 1857, 1303, 1, 3, 183, 95, 4, 12, 36, 5665, 32, 361, 1504, 2766, 15, 6490, 1, 1504, 2766, 3, 8790, 3743, 3653, 4, 2202, 3332, 5, 45411, 1, 1037, 881, 71, 1419, 8, 4337, 2, 26927, 10470, 1, 991, 3743, 2414, 5, 1283, 128, 26, 206, 303, 897, 3, 940, 2, 1581, 1, 1504, 2766, 526, 29, 142, 20406, 4, 3, 24, 1, 2, 2, 3, 1728, 5219, 46, 1413, 4, 352, 6, 3, 850, 12729, 18187, 2, 3, 38478, 6490, 8, 207, 1, 127, 9045, 2411, 47, 443, 1783, 4, 38, 143, 2, 4, 693, 2492, 4, 1454, 21, 303, 1222, 23, 3, 1574, 2, 1037, 451, 1, 3, 9045, 526, 420, 10015, 92, 1949, 174, 9, 402, 193, 22, 8, 217, 189, 420, 9, 132, 31, 441, 141, 442, 1193]",1310.0,20370646,494
Richter's transformation in chronic lymphocytic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2007-10-01,"Richter's syndrome (RS) is the development of high-grade non-Hodgkin's lymphoma (NHL) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. This process may be triggered by viral infections (eg, Epstein-Barr virus infection), which are common in immunosuppressed patients. The large cells of RS either arise through a transformation of the original CLL clone or, less frequently, represent a new or secondary neoplasm. Karyotypic changes, including trisomy 12, chromosome 11 abnormalities, and multiple cell-cycle regulator disruptions, have been found in patients with RS. Although these genetic defects are believed to cause CLL cells to proliferate and, by facilitating the acquisition of new genetic abnormalities, to transform into RS cells, none appears predominantly responsible for the transformation. The prognosis is generally poor, and most patients do not have long-term (durable) responses to therapy. Rituximab and cytotoxic combination therapy followed by stem cell transplantation is associated with improved clinical outcome. Curative treatment strategies are needed.",Journal Article,4495.0,15.0,Richter 's syndrome RS is the development of high-grade 's NHL in patients with chronic lymphocytic CLL or small lymphocytic This process may be triggered by viral infections eg Epstein-Barr virus infection which are common in immunosuppressed patients The large cells of RS either arise through a transformation of the original CLL clone or less frequently represent a new or secondary neoplasm Karyotypic changes including trisomy 12 chromosome 11 abnormalities and multiple cell-cycle regulator disruptions have been found in patients with RS Although these genetic defects are believed to cause CLL cells to proliferate and by facilitating the acquisition of new genetic abnormalities to transform into RS cells none appears predominantly responsible for the transformation The prognosis is generally poor and most patients do not have long-term durable responses to therapy Rituximab and cytotoxic combination therapy followed by stem cell transplantation is associated with improved clinical outcome Curative treatment strategies are needed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 292, 681, 2250, 16, 3, 193, 1, 64, 88, 292, 1176, 4, 7, 5, 442, 1193, 552, 15, 302, 1193, 26, 1129, 68, 40, 4173, 20, 1667, 1875, 2887, 5212, 5190, 1450, 930, 92, 32, 186, 4, 12749, 7, 3, 375, 37, 1, 2250, 361, 3043, 298, 8, 1392, 1, 3, 2279, 552, 3910, 15, 299, 746, 1231, 8, 217, 15, 568, 2131, 9465, 400, 141, 6317, 133, 1170, 175, 1171, 2, 232, 31, 417, 2452, 11594, 47, 85, 204, 4, 7, 5, 2250, 242, 46, 336, 2945, 32, 3979, 6, 708, 552, 37, 6, 9554, 2, 20, 5379, 3, 3405, 1, 217, 336, 1171, 6, 7136, 237, 2250, 37, 1292, 1233, 2117, 2327, 9, 3, 1392, 3, 356, 16, 1228, 334, 2, 96, 7, 1022, 44, 47, 319, 337, 1480, 253, 6, 36, 855, 2, 759, 150, 36, 370, 20, 452, 31, 497, 16, 41, 5, 231, 38, 228, 1075, 24, 422, 32, 575]",1046.0,20425379,107
Prognostic factors in chronic lymphocytic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2007-02-01,"Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, beta-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.",Journal Article,4737.0,7.0,Chronic lymphocytic CLL is truly a heterogeneous disease in which individual outcomes range from no need for therapeutic intervention to very aggressive nonresponding disease The ability to develop clear sound prognostic information that permits reliable counsel must be our goal A combination of easily obtainable traditional prognostic parameters marrow infiltration patterns beta-2 microglobulin along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL However novel parameters such as defects detectable on fluorescence in situ hybridization FISH expression levels of CD38 and ZAP-70 and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 7260, 8, 1564, 34, 4, 92, 797, 123, 184, 29, 77, 594, 9, 189, 788, 6, 923, 571, 13488, 34, 3, 801, 6, 690, 885, 11475, 177, 487, 17, 8504, 2450, 9892, 1642, 40, 114, 1326, 8, 150, 1, 4697, 22461, 1847, 177, 1038, 581, 2084, 764, 1090, 18, 5371, 1510, 5, 3, 38, 4121, 82, 16, 1234, 746, 95, 4, 3, 388, 43, 1541, 1, 7, 5, 552, 137, 229, 1038, 225, 22, 2945, 2083, 23, 1591, 4, 957, 1554, 1277, 55, 148, 1, 4469, 2, 6251, 431, 2, 2593, 4013, 1260, 1347, 1053, 156, 122, 4178, 93, 177, 487, 545, 8, 447, 69, 5, 552, 832, 6, 3360, 46, 2246, 895, 262, 3, 1533, 1, 3, 80, 1847, 1038, 9, 8, 69, 5, 8, 217, 147, 16, 3, 1222, 1, 93, 4346, 389, 3, 228, 1, 26, 389, 71, 1268, 9, 1434, 38, 91, 151, 2, 3, 51, 2, 654, 1, 51, 6, 36, 22, 149, 22, 9, 4051, 64, 43, 7, 54, 303, 594, 1677, 15, 80, 112, 24, 611]",1195.0,20425388,302
"Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.",Blood,Blood,2010-04-28,"Forodesine is a new and potent purine nucleoside phosphorylase (PNP) inhibitor. Patients with chronic lymphocytic leukemia (CLL) with primary resistance to fludarabine-based therapy or with progressive disease were eligible for oral forodesine (200 mg/d) for up to 24 weeks. Eight patients with median lymphocyte count of 35.9 x 10(9)/L and median serum beta2 microglobulin level of 6.45 mg/L were treated. Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5). Two had transient decrease in lymphocyte count to normal, whereas in 5, disease progressed. Adverse events were mild. Steady-state level of forodesine ranged from 200 to 1300 nM and did not reach desired 2 microM level. PNP inhibition ranged from 57% to 89% and steady-state 2'-deoxyguanosine (dGuo) concentration median was 1.8 microM. Intracellular deoxyguanosine triphosphate (dGTP) increase was very modest, from median of 6 microM to 10 microM. Compared with in vivo, in vitro incubations of CLL lymphocytes with 10 or 20 microM dGuo and forodesine (2 microM) resulted in accumulation of higher levels of dGTP (40-250 microM) which resulted in increase in apoptosis. Forodesine has biologic activity in CLL; pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population.","Clinical Trial, Phase II",3555.0,37.0,Forodesine is a new and potent purine nucleoside phosphorylase PNP inhibitor Patients with chronic lymphocytic CLL with primary resistance to fludarabine-based therapy or with progressive disease were eligible for oral forodesine 200 mg/d for up to 24 weeks Eight patients with median lymphocyte count of 35.9 x 10 9 /L and median serum beta2 microglobulin level of 6.45 mg/L were treated Six had Rai stage III to IV and were previously heavily treated median prior therapy 5 Two had transient decrease in lymphocyte count to normal whereas in 5 disease progressed Adverse events were mild Steady-state level of forodesine ranged from 200 to 1300 nM and did not reach desired 2 microM level PNP inhibition ranged from 57 to 89 and steady-state 2'-deoxyguanosine dGuo concentration median was 1.8 microM Intracellular deoxyguanosine triphosphate dGTP increase was very modest from median of 6 microM to 10 microM Compared with in vivo in vitro incubations of CLL lymphocytes with 10 or 20 microM dGuo and forodesine 2 microM resulted in accumulation of higher levels of dGTP 40-250 microM which resulted in increase in apoptosis Forodesine has biologic activity in CLL pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[10483, 16, 8, 217, 2, 1157, 5006, 4032, 10658, 13133, 230, 7, 5, 442, 1193, 552, 5, 86, 251, 6, 2027, 90, 36, 15, 5, 1014, 34, 11, 625, 9, 518, 10483, 1250, 81, 427, 9, 126, 6, 259, 244, 659, 7, 5, 52, 1448, 1276, 1, 465, 83, 1006, 79, 83, 805, 2, 52, 524, 8911, 5371, 301, 1, 49, 512, 81, 805, 11, 73, 437, 42, 4121, 82, 316, 6, 478, 2, 11, 373, 2447, 73, 52, 324, 36, 33, 100, 42, 2473, 775, 4, 1448, 1276, 6, 295, 547, 4, 33, 34, 1839, 290, 281, 11, 1980, 4152, 1309, 301, 1, 10483, 1869, 29, 1250, 6, 17088, 2878, 2, 205, 44, 3690, 6115, 18, 3550, 301, 13133, 297, 1869, 29, 696, 6, 887, 2, 4152, 1309, 6135, 17863, 17864, 1227, 52, 10, 14, 66, 3550, 2087, 17863, 7345, 16319, 344, 10, 923, 1721, 29, 52, 1, 49, 3550, 6, 79, 3550, 72, 5, 4, 386, 4, 439, 30844, 1, 552, 1594, 5, 79, 15, 179, 3550, 17864, 2, 10483, 18, 3550, 627, 4, 1835, 1, 142, 148, 1, 16319, 327, 2039, 3550, 92, 627, 4, 344, 4, 351, 10483, 71, 1283, 128, 4, 552, 2424, 1038, 309, 17, 35, 4689, 1280, 1055, 2, 15, 142, 415, 6, 1359, 378, 2087, 16319, 68, 40, 2524, 4, 26, 69, 266]",1339.0,20427701,284
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.,Blood,Blood,2010-05-04,"Forodesine, a purine nucleoside phosphorylase inhibitor, displays in vitro activity in chronic lymphocytic leukemia (CLL) cells in presence of dGuo, which is the basis for an ongoing clinical trial in patients with fludarabine-refractory CLL. Initial clinical data indicate forodesine has significant activity on circulating CLL cells, but less activity in clearing CLL cells from tissues such as marrow. In tissue microenvironments, lymphocytes interact with accessory stromal cells that provide survival and drug-resistance signals, which may account for residual disease. Therefore, we investigated the impact of marrow stromal cells (MSCs) on forodesine-induced response in CLL lymphocytes. We demonstrate that spontaneous and forodesine-induced apoptosis of CLL cells was significantly inhibited by human and murine MSCs. Forodesine-promoted dGuo triphosphate (dGTP) accumulation and GTP and ATP depletion in CLL cells was inhibited by MSCs, providing a mechanism for resistance. Also, MSCs rescued CLL cells from forodesine-induced RNA- and protein-synthesis inhibition and stabilized and increased Mcl-1 transcript and protein levels. Conversely, MSC viability was not affected by forodesine and dGuo. Collectively, MSC-induced biochemical changes antagonized forodesine-induced CLL cell apoptosis. This provides a biochemical mechanism for MSC-derived resistance to forodesine and emphasizes the need to move toward combinations with agents that interfere with the microenvironment's protective role for improving current therapeutic efforts.",Journal Article,3549.0,44.0,Forodesine a purine nucleoside phosphorylase inhibitor displays in vitro activity in chronic lymphocytic CLL cells in presence of dGuo which is the basis for an ongoing clinical trial in patients with fludarabine-refractory CLL Initial clinical data indicate forodesine has significant activity on circulating CLL cells but less activity in clearing CLL cells from tissues such as marrow In tissue microenvironments lymphocytes interact with accessory stromal cells that provide survival and drug-resistance signals which may account for residual disease Therefore we investigated the impact of marrow stromal cells MSCs on forodesine-induced response in CLL lymphocytes We demonstrate that spontaneous and forodesine-induced apoptosis of CLL cells was significantly inhibited by human and murine MSCs Forodesine-promoted dGuo triphosphate dGTP accumulation and GTP and ATP depletion in CLL cells was inhibited by MSCs providing a mechanism for resistance Also MSCs rescued CLL cells from forodesine-induced RNA- and protein-synthesis inhibition and stabilized and increased Mcl-1 transcript and protein levels Conversely MSC viability was not affected by forodesine and dGuo Collectively MSC-induced biochemical changes antagonized forodesine-induced CLL cell apoptosis This provides a biochemical mechanism for MSC-derived resistance to forodesine and emphasizes the need to move toward combinations with agents that interfere with the microenvironment 's protective role for improving current therapeutic efforts,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[10483, 8, 5006, 4032, 10658, 230, 7196, 4, 439, 128, 4, 442, 1193, 552, 37, 4, 463, 1, 17864, 92, 16, 3, 877, 9, 35, 942, 38, 160, 4, 7, 5, 2027, 430, 552, 388, 38, 74, 1008, 10483, 71, 93, 128, 23, 1033, 552, 37, 84, 299, 128, 4, 17090, 552, 37, 29, 742, 225, 22, 581, 4, 246, 9912, 1594, 4491, 5, 12082, 1126, 37, 17, 377, 25, 2, 234, 251, 2312, 92, 68, 1967, 9, 753, 34, 673, 21, 565, 3, 345, 1, 581, 1126, 37, 4460, 23, 10483, 277, 51, 4, 552, 1594, 21, 608, 17, 3280, 2, 10483, 277, 351, 1, 552, 37, 10, 97, 879, 20, 171, 2, 1471, 4460, 10483, 2992, 17864, 7345, 16319, 1835, 2, 9969, 2, 3918, 2286, 4, 552, 37, 10, 879, 20, 4460, 1736, 8, 670, 9, 251, 120, 4460, 7008, 552, 37, 29, 10483, 277, 893, 2, 178, 2525, 297, 2, 7368, 2, 101, 1308, 14, 3268, 2, 178, 148, 3154, 4150, 2120, 10, 44, 1424, 20, 10483, 2, 17864, 2535, 4150, 277, 1487, 400, 15259, 10483, 277, 552, 31, 351, 26, 777, 8, 1487, 670, 9, 4150, 526, 251, 6, 10483, 2, 7519, 3, 594, 6, 6759, 1317, 1247, 5, 183, 17, 6178, 5, 3, 995, 292, 2864, 200, 9, 1673, 291, 189, 1413]",1515.0,20442367,512
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.,Haematologica,Haematologica,2010-05-11,"A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous infusion (IVB/CIVI) is active in fludarabine-refractory chronic lymphocytic leukemia, but no studies examining the feasibility and maximum tolerated dose of this schedule have been reported in acute leukemia. We conducted a phase I dose escalation trial of single-agent flavopiridol in adults with relapsed/refractory acute leukemias, utilizing a modification of the intravenous bolus/continuous intravenous infusion approach, intensifying treatment for administration on days 1, 2, and 3 of 21-day cycles. Twenty-four adults with relapsed/refractory acute myeloid leukemia (n=19) or acute lymphoblastic leukemia (n=5) were enrolled. The median age was 62 years (range, 23-78). The maximum tolerated dose of flavopiridol was 40 mg/m(2) intravenous bolus plus 60 mg/m(2) continuous intravenous infusion (40/60). The dose limiting toxicity was secretory diarrhea. Life-threatening hyperacute tumor lysis syndrome requiring hemodialysis on day 1 was observed in one patient. Pharmacokinetics were dose-dependent with increased clearance observed at the two highest dose levels. Diarrhea occurrence and severity significantly correlated with flavopiridol concentrations at the end of the 4-hour infusion, volume of distribution, and elimination half-life. Modest anti-leukemic activity was observed, with most patients experiencing dramatic but transient reduction/clearance of circulating blasts lasting for 10-14 days. One refractory acute myeloid leukemia patient had short-lived complete remission with incomplete count recovery. Flavopiridol as a single agent given by intravenous bolus/continuous intravenous infusion causes marked, immediate cytoreduction in relapsed/refractory acute leukemias, but objective clinical responses were uncommon. With this schedule, the dose is limited by secretory diarrhea.","Clinical Trial, Phase I",3542.0,40.0,A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous infusion IVB/CIVI is active in fludarabine-refractory chronic lymphocytic but no studies examining the feasibility and maximum tolerated dose of this schedule have been reported in acute We conducted a phase I dose escalation trial of single-agent flavopiridol in adults with relapsed/refractory acute leukemias utilizing a modification of the intravenous bolus/continuous intravenous infusion approach intensifying treatment for administration on days 1 2 and 3 of 21-day cycles Twenty-four adults with relapsed/refractory acute myeloid n=19 or acute lymphoblastic n=5 were enrolled The median age was 62 years range 23-78 The maximum tolerated dose of flavopiridol was 40 mg/m 2 intravenous bolus plus 60 mg/m 2 continuous intravenous infusion 40/60 The dose limiting toxicity was secretory diarrhea Life-threatening hyperacute tumor lysis syndrome requiring hemodialysis on day 1 was observed in one patient Pharmacokinetics were dose-dependent with increased clearance observed at the two highest dose levels Diarrhea occurrence and severity significantly correlated with flavopiridol concentrations at the end of the 4-hour infusion volume of distribution and elimination half-life Modest anti-leukemic activity was observed with most patients experiencing dramatic but transient reduction/clearance of circulating blasts lasting for 10-14 days One refractory acute myeloid patient had short-lived complete remission with incomplete count recovery Flavopiridol as a single agent given by intravenous bolus/continuous intravenous infusion causes marked immediate cytoreduction in relapsed/refractory acute leukemias but objective clinical responses were uncommon With this schedule the dose is limited by secretory diarrhea,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[8, 14920, 526, 1055, 1, 3030, 468, 22, 8, 201, 1538, 1262, 3604, 370, 20, 39, 2583, 1314, 1262, 904, 7042, 18907, 16, 544, 4, 2027, 430, 442, 1193, 84, 77, 94, 3282, 3, 1437, 2, 689, 421, 61, 1, 26, 1055, 47, 85, 210, 4, 286, 21, 426, 8, 124, 70, 61, 1125, 160, 1, 226, 420, 3030, 4, 857, 5, 591, 430, 286, 2792, 2600, 8, 2437, 1, 3, 1262, 3604, 1314, 1262, 904, 353, 20150, 24, 9, 634, 23, 162, 14, 18, 2, 27, 1, 239, 218, 410, 737, 294, 857, 5, 591, 430, 286, 533, 78, 326, 15, 286, 1275, 78, 33, 11, 346, 3, 52, 89, 10, 744, 60, 184, 382, 833, 3, 689, 421, 61, 1, 3030, 10, 327, 81, 188, 18, 1262, 3604, 349, 335, 81, 188, 18, 1314, 1262, 904, 327, 335, 3, 61, 817, 155, 10, 7106, 1172, 358, 3691, 44487, 30, 4783, 681, 1888, 11170, 23, 218, 14, 10, 164, 4, 104, 69, 1159, 11, 61, 470, 5, 101, 1960, 164, 28, 3, 100, 1076, 61, 148, 1172, 2291, 2, 1702, 97, 438, 5, 3030, 1003, 28, 3, 396, 1, 3, 39, 2583, 904, 433, 1, 1395, 2, 3730, 1303, 358, 1721, 312, 2015, 128, 10, 164, 5, 96, 7, 2985, 3079, 84, 2473, 628, 1960, 1, 1033, 2438, 3443, 9, 79, 213, 162, 104, 430, 286, 533, 69, 42, 978, 4813, 236, 734, 5, 2610, 1276, 1602, 3030, 22, 8, 226, 420, 447, 20, 1262, 3604, 1314, 1262, 904, 1626, 2003, 2181, 2844, 4, 591, 430, 286, 2792, 84, 461, 38, 253, 11, 2052, 5, 26, 1055, 3, 61, 16, 383, 20, 7106, 1172]",1867.0,20460644,125
"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-05-17,"SNS-032 is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells. A phase I dose-escalation study of SNS-032 was conducted to evaluate safety, pharmacokinetics, biomarkers of mechanism-based pharmacodynamic (PD) activity, and clinical efficacy. Parallel cohorts of previously treated patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) received SNS-032 as a loading dose followed by 6-hour infusion weekly for 3 weeks of each 4-week course. There were 19 patients with CLL and 18 with MM treated. Tumor lysis syndrome was the dose-limiting toxicity (DLT) for CLL, the maximum-tolerated dose (MTD) was 75 mg/m(2), and the most frequent grade 3 to 4 toxicity was myelosuppression. One patient with CLL had more than 50% reduction in measurable disease without improvement in hematologic parameters. Another patient with low tumor burden had stable disease for four courses. For patients with MM, no DLT was observed and MTD was not identified at up to 75 mg/m(2), owing to early study closure. Two patients with MM had stable disease and one had normalization of spleen size with treatment. Biomarker analyses demonstrated mechanism-based PD activity with inhibition of Cdk7 and Cdk9, decreases in Mcl-1 and XIAP expression level, and associated CLL cell apoptosis. SNS-032 demonstrated mechanism-based target modulation and limited clinical activity in heavily pretreated patients with CLL and MM. Further single-agent, PD-based, dose and schedule modification is warranted to maximize clinical efficacy.","Clinical Trial, Phase I",3536.0,125.0,SNS-032 is a highly selective and potent inhibitor of cyclin-dependent kinases Cdks 2 7 and 9 with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells A phase I dose-escalation study of SNS-032 was conducted to evaluate safety pharmacokinetics biomarkers of mechanism-based pharmacodynamic PD activity and clinical efficacy Parallel cohorts of previously treated patients with chronic lymphocytic CLL and multiple MM received SNS-032 as a loading dose followed by 6-hour infusion weekly for 3 weeks of each 4-week course There were 19 patients with CLL and 18 with MM treated Tumor lysis syndrome was the dose-limiting toxicity DLT for CLL the maximum-tolerated dose MTD was 75 mg/m 2 and the most frequent grade 3 to 4 toxicity was myelosuppression One patient with CLL had more than 50 reduction in measurable disease without improvement in hematologic parameters Another patient with low tumor burden had stable disease for four courses For patients with MM no DLT was observed and MTD was not identified at up to 75 mg/m 2 owing to early study closure Two patients with MM had stable disease and one had normalization of spleen size with treatment Biomarker analyses demonstrated mechanism-based PD activity with inhibition of Cdk7 and Cdk9 decreases in Mcl-1 and XIAP expression level and associated CLL cell apoptosis SNS-032 demonstrated mechanism-based target modulation and limited clinical activity in heavily pretreated patients with CLL and MM Further single-agent PD-based dose and schedule modification is warranted to maximize clinical efficacy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7323, 4708, 16, 8, 561, 1094, 2, 1157, 230, 1, 1226, 470, 1549, 9336, 18, 67, 2, 83, 5, 4, 439, 129, 1810, 176, 2, 801, 6, 1290, 351, 4, 393, 132, 37, 8, 124, 70, 61, 1125, 45, 1, 7323, 4708, 10, 426, 6, 376, 367, 1159, 582, 1, 670, 90, 2424, 333, 128, 2, 38, 209, 2755, 736, 1, 373, 73, 7, 5, 442, 1193, 552, 2, 232, 321, 103, 7323, 4708, 22, 8, 4717, 61, 370, 20, 49, 2583, 904, 709, 9, 27, 244, 1, 296, 39, 647, 906, 125, 11, 326, 7, 5, 552, 2, 203, 5, 321, 73, 30, 4783, 681, 10, 3, 61, 817, 155, 2059, 9, 552, 3, 689, 421, 61, 961, 10, 481, 81, 188, 18, 2, 3, 96, 908, 88, 27, 6, 39, 155, 10, 2858, 104, 69, 5, 552, 42, 80, 76, 212, 628, 4, 1884, 34, 187, 767, 4, 813, 1038, 1809, 69, 5, 154, 30, 892, 42, 585, 34, 9, 294, 1993, 9, 7, 5, 321, 77, 2059, 10, 164, 2, 961, 10, 44, 108, 28, 126, 6, 481, 81, 188, 18, 3421, 6, 191, 45, 4830, 100, 7, 5, 321, 42, 585, 34, 2, 104, 42, 5924, 1, 4071, 444, 5, 24, 901, 318, 264, 670, 90, 333, 128, 5, 297, 1, 19055, 2, 11333, 2140, 4, 1308, 14, 2, 5387, 55, 301, 2, 41, 552, 31, 351, 7323, 4708, 264, 670, 90, 283, 2356, 2, 383, 38, 128, 4, 2447, 2193, 7, 5, 552, 2, 321, 195, 226, 420, 333, 90, 61, 2, 1055, 2437, 16, 1197, 6, 4116, 38, 209]",1595.0,20479412,590
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.,Epigenetics,Epigenetics,2010-08-16,"We performed a genome-wide analysis of aberrant DNA methylation in chronic lymphocytic leukemia (CLL) using methylated CpG island amplification (MCA) coupled with a promoter microarray. We identified 280 potential targets of aberrant DNA methylation in CLL. These genes were located more frequently in chromosomes 19 (16%, p=0.001), 16 (11%, p=0.001), 17 (10%, p=0.02) and 11 (9%, p=0.02) and could be grouped in several functional networks. Methylation status was confirmed for 22 of these genes (SOX11, DLX1, FAM62C, SOX14, RSPO1, ADCY5, HAND2,SPOCK, MLL, ING1, PRIMA1, BCL11B, LTBP2, BNC1, NR2F2, SALL1, GALGT2, LHX1, DLX4, KLK10, TFAP2 and APP) in 78 CLL patients by pyrosequencing. As a proof of principle, we analyzed the expression of 2 genes, PRIMA1 and APP, in primary cells and of GALGT2, TFAP2C and PRIMA1 in leukemia cells. There was an inverse association between methylation and gene expression. This could be reversed by treatment with 5-aza-2'-deoxycytidine in cell lines. Treatment in a clinical trial with 5-azacitidine resulted in decreased methylation of LINE, DLX4 and SALL1 in the peripheral blood B-cells of patients with CLL. IgVH mutational status or ZAP-70 expression were not associated with specific methylation profiles. By multivariate analysis, methylation of LINE and APP was associated with shorter overall survival (p = 0.045 and 0.0035, respectively). This study demonstrates that aberrant DNA methylation is common and has potential prognostic and therapeutic value in CLL.",Journal Article,3445.0,89.0,We performed a genome-wide analysis of aberrant DNA methylation in chronic lymphocytic CLL using methylated CpG island amplification MCA coupled with a promoter microarray We identified 280 potential targets of aberrant DNA methylation in CLL These genes were located more frequently in chromosomes 19 16 p=0.001 16 11 p=0.001 17 10 p=0.02 and 11 9 p=0.02 and could be grouped in several functional networks Methylation status was confirmed for 22 of these genes SOX11 DLX1 FAM62C SOX14 RSPO1 ADCY5 HAND2 SPOCK MLL ING1 PRIMA1 BCL11B LTBP2 BNC1 NR2F2 SALL1 GALGT2 LHX1 DLX4 KLK10 TFAP2 and APP in 78 CLL patients by pyrosequencing As a proof of principle we analyzed the expression of 2 genes PRIMA1 and APP in primary cells and of GALGT2 TFAP2C and PRIMA1 in cells There was an inverse association between methylation and gene expression This could be reversed by treatment with 5-aza-2'-deoxycytidine in cell lines Treatment in a clinical trial with 5-azacitidine resulted in decreased methylation of LINE DLX4 and SALL1 in the peripheral blood B-cells of patients with CLL IgVH mutational status or ZAP-70 expression were not associated with specific methylation profiles By multivariate analysis methylation of LINE and APP was associated with shorter overall survival p 0.045 and 0.0035 respectively This study demonstrates that aberrant DNA methylation is common and has potential prognostic and therapeutic value in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 173, 8, 898, 1019, 65, 1, 1898, 261, 569, 4, 442, 1193, 552, 75, 2963, 2075, 3454, 1073, 13304, 3332, 5, 8, 973, 1727, 21, 108, 5775, 174, 637, 1, 1898, 261, 569, 4, 552, 46, 214, 11, 2308, 80, 746, 4, 3560, 326, 245, 19, 13, 144, 245, 175, 19, 13, 144, 269, 79, 19, 13, 588, 2, 175, 83, 19, 13, 588, 2, 359, 40, 3706, 4, 392, 583, 3991, 569, 156, 10, 557, 9, 350, 1, 46, 214, 13428, 58976, 58977, 58978, 46043, 58979, 58980, 58981, 3049, 58982, 39333, 25260, 46044, 26945, 46045, 39260, 46046, 58983, 46047, 21161, 58984, 2, 22604, 4, 833, 552, 7, 20, 6031, 22, 8, 3840, 1, 4968, 21, 311, 3, 55, 1, 18, 214, 39333, 2, 22604, 4, 86, 37, 2, 1, 46046, 34898, 2, 39333, 4, 37, 125, 10, 35, 2931, 248, 59, 569, 2, 145, 55, 26, 359, 40, 3682, 20, 24, 5, 33, 3924, 6135, 6750, 4, 31, 285, 24, 4, 8, 38, 160, 5, 33, 3752, 627, 4, 340, 569, 1, 328, 46047, 2, 39260, 4, 3, 672, 315, 132, 37, 1, 7, 5, 552, 14484, 1619, 156, 15, 6251, 431, 55, 11, 44, 41, 5, 112, 569, 1241, 20, 331, 65, 569, 1, 328, 2, 22604, 10, 41, 5, 985, 63, 25, 19, 13, 4918, 2, 13, 15569, 106, 26, 45, 1902, 17, 1898, 261, 569, 16, 186, 2, 71, 174, 177, 2, 189, 549, 4, 552]",1426.0,20484983,172
Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.,Epigenomics,Epigenomics,2009-10-01,"B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy that clinically ranges from indolent to rapidly progressive. CLL, like other cancers, can be affected by epigenetic alterations. A microarray discovery-based study was initiated to determine DNA methylation in CLL cases with a range of CD38 expression (192%). Many loci were either methylated or unmethylated across all CD38 levels, but differential methylation was also observed for some genes. Genomic sequencing of DLEU7 confirmed extensive cytosine methylation preferentially in patient samples with low CD38 expression, whereas NRP2, SFRP2 and ADAM12 were more commonly methylated in those with high CD38 expression. This study demonstrates that CLL is affected by CpG island methylation in some genes that segregate with CD38 expression levels, while most others show similar methylation patterns across all levels. The CpG island methylation in certain functional gene groups and pathway-associated genes that are known to be deregulated in CLL provides additional insights into the CLL methylome and epigenetic contribution to cellular dysfunction. It will now be useful to investigate the effectiveness of epigenetic therapeutic reversal of these alterations to develop effective treatments for the disease.",Journal Article,3764.0,40.0,B-cell chronic lymphocytic CLL is a heterogeneous malignancy that clinically ranges from indolent to rapidly progressive CLL like other cancers can be affected by epigenetic alterations A microarray discovery-based study was initiated to determine DNA methylation in CLL cases with a range of CD38 expression 192 Many loci were either methylated or unmethylated across all CD38 levels but differential methylation was also observed for some genes Genomic sequencing of DLEU7 confirmed extensive cytosine methylation preferentially in patient samples with low CD38 expression whereas NRP2 SFRP2 and ADAM12 were more commonly methylated in those with high CD38 expression This study demonstrates that CLL is affected by CpG island methylation in some genes that segregate with CD38 expression levels while most others show similar methylation patterns across all levels The CpG island methylation in certain functional gene groups and pathway-associated genes that are known to be deregulated in CLL provides additional insights into the CLL methylome and epigenetic contribution to cellular dysfunction It will now be useful to investigate the effectiveness of epigenetic therapeutic reversal of these alterations to develop effective treatments for the disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 8, 1564, 710, 17, 505, 5632, 29, 2316, 6, 1755, 1014, 552, 733, 127, 163, 122, 40, 1424, 20, 1418, 593, 8, 1727, 1574, 90, 45, 10, 1917, 6, 223, 261, 569, 4, 552, 140, 5, 8, 184, 1, 4469, 55, 58994, 445, 2012, 11, 361, 2963, 15, 8100, 716, 62, 4469, 148, 84, 1777, 569, 10, 120, 164, 9, 476, 214, 572, 615, 1, 58995, 557, 1344, 6903, 569, 3509, 4, 69, 347, 5, 154, 4469, 55, 547, 18537, 16882, 2, 34901, 11, 80, 841, 2963, 4, 135, 5, 64, 4469, 55, 26, 45, 1902, 17, 552, 16, 1424, 20, 2075, 3454, 569, 4, 476, 214, 17, 13258, 5, 4469, 55, 148, 369, 96, 1749, 514, 288, 569, 764, 716, 62, 148, 3, 2075, 3454, 569, 4, 1840, 583, 145, 271, 2, 308, 41, 214, 17, 32, 440, 6, 40, 5415, 4, 552, 777, 402, 1957, 237, 3, 552, 11362, 2, 1418, 2925, 6, 763, 1527, 192, 303, 1134, 40, 999, 6, 963, 3, 1236, 1, 1418, 189, 5933, 1, 46, 593, 6, 690, 323, 640, 9, 3, 34]",1261.0,20495622,359
Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2010-07-01,"Statins and non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications. In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular lymphoma. Other studies have suggested that statins reduce the efficacy of rituximab by inhibiting binding to CD20. We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy. At diagnosis, 136 (20%) patients took statins and 230 (34%) scheduled daily aspirin, ibuprofen, or naproxen. No difference in time to treatment was observed based on statin or NSAID use. Among patients receiving a rituximab-containing first-line therapy, no difference in time to salvage treatment was observed based on statin use. Although previous studies suggested statins may improve event free survival among patients with follicular lymphoma, we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL. The in vitro observation that statins reduce rituximab efficacy does not appear to have clinical significance in CLL care.",Journal Article,3491.0,13.0,Statins and non-steroidal anti-inflammatory drugs NSAIDs are among the most commonly prescribed medications In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade lymphomas including chronic lymphocytic CLL and a recent observational study found statin use was associated with improved event free survival in patients with follicular Other studies have suggested that statins reduce the efficacy of rituximab by inhibiting binding to CD20 We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy At diagnosis 136 20 patients took statins and 230 34 scheduled daily aspirin ibuprofen or naproxen No difference in time to treatment was observed based on statin or NSAID use Among patients receiving a rituximab-containing first-line therapy no difference in time to salvage treatment was observed based on statin use Although previous studies suggested statins may improve event free survival among patients with follicular we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL The in vitro observation that statins reduce rituximab efficacy does not appear to have clinical significance in CLL care,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5241, 2, 220, 7745, 312, 1291, 600, 5225, 32, 107, 3, 96, 841, 2746, 2679, 4, 439, 94, 309, 17, 5241, 2, 5225, 68, 47, 174, 22, 1475, 235, 4, 154, 88, 1557, 141, 442, 1193, 552, 2, 8, 435, 2495, 45, 204, 4295, 119, 10, 41, 5, 231, 774, 115, 25, 4, 7, 5, 1974, 127, 94, 47, 1148, 17, 5241, 969, 3, 209, 1, 855, 20, 2062, 791, 6, 2198, 21, 673, 426, 35, 2495, 180, 45, 1, 12324, 7, 5, 732, 265, 4121, 82, 13, 552, 6, 376, 317, 4295, 15, 6732, 119, 10, 139, 6, 136, 38, 228, 15, 2574, 3, 209, 1, 855, 36, 28, 147, 4829, 179, 7, 5060, 5241, 2, 6136, 562, 4394, 391, 2085, 13060, 15, 58997, 77, 523, 4, 98, 6, 24, 10, 164, 90, 23, 4295, 15, 6732, 119, 107, 7, 357, 8, 855, 1101, 157, 328, 36, 77, 523, 4, 98, 6, 992, 24, 10, 164, 90, 23, 4295, 119, 242, 698, 94, 1148, 5241, 68, 401, 774, 115, 25, 107, 7, 5, 1974, 21, 2469, 77, 345, 1, 5241, 23, 98, 6, 388, 36, 4, 26, 375, 45, 1, 7, 5, 4121, 82, 13, 552, 3, 4, 439, 1664, 17, 5241, 969, 855, 209, 1097, 44, 1322, 6, 47, 38, 724, 4, 552, 165]",1377.0,20496995,714
Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.,Blood,Blood,2010-06-03,"Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new treatment paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion protein kinase but instead displays increased phosphatidylinositol 3-kinase (PI3K) activity. To date, PI3K inhibitor development has been limited because of the requirement of this pathway for many essential cellular functions. Identification of the hematopoietic-selective isoform PI3K- unlocks a new therapeutic potential for B-cell malignancies. Herein, we demonstrate that PI3K has increased enzymatic activity and that PI3K- is expressed in CLL cells. A PI3K- selective inhibitor CAL-101 promoted apoptosis in primary CLL cells ex vivo in a dose- and time-dependent fashion that was independent of common prognostic markers. CAL-101-mediated cytotoxicity was caspase dependent and was not diminished by coculture on stromal cells. In addition, CAL-101 abrogated protection from spontaneous apoptosis induced by B cell-activating factors CD40L, TNF-, and fibronectin. In contrast to malignant cells, CAL-101 does not promote apoptosis in normal T cells or natural killer cells, nor does it diminish antibody-dependent cellular cytotoxicity. However, CAL-101 did decrease activated T-cell production of various inflammatory and antiapoptotic cytokines. Collectively, these studies provide rationale for the clinical development of CAL-101 as a first-in-class targeted therapy for CLL and related B-cell lymphoproliferative disorders.",Journal Article,3519.0,400.0,Targeted therapy with imatinib in chronic myeloid CML prompted a new treatment paradigm Unlike CML chronic lymphocytic CLL lacks an aberrant fusion protein kinase but instead displays increased phosphatidylinositol 3-kinase PI3K activity To date PI3K inhibitor development has been limited because of the requirement of this pathway for many essential cellular functions Identification of the hematopoietic-selective isoform PI3K- unlocks a new therapeutic potential for B-cell malignancies Herein we demonstrate that PI3K has increased enzymatic activity and that PI3K- is expressed in CLL cells A PI3K- selective inhibitor CAL-101 promoted apoptosis in primary CLL cells ex vivo in a dose- and time-dependent fashion that was independent of common prognostic markers CAL-101-mediated cytotoxicity was caspase dependent and was not diminished by coculture on stromal cells In addition CAL-101 abrogated protection from spontaneous apoptosis induced by B cell-activating factors CD40L TNF- and fibronectin In contrast to malignant cells CAL-101 does not promote apoptosis in normal T cells or natural killer cells nor does it diminish antibody-dependent cellular cytotoxicity However CAL-101 did decrease activated T-cell production of various inflammatory and antiapoptotic cytokines Collectively these studies provide rationale for the clinical development of CAL-101 as a first-in-class targeted therapy for CLL and related B-cell lymphoproliferative disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[238, 36, 5, 577, 4, 442, 533, 903, 4140, 8, 217, 24, 2431, 4246, 903, 442, 1193, 552, 6856, 35, 1898, 1212, 178, 216, 84, 3496, 7196, 101, 3415, 27, 216, 974, 128, 6, 1244, 974, 230, 193, 71, 85, 383, 408, 1, 3, 4701, 1, 26, 308, 9, 445, 1452, 763, 1681, 911, 1, 3, 1007, 1094, 3995, 974, 7339, 59029, 8, 217, 189, 174, 9, 132, 31, 441, 1986, 21, 608, 17, 974, 71, 101, 5226, 128, 2, 17, 974, 7339, 16, 570, 4, 552, 37, 8, 974, 7339, 1094, 230, 10368, 2338, 2992, 351, 4, 86, 552, 37, 2581, 386, 4, 8, 61, 2, 98, 470, 3240, 17, 10, 306, 1, 186, 177, 525, 10368, 2338, 517, 1408, 10, 1469, 470, 2, 10, 44, 2849, 20, 7604, 23, 1126, 37, 4, 352, 10368, 2338, 3728, 3525, 29, 3280, 351, 277, 20, 132, 31, 1616, 130, 8285, 2254, 2014, 2, 8629, 4, 748, 6, 393, 37, 10368, 2338, 1097, 44, 1617, 351, 4, 295, 102, 37, 15, 1504, 3458, 37, 2110, 1097, 192, 8440, 548, 470, 763, 1408, 137, 10368, 2338, 205, 775, 735, 102, 31, 1529, 1, 747, 1291, 2, 4176, 1886, 2535, 46, 94, 377, 1728, 9, 3, 38, 193, 1, 10368, 2338, 22, 8, 157, 4, 1040, 238, 36, 9, 552, 2, 139, 132, 31, 4192, 1997]",1467.0,20522708,398
Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2010-06-01,"Monoclonal antibodies (MoAbs) directed against the CD20 antigen on B cells have dramatically altered the treatment landscape for patients with chronic lymphocytic leukemia (CLL). Rituximab, a chimeric mouse/human MoAb, was the first antibody to be approved for the treatment of indolent B-cell lymphomas. Although single-agent, standard-dose rituximab has limited activity as first-line therapy for patients with CLL, it has synergistic therapeutic activity when combined with chemotherapy. Indeed, chemoimmunotherapy with combined fludarabine (F), cyclophosphamide (C), and rituximab was shown to improve both progression-free and overall survival in a randomized phase III clinical trial compared with FC in previously untreated patients with CLL. In this article, we review important clinical trials that have incorporated rituximab with other agents for treatment-naive patients with CLL. We also highlight second- and third-generation CD20 MoAbs approved or in development for the treatment of CLL.",Journal Article,3521.0,4.0,Monoclonal antibodies MoAbs directed against the CD20 antigen on B cells have dramatically altered the treatment landscape for patients with chronic lymphocytic CLL Rituximab a chimeric mouse/human MoAb was the first antibody to be approved for the treatment of indolent B-cell lymphomas Although single-agent standard-dose rituximab has limited activity as first-line therapy for patients with CLL it has synergistic therapeutic activity when combined with chemotherapy Indeed chemoimmunotherapy with combined fludarabine F cyclophosphamide C and rituximab was shown to improve both progression-free and overall survival in a randomized phase III clinical trial compared with FC in previously untreated patients with CLL In this article we review important clinical trials that have incorporated rituximab with other agents for treatment-naive patients with CLL We also highlight second- and third-generation CD20 MoAbs approved or in development for the treatment of CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 890, 19109, 1166, 480, 3, 2198, 448, 23, 132, 37, 47, 2729, 1495, 3, 24, 2801, 9, 7, 5, 442, 1193, 552, 855, 8, 2897, 830, 171, 11407, 10, 3, 157, 548, 6, 40, 850, 9, 3, 24, 1, 2316, 132, 31, 1557, 242, 226, 420, 260, 61, 855, 71, 383, 128, 22, 157, 328, 36, 9, 7, 5, 552, 192, 71, 1806, 189, 128, 198, 397, 5, 56, 4462, 4438, 5, 397, 2027, 1068, 1112, 256, 2, 855, 10, 443, 6, 401, 110, 91, 115, 2, 63, 25, 4, 8, 384, 124, 316, 38, 160, 72, 5, 4127, 4, 373, 1278, 7, 5, 552, 4, 26, 946, 21, 206, 305, 38, 143, 17, 47, 2449, 855, 5, 127, 183, 9, 24, 2462, 7, 5, 552, 21, 120, 1817, 419, 2, 1282, 914, 2198, 19109, 850, 15, 4, 193, 9, 3, 24, 1, 552]",972.0,20529805,278
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.,PloS one,PLoS ONE,2010-06-03,"While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies. In mantle cell lymphoma (JeKo-1), Burkitt's lymphoma (Raji), and acute lymphoblastic leukemia (697) cell lines, the 48-hr IC(50) (50% growth inhibitory concentration) of AR-42 is 0.61 microM or less. In chronic lymphocytic leukemia (CLL) patient cells, the 48-hr LC(50) (concentration lethal to 50%) of AR-42 is 0.76 microM. AR-42 produces dose- and time-dependent acetylation both of histones and tubulin, and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells. AR-42 also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand (TRAIL), potentially through reduction of c-FLIP. AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity. Together, these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses. These results strongly support upcoming phase I testing of AR-42 in B-cell malignancies.",Journal Article,3519.0,42.0,While deacetylase DAC inhibitors show promise for the treatment of B-cell malignancies those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only and have shown suboptimal activity or unacceptable toxicities We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies In mantle cell JeKo-1 's Raji and acute lymphoblastic 697 cell lines the 48-hr IC 50 50 growth inhibitory concentration of AR-42 is 0.61 microM or less In chronic lymphocytic CLL patient cells the 48-hr LC 50 concentration lethal to 50 of AR-42 is 0.76 microM AR-42 produces dose- and time-dependent acetylation both of histones and tubulin and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells AR-42 also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand TRAIL potentially through reduction of c-FLIP AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity Together these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses These results strongly support upcoming phase I testing of AR-42 in B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,"[369, 2732, 6140, 222, 514, 1783, 9, 3, 24, 1, 132, 31, 441, 135, 3955, 6, 1244, 32, 4241, 222, 1, 1040, 70, 2, 215, 59052, 15, 1157, 222, 1, 1040, 70, 6140, 158, 2, 47, 443, 3291, 128, 15, 3215, 385, 21, 673, 565, 3, 229, 6140, 230, 754, 595, 6, 223, 211, 209, 4, 132, 31, 441, 4, 2757, 31, 22435, 14, 292, 9868, 2, 286, 1275, 11989, 31, 285, 3, 576, 168, 2340, 212, 212, 129, 1810, 1227, 1, 754, 595, 16, 13, 713, 3550, 15, 299, 4, 442, 1193, 552, 69, 37, 3, 576, 168, 1837, 212, 1227, 2266, 6, 212, 1, 754, 595, 16, 13, 846, 3550, 754, 595, 4042, 61, 2, 98, 470, 4145, 110, 1, 8457, 2, 5303, 2, 1516, 1469, 470, 351, 17, 16, 44, 405, 4, 3, 463, 1, 1126, 37, 754, 595, 120, 6229, 552, 37, 6, 2254, 139, 351, 1958, 1232, 2585, 751, 298, 628, 1, 256, 9334, 754, 595, 97, 405, 3627, 1911, 2, 15, 1069, 25, 4, 169, 2282, 830, 274, 1, 132, 31, 710, 187, 241, 1, 155, 1162, 46, 74, 608, 17, 754, 595, 71, 4, 439, 2, 4, 386, 209, 28, 2668, 415, 46, 99, 1327, 538, 11974, 124, 70, 471, 1, 754, 595, 4, 132, 31, 441]",1251.0,20532179,557
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.,Leukemia & lymphoma,Leuk. Lymphoma,2010-07-01,"Fludarabine-refractory chronic lymphocytic leukemia is associated with poor survival rates. Chemoimmunotherapy combinations that include purine analogs, alkylating agents, and monoclonal antibodies have shown the highest response rates to date. Intensive treatment approaches can be associated with poor tolerability that is often characterized by deteriorating immune functions and high infection rates. Treatment with some monoclonal antibodies is often complicated by infusion-related adverse events and increased risk of infections. Several novel agents are currently being investigated for this difficult-to-treat patient population. Ofatumumab is an anti-CD20 monoclonal antibody that targets a different epitope from the one targeted by rituximab and, it has shown promising antileukemia activity. Lenalidomide is an immunomodulatory agent that has shown promising activity in patients with fludarabine-refractory chronic lymphocytic leukemia, many of whom had poor prognostic features and bulky disease. Encouraging results have been observed with each of these agents individually. However, given the diverse mechanisms governing CLL pathogenesis and disease progression, ongoing clinical trials combinations of these agents may improve clinical outcomes for this patient population.",Journal Article,3491.0,9.0,Fludarabine-refractory chronic lymphocytic is associated with poor survival rates Chemoimmunotherapy combinations that include purine analogs alkylating agents and monoclonal antibodies have shown the highest response rates to date Intensive treatment approaches can be associated with poor tolerability that is often characterized by deteriorating immune functions and high infection rates Treatment with some monoclonal antibodies is often complicated by infusion-related adverse events and increased risk of infections Several novel agents are currently being investigated for this difficult-to-treat patient population Ofatumumab is an anti-CD20 monoclonal antibody that targets a different epitope from the one targeted by rituximab and it has shown promising antileukemia activity Lenalidomide is an immunomodulatory agent that has shown promising activity in patients with fludarabine-refractory chronic lymphocytic many of whom had poor prognostic features and bulky disease Encouraging results have been observed with each of these agents individually However given the diverse mechanisms governing CLL pathogenesis and disease progression ongoing clinical trials combinations of these agents may improve clinical outcomes for this patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 430, 442, 1193, 16, 41, 5, 334, 25, 151, 4438, 1247, 17, 643, 5006, 4063, 3410, 183, 2, 848, 890, 47, 443, 3, 1076, 51, 151, 6, 1244, 1686, 24, 611, 122, 40, 41, 5, 334, 1543, 17, 16, 629, 765, 20, 26925, 250, 1681, 2, 64, 930, 151, 24, 5, 476, 848, 890, 16, 629, 4286, 20, 904, 139, 290, 281, 2, 101, 43, 1, 1875, 392, 229, 183, 32, 694, 486, 565, 9, 26, 1740, 6, 943, 69, 266, 5732, 16, 35, 312, 2198, 848, 548, 17, 637, 8, 338, 4430, 29, 3, 104, 238, 20, 855, 2, 192, 71, 443, 721, 9169, 128, 1288, 16, 35, 2555, 420, 17, 71, 443, 721, 128, 4, 7, 5, 2027, 430, 442, 1193, 445, 1, 953, 42, 334, 177, 404, 2, 4112, 34, 2269, 99, 47, 85, 164, 5, 296, 1, 46, 183, 4257, 137, 447, 3, 1867, 483, 10179, 552, 1384, 2, 34, 91, 942, 38, 143, 1247, 1, 46, 183, 68, 401, 38, 123, 9, 26, 69, 266]",1259.0,20545582,660
CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.,"Cytometry. Part B, Clinical cytometry",Cytometry B Clin Cytom,2010-01-01,"The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e. CD5+B-CLPD) are poorly defined. We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy. We identified 229 patients with CD5+B-CLPD. A definitive pathological diagnosis was made in all 61 (27%) CD5+B-CLPD patients with nonbone marrow (BM) biopsy specimens considered adequate for a comprehensive pathological examination. The most common diagnosis among these 61 patients was CLL (44%) followed by the leukemic phase of marginal zone lymphoma (34%), lymphoplasmacytic lymphoma (11%), diffuse large B cell lymphoma (8%), and high-grade B cell lymphoma not otherwise specified (2%). In contrast, among 168 patients without a non-BM tissue biopsy specimen, a specific diagnosis could be made on review of all available data in only 24 (14%) with 144 (86%) remaining ""unclassified."" In patients with CD5+B-CLPD, a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease. We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment.",Journal Article,3672.0,19.0,The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic CLL or mantle cell i.e CD5+B-CLPD are poorly defined We studied patients with CD5+B-CLPD to 1 more completely define the clinical features and pathology of CD5+B-CLPD 2 compare these features to patients presenting with typical CLL and 3 test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy We identified 229 patients with CD5+B-CLPD A definitive pathological diagnosis was made in all 61 27 CD5+B-CLPD patients with nonbone marrow BM biopsy specimens considered adequate for a comprehensive pathological examination The most common diagnosis among these 61 patients was CLL 44 followed by the leukemic phase of marginal zone 34 lymphoplasmacytic 11 diffuse large B cell 8 and high-grade B cell not otherwise specified 2 In contrast among 168 patients without a non-BM tissue biopsy specimen a specific diagnosis could be made on review of all available data in only 24 14 with 144 86 remaining `` unclassified '' In patients with CD5+B-CLPD a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1117, 2, 38, 906, 1, 7, 5, 6349, 442, 132, 31, 4192, 1997, 3207, 135, 17, 364, 5, 3476, 442, 1193, 2647, 302, 1193, 552, 15, 2757, 31, 70, 563, 6349, 132, 19233, 32, 1240, 395, 21, 656, 7, 5, 6349, 132, 19233, 6, 14, 80, 2500, 1107, 3, 38, 404, 2, 1117, 1, 6349, 132, 19233, 18, 932, 46, 404, 6, 7, 1656, 5, 3476, 552, 2, 27, 412, 3, 1492, 17, 8, 697, 1, 7, 5, 6349, 132, 19233, 359, 47, 8, 991, 132, 31, 710, 21, 108, 7584, 7, 5, 6349, 132, 19233, 8, 1057, 1301, 147, 10, 1229, 4, 62, 713, 428, 6349, 132, 19233, 7, 5, 34930, 581, 1246, 411, 623, 515, 1658, 9, 8, 949, 1301, 1385, 3, 96, 186, 147, 107, 46, 713, 7, 10, 552, 584, 370, 20, 3, 2015, 124, 1, 3450, 3614, 562, 5325, 175, 1388, 375, 132, 31, 66, 2, 64, 88, 132, 31, 44, 2632, 3575, 18, 4, 748, 107, 5359, 7, 187, 8, 220, 1246, 246, 411, 2360, 8, 112, 147, 359, 40, 1229, 23, 206, 1, 62, 390, 74, 4, 158, 259, 213, 5, 4415, 868, 1844, 7096, 522, 4, 7, 5, 6349, 132, 19233, 8, 1057, 147, 122, 40, 1229, 23, 35, 1658, 220, 1246, 246, 411, 802, 17, 26, 2983, 1097, 44, 643, 8, 229, 34, 21, 2237, 17, 62, 7, 5, 6349, 132, 19233, 257, 47, 8, 220, 1246, 246, 411, 6, 2378, 8, 1057, 147, 324, 6, 1118, 1, 24]",1456.0,20568273,680
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.,Blood,Blood,2010-06-23,"Chronic lymphocytic leukemia (CLL) is an incurable progressive disease for which new therapies are required. Therapy with monoclonal antibodies (mAbs) has improved the outcome of patients with CLL, making further investigation of novel antibodies directed against alternative and specific targets on B cells an important area of translational research. We now describe functional properties of an antagonistic humanized mAb to CD74, milatuzumab, showing that milatuzumab combined with a crosslinking antibody induces cytotoxicity in vitro in CLL cells in a caspase- and stromal-independent manner associated with aggregation of CD74 on the cell surface. Furthermore, incorporation of milatuzumab into an immunoliposome induces even more of a cytotoxic response than in vitro crosslinking, representing a novel therapeutic formulation for this mAb. Based on these data, future development of the milatuzumab-immunoliposome formulation as a therapeutic agent for CLL is warranted.",Journal Article,3499.0,29.0,Chronic lymphocytic CLL is an incurable progressive disease for which new therapies are required Therapy with monoclonal antibodies mAbs has improved the outcome of patients with CLL making further investigation of novel antibodies directed against alternative and specific targets on B cells an important area of translational research We now describe functional properties of an antagonistic humanized mAb to CD74 milatuzumab showing that milatuzumab combined with a crosslinking antibody induces cytotoxicity in vitro in CLL cells in a caspase- and stromal-independent manner associated with aggregation of CD74 on the cell surface Furthermore incorporation of milatuzumab into an immunoliposome induces even more of a cytotoxic response than in vitro crosslinking representing a novel therapeutic formulation for this mAb Based on these data future development of the milatuzumab-immunoliposome formulation as a therapeutic agent for CLL is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 35, 2641, 1014, 34, 9, 92, 217, 235, 32, 616, 36, 5, 848, 890, 5207, 71, 231, 3, 228, 1, 7, 5, 552, 1079, 195, 940, 1, 229, 890, 1166, 480, 1091, 2, 112, 637, 23, 132, 37, 35, 305, 965, 1, 2460, 389, 21, 1134, 897, 583, 1571, 1, 35, 9863, 3619, 2780, 6, 7780, 12038, 2069, 17, 12038, 397, 5, 8, 12984, 548, 1516, 1408, 4, 439, 4, 552, 37, 4, 8, 1469, 2, 1126, 306, 1708, 41, 5, 6598, 1, 7780, 23, 3, 31, 1255, 798, 2838, 1, 12038, 237, 35, 38641, 1516, 871, 80, 1, 8, 759, 51, 76, 4, 439, 12984, 2861, 8, 229, 189, 3583, 9, 26, 2780, 90, 23, 46, 74, 508, 193, 1, 3, 12038, 38641, 3583, 22, 8, 189, 420, 9, 552, 16, 1197]",954.0,20574049,288
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2010-10-01,"A study was undertaken to analyze the survival of chronic lymphocytic leukemia (CLL) patients relative to age-matched individuals in the general population and determine the age-stratified utility of prognostic testing. All 2487 patients diagnosed with CLL between January 1995 and June 2008 and cared for in the Mayo Clinic Division of Hematology were categorized by age at diagnosis and evaluated for differences in clinical characteristics, time to first treatment, and overall survival (OS). Among Rai stage 0 patients, survival was shorter than the age-matched general population for patients aged <55 years (P < .001), 55 to 64 years (P < .001), and 65 to 74 years (P < .001), but not those aged 75 years at diagnosis (P = not significant). CD38, IGHV mutation, and ZAP-70 each predicted time to first treatment independent of stage for all age groups (all P < .04), but had less value for predicting OS, particularly as age increased. IGHV and fluorescent in situ hybridization (FISH) predicted OS independent of stage for patients aged <55 years (P  .001), 55 to 64 years (P  .004), and 65 to 74 years (P  .001), but not those aged 75 years. CD38 and ZAP-70 each predicted OS independent of stage for only 2 of 4 age categories. Among Rai 0 patients aged <75 years, survival was shorter than the age-matched population only for IGHV unmutated (P < .001) patients or those with unfavorable FISH (P < .001). Survival of CLL patients aged <75 years is shorter than the age-matched general population regardless of disease stage. Among patients aged <75 years, the simple combinations of stage and IGHV or stage and FISH identifies those with excess risk of death relative to the age-matched population. Although useful for predicting time to first treatment independent of stage for patients of all ages, prognostic testing had little utility for predicting OS independent of stage among patients aged 75 years.",Evaluation Study,3399.0,75.0,A study was undertaken to analyze the survival of chronic lymphocytic CLL patients relative to age-matched individuals in the general population and determine the age-stratified utility of prognostic testing All 2487 patients diagnosed with CLL between January 1995 and June 2008 and cared for in the Mayo Clinic Division of Hematology were categorized by age at diagnosis and evaluated for differences in clinical characteristics time to first treatment and overall survival OS Among Rai stage 0 patients survival was shorter than the age-matched general population for patients aged 55 years P .001 55 to 64 years P .001 and 65 to 74 years P .001 but not those aged 75 years at diagnosis P not significant CD38 IGHV mutation and ZAP-70 each predicted time to first treatment independent of stage for all age groups all P .04 but had less value for predicting OS particularly as age increased IGHV and fluorescent in situ hybridization FISH predicted OS independent of stage for patients aged 55 years P  .001 55 to 64 years P  .004 and 65 to 74 years P  .001 but not those aged 75 years CD38 and ZAP-70 each predicted OS independent of stage for only 2 of 4 age categories Among Rai 0 patients aged 75 years survival was shorter than the age-matched population only for IGHV unmutated P .001 patients or those with unfavorable FISH P .001 Survival of CLL patients aged 75 years is shorter than the age-matched general population regardless of disease stage Among patients aged 75 years the simple combinations of stage and IGHV or stage and FISH identifies those with excess risk of death relative to the age-matched population Although useful for predicting time to first treatment independent of stage for patients of all ages prognostic testing had little utility for predicting OS independent of stage among patients aged 75 years,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 45, 10, 2789, 6, 1992, 3, 25, 1, 442, 1193, 552, 7, 580, 6, 89, 655, 869, 4, 3, 1083, 266, 2, 223, 3, 89, 1173, 1207, 1, 177, 471, 62, 59113, 7, 265, 5, 552, 59, 1024, 2323, 2, 1924, 1375, 2, 12743, 9, 4, 3, 2486, 1188, 5750, 1, 6216, 11, 2320, 20, 89, 28, 147, 2, 194, 9, 362, 4, 38, 374, 98, 6, 157, 24, 2, 63, 25, 118, 107, 4121, 82, 13, 7, 25, 10, 985, 76, 3, 89, 655, 1083, 266, 9, 7, 1032, 614, 60, 19, 144, 614, 6, 660, 60, 19, 144, 2, 556, 6, 794, 60, 19, 144, 84, 44, 135, 1032, 8999, 60, 28, 147, 19, 44, 93, 4469, 6220, 258, 2, 6251, 431, 296, 783, 98, 6, 157, 24, 306, 1, 82, 9, 62, 89, 271, 62, 19, 755, 84, 42, 299, 549, 9, 1434, 118, 823, 22, 89, 101, 6220, 2, 2910, 4, 957, 1554, 1277, 783, 118, 306, 1, 82, 9, 7, 1032, 614, 60, 19, 1552, 144, 614, 6, 660, 60, 19, 1552, 1520, 2, 556, 6, 794, 60, 19, 1552, 144, 84, 44, 135, 1032, 8999, 60, 4469, 2, 6251, 431, 296, 783, 118, 306, 1, 82, 9, 158, 18, 1, 39, 89, 1996, 107, 4121, 13, 7, 1032, 481, 60, 25, 10, 985, 76, 3, 89, 655, 266, 158, 9, 6220, 7216, 19, 144, 7, 15, 135, 5, 2483, 1277, 19, 144, 25, 1, 552, 7, 1032, 481, 60, 16, 985, 76, 3, 89, 655, 1083, 266, 1583, 1, 34, 82, 107, 7, 1032, 481, 60, 3, 2763, 1247, 1, 82, 2, 6220, 15, 82, 2, 1277, 2953, 135, 5, 2612, 43, 1, 273, 580, 6, 3, 89, 655, 266, 242, 999, 9, 1434, 98, 6, 157, 24, 306, 1, 82, 9, 7, 1, 62, 2165, 177, 471, 42, 1215, 1207, 9, 1434, 118, 306, 1, 82, 107, 7, 1032, 8999, 60]",1842.0,20578179,633
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.,Blood,Blood,2010-07-01,"The canonical Wnt signaling pathway is pathogenic in a variety of cancers. We previously identified aberrant expression of the Wnt pathway transcription factor and target gene lymphoid enhancer binding factor-1 (LEF1) in chronic lymphocytic leukemia (CLL). This suggested that the Wnt signaling pathway has a role in the biology of CLL. In this study, we performed a Wnt pathway analysis using gene expression profiling and identified aberrant regulation of Wnt pathway target genes, ligands, and signaling members in CLL cells. Furthermore, we identified aberrant protein expression of LEF-1 specifically in CLL but not in normal mature B-cell subsets or after B-cell activation. Using the T cell-specific transcription factor/LEF (TCF/LEF) dual luciferase reporter assay, we demonstrated constitutive Wnt pathway activation in CLL, although the pathway was inactive in normal peripheral B cells. Importantly, LEF-1 knockdown decreased CLL B-cell survival. We also identified LEF-1 expression in CD19(+)/CD5(+) cells obtained from patients with monoclonal B-cell lymphocytosis, suggesting a role for LEF-1 early in CLL leukemogenesis. This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis.",Journal Article,3491.0,91.0,The canonical Wnt signaling pathway is pathogenic in a variety of cancers We previously identified aberrant expression of the Wnt pathway transcription factor and target gene lymphoid enhancer binding factor-1 LEF1 in chronic lymphocytic CLL This suggested that the Wnt signaling pathway has a role in the biology of CLL In this study we performed a Wnt pathway analysis using gene expression profiling and identified aberrant regulation of Wnt pathway target genes ligands and signaling members in CLL cells Furthermore we identified aberrant protein expression of LEF-1 specifically in CLL but not in normal mature B-cell subsets or after B-cell activation Using the T cell-specific transcription factor/LEF TCF/LEF dual luciferase reporter assay we demonstrated constitutive Wnt pathway activation in CLL although the pathway was inactive in normal peripheral B cells Importantly LEF-1 knockdown decreased CLL B-cell survival We also identified LEF-1 expression in CD19 /CD5 cells obtained from patients with monoclonal B-cell lymphocytosis suggesting a role for LEF-1 early in CLL leukemogenesis This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4471, 2112, 314, 308, 16, 2806, 4, 8, 1362, 1, 163, 21, 373, 108, 1898, 55, 1, 3, 2112, 308, 866, 161, 2, 283, 145, 2303, 4239, 791, 161, 14, 12009, 4, 442, 1193, 552, 26, 1148, 17, 3, 2112, 314, 308, 71, 8, 200, 4, 3, 891, 1, 552, 4, 26, 45, 21, 173, 8, 2112, 308, 65, 75, 145, 55, 1080, 2, 108, 1898, 863, 1, 2112, 308, 283, 214, 3123, 2, 314, 1684, 4, 552, 37, 798, 21, 108, 1898, 178, 55, 1, 14136, 14, 1225, 4, 552, 84, 44, 4, 295, 2908, 132, 31, 1890, 15, 50, 132, 31, 363, 75, 3, 102, 31, 112, 866, 161, 14136, 8108, 14136, 1828, 3864, 3674, 719, 21, 264, 3178, 2112, 308, 363, 4, 552, 242, 3, 308, 10, 5002, 4, 295, 672, 132, 37, 1859, 14136, 14, 1563, 340, 552, 132, 31, 25, 21, 120, 108, 14136, 14, 55, 4, 3158, 6349, 37, 683, 29, 7, 5, 848, 132, 31, 8125, 802, 8, 200, 9, 14136, 14, 191, 4, 552, 5661, 26, 45, 71, 108, 3, 3178, 363, 2, 7331, 343, 1, 14136, 14, 2, 3, 2112, 308, 4, 552, 2, 5601, 8, 899, 200, 9, 46, 130, 4, 3, 19788, 1309, 1, 848, 132, 31, 8125]",1322.0,20595513,451
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.,Blood,Blood,2010-07-07,"Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia. Treatment with chemotherapy over the past 3 decades has been palliative. The introduction of therapeutic antibodies has increased the number of treatment options for this disease. Despite this increase, our true understanding of the mechanism of action of antibody therapy in CLL remains limited. Rituximab, a CD20 antibody, is currently widely used in combination-based strategies for both previously untreated symptomatic CLL and as salvage therapy. Recent data suggest that the addition of rituximab to fludarabine with or without cyclophosphamide prolongs survival in younger patients with CLL. Other improved CD20 antibodies with promising clinical activity, including ofatumumab and GA-101, are coming forward. Alemtuzumab, a CD52 antibody, likewise has demonstrated benefit in both symptomatic, previously untreated CLL and in patients with relapsed disease but has less selectivity. Development of other therapeutic antibodies targeting alternative B-cell-specific antigens in CLL has been less successful, although many promising candidate antibodies and/or small modular immune pharmaceuticals (SMIPs) are coming forward. In addition, recent efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative non-chemotherapy-based treatment approaches.",Journal Article,3485.0,85.0,Chronic lymphocytic CLL represents the most prevalent adult Treatment with chemotherapy over the past 3 decades has been palliative The introduction of therapeutic antibodies has increased the number of treatment options for this disease Despite this increase our true understanding of the mechanism of action of antibody therapy in CLL remains limited Rituximab a CD20 antibody is currently widely used in combination-based strategies for both previously untreated symptomatic CLL and as salvage therapy Recent data suggest that the addition of rituximab to fludarabine with or without cyclophosphamide prolongs survival in younger patients with CLL Other improved CD20 antibodies with promising clinical activity including ofatumumab and GA-101 are coming forward Alemtuzumab a CD52 antibody likewise has demonstrated benefit in both symptomatic previously untreated CLL and in patients with relapsed disease but has less selectivity Development of other therapeutic antibodies targeting alternative B-cell-specific antigens in CLL has been less successful although many promising candidate antibodies and/or small modular immune pharmaceuticals SMIPs are coming forward In addition recent efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative non-chemotherapy-based treatment approaches,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 1449, 3, 96, 2485, 780, 24, 5, 56, 252, 3, 1219, 27, 1968, 71, 85, 994, 3, 2456, 1, 189, 890, 71, 101, 3, 207, 1, 24, 838, 9, 26, 34, 550, 26, 344, 114, 2501, 612, 1, 3, 670, 1, 1578, 1, 548, 36, 4, 552, 469, 383, 855, 8, 2198, 548, 16, 694, 1792, 95, 4, 150, 90, 422, 9, 110, 373, 1278, 1704, 552, 2, 22, 992, 36, 435, 74, 309, 17, 3, 352, 1, 855, 6, 2027, 5, 15, 187, 1112, 5613, 25, 4, 773, 7, 5, 552, 127, 231, 2198, 890, 5, 721, 38, 128, 141, 5732, 2, 3414, 2338, 32, 10671, 4674, 3579, 8, 7189, 548, 6269, 71, 264, 247, 4, 110, 1704, 373, 1278, 552, 2, 4, 7, 5, 591, 34, 84, 71, 299, 6072, 193, 1, 127, 189, 890, 529, 1091, 132, 31, 112, 1575, 4, 552, 71, 85, 299, 1401, 242, 445, 721, 1609, 890, 2, 15, 302, 14236, 250, 5888, 59142, 32, 10671, 4674, 4, 352, 435, 1413, 6, 4680, 694, 1498, 189, 890, 5, 127, 1283, 2, 238, 235, 5, 209, 4, 552, 2339, 3, 174, 6, 6759, 1317, 1091, 220, 56, 90, 24, 611]",1407.0,20610811,421
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.,Nature genetics,Nat. Genet.,2010-07-18,"To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 x 10(-29) and rs7755224, combined P = 2.00 x 10(-19); r(2) = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 x 10(-9)).",Journal Article,3474.0,111.0,To identify susceptibility loci for subtypes we conducted a three-stage genome-wide association study We identified two variants associated with follicular at 6p21.32 rs10484561 combined P 1.12 x 10 -29 and rs7755224 combined P 2.00 x 10 -19 r 2 1.0 supporting the idea that major histocompatibility complex genetic variation influences follicular susceptibility We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic and rs735665 combined P 4.24 x 10 -9,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 255, 1432, 2012, 9, 814, 21, 426, 8, 169, 82, 898, 1019, 248, 45, 21, 108, 100, 839, 41, 5, 1974, 28, 12479, 531, 46125, 397, 19, 14, 133, 1006, 79, 462, 2, 59169, 397, 19, 18, 2038, 1006, 79, 326, 668, 18, 14, 13, 1912, 3, 8098, 17, 458, 6537, 840, 336, 1380, 3859, 1974, 1432, 21, 120, 204, 5697, 241, 1, 8, 373, 210, 248, 59, 442, 1193, 2647, 302, 1193, 2, 45942, 397, 19, 39, 259, 1006, 79, 83]",527.0,20639881,134
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2010-07-23,"Zeta-associated protein-70 (ZAP70) expression measured by flow cytometry has been proposed as a surrogate marker of the somatic mutation status of the immunoglobulin heavy chain variable region (IGHV) genes in chronic lymphocytic leukemia. However, attempts to implement this approach in clinical flow cytometry laboratories have been problematic; many commercially available antibodies give unreliable results. Assessment of ZAP70 protein expression by immunohistochemistry in chronic lymphocytic leukemia tissue sections is an easy, alternative approach, although lack of quantitation and subjective interpretation of results are potential pitfalls. In this study, we correlated ZAP70 protein expression, assessed by immunohistochemistry, with ZAP70 messenger RNA (mRNA) transcript expression, assessed by semi-quantitative real-time reverse transcriptase-polymerase chain reaction assay, with the somatic mutation status of the IGHV genes in previously untreated patients with chronic lymphocytic leukemia. Expression of ZAP70 protein and mRNA transcripts correlated strongly (P=8.238  10(-12)). Expression of ZAP70 protein and mRNA transcripts also correlated strongly with the somatic mutation status of the IGHV genes (P=0.000071 and P=0.00076, respectively). Further, ZAP70 positivity by immunohistochemistry was associated with an increased risk of progression to therapy requirement (3-year risk 83% vs 31% for ZAP70 negative by immunohistochemistry, P=0.03). These results show that ZAP70 expression assessed by immunohistochemistry is a reliable surrogate marker of the somatic mutation status of the IGHV genes, and predicts time to progression.",Journal Article,3469.0,16.0,Zeta-associated protein-70 ZAP70 expression measured by flow cytometry has been proposed as a surrogate marker of the somatic mutation status of the immunoglobulin heavy chain variable region IGHV genes in chronic lymphocytic However attempts to implement this approach in clinical flow cytometry laboratories have been problematic many commercially available antibodies give unreliable results Assessment of ZAP70 protein expression by immunohistochemistry in chronic lymphocytic tissue sections is an easy alternative approach although lack of quantitation and subjective interpretation of results are potential pitfalls In this study we correlated ZAP70 protein expression assessed by immunohistochemistry with ZAP70 messenger RNA mRNA transcript expression assessed by semi-quantitative real-time reverse transcriptase-polymerase chain reaction assay with the somatic mutation status of the IGHV genes in previously untreated patients with chronic lymphocytic Expression of ZAP70 protein and mRNA transcripts correlated strongly P=8.238 10 -12 Expression of ZAP70 protein and mRNA transcripts also correlated strongly with the somatic mutation status of the IGHV genes P=0.000071 and P=0.00076 respectively Further ZAP70 positivity by immunohistochemistry was associated with an increased risk of progression to therapy requirement 3-year risk 83 vs 31 for ZAP70 negative by immunohistochemistry P=0.03 These results show that ZAP70 expression assessed by immunohistochemistry is a reliable surrogate marker of the somatic mutation status of the IGHV genes and predicts time to progression,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[12105, 41, 178, 431, 12921, 55, 644, 20, 1412, 1914, 71, 85, 1587, 22, 8, 2592, 952, 1, 3, 1119, 258, 156, 1, 3, 2593, 4013, 1260, 1347, 1053, 6220, 214, 4, 442, 1193, 137, 4374, 6, 6207, 26, 353, 4, 38, 1412, 1914, 4884, 47, 85, 6594, 445, 5262, 390, 890, 4978, 15198, 99, 455, 1, 12921, 178, 55, 20, 888, 4, 442, 1193, 246, 3013, 16, 35, 6261, 1091, 353, 242, 926, 1, 7887, 2, 5571, 3037, 1, 99, 32, 174, 9631, 4, 26, 45, 21, 438, 12921, 178, 55, 275, 20, 888, 5, 12921, 5992, 893, 956, 3268, 55, 275, 20, 6399, 1156, 1589, 98, 1772, 4456, 1451, 1260, 1329, 719, 5, 3, 1119, 258, 156, 1, 3, 6220, 214, 4, 373, 1278, 7, 5, 442, 1193, 55, 1, 12921, 178, 2, 956, 2680, 438, 1327, 19, 66, 6883, 79, 133, 55, 1, 12921, 178, 2, 956, 2680, 120, 438, 1327, 5, 3, 1119, 258, 156, 1, 3, 6220, 214, 19, 13, 59205, 2, 19, 13, 59206, 106, 195, 12921, 1887, 20, 888, 10, 41, 5, 35, 101, 43, 1, 91, 6, 36, 4701, 27, 111, 43, 852, 105, 456, 9, 12921, 199, 20, 888, 19, 13, 680, 46, 99, 514, 17, 12921, 55, 275, 20, 888, 16, 8, 2450, 2592, 952, 1, 3, 1119, 258, 156, 1, 3, 6220, 214, 2, 2623, 98, 6, 91]",1593.0,20657554,288
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-08-09,"To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia. Patients (n = 102) received fludarabine 25 mg/m(2) intravenously days 1 to 5 and rituximab 50 mg/m(2) day 1, 325 mg/m(2) day 3, and 375 mg/m(2) day 5 of cycle 1 and then 375 mg/m(2) day 1 of cycles 2 to 6; fludarabine plus rituximab (FR) administration was repeated every 28 days for six cycles. Three months after completion of FR, patients with stable disease or better response received subcutaneous alemtuzumab 3 mg day 1, 10 mg day 3, and 30 mg day 5 and then 30 mg three times per week for 5 weeks. Overall response (OR), complete response (CR), and partial response (PR) rates were 90%, 29%, and 61% after FR, respectively; 15% of patients were minimal residual disease (MRD) negative. Of 102 patients, 58 received alemtuzumab; 28 (61%) of 46 patients achieving PR after FR attained CR after alemtuzumab. By intent to treat (n = 102), OR and CR rates were 90% and 57% after alemtuzumab, respectively; 42% of patients became MRD negative. With median follow-up of 36 months, median PFS was 36 months, 2-year PFS was 72%, and 2-year OS was 86%. In patients achieving CR after FR, alemtuzumab was associated with five deaths resulting from infection (viral and Listeria meningitis and Legionella, cytomegalovirus, and Pneumocystis pneumonias), which occurred up to 7 months after last therapy. The study was amended to exclude CR patients from receiving alemtuzumab. Alemtuzumab consolidation improved CR and MRD-negative rates after FR induction but caused serious infections in patients who had already achieved CR after induction and did not improve 2-year PFS or survival.","Clinical Trial, Phase II",3452.0,60.0,To determine if alemtuzumab consolidation improves response rate and progression-free survival PFS after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic Patients n 102 received fludarabine 25 mg/m 2 intravenously days 1 to 5 and rituximab 50 mg/m 2 day 1 325 mg/m 2 day 3 and 375 mg/m 2 day 5 of cycle 1 and then 375 mg/m 2 day 1 of cycles 2 to 6 fludarabine plus rituximab FR administration was repeated every 28 days for six cycles Three months after completion of FR patients with stable disease or better response received subcutaneous alemtuzumab 3 mg day 1 10 mg day 3 and 30 mg day 5 and then 30 mg three times per week for 5 weeks Overall response OR complete response CR and partial response PR rates were 90 29 and 61 after FR respectively 15 of patients were minimal residual disease MRD negative Of 102 patients 58 received alemtuzumab 28 61 of 46 patients achieving PR after FR attained CR after alemtuzumab By intent to treat n 102 OR and CR rates were 90 and 57 after alemtuzumab respectively 42 of patients became MRD negative With median follow-up of 36 months median PFS was 36 months 2-year PFS was 72 and 2-year OS was 86 In patients achieving CR after FR alemtuzumab was associated with five deaths resulting from infection viral and Listeria meningitis and Legionella cytomegalovirus and Pneumocystis pneumonias which occurred up to 7 months after last therapy The study was amended to exclude CR patients from receiving alemtuzumab Alemtuzumab consolidation improved CR and MRD-negative rates after FR induction but caused serious infections in patients who had already achieved CR after induction and did not improve 2-year PFS or survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 223, 492, 3579, 2173, 1804, 51, 116, 2, 91, 115, 25, 300, 50, 504, 4438, 4, 373, 1278, 1704, 7, 5, 442, 1193, 7, 78, 2867, 103, 2027, 243, 81, 188, 18, 1672, 162, 14, 6, 33, 2, 855, 212, 81, 188, 18, 218, 14, 7139, 81, 188, 18, 218, 27, 2, 4175, 81, 188, 18, 218, 33, 1, 417, 14, 2, 818, 4175, 81, 188, 18, 218, 14, 1, 410, 18, 6, 49, 2027, 349, 855, 6413, 634, 10, 2113, 454, 339, 162, 9, 437, 410, 169, 53, 50, 1438, 1, 6413, 7, 5, 585, 34, 15, 380, 51, 103, 2529, 3579, 27, 81, 218, 14, 79, 81, 218, 27, 2, 201, 81, 218, 33, 2, 818, 201, 81, 169, 1072, 379, 647, 9, 33, 244, 63, 51, 15, 236, 51, 684, 2, 450, 51, 998, 151, 11, 424, 462, 2, 713, 50, 6413, 106, 167, 1, 7, 11, 1048, 753, 34, 2029, 199, 1, 2867, 7, 717, 103, 3579, 339, 713, 1, 641, 7, 1785, 998, 50, 6413, 5105, 684, 50, 3579, 20, 1697, 6, 943, 78, 2867, 15, 2, 684, 151, 11, 424, 2, 696, 50, 3579, 106, 595, 1, 7, 3451, 2029, 199, 5, 52, 166, 126, 1, 511, 53, 52, 300, 10, 511, 53, 18, 111, 300, 10, 720, 2, 18, 111, 118, 10, 868, 4, 7, 1785, 684, 50, 6413, 3579, 10, 41, 5, 365, 1043, 1113, 29, 930, 1667, 2, 14582, 10792, 2, 59236, 7314, 2, 13243, 34957, 92, 489, 126, 6, 67, 53, 50, 1060, 36, 3, 45, 10, 7595, 6, 6262, 684, 7, 29, 357, 3579, 3579, 2173, 231, 684, 2, 2029, 199, 151, 50, 6413, 504, 84, 1546, 1762, 1875, 4, 7, 54, 42, 3298, 513, 684, 50, 504, 2, 205, 44, 401, 18, 111, 300, 15, 25]",1714.0,20697069,666
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.,American journal of clinical pathology,Am. J. Clin. Pathol.,2010-09-01,"Serum thymidine kinase 1 (TK1) levels have been reported to have prognostic significance in patients with chronic lymphocytic leukemia (CLL). Until recently, serum TK1 levels were assessed using inconvenient radioenzyme assays. In this study, we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination. We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome). Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens. We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL.",Journal Article,3429.0,26.0,Serum thymidine kinase 1 TK1 levels have been reported to have prognostic significance in patients with chronic lymphocytic CLL Until recently serum TK1 levels were assessed using inconvenient radioenzyme assays In this study we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes CD38 and ZAP-70 expression and subsequent risk of developing large B-cell Richter syndrome Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[524, 6403, 216, 14, 16011, 148, 47, 85, 210, 6, 47, 177, 724, 4, 7, 5, 442, 1193, 552, 1100, 761, 524, 16011, 148, 11, 275, 75, 23338, 59259, 1013, 4, 26, 45, 21, 95, 8, 229, 28862, 719, 6, 423, 524, 16011, 148, 4, 7, 5, 552, 28, 3, 98, 1, 157, 1385, 21, 514, 17, 64, 524, 16011, 148, 678, 1769, 63, 25, 2, 1513, 5, 7216, 2593, 1347, 1053, 214, 4469, 2, 6251, 431, 55, 2, 706, 43, 1, 931, 375, 132, 31, 8452, 681, 288, 272, 11, 164, 4, 8, 697, 1, 7, 73, 5, 291, 2027, 90, 56, 472, 21, 309, 17, 524, 16011, 148, 311, 75, 26, 7048, 28862, 719, 68, 40, 999, 4, 3, 43, 455, 1, 7, 5, 552]",832.0,20716805,53
"Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.",Cancer,Cancer,2010-08-30,"Alemtuzumab is highly effective at treating chronic lymphocytic leukemia (CLL) in bone marrow, which is the usual site of residual disease after fludarabine-based treatment. Eliminating residual disease potentially is associated with longer remission and overall survival. The authors of this report evaluated the ability of subcutaneous alemtuzumab to treat residual disease. Patients in partial remission (PR), nodular PR (nPR), or complete remission (CR) who had disease in bone marrow established by 2-color flow cytometry analysis were enrolled and received alemtuzumab 30 mg subcutaneously 3 times weekly for 4 weeks, and patients had the option to self-administer alemtuzumab. Responders were patients in PR who converted to an nPR or a CR, patients in nPR who converted to a CR, and patients in CR who had no evidence of disease on 2-color flow cytometry analysis after treatment. There were 31 patients enrolled, of whom 29 were evaluable, and there were 23 responders (4 of 4 patients who achieved a CR, 8 of 9 patients who achieved an nPR, and 11 of 16 patients who achieved a PR. Nonresponders had significantly lower plasma alemtuzumab levels at the end of treatment. Furthermore, higher plasma alemtuzumab levels at the end of treatment were correlated with a longer response duration. Compared with the results from an historic group that received intravenous alemtuzumab for residual disease, there was a trend toward a higher response rate but a shorter response duration with subcutaneous alemtuzumab. The current results demonstrated that self-administered, subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in future alemtuzumab consolidation trials.","Clinical Trial, Phase II",3431.0,16.0,Alemtuzumab is highly effective at treating chronic lymphocytic CLL in marrow which is the usual site of residual disease after fludarabine-based treatment Eliminating residual disease potentially is associated with longer remission and overall survival The authors of this report evaluated the ability of subcutaneous alemtuzumab to treat residual disease Patients in partial remission PR nodular PR nPR or complete remission CR who had disease in marrow established by 2-color flow cytometry analysis were enrolled and received alemtuzumab 30 mg subcutaneously 3 times weekly for 4 weeks and patients had the option to self-administer alemtuzumab Responders were patients in PR who converted to an nPR or a CR patients in nPR who converted to a CR and patients in CR who had no evidence of disease on 2-color flow cytometry analysis after treatment There were 31 patients enrolled of whom 29 were evaluable and there were 23 responders 4 of 4 patients who achieved a CR 8 of 9 patients who achieved an nPR and 11 of 16 patients who achieved a PR Nonresponders had significantly lower plasma alemtuzumab levels at the end of treatment Furthermore higher plasma alemtuzumab levels at the end of treatment were correlated with a longer response duration Compared with the results from an historic group that received intravenous alemtuzumab for residual disease there was a trend toward a higher response rate but a shorter response duration with subcutaneous alemtuzumab The current results demonstrated that self-administered subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in future alemtuzumab consolidation trials,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3579, 16, 561, 323, 28, 1367, 442, 1193, 552, 4, 581, 92, 16, 3, 3521, 606, 1, 753, 34, 50, 2027, 90, 24, 6923, 753, 34, 751, 16, 41, 5, 589, 734, 2, 63, 25, 3, 738, 1, 26, 414, 194, 3, 801, 1, 2529, 3579, 6, 943, 753, 34, 7, 4, 450, 734, 998, 4481, 998, 23816, 15, 236, 734, 684, 54, 42, 34, 4, 581, 635, 20, 18, 6052, 1412, 1914, 65, 11, 346, 2, 103, 3579, 201, 81, 3928, 27, 1072, 709, 9, 39, 244, 2, 7, 42, 3, 1501, 6, 1074, 6888, 3579, 1983, 11, 7, 4, 998, 54, 4764, 6, 35, 23816, 15, 8, 684, 7, 4, 23816, 54, 4764, 6, 8, 684, 2, 7, 4, 684, 54, 42, 77, 241, 1, 34, 23, 18, 6052, 1412, 1914, 65, 50, 24, 125, 11, 456, 7, 346, 1, 953, 462, 11, 859, 2, 125, 11, 382, 1983, 39, 1, 39, 7, 54, 513, 8, 684, 66, 1, 83, 7, 54, 513, 35, 23816, 2, 175, 1, 245, 7, 54, 513, 8, 998, 4498, 42, 97, 280, 554, 3579, 148, 28, 3, 396, 1, 24, 798, 142, 554, 3579, 148, 28, 3, 396, 1, 24, 11, 438, 5, 8, 589, 51, 654, 72, 5, 3, 99, 29, 35, 6875, 87, 17, 103, 1262, 3579, 9, 753, 34, 125, 10, 8, 853, 1317, 8, 142, 51, 116, 84, 8, 985, 51, 654, 5, 2529, 3579, 3, 291, 99, 264, 17, 1074, 468, 2529, 3579, 10, 1165, 2, 544, 9, 753, 34, 2, 17, 554, 3579, 148, 2, 1589, 98, 1048, 753, 34, 451, 32, 305, 1387, 6, 3334, 4, 508, 3579, 2173, 143]",1755.0,20806349,389
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-09-13,"Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a validated target in mantle cell lymphoma, but has not been extensively evaluated in other lymphomas. We performed a phase II trial of single-agent temsirolimus 25-mg weekly in patients with relapsed aggressive and indolent lymphomas. The primary objective was overall and complete response rate. Patients were stratified by histology: group A (diffuse large B-cell lymphoma, transformed follicular lymphoma), group B (follicular lymphoma), and group C (chronic lymphocytic leukemia/small lymphocytic lymphoma, and other indolent lymphomas). Eighty-nine patients were treated, with outcome strongly dependent on histology. Group A had an overall and complete response rate of 28.1% and 12.5%, respectively, and median progression-free survival (PFS) of 2.6 months and median overall survival (OS) of 7.2 months. Group B had overall and complete response rates of 53.8% and 25.6%, respectively, and median PFS of 12.7 months; median OS has not yet been reached. Group C had a partial response rate of 11% with no complete responders. Toxicity was mainly mild and/or reversible myelosuppression and mucositis; however, four patients developed pneumonitis. Single-agent temsirolimus has significant activity in both diffuse large B-cell lymphoma and follicular lymphoma, although the durability of responses and PFS are longer for patients with follicular lymphoma. This is the first report of substantial activity of temsirolimus in lymphomas other than mantle cell lymphoma, and supports further evaluation of mTOR as a target in these diseases.","Clinical Trial, Phase II",3417.0,139.0,Despite high initial remission rates most lymphomas relapse and require further therapy The mammalian target of rapamycin mTOR pathway is a validated target in mantle cell but has not been extensively evaluated in other lymphomas We performed a phase II trial of single-agent temsirolimus 25-mg weekly in patients with relapsed aggressive and indolent lymphomas The primary objective was overall and complete response rate Patients were stratified by histology group A diffuse large B-cell transformed follicular group B follicular and group C chronic lymphocytic leukemia/small lymphocytic and other indolent lymphomas Eighty-nine patients were treated with outcome strongly dependent on histology Group A had an overall and complete response rate of 28.1 and 12.5 respectively and median progression-free survival PFS of 2.6 months and median overall survival OS of 7.2 months Group B had overall and complete response rates of 53.8 and 25.6 respectively and median PFS of 12.7 months median OS has not yet been reached Group C had a partial response rate of 11 with no complete responders Toxicity was mainly mild and/or reversible myelosuppression and mucositis however four patients developed pneumonitis Single-agent temsirolimus has significant activity in both diffuse large B-cell and follicular although the durability of responses and PFS are longer for patients with follicular This is the first report of substantial activity of temsirolimus in lymphomas other than mantle cell and supports further evaluation of mTOR as a target in these diseases,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 64, 388, 734, 151, 96, 1557, 429, 2, 1353, 195, 36, 3, 2359, 283, 1, 1620, 873, 308, 16, 8, 938, 283, 4, 2757, 31, 84, 71, 44, 85, 3576, 194, 4, 127, 1557, 21, 173, 8, 124, 215, 160, 1, 226, 420, 2831, 243, 81, 709, 4, 7, 5, 591, 571, 2, 2316, 1557, 3, 86, 461, 10, 63, 2, 236, 51, 116, 7, 11, 1173, 20, 784, 87, 8, 1388, 375, 132, 31, 2423, 1974, 87, 132, 1974, 2, 87, 256, 442, 1193, 2647, 302, 1193, 2, 127, 2316, 1557, 2207, 762, 7, 11, 73, 5, 228, 1327, 470, 23, 784, 87, 8, 42, 35, 63, 2, 236, 51, 116, 1, 339, 14, 2, 133, 33, 106, 2, 52, 91, 115, 25, 300, 1, 18, 49, 53, 2, 52, 63, 25, 118, 1, 67, 18, 53, 87, 132, 42, 63, 2, 236, 51, 151, 1, 699, 66, 2, 243, 49, 106, 2, 52, 300, 1, 133, 67, 53, 52, 118, 71, 44, 1145, 85, 1300, 87, 256, 42, 8, 450, 51, 116, 1, 175, 5, 77, 236, 1983, 155, 10, 2615, 1980, 2, 15, 2786, 2858, 2, 2606, 137, 294, 7, 276, 2949, 226, 420, 2831, 71, 93, 128, 4, 110, 1388, 375, 132, 31, 2, 1974, 242, 3, 6867, 1, 253, 2, 300, 32, 589, 9, 7, 5, 1974, 26, 16, 3, 157, 414, 1, 1281, 128, 1, 2831, 4, 1557, 127, 76, 2757, 31, 2, 2304, 195, 451, 1, 873, 22, 8, 283, 4, 46, 1342]",1560.0,20837940,40
"A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.",Investigational new drugs,Invest New Drugs,2010-10-12,"Based on the promising activity and tolerability of flavopiridol administered with a pharmacokinetically-derived dosing schedule in chronic lymphocytic leukemia (CLL), we conducted a phase I study using this schedule in patients with advanced solid tumors. Flavopiridol was given IV as a 30-min loading dose followed by a 4-hr infusion weekly for 4 weeks repeated every 6 weeks. Dose-escalation was in cohorts of three patients using the standard 3+3 phase I study design. Blood samples were obtained for pharmacokinetic and pharmacodynamic studies. Thirty-four eligible patients with advanced solid tumors received a total of 208 doses (median 7, range 1-24). Total doses ranged from 40 to 105 mg/m(2). The primary dose limiting toxicity was cytokine release syndrome (CKRS). No antitumor responses were observed. The mean peak plasma concentration across all doses was 1.65  0.86 M. Area under the concentration-versus-time curve ([Formula: see text]) ranged from 4.31 to 32.2 M[Symbol: see text]hr with an overall mean of 13.6  7.0 M[Symbol: see text]hr. Plasma flavopiridol concentrations and AUC increased proportionally with dose. There was no correlation between cytokine levels and clinical outcomes. The maximum-tolerated dose of flavopiridol is 20 mg/m(2) bolus followed by 20 mg/m(2) infusion over 4 h given weekly for 4 weeks on a 6-week cycle in patients with advanced solid tumors. Flavopiridol PK was notably different, and there was a higher frequency of CKRS, despite prophylactic steroids, seen in this patient group compared to previous studies with CLL using a similar dosing schedule.","Clinical Trial, Phase I",3388.0,23.0,Based on the promising activity and tolerability of flavopiridol administered with a pharmacokinetically-derived dosing schedule in chronic lymphocytic CLL we conducted a phase I study using this schedule in patients with advanced solid tumors Flavopiridol was given IV as a 30-min loading dose followed by a 4-hr infusion weekly for 4 weeks repeated every 6 weeks Dose-escalation was in cohorts of three patients using the standard 3+3 phase I study design Blood samples were obtained for pharmacokinetic and pharmacodynamic studies Thirty-four eligible patients with advanced solid tumors received a total of 208 doses median 7 range 1-24 Total doses ranged from 40 to 105 mg/m 2 The primary dose limiting toxicity was cytokine release syndrome CKRS No antitumor responses were observed The mean peak plasma concentration across all doses was 1.65  0.86 M Area under the concentration-versus-time curve Formula see text ranged from 4.31 to 32.2 M Symbol see text hr with an overall mean of 13.6  7.0 M Symbol see text hr Plasma flavopiridol concentrations and AUC increased proportionally with dose There was no correlation between cytokine levels and clinical outcomes The maximum-tolerated dose of flavopiridol is 20 mg/m 2 bolus followed by 20 mg/m 2 infusion over 4 h given weekly for 4 weeks on a 6-week cycle in patients with advanced solid tumors Flavopiridol PK was notably different and there was a higher frequency of CKRS despite prophylactic steroids seen in this patient group compared to previous studies with CLL using a similar dosing schedule,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[90, 23, 3, 721, 128, 2, 1543, 1, 3030, 468, 5, 8, 14920, 526, 1280, 1055, 4, 442, 1193, 552, 21, 426, 8, 124, 70, 45, 75, 26, 1055, 4, 7, 5, 131, 537, 57, 3030, 10, 447, 478, 22, 8, 201, 1538, 4717, 61, 370, 20, 8, 39, 168, 904, 709, 9, 39, 244, 2113, 454, 49, 244, 61, 1125, 10, 4, 736, 1, 169, 7, 75, 3, 260, 27, 27, 124, 70, 45, 771, 315, 347, 11, 683, 9, 1456, 2, 2424, 94, 977, 294, 625, 7, 5, 131, 537, 57, 103, 8, 181, 1, 5920, 415, 52, 67, 184, 14, 259, 181, 415, 1869, 29, 327, 6, 3263, 81, 188, 18, 3, 86, 61, 817, 155, 10, 1675, 2008, 681, 46272, 77, 579, 253, 11, 164, 3, 313, 2944, 554, 1227, 716, 62, 415, 10, 14, 556, 810, 13, 868, 4810, 965, 669, 3, 1227, 185, 98, 1496, 7986, 3764, 6153, 1869, 29, 39, 456, 6, 531, 18, 4810, 21229, 3764, 6153, 168, 5, 35, 63, 313, 1, 233, 49, 810, 67, 13, 4810, 21229, 3764, 6153, 168, 554, 3030, 1003, 2, 1376, 101, 11142, 5, 61, 125, 10, 77, 816, 59, 1675, 148, 2, 38, 123, 3, 689, 421, 61, 1, 3030, 16, 179, 81, 188, 18, 3604, 370, 20, 179, 81, 188, 18, 904, 252, 39, 555, 447, 709, 9, 39, 244, 23, 8, 49, 647, 417, 4, 7, 5, 131, 537, 57, 3030, 2395, 10, 2552, 338, 2, 125, 10, 8, 142, 675, 1, 46272, 550, 1862, 4580, 527, 4, 26, 69, 87, 72, 6, 698, 94, 5, 552, 75, 8, 288, 1280, 1055]",1566.0,20938713,152
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.,Blood,Blood,2010-10-22,"Homoharringtonine (HHT) is a plant alkaloid that inhibits the elongation phase of translation that is currently in clinical trials. Because the intrinsically short-lived antiapoptotic protein myeloid cell leukemia-1 (Mcl-1) has been reported to support the survival of chronic lymphocytic leukemia (CLL) cells, we hypothesized that inhibition of protein synthesis by HHT would decrease Mcl-1 expression and induce apoptosis in CLL. In primary CLL cells, HHT induced significant apoptosis independent of the prognostic characteristics of the patients. This was associated with inhibition of translation and decreased Mcl-1 levels in CLL cells. Mcl-1 reduction was evident as early as 2 hours and continued to decrease in the next 6-8 hours, whereas cell death started in 2 hours and continued to increase for 24 hours. Reduction of the Mcl-1 level was due to translation inhibition and proteasome degradation rather than to transcription inhibition or caspase cleavage. HHT and the transcription inhibitor SNS-032 induced synergistic cell killing. Although stromal cells induced Mcl-1 expression and protected CLL cells from the toxicity of fludarabine, this induction was reversed by HHT, which overcame stromal cell-mediated protection. Thus, these results provide a rationale for clinical development of HHT in CLL as single agent or in combinations.",Journal Article,3378.0,54.0,Homoharringtonine HHT is a plant alkaloid that inhibits the elongation phase of translation that is currently in clinical trials Because the intrinsically short-lived antiapoptotic protein myeloid cell leukemia-1 Mcl-1 has been reported to support the survival of chronic lymphocytic CLL cells we hypothesized that inhibition of protein synthesis by HHT would decrease Mcl-1 expression and induce apoptosis in CLL In primary CLL cells HHT induced significant apoptosis independent of the prognostic characteristics of the patients This was associated with inhibition of translation and decreased Mcl-1 levels in CLL cells Mcl-1 reduction was evident as early as 2 hours and continued to decrease in the next 6-8 hours whereas cell death started in 2 hours and continued to increase for 24 hours Reduction of the Mcl-1 level was due to translation inhibition and proteasome degradation rather than to transcription inhibition or caspase cleavage HHT and the transcription inhibitor SNS-032 induced synergistic cell killing Although stromal cells induced Mcl-1 expression and protected CLL cells from the toxicity of fludarabine this induction was reversed by HHT which overcame stromal cell-mediated protection Thus these results provide a rationale for clinical development of HHT in CLL as single agent or in combinations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[18768, 9249, 16, 8, 9045, 12544, 17, 1576, 3, 12359, 124, 1, 2691, 17, 16, 694, 4, 38, 143, 408, 3, 9759, 978, 4813, 4176, 178, 533, 31, 2647, 14, 1308, 14, 71, 85, 210, 6, 538, 3, 25, 1, 442, 1193, 552, 37, 21, 1237, 17, 297, 1, 178, 2525, 20, 9249, 688, 775, 1308, 14, 55, 2, 1290, 351, 4, 552, 4, 86, 552, 37, 9249, 277, 93, 351, 306, 1, 3, 177, 374, 1, 3, 7, 26, 10, 41, 5, 297, 1, 2691, 2, 340, 1308, 14, 148, 4, 552, 37, 1308, 14, 628, 10, 2853, 22, 191, 22, 18, 1459, 2, 1351, 6, 775, 4, 3, 1305, 49, 66, 1459, 547, 31, 273, 3461, 4, 18, 1459, 2, 1351, 6, 344, 9, 259, 1459, 628, 1, 3, 1308, 14, 301, 10, 520, 6, 2691, 297, 2, 1694, 2373, 1832, 76, 6, 866, 297, 15, 1469, 3155, 9249, 2, 3, 866, 230, 7323, 4708, 277, 1806, 31, 3003, 242, 1126, 37, 277, 1308, 14, 55, 2, 5541, 552, 37, 29, 3, 155, 1, 2027, 26, 504, 10, 3682, 20, 9249, 92, 11097, 1126, 31, 517, 3525, 631, 46, 99, 377, 8, 1728, 9, 38, 193, 1, 9249, 4, 552, 22, 226, 420, 15, 4, 1247]",1322.0,20971952,277
Chronic lymphocytic leukemia: new concepts for future therapy.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2010-10-01,"Over the past several years, we have witnessed rapid advances in our understanding of the biology and treatment of chronic lymphocytic leukemia (CLL). New prognostic factors have been characterized that help identify patients at high risk of rapid disease progression, refractoriness to treatment, and short overall survival (OS). These advances have led to a significant paradigm shift in the management of CLL. Novel therapeutic strategies, including combinations of monoclonal antibodies with conventional chemotherapy, have dramatically improved response rates, remission duration, and recently, OS. However, these benefits do not appear to extend to certain patient subsets, especially those with unfavorable clinical or cytogenetic risk factors. The majority of patients with CLL will invariably relapse following first-line therapy and can acquire high-risk genetic abnormalities. Repeated treatment leads to eventual therapeutic refractoriness and shortened survival compared with age-matched healthy individuals. Several novel agents and strategies, including next-generation anti-CD20 monoclonal antibodies, the alkylating agent bendamustine, the immunomodulatory agent lenalidomide, the cyclin-dependent kinase inhibitor flavopiridol, and small-molecule Bcl2 inhibitors, are currently under clinical investigation as novel agents that will hopefully improve treatment outcomes for CLL. Though allogeneic stem cell transplantation offers curative potential, it also presents clinical challenges in terms of patient appropriateness, donor availability, and timing. The merits and challenges of incorporating these treatment modalities into the treatment algorithm for patients with CLL, as discussed by a panel of experts in CLL, are outlined in this article.",Journal Article,3399.0,13.0,Over the past several years we have witnessed rapid advances in our understanding of the biology and treatment of chronic lymphocytic CLL New prognostic factors have been characterized that help identify patients at high risk of rapid disease progression refractoriness to treatment and short overall survival OS These advances have led to a significant paradigm shift in the management of CLL Novel therapeutic strategies including combinations of monoclonal antibodies with conventional chemotherapy have dramatically improved response rates remission duration and recently OS However these benefits do not appear to extend to certain patient subsets especially those with unfavorable clinical or cytogenetic risk factors The majority of patients with CLL will invariably relapse following first-line therapy and can acquire high-risk genetic abnormalities Repeated treatment leads to eventual therapeutic refractoriness and shortened survival compared with age-matched healthy individuals Several novel agents and strategies including next-generation anti-CD20 monoclonal antibodies the alkylating agent bendamustine the immunomodulatory agent lenalidomide the cyclin-dependent kinase inhibitor flavopiridol and small-molecule Bcl2 inhibitors are currently under clinical investigation as novel agents that will hopefully improve treatment outcomes for CLL Though allogeneic stem cell transplantation offers curative potential it also presents clinical challenges in terms of patient appropriateness donor availability and timing The merits and challenges of incorporating these treatment modalities into the treatment algorithm for patients with CLL as discussed by a panel of experts in CLL are outlined in this article,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 392, 60, 21, 47, 10606, 1321, 954, 4, 114, 612, 1, 3, 891, 2, 24, 1, 442, 1193, 552, 217, 177, 130, 47, 85, 765, 17, 987, 255, 7, 28, 64, 43, 1, 1321, 34, 91, 12483, 6, 24, 2, 978, 63, 25, 118, 46, 954, 47, 836, 6, 8, 93, 2431, 3024, 4, 3, 284, 1, 552, 229, 189, 422, 141, 1247, 1, 848, 890, 5, 809, 56, 47, 2729, 231, 51, 151, 734, 654, 2, 761, 118, 137, 46, 1141, 1022, 44, 1322, 6, 4087, 6, 1840, 69, 1890, 1093, 135, 5, 2483, 38, 15, 1266, 43, 130, 3, 686, 1, 7, 5, 552, 303, 6912, 429, 366, 157, 328, 36, 2, 122, 6206, 64, 43, 336, 1171, 2113, 24, 1940, 6, 6956, 189, 12483, 2, 6151, 25, 72, 5, 89, 655, 1331, 869, 392, 229, 183, 2, 422, 141, 1305, 914, 312, 2198, 848, 890, 3, 3410, 420, 4809, 3, 2555, 420, 1288, 3, 1226, 470, 216, 230, 3030, 2, 302, 1354, 3214, 222, 32, 694, 669, 38, 940, 22, 229, 183, 17, 303, 7464, 401, 24, 123, 9, 552, 2471, 1063, 452, 31, 497, 2339, 1075, 174, 192, 120, 2740, 38, 1427, 4, 1794, 1, 69, 4473, 1488, 2550, 2, 1972, 3, 4986, 2, 1427, 1, 2570, 46, 24, 1558, 237, 3, 24, 2124, 9, 7, 5, 552, 22, 1588, 20, 8, 993, 1, 3186, 4, 552, 32, 6394, 4, 26, 946]",1724.0,21030350,732
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-11-01,"Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 123 patients (median age, 57 years; range, 23-70 years) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total-body irradiation (200 cGy) with or without antithymocyte globulin followed by related donor allogeneic HCT at the University of Minnesota between 2002 and 2008. The cohort included 45 patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), 27 with aggressive non-Hodgkin lymphoma (NHL), 8 with indolent NHL, 10 with Hodgkin lymphoma (HL), 10 with myeloma, and 23 with acute lymphocytic leukemia, chronic myelogenous leukemia, other leukemias, or myeloproliferative disorders. The probability of 4-year overall survival was 73% for patients with indolent NHL, 58% for those with aggressive NHL, 67% for those with HL, 30% for those with AML/MDS, and only 10% for those with myeloma. Corresponding outcomes for relapse in these patients were 0%, 32%, 50%, 33%, and 38%, and those for progression-free survival were 73%, 45%, 27%, 27%, and 10%. The incidence of treatment-related mortality was 14% at day +100 and 22% at 1 year. The incidence of grade II-IV acute graft-versus-host disease was 38% at day +100, and that of chronic graft-versus-host disease was 50% at 2 years. Multivariate analysis revealed superior overall survival and progression-free survival in patients with both indolent and aggressive NHL compared with those with AML/MDS, HL, or myeloma. Worse 1-year treatment-related mortality was observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score  3 and in cytomegalovirus-seropositive recipients. These results suggest that (1) RIC conditioning was well tolerated by an older, heavily pretreated population; (2) patients with indolent and aggressive NHL respond well to RIC conditioning, highlighting the importance of the graft-versus-lymphoma effect; and (3) additional peri-transplantation manipulations are needed to improve outcomes for patients with AML/MDS or myeloma receiving RIC conditioning before HCT.",Clinical Trial,3368.0,27.0,Reduced-intensity conditioning RIC extends the curative potential of allogeneic hematopoietic cell transplantation HCT to patients with hematologic malignancies unable to withstand myeloablative conditioning We prospectively analyzed the outcomes of 123 patients median age 57 years range 23-70 years with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide fludarabine and total-body irradiation 200 cGy with or without antithymocyte globulin followed by related donor allogeneic HCT at the University of Minnesota between 2002 and 2008 The cohort included 45 patients with acute myelogenous AML or syndrome MDS 27 with aggressive NHL 8 with indolent NHL 10 with HL 10 with and 23 with acute lymphocytic chronic myelogenous other leukemias or disorders The probability of 4-year overall survival was 73 for patients with indolent NHL 58 for those with aggressive NHL 67 for those with HL 30 for those with AML/MDS and only 10 for those with Corresponding outcomes for relapse in these patients were 0 32 50 33 and 38 and those for progression-free survival were 73 45 27 27 and 10 The incidence of treatment-related mortality was 14 at day +100 and 22 at 1 year The incidence of grade II-IV acute graft-versus-host disease was 38 at day +100 and that of chronic graft-versus-host disease was 50 at 2 years Multivariate analysis revealed superior overall survival and progression-free survival in patients with both indolent and aggressive NHL compared with those with AML/MDS HL or Worse 1-year treatment-related mortality was observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score  3 and in cytomegalovirus-seropositive recipients These results suggest that 1 RIC conditioning was well tolerated by an older heavily pretreated population 2 patients with indolent and aggressive NHL respond well to RIC conditioning highlighting the importance of the graft-versus-lymphoma effect and 3 additional peri-transplantation manipulations are needed to improve outcomes for patients with AML/MDS or receiving RIC conditioning before HCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[405, 837, 1933, 3365, 8464, 3, 1075, 174, 1, 1063, 1007, 31, 497, 1085, 6, 7, 5, 813, 441, 4253, 6, 21330, 3246, 1933, 21, 1143, 311, 3, 123, 1, 2698, 7, 52, 89, 696, 60, 184, 382, 431, 60, 5, 813, 441, 73, 5, 8, 3490, 3365, 477, 1, 1112, 2027, 2, 181, 642, 1104, 1250, 3071, 5, 15, 187, 11016, 7819, 370, 20, 139, 1488, 1063, 1085, 28, 3, 1652, 1, 8297, 59, 1544, 2, 1375, 3, 180, 159, 512, 7, 5, 286, 2194, 329, 15, 681, 1223, 428, 5, 571, 1176, 66, 5, 2316, 1176, 79, 5, 1718, 79, 5, 2, 382, 5, 286, 1193, 442, 2194, 127, 2792, 15, 1997, 3, 1320, 1, 39, 111, 63, 25, 10, 803, 9, 7, 5, 2316, 1176, 717, 9, 135, 5, 571, 1176, 598, 9, 135, 5, 1718, 201, 9, 135, 5, 329, 1223, 2, 158, 79, 9, 135, 5, 1734, 123, 9, 429, 4, 46, 7, 11, 13, 531, 212, 466, 2, 519, 2, 135, 9, 91, 115, 25, 11, 803, 512, 428, 428, 2, 79, 3, 287, 1, 24, 139, 282, 10, 213, 28, 218, 394, 2, 350, 28, 14, 111, 3, 287, 1, 88, 215, 478, 286, 1599, 185, 1204, 34, 10, 519, 28, 218, 394, 2, 17, 1, 442, 1599, 185, 1204, 34, 10, 212, 28, 18, 60, 331, 65, 553, 1123, 63, 25, 2, 91, 115, 25, 4, 7, 5, 110, 2316, 2, 571, 1176, 72, 5, 135, 5, 329, 1223, 1718, 15, 639, 14, 111, 24, 139, 282, 10, 164, 4, 7, 5, 8, 1007, 31, 497, 1879, 558, 368, 749, 27, 2, 4, 7314, 9909, 2190, 46, 99, 309, 17, 14, 3365, 1933, 10, 149, 421, 20, 35, 434, 2447, 2193, 266, 18, 7, 5, 2316, 2, 571, 1176, 1892, 149, 6, 3365, 1933, 4051, 3, 1187, 1, 3, 1599, 185, 4763, 254, 2, 27, 402, 6164, 497, 13775, 32, 575, 6, 401, 123, 9, 7, 5, 329, 1223, 15, 357, 3365, 1933, 348, 1085]",2091.0,21047561,640
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.,Blood,Blood,2010-11-03,"Vitamin D insufficiency is common globally and low levels are linked to higher cancer incidence. Although vitamin D insufficiency is related to inferior prognosis in some cancers, no data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We evaluated the relationship of 25(OH)D serum levels with time-to-treatment (TTT) and overall survival (OS) in newly diagnosed CLL patients participating in a prospective cohort study (discovery cohort) and a separate cohort of previously untreated patients participating in an observational study (confirmation cohort). Of 390 CLL patients in the discovery cohort, 119 (30.5%) were 25(OH)D insufficient. After a median follow-up of 3 years, TTT (hazard ratio[HR] = 1.66; P = .005) and OS (HR = 2.39; P = .01) were shorter for 25(OH)D-insufficient patients. In the validation cohort, 61 of 153 patients (39.9%) were 25(OH)D insufficient. After a median follow-up of 9.9 years, TTT (HR = 1.59; P = .05) and OS (HR 1.63; P = .06) were again shorter for 25(OH)D-insufficient patients. On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, Rai stage, CD38 status, ZAP-70 status, immunoglobulin heavy chain variable (IGHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing, 25(OH)D insufficiency remained an independent predictor of TTT (HR = 1.47; P = .008), although the association with OS was not significant (HR = 1.47; P = .07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing.",Journal Article,3366.0,89.0,Vitamin D insufficiency is common globally and low levels are linked to higher cancer incidence Although vitamin D insufficiency is related to inferior prognosis in some cancers no data exist for chronic lymphocytic leukemia/small lymphocytic CLL/SLL We evaluated the relationship of 25 OH D serum levels with time-to-treatment TTT and overall survival OS in newly diagnosed CLL patients participating in a prospective cohort study discovery cohort and a separate cohort of previously untreated patients participating in an observational study confirmation cohort Of 390 CLL patients in the discovery cohort 119 30.5 were 25 OH D insufficient After a median follow-up of 3 years TTT hazard ratio HR 1.66 P .005 and OS HR 2.39 P .01 were shorter for 25 OH D-insufficient patients In the validation cohort 61 of 153 patients 39.9 were 25 OH D insufficient After a median follow-up of 9.9 years TTT HR 1.59 P .05 and OS HR 1.63 P .06 were again shorter for 25 OH D-insufficient patients On pooled multivariable analysis of patients in both cohorts adjusting for age sex Rai stage CD38 status ZAP-70 status immunoglobulin heavy chain variable IGHV gene mutation status CD49d status and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing 25 OH D insufficiency remained an independent predictor of TTT HR 1.47 P .008 although the association with OS was not significant HR 1.47 P .07 Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1610, 427, 4360, 16, 186, 6873, 2, 154, 148, 32, 1199, 6, 142, 12, 287, 242, 1610, 427, 4360, 16, 139, 6, 1663, 356, 4, 476, 163, 77, 74, 1923, 9, 442, 1193, 2647, 302, 1193, 552, 5302, 21, 194, 3, 858, 1, 243, 2912, 427, 524, 148, 5, 98, 6, 24, 10630, 2, 63, 25, 118, 4, 732, 265, 552, 7, 3052, 4, 8, 482, 180, 45, 1574, 180, 2, 8, 2282, 180, 1, 373, 1278, 7, 3052, 4, 35, 2495, 45, 3551, 180, 1, 7992, 552, 7, 4, 3, 1574, 180, 4299, 201, 33, 11, 243, 2912, 427, 3027, 50, 8, 52, 166, 126, 1, 27, 60, 10630, 360, 197, 168, 14, 700, 19, 1614, 2, 118, 168, 18, 587, 19, 355, 11, 985, 9, 243, 2912, 427, 3027, 7, 4, 3, 929, 180, 713, 1, 4251, 7, 587, 83, 11, 243, 2912, 427, 3027, 50, 8, 52, 166, 126, 1, 83, 83, 60, 10630, 168, 14, 728, 19, 474, 2, 118, 168, 14, 676, 19, 1460, 11, 5089, 985, 9, 243, 2912, 427, 3027, 7, 23, 1830, 658, 65, 1, 7, 4, 110, 736, 1358, 9, 89, 1035, 4121, 82, 4469, 156, 6251, 431, 156, 2593, 4013, 1260, 1347, 6220, 145, 258, 156, 10485, 156, 2, 1266, 1171, 275, 20, 8081, 2910, 4, 957, 1554, 471, 243, 2912, 427, 4360, 958, 35, 306, 980, 1, 10630, 168, 14, 662, 19, 2155, 242, 3, 248, 5, 118, 10, 44, 93, 168, 14, 662, 19, 1615, 1610, 427, 4360, 16, 41, 5, 1663, 10630, 2, 118, 4, 552, 7, 317, 17161, 1610, 427, 148, 4, 1971, 552, 7, 688, 401, 228, 4986, 38, 471]",1605.0,21048153,91
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.,PloS one,PLoS ONE,2010-11-01,"Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in patients with refractory chronic lymphocytic leukemia. This study aimed to evaluate pharmacogenetic factors associated with inter-individual variability in pharmacokinetics and outcomes associated with flavopiridol therapy. Thirty-five patients who received single-agent flavopiridol via the PK-directed schedule were genotyped for 189 polymorphisms in genes encoding 56 drug metabolizing enzymes and transporters. Genotypes were evaluated in univariate and multivariate analyses as covariates in a population PK model. Transport of flavopiridol and its glucuronide metabolite was evaluated in uptake assays in HEK-293 and MDCK-II cells transiently transfected with SLCO1B1. Polymorphisms in ABCC2, ABCG2, UGT1A1, UGT1A9, and SLCO1B1 were found to significantly correlate with flavopiridol PK in univariate analysis. Transport assay results indicated both flavopiridol and flavopiridol-glucuronide are substrates of the SLCO1B1/OATP1B1 transporter. Covariates incorporated into the final population PK model included bilirubin, SLCO1B1 rs11045819 and ABCC2 rs8187710. Associations were also observed between genotype and response. To validate these findings, a second set of data with 51 patients was evaluated, and overall trends for associations between PK and PGx were found to be consistent. Polymorphisms in transport genes were found to be associated with flavopiridol disposition and outcomes. Observed clinical associations with SLCO1B1 were functionally validated indicating for the first time its relevance as a transporter of flavopiridol and its glucuronide metabolite. A second 51-patient dataset indicated similar trends between genotype in the SLCO1B1 and other candidate genes, thus providing support for these findings. Further study in larger patient populations will be necessary to fully characterize and validate the clinical impact of polymorphisms in SLCO1B1 and other transporter and metabolizing enzyme genes on outcomes from flavopiridol therapy.","Clinical Trial, Phase II",3368.0,37.0,Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer When administered with a pharmacokinetically PK -directed dosing schedule flavopiridol exhibited striking activity in patients with refractory chronic lymphocytic This study aimed to evaluate pharmacogenetic factors associated with inter-individual variability in pharmacokinetics and outcomes associated with flavopiridol therapy Thirty-five patients who received single-agent flavopiridol via the PK-directed schedule were genotyped for 189 polymorphisms in genes encoding 56 drug metabolizing enzymes and transporters Genotypes were evaluated in univariate and multivariate analyses as covariates in a population PK model Transport of flavopiridol and its glucuronide metabolite was evaluated in uptake assays in HEK-293 and MDCK-II cells transiently transfected with SLCO1B1 Polymorphisms in ABCC2 ABCG2 UGT1A1 UGT1A9 and SLCO1B1 were found to significantly correlate with flavopiridol PK in univariate analysis Transport assay results indicated both flavopiridol and flavopiridol-glucuronide are substrates of the SLCO1B1/OATP1B1 transporter Covariates incorporated into the final population PK model included bilirubin SLCO1B1 rs11045819 and ABCC2 rs8187710 Associations were also observed between genotype and response To validate these findings a second set of data with 51 patients was evaluated and overall trends for associations between PK and PGx were found to be consistent Polymorphisms in transport genes were found to be associated with flavopiridol disposition and outcomes Observed clinical associations with SLCO1B1 were functionally validated indicating for the first time its relevance as a transporter of flavopiridol and its glucuronide metabolite A second 51-patient dataset indicated similar trends between genotype in the SLCO1B1 and other candidate genes thus providing support for these findings Further study in larger patient populations will be necessary to fully characterize and validate the clinical impact of polymorphisms in SLCO1B1 and other transporter and metabolizing enzyme genes on outcomes from flavopiridol therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 16, 8, 1226, 470, 216, 230, 4, 124, 215, 38, 193, 9, 24, 1, 747, 2377, 1, 12, 198, 468, 5, 8, 14920, 2395, 1166, 1280, 1055, 3030, 1416, 5133, 128, 4, 7, 5, 430, 442, 1193, 26, 45, 1295, 6, 376, 6578, 130, 41, 5, 3606, 797, 1982, 4, 1159, 2, 123, 41, 5, 3030, 36, 977, 365, 7, 54, 103, 226, 420, 3030, 847, 3, 2395, 1166, 1055, 11, 3053, 9, 5899, 1203, 4, 214, 2362, 664, 234, 9800, 3039, 2, 6733, 2071, 11, 194, 4, 880, 2, 331, 318, 22, 2489, 4, 8, 266, 2395, 202, 4294, 1, 3030, 2, 211, 11435, 3379, 10, 194, 4, 1135, 1013, 4, 22528, 7541, 2, 46319, 215, 37, 9235, 3245, 5, 13693, 1203, 4, 16426, 6447, 6192, 59525, 2, 13693, 11, 204, 6, 97, 1513, 5, 3030, 2395, 4, 880, 65, 4294, 719, 99, 1103, 110, 3030, 2, 3030, 11435, 32, 6063, 1, 3, 13693, 59526, 5246, 2489, 2449, 237, 3, 1457, 266, 2395, 202, 159, 5009, 13693, 59527, 2, 16426, 39471, 685, 11, 120, 164, 59, 1183, 2, 51, 6, 2183, 46, 272, 8, 419, 916, 1, 74, 5, 725, 7, 10, 194, 2, 63, 1963, 9, 685, 59, 2395, 2, 21639, 11, 204, 6, 40, 925, 1203, 4, 4294, 214, 11, 204, 6, 40, 41, 5, 3030, 5814, 2, 123, 164, 38, 685, 5, 13693, 11, 3772, 938, 1716, 9, 3, 157, 98, 211, 2088, 22, 8, 5246, 1, 3030, 2, 211, 11435, 3379, 8, 419, 725, 69, 3014, 1103, 288, 1963, 59, 1183, 4, 3, 13693, 2, 127, 1609, 214, 631, 1736, 538, 9, 46, 272, 195, 45, 4, 1077, 69, 1184, 303, 40, 1493, 6, 1910, 1507, 2, 2183, 3, 38, 345, 1, 1203, 4, 13693, 2, 127, 5246, 2, 9800, 1644, 214, 23, 123, 29, 3030, 36]",2185.0,21072184,64
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.,BMC medical genetics,BMC Med. Genet.,2010-11-16,"Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS. We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia (AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid leukemia, and 95 healthy controls. The G/G genotype was significantly more common in MDS patients (47/187; 25.1%) than in controls (6/95; 6.3%) or in patients with other leukemias (101/813; 12.4%) (all P < 0.001). Individuals with the G/G genotype were more likely than those with other genotypes to have MDS (odd ratio = 4.98; 95% CI = 2.04-12.13). Clinical and follow up data were available for 112 MDS patients and 186 AML patients. There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML. In the MDS group, the GG genotype was significantly associated with shorter complete remission duration, as compared with the TT genotype (P = 0.03). Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G/G genotype (P = 0.02). These findings suggest a strong association between the rs1617640 G/G genotype and MDS. Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy.",Journal Article,3353.0,17.0,syndrome MDS may be induced by certain mutagenic environmental or chemotherapeutic toxins however the role of susceptibility genes remains unclear The G/G genotype of the single-nucleotide polymorphism SNP rs1617640 in the erythropoietin EPO promoter has been shown to be associated with decreased EPO expression We examined the association of rs1617640 genotype with MDS We genotyped the EPO rS1617640 SNP in 189 patients with MDS 257 with acute myeloid AML 106 with acute lymphoblastic 97 with chronic lymphocytic 353 with chronic myeloid and 95 healthy controls The G/G genotype was significantly more common in MDS patients 47/187 25.1 than in controls 6/95 6.3 or in patients with other leukemias 101/813 12.4 all P 0.001 Individuals with the G/G genotype were more likely than those with other genotypes to have MDS odd ratio 4.98 95 CI 2.04-12.13 Clinical and follow up data were available for 112 MDS patients and 186 AML patients There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML In the MDS group the GG genotype was significantly associated with shorter complete remission duration as compared with the TT genotype P 0.03 Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G/G genotype P 0.02 These findings suggest a strong association between the rs1617640 G/G genotype and MDS Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[681, 1223, 68, 40, 277, 20, 1840, 14578, 3766, 15, 1573, 13820, 137, 3, 200, 1, 1432, 214, 469, 1200, 3, 499, 499, 1183, 1, 3, 226, 1579, 1907, 1845, 35006, 4, 3, 6266, 5423, 973, 71, 85, 443, 6, 40, 41, 5, 340, 5423, 55, 21, 409, 3, 248, 1, 35006, 1183, 5, 1223, 21, 3053, 3, 5423, 35006, 1845, 4, 5899, 7, 5, 1223, 7941, 5, 286, 533, 329, 3251, 5, 286, 1275, 1015, 5, 442, 1193, 10065, 5, 442, 533, 2, 48, 1331, 535, 3, 499, 499, 1183, 10, 97, 80, 186, 4, 1223, 7, 662, 5568, 243, 14, 76, 4, 535, 49, 48, 49, 27, 15, 4, 7, 5, 127, 2792, 2338, 15980, 133, 39, 62, 19, 13, 144, 869, 5, 3, 499, 499, 1183, 11, 80, 322, 76, 135, 5, 127, 2071, 6, 47, 1223, 12108, 197, 39, 1096, 48, 58, 18, 755, 133, 233, 38, 2, 166, 126, 74, 11, 390, 9, 3726, 1223, 7, 2, 5869, 329, 7, 125, 10, 77, 816, 59, 5423, 973, 1183, 2, 51, 6, 36, 15, 63, 25, 4, 1223, 15, 329, 4, 3, 1223, 87, 3, 4334, 1183, 10, 97, 41, 5, 985, 236, 734, 654, 22, 72, 5, 3, 3504, 1183, 19, 13, 680, 98, 6, 5700, 1602, 50, 36, 10, 97, 589, 4, 1223, 7, 5, 3, 499, 499, 1183, 19, 13, 588, 46, 272, 309, 8, 1082, 248, 59, 3, 35006, 499, 499, 1183, 2, 1223, 195, 94, 32, 1197, 6, 963, 3, 1207, 1, 453, 9, 26, 952, 4, 869, 2234, 6, 3766, 13820, 15, 56]",1543.0,21078205,174
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.,Blood,Blood,2010-11-22,"Inhibitor of DNA binding protein 4 (ID4) is a member of the dominant-negative basic helix-loop-helix transcription factor family that lacks DNA binding activity and has tumor suppressor function. ID4 promoter methylation has been reported in acute myeloid leukemia and chronic lymphocytic leukemia (CLL), although the expression, function, and clinical relevance of this gene have not been characterized in either disease. We demonstrate that the promoter of ID4 is consistently methylated to various degrees in CLL cells, and increased promoter methylation in a univariable analysis correlates with shortened patient survival. However, ID4 mRNA and protein expression is uniformly silenced in CLL cells irrespective of the degree of promoter methylation. The crossing of ID4(+/-) mice with E-TCL1 mice triggers a more aggressive murine CLL as measured by lymphocyte count and inferior survival. Hemizygous loss of ID4 in nontransformed TCL1-positive B cells enhances cell proliferation triggered by CpG oligonucleotides and decreases sensitivity to dexamethasone-mediated apoptosis. Collectively, this study confirms the importance of the silencing of ID4 in murine and human CLL pathogenesis.",Journal Article,3347.0,51.0,Inhibitor of DNA binding protein 4 ID4 is a member of the dominant-negative basic helix-loop-helix transcription factor family that lacks DNA binding activity and has tumor suppressor function ID4 promoter methylation has been reported in acute myeloid and chronic lymphocytic CLL although the expression function and clinical relevance of this gene have not been characterized in either disease We demonstrate that the promoter of ID4 is consistently methylated to various degrees in CLL cells and increased promoter methylation in a univariable analysis correlates with shortened patient survival However ID4 mRNA and protein expression is uniformly silenced in CLL cells irrespective of the degree of promoter methylation The crossing of ID4 +/- mice with E-TCL1 mice triggers a more aggressive murine CLL as measured by lymphocyte count and inferior survival Hemizygous loss of ID4 in nontransformed TCL1-positive B cells enhances cell proliferation triggered by CpG oligonucleotides and decreases sensitivity to dexamethasone-mediated apoptosis Collectively this study confirms the importance of the silencing of ID4 in murine and human CLL pathogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[230, 1, 261, 791, 178, 39, 15274, 16, 8, 2693, 1, 3, 2156, 199, 2795, 8861, 4432, 8861, 866, 161, 607, 17, 6856, 261, 791, 128, 2, 71, 30, 1245, 343, 15274, 973, 569, 71, 85, 210, 4, 286, 533, 2, 442, 1193, 552, 242, 3, 55, 343, 2, 38, 2088, 1, 26, 145, 47, 44, 85, 765, 4, 361, 34, 21, 608, 17, 3, 973, 1, 15274, 16, 2433, 2963, 6, 747, 4133, 4, 552, 37, 2, 101, 973, 569, 4, 8, 4084, 65, 1871, 5, 6151, 69, 25, 137, 15274, 956, 2, 178, 55, 16, 4254, 5442, 4, 552, 37, 3500, 1, 3, 1444, 1, 973, 569, 3, 15117, 1, 15274, 399, 5, 17467, 8979, 399, 5951, 8, 80, 571, 1471, 552, 22, 644, 20, 1448, 1276, 2, 1663, 25, 11233, 407, 1, 15274, 4, 12264, 8979, 109, 132, 37, 2519, 31, 457, 4173, 20, 2075, 8721, 2, 2140, 485, 6, 1217, 517, 351, 2535, 26, 45, 5120, 3, 1187, 1, 3, 2077, 1, 15274, 4, 1471, 2, 171, 552, 1384]",1159.0,21098398,533
CCL3 (MIP-1) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.,Blood,Blood,2010-11-29,"B-cell receptor (BCR) signaling has been inferred as an important mechanism for disease progression in chronic lymphocytic leukemia (CLL) and other B-cell malignancies. In response to BCR activation, CLL cells secrete the chemokine CCL3, which fosters interactions between CLL cells and the leukemia microenvironment. CCL3 secretion correlates with expression of the 70-kDa -associated protein (ZAP-70) and responsiveness of the CLL clone to BCR stimulation. Here, we measured CCL3 plasma levels by enzyme-linked immunosorbent assay (ELISA) in 351 CLL patients and examined CCL3 levels for associations with established prognostic markers and time from diagnosis to initial therapy. We found that CCL3 plasma concentrations were strongly associated with established prognostic markers. In a Cox proportional hazards regression model, CCL3 as well as established prognostic markers (immunoglobulin heavy chain variable-region mutation status, CD38 or ZAP-70 cytogenetics, clinical stage) were significantly associated with time to treatment. Multivariable analysis revealed that CCL3 (hazard ratio [HR] = 2.33, P < .0001), advanced clinical stage (HR = 2.75, P = .0025), poor risk cytogenetics (del 17p, HR = 2.38; del11q, HR = 2.36, P = .001), and CD38 expression (HR = 1.43, P = .023) were independent prognostic markers. Collectively, CCL3 is a novel, robust, and independent prognostic marker in CLL that can easily and reliably be measured by ELISA. CCL3 therefore should become useful for risk assessment in patients with CLL.",Journal Article,3340.0,,B-cell receptor BCR signaling has been inferred as an important mechanism for disease progression in chronic lymphocytic CLL and other B-cell malignancies In response to BCR activation CLL cells secrete the chemokine CCL3 which fosters interactions between CLL cells and the microenvironment CCL3 secretion correlates with expression of the 70-kDa -associated protein ZAP-70 and responsiveness of the CLL clone to BCR stimulation Here we measured CCL3 plasma levels by enzyme-linked immunosorbent assay ELISA in 351 CLL patients and examined CCL3 levels for associations with established prognostic markers and time from diagnosis to initial therapy We found that CCL3 plasma concentrations were strongly associated with established prognostic markers In a Cox proportional hazards regression model CCL3 as well as established prognostic markers immunoglobulin heavy chain variable-region mutation status CD38 or ZAP-70 cytogenetics clinical stage were significantly associated with time to treatment Multivariable analysis revealed that CCL3 hazard ratio HR 2.33 P .0001 advanced clinical stage HR 2.75 P .0025 poor risk cytogenetics del 17p HR 2.38 del11q HR 2.36 P .001 and CD38 expression HR 1.43 P .023 were independent prognostic markers Collectively CCL3 is a novel robust and independent prognostic marker in CLL that can easily and reliably be measured by ELISA CCL3 therefore should become useful for risk assessment in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 153, 1062, 314, 71, 85, 13782, 22, 35, 305, 670, 9, 34, 91, 4, 442, 1193, 552, 2, 127, 132, 31, 441, 4, 51, 6, 1062, 363, 552, 37, 6401, 3, 3596, 9711, 92, 29099, 1286, 59, 552, 37, 2, 3, 995, 9711, 2935, 1871, 5, 55, 1, 3, 431, 6362, 14668, 41, 178, 6251, 431, 2, 3642, 1, 3, 552, 3910, 6, 1062, 2503, 467, 21, 644, 9711, 554, 148, 20, 1644, 1199, 5339, 719, 3664, 4, 7270, 552, 7, 2, 409, 9711, 148, 9, 685, 5, 635, 177, 525, 2, 98, 29, 147, 6, 388, 36, 21, 204, 17, 9711, 554, 1003, 11, 1327, 41, 5, 635, 177, 525, 4, 8, 418, 831, 1017, 320, 202, 9711, 22, 149, 22, 635, 177, 525, 2593, 4013, 1260, 1347, 1053, 258, 156, 4469, 15, 6251, 431, 2510, 38, 82, 11, 97, 41, 5, 98, 6, 24, 658, 65, 553, 17, 9711, 360, 197, 168, 18, 466, 19, 488, 131, 38, 82, 168, 18, 481, 19, 12615, 334, 43, 2510, 3084, 4135, 168, 18, 519, 15402, 168, 18, 511, 19, 144, 2, 4469, 55, 168, 14, 601, 19, 4482, 11, 306, 177, 525, 2535, 9711, 16, 8, 229, 1922, 2, 306, 177, 952, 4, 552, 17, 122, 4697, 2, 4092, 40, 644, 20, 3664, 9711, 673, 257, 1417, 999, 9, 43, 455, 4, 7, 5, 552]",1448.0,21115978,302
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.,Blood,Blood,2010-12-03,"Prior genome-wide association (GWA) studies have identified 10 susceptibility loci for risk of chronic lymphocytic leukemia (CLL). To identify additional loci, we performed a GWA study in 407 CLL cases (of which 102 had a family history of CLL) and 296 controls. Moreover, given the strong familial risk of CLL, we further subset our GWA analysis to the CLL cases with a family history of CLL to identify loci specific to these familial CLL cases. Our top hits from these analyses were evaluated in an additional sample of 252 familial CLL cases and 965 controls. Using all available data, we identified and confirmed an independent association of 4 single-nucleotide polymorphisms (SNPs) that met genome-wide statistical significance within the IRF8 (interferon regulatory factor 8) gene (combined P values  3.37  10(-8)), located in the previously identified 16q24.1 locus. Subsetting to familial CLL cases, we identified and confirmed a new locus on chromosome 6p21.3 (combined P value = 6.92  10(-9)). This novel region harbors the HLA-DQA1 and HLA-DRB5 genes. Finally, we evaluated the 10 previously reported SNPs in the overall sample and replicated 8 of them. Our findings support the hypothesis that familial CLL cases have additional genetic variants not seen in sporadic CLL. Additional loci among familial CLL cases may be identified through larger studies.",Journal Article,3336.0,87.0,Prior genome-wide association GWA studies have identified 10 susceptibility loci for risk of chronic lymphocytic CLL To identify additional loci we performed a GWA study in 407 CLL cases of which 102 had a family history of CLL and 296 controls Moreover given the strong familial risk of CLL we further subset our GWA analysis to the CLL cases with a family history of CLL to identify loci specific to these familial CLL cases Our top hits from these analyses were evaluated in an additional sample of 252 familial CLL cases and 965 controls Using all available data we identified and confirmed an independent association of 4 single-nucleotide polymorphisms SNPs that met genome-wide statistical significance within the IRF8 interferon regulatory factor 8 gene combined P values  3.37 10 -8 located in the previously identified 16q24.1 locus Subsetting to familial CLL cases we identified and confirmed a new locus on chromosome 6p21.3 combined P value 6.92 10 -9 This novel region harbors the HLA-DQA1 and HLA-DRB5 genes Finally we evaluated the 10 previously reported SNPs in the overall sample and replicated 8 of them Our findings support the hypothesis that familial CLL cases have additional genetic variants not seen in sporadic CLL Additional loci among familial CLL cases may be identified through larger studies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[324, 898, 1019, 248, 22644, 94, 47, 108, 79, 1432, 2012, 9, 43, 1, 442, 1193, 552, 6, 255, 402, 2012, 21, 173, 8, 22644, 45, 4, 11595, 552, 140, 1, 92, 2867, 42, 8, 607, 532, 1, 552, 2, 10340, 535, 1393, 447, 3, 1082, 2200, 43, 1, 552, 21, 195, 697, 114, 22644, 65, 6, 3, 552, 140, 5, 8, 607, 532, 1, 552, 6, 255, 2012, 112, 6, 46, 2200, 552, 140, 114, 3150, 12397, 29, 46, 318, 11, 194, 4, 35, 402, 1000, 1, 6951, 2200, 552, 140, 2, 15102, 535, 75, 62, 390, 74, 21, 108, 2, 557, 35, 306, 248, 1, 39, 226, 1579, 1203, 1109, 17, 543, 898, 1019, 1050, 724, 262, 3, 12933, 1688, 1253, 161, 66, 145, 397, 19, 1030, 1552, 27, 567, 79, 66, 2308, 4, 3, 373, 108, 30322, 14, 2474, 59596, 6, 2200, 552, 140, 21, 108, 2, 557, 8, 217, 2474, 23, 1170, 12479, 27, 397, 19, 549, 49, 937, 79, 83, 26, 229, 1053, 8475, 3, 1160, 35017, 2, 1160, 42942, 214, 1368, 21, 194, 3, 79, 373, 210, 1109, 4, 3, 63, 1000, 2, 6714, 66, 1, 1370, 114, 272, 538, 3, 1492, 17, 2200, 552, 140, 47, 402, 336, 839, 44, 527, 4, 1928, 552, 402, 2012, 107, 2200, 552, 140, 68, 40, 108, 298, 1077, 94]",1323.0,21131588,3
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.,Blood,Blood,2010-12-06,"Recently, we detected that chronic lymphocytic leukemia (CLL) B-cell-derived microvesicles in CLL plasma carry a constitutively phosphorylated novel receptor tyrosine kinase (RTK), Axl, indicating that Axl was acquired from the leukemic B cells. To examine Axl status in CLL, we determined the expression of phosphorylated-Axl (P-Axl) in freshly isolated CLL B cells by Western blot analysis. We detected differential levels of P-Axl in CLL B cells, and further analysis showed that expression of P-Axl was correlated with the other constitutively phosphorylated kinases, including Lyn, phosphoinositide-3 kinase, SyK/-associated protein of 70 kDa, phospholipase C 2 in CLL B cells. We found that these intracellular signaling molecules were complexed with P-Axl in primary CLL B cells. When Axl and Src kinases were targeted by a Src/Abl kinase inhibitor, bosutinib (SKI-606), or a specific-inhibitor of Axl (R428), robust induction of CLL B-cell apoptosis was observed in both a dose- and time-dependent manner. Therefore, we have identified a novel RTK in CLL B cells which appears to work as a docking site for multiple non-RTKs and drives leukemic cell survival signals. These findings highlight a unique target for CLL treatment.",Journal Article,3333.0,78.0,Recently we detected that chronic lymphocytic CLL B-cell-derived microvesicles in CLL plasma carry a constitutively phosphorylated novel receptor tyrosine kinase RTK Axl indicating that Axl was acquired from the leukemic B cells To examine Axl status in CLL we determined the expression of phosphorylated-Axl P-Axl in freshly isolated CLL B cells by Western blot analysis We detected differential levels of P-Axl in CLL B cells and further analysis showed that expression of P-Axl was correlated with the other constitutively phosphorylated kinases including Lyn phosphoinositide-3 kinase SyK/-associated protein of 70 kDa phospholipase C 2 in CLL B cells We found that these intracellular signaling molecules were complexed with P-Axl in primary CLL B cells When Axl and Src kinases were targeted by a Src/Abl kinase inhibitor bosutinib SKI-606 or a specific-inhibitor of Axl R428 robust induction of CLL B-cell apoptosis was observed in both a dose- and time-dependent manner Therefore we have identified a novel RTK in CLL B cells which appears to work as a docking site for multiple non-RTKs and drives leukemic cell survival signals These findings highlight a unique target for CLL treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[761, 21, 530, 17, 442, 1193, 552, 132, 31, 526, 25307, 4, 552, 554, 3542, 8, 2818, 2365, 229, 153, 564, 216, 5261, 4197, 1716, 17, 4197, 10, 1294, 29, 3, 2015, 132, 37, 6, 1004, 4197, 156, 4, 552, 21, 509, 3, 55, 1, 2365, 4197, 19, 4197, 4, 9957, 1355, 552, 132, 37, 20, 1521, 2639, 65, 21, 530, 1777, 148, 1, 19, 4197, 4, 552, 132, 37, 2, 195, 65, 224, 17, 55, 1, 19, 4197, 10, 438, 5, 3, 127, 2818, 2365, 1549, 141, 8309, 4497, 27, 216, 6792, 14668, 41, 178, 1, 431, 6362, 16685, 256, 31713, 4, 552, 132, 37, 21, 204, 17, 46, 2087, 314, 1598, 11, 17102, 5, 19, 4197, 4, 86, 552, 132, 37, 198, 4197, 2, 2023, 1549, 11, 238, 20, 8, 2023, 1425, 216, 230, 5936, 13314, 14495, 15, 8, 112, 230, 1, 4197, 46353, 1922, 504, 1, 552, 132, 31, 351, 10, 164, 4, 110, 8, 61, 2, 98, 470, 1708, 673, 21, 47, 108, 8, 229, 5261, 4, 552, 132, 37, 92, 1233, 6, 1357, 22, 8, 12593, 606, 9, 232, 220, 6798, 2, 5267, 2015, 31, 25, 2312, 46, 272, 1817, 8, 991, 283, 9, 552, 24]",1198.0,21135257,356
What is the best frontline therapy for patients with CLL and 17p deletion?,Current hematologic malignancy reports,Curr Hematol Malig Rep,2011-03-01,"Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with significant variation in disease progression, response to therapy, and survival outcome. Deletions of 17p or mutations of TP53 have been identified as one of the poorest prognostic factors, being predictive of short time for disease progression, lack of response to therapy, short response duration, and short overall survival. The treatment of patients with CLL has improved significantly with the development of chemoimmunotherapy, but this benefit was not pronounced in patients with 17p deletion. We compare various treatment strategies used in these patients, including FCR-like chemoimmunotherapy, alemtuzumab, other antibody combinations, or novel targeted therapies with promising results. Allogeneic stem cell transplantation offers the possibility for long-term disease control in these patients and should be considered early in younger, transplant-eligible patients. The current state of therapy is far from optimal and resources should be applied to studying therapeutic options for patients who have CLL with loss of p53 function.",Journal Article,3248.0,24.0,Chronic lymphocytic CLL is a lymphoproliferative disease with significant variation in disease progression response to therapy and survival outcome Deletions of 17p or mutations of TP53 have been identified as one of the poorest prognostic factors being predictive of short time for disease progression lack of response to therapy short response duration and short overall survival The treatment of patients with CLL has improved significantly with the development of chemoimmunotherapy but this benefit was not pronounced in patients with 17p deletion We compare various treatment strategies used in these patients including FCR-like chemoimmunotherapy alemtuzumab other antibody combinations or novel targeted therapies with promising results Allogeneic stem cell transplantation offers the possibility for long-term disease control in these patients and should be considered early in younger transplant-eligible patients The current state of therapy is far from optimal and resources should be applied to studying therapeutic options for patients who have CLL with loss of p53 function,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 4192, 34, 5, 93, 1380, 4, 34, 91, 51, 6, 36, 2, 25, 228, 2439, 1, 4135, 15, 138, 1, 1206, 47, 85, 108, 22, 104, 1, 3, 11136, 177, 130, 486, 464, 1, 978, 98, 9, 34, 91, 926, 1, 51, 6, 36, 978, 51, 654, 2, 978, 63, 25, 3, 24, 1, 7, 5, 552, 71, 231, 97, 5, 3, 193, 1, 4438, 84, 26, 247, 10, 44, 3517, 4, 7, 5, 4135, 1528, 21, 932, 747, 24, 422, 95, 4, 46, 7, 141, 4953, 733, 4438, 3579, 127, 548, 1247, 15, 229, 238, 235, 5, 721, 99, 1063, 452, 31, 497, 2339, 3, 2526, 9, 319, 337, 34, 182, 4, 46, 7, 2, 257, 40, 515, 191, 4, 773, 941, 625, 7, 3, 291, 1309, 1, 36, 16, 3272, 29, 665, 2, 2892, 257, 40, 1498, 6, 4559, 189, 838, 9, 7, 54, 47, 552, 5, 407, 1, 624, 343]",1088.0,21153774,470
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2010-12-01,"Five laboratories in the Chronic Lymphocytic Leukemia (CLL) Research Consortium (CRC) investigated standardizing and pooling of fluorescence in situ hybridization (FISH) results as a collaborative research project. This investigation used fixed bone marrow and blood cells available from previous conventional cytogenetic or FISH studies in two pilot studies, a one-day workshop, and proficiency test. Multiple FISH probe strategies were used to detect 6q-, 11q-, +12, 13q-, 17p-, and IGH rearrangements. Ten specimens were studied by participants who used their own probes (pilot study 1). Of 312 FISH interpretations, 224 (72%) were true-negative, 74 (24%) true-positive, 6 (2%) false-negative, and 8 (3%) false-positive. In pilot study no. 2, each participant studied two specimens using identical FISH probe sets to control for variation due to probe sets and probe strategies. Of 80 FISH interpretations, no false interpretations were identified. At a subsequent workshop, discussions produced agreement on scoring criteria. The proficiency test that followed produced no false-negative results and 4% (3/68) false-positive interpretations. Interpretation disagreements among laboratories were primarily attributable to inadequate normal cutoffs, inconsistent scoring criteria, and the use of different FISH probe strategies. Collaborative organizations that use pooled FISH results may wish to impose more conservative empiric normal cutoff values or use an equivocal range between the normal cutoff and the abnormal reference range to eliminate false-positive interpretations. False-negative results will still occur, and would be expected in low-percentage positive cases; these would likely have less clinical significance than false positive results. Individual laboratories can help by closely following rigorous quality assurance guidelines to ensure accurate and consistent FISH studies in their clinical practice and research.",Journal Article,3338.0,13.0,Five laboratories in the Chronic Lymphocytic CLL Research Consortium CRC investigated standardizing and pooling of fluorescence in situ hybridization FISH results as a collaborative research project This investigation used fixed marrow and blood cells available from previous conventional cytogenetic or FISH studies in two pilot studies a one-day workshop and proficiency test Multiple FISH probe strategies were used to detect 6q- 11q- +12 13q- 17p- and IGH rearrangements Ten specimens were studied by participants who used their own probes pilot study 1 Of 312 FISH interpretations 224 72 were true-negative 74 24 true-positive 6 2 false-negative and 8 3 false-positive In pilot study no 2 each participant studied two specimens using identical FISH probe sets to control for variation due to probe sets and probe strategies Of 80 FISH interpretations no false interpretations were identified At a subsequent workshop discussions produced agreement on scoring criteria The proficiency test that followed produced no false-negative results and 4 3/68 false-positive interpretations Interpretation disagreements among laboratories were primarily attributable to inadequate normal cutoffs inconsistent scoring criteria and the use of different FISH probe strategies Collaborative organizations that use pooled FISH results may wish to impose more conservative empiric normal cutoff values or use an equivocal range between the normal cutoff and the abnormal reference range to eliminate false-positive interpretations False-negative results will still occur and would be expected in low-percentage positive cases these would likely have less clinical significance than false positive results Individual laboratories can help by closely following rigorous quality assurance guidelines to ensure accurate and consistent FISH studies in their clinical practice and research,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[365, 4884, 4, 3, 442, 1193, 552, 389, 2404, 590, 565, 15343, 2, 9419, 1, 1591, 4, 957, 1554, 1277, 99, 22, 8, 3737, 389, 3105, 26, 940, 95, 1959, 581, 2, 315, 37, 390, 29, 698, 809, 1266, 15, 1277, 94, 4, 100, 2281, 94, 8, 104, 218, 4014, 2, 11266, 412, 232, 1277, 2888, 422, 11, 95, 6, 1426, 10961, 7203, 133, 8453, 4135, 2, 5221, 2072, 1618, 623, 11, 656, 20, 776, 54, 95, 136, 4165, 3701, 2281, 45, 14, 1, 8187, 1277, 11158, 5908, 720, 11, 2501, 199, 794, 259, 2501, 109, 49, 18, 2133, 199, 2, 66, 27, 2133, 109, 4, 2281, 45, 77, 18, 296, 5705, 656, 100, 623, 75, 3038, 1277, 2888, 2270, 6, 182, 9, 1380, 520, 6, 2888, 2270, 2, 2888, 422, 1, 493, 1277, 11158, 77, 2133, 11158, 11, 108, 28, 8, 706, 4014, 3173, 1687, 2024, 23, 2504, 371, 3, 11266, 412, 17, 370, 1687, 77, 2133, 199, 99, 2, 39, 27, 806, 2133, 109, 11158, 3037, 21496, 107, 4884, 11, 1561, 2971, 6, 3358, 295, 8339, 4923, 2504, 371, 2, 3, 119, 1, 338, 1277, 2888, 422, 3737, 6283, 17, 119, 1830, 1277, 99, 68, 11443, 6, 15099, 80, 4476, 7866, 295, 2779, 1030, 15, 119, 35, 5068, 184, 59, 3, 295, 2779, 2, 3, 1668, 2482, 184, 6, 4964, 2133, 109, 11158, 2133, 199, 99, 303, 1234, 1271, 2, 688, 40, 1336, 4, 154, 1150, 109, 140, 46, 688, 322, 47, 299, 38, 724, 76, 2133, 109, 99, 797, 4884, 122, 987, 20, 3210, 366, 6496, 372, 8050, 677, 6, 3478, 1481, 2, 925, 1277, 94, 4, 136, 38, 758, 2, 389]",1871.0,21156226,623
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2010-12-01,"To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic leukemia (CLL), we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease. We used array-based comparative genomic hybridization (aCGH) with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial. We identified chromosomal gain or loss in 6% of the patients on chromosomes 3, 8, 9, 10, 11, 12, 13, 14, and 17. Higher genomic complexity, as a mechanism favoring clonal selection, was associated with shorter progression-free survival, and predicted a poor response to treatment. Of interest, CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses.",Journal Article,3338.0,30.0,To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic CLL we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease We used array-based comparative genomic hybridization aCGH with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial We identified chromosomal gain or loss in 6 of the patients on chromosomes 3 8 9 10 11 12 13 14 and 17 Higher genomic complexity as a mechanism favoring clonal selection was associated with shorter progression-free survival and predicted a poor response to treatment Of interest CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 380, 1640, 3, 1268, 1, 572, 1753, 2, 228, 4, 132, 31, 442, 1193, 552, 21, 990, 6, 1539, 572, 3082, 22, 8, 980, 1, 5522, 2, 2050, 38, 228, 4, 26, 34, 21, 95, 1926, 90, 2352, 572, 1554, 8879, 5, 8, 104, 3346, 2888, 1926, 2, 108, 3849, 2, 5324, 1, 336, 3692, 4, 576, 7, 73, 23, 8, 4438, 38, 160, 21, 108, 1860, 1803, 15, 407, 4, 6258, 1, 3, 7, 23, 3560, 27, 66, 83, 79, 175, 133, 233, 213, 2, 269, 142, 572, 3082, 22, 8, 670, 6238, 1946, 881, 10, 41, 5, 985, 91, 115, 25, 2, 783, 8, 334, 51, 6, 24, 1, 1333, 552, 140, 5, 407, 1, 624, 617, 224, 80, 840, 572, 404, 2, 11, 204, 110, 4, 7, 5, 8, 7526, 14, 1528, 2, 4, 3, 80, 913, 336, 875, 765, 20, 3, 463, 1, 13221, 14, 1528, 26, 8879, 45, 6659, 487, 23, 3, 248, 59, 334, 160, 51, 2, 602, 336, 3082, 22, 552, 6752]",1070.0,21156228,702
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-12-27,"As success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies primarily on graft-versus-leukemia (GVL) activity, increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes. To assess whether use of unrelated donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (MRD), we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD (n = 246) and MRD (n = 187) RIC HSCT for hematologic malignancies at our institution. Diseases included: acute myelogenous leukemia (AML) (127), non-Hodgkin lymphoma (NHL) (71), chronic lymphocytic leukemia (CLL) (68), myelodysplastic syndrome (MDS) (64), Hodgkin disease (HD) (40), chronic myeloid leukemia (CML) (25), multiple myeloma (MM) (23), myeloproliferative disorder (MPD) (12), acute lymphoblastic leukemia (ALL) (7), and other leukemia (1). All received uniform fludarabine and intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/sirolimus  mini-MTX. Unrelated donors were younger compared to MRD (median donor age: 33 years versus 52 years, P < .0001), and provided larger CD34(+) products (median CD34(+) cells infused: 8.7  10(6)/kg versus 7.5  10(6)/kg, P = .002). Distribution of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts. Cumulative incidence of grade II-IV acute GVHD (at day +180), 2-year chronic GVHD, and 2-year nonrelapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and MRD, respectively (P= NS). Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P = .005). With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly better in unrelated donor transplants, 39.5% for URD, and 29% for MRD (P = .01). Overall survival (OS) at 2years were 56% for URD versus 50% for MRD (P = .53). In multivariable analysis, URD was associated with a lower risk of relapse (hazard ratio [HR] 0.67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT.",Comparative Study,3312.0,45.0,As success of reduced-intensity conditioning RIC hematopoietic stem cell transplantation HSCT relies primarily on graft-versus-leukemia GVL activity increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes To assess whether use of unrelated donors URD engenders more potent GVL in RIC HSCT compared to matched related donors MRD we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD n 246 and MRD n 187 RIC HSCT for hematologic malignancies at our institution Diseases included acute myelogenous AML 127 NHL 71 chronic lymphocytic CLL 68 syndrome MDS 64 disease HD 40 chronic myeloid CML 25 multiple MM 23 disorder MPD 12 acute lymphoblastic ALL 7 and other 1 All received uniform fludarabine and intravenous busulfan conditioning and GVHD prophylaxis with tacrolimus/mini-methroxate mini-MTX or tacrolimus/sirolimus  mini-MTX Unrelated donors were younger compared to MRD median donor age 33 years versus 52 years P .0001 and provided larger CD34 products median CD34 cells infused 8.7 10 6 /kg versus 7.5 10 6 /kg P .002 Distribution of diseases disease risk prior transplant and cytomegalovirus CMV status was similar in both cohorts Cumulative incidence of grade II-IV acute GVHD at day +180 2-year chronic GVHD and 2-year nonrelapse mortality NRM were 20 versus 16 55 versus 50 and 8 versus 6 in URD and MRD respectively P NS Cumulative incidence of relapse at 2 years was lower in URD 52 versus 65 P .005 With median follow-up of 26.5 and 35.8 months 2-year progression-free survival PFS was significantly better in unrelated donor transplants 39.5 for URD and 29 for MRD P .01 Overall survival OS at 2 years were 56 for URD versus 50 for MRD P .53 In multivariable analysis URD was associated with a lower risk of relapse hazard ratio HR 0.67 P .002 and superior PFS HR 0.69 P .002 These results suggest that URD is associated with greater GVL activity than MRD and could have practice changing impact on future donor selection in RIC HSCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22, 1825, 1, 405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 6495, 1561, 23, 1599, 185, 2647, 8149, 128, 101, 2278, 1160, 4326, 4, 2092, 72, 6, 139, 2344, 359, 47, 8, 93, 345, 23, 941, 123, 6, 423, 317, 119, 1, 2092, 2344, 5847, 39508, 80, 1157, 8149, 4, 3365, 1703, 72, 6, 655, 139, 2344, 2029, 21, 894, 656, 13224, 935, 102, 11151, 49, 49, 1160, 655, 5847, 78, 6907, 2, 2029, 78, 5568, 3365, 1703, 9, 813, 441, 28, 114, 731, 1342, 159, 286, 2194, 329, 4080, 1176, 792, 442, 1193, 552, 806, 681, 1223, 660, 34, 2701, 327, 442, 533, 903, 243, 232, 321, 382, 2645, 7712, 133, 286, 1275, 62, 67, 2, 127, 14, 62, 103, 3490, 2027, 2, 1262, 3906, 1933, 2, 1562, 2049, 5, 5643, 7313, 59688, 7313, 3453, 15, 5643, 4519, 810, 7313, 3453, 2092, 2344, 11, 773, 72, 6, 2029, 52, 1488, 89, 466, 60, 185, 653, 60, 19, 488, 2, 1052, 1077, 2215, 2766, 52, 2215, 37, 4524, 66, 67, 79, 49, 503, 185, 67, 33, 79, 49, 503, 19, 1111, 1395, 1, 1342, 34, 43, 324, 941, 2, 7314, 3879, 156, 10, 288, 4, 110, 736, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 218, 3172, 18, 111, 442, 1562, 2, 18, 111, 4640, 282, 4296, 11, 179, 185, 245, 614, 185, 212, 2, 66, 185, 49, 4, 5847, 2, 2029, 106, 19, 4044, 967, 287, 1, 429, 28, 18, 60, 10, 280, 4, 5847, 653, 185, 556, 19, 1614, 5, 52, 166, 126, 1, 432, 33, 2, 465, 66, 53, 18, 111, 91, 115, 25, 300, 10, 97, 380, 4, 2092, 1488, 4016, 587, 33, 9, 5847, 2, 462, 9, 2029, 19, 355, 63, 25, 118, 28, 18, 60, 11, 664, 9, 5847, 185, 212, 9, 2029, 19, 699, 4, 658, 65, 5847, 10, 41, 5, 8, 280, 43, 1, 429, 360, 197, 168, 13, 598, 19, 1111, 2, 1123, 300, 168, 13, 790, 19, 1111, 46, 99, 309, 17, 5847, 16, 41, 5, 378, 8149, 128, 76, 2029, 2, 359, 47, 758, 3600, 345, 23, 508, 1488, 881, 4, 3365, 1703]",2034.0,21193054,718
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.,Blood,Blood,2011-01-14,"Flavopiridol is a protein bound, cytotoxic, cyclin-dependent kinase inhibitor. Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias. A pharmacologically derived ""hybrid"" schedule (30-minute bolus followed by 4-hour infusion) of flavopiridol was more effective than bolus administration in refractory chronic lymphocytic leukemia. Our phase 1 trial ""hybrid FLAM"" in 55 adults with relapsed/refractory acute leukemias began at a total flavopiridol dose of 50 mg/m(2) per day 3 times (20-mg/m(2) bolus, 30-mg/m(2) infusion). Dose-limiting toxicity occurred at level 6 (30-mg/m(2) bolus, 70-mg/m(2) infusion) with tumor lysis, hyperbilirubinemia, and mucositis. Death occurred in 5 patients (9%). Complete remission occurred in 22 (40%) across all doses. Overall and disease-free survivals for complete remission patients are more than 60% at more than 2 years. Pharmacokinetics demonstrated a dose-response for total and unbound plasma flavopiridol unrelated to total protein, albumin, peripheral blast count, or toxicity. Pharmacodynamically, flavopiridol inhibited mRNAs of multiple cell cycle regulators, but with uniform increases in bcl-2. ""Hybrid FLAM"" is active in relapsed/refractory acute leukemias, with a recommended ""hybrid"" dose of bolus 30 mg/m(2) followed by infusion of 60 mg/m(2) daily for 3 days. This clinical trial is registered at www.clinicaltrials.gov as #NCT00470197.","Clinical Trial, Phase I",3294.0,63.0,Flavopiridol is a protein bound cytotoxic cyclin-dependent kinase inhibitor Flavopiridol given by 1-hour bolus at 50 mg/m 2 daily 3 times followed by cytosine arabinoside and mitoxantrone FLAM is active in adults with poor-risk acute leukemias A pharmacologically derived `` hybrid '' schedule 30-minute bolus followed by 4-hour infusion of flavopiridol was more effective than bolus administration in refractory chronic lymphocytic Our phase 1 trial `` hybrid FLAM '' in 55 adults with relapsed/refractory acute leukemias began at a total flavopiridol dose of 50 mg/m 2 per day 3 times 20-mg/m 2 bolus 30-mg/m 2 infusion Dose-limiting toxicity occurred at level 6 30-mg/m 2 bolus 70-mg/m 2 infusion with tumor lysis hyperbilirubinemia and mucositis Death occurred in 5 patients 9 Complete remission occurred in 22 40 across all doses Overall and disease-free survivals for complete remission patients are more than 60 at more than 2 years Pharmacokinetics demonstrated a dose-response for total and unbound plasma flavopiridol unrelated to total protein albumin peripheral blast count or toxicity Pharmacodynamically flavopiridol inhibited mRNAs of multiple cell cycle regulators but with uniform increases in bcl-2 `` Hybrid FLAM '' is active in relapsed/refractory acute leukemias with a recommended `` hybrid '' dose of bolus 30 mg/m 2 followed by infusion of 60 mg/m 2 daily for 3 days This clinical trial is registered at www.clinicaltrials.gov as NCT00470197,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 16, 8, 178, 2951, 759, 1226, 470, 216, 230, 3030, 447, 20, 14, 2583, 3604, 28, 212, 81, 188, 18, 391, 27, 1072, 370, 20, 6903, 11563, 2, 4419, 16475, 16, 544, 4, 857, 5, 334, 43, 286, 2792, 8, 7854, 526, 4542, 522, 1055, 201, 3949, 3604, 370, 20, 39, 2583, 904, 1, 3030, 10, 80, 323, 76, 3604, 634, 4, 430, 442, 1193, 114, 124, 14, 160, 4542, 16475, 522, 4, 614, 857, 5, 591, 430, 286, 2792, 4603, 28, 8, 181, 3030, 61, 1, 212, 81, 188, 18, 379, 218, 27, 1072, 179, 81, 188, 18, 3604, 201, 81, 188, 18, 904, 61, 817, 155, 489, 28, 301, 49, 201, 81, 188, 18, 3604, 431, 81, 188, 18, 904, 5, 30, 4783, 7236, 2, 2606, 273, 489, 4, 33, 7, 83, 236, 734, 489, 4, 350, 327, 716, 62, 415, 63, 2, 34, 115, 3794, 9, 236, 734, 7, 32, 80, 76, 335, 28, 80, 76, 18, 60, 1159, 264, 8, 61, 51, 9, 181, 2, 9589, 554, 3030, 2092, 6, 181, 178, 2799, 672, 3112, 1276, 15, 155, 22565, 3030, 879, 7503, 1, 232, 31, 417, 3196, 84, 5, 3490, 1106, 4, 1044, 18, 4542, 16475, 522, 16, 544, 4, 591, 430, 286, 2792, 5, 8, 793, 4542, 522, 61, 1, 3604, 201, 81, 188, 18, 370, 20, 904, 1, 335, 81, 188, 18, 391, 9, 27, 162, 26, 38, 160, 16, 1653, 28, 3064, 1252, 1239, 22, 59735]",1465.0,21239698,424
Treatment of younger patients with chronic lymphocytic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2010-01-01,"Younger patients (defined as patients younger than 50-55 years of age) represent a small group of newly diagnosed patients with chronic lymphocytic leukemia, accounting only for 10% to 20% of newly diagnosed cases. However, once these patients become symptomatic and require treatment, their life expectancy is significantly reduced. Therapeutic approaches for younger patients should be directed at improving survival by achieving a complete remission and, where possible, eradicating minimal residual disease. Chemoimmunotherapy combinations carry the highest response rates and are commonly offered to younger patients. Additional strategies that should be considered for younger patients include early referral for stem-cell transplantation and clinical trials of consolidation therapy to eliminate minimal residual disease.",Journal Article,3672.0,10.0,Younger patients defined as patients younger than 50-55 years of age represent a small group of newly diagnosed patients with chronic lymphocytic accounting only for 10 to 20 of newly diagnosed cases However once these patients become symptomatic and require treatment their life expectancy is significantly reduced Therapeutic approaches for younger patients should be directed at improving survival by achieving a complete remission and where possible eradicating minimal residual disease Chemoimmunotherapy combinations carry the highest response rates and are commonly offered to younger patients Additional strategies that should be considered for younger patients include early referral for stem-cell transplantation and clinical trials of consolidation therapy to eliminate minimal residual disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[773, 7, 395, 22, 7, 773, 76, 212, 614, 60, 1, 89, 1231, 8, 302, 87, 1, 732, 265, 7, 5, 442, 1193, 3116, 158, 9, 79, 6, 179, 1, 732, 265, 140, 137, 1059, 46, 7, 1417, 1704, 2, 1353, 24, 136, 358, 3399, 16, 97, 405, 189, 611, 9, 773, 7, 257, 40, 1166, 28, 1673, 25, 20, 1785, 8, 236, 734, 2, 1257, 899, 11001, 1048, 753, 34, 4438, 1247, 3542, 3, 1076, 51, 151, 2, 32, 841, 2216, 6, 773, 7, 402, 422, 17, 257, 40, 515, 9, 773, 7, 643, 191, 2096, 9, 452, 31, 497, 2, 38, 143, 1, 2173, 36, 6, 4964, 1048, 753, 34]",805.0,21239775,81
Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2010-01-01,"A 55-year-old man presented with fever, night sweats, and weight loss of about 20 lbs. in the prior 6 months. Physical examination revealed multiple cervical, axillary, and inguinal lymphadenopathy. The spleen was enlarged. A complete blood count revealed leukocytosis with absolute lymphocytosis: 30,000/L. Peripheral blood-flow cytometric analysis showed a clonal lymphocyte population with immunophenotypes positive for CD5, CD20(dim), and monotypic kappa light chain. Fluorescence in situ hybridization (FISH) analysis revealed del(11q22.3), but negative for t(11:14). What should be used to treat his chronic lymphocytic leukemia (CLL) disease?",Journal Article,3672.0,15.0,"A 55-year-old man presented with fever night sweats and weight loss of about 20 lbs in the prior 6 months Physical examination revealed multiple axillary and inguinal lymphadenopathy The spleen was enlarged A complete blood count revealed leukocytosis with absolute lymphocytosis 30,000/L Peripheral blood-flow cytometric analysis showed a clonal lymphocyte population with immunophenotypes positive for CD5 CD20 dim and monotypic kappa light chain Fluorescence in situ hybridization FISH analysis revealed del 11q22.3 but negative for t 11:14 What should be used to treat his chronic lymphocytic CLL disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[8, 614, 111, 1095, 3628, 917, 5, 2775, 8955, 13298, 2, 924, 407, 1, 545, 179, 35044, 4, 3, 324, 49, 53, 900, 1385, 553, 232, 1210, 2, 4907, 4962, 3, 4071, 10, 7547, 8, 236, 315, 1276, 553, 7463, 5, 1766, 8125, 201, 984, 5513, 672, 315, 1412, 6226, 65, 224, 8, 1946, 1448, 266, 5, 16679, 109, 9, 6349, 2198, 8657, 2, 30771, 3096, 1691, 1260, 1591, 4, 957, 1554, 1277, 65, 553, 3084, 12647, 27, 84, 199, 9, 102, 175, 213, 2067, 257, 40, 95, 6, 943, 3224, 442, 1193, 552, 34]",609.0,21239776,300
Signal transduction inhibitor therapy for lymphoma.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2010-01-01,"Current research in lymphoma is focused on two areas of lymphoma biology-the signal transduction pathways used to maintain the growth of malignant lymphocytes and the role of the tumor microenvironment in lymphoma growth and survival. This review focuses on three signaling pathways: the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway, the B-cell receptor/spleen tyrosine kinase (BCR/Syk) pathway, and the protein kinase C-beta (PKC-) pathway, known to be important to lymphoma cells. The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of lymphoma, the Syk inhibitor fostamatinib has activity in diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and the PKC- inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell lymphoma. This review discusses the biology behind the development of each new agent and the results of initial clinical trials. The goal is to provide the hematologist/oncologist background information on these new agents and understand their current and potential role in the management of patients.",Journal Article,3672.0,38.0,Current research in is focused on two areas of biology-the signal transduction pathways used to maintain the growth of malignant lymphocytes and the role of the tumor microenvironment in growth and survival This review focuses on three signaling pathways the phosphatidylinositol 3-kinase/mammalian target of rapamycin PI3K/mTOR pathway the B-cell receptor/spleen tyrosine kinase BCR/Syk pathway and the protein kinase C-beta PKC- pathway known to be important to cells The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of the Syk inhibitor fostamatinib has activity in diffuse large B-cell and chronic lymphocytic and the PKC- inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell This review discusses the biology behind the development of each new agent and the results of initial clinical trials The goal is to provide the hematologist/oncologist background information on these new agents and understand their current and potential role in the management of patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[291, 389, 4, 16, 1649, 23, 100, 1361, 1, 891, 3, 1235, 2761, 460, 95, 6, 3040, 3, 129, 1, 393, 1594, 2, 3, 200, 1, 3, 30, 995, 4, 129, 2, 25, 26, 206, 3026, 23, 169, 314, 460, 3, 3415, 27, 216, 2359, 283, 1, 1620, 974, 873, 308, 3, 132, 31, 153, 4071, 564, 216, 1062, 6792, 308, 2, 3, 178, 216, 256, 1090, 4644, 1458, 308, 440, 6, 40, 305, 6, 37, 3, 873, 222, 2831, 2, 1400, 47, 264, 579, 128, 4, 62, 630, 1, 3, 6792, 230, 27018, 71, 128, 4, 1388, 375, 132, 31, 2, 442, 1193, 2, 3, 4644, 1458, 230, 5086, 16, 486, 95, 22, 2173, 36, 50, 734, 4, 1388, 375, 132, 31, 26, 206, 2759, 3, 891, 5219, 3, 193, 1, 296, 217, 420, 2, 3, 99, 1, 388, 38, 143, 3, 1326, 16, 6, 377, 3, 15278, 2709, 2426, 487, 23, 46, 217, 183, 2, 1640, 136, 291, 2, 174, 200, 4, 3, 284, 1, 7]",1068.0,21239804,276
"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.",Blood,Blood,2011-01-18,"Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in patients beyond first relapse, patients with prior exposure to fludarabine and alkylating agent combinations, and patients with prior exposure to rituximab. The FCR regimen was administered to 284 previously treated patients with CLL. Patients were assessed for response and progression by 1996 National Cancer Institute-Working Group (NCI-WG) criteria for CLL and followed for survival. The overall response rate was 74%, with 30% complete remission. The estimated median overall survival was 47 months and median progression-free survival for all patients was 21 months. Subgroup analyses indicated that the following patients were most suitable for FCR treatment: patients with up to 3 prior treatments, fludarabine-sensitive patients irrespective of prior rituximab exposure, and patients without chromosome 17 abnormalities. FCR is an active and well-tolerated therapy for patients with relapsed CLL. The addition of rituximab to FC improved quality and durability of response in this patient population.","Clinical Trial, Phase II",3290.0,133.0,Optimal management of patients with relapsed/refractory chronic lymphocytic CLL is dictated by patient characteristics prior therapy and response to prior therapy We report the final analysis of combined fludarabine cyclophosphamide and rituximab FCR for previously treated patients with CLL and identify patients who benefit most from this therapy We explore efficacy of FCR in patients beyond first relapse patients with prior exposure to fludarabine and alkylating agent combinations and patients with prior exposure to rituximab The FCR regimen was administered to 284 previously treated patients with CLL Patients were assessed for response and progression by 1996 National Cancer Institute-Working Group NCI-WG criteria for CLL and followed for survival The overall response rate was 74 with 30 complete remission The estimated median overall survival was 47 months and median progression-free survival for all patients was 21 months Subgroup analyses indicated that the following patients were most suitable for FCR treatment patients with up to 3 prior treatments fludarabine-sensitive patients irrespective of prior rituximab exposure and patients without chromosome 17 abnormalities FCR is an active and well-tolerated therapy for patients with relapsed CLL The addition of rituximab to FC improved quality and durability of response in this patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[665, 284, 1, 7, 5, 591, 430, 442, 1193, 552, 16, 10575, 20, 69, 374, 324, 36, 2, 51, 6, 324, 36, 21, 414, 3, 1457, 65, 1, 397, 2027, 1112, 2, 855, 4953, 9, 373, 73, 7, 5, 552, 2, 255, 7, 54, 247, 96, 29, 26, 36, 21, 1645, 209, 1, 4953, 4, 7, 1654, 157, 429, 7, 5, 324, 645, 6, 2027, 2, 3410, 420, 1247, 2, 7, 5, 324, 645, 6, 855, 3, 4953, 477, 10, 468, 6, 8843, 373, 73, 7, 5, 552, 7, 11, 275, 9, 51, 2, 91, 20, 2648, 657, 12, 1377, 2644, 87, 2580, 12906, 371, 9, 552, 2, 370, 9, 25, 3, 63, 51, 116, 10, 794, 5, 201, 236, 734, 3, 661, 52, 63, 25, 10, 662, 53, 2, 52, 91, 115, 25, 9, 62, 7, 10, 239, 53, 1363, 318, 1103, 17, 3, 366, 7, 11, 96, 2884, 9, 4953, 24, 7, 5, 126, 6, 27, 324, 640, 2027, 745, 7, 3500, 1, 324, 855, 645, 2, 7, 187, 1170, 269, 1171, 4953, 16, 35, 544, 2, 149, 421, 36, 9, 7, 5, 591, 552, 3, 352, 1, 855, 6, 4127, 231, 372, 2, 6867, 1, 51, 4, 26, 69, 266]",1370.0,21245487,311
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.,Cancer,Cancer,2011-01-18,"Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum -2 microglobulin (2M) levels were associated with more rapid disease progression and shorter survival (OS). An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with 2M level  2 mg/dL. Long-term follow-up and results are reported. The overall response rate in 34 patients was 82% (9% complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74% (median follow-up, 102 months). Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.",Journal Article,3290.0,12.0,Management of asymptomatic early stage chronic lymphocytic CLL centered on expectant surveillance for active disease warranting chemotherapy In CLL elevated serum -2 microglobulin 2M levels were associated with more rapid disease progression and shorter survival OS An early intervention trial was designed to assess response time-to-progression TTP and OS after immunotherapy with standard-dose rituximab 375 mg/m intravenously weekly for 8 consecutive weeks in 34 asymptomatic untreated early stage CLL with 2M level  2 mg/dL Long-term follow-up and results are reported The overall response rate in 34 patients was 82 9 complete CR median TTP in the 28 responders was 23 months the median time to subsequent treatment was 43 months and the 8-year OS rate was 74 median follow-up 102 months Early treatment with rituximab was well tolerated and safe Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[284, 1, 2100, 191, 82, 442, 1193, 552, 4846, 23, 16351, 617, 9, 544, 34, 7643, 56, 4, 552, 804, 524, 1458, 18, 5371, 27019, 148, 11, 41, 5, 80, 1321, 34, 91, 2, 985, 25, 118, 35, 191, 788, 160, 10, 1114, 6, 423, 51, 98, 6, 91, 2422, 2, 118, 50, 726, 5, 260, 61, 855, 4175, 81, 4709, 1672, 709, 9, 66, 935, 244, 4, 562, 2100, 1278, 191, 82, 552, 5, 27019, 301, 749, 18, 81, 1826, 319, 337, 166, 126, 2, 99, 32, 210, 3, 63, 51, 116, 4, 562, 7, 10, 878, 83, 236, 684, 52, 2422, 4, 3, 339, 1983, 10, 382, 53, 3, 52, 98, 6, 706, 24, 10, 601, 53, 2, 3, 66, 111, 118, 116, 10, 794, 52, 166, 126, 2867, 53, 191, 24, 5, 855, 10, 149, 421, 2, 1165, 195, 94, 32, 575, 6, 223, 492, 26, 788, 122, 775, 552, 139, 787, 2, 282]",966.0,21246526,119
Primary subcutaneous Alternaria alternata infection of the hand in an immunocompromised host.,Medical mycology,Med. Mycol.,2011-02-07,"We describe a case of a progressive subcutaneous Alternaria alternata infection in the hand of a patient with chronic lymphocytic leukemia (CLL). The diagnosis was based upon the examination of tissue biopsy and isolation of the etiologic agent in culture. The identity of the isolate was determined by phenotypic characteristics and by sequencing the ITS and D1/D2 regions of the rDNA. Despite combination therapy with voriconazole and micafungin, the lesion continued to progress. Posaconazole therapy, along with surgical excision of the infected tissue, resulted in the eradication of infection. The limitations of the clinical management of invasive Alternaria infections are discussed.",Case Reports,3270.0,12.0,We describe a case of a progressive subcutaneous Alternaria alternata infection in the hand of a patient with chronic lymphocytic CLL The diagnosis was based upon the examination of tissue biopsy and isolation of the etiologic agent in culture The identity of the isolate was determined by phenotypic characteristics and by sequencing the ITS and D1/D2 regions of the rDNA Despite combination therapy with voriconazole and micafungin the lesion continued to progress Posaconazole therapy along with surgical excision of the infected tissue resulted in the eradication of infection The limitations of the clinical management of invasive Alternaria infections are discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 897, 8, 473, 1, 8, 1014, 2529, 46438, 59812, 930, 4, 3, 2833, 1, 8, 69, 5, 442, 1193, 552, 3, 147, 10, 90, 1548, 3, 1385, 1, 246, 411, 2, 5019, 1, 3, 6604, 420, 4, 2099, 3, 7710, 1, 3, 7910, 10, 509, 20, 3290, 374, 2, 20, 615, 3, 211, 2, 2146, 4171, 1374, 1, 3, 19933, 550, 150, 36, 5, 12916, 2, 17479, 3, 1180, 1351, 6, 1466, 10886, 36, 1510, 5, 221, 1366, 1, 3, 3369, 246, 627, 4, 3, 5173, 1, 930, 3, 1939, 1, 3, 38, 284, 1, 416, 46438, 1875, 32, 1588]",671.0,21299373,139
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.,Blood,Blood,2011-02-10,"We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic leukemia (CLL) patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes. However, little is known about the normal function of LDOC1, its contribution to the pathophysiology of CLL, or its prognostic significance. In this study, we have investigated LDOC1 mRNA expression in a large cohort of untreated CLL patients, as well as in normal peripheral blood B-cell (NBC) subsets and primary B-cell lymphoma samples. We have confirmed that LDOC1 is dramatically down-regulated in mutated CLL cases compared with unmutated cases, and have identified a new splice variant, LDOC1S. We show that LDOC1 is expressed in NBC subsets (naive > memory), suggesting that it may play a role in normal B-cell development. It is also expressed in primary B-cell lymphoma samples, in which its expression is associated with somatic mutation status. In CLL, we show that high levels of LDOC1 correlate with biomarkers of poor prognosis, including cytogenetic markers, unmutated somatic mutation status, and ZAP70 expression. Finally, we demonstrate that LDOC1 mRNA expression is an excellent predictor of overall survival in untreated CLL patients.",Journal Article,3267.0,22.0,We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic CLL patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes However little is known about the normal function of LDOC1 its contribution to the pathophysiology of CLL or its prognostic significance In this study we have investigated LDOC1 mRNA expression in a large cohort of untreated CLL patients as well as in normal peripheral blood B-cell NBC subsets and primary B-cell samples We have confirmed that LDOC1 is dramatically down-regulated in mutated CLL cases compared with unmutated cases and have identified a new splice variant LDOC1S We show that LDOC1 is expressed in NBC subsets naive memory suggesting that it may play a role in normal B-cell development It is also expressed in primary B-cell samples in which its expression is associated with somatic mutation status In CLL we show that high levels of LDOC1 correlate with biomarkers of poor prognosis including cytogenetic markers unmutated somatic mutation status and ZAP70 expression Finally we demonstrate that LDOC1 mRNA expression is an excellent predictor of overall survival in untreated CLL patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 373, 108, 27031, 22, 104, 1, 3, 96, 97, 2478, 570, 214, 4, 1278, 442, 1193, 552, 7, 5, 2184, 6, 3, 1119, 258, 156, 1, 3, 2593, 4013, 1260, 1347, 1053, 214, 137, 1215, 16, 440, 545, 3, 295, 343, 1, 27031, 211, 2925, 6, 3, 4320, 1, 552, 15, 211, 177, 724, 4, 26, 45, 21, 47, 565, 27031, 956, 55, 4, 8, 375, 180, 1, 1278, 552, 7, 22, 149, 22, 4, 295, 672, 315, 132, 31, 46448, 1890, 2, 86, 132, 31, 347, 21, 47, 557, 17, 27031, 16, 2729, 1328, 1065, 4, 1185, 552, 140, 72, 5, 7216, 140, 2, 47, 108, 8, 217, 4371, 1142, 59829, 21, 514, 17, 27031, 16, 570, 4, 46448, 1890, 2462, 2407, 802, 17, 192, 68, 1343, 8, 200, 4, 295, 132, 31, 193, 192, 16, 120, 570, 4, 86, 132, 31, 347, 4, 92, 211, 55, 16, 41, 5, 1119, 258, 156, 4, 552, 21, 514, 17, 64, 148, 1, 27031, 1513, 5, 582, 1, 334, 356, 141, 1266, 525, 7216, 1119, 258, 156, 2, 12921, 55, 1368, 21, 608, 17, 27031, 956, 55, 16, 35, 1503, 980, 1, 63, 25, 4, 1278, 552, 7]",1251.0,21310924,319
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-02-14,"The addition of rituximab to fludarabine-based regimens in chronic lymphocytic leukemia (CLL) has been shown to produce high response rates with extended remissions. The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of genomic risk factors has been limited. We report the long-term follow-up of the chemoimmunotherapy trial CALGB 9712 from the Cancer and Leukemia Group B, for which treatment regimen was previously reported, to examine end points of progression-free survival (PFS), overall survival (OS), impact of genomic features, and risk of therapy-related myeloid neoplasm (t-MN). A total of 104 patients were enrolled on this study and now have a median follow-up of 117 months (range, 66 to 131 months). The median OS was 85 months, and 71% of patients were alive at 5 years. The median PFS was 42 months, and 27% were progression free at 5 years. An estimated 13% remained free of progression at almost 10 years of follow-up. Multivariable models of PFS and OS showed that immunoglobulin heavy chain variable region mutational status was significant for both, whereas cytogenetic abnormalities were significant only for OS. No patient developed t-MN before relapse. Long-term follow-up of CALGB 9712 demonstrates extended OS and PFS with fludarabine plus rituximab. Patients treated with fludarabine plus rituximab administered concurrently or sequentially have a low risk of t-MN. These long-term data support fludarabine plus rituximab as one acceptable first-line treatment for symptomatic patients with CLL.",Journal Article,3263.0,107.0,The addition of rituximab to fludarabine-based regimens in chronic lymphocytic CLL has been shown to produce high response rates with extended remissions The long-term follow-up of these regimens with respect to progression survival risk of secondary and impact of genomic risk factors has been limited We report the long-term follow-up of the chemoimmunotherapy trial CALGB 9712 from the Cancer and Group B for which treatment regimen was previously reported to examine end points of progression-free survival PFS overall survival OS impact of genomic features and risk of therapy-related myeloid neoplasm t-MN A total of 104 patients were enrolled on this study and now have a median follow-up of 117 months range 66 to 131 months The median OS was 85 months and 71 of patients were alive at 5 years The median PFS was 42 months and 27 were progression free at 5 years An estimated 13 remained free of progression at almost 10 years of follow-up Multivariable models of PFS and OS showed that immunoglobulin heavy chain variable region mutational status was significant for both whereas cytogenetic abnormalities were significant only for OS No patient developed t-MN before relapse Long-term follow-up of CALGB 9712 demonstrates extended OS and PFS with fludarabine plus rituximab Patients treated with fludarabine plus rituximab administered concurrently or sequentially have a low risk of t-MN These long-term data support fludarabine plus rituximab as one acceptable first-line treatment for symptomatic patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 352, 1, 855, 6, 2027, 90, 472, 4, 442, 1193, 552, 71, 85, 443, 6, 2410, 64, 51, 151, 5, 1747, 3166, 3, 319, 337, 166, 126, 1, 46, 472, 5, 2184, 6, 91, 25, 43, 1, 568, 2, 345, 1, 572, 43, 130, 71, 85, 383, 21, 414, 3, 319, 337, 166, 126, 1, 3, 4438, 160, 4077, 30595, 29, 3, 12, 2, 87, 132, 9, 92, 24, 477, 10, 373, 210, 6, 1004, 396, 862, 1, 91, 115, 25, 300, 63, 25, 118, 345, 1, 572, 404, 2, 43, 1, 36, 139, 533, 2131, 102, 4691, 8, 181, 1, 3407, 7, 11, 346, 23, 26, 45, 2, 1134, 47, 8, 52, 166, 126, 1, 3843, 53, 184, 700, 6, 2229, 53, 3, 52, 118, 10, 772, 53, 2, 792, 1, 7, 11, 1701, 28, 33, 60, 3, 52, 300, 10, 595, 53, 2, 428, 11, 91, 115, 28, 33, 60, 35, 661, 233, 958, 115, 1, 91, 28, 2214, 79, 60, 1, 166, 126, 658, 274, 1, 300, 2, 118, 224, 17, 2593, 4013, 1260, 1347, 1053, 1619, 156, 10, 93, 9, 110, 547, 1266, 1171, 11, 93, 158, 9, 118, 77, 69, 276, 102, 4691, 348, 429, 319, 337, 166, 126, 1, 4077, 30595, 1902, 1747, 118, 2, 300, 5, 2027, 349, 855, 7, 73, 5, 2027, 349, 855, 468, 3294, 15, 5455, 47, 8, 154, 43, 1, 102, 4691, 46, 319, 337, 74, 538, 2027, 349, 855, 22, 104, 1595, 157, 328, 24, 9, 1704, 7, 5, 552]",1527.0,21321292,495
Chronic lymphocytic leukemia: prognostic factors and impact on treatment.,Discovery medicine,Discov Med,2011-02-01,"Chronic lymphocytic leukemia (CLL) is a clonal malignancy of mature B cells that displays immense clinical heterogeneity as reflected by the observation that many patients have an indolent disease that will not require intervention for many years while others will present with an aggressive and symptomatic leukemia requiring immediate treatment. Although there is no cure for CLL, the disease is treatable and current standard chemotherapy regimens have been shown to prolong survival. There is no obvious survival advantage to early treatment versus observation but the timing as to when a patient will require treatment is highly unpredictable. Thus, there has been great interest in identifying prognostic markers that can be used to distinguish those patients who may have an aggressive form of CLL and might benefit from early intervention. While clinical staging systems have been used to stratify patients into risk categories, they lack the ability to predict disease progression or response to therapy. Recent advances in our understanding of the biology of CLL have led to the identification of numerous cellular and molecular markers with potential prognostic and therapeutic significance. This review provides a concise overview of prognostic markers in CLL and a discussion of how those markers have impacted the clinical management of the disease.",Journal Article,3276.0,33.0,Chronic lymphocytic CLL is a clonal malignancy of mature B cells that displays immense clinical heterogeneity as reflected by the observation that many patients have an indolent disease that will not require intervention for many years while others will present with an aggressive and symptomatic requiring immediate treatment Although there is no cure for CLL the disease is treatable and current standard chemotherapy regimens have been shown to prolong survival There is no obvious survival advantage to early treatment versus observation but the timing as to when a patient will require treatment is highly unpredictable Thus there has been great interest in identifying prognostic markers that can be used to distinguish those patients who may have an aggressive form of CLL and might benefit from early intervention While clinical staging systems have been used to stratify patients into risk categories they lack the ability to predict disease progression or response to therapy Recent advances in our understanding of the biology of CLL have led to the identification of numerous cellular and molecular markers with potential prognostic and therapeutic significance This review provides a concise overview of prognostic markers in CLL and a discussion of how those markers have impacted the clinical management of the disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 1946, 710, 1, 2908, 132, 37, 17, 7196, 17980, 38, 1144, 22, 4686, 20, 3, 1664, 17, 445, 7, 47, 35, 2316, 34, 17, 303, 44, 1353, 788, 9, 445, 60, 369, 1749, 303, 364, 5, 35, 571, 2, 1704, 1888, 2181, 24, 242, 125, 16, 77, 1722, 9, 552, 3, 34, 16, 9437, 2, 291, 260, 56, 472, 47, 85, 443, 6, 3615, 25, 125, 16, 77, 6228, 25, 1874, 6, 191, 24, 185, 1664, 84, 3, 1972, 22, 6, 198, 8, 69, 303, 1353, 24, 16, 561, 8907, 631, 125, 71, 85, 2797, 1333, 4, 1386, 177, 525, 17, 122, 40, 95, 6, 3081, 135, 7, 54, 68, 47, 35, 571, 1297, 1, 552, 2, 822, 247, 29, 191, 788, 369, 38, 632, 1530, 47, 85, 95, 6, 3570, 7, 237, 43, 1996, 491, 926, 3, 801, 6, 678, 34, 91, 15, 51, 6, 36, 435, 954, 4, 114, 612, 1, 3, 891, 1, 552, 47, 836, 6, 3, 911, 1, 2331, 763, 2, 219, 525, 5, 174, 177, 2, 189, 724, 26, 206, 777, 8, 11071, 2901, 1, 177, 525, 4, 552, 2, 8, 2488, 1, 832, 135, 525, 47, 4619, 3, 38, 284, 1, 3, 34]",1333.0,21356166,741
STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.,Molecular cancer research : MCR,Mol. Cancer Res.,2011-03-01,"NF-B plays a major role in the pathogenesis of B-cell neoplasms. A broad array of mostly extracellular stimuli has been reported to activate NF-B, to various degrees, in chronic lymphocytic leukemia (CLL) cells. Because CLL cells harbor high levels of unphosphorylated STAT-3 (USTAT-3) and USTAT-3 was reported to activate NF-B, we sought to determine whether USTAT-3 activates NF-B in CLL. Using the electrophoretic mobility shift assay (EMSA), we studied peripheral blood low-density cells from 15 patients with CLL and found that CLL cell nuclear extracts from all the samples bound to an NF-B DNA probe, suggesting that NF-B is constitutively activated in CLL. Immunoprecipitation studies showed that STAT-3 bound NF-B p65, and confocal microscopy studies detected USTAT-3/NF-B complexes in the nuclei of CLL cells, thereby confirming these findings. Furthermore, infection of CLL cells with retroviral STAT-3-short hairpin RNA attenuated the binding of NF-B to DNA, as assessed by EMSA, and downregulated mRNA levels of NF-B-regulated genes, as assessed by quantitative PCR. Taken together, our data suggest that USTAT-3 binds to the NF-B p50/p65 dimers and that the USTAT-3/NF-B complexes bind to DNA and activate NF-B-regulated genes in CLL cells.",Journal Article,3248.0,46.0,NF-B plays a major role in the pathogenesis of B-cell neoplasms A broad array of mostly extracellular stimuli has been reported to activate NF-B to various degrees in chronic lymphocytic CLL cells Because CLL cells harbor high levels of unphosphorylated STAT-3 USTAT-3 and USTAT-3 was reported to activate NF-B we sought to determine whether USTAT-3 activates NF-B in CLL Using the electrophoretic mobility shift assay EMSA we studied peripheral blood low-density cells from 15 patients with CLL and found that CLL cell nuclear extracts from all the samples bound to an NF-B DNA probe suggesting that NF-B is constitutively activated in CLL Immunoprecipitation studies showed that STAT-3 bound NF-B p65 and confocal microscopy studies detected USTAT-3/NF-B complexes in the nuclei of CLL cells thereby confirming these findings Furthermore infection of CLL cells with retroviral STAT-3-short hairpin RNA attenuated the binding of NF-B to DNA as assessed by EMSA and downregulated mRNA levels of NF-B-regulated genes as assessed by quantitative PCR Taken together our data suggest that USTAT-3 binds to the NF-B p50/p65 dimers and that the USTAT-3/NF-B complexes bind to DNA and activate NF-B-regulated genes in CLL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1365, 2448, 1698, 8, 458, 200, 4, 3, 1384, 1, 132, 31, 1179, 8, 2094, 1926, 1, 2754, 1976, 7478, 71, 85, 210, 6, 2977, 1365, 2448, 6, 747, 4133, 4, 442, 1193, 552, 37, 408, 552, 37, 2760, 64, 148, 1, 27040, 4168, 27, 29125, 27, 2, 29125, 27, 10, 210, 6, 2977, 1365, 2448, 21, 990, 6, 223, 317, 29125, 27, 3932, 1365, 2448, 4, 552, 75, 3, 10980, 5717, 3024, 719, 15941, 21, 656, 672, 315, 154, 1263, 37, 29, 167, 7, 5, 552, 2, 204, 17, 552, 31, 928, 8162, 29, 62, 3, 347, 2951, 6, 35, 1365, 2448, 261, 2888, 802, 17, 1365, 2448, 16, 2818, 735, 4, 552, 4857, 94, 224, 17, 4168, 27, 2951, 1365, 2448, 6781, 2, 6541, 3804, 94, 530, 29125, 27, 1365, 2448, 3817, 4, 3, 4725, 1, 552, 37, 2267, 5030, 46, 272, 798, 930, 1, 552, 37, 5, 8658, 4168, 27, 978, 5957, 893, 2656, 3, 791, 1, 1365, 2448, 6, 261, 22, 275, 20, 15941, 2, 3315, 956, 148, 1, 1365, 2448, 1065, 214, 22, 275, 20, 1156, 604, 1633, 1162, 114, 74, 309, 17, 29125, 27, 3333, 6, 3, 1365, 2448, 16197, 6781, 12608, 2, 17, 3, 29125, 27, 1365, 2448, 3817, 4060, 6, 261, 2, 2977, 1365, 2448, 1065, 214, 4, 552, 37]",1233.0,21364020,439
The role of phosphatidylinositol 3-kinase- in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.,Blood,Blood,2011-03-04,"In patients with chronic lymphocytic leukemia (CLL), lenalidomide can promote humoral immune responses but also induces a distinct disease-specific toxicity of tumor flare and cytokine release. These CLL-specific events result from increased expression of costimulatory molecules on B cells. Here we demonstrate that lenalidomide activation of CLL cells depends on the phosphatidylinositol 3-kinase p110 (PI3K-) pathway. Inhibition of PI3K- signaling by the PI3K--inhibiting drug, CAL-101, or by siRNA knockdown of p110, abrogates CLL cell activation, costimulatory molecule expression, and vascular endothelial growth factor and basic fibroblast growth factor gene expression that is induced by lenalidomide. In addition, CAL-101 attenuates lenalidomide-mediated increases in immunoglobulin M production by normal B cells. Collectively, these data demonstrate the importance of PI3K- signaling for lenalidomide immune modulation. These findings may guide development of strategies for the treatment of CLL that combine lenalidomide with CAL-101, with other inhibitors of the PI3K- pathway, or with other agents that target downstream kinases of this signaling pathway.",Journal Article,3245.0,77.0,In patients with chronic lymphocytic CLL lenalidomide can promote humoral immune responses but also induces a distinct disease-specific toxicity of tumor flare and cytokine release These CLL-specific events result from increased expression of costimulatory molecules on B cells Here we demonstrate that lenalidomide activation of CLL cells depends on the phosphatidylinositol 3-kinase p110 PI3K- pathway Inhibition of PI3K- signaling by the PI3K--inhibiting drug CAL-101 or by siRNA knockdown of p110 abrogates CLL cell activation costimulatory molecule expression and vascular endothelial growth factor and basic fibroblast growth factor gene expression that is induced by lenalidomide In addition CAL-101 attenuates lenalidomide-mediated increases in immunoglobulin M production by normal B cells Collectively these data demonstrate the importance of PI3K- signaling for lenalidomide immune modulation These findings may guide development of strategies for the treatment of CLL that combine lenalidomide with CAL-101 with other inhibitors of the PI3K- pathway or with other agents that target downstream kinases of this signaling pathway,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 7, 5, 442, 1193, 552, 1288, 122, 1617, 5498, 250, 253, 84, 120, 1516, 8, 834, 34, 112, 155, 1, 30, 6915, 2, 1675, 2008, 46, 552, 112, 281, 757, 29, 101, 55, 1, 5555, 1598, 23, 132, 37, 467, 21, 608, 17, 1288, 363, 1, 552, 37, 3828, 23, 3, 3415, 27, 216, 15762, 974, 7339, 308, 297, 1, 974, 7339, 314, 20, 3, 974, 7339, 2062, 234, 10368, 2338, 15, 20, 1919, 1563, 1, 15762, 8044, 552, 31, 363, 5555, 1354, 55, 2, 756, 845, 129, 161, 2, 2795, 3758, 129, 161, 145, 55, 17, 16, 277, 20, 1288, 4, 352, 10368, 2338, 9100, 1288, 517, 1106, 4, 2593, 188, 1529, 20, 295, 132, 37, 2535, 46, 74, 608, 3, 1187, 1, 974, 7339, 314, 9, 1288, 250, 2356, 46, 272, 68, 1597, 193, 1, 422, 9, 3, 24, 1, 552, 17, 4680, 1288, 5, 10368, 2338, 5, 127, 222, 1, 3, 974, 7339, 308, 15, 5, 127, 183, 17, 283, 1489, 1549, 1, 26, 314, 308]",1146.0,21378270,41
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2011-03-14,"Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. Patients were eligible for this phase II trial if they had documented CLL/SLL and had failed at least 1 prior therapy with a fludarabine-containing regimen and if they required therapy according to NCI-WG criteria. The starting dose of dasatinib was 140 mg daily. Fifteen patients were enrolled, with a median age of 59 and a median of 3 prior regimens. All patients had received fludarabine, and 5 were fludarabine-refractory. Eleven of the 15 (73%) had high risk del(11q) or del(17p) cytogenetics. The primary toxicity was myelosuppression, with grade 3 or 4 neutropenia and thrombocytopenia in 10 and 6 patients, respectively. Partial responses by NCI-WG criteria were achieved in 3 of the 15 patients (20%; 90% CI: 6-44). Among the remaining 12 patients, 5 had nodal responses by physical exam, and 1 patient had a nodal and lymphocyte response but with severe myelosuppression. Pharmacodynamic studies indicated apoptosis in peripheral blood CLL cells within 3 to 6 hours after dasatinib administration, associated with downregulation of Syk (spleen tyrosine kinase) mRNA. Dasatinib as a single agent has activity in relapsed and refractory CLL.","Clinical Trial, Phase II",3235.0,93.0,Chronic lymphocytic CLL cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase Thus in this study we tested the activity of dasatinib in patients with relapsed CLL Patients were eligible for this phase II trial if they had documented CLL/SLL and had failed at least 1 prior therapy with a fludarabine-containing regimen and if they required therapy according to NCI-WG criteria The starting dose of dasatinib was 140 mg daily Fifteen patients were enrolled with a median age of 59 and a median of 3 prior regimens All patients had received fludarabine and 5 were fludarabine-refractory Eleven of the 15 73 had high risk del 11q or del 17p cytogenetics The primary toxicity was myelosuppression with grade 3 or 4 neutropenia and thrombocytopenia in 10 and 6 patients respectively Partial responses by NCI-WG criteria were achieved in 3 of the 15 patients 20 90 CI 6-44 Among the remaining 12 patients 5 had nodal responses by physical exam and 1 patient had a nodal and lymphocyte response but with severe myelosuppression Pharmacodynamic studies indicated apoptosis in peripheral blood CLL cells within 3 to 6 hours after dasatinib administration associated with downregulation of Syk spleen tyrosine kinase mRNA Dasatinib as a single agent has activity in relapsed and refractory CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 37, 73, 5, 1674, 4, 439, 1251, 351, 847, 297, 1, 8309, 216, 631, 4, 26, 45, 21, 650, 3, 128, 1, 1674, 4, 7, 5, 591, 552, 7, 11, 625, 9, 26, 124, 215, 160, 492, 491, 42, 1405, 552, 5302, 2, 42, 1551, 28, 506, 14, 324, 36, 5, 8, 2027, 1101, 477, 2, 492, 491, 616, 36, 768, 6, 2580, 12906, 371, 3, 1723, 61, 1, 1674, 10, 3304, 81, 391, 3057, 7, 11, 346, 5, 8, 52, 89, 1, 728, 2, 8, 52, 1, 27, 324, 472, 62, 7, 42, 103, 2027, 2, 33, 11, 2027, 430, 2627, 1, 3, 167, 803, 42, 64, 43, 3084, 7203, 15, 3084, 4135, 2510, 3, 86, 155, 10, 2858, 5, 88, 27, 15, 39, 778, 2, 1340, 4, 79, 2, 49, 7, 106, 450, 253, 20, 2580, 12906, 371, 11, 513, 4, 27, 1, 3, 167, 7, 179, 424, 58, 49, 584, 107, 3, 1844, 133, 7, 33, 42, 779, 253, 20, 900, 6747, 2, 14, 69, 42, 8, 779, 2, 1448, 51, 84, 5, 905, 2858, 2424, 94, 1103, 351, 4, 672, 315, 552, 37, 262, 27, 6, 49, 1459, 50, 1674, 634, 41, 5, 2475, 1, 6792, 4071, 564, 216, 956, 1674, 22, 8, 226, 420, 71, 128, 4, 591, 2, 430, 552]",1314.0,21402714,171
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.,PloS one,PLoS ONE,2011-03-08,"Chronic lymphocytic leukemia (CLL) is thought to be a disease of resting lymphocytes. However, recent data suggest that CLL cells may more closely resemble activated B cells. Using microRNA (miRNA) expression profiling of highly-enriched CLL cells from 38 patients and 9 untransformed B cells from normal donors before acute CpG activation and 5 matched B cells after acute CpG activation, we demonstrate an activated B cell status for CLL. Gene set enrichment analysis (GSEA) identified statistically-significant similarities in miRNA expression between activated B cells and CLL cells including upregulation of miR-34a, miR-155, and miR-342-3p and downregulation of miR-103, miR-181a and miR-181b. Additionally, decreased levels of two CLL signature miRNAs miR-29c and miR-223 are associated with ZAP70(+) and IgV(H) unmutated status and with shorter time to first therapy. These data indicate an activated B cell status for CLL cells and suggest that the direction of change of individual miRNAs may predict clinical course in CLL.",Journal Article,3241.0,57.0,Chronic lymphocytic CLL is thought to be a disease of resting lymphocytes However recent data suggest that CLL cells may more closely resemble activated B cells Using microRNA miRNA expression profiling of highly-enriched CLL cells from 38 patients and 9 untransformed B cells from normal donors before acute CpG activation and 5 matched B cells after acute CpG activation we demonstrate an activated B cell status for CLL Gene set enrichment analysis GSEA identified statistically-significant similarities in miRNA expression between activated B cells and CLL cells including upregulation of miR-34a miR-155 and miR-342-3p and downregulation of miR-103 miR-181a and miR-181b Additionally decreased levels of two CLL signature miRNAs miR-29c and miR-223 are associated with ZAP70 and IgV H unmutated status and with shorter time to first therapy These data indicate an activated B cell status for CLL cells and suggest that the direction of change of individual miRNAs may predict clinical course in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 2739, 6, 40, 8, 34, 1, 11620, 1594, 137, 435, 74, 309, 17, 552, 37, 68, 80, 3210, 8247, 735, 132, 37, 75, 3213, 2053, 55, 1080, 1, 561, 2220, 552, 37, 29, 519, 7, 2, 83, 31195, 132, 37, 29, 295, 2344, 348, 286, 2075, 363, 2, 33, 655, 132, 37, 50, 286, 2075, 363, 21, 608, 35, 735, 132, 31, 156, 9, 552, 145, 916, 3020, 65, 16461, 108, 712, 93, 6089, 4, 2053, 55, 59, 735, 132, 37, 2, 552, 37, 141, 2218, 1, 722, 6881, 722, 3735, 2, 722, 8906, 4302, 2, 2475, 1, 722, 3283, 722, 14652, 2, 722, 22541, 1724, 340, 148, 1, 100, 552, 1651, 2028, 722, 14352, 2, 722, 3907, 32, 41, 5, 12921, 2, 12179, 555, 7216, 156, 2, 5, 985, 98, 6, 157, 36, 46, 74, 1008, 35, 735, 132, 31, 156, 9, 552, 37, 2, 309, 17, 3, 4651, 1, 707, 1, 797, 2028, 68, 678, 38, 906, 4, 552]",1003.0,21408091,27
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.,Blood,Blood,2011-03-21,"B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse models its mutation has a relatively B cell-specific phenotype. Herein, we demonstrate that BTK protein and mRNA are significantly over expressed in CLL compared with normal B cells. Although BTK is not always constitutively active in CLL cells, BCR or CD40 signaling is accompanied by effective activation of this pathway. Using the irreversible BTK inhibitor PCI-32765, we demonstrate modest apoptosis in CLL cells that is greater than that observed in normal B cells. No influence of PCI-32765 on T-cell survival is observed. Treatment of CD40 or BCR activated CLL cells with PCI-32765 results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-B. In addition, PCI-32765 inhibits activation-induced proliferation of CLL cells in vitro, and effectively blocks survival signals provided externally to CLL cells from the microenvironment including soluble factors (CD40L, BAFF, IL-6, IL-4, and TNF-), fibronectin engagement, and stromal cell contact. Based on these collective data, future efforts targeting BTK with the irreversible inhibitor PCI-32765 in clinical trials of CLL patients is warranted.",Journal Article,3228.0,483.0,B-cell receptor BCR signaling is aberrantly activated in chronic lymphocytic CLL Bruton tyrosine kinase BTK is essential to BCR signaling and in knockout mouse models its mutation has a relatively B cell-specific phenotype Herein we demonstrate that BTK protein and mRNA are significantly over expressed in CLL compared with normal B cells Although BTK is not always constitutively active in CLL cells BCR or CD40 signaling is accompanied by effective activation of this pathway Using the irreversible BTK inhibitor PCI-32765 we demonstrate modest apoptosis in CLL cells that is greater than that observed in normal B cells No influence of PCI-32765 on T-cell survival is observed Treatment of CD40 or BCR activated CLL cells with PCI-32765 results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2 PI3K and NF-B In addition PCI-32765 inhibits activation-induced proliferation of CLL cells in vitro and effectively blocks survival signals provided externally to CLL cells from the microenvironment including soluble factors CD40L BAFF IL-6 IL-4 and TNF- fibronectin engagement and stromal cell contact Based on these collective data future efforts targeting BTK with the irreversible inhibitor PCI-32765 in clinical trials of CLL patients is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[132, 31, 153, 1062, 314, 16, 5619, 735, 4, 442, 1193, 552, 5796, 564, 216, 3611, 16, 1452, 6, 1062, 314, 2, 4, 5687, 830, 274, 211, 258, 71, 8, 1352, 132, 31, 112, 1005, 1986, 21, 608, 17, 3611, 178, 2, 956, 32, 97, 252, 570, 4, 552, 72, 5, 295, 132, 37, 242, 3611, 16, 44, 3763, 2818, 544, 4, 552, 37, 1062, 15, 5040, 314, 16, 2756, 20, 323, 363, 1, 26, 308, 75, 3, 4422, 3611, 230, 3943, 12229, 21, 608, 1721, 351, 4, 552, 37, 17, 16, 378, 76, 17, 164, 4, 295, 132, 37, 77, 1054, 1, 3943, 12229, 23, 102, 31, 25, 16, 164, 24, 1, 5040, 15, 1062, 735, 552, 37, 5, 3943, 12229, 99, 4, 297, 1, 3611, 564, 982, 2, 120, 1856, 8044, 1489, 25, 460, 735, 20, 26, 216, 141, 3533, 18, 974, 2, 1365, 2448, 4, 352, 3943, 12229, 1576, 363, 277, 457, 1, 552, 37, 4, 439, 2, 1856, 2860, 25, 2312, 1052, 7753, 6, 552, 37, 29, 3, 995, 141, 2968, 130, 8285, 6587, 501, 49, 501, 39, 2, 2254, 2014, 8629, 5103, 2, 1126, 31, 4393, 90, 23, 46, 9549, 74, 508, 1413, 529, 3611, 5, 3, 4422, 230, 3943, 12229, 4, 38, 143, 1, 552, 7, 16, 1197]",1351.0,21422473,793
Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.,Cancer,Cancer,2010-11-08,"Little is known about the patterns of care relating to the diagnosis of chronic lymphocytic leukemia (CLL), including the use of modern diagnostic techniques such as flow cytometry. The authors used the SEER-Medicare database to identify subjects diagnosed with CLL from 1992 to 2002 and defined diagnostic delay as present when the number of days between the first claim for a CLL-associated sign or symptom and SEER diagnosis date met or exceeded the median for the sample. The authors then used logistic regression to estimate the likelihood of delay and Cox regression to examine survival. For the 5086 patients analyzed, the median time between sign or symptom and CLL diagnosis was 63 days (interquartile range [IQR] = 0-251). Predictors of delay included age 75 (OR 1.45 [1.27-1.65]), female gender (OR 1.22 [1.07-1.39]), urban residence (OR 1.46 [1.19 to 1.79]), 1 comorbidities (OR 2.83 [2.45-3.28]) and care in a teaching hospital (OR 1.20 [1.05-1.38]). Delayed diagnosis was not associated with survival (HR 1.11 [0.99-1.25]), but receipt of flow cytometry within thirty days before or after diagnosis was (HR 0.84 [0.76-0.91]). Sociodemographic characteristics affect diagnostic delay for CLL, although delay does not seem to impact mortality. In contrast, receipt of flow cytometry near the time of diagnosis is associated with improved survival.",Journal Article,3361.0,16.0,Little is known about the patterns of care relating to the diagnosis of chronic lymphocytic CLL including the use of modern diagnostic techniques such as flow cytometry The authors used the SEER-Medicare database to identify subjects diagnosed with CLL from 1992 to 2002 and defined diagnostic delay as present when the number of days between the first claim for a CLL-associated sign or symptom and SEER diagnosis date met or exceeded the median for the sample The authors then used logistic regression to estimate the likelihood of delay and Cox regression to examine survival For the 5086 patients analyzed the median time between sign or symptom and CLL diagnosis was 63 days interquartile range IQR 0-251 Predictors of delay included age 75 OR 1.45 1.27-1.65 female gender OR 1.22 1.07-1.39 urban residence OR 1.46 1.19 to 1.79 1 comorbidities OR 2.83 2.45-3.28 and care in a teaching hospital OR 1.20 1.05-1.38 Delayed diagnosis was not associated with survival HR 1.11 0.99-1.25 but receipt of flow cytometry within thirty days before or after diagnosis was HR 0.84 0.76-0.91 Sociodemographic characteristics affect diagnostic delay for CLL although delay does not seem to impact mortality In contrast receipt of flow cytometry near the time of diagnosis is associated with improved survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 16, 440, 545, 3, 764, 1, 165, 7750, 6, 3, 147, 1, 442, 1193, 552, 141, 3, 119, 1, 2366, 752, 1092, 225, 22, 1412, 1914, 3, 738, 95, 3, 1605, 1378, 609, 6, 255, 976, 265, 5, 552, 29, 2846, 6, 1544, 2, 395, 752, 1984, 22, 364, 198, 3, 207, 1, 162, 59, 3, 157, 10429, 9, 8, 552, 41, 7636, 15, 934, 2, 1605, 147, 1244, 543, 15, 4726, 3, 52, 9, 3, 1000, 3, 738, 818, 95, 812, 320, 6, 1191, 3, 1420, 1, 1984, 2, 418, 320, 6, 1004, 25, 9, 3, 59950, 7, 311, 3, 52, 98, 59, 7636, 15, 934, 2, 552, 147, 10, 676, 162, 2899, 184, 2245, 13, 7288, 674, 1, 1984, 159, 89, 8999, 15, 14, 512, 14, 428, 14, 556, 1061, 1632, 15, 14, 350, 14, 1615, 14, 587, 5532, 5562, 15, 14, 641, 14, 326, 6, 14, 842, 3567, 1909, 15, 18, 852, 18, 512, 27, 339, 2, 165, 4, 8, 6292, 702, 15, 14, 179, 14, 474, 14, 519, 1612, 147, 10, 44, 41, 5, 25, 168, 14, 175, 13, 1058, 14, 243, 84, 1699, 1, 1412, 1914, 262, 977, 162, 348, 15, 50, 147, 10, 168, 13, 874, 13, 846, 13, 970, 4221, 374, 1158, 752, 1984, 9, 552, 242, 1984, 1097, 44, 3233, 6, 345, 282, 4, 748, 1699, 1, 1412, 1914, 1829, 3, 98, 1, 147, 16, 41, 5, 231, 25]",1300.0,21425148,81
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2011-03-22,"Clinical trials using vaccine measles virus (MV) as anticancer therapy are already underway. We compared the oncolytic potential of MV in two B-cell malignancies; adult acute lymphoblastic leukemia (ALL, an aggressive leukemia) and chronic lymphocytic leukemia (CLL, an indolent leukemia overexpressing Bcl-2) using patient-derived material. In vitro, distinct cytopathological effects were observed between MV-infected primary ALL and CLL cells, with large multinucleated syncytia forming in ALL cultures compared to minimal cell-to-cell fusion in infected CLL cells. Cell viability and immunoblotting studies confirmed rapid cell death in MV-infected ALL cultures and slower MV oncolysis of CLL cells. In cell lines, overexpression of Bcl-2 diminished MV-induced cell death providing a possible mechanism for the slower kinetic of MV oncolysis in CLL. In vivo, intratumoral MV treatment of established subcutaneous ALL xenografts had striking antitumor activity leading to complete resolution of all tumors. The antitumor activity of MV was also evident in disseminated ALL xenograft models. In summary, both ALL and CLL are targets for MV-mediated lysis albeit with different kinetics. The marked sensitivity of both primary ALL cells and ALL xenografts to MV oncolysis highlights the tremendous potential of MV as a novel replicating-virus therapy for adult ALL.",Journal Article,3227.0,,Clinical trials using vaccine measles virus MV as anticancer therapy are already underway We compared the oncolytic potential of MV in two B-cell malignancies adult acute lymphoblastic ALL an aggressive and chronic lymphocytic CLL an indolent overexpressing Bcl-2 using patient-derived material In vitro distinct cytopathological effects were observed between MV-infected primary ALL and CLL cells with large multinucleated syncytia forming in ALL cultures compared to minimal cell-to-cell fusion in infected CLL cells Cell viability and immunoblotting studies confirmed rapid cell death in MV-infected ALL cultures and slower MV oncolysis of CLL cells In cell lines overexpression of Bcl-2 diminished MV-induced cell death providing a possible mechanism for the slower kinetic of MV oncolysis in CLL In vivo intratumoral MV treatment of established subcutaneous ALL xenografts had striking antitumor activity leading to complete resolution of all tumors The antitumor activity of MV was also evident in disseminated ALL xenograft models In summary both ALL and CLL are targets for MV-mediated lysis albeit with different kinetics The marked sensitivity of both primary ALL cells and ALL xenografts to MV oncolysis highlights the tremendous potential of MV as a novel replicating-virus therapy for adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[38, 143, 75, 1274, 7424, 1450, 3491, 22, 1475, 36, 32, 3298, 3948, 21, 72, 3, 3236, 174, 1, 3491, 4, 100, 132, 31, 441, 780, 286, 1275, 62, 35, 571, 2, 442, 1193, 552, 35, 2316, 2810, 1044, 18, 75, 69, 526, 3692, 4, 439, 834, 43365, 176, 11, 164, 59, 3491, 3369, 86, 62, 2, 552, 37, 5, 375, 15649, 22231, 4525, 4, 62, 3231, 72, 6, 1048, 31, 6, 31, 1212, 4, 3369, 552, 37, 31, 2120, 2, 5293, 94, 557, 1321, 31, 273, 4, 3491, 3369, 62, 3231, 2, 6715, 3491, 9739, 1, 552, 37, 4, 31, 285, 851, 1, 1044, 18, 2849, 3491, 277, 31, 273, 1736, 8, 899, 670, 9, 3, 6715, 7009, 1, 3491, 9739, 4, 552, 4, 386, 2074, 3491, 24, 1, 635, 2529, 62, 1348, 42, 5133, 579, 128, 1049, 6, 236, 2125, 1, 62, 57, 3, 579, 128, 1, 3491, 10, 120, 2853, 4, 3605, 62, 1330, 274, 4, 1962, 110, 62, 2, 552, 32, 637, 9, 3491, 517, 4783, 5993, 5, 338, 3839, 3, 2003, 485, 1, 110, 86, 62, 37, 2, 62, 1348, 6, 3491, 9739, 2527, 3, 6678, 174, 1, 3491, 22, 8, 229, 13012, 1450, 36, 9, 780, 62]",1307.0,21427708,790
IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrm's macroglobulinemia (SWM).,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-02-01,"Monoclonal gammopathy of undetermined significance of IgM class (IgM MGUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in Southeastern Minnesota from 1960 to 1994. During long-term follow-up 29 (14%) developed non-Hodgkin lymphoma (n=17), Waldenstrm's macroglobulinemia (n=6), chronic lymphocytic leukemia (n=3), and AL amyloidosis (n=3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year.Forty-eight patients with SWM were identified at Mayo Clinic from 1974 to 1995. During 285 cumulative person-years of follow-up (median, 15.4 years) 34 (71%) progressed to Waldenstrm's macroglobulinemia (WM), 1 to AL amyloidosis, and 1 to lymphoma (total, 36 [75%]). The cumulative probability of progressing to WM, amyloidosis, or lymphoma was 6% at 1 year, 39% at 3 years, and 59% at 5 years (12% per year).",Journal Article,3276.0,23.0,Monoclonal gammopathy of undetermined significance of IgM class IgM MGUS was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in Southeastern Minnesota from 1960 to 1994 During long-term follow-up 29 14 developed n=17 Waldenstrm 's macroglobulinemia n=6 chronic lymphocytic n=3 and AL amyloidosis n=3 with relative risks of 15- 262- 6- and 16-fold respectively The cumulative probability of progression to one of these disorders was 10 at 5 years 18 at 10 years and 24 at 15 years approximately 1.5 per year.Forty-eight patients with SWM were identified at Mayo Clinic from 1974 to 1995 During 285 cumulative person-years of follow-up median 15.4 years 34 71 progressed to Waldenstrm 's macroglobulinemia WM 1 to AL amyloidosis and 1 to total 36 75 The cumulative probability of progressing to WM amyloidosis or was 6 at 1 year 39 at 3 years and 59 at 5 years 12 per year,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 5334, 1, 5206, 724, 1, 2852, 1040, 2852, 3226, 10, 265, 4, 5833, 2486, 1188, 7, 54, 11, 5662, 1, 175, 8257, 4, 20167, 8297, 29, 10391, 6, 3023, 190, 319, 337, 166, 126, 462, 213, 276, 78, 269, 3700, 292, 3389, 78, 49, 442, 1193, 78, 27, 2, 2171, 3919, 78, 27, 5, 580, 1098, 1, 167, 7801, 49, 2, 245, 1116, 106, 3, 967, 1320, 1, 91, 6, 104, 1, 46, 1997, 10, 79, 28, 33, 60, 203, 28, 79, 60, 2, 259, 28, 167, 60, 705, 14, 33, 379, 111, 1213, 659, 7, 5, 25340, 11, 108, 28, 2486, 1188, 29, 10201, 6, 2323, 190, 8121, 967, 2719, 60, 1, 166, 126, 52, 167, 39, 60, 562, 792, 1839, 6, 3700, 292, 3389, 1518, 14, 6, 2171, 3919, 2, 14, 6, 181, 511, 481, 3, 967, 1320, 1, 4527, 6, 1518, 3919, 15, 10, 49, 28, 14, 111, 587, 28, 27, 60, 2, 728, 28, 33, 60, 133, 379, 111]",896.0,21454195,43
"Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.",Cancer,Cancer,2011-03-31,"The role of nonmyeloablative allogeneic stem cell transplantation (NST) in the treatment of chronic lymphocytic leukemia (CLL) is not well established. The authors report on long-term experience with NST in relapsed/refractory CLL and define prognostic factors associated with outcome. The authors reviewed the outcome of 86 patients with relapsed/relapsed CLL enrolled in sequential NST protocols. The median patient age was 58 years. Patients were heavily pretreated before transplantation, and 43 required immunomanipulation after NST for persistent or recurrent disease. Immunomanipulation included withdrawal of immunosuppression, rituximab, and step-wise donor lymphocyte infusions. Of 43 patients receiving immunomanipulation, 20 (47%) experienced a complete remission. Patients with human leukocyte antigen (HLA) genotype A1(+) /A2(-) /B44(-) were more likely to experience a complete remission (P = .0009), with rates of 9%, 36%, 50%, and 91%, respectively, for 0, 1, 2, and 3 of these HLA factors. This resulted in significant improvement in progression-free-survival rates of 68.2% at 5 years for patients with all 3 HLA factors. Overall, the estimated 5-year survival rate was 51%. In a multivariate model, a CD4 count of <100/mm(3) and a below normal serum immunoglobulin G level at study entry were associated with a short survival duration (P < .0001). These results confirm the potential cure of relapsed/refractory CLL with NST and provide the first evidence that immunoglobulin G and CD4 levels are predictive of overall survival after NST in CLL and that human leukocyte antigen alleles predict response to immunomanipulation.",Journal Article,3218.0,77.0,The role of nonmyeloablative allogeneic stem cell transplantation NST in the treatment of chronic lymphocytic CLL is not well established The authors report on long-term experience with NST in relapsed/refractory CLL and define prognostic factors associated with outcome The authors reviewed the outcome of 86 patients with relapsed/relapsed CLL enrolled in sequential NST protocols The median patient age was 58 years Patients were heavily pretreated before transplantation and 43 required immunomanipulation after NST for persistent or recurrent disease Immunomanipulation included withdrawal of immunosuppression rituximab and step-wise donor lymphocyte infusions Of 43 patients receiving immunomanipulation 20 47 experienced a complete remission Patients with human leukocyte antigen HLA genotype A1 /A2 /B44 were more likely to experience a complete remission P .0009 with rates of 9 36 50 and 91 respectively for 0 1 2 and 3 of these HLA factors This resulted in significant improvement in progression-free-survival rates of 68.2 at 5 years for patients with all 3 HLA factors Overall the estimated 5-year survival rate was 51 In a multivariate model a CD4 count of 100/mm 3 and a below normal serum immunoglobulin G level at study entry were associated with a short survival duration P .0001 These results confirm the potential cure of relapsed/refractory CLL with NST and provide the first evidence that immunoglobulin G and CD4 levels are predictive of overall survival after NST in CLL and that human leukocyte antigen alleles predict response to immunomanipulation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 200, 1, 6094, 1063, 452, 31, 497, 5976, 4, 3, 24, 1, 442, 1193, 552, 16, 44, 149, 635, 3, 738, 414, 23, 319, 337, 730, 5, 5976, 4, 591, 430, 552, 2, 1107, 177, 130, 41, 5, 228, 3, 738, 446, 3, 228, 1, 868, 7, 5, 591, 591, 552, 346, 4, 1787, 5976, 2189, 3, 52, 69, 89, 10, 717, 60, 7, 11, 2447, 2193, 348, 497, 2, 601, 616, 28175, 50, 5976, 9, 1882, 15, 387, 34, 28175, 159, 3683, 1, 3646, 855, 2, 2458, 11663, 1488, 1448, 3435, 1, 601, 7, 357, 28175, 179, 662, 592, 8, 236, 734, 7, 5, 171, 3627, 448, 1160, 1183, 6044, 4099, 24441, 11, 80, 322, 6, 730, 8, 236, 734, 19, 7946, 5, 151, 1, 83, 511, 212, 2, 970, 106, 9, 13, 14, 18, 2, 27, 1, 46, 1160, 130, 26, 627, 4, 93, 767, 4, 91, 115, 25, 151, 1, 806, 18, 28, 33, 60, 9, 7, 5, 62, 27, 1160, 130, 63, 3, 661, 33, 111, 25, 116, 10, 725, 4, 8, 331, 202, 8, 1440, 1276, 1, 394, 321, 27, 2, 8, 2736, 295, 524, 2593, 499, 301, 28, 45, 3001, 11, 41, 5, 8, 978, 25, 654, 19, 488, 46, 99, 1843, 3, 174, 1722, 1, 591, 430, 552, 5, 5976, 2, 377, 3, 157, 241, 17, 2593, 499, 2, 1440, 148, 32, 464, 1, 63, 25, 50, 5976, 4, 552, 2, 17, 171, 3627, 448, 2558, 678, 51, 6, 28175]",1575.0,21455998,590
Salvage therapy for relapsed chronic lymphocytic leukemia.,Expert review of hematology,Expert Rev Hematol,2011-04-01,"Chronic lymphocytic leukemia is a common hematologic malignancy with a highly variable clinical course. While the median age at diagnosis is 72 years of age and fewer than 10% of patients are diagnosed before the age of 60 years, the majority of patients who require therapy will ultimately relapse. Advances in upfront therapy and supportive care have dramatically improved initial responses compared with traditional akylator-based chemotherapy. However, comparable results are not generally observed in the salvage setting. Careful planning that takes into account the duration of the initial response, patient age and/or comorbidities, and cytogenetic and molecular profiles are critical for the successful management of patients with relapsed chronic lymphocytic leukemia.",Journal Article,3217.0,0.0,Chronic lymphocytic is a common hematologic malignancy with a highly variable clinical course While the median age at diagnosis is 72 years of age and fewer than 10 of patients are diagnosed before the age of 60 years the majority of patients who require therapy will ultimately relapse Advances in upfront therapy and supportive care have dramatically improved initial responses compared with traditional akylator-based chemotherapy However comparable results are not generally observed in the salvage setting Careful planning that takes into account the duration of the initial response patient age and/or comorbidities and cytogenetic and molecular profiles are critical for the successful management of patients with relapsed chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 16, 8, 186, 813, 710, 5, 8, 561, 1347, 38, 906, 369, 3, 52, 89, 28, 147, 16, 720, 60, 1, 89, 2, 1497, 76, 79, 1, 7, 32, 265, 348, 3, 89, 1, 335, 60, 3, 686, 1, 7, 54, 1353, 36, 303, 2050, 429, 954, 4, 2941, 36, 2, 1877, 165, 47, 2729, 231, 388, 253, 72, 5, 1847, 60027, 90, 56, 137, 1279, 99, 32, 44, 1228, 164, 4, 3, 992, 546, 3465, 1349, 17, 8512, 237, 1967, 3, 654, 1, 3, 388, 51, 69, 89, 2, 15, 1909, 2, 1266, 2, 219, 1241, 32, 740, 9, 3, 1401, 284, 1, 7, 5, 591, 442, 1193]",749.0,21495929,363
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.,Blood,Blood,2011-04-15,"We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m(2) and cyclophosphamide 250 mg/m(2) days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had 2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete response (CR) rate as assessed by an independent review committee was 32% for the 500-mg and 50% for the 1000-mg cohort; the overall response (OR) rate was 77% and 73%, respectively. Based on univariable regression analyses, 2-microglobulin and the number of O-FC courses were significantly correlated (P < .05) with CR and OR rates and progression-free survival (PFS). The most frequent Common Terminology Criteria (CTC) grade 3-4 investigator-reported adverse events were neutropenia (48%), thrombocytopenia (15%), anemia (13%), and infection (8%). O-FC is active and safe in treatment-naive patients with CLL, including high-risk patients. This trial was registered at www.clinicaltrials.gov as NCT00410163.","Clinical Trial, Phase II",3203.0,99.0,We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab a human CD20 mAb combined with fludarabine and cyclophosphamide O-FC as frontline therapy for chronic lymphocytic CLL Patients with active CLL were randomized to ofatumumab 500 mg n 31 or 1000 mg n 30 day 1 with fludarabine 25 mg/m 2 and cyclophosphamide 250 mg/m 2 days 2-4 course 1 days 1-3 courses 2-6 every 4 weeks for 6 courses The first ofatumumab dose was 300 mg for both cohorts The median age was 56 years 13 of patients had a 17p deletion 64 had 2-microglobulin 3.5 mg/L Based on the 1996 National Cancer Institute Working Group NCI-WG guidelines the complete response CR rate as assessed by an independent review committee was 32 for the 500-mg and 50 for the 1000-mg cohort the overall response OR rate was 77 and 73 respectively Based on univariable regression analyses 2-microglobulin and the number of O-FC courses were significantly correlated P .05 with CR and OR rates and progression-free survival PFS The most frequent Common Terminology Criteria CTC grade 3-4 investigator-reported adverse events were neutropenia 48 thrombocytopenia 15 anemia 13 and infection 8 O-FC is active and safe in treatment-naive patients with CLL including high-risk patients This trial was registered at www.clinicaltrials.gov as NCT00410163,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 426, 35, 944, 124, 18, 160, 6, 376, 18, 61, 148, 1, 5732, 8, 171, 2198, 2780, 397, 5, 2027, 2, 1112, 1990, 4127, 22, 3171, 36, 9, 442, 1193, 552, 7, 5, 544, 552, 11, 384, 6, 5732, 1666, 81, 78, 456, 15, 2345, 81, 78, 201, 218, 14, 5, 2027, 243, 81, 188, 18, 2, 1112, 2039, 81, 188, 18, 162, 18, 39, 906, 14, 162, 14, 27, 1993, 18, 49, 454, 39, 244, 9, 49, 1993, 3, 157, 5732, 61, 10, 2036, 81, 9, 110, 736, 3, 52, 89, 10, 664, 60, 233, 1, 7, 42, 8, 4135, 1528, 660, 42, 9314, 5371, 27, 33, 81, 805, 90, 23, 3, 2648, 657, 12, 1377, 2644, 87, 2580, 12906, 677, 3, 236, 51, 684, 116, 22, 275, 20, 35, 306, 206, 2002, 10, 531, 9, 3, 1666, 81, 2, 212, 9, 3, 2345, 81, 180, 3, 63, 51, 15, 116, 10, 849, 2, 803, 106, 90, 23, 4084, 320, 318, 9314, 5371, 2, 3, 207, 1, 1990, 4127, 1993, 11, 97, 438, 19, 474, 5, 684, 2, 15, 151, 2, 91, 115, 25, 300, 3, 96, 908, 186, 3462, 371, 1775, 88, 27, 39, 3464, 210, 290, 281, 11, 778, 576, 1340, 167, 1545, 233, 2, 930, 66, 1990, 4127, 16, 544, 2, 1165, 4, 24, 2462, 7, 5, 552, 141, 64, 43, 7, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 46538]",1326.0,21498674,134
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.,Cancer,Cancer,2010-11-29,"In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown. Forty-five patients with CLL who were treated with lenalidomide in a phase 2 clinical trial were evaluated for the clinical features, intensity, and duration of TFR. Correlation was made with tumor response and the immune cellular microenvironment. Steroids for the prophylaxis of TFR was not given to patients in Group A (n = 29) whereas patients in Group B (n = 16) received low-dose prednisone as well as a slow dose escalation of lenalidomide for the prevention of TFR. Thirty (67%) patients experienced a TFR, with a grade 2 or 3 reaction (according to National Cancer Institute Common Toxicity Criteria [version 3.0]) observed in 33% of patients (47% in Group A and 9% in Group B; P = .05). The median time to onset of the TFR was 6 days, and was longer in the patients receiving prophylaxis (4 days vs 9 days, respectively; P = .01). A complete response was observed in 7 of 30 (23%) patients with TFR and 1 of 15 (7%) patients without TFR. The median progression-free survival was 19.9 months and 19.4 months, respectively, for patients with versus those without TFR (P = .92). TFR is a unique immune-mediated phenomenon noted with lenalidomide treatment only in patients with CLL that correlates with clinical response. It can be effectively managed with anti-inflammatory agents.","Clinical Trial, Phase II",3340.0,62.0,In patients with chronic lymphocytic CLL treatment with lenalidomide induces a unique previously uncharacterized immune response called tumor flare reaction TFR The clinical significance of this reaction remains unknown Forty-five patients with CLL who were treated with lenalidomide in a phase 2 clinical trial were evaluated for the clinical features intensity and duration of TFR Correlation was made with tumor response and the immune cellular microenvironment Steroids for the prophylaxis of TFR was not given to patients in Group A n 29 whereas patients in Group B n 16 received low-dose prednisone as well as a slow dose escalation of lenalidomide for the prevention of TFR Thirty 67 patients experienced a TFR with a grade 2 or 3 reaction according to National Cancer Institute Common Toxicity Criteria version 3.0 observed in 33 of patients 47 in Group A and 9 in Group B P .05 The median time to onset of the TFR was 6 days and was longer in the patients receiving prophylaxis 4 days vs 9 days respectively P .01 A complete response was observed in 7 of 30 23 patients with TFR and 1 of 15 7 patients without TFR The median progression-free survival was 19.9 months and 19.4 months respectively for patients with versus those without TFR P .92 TFR is a unique immune-mediated phenomenon noted with lenalidomide treatment only in patients with CLL that correlates with clinical response It can be effectively managed with anti-inflammatory agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 7, 5, 442, 1193, 552, 24, 5, 1288, 1516, 8, 991, 373, 10607, 250, 51, 3472, 30, 6915, 1329, 18609, 3, 38, 724, 1, 26, 1329, 469, 860, 1213, 365, 7, 5, 552, 54, 11, 73, 5, 1288, 4, 8, 124, 18, 38, 160, 11, 194, 9, 3, 38, 404, 837, 2, 654, 1, 18609, 816, 10, 1229, 5, 30, 51, 2, 3, 250, 763, 995, 4580, 9, 3, 2049, 1, 18609, 10, 44, 447, 6, 7, 4, 87, 8, 78, 462, 547, 7, 4, 87, 132, 78, 245, 103, 154, 61, 1979, 22, 149, 22, 8, 3645, 61, 1125, 1, 1288, 9, 3, 1070, 1, 18609, 977, 598, 7, 592, 8, 18609, 5, 8, 88, 18, 15, 27, 1329, 768, 6, 657, 12, 1377, 186, 155, 371, 2256, 27, 13, 164, 4, 466, 1, 7, 662, 4, 87, 8, 2, 83, 4, 87, 132, 19, 474, 3, 52, 98, 6, 1707, 1, 3, 18609, 10, 49, 162, 2, 10, 589, 4, 3, 7, 357, 2049, 39, 162, 105, 83, 162, 106, 19, 355, 8, 236, 51, 10, 164, 4, 67, 1, 201, 382, 7, 5, 18609, 2, 14, 1, 167, 67, 7, 187, 18609, 3, 52, 91, 115, 25, 10, 326, 83, 53, 2, 326, 39, 53, 106, 9, 7, 5, 185, 135, 187, 18609, 19, 937, 18609, 16, 8, 991, 250, 517, 3936, 1051, 5, 1288, 24, 158, 4, 7, 5, 552, 17, 1871, 5, 38, 51, 192, 122, 40, 1856, 2231, 5, 312, 1291, 183]",1455.0,21523725,563
Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.,Leukemia & lymphoma,Leuk. Lymphoma,2011-06-01,"Hairy cell leukemia (HCL) was once considered an untreatable form of chronic lymphoid malignancy. Based upon the recognition of the importance of adenosine deaminase to the normal B cell survival and proliferation, a hypothesis was developed that temporary inhibition of this enzyme might be therapeutically successful in treating chronic B cell leukemias. Pentostatin was initially explored in patients with refractory chronic lymphocytic leukemia (CLL). Both pentostatin and cladribine, purine nucleoside analogs, have been utilized to successfully treat HCL. The high degree of complete and durable remission observed with either agent resulted in many believing that the treatment of this rare disease had been fully optimized. However, a considerable number of patients will relapse. While tremendous progress has been made in initial management, the issues related to optimal therapy, timing of initiation of treatment, and discovery of novel agents that may be effective in those who have relapsed are important. Investigational agents currently being explored in chronic lymphocytic leukemia may also have benefit for those patients who have relapsed or are resistant to therapy of hairy cell leukemia. Many important questions remain (e.g. importance of minimal residual disease) and will require international collaboration to fully address these unanswered questions. The Hairy Cell Leukemia Consortium was established to address these unanswered questions.",Journal Article,3156.0,4.0,Hairy cell HCL was once considered an untreatable form of chronic lymphoid malignancy Based upon the recognition of the importance of adenosine deaminase to the normal B cell survival and proliferation a hypothesis was developed that temporary inhibition of this enzyme might be therapeutically successful in treating chronic B cell leukemias Pentostatin was initially explored in patients with refractory chronic lymphocytic CLL Both pentostatin and cladribine purine nucleoside analogs have been utilized to successfully treat HCL The high degree of complete and durable remission observed with either agent resulted in many believing that the treatment of this rare disease had been fully optimized However a considerable number of patients will relapse While tremendous progress has been made in initial management the issues related to optimal therapy timing of initiation of treatment and discovery of novel agents that may be effective in those who have relapsed are important Investigational agents currently being explored in chronic lymphocytic may also have benefit for those patients who have relapsed or are resistant to therapy of hairy cell Many important questions remain e.g importance of minimal residual disease and will require international collaboration to fully address these unanswered questions The Hairy Cell Consortium was established to address these unanswered questions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7152, 31, 4623, 10, 1059, 515, 35, 20322, 1297, 1, 442, 2303, 710, 90, 1548, 3, 2335, 1, 3, 1187, 1, 4938, 10197, 6, 3, 295, 132, 31, 25, 2, 457, 8, 1492, 10, 276, 17, 7579, 297, 1, 26, 1644, 822, 40, 4602, 1401, 4, 1367, 442, 132, 31, 2792, 7596, 10, 1625, 1443, 4, 7, 5, 430, 442, 1193, 552, 110, 7596, 2, 8251, 5006, 4032, 4063, 47, 85, 2080, 6, 1878, 943, 4623, 3, 64, 1444, 1, 236, 2, 1480, 734, 164, 5, 361, 420, 627, 4, 445, 26261, 17, 3, 24, 1, 26, 622, 34, 42, 85, 1910, 4039, 137, 8, 2658, 207, 1, 7, 303, 429, 369, 6678, 1466, 71, 85, 1229, 4, 388, 284, 3, 1553, 139, 6, 665, 36, 1972, 1, 1118, 1, 24, 2, 1574, 1, 229, 183, 17, 68, 40, 323, 4, 135, 54, 47, 591, 32, 305, 3093, 183, 694, 486, 1443, 4, 442, 1193, 68, 120, 47, 247, 9, 135, 7, 54, 47, 591, 15, 32, 436, 6, 36, 1, 7152, 31, 445, 305, 1937, 918, 563, 499, 1187, 1, 1048, 753, 34, 2, 303, 1353, 944, 4119, 6, 1910, 1539, 46, 7550, 1937, 3, 7152, 31, 2404, 10, 635, 6, 1539, 46, 7550, 1937]",1399.0,21599604,281
"Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.",Blood,Blood,2011-06-13,"Patients with relapsed chronic lymphocytic leukemia (CLL) and high-risk features, such as fludarabine refractoriness, complex karyotype, or abnormalities of chromosome 17p, experience poor outcomes after standard fludaradine-based regimens. Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion. We report the outcome for 80 relapsed or refractory patients with CLL enrolled in a phase 2 study of cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR). All patients were assessed for response and progression according to the 1996 CLL-working group criteria. For the intention-to-treat analysis, the overall response rate was 65%, including 29% complete response. The estimated progression-free survival was 10.6 months and median overall survival was 16.7 months. Although we noted higher complete response in high-risk patients after CFAR compared with a similar population who had received fludarabine, cyclophosphamide, and rituximab as salvage therapy, there was no significant improvement in progression-free survival and overall survival appeared worse. CFAR was associated with a high rate of infectious complications with 37 patients (46%) experiencing a serious infection during therapy and 28% of evaluable patients experiencing late serious infections. Although CFAR produced good response rates in this highly pretreated high-risk group of patients, there was no benefit in survival outcomes.","Clinical Trial, Phase II",3144.0,52.0,Patients with relapsed chronic lymphocytic CLL and high-risk features such as fludarabine refractoriness complex karyotype or abnormalities of chromosome 17p experience poor outcomes after standard fludaradine-based regimens Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion We report the outcome for 80 relapsed or refractory patients with CLL enrolled in a phase 2 study of cyclophosphamide fludarabine alemtuzumab and rituximab CFAR All patients were assessed for response and progression according to the 1996 CLL-working group criteria For the intention-to-treat analysis the overall response rate was 65 including 29 complete response The estimated progression-free survival was 10.6 months and median overall survival was 16.7 months Although we noted higher complete response in high-risk patients after CFAR compared with a similar population who had received fludarabine cyclophosphamide and rituximab as salvage therapy there was no significant improvement in progression-free survival and overall survival appeared worse CFAR was associated with a high rate of infectious complications with 37 patients 46 experiencing a serious infection during therapy and 28 of evaluable patients experiencing late serious infections Although CFAR produced good response rates in this highly pretreated high-risk group of patients there was no benefit in survival outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 591, 442, 1193, 552, 2, 64, 43, 404, 225, 22, 2027, 12483, 840, 3385, 15, 1171, 1, 1170, 4135, 730, 334, 123, 50, 260, 60228, 90, 472, 3579, 16, 8, 2897, 7189, 848, 548, 5, 128, 4, 552, 7, 5, 2027, 430, 34, 2, 4135, 1528, 21, 414, 3, 228, 9, 493, 591, 15, 430, 7, 5, 552, 346, 4, 8, 124, 18, 45, 1, 1112, 2027, 3579, 2, 855, 25141, 62, 7, 11, 275, 9, 51, 2, 91, 768, 6, 3, 2648, 552, 2644, 87, 371, 9, 3, 3205, 6, 943, 65, 3, 63, 51, 116, 10, 556, 141, 462, 236, 51, 3, 661, 91, 115, 25, 10, 79, 49, 53, 2, 52, 63, 25, 10, 245, 67, 53, 242, 21, 1051, 142, 236, 51, 4, 64, 43, 7, 50, 25141, 72, 5, 8, 288, 266, 54, 42, 103, 2027, 1112, 2, 855, 22, 992, 36, 125, 10, 77, 93, 767, 4, 91, 115, 25, 2, 63, 25, 2121, 639, 25141, 10, 41, 5, 8, 64, 116, 1, 3398, 521, 5, 567, 7, 641, 2985, 8, 1762, 930, 190, 36, 2, 339, 1, 859, 7, 2985, 807, 1762, 1875, 242, 25141, 1687, 1178, 51, 151, 4, 26, 561, 2193, 64, 43, 87, 1, 7, 125, 10, 77, 247, 4, 25, 123]",1454.0,21670470,293
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.,Blood,Blood,2011-07-01,"The best initial therapy for elderly patients with chronic lymphocytic leukemia (CLL) has not yet been defined. We investigated the activity of lenalidomide as initial therapy for elderly patients with CLL. Sixty patients with CLL 65 years of age and older received treatment with lenalidomide orally 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated. Treatment was continued until disease progression. At a median follow-up of 29 months, 53 patients (88%) are alive and 32 patients (53%) remain on therapy. Estimated 2-year progression-free survival is 60%. The overall response rate to lenalidomide therapy is 65%, including 10% complete response, 5% complete response with residual cytopenia, 7% nodular partial response, and 43% partial response. Neutropenia is the most common grade 3 or 4 treatment-related toxicity observed in 34% of treatment cycles. Major infections or neutropenic fever occurred in 13% of patients. Compared with baseline levels, we noted an increase in serum immunoglobulin levels across all classes, and a reduction in CCL3 and CCL4 plasma levels was noted in responding patients. Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL. This study was registered at www.clinicaltrials.gov as #NCT00535873.","Clinical Trial, Phase II",3126.0,143.0,The best initial therapy for elderly patients with chronic lymphocytic CLL has not yet been defined We investigated the activity of lenalidomide as initial therapy for elderly patients with CLL Sixty patients with CLL 65 years of age and older received treatment with lenalidomide orally 5 mg daily for 56 days then titrated up to 25 mg/d as tolerated Treatment was continued until disease progression At a median follow-up of 29 months 53 patients 88 are alive and 32 patients 53 remain on therapy Estimated 2-year progression-free survival is 60 The overall response rate to lenalidomide therapy is 65 including 10 complete response 5 complete response with residual cytopenia 7 nodular partial response and 43 partial response Neutropenia is the most common grade 3 or 4 treatment-related toxicity observed in 34 of treatment cycles Major infections or neutropenic fever occurred in 13 of patients Compared with baseline levels we noted an increase in serum immunoglobulin levels across all classes and a reduction in CCL3 and CCL4 plasma levels was noted in responding patients Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly symptomatic patients with CLL This study was registered at www.clinicaltrials.gov as NCT00535873,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 824, 388, 36, 9, 1216, 7, 5, 442, 1193, 552, 71, 44, 1145, 85, 395, 21, 565, 3, 128, 1, 1288, 22, 388, 36, 9, 1216, 7, 5, 552, 1746, 7, 5, 552, 556, 60, 1, 89, 2, 434, 103, 24, 5, 1288, 1428, 33, 81, 391, 9, 664, 162, 818, 15875, 126, 6, 243, 81, 427, 22, 421, 24, 10, 1351, 1100, 34, 91, 28, 8, 52, 166, 126, 1, 462, 53, 699, 7, 889, 32, 1701, 2, 531, 7, 699, 918, 23, 36, 661, 18, 111, 91, 115, 25, 16, 335, 3, 63, 51, 116, 6, 1288, 36, 16, 556, 141, 79, 236, 51, 33, 236, 51, 5, 753, 8165, 67, 4481, 450, 51, 2, 601, 450, 51, 778, 16, 3, 96, 186, 88, 27, 15, 39, 24, 139, 155, 164, 4, 562, 1, 24, 410, 458, 1875, 15, 3659, 2775, 489, 4, 233, 1, 7, 72, 5, 330, 148, 21, 1051, 35, 344, 4, 524, 2593, 148, 716, 62, 3211, 2, 8, 628, 4, 9711, 2, 12660, 554, 148, 10, 1051, 4, 3261, 7, 1288, 36, 10, 149, 421, 2, 277, 1480, 3166, 4, 26, 266, 1, 1216, 1704, 7, 5, 552, 26, 45, 10, 1653, 28, 3064, 1252, 1239, 22, 46654]",1279.0,21725050,368
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.,Human pathology,Hum. Pathol.,2011-07-05,"Chronic lymphocytic leukemia bone marrow is characterized by increased angiogenesis. However, the molecular mediators of neovascularization and the biologic significance of increased endothelial cell proliferation in chronic lymphocytic leukemia require further investigation. Because signal transducer and activator of transcription 3 is constitutively activated in chronic lymphocytic leukemia, we studied the role of signal transducer and activator of transcription 3 in modulating vascular endothelial growth factor expression and the effect of vascular endothelial cells on chronic lymphocytic leukemia cells. Using chromatin immunoprecipitation, we found that anti-signal transducer and activator of transcription 3 antibodies immunoprecipitated DNA of signal transducer and activator of transcription 3, vascular endothelial growth factor, and other signal transducer and activator of transcription 3-regulated genes. In addition, signal transducer and activator of transcription 3-short interfering RNA significantly reduced messenger RNA levels of vascular endothelial growth factor in chronic lymphocytic leukemia cells, suggesting that signal transducer and activator of transcription 3 induces vascular endothelial growth factor expression in chronic lymphocytic leukemia. Remarkably, bone marrow chronic lymphocytic leukemia cells expressed high levels of vascular endothelial growth factor, and high vascular endothelial growth factor levels were detected in the plasma of patients with untreated chronic lymphocytic leukemia and correlated with white blood cell count. Chronic lymphocytic leukemia bone marrow biopsies revealed increased microvascular density and attachment of chronic lymphocytic leukemia cells to endothelial cells. Coculture of chronic lymphocytic leukemia cells and human umbilical vein endothelial cells showed a similar attachment. Furthermore, coculture studies with human umbilical vein endothelial cells showed that human umbilical vein endothelial cells protected chronic lymphocytic leukemia cells from spontaneous apoptosis by direct cell-to-cell contact as assessed by flow cytometry using annexin V. Our data suggest that constitutively activated signal transducer and activator of transcription 3 induces vascular endothelial growth factor production by chronic lymphocytic leukemia cells and that chronic lymphocytic leukemia cells derive a survival advantage from endothelial cells via cell-to-cell contact.",Journal Article,3122.0,15.0,Chronic lymphocytic marrow is characterized by increased angiogenesis However the molecular mediators of neovascularization and the biologic significance of increased endothelial cell proliferation in chronic lymphocytic require further investigation Because signal transducer and activator of transcription 3 is constitutively activated in chronic lymphocytic we studied the role of signal transducer and activator of transcription 3 in modulating vascular endothelial growth factor expression and the effect of vascular endothelial cells on chronic lymphocytic cells Using chromatin immunoprecipitation we found that anti-signal transducer and activator of transcription 3 antibodies immunoprecipitated DNA of signal transducer and activator of transcription 3 vascular endothelial growth factor and other signal transducer and activator of transcription 3-regulated genes In addition signal transducer and activator of transcription 3-short interfering RNA significantly reduced messenger RNA levels of vascular endothelial growth factor in chronic lymphocytic cells suggesting that signal transducer and activator of transcription 3 induces vascular endothelial growth factor expression in chronic lymphocytic Remarkably marrow chronic lymphocytic cells expressed high levels of vascular endothelial growth factor and high vascular endothelial growth factor levels were detected in the plasma of patients with untreated chronic lymphocytic and correlated with white blood cell count Chronic lymphocytic marrow biopsies revealed increased microvascular density and attachment of chronic lymphocytic cells to endothelial cells Coculture of chronic lymphocytic cells and human umbilical vein endothelial cells showed a similar attachment Furthermore coculture studies with human umbilical vein endothelial cells showed that human umbilical vein endothelial cells protected chronic lymphocytic cells from spontaneous apoptosis by direct cell-to-cell contact as assessed by flow cytometry using annexin V. Our data suggest that constitutively activated signal transducer and activator of transcription 3 induces vascular endothelial growth factor production by chronic lymphocytic cells and that chronic lymphocytic cells derive a survival advantage from endothelial cells via cell-to-cell contact,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 581, 16, 765, 20, 101, 1056, 137, 3, 219, 4425, 1, 10551, 2, 3, 1283, 724, 1, 101, 845, 31, 457, 4, 442, 1193, 1353, 195, 940, 408, 1235, 5182, 2, 3393, 1, 866, 27, 16, 2818, 735, 4, 442, 1193, 21, 656, 3, 200, 1, 1235, 5182, 2, 3393, 1, 866, 27, 4, 3712, 756, 845, 129, 161, 55, 2, 3, 254, 1, 756, 845, 37, 23, 442, 1193, 37, 75, 2287, 4857, 21, 204, 17, 312, 1235, 5182, 2, 3393, 1, 866, 27, 890, 22170, 261, 1, 1235, 5182, 2, 3393, 1, 866, 27, 756, 845, 129, 161, 2, 127, 1235, 5182, 2, 3393, 1, 866, 27, 1065, 214, 4, 352, 1235, 5182, 2, 3393, 1, 866, 27, 978, 3449, 893, 97, 405, 5992, 893, 148, 1, 756, 845, 129, 161, 4, 442, 1193, 37, 802, 17, 1235, 5182, 2, 3393, 1, 866, 27, 1516, 756, 845, 129, 161, 55, 4, 442, 1193, 4856, 581, 442, 1193, 37, 570, 64, 148, 1, 756, 845, 129, 161, 2, 64, 756, 845, 129, 161, 148, 11, 530, 4, 3, 554, 1, 7, 5, 1278, 442, 1193, 2, 438, 5, 886, 315, 31, 1276, 442, 1193, 581, 1154, 553, 101, 6466, 1263, 2, 9364, 1, 442, 1193, 37, 6, 845, 37, 7604, 1, 442, 1193, 37, 2, 171, 5998, 2762, 845, 37, 224, 8, 288, 9364, 798, 7604, 94, 5, 171, 5998, 2762, 845, 37, 224, 17, 171, 5998, 2762, 845, 37, 5541, 442, 1193, 37, 29, 3280, 351, 20, 1196, 31, 6, 31, 4393, 22, 275, 20, 1412, 1914, 75, 4850, 603, 114, 74, 309, 17, 2818, 735, 1235, 5182, 2, 3393, 1, 866, 27, 1516, 756, 845, 129, 161, 1529, 20, 442, 1193, 37, 2, 17, 442, 1193, 37, 3823, 8, 25, 1874, 29, 845, 37, 847, 31, 6, 31, 4393]",2296.0,21733558,694
"Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.",Blood,Blood,2011-07-12,"Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum -2 microglobulin (2M)  4 mg/L. Sixty patients were enrolled; median age was 59 years (range, 42-69); 75% were male; median 2M was 5.1 mg/L (range, 4-11.6); and 51% were Rai III-IV. Complete remission (CR) was achieved in 70%, partial remission (PR) in 18%, nodular PR in 3%, for an overall response of 92%. Of 14 patients with 17p deletion, CR was achieved by 8 (57%). Of 57 BM samples evaluated by 3-color flow cytometry at the end of treatment, 41 (72%) were negative for residual disease. Grade 3-4 neutropenia and thrombocytopenia occurred with 33% and 13% courses, respectively. The median progression-free survival was 38 months and median OS was not reached. In conclusion, CFAR is an active frontline regimen for high-risk CLL. Response rates and survival are comparable with historic high-risk FCR-treated patients. CFAR may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation.","Clinical Trial, Phase II",3115.0,70.0,Frontline chemoimmunotherapy with fludarabine cyclophosphamide and rituximab FCR is associated with superior overall survival OS for patients with chronic lymphocytic CLL Alemtuzumab A was added to FCR CFAR in a phase 2 trial for high-risk untreated patients 70 years with serum -2 microglobulin 2M  4 mg/L Sixty patients were enrolled median age was 59 years range 42-69 75 were male median 2M was 5.1 mg/L range 4-11.6 and 51 were Rai III-IV Complete remission CR was achieved in 70 partial remission PR in 18 nodular PR in 3 for an overall response of 92 Of 14 patients with 17p deletion CR was achieved by 8 57 Of 57 BM samples evaluated by 3-color flow cytometry at the end of treatment 41 72 were negative for residual disease Grade 3-4 neutropenia and thrombocytopenia occurred with 33 and 13 courses respectively The median progression-free survival was 38 months and median OS was not reached In conclusion CFAR is an active frontline regimen for high-risk CLL Response rates and survival are comparable with historic high-risk FCR-treated patients CFAR may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3171, 4438, 5, 2027, 1112, 2, 855, 4953, 16, 41, 5, 1123, 63, 25, 118, 9, 7, 5, 442, 1193, 552, 3579, 8, 10, 1953, 6, 4953, 25141, 4, 8, 124, 18, 160, 9, 64, 43, 1278, 7, 431, 60, 5, 524, 1458, 18, 5371, 27019, 749, 39, 81, 805, 1746, 7, 11, 346, 52, 89, 10, 728, 60, 184, 595, 790, 481, 11, 1045, 52, 27019, 10, 33, 14, 81, 805, 184, 39, 175, 49, 2, 725, 11, 4121, 316, 478, 236, 734, 684, 10, 513, 4, 431, 450, 734, 998, 4, 203, 4481, 998, 4, 27, 9, 35, 63, 51, 1, 937, 1, 213, 7, 5, 4135, 1528, 684, 10, 513, 20, 66, 696, 1, 696, 1246, 347, 194, 20, 27, 6052, 1412, 1914, 28, 3, 396, 1, 24, 605, 720, 11, 199, 9, 753, 34, 88, 27, 39, 778, 2, 1340, 489, 5, 466, 2, 233, 1993, 106, 3, 52, 91, 115, 25, 10, 519, 53, 2, 52, 118, 10, 44, 1300, 4, 1221, 25141, 16, 35, 544, 3171, 477, 9, 64, 43, 552, 51, 151, 2, 25, 32, 1279, 5, 6875, 64, 43, 4953, 73, 7, 25141, 68, 40, 8, 999, 3171, 477, 6, 1359, 684, 4, 7, 5, 4135, 1528, 348, 1063, 452, 31, 497]",1188.0,21750315,609
High-sensitivity TFA-free LC-MS for profiling histones.,Proteomics,Proteomics,2011-08-01,"The analysis of proteins by RPLC commonly involves the use of TFA as an ion-pairing agent, even though it forms adducts and suppresses sensitivity. The presence of adducts can complicate protein molecular weight assignment especially when protein isoforms coelute as in the case of histones. To mitigate the complicating effects of TFA adducts in protein LC-MS, we have optimized TFA-free methods for protein separation. Protein standards and histones were used to evaluate TFA-free separations using capillary (0.3mm id) and nanoscale (0.1mm id) C(8) columns with the ion-pairing agents, formic acid or acetic acid. The optimized method was then used to examine the applicability of the approach for histone characterization in human cancer cell lines and primary tumor cells from chronic lymphocytic leukemia patients.",Journal Article,3095.0,8.0,The analysis of proteins by RPLC commonly involves the use of TFA as an ion-pairing agent even though it forms adducts and suppresses sensitivity The presence of adducts can complicate protein molecular weight assignment especially when protein isoforms coelute as in the case of histones To mitigate the complicating effects of TFA adducts in protein LC-MS we have optimized TFA-free methods for protein separation Protein standards and histones were used to evaluate TFA-free separations using capillary 0.3 mm id and nanoscale 0.1 mm id C 8 columns with the ion-pairing agents formic acid or acetic acid The optimized method was then used to examine the applicability of the approach for histone characterization in human cancer cell lines and primary tumor cells from chronic lymphocytic patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 65, 1, 652, 20, 60343, 841, 2921, 3, 119, 1, 31838, 22, 35, 7714, 19737, 420, 871, 2471, 192, 2377, 9722, 2, 4079, 485, 3, 463, 1, 9722, 122, 11157, 178, 219, 924, 4392, 1093, 198, 178, 3913, 60344, 22, 4, 3, 473, 1, 8457, 6, 5626, 3, 13630, 176, 1, 31838, 9722, 4, 178, 1837, 2307, 21, 47, 4039, 31838, 115, 636, 9, 178, 5422, 178, 3371, 2, 8457, 11, 95, 6, 376, 31838, 115, 43854, 75, 8943, 13, 27, 321, 4937, 2, 12908, 13, 14, 321, 4937, 256, 66, 29180, 5, 3, 7714, 19737, 183, 20616, 971, 15, 16812, 971, 3, 4039, 596, 10, 818, 95, 6, 1004, 3, 5412, 1, 3, 353, 9, 1508, 2136, 4, 171, 12, 31, 285, 2, 86, 30, 37, 29, 442, 1193, 7]",800.0,21751347,641
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.,Cancer,Cancer,2011-07-14,"Despite the high complete response rates achieved with fludarabine-based regimens, relapse is inevitable in chronic lymphocytic leukemia (CLL). Relapsed patients often acquire deletions of the short arm of chromosome 17 (del[17p]), which are closely associated with tumor protein 53 (TP53) mutations. Wild-type p53 up-regulates and activates B-cell CLL/lymphoma 2 (BCL-2)-associated X protein (BAX), and it down-regulates and inactivates BCL-2. The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer (BAK)-dependent manner. The role of p53 in sensitivity of CLL cells to BCL-2 inhibition has not been extensively investigated. The authors investigated the association of del(17p) with ABT-737 sensitivity in CLL cells from 50 patients. Stable p53 and BAX knockdown cells were used for mechanistic studies. CLL cells with del(17p) were less sensitive to ABT-737-induced BAX activation and apoptosis than CLL cells without del(17p) (39%  7.3% vs 63.7%  2.9% [specific annexin V induction]; P < .01). A positive correlation between the degrees of apoptosis induced by ABT-737 and by the p53-activating binding protein homolog murine double minute (MDM2) antagonist nutlin-3a (correlation coefficient [r] = 0.75; P < .0001) was observed. CLL cells with del(17p) expressed lower levels of BAX than those without del(17p) (0.67  0.12 vs 1.27  0.10 in relative protein expression levels; P < .01). Knockdown of p53 or BAX in leukemia cells resulted in decreased apoptosis induced by ABT-737. The current data indicated that p53 dysfunction may lead to decreased apoptosis induction by ABT-737.",Journal Article,3113.0,14.0,Despite the high complete response rates achieved with fludarabine-based regimens relapse is inevitable in chronic lymphocytic CLL Relapsed patients often acquire deletions of the short arm of chromosome 17 del 17p which are closely associated with tumor protein 53 TP53 mutations Wild-type p53 up-regulates and activates B-cell CLL/lymphoma 2 BCL-2 -associated X protein BAX and it down-regulates and inactivates BCL-2 The small-molecule BCL-2 inhibitor ABT-737 induces apoptosis in a BAX-dependent and BCL-2 homologous antagonist-killer BAK -dependent manner The role of p53 in sensitivity of CLL cells to BCL-2 inhibition has not been extensively investigated The authors investigated the association of del 17p with ABT-737 sensitivity in CLL cells from 50 patients Stable p53 and BAX knockdown cells were used for mechanistic studies CLL cells with del 17p were less sensitive to ABT-737-induced BAX activation and apoptosis than CLL cells without del 17p 39  7.3 vs 63.7  2.9 specific annexin V induction P .01 A positive correlation between the degrees of apoptosis induced by ABT-737 and by the p53-activating binding protein homolog murine double minute MDM2 antagonist nutlin-3a correlation coefficient r 0.75 P .0001 was observed CLL cells with del 17p expressed lower levels of BAX than those without del 17p 0.67  0.12 vs 1.27  0.10 in relative protein expression levels P .01 Knockdown of p53 or BAX in cells resulted in decreased apoptosis induced by ABT-737 The current data indicated that p53 dysfunction may lead to decreased apoptosis induction by ABT-737,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 3, 64, 236, 51, 151, 513, 5, 2027, 90, 472, 429, 16, 11077, 4, 442, 1193, 552, 591, 7, 629, 6206, 2439, 1, 3, 978, 475, 1, 1170, 269, 3084, 4135, 92, 32, 3210, 41, 5, 30, 178, 699, 1206, 138, 955, 267, 624, 126, 2468, 2, 3932, 132, 31, 552, 4763, 18, 1044, 18, 41, 1006, 178, 3119, 2, 192, 1328, 2468, 2, 14521, 1044, 18, 3, 302, 1354, 1044, 18, 230, 3095, 4933, 1516, 351, 4, 8, 3119, 470, 2, 1044, 18, 3894, 3137, 3458, 5599, 470, 1708, 3, 200, 1, 624, 4, 485, 1, 552, 37, 6, 1044, 18, 297, 71, 44, 85, 3576, 565, 3, 738, 565, 3, 248, 1, 3084, 4135, 5, 3095, 4933, 485, 4, 552, 37, 29, 212, 7, 585, 624, 2, 3119, 1563, 37, 11, 95, 9, 2716, 94, 552, 37, 5, 3084, 4135, 11, 299, 745, 6, 3095, 4933, 277, 3119, 363, 2, 351, 76, 552, 37, 187, 3084, 4135, 587, 810, 67, 27, 105, 676, 67, 810, 18, 83, 112, 4850, 603, 504, 19, 355, 8, 109, 816, 59, 3, 4133, 1, 351, 277, 20, 3095, 4933, 2, 20, 3, 624, 1616, 791, 178, 3412, 1471, 1627, 3949, 3277, 3137, 7449, 6981, 816, 3200, 668, 13, 481, 19, 488, 10, 164, 552, 37, 5, 3084, 4135, 570, 280, 148, 1, 3119, 76, 135, 187, 3084, 4135, 13, 598, 810, 13, 133, 105, 14, 428, 810, 13, 79, 4, 580, 178, 55, 148, 19, 355, 1563, 1, 624, 15, 3119, 4, 37, 627, 4, 340, 351, 277, 20, 3095, 4933, 3, 291, 74, 1103, 17, 624, 1527, 68, 1122, 6, 340, 351, 504, 20, 3095, 4933]",1578.0,21761401,569
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.,Blood,Blood,2011-07-15,"Free light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated  and/or  with abnormal FLC ratio), polyclonal elevated FLC (elevated  and/or  with normal FLC ratio), and ratio-only FLC abnormality (normal range  and  with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.",Journal Article,3112.0,35.0,Free light chains FLCs are the most commonly detected paraproteins in chronic lymphocytic CLL We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL Three types of FLC abnormalities were identified monoclonal elevated FLC elevated  and/or  with abnormal FLC ratio polyclonal elevated FLC elevated  and/or  with normal FLC ratio and ratio-only FLC abnormality normal range  and  with abnormal FLC ratio One hundred sixty-five patients 49 had a FLC abnormality with approximately equal distribution among monoclonal elevation polyclonal elevation and ratio-only abnormality All FLC abnormalities were associated with poor time to first treatment monoclonal FLC hazard ratio HR 4.99 95 confidence interval CI 2.94-8.48 polyclonal FLC HR 2.40 95 CI 1.24-4.64 ratio-only FLC HR 2.57 95 CI 1.40-4.69 Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC Results remained significant after adjusting for Rai stage The FLC assay is a simple widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL Among persons with FLC abnormalities the type of abnormality affects prognostic significance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[115, 1691, 7802, 17307, 32, 3, 96, 841, 530, 19930, 4, 442, 1193, 552, 21, 409, 3, 630, 1, 4266, 1171, 2, 177, 1207, 1, 3, 4266, 719, 72, 5, 260, 177, 582, 4, 8, 482, 180, 1, 7881, 7, 5, 732, 265, 552, 169, 630, 1, 4266, 1171, 11, 108, 848, 804, 4266, 804, 4627, 2, 15, 12441, 5, 1668, 4266, 197, 6350, 804, 4266, 804, 4627, 2, 15, 12441, 5, 295, 4266, 197, 2, 197, 158, 4266, 3698, 295, 184, 4627, 2, 12441, 5, 1668, 4266, 197, 104, 1128, 1746, 365, 7, 739, 42, 8, 4266, 3698, 5, 705, 2997, 1395, 107, 848, 3292, 6350, 3292, 2, 197, 158, 3698, 62, 4266, 1171, 11, 41, 5, 334, 98, 6, 157, 24, 848, 4266, 360, 197, 168, 39, 1058, 48, 307, 268, 58, 18, 960, 66, 576, 6350, 4266, 168, 18, 327, 48, 58, 14, 259, 39, 660, 197, 158, 4266, 168, 18, 696, 48, 58, 14, 327, 39, 790, 848, 4266, 2, 6350, 4266, 11, 41, 5, 334, 63, 25, 72, 5, 7, 5, 295, 4266, 99, 958, 93, 50, 1358, 9, 4121, 82, 3, 4266, 719, 16, 8, 2763, 1792, 390, 38, 412, 5, 288, 177, 1207, 22, 3066, 95, 177, 582, 9, 552, 107, 4327, 5, 4266, 1171, 3, 267, 1, 3698, 2561, 177, 724]",1342.0,21765023,387
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.,Blood,Blood,2011-07-29,"Chemotherapy-related myeloid neoplasia (t-MN) is a significant late toxicity concern after cancer therapy. In the randomized intergroup phase 3 E2997 trial, initial therapy of chronic lymphocytic leukemia with fludarabine plus cyclophosphamide (FC) compared with fludarabine alone yielded higher complete and overall response rates and longer progression-free, but not overall, survival. Here, we report t-MN incidence in 278 patients enrolled in E2997 with a median 6.4-year follow-up. Thirteen cases (4.7%) of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic leukemia, 9 after FC and 4 after fludarabine alone. By cumulative incidence methodology, rates of t-MN at 7 years were 8.2% after FC and 4.6% after fludarabine alone (P = .09). Seven of the 9 cases of t-MN after FC occurred without additional therapy. Abnormalities involving chromosomes 5 or 7 were found in 10 cases, which suggests alkylator involvement. These data suggest that FC may induce more t-MN than fludarabine alone.",Journal Article,3098.0,37.0,Chemotherapy-related myeloid neoplasia t-MN is a significant late toxicity concern after cancer therapy In the randomized intergroup phase 3 E2997 trial initial therapy of chronic lymphocytic with fludarabine plus cyclophosphamide FC compared with fludarabine alone yielded higher complete and overall response rates and longer progression-free but not overall survival Here we report t-MN incidence in 278 patients enrolled in E2997 with a median 6.4-year follow-up Thirteen cases 4.7 of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic 9 after FC and 4 after fludarabine alone By cumulative incidence methodology rates of t-MN at 7 years were 8.2 after FC and 4.6 after fludarabine alone P .09 Seven of the 9 cases of t-MN after FC occurred without additional therapy Abnormalities involving chromosomes 5 or 7 were found in 10 cases which suggests alkylator involvement These data suggest that FC may induce more t-MN than fludarabine alone,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[56, 139, 533, 2298, 102, 4691, 16, 8, 93, 807, 155, 2893, 50, 12, 36, 4, 3, 384, 4839, 124, 27, 23577, 160, 388, 36, 1, 442, 1193, 5, 2027, 349, 1112, 4127, 72, 5, 2027, 279, 2178, 142, 236, 2, 63, 51, 151, 2, 589, 91, 115, 84, 44, 63, 25, 467, 21, 414, 102, 4691, 287, 4, 9128, 7, 346, 4, 23577, 5, 8, 52, 49, 39, 111, 166, 126, 3170, 140, 39, 67, 1, 102, 4691, 489, 28, 8, 52, 1, 33, 60, 29, 388, 36, 9, 442, 1193, 83, 50, 4127, 2, 39, 50, 2027, 279, 20, 967, 287, 3209, 151, 1, 102, 4691, 28, 67, 60, 11, 66, 18, 50, 4127, 2, 39, 49, 50, 2027, 279, 19, 1730, 648, 1, 3, 83, 140, 1, 102, 4691, 50, 4127, 489, 187, 402, 36, 1171, 1267, 3560, 33, 15, 67, 11, 204, 4, 79, 140, 92, 844, 9346, 799, 46, 74, 309, 17, 4127, 68, 1290, 80, 102, 4691, 76, 2027, 279]",976.0,21803850,382
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2011-09-19,"CpG oligonucleotide 7909 (CpG 7909, PF-03512676), a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells, is immunomodulatory and can cause activation-induced death of chronic lymphocytic leukemia (CLL) cells. We report a phase I study of CpG 7909 in 41 patients with early relapsed CLL. A single intravenous dose of CpG 7909 was well tolerated with no clinical effects and no significant toxicity up to 1.05 mg/kg. Single dose subcutaneous CpG 7909 had a maximum tolerated dose (MTD) of 0.45 mg/kg with dose limiting toxicity of myalgia and constitutional effects. Multiple weekly subcutaneous doses at the MTD were well tolerated. CpG 7909 administration induced immunologic changes in CLL and non-malignant cells that were dose and route dependent. We conclude that multidose therapy with subcutaneous CpG 7909 (0.45 mg/kg) could be used in future phase II combination clinical trials for CLL.","Clinical Trial, Phase I",3046.0,58.0,CpG oligonucleotide 7909 CpG 7909 PF-03512676 a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells is immunomodulatory and can cause activation-induced death of chronic lymphocytic CLL cells We report a phase I study of CpG 7909 in 41 patients with early relapsed CLL A single intravenous dose of CpG 7909 was well tolerated with no clinical effects and no significant toxicity up to 1.05 mg/kg Single dose subcutaneous CpG 7909 had a maximum tolerated dose MTD of 0.45 mg/kg with dose limiting toxicity of myalgia and constitutional effects Multiple weekly subcutaneous doses at the MTD were well tolerated CpG 7909 administration induced immunologic changes in CLL and non-malignant cells that were dose and route dependent We conclude that multidose therapy with subcutaneous CpG 7909 0.45 mg/kg could be used in future phase II combination clinical trials for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2075, 4727, 20582, 2075, 20582, 3313, 60418, 8, 3273, 60419, 226, 9021, 3821, 1, 11202, 570, 20, 132, 37, 2, 7978, 2464, 37, 16, 2555, 2, 122, 708, 363, 277, 273, 1, 442, 1193, 552, 37, 21, 414, 8, 124, 70, 45, 1, 2075, 20582, 4, 605, 7, 5, 191, 591, 552, 8, 226, 1262, 61, 1, 2075, 20582, 10, 149, 421, 5, 77, 38, 176, 2, 77, 93, 155, 126, 6, 14, 474, 81, 503, 226, 61, 2529, 2075, 20582, 42, 8, 689, 421, 61, 961, 1, 13, 512, 81, 503, 5, 61, 817, 155, 1, 8490, 2, 5962, 176, 232, 709, 2529, 415, 28, 3, 961, 11, 149, 421, 2075, 20582, 634, 277, 3042, 400, 4, 552, 2, 220, 393, 37, 17, 11, 61, 2, 5841, 470, 21, 2060, 17, 33202, 36, 5, 2529, 2075, 20582, 13, 512, 81, 503, 359, 40, 95, 4, 508, 124, 215, 150, 38, 143, 9, 552]",918.0,21812536,796
Colposcopic and cytologic detection of chronic lymphocytic leukemia in the vagina: a case report.,The Journal of reproductive medicine,J Reprod Med,,"Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders. CLL has a wide range of physical findings at the time of initial discovery, with lymphadenopathy being the most common. We report the first case of primary presentation of CLL of the vaginal cuff in an asymptomatic patient. A 68-year-old, white woman status post-total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometriosis 25 years earlier, was referred for colposcopic evaluation of low-grade squamous intraepithelial lesion of the vagina. Pathologic examination, immunohistochemical studies, and immunoglobulin gene rearrangement studies of the biopsy specimens were performed. All of these findings were supportive of a diagnosis of CLL. CLL in the vagina may present as an asymptomatic lesion. Hematologic malignancies should be considered in the differential diagnosis during workup of abnormal vaginal cytology.",Case Reports,,3.0,Chronic lymphocytic CLL is one of the chronic lymphoproliferative disorders CLL has a wide range of physical findings at the time of initial discovery with lymphadenopathy being the most common We report the first case of primary presentation of CLL of the cuff in an asymptomatic patient A 68-year-old white woman status post-total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometriosis 25 years earlier was referred for colposcopic evaluation of low-grade squamous intraepithelial lesion of the vagina Pathologic examination immunohistochemical studies and immunoglobulin gene rearrangement studies of the biopsy specimens were performed All of these findings were supportive of a diagnosis of CLL CLL in the vagina may present as an asymptomatic lesion Hematologic malignancies should be considered in the differential diagnosis during workup of abnormal cytology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 104, 1, 3, 442, 4192, 1997, 552, 71, 8, 1019, 184, 1, 900, 272, 28, 3, 98, 1, 388, 1574, 5, 4962, 486, 3, 96, 186, 21, 414, 3, 157, 473, 1, 86, 1031, 1, 552, 1, 3, 11445, 4, 35, 2100, 69, 8, 806, 111, 1095, 886, 2854, 156, 539, 181, 1467, 2622, 2, 1607, 5690, 3470, 9, 7915, 243, 60, 1677, 10, 1995, 9, 14131, 451, 1, 154, 88, 691, 4153, 1180, 1, 3, 7553, 510, 1385, 1382, 94, 2, 2593, 145, 2675, 94, 1, 3, 411, 623, 11, 173, 62, 1, 46, 272, 11, 1877, 1, 8, 147, 1, 552, 552, 4, 3, 7553, 68, 364, 22, 35, 2100, 1180, 813, 441, 257, 40, 515, 4, 3, 1777, 147, 190, 4755, 1, 1668, 2045]",888.0,21838166,480
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.,Blood,Blood,2011-08-16,"Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.",Journal Article,3080.0,66.0,Success of tyrosine kinase inhibitors TKIs in chronic myeloid CML has given patients hope for a long disease-free-survival A longer survival raises the question of late effects including development of another malignancy Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies other than acute myeloid acute lymphocytic or syndrome The number of second cancers was compared with the number expected from the Surveillance Epidemiology and End Results database After a median follow-up of 107 months range 13-362 months after CML/myeloproliferative neoplasm diagnosis 66 patients 4.6 developed 80 second cancers including 31 15 13 digestive system 10 4 4 3 chronic lymphocytic 3 hepatobiliary 3 and other cancers 14 Excluding nonmelanoma cancers 55 second cancers were seen in 51 3.5 of all patients treated The risk of second cancer was lower than expected observed-to-expected ratio 0.6 95 confidence interval 0.44-0.81 Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies mostly CML No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,"[1825, 1, 564, 216, 222, 1671, 4, 442, 533, 903, 71, 447, 7, 3045, 9, 8, 319, 34, 115, 25, 8, 589, 25, 5789, 3, 2840, 1, 807, 176, 141, 193, 1, 1809, 710, 1064, 1, 35181, 7, 5, 903, 10857, 2131, 15, 127, 813, 441, 73, 5, 1671, 11, 446, 6, 963, 675, 2, 374, 1, 419, 441, 127, 76, 286, 533, 286, 1193, 15, 681, 3, 207, 1, 419, 163, 10, 72, 5, 3, 207, 1336, 29, 3, 617, 1284, 2, 396, 99, 609, 50, 8, 52, 166, 126, 1, 3650, 53, 184, 233, 10530, 53, 50, 903, 10857, 2131, 147, 700, 7, 39, 49, 276, 493, 419, 163, 141, 456, 167, 233, 9117, 398, 79, 39, 39, 27, 442, 1193, 27, 4718, 27, 2, 127, 163, 213, 3207, 7814, 163, 614, 419, 163, 11, 527, 4, 725, 27, 33, 1, 62, 7, 73, 3, 43, 1, 419, 12, 10, 280, 76, 1336, 164, 6, 1336, 197, 13, 49, 48, 307, 268, 13, 584, 13, 865, 419, 163, 1271, 4, 8, 302, 1150, 1, 7, 357, 36, 5, 1671, 9, 813, 441, 2754, 903, 77, 241, 28, 3, 12854, 844, 17, 645, 6, 1671, 1106, 3, 43, 1, 931, 419, 163]",1287.0,21846902,517
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.,Blood,Blood,2011-08-17,"We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-generation chimeric antigen (Ag) receptor specific to the B-cell lineage Ag CD19. Eight of the 9 treated patients tolerated 19-28z(+) T-cell infusions well. Three of 4 evaluable patients with bulky CLL who received prior conditioning with cyclophosphamide exhibited either a significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cell aplasia. In contrast, one patient with relapsed ALL who was treated in remission with a similar T-cell dose developed a predicted B-cell aplasia. The short-term persistence of infused T cells was enhanced by prior cyclophosphamide administration and inversely proportional to the peripheral blood tumor burden. Further analyses showed rapid trafficking of modified T cells to tumor and retained ex vivo cytotoxic potential of CD19-targeted T cells retrieved 8 days after infusion. We conclude that this adoptive T-cell approach is promising and more likely to show clinical benefit in the setting of prior conditioning chemotherapy and low tumor burden or minimal residual disease. These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol).","Clinical Trial, Phase I",3079.0,738.0,We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic CLL or relapsed B-cell acute lymphoblastic ALL we have enrolled for treatment with autologous T cells modified to express 19-28z a second-generation chimeric antigen Ag receptor specific to the B-cell lineage Ag CD19 Eight of the 9 treated patients tolerated 19-28z T-cell infusions well Three of 4 evaluable patients with bulky CLL who received prior conditioning with cyclophosphamide exhibited either a significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cell aplasia In contrast one patient with relapsed ALL who was treated in remission with a similar T-cell dose developed a predicted B-cell aplasia The short-term persistence of infused T cells was enhanced by prior cyclophosphamide administration and inversely proportional to the peripheral blood tumor burden Further analyses showed rapid trafficking of modified T cells to tumor and retained ex vivo cytotoxic potential of CD19-targeted T cells retrieved 8 days after infusion We conclude that this adoptive T-cell approach is promising and more likely to show clinical benefit in the setting of prior conditioning chemotherapy and low tumor burden or minimal residual disease These studies are registered at www.clinicaltrials.org as NCT00466531 CLL protocol and NCT01044069 B-ALL protocol,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[21, 414, 3, 272, 29, 3, 157, 79, 7, 5, 56, 430, 442, 1193, 552, 15, 591, 132, 31, 286, 1275, 62, 21, 47, 346, 9, 24, 5, 1028, 102, 37, 1230, 6, 1669, 326, 19130, 8, 419, 914, 2897, 448, 2741, 153, 112, 6, 3, 132, 31, 2542, 2741, 3158, 659, 1, 3, 83, 73, 7, 421, 326, 19130, 102, 31, 3435, 149, 169, 1, 39, 859, 7, 5, 4112, 552, 54, 103, 324, 1933, 5, 1112, 1416, 361, 8, 93, 628, 15, 8, 1739, 51, 4, 4962, 187, 1781, 193, 1, 132, 31, 12307, 4, 748, 104, 69, 5, 591, 62, 54, 10, 73, 4, 734, 5, 8, 288, 102, 31, 61, 276, 8, 783, 132, 31, 12307, 3, 978, 337, 4108, 1, 4524, 102, 37, 10, 651, 20, 324, 1112, 634, 2, 2659, 831, 6, 3, 672, 315, 30, 892, 195, 318, 224, 1321, 6105, 1, 1230, 102, 37, 6, 30, 2, 3532, 2581, 386, 759, 174, 1, 3158, 238, 102, 37, 4539, 66, 162, 50, 904, 21, 2060, 17, 26, 3159, 102, 31, 353, 16, 721, 2, 80, 322, 6, 514, 38, 247, 4, 3, 546, 1, 324, 1933, 56, 2, 154, 30, 892, 15, 1048, 753, 34, 46, 94, 32, 1653, 28, 3064, 1252, 5598, 22, 60468, 552, 1182, 2, 35182, 132, 62, 1182]",1397.0,21849486,6
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.,Blood,Blood,2011-08-19,"Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (> 5 cm) lymph nodes (BF-ref). To potentially gain insight into outcomes in patients previously treated with or refractory to rituximab, we performed an ad hoc retrospective analysis in the final 96 FA-ref and 111 BF-ref patients. There were 117 patients previously treated with rituximab (98 rituximab-refractory); 89 patients were rituximab-naive. For rituximab-treated, rituximab-refractory, and rituximab-naive patients, overall response rate was 43%, 44%, and 53%; median progression-free survival was 5.3, 5.5, and 5.6 months; and median overall survival was 15.5, 15.5, and 20.2 months. There were no significant differences in ofatumumab-related infusion reactions, or hematologic or infectious adverse events between subgroups. In summary, ofatumumab monotherapy was effective and well tolerated in patients with fludarabine-refractory chronic lymphocytic leukemia, including in patients with previous rituximab exposure. This trial was registered at www.clinicaltrials.gov as #NCT00349349.","Clinical Trial, Phase II",3077.0,136.0,Ofatumumab the human CD20 monoclonal antibody that binds a distinct epitope from rituximab has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic refractory to fludarabine and alemtuzumab FA-ref and patients refractory to fludarabine with bulky 5 cm lymph nodes BF-ref To potentially gain insight into outcomes in patients previously treated with or refractory to rituximab we performed an ad hoc retrospective analysis in the final 96 FA-ref and 111 BF-ref patients There were 117 patients previously treated with rituximab 98 rituximab-refractory 89 patients were rituximab-naive For rituximab-treated rituximab-refractory and rituximab-naive patients overall response rate was 43 44 and 53 median progression-free survival was 5.3 5.5 and 5.6 months and median overall survival was 15.5 15.5 and 20.2 months There were no significant differences in ofatumumab-related infusion reactions or hematologic or infectious adverse events between subgroups In summary ofatumumab monotherapy was effective and well tolerated in patients with fludarabine-refractory chronic lymphocytic including in patients with previous rituximab exposure This trial was registered at www.clinicaltrials.gov as NCT00349349,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5732, 3, 171, 2198, 848, 548, 17, 3333, 8, 834, 4430, 29, 855, 71, 264, 38, 247, 22, 1411, 9, 7, 5, 442, 1193, 430, 6, 2027, 2, 3579, 4307, 7357, 2, 7, 430, 6, 2027, 5, 4112, 33, 494, 263, 502, 6139, 7357, 6, 751, 1803, 2670, 237, 123, 4, 7, 373, 73, 5, 15, 430, 6, 855, 21, 173, 35, 1985, 5428, 459, 65, 4, 3, 1457, 921, 4307, 7357, 2, 3167, 6139, 7357, 7, 125, 11, 3843, 7, 373, 73, 5, 855, 1096, 855, 430, 887, 7, 11, 855, 2462, 9, 855, 73, 855, 430, 2, 855, 2462, 7, 63, 51, 116, 10, 601, 584, 2, 699, 52, 91, 115, 25, 10, 33, 27, 33, 33, 2, 33, 49, 53, 2, 52, 63, 25, 10, 167, 33, 167, 33, 2, 179, 18, 53, 125, 11, 77, 93, 362, 4, 5732, 139, 904, 2428, 15, 813, 15, 3398, 290, 281, 59, 1453, 4, 1962, 5732, 1411, 10, 323, 2, 149, 421, 4, 7, 5, 2027, 430, 442, 1193, 141, 4, 7, 5, 698, 855, 645, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 60481]",1232.0,21856867,134
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2011-02-24,"Lenalidomide, an immunomodulatory agent, has activity in lymphoproliferative disorders. The authors, therefore, evaluated its effects on T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (CLL). To study the immunomodulatory effects of lenalidomide in CLL, the authors recruited 24 patients with untreated CLL enrolled in a phase 2 clinical trial of lenalidomide and obtained peripheral blood specimens for immunologic studies consisting of enumeration of T cells and assessing their ability to synthesize cytokines after activation through T-cell receptor (TCR). After 3 cycles of therapy, patients had a significant reduction in percentage (%) and absolute lymphocyte count (ALC) and an increase in percentage of T cells, percentage of activated CD8(+) T cells producing IFN-, and percentage of regulatory T (T(R) ) cells when compared with their respective levels before treatment. After 15 cycles of treatment, responder patients had significant reduction in percentage of lymphocytes and ALC, percentage of activated CD4(+) T cells producing IL-2, IFN-, or TNF-, and percentage of T(R) cells when compared with their perspective levels after 3 cycles of treatment. Furthermore, the numbers of activated CD4(+) T cells producing IL-2, IFN-, or TNF-, activated CD8(+) T cells producing IFN-, and T(R) cells normalized to the range of healthy subjects. Treatment with lenalidomide resulted in the normalization of functional T-cell subsets in responders, suggesting that lenalidomide may modulate cell-mediated immunity in patients with CLL.",Journal Article,3253.0,57.0,Lenalidomide an immunomodulatory agent has activity in lymphoproliferative disorders The authors therefore evaluated its effects on T-cell immunophenotype and cytokine production in patients with chronic lymphocytic CLL To study the immunomodulatory effects of lenalidomide in CLL the authors recruited 24 patients with untreated CLL enrolled in a phase 2 clinical trial of lenalidomide and obtained peripheral blood specimens for immunologic studies consisting of enumeration of T cells and assessing their ability to synthesize cytokines after activation through T-cell receptor TCR After 3 cycles of therapy patients had a significant reduction in percentage and absolute lymphocyte count ALC and an increase in percentage of T cells percentage of activated CD8 T cells producing IFN- and percentage of regulatory T T R cells when compared with their respective levels before treatment After 15 cycles of treatment responder patients had significant reduction in percentage of lymphocytes and ALC percentage of activated CD4 T cells producing IL-2 IFN- or TNF- and percentage of T R cells when compared with their perspective levels after 3 cycles of treatment Furthermore the numbers of activated CD4 T cells producing IL-2 IFN- or TNF- activated CD8 T cells producing IFN- and T R cells normalized to the range of healthy subjects Treatment with lenalidomide resulted in the normalization of functional T-cell subsets in responders suggesting that lenalidomide may modulate cell-mediated immunity in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 35, 2555, 420, 71, 128, 4, 4192, 1997, 3, 738, 673, 194, 211, 176, 23, 102, 31, 5496, 2, 1675, 1529, 4, 7, 5, 442, 1193, 552, 6, 45, 3, 2555, 176, 1, 1288, 4, 552, 3, 738, 2619, 259, 7, 5, 1278, 552, 346, 4, 8, 124, 18, 38, 160, 1, 1288, 2, 683, 672, 315, 623, 9, 3042, 94, 2273, 1, 7014, 1, 102, 37, 2, 1977, 136, 801, 6, 11254, 1886, 50, 363, 298, 102, 31, 153, 4134, 50, 27, 410, 1, 36, 7, 42, 8, 93, 628, 4, 1150, 2, 1766, 1448, 1276, 3749, 2, 35, 344, 4, 1150, 1, 102, 37, 1150, 1, 735, 968, 102, 37, 3787, 1256, 2655, 2, 1150, 1, 1253, 102, 102, 668, 37, 198, 72, 5, 136, 3847, 148, 348, 24, 50, 167, 410, 1, 24, 8735, 7, 42, 93, 628, 4, 1150, 1, 1594, 2, 3749, 1150, 1, 735, 1440, 102, 37, 3787, 501, 18, 1256, 2655, 15, 2254, 2014, 2, 1150, 1, 102, 668, 37, 198, 72, 5, 136, 3727, 148, 50, 27, 410, 1, 24, 798, 3, 1870, 1, 735, 1440, 102, 37, 3787, 501, 18, 1256, 2655, 15, 2254, 2014, 735, 968, 102, 37, 3787, 1256, 2655, 2, 102, 668, 37, 4207, 6, 3, 184, 1, 1331, 976, 24, 5, 1288, 627, 4, 3, 5924, 1, 583, 102, 31, 1890, 4, 1983, 802, 17, 1288, 68, 3319, 31, 517, 1604, 4, 7, 5, 552]",1528.0,21858802,234
Adverse prognostic features in chronic lymphocytic leukemia.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2011-07-01,"Patients with chronic lymphocytic leukemia (CLL) can have variable courses, from indolent disease to rapid progression with limited response to treatment. The Rai and Binet staging systems were the first to classify patients into prognostic categories. Newer prognostic markers that correlate with shorter time to progression and time to treatment include elevated serum beta2M, TK, ZAP-70, and CD38, as well as unmutated IgV(H). Abnormal cytogenetics are found in the majority of patients with CLL. Del(17p), as well as mutations of TP53, is associated with an aggressive clinical course and short overall survival. Nearly one-fifth of patients have del(11q) and have a significantly shorter median progression-free survival; mutations in the ATM gene, located on 11q, may also have adverse prognostic implications. Intermediate-risk cytogenetic findings include trisomy 12 and del(6q). Patients with del(17p) should be evaluated for novel agents and/or allogeneic stem cell transplantation in first remission. Patients with del(11q) require treatment with an alkylating agent in addition to nucleoside analogs and rituximab, and patients with trisomy 12q may express higher levels of CD20, thereby making the malignant cells more susceptible to biologic agents that target CD20. Despite advances in stratifying patients and improved chemoimmunotherapeutic regimens, additional research in prognostication and treatment is needed.",Journal Article,3126.0,6.0,Patients with chronic lymphocytic CLL can have variable courses from indolent disease to rapid progression with limited response to treatment The Rai and Binet staging systems were the first to classify patients into prognostic categories Newer prognostic markers that correlate with shorter time to progression and time to treatment include elevated serum beta2M TK ZAP-70 and CD38 as well as unmutated IgV H Abnormal cytogenetics are found in the majority of patients with CLL Del 17p as well as mutations of TP53 is associated with an aggressive clinical course and short overall survival Nearly one-fifth of patients have del 11q and have a significantly shorter median progression-free survival mutations in the ATM gene located on 11q may also have adverse prognostic implications Intermediate-risk cytogenetic findings include trisomy 12 and del 6q Patients with del 17p should be evaluated for novel agents and/or allogeneic stem cell transplantation in first remission Patients with del 11q require treatment with an alkylating agent in addition to nucleoside analogs and rituximab and patients with trisomy 12q may express higher levels of CD20 thereby making the malignant cells more susceptible to biologic agents that target CD20 Despite advances in stratifying patients and improved chemoimmunotherapeutic regimens additional research in prognostication and treatment is needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 122, 47, 1347, 1993, 29, 2316, 34, 6, 1321, 91, 5, 383, 51, 6, 24, 3, 4121, 2, 17129, 632, 1530, 11, 3, 157, 6, 4896, 7, 237, 177, 1996, 2246, 177, 525, 17, 1513, 5, 985, 98, 6, 91, 2, 98, 6, 24, 643, 804, 524, 12130, 5067, 6251, 431, 2, 4469, 22, 149, 22, 7216, 12179, 555, 1668, 2510, 32, 204, 4, 3, 686, 1, 7, 5, 552, 3084, 4135, 22, 149, 22, 138, 1, 1206, 16, 41, 5, 35, 571, 38, 906, 2, 978, 63, 25, 1857, 104, 5780, 1, 7, 47, 3084, 7203, 2, 47, 8, 97, 985, 52, 91, 115, 25, 138, 4, 3, 3552, 145, 2308, 23, 7203, 68, 120, 47, 290, 177, 1268, 919, 43, 1266, 272, 643, 6317, 133, 2, 3084, 10961, 7, 5, 3084, 4135, 257, 40, 194, 9, 229, 183, 2, 15, 1063, 452, 31, 497, 4, 157, 734, 7, 5, 3084, 7203, 1353, 24, 5, 35, 3410, 420, 4, 352, 6, 4032, 4063, 2, 855, 2, 7, 5, 6317, 18763, 68, 1669, 142, 148, 1, 2198, 2267, 1079, 3, 393, 37, 80, 4012, 6, 1283, 183, 17, 283, 2198, 550, 954, 4, 5035, 7, 2, 231, 45519, 472, 402, 389, 4, 4260, 2, 24, 16, 575]",1391.0,21874830,148
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2011-11-15,"Based on clinical activity in phase 2 studies, lenalidomide was evaluated in a phase 2/3 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Following tumor lysis syndrome (TLS) complications, the protocol was amended to a phase 1 study to identify the maximum tolerated dose-escalation level (MTDEL). Fifty-two heavily pretreated patients, 69% with bulky disease and 48% with high-risk genomic abnormalities, initiated lenalidomide at 2.5 mg/day, with dose escalation until the MTDEL or the maximum assigned dose was attained. Lenalidomide was safely titrated to 20 mg/day; the MTDEL was not reached. Most common grade 3-4 adverse events were neutropenia and thrombocytopenia; TLS was mild and rare. The low starting dose and conservative dose escalation strategy resulted in six partial responders and 30 patients obtaining stable disease. In summary, lenalidomide 2.5 mg/day is a safe starting dose that can be titrated up to 20 mg/day in patients with CLL.","Clinical Trial, Phase I",2989.0,47.0,Based on clinical activity in phase 2 studies lenalidomide was evaluated in a phase 2/3 study in patients with relapsed/refractory chronic lymphocytic CLL Following tumor lysis syndrome TLS complications the protocol was amended to a phase 1 study to identify the maximum tolerated dose-escalation level MTDEL Fifty-two heavily pretreated patients 69 with bulky disease and 48 with high-risk genomic abnormalities initiated lenalidomide at 2.5 mg/day with dose escalation until the MTDEL or the maximum assigned dose was attained Lenalidomide was safely titrated to 20 mg/day the MTDEL was not reached Most common grade 3-4 adverse events were neutropenia and thrombocytopenia TLS was mild and rare The low starting dose and conservative dose escalation strategy resulted in six partial responders and 30 patients obtaining stable disease In summary lenalidomide 2.5 mg/day is a safe starting dose that can be titrated up to 20 mg/day in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[90, 23, 38, 128, 4, 124, 18, 94, 1288, 10, 194, 4, 8, 124, 18, 27, 45, 4, 7, 5, 591, 430, 442, 1193, 552, 366, 30, 4783, 681, 8778, 521, 3, 1182, 10, 7595, 6, 8, 124, 14, 45, 6, 255, 3, 689, 421, 61, 1125, 301, 39743, 1461, 100, 2447, 2193, 7, 790, 5, 4112, 34, 2, 576, 5, 64, 43, 572, 1171, 1917, 1288, 28, 18, 33, 81, 218, 5, 61, 1125, 1100, 3, 39743, 15, 3, 689, 896, 61, 10, 5105, 1288, 10, 2268, 15875, 6, 179, 81, 218, 3, 39743, 10, 44, 1300, 96, 186, 88, 27, 39, 290, 281, 11, 778, 2, 1340, 8778, 10, 1980, 2, 622, 3, 154, 1723, 61, 2, 4476, 61, 1125, 692, 627, 4, 437, 450, 1983, 2, 201, 7, 5244, 585, 34, 4, 1962, 1288, 18, 33, 81, 218, 16, 8, 1165, 1723, 61, 17, 122, 40, 15875, 126, 6, 179, 81, 218, 4, 7, 5, 552]",955.0,21879809,237
Signal transduction inhibitors in chronic lymphocytic leukemia.,Current opinion in oncology,Curr Opin Oncol,2011-11-01,"Chronic lymphocytic leukemia (CLL) therapy has evolved over the past few decades as modern chemo-immunotherapy significantly improved the response and survival of CLL patients. However, treatment toxicity of the intensive chemo-immunotherapy often limits its use in the mostly elderly population of patients. Further, the disease eventually relapses and additional therapy options are required. Of particular interest are molecular targeted therapies that interfere with critical signal transduction pathways controlling cell growth and survival. This review will provide an update on the most recent preclinical and clinical development of signal transduction targeted therapy in CLL. Small molecular kinase inhibitors have been developed to target the proximal B-cell receptor signaling pathway (e.g. spleen tyrosine kinase inhibitors and Bruton's tyrosine kinase inhibitors) or the downstream phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin pathway. These agents showed unique in-vitro activities by inducing apoptosis and blocking interaction of CLL cells and the protective microenvironment. They have also shown promising clinical activity in early-phase clinical studies and appear to alter lymphocyte trafficking. Inhibitors of the B-cell CLL/lymphoma 2 (BCL-2) family of antiapoptotic proteins and Cdk inhibitors are in active clinical development. Strategies modulating the CLL interaction with the microenvironment niche are emerging. Further understanding of novel signaling pathways helps to identify additional potential therapeutic targets. Signal transduction inhibitors are promising new strategy for targeted CLL treatment. Identification of novel molecular targets and therapeutic agents will further expand our therapeutic options.",Journal Article,3003.0,13.0,Chronic lymphocytic CLL therapy has evolved over the past few decades as modern chemo-immunotherapy significantly improved the response and survival of CLL patients However treatment toxicity of the intensive chemo-immunotherapy often limits its use in the mostly elderly population of patients Further the disease eventually relapses and additional therapy options are required Of particular interest are molecular targeted therapies that interfere with critical signal transduction pathways controlling cell growth and survival This review will provide an update on the most recent preclinical and clinical development of signal transduction targeted therapy in CLL Small molecular kinase inhibitors have been developed to target the proximal B-cell receptor signaling pathway e.g spleen tyrosine kinase inhibitors and Bruton 's tyrosine kinase inhibitors or the downstream phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin pathway These agents showed unique in-vitro activities by inducing apoptosis and blocking interaction of CLL cells and the protective microenvironment They have also shown promising clinical activity in early-phase clinical studies and appear to alter lymphocyte trafficking Inhibitors of the B-cell CLL/lymphoma 2 BCL-2 family of antiapoptotic proteins and Cdk inhibitors are in active clinical development Strategies modulating the CLL interaction with the microenvironment niche are emerging Further understanding of novel signaling pathways helps to identify additional potential therapeutic targets Signal transduction inhibitors are promising new strategy for targeted CLL treatment Identification of novel molecular targets and therapeutic agents will further expand our therapeutic options,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 36, 71, 3937, 252, 3, 1219, 1021, 1968, 22, 2366, 3341, 726, 97, 231, 3, 51, 2, 25, 1, 552, 7, 137, 24, 155, 1, 3, 1686, 3341, 726, 629, 3526, 211, 119, 4, 3, 2754, 1216, 266, 1, 7, 195, 3, 34, 3124, 3713, 2, 402, 36, 838, 32, 616, 1, 1454, 1333, 32, 219, 238, 235, 17, 6178, 5, 740, 1235, 2761, 460, 1893, 31, 129, 2, 25, 26, 206, 303, 377, 35, 2991, 23, 3, 96, 435, 693, 2, 38, 193, 1, 1235, 2761, 238, 36, 4, 552, 302, 219, 216, 222, 47, 85, 276, 6, 283, 3, 2805, 132, 31, 153, 314, 308, 563, 499, 4071, 564, 216, 222, 2, 5796, 292, 564, 216, 222, 15, 3, 1489, 3415, 27, 216, 649, 2359, 283, 1, 1620, 308, 46, 183, 224, 991, 4, 439, 2042, 20, 1958, 351, 2, 2521, 915, 1, 552, 37, 2, 3, 2864, 995, 491, 47, 120, 443, 721, 38, 128, 4, 191, 124, 38, 94, 2, 1322, 6, 2688, 1448, 6105, 222, 1, 3, 132, 31, 552, 4763, 18, 1044, 18, 607, 1, 4176, 652, 2, 3954, 222, 32, 4, 544, 38, 193, 422, 3712, 3, 552, 915, 5, 3, 995, 4385, 32, 1478, 195, 612, 1, 229, 314, 460, 6484, 6, 255, 402, 174, 189, 637, 1235, 2761, 222, 32, 721, 217, 692, 9, 238, 552, 24, 911, 1, 229, 219, 637, 2, 189, 183, 303, 195, 4082, 114, 189, 838]",1737.0,21892084,704
Quantitative analyses of DAPK1 methylation in AML and MDS.,International journal of cancer,Int. J. Cancer,2011-11-28,"Aberrant DNA methylation and concomitant transcriptional silencing of death-associated protein kinase 1 (DAPK1) have been demonstrated to be key pathogenic events in chronic lymphocytic leukemia (CLL). In acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), however, the presence of elevated DNA methylation levels has been a matter of continued controversy. Several studies demonstrated highly variable frequencies of DAPK1 promoter methylation by the use of methylation-specific PCR (MSP). By quantitative high-resolution assessment, we demonstrate that aberrant DNA methylation is an extremely rare event in this region. We observed elevated levels just in one out of 246 (0.4%) AML patients, all 42 MDS patients were unmethylated. In conclusion, we present a refined DAPK1 methylation analysis in a large representative patient cohort of AML and MDS patients proofing almost complete absence of elevated DNA methylation. Our results highlight the importance of quantitative measurements for translational research questions on primary patient specimens, particularly.",Journal Article,2976.0,27.0,Aberrant DNA methylation and concomitant transcriptional silencing of death-associated protein kinase 1 DAPK1 have been demonstrated to be key pathogenic events in chronic lymphocytic CLL In acute myeloid AML and syndrome MDS however the presence of elevated DNA methylation levels has been a matter of continued controversy Several studies demonstrated highly variable frequencies of DAPK1 promoter methylation by the use of methylation-specific PCR MSP By quantitative high-resolution assessment we demonstrate that aberrant DNA methylation is an extremely rare event in this region We observed elevated levels just in one out of 246 0.4 AML patients all 42 MDS patients were unmethylated In conclusion we present a refined DAPK1 methylation analysis in a large representative patient cohort of AML and MDS patients proofing almost complete absence of elevated DNA methylation Our results highlight the importance of quantitative measurements for translational research questions on primary patient specimens particularly,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1898, 261, 569, 2, 1781, 1431, 2077, 1, 273, 41, 178, 216, 14, 11503, 47, 85, 264, 6, 40, 825, 2806, 281, 4, 442, 1193, 552, 4, 286, 533, 329, 2, 681, 1223, 137, 3, 463, 1, 804, 261, 569, 148, 71, 85, 8, 5090, 1, 1351, 4089, 392, 94, 264, 561, 1347, 2722, 1, 11503, 973, 569, 20, 3, 119, 1, 569, 112, 604, 8858, 20, 1156, 64, 2125, 455, 21, 608, 17, 1898, 261, 569, 16, 35, 2938, 622, 774, 4, 26, 1053, 21, 164, 804, 148, 4673, 4, 104, 1205, 1, 6907, 13, 39, 329, 7, 62, 595, 1223, 7, 11, 8100, 4, 1221, 21, 364, 8, 5332, 11503, 569, 65, 4, 8, 375, 3724, 69, 180, 1, 329, 2, 1223, 7, 60548, 2214, 236, 1127, 1, 804, 261, 569, 114, 99, 1817, 3, 1187, 1, 1156, 1685, 9, 2460, 389, 1937, 23, 86, 69, 623, 823]",1023.0,21918973,113
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-10-03,"The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram-a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.",Journal Article,3032.0,85.0,The clinical course for patients with chronic lymphocytic CLL is diverse some patients have indolent disease never needing treatment whereas others have aggressive disease requiring early treatment We continue to use criteria for active disease to initiate therapy Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL Traditional laboratory clinical prognostic and newer prognostic factors such as fluorescent in situ hybridization FISH IGHV mutation status and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment This multivariable model was used to develop a nomogram-a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment There were 930 previously untreated patients who had traditional and new prognostic factors evaluated they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment The following were independently associated with shorter time to first treatment three involved lymph node sites increased size of lymph nodes presence of 17p deletion or 11q deletion by FISH increased serum lactate dehydrogenase and unmutated IGHV mutation status We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment This model may be useful to identify patients for early interventional trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[3, 38, 906, 9, 7, 5, 442, 1193, 552, 16, 1867, 476, 7, 47, 2316, 34, 1737, 12864, 24, 547, 1749, 47, 571, 34, 1888, 191, 24, 21, 1906, 6, 119, 371, 9, 544, 34, 6, 4565, 36, 658, 65, 10, 173, 6, 255, 177, 130, 1042, 41, 5, 98, 6, 157, 24, 9, 7, 5, 552, 1847, 1624, 38, 177, 2, 2246, 177, 130, 225, 22, 2910, 4, 957, 1554, 1277, 6220, 258, 156, 2, 6251, 431, 55, 194, 28, 157, 69, 2807, 6, 2244, 1929, 12, 574, 11, 438, 20, 658, 65, 5, 98, 6, 157, 24, 26, 658, 202, 10, 95, 6, 690, 8, 1981, 8, 2337, 1515, 6, 3232, 18, 2, 39, 111, 1320, 1, 24, 2, 1191, 52, 98, 6, 157, 24, 125, 11, 13416, 373, 1278, 7, 54, 42, 1847, 2, 217, 177, 130, 194, 491, 205, 44, 47, 544, 552, 1888, 1118, 1, 24, 262, 27, 53, 1, 157, 2807, 2, 11, 164, 9, 98, 6, 157, 24, 3, 366, 11, 1042, 41, 5, 985, 98, 6, 157, 24, 169, 646, 263, 289, 633, 101, 444, 1, 263, 502, 463, 1, 4135, 1528, 15, 7203, 1528, 20, 1277, 101, 524, 3330, 2374, 2, 7216, 6220, 258, 156, 21, 276, 8, 658, 202, 17, 6175, 1847, 2, 2246, 177, 130, 6, 255, 7, 28, 64, 43, 9, 91, 6, 24, 26, 202, 68, 40, 999, 6, 255, 7, 9, 191, 6182, 143]",1613.0,21969505,314
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.,Blood,Blood,2011-10-14,"We previously demonstrated that the gene encoding PTPROt, the truncated form of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, is a candidate tumor suppressor and is down-regulated in chronic lymphocytic leukemia (CLL). Here, we show that PTPROt expression is significantly reduced in CD19(+) spleen B cells from E-T cell leukemia 1 (TCL1) transgenic mice relative to the wild-type mice. Strikingly, as much as a 60% decrease in PTPROt expression occurs at 7 weeks independently of promoter methylation. To elucidate the potential mechanism for this early suppression of PTPROt in these mice, we explored the role of activating protein-1 (AP-1) in its expression. We first demonstrate that AP-1 activation by 12-O-tetradecanoylphorbol-13-acetate induces PTPROt expression with concurrent recruitment of c-fos and c-jun to its promoter. The PTPROt promoter is also responsive to over- and underexpression of AP-1, confirming the role of AP-1 in PTPROt expression. Next, we demonstrate that TCL1 can repress the PTPROt promoter by altering c-fos expression and c-jun activation state. Finally, using primary CLL cells we have shown an inverse relationship between TCL1 and PTPROt expression. These findings further substantiate the role of TCL1 in PTPROt suppression and its importance in the pathogenesis of CLL.",Journal Article,3021.0,14.0,We previously demonstrated that the gene encoding PTPROt the truncated form of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells is a candidate tumor suppressor and is down-regulated in chronic lymphocytic CLL Here we show that PTPROt expression is significantly reduced in CD19 spleen B cells from E-T cell 1 TCL1 transgenic mice relative to the wild-type mice Strikingly as much as a 60 decrease in PTPROt expression occurs at 7 weeks independently of promoter methylation To elucidate the potential mechanism for this early suppression of PTPROt in these mice we explored the role of activating protein-1 AP-1 in its expression We first demonstrate that AP-1 activation by 12-O-tetradecanoylphorbol-13-acetate induces PTPROt expression with concurrent recruitment of c-fos and c-jun to its promoter The PTPROt promoter is also responsive to over- and underexpression of AP-1 confirming the role of AP-1 in PTPROt expression Next we demonstrate that TCL1 can repress the PTPROt promoter by altering c-fos expression and c-jun activation state Finally using primary CLL cells we have shown an inverse relationship between TCL1 and PTPROt expression These findings further substantiate the role of TCL1 in PTPROt suppression and its importance in the pathogenesis of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 373, 264, 17, 3, 145, 2362, 18508, 3, 6502, 1297, 1, 178, 564, 2577, 153, 267, 1990, 570, 2117, 4, 1007, 37, 16, 8, 1609, 30, 1245, 2, 16, 1328, 1065, 4, 442, 1193, 552, 467, 21, 514, 17, 18508, 55, 16, 97, 405, 4, 3158, 4071, 132, 37, 29, 17467, 102, 31, 14, 8979, 2862, 399, 580, 6, 3, 955, 267, 399, 6787, 22, 1802, 22, 8, 335, 775, 4, 18508, 55, 1780, 28, 67, 244, 1042, 1, 973, 569, 6, 3061, 3, 174, 670, 9, 26, 191, 1332, 1, 18508, 4, 46, 399, 21, 1443, 3, 200, 1, 1616, 178, 14, 2517, 14, 4, 211, 55, 21, 157, 608, 17, 2517, 14, 363, 20, 133, 1990, 28692, 233, 3424, 1516, 18508, 55, 5, 750, 3202, 1, 256, 9737, 2, 256, 4578, 6, 211, 973, 3, 18508, 973, 16, 120, 2443, 6, 252, 2, 22250, 1, 2517, 14, 5030, 3, 200, 1, 2517, 14, 4, 18508, 55, 1305, 21, 608, 17, 8979, 122, 11385, 3, 18508, 973, 20, 4831, 256, 9737, 55, 2, 256, 4578, 363, 1309, 1368, 75, 86, 552, 37, 21, 47, 443, 35, 2931, 858, 59, 8979, 2, 18508, 55, 46, 272, 195, 16249, 3, 200, 1, 8979, 4, 18508, 1332, 2, 211, 1187, 4, 3, 1384, 1, 552]",1313.0,22001392,58
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).,Cancer,Cancer,2011-08-26,"The impact of physicians' disease-specific expertise on patient outcome is unknown. Although previous studies suggest a survival advantage for cancer patients cared for at high-volume centers, these observations may simply reflect referral bias or better access to advanced technologies, clinical trials, and multidisciplinary support at large centers. We evaluated time to first treatment (TTFT) and overall survival (OS) of patients with newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) at a single academic center based on whether they were cared for by a hematologist/oncologist who subspecializes in CLL (CLL hematologist) or a hematologist/oncologist with expertise in other areas (non-CLL hematologist). Among 1309 newly diagnosed patients with CLL cared for between 1999 and 2009, 773(59%) were cared for by CLL hematologists and 536 were cared for by non-CLL hematologists. Among early-stage patients (Rai 0-I), median TTFT (9.2 vs 6.1 years; P < .001) and OS (10.5 years vs 8.8 years; P < .001) were longer for patients cared for by CLL hematologists. For all patients, OS was superior for patients cared for by CLL hematologists (10.5 years vs 8.4 years; P = .001). Physician's disease-specific expertise remained an independent predictor of OS after adjusting for age, sex, stage, and lymphocyte count at diagnosis. Patients seen by a CLL hematologist were also more likely to participate in clinical trials (48% vs 16%; P < .001). Physician disease-specific expertise appears to influence outcome in patients with CLL. To the greatest extent possible, patients should be cared for by a hematologist/oncologist expert in the care of their specific malignancy. When not possible, practice guidelines developed by disease-specific experts should be followed.",Journal Article,3070.0,21.0,The impact of physicians disease-specific expertise on patient outcome is unknown Although previous studies suggest a survival advantage for cancer patients cared for at high-volume centers these observations may simply reflect referral bias or better access to advanced technologies clinical trials and multidisciplinary support at large centers We evaluated time to first treatment TTFT and overall survival OS of patients with newly diagnosed chronic lymphocytic leukemia/small lymphocytic CLL at a single academic center based on whether they were cared for by a hematologist/oncologist who subspecializes in CLL CLL hematologist or a hematologist/oncologist with expertise in other areas non-CLL hematologist Among 1309 newly diagnosed patients with CLL cared for between 1999 and 2009 773 59 were cared for by CLL hematologists and 536 were cared for by non-CLL hematologists Among early-stage patients Rai 0-I median TTFT 9.2 vs 6.1 years P .001 and OS 10.5 years vs 8.8 years P .001 were longer for patients cared for by CLL hematologists For all patients OS was superior for patients cared for by CLL hematologists 10.5 years vs 8.4 years P .001 Physician 's disease-specific expertise remained an independent predictor of OS after adjusting for age sex stage and lymphocyte count at diagnosis Patients seen by a CLL hematologist were also more likely to participate in clinical trials 48 vs 16 P .001 Physician disease-specific expertise appears to influence outcome in patients with CLL To the greatest extent possible patients should be cared for by a hematologist/oncologist expert in the care of their specific malignancy When not possible practice guidelines developed by disease-specific experts should be followed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 345, 1, 1261, 34, 112, 4935, 23, 69, 228, 16, 860, 242, 698, 94, 309, 8, 25, 1874, 9, 12, 7, 12743, 9, 28, 64, 433, 1168, 46, 2172, 68, 8908, 2694, 2096, 2947, 15, 380, 1655, 6, 131, 2590, 38, 143, 2, 1643, 538, 28, 375, 1168, 21, 194, 98, 6, 157, 24, 14035, 2, 63, 25, 118, 1, 7, 5, 732, 265, 442, 1193, 2647, 302, 1193, 552, 28, 8, 226, 1916, 574, 90, 23, 317, 491, 11, 12743, 9, 20, 8, 15278, 2709, 54, 60704, 4, 552, 552, 15278, 15, 8, 15278, 2709, 5, 4935, 4, 127, 1361, 220, 552, 15278, 107, 27106, 732, 265, 7, 5, 552, 12743, 9, 59, 2043, 2, 1238, 13406, 728, 11, 12743, 9, 20, 552, 11474, 2, 11274, 11, 12743, 9, 20, 220, 552, 11474, 107, 191, 82, 7, 4121, 13, 70, 52, 14035, 83, 18, 105, 49, 14, 60, 19, 144, 2, 118, 79, 33, 60, 105, 66, 66, 60, 19, 144, 11, 589, 9, 7, 12743, 9, 20, 552, 11474, 9, 62, 7, 118, 10, 1123, 9, 7, 12743, 9, 20, 552, 11474, 79, 33, 60, 105, 66, 39, 60, 19, 144, 1473, 292, 34, 112, 4935, 958, 35, 306, 980, 1, 118, 50, 1358, 9, 89, 1035, 82, 2, 1448, 1276, 28, 147, 7, 527, 20, 8, 552, 15278, 11, 120, 80, 322, 6, 3506, 4, 38, 143, 576, 105, 245, 19, 144, 1473, 34, 112, 4935, 1233, 6, 1054, 228, 4, 7, 5, 552, 6, 3, 2199, 1039, 899, 7, 257, 40, 12743, 9, 20, 8, 15278, 2709, 2005, 4, 3, 165, 1, 136, 112, 710, 198, 44, 899, 758, 677, 276, 20, 34, 112, 3186, 257, 40, 370]",1730.0,22009554,418
"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2011-11-11,"This study is focused on therapy-related myeloid neoplasms after the most promising frontline FCR (fludarabine, cyclophosphamide, and rituximab) therapy in previously untreated chronic lymphocytic leukemia patients. A total of 28 therapy-related myeloid neoplasm patients were identified, including 19 patients from 3 well-controlled FCR frontline trials (n=426 patients), giving an estimated frequency of 4.5% (1.9-8.3%) in a follow-up period of 44 months (range 5-122 months). Clinically, therapy-related myeloid neoplasms could emerge directly from 'prolonged myelosuppression' after FCR (10 patients), or after achieving complete hematological recovery (n=18). The overall latency was 35 months (range 3-118 months), with the former group of 23 months and the latter 42 months (P<0.001). In all, 10 cases presented as therapy-related acute myeloid leukemia and 18 as therapy-related myelodysplastic syndromes. Abnormal cytogenetics was present in 26 of 27 (96%) patients, with frequent chromosomes 5 and 7 abnormalities. The median survival was 7 months after therapy-related myeloid neoplasms. Our results indicate that the risk of therapy-related myeloid neoplasms secondary to frontline FCR therapy may not be as high as previously reported after removing the confounding factor of previous cytotoxic exposure, but this risk increased with older age and likely growth factor co-administration. Therapy-related myeloid neoplasms after FCR therapy shares clinicopathological features with therapy-related myeloid neoplasms secondary to other alkylating agents, but has a shorter latency interval indicating possible synergetic effects of the nucleotide analog fludarabine. The fact that therapy-related myeloid neoplasms can directly emerge from 'prolonged myelosuppression' warrants a bone marrow examination to rule out therapy-related myeloid neoplasms in this clinical setting.",Journal Article,2993.0,48.0,This study is focused on therapy-related myeloid neoplasms after the most promising frontline FCR fludarabine cyclophosphamide and rituximab therapy in previously untreated chronic lymphocytic patients A total of 28 therapy-related myeloid neoplasm patients were identified including 19 patients from 3 well-controlled FCR frontline trials n=426 patients giving an estimated frequency of 4.5 1.9-8.3 in a follow-up period of 44 months range 5-122 months Clinically therapy-related myeloid neoplasms could emerge directly from 'prolonged myelosuppression after FCR 10 patients or after achieving complete hematological recovery n=18 The overall latency was 35 months range 3-118 months with the former group of 23 months and the latter 42 months P 0.001 In all 10 cases presented as therapy-related acute myeloid and 18 as therapy-related syndromes Abnormal cytogenetics was present in 26 of 27 96 patients with frequent chromosomes 5 and 7 abnormalities The median survival was 7 months after therapy-related myeloid neoplasms Our results indicate that the risk of therapy-related myeloid neoplasms secondary to frontline FCR therapy may not be as high as previously reported after removing the confounding factor of previous cytotoxic exposure but this risk increased with older age and likely growth factor co-administration Therapy-related myeloid neoplasms after FCR therapy shares clinicopathological features with therapy-related myeloid neoplasms secondary to other alkylating agents but has a shorter latency interval indicating possible synergetic effects of the nucleotide analog fludarabine The fact that therapy-related myeloid neoplasms can directly emerge from 'prolonged myelosuppression warrants a marrow examination to rule out therapy-related myeloid neoplasms in this clinical setting,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 45, 16, 1649, 23, 36, 139, 533, 1179, 50, 3, 96, 721, 3171, 4953, 2027, 1112, 2, 855, 36, 4, 373, 1278, 442, 1193, 7, 8, 181, 1, 339, 36, 139, 533, 2131, 7, 11, 108, 141, 326, 7, 29, 27, 149, 1149, 4953, 3171, 143, 78, 12114, 7, 7375, 35, 661, 675, 1, 39, 33, 14, 83, 66, 27, 4, 8, 166, 126, 727, 1, 584, 53, 184, 33, 3285, 53, 505, 36, 139, 533, 1179, 359, 6371, 1606, 29, 46881, 2858, 50, 4953, 79, 7, 15, 50, 1785, 236, 2890, 1602, 78, 203, 3, 63, 5301, 10, 465, 53, 184, 27, 4002, 53, 5, 3, 3623, 87, 1, 382, 53, 2, 3, 3286, 595, 53, 19, 13, 144, 4, 62, 79, 140, 917, 22, 36, 139, 286, 533, 2, 203, 22, 36, 139, 2040, 1668, 2510, 10, 364, 4, 432, 1, 428, 921, 7, 5, 908, 3560, 33, 2, 67, 1171, 3, 52, 25, 10, 67, 53, 50, 36, 139, 533, 1179, 114, 99, 1008, 17, 3, 43, 1, 36, 139, 533, 1179, 568, 6, 3171, 4953, 36, 68, 44, 40, 22, 64, 22, 373, 210, 50, 9026, 3, 4339, 161, 1, 698, 759, 645, 84, 26, 43, 101, 5, 434, 89, 2, 322, 129, 161, 1269, 634, 36, 139, 533, 1179, 50, 4953, 36, 10641, 2721, 404, 5, 36, 139, 533, 1179, 568, 6, 127, 3410, 183, 84, 71, 8, 985, 5301, 268, 1716, 899, 31884, 176, 1, 3, 1579, 3497, 2027, 3, 1991, 17, 36, 139, 533, 1179, 122, 1606, 6371, 29, 46881, 2858, 2782, 8, 581, 1385, 6, 5340, 1205, 36, 139, 533, 1179, 4, 26, 38, 546]",1803.0,22080061,85
"Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.",Blood,Blood,2011-11-16,"Chronic lymphocytic leukemia (CLL) demonstrates a global down-regulation of miR-15a and miR-16 and a selective silencing of the related miR-29b in aggressive disease. Deletions in chromosome 13 [del(13q14)] partially account for the loss of expression of miR-15a and miR-16, but the mechanisms by which miR-29b becomes silenced is unknown. In the present study, we show that the histone deacetylases (HDACs) are overexpressed in CLL and mediate the epigenetic silencing of miR-15a, miR-16, and miR-29b. HDAC inhibition triggered the accumulation of the transcriptionally activating chromatin modification H3K4me2 and restored the expression of miR-15a, miR-16, and miR-29b in approximately 35% of samples. Ectopic expression of miR-15a and miR-16 and HDAC inhibition-induced expression of miR-15a, miR-16, or miR-29b in primary CLL cells was associated with declines in the levels of Mcl-1, but not Bcl-2, mitochondrial dysfunction, and induction of cell death. Therefore, our results show that HDACs aberrantly silence the expression of the critical tumor suppressors miR-15a, miR-16, and miR-29b in CLL. Deacetylase inhibition may be a therapeutic strategy that restores the expression of these miRs to antagonize Mcl-1, an important survival protein in these cells. Consequently, CLL patients who exhibit such epigenetic silencing may benefit from HDAC inhibitor-based therapy.",Journal Article,2988.0,130.0,Chronic lymphocytic CLL demonstrates a global down-regulation of miR-15a and miR-16 and a selective silencing of the related miR-29b in aggressive disease Deletions in chromosome 13 del 13q14 partially account for the loss of expression of miR-15a and miR-16 but the mechanisms by which miR-29b becomes silenced is unknown In the present study we show that the histone deacetylases HDACs are overexpressed in CLL and mediate the epigenetic silencing of miR-15a miR-16 and miR-29b HDAC inhibition triggered the accumulation of the transcriptionally activating chromatin modification H3K4me2 and restored the expression of miR-15a miR-16 and miR-29b in approximately 35 of samples Ectopic expression of miR-15a and miR-16 and HDAC inhibition-induced expression of miR-15a miR-16 or miR-29b in primary CLL cells was associated with declines in the levels of Mcl-1 but not Bcl-2 mitochondrial dysfunction and induction of cell death Therefore our results show that HDACs aberrantly silence the expression of the critical tumor suppressors miR-15a miR-16 and miR-29b in CLL Deacetylase inhibition may be a therapeutic strategy that restores the expression of these miRs to antagonize Mcl-1 an important survival protein in these cells Consequently CLL patients who exhibit such epigenetic silencing may benefit from HDAC inhibitor-based therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 1902, 8, 1648, 1328, 863, 1, 722, 15377, 2, 722, 245, 2, 8, 1094, 2077, 1, 3, 139, 722, 9609, 4, 571, 34, 2439, 4, 1170, 233, 3084, 13221, 2995, 1967, 9, 3, 407, 1, 55, 1, 722, 15377, 2, 722, 245, 84, 3, 483, 20, 92, 722, 9609, 5366, 5442, 16, 860, 4, 3, 364, 45, 21, 514, 17, 3, 1508, 9758, 7803, 32, 1711, 4, 552, 2, 3367, 3, 1418, 2077, 1, 722, 15377, 722, 245, 2, 722, 9609, 2654, 297, 4173, 3, 1835, 1, 3, 6851, 1616, 2287, 2437, 31652, 2, 4138, 3, 55, 1, 722, 15377, 722, 245, 2, 722, 9609, 4, 705, 465, 1, 347, 3647, 55, 1, 722, 15377, 2, 722, 245, 2, 2654, 297, 277, 55, 1, 722, 15377, 722, 245, 15, 722, 9609, 4, 86, 552, 37, 10, 41, 5, 4264, 4, 3, 148, 1, 1308, 14, 84, 44, 1044, 18, 2019, 1527, 2, 504, 1, 31, 273, 673, 114, 99, 514, 17, 7803, 5619, 13557, 3, 55, 1, 3, 740, 30, 5704, 722, 15377, 722, 245, 2, 722, 9609, 4, 552, 2732, 297, 68, 40, 8, 189, 692, 17, 8489, 3, 55, 1, 46, 7569, 6, 12718, 1308, 14, 35, 305, 25, 178, 4, 46, 37, 3244, 552, 7, 54, 2239, 225, 1418, 2077, 68, 247, 29, 2654, 230, 90, 36]",1339.0,22096249,31
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2011-11-24,"The management of lymphoid malignancies has greatly evolved in the last decade with the advent of targeted therapies, which have improved response and survival in patients with Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and plasma cell myeloma (PCM). The PI3K pathway seems to play a seminal role in the development of lymphoid malignancies. CAL-101 is a highly selective PI3K p110 inhibitor currently undergoing clinical development. The aims of this review are to summarize our understanding of the PI3K pathway, its role in lymphoid malignancies, the preclinical and clinical experience accumulated with CAL-101, a PI3K inhibitor, and potential areas of future development. CAL-101 is a novel drug that has shown preclinical activity against CLL, NHL, HL and PCM cells. There is early evidence of clinical efficacy in CLL and indolent NHL. Studies using CAL-101 alone or in combination are also ongoing in PCM, HL and aggressive NHL. However, additional studies are needed to prove CAL-101 is effective and safe as the goals of therapy for patients with lymphoid neoplasms are not only directed towards improving response and cure rates but also prolonging survival without affecting quality of life.",Journal Article,2980.0,61.0,The management of lymphoid malignancies has greatly evolved in the last decade with the advent of targeted therapies which have improved response and survival in patients with 's HL 's NHL chronic lymphocytic CLL and plasma cell PCM The PI3K pathway seems to play a seminal role in the development of lymphoid malignancies CAL-101 is a highly selective PI3K p110 inhibitor currently undergoing clinical development The aims of this review are to summarize our understanding of the PI3K pathway its role in lymphoid malignancies the preclinical and clinical experience accumulated with CAL-101 a PI3K inhibitor and potential areas of future development CAL-101 is a novel drug that has shown preclinical activity against CLL NHL HL and PCM cells There is early evidence of clinical efficacy in CLL and indolent NHL Studies using CAL-101 alone or in combination are also ongoing in PCM HL and aggressive NHL However additional studies are needed to prove CAL-101 is effective and safe as the goals of therapy for patients with lymphoid neoplasms are not only directed towards improving response and cure rates but also prolonging survival without affecting quality of life,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 284, 1, 2303, 441, 71, 3510, 3937, 4, 3, 1060, 2025, 5, 3, 4114, 1, 238, 235, 92, 47, 231, 51, 2, 25, 4, 7, 5, 292, 1718, 292, 1176, 442, 1193, 552, 2, 554, 31, 12450, 3, 974, 308, 2744, 6, 1343, 8, 4786, 200, 4, 3, 193, 1, 2303, 441, 10368, 2338, 16, 8, 561, 1094, 974, 15762, 230, 694, 479, 38, 193, 3, 2970, 1, 26, 206, 32, 6, 2479, 114, 612, 1, 3, 974, 308, 211, 200, 4, 2303, 441, 3, 693, 2, 38, 730, 6664, 5, 10368, 2338, 8, 11063, 230, 2, 174, 1361, 1, 508, 193, 10368, 2338, 16, 8, 229, 234, 17, 71, 443, 693, 128, 480, 552, 1176, 1718, 2, 12450, 37, 125, 16, 191, 241, 1, 38, 209, 4, 552, 2, 2316, 1176, 94, 75, 10368, 2338, 279, 15, 4, 150, 32, 120, 942, 4, 12450, 1718, 2, 571, 1176, 137, 402, 94, 32, 575, 6, 4361, 10368, 2338, 16, 323, 2, 1165, 22, 3, 2802, 1, 36, 9, 7, 5, 2303, 1179, 32, 44, 158, 1166, 3113, 1673, 51, 2, 1722, 151, 84, 120, 5559, 25, 187, 2319, 372, 1, 358]",1172.0,22112004,768
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.,Cancer,Cancer,2011-12-02,"Fluorescence in situ hybridization can detect genomic abnormalities in up to 80% of cases and provides prognostic information on patients with chronic lymphocytic leukemia (CLL). Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis, there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q. The authors reviewed the electronic database for patients with CLL who carried the 13q deletion as the sole abnormality and presented to The University of Texas MD Anderson Cancer Center (MDACC). Untreated patients were separated into 2 groups: those having monoallelic versus those with biallelic deletion of 13q. Using Mann-Whitney, chi-square, and Kaplan-Meier analysis, the baseline quantitative and qualitative variables for each group, along with the time from presentation to MDACC to treatment, were compared. A total of 176 patients were identified; 143 patients had a monoallelic deletion of 13q, whereas 33 patients had a biallelic deletion. The only significantly different values between the groups were albumin (4.5 g/dL vs 4.4 g/dL; P = .01) and zeta-chain-associated protein kinase 70 (ZAP70) expression (1.7% vs 4.8%; P = .010). The median time from fluorescence in situ hybridization analysis to treatment in both the monoallelic and biallelic groups had not been reached (P = not significant). Except for inconsequential differences in albumin and ZAP70 expression, there was no difference in the baseline characteristics between patients with CLL who had monoallelic or biallelic deletion of 13q. In addition, there was no significant difference in endpoints, including time to treatment.",Journal Article,2972.0,21.0,Fluorescence in situ hybridization can detect genomic abnormalities in up to 80 of cases and provides prognostic information on patients with chronic lymphocytic CLL Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q The authors reviewed the electronic database for patients with CLL who carried the 13q deletion as the sole abnormality and presented to The University of Texas MD Anderson Cancer Center MDACC Untreated patients were separated into 2 groups those having monoallelic versus those with biallelic deletion of 13q Using Mann-Whitney chi-square and Kaplan-Meier analysis the baseline quantitative and qualitative variables for each group along with the time from presentation to MDACC to treatment were compared A total of 176 patients were identified 143 patients had a monoallelic deletion of 13q whereas 33 patients had a biallelic deletion The only significantly different values between the groups were albumin 4.5 g/dL vs 4.4 g/dL P .01 and zeta-chain-associated protein kinase 70 ZAP70 expression 1.7 vs 4.8 P .010 The median time from fluorescence in situ hybridization analysis to treatment in both the monoallelic and biallelic groups had not been reached P not significant Except for inconsequential differences in albumin and ZAP70 expression there was no difference in the baseline characteristics between patients with CLL who had monoallelic or biallelic deletion of 13q In addition there was no significant difference in endpoints including time to treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1591, 4, 957, 1554, 122, 1426, 572, 1171, 4, 126, 6, 493, 1, 140, 2, 777, 177, 487, 23, 7, 5, 442, 1193, 552, 242, 8453, 1528, 22, 3, 4991, 3698, 71, 85, 204, 6, 2913, 8, 913, 356, 125, 32, 1215, 74, 22, 6, 317, 125, 16, 8, 523, 4, 177, 549, 59, 11950, 185, 6435, 1528, 1, 8453, 3, 738, 446, 3, 3098, 609, 9, 7, 5, 552, 54, 2629, 3, 8453, 1528, 22, 3, 4991, 3698, 2, 917, 6, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 7412, 1278, 7, 11, 4910, 237, 18, 271, 135, 1041, 11950, 185, 135, 5, 6435, 1528, 1, 8453, 75, 7470, 7471, 3163, 3219, 2, 876, 882, 65, 3, 330, 1156, 2, 3926, 682, 9, 296, 87, 1510, 5, 3, 98, 29, 1031, 6, 7412, 6, 24, 11, 72, 8, 181, 1, 5800, 7, 11, 108, 4400, 7, 42, 8, 11950, 1528, 1, 8453, 547, 466, 7, 42, 8, 6435, 1528, 3, 158, 97, 338, 1030, 59, 3, 271, 11, 2799, 39, 33, 499, 1826, 105, 39, 39, 499, 1826, 19, 355, 2, 12105, 1260, 41, 178, 216, 431, 12921, 55, 14, 67, 105, 39, 66, 19, 4873, 3, 52, 98, 29, 1591, 4, 957, 1554, 65, 6, 24, 4, 110, 3, 11950, 2, 6435, 271, 42, 44, 85, 1300, 19, 44, 93, 2187, 9, 35245, 362, 4, 2799, 2, 12921, 55, 125, 10, 77, 523, 4, 3, 330, 374, 59, 7, 5, 552, 54, 42, 11950, 15, 6435, 1528, 1, 8453, 4, 352, 125, 10, 77, 93, 523, 4, 1387, 141, 98, 6, 24]",1659.0,22139735,336
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2011-12-12,"The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood. We obtained DNA samples from leukemia cells in 91 patients with chronic lymphocytic leukemia and performed massively parallel sequencing of 88 whole exomes and whole genomes, together with sequencing of matched germline DNA, to characterize the spectrum of somatic mutations in this disease. Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients). SF3B1 mutations occurred primarily in tumors with deletions in chromosome 11q, which are associated with a poor prognosis in patients with chronic lymphocytic leukemia. We further discovered that tumor samples with mutations in SF3B1 had alterations in pre-messenger RNA (mRNA) splicing. Our study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocytic leukemia.",Journal Article,2962.0,725.0,The somatic genetic basis of chronic lymphocytic a common and clinically heterogeneous occurring in adults remains poorly understood We obtained DNA samples from cells in 91 patients with chronic lymphocytic and performed massively parallel sequencing of 88 whole exomes and whole genomes together with sequencing of matched germline DNA to characterize the spectrum of somatic mutations in this disease Nine genes that are mutated at significant frequencies were identified including four with established roles in chronic lymphocytic TP53 in 15 of patients ATM in 9 MYD88 in 10 and NOTCH1 in 4 and five with unestablished roles SF3B1 ZMYM3 MAPK1 FBXW7 and DDX3X SF3B1 which functions at the catalytic core of the spliceosome was the second most frequently mutated gene with mutations occurring in 15 of patients SF3B1 mutations occurred primarily in tumors with deletions in chromosome 11q which are associated with a poor prognosis in patients with chronic lymphocytic We further discovered that tumor samples with mutations in SF3B1 had alterations in pre-messenger RNA mRNA splicing Our study defines the landscape of somatic mutations in chronic lymphocytic and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1119, 336, 877, 1, 442, 1193, 8, 186, 2, 505, 1564, 1821, 4, 857, 469, 1240, 1784, 21, 683, 261, 347, 29, 37, 4, 970, 7, 5, 442, 1193, 2, 173, 7284, 2755, 615, 1, 889, 902, 12233, 2, 902, 5085, 1162, 5, 615, 1, 655, 1009, 261, 6, 1507, 3, 1873, 1, 1119, 138, 4, 26, 34, 762, 214, 17, 32, 1185, 28, 93, 2722, 11, 108, 141, 294, 5, 635, 1790, 4, 442, 1193, 1206, 4, 167, 1, 7, 3552, 4, 83, 3986, 4, 79, 2, 4607, 4, 39, 2, 365, 5, 46706, 1790, 10132, 35253, 16563, 8352, 2, 21696, 10132, 92, 1681, 28, 3, 4784, 1793, 1, 3, 13443, 10, 3, 419, 96, 746, 1185, 145, 5, 138, 1821, 4, 167, 1, 7, 10132, 138, 489, 1561, 4, 57, 5, 2439, 4, 1170, 7203, 92, 32, 41, 5, 8, 334, 356, 4, 7, 5, 442, 1193, 21, 195, 2747, 17, 30, 347, 5, 138, 4, 10132, 42, 593, 4, 671, 5992, 893, 956, 3895, 114, 45, 5849, 3, 2801, 1, 1119, 138, 4, 442, 1193, 2, 2527, 671, 956, 3895, 22, 8, 740, 763, 1129, 3156, 6, 442, 1193]",1263.0,22150006,795
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.,Blood,Blood,2011-12-16,"B-cell receptor (BCR) signaling is a critical pathway in the pathogenesis of several B-cell malignancies, including chronic lymphocytic leukemia (CLL), and can be targeted by inhibitors of BCR-associated kinases, such as Bruton tyrosine kinase (Btk). PCI-32765, a selective, irreversible Btk inhibitor, is a novel, molecularly targeted agent for patients with B-cell malignancies, and is particularly active in patients with CLL. In this study, we analyzed the mechanism of action of PCI-32765 in CLL, using in vitro and in vivo models, and performed correlative studies on specimens from patients receiving therapy with PCI-32765. PCI-32765 significantly inhibited CLL cell survival, DNA synthesis, and migration in response to tissue homing chemokines (CXCL12, CXCL13). PCI-32765 also down-regulated secretion of BCR-dependent chemokines (CCL3, CCL4) by the CLL cells, both in vitro and in vivo. In an adoptive transfer TCL1 mouse model of CLL, PCI-32765 affected disease progression. In this model, PCI-32765 caused a transient early lymphocytosis, and profoundly inhibited CLL progression, as assessed by weight, development, and extent of hepatospenomegaly, and survival. Our data demonstrate that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent.",Journal Article,2958.0,392.0,B-cell receptor BCR signaling is a critical pathway in the pathogenesis of several B-cell malignancies including chronic lymphocytic CLL and can be targeted by inhibitors of BCR-associated kinases such as Bruton tyrosine kinase Btk PCI-32765 a selective irreversible Btk inhibitor is a novel molecularly targeted agent for patients with B-cell malignancies and is particularly active in patients with CLL In this study we analyzed the mechanism of action of PCI-32765 in CLL using in vitro and in vivo models and performed correlative studies on specimens from patients receiving therapy with PCI-32765 PCI-32765 significantly inhibited CLL cell survival DNA synthesis and migration in response to tissue homing chemokines CXCL12 CXCL13 PCI-32765 also down-regulated secretion of BCR-dependent chemokines CCL3 CCL4 by the CLL cells both in vitro and in vivo In an adoptive transfer TCL1 mouse model of CLL PCI-32765 affected disease progression In this model PCI-32765 caused a transient early lymphocytosis and profoundly inhibited CLL progression as assessed by weight development and extent of hepatospenomegaly and survival Our data demonstrate that PCI-32765 effectively inhibits CLL cell migration and survival possibly explaining some of the characteristic clinical activity of this new targeted agent,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 153, 1062, 314, 16, 8, 740, 308, 4, 3, 1384, 1, 392, 132, 31, 441, 141, 442, 1193, 552, 2, 122, 40, 238, 20, 222, 1, 1062, 41, 1549, 225, 22, 5796, 564, 216, 3611, 3943, 12229, 8, 1094, 4422, 3611, 230, 16, 8, 229, 2372, 238, 420, 9, 7, 5, 132, 31, 441, 2, 16, 823, 544, 4, 7, 5, 552, 4, 26, 45, 21, 311, 3, 670, 1, 1578, 1, 3943, 12229, 4, 552, 75, 4, 439, 2, 4, 386, 274, 2, 173, 3679, 94, 23, 623, 29, 7, 357, 36, 5, 3943, 12229, 3943, 12229, 97, 879, 552, 31, 25, 261, 2525, 2, 1381, 4, 51, 6, 246, 5515, 4906, 5807, 9462, 3943, 12229, 120, 1328, 1065, 2935, 1, 1062, 470, 4906, 9711, 12660, 20, 3, 552, 37, 110, 4, 439, 2, 4, 386, 4, 35, 3159, 2602, 8979, 830, 202, 1, 552, 3943, 12229, 1424, 34, 91, 4, 26, 202, 3943, 12229, 1546, 8, 2473, 191, 8125, 2, 8802, 879, 552, 91, 22, 275, 20, 924, 193, 2, 1039, 1, 60901, 2, 25, 114, 74, 608, 17, 3943, 12229, 1856, 1576, 552, 31, 1381, 2, 25, 2150, 8290, 476, 1, 3, 2037, 38, 128, 1, 26, 217, 238, 420]",1308.0,22180443,29
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-12-19,"BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of oral navitoclax. Twenty-nine patients with relapsed or refractory CLL received daily navitoclax for 14 days (10, 110, 200, or 250 mg/d; n = 15) or 21 days (125, 200, 250, or 300 mg/d; n = 14) of each 21-day cycle. Dose escalation decisions were informed by continual reassessment methodology. Lymphocytosis was reduced by more than 50% in 19 of 21 patients with baseline lymphocytosis. Among 26 patients treated with navitoclax  110 mg/d, nine (35%) achieved a partial response and seven maintained stable disease for more than 6 months. Median treatment duration was 7 months (range, 1 to  29 months). Median progression-free survival was 25 months. Activity was observed in patients with fludarabine-refractory disease, bulky adenopathy, and del(17p) CLL. Thrombocytopenia due to BCL-x(l) inhibition was the major dose-limiting toxicity and was dose-related. Low MCL1 expression and high BIM:MCL1 or BIM:BCL2 ratios in leukemic cells correlated with response. We determined that the navitoclax dose of 250 mg/d in a continuous dosing schedule was optimal for phase II studies. BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.","Clinical Trial, Phase I",2955.0,497.0,BCL2 overexpression is a hallmark of chronic lymphocytic CLL The novel BH3 mimetic navitoclax ABT-263 specifically inhibits BCL2 and related proteins BCL-x l and BCL-w potently inducing apoptosis of CLL cells in vitro A phase I trial in patients with CLL was conducted to evaluate the safety pharmacokinetics and biologic activity of oral navitoclax Twenty-nine patients with relapsed or refractory CLL received daily navitoclax for 14 days 10 110 200 or 250 mg/d n 15 or 21 days 125 200 250 or 300 mg/d n 14 of each 21-day cycle Dose escalation decisions were informed by continual reassessment methodology Lymphocytosis was reduced by more than 50 in 19 of 21 patients with baseline lymphocytosis Among 26 patients treated with navitoclax  110 mg/d nine 35 achieved a partial response and seven maintained stable disease for more than 6 months Median treatment duration was 7 months range 1 to  29 months Median progression-free survival was 25 months Activity was observed in patients with fludarabine-refractory disease bulky adenopathy and del 17p CLL Thrombocytopenia due to BCL-x l inhibition was the major dose-limiting toxicity and was dose-related Low MCL1 expression and high BIM MCL1 or BIM BCL2 ratios in leukemic cells correlated with response We determined that the navitoclax dose of 250 mg/d in a continuous dosing schedule was optimal for phase II studies BCL2 is a valid therapeutic target in CLL and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3214, 851, 16, 8, 4683, 1, 442, 1193, 552, 3, 229, 5486, 7343, 9316, 3095, 6098, 1225, 1576, 3214, 2, 139, 652, 1044, 1006, 805, 2, 1044, 5444, 4684, 1958, 351, 1, 552, 37, 4, 439, 8, 124, 70, 160, 4, 7, 5, 552, 10, 426, 6, 376, 3, 367, 1159, 2, 1283, 128, 1, 518, 9316, 737, 762, 7, 5, 591, 15, 430, 552, 103, 391, 9316, 9, 213, 162, 79, 3129, 1250, 15, 2039, 81, 427, 78, 167, 15, 239, 162, 1731, 1250, 2039, 15, 2036, 81, 427, 78, 213, 1, 296, 239, 218, 417, 61, 1125, 1526, 11, 2767, 20, 9451, 8756, 3209, 8125, 10, 405, 20, 80, 76, 212, 4, 326, 1, 239, 7, 5, 330, 8125, 107, 432, 7, 73, 5, 9316, 749, 3129, 81, 427, 762, 465, 513, 8, 450, 51, 2, 648, 1955, 585, 34, 9, 80, 76, 49, 53, 52, 24, 654, 10, 67, 53, 184, 14, 6, 749, 462, 53, 52, 91, 115, 25, 10, 243, 53, 128, 10, 164, 4, 7, 5, 2027, 430, 34, 4112, 7741, 2, 3084, 4135, 552, 1340, 520, 6, 1044, 1006, 805, 297, 10, 3, 458, 61, 817, 155, 2, 10, 61, 139, 154, 8132, 55, 2, 64, 3595, 8132, 15, 3595, 3214, 1137, 4, 2015, 37, 438, 5, 51, 21, 509, 17, 3, 9316, 61, 1, 2039, 81, 427, 4, 8, 1314, 1280, 1055, 10, 665, 9, 124, 215, 94, 3214, 16, 8, 4406, 189, 283, 4, 552, 2, 211, 297, 20, 9316, 2782, 195, 451, 22, 1411, 2, 4, 150, 4, 26, 34]",1528.0,22184378,650
"A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.",PloS one,PLoS ONE,2011-12-14,"We developed and validated a two-gene signature that predicts prognosis in previously-untreated chronic lymphocytic leukemia (CLL) patients. Using a 65 sample training set, from a cohort of 131 patients, we identified the best clinical models to predict time-to-treatment (TTT) and overall survival (OS). To identify individual genes or combinations in the training set with expression related to prognosis, we cross-validated univariate and multivariate models to predict TTT. We identified four gene sets (5, 6, 12, or 13 genes) to construct multivariate prognostic models. By optimizing each gene set on the training set, we constructed 11 models to predict the time from diagnosis to treatment. Each model also predicted OS and added value to the best clinical models. To determine which contributed the most value when added to clinical variables, we applied the Akaike Information Criterion. Two genes were consistently retained in the models with clinical variables: SKI (v-SKI avian sarcoma viral oncogene homolog) and SLAMF1 (signaling lymphocytic activation molecule family member 1; CD150). We optimized a two-gene model and validated it on an independent test set of 66 samples. This two-gene model predicted prognosis better on the test set than any of the known predictors, including ZAP70 and serum 2-microglobulin.",Journal Article,2960.0,12.0,We developed and validated a two-gene signature that predicts prognosis in previously-untreated chronic lymphocytic CLL patients Using a 65 sample training set from a cohort of 131 patients we identified the best clinical models to predict time-to-treatment TTT and overall survival OS To identify individual genes or combinations in the training set with expression related to prognosis we cross-validated univariate and multivariate models to predict TTT We identified four gene sets 5 6 12 or 13 genes to construct multivariate prognostic models By optimizing each gene set on the training set we constructed 11 models to predict the time from diagnosis to treatment Each model also predicted OS and added value to the best clinical models To determine which contributed the most value when added to clinical variables we applied the Akaike Information Criterion Two genes were consistently retained in the models with clinical variables SKI v-SKI avian viral oncogene homolog and SLAMF1 signaling lymphocytic activation molecule family member 1 CD150 We optimized a two-gene model and validated it on an independent test set of 66 samples This two-gene model predicted prognosis better on the test set than any of the known predictors including ZAP70 and serum 2-microglobulin,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 276, 2, 938, 8, 100, 145, 1651, 17, 2623, 356, 4, 373, 1278, 442, 1193, 552, 7, 75, 8, 556, 1000, 1741, 916, 29, 8, 180, 1, 2229, 7, 21, 108, 3, 824, 38, 274, 6, 678, 98, 6, 24, 10630, 2, 63, 25, 118, 6, 255, 797, 214, 15, 1247, 4, 3, 1741, 916, 5, 55, 139, 6, 356, 21, 1383, 938, 880, 2, 331, 274, 6, 678, 10630, 21, 108, 294, 145, 2270, 33, 49, 133, 15, 233, 214, 6, 3883, 331, 177, 274, 20, 4336, 296, 145, 916, 23, 3, 1741, 916, 21, 2776, 175, 274, 6, 678, 3, 98, 29, 147, 6, 24, 296, 202, 120, 783, 118, 2, 1953, 549, 6, 3, 824, 38, 274, 6, 223, 92, 3447, 3, 96, 549, 198, 1953, 6, 38, 682, 21, 1498, 3, 13429, 487, 4643, 100, 214, 11, 2433, 3532, 4, 3, 274, 5, 38, 682, 13314, 603, 13314, 16811, 1667, 1836, 3412, 2, 60925, 314, 1193, 363, 1354, 607, 2693, 14, 60926, 21, 4039, 8, 100, 145, 202, 2, 938, 192, 23, 35, 306, 412, 916, 1, 700, 347, 26, 100, 145, 202, 783, 356, 380, 23, 3, 412, 916, 76, 500, 1, 3, 440, 674, 141, 12921, 2, 524, 9314, 5371]",1281.0,22194822,659
"PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.",Blood,Blood,2011-12-30,"GS-1101 (CAL-101) is an oral PI3K-specific inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. To investigate the potential role of PI3K in Hodgkin lymphoma (HL), we screened 5 HL cell lines and primary samples from patients with HL for PI3K isoform expression and constitutive PI3K pathway activation. Inhibition of PI3K by GS-1101 resulted in the inhibition of Akt phosphorylation. Cocultures with stroma cells induced Akt activation in HL cells, and this effect was blocked by GS-1101. Conversely, production of the stroma-stimulating chemokine, CCL5, by HL cells was reduced by GS-1101. GS-1101 also induced dose-dependent apoptosis of HL cells at 48 hours. Reductions in cell viability and apoptosis were enhanced when combining GS-1101 with the mTOR inhibitor everolimus. Our findings suggest that excessive PI3K activity is characteristic in HL and support clinical evaluation of GS-1101, alone and in combination, as targeted therapy for HL.",Journal Article,2944.0,120.0,GS-1101 CAL-101 is an oral PI3K-specific inhibitor that has shown preclinical and clinical activity in and chronic lymphocytic To investigate the potential role of PI3K in HL we screened 5 HL cell lines and primary samples from patients with HL for PI3K isoform expression and constitutive PI3K pathway activation Inhibition of PI3K by GS-1101 resulted in the inhibition of Akt phosphorylation Cocultures with stroma cells induced Akt activation in HL cells and this effect was blocked by GS-1101 Conversely production of the stroma-stimulating chemokine CCL5 by HL cells was reduced by GS-1101 GS-1101 also induced dose-dependent apoptosis of HL cells at 48 hours Reductions in cell viability and apoptosis were enhanced when combining GS-1101 with the mTOR inhibitor everolimus Our findings suggest that excessive PI3K activity is characteristic in HL and support clinical evaluation of GS-1101 alone and in combination as targeted therapy for HL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3815, 15129, 10368, 2338, 16, 35, 518, 11063, 112, 230, 17, 71, 443, 693, 2, 38, 128, 4, 2, 442, 1193, 6, 963, 3, 174, 200, 1, 11063, 4, 1718, 21, 2261, 33, 1718, 31, 285, 2, 86, 347, 29, 7, 5, 1718, 9, 11063, 3995, 55, 2, 3178, 974, 308, 363, 297, 1, 11063, 20, 3815, 15129, 627, 4, 3, 297, 1, 649, 982, 16398, 5, 2477, 37, 277, 649, 363, 4, 1718, 37, 2, 26, 254, 10, 2582, 20, 3815, 15129, 3154, 1529, 1, 3, 2477, 2122, 3596, 10632, 20, 1718, 37, 10, 405, 20, 3815, 15129, 3815, 15129, 120, 277, 61, 470, 351, 1, 1718, 37, 28, 576, 1459, 2153, 4, 31, 2120, 2, 351, 11, 651, 198, 1525, 3815, 15129, 5, 3, 873, 230, 1400, 114, 272, 309, 17, 4529, 11063, 128, 16, 2037, 4, 1718, 2, 538, 38, 451, 1, 3815, 15129, 279, 2, 4, 150, 22, 238, 36, 9, 1718]",953.0,22210877,74
Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2012-01-01,"Over the past decade, numerous advances have been made in elucidating the biology of and improving treatment for chronic lymphocytic leukemia (CLL). These studies have led to identification of select CLL patient groups that generally have short survival dating from time of treatment or initial disease relapse who benefit from more aggressive therapeutic interventions. Allogeneic transplantation represents the only potentially curative option for CLL, but fully ablative regimens applied in the past have been associated with significant morbidity and mortality. Reduced-intensity preparative regimens has made application of allogeneic transplant to CLL patients much more feasible and increased the number of patients proceeding to this modality. Arising from this has been establishment of guidelines where allogeneic stem cell transplantation should be considered in CLL. Introduction of new targeted therapies with less morbidity, which can produce durable remissions has the potential to redefine where transplantation is initiated in CLL. This review briefly summarizes the field of allogeneic stem cell transplant in CLL and the interface of new therapeutics with this modality.",Journal Article,2942.0,9.0,Over the past decade numerous advances have been made in elucidating the biology of and improving treatment for chronic lymphocytic CLL These studies have led to identification of select CLL patient groups that generally have short survival dating from time of treatment or initial disease relapse who benefit from more aggressive therapeutic interventions Allogeneic transplantation represents the only potentially curative option for CLL but fully ablative regimens applied in the past have been associated with significant morbidity and mortality Reduced-intensity preparative regimens has made application of allogeneic transplant to CLL patients much more feasible and increased the number of patients proceeding to this modality Arising from this has been establishment of guidelines where allogeneic stem cell transplantation should be considered in CLL Introduction of new targeted therapies with less morbidity which can produce durable remissions has the potential to redefine where transplantation is initiated in CLL This review briefly summarizes the field of allogeneic stem cell transplant in CLL and the interface of new therapeutics with this modality,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 2025, 2331, 954, 47, 85, 1229, 4, 7980, 3, 891, 1, 2, 1673, 24, 9, 442, 1193, 552, 46, 94, 47, 836, 6, 911, 1, 1717, 552, 69, 271, 17, 1228, 47, 978, 25, 34700, 29, 98, 1, 24, 15, 388, 34, 429, 54, 247, 29, 80, 571, 189, 1151, 1063, 497, 1449, 3, 158, 751, 1075, 1501, 9, 552, 84, 1910, 4504, 472, 1498, 4, 3, 1219, 47, 85, 41, 5, 93, 787, 2, 282, 405, 837, 6085, 472, 71, 1229, 1581, 1, 1063, 941, 6, 552, 7, 1802, 80, 1313, 2, 101, 3, 207, 1, 7, 13053, 6, 26, 1396, 2635, 29, 26, 71, 85, 5346, 1, 677, 1257, 1063, 452, 31, 497, 257, 40, 515, 4, 552, 2456, 1, 217, 238, 235, 5, 299, 787, 92, 122, 2410, 1480, 3166, 71, 3, 174, 6, 17335, 1257, 497, 16, 1917, 4, 552, 26, 206, 6277, 2869, 3, 1067, 1, 1063, 452, 31, 941, 4, 552, 2, 3, 7074, 1, 217, 1943, 5, 26, 1396]",1168.0,22226097,161
"A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia.",The journal of supportive oncology,J Support Oncol,2012-01-23,"Chronic lymphocytic leukemia (CLL) patients are at high risk for acute respiratory illness (ARI). We evaluated the safety and efficacy of a proprietary extract of Panax quinquefolius, CVT-E002, in reducing ARI. This was a double-blind, placebo-controlled, randomized trial of 293 subjects with early-stage, untreated CLL conducted January-March 2009. ARI was common, occurring on about 10% of days during the study period. There were no significant differences of the 2 a priori primary end points: ARI days (8.5  17.2 for CVT-E002 vs 6.8  13.3 for placebo) and severe ARI days (2.9  9.5 for CVT-E002 vs 2.6  9.8 for placebo). However, 51% of CVT-E002 vs 56% of placebo recipients experienced at least 1 ARI (difference, -5%; 95% confidence interval [CI], -16% to 7%); more intense ARI occurred in 32% of CVT-E002 vs 39% of placebo recipients (difference, -7%; 95% CI, -18% to 4%), and symptom-specific evaluation showed reduced moderate to severe sore throat (P = .004) and a lower rate of grade 3 toxicities (P = .02) in CVT-E002 recipients. Greater seroconversion (4-fold increases in antibody titer) vs 9 common viral pathogens was documented in CVT-E002 recipients (16% vs 7%, P = .04). Serologic evaluation of antibody titers was not tied to a specific illness, but covered the entire study period. CVT-E002 was well tolerated. It did not reduce the number of ARI days or antibiotic use; however, there was a trend toward reduced rates of moderate to severe ARI and significantly less sore throat, suggesting that the increased rate of seroconversion most likely reflects CVT-E002-enhanced antibody responses.",Journal Article,2920.0,7.0,Chronic lymphocytic CLL patients are at high risk for acute respiratory illness ARI We evaluated the safety and efficacy of a proprietary extract of Panax quinquefolius CVT-E002 in reducing ARI This was a double-blind placebo-controlled randomized trial of 293 subjects with early-stage untreated CLL conducted January-March 2009 ARI was common occurring on about 10 of days during the study period There were no significant differences of the 2 a priori primary end points ARI days 8.5  17.2 for CVT-E002 vs 6.8  13.3 for placebo and severe ARI days 2.9  9.5 for CVT-E002 vs 2.6  9.8 for placebo However 51 of CVT-E002 vs 56 of placebo recipients experienced at least 1 ARI difference -5 95 confidence interval CI -16 to 7 more intense ARI occurred in 32 of CVT-E002 vs 39 of placebo recipients difference -7 95 CI -18 to 4 and symptom-specific evaluation showed reduced moderate to severe sore throat P .004 and a lower rate of grade 3 toxicities P .02 in CVT-E002 recipients Greater seroconversion 4-fold increases in antibody titer vs 9 common viral pathogens was documented in CVT-E002 recipients 16 vs 7 P .04 Serologic evaluation of antibody titers was not tied to a specific illness but covered the entire study period CVT-E002 was well tolerated It did not reduce the number of ARI days or antibiotic use however there was a trend toward reduced rates of moderate to severe ARI and significantly less sore throat suggesting that the increased rate of seroconversion most likely reflects CVT-E002-enhanced antibody responses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 7, 32, 28, 64, 43, 9, 286, 2718, 2973, 18048, 21, 194, 3, 367, 2, 209, 1, 8, 14950, 7164, 1, 20757, 47007, 22720, 23953, 4, 1818, 18048, 26, 10, 8, 1627, 3142, 619, 1149, 384, 160, 1, 7541, 976, 5, 191, 82, 1278, 552, 426, 1024, 2363, 1238, 18048, 10, 186, 1821, 23, 545, 79, 1, 162, 190, 3, 45, 727, 125, 11, 77, 93, 362, 1, 3, 18, 8, 7499, 86, 396, 862, 18048, 162, 66, 33, 810, 269, 18, 9, 22720, 23953, 105, 49, 66, 810, 233, 27, 9, 619, 2, 905, 18048, 162, 18, 83, 810, 83, 33, 9, 22720, 23953, 105, 18, 49, 810, 83, 66, 9, 619, 137, 725, 1, 22720, 23953, 105, 664, 1, 619, 2190, 592, 28, 506, 14, 18048, 523, 33, 48, 307, 268, 58, 245, 6, 67, 80, 3933, 18048, 489, 4, 531, 1, 22720, 23953, 105, 587, 1, 619, 2190, 523, 67, 48, 58, 203, 6, 39, 2, 934, 112, 451, 224, 405, 1163, 6, 905, 25325, 14896, 19, 1520, 2, 8, 280, 116, 1, 88, 2608, 385, 19, 588, 4, 22720, 23953, 2190, 378, 23868, 39, 1116, 1106, 4, 548, 8444, 105, 83, 186, 1667, 9275, 10, 1405, 4, 22720, 23953, 2190, 245, 105, 67, 19, 755, 7850, 451, 1, 548, 6671, 10, 44, 15945, 6, 8, 112, 2973, 84, 4306, 3, 1797, 45, 727, 22720, 23953, 10, 149, 421, 192, 205, 44, 969, 3, 207, 1, 18048, 162, 15, 5210, 119, 137, 125, 10, 8, 853, 1317, 405, 151, 1, 1163, 6, 905, 18048, 2, 97, 299, 25325, 14896, 802, 17, 3, 101, 116, 1, 23868, 96, 322, 5224, 22720, 23953, 651, 548, 253]",1537.0,22266154,782
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.,Haematologica,Haematologica,2012-01-22,"Older chronic lymphocytic leukemia patients have poor outcomes with standard treatments and are underrepresented in clinical trials. We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (70 and <70 years) treated with single-agent flavopiridol, a drug active in genomically high-risk patients, during two trials. No significant difference between older and younger patients was observed in response rates (43 vs. 47%) or progression-free survival (median 8.7 vs. 9.9 months, P>0.80). Although overall survival was worse in older patients (median 2.1 vs. 2.4 years, P=0.02); when adjusted for other factors this difference was no longer significant (P0.10). With the exception of infections (older 29% vs. younger 62%) no significant association with toxicity was observed. These data demonstrate that flavopiridol administration to older chronic lymphocytic leukemia patients is feasible, tolerable, and may have similar efficacy to that in younger patients. Development of treatment approaches including flavopiridol should be considered for these older patients.",Journal Article,2921.0,13.0,Older chronic lymphocytic patients have poor outcomes with standard treatments and are underrepresented in clinical trials We retrospectively reviewed outcomes of refractory chronic lymphocytic patients in two age categories 70 and 70 years treated with single-agent flavopiridol a drug active in genomically high-risk patients during two trials No significant difference between older and younger patients was observed in response rates 43 vs. 47 or progression-free survival median 8.7 vs. 9.9 months P 0.80 Although overall survival was worse in older patients median 2.1 vs. 2.4 years P=0.02 when adjusted for other factors this difference was no longer significant P0.10 With the exception of infections older 29 vs. younger 62 no significant association with toxicity was observed These data demonstrate that flavopiridol administration to older chronic lymphocytic patients is feasible tolerable and may have similar efficacy to that in younger patients Development of treatment approaches including flavopiridol should be considered for these older patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[434, 442, 1193, 7, 47, 334, 123, 5, 260, 640, 2, 32, 9900, 4, 38, 143, 21, 894, 446, 123, 1, 430, 442, 1193, 7, 4, 100, 89, 1996, 6146, 2, 431, 60, 73, 5, 226, 420, 3030, 8, 234, 544, 4, 7218, 64, 43, 7, 190, 100, 143, 77, 93, 523, 59, 434, 2, 773, 7, 10, 164, 4, 51, 151, 601, 105, 662, 15, 91, 115, 25, 52, 66, 67, 105, 83, 83, 53, 19, 13, 493, 242, 63, 25, 10, 639, 4, 434, 7, 52, 18, 14, 105, 18, 39, 60, 19, 13, 588, 198, 586, 9, 127, 130, 26, 523, 10, 77, 589, 93, 61037, 79, 5, 3, 4188, 1, 1875, 434, 462, 105, 773, 744, 77, 93, 248, 5, 155, 10, 164, 46, 74, 608, 17, 3030, 634, 6, 434, 442, 1193, 7, 16, 1313, 2668, 2, 68, 47, 288, 209, 6, 17, 4, 773, 7, 193, 1, 24, 611, 141, 3030, 257, 40, 515, 9, 46, 434, 7]",1067.0,22271900,106
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2012-02-03,"There has been a significant paradigm shift in the manner in which lymphoid malignancies are treated and managed. Treatment has been moving away from conventional chemotherapy and towards targeted therapy. The success of new classes of agents such as monoclonal antibodies, proteasome inhibitors and immunomodulatory derivatives has sparked further searches for novel pathways to inhibit. The Bruton's tyrosine kinase (Btk) pathway is a downstream mediator of the B-cell receptor (BCR) pathway, which is crucial in B-cell production and maintenance, and a potential therapeutic target. This review will summarize the current knowledge of the Btk pathway and its role in lymphoid malignancies. It will also discuss the present data about PCI-32765 in both the preclinical and clinical setting. PCI-32765 is an oral irreversible Btk inhibitor with high potency and both preclinical and clinical activity in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Phase I studies have demonstrated that it is well tolerated and has an excellent safety profile. Further studies are ongoing as a single agent and in combination with other targeted and conventional therapies. PCI-32765 is a very promising targeted therapy, and the data from these trials will ultimately decide its future role and success.",Journal Article,2909.0,34.0,There has been a significant paradigm shift in the manner in which lymphoid malignancies are treated and managed Treatment has been moving away from conventional chemotherapy and towards targeted therapy The success of new classes of agents such as monoclonal antibodies proteasome inhibitors and immunomodulatory derivatives has sparked further searches for novel pathways to inhibit The Bruton 's tyrosine kinase Btk pathway is a downstream mediator of the B-cell receptor BCR pathway which is crucial in B-cell production and maintenance and a potential therapeutic target This review will summarize the current knowledge of the Btk pathway and its role in lymphoid malignancies It will also discuss the present data about PCI-32765 in both the preclinical and clinical setting PCI-32765 is an oral irreversible Btk inhibitor with high potency and both preclinical and clinical activity in chronic lymphocytic CLL and 's NHL Phase I studies have demonstrated that it is well tolerated and has an excellent safety profile Further studies are ongoing as a single agent and in combination with other targeted and conventional therapies PCI-32765 is a very promising targeted therapy and the data from these trials will ultimately decide its future role and success,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[125, 71, 85, 8, 93, 2431, 3024, 4, 3, 1708, 4, 92, 2303, 441, 32, 73, 2, 2231, 24, 71, 85, 8324, 6565, 29, 809, 56, 2, 3113, 238, 36, 3, 1825, 1, 217, 3211, 1, 183, 225, 22, 848, 890, 1694, 222, 2, 2555, 6490, 71, 19720, 195, 6769, 9, 229, 460, 6, 1433, 3, 5796, 292, 564, 216, 3611, 308, 16, 8, 1489, 3810, 1, 3, 132, 31, 153, 1062, 308, 92, 16, 2653, 4, 132, 31, 1529, 2, 1146, 2, 8, 174, 189, 283, 26, 206, 303, 2479, 3, 291, 922, 1, 3, 3611, 308, 2, 211, 200, 4, 2303, 441, 192, 303, 120, 1139, 3, 364, 74, 545, 3943, 12229, 4, 110, 3, 693, 2, 38, 546, 3943, 12229, 16, 35, 518, 4422, 3611, 230, 5, 64, 3593, 2, 110, 693, 2, 38, 128, 4, 442, 1193, 552, 2, 292, 1176, 124, 70, 94, 47, 264, 17, 192, 16, 149, 421, 2, 71, 35, 1503, 367, 800, 195, 94, 32, 942, 22, 8, 226, 420, 2, 4, 150, 5, 127, 238, 2, 809, 235, 3943, 12229, 16, 8, 923, 721, 238, 36, 2, 3, 74, 29, 46, 143, 303, 2050, 11008, 211, 508, 200, 2, 1825]",1264.0,22300471,238
Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-02-13,"To delineate outcomes of malignant melanoma (MM) and Merkel cell carcinoma (MCC) in patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). We identified patients with MM or MCC reported to the Surveillance, Epidemiology, and End Results program and analyzed the effects of history of CLL/NHL on overall (OS) and cause-specific survival after MM or MCC. Expected survival was derived from patients with MM or MCC without CLL/NHL. From 1990 to 2006, 212,245 patients with MM and 3,613 patients with MCC were identified, of whom 1,246 with MM and 90 with MCC had a prior diagnosis of CLL/NHL. Patients with MM and a history of CLL/NHL had worse-than-expected OS as measured by standardized mortality ratio (SMR; SMR for CLL, 2.6; 95% CI, 2.3 to 3.0; SMR for NHL, 2.3; 95% CI, 2.1 to 2.6). MM cause-specific survival was worse than expected for patients with a history of CLL (SMR, 2.8; 95% CI, 2.2 to 3.4) or NHL (SMR, 2.1; 95% CI, 1.7 to 2.6). Among patients with MCC, OS was worse than expected for those with a history of CLL (SMR, 3.1; 95% CI, 2.2 to 4.3) or NHL (SMR, 1.9; 95% CI, 1.3 to 2.8). MCC cause-specific survival was worse than expected for patients with a history of CLL (SMR, 3.8; 95% CI, 2.5 to 5.9), but no difference was observed for NHL (SMR, 0.9; 95% CI, 0.4 to 2.1). Patients with CLL before diagnosis of MM or MCC have significantly worse OS and MM or MCC cause-specific survival than those without a history of CLL/NHL.",Journal Article,2899.0,66.0,"To delineate outcomes of malignant MM and Merkel cell carcinoma MCC in patients with chronic lymphocytic CLL or 's NHL We identified patients with MM or MCC reported to the Surveillance Epidemiology and End Results program and analyzed the effects of history of CLL/NHL on overall OS and cause-specific survival after MM or MCC Expected survival was derived from patients with MM or MCC without CLL/NHL From 1990 to 2006 212,245 patients with MM and 3,613 patients with MCC were identified of whom 1,246 with MM and 90 with MCC had a prior diagnosis of CLL/NHL Patients with MM and a history of CLL/NHL had worse-than-expected OS as measured by standardized mortality ratio SMR SMR for CLL 2.6 95 CI 2.3 to 3.0 SMR for NHL 2.3 95 CI 2.1 to 2.6 MM cause-specific survival was worse than expected for patients with a history of CLL SMR 2.8 95 CI 2.2 to 3.4 or NHL SMR 2.1 95 CI 1.7 to 2.6 Among patients with MCC OS was worse than expected for those with a history of CLL SMR 3.1 95 CI 2.2 to 4.3 or NHL SMR 1.9 95 CI 1.3 to 2.8 MCC cause-specific survival was worse than expected for patients with a history of CLL SMR 3.8 95 CI 2.5 to 5.9 but no difference was observed for NHL SMR 0.9 95 CI 0.4 to 2.1 Patients with CLL before diagnosis of MM or MCC have significantly worse OS and MM or MCC cause-specific survival than those without a history of CLL/NHL",0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 5092, 123, 1, 393, 321, 2, 5855, 31, 134, 4384, 4, 7, 5, 442, 1193, 552, 15, 292, 1176, 21, 108, 7, 5, 321, 15, 4384, 210, 6, 3, 617, 1284, 2, 396, 99, 1243, 2, 311, 3, 176, 1, 532, 1, 552, 1176, 23, 63, 118, 2, 708, 112, 25, 50, 321, 15, 4384, 1336, 25, 10, 526, 29, 7, 5, 321, 15, 4384, 187, 552, 1176, 29, 2289, 6, 1324, 6586, 7373, 7, 5, 321, 2, 27, 9819, 7, 5, 4384, 11, 108, 1, 953, 14, 6907, 5, 321, 2, 424, 5, 4384, 42, 8, 324, 147, 1, 552, 1176, 7, 5, 321, 2, 8, 532, 1, 552, 1176, 42, 639, 76, 1336, 118, 22, 644, 20, 1670, 282, 197, 7071, 7071, 9, 552, 18, 49, 48, 58, 18, 27, 6, 27, 13, 7071, 9, 1176, 18, 27, 48, 58, 18, 14, 6, 18, 49, 321, 708, 112, 25, 10, 639, 76, 1336, 9, 7, 5, 8, 532, 1, 552, 7071, 18, 66, 48, 58, 18, 18, 6, 27, 39, 15, 1176, 7071, 18, 14, 48, 58, 14, 67, 6, 18, 49, 107, 7, 5, 4384, 118, 10, 639, 76, 1336, 9, 135, 5, 8, 532, 1, 552, 7071, 27, 14, 48, 58, 18, 18, 6, 39, 27, 15, 1176, 7071, 14, 83, 48, 58, 14, 27, 6, 18, 66, 4384, 708, 112, 25, 10, 639, 76, 1336, 9, 7, 5, 8, 532, 1, 552, 7071, 27, 66, 48, 58, 18, 33, 6, 33, 83, 84, 77, 523, 10, 164, 9, 1176, 7071, 13, 83, 48, 58, 13, 39, 6, 18, 14, 7, 5, 552, 348, 147, 1, 321, 15, 4384, 47, 97, 639, 118, 2, 321, 15, 4384, 708, 112, 25, 76, 135, 187, 8, 532, 1, 552, 1176]",1356.0,22331952,1
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.,Leukemia & lymphoma,Leuk. Lymphoma,2012-06-02,"The impact of mutation of the ATM (ataxia telangiectasia mutated) gene in chronic lymphocytic leukemia (CLL) treatment outcome has not been examined. We studied ATM mutations in 73 patients treated with fludarabine and rituximab. ATM gene mutation analysis was performed using temperature gradient capillary electrophoresis. The impact of detected variants on overall survival (OS) and progression-free survival (PFS) was tested with proportional hazards models. None of the 73 patients demonstrated truncating ATM mutations; 17 (23%, 95% confidence interval 14-35%) had non-silent variants (ATM-NSVs), including 13 known ATM polymorphisms and four missense variants. ATM-NSVs were not significantly associated with any baseline characteristics including immunoglobulin heavy chain variable gene (IGVH) status. In multivariable models, no significant differences in complete response (p =0.70), PFS (p =0.59) or OS (p =0.13) were observed. Our data indicate that truncating ATM mutations are rare in patients with CLL. Furthermore, in this dataset, these non-silent variants had limited impact on PFS and OS.",Journal Article,2789.0,10.0,The impact of mutation of the ATM ataxia telangiectasia mutated gene in chronic lymphocytic CLL treatment outcome has not been examined We studied ATM mutations in 73 patients treated with fludarabine and rituximab ATM gene mutation analysis was performed using temperature gradient capillary electrophoresis The impact of detected variants on overall survival OS and progression-free survival PFS was tested with proportional hazards models None of the 73 patients demonstrated truncating ATM mutations 17 23 95 confidence interval 14-35 had non-silent variants ATM-NSVs including 13 known ATM polymorphisms and four missense variants ATM-NSVs were not significantly associated with any baseline characteristics including immunoglobulin heavy chain variable gene IGVH status In multivariable models no significant differences in complete response p =0.70 PFS p =0.59 or OS p =0.13 were observed Our data indicate that truncating ATM mutations are rare in patients with CLL Furthermore in this dataset these non-silent variants had limited impact on PFS and OS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 345, 1, 258, 1, 3, 3552, 8299, 8524, 1185, 145, 4, 442, 1193, 552, 24, 228, 71, 44, 85, 409, 21, 656, 3552, 138, 4, 803, 7, 73, 5, 2027, 2, 855, 3552, 145, 258, 65, 10, 173, 75, 6882, 7099, 8943, 6777, 3, 345, 1, 530, 839, 23, 63, 25, 118, 2, 91, 115, 25, 300, 10, 650, 5, 831, 1017, 274, 1292, 1, 3, 803, 7, 264, 7994, 3552, 138, 269, 382, 48, 307, 268, 213, 465, 42, 220, 9890, 839, 3552, 47092, 141, 233, 440, 3552, 1203, 2, 294, 4007, 839, 3552, 47092, 11, 44, 97, 41, 5, 500, 330, 374, 141, 2593, 4013, 1260, 1347, 145, 14484, 156, 4, 658, 274, 77, 93, 362, 4, 236, 51, 19, 13, 431, 300, 19, 13, 728, 15, 118, 19, 13, 233, 11, 164, 114, 74, 1008, 17, 7994, 3552, 138, 32, 622, 4, 7, 5, 552, 798, 4, 26, 3014, 46, 220, 9890, 839, 42, 383, 345, 23, 300, 2, 118]",1060.0,22369572,104
RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.,Blood,Blood,2012-04-03,"Trafficking of B-cell chronic lymphocytic leukemia (CLL) cells to the bone marrow and interaction with supporting stromal cells mediates important survival and proliferation signals. Previous studies have demonstrated that deletion of Rhoh led to a delayed disease onset in a murine model of CLL. Here we assessed the impact of RhoH on homing, migration, and cell-contact dependent interactions of CLL cells. Rhoh(-/-) CLL cells exhibited reduced marrow homing and subsequent engraftment. In vitro migration toward the chemokines CXCL12 and CXCL13 and cell-cell interactions between Rhoh(-/-) CLL cells and the supporting microenvironment was reduced. In the absence of RhoH the distribution of phosphorylated focal adhesion kinase, a protein known to coordinate activation of the Rho GTPases RhoA and Rac, appeared less polarized in chemokine-stimulated Rhoh(-/-) CLL cells, and activation and localization of RhoA and Rac was dysregulated leading to defective integrin function. These findings in the Rhoh(-/-) CLL cells were subsequently demonstrated to closely resemble changes in GTPase activation observed in human CLL samples after in vitro and in vivo treatment with lenalidomide, an agent with known influence on microenvironment protection, and suggest that RhoH plays a critical role in prosurvival CLL cell-cell and cell-microenvironment interactions with this agent.",Journal Article,2849.0,38.0,Trafficking of B-cell chronic lymphocytic CLL cells to the marrow and interaction with supporting stromal cells mediates important survival and proliferation signals Previous studies have demonstrated that deletion of Rhoh led to a delayed disease onset in a murine model of CLL Here we assessed the impact of RhoH on homing migration and cell-contact dependent interactions of CLL cells Rhoh -/- CLL cells exhibited reduced marrow homing and subsequent engraftment In vitro migration toward the chemokines CXCL12 and CXCL13 and cell-cell interactions between Rhoh -/- CLL cells and the supporting microenvironment was reduced In the absence of RhoH the distribution of phosphorylated focal adhesion kinase a protein known to coordinate activation of the Rho GTPases RhoA and Rac appeared less polarized in chemokine-stimulated Rhoh -/- CLL cells and activation and localization of RhoA and Rac was dysregulated leading to defective integrin function These findings in the Rhoh -/- CLL cells were subsequently demonstrated to closely resemble changes in GTPase activation observed in human CLL samples after in vitro and in vivo treatment with lenalidomide an agent with known influence on microenvironment protection and suggest that RhoH plays a critical role in prosurvival CLL cell-cell and cell-microenvironment interactions with this agent,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[6105, 1, 132, 31, 442, 1193, 552, 37, 6, 3, 581, 2, 915, 5, 1912, 1126, 37, 3961, 305, 25, 2, 457, 2312, 698, 94, 47, 264, 17, 1528, 1, 25428, 836, 6, 8, 1612, 34, 1707, 4, 8, 1471, 202, 1, 552, 467, 21, 275, 3, 345, 1, 25428, 23, 5515, 1381, 2, 31, 4393, 470, 1286, 1, 552, 37, 25428, 552, 37, 1416, 405, 581, 5515, 2, 706, 2881, 4, 439, 1381, 1317, 3, 4906, 5807, 2, 9462, 2, 31, 31, 1286, 59, 25428, 552, 37, 2, 3, 1912, 995, 10, 405, 4, 3, 1127, 1, 25428, 3, 1395, 1, 2365, 2137, 2128, 216, 8, 178, 440, 6, 9767, 363, 1, 3, 5722, 13895, 8884, 2, 11173, 2121, 299, 12852, 4, 3596, 2816, 25428, 552, 37, 2, 363, 2, 2145, 1, 8884, 2, 11173, 10, 4288, 1049, 6, 4552, 2876, 343, 46, 272, 4, 3, 25428, 552, 37, 11, 1611, 264, 6, 3210, 8247, 400, 4, 9189, 363, 164, 4, 171, 552, 347, 50, 4, 439, 2, 4, 386, 24, 5, 1288, 35, 420, 5, 440, 1054, 23, 995, 3525, 2, 309, 17, 25428, 1698, 8, 740, 200, 4, 7331, 552, 31, 31, 2, 31, 995, 1286, 5, 26, 420]",1345.0,22474251,442
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2012-06-12,"Lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L with CD40 and also mediates antibody-dependent cell-mediated cytotoxicity (ADCC). We evaluated lucatumumab in a phase I clinical trial in chronic lymphocytic leukemia (CLL). Twenty-six patients with relapsed CLL were enrolled on five different dose cohorts administered weekly for 4 weeks. The maximally tolerated dose (MTD) of lucatumumab was 3.0 mg/kg. Four patients at doses of 4.5 mg/kg and 6.0 mg/kg experienced grade 3 or 4 asymptomatic elevated amylase and lipase levels. Of the 26 patients enrolled, 17 patients had stable disease (mean duration of 76 days, range 29-504 days) and one patient had a nodular partial response for 230 days. Saturation of CD40 receptor on CLL cells was uniform at all doses post-treatment but also persisted at trough time points in the 3.0 mg/kg or greater cohorts. At the MTD, the median half-life of lucatumumab was 50 h following the first infusion, and 124 h following the fourth infusion. In summary, lucatumumab had acceptable tolerability, pharmacokinetics that supported chronic dosing and pharmacodynamic target antagonism at doses of 3.0 mg/kg, but demonstrated minimal single-agent activity. Future efforts with lucatumumab in CLL should focus on combination-based therapy.","Clinical Trial, Phase I",2779.0,71.0,Lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L with CD40 and also mediates antibody-dependent cell-mediated cytotoxicity ADCC We evaluated lucatumumab in a phase I clinical trial in chronic lymphocytic CLL Twenty-six patients with relapsed CLL were enrolled on five different dose cohorts administered weekly for 4 weeks The maximally tolerated dose MTD of lucatumumab was 3.0 mg/kg Four patients at doses of 4.5 mg/kg and 6.0 mg/kg experienced grade 3 or 4 asymptomatic elevated amylase and lipase levels Of the 26 patients enrolled 17 patients had stable disease mean duration of 76 days range 29-504 days and one patient had a nodular partial response for 230 days Saturation of CD40 receptor on CLL cells was uniform at all doses post-treatment but also persisted at trough time points in the 3.0 mg/kg or greater cohorts At the MTD the median half-life of lucatumumab was 50 h following the first infusion and 124 h following the fourth infusion In summary lucatumumab had acceptable tolerability pharmacokinetics that supported chronic dosing and pharmacodynamic target antagonism at doses of 3.0 mg/kg but demonstrated minimal single-agent activity Future efforts with lucatumumab in CLL should focus on combination-based therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21722, 16, 8, 1910, 3619, 312, 5040, 548, 17, 2860, 915, 1, 8285, 5, 5040, 2, 120, 3961, 548, 470, 31, 517, 1408, 5551, 21, 194, 21722, 4, 8, 124, 70, 38, 160, 4, 442, 1193, 552, 737, 437, 7, 5, 591, 552, 11, 346, 23, 365, 338, 61, 736, 468, 709, 9, 39, 244, 3, 6402, 421, 61, 961, 1, 21722, 10, 27, 13, 81, 503, 294, 7, 28, 415, 1, 39, 33, 81, 503, 2, 49, 13, 81, 503, 592, 88, 27, 15, 39, 2100, 804, 11149, 2, 7272, 148, 1, 3, 432, 7, 346, 269, 7, 42, 585, 34, 313, 654, 1, 846, 162, 184, 462, 8362, 162, 2, 104, 69, 42, 8, 4481, 450, 51, 9, 6136, 162, 7506, 1, 5040, 153, 23, 552, 37, 10, 3490, 28, 62, 415, 539, 24, 84, 120, 3760, 28, 6000, 98, 862, 4, 3, 27, 13, 81, 503, 15, 378, 736, 28, 3, 961, 3, 52, 1303, 358, 1, 21722, 10, 212, 555, 366, 3, 157, 904, 2, 2834, 555, 366, 3, 3608, 904, 4, 1962, 21722, 42, 1595, 1543, 1159, 17, 2708, 442, 1280, 2, 2424, 283, 7537, 28, 415, 1, 27, 13, 81, 503, 84, 264, 1048, 226, 420, 128, 508, 1413, 5, 21722, 4, 552, 257, 1222, 23, 150, 90, 36]",1274.0,22475052,11
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.,Leukemia & lymphoma,Leuk. Lymphoma,2012-05-21,"Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic lymphocytic leukemia (CLL). We hypothesized that alemtuzumab (ALM) mediated CDC would be increased by the addition of ofatumumab (OFA). CLL cells from 21 previously untreated patients with progressive disease were tested in vitro for mAb binding, complement activation and CDC. The subpopulation of CDC resistant CLL cells was examined for levels of C3b and C5b-9 binding, and expression of complement regulatory proteins. OFA significantly increased complement activation and CDC in ALM-treated CLL cells, suggesting that combining ALM and OFA could improve clinical outcome in patients with CLL. Approximately 10% of CLL cells were resistant to CDC because of lower levels of complement activation or decreased cytotoxicity of activated complement. Improvement of clinical responses will require determining the mechanisms of CDC resistance and developing methods to overcome this problem.",Journal Article,2801.0,27.0,Complement dependent cytotoxicity CDC is an important mechanism of action for monoclonal antibodies mAbs used in the treatment of chronic lymphocytic CLL We hypothesized that alemtuzumab ALM mediated CDC would be increased by the addition of ofatumumab OFA CLL cells from 21 previously untreated patients with progressive disease were tested in vitro for mAb binding complement activation and CDC The subpopulation of CDC resistant CLL cells was examined for levels of C3b and C5b-9 binding and expression of complement regulatory proteins OFA significantly increased complement activation and CDC in ALM-treated CLL cells suggesting that combining ALM and OFA could improve clinical outcome in patients with CLL Approximately 10 of CLL cells were resistant to CDC because of lower levels of complement activation or decreased cytotoxicity of activated complement Improvement of clinical responses will require determining the mechanisms of CDC resistance and developing methods to overcome this problem,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3731, 470, 1408, 9665, 16, 35, 305, 670, 1, 1578, 9, 848, 890, 5207, 95, 4, 3, 24, 1, 442, 1193, 552, 21, 1237, 17, 3579, 31934, 517, 9665, 688, 40, 101, 20, 3, 352, 1, 5732, 19977, 552, 37, 29, 239, 373, 1278, 7, 5, 1014, 34, 11, 650, 4, 439, 9, 2780, 791, 3731, 363, 2, 9665, 3, 5518, 1, 9665, 436, 552, 37, 10, 409, 9, 148, 1, 37636, 2, 61302, 83, 791, 2, 55, 1, 3731, 1253, 652, 19977, 97, 101, 3731, 363, 2, 9665, 4, 31934, 73, 552, 37, 802, 17, 1525, 31934, 2, 19977, 359, 401, 38, 228, 4, 7, 5, 552, 705, 79, 1, 552, 37, 11, 436, 6, 9665, 408, 1, 280, 148, 1, 3731, 363, 15, 340, 1408, 1, 735, 3731, 767, 1, 38, 253, 303, 1353, 2196, 3, 483, 1, 9665, 251, 2, 931, 636, 6, 1768, 26, 2497]",1003.0,22475085,19
Improving treatment for patients with chronic lymphocytic leukemia.,"Hematology (Amsterdam, Netherlands)",Hematology,2012-04-01,"The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic lymphoma (CLL). Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival. Despite these improved outcomes, only  45% of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy. Although new combinations of traditional agents may lead to incremental progress, more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting: (1) leukemia cell apoptotic resistance; (2) survival signals mediated through the B-cell receptor; and (3) nurturing interactions with the microenvironment. In this mini-review, we summarize Mayo Clinic's recent efforts to improve CIT for patients with CLL.",Journal Article,2851.0,1.0,The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic CLL Chemoimmunotherapy CIT combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates progression-free survival and overall survival Despite these improved outcomes only  45 of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy Although new combinations of traditional agents may lead to incremental progress more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting 1 cell apoptotic resistance 2 survival signals mediated through the B-cell receptor and 3 nurturing interactions with the microenvironment In this mini-review we summarize Mayo Clinic 's recent efforts to improve CIT for patients with CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1060, 100, 1968, 47, 85, 98, 1, 6678, 1466, 4, 24, 9, 7, 5, 442, 1193, 552, 4438, 9192, 1525, 312, 2198, 848, 890, 5, 5006, 4032, 4063, 71, 85, 8, 1281, 3148, 9, 7, 5, 552, 2, 99, 4, 101, 51, 151, 91, 115, 25, 2, 63, 25, 550, 46, 231, 123, 158, 19267, 512, 1, 7, 1359, 8, 236, 734, 5, 9192, 2, 1857, 62, 7, 3124, 429, 2, 136, 469, 8, 594, 6, 401, 209, 242, 217, 1247, 1, 1847, 183, 68, 1122, 6, 3648, 1466, 80, 14940, 1474, 32, 322, 6, 757, 298, 189, 529, 1, 229, 460, 740, 6, 552, 132, 31, 25, 141, 529, 14, 31, 1631, 251, 18, 25, 2312, 517, 298, 3, 132, 31, 153, 2, 27, 61351, 1286, 5, 3, 995, 4, 26, 7313, 206, 21, 2479, 2486, 1188, 292, 435, 1413, 6, 401, 9192, 9, 7, 5, 552]",1000.0,22507801,162
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-05-07,"Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic leukemia (CLL). Current methods for accurately measuring ZAP-70 expression are problematic, preventing widespread application of these tests in clinical decision making. We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control. High-resolution quantitative DNA methylation analysis of the entire ZAP-70 gene regulatory regions was conducted on 247 samples from patients with CLL from four independent clinical studies. Through this comprehensive analysis, we identified a small area in the 5' regulatory region of ZAP-70 that showed large variability in methylation in CLL samples but was universally methylated in normal B cells. High correlation with mRNA and protein expression, as well as activity in promoter reporter assays, revealed that within this differentially methylated region, a single CpG dinucleotide and neighboring nucleotides are particularly important in ZAP-70 transcriptional regulation. Furthermore, by using clustering approaches, we identified a prognostic role for this site in four independent data sets of patients with CLL using time to treatment, progression-free survival, and overall survival as clinical end points. Comprehensive quantitative DNA methylation analysis of the ZAP-70 gene in CLL identified important regions responsible for transcriptional regulation. In addition, loss of methylation at a specific single CpG dinucleotide in the ZAP-70 5' regulatory sequence is a highly predictive and reproducible biomarker of poor prognosis in this disease. This work demonstrates the feasibility of using quantitative specific ZAP-70 methylation analysis as a relevant clinically applicable prognostic test in CLL.",Journal Article,2815.0,84.0,Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic CLL Current methods for accurately measuring ZAP-70 expression are problematic preventing widespread application of these tests in clinical decision making We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control High-resolution quantitative DNA methylation analysis of the entire ZAP-70 gene regulatory regions was conducted on 247 samples from patients with CLL from four independent clinical studies Through this comprehensive analysis we identified a small area in the 5 regulatory region of ZAP-70 that showed large variability in methylation in CLL samples but was universally methylated in normal B cells High correlation with mRNA and protein expression as well as activity in promoter reporter assays revealed that within this differentially methylated region a single CpG dinucleotide and neighboring nucleotides are particularly important in ZAP-70 transcriptional regulation Furthermore by using clustering approaches we identified a prognostic role for this site in four independent data sets of patients with CLL using time to treatment progression-free survival and overall survival as clinical end points Comprehensive quantitative DNA methylation analysis of the ZAP-70 gene in CLL identified important regions responsible for transcriptional regulation In addition loss of methylation at a specific single CpG dinucleotide in the ZAP-70 5 regulatory sequence is a highly predictive and reproducible biomarker of poor prognosis in this disease This work demonstrates the feasibility of using quantitative specific ZAP-70 methylation analysis as a relevant clinically applicable prognostic test in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[101, 6251, 431, 55, 2623, 334, 356, 4, 442, 1193, 552, 291, 636, 9, 2141, 2978, 6251, 431, 55, 32, 6594, 3017, 3029, 1581, 1, 46, 895, 4, 38, 948, 1079, 21, 673, 95, 949, 261, 569, 1080, 1, 3, 6251, 431, 1253, 1053, 6, 255, 633, 305, 9, 1431, 182, 64, 2125, 1156, 261, 569, 65, 1, 3, 1797, 6251, 431, 145, 1253, 1374, 10, 426, 23, 7708, 347, 29, 7, 5, 552, 29, 294, 306, 38, 94, 298, 26, 949, 65, 21, 108, 8, 302, 965, 4, 3, 33, 1253, 1053, 1, 6251, 431, 17, 224, 375, 1982, 4, 569, 4, 552, 347, 84, 10, 6813, 2963, 4, 295, 132, 37, 64, 816, 5, 956, 2, 178, 55, 22, 149, 22, 128, 4, 973, 3674, 1013, 553, 17, 262, 26, 2478, 2963, 1053, 8, 226, 2075, 11816, 2, 10669, 11381, 32, 823, 305, 4, 6251, 431, 1431, 863, 798, 20, 75, 3147, 611, 21, 108, 8, 177, 200, 9, 26, 606, 4, 294, 306, 74, 2270, 1, 7, 5, 552, 75, 98, 6, 24, 91, 115, 25, 2, 63, 25, 22, 38, 396, 862, 949, 1156, 261, 569, 65, 1, 3, 6251, 431, 145, 4, 552, 108, 305, 1374, 2327, 9, 1431, 863, 4, 352, 407, 1, 569, 28, 8, 112, 226, 2075, 11816, 4, 3, 6251, 431, 33, 1253, 1532, 16, 8, 561, 464, 2, 4172, 901, 1, 334, 356, 4, 26, 34, 26, 1357, 1902, 3, 1437, 1, 75, 1156, 112, 6251, 431, 569, 65, 22, 8, 867, 505, 3801, 177, 412, 4, 552]",1781.0,22564988,299
Neuroleukemiosis: an unusual cause of peripheral neuropathy.,Leukemia & lymphoma,Leuk. Lymphoma,2012-05-28,"Leukemia may initially present as a peripheral neuropathy, leading to a delay in diagnosis. Leukemic infiltration of peripheral nerves, or neuroleukemiosis (NL), is exceedingly rare, with no established diagnostic or therapeutic guidelines. Five cases are presented. All patients were men with a median age of 68 years (range 46-72). Three patients had acute myeloid leukemia (AML) and two had chronic lymphocytic leukemia (CLL). In two patients, leukemia presented with peripheral nerve involvement and both were found to have positive cerebrospinal fluid (CSF) cytology, making the diagnosis AML, despite negative bone marrow and peripheral smear. All patients had painful, progressive, motor and sensory deficits. Clinical patterns were mononeuropathy (n =1), multiple mononeuropathies (n =1) and plexopathy (n =3). Magnetic resonance imaging (MRI) detected mass lesions in 4/5 cases, with avid fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) useful in all of these for following clinical disease progression. Three cases of nerve biopsy were performed, two of which were diagnostic of leukemic infiltration. Radiation treatment rapidly relieved pain in patients with mass lesions, in combination with chemotherapy. Four patients had disease relapse, four systemic and one also in peripheral nerves. These cases are discussed in the context of the broader literature.",Case Reports,2794.0,18.0,may initially present as a peripheral neuropathy leading to a delay in diagnosis Leukemic infiltration of peripheral nerves or neuroleukemiosis NL is exceedingly rare with no established diagnostic or therapeutic guidelines Five cases are presented All patients were men with a median age of 68 years range 46-72 Three patients had acute myeloid AML and two had chronic lymphocytic CLL In two patients presented with peripheral nerve involvement and both were found to have positive cerebrospinal fluid CSF cytology making the diagnosis AML despite negative marrow and peripheral smear All patients had painful progressive motor and sensory deficits Clinical patterns were mononeuropathy n =1 multiple mononeuropathies n =1 and plexopathy n =3 Magnetic resonance imaging MRI detected mass lesions in 4/5 cases with avid fluorodeoxyglucose FDG uptake on positron emission tomography PET useful in all of these for following clinical disease progression Three cases of nerve biopsy were performed two of which were diagnostic of leukemic infiltration Radiation treatment rapidly relieved pain in patients with mass lesions in combination with chemotherapy Four patients had disease relapse four systemic and one also in peripheral nerves These cases are discussed in the context of the broader literature,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[68, 1625, 364, 22, 8, 672, 1751, 1049, 6, 8, 1984, 4, 147, 2015, 2084, 1, 672, 6721, 15, 61427, 15830, 16, 10303, 622, 5, 77, 635, 752, 15, 189, 677, 365, 140, 32, 917, 62, 7, 11, 325, 5, 8, 52, 89, 1, 806, 60, 184, 641, 720, 169, 7, 42, 286, 533, 329, 2, 100, 42, 442, 1193, 552, 4, 100, 7, 917, 5, 672, 2476, 799, 2, 110, 11, 204, 6, 47, 109, 5156, 2357, 1211, 2045, 1079, 3, 147, 329, 550, 199, 581, 2, 672, 8379, 62, 7, 42, 7041, 1014, 3482, 2, 4148, 2752, 38, 764, 11, 61428, 78, 14, 232, 61429, 78, 14, 2, 17241, 78, 27, 1484, 1535, 270, 704, 530, 782, 406, 4, 39, 33, 140, 5, 5189, 4085, 1285, 1135, 23, 1900, 1799, 872, 495, 999, 4, 62, 1, 46, 9, 366, 38, 34, 91, 169, 140, 1, 2476, 411, 11, 173, 100, 1, 92, 11, 752, 1, 2015, 2084, 121, 24, 1755, 14429, 559, 4, 7, 5, 782, 406, 4, 150, 5, 56, 294, 7, 42, 34, 429, 294, 403, 2, 104, 120, 4, 672, 6721, 46, 140, 32, 1588, 4, 3, 1533, 1, 3, 5410, 789]",1302.0,22571477,262
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-06-01,"A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m(2) intravenously(IV) twice daily for 4 days as a phase II study schedule. Alkylating agents have shown activity in leukemia. Bendamustine, an active alkylating agent in lymphoma and chronic lymphocytic leukemia, was given in a fractionated twice daily schedule for 4 days to patients with acute leukemia and myelodysplastic syndrome (MDS) to define the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD). Adults with refractory acute leukemia or high-risk MDS were treated with bendamustine at a starting dose of 50 mg/m(2) IV over 1-2 hours twice daily for 4 days. Dose escalations were by 25 mg/m(2) in the 1st 3 levels. The study used the 3 + 3 design. A total of 25 patients were treated. Their median age was 57 years; the median salvage number was 3. Grade 2 creatinine elevations were observed in 1 of 6 patients at the 50 mg/m(2) dose, in 2 of 13 patients at the 75 mg/m(2) dose, and in 3 of 6 patients at the 100 mg/m(2) dose. This was considered significant, even though DLT was not reached. One patient achieved marrow complete remission. Significant reductions of marrow blasts (50% or more) were observed in 6 of 25 patients (24%). Bendamustine fractionated dose level of 100 mg/m(2) IV twice daily for 4 days (800 mg/m(2) per course) was associated with Grade 2 renal toxicity. The proposed phase II schedule is 75 mg/m(2) IV twice daily for 4 days. Future studies should evaluate this schedule in less heavily treated patients.","Clinical Trial, Phase I",2790.0,3.0,A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m 2 intravenously IV twice daily for 4 days as a phase II study schedule Alkylating agents have shown activity in Bendamustine an active alkylating agent in and chronic lymphocytic was given in a fractionated twice daily schedule for 4 days to patients with acute and syndrome MDS to define the dose-limiting toxicities DLT and maximum tolerated dose MTD Adults with refractory acute or high-risk MDS were treated with bendamustine at a starting dose of 50 mg/m 2 IV over 1-2 hours twice daily for 4 days Dose escalations were by 25 mg/m 2 in the 1st 3 levels The study used the 3 3 design A total of 25 patients were treated Their median age was 57 years the median salvage number was 3 Grade 2 creatinine elevations were observed in 1 of 6 patients at the 50 mg/m 2 dose in 2 of 13 patients at the 75 mg/m 2 dose and in 3 of 6 patients at the 100 mg/m 2 dose This was considered significant even though DLT was not reached One patient achieved marrow complete remission Significant reductions of marrow blasts 50 or more were observed in 6 of 25 patients 24 Bendamustine fractionated dose level of 100 mg/m 2 IV twice daily for 4 days 800 mg/m 2 per course was associated with Grade 2 toxicity The proposed phase II schedule is 75 mg/m 2 IV twice daily for 4 days Future studies should evaluate this schedule in less heavily treated patients,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 124, 70, 215, 45, 1, 4809, 3950, 936, 391, 1055, 9, 39, 162, 108, 481, 81, 188, 18, 1672, 478, 936, 391, 9, 39, 162, 22, 8, 124, 215, 45, 1055, 3410, 183, 47, 443, 128, 4, 4809, 35, 544, 3410, 420, 4, 2, 442, 1193, 10, 447, 4, 8, 3950, 936, 391, 1055, 9, 39, 162, 6, 7, 5, 286, 2, 681, 1223, 6, 1107, 3, 61, 817, 385, 2059, 2, 689, 421, 61, 961, 857, 5, 430, 286, 15, 64, 43, 1223, 11, 73, 5, 4809, 28, 8, 1723, 61, 1, 212, 81, 188, 18, 478, 252, 14, 18, 1459, 936, 391, 9, 39, 162, 61, 11388, 11, 20, 243, 81, 188, 18, 4, 3, 9524, 27, 148, 3, 45, 95, 3, 27, 27, 771, 8, 181, 1, 243, 7, 11, 73, 136, 52, 89, 10, 696, 60, 3, 52, 992, 207, 10, 27, 88, 18, 3177, 4712, 11, 164, 4, 14, 1, 49, 7, 28, 3, 212, 81, 188, 18, 61, 4, 18, 1, 233, 7, 28, 3, 481, 81, 188, 18, 61, 2, 4, 27, 1, 49, 7, 28, 3, 394, 81, 188, 18, 61, 26, 10, 515, 93, 871, 2471, 2059, 10, 44, 1300, 104, 69, 513, 581, 236, 734, 93, 2153, 1, 581, 2438, 212, 15, 80, 11, 164, 4, 49, 1, 243, 7, 259, 4809, 3950, 61, 301, 1, 394, 81, 188, 18, 478, 936, 391, 9, 39, 162, 2796, 81, 188, 18, 379, 906, 10, 41, 5, 88, 18, 155, 3, 1587, 124, 215, 1055, 16, 481, 81, 188, 18, 478, 936, 391, 9, 39, 162, 508, 94, 257, 376, 26, 1055, 4, 299, 2447, 73, 7]",1440.0,22578814,641
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-05-23,"The disease course of chronic lymphocytic leukemia (CLL) varies significantly within cytogenetic groups. We hypothesized that high-resolution genomic analysis of CLL would identify additional recurrent abnormalities associated with short time-to-first therapy (TTFT). We undertook high-resolution genomic analysis of 161 prospectively enrolled CLLs using Affymetrix 6.0 SNP arrays, and integrated analysis of this data set with gene expression profiles. Copy number analysis (CNA) of nonprogressive CLL reveals a stable genotype, with a median of only 1 somatic CNA per sample. Progressive CLL with 13q deletion was associated with additional somatic CNAs, and a greater number of CNAs was predictive of TTFT. We identified other recurrent CNAs associated with short TTFT: 8q24 amplification focused on the cancer susceptibility locus near MYC in 3.7%; 3q26 amplifications focused on PIK3CA in 5.6%; and 8p deletions in 5% of patients. Sequencing of MYC further identified somatic mutations in two CLLs. We determined which catalytic subunits of phosphoinositide 3-kinase (PI3K) were in active complex with the p85 regulatory subunit and showed enrichment for the  subunit in three CLLs carrying PIK3CA amplification. Our findings implicate amplifications of 3q26 focused on PIK3CA and 8q24 focused on MYC in CLL.",Journal Article,2799.0,59.0,The disease course of chronic lymphocytic CLL varies significantly within cytogenetic groups We hypothesized that high-resolution genomic analysis of CLL would identify additional recurrent abnormalities associated with short time-to-first therapy TTFT We undertook high-resolution genomic analysis of 161 prospectively enrolled CLLs using Affymetrix 6.0 SNP arrays and integrated analysis of this data set with gene expression profiles Copy number analysis CNA of nonprogressive CLL reveals a stable genotype with a median of only 1 somatic CNA per sample Progressive CLL with 13q deletion was associated with additional somatic CNAs and a greater number of CNAs was predictive of TTFT We identified other recurrent CNAs associated with short TTFT 8q24 amplification focused on the cancer susceptibility locus near MYC in 3.7 3q26 amplifications focused on PIK3CA in 5.6 and 8p deletions in 5 of patients Sequencing of MYC further identified somatic mutations in two CLLs We determined which catalytic subunits of phosphoinositide 3-kinase PI3K were in active complex with the p85 regulatory subunit and showed enrichment for the subunit in three CLLs carrying PIK3CA amplification Our findings implicate amplifications of 3q26 focused on PIK3CA and 8q24 focused on MYC in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 34, 906, 1, 442, 1193, 552, 4037, 97, 262, 1266, 271, 21, 1237, 17, 64, 2125, 572, 65, 1, 552, 688, 255, 402, 387, 1171, 41, 5, 978, 98, 6, 157, 36, 14035, 21, 5418, 64, 2125, 572, 65, 1, 5377, 1143, 346, 31974, 75, 5318, 49, 13, 1845, 3923, 2, 2102, 65, 1, 26, 74, 916, 5, 145, 55, 1241, 1337, 207, 65, 8986, 1, 23986, 552, 4054, 8, 585, 1183, 5, 8, 52, 1, 158, 14, 1119, 8986, 379, 1000, 1014, 552, 5, 8453, 1528, 10, 41, 5, 402, 1119, 7452, 2, 8, 378, 207, 1, 7452, 10, 464, 1, 14035, 21, 108, 127, 387, 7452, 41, 5, 978, 14035, 6069, 1073, 1649, 23, 3, 12, 1432, 2474, 1829, 1371, 4, 27, 67, 10678, 4877, 1649, 23, 1506, 4, 33, 49, 2, 12251, 2439, 4, 33, 1, 7, 615, 1, 1371, 195, 108, 1119, 138, 4, 100, 31974, 21, 509, 92, 4784, 6166, 1, 4497, 27, 216, 974, 11, 4, 544, 840, 5, 3, 11727, 1253, 3350, 2, 224, 3020, 9, 3, 3350, 4, 169, 31974, 2934, 1506, 1073, 114, 272, 5545, 4877, 1, 10678, 1649, 23, 1506, 2, 6069, 1649, 23, 1371, 4, 552]",1277.0,22623730,715
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.,Blood,Blood,2012-05-29,"Immunotherapy with therapeutic idiotype vaccines offers promise for treatment of B-cell malignancies. However, identification of novel immunogenic lymphoma-associated antigens that are universally expressed is necessary to overcome the barriers of patient-specific idiotype vaccines. Here, we determined whether T-cell leukemia/lymphoma 1 (TCL1) oncoprotein encoded by the TCL1 gene could be a target for immunotherapy of B-cell malignancies. We show that TCL1 mRNA and protein are selectively expressed in normal B cells but markedly hyperexpressed in multiple human B-cell lymphomas, including follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and splenic marginal zone B-cell lymphoma. We demonstrated that TCL1-specific CD8(+) T cells can be generated from HLA-A*0201 (HLA-A2)(+) normal donors and identified TCL1(71-78) (LLPIMWQL) as the minimal epitope recognized by these T cells. More importantly, TCL1(71-78) peptide-specific T cells were present in the peripheral blood and tumor-infiltrating lymphocytes of lymphoma patients, could be expanded in vitro, and lysed autologous tumor cells but not normal B cells in an HLA-A2-restricted manner. Our results suggest that TCL1 is naturally processed and presented on the surface of lymphoma cells for recognition by cytotoxic T cells and can serve as a novel target for development of immunotherapeutic strategies against common B-cell lymphomas.",Journal Article,2793.0,19.0,Immunotherapy with therapeutic idiotype vaccines offers promise for treatment of B-cell malignancies However identification of novel immunogenic lymphoma-associated antigens that are universally expressed is necessary to overcome the barriers of patient-specific idiotype vaccines Here we determined whether T-cell leukemia/lymphoma 1 TCL1 oncoprotein encoded by the TCL1 gene could be a target for immunotherapy of B-cell malignancies We show that TCL1 mRNA and protein are selectively expressed in normal B cells but markedly hyperexpressed in multiple human B-cell lymphomas including follicular chronic lymphocytic mantle cell diffuse large B-cell and splenic marginal zone B-cell We demonstrated that TCL1-specific CD8 T cells can be generated from HLA-A*0201 HLA-A2 normal donors and identified TCL1 71-78 LLPIMWQL as the minimal epitope recognized by these T cells More importantly TCL1 71-78 peptide-specific T cells were present in the peripheral blood and tumor-infiltrating lymphocytes of patients could be expanded in vitro and lysed autologous tumor cells but not normal B cells in an HLA-A2-restricted manner Our results suggest that TCL1 is naturally processed and presented on the surface of cells for recognition by cytotoxic T cells and can serve as a novel target for development of immunotherapeutic strategies against common B-cell lymphomas,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[726, 5, 189, 17615, 1842, 2339, 1783, 9, 24, 1, 132, 31, 441, 137, 911, 1, 229, 4190, 4763, 41, 1575, 17, 32, 6813, 570, 16, 1493, 6, 1768, 3, 2160, 1, 69, 112, 17615, 1842, 467, 21, 509, 317, 102, 31, 2647, 4763, 14, 8979, 6159, 4587, 20, 3, 8979, 145, 359, 40, 8, 283, 9, 726, 1, 132, 31, 441, 21, 514, 17, 8979, 956, 2, 178, 32, 2382, 570, 4, 295, 132, 37, 84, 2195, 61514, 4, 232, 171, 132, 31, 1557, 141, 1974, 442, 1193, 2757, 31, 1388, 375, 132, 31, 2, 5237, 3450, 3614, 132, 31, 21, 264, 17, 8979, 112, 968, 102, 37, 122, 40, 1419, 29, 1160, 8, 8529, 1160, 4099, 295, 2344, 2, 108, 8979, 792, 833, 61515, 22, 3, 1048, 4430, 1904, 20, 46, 102, 37, 80, 1859, 8979, 792, 833, 1389, 112, 102, 37, 11, 364, 4, 3, 672, 315, 2, 30, 2097, 1594, 1, 7, 359, 40, 2064, 4, 439, 2, 14098, 1028, 30, 37, 84, 44, 295, 132, 37, 4, 35, 1160, 4099, 2016, 1708, 114, 99, 309, 17, 8979, 16, 6045, 5232, 2, 917, 23, 3, 1255, 1, 37, 9, 2335, 20, 759, 102, 37, 2, 122, 1833, 22, 8, 229, 283, 9, 193, 1, 3222, 422, 480, 186, 132, 31, 1557]",1362.0,22645177,110
Chronic lymphocytic leukemia in African Americans.,Leukemia & lymphoma,Leuk. Lymphoma,2012-07-09,"Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United States with almost 4390 attributable deaths per year. Epidemiologic data compiled by the Surveillance, Epidemiology and End Results (SEER) program identifies important differences in incidence and survival for African Americans with CLL. Although the incidence of CLL is lower among African Americans than among Caucasians (4.6 and 6.2 per 100 000 men, respectively), age-adjusted survival is inferior. African American patients with CLL are almost twice as likely to die from a CLL-related complication in the first 5 years after diagnosis as are Caucasian patients with CLL. The biologic basis for these observations is almost entirely unexplored, and a comprehensive clinical analysis of African American patients with CLL is lacking. This is the subject of the present review.",Journal Article,2752.0,9.0,Chronic lymphocytic CLL is the most prevalent in the United States with almost 4390 attributable deaths per year Epidemiologic data compiled by the Surveillance Epidemiology and End Results SEER program identifies important differences in incidence and survival for African Americans with CLL Although the incidence of CLL is lower among African Americans than among Caucasians 4.6 and 6.2 per 100 000 men respectively age-adjusted survival is inferior African American patients with CLL are almost twice as likely to die from a CLL-related complication in the first 5 years after diagnosis as are Caucasian patients with CLL The biologic basis for these observations is almost entirely unexplored and a comprehensive clinical analysis of African American patients with CLL is lacking This is the subject of the present review,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 2485, 4, 3, 1088, 907, 5, 2214, 61516, 2971, 1043, 379, 111, 3609, 74, 8535, 20, 3, 617, 1284, 2, 396, 99, 1605, 1243, 2953, 305, 362, 4, 287, 2, 25, 9, 1410, 2731, 5, 552, 242, 3, 287, 1, 552, 16, 280, 107, 1410, 2731, 76, 107, 5396, 39, 49, 2, 49, 18, 379, 394, 984, 325, 106, 89, 586, 25, 16, 1663, 1410, 597, 7, 5, 552, 32, 2214, 936, 22, 322, 6, 3384, 29, 8, 552, 139, 1447, 4, 3, 157, 33, 60, 50, 147, 22, 32, 3229, 7, 5, 552, 3, 1283, 877, 9, 46, 2172, 16, 2214, 6848, 8398, 2, 8, 949, 38, 65, 1, 1410, 597, 7, 5, 552, 16, 1941, 26, 16, 3, 2974, 1, 3, 364, 206]",826.0,22646816,517
BCL2 suppresses PARP1 function and nonapoptotic cell death.,Cancer research,Cancer Res.,2012-06-11,"BCL2 suppresses apoptosis by binding the BH3 domain of proapoptotic factors and thereby regulating outer mitochondrial membrane permeabilization. Many tumor types, including B-cell lymphomas and chronic lymphocytic leukemia, are dependent on BCL2 for survival but become resistant to apoptosis after treatment. Here, we identified a direct interaction between the antiapoptotic protein BCL2 and the enzyme PARP1, which suppresses PARP1 enzymatic activity and inhibits PARP1-dependent DNA repair in diffuse large B-cell lymphoma cells. The BH3 mimetic ABT-737 displaced PARP1 from BCL2 in a dose-dependent manner, reestablishing PARP1 activity and DNA repair and promoting nonapoptotic cell death. This form of cell death was unaffected by resistance to single-agent ABT-737 that results from upregulation of antiapoptotic BCL2 family members. On the basis of the ability of BCL2 to suppress PARP1 function, we hypothesized that ectopic BCL2 expression would kill PARP inhibitor-sensitive cells. Strikingly, BCL2 expression reduced the survival of PARP inhibitor-sensitive breast cancer and lung cancer cells by 90% to 100%, and these effects were reversed by ABT-737. Taken together, our findings show that a novel interaction between BCL2 and PARP1 blocks PARP1 enzymatic activity and suppresses PARP1-dependent repair. Targeted disruption of the BCL2-PARP1 interaction therefore may represent a potential therapeutic approach for BCL2-expressing tumors resistant to apoptosis.",Journal Article,2780.0,25.0,BCL2 suppresses apoptosis by binding the BH3 domain of proapoptotic factors and thereby regulating outer mitochondrial membrane permeabilization Many tumor types including B-cell lymphomas and chronic lymphocytic are dependent on BCL2 for survival but become resistant to apoptosis after treatment Here we identified a direct interaction between the antiapoptotic protein BCL2 and the enzyme PARP1 which suppresses PARP1 enzymatic activity and inhibits PARP1-dependent DNA repair in diffuse large B-cell cells The BH3 mimetic ABT-737 displaced PARP1 from BCL2 in a dose-dependent manner reestablishing PARP1 activity and DNA repair and promoting nonapoptotic cell death This form of cell death was unaffected by resistance to single-agent ABT-737 that results from upregulation of antiapoptotic BCL2 family members On the basis of the ability of BCL2 to suppress PARP1 function we hypothesized that ectopic BCL2 expression would kill PARP inhibitor-sensitive cells Strikingly BCL2 expression reduced the survival of PARP inhibitor-sensitive cancer and cancer cells by 90 to 100 and these effects were reversed by ABT-737 Taken together our findings show that a novel interaction between BCL2 and PARP1 blocks PARP1 enzymatic activity and suppresses PARP1-dependent repair Targeted disruption of the BCL2-PARP1 interaction therefore may represent a potential therapeutic approach for BCL2-expressing tumors resistant to apoptosis,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3214, 4079, 351, 20, 791, 3, 5486, 1398, 1, 4118, 130, 2, 2267, 2681, 7808, 2019, 1905, 19717, 445, 30, 630, 141, 132, 31, 1557, 2, 442, 1193, 32, 470, 23, 3214, 9, 25, 84, 1417, 436, 6, 351, 50, 24, 467, 21, 108, 8, 1196, 915, 59, 3, 4176, 178, 3214, 2, 3, 1644, 6033, 92, 4079, 6033, 5226, 128, 2, 1576, 6033, 470, 261, 972, 4, 1388, 375, 132, 31, 37, 3, 5486, 7343, 3095, 4933, 17178, 6033, 29, 3214, 4, 8, 61, 470, 1708, 46583, 6033, 128, 2, 261, 972, 2, 2388, 26195, 31, 273, 26, 1297, 1, 31, 273, 10, 4585, 20, 251, 6, 226, 420, 3095, 4933, 17, 99, 29, 2218, 1, 4176, 3214, 607, 1684, 23, 3, 877, 1, 3, 801, 1, 3214, 6, 3134, 6033, 343, 21, 1237, 17, 3647, 3214, 55, 688, 5097, 2041, 230, 745, 37, 6787, 3214, 55, 405, 3, 25, 1, 2041, 230, 745, 12, 2, 12, 37, 20, 424, 6, 394, 2, 46, 176, 11, 3682, 20, 3095, 4933, 1633, 1162, 114, 272, 514, 17, 8, 229, 915, 59, 3214, 2, 6033, 2860, 6033, 5226, 128, 2, 4079, 6033, 470, 972, 238, 3220, 1, 3, 3214, 6033, 915, 673, 68, 1231, 8, 174, 189, 353, 9, 3214, 1046, 57, 436, 6, 351]",1428.0,22689920,105
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.,Blood,Blood,2012-06-13,"We performed a meta-analysis of 3 genome-wide association studies to identify additional common variants influencing chronic lymphocytic leukemia (CLL) risk. The discovery phase was composed of genome-wide association study data from 1121 cases and 3745 controls. Replication analysis was performed in 861 cases and 2033 controls. We identified a novel CLL risk locus at 6p21.33 (rs210142; intronic to the BAK1 gene, BCL2 antagonist killer 1; P = 9.47  10(-16)). A strong relationship between risk genotype and reduced BAK1 expression was shown in lymphoblastoid cell lines. This finding provides additional support for polygenic inheritance to CLL and provides further insight into the biologic basis of disease development.",Journal Article,2778.0,41.0,We performed a meta-analysis of 3 genome-wide association studies to identify additional common variants influencing chronic lymphocytic CLL risk The discovery phase was composed of genome-wide association study data from 1121 cases and 3745 controls Replication analysis was performed in 861 cases and 2033 controls We identified a novel CLL risk locus at 6p21.33 rs210142 intronic to the BAK1 gene BCL2 antagonist killer 1 P 9.47 10 -16 A strong relationship between risk genotype and reduced BAK1 expression was shown in lymphoblastoid cell lines This finding provides additional support for polygenic inheritance to CLL and provides further insight into the biologic basis of disease development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 173, 8, 1742, 65, 1, 27, 898, 1019, 248, 94, 6, 255, 402, 186, 839, 4743, 442, 1193, 552, 43, 3, 1574, 124, 10, 3317, 1, 898, 1019, 248, 45, 74, 29, 21253, 140, 2, 40018, 535, 2079, 65, 10, 173, 4, 13668, 140, 2, 39566, 535, 21, 108, 8, 229, 552, 43, 2474, 28, 12479, 466, 47248, 7998, 6, 3, 22437, 145, 3214, 3137, 3458, 14, 19, 83, 662, 79, 245, 8, 1082, 858, 59, 43, 1183, 2, 405, 22437, 55, 10, 443, 4, 10994, 31, 285, 26, 1567, 777, 402, 538, 9, 11709, 10070, 6, 552, 2, 777, 195, 2670, 237, 3, 1283, 877, 1, 34, 193]",699.0,22700719,569
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia.,Cancer research,Cancer Res.,2012-06-18,"Dysregulated microRNA (miRNA) expression contributes to the pathogenesis of hematopoietic malignancies, including chronic lymphocytic leukemia (CLL). However, an understanding of the mechanisms that cause aberrant miRNA transcriptional control is lacking. In this study, we comprehensively investigated the role and extent of miRNA epigenetic regulation in CLL. Genome-wide profiling conducted on 24 CLL and 10 healthy B cell samples revealed global DNA methylation patterns upstream of miRNA sequences that distinguished malignant from healthy cells and identified putative miRNA promoters. Integration of DNA methylation and miRNA promoter data led to the identification of 128 recurrent miRNA targets for aberrant promoter DNA methylation. DNA hypomethylation accounted for more than 60% of all aberrant promoter-associated DNA methylation in CLL, and promoter DNA hypomethylation was restricted to well-defined regions. Individual hyper- and hypomethylated promoters allowed discrimination of CLL samples from healthy controls. Promoter DNA methylation patterns were confirmed in an independent patient cohort, with 11 miRNAs consistently showing an inverse correlation between DNA methylation status and expression level. Together, our findings characterize the role of epigenetic changes in the regulation of miRNA transcription and create a repository of disease-specific promoter regions that may provide additional insights into the pathogenesis of CLL.",Journal Article,2773.0,88.0,Dysregulated microRNA miRNA expression contributes to the pathogenesis of hematopoietic malignancies including chronic lymphocytic CLL However an understanding of the mechanisms that cause aberrant miRNA transcriptional control is lacking In this study we comprehensively investigated the role and extent of miRNA epigenetic regulation in CLL Genome-wide profiling conducted on 24 CLL and 10 healthy B cell samples revealed global DNA methylation patterns upstream of miRNA sequences that distinguished malignant from healthy cells and identified putative miRNA promoters Integration of DNA methylation and miRNA promoter data led to the identification of 128 recurrent miRNA targets for aberrant promoter DNA methylation DNA hypomethylation accounted for more than 60 of all aberrant promoter-associated DNA methylation in CLL and promoter DNA hypomethylation was restricted to well-defined regions Individual hyper- and hypomethylated promoters allowed discrimination of CLL samples from healthy controls Promoter DNA methylation patterns were confirmed in an independent patient cohort with 11 miRNAs consistently showing an inverse correlation between DNA methylation status and expression level Together our findings characterize the role of epigenetic changes in the regulation of miRNA transcription and create a repository of disease-specific promoter regions that may provide additional insights into the pathogenesis of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4288, 3213, 2053, 55, 2444, 6, 3, 1384, 1, 1007, 441, 141, 442, 1193, 552, 137, 35, 612, 1, 3, 483, 17, 708, 1898, 2053, 1431, 182, 16, 1941, 4, 26, 45, 21, 5627, 565, 3, 200, 2, 1039, 1, 2053, 1418, 863, 4, 552, 898, 1019, 1080, 426, 23, 259, 552, 2, 79, 1331, 132, 31, 347, 553, 1648, 261, 569, 764, 3988, 1, 2053, 2866, 17, 4735, 393, 29, 1331, 37, 2, 108, 2743, 2053, 4347, 2676, 1, 261, 569, 2, 2053, 973, 74, 836, 6, 3, 911, 1, 3990, 387, 2053, 637, 9, 1898, 973, 261, 569, 261, 4441, 3688, 9, 80, 76, 335, 1, 62, 1898, 973, 41, 261, 569, 4, 552, 2, 973, 261, 4441, 10, 2016, 6, 149, 395, 1374, 797, 4855, 2, 16372, 4347, 2313, 3520, 1, 552, 347, 29, 1331, 535, 973, 261, 569, 764, 11, 557, 4, 35, 306, 69, 180, 5, 175, 2028, 2433, 2069, 35, 2931, 816, 59, 261, 569, 156, 2, 55, 301, 1162, 114, 272, 1507, 3, 200, 1, 1418, 400, 4, 3, 863, 1, 2053, 866, 2, 3736, 8, 12841, 1, 34, 112, 973, 1374, 17, 68, 377, 402, 1957, 237, 3, 1384, 1, 552]",1433.0,22710432,57
The B-cell receptor signaling pathway as a therapeutic target in CLL.,Blood,Blood,2012-06-19,"Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration amenable to therapeutic targeting. However, our understanding of normal B-cell versus CLL biology points to differences in properties of B-cell receptor (BCR) signaling that may be amenable to selective therapeutic targeting. The application of mouse models has further expanded this understanding and provides information about targets in the BCR signaling pathway that may have other important functions in cell development or long-term health. In addition, overexpression or knockout of selected targets offers the potential to validate targets genetically using new mouse models of CLL. The initial success of BCR-targeted therapies has promoted much excitement in the field of CLL. At the present time, GS-1101, which reversibly inhibits PI3K, and ibrutinib (PCI-32765), an irreversible inhibitor of Bruton tyrosine kinase, have generated the most promising early results in clinical trials including predominately refractory CLL where durable disease control has been observed. This review provides a summary of BCR signaling, tools for studying this pathway relevant to drug development in CLL, and early progress made with therapeutics targeting BCR-related kinases.",Journal Article,2772.0,237.0,Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed the treatment of chronic myeloid Unlike chronic myeloid chronic lymphocytic CLL lacks a common genetic aberration amenable to therapeutic targeting However our understanding of normal B-cell versus CLL biology points to differences in properties of B-cell receptor BCR signaling that may be amenable to selective therapeutic targeting The application of mouse models has further expanded this understanding and provides information about targets in the BCR signaling pathway that may have other important functions in cell development or long-term health In addition overexpression or knockout of selected targets offers the potential to validate targets genetically using new mouse models of CLL The initial success of BCR-targeted therapies has promoted much excitement in the field of CLL At the present time GS-1101 which reversibly inhibits PI3K and ibrutinib PCI-32765 an irreversible inhibitor of Bruton tyrosine kinase have generated the most promising early results in clinical trials including predominately refractory CLL where durable disease control has been observed This review provides a summary of BCR signaling tools for studying this pathway relevant to drug development in CLL and early progress made with therapeutics targeting BCR-related kinases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[238, 36, 5, 577, 2, 127, 1094, 564, 216, 222, 71, 2423, 3, 24, 1, 442, 533, 4246, 442, 533, 442, 1193, 552, 6856, 8, 186, 336, 7794, 4070, 6, 189, 529, 137, 114, 612, 1, 295, 132, 31, 185, 552, 891, 862, 6, 362, 4, 1571, 1, 132, 31, 153, 1062, 314, 17, 68, 40, 4070, 6, 1094, 189, 529, 3, 1581, 1, 830, 274, 71, 195, 2064, 26, 612, 2, 777, 487, 545, 637, 4, 3, 1062, 314, 308, 17, 68, 47, 127, 305, 1681, 4, 31, 193, 15, 319, 337, 341, 4, 352, 851, 15, 5687, 1, 715, 637, 2339, 3, 174, 6, 2183, 637, 2301, 75, 217, 830, 274, 1, 552, 3, 388, 1825, 1, 1062, 238, 235, 71, 2992, 1802, 14755, 4, 3, 1067, 1, 552, 28, 3, 364, 98, 3815, 15129, 92, 15837, 1576, 11063, 2, 1795, 3943, 12229, 35, 4422, 230, 1, 5796, 564, 216, 47, 1419, 3, 96, 721, 191, 99, 4, 38, 143, 141, 11583, 430, 552, 1257, 1480, 34, 182, 71, 85, 164, 26, 206, 777, 8, 1962, 1, 1062, 314, 1896, 9, 4559, 26, 308, 867, 6, 234, 193, 4, 552, 2, 191, 1466, 1229, 5, 1943, 529, 1062, 139, 1549]",1363.0,22715122,498
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.,Blood,Blood,2012-06-27,"Cyclin dependent kinase (CDK) inhibitors, such as flavopiridol, demonstrate significant single-agent activity in chronic lymphocytic leukemia (CLL), but the mechanism of action in these nonproliferating cells is unclear. Here we demonstrate that CLL cells undergo autophagy after treatment with therapeutic agents, including fludarabine, CAL-101, and flavopiridol as well as the endoplasmic reticulum (ER) stress-inducing agent thapsigargin. The addition of chloroquine or siRNA against autophagy components enhanced the cytotoxic effects of flavopiridol and thapsigargin, but not the other agents. Similar to thapsigargin, flavopiridol robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Both autophagy and ER stress were documented in tumor cells from CLL patients receiving flavopiridol. Thus, CLL cells undergo autophagy after multiple stimuli, including therapeutic agents, but only with ER stress mediators and CDK inhibitors is autophagy a mechanism of resistance to cell death. These findings collectively demonstrate, for the first time, a novel mechanism of action (ER stress) and drug resistance (autophagy) for CDK inhibitors, such as flavopiridol in CLL, and provide avenues for new therapeutic combination approaches in this disease.",Evaluation Study,2764.0,67.0,Cyclin dependent kinase CDK inhibitors such as flavopiridol demonstrate significant single-agent activity in chronic lymphocytic CLL but the mechanism of action in these nonproliferating cells is unclear Here we demonstrate that CLL cells undergo autophagy after treatment with therapeutic agents including fludarabine CAL-101 and flavopiridol as well as the endoplasmic reticulum ER stress-inducing agent thapsigargin The addition of chloroquine or siRNA against autophagy components enhanced the cytotoxic effects of flavopiridol and thapsigargin but not the other agents Similar to thapsigargin flavopiridol robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases Both autophagy and ER stress were documented in tumor cells from CLL patients receiving flavopiridol Thus CLL cells undergo autophagy after multiple stimuli including therapeutic agents but only with ER stress mediators and CDK inhibitors is autophagy a mechanism of resistance to cell death These findings collectively demonstrate for the first time a novel mechanism of action ER stress and drug resistance autophagy for CDK inhibitors such as flavopiridol in CLL and provide avenues for new therapeutic combination approaches in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1226, 470, 216, 3954, 222, 225, 22, 3030, 608, 93, 226, 420, 128, 4, 442, 1193, 552, 84, 3, 670, 1, 1578, 4, 46, 30207, 37, 16, 1200, 467, 21, 608, 17, 552, 37, 1251, 2240, 50, 24, 5, 189, 183, 141, 2027, 10368, 2338, 2, 3030, 22, 149, 22, 3, 6057, 6078, 516, 1531, 1958, 420, 10414, 3, 352, 1, 14325, 15, 1919, 480, 2240, 1628, 651, 3, 759, 176, 1, 3030, 2, 10414, 84, 44, 3, 127, 183, 288, 6, 10414, 3030, 8547, 1516, 8, 834, 1177, 1, 516, 1531, 4, 552, 37, 17, 2444, 6, 31, 273, 298, 17744, 517, 363, 1, 31994, 2, 2150, 1489, 7629, 110, 2240, 2, 516, 1531, 11, 1405, 4, 30, 37, 29, 552, 7, 357, 3030, 631, 552, 37, 1251, 2240, 50, 232, 7478, 141, 189, 183, 84, 158, 5, 516, 1531, 4425, 2, 3954, 222, 16, 2240, 8, 670, 1, 251, 6, 31, 273, 46, 272, 2535, 608, 9, 3, 157, 98, 8, 229, 670, 1, 1578, 516, 1531, 2, 234, 251, 2240, 9, 3954, 222, 225, 22, 3030, 4, 552, 2, 377, 6612, 9, 217, 189, 150, 611, 4, 26, 34]",1322.0,22740450,370
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.,Blood,Blood,2012-06-28,"The incidence of chronic lymphocytic leukemia (CLL) is significantly lower in African Americans than whites, but overall survival is inferior. The biologic basis for these observations remains unexplored. We hypothesized that germline genetic predispositions differ between African Americans and whites with CLL and yield inferior clinical outcomes among African Americans. We examined a discovery cohort of 42 African American CLL patients ascertained at Duke University and found that the risk allele frequency of most single nucleotide polymorphisms known to confer risk of development for CLL is significantly lower among African Americans than whites. We then confirmed our results in a distinct cohort of 68 African American patients ascertained by the CLL Research Consortium. These results provide the first evidence supporting differential genetic risk for CLL between African Americans compared with whites. A fuller understanding of differential genetic risk may improve prognostication and therapeutic decision making for all CLL patients.",Journal Article,2763.0,10.0,The incidence of chronic lymphocytic CLL is significantly lower in African Americans than whites but overall survival is inferior The biologic basis for these observations remains unexplored We hypothesized that germline genetic predispositions differ between African Americans and whites with CLL and yield inferior clinical outcomes among African Americans We examined a discovery cohort of 42 African American CLL patients ascertained at Duke University and found that the risk allele frequency of most single nucleotide polymorphisms known to confer risk of development for CLL is significantly lower among African Americans than whites We then confirmed our results in a distinct cohort of 68 African American patients ascertained by the CLL Research Consortium These results provide the first evidence supporting differential genetic risk for CLL between African Americans compared with whites A fuller understanding of differential genetic risk may improve prognostication and therapeutic decision making for all CLL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 287, 1, 442, 1193, 552, 16, 97, 280, 4, 1410, 2731, 76, 2556, 84, 63, 25, 16, 1663, 3, 1283, 877, 9, 46, 2172, 469, 8398, 21, 1237, 17, 1009, 336, 19697, 1505, 59, 1410, 2731, 2, 2556, 5, 552, 2, 2309, 1663, 38, 123, 107, 1410, 2731, 21, 409, 8, 1574, 180, 1, 595, 1410, 597, 552, 7, 5240, 28, 11543, 1652, 2, 204, 17, 3, 43, 1254, 675, 1, 96, 226, 1579, 1203, 440, 6, 2913, 43, 1, 193, 9, 552, 16, 97, 280, 107, 1410, 2731, 76, 2556, 21, 818, 557, 114, 99, 4, 8, 834, 180, 1, 806, 1410, 597, 7, 5240, 20, 3, 552, 389, 2404, 46, 99, 377, 3, 157, 241, 1912, 1777, 336, 43, 9, 552, 59, 1410, 2731, 72, 5, 2556, 8, 38312, 612, 1, 1777, 336, 43, 68, 401, 4260, 2, 189, 948, 1079, 9, 62, 552, 7]",1032.0,22745306,326
"Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.",Cancer,Cancer,2012-07-03,"The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an absolute lymphocyte count (ALC)  10  10(9) /L were eligible for this phase 2 trial. Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily. A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months. Of these patients, 29 (69%) had Rai stage I to II disease. Patients received a median of 6 cycles of treatment (range, 1 cycle-6 cycles). The most common grade 3 side effects (according to National Cancer Institute Common Terminology Criteria for Adverse Events) were transaminitis (1 patient), abdominal pain (1 patient), and fatigue (1 patient). Clinical activity was observed, with 13 patients (31%) experiencing a sustained reduction of  20% in the ALC and 20 of 29 patients (69%) with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all lymph node areas. EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy (correlation co-efficient, 0.44; P = .02). Overall, 29 patients (69%) fulfilled the criteria for a biologic response with either a sustained decline  20% in the ALC and/or a reduction  30% in the sum of the products of all lymph node areas at some point during the 6 months of active treatment. Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial. Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients.","Clinical Trial, Phase II",2758.0,81.0,The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic CLL Previously untreated patients with asymptomatic Rai stage 0 to II CLL and an absolute lymphocyte count ALC  10 10 9 /L were eligible for this phase 2 trial Polyphenon E with a standardized dose of epigallocatechin gallate EGCG 2000 mg per dose was administered twice daily A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months Of these patients 29 69 had Rai stage I to II disease Patients received a median of 6 cycles of treatment range 1 cycle-6 cycles The most common grade 3 side effects according to National Cancer Institute Common Terminology Criteria for Adverse Events were transaminitis 1 patient abdominal pain 1 patient and fatigue 1 patient Clinical activity was observed with 13 patients 31 experiencing a sustained reduction of  20 in the ALC and 20 of 29 patients 69 with palpable adenopathy experiencing at least a 50 reduction in the sum of the products of all lymph node areas EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy correlation co-efficient 0.44 P .02 Overall 29 patients 69 fulfilled the criteria for a biologic response with either a sustained decline  20 in the ALC and/or a reduction  30 in the sum of the products of all lymph node areas at some point during the 6 months of active treatment Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 461, 1, 3, 291, 45, 10, 6, 166, 126, 3, 99, 1, 124, 14, 471, 20, 1435, 3, 38, 209, 1, 3, 4658, 8854, 7164, 22545, 563, 9, 7, 5, 191, 82, 442, 1193, 552, 373, 1278, 7, 5, 2100, 4121, 82, 13, 6, 215, 552, 2, 35, 1766, 1448, 1276, 3749, 749, 79, 79, 83, 805, 11, 625, 9, 26, 124, 18, 160, 22545, 563, 5, 8, 1670, 61, 1, 15613, 15965, 7729, 1081, 81, 379, 61, 10, 468, 936, 391, 8, 181, 1, 595, 7, 103, 22545, 563, 28, 8, 61, 1, 1081, 81, 936, 391, 9, 126, 6, 49, 53, 1, 46, 7, 462, 790, 42, 4121, 82, 70, 6, 215, 34, 7, 103, 8, 52, 1, 49, 410, 1, 24, 184, 14, 417, 49, 410, 3, 96, 186, 88, 27, 1152, 176, 768, 6, 657, 12, 1377, 186, 3462, 371, 9, 290, 281, 11, 8181, 14, 69, 1467, 559, 14, 69, 2, 613, 14, 69, 38, 128, 10, 164, 5, 233, 7, 456, 2985, 8, 2275, 628, 1, 749, 179, 4, 3, 3749, 2, 179, 1, 462, 7, 790, 5, 4880, 7741, 2985, 28, 506, 8, 212, 628, 4, 3, 3216, 1, 3, 2766, 1, 62, 263, 289, 1361, 7729, 554, 148, 50, 14, 811, 1, 36, 11, 204, 6, 40, 438, 5, 2153, 4, 4962, 816, 1269, 2547, 13, 584, 19, 588, 63, 462, 7, 790, 9091, 3, 371, 9, 8, 1283, 51, 5, 361, 8, 2275, 1858, 749, 179, 4, 3, 3749, 2, 15, 8, 628, 749, 201, 4, 3, 3216, 1, 3, 2766, 1, 62, 263, 289, 1361, 28, 476, 741, 190, 3, 49, 53, 1, 544, 24, 391, 518, 7729, 4, 3, 22545, 563, 4824, 10, 149, 421, 20, 7, 5, 552, 4, 26, 124, 18, 160, 1480, 4264, 4, 3, 3749, 2, 15, 4962, 11, 164, 4, 3, 686, 1, 7]",1745.0,22760587,259
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.,PloS one,PLoS ONE,2012-07-27,"The nucleoside analogues 8-amino-adenosine and 8-chloro-adenosine have been investigated in the context of B-lineage lymphoid malignancies by our laboratories due to the selective cytotoxicity they exhibit toward multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL) cell lines and primary cells. Encouraging pharmacokinetic and pharmacodynamic properties of 8-chloro-adenosine being documented in an ongoing Phase I trial in CLL provide additional impetus for the study of these promising drugs. In order to foster a deeper understanding of the commonalities between their mechanisms of action and gain insight into specific patient cohorts positioned to achieve maximal benefit from treatment, we devised a novel two-tiered chemoinformatic screen to identify molecular determinants of responsiveness to these compounds. This screen entailed: 1) the elucidation of gene expression patterns highly associated with the anti-tumor activity of 8-chloro-adenosine in the NCI-60 cell line panel, 2) characterization of altered transcript abundances between paired MM and MCL cell lines exhibiting differential susceptibility to 8-amino-adenosine, and 3) integration of the resulting datasets. This approach generated a signature of seven unique genes including G6PD which encodes the rate-determining enzyme of the pentose phosphate pathway (PPP), glucose-6-phosphate dehydrogenase. Bioinformatic analysis of primary cell gene expression data demonstrated that G6PD is frequently overexpressed in MM and CLL, highlighting the potential clinical implications of this finding. Utilizing the paired sensitive and resistant MM and MCL cell lines as a model system, we go on to demonstrate through loss-of-function and gain-of-function studies that elevated G6PD expression is necessary to maintain resistance to 8-amino- and 8-chloro-adenosine but insufficient to induce de novo resistance in sensitive cells. Taken together, these results indicate that G6PD activity antagonizes the cytotoxicity of 8-substituted adenosine analogues and suggests that administration of these agents to patients with B-cell malignancies exhibiting normal levels of G6PD expression may be particularly efficacious.",Journal Article,2734.0,5.0,The nucleoside analogues 8-amino-adenosine and 8-chloro-adenosine have been investigated in the context of B-lineage lymphoid malignancies by our laboratories due to the selective cytotoxicity they exhibit toward multiple MM chronic lymphocytic CLL and mantle cell MCL cell lines and primary cells Encouraging pharmacokinetic and pharmacodynamic properties of 8-chloro-adenosine being documented in an ongoing Phase I trial in CLL provide additional impetus for the study of these promising drugs In order to foster a deeper understanding of the commonalities between their mechanisms of action and gain insight into specific patient cohorts positioned to achieve maximal benefit from treatment we devised a novel two-tiered chemoinformatic screen to identify molecular determinants of responsiveness to these compounds This screen entailed 1 the elucidation of gene expression patterns highly associated with the anti-tumor activity of 8-chloro-adenosine in the NCI-60 cell line panel 2 characterization of altered transcript abundances between paired MM and MCL cell lines exhibiting differential susceptibility to 8-amino-adenosine and 3 integration of the resulting datasets This approach generated a signature of seven unique genes including G6PD which encodes the rate-determining enzyme of the pentose phosphate pathway PPP glucose-6-phosphate dehydrogenase Bioinformatic analysis of primary cell gene expression data demonstrated that G6PD is frequently overexpressed in MM and CLL highlighting the potential clinical implications of this finding Utilizing the paired sensitive and resistant MM and MCL cell lines as a model system we go on to demonstrate through loss-of-function and gain-of-function studies that elevated G6PD expression is necessary to maintain resistance to 8-amino- and 8-chloro-adenosine but insufficient to induce de novo resistance in sensitive cells Taken together these results indicate that G6PD activity antagonizes the cytotoxicity of 8-substituted adenosine analogues and suggests that administration of these agents to patients with B-cell malignancies exhibiting normal levels of G6PD expression may be particularly efficacious,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4032, 4768, 66, 3078, 4938, 2, 66, 14778, 4938, 47, 85, 565, 4, 3, 1533, 1, 132, 2542, 2303, 441, 20, 114, 4884, 520, 6, 3, 1094, 1408, 491, 2239, 1317, 232, 321, 442, 1193, 552, 2, 2757, 31, 1308, 31, 285, 2, 86, 37, 2269, 1456, 2, 2424, 1571, 1, 66, 14778, 4938, 486, 1405, 4, 35, 942, 124, 70, 160, 4, 552, 377, 402, 11582, 9, 3, 45, 1, 46, 721, 600, 4, 1732, 6, 9899, 8, 6029, 612, 1, 3, 20534, 59, 136, 483, 1, 1578, 2, 1803, 2670, 237, 112, 69, 736, 14240, 6, 1359, 2725, 247, 29, 24, 21, 10085, 8, 229, 100, 14526, 61718, 2413, 6, 255, 219, 3403, 1, 3642, 6, 46, 2411, 26, 2413, 22116, 14, 3, 7481, 1, 145, 55, 764, 561, 41, 5, 3, 312, 30, 128, 1, 66, 14778, 4938, 4, 3, 2580, 335, 31, 328, 993, 18, 2136, 1, 1495, 3268, 19988, 59, 2355, 321, 2, 1308, 31, 285, 4801, 1777, 1432, 6, 66, 3078, 4938, 2, 27, 2676, 1, 3, 1113, 3455, 26, 353, 1419, 8, 1651, 1, 648, 991, 214, 141, 16146, 92, 4322, 3, 116, 2196, 1644, 1, 3, 19943, 4849, 308, 16951, 2522, 49, 4849, 2374, 10121, 65, 1, 86, 31, 145, 55, 74, 264, 17, 16146, 16, 746, 1711, 4, 321, 2, 552, 4051, 3, 174, 38, 1268, 1, 26, 1567, 2600, 3, 2355, 745, 2, 436, 321, 2, 1308, 31, 285, 22, 8, 202, 398, 21, 3537, 23, 6, 608, 298, 407, 1, 343, 2, 1803, 1, 343, 94, 17, 804, 16146, 55, 16, 1493, 6, 3040, 251, 6, 66, 3078, 2, 66, 14778, 4938, 84, 3027, 6, 1290, 1566, 2018, 251, 4, 745, 37, 1633, 1162, 46, 99, 1008, 17, 16146, 128, 11574, 3, 1408, 1, 66, 10536, 4938, 4768, 2, 844, 17, 634, 1, 46, 183, 6, 7, 5, 132, 31, 441, 4801, 295, 148, 1, 16146, 55, 68, 40, 823, 3289]",2168.0,22848499,634
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.,Leukemia & lymphoma,Leuk. Lymphoma,2012-08-22,"Thirty-three previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) were treated before meeting standard criteria with alemtuzumab and rituximab. Granulocyte macrophage colony stimulating factor (GM-CSF) was added to the regimen to determine whether it would improve treatment efficacy without increasing toxicity. High risk was defined as at least one of the following: 17p13-; 11q22.3-; unmutated IGHV (or use of VH3-21) together with elevated expression of ZAP-70 and/or CD38. Treatment was subcutaneous GM-CSF 250 g Monday-Wednesday-Friday for 6 weeks from day 1, subcutaneous alemtuzumab 3 mg-10 mg-30 mg from day 3 and then 30 mg Monday-Wednesday-Friday for 4 weeks, and intravenous rituximab (375 mg/m(2)/week) for 4 weeks from day 8. Patients received standard supportive care and were monitored weekly for cytomegalovirus (CMV) reactivation. Using standard criteria, 31 (94%) patients responded to treatment, with nine (27%) complete responses (one with persistent cytopenia) and nine (27%) nodular partial responses. Median progression-free survival was 13.0 months and time to next treatment was 33.5 months. No patient died during treatment, seven (21%) had grade 3-4 toxicities attributable to treatment, and 10 (30%) had CMV viremia. Addition of GM-CSF to therapy with alemtuzumab and rituximab decreased treatment efficacy and increased the rate of CMV reactivation compared to a historical control.",Clinical Trial,2708.0,8.0,Thirty-three previously untreated patients with high-risk chronic lymphocytic CLL were treated before meeting standard criteria with alemtuzumab and rituximab Granulocyte macrophage colony stimulating factor GM-CSF was added to the regimen to determine whether it would improve treatment efficacy without increasing toxicity High risk was defined as at least one of the following 17p13- 11q22.3- unmutated IGHV or use of VH3-21 together with elevated expression of ZAP-70 and/or CD38 Treatment was subcutaneous GM-CSF 250 g Monday-Wednesday-Friday for 6 weeks from day 1 subcutaneous alemtuzumab 3 mg-10 mg-30 mg from day 3 and then 30 mg Monday-Wednesday-Friday for 4 weeks and intravenous rituximab 375 mg/m 2 /week for 4 weeks from day 8 Patients received standard supportive care and were monitored weekly for cytomegalovirus CMV reactivation Using standard criteria 31 94 patients responded to treatment with nine 27 complete responses one with persistent cytopenia and nine 27 nodular partial responses Median progression-free survival was 13.0 months and time to next treatment was 33.5 months No patient died during treatment seven 21 had grade 3-4 toxicities attributable to treatment and 10 30 had CMV viremia Addition of GM-CSF to therapy with alemtuzumab and rituximab decreased treatment efficacy and increased the rate of CMV reactivation compared to a historical control,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[977, 169, 373, 1278, 7, 5, 64, 43, 442, 1193, 552, 11, 73, 348, 2238, 260, 371, 5, 3579, 2, 855, 2764, 2674, 1975, 2122, 161, 2147, 1211, 10, 1953, 6, 3, 477, 6, 223, 317, 192, 688, 401, 24, 209, 187, 602, 155, 64, 43, 10, 395, 22, 28, 506, 104, 1, 3, 366, 7526, 12647, 27, 7216, 6220, 15, 119, 1, 33428, 239, 1162, 5, 804, 55, 1, 6251, 431, 2, 15, 4469, 24, 10, 2529, 2147, 1211, 2039, 3802, 9339, 14412, 9872, 9, 49, 244, 29, 218, 14, 2529, 3579, 27, 81, 79, 81, 201, 81, 29, 218, 27, 2, 818, 201, 81, 9339, 14412, 9872, 9, 39, 244, 2, 1262, 855, 4175, 81, 188, 18, 647, 9, 39, 244, 29, 218, 66, 7, 103, 260, 1877, 165, 2, 11, 2909, 709, 9, 7314, 3879, 3834, 75, 260, 371, 456, 960, 7, 2211, 6, 24, 5, 762, 428, 236, 253, 104, 5, 1882, 8165, 2, 762, 428, 4481, 450, 253, 52, 91, 115, 25, 10, 233, 13, 53, 2, 98, 6, 1305, 24, 10, 466, 33, 53, 77, 69, 1016, 190, 24, 648, 239, 42, 88, 27, 39, 385, 2971, 6, 24, 2, 79, 201, 42, 3879, 10008, 352, 1, 2147, 1211, 6, 36, 5, 3579, 2, 855, 340, 24, 209, 2, 101, 3, 116, 1, 3879, 3834, 72, 6, 8, 2252, 182]",1386.0,22853816,486
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.,Blood,Blood,2012-08-02,"Chronic lymphoproliferative disorders of natural killer cells (CLPD-NKs) and T-cell large granular lymphocytic leukemias (T-LGLs) are clonal lymphoproliferations arising from either natural killer cells or cytotoxic T lymphocytes (CTLs). We have investigated for distribution and functional significance of mutations in 50 CLPD-NKs and 120 T-LGL patients by direct sequencing, allele-specific PCR, and microarray analysis. STAT3 gene mutations are present in both T and NK diseases: approximately one-third of patients with each type of disorder convey these mutations. Mutations were found in exons 21 and 20, encoding the Src homology 2 domain. Patients with mutations are characterized by symptomatic disease (75%), history of multiple treatments, and a specific pattern of STAT3 activation and gene deregulation, including increased expression of genes activated by STAT3. Many of these features are also found in patients with wild-type STAT3, indicating that other mechanisms of STAT3 activation can be operative in these chronic lymphoproliferative disorders. Treatment with STAT3 inhibitors, both in wild-type and mutant cases, resulted in accelerated apoptosis. STAT3 mutations are frequent in large granular lymphocytes suggesting a similar molecular dysregulation in malignant chronic expansions of NK and CTL origin. STAT3 mutations may distinguish truly malignant lymphoproliferations involving T and NK cells from reactive expansions.",Journal Article,2728.0,207.0,Chronic lymphoproliferative disorders of natural killer cells CLPD-NKs and T-cell large granular lymphocytic leukemias T-LGLs are clonal lymphoproliferations arising from either natural killer cells or cytotoxic T lymphocytes CTLs We have investigated for distribution and functional significance of mutations in 50 CLPD-NKs and 120 T-LGL patients by direct sequencing allele-specific PCR and microarray analysis STAT3 gene mutations are present in both T and NK diseases approximately one-third of patients with each type of disorder convey these mutations Mutations were found in exons 21 and 20 encoding the Src homology 2 domain Patients with mutations are characterized by symptomatic disease 75 history of multiple treatments and a specific pattern of STAT3 activation and gene deregulation including increased expression of genes activated by STAT3 Many of these features are also found in patients with wild-type STAT3 indicating that other mechanisms of STAT3 activation can be operative in these chronic lymphoproliferative disorders Treatment with STAT3 inhibitors both in wild-type and mutant cases resulted in accelerated apoptosis STAT3 mutations are frequent in large granular lymphocytes suggesting a similar molecular dysregulation in malignant chronic expansions of NK and CTL origin STAT3 mutations may distinguish truly malignant lymphoproliferations involving T and NK cells from reactive expansions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 4192, 1997, 1, 1504, 3458, 37, 19233, 47321, 2, 102, 31, 375, 7694, 1193, 2792, 102, 26494, 32, 1946, 35408, 2635, 29, 361, 1504, 3458, 37, 15, 759, 102, 1594, 5416, 21, 47, 565, 9, 1395, 2, 583, 724, 1, 138, 4, 212, 19233, 47321, 2, 2031, 102, 7816, 7, 20, 1196, 615, 1254, 112, 604, 2, 1727, 65, 1439, 145, 138, 32, 364, 4, 110, 102, 2, 1765, 1342, 705, 104, 1282, 1, 7, 5, 296, 267, 1, 2645, 11415, 46, 138, 138, 11, 204, 4, 3885, 239, 2, 179, 2362, 3, 2023, 7984, 18, 1398, 7, 5, 138, 32, 765, 20, 1704, 34, 481, 532, 1, 232, 640, 2, 8, 112, 1177, 1, 1439, 363, 2, 145, 4765, 141, 101, 55, 1, 214, 735, 20, 1439, 445, 1, 46, 404, 32, 120, 204, 4, 7, 5, 955, 267, 1439, 1716, 17, 127, 483, 1, 1439, 363, 122, 40, 1208, 4, 46, 442, 4192, 1997, 24, 5, 1439, 222, 110, 4, 955, 267, 2, 620, 140, 627, 4, 2241, 351, 1439, 138, 32, 908, 4, 375, 7694, 1594, 802, 8, 288, 219, 3935, 4, 393, 442, 12384, 1, 1765, 2, 3872, 1938, 1439, 138, 68, 3081, 7260, 393, 35408, 1267, 102, 2, 1765, 37, 29, 2163, 12384]",1420.0,22859607,27
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-08-14,"We conducted a phase I study to determine the safety, maximum-tolerated dose (MTD), and efficacy of weekly bolus recombinant human interleukin-21 (rIL-21) plus rituximab in patients with indolent B-cell malignancies. One week after a lead-in rituximab dose, cohorts of three patients were treated with 30, 100, or 150 g/kg rIL-21 weekly for four weeks, concurrent with four weekly doses of rituximab. Patients with stable disease or better were eligible for a second course of therapy. Twenty-one patients with relapsed small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL, n = 11), follicular lymphoma (n = 9), or marginal zone lymphoma (n = 1) were enrolled, with 19 completing at least one course of therapy. The MTD for rIL-21 was 100 g/kg, based on observed toxicities including nausea, vomiting, diarrhea, hypotension, edema, and hypophosphatemia. Clinical responses were seen in 8 of 19 evaluable patients (42%; 3 CR/CRu, 5 PR), with 4 of longer duration than the patient's previous response to rituximab-based treatment (median 9 months vs. 3 months). Outpatient therapy of indolent B-cell malignancies with rituximab and weekly rIL-21 was well tolerated and clinically active, with durable complete remissions in a small subset of patients. Additional studies of rIL-21 and anti-CD20 antibodies in lymphoma and SLL/CLL are warranted.","Clinical Trial, Phase I",2716.0,38.0,We conducted a phase I study to determine the safety maximum-tolerated dose MTD and efficacy of weekly bolus recombinant human interleukin-21 rIL-21 plus rituximab in patients with indolent B-cell malignancies One week after a lead-in rituximab dose cohorts of three patients were treated with 30 100 or 150 g/kg rIL-21 weekly for four weeks concurrent with four weekly doses of rituximab Patients with stable disease or better were eligible for a second course of therapy Twenty-one patients with relapsed small lymphocytic lymphoma/chronic lymphocytic SLL/CLL n 11 follicular n 9 or marginal zone n 1 were enrolled with 19 completing at least one course of therapy The MTD for rIL-21 was 100 g/kg based on observed toxicities including nausea vomiting diarrhea hypotension edema and hypophosphatemia Clinical responses were seen in 8 of 19 evaluable patients 42 3 CR/CRu 5 PR with 4 of longer duration than the patient 's previous response to rituximab-based treatment median 9 months vs. 3 months Outpatient therapy of indolent B-cell malignancies with rituximab and weekly rIL-21 was well tolerated and clinically active with durable complete remissions in a small subset of patients Additional studies of rIL-21 and anti-CD20 antibodies in and SLL/CLL are warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 426, 8, 124, 70, 45, 6, 223, 3, 367, 689, 421, 61, 961, 2, 209, 1, 709, 3604, 2835, 171, 1603, 239, 8000, 239, 349, 855, 4, 7, 5, 2316, 132, 31, 441, 104, 647, 50, 8, 1122, 4, 855, 61, 736, 1, 169, 7, 11, 73, 5, 201, 394, 15, 1577, 3802, 503, 8000, 239, 709, 9, 294, 244, 750, 5, 294, 709, 415, 1, 855, 7, 5, 585, 34, 15, 380, 11, 625, 9, 8, 419, 906, 1, 36, 737, 104, 7, 5, 591, 302, 1193, 4763, 442, 1193, 5302, 552, 78, 175, 1974, 78, 83, 15, 3450, 3614, 78, 14, 11, 346, 5, 326, 4144, 28, 506, 104, 906, 1, 36, 3, 961, 9, 8000, 239, 10, 394, 3802, 503, 90, 23, 164, 385, 141, 1218, 1966, 1172, 6577, 3306, 2, 8021, 38, 253, 11, 527, 4, 66, 1, 326, 859, 7, 595, 27, 684, 12624, 33, 998, 5, 39, 1, 589, 654, 76, 3, 69, 292, 698, 51, 6, 855, 90, 24, 52, 83, 53, 105, 27, 53, 2379, 36, 1, 2316, 132, 31, 441, 5, 855, 2, 709, 8000, 239, 10, 149, 421, 2, 505, 544, 5, 1480, 236, 3166, 4, 8, 302, 697, 1, 7, 402, 94, 1, 8000, 239, 2, 312, 2198, 890, 4, 2, 5302, 552, 32, 1197]",1272.0,22893631,337
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).,Leukemia & lymphoma,Leuk. Lymphoma,2012-09-08,"The impact of initial fludarabine therapy on transformation to Richter syndrome (RS) or prolymphocytic leukemia (PLL) in patients with chronic lymphocytic leukemia (CLL) is uncertain. We studied the outcomes of 521 patients with CLL who were randomized to initial fludarabine (F), chlorambucil (C) or F + C therapy on an intergroup trial (CALGB 9011). RS developed in 34 (7%) patients and PLL in 10 (2%). RS and PLL occurred in 14 (7%) and three (2%) of 188 patients randomized to F; nine (5%) and four (2%) of 191 patients treated with C; and 11 (8%) and three (2%) of 142 receiving F + C, respectively. Four percent of the 206 patients with Rai stage III/IV developed PLL, compared to only 1% of the 315 patients with Rai stage I/II (p = 0.02). Initial fludarabine therapy in patients with CLL did not impact transformation to RS or PLL, nor were any other baseline characteristics predictive for such transformation in this series.",Journal Article,2691.0,23.0,The impact of initial fludarabine therapy on transformation to Richter syndrome RS or prolymphocytic PLL in patients with chronic lymphocytic CLL is uncertain We studied the outcomes of 521 patients with CLL who were randomized to initial fludarabine F chlorambucil C or F C therapy on an intergroup trial CALGB 9011 RS developed in 34 7 patients and PLL in 10 2 RS and PLL occurred in 14 7 and three 2 of 188 patients randomized to F nine 5 and four 2 of 191 patients treated with C and 11 8 and three 2 of 142 receiving F C respectively Four percent of the 206 patients with Rai stage III/IV developed PLL compared to only 1 of the 315 patients with Rai stage I/II p 0.02 Initial fludarabine therapy in patients with CLL did not impact transformation to RS or PLL nor were any other baseline characteristics predictive for such transformation in this series,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 345, 1, 388, 2027, 36, 23, 1392, 6, 8452, 681, 2250, 15, 14779, 10555, 4, 7, 5, 442, 1193, 552, 16, 2717, 21, 656, 3, 123, 1, 11925, 7, 5, 552, 54, 11, 384, 6, 388, 2027, 1068, 11585, 256, 15, 1068, 256, 36, 23, 35, 4839, 160, 4077, 33264, 2250, 276, 4, 562, 67, 7, 2, 10555, 4, 79, 18, 2250, 2, 10555, 489, 4, 213, 67, 2, 169, 18, 1, 5664, 7, 384, 6, 1068, 762, 33, 2, 294, 18, 1, 6130, 7, 73, 5, 256, 2, 175, 66, 2, 169, 18, 1, 4785, 357, 1068, 256, 106, 294, 714, 1, 3, 5956, 7, 5, 4121, 82, 316, 478, 276, 10555, 72, 6, 158, 14, 1, 3, 7362, 7, 5, 4121, 82, 70, 215, 19, 13, 588, 388, 2027, 36, 4, 7, 5, 552, 205, 44, 345, 1392, 6, 2250, 15, 10555, 2110, 11, 500, 127, 330, 374, 464, 9, 225, 1392, 4, 26, 988]",859.0,22897733,219
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2012-08-21,"Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology. To identify susceptibility immune genes, we conducted a 2-stage analysis of single-nucleotide polymorphisms (SNP) from 1,253 genes using the Immune and Inflammation Panel. In Stage 1, we genotyped 7,670 SNPs in 425 NHL cases and 465 controls, and in Stage 2 we genotyped the top 768 SNPs on an additional 584 cases and 768 controls. The association of individual SNPs with NHL risk from a log-additive model was assessed using the OR and 95% confidence intervals (CI). In the pooled analysis, only the TAP2 coding SNP rs241447 (minor allele frequency = 0.26; Thr655Ala) at 6p21.3 (OR = 1.34, 95% CI 1.17-1.53) achieved statistical significance after accounting for multiple testing (P = 3.1  10(-5)). The TAP2 SNP was strongly associated with follicular lymphoma (FL, OR = 1.82, 95%CI 1.46-2.26; p = 6.9  10(-8)), and was independent of other known loci (rs10484561 and rs2647012) from this region. The TAP2 SNP was also associated with diffuse large B-cell lymphoma (DLBCL, OR = 1.38, 95% CI 1.08-1.77; P = 0.011), but not chronic lymphocytic leukemia (OR = 1.08; 95% CI 0.88-1.32). Higher TAP2 expression was associated with the risk allele in both FL and DLBCL tumors. Genetic variation in TAP2 was associated with NHL risk overall, and FL risk in particular, and this was independent of other established loci from 6p21.3. Genetic variation in antigen presentation of HLA class I molecules may play a role in lymphomagenesis.",Journal Article,2709.0,16.0,"NHL is a malignancy of lymphocytes and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology To identify susceptibility immune genes we conducted a 2-stage analysis of single-nucleotide polymorphisms SNP from 1,253 genes using the Immune and Inflammation Panel In Stage 1 we genotyped 7,670 SNPs in 425 NHL cases and 465 controls and in Stage 2 we genotyped the top 768 SNPs on an additional 584 cases and 768 controls The association of individual SNPs with NHL risk from a log-additive model was assessed using the OR and 95 confidence intervals CI In the pooled analysis only the TAP2 coding SNP rs241447 minor allele frequency 0.26 Thr655Ala at 6p21.3 OR 1.34 95 CI 1.17-1.53 achieved statistical significance after accounting for multiple testing P 3.1 10 -5 The TAP2 SNP was strongly associated with follicular FL OR 1.82 95 CI 1.46-2.26 p 6.9 10 -8 and was independent of other known loci rs10484561 and rs2647012 from this region The TAP2 SNP was also associated with diffuse large B-cell DLBCL OR 1.38 95 CI 1.08-1.77 P 0.011 but not chronic lymphocytic OR 1.08 95 CI 0.88-1.32 Higher TAP2 expression was associated with the risk allele in both FL and DLBCL tumors Genetic variation in TAP2 was associated with NHL risk overall and FL risk in particular and this was independent of other established loci from 6p21.3 Genetic variation in antigen presentation of HLA class I molecules may play a role in lymphomagenesis",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1176, 16, 8, 710, 1, 1594, 2, 125, 16, 1921, 241, 9, 8, 200, 1, 1009, 336, 1380, 4, 250, 214, 4, 1176, 2855, 6, 255, 1432, 250, 214, 21, 426, 8, 18, 82, 65, 1, 226, 1579, 1203, 1845, 29, 14, 8105, 214, 75, 3, 250, 2, 1815, 993, 4, 82, 14, 21, 3053, 67, 10335, 1109, 4, 8544, 1176, 140, 2, 9940, 535, 2, 4, 82, 18, 21, 3053, 3, 3150, 15188, 1109, 23, 35, 402, 9640, 140, 2, 15188, 535, 3, 248, 1, 797, 1109, 5, 1176, 43, 29, 8, 1066, 3396, 202, 10, 275, 75, 3, 15, 2, 48, 307, 1582, 58, 4, 3, 1830, 65, 158, 3, 29336, 3097, 1845, 61782, 2278, 1254, 675, 13, 432, 61783, 28, 12479, 27, 15, 14, 562, 48, 58, 14, 269, 14, 699, 513, 1050, 724, 50, 3116, 9, 232, 471, 19, 27, 14, 79, 33, 3, 29336, 1845, 10, 1327, 41, 5, 1974, 2633, 15, 14, 878, 48, 58, 14, 641, 18, 432, 19, 49, 83, 79, 66, 2, 10, 306, 1, 127, 440, 2012, 46125, 2, 61784, 29, 26, 1053, 3, 29336, 1845, 10, 120, 41, 5, 1388, 375, 132, 31, 1446, 15, 14, 519, 48, 58, 14, 1592, 14, 849, 19, 13, 3651, 84, 44, 442, 1193, 15, 14, 1592, 48, 58, 13, 889, 14, 531, 142, 29336, 55, 10, 41, 5, 3, 43, 1254, 4, 110, 2633, 2, 1446, 57, 336, 1380, 4, 29336, 10, 41, 5, 1176, 43, 63, 2, 2633, 43, 4, 1454, 2, 26, 10, 306, 1, 127, 635, 2012, 29, 12479, 27, 336, 1380, 4, 448, 1031, 1, 1160, 1040, 70, 1598, 68, 1343, 8, 200, 4, 12366]",1472.0,22911334,661
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.,Human pathology,Hum. Pathol.,2012-08-31,"Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) share many features and both arise from CD5+ B-cells; their distinction is critical as MCL is a more aggressive neoplasm. Rarely, cases of composite MCL and CLL/SLL have been reported. Little is known about the nature of these cases and, in particular, the clonal relationship of the 2 lymphomas. Eleven composite MCL and CLL/SLL cases were identified. The clinical, morphologic and immunophenotypic features of the MCL and CLL/SLL were characterized. IGH (immunoglobulin heavy chain) gene analysis was performed on microdissected MCL and CLL/SLL components to assess their clonal relationship. Ten patients had lymphadenopathy, and 7 patients had bone marrow involvement. The MCL component had the following growth patterns: in situ (n = 1), mantle zone (n = 3), nodular and diffuse (n = 3), diffuse (n = 3), and interstitial in the bone marrow (the only patient without lymphadenopathy) (n = 1); 6 MCLs had blastoid or pleomorphic and 5 small lymphocytic features. The CLL/SLL component was nodular (n = 9) or diffuse (n = 2). All MCL were CD5(+) and cyclin D1(+) with t(11;14) translocation. All CLL/SLL were CD5(+), CD23(+) and negative for cyclin D1 or t(11;14). IGH gene analysis showed that the MCL and CLL/SLL components displayed different sized fragments, indicating that the MCL and CLL/SLL are likely derived from different neoplastic B-cell clones. The lack of a clonal relationship between the MCL and CLL/SLL components suggests that MCL and CLL/SLL components represent distinct disease processes and do not share a common progenitor B-cell.",Case Reports,2699.0,20.0,Mantle cell MCL and chronic lymphocytic leukemia/small lymphocytic CLL/SLL share many features and both arise from CD5+ B-cells their distinction is critical as MCL is a more aggressive neoplasm Rarely cases of composite MCL and CLL/SLL have been reported Little is known about the nature of these cases and in particular the clonal relationship of the 2 lymphomas Eleven composite MCL and CLL/SLL cases were identified The clinical morphologic and immunophenotypic features of the MCL and CLL/SLL were characterized IGH immunoglobulin heavy chain gene analysis was performed on microdissected MCL and CLL/SLL components to assess their clonal relationship Ten patients had lymphadenopathy and 7 patients had marrow involvement The MCL component had the following growth patterns in situ n 1 mantle zone n 3 nodular and diffuse n 3 diffuse n 3 and interstitial in the marrow the only patient without lymphadenopathy n 1 6 MCLs had blastoid or pleomorphic and 5 small lymphocytic features The CLL/SLL component was nodular n 9 or diffuse n 2 All MCL were CD5 and cyclin D1 with t 11 14 translocation All CLL/SLL were CD5 CD23 and negative for cyclin D1 or t 11 14 IGH gene analysis showed that the MCL and CLL/SLL components displayed different sized fragments indicating that the MCL and CLL/SLL are likely derived from different neoplastic B-cell clones The lack of a clonal relationship between the MCL and CLL/SLL components suggests that MCL and CLL/SLL components represent distinct disease processes and do not share a common progenitor B-cell,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2757, 31, 1308, 2, 442, 1193, 2647, 302, 1193, 552, 5302, 4349, 445, 404, 2, 110, 3043, 29, 6349, 132, 37, 136, 6628, 16, 740, 22, 1308, 16, 8, 80, 571, 2131, 2416, 140, 1, 3308, 1308, 2, 552, 5302, 47, 85, 210, 1215, 16, 440, 545, 3, 2202, 1, 46, 140, 2, 4, 1454, 3, 1946, 858, 1, 3, 18, 1557, 2627, 3308, 1308, 2, 552, 5302, 140, 11, 108, 3, 38, 2815, 2, 6599, 404, 1, 3, 1308, 2, 552, 5302, 11, 765, 5221, 2593, 4013, 1260, 145, 65, 10, 173, 23, 9418, 1308, 2, 552, 5302, 1628, 6, 423, 136, 1946, 858, 1618, 7, 42, 4962, 2, 67, 7, 42, 581, 799, 3, 1308, 1249, 42, 3, 366, 129, 764, 4, 957, 78, 14, 2757, 3614, 78, 27, 4481, 2, 1388, 78, 27, 1388, 78, 27, 2, 4543, 4, 3, 581, 3, 158, 69, 187, 4962, 78, 14, 49, 20994, 42, 16186, 15, 4581, 2, 33, 302, 1193, 404, 3, 552, 5302, 1249, 10, 4481, 78, 83, 15, 1388, 78, 18, 62, 1308, 11, 6349, 2, 1226, 2146, 5, 102, 175, 213, 2006, 62, 552, 5302, 11, 6349, 9937, 2, 199, 9, 1226, 2146, 15, 102, 175, 213, 5221, 145, 65, 224, 17, 3, 1308, 2, 552, 5302, 1628, 2507, 338, 8568, 5843, 1716, 17, 3, 1308, 2, 552, 5302, 32, 322, 526, 29, 338, 2000, 132, 31, 2749, 3, 926, 1, 8, 1946, 858, 59, 3, 1308, 2, 552, 5302, 1628, 844, 17, 1308, 2, 552, 5302, 1628, 1231, 834, 34, 1849, 2, 1022, 44, 4349, 8, 186, 2520, 132, 31]",1549.0,22944294,20
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.,Blood,Blood,2012-09-13,"Cytokines within the tumor microenvironment play an important role in supporting the growth and survival of B-cell malignancies. One such cytokine, IL-21, promotes the growth of myeloma and Hodgkin lymphoma cells while inducing apoptosis in chronic lymphocytic leukemia. However, the biologic significance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma characterized by elevated serum IgM and a lymphoplasmacytic bone marrow infiltrate. We report here on the presence of IL-21 in the bone marrow of patients with WM and have identified activated T cells as the source of this cytokine. We readily detected the IL-21 receptor on malignant WM B cells and show that IL-21 significantly increases both IgM secretion and cellular proliferation of these cells with no effect on viability. IL-21 rapidly induces phosphorylation of STAT3 in WM cells, and treatment of the WM cell line MWCL-1 with a STAT3 inhibitor abolished the IL-21-mediated increases in cellular proliferation and IgM secretion. IL-21 also increased the expression of known STAT3 targets involved in B-cell differentiation, including BLIMP-1, XBP-1, IL-6, and IL-10. Overall, our data indicate that IL-21 in the bone marrow microenvironment significantly affects the biology of WM tumor cells through a STAT3-dependent mechanism.",Journal Article,2686.0,25.0,Cytokines within the tumor microenvironment play an important role in supporting the growth and survival of B-cell malignancies One such cytokine IL-21 promotes the growth of and cells while inducing apoptosis in chronic lymphocytic However the biologic significance of IL-21 has not been examined in Waldenstrom macroglobulinemia WM a B-cell characterized by elevated serum IgM and a lymphoplasmacytic marrow infiltrate We report here on the presence of IL-21 in the marrow of patients with WM and have identified activated T cells as the source of this cytokine We readily detected the IL-21 receptor on malignant WM B cells and show that IL-21 significantly increases both IgM secretion and cellular proliferation of these cells with no effect on viability IL-21 rapidly induces phosphorylation of STAT3 in WM cells and treatment of the WM cell line MWCL-1 with a STAT3 inhibitor abolished the IL-21-mediated increases in cellular proliferation and IgM secretion IL-21 also increased the expression of known STAT3 targets involved in B-cell differentiation including BLIMP-1 XBP-1 IL-6 and IL-10 Overall our data indicate that IL-21 in the marrow microenvironment significantly affects the biology of WM tumor cells through a STAT3-dependent mechanism,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1886, 262, 3, 30, 995, 1343, 35, 305, 200, 4, 1912, 3, 129, 2, 25, 1, 132, 31, 441, 104, 225, 1675, 501, 239, 2148, 3, 129, 1, 2, 37, 369, 1958, 351, 4, 442, 1193, 137, 3, 1283, 724, 1, 501, 239, 71, 44, 85, 409, 4, 7933, 3389, 1518, 8, 132, 31, 765, 20, 804, 524, 2852, 2, 8, 5325, 581, 5172, 21, 414, 467, 23, 3, 463, 1, 501, 239, 4, 3, 581, 1, 7, 5, 1518, 2, 47, 108, 735, 102, 37, 22, 3, 2353, 1, 26, 1675, 21, 3860, 530, 3, 501, 239, 153, 23, 393, 1518, 132, 37, 2, 514, 17, 501, 239, 97, 1106, 110, 2852, 2935, 2, 763, 457, 1, 46, 37, 5, 77, 254, 23, 2120, 501, 239, 1755, 1516, 982, 1, 1439, 4, 1518, 37, 2, 24, 1, 3, 1518, 31, 328, 27045, 14, 5, 8, 1439, 230, 6020, 3, 501, 239, 517, 1106, 4, 763, 457, 2, 2852, 2935, 501, 239, 120, 101, 3, 55, 1, 440, 1439, 637, 646, 4, 132, 31, 910, 141, 24545, 14, 14836, 14, 501, 49, 2, 501, 79, 63, 114, 74, 1008, 17, 501, 239, 4, 3, 581, 995, 97, 2561, 3, 891, 1, 1518, 30, 37, 298, 8, 1439, 470, 670]",1254.0,22976953,114
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.,Blood,Blood,2012-10-03,"The nuclear export protein XPO1 is overexpressed in cancer, leading to the cytoplasmic mislocalization of multiple tumor suppressor proteins. Existing XPO1-targeting agents lack selectivity and have been associated with significant toxicity. Small molecule selective inhibitors of nuclear export (SINEs) were designed that specifically inhibit XPO1. Genetic experiments and X-ray structures demonstrate that SINE covalently bind to a cysteine residue in the cargo-binding groove of XPO1, thereby inhibiting nuclear export of cargo proteins. The clinical relevance of SINEs was explored in chronic lymphocytic leukemia (CLL), a disease associated with recurrent XPO1 mutations. Evidence is presented that SINEs can restore normal regulation to the majority of the dysregulated pathways in CLL both in vitro and in vivo and induce apoptosis of CLL cells with a favorable therapeutic index, with enhanced killing of genomically high-risk CLL cells that are typically unresponsive to traditional therapies. More importantly, SINE slows disease progression, and improves overall survival in the E-TCL1-SCID mouse model of CLL with minimal weight loss or other toxicities. Together, these findings demonstrate that XPO1 is a valid target in CLL with minimal effects on normal cells and provide a basis for the development of SINEs in CLL and related hematologic malignancies.",Journal Article,2666.0,162.0,The nuclear export protein XPO1 is overexpressed in cancer leading to the cytoplasmic mislocalization of multiple tumor suppressor proteins Existing XPO1-targeting agents lack selectivity and have been associated with significant toxicity Small molecule selective inhibitors of nuclear export SINEs were designed that specifically inhibit XPO1 Genetic experiments and X-ray structures demonstrate that SINE covalently bind to a cysteine residue in the cargo-binding groove of XPO1 thereby inhibiting nuclear export of cargo proteins The clinical relevance of SINEs was explored in chronic lymphocytic CLL a disease associated with recurrent XPO1 mutations Evidence is presented that SINEs can restore normal regulation to the majority of the dysregulated pathways in CLL both in vitro and in vivo and induce apoptosis of CLL cells with a favorable therapeutic index with enhanced killing of genomically high-risk CLL cells that are typically unresponsive to traditional therapies More importantly SINE slows disease progression and improves overall survival in the E-TCL1-SCID mouse model of CLL with minimal weight loss or other toxicities Together these findings demonstrate that XPO1 is a valid target in CLL with minimal effects on normal cells and provide a basis for the development of SINEs in CLL and related hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 928, 8202, 178, 9933, 16, 1711, 4, 12, 1049, 6, 3, 2828, 16888, 1, 232, 30, 1245, 652, 1692, 9933, 529, 183, 926, 6072, 2, 47, 85, 41, 5, 93, 155, 302, 1354, 1094, 222, 1, 928, 8202, 35441, 11, 1114, 17, 1225, 1433, 9933, 336, 2332, 2, 1006, 5520, 2414, 608, 17, 17407, 10732, 4060, 6, 8, 6943, 7840, 4, 3, 21176, 791, 17860, 1, 9933, 2267, 2062, 928, 8202, 1, 21176, 652, 3, 38, 2088, 1, 35441, 10, 1443, 4, 442, 1193, 552, 8, 34, 41, 5, 387, 9933, 138, 241, 16, 917, 17, 35441, 122, 6075, 295, 863, 6, 3, 686, 1, 3, 4288, 460, 4, 552, 110, 4, 439, 2, 4, 386, 2, 1290, 351, 1, 552, 37, 5, 8, 913, 189, 558, 5, 651, 3003, 1, 7218, 64, 43, 552, 37, 17, 32, 1969, 7244, 6, 1847, 235, 80, 1859, 17407, 21073, 34, 91, 2, 1804, 63, 25, 4, 3, 17467, 8979, 4129, 830, 202, 1, 552, 5, 1048, 924, 407, 15, 127, 385, 1162, 46, 272, 608, 17, 9933, 16, 8, 4406, 283, 4, 552, 5, 1048, 176, 23, 295, 37, 2, 377, 8, 877, 9, 3, 193, 1, 35441, 4, 552, 2, 139, 813, 441]",1342.0,23034282,236
Phytanic acid and the risk of non-Hodgkin lymphoma.,Carcinogenesis,Carcinogenesis,2012-10-05,"Greater consumption of red meat, processed meat and dairy products has been associated with an increased risk of non-Hodgkin lymphoma (NHL) in several previous reports. Phytanic acid, a saturated fatty acid obtained primarily through the consumption of ruminant meat and dairy products, may offer a potential underlying mechanism for these associations. In a population-based case-control study of 336 cases and 460 controls conducted in Nebraska during 1999-2002, we examined whether phytanic acid-containing foods or total phytanic acid intake, estimated from a food frequency questionnaire and the published phytanic acid values of 151 food items, were associated with increased NHL risk. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals for overall NHL and the common NHL histologic subtypes. In multivariable models, higher intakes of density-adjusted beef [OR(T3 vs. T1) = 1.5 (1.1-2.2); P(trend) = 0.02], total dairy products [OR = 1.5 (1.1-2.2); P(trend) = 0.02) and milk [OR = 1.6 (1.1-2.3); P(trend) = 0.01] were associated with an increased risk of NHL. Intake of total phytanic acid was positively associated with NHL risk [OR = 1.5 (1.0-2.1); P(trend) = 0.04]. In analyses stratified by NHL subtype, greater consumption of beef was associated with an increased risk of diffuse large B-cell lymphoma, and greater consumption of milk was associated with an increased risk of follicular lymphoma (FL). Total phytanic acid intake was associated with an increased risk of FL and small lymphocytic lymphoma/chronic lymphocytic leukemia. Our results provide support that total phytanic acid and phytanic acid-containing foods may increase NHL risk.",Journal Article,2664.0,18.0,Greater consumption of red meat processed meat and dairy products has been associated with an increased risk of NHL in several previous reports Phytanic acid a saturated fatty acid obtained primarily through the consumption of ruminant meat and dairy products may offer a potential underlying mechanism for these associations In a population-based case-control study of 336 cases and 460 controls conducted in Nebraska during 1999-2002 we examined whether phytanic acid-containing foods or total phytanic acid intake estimated from a food frequency questionnaire and the published phytanic acid values of 151 food items were associated with increased NHL risk Unconditional logistic regression was used to calculate odds ratios ORs and 95 confidence intervals for overall NHL and the common NHL histologic subtypes In multivariable models higher intakes of density-adjusted beef OR T3 vs. T1 1.5 1.1-2.2 P trend 0.02 total dairy products OR 1.5 1.1-2.2 P trend 0.02 and milk OR 1.6 1.1-2.3 P trend 0.01 were associated with an increased risk of NHL Intake of total phytanic acid was positively associated with NHL risk OR 1.5 1.0-2.1 P trend 0.04 In analyses stratified by NHL subtype greater consumption of beef was associated with an increased risk of diffuse large B-cell and greater consumption of milk was associated with an increased risk of follicular FL Total phytanic acid intake was associated with an increased risk of FL and small lymphocytic lymphoma/chronic lymphocytic Our results provide support that total phytanic acid and phytanic acid-containing foods may increase NHL risk,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[378, 2421, 1, 3422, 5854, 5232, 5854, 2, 11555, 2766, 71, 85, 41, 5, 35, 101, 43, 1, 1176, 4, 392, 698, 1198, 25472, 971, 8, 14127, 4038, 971, 683, 1561, 298, 3, 2421, 1, 61962, 5854, 2, 11555, 2766, 68, 1918, 8, 174, 1181, 670, 9, 46, 685, 4, 8, 266, 90, 473, 182, 45, 1, 10047, 140, 2, 11021, 535, 426, 4, 24674, 190, 2043, 1544, 21, 409, 317, 25472, 971, 1101, 7484, 15, 181, 25472, 971, 1514, 661, 29, 8, 1773, 675, 1770, 2, 3, 983, 25472, 971, 1030, 1, 5075, 1773, 2980, 11, 41, 5, 101, 1176, 43, 6438, 812, 320, 10, 95, 6, 3232, 610, 1137, 3694, 2, 48, 307, 1582, 9, 63, 1176, 2, 3, 186, 1176, 884, 814, 4, 658, 274, 142, 5397, 1, 1263, 586, 24440, 15, 2065, 105, 1534, 14, 33, 14, 14, 18, 18, 19, 853, 13, 588, 181, 11555, 2766, 15, 14, 33, 14, 14, 18, 18, 19, 853, 13, 588, 2, 12604, 15, 14, 49, 14, 14, 18, 27, 19, 853, 13, 355, 11, 41, 5, 35, 101, 43, 1, 1176, 1514, 1, 181, 25472, 971, 10, 2375, 41, 5, 1176, 43, 15, 14, 33, 14, 13, 18, 14, 19, 853, 13, 755, 4, 318, 1173, 20, 1176, 875, 378, 2421, 1, 24440, 10, 41, 5, 35, 101, 43, 1, 1388, 375, 132, 31, 2, 378, 2421, 1, 12604, 10, 41, 5, 35, 101, 43, 1, 1974, 2633, 181, 25472, 971, 1514, 10, 41, 5, 35, 101, 43, 1, 2633, 2, 302, 1193, 4763, 442, 1193, 114, 99, 377, 538, 17, 181, 25472, 971, 2, 25472, 971, 1101, 7484, 68, 344, 1176, 43]",1593.0,23042099,73
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-10-08,"Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK, in patients with B-cell malignancies. Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib. Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing. Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe. Dose escalation proceeded until either the maximum-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib. Response was evaluated every two cycles. Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts. Most adverse events were grade 1 and 2 in severity and self-limited. Dose-limiting events were not observed, even with prolonged dosing. Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD. Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 hours, consistent with the irreversible mechanism. Objective response rate in 50 evaluable patients was 60%, including complete response of 16%. Median progression-free survival in all patients was 13.6 months. Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.","Clinical Trial, Phase I",2661.0,696.0,Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor and Bruton tyrosine kinase BTK is a critical signaling kinase in this pathway We evaluated ibrutinib PCI-32765 a small-molecule irreversible inhibitor of BTK in patients with B-cell malignancies Patients with relapsed or refractory B-cell and chronic lymphocytic received escalating oral doses of ibrutinib Two schedules were evaluated one 28 days on 7 days off and two once-daily continuous dosing Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe Dose escalation proceeded until either the maximum-tolerated dose MTD was achieved or in the absence of MTD until three dose levels above full BTK occupancy by ibrutinib Response was evaluated every two cycles Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts Most adverse events were grade 1 and 2 in severity and self-limited Dose-limiting events were not observed even with prolonged dosing Full occupancy of the BTK active site occurred at 2.5 mg/kg per day and dose escalation continued to 12.5 mg/kg per day without reaching MTD Pharmacokinetic data indicated rapid absorption and elimination yet BTK occupancy was maintained for at least 24 hours consistent with the irreversible mechanism Objective response rate in 50 evaluable patients was 60 including complete response of 16 Median progression-free survival in all patients was 13.6 months Ibrutinib a novel BTK-targeting inhibitor is well tolerated with substantial activity across B-cell histologies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[25, 2, 91, 1, 2908, 132, 31, 441, 4533, 23, 2312, 29, 3, 132, 31, 448, 153, 2, 5796, 564, 216, 3611, 16, 8, 740, 314, 216, 4, 26, 308, 21, 194, 1795, 3943, 12229, 8, 302, 1354, 4422, 230, 1, 3611, 4, 7, 5, 132, 31, 441, 7, 5, 591, 15, 430, 132, 31, 2, 442, 1193, 103, 2922, 518, 415, 1, 1795, 100, 2314, 11, 194, 104, 339, 162, 23, 67, 162, 1889, 2, 100, 1059, 391, 1314, 1280, 8509, 1, 3611, 20, 1795, 4, 672, 315, 10, 2909, 75, 8, 2910, 3601, 2888, 61, 1125, 6406, 1100, 361, 3, 689, 421, 61, 961, 10, 513, 15, 4, 3, 1127, 1, 961, 1100, 169, 61, 148, 2090, 1647, 3611, 8509, 20, 1795, 51, 10, 194, 454, 100, 410, 1461, 437, 7, 5, 8, 1362, 1, 132, 31, 441, 11, 73, 252, 648, 736, 96, 290, 281, 11, 88, 14, 2, 18, 4, 1702, 2, 1074, 383, 61, 817, 281, 11, 44, 164, 871, 5, 1069, 1280, 1647, 8509, 1, 3, 3611, 544, 606, 489, 28, 18, 33, 81, 503, 379, 218, 2, 61, 1125, 1351, 6, 133, 33, 81, 503, 379, 218, 187, 6168, 961, 1456, 74, 1103, 1321, 6125, 2, 3730, 1145, 3611, 8509, 10, 1955, 9, 28, 506, 259, 1459, 925, 5, 3, 4422, 670, 461, 51, 116, 4, 212, 859, 7, 10, 335, 141, 236, 51, 1, 245, 52, 91, 115, 25, 4, 62, 7, 10, 233, 49, 53, 1795, 8, 229, 3611, 529, 230, 16, 149, 421, 5, 1281, 128, 716, 132, 31, 3489]",1606.0,23045577,697
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.,Blood,Blood,2012-10-09,"To identify genomic alterations in chronic lymphocytic leukemia (CLL), we performed single-nucleotide polymorphism-array analysis using Affymetrix Version 6.0 on 353 samples from untreated patients entered in the CLL8 treatment trial. Based on paired-sample analysis (n = 144), a mean of 1.8 copy number alterations per patient were identified; approximately 60% of patients carried no copy number alterations other than those detected by fluorescence in situ hybridization analysis. Copy-neutral loss-of-heterozygosity was detected in 6% of CLL patients and was found most frequently on 13q, 17p, and 11q. Minimally deleted regions were refined on 13q14 (deleted in 61% of patients) to the DLEU1 and DLEU2 genes, on 11q22.3 (27% of patients) to ATM, on 2p16.1-2p15 (gained in 7% of patients) to a 1.9-Mb fragment containing 9 genes, and on 8q24.21 (5% of patients) to a segment 486 kb proximal to the MYC locus. 13q deletions exhibited proximal and distal breakpoint cluster regions. Among the most common novel lesions were deletions at 15q15.1 (4% of patients), with the smallest deletion (70.48 kb) found in the MGA locus. Sequence analysis of MGA in 59 samples revealed a truncating mutation in one CLL patient lacking a 15q deletion. MNT at 17p13.3, which in addition to MGA and MYC encodes for the network of MAX-interacting proteins, was also deleted recurrently.",Journal Article,2660.0,113.0,To identify genomic alterations in chronic lymphocytic CLL we performed single-nucleotide polymorphism-array analysis using Affymetrix Version 6.0 on 353 samples from untreated patients entered in the CLL8 treatment trial Based on paired-sample analysis n 144 a mean of 1.8 copy number alterations per patient were identified approximately 60 of patients carried no copy number alterations other than those detected by fluorescence in situ hybridization analysis Copy-neutral loss-of-heterozygosity was detected in 6 of CLL patients and was found most frequently on 13q 17p and 11q Minimally deleted regions were refined on 13q14 deleted in 61 of patients to the DLEU1 and DLEU2 genes on 11q22.3 27 of patients to ATM on 2p16.1-2p15 gained in 7 of patients to a 1.9-Mb fragment containing 9 genes and on 8q24.21 5 of patients to a segment 486 kb proximal to the MYC locus 13q deletions exhibited proximal and distal breakpoint cluster regions Among the most common novel lesions were deletions at 15q15.1 4 of patients with the smallest deletion 70.48 kb found in the MGA locus Sequence analysis of MGA in 59 samples revealed a truncating mutation in one CLL patient lacking a 15q deletion MNT at 17p13.3 which in addition to MGA and MYC encodes for the network of MAX-interacting proteins was also deleted recurrently,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 255, 572, 593, 4, 442, 1193, 552, 21, 173, 226, 1579, 1907, 1926, 65, 75, 5318, 2256, 49, 13, 23, 10065, 347, 29, 1278, 7, 2836, 4, 3, 47434, 24, 160, 90, 23, 2355, 1000, 65, 78, 4415, 8, 313, 1, 14, 66, 1337, 207, 593, 379, 69, 11, 108, 705, 335, 1, 7, 2629, 77, 1337, 207, 593, 127, 76, 135, 530, 20, 1591, 4, 957, 1554, 65, 1337, 6338, 407, 1, 3963, 10, 530, 4, 49, 1, 552, 7, 2, 10, 204, 96, 746, 23, 8453, 4135, 2, 7203, 2144, 4389, 1374, 11, 5332, 23, 13221, 4389, 4, 713, 1, 7, 6, 3, 61974, 2, 61975, 214, 23, 12647, 27, 428, 1, 7, 6, 3552, 23, 29266, 14, 61976, 3711, 4, 67, 1, 7, 6, 8, 14, 83, 2571, 5245, 1101, 83, 214, 2, 23, 6069, 239, 33, 1, 7, 6, 8, 4610, 7582, 5116, 2805, 6, 3, 1371, 2474, 8453, 2439, 1416, 2805, 2, 2107, 8567, 3132, 1374, 107, 3, 96, 186, 229, 406, 11, 2439, 28, 35444, 14, 39, 1, 7, 5, 3, 11249, 1528, 431, 576, 5116, 204, 4, 3, 22763, 2474, 1532, 65, 1, 22763, 4, 728, 347, 553, 8, 7994, 258, 4, 104, 552, 69, 1941, 8, 20336, 1528, 47435, 28, 7526, 27, 92, 4, 352, 6, 22763, 2, 1371, 4322, 9, 3, 1801, 1, 2649, 5505, 652, 10, 120, 4389, 8820]",1318.0,23047824,741
Progressive chronic lymphocytic leukemia after allogeneic hematopoietic cell transplantation.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2012-10-01,This case report presents a patient with poor-prognosis chronic lymphocytic leukemia (CLL) who was treated with chemotherapy and underwent allogeneic hematopoietic cell transplant (alloHCT) but ultimately progressed. The application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL and the impact of alloHCT on secondary therapy for progressive CLL are discussed.,Case Reports,2668.0,0.0,This case report presents a patient with poor-prognosis chronic lymphocytic CLL who was treated with chemotherapy and underwent allogeneic hematopoietic cell transplant alloHCT but ultimately progressed The application of the NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines for CLL and the impact of alloHCT on secondary therapy for progressive CLL are discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 473, 414, 2740, 8, 69, 5, 334, 356, 442, 1193, 552, 54, 10, 73, 5, 56, 2, 208, 1063, 1007, 31, 941, 5514, 84, 2050, 1839, 3, 1581, 1, 3, 1944, 38, 758, 677, 4, 413, 1944, 677, 9, 552, 2, 3, 345, 1, 5514, 23, 568, 36, 9, 1014, 552, 32, 1588]",376.0,23054874,791
Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability.,Genome research,Genome Res.,2012-11-02,"Whole-genome sequencing using massively parallel sequencing technologies enables accurate detection of somatic rearrangements in cancer. Pinpointing large numbers of rearrangement breakpoints to base-pair resolution allows analysis of rearrangement microhomology and genomic location for every sample. Here we analyze 95 tumor genome sequences from breast, head and neck, colorectal, and prostate carcinomas, and from melanoma, multiple myeloma, and chronic lymphocytic leukemia. We discover three genomic factors that are significantly correlated with the distribution of rearrangements: replication time, transcription rate, and GC content. The correlation is complex, and different patterns are observed between tumor types, within tumor types, and even between different types of rearrangements. Mutations in the APC gene correlate with and, hence, potentially contribute to DNA breakage in late-replicating, low %GC, untranscribed regions of the genome. We show that somatic rearrangements display less microhomology than germline rearrangements, and that breakpoint loci are correlated with local hypermutability with a particular enrichment for   transversions.",Journal Article,2636.0,84.0,Whole-genome sequencing using massively parallel sequencing technologies enables accurate detection of somatic rearrangements in cancer Pinpointing large numbers of rearrangement breakpoints to base-pair resolution allows analysis of rearrangement microhomology and genomic location for every sample Here we analyze 95 tumor genome sequences from head and and carcinomas and from multiple and chronic lymphocytic We discover three genomic factors that are significantly correlated with the distribution of rearrangements replication time transcription rate and GC content The correlation is complex and different patterns are observed between tumor types within tumor types and even between different types of rearrangements Mutations in the APC gene correlate with and hence potentially contribute to DNA breakage in late-replicating low GC untranscribed regions of the genome We show that somatic rearrangements display less microhomology than germline rearrangements and that breakpoint loci are correlated with local hypermutability with a particular enrichment for transversions,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[902, 898, 615, 75, 7284, 2755, 615, 2590, 4843, 1481, 638, 1, 1119, 2072, 4, 12, 34431, 375, 1870, 1, 2675, 7843, 6, 1782, 4767, 2125, 2333, 65, 1, 2675, 27116, 2, 572, 1147, 9, 454, 1000, 467, 21, 1992, 48, 30, 898, 2866, 29, 718, 2, 2, 826, 2, 29, 232, 2, 442, 1193, 21, 6134, 169, 572, 130, 17, 32, 97, 438, 5, 3, 1395, 1, 2072, 2079, 98, 866, 116, 2, 1709, 2457, 3, 816, 16, 840, 2, 338, 764, 32, 164, 59, 30, 630, 262, 30, 630, 2, 871, 59, 338, 630, 1, 2072, 138, 4, 3, 2528, 145, 1513, 5, 2, 3665, 751, 1248, 6, 261, 14101, 4, 807, 13012, 154, 1709, 62083, 1374, 1, 3, 898, 21, 514, 17, 1119, 2072, 3640, 299, 27116, 76, 1009, 2072, 2, 17, 8567, 2012, 32, 438, 5, 293, 47476, 5, 8, 1454, 3020, 9, 24398]",1083.0,23124520,272
Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2013-02-20,"We examined the qualitative polymorphonuclear neutrophil (PMN)-associated immune impairment in patients with chronic lymphocytic leukemia (CLL) by characterizing phagocytic killing of key non-opsonized bacterial (Staphylococcus aureus and Pseudomonas aeruginosa) and fungal (Candida albicans and Aspergillus fumigatus) pathogens. Neutrophils were collected from 47 non-neutropenic patients with CLL (PMN count > 1000/mm(3)) and age-matched and young healthy controls (five each). A subset of patients (13%) had prior or subsequent infections. We found that the patients with CLL had diminished PMN microbicidal response against bacteria but not against fungi compared with the controls. Compared to patients with effective PMN responses, we did not identify differences of basal PMN pathogen-associated molecular pattern receptor gene expression, soluble pathogen-associated molecular pattern gene expression or inflammatory cytokine signatures in patients with impaired PMN responses when PMNs were analyzed in multiplex real-time polymerase chain reaction assays. However, differences in PMN microbicidal response against A. fumigatus in patients with CLL were associated with the degree of hypogammaglobulinemia.",Journal Article,2526.0,17.0,We examined the qualitative polymorphonuclear neutrophil PMN -associated immune impairment in patients with chronic lymphocytic CLL by characterizing phagocytic killing of key non-opsonized bacterial Staphylococcus aureus and Pseudomonas aeruginosa and fungal Candida albicans and Aspergillus fumigatus pathogens Neutrophils were collected from 47 non-neutropenic patients with CLL PMN count 1000/mm 3 and age-matched and young healthy controls five each A subset of patients 13 had prior or subsequent infections We found that the patients with CLL had diminished PMN microbicidal response against bacteria but not against fungi compared with the controls Compared to patients with effective PMN responses we did not identify differences of basal PMN pathogen-associated molecular pattern receptor gene expression soluble pathogen-associated molecular pattern gene expression or inflammatory cytokine signatures in patients with impaired PMN responses when PMNs were analyzed in multiplex real-time polymerase chain reaction assays However differences in PMN microbicidal response against A. fumigatus in patients with CLL were associated with the degree of hypogammaglobulinemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 409, 3, 3926, 19013, 2595, 14009, 41, 250, 2315, 4, 7, 5, 442, 1193, 552, 20, 5723, 19415, 3003, 1, 825, 220, 22192, 5117, 14739, 14772, 2, 13538, 20506, 2, 7800, 13321, 24644, 2, 16675, 23369, 9275, 5700, 11, 786, 29, 662, 220, 3659, 7, 5, 552, 14009, 1276, 2345, 321, 27, 2, 89, 655, 2, 1169, 1331, 535, 365, 296, 8, 697, 1, 7, 233, 42, 324, 15, 706, 1875, 21, 204, 17, 3, 7, 5, 552, 42, 2849, 14009, 47498, 51, 480, 8841, 84, 44, 480, 30222, 72, 5, 3, 535, 72, 6, 7, 5, 323, 14009, 253, 21, 205, 44, 255, 362, 1, 2135, 14009, 15956, 41, 219, 1177, 153, 145, 55, 2968, 15956, 41, 219, 1177, 145, 55, 15, 1291, 1675, 2210, 4, 7, 5, 2364, 14009, 253, 198, 40182, 11, 311, 4, 4908, 1589, 98, 1451, 1260, 1329, 1013, 137, 362, 4, 14009, 47498, 51, 480, 8, 23369, 4, 7, 5, 552, 11, 41, 5, 3, 1444, 1, 13242]",1180.0,23163595,774
A collision of diseases: chronic lymphocytic leukemia discovered during lymph node biopsy for melanoma.,Annals of surgical oncology,Ann. Surg. Oncol.,2012-11-20,"In the United States in 2012, there were 16,060 new cases of chronic lymphocytic leukemia (CLL). Often CLL is clinically occult and first detected during pathologic evaluation of the sentinel lymph node biopsy (SLNB). We reviewed our experience of patients with the coexisting diagnosis of melanoma and CLL. An institutional review board-approved review was performed on patients with CLL and melanoma treated from 1995 to 2009 at Moffitt Cancer Center and compared with the incidence of melanoma and CLL in our tumor registry patients with breast, prostate, lung, and colon cancer. Fifty-two patients (44 males; median age, 71years [range, 46-88]) were identified with concurrent diagnoses of melanoma and CLL. Twenty-two patients (42%) had CLL on SLNB for their melanoma. Thirty-two patients (62%) were diagnosed with melanoma before CLL. Concomitant or prior cancer diagnoses included nonmelanoma skin cancers (N=29), prostate (N=6), colorectal (N=2), and Merkel cell carcinoma (N=2). Five of 20 patients (25%) had metastatic melanoma found at the time of SLNB. Patients with melanoma had a tenfold increase of CLL diagnosis compared with colorectal cancer patients, an eightfold increase compared to prostate cancer patients, and a fourfold increase compared with breast cancer patients. We have confirmed an increased association of CLL and melanoma. This may be related to an underlying immunologic defect; however, there has been scant investigation into this phenomenon. Surgeons and pathologists should understand this occurrence and recognize that not all grossly enlarged or abnormal sentinel lymph nodes in melanoma patients represent melanoma.",Journal Article,2618.0,9.0,"In the United States in 2012 there were 16,060 new cases of chronic lymphocytic CLL Often CLL is clinically occult and first detected during pathologic evaluation of the sentinel lymph node biopsy SLNB We reviewed our experience of patients with the coexisting diagnosis of and CLL An institutional review board-approved review was performed on patients with CLL and treated from 1995 to 2009 at Moffitt Cancer Center and compared with the incidence of and CLL in our tumor registry patients with and cancer Fifty-two patients 44 males median age 71 years range 46-88 were identified with concurrent diagnoses of and CLL Twenty-two patients 42 had CLL on SLNB for their Thirty-two patients 62 were diagnosed with before CLL Concomitant or prior cancer diagnoses included nonmelanoma cancers N 29 N 6 N 2 and Merkel cell carcinoma N 2 Five of 20 patients 25 had metastatic found at the time of SLNB Patients with had a tenfold increase of CLL diagnosis compared with cancer patients an eightfold increase compared to cancer patients and a fourfold increase compared with cancer patients We have confirmed an increased association of CLL and This may be related to an underlying immunologic defect however there has been scant investigation into this phenomenon Surgeons and pathologists should understand this occurrence and recognize that not all grossly enlarged or abnormal sentinel lymph nodes in patients represent",1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[4, 3, 1088, 907, 4, 1195, 125, 11, 245, 9972, 217, 140, 1, 442, 1193, 552, 629, 552, 16, 505, 2879, 2, 157, 530, 190, 510, 451, 1, 3, 1323, 263, 289, 411, 2272, 21, 446, 114, 730, 1, 7, 5, 3, 8859, 147, 1, 2, 552, 35, 1115, 206, 2620, 850, 206, 10, 173, 23, 7, 5, 552, 2, 73, 29, 2323, 6, 1238, 28, 9054, 12, 574, 2, 72, 5, 3, 287, 1, 2, 552, 4, 114, 30, 1608, 7, 5, 2, 12, 1461, 100, 7, 584, 2296, 52, 89, 792, 60, 184, 641, 889, 11, 108, 5, 750, 2403, 1, 2, 552, 737, 100, 7, 595, 42, 552, 23, 2272, 9, 136, 977, 100, 7, 744, 11, 265, 5, 348, 552, 1781, 15, 324, 12, 2403, 159, 7814, 163, 78, 462, 78, 49, 78, 18, 2, 5855, 31, 134, 78, 18, 365, 1, 179, 7, 243, 42, 113, 204, 28, 3, 98, 1, 2272, 7, 5, 42, 8, 31509, 344, 1, 552, 147, 72, 5, 12, 7, 35, 26181, 344, 72, 6, 12, 7, 2, 8, 15155, 344, 72, 5, 12, 7, 21, 47, 557, 35, 101, 248, 1, 552, 2, 26, 68, 40, 139, 6, 35, 1181, 3042, 5398, 137, 125, 71, 85, 11578, 940, 237, 26, 3936, 1613, 2, 3354, 257, 1640, 26, 2291, 2, 4237, 17, 44, 62, 7185, 7547, 15, 1668, 1323, 263, 502, 4, 7, 1231]",1418.0,23179994,495
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-12-03,"Corticosteroids are widely used for the treatment of B-cell malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia; however, this class of drug is associated with undesirable off-target effects. Herein, we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74(+) B-cell malignancies and explored its effect against the disease. The targeting efficiency of milatuzumab-targeted liposomes to CD74(+) cells was evaluated in vitro. The effect of CD74-targeted liposomal dexamethasone was compared with free dexamethasone in primary CLL cells and cell lines in vitro. The therapeutic efficacy of CD74-targeted liposomal dexamethasone was evaluated in a Raji-severe combined immunodeficient (SCID) xenograft model in vivo. Milatuzumab-targeted liposomes promoted selective incorporation of carrier molecules into transformed CD74-positive B cells as compared with CD74-negative T-cells. The CD74-dexamethasone-targeted liposomes (CD74-IL-DEX) promoted and increased killing in CD74-positive tumor cells and primary CLL cells. Furthermore, the targeted drug liposomes showed enhanced therapeutic efficacy against a CD74-positive B-cell model as compared with free, or non-targeted, liposomal dexamethasone in SCID mice engrafted with Raji cells in vivo. These studies provide evidence and support for a potential use of CD74-targeted liposomal dexamethasone as a new therapy for B-cell malignancies.",Journal Article,2605.0,28.0,Corticosteroids are widely used for the treatment of B-cell malignancies including chronic lymphocytic CLL and acute lymphoblastic however this class of drug is associated with undesirable off-target effects Herein we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74 B-cell malignancies and explored its effect against the disease The targeting efficiency of milatuzumab-targeted liposomes to CD74 cells was evaluated in vitro The effect of CD74-targeted liposomal dexamethasone was compared with free dexamethasone in primary CLL cells and cell lines in vitro The therapeutic efficacy of CD74-targeted liposomal dexamethasone was evaluated in a Raji-severe combined immunodeficient SCID xenograft model in vivo Milatuzumab-targeted liposomes promoted selective incorporation of carrier molecules into transformed CD74-positive B cells as compared with CD74-negative T-cells The CD74-dexamethasone-targeted liposomes CD74-IL-DEX promoted and increased killing in CD74-positive tumor cells and primary CLL cells Furthermore the targeted drug liposomes showed enhanced therapeutic efficacy against a CD74-positive B-cell model as compared with free or non-targeted liposomal dexamethasone in SCID mice engrafted with Raji cells in vivo These studies provide evidence and support for a potential use of CD74-targeted liposomal dexamethasone as a new therapy for B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3876, 32, 1792, 95, 9, 3, 24, 1, 132, 31, 441, 141, 442, 1193, 552, 2, 286, 1275, 137, 26, 1040, 1, 234, 16, 41, 5, 13572, 1889, 283, 176, 1986, 21, 276, 229, 12038, 3868, 7438, 22, 8, 238, 1217, 4715, 9, 189, 989, 4, 7780, 132, 31, 441, 2, 1443, 211, 254, 480, 3, 34, 3, 529, 2904, 1, 12038, 238, 7438, 6, 7780, 37, 10, 194, 4, 439, 3, 254, 1, 7780, 238, 3275, 1217, 10, 72, 5, 115, 1217, 4, 86, 552, 37, 2, 31, 285, 4, 439, 3, 189, 209, 1, 7780, 238, 3275, 1217, 10, 194, 4, 8, 9868, 905, 397, 5031, 4129, 1330, 202, 4, 386, 12038, 238, 7438, 2992, 1094, 2838, 1, 4715, 1598, 237, 2423, 7780, 109, 132, 37, 22, 72, 5, 7780, 199, 102, 37, 3, 7780, 1217, 238, 7438, 7780, 501, 4844, 2992, 2, 101, 3003, 4, 7780, 109, 30, 37, 2, 86, 552, 37, 798, 3, 238, 234, 7438, 224, 651, 189, 209, 480, 8, 7780, 109, 132, 31, 202, 22, 72, 5, 115, 15, 220, 238, 3275, 1217, 4, 4129, 399, 6914, 5, 9868, 37, 4, 386, 46, 94, 377, 241, 2, 538, 9, 8, 174, 119, 1, 7780, 238, 3275, 1217, 22, 8, 217, 36, 9, 132, 31, 441]",1447.0,23209030,336
"Non-Hodgkin's Lymphomas, version 3.2012.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2012-12-01,"These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas (NHL) and describe the clinical evidence supporting the updates. The featured updates include changes to the recommendations for treatment options in patients with chronic lymphocytic leukemia (including in elderly or frail patients and patients with poor-risk cytogenetics), guidance surrounding surveillance imaging for follow-up of patients with NHL, and the addition of first-line consolidation options for patients with mantle cell lymphoma.",Journal Article,2607.0,27.0,These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines for 's Lymphomas NHL and describe the clinical evidence supporting the updates The featured updates include changes to the recommendations for treatment options in patients with chronic lymphocytic including in elderly or frail patients and patients with poor-risk cytogenetics guidance surrounding surveillance imaging for follow-up of patients with NHL and the addition of first-line consolidation options for patients with mantle cell,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[46, 1944, 677, 1957, 2479, 392, 825, 5454, 6, 3, 1195, 1944, 38, 758, 677, 4, 413, 1944, 677, 9, 292, 1557, 1176, 2, 897, 3, 38, 241, 1912, 3, 5454, 3, 11857, 5454, 643, 400, 6, 3, 883, 9, 24, 838, 4, 7, 5, 442, 1193, 141, 4, 1216, 15, 7226, 7, 2, 7, 5, 334, 43, 2510, 2753, 2976, 617, 270, 9, 166, 126, 1, 7, 5, 1176, 2, 3, 352, 1, 157, 328, 2173, 838, 9, 7, 5, 2757, 31]",572.0,23221787,765
CARs in chronic lymphocytic leukemia -- ready to drive.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2013-03-01,"Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR(+) T cell therapy.",Journal Article,2517.0,14.0,Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic CLL To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens TAAs robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors CARs to redirect specificity have been produced Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency Clinical trials utilizing this technology demonstrate feasibility and increasingly these early-phase trials are demonstrating impressive anti-tumor effects particularly for CLL patients paving the way for multi-center trials to establish the efficacy of CAR T cell therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3159, 2602, 1, 448, 112, 102, 37, 71, 85, 3716, 20, 2394, 9, 24, 1, 442, 1193, 552, 6, 1768, 1553, 1, 250, 2614, 92, 3526, 3, 2682, 2454, 250, 51, 6, 30, 41, 1575, 18263, 1922, 1530, 9, 3, 336, 2437, 2, 2136, 1, 102, 37, 1046, 2897, 448, 1186, 7441, 6, 14744, 1121, 47, 85, 1687, 10518, 5, 8930, 6, 4108, 2, 6105, 1, 3, 2301, 1230, 102, 37, 32, 3948, 6, 987, 401, 3593, 38, 143, 2600, 26, 2033, 608, 1437, 2, 1635, 46, 191, 124, 143, 32, 2219, 5790, 312, 30, 176, 823, 9, 552, 7, 14246, 3, 2255, 9, 1414, 574, 143, 6, 1811, 3, 209, 1, 1881, 102, 31, 36]",810.0,23225251,458
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-12-10,"Chronic lymphocytic leukemia (CLL) is a disease of the elderly, yet few clinical trials include a significant number of older patients, and outcomes after specific therapies can be different depending on age. We examined patients enrolled onto successive first-line CALGB CLL trials to determine whether efficacy of regimens varied by age, focusing on ideal chemotherapy choice and benefit of immunotherapy addition to chemotherapy in older patients. Regimens included chlorambucil, fludarabine, fludarabine plus rituximab (FR), fludarabine with consolidation alemtuzumab, and FR with consolidation alemtuzumab. A total of 663 patients were evaluated for response, progression-free survival (PFS), and overall survival (OS) by age group. Interaction effects of fludarabine versus chlorambucil by age group (PFS, P = .046; OS, P = .006) showed that among patients younger than 70 years, PFS and OS was improved with fludarabine over chlorambucil (PFS: hazard ratio [HR] = 0.6, 95% CI, 0.5 to 0.8; OS: HR = 0.7, 95% CI, 0.5 to 0.9), but not in older adults (PFS, HR = 1.0, 95% CI, 0.6 to 1.7; OS: HR = 1.5, 95% CI, 0.9 to 2.3). In contrast, FR improved outcomes relative to fludarabine, irrespective of age (PFS: HR = 0.6, 95% CI, 0.4 to 0.7; OS: HR = 0.7, 95% CI, 0.5 to 0.9). Alemtuzumab consolidation did not provide benefit over similar regimens without alemtuzumab (P > .20), irrespective of age. These data support the use of chlorambucil as an acceptable treatment for many older patients with CLL and suggest rituximab is beneficial regardless of age. These findings bear relevance to both routine care of CLL patients 70 years and older and also future clinical trials in this population.",Comparative Study,2598.0,50.0,Chronic lymphocytic CLL is a disease of the elderly yet few clinical trials include a significant number of older patients and outcomes after specific therapies can be different depending on age We examined patients enrolled onto successive first-line CALGB CLL trials to determine whether efficacy of regimens varied by age focusing on ideal chemotherapy choice and benefit of immunotherapy addition to chemotherapy in older patients Regimens included chlorambucil fludarabine fludarabine plus rituximab FR fludarabine with consolidation alemtuzumab and FR with consolidation alemtuzumab A total of 663 patients were evaluated for response progression-free survival PFS and overall survival OS by age group Interaction effects of fludarabine versus chlorambucil by age group PFS P .046 OS P .006 showed that among patients younger than 70 years PFS and OS was improved with fludarabine over chlorambucil PFS hazard ratio HR 0.6 95 CI 0.5 to 0.8 OS HR 0.7 95 CI 0.5 to 0.9 but not in older adults PFS HR 1.0 95 CI 0.6 to 1.7 OS HR 1.5 95 CI 0.9 to 2.3 In contrast FR improved outcomes relative to fludarabine irrespective of age PFS HR 0.6 95 CI 0.4 to 0.7 OS HR 0.7 95 CI 0.5 to 0.9 Alemtuzumab consolidation did not provide benefit over similar regimens without alemtuzumab P .20 irrespective of age These data support the use of chlorambucil as an acceptable treatment for many older patients with CLL and suggest rituximab is beneficial regardless of age These findings bear relevance to both routine care of CLL patients 70 years and older and also future clinical trials in this population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 34, 1, 3, 1216, 1145, 1021, 38, 143, 643, 8, 93, 207, 1, 434, 7, 2, 123, 50, 112, 235, 122, 40, 338, 3221, 23, 89, 21, 409, 7, 346, 3301, 6808, 157, 328, 4077, 552, 143, 6, 223, 317, 209, 1, 472, 2051, 20, 89, 3312, 23, 3662, 56, 1866, 2, 247, 1, 726, 352, 6, 56, 4, 434, 7, 472, 159, 11585, 2027, 2027, 349, 855, 6413, 2027, 5, 2173, 3579, 2, 6413, 5, 2173, 3579, 8, 181, 1, 10693, 7, 11, 194, 9, 51, 91, 115, 25, 300, 2, 63, 25, 118, 20, 89, 87, 915, 176, 1, 2027, 185, 11585, 20, 89, 87, 300, 19, 4902, 118, 19, 1861, 224, 17, 107, 7, 773, 76, 431, 60, 300, 2, 118, 10, 231, 5, 2027, 252, 11585, 300, 360, 197, 168, 13, 49, 48, 58, 13, 33, 6, 13, 66, 118, 168, 13, 67, 48, 58, 13, 33, 6, 13, 83, 84, 44, 4, 434, 857, 300, 168, 14, 13, 48, 58, 13, 49, 6, 14, 67, 118, 168, 14, 33, 48, 58, 13, 83, 6, 18, 27, 4, 748, 6413, 231, 123, 580, 6, 2027, 3500, 1, 89, 300, 168, 13, 49, 48, 58, 13, 39, 6, 13, 67, 118, 168, 13, 67, 48, 58, 13, 33, 6, 13, 83, 3579, 2173, 205, 44, 377, 247, 252, 288, 472, 187, 3579, 19, 179, 3500, 1, 89, 46, 74, 538, 3, 119, 1, 11585, 22, 35, 1595, 24, 9, 445, 434, 7, 5, 552, 2, 309, 855, 16, 2524, 1583, 1, 89, 46, 272, 10952, 2088, 6, 110, 1311, 165, 1, 552, 7, 431, 60, 2, 434, 2, 120, 508, 38, 143, 4, 26, 266]",1595.0,23233702,540
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-12-21,"Treatment of fludarabine-refractory disease in patients with chronic lymphocytic leukemia (CLL) remains a challenge. Because a recent genome-wide methylation analysis of CLL cells suggested that demethylation therapy might be beneficial in CLL, we conducted a phase II trial with the hypomethylating agent azacitidine in patients with recurrent fludarabine-refractory CLL. Nine patients with recurrent fludarabine-refractory Rai stage IV CLL (median age, 74 years; range, 49-81 years) were enrolled. Azacitidine (75 mg/m(2)) was administered by subcutaneous injection daily for 7 consecutive days every 3 to 8 weeks, and the data were analyzed at a median follow-up of 9 months (range 3-47 months). The trial was prematurely discontinued because of lack of response and slow accrual. The number of cycles administered ranged from 1 to 6. Three patients received 1 cycle, 3 patients received 2 cycles, and the remaining 3 patients received 4, 5, or 6 cycles. Side effects included grade 2 or 3 infectious episodes (resulting from immunosuppression and drug-induced neutropenia), diarrhea, rash, vomiting, anemia, and thrombocytopenia. One patient experienced reduction of hepatosplenomegaly and a substantial increase in platelet count after 4 cycles of therapy. However this response did not qualify as a partial response according to the National Cancer Institute International Workshop on CLL (NCI-IWCLL) criteria. At a median follow-up of 9 months after the start of azacitidine treatment, 3 patients (33%) who went on to receive other treatments were alive. Although no partial or complete responses occurred in these heavily pretreated patients, the encouraging response in 1 of these patients may warrant further studies to investigate the effects of azacitidine in CLL.","Clinical Trial, Phase II",2587.0,9.0,Treatment of fludarabine-refractory disease in patients with chronic lymphocytic CLL remains a challenge Because a recent genome-wide methylation analysis of CLL cells suggested that demethylation therapy might be beneficial in CLL we conducted a phase II trial with the hypomethylating agent azacitidine in patients with recurrent fludarabine-refractory CLL Nine patients with recurrent fludarabine-refractory Rai stage IV CLL median age 74 years range 49-81 years were enrolled Azacitidine 75 mg/m 2 was administered by subcutaneous injection daily for 7 consecutive days every 3 to 8 weeks and the data were analyzed at a median follow-up of 9 months range 3-47 months The trial was prematurely discontinued because of lack of response and slow accrual The number of cycles administered ranged from 1 to 6 Three patients received 1 cycle 3 patients received 2 cycles and the remaining 3 patients received 4 5 or 6 cycles Side effects included grade 2 or 3 infectious episodes resulting from immunosuppression and drug-induced neutropenia diarrhea rash vomiting anemia and thrombocytopenia One patient experienced reduction of hepatosplenomegaly and a substantial increase in platelet count after 4 cycles of therapy However this response did not qualify as a partial response according to the National Cancer Institute International Workshop on CLL NCI-IWCLL criteria At a median follow-up of 9 months after the start of azacitidine treatment 3 patients 33 who went on to receive other treatments were alive Although no partial or complete responses occurred in these heavily pretreated patients the encouraging response in 1 of these patients may warrant further studies to investigate the effects of azacitidine in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[24, 1, 2027, 430, 34, 4, 7, 5, 442, 1193, 552, 469, 8, 1745, 408, 8, 435, 898, 1019, 569, 65, 1, 552, 37, 1148, 17, 6800, 36, 822, 40, 2524, 4, 552, 21, 426, 8, 124, 215, 160, 5, 3, 4931, 420, 3752, 4, 7, 5, 387, 2027, 430, 552, 762, 7, 5, 387, 2027, 430, 4121, 82, 478, 552, 52, 89, 794, 60, 184, 739, 865, 60, 11, 346, 3752, 481, 81, 188, 18, 10, 468, 20, 2529, 1754, 391, 9, 67, 935, 162, 454, 27, 6, 66, 244, 2, 3, 74, 11, 311, 28, 8, 52, 166, 126, 1, 83, 53, 184, 27, 662, 53, 3, 160, 10, 9771, 2402, 408, 1, 926, 1, 51, 2, 3645, 2262, 3, 207, 1, 410, 468, 1869, 29, 14, 6, 49, 169, 7, 103, 14, 417, 27, 7, 103, 18, 410, 2, 3, 1844, 27, 7, 103, 39, 33, 15, 49, 410, 1152, 176, 159, 88, 18, 15, 27, 3398, 3750, 1113, 29, 3646, 2, 234, 277, 778, 1172, 1641, 1966, 1545, 2, 1340, 104, 69, 592, 628, 1, 15144, 2, 8, 1281, 344, 4, 1596, 1276, 50, 39, 410, 1, 36, 137, 26, 51, 205, 44, 13657, 22, 8, 450, 51, 768, 6, 3, 657, 12, 1377, 944, 4014, 23, 552, 2580, 16575, 371, 28, 8, 52, 166, 126, 1, 83, 53, 50, 3, 2435, 1, 3752, 24, 27, 7, 466, 54, 7109, 23, 6, 560, 127, 640, 11, 1701, 242, 77, 450, 15, 236, 253, 489, 4, 46, 2447, 2193, 7, 3, 2269, 51, 4, 14, 1, 46, 7, 68, 2946, 195, 94, 6, 963, 3, 176, 1, 3752, 4, 552]",1723.0,23265768,150
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-12-26,"Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. Fifty-nine adult patients (age 42 to 82 years) with relapsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab. Patients had received prior fludarabine-based therapy or chemoimmunotherapy. Rituximab (375 mg/m(2) intravenously) was administered weekly during cycle one and on day 1 of cycles three to 12. Lenalidomide was started on day 9 of cycle one at 10 mg orally and administered daily continuously. Each cycle was 28 days. Rituximab was administered for 12 cycles; lenalidomide could continue indefinitely if patients benefitted clinically. The overall response rate was 66%, including 12% complete responses and 12% nodular partial remissions. Time to treatment failure was 17.4 months. Median overall survival has not been reached; estimated survival at 36 months is 71%. The most common grade 3 or 4 toxicity was neutropenia (73% of patients). Fourteen patients (24%) experienced a grade 3 to 4 infection or febrile episode. There was one episode of grade 3 tumor lysis; one patient experienced renal failure during the first cycle of therapy, and one venous thromboembolic event occurred during the study. The combination of lenalidomide and rituximab is active in patients with recurrent CLL and warrants further investigation.","Clinical Trial, Phase II",2582.0,108.0,Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic CLL We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL Fifty-nine adult patients age 42 to 82 years with relapsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab Patients had received prior fludarabine-based therapy or chemoimmunotherapy Rituximab 375 mg/m 2 intravenously was administered weekly during cycle one and on day 1 of cycles three to 12 Lenalidomide was started on day 9 of cycle one at 10 mg orally and administered daily continuously Each cycle was 28 days Rituximab was administered for 12 cycles lenalidomide could continue indefinitely if patients benefitted clinically The overall response rate was 66 including 12 complete responses and 12 nodular partial remissions Time to treatment failure was 17.4 months Median overall survival has not been reached estimated survival at 36 months is 71 The most common grade 3 or 4 toxicity was neutropenia 73 of patients Fourteen patients 24 experienced a grade 3 to 4 infection or febrile episode There was one episode of grade 3 tumor lysis one patient experienced failure during the first cycle of therapy and one venous thromboembolic event occurred during the study The combination of lenalidomide and rituximab is active in patients with recurrent CLL and warrants further investigation,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 16, 35, 2555, 234, 544, 22, 992, 36, 9, 442, 1193, 552, 21, 397, 1288, 5, 855, 6, 401, 51, 151, 4, 7, 5, 591, 15, 430, 552, 1461, 762, 780, 7, 89, 595, 6, 878, 60, 5, 591, 15, 430, 552, 11, 346, 3301, 8, 124, 215, 45, 1, 1288, 2, 855, 7, 42, 103, 324, 2027, 90, 36, 15, 4438, 855, 4175, 81, 188, 18, 1672, 10, 468, 709, 190, 417, 104, 2, 23, 218, 14, 1, 410, 169, 6, 133, 1288, 10, 3461, 23, 218, 83, 1, 417, 104, 28, 79, 81, 1428, 2, 468, 391, 4285, 296, 417, 10, 339, 162, 855, 10, 468, 9, 133, 410, 1288, 359, 1906, 13931, 492, 7, 20703, 505, 3, 63, 51, 116, 10, 700, 141, 133, 236, 253, 2, 133, 4481, 450, 3166, 98, 6, 24, 496, 10, 269, 39, 53, 52, 63, 25, 71, 44, 85, 1300, 661, 25, 28, 511, 53, 16, 792, 3, 96, 186, 88, 27, 15, 39, 155, 10, 778, 803, 1, 7, 3225, 7, 259, 592, 8, 88, 27, 6, 39, 930, 15, 2498, 6934, 125, 10, 104, 6934, 1, 88, 27, 30, 4783, 104, 69, 592, 496, 190, 3, 157, 417, 1, 36, 2, 104, 2167, 4703, 774, 489, 190, 3, 45, 3, 150, 1, 1288, 2, 855, 16, 544, 4, 7, 5, 387, 552, 2, 2782, 195, 940]",1437.0,23270003,133
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.,The Journal of molecular diagnostics : JMD,J Mol Diagn,2012-12-27,"Genomic abnormalities, such as deletions in 11q22 or 17p13, are associated with poorer prognosis in patients with chronic lymphocytic leukemia (CLL). We hypothesized that unknown regions of copy number variation (CNV) affect clinical outcome and can be detected by array-based single-nucleotide polymorphism (SNP) genotyping. We compared SNP genotypes from 168 untreated patients with CLL with genotypes from 73 white HapMap controls. We identified 322 regions of recurrent CNV, 82 of which occurred significantly more often in CLL than in HapMap (CLL-specific CNV), including regions typically aberrant in CLL: deletions in 6q21, 11q22, 13q14, and 17p13 and trisomy 12. In univariate analyses, 35 of total and 11 of CLL-specific CNVs were associated with unfavorable time-to-event outcomes, including gains or losses in chromosomes 2p, 4p, 4q, 6p, 6q, 7q, 11p, 11q, and 17p. In multivariate analyses, six CNVs (ie, CLL-specific variations in 11p15.1-15.4 or 6q27) predicted time-to-treatment or overall survival independently of established markers of prognosis. Moreover, genotypic complexity (ie, the number of independent CNVs per patient) significantly predicted prognosis, with a median time-to-treatment of 64 months versus 23 months in patients with zero to one versus two or more CNVs, respectively (P = 3.3  10(-8)). In summary, a comparison of SNP genotypes from patients with CLL with HapMap controls allowed us to identify known and unknown recurrent CNVs and to determine regions and rates of CNV that predict poorer prognosis in patients with CLL.",Journal Article,2581.0,15.0,Genomic abnormalities such as deletions in 11q22 or 17p13 are associated with poorer prognosis in patients with chronic lymphocytic CLL We hypothesized that unknown regions of copy number variation CNV affect clinical outcome and can be detected by array-based single-nucleotide polymorphism SNP genotyping We compared SNP genotypes from 168 untreated patients with CLL with genotypes from 73 white HapMap controls We identified 322 regions of recurrent CNV 82 of which occurred significantly more often in CLL than in HapMap CLL-specific CNV including regions typically aberrant in CLL deletions in 6q21 11q22 13q14 and 17p13 and trisomy 12 In univariate analyses 35 of total and 11 of CLL-specific CNVs were associated with unfavorable time-to-event outcomes including gains or losses in chromosomes 2p 4p 4q 6p 6q 7q 11p 11q and 17p In multivariate analyses six CNVs ie CLL-specific variations in 11p15.1-15.4 or 6q27 predicted time-to-treatment or overall survival independently of established markers of prognosis Moreover genotypic complexity ie the number of independent CNVs per patient significantly predicted prognosis with a median time-to-treatment of 64 months versus 23 months in patients with zero to one versus two or more CNVs respectively P 3.3 10 -8 In summary a comparison of SNP genotypes from patients with CLL with HapMap controls allowed us to identify known and unknown recurrent CNVs and to determine regions and rates of CNV that predict poorer prognosis in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[572, 1171, 225, 22, 2439, 4, 12647, 15, 7526, 32, 41, 5, 1769, 356, 4, 7, 5, 442, 1193, 552, 21, 1237, 17, 860, 1374, 1, 1337, 207, 1380, 9926, 1158, 38, 228, 2, 122, 40, 530, 20, 1926, 90, 226, 1579, 1907, 1845, 2686, 21, 72, 1845, 2071, 29, 5359, 1278, 7, 5, 552, 5, 2071, 29, 803, 886, 13961, 535, 21, 108, 8024, 1374, 1, 387, 9926, 878, 1, 92, 489, 97, 80, 629, 4, 552, 76, 4, 13961, 552, 112, 9926, 141, 1374, 1969, 1898, 4, 552, 2439, 4, 20225, 12647, 13221, 2, 7526, 2, 6317, 133, 4, 880, 318, 465, 1, 181, 2, 175, 1, 552, 112, 11712, 11, 41, 5, 2483, 98, 6, 774, 123, 141, 3849, 15, 5324, 4, 3560, 10957, 30528, 26806, 20259, 10961, 9723, 21440, 7203, 2, 4135, 4, 331, 318, 437, 11712, 2523, 552, 112, 2293, 4, 12074, 14, 167, 39, 15, 44843, 783, 98, 6, 24, 15, 63, 25, 1042, 1, 635, 525, 1, 356, 1393, 10030, 3082, 2523, 3, 207, 1, 306, 11712, 379, 69, 97, 783, 356, 5, 8, 52, 98, 6, 24, 1, 660, 53, 185, 382, 53, 4, 7, 5, 5115, 6, 104, 185, 100, 15, 80, 11712, 106, 19, 27, 27, 79, 66, 4, 1962, 8, 1155, 1, 1845, 2071, 29, 7, 5, 552, 5, 13961, 535, 2313, 843, 6, 255, 440, 2, 860, 387, 11712, 2, 6, 223, 1374, 2, 151, 1, 9926, 17, 678, 1769, 356, 4, 7, 5, 552]",1502.0,23273604,360
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2013-01-08,"Flavopiridol, the first clinically evaluated cyclin-dependent kinase inhibitor, shows activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major barrier to its broad clinical use. The purpose of this study was to investigate the relationships between pretreatment risk factors, drug pharmacokinetics, and TLS. A population pharmacokinetic/pharmacodynamic model linking drug exposure and TLS was developed. Plasma data of flavopiridol and its glucuronide metabolite (flavo-G) were obtained from 111 patients treated in early-phase trials with frequent sampling following initial and/or escalated doses. TLS grading was modeled with logistic regression as a pharmacodynamic endpoint. Demographics, baseline disease status, and blood chemistry variables were evaluated as covariates. Gender was the most significant pharmacokinetic covariate, with females displaying higher flavo-G exposure than males. Glucuronide metabolite exposure was predictive of TLS occurrence, and bulky lymphadenopathy was identified as a significant covariate on TLS probability. The estimated probability of TLS occurrence in patients with baseline bulky lymphadenopathy less than 10 cm or 10 cm or more during the first 2 treatments was 0.111 (SE% 13.0%) and 0.265 (SE% 17.9%), respectively, when flavo-G area under the plasma concentration versus time curve was at its median value in whole-patient group. This is the first population pharmacokinetic/pharmacodynamic model of TLS. Further work is needed to explore potential mechanisms and to determine whether the associations between TLS, gender, and glucuronide metabolites are relevant in patients with chronic lymphocytic leukemia treated with other cyclin-dependent kinase inhibitors.","Clinical Trial, Phase I",2569.0,14.0,Flavopiridol the first clinically evaluated cyclin-dependent kinase inhibitor shows activity in patients with refractory chronic lymphocytic but prevalent and unpredictable tumor lysis syndrome TLS presents a major barrier to its broad clinical use The purpose of this study was to investigate the relationships between pretreatment risk factors drug pharmacokinetics and TLS A population pharmacokinetic/pharmacodynamic model linking drug exposure and TLS was developed Plasma data of flavopiridol and its glucuronide metabolite flavo-G were obtained from 111 patients treated in early-phase trials with frequent sampling following initial and/or escalated doses TLS grading was modeled with logistic regression as a pharmacodynamic endpoint Demographics baseline disease status and blood chemistry variables were evaluated as covariates Gender was the most significant pharmacokinetic covariate with females displaying higher flavo-G exposure than males Glucuronide metabolite exposure was predictive of TLS occurrence and bulky lymphadenopathy was identified as a significant covariate on TLS probability The estimated probability of TLS occurrence in patients with baseline bulky lymphadenopathy less than 10 cm or 10 cm or more during the first 2 treatments was 0.111 SE 13.0 and 0.265 SE 17.9 respectively when flavo-G area under the plasma concentration versus time curve was at its median value in whole-patient group This is the first population pharmacokinetic/pharmacodynamic model of TLS Further work is needed to explore potential mechanisms and to determine whether the associations between TLS gender and glucuronide metabolites are relevant in patients with chronic lymphocytic treated with other cyclin-dependent kinase inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 3, 157, 505, 194, 1226, 470, 216, 230, 1949, 128, 4, 7, 5, 430, 442, 1193, 84, 2485, 2, 8907, 30, 4783, 681, 8778, 2740, 8, 458, 3318, 6, 211, 2094, 38, 119, 3, 743, 1, 26, 45, 10, 6, 963, 3, 2467, 59, 1194, 43, 130, 234, 1159, 2, 8778, 8, 266, 1456, 2424, 202, 5806, 234, 645, 2, 8778, 10, 276, 554, 74, 1, 3030, 2, 211, 11435, 3379, 40222, 499, 11, 683, 29, 3167, 7, 73, 4, 191, 124, 143, 5, 908, 2874, 366, 388, 2, 15, 2842, 415, 8778, 3452, 10, 4666, 5, 812, 320, 22, 8, 2424, 1138, 2221, 330, 34, 156, 2, 315, 9352, 682, 11, 194, 22, 2489, 1632, 10, 3, 96, 93, 1456, 6322, 5, 2451, 6609, 142, 40222, 499, 645, 76, 2296, 11435, 3379, 645, 10, 464, 1, 8778, 2291, 2, 4112, 4962, 10, 108, 22, 8, 93, 6322, 23, 8778, 1320, 3, 661, 1320, 1, 8778, 2291, 4, 7, 5, 330, 4112, 4962, 299, 76, 79, 494, 15, 79, 494, 15, 80, 190, 3, 157, 18, 640, 10, 13, 3167, 3428, 233, 13, 2, 13, 7298, 3428, 269, 83, 106, 198, 40222, 499, 965, 669, 3, 554, 1227, 185, 98, 1496, 10, 28, 211, 52, 549, 4, 902, 69, 87, 26, 16, 3, 157, 266, 1456, 2424, 202, 1, 8778, 195, 1357, 16, 575, 6, 1645, 174, 483, 2, 6, 223, 317, 3, 685, 59, 8778, 1632, 2, 11435, 3406, 32, 867, 4, 7, 5, 442, 1193, 73, 5, 127, 1226, 470, 216, 222]",1747.0,23300276,479
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2013-01-10,"Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk. To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes. The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3' untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81  10(-6)). This SNP was not associated with the other NHL subtypes (all P > 0.05). We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology. These data provide support that a functional variant within the 3'UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk.",Comparative Study,2567.0,9.0,"Our genome-wide association study GWAS of chronic lymphocytic CLL identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL supporting the IRF8 gene as a strong candidate for CLL risk To refine the genetic association of CLL risk we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls We then conducted fine mapping by genotyping 39 variants of which 10 were identified from sequencing in 745 CLL cases and 1,521 controls We also assessed these associations with risk of other NHL subtypes The strongest association with CLL risk was observed with a common single-nucleotide polymorphism SNP located within the 3 untranslated region UTR of IRF8 rs1044873 log additive OR 0.7 P 1.81 10 -6 This SNP was not associated with the other NHL subtypes all P 0.05 We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk This association appears to be unique to CLL with little support for association with other common NHL subtypes Future work is needed to assess functional role of IRF8 in CLL etiology These data provide support that a functional variant within the 3'UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[114, 898, 1019, 248, 45, 3297, 1, 442, 1193, 552, 108, 39, 561, 438, 7998, 839, 262, 3, 12933, 145, 17, 11, 41, 5, 552, 46, 99, 11, 195, 2708, 20, 8, 435, 1742, 65, 1, 114, 3297, 5, 100, 127, 3297, 1, 552, 1912, 3, 12933, 145, 22, 8, 1082, 1609, 9, 552, 43, 6, 5003, 3, 336, 248, 1, 552, 43, 21, 426, 7285, 615, 1, 12933, 4, 960, 552, 140, 2, 921, 535, 21, 818, 426, 2924, 2568, 20, 2686, 587, 839, 1, 92, 79, 11, 108, 29, 615, 4, 14509, 552, 140, 2, 14, 11925, 535, 21, 120, 275, 46, 685, 5, 43, 1, 127, 1176, 814, 3, 3311, 248, 5, 552, 43, 10, 164, 5, 8, 186, 226, 1579, 1907, 1845, 2308, 262, 3, 27, 7379, 1053, 8196, 1, 12933, 47566, 1066, 3396, 15, 13, 67, 19, 14, 865, 79, 49, 26, 1845, 10, 44, 41, 5, 3, 127, 1176, 814, 62, 19, 13, 474, 21, 377, 241, 17, 47566, 4, 3, 12933, 145, 4162, 9, 3, 388, 3297, 1235, 9, 552, 43, 26, 248, 1233, 6, 40, 991, 6, 552, 5, 1215, 538, 9, 248, 5, 127, 186, 1176, 814, 508, 1357, 16, 575, 6, 423, 583, 200, 1, 12933, 4, 552, 2855, 46, 74, 377, 538, 17, 8, 583, 1142, 262, 3, 9990, 1, 12933, 68, 40, 4057, 3, 3297, 1235, 527, 23, 30322, 14, 9, 552, 43]",1338.0,23307532,384
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2012-11-01,"Chronic lymphocytic leukemia (CLL) is a very heterogeneous disease with significant variation in clinical presentation, time to disease progression, survival, and aggressiveness of clinical course. A subgroup of patients who have been repeatedly identified as having a poor response to therapy are those with del(17p13.1)--identified by either interphase cytogenetics or other comparable strategies. Although there has been much progress over the past few years in the development of new therapeutic targets for CLL patients, this subgroup has continued to lag behind others. Because of the poor response or significant therapy-related toxicity experienced by patients with del(17p13.1)--and the small number of these patients included in clinical trials--current guidelines are unable to provide suggestions for the care of newly diagnosed, symptomatic but untreated patients (as well as relapsed patients) in this subgroup on account of the modest amount of evidence. However, novel agents are on the horizon that appear to be significantly more effective in this patient population, and these will likely shape the standard of care for these patients in the future.",Journal Article,2637.0,7.0,Chronic lymphocytic CLL is a very heterogeneous disease with significant variation in clinical presentation time to disease progression survival and aggressiveness of clinical course A subgroup of patients who have been repeatedly identified as having a poor response to therapy are those with del 17p13.1 -- identified by either interphase cytogenetics or other comparable strategies Although there has been much progress over the past few years in the development of new therapeutic targets for CLL patients this subgroup has continued to lag behind others Because of the poor response or significant therapy-related toxicity experienced by patients with del 17p13.1 -- and the small number of these patients included in clinical trials -- current guidelines are unable to provide suggestions for the care of newly diagnosed symptomatic but untreated patients as well as relapsed patients in this subgroup on account of the modest amount of evidence However novel agents are on the horizon that appear to be significantly more effective in this patient population and these will likely shape the standard of care for these patients in the future,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 923, 1564, 34, 5, 93, 1380, 4, 38, 1031, 98, 6, 34, 91, 25, 2, 3908, 1, 38, 906, 8, 1363, 1, 7, 54, 47, 85, 11132, 108, 22, 1041, 8, 334, 51, 6, 36, 32, 135, 5, 3084, 7526, 14, 108, 20, 361, 8081, 2510, 15, 127, 1279, 422, 242, 125, 71, 85, 1802, 1466, 252, 3, 1219, 1021, 60, 4, 3, 193, 1, 217, 189, 637, 9, 552, 7, 26, 1363, 71, 1351, 6, 7650, 5219, 1749, 408, 1, 3, 334, 51, 15, 93, 36, 139, 155, 592, 20, 7, 5, 3084, 7526, 14, 2, 3, 302, 207, 1, 46, 7, 159, 4, 38, 143, 291, 677, 32, 4253, 6, 377, 9796, 9, 3, 165, 1, 732, 265, 1704, 84, 1278, 7, 22, 149, 22, 591, 7, 4, 26, 1363, 23, 1967, 1, 3, 1721, 3108, 1, 241, 137, 229, 183, 32, 23, 3, 8704, 17, 1322, 6, 40, 97, 80, 323, 4, 26, 69, 266, 2, 46, 303, 322, 5465, 3, 260, 1, 165, 9, 46, 7, 4, 3, 508]",1147.0,23330344,390
"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-01-22,"Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Patients with cancers of the breast (hazard ratio [HR], 1.70; P < .001), colorectum (HR, 1.65; P < .001), kidney (HR, 1.54; P < .001), prostate (HR, 1.92; P < .001), or lung (HR, 1.19; P < .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P < .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.",Journal Article,2555.0,30.0,"Chronic lymphocytic CLL is associated with an increased risk of developing second cancers However it is unknown whether CLL alters the disease course of these cancers once they occur All patients with cancers of the n 579,164 colorectum n 412,366 n 631,616 n 489,053 n 95,795 n 82,116 and ovary n 61,937 reported to the SEER program from 1990 to 2007 were identified Overall survival OS death resulting from any cause and cancer-specific survival were examined comparing patients with and without pre-existing CLL Cancer-specific survival was evaluated for each tumor type in a site-specific manner eg death resulting from cancer in a patient with cancer Patients with cancers of the hazard ratio HR 1.70 P .001 colorectum HR 1.65 P .001 HR 1.54 P .001 HR 1.92 P .001 or HR 1.19 P .001 had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age sex race and disease stage These results for OS remained significant for patients with cancers of the colorectum and after excluding or censoring CLL-related deaths Cancer-specific survival was also inferior for patients with cancers of the HR 1.41 P .005 and colorectum HR 1.46 P .001 who had pre-existing CLL after adjusting for age sex race and disease stage Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed",1,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 41, 5, 35, 101, 43, 1, 931, 419, 163, 137, 192, 16, 860, 317, 552, 6745, 3, 34, 906, 1, 46, 163, 1059, 491, 1271, 62, 7, 5, 163, 1, 3, 78, 11414, 5279, 12355, 78, 9963, 9797, 78, 14576, 14249, 78, 12283, 9948, 78, 48, 12823, 78, 878, 3790, 2, 3631, 78, 713, 15361, 210, 6, 3, 1605, 1243, 29, 2289, 6, 1307, 11, 108, 63, 25, 118, 273, 1113, 29, 500, 708, 2, 12, 112, 25, 11, 409, 1430, 7, 5, 2, 187, 671, 1692, 552, 12, 112, 25, 10, 194, 9, 296, 30, 267, 4, 8, 606, 112, 1708, 2887, 273, 1113, 29, 12, 4, 8, 69, 5, 12, 7, 5, 163, 1, 3, 360, 197, 168, 14, 431, 19, 144, 12355, 168, 14, 556, 19, 144, 168, 14, 667, 19, 144, 168, 14, 937, 19, 144, 15, 168, 14, 326, 19, 144, 42, 1663, 118, 492, 491, 42, 8, 671, 1692, 147, 1, 552, 50, 1358, 9, 89, 1035, 1047, 2, 34, 82, 46, 99, 9, 118, 958, 93, 9, 7, 5, 163, 1, 3, 12355, 2, 50, 3207, 15, 11732, 552, 139, 1043, 12, 112, 25, 10, 120, 1663, 9, 7, 5, 163, 1, 3, 168, 14, 605, 19, 1614, 2, 12355, 168, 14, 641, 19, 144, 54, 42, 671, 1692, 552, 50, 1358, 9, 89, 1035, 1047, 2, 34, 82, 1663, 118, 2, 12, 112, 25, 10, 164, 9, 392, 186, 163, 4, 7, 5, 671, 1692, 552, 402, 94, 32, 575, 6, 223, 3, 665, 284, 1, 46, 441, 4, 7, 5, 552, 2, 317, 80, 571, 453, 15, 1091, 611, 6, 249, 36, 32, 575]",1550.0,23341508,217
Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia.,PloS one,PLoS ONE,2013-01-28,"We previously reported a rare germline variant (c.1-6531) that resulted in allele-specific expression (ASE) of death-associated protein kinase 1 (DAPK1) and predisposition to chronic lymphocytic leukemia (CLL). We investigated a cohort of CLL patients lacking this mutation for the presence of ASE of DAPK1. We developed a novel strategy that combines single-nucleotide primer extension (SNuPE) with MALDI-TOF mass spectrometry, and detected germline DAPK1 ASE in 17 out of 120 (14.2%) CLL patients associated with a trend towards younger age at diagnosis. ASE was absent in 63 healthy controls. Germline cells of CLL patients with ASE showed increased levels of DNA methylation in the promoter region, however, neither genetic nor further epigenetic aberrations could be identified in the DAPK1 5' upstream regulatory region, within distinct exons or in the 3'-UTR. We identified B-lymphoid malignancy related cell line models harboring allelic imbalance and found that allele-specific methylation in DAPK1 is associated with ASE. Our data indicate that ASE at the DAPK1 gene locus is a recurrent event, mediated by epigenetic mechanisms and potentially predisposing to CLL.",Journal Article,2549.0,12.0,We previously reported a rare germline variant c.1-6531 that resulted in allele-specific expression ASE of death-associated protein kinase 1 DAPK1 and predisposition to chronic lymphocytic CLL We investigated a cohort of CLL patients lacking this mutation for the presence of ASE of DAPK1 We developed a novel strategy that combines single-nucleotide primer extension SNuPE with MALDI-TOF mass spectrometry and detected germline DAPK1 ASE in 17 out of 120 14.2 CLL patients associated with a trend towards younger age at diagnosis ASE was absent in 63 healthy controls Germline cells of CLL patients with ASE showed increased levels of DNA methylation in the promoter region however neither genetic nor further epigenetic aberrations could be identified in the DAPK1 5 upstream regulatory region within distinct exons or in the 3'-UTR We identified B-lymphoid malignancy related cell line models harboring allelic imbalance and found that allele-specific methylation in DAPK1 is associated with ASE Our data indicate that ASE at the DAPK1 gene locus is a recurrent event mediated by epigenetic mechanisms and potentially predisposing to CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 373, 210, 8, 622, 1009, 1142, 256, 14, 38661, 17, 627, 4, 1254, 112, 55, 17952, 1, 273, 41, 178, 216, 14, 11503, 2, 2863, 6, 442, 1193, 552, 21, 565, 8, 180, 1, 552, 7, 1941, 26, 258, 9, 3, 463, 1, 17952, 1, 11503, 21, 276, 8, 229, 692, 17, 6705, 226, 1579, 9684, 2401, 62436, 5, 12788, 12789, 782, 3680, 2, 530, 1009, 11503, 17952, 4, 269, 1205, 1, 2031, 213, 18, 552, 7, 41, 5, 8, 853, 3113, 773, 89, 28, 147, 17952, 10, 3269, 4, 676, 1331, 535, 1009, 37, 1, 552, 7, 5, 17952, 224, 101, 148, 1, 261, 569, 4, 3, 973, 1053, 137, 2174, 336, 2110, 195, 1418, 2152, 359, 40, 108, 4, 3, 11503, 33, 3988, 1253, 1053, 262, 834, 3885, 15, 4, 3, 5435, 8196, 21, 108, 132, 2303, 710, 139, 31, 328, 274, 2105, 3861, 6088, 2, 204, 17, 1254, 112, 569, 4, 11503, 16, 41, 5, 17952, 114, 74, 1008, 17, 17952, 28, 3, 11503, 145, 2474, 16, 8, 387, 774, 517, 20, 1418, 483, 2, 751, 6885, 6, 552]",1140.0,23383130,142
CGH protocols: chronic lymphocytic leukemia.,"Methods in molecular biology (Clifton, N.J.)",Methods Mol. Biol.,2013-01-01,Array-based comparative genomic hybridization (aCGH) is a powerful assay to identify copy number abnormalities underlying the pathogenesis of cancer. aCGH has become the gold standard for whole genome copy number analysis in medium and large cohorts in clinical and research laboratories. Identifying the best workflow is critical to achieving the optimal performance for this assay. Here we describe the aCGH protocol used by our group in the study of B-chronic lymphocytic leukemia (CLL). We also describe some initial applications of aCGH in association with clinical outcome for CLL.,Journal Article,2576.0,2.0,Array-based comparative genomic hybridization aCGH is a powerful assay to identify copy number abnormalities underlying the pathogenesis of cancer aCGH has become the gold standard for whole genome copy number analysis in medium and large cohorts in clinical and research laboratories Identifying the best workflow is critical to achieving the optimal performance for this assay Here we describe the aCGH protocol used by our group in the study of B-chronic lymphocytic CLL We also describe some initial applications of aCGH in association with clinical outcome for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1926, 90, 2352, 572, 1554, 8879, 16, 8, 3757, 719, 6, 255, 1337, 207, 1171, 1181, 3, 1384, 1, 12, 8879, 71, 1417, 3, 4159, 260, 9, 902, 898, 1337, 207, 65, 4, 3759, 2, 375, 736, 4, 38, 2, 389, 4884, 1386, 3, 824, 8825, 16, 740, 6, 1785, 3, 665, 528, 9, 26, 719, 467, 21, 897, 3, 8879, 1182, 95, 20, 114, 87, 4, 3, 45, 1, 132, 442, 1193, 552, 21, 120, 897, 476, 388, 2911, 1, 8879, 4, 248, 5, 38, 228, 9, 552]",569.0,23412785,10
Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2013-02-12,"To investigate clinical and pathologic factors significant in predicting local response and time to further treatment after low-dose involved-field radiation therapy (LD-IFRT) for non-Hodgkin lymphoma (NHL). Records of NHL patients treated at a single institution between April 2004 and September 2011 were retrospectively reviewed. Low-dose involved-field radiation therapy was given as 4 Gy in 2 fractions over 2 consecutive days. Treatment response and disease control were determined by radiographic studies and/or physical examination. A generalized estimating equation model was used to assess the effect of tumor and patient characteristics on disease response. A Cox proportional hazards regression model was used to assess time to further treatment. We treated a total of 187 sites in 127 patients with LD-IFRT. Histologies included 66% follicular, 9% chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, 10% marginal zone, 6% mantle cell lymphoma (MCL), and 8% other. Median follow-up time was 23.4 months (range, 0.03-92.2 months). The complete response, partial response, and overall response rates were 57%, 25%, and 82%, respectively. A CLL histology was associated with a lower response rate (odds ratio 0.2, 95% confidence interval 0.1-0.5, P=.02). Tumor size, site, age at diagnosis, and prior systemic therapy were not associated with response. The median time to first recurrence was 13.6 months. Those with CLL and age  50 years at diagnosis had a shorter time to further treatment for local failures (hazard ratio [HR] 3.63, P=.01 and HR 5.50, P=.02, respectively). Those with CLL and MCL had a shorter time to further treatment for distant failures (HR 11.1 and 16.3, respectively, P<.0001). High local response rates were achieved with LD-IFRT across most histologies. Chronic lymphocytic leukemia and MCL histologies and age  50 years at diagnosis had a shorter time to further treatment after LD-IFRT.",Journal Article,2534.0,27.0,To investigate clinical and pathologic factors significant in predicting local response and time to further treatment after low-dose involved-field radiation therapy LD-IFRT for NHL Records of NHL patients treated at a single institution between April 2004 and September 2011 were retrospectively reviewed Low-dose involved-field radiation therapy was given as 4 Gy in 2 fractions over 2 consecutive days Treatment response and disease control were determined by radiographic studies and/or physical examination A generalized estimating equation model was used to assess the effect of tumor and patient characteristics on disease response A Cox proportional hazards regression model was used to assess time to further treatment We treated a total of 187 sites in 127 patients with LD-IFRT Histologies included 66 follicular 9 chronic lymphocytic CLL /small lymphocytic 10 marginal zone 6 mantle cell MCL and 8 other Median follow-up time was 23.4 months range 0.03-92.2 months The complete response partial response and overall response rates were 57 25 and 82 respectively A CLL histology was associated with a lower response rate odds ratio 0.2 95 confidence interval 0.1-0.5 P=.02 Tumor size site age at diagnosis and prior systemic therapy were not associated with response The median time to first recurrence was 13.6 months Those with CLL and age  50 years at diagnosis had a shorter time to further treatment for local failures hazard ratio HR 3.63 P=.01 and HR 5.50 P=.02 respectively Those with CLL and MCL had a shorter time to further treatment for distant failures HR 11.1 and 16.3 respectively P .0001 High local response rates were achieved with LD-IFRT across most histologies Chronic lymphocytic and MCL histologies and age  50 years at diagnosis had a shorter time to further treatment after LD-IFRT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 963, 38, 2, 510, 130, 93, 4, 1434, 293, 51, 2, 98, 6, 195, 24, 50, 154, 61, 646, 1067, 121, 36, 5403, 6375, 9, 1176, 1064, 1, 1176, 7, 73, 28, 8, 226, 731, 59, 2292, 1131, 2, 2636, 1132, 11, 894, 446, 154, 61, 646, 1067, 121, 36, 10, 447, 22, 39, 381, 4, 18, 1550, 252, 18, 935, 162, 24, 51, 2, 34, 182, 11, 509, 20, 1580, 94, 2, 15, 900, 1385, 8, 4169, 4563, 5747, 202, 10, 95, 6, 423, 3, 254, 1, 30, 2, 69, 374, 23, 34, 51, 8, 418, 831, 1017, 320, 202, 10, 95, 6, 423, 98, 6, 195, 24, 21, 73, 8, 181, 1, 5568, 633, 4, 4080, 7, 5, 5403, 6375, 3489, 159, 700, 1974, 83, 442, 1193, 552, 302, 1193, 79, 3450, 3614, 49, 2757, 31, 1308, 2, 66, 127, 52, 166, 126, 98, 10, 382, 39, 53, 184, 13, 680, 937, 18, 53, 3, 236, 51, 450, 51, 2, 63, 51, 151, 11, 696, 243, 2, 878, 106, 8, 552, 784, 10, 41, 5, 8, 280, 51, 116, 610, 197, 13, 18, 48, 307, 268, 13, 14, 13, 33, 19, 588, 30, 444, 606, 89, 28, 147, 2, 324, 403, 36, 11, 44, 41, 5, 51, 3, 52, 98, 6, 157, 146, 10, 233, 49, 53, 135, 5, 552, 2, 89, 1552, 212, 60, 28, 147, 42, 8, 985, 98, 6, 195, 24, 9, 293, 3368, 360, 197, 168, 27, 676, 19, 355, 2, 168, 33, 212, 19, 588, 106, 135, 5, 552, 2, 1308, 42, 8, 985, 98, 6, 195, 24, 9, 626, 3368, 168, 175, 14, 2, 245, 27, 106, 19, 488, 64, 293, 51, 151, 11, 513, 5, 5403, 6375, 716, 96, 3489, 442, 1193, 2, 1308, 3489, 2, 89, 1552, 212, 60, 28, 147, 42, 8, 985, 98, 6, 195, 24, 50, 5403, 6375]",1818.0,23414765,540
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.,Cell,Cell,2013-02-01,"Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome sequence and copy number to measure the fraction of cancer cells harboring each somatic mutation. We identified driver mutations as predominantly clonal (e.g., MYD88, trisomy 12, and del(13q)) or subclonal (e.g., SF3B1 and TP53), corresponding to earlier and later events in CLL evolution. We sampled leukemia cells from 18 patients at two time points. Ten of twelve CLL cases treated with chemotherapy (but only one of six without treatment) underwent clonal evolution, predominantly involving subclones with driver mutations (e.g., SF3B1 and TP53) that expanded over time. Furthermore, presence of a subclonal driver mutation was an independent risk factor for rapid disease progression. Our study thus uncovers patterns of clonal evolution in CLL, providing insights into its stepwise transformation, and links the presence of subclones with adverse clinical outcomes.",Journal Article,2545.0,787.0,Clonal evolution is a key feature of cancer progression and relapse We studied intratumoral heterogeneity in 149 chronic lymphocytic CLL cases by integrating whole-exome sequence and copy number to measure the fraction of cancer cells harboring each somatic mutation We identified driver mutations as predominantly clonal e.g. MYD88 trisomy 12 and del 13q or subclonal e.g. SF3B1 and TP53 corresponding to earlier and later events in CLL evolution We sampled cells from 18 patients at two time points Ten of twelve CLL cases treated with chemotherapy but only one of six without treatment underwent clonal evolution predominantly involving subclones with driver mutations e.g. SF3B1 and TP53 that expanded over time Furthermore presence of a subclonal driver mutation was an independent risk factor for rapid disease progression Our study thus uncovers patterns of clonal evolution in CLL providing insights into its stepwise transformation and links the presence of subclones with adverse clinical outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1946, 2554, 16, 8, 825, 2705, 1, 12, 91, 2, 429, 21, 656, 2074, 1144, 4, 4928, 442, 1193, 552, 140, 20, 4568, 902, 2865, 1532, 2, 1337, 207, 6, 1463, 3, 1509, 1, 12, 37, 2105, 296, 1119, 258, 21, 108, 2228, 138, 22, 2117, 1946, 563, 499, 3986, 6317, 133, 2, 3084, 8453, 15, 9210, 563, 499, 10132, 2, 1206, 1734, 6, 1677, 2, 1559, 281, 4, 552, 2554, 21, 5919, 37, 29, 203, 7, 28, 100, 98, 862, 1618, 1, 2544, 552, 140, 73, 5, 56, 84, 158, 104, 1, 437, 187, 24, 208, 1946, 2554, 2117, 1267, 8881, 5, 2228, 138, 563, 499, 10132, 2, 1206, 17, 2064, 252, 98, 798, 463, 1, 8, 9210, 2228, 258, 10, 35, 306, 43, 161, 9, 1321, 34, 91, 114, 45, 631, 18562, 764, 1, 1946, 2554, 4, 552, 1736, 1957, 237, 211, 5497, 1392, 2, 6491, 3, 463, 1, 8881, 5, 290, 38, 123]",1007.0,23415222,133
"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.","Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2013-02-15,"CD20 is a widely validated, B cell-specific target for therapy in B cell malignancies. Rituximab is an anti-CD20 Ab that prolongs survival of chronic lymphocytic leukemia (CLL) patients when combined with chemotherapy. Ofatumumab and GA101 (obinutuzumab) are CD20-directed Abs currently being developed as alternative agents to rituximab in CLL based upon different properties of enhanced direct cell death, NK cell-mediated Ab-dependent cellular cytotoxicity, or complement-dependent cytotoxicity. Despite widespread study, ofatumumab and GA101 have not been compared with each other, nor studied for their interactions with monocytes and macrophages which are critical for the efficacy of anti-CD20 Abs in murine models. In CLL cells, we show that direct cell death and complement-dependent cytotoxicity are greatest with GA101 and ofatumumab, respectively. GA101 promotes enhanced NK cell activation and Ab-dependent cellular cytotoxicity at high Ab concentrations. Ofatumumab elicits superior Ab-dependent cellular phagocytosis with monocyte-derived macrophages. GA101 demonstrated reduced activation of monocytes with diminished pERK, TNF- release, and FcRIIa recruitment to lipid rafts. These data demonstrate that GA101 and ofatumumab are both superior to rituximab against CLL cells via different mechanisms of potential tumor elimination. These findings bear relevance to potential combination strategies with each of these anti-CD20 Abs in the treatment of CLL.",Comparative Study,2531.0,65.0,CD20 is a widely validated B cell-specific target for therapy in B cell malignancies Rituximab is an anti-CD20 Ab that prolongs survival of chronic lymphocytic CLL patients when combined with chemotherapy Ofatumumab and GA101 obinutuzumab are CD20-directed Abs currently being developed as alternative agents to rituximab in CLL based upon different properties of enhanced direct cell death NK cell-mediated Ab-dependent cellular cytotoxicity or complement-dependent cytotoxicity Despite widespread study ofatumumab and GA101 have not been compared with each other nor studied for their interactions with monocytes and macrophages which are critical for the efficacy of anti-CD20 Abs in murine models In CLL cells we show that direct cell death and complement-dependent cytotoxicity are greatest with GA101 and ofatumumab respectively GA101 promotes enhanced NK cell activation and Ab-dependent cellular cytotoxicity at high Ab concentrations Ofatumumab elicits superior Ab-dependent cellular phagocytosis with monocyte-derived macrophages GA101 demonstrated reduced activation of monocytes with diminished pERK TNF- release and FcRIIa recruitment to lipid rafts These data demonstrate that GA101 and ofatumumab are both superior to rituximab against CLL cells via different mechanisms of potential tumor elimination These findings bear relevance to potential combination strategies with each of these anti-CD20 Abs in the treatment of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2198, 16, 8, 1792, 938, 132, 31, 112, 283, 9, 36, 4, 132, 31, 441, 855, 16, 35, 312, 2198, 5094, 17, 5613, 25, 1, 442, 1193, 552, 7, 198, 397, 5, 56, 5732, 2, 27260, 10380, 32, 2198, 1166, 7723, 694, 486, 276, 22, 1091, 183, 6, 855, 4, 552, 90, 1548, 338, 1571, 1, 651, 1196, 31, 273, 1765, 31, 517, 5094, 470, 763, 1408, 15, 3731, 470, 1408, 550, 3029, 45, 5732, 2, 27260, 47, 44, 85, 72, 5, 296, 127, 2110, 656, 9, 136, 1286, 5, 5078, 2, 2748, 92, 32, 740, 9, 3, 209, 1, 312, 2198, 7723, 4, 1471, 274, 4, 552, 37, 21, 514, 17, 1196, 31, 273, 2, 3731, 470, 1408, 32, 2199, 5, 27260, 2, 5732, 106, 27260, 2148, 651, 1765, 31, 363, 2, 5094, 470, 763, 1408, 28, 64, 5094, 1003, 5732, 8748, 1123, 5094, 470, 763, 11788, 5, 5231, 526, 2748, 27260, 264, 405, 363, 1, 5078, 5, 2849, 6621, 2254, 2014, 2008, 2, 27095, 3202, 6, 3121, 12015, 46, 74, 608, 17, 27260, 2, 5732, 32, 110, 1123, 6, 855, 480, 552, 37, 847, 338, 483, 1, 174, 30, 3730, 46, 272, 10952, 2088, 6, 174, 150, 422, 5, 296, 1, 46, 312, 2198, 7723, 4, 3, 24, 1, 552]",1441.0,23418626,529
Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.,Autophagy,Autophagy,2013-03-01,"Chronic lymphocytic leukemia (CLL) is a mature B cell malignancy and is the most prevalent type of leukemia in adults. There is no curative therapy for this disease; however, several new agents have shown very promising results. Autophagy has not been studied in CLL and in this study we first sought to determine if autophagy was functional in CLL with classic inducers, and if this contributes to direct cytotoxicity or protection from cell death. While autophagy is activated with all classic stimuli of this process, only unfolded protein endoplasmic reticulum (ER) stress-mediated autophagy protects from cell death. Interestingly, select therapeutic agents (fludarabine, GS-1101, flavopiridol), which are active in CLL, also induce autophagy. Of interest, only the broad cyclin-dependent kinase inhibitor flavopiridol has improved efficacy when autophagy is antagonized biochemically (chloroquine) or by siRNA. This promoted an investigation which demonstrated unexpectedly that flavopiridol mediates ER stress and downstream activation of MAP3K5/ASK1, which ultimately is responsible for cell death. Similarly, autophagy activated in part via ER stress and also CDK5 inhibition is protective against cell death induced by this process. Collectively, our studies demonstrate that in CLL, autophagy is induced by multiple stimuli but only acts as a mechanism of resistance against ER stress-mediating agents. Similarly, flavopiridol mediates ER stress as a primary mechanism of action in CLL, and autophagy serves as a mechanism of resistance to this agent.",Journal Article,2517.0,,Chronic lymphocytic CLL is a mature B cell malignancy and is the most prevalent type of in adults There is no curative therapy for this disease however several new agents have shown very promising results Autophagy has not been studied in CLL and in this study we first sought to determine if autophagy was functional in CLL with classic inducers and if this contributes to direct cytotoxicity or protection from cell death While autophagy is activated with all classic stimuli of this process only unfolded protein endoplasmic reticulum ER stress-mediated autophagy protects from cell death Interestingly select therapeutic agents fludarabine GS-1101 flavopiridol which are active in CLL also induce autophagy Of interest only the broad cyclin-dependent kinase inhibitor flavopiridol has improved efficacy when autophagy is antagonized biochemically chloroquine or by siRNA This promoted an investigation which demonstrated unexpectedly that flavopiridol mediates ER stress and downstream activation of MAP3K5/ASK1 which ultimately is responsible for cell death Similarly autophagy activated in part via ER stress and also CDK5 inhibition is protective against cell death induced by this process Collectively our studies demonstrate that in CLL autophagy is induced by multiple stimuli but only acts as a mechanism of resistance against ER stress-mediating agents Similarly flavopiridol mediates ER stress as a primary mechanism of action in CLL and autophagy serves as a mechanism of resistance to this agent,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 2908, 132, 31, 710, 2, 16, 3, 96, 2485, 267, 1, 4, 857, 125, 16, 77, 1075, 36, 9, 26, 34, 137, 392, 217, 183, 47, 443, 923, 721, 99, 2240, 71, 44, 85, 656, 4, 552, 2, 4, 26, 45, 21, 157, 990, 6, 223, 492, 2240, 10, 583, 4, 552, 5, 3168, 12780, 2, 492, 26, 2444, 6, 1196, 1408, 15, 3525, 29, 31, 273, 369, 2240, 16, 735, 5, 62, 3168, 7478, 1, 26, 1129, 158, 12146, 178, 6057, 6078, 516, 1531, 517, 2240, 8170, 29, 31, 273, 2873, 1717, 189, 183, 2027, 3815, 15129, 3030, 92, 32, 544, 4, 552, 120, 1290, 2240, 1, 1333, 158, 3, 2094, 1226, 470, 216, 230, 3030, 71, 231, 209, 198, 2240, 16, 15259, 7944, 14325, 15, 20, 1919, 26, 2992, 35, 940, 92, 264, 6016, 17, 3030, 3961, 516, 1531, 2, 1489, 363, 1, 26630, 31994, 92, 2050, 16, 2327, 9, 31, 273, 1813, 2240, 735, 4, 760, 847, 516, 1531, 2, 120, 16967, 297, 16, 2864, 480, 31, 273, 277, 20, 26, 1129, 2535, 114, 94, 608, 17, 4, 552, 2240, 16, 277, 20, 232, 7478, 84, 158, 4459, 22, 8, 670, 1, 251, 480, 516, 1531, 3941, 183, 1813, 3030, 3961, 516, 1531, 22, 8, 86, 670, 1, 1578, 4, 552, 2, 2240, 4711, 22, 8, 670, 1, 251, 6, 26, 420]",1510.0,23422081,538
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.,American journal of hematology,Am. J. Hematol.,2013-03-01,"Some patients with systemic mastocytosis have concurrent hematological neoplasms, designated in the World Health Organization (WHO) classification as systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD). In this study, we analyzed 29 patients with SM-AHNMD and compared them to 40 patients with pure SM. The AHNMDs were classified as chronic myelomonocytic leukemia (CMML) (n = 10), myelodysplastic syndrome (MDS) (n = 7), myeloproliferative neoplasms (n = 4), B-cell lymphoma/leukemia/plasma cell neoplasms (n = 7), and acute myeloid leukemia (n = 1). Patients with SM-AHNMD were older, more frequently had constitutional symptoms and hematological abnormalities, less often had skin lesions, and had an inferior overall survival compared with pure SM patients (48 months vs. not-reached, P < 0.001). Karyotypic abnormalities were detected in 9/28 (32%) patients with SM-AHNMD but not in pure SM patients (P < 0.001). Combined imaging/ fluorescence-in-situ hybridization performed in four SM-AHNMD cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-CMML and one patient with SM-MDS, but not in the mast cells of a case SM-associated with chronic lymphocytic leukemia with ATM-deletion. Quantitative mutation analysis showed higher levels of mutant KIT D816V in SM-CMML and SM-MDS than in pure SM (P < 0.001). Our data indicate that the SM-AHNMD category in the WHO classification is heterogeneous, including clonally related and unrelated forms of AHNMD. The presentation, treatment, and outcome of patients with SM-AHNMD is often dictated by the type of AHNMD.",Comparative Study,2517.0,,Some patients with systemic mastocytosis have concurrent hematological neoplasms designated in the World Health Organization WHO classification as systemic mastocytosis with associated clonal hematological non-mast cell lineage disease SM-AHNMD In this study we analyzed 29 patients with SM-AHNMD and compared them to 40 patients with pure SM The AHNMDs were classified as chronic myelomonocytic CMML n 10 syndrome MDS n 7 neoplasms n 4 B-cell lymphoma/leukemia/plasma cell neoplasms n 7 and acute myeloid n 1 Patients with SM-AHNMD were older more frequently had constitutional symptoms and hematological abnormalities less often had lesions and had an inferior overall survival compared with pure SM patients 48 months vs. not-reached P 0.001 Karyotypic abnormalities were detected in 9/28 32 patients with SM-AHNMD but not in pure SM patients P 0.001 Combined imaging/ fluorescence-in-situ hybridization performed in four SM-AHNMD cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-CMML and one patient with SM-MDS but not in the mast cells of a case SM-associated with chronic lymphocytic with ATM-deletion Quantitative mutation analysis showed higher levels of mutant KIT D816V in SM-CMML and SM-MDS than in pure SM P 0.001 Our data indicate that the SM-AHNMD category in the WHO classification is heterogeneous including clonally related and unrelated forms of AHNMD The presentation treatment and outcome of patients with SM-AHNMD is often dictated by the type of AHNMD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[476, 7, 5, 403, 7224, 47, 750, 2890, 1179, 4107, 4, 3, 1956, 341, 2533, 54, 947, 22, 403, 7224, 5, 41, 1946, 2890, 220, 5563, 31, 2542, 34, 3635, 21751, 4, 26, 45, 21, 311, 462, 7, 5, 3635, 21751, 2, 72, 1370, 6, 327, 7, 5, 3092, 3635, 3, 62493, 11, 1373, 22, 442, 5451, 3382, 78, 79, 681, 1223, 78, 67, 1179, 78, 39, 132, 31, 4763, 2647, 554, 31, 1179, 78, 67, 2, 286, 533, 78, 14, 7, 5, 3635, 21751, 11, 434, 80, 746, 42, 5962, 507, 2, 2890, 1171, 299, 629, 42, 406, 2, 42, 35, 1663, 63, 25, 72, 5, 3092, 3635, 7, 576, 53, 105, 44, 1300, 19, 13, 144, 9465, 1171, 11, 530, 4, 83, 339, 531, 7, 5, 3635, 21751, 84, 44, 4, 3092, 3635, 7, 19, 13, 144, 397, 270, 1591, 4, 957, 1554, 173, 4, 294, 3635, 21751, 140, 553, 2664, 1668, 2312, 4, 5563, 37, 2, 533, 37, 4, 100, 7, 5, 3635, 3382, 2, 104, 69, 5, 3635, 1223, 84, 44, 4, 3, 5563, 37, 1, 8, 473, 3635, 41, 5, 442, 1193, 5, 3552, 1528, 1156, 258, 65, 224, 142, 148, 1, 620, 1164, 12643, 4, 3635, 3382, 2, 3635, 1223, 76, 4, 3092, 3635, 19, 13, 144, 114, 74, 1008, 17, 3, 3635, 21751, 2169, 4, 3, 54, 947, 16, 1564, 141, 9157, 139, 2, 2092, 2377, 1, 21751, 3, 1031, 24, 2, 228, 1, 7, 5, 3635, 21751, 16, 629, 10575, 20, 3, 267, 1, 21751]",1520.0,23440662,15
Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.,Leukemia & lymphoma,Leuk. Lymphoma,2013-04-16,"The endoplasmic reticulum (ER) plays a vital function in multiple cellular processes. There is a growing interest in developing therapeutic agents that can target the ER in cancer cells, inducing a stress response that leads to cell death. However, ER stress-inducing agents can also induce autophagy, a survival strategy of cancer cells. Therefore, by inhibiting autophagy we can increase the efficacy of the ER stress-inducing agents. Nelfinavir, a human immunodeficiency virus (HIV) protease inhibitor with anti-cancer properties, can induce ER stress. Nelfinavir's effects on chronic lymphocytic leukemia (CLL) are yet to be elucidated. Herein we demonstrate that nelfinavir induces ER morphological changes and stress response, along with an autophagic protective strategy. Our data reveal that chloroquine, an autophagy inhibitor, significantly increases nelfinavir cytotoxicity. These results identify a novel strategy potentially effective in CLL treatment, by repositioning two well-known drugs as a combinatorial therapy with anti-cancer properties.",Journal Article,2471.0,16.0,The endoplasmic reticulum ER plays a vital function in multiple cellular processes There is a growing interest in developing therapeutic agents that can target the ER in cancer cells inducing a stress response that leads to cell death However ER stress-inducing agents can also induce autophagy a survival strategy of cancer cells Therefore by inhibiting autophagy we can increase the efficacy of the ER stress-inducing agents Nelfinavir a human immunodeficiency virus HIV protease inhibitor with anti-cancer properties can induce ER stress Nelfinavir 's effects on chronic lymphocytic CLL are yet to be elucidated Herein we demonstrate that nelfinavir induces ER morphological changes and stress response along with an autophagic protective strategy Our data reveal that chloroquine an autophagy inhibitor significantly increases nelfinavir cytotoxicity These results identify a novel strategy potentially effective in CLL treatment by repositioning two well-known drugs as a combinatorial therapy with anti-cancer properties,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 6057, 6078, 516, 1698, 8, 3511, 343, 4, 232, 763, 1849, 125, 16, 8, 1921, 1333, 4, 931, 189, 183, 17, 122, 283, 3, 516, 4, 12, 37, 1958, 8, 1531, 51, 17, 1940, 6, 31, 273, 137, 516, 1531, 1958, 183, 122, 120, 1290, 2240, 8, 25, 692, 1, 12, 37, 673, 20, 2062, 2240, 21, 122, 344, 3, 209, 1, 3, 516, 1531, 1958, 183, 8890, 8, 171, 5323, 1450, 1942, 5125, 230, 5, 312, 12, 1571, 122, 1290, 516, 1531, 8890, 292, 176, 23, 442, 1193, 552, 32, 1145, 6, 40, 3901, 1986, 21, 608, 17, 8890, 1516, 516, 4268, 400, 2, 1531, 51, 1510, 5, 35, 8810, 2864, 692, 114, 74, 2396, 17, 14325, 35, 2240, 230, 97, 1106, 8890, 1408, 46, 99, 255, 8, 229, 692, 751, 323, 4, 552, 24, 20, 15327, 100, 149, 440, 600, 22, 8, 3866, 36, 5, 312, 12, 1571]",1026.0,23469959,695
Genomic abnormalities of Waldenstrm macroglobulinemia and related low-grade B-cell lymphomas.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-03-09,"Waldenstrm macroglobulinemia (WM) is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and monoclonal immunoglobulin M production. WM shows similarities in presentations with related B-cell malignancies, sometimes making it difficult to distinguish them. To better characterize the genetic basis of WM, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. Overall, WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies. Trisomy 4 is unique to WM; however, no candidate genes have been identified in the chromosome. Abnormalities that affect myeloid differentiation primary response 88 (MYD88)--interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-B) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.",Journal Article,2509.0,8.0,Waldenstrm macroglobulinemia WM is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic marrow infiltrate and monoclonal immunoglobulin M production WM shows similarities in presentations with related B-cell malignancies sometimes making it difficult to distinguish them To better characterize the genetic basis of WM we performed a comparative genomic analysis with the related entities lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein marginal zone lymphomas chronic lymphocytic and monoclonal gammopathy of undetermined significance Overall WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies Trisomy 4 is unique to WM however no candidate genes have been identified in the chromosome Abnormalities that affect myeloid differentiation primary response 88 MYD88 -- interleukin-1 receptor-associated kinase 4 IRAK4 and nuclear factor kappa B NF-B signaling pathways were found in a significant proportion of WM cases which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3700, 3389, 1518, 16, 8, 4192, 34, 765, 20, 8, 1564, 5325, 581, 5172, 2, 848, 2593, 188, 1529, 1518, 1949, 6089, 4, 4261, 5, 139, 132, 31, 441, 5164, 1079, 192, 1740, 6, 3081, 1370, 6, 380, 1507, 3, 336, 877, 1, 1518, 21, 173, 8, 2352, 572, 65, 5, 3, 139, 4613, 5325, 1557, 187, 848, 2593, 188, 178, 3450, 3614, 1557, 442, 1193, 2, 848, 5334, 1, 5206, 724, 63, 1518, 1949, 8, 923, 585, 3385, 2, 10641, 96, 1, 3, 1860, 1171, 5, 96, 1, 3, 2316, 132, 31, 441, 6317, 39, 16, 991, 6, 1518, 137, 77, 1609, 214, 47, 85, 108, 4, 3, 1170, 1171, 17, 1158, 533, 910, 86, 51, 889, 3986, 1603, 14, 153, 41, 216, 39, 40299, 2, 928, 161, 3096, 132, 1365, 2448, 314, 460, 11, 204, 4, 8, 93, 920, 1, 1518, 140, 92, 309, 136, 2088, 4, 3, 1384, 1, 3, 34, 2, 11677, 217, 6612, 17, 68, 40, 8, 1597, 6, 771, 229, 189, 611]",1194.0,23477936,50
"Non-Hodgkin's lymphomas, version 1.2013.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2013-03-01,These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.,Journal Article,2517.0,,These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for 's Lymphomas NHL and provide a discussion of the clinical evidence that support the updates The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[46, 1944, 677, 1957, 2479, 392, 825, 5454, 6, 3, 1944, 677, 9, 292, 1557, 1176, 2, 377, 8, 2488, 1, 3, 38, 241, 17, 538, 3, 5454, 3, 5454, 1588, 4, 26, 946, 2705, 883, 9, 402, 24, 838, 4, 7, 5, 442, 1193, 2, 2753, 2976, 3, 284, 1, 3002, 1450, 3834, 1875, 4, 64, 43, 7, 5, 1176, 479, 579, 36]",454.0,23486452,419
Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma.,The Journal of nutrition,J. Nutr.,2013-03-13,"We evaluated the association of dietary fat and protein intake with risk of non-Hodgkin lymphoma (NHL) in a clinic-based study in 603 cases (including 218 chronic lymphocytic leukemia/small lymphocytic lymphoma, 146 follicular lymphoma, and 105 diffuse large B-cell lymphoma) and 1007 frequency-matched controls. Usual diet was assessed with a 128-item food-frequency questionnaire. Unconditional logistic regression was used to estimate ORs and 95% CIs, and polytomous logistic regression was used to assess subtype-specific risks. trans Fatty acid (TFA) intake was positively associated with NHL risk [OR = 1.60 for highest vs. lowest quartile (95% CI = 1.18, 2.15); P-trend = 0.0014], n3 (3) fatty acid intake was inversely associated with risk [OR = 0.48 (95% CI = 0.35, 0.65); P-trend < 0.0001], and there was no association with total, animal, plant-based, or saturated fat intake. When examining intake of specific foods, processed meat [OR = 1.37 (95% CI = 1.02, 1.83); P-trend = 0.03], milk containing any fat [OR = 1.47 (95% CI = 1.16, 1.88); P-trend = 0.0025], and high-fat ice cream [OR = 4.03 (95% CI = 2.80, 5.80); P-trend < 0.0001], intakes were positively associated with risk, whereas intakes of fresh fish and total seafood [OR = 0.61 (95% CI = 0.46, 0.80); P-trend = 0.0025] were inversely associated with risk. Overall, there was little evidence for NHL subtype-specific heterogeneity. In conclusion, diets high in TFAs, processed meats, and higher fat dairy products were positively associated with NHL risk, whereas diets high in n3 fatty acids and total seafood were inversely associated with risk.",Journal Article,2505.0,22.0,We evaluated the association of dietary fat and protein intake with risk of NHL in a clinic-based study in 603 cases including 218 chronic lymphocytic leukemia/small lymphocytic 146 follicular and 105 diffuse large B-cell and 1007 frequency-matched controls Usual diet was assessed with a 128-item food-frequency questionnaire Unconditional logistic regression was used to estimate ORs and 95 CIs and polytomous logistic regression was used to assess subtype-specific risks trans Fatty acid TFA intake was positively associated with NHL risk OR 1.60 for highest vs. lowest quartile 95 CI 1.18 2.15 P-trend 0.0014 n3 3 fatty acid intake was inversely associated with risk OR 0.48 95 CI 0.35 0.65 P-trend 0.0001 and there was no association with total animal plant-based or saturated fat intake When examining intake of specific foods processed meat OR 1.37 95 CI 1.02 1.83 P-trend 0.03 milk containing any fat OR 1.47 95 CI 1.16 1.88 P-trend 0.0025 and high-fat ice cream OR 4.03 95 CI 2.80 5.80 P-trend 0.0001 intakes were positively associated with risk whereas intakes of fresh fish and total seafood OR 0.61 95 CI 0.46 0.80 P-trend 0.0025 were inversely associated with risk Overall there was little evidence for NHL subtype-specific heterogeneity In conclusion diets high in TFAs processed meats and higher fat dairy products were positively associated with NHL risk whereas diets high in n3 fatty acids and total seafood were inversely associated with risk,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 3, 248, 1, 2013, 2300, 2, 178, 1514, 5, 43, 1, 1176, 4, 8, 1188, 90, 45, 4, 9696, 140, 141, 6070, 442, 1193, 2647, 302, 1193, 4909, 1974, 2, 3263, 1388, 375, 132, 31, 2, 20608, 675, 655, 535, 3521, 2453, 10, 275, 5, 8, 3990, 3471, 1773, 675, 1770, 6438, 812, 320, 10, 95, 6, 1191, 3694, 2, 48, 1927, 2, 13540, 812, 320, 10, 95, 6, 423, 875, 112, 1098, 3437, 4038, 971, 31838, 1514, 10, 2375, 41, 5, 1176, 43, 15, 14, 335, 9, 1076, 105, 2101, 3708, 48, 58, 14, 203, 18, 167, 19, 853, 13, 11408, 5749, 62575, 4038, 971, 1514, 10, 2659, 41, 5, 43, 15, 13, 576, 48, 58, 13, 465, 13, 556, 19, 853, 13, 488, 2, 125, 10, 77, 248, 5, 181, 2026, 9045, 90, 15, 14127, 2300, 1514, 198, 3282, 1514, 1, 112, 7484, 5232, 5854, 15, 14, 567, 48, 58, 14, 588, 14, 852, 19, 853, 13, 680, 12604, 1101, 500, 2300, 15, 14, 662, 48, 58, 14, 245, 14, 889, 19, 853, 13, 12615, 2, 64, 2300, 5995, 14572, 15, 39, 680, 48, 58, 18, 493, 33, 493, 19, 853, 13, 488, 5397, 11, 2375, 41, 5, 43, 547, 5397, 1, 4329, 1277, 2, 181, 22784, 15, 13, 713, 48, 58, 13, 641, 13, 493, 19, 853, 13, 12615, 11, 2659, 41, 5, 43, 63, 125, 10, 1215, 241, 9, 1176, 875, 112, 1144, 4, 1221, 6906, 64, 4, 62576, 5232, 19777, 2, 142, 2300, 11555, 2766, 11, 2375, 41, 5, 1176, 43, 547, 6906, 64, 4, 5749, 4038, 4562, 2, 181, 22784, 11, 2659, 41, 5, 43]",1462.0,23486982,176
Emerging drug profile: cyclin-dependent kinase inhibitors.,Leukemia & lymphoma,Leuk. Lymphoma,2013-07-29,"Abstract As the rational application of targeted therapies in cancer supplants traditional cytotoxic chemotherapy, there is an ever-greater need for a thorough understanding of the complex machinery of the cell and an application of this knowledge to the development of novel therapeutics and combinations of agents. Here, we review the current state of knowledge of the class of targeted agents known as cyclin-dependent kinase (CDK) inhibitors, with a focus on chronic lymphocytic leukemia (CLL). Flavopiridol (alvocidib) is the best studied of the CDK inhibitors, producing a dramatic cytotoxic effect in vitro and in vivo, with the principal limiting factor of acute tumor lysis. Unfortunately, flavopiridol has a narrow therapeutic window and is relatively non-selective with several off-target (i.e. non-CDK) effects, which prompted development of the second-generation CDK inhibitor dinaciclib. Dinaciclib appears to be both more potent and selective than flavopiridol, with at least an order of magnitude greater therapeutic index, and is currently in phase III clinical trials. In additional to flavopiridol and dinaciclib, we also review the current status of other members of this class, and provide commentary as to the future direction of combination therapy including CDK inhibitors. ",Journal Article,2367.0,43.0,Abstract As the rational application of targeted therapies in cancer supplants traditional cytotoxic chemotherapy there is an ever-greater need for a thorough understanding of the complex machinery of the cell and an application of this knowledge to the development of novel therapeutics and combinations of agents Here we review the current state of knowledge of the class of targeted agents known as cyclin-dependent kinase CDK inhibitors with a focus on chronic lymphocytic CLL Flavopiridol alvocidib is the best studied of the CDK inhibitors producing a dramatic cytotoxic effect in vitro and in vivo with the principal limiting factor of acute tumor lysis Unfortunately flavopiridol has a narrow therapeutic window and is relatively non-selective with several off-target i.e non-CDK effects which prompted development of the second-generation CDK inhibitor dinaciclib Dinaciclib appears to be both more potent and selective than flavopiridol with at least an order of magnitude greater therapeutic index and is currently in phase III clinical trials In additional to flavopiridol and dinaciclib we also review the current status of other members of this class and provide commentary as to the future direction of combination therapy including CDK inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8161, 22, 3, 2696, 1581, 1, 238, 235, 4, 12, 62578, 1847, 759, 56, 125, 16, 35, 3353, 378, 594, 9, 8, 5506, 612, 1, 3, 840, 6415, 1, 3, 31, 2, 35, 1581, 1, 26, 922, 6, 3, 193, 1, 229, 1943, 2, 1247, 1, 183, 467, 21, 206, 3, 291, 1309, 1, 922, 1, 3, 1040, 1, 238, 183, 440, 22, 1226, 470, 216, 3954, 222, 5, 8, 1222, 23, 442, 1193, 552, 3030, 14030, 16, 3, 824, 656, 1, 3, 3954, 222, 3787, 8, 3079, 759, 254, 4, 439, 2, 4, 386, 5, 3, 4312, 817, 161, 1, 286, 30, 4783, 3869, 3030, 71, 8, 6958, 189, 5421, 2, 16, 1352, 220, 1094, 5, 392, 1889, 283, 70, 563, 220, 3954, 176, 92, 4140, 193, 1, 3, 419, 914, 3954, 230, 7619, 7619, 1233, 6, 40, 110, 80, 1157, 2, 1094, 76, 3030, 5, 28, 506, 35, 1732, 1, 3131, 378, 189, 558, 2, 16, 694, 4, 124, 316, 38, 143, 4, 402, 6, 3030, 2, 7619, 21, 120, 206, 3, 291, 156, 1, 127, 1684, 1, 26, 1040, 2, 377, 4662, 22, 6, 3, 508, 4651, 1, 150, 36, 141, 3954, 222]",1262.0,23488658,705
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).,Blood,Blood,2013-03-14,"Immunotherapy that facilitates endogenous T-cell activity has the potential to target therapy-resistant tumor clones. In vitro studies have demonstrated that lenalidomide repairs the T-cell immunologic synapse defect in chronic lymphocytic leukemia (CLL). Pentostatin, cyclophosphamide, and rituximab (PCR) in CLL is clinically active with modest toxicity, indicating suitability of this chemoimmunotherapy (CIT) platform for combination with immunotherapy. Here we report on a trial of PCR followed by lenalidomide consolidation. Of 34 patients who received lenalidomide, 24% improved their quality of response and 4 patients converted to minimal residual disease negative status. Retrospective comparison to a historical PCR trial indicated that lenalidomide consolidation extends time to progression requiring salvage therapy. Longitudinal analysis showed that antitumor T-cell immune synapse activity improved post-PCR and was further enhanced after lenalidomide consolidation. These novel data showing repair of T-cell defects provide proof-of-principle that lenalidomide-based consolidation after CIT could have a beneficial clinical and immunologic role in CLL.","Clinical Trial, Phase II",2504.0,63.0,Immunotherapy that facilitates endogenous T-cell activity has the potential to target therapy-resistant tumor clones In vitro studies have demonstrated that lenalidomide repairs the T-cell immunologic synapse defect in chronic lymphocytic CLL Pentostatin cyclophosphamide and rituximab PCR in CLL is clinically active with modest toxicity indicating suitability of this chemoimmunotherapy CIT platform for combination with immunotherapy Here we report on a trial of PCR followed by lenalidomide consolidation Of 34 patients who received lenalidomide 24 improved their quality of response and 4 patients converted to minimal residual disease negative status Retrospective comparison to a historical PCR trial indicated that lenalidomide consolidation extends time to progression requiring salvage therapy Longitudinal analysis showed that antitumor T-cell immune synapse activity improved post-PCR and was further enhanced after lenalidomide consolidation These novel data showing repair of T-cell defects provide proof-of-principle that lenalidomide-based consolidation after CIT could have a beneficial clinical and immunologic role in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[726, 17, 4936, 2682, 102, 31, 128, 71, 3, 174, 6, 283, 36, 436, 30, 2749, 4, 439, 94, 47, 264, 17, 1288, 18439, 3, 102, 31, 3042, 15533, 5398, 4, 442, 1193, 552, 7596, 1112, 2, 855, 604, 4, 552, 16, 505, 544, 5, 1721, 155, 1716, 10163, 1, 26, 4438, 9192, 2243, 9, 150, 5, 726, 467, 21, 414, 23, 8, 160, 1, 604, 370, 20, 1288, 2173, 1, 562, 7, 54, 103, 1288, 259, 231, 136, 372, 1, 51, 2, 39, 7, 4764, 6, 1048, 753, 34, 199, 156, 459, 1155, 6, 8, 2252, 604, 160, 1103, 17, 1288, 2173, 8464, 98, 6, 91, 1888, 992, 36, 2380, 65, 224, 17, 579, 102, 31, 250, 15533, 128, 231, 539, 604, 2, 10, 195, 651, 50, 1288, 2173, 46, 229, 74, 2069, 972, 1, 102, 31, 2945, 377, 3840, 1, 4968, 17, 1288, 90, 2173, 50, 9192, 359, 47, 8, 2524, 38, 2, 3042, 200, 4, 552]",1140.0,23493782,55
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.,American journal of hematology,Am. J. Hematol.,2013-03-19,"To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non-AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non-AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non-AL is nearly as common. Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis.",Journal Article,2499.0,20.0,To clarify the presentation and course of patients with chronic lymphocytic CLL and amyloidosis Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic Rochester from January 1974 to October 2012 Charts were abstracted and data analyzed Of the 33 patients identified 20 61 were diagnosed with AL and 13 39 with non-AL Only four patients had immunoglobulin light chain amyloidosis AL that could be solely attributed to the CLL clone another six had both a plasma cell clone and a CLL clone that shared the same light chain Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells lymphocytes or both and for patients with non-AL no specific amyloid treatment was administered AL is a rare complication of CLL but in this elderly population of patients non-AL is nearly as common Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 3968, 3, 1031, 2, 906, 1, 7, 5, 442, 1193, 552, 2, 3919, 2486, 2348, 11, 7227, 9, 7, 54, 2629, 8, 147, 1, 3919, 2, 552, 194, 28, 2486, 1188, 5801, 29, 1024, 10201, 6, 2551, 1195, 4413, 11, 4106, 2, 74, 311, 1, 3, 466, 7, 108, 179, 713, 11, 265, 5, 2171, 2, 233, 587, 5, 220, 2171, 158, 294, 7, 42, 2593, 1691, 1260, 3919, 2171, 17, 359, 40, 5558, 3073, 6, 3, 552, 3910, 1809, 437, 42, 110, 8, 554, 31, 3910, 2, 8, 552, 3910, 17, 2664, 3, 827, 1691, 1260, 52, 63, 25, 10, 167, 49, 53, 9, 7, 5, 2171, 2, 717, 14, 53, 9, 7, 5, 220, 2171, 9, 7, 5, 2171, 284, 646, 56, 238, 1317, 848, 554, 37, 1594, 15, 110, 2, 9, 7, 5, 220, 2171, 77, 112, 6655, 24, 10, 468, 2171, 16, 8, 622, 1447, 1, 552, 84, 4, 26, 1216, 266, 1, 7, 220, 2171, 16, 1857, 22, 186, 4508, 59, 46, 100, 271, 16, 1452, 1192, 7, 5, 220, 2171, 3919, 47, 380, 123, 2, 491, 1022, 44, 1353, 759, 56, 6, 943, 136, 3919]",1165.0,23508840,83
The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-B response in chronic lymphocytic leukemia cells.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2013-03-20,"The proteasome consists of chymotrypsin-like (CT-L), trypsin-like, and caspase-like subunits that cleave substrates preferentially by amino acid sequence. Proteasomes mediate degradation of regulatory proteins of the p53, Bcl-2, and nuclear factor-B (NF-B) families that are aberrantly active in chronic lymphocytic leukemia (CLL). CLL remains an incurable disease, and new treatments are especially needed in the relapsed/refractory setting. We therefore investigated the effects of the proteasome inhibitor carfilzomib (CFZ) in CLL cells. Tumor cells from CLL patients were assayed in vitro using immunoblotting, real-time polymerase chain reaction, and electrophoretic mobility shift assays. In addition, a p53 dominant-negative construct was generated in a human B-cell line. Unlike bortezomib, CFZ potently induces apoptosis in CLL patient cells in the presence of human serum. CLL cells have significantly lower basal CT-L activity compared to normal B and T cells, although activity is inhibited similarly in T cells versus CLL. Co-culture of CLL cells on stroma protected from CFZ-mediated cytotoxicity; however, PI3K inhibition significantly diminished this stromal protection. CFZ-mediated cytotoxicity in leukemic B cells is caspase-dependent and occurs irrespective of p53 status. In CLL cells, CFZ promotes atypical activation of NF-B evidenced by loss of cytoplasmic IB, phosphorylation of IB, and increased p50/p65 DNA binding, without subsequent increases in canonical NF-B target gene transcription. Together, these data provide new mechanistic insights into the activity of CFZ in CLL and support phase I investigation of CFZ in this disease.",Journal Article,2498.0,24.0,The proteasome consists of chymotrypsin-like CT-L trypsin-like and caspase-like subunits that cleave substrates preferentially by amino acid sequence Proteasomes mediate degradation of regulatory proteins of the p53 Bcl-2 and nuclear factor-B NF-B families that are aberrantly active in chronic lymphocytic CLL CLL remains an incurable disease and new treatments are especially needed in the relapsed/refractory setting We therefore investigated the effects of the proteasome inhibitor carfilzomib CFZ in CLL cells Tumor cells from CLL patients were assayed in vitro using immunoblotting real-time polymerase chain reaction and electrophoretic mobility shift assays In addition a p53 dominant-negative construct was generated in a human B-cell line Unlike bortezomib CFZ potently induces apoptosis in CLL patient cells in the presence of human serum CLL cells have significantly lower basal CT-L activity compared to normal B and T cells although activity is inhibited similarly in T cells versus CLL Co-culture of CLL cells on stroma protected from CFZ-mediated cytotoxicity however PI3K inhibition significantly diminished this stromal protection CFZ-mediated cytotoxicity in leukemic B cells is caspase-dependent and occurs irrespective of p53 status In CLL cells CFZ promotes atypical activation of NF-B evidenced by loss of cytoplasmic IB phosphorylation of IB and increased p50/p65 DNA binding without subsequent increases in canonical NF-B target gene transcription Together these data provide new mechanistic insights into the activity of CFZ in CLL and support phase I investigation of CFZ in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[3, 1694, 5132, 1, 19118, 733, 425, 805, 15990, 733, 2, 1469, 733, 6166, 17, 23247, 6063, 3509, 20, 3078, 971, 1532, 24715, 3367, 2373, 1, 1253, 652, 1, 3, 624, 1044, 18, 2, 928, 161, 2448, 1365, 2448, 1954, 17, 32, 5619, 544, 4, 442, 1193, 552, 552, 469, 35, 2641, 34, 2, 217, 640, 32, 1093, 575, 4, 3, 591, 430, 546, 21, 673, 565, 3, 176, 1, 3, 1694, 230, 3668, 13427, 4, 552, 37, 30, 37, 29, 552, 7, 11, 4499, 4, 439, 75, 5293, 1589, 98, 1451, 1260, 1329, 2, 10980, 5717, 3024, 1013, 4, 352, 8, 624, 2156, 199, 3883, 10, 1419, 4, 8, 171, 132, 31, 328, 4246, 819, 13427, 4684, 1516, 351, 4, 552, 69, 37, 4, 3, 463, 1, 171, 524, 552, 37, 47, 97, 280, 2135, 425, 805, 128, 72, 6, 295, 132, 2, 102, 37, 242, 128, 16, 879, 1813, 4, 102, 37, 185, 552, 1269, 2099, 1, 552, 37, 23, 2477, 5541, 29, 13427, 517, 1408, 137, 974, 297, 97, 2849, 26, 1126, 3525, 13427, 517, 1408, 4, 2015, 132, 37, 16, 1469, 470, 2, 1780, 3500, 1, 624, 156, 4, 552, 37, 13427, 2148, 1973, 363, 1, 1365, 2448, 4728, 20, 407, 1, 2828, 15032, 982, 1, 15032, 2, 101, 16197, 6781, 261, 791, 187, 706, 1106, 4, 4471, 1365, 2448, 283, 145, 866, 1162, 46, 74, 377, 217, 2716, 1957, 237, 3, 128, 1, 13427, 4, 552, 2, 538, 124, 70, 940, 1, 13427, 4, 26, 34]",1622.0,23515408,378
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.,Leukemia & lymphoma,Leuk. Lymphoma,2013-05-09,"Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic leukemia (CLL). The impact on genomic high-risk disease remains unknown. Cancer and Leukemia Group B (CALGB) 19901 and 10101 enrolled previously untreated patients to receive alemtuzumab consolidation after fludarabine-based induction. Immunoglobulin heavy chain gene (IGVH) mutation status and interphase cytogenetics were assessed retrospectively. Treatment response with these alemtuzumab-containing regimens was similar, regardless of genomic risk, except for patients harboring del(17p), where few complete remissions were observed. Progression-free survival (PFS) was similar between IGVH groups, but overall survival (OS) was inferior in IGVH unmutated patients (p = 0.03). Cytogenetic risk group was associated with PFS and OS (p = 0.01 for both), with similarly short PFS in patients with del(17p) and del(11q) and particularly short OS in patients with del(17p). Cytogenetic risk group remained significantly associated with PFS and OS when controlling for other prognostic factors (PFS: p = 0.009; OS: p = 0.02), as did the negative association of IGVH unmutated disease with OS (p = 0.004). Results were similar when restricting to patients who received at least one dose of alemtuzumab consolidation, demonstrating limited ability to overcome the poor outcome associated with high-risk genetic features.",Journal Article,2448.0,7.0,Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic CLL The impact on genomic high-risk disease remains unknown Cancer and Group B CALGB 19901 and 10101 enrolled previously untreated patients to receive alemtuzumab consolidation after fludarabine-based induction Immunoglobulin heavy chain gene IGVH mutation status and interphase cytogenetics were assessed retrospectively Treatment response with these alemtuzumab-containing regimens was similar regardless of genomic risk except for patients harboring del 17p where few complete remissions were observed Progression-free survival PFS was similar between IGVH groups but overall survival OS was inferior in IGVH unmutated patients p 0.03 Cytogenetic risk group was associated with PFS and OS p 0.01 for both with similarly short PFS in patients with del 17p and del 11q and particularly short OS in patients with del 17p Cytogenetic risk group remained significantly associated with PFS and OS when controlling for other prognostic factors PFS p 0.009 OS p 0.02 as did the negative association of IGVH unmutated disease with OS p 0.004 Results were similar when restricting to patients who received at least one dose of alemtuzumab consolidation demonstrating limited ability to overcome the poor outcome associated with high-risk genetic features,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3579, 2173, 71, 85, 565, 6, 401, 734, 654, 50, 2027, 90, 504, 9, 442, 1193, 552, 3, 345, 23, 572, 64, 43, 34, 469, 860, 12, 2, 87, 132, 4077, 62666, 2, 62667, 346, 373, 1278, 7, 6, 560, 3579, 2173, 50, 2027, 90, 504, 2593, 4013, 1260, 145, 14484, 258, 156, 2, 8081, 2510, 11, 275, 894, 24, 51, 5, 46, 3579, 1101, 472, 10, 288, 1583, 1, 572, 43, 2187, 9, 7, 2105, 3084, 4135, 1257, 1021, 236, 3166, 11, 164, 91, 115, 25, 300, 10, 288, 59, 14484, 271, 84, 63, 25, 118, 10, 1663, 4, 14484, 7216, 7, 19, 13, 680, 1266, 43, 87, 10, 41, 5, 300, 2, 118, 19, 13, 355, 9, 110, 5, 1813, 978, 300, 4, 7, 5, 3084, 4135, 2, 3084, 7203, 2, 823, 978, 118, 4, 7, 5, 3084, 4135, 1266, 43, 87, 958, 97, 41, 5, 300, 2, 118, 198, 1893, 9, 127, 177, 130, 300, 19, 13, 2376, 118, 19, 13, 588, 22, 205, 3, 199, 248, 1, 14484, 7216, 34, 5, 118, 19, 13, 1520, 99, 11, 288, 198, 9998, 6, 7, 54, 103, 28, 506, 104, 61, 1, 3579, 2173, 2219, 383, 801, 6, 1768, 3, 334, 228, 41, 5, 64, 43, 336, 404]",1383.0,23547837,558
Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2013-04-01,"Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically throughout the years. In 1997, rituximab (Rituxan), a CD20 monoclonal antibody (mAb), became the first mAb approved by the Food and Drug Administration for marketing in the treatment of cancer, specifically targeting B-cell malignancies. Over the last 10 years, rituximab or other mAbs including alemtuzumab and ofatumumab have become an integral part of the standard of care for CLL patients as single agents or in combination with chemotherapy or other immunotherapy. This review discusses the currently approved and novel mAbs for the treatment of CLL.",Journal Article,2486.0,11.0,Therapy for chronic lymphocytic CLL has evolved dramatically throughout the years In 1997 rituximab Rituxan a CD20 monoclonal antibody mAb became the first mAb approved by the Food and Drug Administration for marketing in the treatment of cancer specifically targeting B-cell malignancies Over the last 10 years rituximab or other mAbs including alemtuzumab and ofatumumab have become an integral part of the standard of care for CLL patients as single agents or in combination with chemotherapy or other immunotherapy This review discusses the currently approved and novel mAbs for the treatment of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[36, 9, 442, 1193, 552, 71, 3937, 2729, 2432, 3, 60, 4, 2341, 855, 25976, 8, 2198, 848, 548, 2780, 3451, 3, 157, 2780, 850, 20, 3, 1773, 2, 234, 634, 9, 13362, 4, 3, 24, 1, 12, 1225, 529, 132, 31, 441, 252, 3, 1060, 79, 60, 855, 15, 127, 5207, 141, 3579, 2, 5732, 47, 1417, 35, 4450, 760, 1, 3, 260, 1, 165, 9, 552, 7, 22, 226, 183, 15, 4, 150, 5, 56, 15, 127, 726, 26, 206, 2759, 3, 694, 850, 2, 229, 5207, 9, 3, 24, 1, 552]",603.0,23561475,140
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2013-04-01,"Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL. Because adoptive transfer of CAR-modified T cells is a novel approach, there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients. This article reviews the impact of CAR design, T-cell production, T-cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy.",Journal Article,2486.0,11.0,Chimeric antigen receptor CAR -modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic CLL recent results highlight the potential of this therapy for patients with relapsed CLL Because adoptive transfer of CAR-modified T cells is a novel approach there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients This article reviews the impact of CAR design T-cell production T-cell dose conditioning regimens and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2897, 448, 153, 1881, 1230, 102, 37, 529, 3158, 570, 20, 295, 2, 393, 132, 37, 16, 8, 991, 36, 9, 7, 5, 442, 1193, 552, 435, 99, 1817, 3, 174, 1, 26, 36, 9, 7, 5, 591, 552, 408, 3159, 2602, 1, 1881, 1230, 102, 37, 16, 8, 229, 353, 125, 32, 1553, 9, 3, 484, 2709, 6, 2419, 198, 1435, 291, 2, 508, 38, 143, 9, 552, 7, 26, 946, 2004, 3, 345, 1, 1881, 771, 102, 31, 1529, 102, 31, 61, 1933, 472, 2, 30, 892, 28, 3, 98, 1, 1881, 1230, 102, 31, 904, 23, 3, 209, 1, 26, 36]",637.0,23561477,116
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-04-28,"One limitation of reduced-intensity preparative regimens is potential for graft failure. We have developed a regimen that targets CD4(+) lymphodepletion to ensure early and durable engraftment. The primary endpoint was achievement of 50% CD3(+) donor chimerism by day +28. Forty-two patients (median age, 53 years; range, 29 to 73 years) received pentostatin 4 mg/m(2) i.v. on days -28, -21, and -14 when the CD4(+) cell count was >100 cells/L and on days -4 and -3 regardless of CD4(+) level. Rituximab 375 mg/m(2) was administered to patients with CD20(+) malignancies on days -21, -14, -7, +1, and +8. Busulfan 200 mg/m(2) i.v. was administered on days -4 and -2 at a dose to target a cumulative AUC dose of 16,000 (10%) molmin/L. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus plus methotrexate in 86% of patients. Donors were matched-related (47%), matched unrelated (43%), or mismatched unrelated (10%). Chronic lymphocytic leukemia (45%) and follicular non-Hodgkin lymphoma (14%) were the most common diagnoses. Disease status at initiation of the preparative regimen was complete remission in 22%, partial response in 55%, and stable/progression in 24%. The median percent CD4(+) cell count decrease from baseline (day -28) was 52% to day -21, 66% to day -14, 62% to day -7, and 91% to day 0. At day +28, all 42 patients (100%) had 50% CD3(+) donor chimerism. No patient experienced graft failure. Overall response rate was 82% (complete remisson, 67%). The day +100 cumulative incidence of grade II-IV acute GVHD was 59% (grade III-IV acute GVHD, 19%), and the 2 year cumulative incidence of chronic GVHD was 69% (moderate/severe, 58%). Nonrelapse mortality was 2% at day +100 and 17% at 2 years. Two-year PFS was 55%, and OS was 68%. This regimen ensures durable engraftment, is effective against persistent disease, and results in relatively low mortality from causes other than relapse.","Clinical Trial, Phase II",2459.0,9.0,"One limitation of reduced-intensity preparative regimens is potential for graft failure We have developed a regimen that targets CD4 lymphodepletion to ensure early and durable engraftment The primary endpoint was achievement of 50 CD3 donor chimerism by day +28 Forty-two patients median age 53 years range 29 to 73 years received pentostatin 4 mg/m 2 i.v on days -28 -21 and -14 when the CD4 cell count was 100 cells/L and on days -4 and -3 regardless of CD4 level Rituximab 375 mg/m 2 was administered to patients with CD20 malignancies on days -21 -14 -7 +1 and +8 Busulfan 200 mg/m 2 i.v was administered on days -4 and -2 at a dose to target a cumulative AUC dose of 16,000 10 molmin/L Graft-versus-host disease GVHD prophylaxis consisted of tacrolimus plus methotrexate in 86 of patients Donors were matched-related 47 matched unrelated 43 or mismatched unrelated 10 Chronic lymphocytic 45 and follicular 14 were the most common diagnoses Disease status at initiation of the preparative regimen was complete remission in 22 partial response in 55 and stable/progression in 24 The median percent CD4 cell count decrease from baseline day -28 was 52 to day -21 66 to day -14 62 to day -7 and 91 to day 0 At day +28 all 42 patients 100 had 50 CD3 donor chimerism No patient experienced graft failure Overall response rate was 82 complete remisson 67 The day +100 cumulative incidence of grade II-IV acute GVHD was 59 grade III-IV acute GVHD 19 and the 2 year cumulative incidence of chronic GVHD was 69 moderate/severe 58 Nonrelapse mortality was 2 at day +100 and 17 at 2 years Two-year PFS was 55 and OS was 68 This regimen ensures durable engraftment is effective against persistent disease and results in relatively low mortality from causes other than relapse",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[104, 5039, 1, 405, 837, 6085, 472, 16, 174, 9, 1599, 496, 21, 47, 276, 8, 477, 17, 637, 1440, 16876, 6, 3478, 191, 2, 1480, 2881, 3, 86, 1138, 10, 5088, 1, 5660, 3117, 1488, 6047, 20, 218, 339, 1213, 100, 7, 52, 89, 699, 60, 184, 462, 6, 803, 60, 103, 7596, 39, 81, 188, 18, 70, 603, 23, 162, 339, 239, 2, 213, 198, 3, 1440, 31, 1276, 10, 394, 37, 5513, 2, 23, 162, 39, 2, 27, 1583, 1, 1440, 301, 855, 4175, 81, 188, 18, 10, 468, 6, 7, 5, 2198, 441, 23, 162, 239, 213, 67, 14, 2, 66, 3906, 1250, 81, 188, 18, 70, 603, 10, 468, 23, 162, 39, 2, 18, 28, 8, 61, 6, 283, 8, 967, 1376, 61, 1, 245, 984, 26993, 62746, 805, 1599, 185, 1204, 34, 1562, 2049, 1695, 1, 5643, 349, 2116, 4, 868, 1, 7, 2344, 11, 655, 139, 662, 655, 2092, 601, 15, 5095, 2092, 79, 442, 1193, 512, 2, 1974, 213, 11, 3, 96, 186, 2403, 34, 156, 28, 1118, 1, 3, 6085, 477, 10, 236, 734, 4, 350, 450, 51, 4, 614, 2, 585, 91, 4, 259, 3, 52, 714, 1440, 31, 1276, 775, 29, 330, 218, 339, 10, 653, 6, 218, 239, 700, 6, 218, 213, 744, 6, 218, 67, 2, 970, 6, 218, 13, 28, 218, 339, 62, 595, 7, 394, 42, 5660, 3117, 1488, 6047, 77, 69, 592, 1599, 496, 63, 51, 116, 10, 878, 236, 62747, 598, 3, 218, 394, 967, 287, 1, 88, 215, 478, 286, 1562, 10, 728, 88, 316, 478, 286, 1562, 326, 2, 3, 18, 111, 967, 287, 1, 442, 1562, 10, 790, 1163, 905, 717, 4640, 282, 10, 18, 28, 218, 394, 2, 269, 28, 18, 60, 100, 111, 300, 10, 614, 2, 118, 10, 806, 26, 477, 18467, 1480, 2881, 16, 323, 480, 1882, 34, 2, 99, 4, 1352, 154, 282, 29, 1626, 127, 76, 429]",1774.0,23632090,609
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.,Haematologica,Haematologica,2013-05-03,"This study assessed the safety and preliminary efficacy of escalated dose subcutaneous alemtuzumab in combination with rituximab in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly rituximab at 375 mg/m(2) and alemtuzumab doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a rituximab infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80% of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab, and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance. We conclude that escalated subcutaneous doses of alemtuzumab given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).","Clinical Trial, Phase I",2454.0,11.0,This study assessed the safety and preliminary efficacy of escalated dose subcutaneous alemtuzumab in combination with rituximab in chronic lymphocytic Twenty-eight patients with relapsed refractory chronic lymphocytic were treated on four dosing cohorts of weekly rituximab at 375 mg/m 2 and alemtuzumab doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks culminating with 90 mg weekly One dose limiting toxicity of a rituximab infusion reaction was seen in cohort 2 but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort The overall response rate by National Cancer Institute-Working Group criteria was 61 and the rate of complete marrow response was 43 most of whom were negative for minimal residual disease The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic 2008 criteria reduced the overall response rate to 14 Median overall survival was 35 months with 12 patients able to proceed to stem cell transplantation Pharmacokinetic studies showed that chronic lymphocytic involving more than 80 of the marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab and that higher trough serum concentrations of alemtuzumab were associated with complete marrow clearance We conclude that escalated subcutaneous doses of alemtuzumab given weekly are well tolerated and result in excellent marrow clearance of chronic lymphocytic helping patients to proceed to stem cell transplantation This study is registered at ClinicalTrials.gov Identifier:00330252,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 45, 275, 3, 367, 2, 1676, 209, 1, 2842, 61, 2529, 3579, 4, 150, 5, 855, 4, 442, 1193, 737, 659, 7, 5, 591, 430, 442, 1193, 11, 73, 23, 294, 1280, 736, 1, 709, 855, 28, 4175, 81, 188, 18, 2, 3579, 415, 17, 3461, 28, 201, 81, 169, 1072, 379, 647, 2, 2842, 6, 709, 1280, 252, 294, 244, 15305, 5, 424, 81, 709, 104, 61, 817, 155, 1, 8, 855, 904, 1329, 10, 527, 4, 180, 18, 84, 3, 477, 10, 2632, 149, 421, 187, 241, 1, 1777, 155, 20, 180, 3, 63, 51, 116, 20, 657, 12, 1377, 2644, 87, 371, 10, 713, 2, 3, 116, 1, 236, 581, 51, 10, 601, 96, 1, 953, 11, 199, 9, 1048, 753, 34, 3, 352, 1, 425, 1657, 451, 379, 944, 4014, 23, 442, 1193, 1375, 371, 405, 3, 63, 51, 116, 6, 213, 52, 63, 25, 10, 465, 53, 5, 133, 7, 1665, 6, 6174, 6, 452, 31, 497, 1456, 94, 224, 17, 442, 1193, 1267, 80, 76, 493, 1, 3, 581, 28, 45, 2435, 10, 41, 5, 280, 6000, 1003, 1, 3579, 2, 855, 2, 17, 142, 6000, 524, 1003, 1, 3579, 11, 41, 5, 236, 581, 1960, 21, 2060, 17, 2842, 2529, 415, 1, 3579, 447, 709, 32, 149, 421, 2, 757, 4, 1503, 581, 1960, 1, 442, 1193, 7188, 7, 6, 6174, 6, 452, 31, 497, 26, 45, 16, 1653, 28, 1252, 1239, 3719, 62767]",1608.0,23645694,77
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.,The Journal of clinical investigation,J. Clin. Invest.,2013-05-15,"Current strategies to suppress graft-versus-host disease (GVHD) also compromise graft-versus-tumor (GVT) responses. Furthermore, most experimental strategies to separate GVHD and GVT responses merely spare GVT function without actually enhancing it. We have previously shown that endogenously expressed TNF-related apoptosis-inducing ligand (TRAIL) is required for optimal GVT activity against certain malignancies in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In order to model a donor-derived cellular therapy, we genetically engineered T cells to overexpress TRAIL and adoptively transferred donor-type unsorted TRAIL+ T cells into mouse models of allo-HSCT. We found that murine TRAIL+ T cells induced apoptosis of alloreactive T cells, thereby reducing GVHD in a DR5-dependent manner. Furthermore, murine TRAIL+ T cells mediated enhanced in vitro and in vivo antilymphoma GVT response. Moreover, human TRAIL+ T cells mediated enhanced in vitro cytotoxicity against both human leukemia cell lines and against freshly isolated chronic lymphocytic leukemia (CLL) cells. Finally, as a model of off-the-shelf, donor-unrestricted antitumor cellular therapy, in vitro-generated TRAIL+ precursor T cells from third-party donors also mediated enhanced GVT response in the absence of GVHD. These data indicate that TRAIL-overexpressing donor T cells could potentially enhance the curative potential of allo-HSCT by increasing GVT response and suppressing GVHD.",Journal Article,2442.0,17.0,Current strategies to suppress graft-versus-host disease GVHD also compromise graft-versus-tumor GVT responses Furthermore most experimental strategies to separate GVHD and GVT responses merely spare GVT function without actually enhancing it We have previously shown that endogenously expressed TNF-related apoptosis-inducing ligand TRAIL is required for optimal GVT activity against certain malignancies in recipients of allogeneic hematopoietic stem cell transplantation allo-HSCT In order to model a donor-derived cellular therapy we genetically engineered T cells to overexpress TRAIL and adoptively transferred donor-type unsorted TRAIL+ T cells into mouse models of allo-HSCT We found that murine TRAIL+ T cells induced apoptosis of alloreactive T cells thereby reducing GVHD in a DR5-dependent manner Furthermore murine TRAIL+ T cells mediated enhanced in vitro and in vivo antilymphoma GVT response Moreover human TRAIL+ T cells mediated enhanced in vitro cytotoxicity against both human cell lines and against freshly isolated chronic lymphocytic CLL cells Finally as a model of off-the-shelf donor-unrestricted antitumor cellular therapy in vitro-generated TRAIL+ precursor T cells from third-party donors also mediated enhanced GVT response in the absence of GVHD These data indicate that TRAIL-overexpressing donor T cells could potentially enhance the curative potential of allo-HSCT by increasing GVT response and suppressing GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[291, 422, 6, 3134, 1599, 185, 1204, 34, 1562, 120, 4665, 1599, 185, 30, 9677, 253, 798, 96, 1560, 422, 6, 2282, 1562, 2, 9677, 253, 17187, 8539, 9677, 343, 187, 6742, 2430, 192, 21, 47, 373, 443, 17, 11748, 570, 2254, 139, 351, 1958, 1232, 2585, 16, 616, 9, 665, 9677, 128, 480, 1840, 441, 4, 2190, 1, 1063, 1007, 452, 31, 497, 2564, 1703, 4, 1732, 6, 202, 8, 1488, 526, 763, 36, 21, 2301, 2794, 102, 37, 6, 5612, 2585, 2, 8269, 4747, 1488, 267, 26379, 2585, 102, 37, 237, 830, 274, 1, 2564, 1703, 21, 204, 17, 1471, 2585, 102, 37, 277, 351, 1, 13831, 102, 37, 2267, 1818, 1562, 4, 8, 10351, 470, 1708, 798, 1471, 2585, 102, 37, 517, 651, 4, 439, 2, 4, 386, 17818, 9677, 51, 1393, 171, 2585, 102, 37, 517, 651, 4, 439, 1408, 480, 110, 171, 31, 285, 2, 480, 9957, 1355, 442, 1193, 552, 37, 1368, 22, 8, 202, 1, 1889, 3, 26582, 1488, 16806, 579, 763, 36, 4, 439, 1419, 2585, 2765, 102, 37, 29, 1282, 11429, 2344, 120, 517, 651, 9677, 51, 4, 3, 1127, 1, 1562, 46, 74, 1008, 17, 2585, 2810, 1488, 102, 37, 359, 751, 1304, 3, 1075, 174, 1, 2564, 1703, 20, 602, 9677, 51, 2, 4669, 1562]",1445.0,23676461,32
Recent advances in the treatment of non-Hodgkin's lymphomas.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2013-05-01,"Non-Hodgkin's lymphomas (NHL) represent a diverse set of diseases, with different treatment pathways based on the stage and type of hematologic cancer. In their presentation at the NCCN 18th Annual Conference, Dr. Jeremy Abramson and Dr. Andrew D. Zelenetz discuss 3 specific B-cell NHLs: follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. They provided an overview of the treatment strategies for patients with these hematologic malignancies, and offered highlights from recent clinical trials supporting these recommendations.",Journal Article,2456.0,8.0,'s lymphomas NHL represent a diverse set of diseases with different treatment pathways based on the stage and type of hematologic cancer In their presentation at the NCCN 18th Annual Conference Dr. Jeremy Abramson and Dr. Andrew D. Zelenetz discuss 3 specific B-cell NHLs follicular mantle cell and chronic lymphocytic They provided an overview of the treatment strategies for patients with these hematologic malignancies and offered highlights from recent clinical trials supporting these recommendations,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[292, 1557, 1176, 1231, 8, 1867, 916, 1, 1342, 5, 338, 24, 460, 90, 23, 3, 82, 2, 267, 1, 813, 12, 4, 136, 1031, 28, 3, 1944, 29439, 2114, 4180, 3436, 62853, 62854, 2, 3436, 37332, 427, 47760, 1139, 27, 112, 132, 31, 11440, 1974, 2757, 31, 2, 442, 1193, 491, 1052, 35, 2901, 1, 3, 24, 422, 9, 7, 5, 46, 813, 441, 2, 2216, 2527, 29, 435, 38, 143, 1912, 46, 883]",505.0,23704240,644
Individualizing treatment decisions for older adults with hematologic malignancies.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2013-01-01,"Hematologic malignancies are a common cause of morbidity and mortality among older adults, who represent the majority of patients diagnosed with these diseases. Treatment options and disease outcomes have improved in recent years because of the development of novel treatment strategies and the design of elderly-specific clinical trials. Despite this, extrapolation of clinical trial data to patients routinely seen in practice is challenging because of the presence of multimorbidity and functional impairments. Individualized treatment decision making requires not only an understanding of underlying tumor biology but also careful estimation of an older patient's anticipated ability to withstand the stresses of therapy. This article will discuss approaches to standardizing patient assessment strategies and tailoring therapeutic decisions for older adults with hematologic malignancies with a focus on acute myeloid leukemia (AML), allogeneic bone marrow transplantation, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). ",Journal Article,2576.0,6.0,Hematologic malignancies are a common cause of morbidity and mortality among older adults who represent the majority of patients diagnosed with these diseases Treatment options and disease outcomes have improved in recent years because of the development of novel treatment strategies and the design of elderly-specific clinical trials Despite this extrapolation of clinical trial data to patients routinely seen in practice is challenging because of the presence of multimorbidity and functional impairments Individualized treatment decision making requires not only an understanding of underlying tumor biology but also careful estimation of an older patient 's anticipated ability to withstand the stresses of therapy This article will discuss approaches to standardizing patient assessment strategies and tailoring therapeutic decisions for older adults with hematologic malignancies with a focus on acute myeloid AML allogeneic marrow transplantation multiple MM and chronic lymphocytic CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[813, 441, 32, 8, 186, 708, 1, 787, 2, 282, 107, 434, 857, 54, 1231, 3, 686, 1, 7, 265, 5, 46, 1342, 24, 838, 2, 34, 123, 47, 231, 4, 435, 60, 408, 1, 3, 193, 1, 229, 24, 422, 2, 3, 771, 1, 1216, 112, 38, 143, 550, 26, 14115, 1, 38, 160, 74, 6, 7, 3066, 527, 4, 758, 16, 1950, 408, 1, 3, 463, 1, 40379, 2, 583, 6948, 2596, 24, 948, 1079, 1706, 44, 158, 35, 612, 1, 1181, 30, 891, 84, 120, 3465, 4470, 1, 35, 434, 69, 292, 4078, 801, 6, 21330, 3, 11804, 1, 36, 26, 946, 303, 1139, 611, 6, 15343, 69, 455, 422, 2, 7101, 189, 1526, 9, 434, 857, 5, 813, 441, 5, 8, 1222, 23, 286, 533, 329, 1063, 581, 497, 232, 321, 2, 442, 1193, 552]",995.0,23714504,758
Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.,Leukemia & lymphoma,Leuk. Lymphoma,2013-07-01,"Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated neem leaf extract (NLE) after a patient with CLL demonstrated disease regression upon taking oral NLE. NLE-mediated apoptosis was examined in peripheral blood mononuclear cells (PBMCs) from 41 patients with CLL. NLE induced a dose-dependent reduction in CLL cell viability with significant apoptosis observed at 0.06% (w/v) by 24 h. Annexin-V staining and poly(ADP-ribose) polymerase 1 (PARP-1) and caspase 3 cleavage were observed after NLE treatment. However, a pan-caspase inhibitor only partially blocked NLE-mediated cell death. NLE also caused loss of mitochondrial outer membrane permeability and nuclear translocation of apoptosis-inducing factor. Furthermore, NLE treatment resulted in LC3-I cleavage. Biochemical analyses revealed that NLE also inhibits Bcl-2 and p53 proteins. In summary, NLE exhibits anti-leukemic properties in patient primary CLL cells and demonstrates clinical efficacy, warranting further investigation as a potential therapy for CLL.",Journal Article,2395.0,11.0,Chronic lymphocytic CLL is the most common adult and is currently incurable To expand the therapeutic armamentarium we investigated neem leaf extract NLE after a patient with CLL demonstrated disease regression upon taking oral NLE NLE-mediated apoptosis was examined in peripheral blood mononuclear cells PBMCs from 41 patients with CLL NLE induced a dose-dependent reduction in CLL cell viability with significant apoptosis observed at 0.06 w/v by 24 h. Annexin-V staining and poly ADP-ribose polymerase 1 PARP-1 and caspase 3 cleavage were observed after NLE treatment However a pan-caspase inhibitor only partially blocked NLE-mediated cell death NLE also caused loss of mitochondrial outer membrane permeability and nuclear translocation of apoptosis-inducing factor Furthermore NLE treatment resulted in LC3-I cleavage Biochemical analyses revealed that NLE also inhibits Bcl-2 and p53 proteins In summary NLE exhibits anti-leukemic properties in patient primary CLL cells and demonstrates clinical efficacy warranting further investigation as a potential therapy for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 780, 2, 16, 694, 2641, 6, 4082, 3, 189, 5543, 21, 565, 62878, 17976, 7164, 21563, 50, 8, 69, 5, 552, 264, 34, 320, 1548, 2727, 518, 21563, 21563, 517, 351, 10, 409, 4, 672, 315, 3041, 37, 4617, 29, 605, 7, 5, 552, 21563, 277, 8, 61, 470, 628, 4, 552, 31, 2120, 5, 93, 351, 164, 28, 13, 1460, 5444, 603, 20, 259, 555, 4850, 603, 1029, 2, 2699, 3638, 3507, 1451, 14, 2041, 14, 2, 1469, 27, 3155, 11, 164, 50, 21563, 24, 137, 8, 3055, 1469, 230, 158, 2995, 2582, 21563, 517, 31, 273, 21563, 120, 1546, 407, 1, 2019, 7808, 1905, 4757, 2, 928, 2006, 1, 351, 1958, 161, 798, 21563, 24, 627, 4, 7568, 70, 3155, 1487, 318, 553, 17, 21563, 120, 1576, 1044, 18, 2, 624, 652, 4, 1962, 21563, 4273, 312, 2015, 1571, 4, 69, 86, 552, 37, 2, 1902, 38, 209, 7643, 195, 940, 22, 8, 174, 36, 9, 552]",1077.0,23721511,335
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.,Molecular cancer,Mol. Cancer,2013-06-01,"Approximately 1,000 microRNAs (miRs) are present in the human genome; however, little is known about the regulation of miR transcription. Because miR levels are deregulated in chronic lymphocytic leukemia (CLL) and signal transducer and activator of transcription (STAT)-3 is constitutively activated in CLL, we sought to determine whether STAT3 affects the transcription of miR genes in CLL cells. We used publically available data from the ENCODE project to identify putative STAT3 binding sites in the promoters of miR genes. Then we transfected CLL cells with STAT3-shRNA or with an empty vector, and to determine which miRs are differentially expressed, we used a miR microarray approach followed by validation of the microarray results for 6 miRs using quantitative real-time polymerase chain reaction (qRT-PCR). We identified putative STAT3 binding sites in 160 promoter regions of 200 miRs, including miR-21, miR-29, and miR-155, whose levels have been reported to be upregulated in CLL. Levels of 72 miRs were downregulated (n = 63) or upregulated (n = 9). qRT-PCR confirmed the array data in 5 of 6 miRs. The presence of activated STAT3 has a profound effect on miR expression in CLL cells.",Journal Article,2425.0,43.0,"Approximately 1,000 microRNAs miRs are present in the human genome however little is known about the regulation of miR transcription Because miR levels are deregulated in chronic lymphocytic CLL and signal transducer and activator of transcription STAT -3 is constitutively activated in CLL we sought to determine whether STAT3 affects the transcription of miR genes in CLL cells We used publically available data from the ENCODE project to identify putative STAT3 binding sites in the promoters of miR genes Then we transfected CLL cells with STAT3-shRNA or with an empty vector and to determine which miRs are differentially expressed we used a miR microarray approach followed by validation of the microarray results for 6 miRs using quantitative real-time polymerase chain reaction qRT-PCR We identified putative STAT3 binding sites in 160 promoter regions of 200 miRs including miR-21 miR-29 and miR-155 whose levels have been reported to be upregulated in CLL Levels of 72 miRs were downregulated n 63 or upregulated n 9 qRT-PCR confirmed the array data in 5 of 6 miRs The presence of activated STAT3 has a profound effect on miR expression in CLL cells",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[705, 14, 984, 3515, 7569, 32, 364, 4, 3, 171, 898, 137, 1215, 16, 440, 545, 3, 863, 1, 722, 866, 408, 722, 148, 32, 5415, 4, 442, 1193, 552, 2, 1235, 5182, 2, 3393, 1, 866, 4168, 27, 16, 2818, 735, 4, 552, 21, 990, 6, 223, 317, 1439, 2561, 3, 866, 1, 722, 214, 4, 552, 37, 21, 95, 15614, 390, 74, 29, 3, 6924, 3105, 6, 255, 2743, 1439, 791, 633, 4, 3, 4347, 1, 722, 214, 818, 21, 3245, 552, 37, 5, 1439, 3976, 15, 5, 35, 9436, 3374, 2, 6, 223, 92, 7569, 32, 2478, 570, 21, 95, 8, 722, 1727, 353, 370, 20, 929, 1, 3, 1727, 99, 9, 49, 7569, 75, 1156, 1589, 98, 1451, 1260, 1329, 5822, 604, 21, 108, 2743, 1439, 791, 633, 4, 3457, 973, 1374, 1, 1250, 7569, 141, 722, 239, 722, 462, 2, 722, 3735, 1310, 148, 47, 85, 210, 6, 40, 2684, 4, 552, 148, 1, 720, 7569, 11, 3315, 78, 676, 15, 2684, 78, 83, 5822, 604, 557, 3, 1926, 74, 4, 33, 1, 49, 7569, 3, 463, 1, 735, 1439, 71, 8, 4399, 254, 23, 722, 55, 4, 552, 37]",1159.0,23725032,515
Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.,Biomaterials,Biomaterials,2013-05-28,"Despite advances in chemoand immunotherapeutic agents for B chronic lymphocytic leukemia (B-CLL), the undesirable adverse side effects due to non-specific cellular uptake remain to be addressed. We identified anti-CD37 monoclonal antibody immunoliposomes (ILs) as vehicles for targeted delivery to B chronic lymphocytic leukemia cells. To achieve maximal benefits for all patients, a new strategy of dual-ligand immunoliposomes (dILs) was developed. A combinatorial antibody microarray technology was adapted to quickly identify optimal antibody combinations for individual patient cells. For proof-of-concept, a B-cell specific antibody, either anti-CD19 or anti-CD20, was combined with anti-CD37 to construct dILs with enhanced selectivity and efficacy. Consistent with data from the antibody microarray, these dILs provided highly specific targeting to both leukemia cell lines and B-CLL patient cells. Compared with the single antibody ILs, the anti-CD19/CD37 dILs clearly demonstrated superior delivery efficiency and apoptosis induction to B-CLL patient cells, whereas the anti-CD20/anti-CD37 dILs were found to be the most efficient for delivery to leukemia cell lines. In addition, it was observed that anti-CD37 ILs without payload drug mediated effective CD37 cross-linking and induced potent apoptosis induction. The anti-CD19/CD20 dILs showed the improved cell apoptosis induction compared to either anti-CD19 ILs or anti-CD20 ILs. Our findings suggest that the dual-ligand ILs may provide a preferred strategy of personalized nanomedicine for the treatment of B-cell malignancies.",Journal Article,2429.0,29.0,Despite advances in chemo and immunotherapeutic agents for B chronic lymphocytic B-CLL the undesirable adverse side effects due to non-specific cellular uptake remain to be addressed We identified anti-CD37 monoclonal antibody immunoliposomes ILs as vehicles for targeted delivery to B chronic lymphocytic cells To achieve maximal benefits for all patients a new strategy of dual-ligand immunoliposomes dILs was developed A combinatorial antibody microarray technology was adapted to quickly identify optimal antibody combinations for individual patient cells For proof-of-concept a B-cell specific antibody either anti-CD19 or anti-CD20 was combined with anti-CD37 to construct dILs with enhanced selectivity and efficacy Consistent with data from the antibody microarray these dILs provided highly specific targeting to both cell lines and B-CLL patient cells Compared with the single antibody ILs the anti-CD19/CD37 dILs clearly demonstrated superior delivery efficiency and apoptosis induction to B-CLL patient cells whereas the anti-CD20/anti-CD37 dILs were found to be the most efficient for delivery to cell lines In addition it was observed that anti-CD37 ILs without payload drug mediated effective CD37 cross-linking and induced potent apoptosis induction The anti-CD19/CD20 dILs showed the improved cell apoptosis induction compared to either anti-CD19 ILs or anti-CD20 ILs Our findings suggest that the dual-ligand ILs may provide a preferred strategy of personalized nanomedicine for the treatment of B-cell malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 954, 4, 3341, 2, 3222, 183, 9, 132, 442, 1193, 132, 552, 3, 13572, 290, 1152, 176, 520, 6, 220, 112, 763, 1135, 918, 6, 40, 2814, 21, 108, 312, 10006, 848, 548, 31220, 20010, 22, 11327, 9, 238, 989, 6, 132, 442, 1193, 37, 6, 1359, 2725, 1141, 9, 62, 7, 8, 217, 692, 1, 1828, 1232, 31220, 29442, 10, 276, 8, 3866, 548, 1727, 2033, 10, 3716, 6, 7325, 255, 665, 548, 1247, 9, 797, 69, 37, 9, 3840, 1, 2545, 8, 132, 31, 112, 548, 361, 312, 3158, 15, 312, 2198, 10, 397, 5, 312, 10006, 6, 3883, 29442, 5, 651, 6072, 2, 209, 925, 5, 74, 29, 3, 548, 1727, 46, 29442, 1052, 561, 112, 529, 6, 110, 31, 285, 2, 132, 552, 69, 37, 72, 5, 3, 226, 548, 20010, 3, 312, 3158, 10006, 29442, 2536, 264, 1123, 989, 2904, 2, 351, 504, 6, 132, 552, 69, 37, 547, 3, 312, 2198, 312, 10006, 29442, 11, 204, 6, 40, 3, 96, 2547, 9, 989, 6, 31, 285, 4, 352, 192, 10, 164, 17, 312, 10006, 20010, 187, 14619, 234, 517, 323, 10006, 1383, 5806, 2, 277, 1157, 351, 504, 3, 312, 3158, 2198, 29442, 224, 3, 231, 31, 351, 504, 72, 6, 361, 312, 3158, 20010, 15, 312, 2198, 20010, 114, 272, 309, 17, 3, 1828, 1232, 20010, 68, 377, 8, 2514, 692, 1, 2175, 11221, 9, 3, 24, 1, 132, 31, 441]",1533.0,23726226,326
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2013-06-08,"This analysis examined associations between gender and health-related quality of life (HRQOL) in patients with B-cell chronic lymphocytic leukemia (CLL) as they initiate therapy for CLL outside the clinical trial setting. Baseline data were collected as part of Connect CLL Registry, a prospective observational study initiated in community, academic, and government centers. Patient demographics and clinical characteristics were provided by clinicians. Patients reported HRQOL using the Brief Fatigue Inventory (BFI), EQ-5D, and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Mean scores were analyzed, with statistical significance of differences determined by ANOVA. Multivariate analysis also considered age and line of therapy. Baseline HRQOL data were available for 1,140 patients: 710 (62 %) men and 430 (38 %) women from 161 centers. Patients were predominantly white (89 %) with mean age 6911 years. Women reported significantly worse global fatigue (P <0.0001), fatigue severity (P <0.0001), and fatigue-related interference (P=0.0005) versus men (BFI). Pain/discomfort (P=0.0077), usual activities (P=0.0015), and anxiety/depression (P=0.0117) were significantly worse in women than in men (EQ-5D). With women reporting a better social/family score (P=0.0238) and men reporting a better physical score (P=0.0002), the mean FACT-G total score did not differ by gender. However, the mean FACT-Leu total score was better among men versus women (P=0.0223), primarily because the mean leukemia subscale score was significantly better among men (P <0.0001). Multivariate analysis qualitatively confirmed these findings. Connect CLL Registry results indicate that significant differences exist in certain HRQOL domains, as women reported greater levels of fatigue and worse functioning in physical domains.",Journal Article,2418.0,16.0,"This analysis examined associations between gender and health-related quality of life HRQOL in patients with B-cell chronic lymphocytic CLL as they initiate therapy for CLL outside the clinical trial setting Baseline data were collected as part of Connect CLL Registry a prospective observational study initiated in community academic and government centers Patient demographics and clinical characteristics were provided by clinicians Patients reported HRQOL using the Brief Fatigue Inventory BFI EQ-5D and Functional Assessment of Cancer Therapy-Leukemia FACT-Leu Mean scores were analyzed with statistical significance of differences determined by ANOVA Multivariate analysis also considered age and line of therapy Baseline HRQOL data were available for 1,140 patients 710 62 men and 430 38 women from 161 centers Patients were predominantly white 89 with mean age 69  11 years Women reported significantly worse global fatigue P 0.0001 fatigue severity P 0.0001 and fatigue-related interference P 0.0005 versus men BFI Pain/discomfort P 0.0077 usual activities P 0.0015 and anxiety/depression P 0.0117 were significantly worse in women than in men EQ-5D With women reporting a better social/family score P 0.0238 and men reporting a better physical score P 0.0002 the mean FACT-G total score did not differ by gender However the mean FACT-Leu total score was better among men versus women P 0.0223 primarily because the mean subscale score was significantly better among men P 0.0001 Multivariate analysis qualitatively confirmed these findings Connect CLL Registry results indicate that significant differences exist in certain HRQOL domains as women reported greater levels of fatigue and worse functioning in physical domains",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 65, 409, 685, 59, 1632, 2, 341, 139, 372, 1, 358, 2534, 4, 7, 5, 132, 31, 442, 1193, 552, 22, 491, 4565, 36, 9, 552, 2513, 3, 38, 160, 546, 330, 74, 11, 786, 22, 760, 1, 47777, 552, 1608, 8, 482, 2495, 45, 1917, 4, 1714, 1916, 2, 7608, 1168, 69, 2221, 2, 38, 374, 11, 1052, 20, 1490, 7, 210, 2534, 75, 3, 3190, 613, 3818, 13173, 6646, 6556, 2, 583, 455, 1, 12, 36, 2647, 1991, 11539, 313, 703, 11, 311, 5, 1050, 724, 1, 362, 509, 20, 9008, 331, 65, 120, 515, 89, 2, 328, 1, 36, 330, 2534, 74, 11, 390, 9, 14, 3304, 7, 9232, 744, 325, 2, 10083, 519, 117, 29, 5377, 1168, 7, 11, 2117, 886, 887, 5, 313, 89, 790, 810, 175, 60, 117, 210, 97, 639, 1648, 613, 19, 13, 488, 613, 1702, 19, 13, 488, 2, 613, 139, 3182, 19, 13, 4252, 185, 325, 13173, 559, 7381, 19, 13, 18176, 3521, 2042, 19, 13, 9490, 2, 2021, 1774, 19, 13, 39605, 11, 97, 639, 4, 117, 76, 4, 325, 6646, 6556, 5, 117, 1760, 8, 380, 2032, 607, 368, 19, 13, 62904, 2, 325, 1760, 8, 380, 900, 368, 19, 13, 3531, 3, 313, 1991, 499, 181, 368, 205, 44, 1505, 20, 1632, 137, 3, 313, 1991, 11539, 181, 368, 10, 380, 107, 325, 185, 117, 19, 13, 47778, 1561, 408, 3, 313, 5593, 368, 10, 97, 380, 107, 325, 19, 13, 488, 331, 65, 8040, 557, 46, 272, 47777, 552, 1608, 99, 1008, 17, 93, 362, 1923, 4, 1840, 2534, 2703, 22, 117, 210, 378, 148, 1, 613, 2, 639, 2702, 4, 900, 2703]",1736.0,23748484,327
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.,Nature genetics,Nat. Genet.,2013-06-16,"Genome-wide association studies (GWAS) have previously identified 13 loci associated with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL). To identify additional CLL susceptibility loci, we conducted the largest meta-analysis for CLL thus far, including four GWAS with a total of 3,100 individuals with CLL (cases) and 7,667 controls. In the meta-analysis, we identified ten independent associated SNPs in nine new loci at 10q23.31 (ACTA2 or FAS (ACTA2/FAS), P=1.2210(-14)), 18q21.33 (BCL2, P=7.7610(-11)), 11p15.5 (C11orf21, P=2.1510(-10)), 4q25 (LEF1, P=4.2410(-10)), 2q33.1 (CASP10 or CASP8 (CASP10/CASP8), P=2.5010(-9)), 9p21.3 (CDKN2B-AS1, P=1.2710(-8)), 18q21.32 (PMAIP1, P=2.5110(-8)), 15q15.1 (BMF, P=2.7110(-10)) and 2p22.2 (QPCT, P=1.6810(-8)), as well as an independent signal at an established locus (2q13, ACOXL, P=2.0810(-18)). We also found evidence for two additional promising loci below genome-wide significance at 8q22.3 (ODF1, P=5.4010(-8)) and 5p15.33 (TERT, P=1.9210(-7)). Although further studies are required, the proximity of several of these loci to genes involved in apoptosis suggests a plausible underlying biological mechanism.",Journal Article,2410.0,118.0,"Genome-wide association studies GWAS have previously identified 13 loci associated with risk of chronic lymphocytic or small lymphocytic CLL To identify additional CLL susceptibility loci we conducted the largest meta-analysis for CLL thus far including four GWAS with a total of 3,100 individuals with CLL cases and 7,667 controls In the meta-analysis we identified ten independent associated SNPs in nine new loci at 10q23.31 ACTA2 or FAS ACTA2/FAS P=1.2210 -14 18q21.33 BCL2 P=7.7610 -11 11p15.5 C11orf21 P=2.1510 -10 4q25 LEF1 P=4.2410 -10 2q33.1 CASP10 or CASP8 CASP10/CASP8 P=2.5010 -9 9p21.3 CDKN2B-AS1 P=1.2710 -8 18q21.32 PMAIP1 P=2.5110 -8 15q15.1 BMF P=2.7110 -10 and 2p22.2 QPCT P=1.6810 -8 as well as an independent signal at an established locus 2q13 ACOXL P=2.0810 -18 We also found evidence for two additional promising loci below genome-wide significance at 8q22.3 ODF1 P=5.4010 -8 and 5p15.33 TERT P=1.9210 -7 Although further studies are required the proximity of several of these loci to genes involved in apoptosis suggests a plausible underlying biological mechanism",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[898, 1019, 248, 94, 3297, 47, 373, 108, 233, 2012, 41, 5, 43, 1, 442, 1193, 15, 302, 1193, 552, 6, 255, 402, 552, 1432, 2012, 21, 426, 3, 2166, 1742, 65, 9, 552, 631, 3272, 141, 294, 3297, 5, 8, 181, 1, 27, 394, 869, 5, 552, 140, 2, 67, 10598, 535, 4, 3, 1742, 65, 21, 108, 1618, 306, 41, 1109, 4, 762, 217, 2012, 28, 13783, 456, 47793, 15, 3625, 47793, 3625, 19, 14, 47794, 213, 17605, 466, 3214, 19, 67, 40392, 175, 12074, 33, 62929, 19, 18, 62930, 79, 62931, 12009, 19, 39, 62932, 79, 27145, 14, 17416, 15, 9212, 17416, 9212, 19, 18, 40393, 83, 9016, 27, 12634, 11718, 19, 14, 62933, 66, 17605, 531, 47795, 19, 18, 47796, 66, 35444, 14, 13680, 19, 18, 62934, 79, 2, 62935, 18, 62936, 19, 14, 62937, 66, 22, 149, 22, 35, 306, 1235, 28, 35, 635, 2474, 32135, 62938, 19, 18, 62939, 203, 21, 120, 204, 241, 9, 100, 402, 721, 2012, 2736, 898, 1019, 724, 28, 42858, 27, 62940, 19, 33, 62941, 66, 2, 11591, 466, 3846, 19, 14, 40394, 67, 242, 195, 94, 32, 616, 3, 6167, 1, 392, 1, 46, 2012, 6, 214, 646, 4, 351, 844, 8, 7761, 1181, 1037, 670]",1100.0,23770605,225
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-06-15,"The discovery that purine nucleoside phosphorylase (PNP) deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias. Forodesine is an orally bioavailable PNP inhibitor with picomolar potency. Because T lymphoblasts and indolent chronic lymphocytic leukemia (CLL) B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate (dGTP), forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic leukemia (T-ALL) and B-cell CLL (B-CLL). However, the use of forodesine in B-cell ALL (B-ALL) is unknown. Leukemic blasts obtained from pediatric patients with de novo B-ALL (n= 10) were incubated with forodesine and deoxyguanosine (dGuo), and the biological end points of apoptosis, intracellular dGTP accumulation, and inhibition of RNA and DNA synthesis were measured. Additionally, adult patients with B-ALL (n= 2) were intravenously infused with 80 mg/m(2)/d dailyfor 5 days. After therapy, clinical response, toxicity, laboratory biomarkers including PNP enzyme inhibition, and plasma forodesine, dGuo, and intracellular dGTP levels were analyzed. Our invitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts. There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis. During therapy, neither patient achieved a complete response (CR), but there was disease stabilization for several weeks in both patients. There was significant maintained inhibition of PNP enzyme in red blood cells, accumulation of forodesine and dGuo in plasma, and intracellular dGTP accumulation in both patients. Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL. However, it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale.","Clinical Trial, Phase I",2411.0,8.0,The discovery that purine nucleoside phosphorylase PNP deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias Forodesine is an orally bioavailable PNP inhibitor with picomolar potency Because T lymphoblasts and indolent chronic lymphocytic CLL B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate dGTP forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic T-ALL and B-cell CLL B-CLL However the use of forodesine in B-cell ALL B-ALL is unknown Leukemic blasts obtained from pediatric patients with de novo B-ALL n 10 were incubated with forodesine and deoxyguanosine dGuo and the biological end points of apoptosis intracellular dGTP accumulation and inhibition of RNA and DNA synthesis were measured Additionally adult patients with B-ALL n 2 were intravenously infused with 80 mg/m 2 /d daily for 5 days After therapy clinical response toxicity laboratory biomarkers including PNP enzyme inhibition and plasma forodesine dGuo and intracellular dGTP levels were analyzed Our in vitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis During therapy neither patient achieved a complete response CR but there was disease stabilization for several weeks in both patients There was significant maintained inhibition of PNP enzyme in red blood cells accumulation of forodesine and dGuo in plasma and intracellular dGTP accumulation in both patients Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL However it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 1574, 17, 5006, 4032, 10658, 13133, 2299, 1940, 6, 102, 31, 3655, 10, 3, 877, 9, 11165, 13133, 222, 9, 102, 31, 2792, 10483, 16, 35, 1428, 6582, 13133, 230, 5, 28450, 3593, 408, 102, 10521, 2, 2316, 442, 1193, 552, 132, 37, 11183, 5487, 913, 1159, 6, 7859, 17863, 7345, 16319, 10483, 264, 721, 128, 4, 693, 2, 38, 1947, 9, 7, 5, 102, 31, 286, 1275, 102, 62, 2, 132, 31, 552, 132, 552, 137, 3, 119, 1, 10483, 4, 132, 31, 62, 132, 62, 16, 860, 2015, 2438, 683, 29, 815, 7, 5, 1566, 2018, 132, 62, 78, 79, 11, 8303, 5, 10483, 2, 17863, 17864, 2, 3, 1037, 396, 862, 1, 351, 2087, 16319, 1835, 2, 297, 1, 893, 2, 261, 2525, 11, 644, 1724, 780, 7, 5, 132, 62, 78, 18, 11, 1672, 4524, 5, 493, 81, 188, 18, 427, 391, 9, 33, 162, 50, 36, 38, 51, 155, 1624, 582, 141, 13133, 1644, 297, 2, 554, 10483, 17864, 2, 2087, 16319, 148, 11, 311, 114, 4, 439, 2492, 264, 17, 10483, 24, 879, 457, 2, 277, 1721, 351, 4, 1566, 2018, 132, 62, 10521, 125, 10, 98, 470, 1835, 1, 16319, 2, 297, 1, 893, 2, 261, 2525, 190, 36, 2174, 69, 513, 8, 236, 51, 684, 84, 125, 10, 34, 3184, 9, 392, 244, 4, 110, 7, 125, 10, 93, 1955, 297, 1, 13133, 1644, 4, 3422, 315, 37, 1835, 1, 10483, 2, 17864, 4, 554, 2, 2087, 16319, 1835, 4, 110, 7, 114, 693, 2, 38, 2492, 309, 17, 10483, 71, 128, 4, 132, 62, 137, 192, 1891, 6, 40, 361, 4524, 5, 17864, 15, 397, 5, 635, 1573, 183, 90, 23, 2716, 1728]",1902.0,23773454,508
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2013-06-19,"The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).","Clinical Trial, Phase I",2407.0,,The treatment of relapsed chronic lymphocytic CLL has resulted in few durable remissions Bruton 's tyrosine kinase BTK an essential component of B-cell-receptor signaling mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells We conducted a phase 1b-2 multicenter study to assess the safety efficacy pharmacokinetics and pharmacodynamics of ibrutinib PCI-32765 a first-in-class oral covalent inhibitor of BTK designed for treatment of B-cell cancers in patients with relapsed or refractory CLL or small lymphocytic A total of 85 patients the majority of whom were considered to have high-risk disease received ibrutinib orally once daily 51 received 420 mg and 34 received 840 mg Toxic effects were predominantly grade 1 or 2 and included transient diarrhea fatigue and upper respiratory tract infection thus patients could receive extended treatment with minimal hematologic toxic effects The overall response rate was the same in the group that received 420 mg and the group that received 840 mg 71 and an additional 20 and 15 of patients in the respective groups had a partial response with lymphocytosis The response was independent of clinical and genomic risk factors present before treatment including advanced-stage disease the number of previous therapies and the 17p13.1 deletion At 26 months the estimated progression-free survival rate was 75 and the rate of overall survival was 83 Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic including patients with high-risk genetic lesions Funded by Pharmacyclics and others ClinicalTrials.gov number NCT01105247,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 24, 1, 591, 442, 1193, 552, 71, 627, 4, 1021, 1480, 3166, 5796, 292, 564, 216, 3611, 35, 1452, 1249, 1, 132, 31, 153, 314, 3961, 1286, 5, 3, 30, 995, 2, 2148, 3, 25, 2, 457, 1, 552, 37, 21, 426, 8, 124, 4693, 18, 1570, 45, 6, 423, 3, 367, 209, 1159, 2, 3587, 1, 1795, 3943, 12229, 8, 157, 4, 1040, 518, 10747, 230, 1, 3611, 1114, 9, 24, 1, 132, 31, 163, 4, 7, 5, 591, 15, 430, 552, 15, 302, 1193, 8, 181, 1, 772, 7, 3, 686, 1, 953, 11, 515, 6, 47, 64, 43, 34, 103, 1795, 1428, 1059, 391, 725, 103, 5401, 81, 2, 562, 103, 10752, 81, 1812, 176, 11, 2117, 88, 14, 15, 18, 2, 159, 2473, 1172, 613, 2, 1726, 2718, 1696, 930, 631, 7, 359, 560, 1747, 24, 5, 1048, 813, 1812, 176, 3, 63, 51, 116, 10, 3, 827, 4, 3, 87, 17, 103, 5401, 81, 2, 3, 87, 17, 103, 10752, 81, 792, 2, 35, 402, 179, 2, 167, 1, 7, 4, 3, 3847, 271, 42, 8, 450, 51, 5, 8125, 3, 51, 10, 306, 1, 38, 2, 572, 43, 130, 364, 348, 24, 141, 131, 82, 34, 3, 207, 1, 698, 235, 2, 3, 7526, 14, 1528, 28, 432, 53, 3, 661, 91, 115, 25, 116, 10, 481, 2, 3, 116, 1, 63, 25, 10, 852, 1795, 10, 41, 5, 8, 64, 675, 1, 1480, 3166, 4, 7, 5, 591, 15, 430, 552, 2, 302, 1193, 141, 7, 5, 64, 43, 336, 406, 3827, 20, 20013, 2, 1749, 1252, 1239, 207, 27296]",1708.0,23782158,518
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-18,"Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies. Little is known about the safety of HSCT in patients age 70 or older. Consecutive patients (n = 54) age 70 or older underwent HSCT between 2007 and 2012. Diseases included acute myelogenous leukemia (n = 25), myelodysplastic syndrome (n = 12), chronic lymphocytic leukemia (n = 5), non-Hodgkin lymphoma (n = 4), acute lymphoblastic leukemia (n = 3), myeloproliferative neoplasm (n = 4), and chronic myelogenous leukemia (n = 1). Median follow-up for survivors was 21 months. All patients received reduced-intensity conditioning regimens, primarily busulfan/fludarabine. All patients received unmanipulated peripheral blood stem cell grafts: 44 from 8/8 matched unrelated donors, 8 from matched related donors, and 2 from 7/8 matched unrelated donors. Graft-versus-host disease (GVHD) prophylaxis was calcineurin inhibitor-based in all patients. The median age at transplantation was 71 years (range, 70 to 76); the median HCT comorbidity index score was 1 (range, 0 to 5). Two patients died before hematopoietic recovery (1 with graft failure and 1 with disease progression), and 1 patient relapsed before hematopoietic recovery; otherwise, all engrafted with median donor chimerism of 94% at 1 month. Cumulative incidence of grades II to IV acute GVHD was 13% and of grades III to IV acute GVHD, 9.3%. At 2 years, the cumulative incidence of chronic GVHD was 36%, progression-free survival was 39%, overall survival was 39%, and relapse was 56%. Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older.",Journal Article,2408.0,46.0,Allogeneic hematopoietic stem cell transplantation HSCT can achieve durable remissions in a number of patients with advanced hematologic malignancies Little is known about the safety of HSCT in patients age 70 or older Consecutive patients n 54 age 70 or older underwent HSCT between 2007 and 2012 Diseases included acute myelogenous n 25 syndrome n 12 chronic lymphocytic n 5 n 4 acute lymphoblastic n 3 neoplasm n 4 and chronic myelogenous n 1 Median follow-up for survivors was 21 months All patients received reduced-intensity conditioning regimens primarily busulfan/fludarabine All patients received unmanipulated peripheral blood stem cell grafts 44 from 8/8 matched unrelated donors 8 from matched related donors and 2 from 7/8 matched unrelated donors Graft-versus-host disease GVHD prophylaxis was calcineurin inhibitor-based in all patients The median age at transplantation was 71 years range 70 to 76 the median HCT comorbidity index score was 1 range 0 to 5 Two patients died before hematopoietic recovery 1 with graft failure and 1 with disease progression and 1 patient relapsed before hematopoietic recovery otherwise all engrafted with median donor chimerism of 94 at 1 month Cumulative incidence of grades II to IV acute GVHD was 13 and of grades III to IV acute GVHD 9.3 At 2 years the cumulative incidence of chronic GVHD was 36 progression-free survival was 39 overall survival was 39 and relapse was 56 Nonrelapse mortality was 3.7 at day +100 and 5.6 at 2 years We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1703, 122, 1359, 1480, 3166, 4, 8, 207, 1, 7, 5, 131, 813, 441, 1215, 16, 440, 545, 3, 367, 1, 1703, 4, 7, 89, 431, 15, 434, 935, 7, 78, 667, 89, 431, 15, 434, 208, 1703, 59, 1307, 2, 1195, 1342, 159, 286, 2194, 78, 243, 681, 78, 133, 442, 1193, 78, 33, 78, 39, 286, 1275, 78, 27, 2131, 78, 39, 2, 442, 2194, 78, 14, 52, 166, 126, 9, 332, 10, 239, 53, 62, 7, 103, 405, 837, 1933, 472, 1561, 3906, 2027, 62, 7, 103, 14413, 672, 315, 452, 31, 4713, 584, 29, 66, 66, 655, 2092, 2344, 66, 29, 655, 139, 2344, 2, 18, 29, 67, 66, 655, 2092, 2344, 1599, 185, 1204, 34, 1562, 2049, 10, 12028, 230, 90, 4, 62, 7, 3, 52, 89, 28, 497, 10, 792, 60, 184, 431, 6, 846, 3, 52, 1085, 1879, 558, 368, 10, 14, 184, 13, 6, 33, 100, 7, 1016, 348, 1007, 1602, 14, 5, 1599, 496, 2, 14, 5, 34, 91, 2, 14, 69, 591, 348, 1007, 1602, 2632, 62, 6914, 5, 52, 1488, 6047, 1, 960, 28, 14, 811, 967, 287, 1, 2276, 215, 6, 478, 286, 1562, 10, 233, 2, 1, 2276, 316, 6, 478, 286, 1562, 83, 27, 28, 18, 60, 3, 967, 287, 1, 442, 1562, 10, 511, 91, 115, 25, 10, 587, 63, 25, 10, 587, 2, 429, 10, 664, 4640, 282, 10, 27, 67, 28, 218, 394, 2, 33, 49, 28, 18, 60, 21, 2060, 17, 1063, 1703, 16, 8, 1165, 2, 323, 1501, 9, 3900, 715, 7, 89, 431, 15, 434]",1597.0,23791626,685
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.,Blood,Blood,2013-06-25,"We evaluated long-term outcomes of 60 patients with chronic lymphocytic leukemia treated with an initial therapy of lenalidomide. At a median follow-up of 4 years, time-to-treatment failure has not been reached and overall survival is 82%. Thirty-five (58%) patients had a response lasting >36 months (long-term responders [LTRs]). Best LTR responses consisted of 25 (71%) complete remissions and 10 (29%) partial remissions. In addition to clinical responses, an increase in IgA, IgG, and IgM levels of >50% from baseline was reported in 61%, 45%, and 42% of LTRs. Normalization in the percentage of CD4+ and CD8+ cells and T-cell numbers was observed in 48%, 71% and 99% of LTRs. Compared with other patients in the study, LTRs had lower baseline plasma levels of -2-microglobulin, were more likely to have trisomy 12, and less likely to have deletion 17p.","Clinical Trial, Phase II",2401.0,56.0,We evaluated long-term outcomes of 60 patients with chronic lymphocytic treated with an initial therapy of lenalidomide At a median follow-up of 4 years time-to-treatment failure has not been reached and overall survival is 82 Thirty-five 58 patients had a response lasting 36 months long-term responders LTRs Best LTR responses consisted of 25 71 complete remissions and 10 29 partial remissions In addition to clinical responses an increase in IgA IgG and IgM levels of 50 from baseline was reported in 61 45 and 42 of LTRs Normalization in the percentage of CD4+ and CD8+ cells and T-cell numbers was observed in 48 71 and 99 of LTRs Compared with other patients in the study LTRs had lower baseline plasma levels of -2-microglobulin were more likely to have trisomy 12 and less likely to have deletion 17p,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 319, 337, 123, 1, 335, 7, 5, 442, 1193, 73, 5, 35, 388, 36, 1, 1288, 28, 8, 52, 166, 126, 1, 39, 60, 98, 6, 24, 496, 71, 44, 85, 1300, 2, 63, 25, 16, 878, 977, 365, 717, 7, 42, 8, 51, 3443, 511, 53, 319, 337, 1983, 19174, 824, 44211, 253, 1695, 1, 243, 792, 236, 3166, 2, 79, 462, 450, 3166, 4, 352, 6, 38, 253, 35, 344, 4, 9368, 3630, 2, 2852, 148, 1, 212, 29, 330, 10, 210, 4, 713, 512, 2, 595, 1, 19174, 5924, 4, 3, 1150, 1, 1440, 2, 968, 37, 2, 102, 31, 1870, 10, 164, 4, 576, 792, 2, 1058, 1, 19174, 72, 5, 127, 7, 4, 3, 45, 19174, 42, 280, 330, 554, 148, 1, 1458, 18, 5371, 11, 80, 322, 6, 47, 6317, 133, 2, 299, 322, 6, 47, 1528, 4135]",810.0,23801633,527
"Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.",Leukemia & lymphoma,Leuk. Lymphoma,2013-07-29,"Fludarabine, cyclophosphamide and rituximab (FCR), the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia (CLL), is associated with a high rate of neutropenia and infectious complications. Granulocyte macrophage colony-stimulating factor (GM-CSF) reduces myelosuppression and can potentiate rituximab activity. We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60 patients with CLL. Eighty-six percent completed all six courses and 18% discontinued GM-CSF for toxicity: grade 3-4 neutropenia was observed in 30% of cycles, and severe infections in 16% of cases. The overall response rate was 100%. Both median event-free survival (EFS) and overall survival (OS) have not been reached. Longer EFS was associated with favorable cytogenetics. GM-CSF led to a lower frequency of infectious complications than in the historical FCR group, albeit similar EFS and OS.",Clinical Trial,2367.0,6.0,Fludarabine cyclophosphamide and rituximab FCR the standard of care for the frontline treatment of patients with chronic lymphocytic CLL is associated with a high rate of neutropenia and infectious complications Granulocyte macrophage colony-stimulating factor GM-CSF reduces myelosuppression and can potentiate rituximab activity We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60 patients with CLL Eighty-six percent completed all six courses and 18 discontinued GM-CSF for toxicity grade 3-4 neutropenia was observed in 30 of cycles and severe infections in 16 of cases The overall response rate was 100 Both median event-free survival EFS and overall survival OS have not been reached Longer EFS was associated with favorable cytogenetics GM-CSF led to a lower frequency of infectious complications than in the historical FCR group albeit similar EFS and OS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 1112, 2, 855, 4953, 3, 260, 1, 165, 9, 3, 3171, 24, 1, 7, 5, 442, 1193, 552, 16, 41, 5, 8, 64, 116, 1, 778, 2, 3398, 521, 2764, 2674, 1975, 2122, 161, 2147, 1211, 2389, 2858, 2, 122, 6428, 855, 128, 21, 426, 8, 38, 160, 1525, 2147, 1211, 5, 4953, 9, 3171, 24, 1, 335, 7, 5, 552, 2207, 437, 714, 781, 62, 437, 1993, 2, 203, 2402, 2147, 1211, 9, 155, 88, 27, 39, 778, 10, 164, 4, 201, 1, 410, 2, 905, 1875, 4, 245, 1, 140, 3, 63, 51, 116, 10, 394, 110, 52, 774, 115, 25, 1683, 2, 63, 25, 118, 47, 44, 85, 1300, 589, 1683, 10, 41, 5, 913, 2510, 2147, 1211, 836, 6, 8, 280, 675, 1, 3398, 521, 76, 4, 3, 2252, 4953, 87, 5993, 288, 1683, 2, 118]",896.0,23808813,623
"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-06-27,"To improve outcomes of patients with Richter syndrome (RS) and relapsed/refractory chronic lymphocytic leukemia (CLL), we modified the OFAR1 regimen (oxaliplatin and cytarabine doses of the oxaliplatin, fludarabine, cytarabine, and rituximab) for this phase I-II study (OFAR2). OFAR2 consisted of oxaliplatin at 30 mg/m(2) on days 1 to 4, fludarabine at 30 mg/m(2), cytarabine at 0.5 g/m(2), rituximab at 375 mg/m(2) on day 3, and pegfilgrastim at 6 mg on day 6. Fludarabine and cytarabine were given on days 2 and 3 (cohort 1), days 2 to 4 (cohort 2), or days 2 to 5 (cohort 3) every 4 weeks. Phase II followed the ""3 + 3"" design of phase I. The 102 patients (CLL, 67; RS, 35) treated had heavily pretreated high-risk disease. Twelve patients were treated in phase I; cohort 2 was the phase II recommended dose. The most common toxicities were hematologic. Response rates (phase II) were 38.7% for RS (complete response [CR], 6.5%) and 50.8% for relapsed/refractory CLL (CR, 4.6%). The median survival durations were 6.6 (RS) and 20.6 (CLL) months. Among 9 patients who underwent allogeneic stem cell transplantation (SCT) as post-remission therapy, none has died (median follow-up, 15.9 months). OFAR2 had significant antileukemic activity in RS and relapsed/refractory CLL. Patients undergoing SCT as post-remission therapy had favorable outcomes.","Clinical Trial, Phase I",2399.0,41.0,To improve outcomes of patients with Richter syndrome RS and relapsed/refractory chronic lymphocytic CLL we modified the OFAR1 regimen oxaliplatin and cytarabine doses of the oxaliplatin fludarabine cytarabine and rituximab for this phase I-II study OFAR2 OFAR2 consisted of oxaliplatin at 30 mg/m 2 on days 1 to 4 fludarabine at 30 mg/m 2 cytarabine at 0.5 g/m 2 rituximab at 375 mg/m 2 on day 3 and pegfilgrastim at 6 mg on day 6 Fludarabine and cytarabine were given on days 2 and 3 cohort 1 days 2 to 4 cohort 2 or days 2 to 5 cohort 3 every 4 weeks Phase II followed the `` 3 3 '' design of phase I The 102 patients CLL 67 RS 35 treated had heavily pretreated high-risk disease Twelve patients were treated in phase I cohort 2 was the phase II recommended dose The most common toxicities were hematologic Response rates phase II were 38.7 for RS complete response CR 6.5 and 50.8 for relapsed/refractory CLL CR 4.6 The median survival durations were 6.6 RS and 20.6 CLL months Among 9 patients who underwent allogeneic stem cell transplantation SCT as post-remission therapy none has died median follow-up 15.9 months OFAR2 had significant antileukemic activity in RS and relapsed/refractory CLL Patients undergoing SCT as post-remission therapy had favorable outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 401, 123, 1, 7, 5, 8452, 681, 2250, 2, 591, 430, 442, 1193, 552, 21, 1230, 3, 63002, 477, 1476, 2, 1855, 415, 1, 3, 1476, 2027, 1855, 2, 855, 9, 26, 124, 70, 215, 45, 40408, 40408, 1695, 1, 1476, 28, 201, 81, 188, 18, 23, 162, 14, 6, 39, 2027, 28, 201, 81, 188, 18, 1855, 28, 13, 33, 499, 188, 18, 855, 28, 4175, 81, 188, 18, 23, 218, 27, 2, 6005, 28, 49, 81, 23, 218, 49, 2027, 2, 1855, 11, 447, 23, 162, 18, 2, 27, 180, 14, 162, 18, 6, 39, 180, 18, 15, 162, 18, 6, 33, 180, 27, 454, 39, 244, 124, 215, 370, 3, 27, 27, 522, 771, 1, 124, 70, 3, 2867, 7, 552, 598, 2250, 465, 73, 42, 2447, 2193, 64, 43, 34, 2544, 7, 11, 73, 4, 124, 70, 180, 18, 10, 3, 124, 215, 793, 61, 3, 96, 186, 385, 11, 813, 51, 151, 124, 215, 11, 519, 67, 9, 2250, 236, 51, 684, 49, 33, 2, 212, 66, 9, 591, 430, 552, 684, 39, 49, 3, 52, 25, 4864, 11, 49, 49, 2250, 2, 179, 49, 552, 53, 107, 83, 7, 54, 208, 1063, 452, 31, 497, 1988, 22, 539, 734, 36, 1292, 71, 1016, 52, 166, 126, 167, 83, 53, 40408, 42, 93, 4512, 128, 4, 2250, 2, 591, 430, 552, 7, 479, 1988, 22, 539, 734, 36, 42, 913, 123]",1273.0,23810245,6
Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-25,"Allogeneic hematopoietic cell transplantation (alloHCT) is a curative therapy for hematologic disorders including acute lymphoblastic and myeloid leukemia, chronic lymphocytic and myeloid leukemia, Hodgkin's and non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndrome. To determine the utilization of alloHCT from unrelated donors (URDs) in the United States, we calculated the number of patients diagnosed with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance, Epidemiology and End Results and 2007 US Census data, estimated the percentage of patients who would be eligible for URD alloHCT after discounting the mortality rate during induction therapy and the rate of severe comorbidities, and compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program. We found that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11% for multiple myeloma to 54% for chronic myeloid leukemia, with an average percentage of 26% for all the disorders considered. In an analysis stratified by age groups (20 to 44, 45 to 64, and 65 to 74 years), the utilization of URD alloHCT was higher in younger patients than in older patients for all disorders. Of acute lymphoblastic and myeloid leukemia patients, approximately 66% underwent URD alloHCT later in the course of their disease (in second or greater complete remission). URD alloHCT is likely underused for potentially curable hematologic disorders, particularly in older patients. Understanding the reasons for low use of alloHCT may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders. ",Journal Article,2401.0,15.0,Allogeneic hematopoietic cell transplantation alloHCT is a curative therapy for hematologic disorders including acute lymphoblastic and myeloid chronic lymphocytic and myeloid 's and multiple and syndrome To determine the utilization of alloHCT from unrelated donors URDs in the United States we calculated the number of patients diagnosed with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance Epidemiology and End Results and 2007 US Census data estimated the percentage of patients who would be eligible for URD alloHCT after discounting the mortality rate during induction therapy and the rate of severe comorbidities and compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program We found that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11 for multiple to 54 for chronic myeloid with an average percentage of 26 for all the disorders considered In an analysis stratified by age groups 20 to 44 45 to 64 and 65 to 74 years the utilization of URD alloHCT was higher in younger patients than in older patients for all disorders Of acute lymphoblastic and myeloid patients approximately 66 underwent URD alloHCT later in the course of their disease in second or greater complete remission URD alloHCT is likely underused for potentially curable hematologic disorders particularly in older patients Understanding the reasons for low use of alloHCT may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 31, 497, 5514, 16, 8, 1075, 36, 9, 813, 1997, 141, 286, 1275, 2, 533, 442, 1193, 2, 533, 292, 2, 232, 2, 681, 6, 223, 3, 1961, 1, 5514, 29, 2092, 2344, 15979, 4, 3, 1088, 907, 21, 981, 3, 207, 1, 7, 265, 5, 813, 1997, 89, 179, 6, 794, 60, 90, 23, 1131, 6, 1375, 617, 1284, 2, 396, 99, 2, 1307, 843, 7319, 74, 661, 3, 1150, 1, 7, 54, 688, 40, 625, 9, 5847, 5514, 50, 34483, 3, 282, 116, 190, 504, 36, 2, 3, 116, 1, 905, 1909, 2, 72, 46, 5, 3, 3480, 1307, 63006, 4667, 20, 3, 657, 581, 1488, 1243, 21, 204, 17, 3, 207, 1, 5847, 5514, 22, 8, 1150, 1, 3, 661, 174, 6779, 1869, 29, 175, 9, 232, 6, 667, 9, 442, 533, 5, 35, 1011, 1150, 1, 432, 9, 62, 3, 1997, 515, 4, 35, 65, 1173, 20, 89, 271, 179, 6, 584, 512, 6, 660, 2, 556, 6, 794, 60, 3, 1961, 1, 5847, 5514, 10, 142, 4, 773, 7, 76, 4, 434, 7, 9, 62, 1997, 1, 286, 1275, 2, 533, 7, 705, 700, 208, 5847, 5514, 1559, 4, 3, 906, 1, 136, 34, 4, 419, 15, 378, 236, 734, 5847, 5514, 16, 322, 11166, 9, 751, 4151, 813, 1997, 823, 4, 434, 7, 612, 3, 2325, 9, 154, 119, 1, 5514, 68, 1122, 6, 422, 6, 4082, 3, 119, 1, 26, 1075, 36, 9, 80, 7, 5, 813, 1997]",1574.0,23811537,625
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.,"Cancer immunology, immunotherapy : CII",Cancer Immunol. Immunother.,2013-06-28,"CXCR5 [chemokine (C-X-C motif) receptor 5; also known as Burkitt lymphoma receptor 1 (BCR1)] is expressed on mature B-cells, subsets of CD4+ and CD8+ T-cells, and skin-derived migratory dendritic cells. Together with its ligand, CXCL13, CXCR5 is involved in guiding B-cells into the B-cell zones of secondary lymphoid organs as well as T-cell migration. This study evaluated the role of common germline genetic variation in CXCR5 in the risk and prognosis of non-Hodgkin lymphoma (NHL) using a clinic-based study of 1,521 controls and 2,694 NHL cases including 710 chronic lymphocytic leukemia/small lymphocytic lymphoma, 586 diffuse large B-cell lymphoma (DLBCL), 588 follicular lymphoma (FL), 137 mantle cell lymphoma (MCL), 230 marginal zone lymphoma (MZL), and 158 peripheral T-cell lymphoma (PTCL). Of the ten CXCR5 tag SNPs in our study, five were associated with risk of NHL, with rs1790192 having the strongest association (OR 1.19, 95% CI 1.08-1.30; p = 0.0003). This SNP was most strongly associated with the risk of FL (OR 1.44, 95 % CI 1.25-1.66; p = 3.1  10(-7)), with a lower degree of association with DLBCL (OR 1.16, 95% CI 1.01-1.33; p = 0.04) and PTCL (OR 1.29, 95 % CI 1.02-1.64; p = 0.04) but no association with the risk of MCL or MZL. For FL patients that were observed as initial disease management, the number of minor alleles of rs1790192 was associated with better event-free survival (HR 0.64; 95% CI 0.47-0.87; p = 0.004). These results provide additional evidence for a role of host genetic variation in CXCR5 in lymphomagenesis, particularly for FL.",Journal Article,2398.0,17.0,"CXCR5 chemokine C-X-C motif receptor 5 also known as receptor 1 BCR1 is expressed on mature B-cells subsets of CD4+ and CD8+ T-cells and skin-derived migratory dendritic cells Together with its ligand CXCL13 CXCR5 is involved in guiding B-cells into the B-cell zones of secondary lymphoid organs as well as T-cell migration This study evaluated the role of common germline genetic variation in CXCR5 in the risk and prognosis of NHL using a clinic-based study of 1,521 controls and 2,694 NHL cases including 710 chronic lymphocytic leukemia/small lymphocytic 586 diffuse large B-cell DLBCL 588 follicular FL 137 mantle cell MCL 230 marginal zone MZL and 158 peripheral T-cell PTCL Of the ten CXCR5 tag SNPs in our study five were associated with risk of NHL with rs1790192 having the strongest association OR 1.19 95 CI 1.08-1.30 p 0.0003 This SNP was most strongly associated with the risk of FL OR 1.44 95 CI 1.25-1.66 p 3.1 10 -7 with a lower degree of association with DLBCL OR 1.16 95 CI 1.01-1.33 p 0.04 and PTCL OR 1.29 95 CI 1.02-1.64 p 0.04 but no association with the risk of MCL or MZL For FL patients that were observed as initial disease management the number of minor alleles of rs1790192 was associated with better event-free survival HR 0.64 95 CI 0.47-0.87 p 0.004 These results provide additional evidence for a role of host genetic variation in CXCR5 in lymphomagenesis particularly for FL",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[13280, 3596, 256, 1006, 256, 5298, 153, 33, 120, 440, 22, 153, 14, 47825, 16, 570, 23, 2908, 132, 37, 1890, 1, 1440, 2, 968, 102, 37, 2, 6290, 526, 7757, 2464, 37, 1162, 5, 211, 1232, 9462, 13280, 16, 646, 4, 5972, 132, 37, 237, 3, 132, 31, 13814, 1, 568, 2303, 2285, 22, 149, 22, 102, 31, 1381, 26, 45, 194, 3, 200, 1, 186, 1009, 336, 1380, 4, 13280, 4, 3, 43, 2, 356, 1, 1176, 75, 8, 1188, 90, 45, 1, 14, 11925, 535, 2, 18, 15172, 1176, 140, 141, 9232, 442, 1193, 2647, 302, 1193, 14128, 1388, 375, 132, 31, 1446, 14064, 1974, 2633, 4352, 2757, 31, 1308, 6136, 3450, 3614, 8277, 2, 5162, 672, 102, 31, 3973, 1, 3, 1618, 13280, 7479, 1109, 4, 114, 45, 365, 11, 41, 5, 43, 1, 1176, 5, 47826, 1041, 3, 3311, 248, 15, 14, 326, 48, 58, 14, 1592, 14, 201, 19, 13, 4418, 26, 1845, 10, 96, 1327, 41, 5, 3, 43, 1, 2633, 15, 14, 584, 48, 58, 14, 243, 14, 700, 19, 27, 14, 79, 67, 5, 8, 280, 1444, 1, 248, 5, 1446, 15, 14, 245, 48, 58, 14, 355, 14, 466, 19, 13, 755, 2, 3973, 15, 14, 462, 48, 58, 14, 588, 14, 660, 19, 13, 755, 84, 77, 248, 5, 3, 43, 1, 1308, 15, 8277, 9, 2633, 7, 17, 11, 164, 22, 388, 34, 284, 3, 207, 1, 2278, 2558, 1, 47826, 10, 41, 5, 380, 774, 115, 25, 168, 13, 660, 48, 58, 13, 662, 13, 912, 19, 13, 1520, 46, 99, 377, 402, 241, 9, 8, 200, 1, 1204, 336, 1380, 4, 13280, 4, 12366, 823, 9, 2633]",1408.0,23812490,359
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.,Blood,Blood,2013-07-02,"Noncoding RNAs play a pivotal role in the pathogenesis of chronic lymphocytic leukemia (CLL). We hypothesized that microRNAs (miRs) are involved in the transition from monoclonal B-cell lymphocytosis (MBL) to CLL and tested miR-15a/16-1 cluster, miR-21, and miR-155 expression in purified B cells of normal individuals, individuals with MBL, and patients with CLL. When we analyzed 224 samples from 2 independent training and validation cohorts, we found that miR-155 was overexpressed in B cells from individuals with MBL, and even more so in B cells from patients with CLL, when compared with B cells from normal individuals. Furthermore, we were able to identify miR-155 in circulating microvesicles from both individuals with MBL and patients with CLL. Next, to examine the prognostic role of miR-155, we measured its expression level in plasma samples collected before treatment initiation in 228 patients with CLL. We found significantly higher miR-155 expression levels in patients who failed to achieve a complete response compared with those who experienced complete response. Our findings support the use of cellular and plasma levels of miR-155 as biomarkers for the risk of progression in individuals with MBL, as well as to identify patients with CLL who may not respond well to therapy. ",Journal Article,2394.0,122.0,Noncoding RNAs play a pivotal role in the pathogenesis of chronic lymphocytic CLL We hypothesized that microRNAs miRs are involved in the transition from monoclonal B-cell lymphocytosis MBL to CLL and tested miR-15a/16-1 cluster miR-21 and miR-155 expression in purified B cells of normal individuals individuals with MBL and patients with CLL When we analyzed 224 samples from 2 independent training and validation cohorts we found that miR-155 was overexpressed in B cells from individuals with MBL and even more so in B cells from patients with CLL when compared with B cells from normal individuals Furthermore we were able to identify miR-155 in circulating microvesicles from both individuals with MBL and patients with CLL Next to examine the prognostic role of miR-155 we measured its expression level in plasma samples collected before treatment initiation in 228 patients with CLL We found significantly higher miR-155 expression levels in patients who failed to achieve a complete response compared with those who experienced complete response Our findings support the use of cellular and plasma levels of miR-155 as biomarkers for the risk of progression in individuals with MBL as well as to identify patients with CLL who may not respond well to therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6420, 4550, 1343, 8, 3754, 200, 4, 3, 1384, 1, 442, 1193, 552, 21, 1237, 17, 3515, 7569, 32, 646, 4, 3, 1970, 29, 848, 132, 31, 8125, 8992, 6, 552, 2, 650, 722, 15377, 245, 14, 3132, 722, 239, 2, 722, 3735, 55, 4, 5963, 132, 37, 1, 295, 869, 869, 5, 8992, 2, 7, 5, 552, 198, 21, 311, 5908, 347, 29, 18, 306, 1741, 2, 929, 736, 21, 204, 17, 722, 3735, 10, 1711, 4, 132, 37, 29, 869, 5, 8992, 2, 871, 80, 1743, 4, 132, 37, 29, 7, 5, 552, 198, 72, 5, 132, 37, 29, 295, 869, 798, 21, 11, 1665, 6, 255, 722, 3735, 4, 1033, 25307, 29, 110, 869, 5, 8992, 2, 7, 5, 552, 1305, 6, 1004, 3, 177, 200, 1, 722, 3735, 21, 644, 211, 55, 301, 4, 554, 347, 786, 348, 24, 1118, 4, 6736, 7, 5, 552, 21, 204, 97, 142, 722, 3735, 55, 148, 4, 7, 54, 1551, 6, 1359, 8, 236, 51, 72, 5, 135, 54, 592, 236, 51, 114, 272, 538, 3, 119, 1, 763, 2, 554, 148, 1, 722, 3735, 22, 582, 9, 3, 43, 1, 91, 4, 869, 5, 8992, 22, 149, 22, 6, 255, 7, 5, 552, 54, 68, 44, 1892, 149, 6, 36]",1267.0,23821659,121
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2013-09-10,"Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. High levels of Bcl-2 family anti-apoptotic proteins are responsible for apoptosis resistance. Besides anti-apoptotic proteins, the microenvironment provides substantial survival signals to CLL leukemic cells. However, in-depth knowledge on the role of individual Bcl-2 family members in the context of the microenvironment is still limited. We performed a comprehensive analysis of transcripts and proteins of 18 Bcl-2 family members using an ""apoptosis array microfluidic card"" in primary cells before and after stromal co-cultures. Our data showed that five of six anti-apoptotic members (excluding Bcl-b), two of three pro-apoptotic members (excluding Bok) and six of nine BH3-only members were present at detectable mRNA levels in CLL cells. Importantly, stromal-mediated extended survival of CLL cells was strongly associated with elevated global transcription. Upon co-culturing with stromal cells, there was an early response of an increase in anti- (2/5) and pro-apoptotic protein (3/8) transcripts on day 1, while an increase in anti-apoptotic proteins was observed on day 3, with no significant change in pro-apoptotic proteins. Our study revealed a differential pattern of expression of both transcripts and proteins following stromal co-cultures, proposing a significance of Bcl-2 family members in the stromal microenvironment.",Journal Article,2324.0,14.0,Chronic lymphocytic CLL is the most common form of adult in the Western world High levels of Bcl-2 family anti-apoptotic proteins are responsible for apoptosis resistance Besides anti-apoptotic proteins the microenvironment provides substantial survival signals to CLL leukemic cells However in-depth knowledge on the role of individual Bcl-2 family members in the context of the microenvironment is still limited We performed a comprehensive analysis of transcripts and proteins of 18 Bcl-2 family members using an `` apoptosis array microfluidic card '' in primary cells before and after stromal co-cultures Our data showed that five of six anti-apoptotic members excluding Bcl-b two of three pro-apoptotic members excluding Bok and six of nine BH3-only members were present at detectable mRNA levels in CLL cells Importantly stromal-mediated extended survival of CLL cells was strongly associated with elevated global transcription Upon co-culturing with stromal cells there was an early response of an increase in anti- 2/5 and pro-apoptotic protein 3/8 transcripts on day 1 while an increase in anti-apoptotic proteins was observed on day 3 with no significant change in pro-apoptotic proteins Our study revealed a differential pattern of expression of both transcripts and proteins following stromal co-cultures proposing a significance of Bcl-2 family members in the stromal microenvironment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 1297, 1, 780, 4, 3, 1521, 1956, 64, 148, 1, 1044, 18, 607, 312, 1631, 652, 32, 2327, 9, 351, 251, 7301, 312, 1631, 652, 3, 995, 777, 1281, 25, 2312, 6, 552, 2015, 37, 137, 4, 2436, 922, 23, 3, 200, 1, 797, 1044, 18, 607, 1684, 4, 3, 1533, 1, 3, 995, 16, 1234, 383, 21, 173, 8, 949, 65, 1, 2680, 2, 652, 1, 203, 1044, 18, 607, 1684, 75, 35, 351, 1926, 9401, 20683, 522, 4, 86, 37, 348, 2, 50, 1126, 1269, 3231, 114, 74, 224, 17, 365, 1, 437, 312, 1631, 1684, 3207, 1044, 132, 100, 1, 169, 1805, 1631, 1684, 3207, 63053, 2, 437, 1, 762, 5486, 158, 1684, 11, 364, 28, 2083, 956, 148, 4, 552, 37, 1859, 1126, 517, 1747, 25, 1, 552, 37, 10, 1327, 41, 5, 804, 1648, 866, 1548, 1269, 16316, 5, 1126, 37, 125, 10, 35, 191, 51, 1, 35, 344, 4, 312, 18, 33, 2, 1805, 1631, 178, 27, 66, 2680, 23, 218, 14, 369, 35, 344, 4, 312, 1631, 652, 10, 164, 23, 218, 27, 5, 77, 93, 707, 4, 1805, 1631, 652, 114, 45, 553, 8, 1777, 1177, 1, 55, 1, 110, 2680, 2, 652, 366, 1126, 1269, 3231, 16204, 8, 724, 1, 1044, 18, 607, 1684, 4, 3, 1126, 995]",1398.0,23837491,435
"Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.",Leukemia research,Leuk. Res.,2013-07-15,"Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-nave, high-risk patients received escalating doses of CAR therapy. Dose limiting toxicity was not experienced. No instances of TLS were observed. Patient responses included three complete remissions and four partial remissions. CAR was tolerable and active in high-risk CLL patients without TLS toxicity. With continued monitoring of toxicities, a phase Ib/II study of this combination as frontline therapy is warranted. ","Clinical Trial, Phase I",2381.0,16.0,Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic CLL patients In this phase I study we combined cyclophosphamide alvocidib and rituximab CAR in a schema designed to mitigate tumor lysis syndrome TLS seen previously with alvocidib Nine nucleoside analog-nave high-risk patients received escalating doses of CAR therapy Dose limiting toxicity was not experienced No instances of TLS were observed Patient responses included three complete remissions and four partial remissions CAR was tolerable and active in high-risk CLL patients without TLS toxicity With continued monitoring of toxicities a phase Ib/II study of this combination as frontline therapy is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[14030, 71, 264, 209, 4, 64, 43, 442, 1193, 552, 7, 4, 26, 124, 70, 45, 21, 397, 1112, 14030, 2, 855, 1881, 4, 8, 8371, 1114, 6, 5626, 30, 4783, 681, 8778, 527, 373, 5, 14030, 762, 4032, 3497, 2809, 64, 43, 7, 103, 2922, 415, 1, 1881, 36, 61, 817, 155, 10, 44, 592, 77, 5342, 1, 8778, 11, 164, 69, 253, 159, 169, 236, 3166, 2, 294, 450, 3166, 1881, 10, 2668, 2, 544, 4, 64, 43, 552, 7, 187, 8778, 155, 5, 1351, 1315, 1, 385, 8, 124, 3180, 215, 45, 1, 26, 150, 22, 3171, 36, 16, 1197]",686.0,23867058,299
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-08-01,"A major conclusion drawn from the accumulated cytogenetic data on solid tumors and some hematologic malignancies is that tumors progress by the acquisition of chromosomal changes, as reflected by more aggressive tumors containing a larger number of chromosomal abnormalities. An additional observation is that some chromosomal changes appear early in the disease progression, and some others appear late. On the basis of this information, a model for karyotypic evolution in chronic lymphocytic leukemia (CLL) is presented. The Mitelman Database of Chromosomes in Cancer was searched, and 1749 abnormal karyotypes were assessed. The main clones were analyzed, and chromosomal gains and losses were used to design a model of genetic acquisition based on the calculation of a variable called time to occurrence (TO). Our comprehensive study of genetic abnormalities in a large number of CLL karyotypes revealed that most CLL has 2 chromosomal aberrations at diagnosis. Moreover, the temporal analysis suggests that trisomy 12 is an early event in the biological evolution of CLL. These results highlight the possibility of targeted therapies affecting the genes located on this chromosome (cyclin D, cyclin D2, cyclin-dependent kinase 2, and cyclin-dependent kinase 4).",Journal Article,2364.0,1.0,A major conclusion drawn from the accumulated cytogenetic data on solid tumors and some hematologic malignancies is that tumors progress by the acquisition of chromosomal changes as reflected by more aggressive tumors containing a larger number of chromosomal abnormalities An additional observation is that some chromosomal changes appear early in the disease progression and some others appear late On the basis of this information a model for karyotypic evolution in chronic lymphocytic CLL is presented The Mitelman Database of Chromosomes in Cancer was searched and 1749 abnormal karyotypes were assessed The main clones were analyzed and chromosomal gains and losses were used to design a model of genetic acquisition based on the calculation of a variable called time to occurrence TO Our comprehensive study of genetic abnormalities in a large number of CLL karyotypes revealed that most CLL has 2 chromosomal aberrations at diagnosis Moreover the temporal analysis suggests that trisomy 12 is an early event in the biological evolution of CLL These results highlight the possibility of targeted therapies affecting the genes located on this chromosome cyclin D cyclin D2 cyclin-dependent kinase 2 and cyclin-dependent kinase 4,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 458, 1221, 5694, 29, 3, 6664, 1266, 74, 23, 537, 57, 2, 476, 813, 441, 16, 17, 57, 1466, 20, 3, 3405, 1, 1860, 400, 22, 4686, 20, 80, 571, 57, 1101, 8, 1077, 207, 1, 1860, 1171, 35, 402, 1664, 16, 17, 476, 1860, 400, 1322, 191, 4, 3, 34, 91, 2, 476, 1749, 1322, 807, 23, 3, 877, 1, 26, 487, 8, 202, 9, 9465, 2554, 4, 442, 1193, 552, 16, 917, 3, 63105, 609, 1, 3560, 4, 12, 10, 3080, 2, 43099, 1668, 6809, 11, 275, 3, 1895, 2749, 11, 311, 2, 1860, 3849, 2, 5324, 11, 95, 6, 771, 8, 202, 1, 336, 3405, 90, 23, 3, 6333, 1, 8, 1347, 3472, 98, 6, 2291, 6, 114, 949, 45, 1, 336, 1171, 4, 8, 375, 207, 1, 552, 6809, 553, 17, 96, 552, 71, 18, 1860, 2152, 28, 147, 1393, 3, 3264, 65, 844, 17, 6317, 133, 16, 35, 191, 774, 4, 3, 1037, 2554, 1, 552, 46, 99, 1817, 3, 2526, 1, 238, 235, 2319, 3, 214, 2308, 23, 26, 1170, 1226, 427, 1226, 4171, 1226, 470, 216, 18, 2, 1226, 470, 216, 39]",1235.0,23876845,34
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.,mAbs,MAbs,2013-06-07,"TRU-016 is a SMIP(TM) (monospecific protein therapeutic) molecule against the tetraspanin transmembrane family protein CD37 that is currently in Phase 2 trials in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). In an attempt to enhance the ADCC function of SMIP-016, the chimeric version of TRU-016, SMIP-016(GV) was engineered with a modification in a glycosylation site in the Fc domain. The wild-type and glycovariant SMIP proteins mediate comparable Type I antibody-like direct cytotoxicity in the presence of anti-human Fc crosslinker and show a similar tyrosine phosphorylation pattern post-treatment. However, NK cells stimulated with the SMIP-016(GV) exhibit enhanced activation and release 3-fold more interferon- compared with SMIP-016. SMIP-016(GV) shows enhanced ADCC function against cells expressing CD37 with NK cell effectors derived from both normal and CLL-affected individuals. Enhanced ADCC is observed against CLL cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) g/mL on cells expressing minimal CD37 antigen. In support of the biological relevance of this, SMIP-016(GV) mediates effective ADCC against primary acute lymphoblastic leukemia (ALL) cells with low surface expression of CD37. Collectively, these data suggest potential use of the novel therapeutic agent SMIP-016(GV) with enhanced effector function for B cell malignancies, including CLL and ALL therapy. ",Journal Article,2419.0,7.0,TRU-016 is a SMIP TM monospecific protein therapeutic molecule against the tetraspanin transmembrane family protein CD37 that is currently in Phase 2 trials in Chronic Lymphocytic CLL and NHL In an attempt to enhance the ADCC function of SMIP-016 the chimeric version of TRU-016 SMIP-016 GV was engineered with a modification in a glycosylation site in the Fc domain The wild-type and glycovariant SMIP proteins mediate comparable Type I antibody-like direct cytotoxicity in the presence of anti-human Fc crosslinker and show a similar tyrosine phosphorylation pattern post-treatment However NK cells stimulated with the SMIP-016 GV exhibit enhanced activation and release 3-fold more interferon- compared with SMIP-016 SMIP-016 GV shows enhanced ADCC function against cells expressing CD37 with NK cell effectors derived from both normal and CLL-affected individuals Enhanced ADCC is observed against CLL cells and is sustained at concentrations of SMIP-016 GV as low at 5E -6 g/mL on cells expressing minimal CD37 antigen In support of the biological relevance of this SMIP-016 GV mediates effective ADCC against primary acute lymphoblastic ALL cells with low surface expression of CD37 Collectively these data suggest potential use of the novel therapeutic agent SMIP-016 GV with enhanced effector function for B cell malignancies including CLL and ALL therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[23092, 3820, 16, 8, 18502, 6547, 63125, 178, 189, 1354, 480, 3, 22598, 5527, 607, 178, 10006, 17, 16, 694, 4, 124, 18, 143, 4, 442, 1193, 552, 2, 1176, 4, 35, 3448, 6, 1304, 3, 5551, 343, 1, 18502, 3820, 3, 2897, 2256, 1, 23092, 3820, 18502, 3820, 17398, 10, 2794, 5, 8, 2437, 4, 8, 9520, 606, 4, 3, 4127, 1398, 3, 955, 267, 2, 63126, 18502, 652, 3367, 1279, 267, 70, 548, 733, 1196, 1408, 4, 3, 463, 1, 312, 171, 4127, 63127, 2, 514, 8, 288, 564, 982, 1177, 539, 24, 137, 1765, 37, 2816, 5, 3, 18502, 3820, 17398, 2239, 651, 363, 2, 2008, 27, 1116, 80, 1688, 2655, 72, 5, 18502, 3820, 18502, 3820, 17398, 1949, 651, 5551, 343, 480, 37, 1046, 10006, 5, 1765, 31, 4926, 526, 29, 110, 295, 2, 552, 1424, 869, 651, 5551, 16, 164, 480, 552, 37, 2, 16, 2275, 28, 1003, 1, 18502, 3820, 17398, 22, 154, 28, 47667, 49, 7570, 542, 23, 37, 1046, 1048, 10006, 448, 4, 538, 1, 3, 1037, 2088, 1, 26, 18502, 3820, 17398, 3961, 323, 5551, 480, 86, 286, 1275, 62, 37, 5, 154, 1255, 55, 1, 10006, 2535, 46, 74, 309, 174, 119, 1, 3, 229, 189, 420, 18502, 3820, 17398, 5, 651, 2070, 343, 9, 132, 31, 441, 141, 552, 2, 62, 36]",1365.0,23883821,529
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.,Blood,Blood,2013-07-25,"Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749. ",Clinical Trial,2371.0,352.0,Given its critical role in T-cell signaling interleukin-2-inducible kinase ITK is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious autoimmune and neoplastic diseases Ablation of ITK subverts Th2 immunity thereby potentiating Th1-based immune responses While small-molecule ITK inhibitors have been identified none have demonstrated clinical utility Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase BTK with outstanding clinical activity and tolerability in B-cell malignancies Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib Using ibrutinib clinical trial samples along with well-characterized neoplastic chronic lymphocytic parasitic infection Leishmania major and infectious disease Listeria monocytogenes models we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility This trial was registered at www.clinicaltrials.gov as NCT01105247 and NCT01217749,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[447, 211, 740, 200, 4, 102, 31, 314, 1603, 18, 2877, 216, 15430, 16, 35, 9458, 189, 283, 17, 122, 1248, 6, 3, 1384, 1, 1840, 3398, 3445, 2, 2000, 1342, 1650, 1, 15430, 42885, 8358, 1604, 2267, 13001, 4714, 90, 250, 253, 369, 302, 1354, 15430, 222, 47, 85, 108, 1292, 47, 264, 38, 1207, 1795, 16, 8, 557, 4422, 230, 1, 5796, 564, 216, 3611, 5, 14565, 38, 128, 2, 1543, 4, 132, 31, 441, 93, 7984, 59, 3611, 2, 15430, 10150, 4, 6648, 12593, 94, 538, 1795, 22, 35, 2555, 230, 1, 110, 15430, 2, 3611, 114, 949, 219, 2, 3290, 65, 5120, 15430, 22, 35, 4422, 102, 31, 283, 1, 1795, 75, 1795, 38, 160, 347, 1510, 5, 149, 765, 2000, 442, 1193, 21463, 930, 47859, 458, 2, 3398, 34, 14582, 16023, 274, 21, 1811, 1795, 22, 8, 505, 867, 2, 9634, 1157, 15430, 230, 5, 2094, 189, 1207, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 27296, 2, 35626]",1198.0,23886836,489
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.,Investigational new drugs,Invest New Drugs,2013-07-26,"Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models. This Phase I study was undertaken to define the toxicity and the maximum tolerated doses (MTD) of the combination in patients with advanced solid tumors. Patients with cytologic or histologic proof of unresectable solid tumors were treated with escalating doses of sorafenib (twice daily) and bortezomib (days 1, 4, 8 and 11 intravenously) with 21-day cycles. Fourteen patients (7 males, median age 65, range 24-74), with renal (3), lung (3), pancreas (2), and breast, adrenal gland, melanoma, spindle cell tumor, chronic lymphocytic leukemia and multiple myeloma (1 each) were enrolled. All patients are off treatment, 10 due to disease progression. DLT was seen in two patients (one grade 3 abdominal pain and grade 4 lipase elevation; one with grade 3 vomiting) at sorafenib 200 mg twice daily and bortezomib 1.3 mg/m(2), establishing the MTD. No grade 4 hematologic or grade 5 toxicities were seen. One patient with renal cell cancer had a partial response and 5 patients attained stable disease. The combination of sorafenib and bortezomib was tolerated well. The recommended phase 2 doses are sorafenib 200 mg twice daily continuously with bortezomib 1 mg/m(2) on days 1, 4, 8, 11 (21 day cycles). The combination shows preliminary signs of efficacy, supporting phase 2 studies.","Clinical Trial, Phase I",2370.0,9.0,Sorafenib a VEGFR and multi-targeted kinase inhibitor and Bortezomib a proteasome inhibitor have clinical antineoplastic activities as single agents and combine synergistically in preclinical models This Phase I study was undertaken to define the toxicity and the maximum tolerated doses MTD of the combination in patients with advanced solid tumors Patients with cytologic or histologic proof of unresectable solid tumors were treated with escalating doses of sorafenib twice daily and bortezomib days 1 4 8 and 11 intravenously with 21-day cycles Fourteen patients 7 males median age 65 range 24-74 with 3 3 2 and adrenal gland spindle cell tumor chronic lymphocytic and multiple 1 each were enrolled All patients are off treatment 10 due to disease progression DLT was seen in two patients one grade 3 abdominal pain and grade 4 lipase elevation one with grade 3 vomiting at sorafenib 200 mg twice daily and bortezomib 1.3 mg/m 2 establishing the MTD No grade 4 hematologic or grade 5 toxicities were seen One patient with cell cancer had a partial response and 5 patients attained stable disease The combination of sorafenib and bortezomib was tolerated well The recommended phase 2 doses are sorafenib 200 mg twice daily continuously with bortezomib 1 mg/m 2 on days 1 4 8 11 21 day cycles The combination shows preliminary signs of efficacy supporting phase 2 studies,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1034, 8, 2134, 2, 1414, 238, 216, 230, 2, 819, 8, 1694, 230, 47, 38, 3940, 2042, 22, 226, 183, 2, 4680, 4240, 4, 693, 274, 26, 124, 70, 45, 10, 2789, 6, 1107, 3, 155, 2, 3, 689, 421, 415, 961, 1, 3, 150, 4, 7, 5, 131, 537, 57, 7, 5, 4195, 15, 884, 3840, 1, 1468, 537, 57, 11, 73, 5, 2922, 415, 1, 1034, 936, 391, 2, 819, 162, 14, 39, 66, 2, 175, 1672, 5, 239, 218, 410, 3225, 7, 67, 2296, 52, 89, 556, 184, 259, 794, 5, 27, 27, 18, 2, 2987, 2326, 4052, 31, 30, 442, 1193, 2, 232, 14, 296, 11, 346, 62, 7, 32, 1889, 24, 79, 520, 6, 34, 91, 2059, 10, 527, 4, 100, 7, 104, 88, 27, 1467, 559, 2, 88, 39, 7272, 3292, 104, 5, 88, 27, 1966, 28, 1034, 1250, 81, 936, 391, 2, 819, 14, 27, 81, 188, 18, 4431, 3, 961, 77, 88, 39, 813, 15, 88, 33, 385, 11, 527, 104, 69, 5, 31, 12, 42, 8, 450, 51, 2, 33, 7, 5105, 585, 34, 3, 150, 1, 1034, 2, 819, 10, 421, 149, 3, 793, 124, 18, 415, 32, 1034, 1250, 81, 936, 391, 4285, 5, 819, 14, 81, 188, 18, 23, 162, 14, 39, 66, 175, 239, 218, 410, 3, 150, 1949, 1676, 3408, 1, 209, 1912, 124, 18, 94]",1373.0,23887852,742
Chronic lymphocytic leukemia in young ( 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.,Haematologica,Haematologica,2013-08-02,"The clinical characteristics and outcomes of younger ( 55 years) patients with chronic lymphocytic leukemia in the era of modern prognostic biomarkers and chemoimmunotherapy are not well understood. Baseline characteristics and outcomes of patients with chronic lymphocytic leukemia  55 years who were seen at the Mayo Clinic between January 1995 and April 2012 were compared with those of patients >55 years. The overall survival of patients  55 years was compared to that of the age- and sex-matched normal population. The characteristics of 844 newly diagnosed chronic lymphocytic leukemia patients  55 years old (median, 50 years) were compared to those of 2324 patients >55 years old (median, 67 years). Younger patients were more likely to have Rai stage I or II disease (P<0.0001), be IGHV unmutated (P=0.002) and express ZAP-70 (P=0.009). These differences became more pronounced when the  55 age group was sub-stratified into age  45, 46-50 and 51-55 years. After a median follow-up of 5.5 years, 426 (51%) patients  55 years old had received treatment, and 192 (23%) had died. The time to treatment was shorter in patients  55 years than in those older than 55 years (4.0 years versus 5.2 years; P=0.001) and those  55 years had longer survival (12.5 years versus 9.5 years; P<0.0001). However, patients  55 years had significantly shorter survival than the age- and sex-matched normal population (12.5 years versus not reached; P<0.0001). Our study is the first comprehensive analysis of younger patients with chronic lymphocytic leukemia in the modern era. Adverse prognostic markers appear more common among young patients. Although the survival of young chronic lymphocytic leukemia patients is longer than that of those >55 years old, their survival relative to the age- and sex-matched normal population is profoundly shortened.",Journal Article,2363.0,29.0,The clinical characteristics and outcomes of younger  55 years patients with chronic lymphocytic in the era of modern prognostic biomarkers and chemoimmunotherapy are not well understood Baseline characteristics and outcomes of patients with chronic lymphocytic  55 years who were seen at the Mayo Clinic between January 1995 and April 2012 were compared with those of patients 55 years The overall survival of patients  55 years was compared to that of the age- and sex-matched normal population The characteristics of 844 newly diagnosed chronic lymphocytic patients  55 years old median 50 years were compared to those of 2324 patients 55 years old median 67 years Younger patients were more likely to have Rai stage I or II disease P 0.0001 be IGHV unmutated P=0.002 and express ZAP-70 P=0.009 These differences became more pronounced when the  55 age group was sub-stratified into age  45 46-50 and 51-55 years After a median follow-up of 5.5 years 426 51 patients  55 years old had received treatment and 192 23 had died The time to treatment was shorter in patients  55 years than in those older than 55 years 4.0 years versus 5.2 years P=0.001 and those  55 years had longer survival 12.5 years versus 9.5 years P 0.0001 However patients  55 years had significantly shorter survival than the age- and sex-matched normal population 12.5 years versus not reached P 0.0001 Our study is the first comprehensive analysis of younger patients with chronic lymphocytic in the modern era Adverse prognostic markers appear more common among young patients Although the survival of young chronic lymphocytic patients is longer than that of those 55 years old their survival relative to the age- and sex-matched normal population is profoundly shortened,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 374, 2, 123, 1, 773, 1552, 614, 60, 7, 5, 442, 1193, 4, 3, 1713, 1, 2366, 177, 582, 2, 4438, 32, 44, 149, 1784, 330, 374, 2, 123, 1, 7, 5, 442, 1193, 1552, 614, 60, 54, 11, 527, 28, 3, 2486, 1188, 59, 1024, 2323, 2, 2292, 1195, 11, 72, 5, 135, 1, 7, 614, 60, 3, 63, 25, 1, 7, 1552, 614, 60, 10, 72, 6, 17, 1, 3, 89, 2, 1035, 655, 295, 266, 3, 374, 1, 15617, 732, 265, 442, 1193, 7, 1552, 614, 60, 1095, 52, 212, 60, 11, 72, 6, 135, 1, 63177, 7, 614, 60, 1095, 52, 598, 60, 773, 7, 11, 80, 322, 6, 47, 4121, 82, 70, 15, 215, 34, 19, 13, 488, 40, 6220, 7216, 19, 13, 1111, 2, 1669, 6251, 431, 19, 13, 2376, 46, 362, 3451, 80, 3517, 198, 3, 1552, 614, 89, 87, 10, 551, 1173, 237, 89, 1552, 512, 641, 212, 2, 725, 614, 60, 50, 8, 52, 166, 126, 1, 33, 33, 60, 12114, 725, 7, 1552, 614, 60, 1095, 42, 103, 24, 2, 5016, 382, 42, 1016, 3, 98, 6, 24, 10, 985, 4, 7, 1552, 614, 60, 76, 4, 135, 434, 76, 614, 60, 39, 13, 60, 185, 33, 18, 60, 19, 13, 144, 2, 135, 1552, 614, 60, 42, 589, 25, 133, 33, 60, 185, 83, 33, 60, 19, 13, 488, 137, 7, 1552, 614, 60, 42, 97, 985, 25, 76, 3, 89, 2, 1035, 655, 295, 266, 133, 33, 60, 185, 44, 1300, 19, 13, 488, 114, 45, 16, 3, 157, 949, 65, 1, 773, 7, 5, 442, 1193, 4, 3, 2366, 1713, 290, 177, 525, 1322, 80, 186, 107, 1169, 7, 242, 3, 25, 1, 1169, 442, 1193, 7, 16, 589, 76, 17, 1, 135, 614, 60, 1095, 136, 25, 580, 6, 3, 89, 2, 1035, 655, 295, 266, 16, 8802, 6151]",1759.0,23911703,440
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.,The Journal of clinical investigation,J. Clin. Invest.,2013-08-05,"Patients with advanced hematologic malignancies remain at risk for relapse following reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT). We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity. We enrolled 22 patients with advanced chronic lymphocytic leukemia (CLL), 18 of whom received up to 6 vaccines initiated between days 30 and 45 after transplantation. Each vaccine consisted of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. Serial patient PBMC samples following transplantation were collected, and the impact of vaccination on T cell activity was evaluated. At a median follow-up of 2.9 (range, 1-4) years, the estimated 2-year progression-free and overall survival rates of vaccinated subjects were 82% (95% CI, 54%-94%) and 88% (95% CI, 59%-97%), respectively. Although vaccination only had a modest impact on recovering T cell numbers, CD8+ T cells from vaccinated patients consistently reacted against autologous tumor, but not alloantigen-bearing recipient cells with increased secretion of the effector cytokine IFN-, unlike T cells from nonvaccinated CLL patients undergoing allo-HSCT. Further analysis confirmed that 17% (range, 13%-33%) of CD8+ T cell clones isolated from 4 vaccinated patients by limiting dilution of bulk tumor-reactive T cells solely reacted against CLL-associated antigens. Our studies suggest that autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allo-HSCT. Clinicaltrials.gov NCT00442130. NCI (5R21CA115043-2), NHLBI (5R01HL103532-03), and Leukemia and Lymphoma Society Translational Research Program.","Clinical Trial, Phase I",2360.0,46.0,Patients with advanced hematologic malignancies remain at risk for relapse following reduced-intensity conditioning RIC allogeneic hematopoietic stem cell transplantation allo-HSCT We conducted a prospective clinical trial to test whether vaccination with whole cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity We enrolled 22 patients with advanced chronic lymphocytic CLL 18 of whom received up to 6 vaccines initiated between days 30 and 45 after transplantation Each vaccine consisted of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells Serial patient PBMC samples following transplantation were collected and the impact of vaccination on T cell activity was evaluated At a median follow-up of 2.9 range 1-4 years the estimated 2-year progression-free and overall survival rates of vaccinated subjects were 82 95 CI 54 -94 and 88 95 CI 59 -97 respectively Although vaccination only had a modest impact on recovering T cell numbers CD8+ T cells from vaccinated patients consistently reacted against autologous tumor but not alloantigen-bearing recipient cells with increased secretion of the effector cytokine IFN- unlike T cells from nonvaccinated CLL patients undergoing allo-HSCT Further analysis confirmed that 17 range 13 -33 of CD8+ T cell clones isolated from 4 vaccinated patients by limiting dilution of bulk tumor-reactive T cells solely reacted against CLL-associated antigens Our studies suggest that autologous tumor cell vaccination is an effective strategy to advance long-term control following allo-HSCT Clinicaltrials.gov NCT00442130 NCI 5R21CA115043-2 NHLBI 5R01HL103532-03 and and Society Translational Research Program,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 131, 813, 441, 918, 28, 43, 9, 429, 366, 405, 837, 1933, 3365, 1063, 1007, 452, 31, 497, 2564, 1703, 21, 426, 8, 482, 38, 160, 6, 412, 317, 1915, 5, 902, 37, 191, 50, 497, 4936, 3, 1422, 1, 2647, 2163, 102, 37, 2, 2267, 2519, 579, 1604, 21, 346, 350, 7, 5, 131, 442, 1193, 552, 203, 1, 953, 103, 126, 6, 49, 1842, 1917, 59, 162, 201, 2, 512, 50, 497, 296, 1274, 1695, 1, 2398, 1028, 30, 37, 14861, 5, 2147, 1211, 5052, 10154, 37, 2108, 69, 5063, 347, 366, 497, 11, 786, 2, 3, 345, 1, 1915, 23, 102, 31, 128, 10, 194, 28, 8, 52, 166, 126, 1, 18, 83, 184, 14, 39, 60, 3, 661, 18, 111, 91, 115, 2, 63, 25, 151, 1, 5130, 976, 11, 878, 48, 58, 667, 960, 2, 889, 48, 58, 728, 1015, 106, 242, 1915, 158, 42, 8, 1721, 345, 23, 17752, 102, 31, 1870, 968, 102, 37, 29, 5130, 7, 2433, 16189, 480, 1028, 30, 84, 44, 35149, 1894, 5783, 37, 5, 101, 2935, 1, 3, 2070, 1675, 1256, 2655, 4246, 102, 37, 29, 63178, 552, 7, 479, 2564, 1703, 195, 65, 557, 17, 269, 184, 233, 466, 1, 968, 102, 31, 2749, 1355, 29, 39, 5130, 7, 20, 817, 10446, 1, 5821, 30, 2163, 102, 37, 5558, 16189, 480, 552, 41, 1575, 114, 94, 309, 17, 1028, 30, 31, 1915, 16, 35, 323, 692, 6, 3148, 319, 337, 182, 366, 2564, 1703, 1252, 1239, 63179, 2580, 63180, 18, 47872, 63181, 680, 2, 2, 1174, 2460, 389, 1243]",1753.0,23912587,92
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2013-08-01,B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is a novel first-in-class selective inhibitor of Bruton tyrosine kinase. Preclinical evidence suggests that ibrutinib inhibits CLL cell survival and proliferation and affects CLL cell migration and homing. Early clinical data in patients with CLL and non-Hodgkin lymphoma is encouraging. It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy. ,Journal Article,2364.0,10.0,B-cell receptor BCR signaling is essential for chronic lymphocytic CLL cell survival Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets Ibrutinib PCI-32765 is a novel first-in-class selective inhibitor of Bruton tyrosine kinase Preclinical evidence suggests that ibrutinib inhibits CLL cell survival and proliferation and affects CLL cell migration and homing Early clinical data in patients with CLL and is encouraging It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 153, 1062, 314, 16, 1452, 9, 442, 1193, 552, 31, 25, 445, 1549, 4, 3, 1062, 314, 308, 32, 486, 656, 22, 174, 189, 637, 1795, 3943, 12229, 16, 8, 229, 157, 4, 1040, 1094, 230, 1, 5796, 564, 216, 693, 241, 844, 17, 1795, 1576, 552, 31, 25, 2, 457, 2, 2561, 552, 31, 1381, 2, 5515, 191, 38, 74, 4, 7, 5, 552, 2, 16, 2269, 192, 16, 322, 17, 1795, 2, 127, 600, 529, 3, 1062, 308, 303, 1417, 35, 4450, 1249, 1, 552, 36]",580.0,23915749,639
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).,Cancer,Cancer,2013-08-06,"Although rituximab-based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40% to 50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumumab is a fully human anti-CD20 monoclonal antibody with greater apparent single-agent activity than rituximab in CLL patients. Previously untreated CLL patients in need of therapy received 6 cycles of CIT induction with pentostatin, cyclophosphamide, and ofatumumab (PCO) followed by response assessment. Of the 48 patients enrolled, 77% completed PCO induction. Adverse events during induction included grade 3+ hematologic toxicity (27%) and grade 3+ nonhematologic toxicity (23%). Median CD4 count after induction and 6 months later were 186  10(6)/L and 272  10(6) /L. The overall response rate was 96% (46 of 48 patients), and the CR rate was 46% (22 of 48 patients). Among the 38 patients who underwent minimal residual disease evaluation, 7 (18%) were negative for minimal residual disease. After median follow-up of 24 months, 10 (21%) patients have progressed and 8 (17%) have required retreatment. The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone (n = 64). Time to retreatment also appeared longer for ofatumumab-based CIT (free of retreatment at 24 months: 86% [95% confidence interval = 75-99] versus 68% [95% confidence interval = 56-81] for rituximab-based CIT). Ofatumumab-based CIT is well tolerated in patients with previously untreated CLL. The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT, suggesting randomized trials comparing ofatumumab-based CIT and rituximab-based CIT should be considered.","Clinical Trial, Phase II",2359.0,39.0,Although rituximab-based chemoimmunotherapy CIT has substantially improved clinical outcomes in chronic lymphocytic CLL only 40 to 50 of patients achieve a complete remission CR There remains interest in identifying new approaches to improve the effectiveness of CIT Ofatumumab is a fully human anti-CD20 monoclonal antibody with greater apparent single-agent activity than rituximab in CLL patients Previously untreated CLL patients in need of therapy received 6 cycles of CIT induction with pentostatin cyclophosphamide and ofatumumab PCO followed by response assessment Of the 48 patients enrolled 77 completed PCO induction Adverse events during induction included grade 3+ hematologic toxicity 27 and grade 3+ nonhematologic toxicity 23 Median CD4 count after induction and 6 months later were 186 10 6 /L and 272 10 6 /L The overall response rate was 96 46 of 48 patients and the CR rate was 46 22 of 48 patients Among the 38 patients who underwent minimal residual disease evaluation 7 18 were negative for minimal residual disease After median follow-up of 24 months 10 21 patients have progressed and 8 17 have required retreatment The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone n 64 Time to retreatment also appeared longer for ofatumumab-based CIT free of retreatment at 24 months 86 95 confidence interval 75-99 versus 68 95 confidence interval 56-81 for rituximab-based CIT Ofatumumab-based CIT is well tolerated in patients with previously untreated CLL The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT suggesting randomized trials comparing ofatumumab-based CIT and rituximab-based CIT should be considered,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 855, 90, 4438, 9192, 71, 2109, 231, 38, 123, 4, 442, 1193, 552, 158, 327, 6, 212, 1, 7, 1359, 8, 236, 734, 684, 125, 469, 1333, 4, 1386, 217, 611, 6, 401, 3, 1236, 1, 9192, 5732, 16, 8, 1910, 171, 312, 2198, 848, 548, 5, 378, 2235, 226, 420, 128, 76, 855, 4, 552, 7, 373, 1278, 552, 7, 4, 594, 1, 36, 103, 49, 410, 1, 9192, 504, 5, 7596, 1112, 2, 5732, 16118, 370, 20, 51, 455, 1, 3, 576, 7, 346, 849, 781, 16118, 504, 290, 281, 190, 504, 159, 88, 27, 813, 155, 428, 2, 88, 27, 3534, 155, 382, 52, 1440, 1276, 50, 504, 2, 49, 53, 1559, 11, 5869, 79, 49, 805, 2, 6905, 79, 49, 805, 3, 63, 51, 116, 10, 921, 641, 1, 576, 7, 2, 3, 684, 116, 10, 641, 350, 1, 576, 7, 107, 3, 519, 7, 54, 208, 1048, 753, 34, 451, 67, 203, 11, 199, 9, 1048, 753, 34, 50, 52, 166, 126, 1, 259, 53, 79, 239, 7, 47, 1839, 2, 66, 269, 47, 616, 6291, 3, 209, 2, 155, 1, 5732, 90, 9192, 932, 5001, 6, 114, 2252, 143, 1, 855, 90, 9192, 75, 35, 3038, 56, 7066, 78, 660, 98, 6, 6291, 120, 2121, 589, 9, 5732, 90, 9192, 115, 1, 6291, 28, 259, 53, 868, 48, 307, 268, 481, 1058, 185, 806, 48, 307, 268, 664, 865, 9, 855, 90, 9192, 5732, 90, 9192, 16, 149, 421, 4, 7, 5, 373, 1278, 552, 3, 209, 1, 5732, 90, 9192, 5815, 5001, 6, 2252, 143, 1, 855, 90, 9192, 802, 384, 143, 1430, 5732, 90, 9192, 2, 855, 90, 9192, 257, 40, 515]",1782.0,23922059,103
"Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.",Cancer,Cancer,2013-08-13,"The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and new-onset cytopenia after the completion of FCR raise concern about disease recurrence, the development of therapy-related myeloid malignancies (TRMM), and infections. A total of 207 patients with CLL who achieved complete response, complete response with incomplete bone marrow recovery, or nodular partial remission were analyzed after frontline FCR therapy. Three months after the completion of therapy, 35% of patients had developed grade 2 to 4 cytopenia (according to Common Terminology Criteria for Adverse Events [version 4.0]). Factors found to be associated with cytopenia at 3 months after therapy were older age, advanced Rai stage disease, and lower baseline blood counts. Moreover, patients with cytopenia were less likely to have completed 6 courses of therapy with FCR. At 6 months and 9 months after therapy, the prevalence of grade 2 to 4 cytopenia was 24% and 12%, respectively. No differences in progression-free survival and overall survival were noted between cytopenic and noncytopenic patients or between patients with persistent and new-onset cytopenia. The prevalence of TRMM was 2.3% and did not differ significantly between cytopenic and noncytopenic patients or between those with persistent and new-onset disease. Late infections were more common in patients who were cytopenic at 9 months (38%) and were mostly bacterial (67%). Cytopenia after the completion of therapy is a common complication of frontline FCR that improves over time, particularly for new-onset cases. The presence of persistent cytopenia (lasting up to 9 months after the completion of therapy) should not raise concern about CLL recurrence of the development of TRMM, but should encourage surveillance for bacterial infections for an additional 9 months.",Journal Article,2352.0,36.0,The combination of fludarabine cyclophosphamide and rituximab FCR has produced improved response rates and a prolonged survival in patients with chronic lymphocytic CLL However its therapeutic power is counterbalanced by significant hematologic toxicity Persistent and new-onset cytopenia after the completion of FCR raise concern about disease recurrence the development of therapy-related myeloid malignancies TRMM and infections A total of 207 patients with CLL who achieved complete response complete response with incomplete marrow recovery or nodular partial remission were analyzed after frontline FCR therapy Three months after the completion of therapy 35 of patients had developed grade 2 to 4 cytopenia according to Common Terminology Criteria for Adverse Events version 4.0 Factors found to be associated with cytopenia at 3 months after therapy were older age advanced Rai stage disease and lower baseline blood counts Moreover patients with cytopenia were less likely to have completed 6 courses of therapy with FCR At 6 months and 9 months after therapy the prevalence of grade 2 to 4 cytopenia was 24 and 12 respectively No differences in progression-free survival and overall survival were noted between cytopenic and noncytopenic patients or between patients with persistent and new-onset cytopenia The prevalence of TRMM was 2.3 and did not differ significantly between cytopenic and noncytopenic patients or between those with persistent and new-onset disease Late infections were more common in patients who were cytopenic at 9 months 38 and were mostly bacterial 67 Cytopenia after the completion of therapy is a common complication of frontline FCR that improves over time particularly for new-onset cases The presence of persistent cytopenia lasting up to 9 months after the completion of therapy should not raise concern about CLL recurrence of the development of TRMM but should encourage surveillance for bacterial infections for an additional 9 months,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 150, 1, 2027, 1112, 2, 855, 4953, 71, 1687, 231, 51, 151, 2, 8, 1069, 25, 4, 7, 5, 442, 1193, 552, 137, 211, 189, 2349, 16, 22111, 20, 93, 813, 155, 1882, 2, 217, 1707, 8165, 50, 3, 1438, 1, 4953, 5008, 2893, 545, 34, 146, 3, 193, 1, 36, 139, 533, 441, 40447, 2, 1875, 8, 181, 1, 5292, 7, 5, 552, 54, 513, 236, 51, 236, 51, 5, 2610, 581, 1602, 15, 4481, 450, 734, 11, 311, 50, 3171, 4953, 36, 169, 53, 50, 3, 1438, 1, 36, 465, 1, 7, 42, 276, 88, 18, 6, 39, 8165, 768, 6, 186, 3462, 371, 9, 290, 281, 2256, 39, 13, 130, 204, 6, 40, 41, 5, 8165, 28, 27, 53, 50, 36, 11, 434, 89, 131, 4121, 82, 34, 2, 280, 330, 315, 1911, 1393, 7, 5, 8165, 11, 299, 322, 6, 47, 781, 49, 1993, 1, 36, 5, 4953, 28, 49, 53, 2, 83, 53, 50, 36, 3, 1078, 1, 88, 18, 6, 39, 8165, 10, 259, 2, 133, 106, 77, 362, 4, 91, 115, 25, 2, 63, 25, 11, 1051, 59, 32164, 2, 47890, 7, 15, 59, 7, 5, 1882, 2, 217, 1707, 8165, 3, 1078, 1, 40447, 10, 18, 27, 2, 205, 44, 1505, 97, 59, 32164, 2, 47890, 7, 15, 59, 135, 5, 1882, 2, 217, 1707, 34, 807, 1875, 11, 80, 186, 4, 7, 54, 11, 32164, 28, 83, 53, 519, 2, 11, 2754, 5117, 598, 8165, 50, 3, 1438, 1, 36, 16, 8, 186, 1447, 1, 3171, 4953, 17, 1804, 252, 98, 823, 9, 217, 1707, 140, 3, 463, 1, 1882, 8165, 3443, 126, 6, 83, 53, 50, 3, 1438, 1, 36, 257, 44, 5008, 2893, 545, 552, 146, 1, 3, 193, 1, 40447, 84, 257, 7113, 617, 9, 5117, 1875, 9, 35, 402, 83, 53]",1979.0,23943357,514
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.,Nucleic acids research,Nucleic Acids Res.,2013-08-16,"Replication-dependent histones are encoded by multigene families found in several large clusters in the human genome and are thought to be functionally redundant. However, the abundance of specific replication-dependent isoforms of histone H2A is altered in patients with chronic lymphocytic leukemia. Similar changes in the abundance of H2A isoforms are also associated with the proliferation and tumorigenicity of bladder cancer cells. To determine whether these H2A isoforms can perform distinct functions, expression of several H2A isoforms was reduced by siRNA knockdown. Reduced expression of the HIST1H2AC locus leads to increased rates of cell proliferation and tumorigenicity. We also observe that regulation of replication-dependent histone H2A expression can occur on a gene-specific level. Specific replication-dependent histone H2A genes are either up- or downregulated in chronic lymphocytic leukemia tumor tissue samples. In addition, discreet elements are identified in the 5' untranslated region of the HIST1H2AC locus that confer translational repression. Taken together, these results indicate that replication-dependent histone isoforms can possess distinct cellular functions and that regulation of these isoforms may play a role in carcinogenesis. ",Journal Article,2349.0,16.0,Replication-dependent histones are encoded by multigene families found in several large clusters in the human genome and are thought to be functionally redundant However the abundance of specific replication-dependent isoforms of histone H2A is altered in patients with chronic lymphocytic Similar changes in the abundance of H2A isoforms are also associated with the proliferation and tumorigenicity of cancer cells To determine whether these H2A isoforms can perform distinct functions expression of several H2A isoforms was reduced by siRNA knockdown Reduced expression of the HIST1H2AC locus leads to increased rates of cell proliferation and tumorigenicity We also observe that regulation of replication-dependent histone H2A expression can occur on a gene-specific level Specific replication-dependent histone H2A genes are either up- or downregulated in chronic lymphocytic tumor tissue samples In addition discreet elements are identified in the 5 untranslated region of the HIST1H2AC locus that confer translational repression Taken together these results indicate that replication-dependent histone isoforms can possess distinct cellular functions and that regulation of these isoforms may play a role in carcinogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,"[2079, 470, 8457, 32, 4587, 20, 6339, 1954, 204, 4, 392, 375, 3780, 4, 3, 171, 898, 2, 32, 2739, 6, 40, 3772, 10716, 137, 3, 4778, 1, 112, 2079, 470, 3913, 1, 1508, 19741, 16, 1495, 4, 7, 5, 442, 1193, 288, 400, 4, 3, 4778, 1, 19741, 3913, 32, 120, 41, 5, 3, 457, 2, 5538, 1, 12, 37, 6, 223, 317, 46, 19741, 3913, 122, 2715, 834, 1681, 55, 1, 392, 19741, 3913, 10, 405, 20, 1919, 1563, 405, 55, 1, 3, 47899, 2474, 1940, 6, 101, 151, 1, 31, 457, 2, 5538, 21, 120, 4635, 17, 863, 1, 2079, 470, 1508, 19741, 55, 122, 1271, 23, 8, 145, 112, 301, 112, 2079, 470, 1508, 19741, 214, 32, 361, 126, 15, 3315, 4, 442, 1193, 30, 246, 347, 4, 352, 28487, 2531, 32, 108, 4, 3, 33, 7379, 1053, 1, 3, 47899, 2474, 17, 2913, 2460, 5255, 1633, 1162, 46, 99, 1008, 17, 2079, 470, 1508, 3913, 122, 5766, 834, 763, 1681, 2, 17, 863, 1, 46, 3913, 68, 1343, 8, 200, 4, 1719]",1229.0,23956221,11
Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia.,Journal of oncology practice,J Oncol Pract,2013-08-27,"Assess compliance with skin cancer screening guidelines in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia (CLL) and evaluate the clinical utility of such screening. We identified patients diagnosed at Mayo Clinic with CLL between January 1, 2004, and June 1, 2012, who resided within 30 miles of Mayo Clinic. We evaluated adherence to skin cancer screening and identified the prevalence of skin malignancies during follow-up. Medical records were reviewed to document skin cancer screening and diagnosis of a skin malignancy. Collectively, 113 individuals who met criteria were diagnosed with CLL during the study interval. Forty-one patients (36%) had a whole body skin examination by either a dermatologist or primary care provider documented within 6 months of diagnosis; of these; nine (8% of overall cohort; 22% of examined patients) had a skin malignancy identified. Fifteen additional skin malignancies were diagnosed during follow-up. There were a total of 24 skin malignancies (21% of cohort) diagnosed, including basal cell carcinoma (n = 10), squamous cell carcinoma (n = 11), sebaceous carcinomas (n = 2), and melanoma (n = 1). We documented a low compliance with guidelines to screen for skin malignancy in a community-dwelling cohort of patients with newly diagnosed CLL. Standardized and systems-based approaches are likely to increase compliance with skin cancer screening guidelines in patients with CLL.",Journal Article,2338.0,12.0,Assess compliance with cancer screening guidelines in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic CLL and evaluate the clinical utility of such screening We identified patients diagnosed at Mayo Clinic with CLL between January 1 2004 and June 1 2012 who resided within 30 miles of Mayo Clinic We evaluated adherence to cancer screening and identified the prevalence of malignancies during follow-up Medical records were reviewed to document cancer screening and diagnosis of a malignancy Collectively 113 individuals who met criteria were diagnosed with CLL during the study interval Forty-one patients 36 had a whole body examination by either a dermatologist or primary care provider documented within 6 months of diagnosis of these nine 8 of overall cohort 22 of examined patients had a malignancy identified Fifteen additional malignancies were diagnosed during follow-up There were a total of 24 malignancies 21 of cohort diagnosed including basal cell carcinoma n 10 squamous cell carcinoma n 11 sebaceous carcinomas n 2 and n 1 We documented a low compliance with guidelines to screen for malignancy in a community-dwelling cohort of patients with newly diagnosed CLL Standardized and systems-based approaches are likely to increase compliance with cancer screening guidelines in patients with CLL,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[423, 3336, 5, 12, 453, 677, 4, 8, 1714, 24883, 180, 1, 7, 5, 732, 265, 442, 1193, 552, 2, 376, 3, 38, 1207, 1, 225, 453, 21, 108, 7, 265, 28, 2486, 1188, 5, 552, 59, 1024, 14, 1131, 2, 1924, 14, 1195, 54, 13472, 262, 201, 7886, 1, 2486, 1188, 21, 194, 2149, 6, 12, 453, 2, 108, 3, 1078, 1, 441, 190, 166, 126, 484, 1064, 11, 446, 6, 4753, 12, 453, 2, 147, 1, 8, 710, 2535, 4259, 869, 54, 543, 371, 11, 265, 5, 552, 190, 3, 45, 268, 1213, 104, 7, 511, 42, 8, 902, 642, 1385, 20, 361, 8, 26301, 15, 86, 165, 3094, 1405, 262, 49, 53, 1, 147, 1, 46, 762, 66, 1, 63, 180, 350, 1, 409, 7, 42, 8, 710, 108, 3057, 402, 441, 11, 265, 190, 166, 126, 125, 11, 8, 181, 1, 259, 441, 239, 1, 180, 265, 141, 2135, 31, 134, 78, 79, 691, 31, 134, 78, 175, 8621, 826, 78, 18, 2, 78, 14, 21, 1405, 8, 154, 3336, 5, 677, 6, 2413, 9, 710, 4, 8, 1714, 24883, 180, 1, 7, 5, 732, 265, 552, 1670, 2, 1530, 90, 611, 32, 322, 6, 344, 3336, 5, 12, 453, 677, 4, 7, 5, 552]",1341.0,23981385,135
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.,Blood,Blood,2013-09-05,"Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to use this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy, we interrogated CLL membrane-specific autologous immunoglobulin G reactivity. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156. ",Clinical Trial,2329.0,21.0,Membrane antigens are critical to the pathogenesis of chronic lymphocytic CLL as they facilitate microenvironment homing proliferation and survival Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development Many tumor membrane targets are simultaneously targeted by humoral immunity thus forming recognizable immunoglobulin responses We sought to use this immune response to identify novel membrane-associated targets for CLL Using a novel strategy we interrogated CLL membrane-specific autologous immunoglobulin G reactivity Our analysis unveiled lymphocyte cytosolic protein 1 LCP1 a lymphocyte-specific target that is highly expressed in CLL LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to marrow in an in vivo xenotransplant model confirming a role for LCP1 in migration Furthermore we demonstrate that the Bruton 's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1 Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity In addition we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance This clinical trial was registered at clinicaltrials.gov study ID number OSU-0025 OSU-0156,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1905, 1575, 32, 740, 6, 3, 1384, 1, 442, 1193, 552, 22, 491, 1876, 995, 5515, 457, 2, 25, 529, 3, 552, 1905, 2, 41, 314, 764, 16, 8, 291, 1222, 1, 189, 193, 445, 30, 1905, 637, 32, 3074, 238, 20, 5498, 1604, 631, 4525, 13908, 2593, 253, 21, 990, 6, 119, 26, 250, 51, 6, 255, 229, 1905, 41, 637, 9, 552, 75, 8, 229, 692, 21, 7227, 552, 1905, 112, 1028, 2593, 499, 4601, 114, 65, 19041, 1448, 7698, 178, 14, 22805, 8, 1448, 112, 283, 17, 16, 561, 570, 4, 552, 22805, 1698, 8, 740, 200, 4, 132, 31, 891, 20, 12984, 1068, 5525, 23442, 2267, 47750, 10055, 2414, 2, 1736, 8, 11547, 9, 740, 314, 460, 302, 3449, 893, 1563, 1, 22805, 2582, 1381, 1317, 5807, 4, 9501, 1013, 2, 6, 581, 4, 35, 4, 386, 28800, 202, 5030, 8, 200, 9, 22805, 4, 1381, 798, 21, 608, 17, 3, 5796, 292, 564, 216, 230, 1795, 15, 3, 974, 230, 7083, 2381, 132, 31, 153, 277, 363, 1, 22805, 114, 74, 608, 8, 229, 692, 6, 255, 12, 1905, 283, 1575, 75, 5498, 312, 30, 1604, 4, 352, 21, 255, 22805, 22, 8, 1905, 41, 283, 4, 552, 5, 557, 2806, 724, 26, 38, 160, 10, 1653, 28, 1252, 1239, 45, 4937, 207, 5984, 12615, 5984, 33312]",1531.0,24009233,235
Isolation and analysis of linker histones across cellular compartments.,Journal of proteomics,J Proteomics,2013-09-05,"Analysis of histones, especially histone H1, is severely limited by immunological reagent availability. This paper describes the application of cellular fractionation with LC-MS for profiling histones in the cytosol and upon chromatin. First, we show that linker histones enriched by cellular fractionation gives less nuclear contamination and higher histone content than when prepared by nuclei isolation. Second, we profiled the soluble linker histones throughout the cell cycle revealing phosphorylation increases as cells reach mitosis. Finally, we monitored histone H1.2-H1.5 translocation to the cytosol in response to the CDK inhibitor flavopiridol in primary CLL cells treated ex vivo. Data shows that all H1 variants translocate in response to drug treatment with no specific order to their cytosolic appearance. The results illustrate the utility of cellular fractionation in conjunction with LC-MS for the analysis of histone H1 throughout the cell. This paper demonstrates the first time application of cellular fractionation to characterize cytosolic histone H1 by liquid chromatography mass spectrometry (LC-MS). Using the Ramos Burkitt's lymphoma cell line, cellular fractionation was shown to give less nuclear contamination and higher histone content than preparations by nuclei isolation. Further application of the cellular fractionation approach was shown by using primary chronic lymphocytic leukemia (CLL) cells to monitor the movement of histone H1 across cellular compartments in response to the cyclin dependent kinase inhibitor flavopiridol. Collectively, these data establish a mass spectrometric method for exploration into the function of cytosolic histone H1.",Journal Article,2329.0,6.0,Analysis of histones especially histone H1 is severely limited by immunological reagent availability This paper describes the application of cellular fractionation with LC-MS for profiling histones in the cytosol and upon chromatin First we show that linker histones enriched by cellular fractionation gives less nuclear contamination and higher histone content than when prepared by nuclei isolation Second we profiled the soluble linker histones throughout the cell cycle revealing phosphorylation increases as cells reach mitosis Finally we monitored histone H1.2-H1.5 translocation to the cytosol in response to the CDK inhibitor flavopiridol in primary CLL cells treated ex vivo Data shows that all H1 variants translocate in response to drug treatment with no specific order to their cytosolic appearance The results illustrate the utility of cellular fractionation in conjunction with LC-MS for the analysis of histone H1 throughout the cell This paper demonstrates the first time application of cellular fractionation to characterize cytosolic histone H1 by liquid chromatography mass spectrometry LC-MS Using the Ramos 's cell line cellular fractionation was shown to give less nuclear contamination and higher histone content than preparations by nuclei isolation Further application of the cellular fractionation approach was shown by using primary chronic lymphocytic CLL cells to monitor the movement of histone H1 across cellular compartments in response to the cyclin dependent kinase inhibitor flavopiridol Collectively these data establish a mass spectrometric method for exploration into the function of cytosolic histone H1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[65, 1, 8457, 1093, 1508, 5199, 16, 7207, 383, 20, 5073, 10989, 2550, 26, 2817, 2677, 3, 1581, 1, 763, 3519, 5, 1837, 2307, 9, 1080, 8457, 4, 3, 11107, 2, 1548, 2287, 157, 21, 514, 17, 8437, 8457, 2220, 20, 763, 3519, 7989, 299, 928, 9866, 2, 142, 1508, 2457, 76, 198, 4421, 20, 4725, 5019, 419, 21, 5490, 3, 2968, 8437, 8457, 2432, 3, 31, 417, 6475, 982, 1106, 22, 37, 3690, 5624, 1368, 21, 2909, 1508, 5199, 18, 5199, 33, 2006, 6, 3, 11107, 4, 51, 6, 3, 3954, 230, 3030, 4, 86, 552, 37, 73, 2581, 386, 74, 1949, 17, 62, 5199, 839, 31047, 4, 51, 6, 234, 24, 5, 77, 112, 1732, 6, 136, 7698, 3592, 3, 99, 4746, 3, 1207, 1, 763, 3519, 4, 3357, 5, 1837, 2307, 9, 3, 65, 1, 1508, 5199, 2432, 3, 31, 26, 2817, 1902, 3, 157, 98, 1581, 1, 763, 3519, 6, 1507, 7698, 1508, 5199, 20, 3165, 5140, 782, 3680, 1837, 2307, 75, 3, 30674, 292, 31, 328, 763, 3519, 10, 443, 6, 4978, 299, 928, 9866, 2, 142, 1508, 2457, 76, 7791, 20, 4725, 5019, 195, 1581, 1, 3, 763, 3519, 353, 10, 443, 20, 75, 86, 442, 1193, 552, 37, 6, 3334, 3, 7950, 1, 1508, 5199, 716, 763, 6473, 4, 51, 6, 3, 1226, 470, 216, 230, 3030, 2535, 46, 74, 1811, 8, 782, 14506, 596, 9, 3370, 237, 3, 343, 1, 7698, 1508, 5199]",1642.0,24013129,155
Immunotherapies in CLL.,Advances in experimental medicine and biology,Adv. Exp. Med. Biol.,2013-01-01,"Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy. For the moment, allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the only potentially curative treatment for patients with CLL, but it is associated with high rates of treatment-related mortality. Immune-based treatment strategies to augment the cytotoxic potential of T cells offer exciting new treatment options for patients with CLL, and provide a unique and powerful spectrum of tools distinct from traditional chemotherapy. Among the most novel and promising of these approaches are chimeric antigen receptor (CAR)-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy. ",Journal Article,2576.0,,Chronic lymphocytic CLL is the most frequently diagnosed in the Western world yet remains essentially incurable Although initial chemotherapy response rates are high patients invariably relapse and subsequently develop resistance to chemotherapy For the moment allogeneic hematopoietic stem cell transplant allo-HSCT remains the only potentially curative treatment for patients with CLL but it is associated with high rates of treatment-related mortality Immune-based treatment strategies to augment the cytotoxic potential of T cells offer exciting new treatment options for patients with CLL and provide a unique and powerful spectrum of tools distinct from traditional chemotherapy Among the most novel and promising of these approaches are chimeric antigen receptor CAR -based cell therapies that combine advances in genetic engineering and adoptive immunotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 746, 265, 4, 3, 1521, 1956, 1145, 469, 7257, 2641, 242, 388, 56, 51, 151, 32, 64, 7, 6912, 429, 2, 1611, 690, 251, 6, 56, 9, 3, 12854, 1063, 1007, 452, 31, 941, 2564, 1703, 469, 3, 158, 751, 1075, 24, 9, 7, 5, 552, 84, 192, 16, 41, 5, 64, 151, 1, 24, 139, 282, 250, 90, 24, 422, 6, 4369, 3, 759, 174, 1, 102, 37, 1918, 4963, 217, 24, 838, 9, 7, 5, 552, 2, 377, 8, 991, 2, 3757, 1873, 1, 1896, 834, 29, 1847, 56, 107, 3, 96, 229, 2, 721, 1, 46, 611, 32, 2897, 448, 153, 1881, 90, 31, 235, 17, 4680, 954, 4, 336, 6717, 2, 3159, 726]",867.0,24014300,138
"Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.",Cancer,Cancer,2013-07-08,"Little is known regarding racial disparities in characteristics and outcomes among patients with chronic lymphocytic leukemia (CLL). The characteristics and outcomes of untreated African American (AA) patients with CLL (n = 84) were analyzed and compared with a reference nonblack (NB) patient population (n = 1571). At the time of presentation, AA patients had lower median hemoglobin levels (12.9 g/dL vs 13.7 g/dL), higher 2 microglobulin levels (2.7 mg/dL vs 2.4 mg/dL), greater frequency of constitutional symptoms (27% vs 10%), unmutated immunoglobulin heavy-chain variable region (IGHV) mutation status (65% vs 47%), -chain-associated protein kinase 70 (ZAP70) expression (58% vs 32%), and deletion of chromosome 17p or chromosome 11q (28% vs 17%; P  02 for each comparison). Fifty-one percent of AA patients and 39% of NB patients required first-line therapy and 91% and 88%, respectively, received chemoimmunotherapy. Overall response rates to treatment were 85% for AA patients and 94% for NB patients (P = .06); and the complete response rates were 56% and 58%, respectively (P = .87). The median survival of AA patients was shorter compared with that of NB patients (event-free survival: 36 months vs 61 months; P = .007; overall survival: 152 months vs not reached; P = .0001). AA race was an independent predictor of shorter event-free and overall survival in multivariable regression models. The current results indicated that AA patients with CLL have more unfavorable prognostic characteristics and shorter survival compared with their NB counterparts.",Comparative Study,2388.0,13.0,Little is known regarding racial disparities in characteristics and outcomes among patients with chronic lymphocytic CLL The characteristics and outcomes of untreated African American AA patients with CLL n 84 were analyzed and compared with a reference nonblack NB patient population n 1571 At the time of presentation AA patients had lower median hemoglobin levels 12.9 g/dL vs 13.7 g/dL higher 2 microglobulin levels 2.7 mg/dL vs 2.4 mg/dL greater frequency of constitutional symptoms 27 vs 10 unmutated immunoglobulin heavy-chain variable region IGHV mutation status 65 vs 47 -chain-associated protein kinase 70 ZAP70 expression 58 vs 32 and deletion of chromosome 17p or chromosome 11q 28 vs 17 P  02 for each comparison Fifty-one percent of AA patients and 39 of NB patients required first-line therapy and 91 and 88 respectively received chemoimmunotherapy Overall response rates to treatment were 85 for AA patients and 94 for NB patients P .06 and the complete response rates were 56 and 58 respectively P .87 The median survival of AA patients was shorter compared with that of NB patients event-free survival 36 months vs 61 months P .007 overall survival 152 months vs not reached P .0001 AA race was an independent predictor of shorter event-free and overall survival in multivariable regression models The current results indicated that AA patients with CLL have more unfavorable prognostic characteristics and shorter survival compared with their NB counterparts,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 16, 440, 666, 2257, 2227, 4, 374, 2, 123, 107, 7, 5, 442, 1193, 552, 3, 374, 2, 123, 1, 1278, 1410, 597, 1519, 7, 5, 552, 78, 874, 11, 311, 2, 72, 5, 8, 2482, 18496, 3446, 69, 266, 78, 40199, 28, 3, 98, 1, 1031, 1519, 7, 42, 280, 52, 2222, 148, 133, 83, 499, 1826, 105, 233, 67, 499, 1826, 142, 9314, 5371, 148, 18, 67, 81, 1826, 105, 18, 39, 81, 1826, 378, 675, 1, 5962, 507, 428, 105, 79, 7216, 2593, 4013, 1260, 1347, 1053, 6220, 258, 156, 556, 105, 662, 14668, 1260, 41, 178, 216, 431, 12921, 55, 717, 105, 531, 2, 1528, 1, 1170, 4135, 15, 1170, 7203, 339, 105, 269, 19, 1552, 588, 9, 296, 1155, 1461, 104, 714, 1, 1519, 7, 2, 587, 1, 3446, 7, 616, 157, 328, 36, 2, 970, 2, 889, 106, 103, 4438, 63, 51, 151, 6, 24, 11, 772, 9, 1519, 7, 2, 960, 9, 3446, 7, 19, 1460, 2, 3, 236, 51, 151, 11, 664, 2, 717, 106, 19, 912, 3, 52, 25, 1, 1519, 7, 10, 985, 72, 5, 17, 1, 3446, 7, 774, 115, 25, 511, 53, 105, 713, 53, 19, 1999, 63, 25, 5370, 53, 105, 44, 1300, 19, 488, 1519, 1047, 10, 35, 306, 980, 1, 985, 774, 115, 2, 63, 25, 4, 658, 320, 274, 3, 291, 99, 1103, 17, 1519, 7, 5, 552, 47, 80, 2483, 177, 374, 2, 985, 25, 72, 5, 136, 3446, 3953]",1480.0,24022787,545
Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012.,Leukemia research,Leuk. Res.,2013-09-06,The prognostic significance of extra-medullary chronic lymphocytic leukemia (EM-CLL) is unknown. We conducted a Medline database systematic search analyzing English language articles published between 1975 and 2012 identifying 192 cases. Patients with EM-CLL were more commonly treated than not (p < .001). Skin and central nervous system (CNS) were the most commonly reported sites of organ involvement. Survival after diagnosis of EM-CLL appeared to depend on the site of EM involvement. Prospective evaluation and further studies of EM-CLL are warranted.,Journal Article,2328.0,20.0,The prognostic significance of extra-medullary chronic lymphocytic EM-CLL is unknown We conducted a Medline database systematic search analyzing English language articles published between 1975 and 2012 identifying 192 cases Patients with EM-CLL were more commonly treated than not p .001 and central nervous system CNS were the most commonly reported sites of organ involvement Survival after diagnosis of EM-CLL appeared to depend on the site of EM involvement Prospective evaluation and further studies of EM-CLL are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[3, 177, 724, 1, 3420, 4564, 442, 1193, 7393, 552, 16, 860, 21, 426, 8, 3388, 609, 1556, 1901, 4449, 4201, 4794, 2384, 983, 59, 7585, 2, 1195, 1386, 5016, 140, 7, 5, 7393, 552, 11, 80, 841, 73, 76, 44, 19, 144, 2, 854, 1880, 398, 1025, 11, 3, 96, 841, 210, 633, 1, 1259, 799, 25, 50, 147, 1, 7393, 552, 2121, 6, 4533, 23, 3, 606, 1, 7393, 799, 482, 451, 2, 195, 94, 1, 7393, 552, 32, 1197]",529.0,24064196,666
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.,PloS one,PLoS ONE,2013-10-09,"Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments. Here we describe a novel CLL cell line (OSU-CLL) generated by EBV transformation, which displays a similar cytogenetic and immunophenotype observed in the patient's CLL (CD5 positive with trisomy 12 and 19). A companion cell line was also generated from the same patient (OSU-NB). This cell line lacked typical CLL characteristics, and is likely derived from the patient's normal B cells. In vitro migration assays demonstrated that OSU-CLL exhibits migratory properties similar to primary CLL cells whereas OSU-NB has significantly reduced ability to migrate spontaneously or towards chemokine. Microarray analysis demonstrated distinct gene expression patterns in the two cell lines, including genes on chromosomes 12 and 19, which is consistent with the cytogenetic profile in this cell line. Finally, OSU-CLL was readily transplantable into NOG mice, producing uniform engraftment by three weeks with leukemic cells detectable in the peripheral blood spleen and bone marrow. These studies describe a new CLL cell line that extends currently available models to study gene function in this disease. ",Journal Article,2295.0,23.0,Studies of chronic lymphocytic CLL have yielded substantial progress however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments Here we describe a novel CLL cell line OSU-CLL generated by EBV transformation which displays a similar cytogenetic and immunophenotype observed in the patient 's CLL CD5 positive with trisomy 12 and 19 A companion cell line was also generated from the same patient OSU-NB This cell line lacked typical CLL characteristics and is likely derived from the patient 's normal B cells In vitro migration assays demonstrated that OSU-CLL exhibits migratory properties similar to primary CLL cells whereas OSU-NB has significantly reduced ability to migrate spontaneously or towards chemokine Microarray analysis demonstrated distinct gene expression patterns in the two cell lines including genes on chromosomes 12 and 19 which is consistent with the cytogenetic profile in this cell line Finally OSU-CLL was readily transplantable into NOG mice producing uniform engraftment by three weeks with leukemic cells detectable in the peripheral blood spleen and marrow These studies describe a new CLL cell line that extends currently available models to study gene function in this disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[94, 1, 442, 1193, 552, 47, 2178, 1281, 1466, 137, 8, 926, 1, 6090, 31, 285, 3724, 1, 3, 86, 34, 71, 6786, 8, 1647, 612, 1, 34, 1384, 2, 193, 1, 217, 640, 467, 21, 897, 8, 229, 552, 31, 328, 5984, 552, 1419, 20, 2672, 1392, 92, 7196, 8, 288, 1266, 2, 5496, 164, 4, 3, 69, 292, 552, 6349, 109, 5, 6317, 133, 2, 326, 8, 6639, 31, 328, 10, 120, 1419, 29, 3, 827, 69, 5984, 3446, 26, 31, 328, 5005, 3476, 552, 374, 2, 16, 322, 526, 29, 3, 69, 292, 295, 132, 37, 4, 439, 1381, 1013, 264, 17, 5984, 552, 4273, 7757, 1571, 288, 6, 86, 552, 37, 547, 5984, 3446, 71, 97, 405, 801, 6, 10389, 6459, 15, 3113, 3596, 1727, 65, 264, 834, 145, 55, 764, 4, 3, 100, 31, 285, 141, 214, 23, 3560, 133, 2, 326, 92, 16, 925, 5, 3, 1266, 800, 4, 26, 31, 328, 1368, 5984, 552, 10, 3860, 11459, 237, 21560, 399, 3787, 3490, 2881, 20, 169, 244, 5, 2015, 37, 2083, 4, 3, 672, 315, 4071, 2, 581, 46, 94, 897, 8, 217, 552, 31, 328, 17, 8464, 694, 390, 274, 6, 45, 145, 343, 4, 26, 34]",1320.0,24130782,595
"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.",Blood,Blood,2013-11-25,"The CXC chemokine ligand (CXCL12, or stromal cell-derived factor-1 as previously known) plays a critical role for homing and retention of chronic lymphocytic leukemia (CLL) cells in tissues such as the bone marrow (BM). In tissues, stromal cells constitutively secrete and present CXCL12 via cell-surface-bound glycosaminoglycans (GAGs), thereby attracting CLL cells and protecting them from cytotoxic drugs, a mechanism that may account for residual disease after conventional CLL therapy. NOX-A12, an RNA oligonucleotide in L-configuration (Spiegelmer) that binds and neutralizes CXCL12, was developed for interference with CXCL12 in the tumor microenvironment and for cell mobilization. Here, we examined effects of NOX-A12 on CLL cell migration and drug sensitivity. We found that NOX-A12 effectively inhibited CXCL12-induced chemotaxis of CLL cells. In contrast, NOX-A12 increased CLL migration underneath a confluent layer of BM stromal cells (BMSCs) due to interference with the CXCL12 gradient established by BMSCs. In particular, NOX-A12 competes with GAGs such as heparin for CXCL12 binding, leading to the release of CXCL12 from stromal cell-surface-bound GAGs, and thereby to neutralization of the chemokine. Furthermore, NOX-A12 sensitizes CLL cells toward bendamustine and fludarabine in BMSC cocultures. These data demonstrate that NOX-A12 effectively interferes with CLL cell migration and BMSC-mediated drug resistance, and establishes a rationale for clinical development of NOX-A12 in combination with conventional agents in CLL. ",Journal Article,2248.0,93.0,The CXC chemokine ligand CXCL12 or stromal cell-derived factor-1 as previously known plays a critical role for homing and retention of chronic lymphocytic CLL cells in tissues such as the marrow BM In tissues stromal cells constitutively secrete and present CXCL12 via cell-surface-bound glycosaminoglycans GAGs thereby attracting CLL cells and protecting them from cytotoxic drugs a mechanism that may account for residual disease after conventional CLL therapy NOX-A12 an RNA oligonucleotide in L-configuration Spiegelmer that binds and neutralizes CXCL12 was developed for interference with CXCL12 in the tumor microenvironment and for cell mobilization Here we examined effects of NOX-A12 on CLL cell migration and drug sensitivity We found that NOX-A12 effectively inhibited CXCL12-induced chemotaxis of CLL cells In contrast NOX-A12 increased CLL migration underneath a confluent layer of BM stromal cells BMSCs due to interference with the CXCL12 gradient established by BMSCs In particular NOX-A12 competes with GAGs such as heparin for CXCL12 binding leading to the release of CXCL12 from stromal cell-surface-bound GAGs and thereby to neutralization of the chemokine Furthermore NOX-A12 sensitizes CLL cells toward bendamustine and fludarabine in BMSC cocultures These data demonstrate that NOX-A12 effectively interferes with CLL cell migration and BMSC-mediated drug resistance and establishes a rationale for clinical development of NOX-A12 in combination with conventional agents in CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[3, 16813, 3596, 1232, 5807, 15, 1126, 31, 526, 161, 14, 22, 373, 440, 1698, 8, 740, 200, 9, 5515, 2, 3947, 1, 442, 1193, 552, 37, 4, 742, 225, 22, 3, 581, 1246, 4, 742, 1126, 37, 2818, 6401, 2, 364, 5807, 847, 31, 1255, 2951, 44380, 40549, 2267, 20253, 552, 37, 2, 11638, 1370, 29, 759, 600, 8, 670, 17, 68, 1967, 9, 753, 34, 50, 809, 552, 36, 22820, 13393, 35, 893, 4727, 4, 805, 13796, 63656, 17, 3333, 2, 21198, 5807, 10, 276, 9, 3182, 5, 5807, 4, 3, 30, 995, 2, 9, 31, 4030, 467, 21, 409, 176, 1, 22820, 13393, 23, 552, 31, 1381, 2, 234, 485, 21, 204, 17, 22820, 13393, 1856, 879, 5807, 277, 12561, 1, 552, 37, 4, 748, 22820, 13393, 101, 552, 1381, 39080, 8, 18223, 8056, 1, 1246, 1126, 37, 12761, 520, 6, 3182, 5, 3, 5807, 7099, 635, 20, 12761, 4, 1454, 22820, 13393, 18898, 5, 40549, 225, 22, 7309, 9, 5807, 791, 1049, 6, 3, 2008, 1, 5807, 29, 1126, 31, 1255, 2951, 40549, 2, 2267, 6, 10422, 1, 3, 3596, 798, 22820, 13393, 6229, 552, 37, 1317, 4809, 2, 2027, 4, 17918, 16398, 46, 74, 608, 17, 22820, 13393, 1856, 12078, 5, 552, 31, 1381, 2, 17918, 517, 234, 251, 2, 7410, 8, 1728, 9, 38, 193, 1, 22820, 13393, 4, 150, 5, 809, 183, 4, 552]",1500.0,24277076,42
Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.,Leukemia & lymphoma,Leuk. Lymphoma,2014-02-17,"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) cells typically have low 2-deoxy-2-[(18)F]fluoro-d-glucose (FDG) avidity, and patients with CLL have an increased risk of developing FDG-avid aggressive lymphomas, second malignancies and infections. We hypothesized that FDG positron emission tomography-computed tomography (PET-CT) of the trunk is a sensitive method of detecting these complications in patients with CLL. Of the of 2299 patients with CLL seen in the Division of Hematology at Mayo Clinic Rochester between 1 January 2006 and 31 December 2011, 272 (11.8%) had 526 PET-CT scans and 472 (89.7%) of these were reported as abnormal. Among the 293 (55.7%) PET-CT scans used for routine evaluation of CLL, the PET component was of clinical value in only one instance. In contrast, in 83 (30.5%) patients, PET-CT scans used to evaluate new clinical complications localized high FDG-avidity lesions for biopsies. This resulted in clinically relevant new diagnoses in 32 patients, including those with more aggressive lymphoma (n = 16), non-hematological malignancies (n = 8) and opportunistic infections (n = 3). Twenty-seven patients had high FDG-avidity CLL, which was associated with prominent lymph node proliferation centers, an increased frequency of poor prognostic factors (17p13 deletion, unmutated immunoglobulin heavy chain variable gene [IGHV], expression of ZAP-70 and CD38) and a shorter overall survival. We conclude that FDG PET scans should not be used for routine surveillance of patients with CLL. However PET-CT scans are sensitive, but not specific, for detection of aggressive lymphomas, other cancers and systemic infections in patients with CLL.",Journal Article,2164.0,24.0,Chronic lymphocytic leukemia/small lymphocytic CLL cells typically have low 2-deoxy-2- 18 F fluoro-d-glucose FDG avidity and patients with CLL have an increased risk of developing FDG-avid aggressive lymphomas second malignancies and infections We hypothesized that FDG positron emission tomography-computed tomography PET-CT of the trunk is a sensitive method of detecting these complications in patients with CLL Of the of 2299 patients with CLL seen in the Division of Hematology at Mayo Clinic Rochester between 1 January 2006 and 31 December 2011 272 11.8 had 526 PET-CT scans and 472 89.7 of these were reported as abnormal Among the 293 55.7 PET-CT scans used for routine evaluation of CLL the PET component was of clinical value in only one instance In contrast in 83 30.5 patients PET-CT scans used to evaluate new clinical complications localized high FDG-avidity lesions for biopsies This resulted in clinically relevant new diagnoses in 32 patients including those with more aggressive n 16 non-hematological malignancies n 8 and opportunistic infections n 3 Twenty-seven patients had high FDG-avidity CLL which was associated with prominent lymph node proliferation centers an increased frequency of poor prognostic factors 17p13 deletion unmutated immunoglobulin heavy chain variable gene IGHV expression of ZAP-70 and CD38 and a shorter overall survival We conclude that FDG PET scans should not be used for routine surveillance of patients with CLL However PET-CT scans are sensitive but not specific for detection of aggressive lymphomas other cancers and systemic infections in patients with CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 2647, 302, 1193, 552, 37, 1969, 47, 154, 18, 6149, 18, 203, 1068, 6231, 427, 2522, 1285, 6071, 2, 7, 5, 552, 47, 35, 101, 43, 1, 931, 1285, 5189, 571, 1557, 419, 441, 2, 1875, 21, 1237, 17, 1285, 1900, 1799, 872, 1220, 872, 495, 425, 1, 3, 5895, 16, 8, 745, 596, 1, 2502, 46, 521, 4, 7, 5, 552, 1, 3, 1, 31328, 7, 5, 552, 527, 4, 3, 5750, 1, 6216, 28, 2486, 1188, 5801, 59, 14, 1024, 1324, 2, 456, 1397, 1132, 6905, 175, 66, 42, 13597, 495, 425, 1441, 2, 10887, 887, 67, 1, 46, 11, 210, 22, 1668, 107, 3, 7541, 614, 67, 495, 425, 1441, 95, 9, 1311, 451, 1, 552, 3, 495, 1249, 10, 1, 38, 549, 4, 158, 104, 10642, 4, 748, 4, 852, 201, 33, 7, 495, 425, 1441, 95, 6, 376, 217, 38, 521, 909, 64, 1285, 6071, 406, 9, 1154, 26, 627, 4, 505, 867, 217, 2403, 4, 531, 7, 141, 135, 5, 80, 571, 78, 245, 220, 2890, 441, 78, 66, 2, 10026, 1875, 78, 27, 737, 648, 7, 42, 64, 1285, 6071, 552, 92, 10, 41, 5, 3689, 263, 289, 457, 1168, 35, 101, 675, 1, 334, 177, 130, 7526, 1528, 7216, 2593, 4013, 1260, 1347, 145, 6220, 55, 1, 6251, 431, 2, 4469, 2, 8, 985, 63, 25, 21, 2060, 17, 1285, 495, 1441, 257, 44, 40, 95, 9, 1311, 617, 1, 7, 5, 552, 137, 495, 425, 1441, 32, 745, 84, 44, 112, 9, 638, 1, 571, 1557, 127, 163, 2, 403, 1875, 4, 7, 5, 552]",1613.0,24286263,729
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.,International journal of hematology,Int. J. Hematol.,2013-12-06,"The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin's lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies. ",Journal Article,2237.0,66.0,The genetic modification of autologous T cells with chimeric antigen receptors CARs represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies By targeting the CD19 antigen we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic B-ALL We demonstrated rapid induction of deep molecular remissions in adults which has been recently confirmed in a case report involving a child with B-ALL In contrast to the results when treating B-ALL outcomes have been more modest in patients with chronic lymphocytic CLL or other 's NHL We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL Lastly we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple and acute myeloid We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 336, 2437, 1, 1028, 102, 37, 5, 2897, 448, 1186, 7441, 1449, 8, 6022, 9, 145, 6717, 22, 8, 12, 36, 9, 813, 441, 20, 529, 3, 3158, 448, 21, 47, 264, 1922, 2, 1321, 312, 2647, 128, 4, 7, 5, 2447, 671, 73, 2, 56, 430, 132, 31, 286, 1275, 132, 62, 21, 264, 1321, 504, 1, 2369, 219, 3166, 4, 857, 92, 71, 85, 761, 557, 4, 8, 473, 414, 1267, 8, 2566, 5, 132, 62, 4, 748, 6, 3, 99, 198, 1367, 132, 62, 123, 47, 85, 80, 1721, 4, 7, 5, 442, 1193, 552, 15, 127, 292, 1176, 21, 206, 3, 38, 160, 730, 529, 132, 62, 2, 552, 2, 11778, 23, 3, 899, 2325, 9, 3, 338, 123, 2, 2548, 174, 3980, 6, 1881, 102, 31, 36, 198, 529, 552, 15, 127, 2316, 1176, 6354, 21, 1139, 3, 671, 38, 193, 2, 174, 9, 38, 2691, 9, 75, 1881, 102, 37, 480, 232, 2, 286, 533, 21, 1817, 3, 174, 1098, 2, 1141, 20, 529, 46, 334, 228, 813, 441]",1127.0,24311149,638
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).,Blood,Blood,2013-12-05,"Chronic lymphocytic leukemia (CLL) is characterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable responsiveness of the BCR to antigen ligation. Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL. Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising, however, raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL. To determine the role of BTK in CLL, we used patient samples and the E-TCL1 (TCL1) transgenic mouse model of CLL, which results in spontaneous leukemia development. Inhibition of BTK in primary human CLL cells by small interfering RNA promotes apoptosis. Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL, demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib. Collectively, our data confirm the importance of kinase-functional BTK in CLL. ",Journal Article,2238.0,95.0,Chronic lymphocytic CLL is characterized by constitutive activation of the B-cell receptor BCR signaling pathway but variable responsiveness of the BCR to antigen ligation Bruton 's tyrosine kinase BTK shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising however raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL To determine the role of BTK in CLL we used patient samples and the E-TCL1 TCL1 transgenic mouse model of CLL which results in spontaneous development Inhibition of BTK in primary human CLL cells by small interfering RNA promotes apoptosis Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib Collectively our data confirm the importance of kinase-functional BTK in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 765, 20, 3178, 363, 1, 3, 132, 31, 153, 1062, 314, 308, 84, 1347, 3642, 1, 3, 1062, 6, 448, 5307, 5796, 292, 564, 216, 3611, 1949, 3178, 128, 4, 552, 2, 16, 3, 283, 1, 4422, 297, 20, 1795, 35, 1428, 6582, 216, 230, 17, 71, 443, 14565, 128, 4, 552, 191, 38, 99, 4, 552, 5, 127, 2786, 2, 4422, 3611, 222, 47, 85, 299, 721, 137, 6627, 3, 2840, 1, 317, 3611, 216, 128, 16, 35, 305, 283, 1, 1795, 2, 120, 4, 552, 6, 223, 3, 200, 1, 3611, 4, 552, 21, 95, 69, 347, 2, 3, 17467, 8979, 8979, 2862, 830, 202, 1, 552, 92, 99, 4, 3280, 193, 297, 1, 3611, 4, 86, 171, 552, 37, 20, 302, 3449, 893, 2148, 351, 297, 1, 3611, 216, 128, 298, 361, 238, 336, 2297, 15, 1795, 4, 3, 8979, 830, 97, 3257, 3, 193, 1, 552, 2219, 17, 3611, 16, 8, 740, 216, 9, 552, 193, 2, 1422, 2, 631, 35, 305, 283, 1, 1795, 2535, 114, 74, 1843, 3, 1187, 1, 216, 583, 3611, 4, 552]",1190.0,24311722,756
"Lymphoma-associated skin cancer: incidence, natural history, and clinical management.",International journal of dermatology,Int. J. Dermatol.,2013-12-10,"The link between immunosuppression and skin cancer has been well described. The two most common situations involving immunosuppression-associated skin cancer are solid organ transplantation and non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). Patients with lymphoma are more likely to have development of a secondary malignancy, with skin cancer being the most common. The most common types of skin cancer in patients with NHL/CLL include melanoma, squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. Many skin cancers demonstrate increased aggressiveness in patients with NHL/CLL and are associated with higher recurrence rates, increased regional metastasis, and death secondary to skin cancer metastases. This review delineates the current research regarding the relationship between NHL/CLL and cutaneous malignancy. Immunosuppressed patients with skin cancer should be treated promptly and aggressively to decrease recurrence and metastases. Regular skin self-examinations, dermatologic examinations, sun-protective habits, and education may prove beneficial in this high-risk patient population. ",Journal Article,2233.0,14.0,The link between immunosuppression and cancer has been well described The two most common situations involving immunosuppression-associated cancer are solid organ transplantation and NHL including chronic lymphocytic CLL Patients with are more likely to have development of a secondary malignancy with cancer being the most common The most common types of cancer in patients with NHL/CLL include squamous cell carcinoma basal cell carcinoma and Merkel cell carcinoma Many cancers demonstrate increased aggressiveness in patients with NHL/CLL and are associated with higher recurrence rates increased regional metastasis and death secondary to cancer metastases This review delineates the current research regarding the relationship between NHL/CLL and cutaneous malignancy Immunosuppressed patients with cancer should be treated promptly and aggressively to decrease recurrence and metastases Regular self-examinations dermatologic examinations sun-protective habits and education may prove beneficial in this high-risk patient population,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[3, 3460, 59, 3646, 2, 12, 71, 85, 149, 1027, 3, 100, 96, 186, 5990, 1267, 3646, 41, 12, 32, 537, 1259, 497, 2, 1176, 141, 442, 1193, 552, 7, 5, 32, 80, 322, 6, 47, 193, 1, 8, 568, 710, 5, 12, 486, 3, 96, 186, 3, 96, 186, 630, 1, 12, 4, 7, 5, 1176, 552, 643, 691, 31, 134, 2135, 31, 134, 2, 5855, 31, 134, 445, 163, 608, 101, 3908, 4, 7, 5, 1176, 552, 2, 32, 41, 5, 142, 146, 151, 101, 951, 278, 2, 273, 568, 6, 12, 196, 26, 206, 16645, 3, 291, 389, 666, 3, 858, 59, 1176, 552, 2, 1486, 710, 12749, 7, 5, 12, 257, 40, 73, 11396, 2, 8503, 6, 775, 146, 2, 196, 3316, 1074, 4209, 4722, 4209, 5479, 2864, 9973, 2, 1848, 68, 4361, 2524, 4, 26, 64, 43, 69, 266]",1038.0,24320558,101
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-12-07,"An allogeneic hematopoietic cell transplantation from an HLA-identical donor after high-dose (myeloablative) pretransplantation conditioning is an effective therapy for some people with chronic lymphocytic leukemia (CLL). Because CLL is a highly radiosensitive cancer, we hypothesized that total body irradiation (TBI) conditioning regimens may be associated with better outcomes than those without TBI. To answer this, we analyzed data from 180 subjects with CLL receiving myeloablative doses of TBI (n = 126) or not (n = 54), who received transplants from an HLA-identical sibling donor between 1995 and 2007 and reported to the Center for International Blood & Marrow Transplant Research. At 5 years, treatment-related mortality was 48% (95% confidence interval [CI], 39% to 57%) versus 50% (95% CI, 36% to 64%); P = NS. Relapse rates were 17% (95% CI, 11% to 25%) versus 22% (95% CI, 11% to 35%); P = NS. Five-year progression-free survival and overall survival were 34% (95% CI, 26% to 43%) versus 28% (95% CI, 15% to 42%); P = NS and 42% (95% CI, 33% to 51%) versus 33% (95% CI, 19% to 48%); P = NS, respectively. The single most common cause of death in both cohorts was recurrent/progressive CLL. No variable tested in the multivariate analysis was found to significantly affect these outcomes, including having failed fludarabine. Within the limitations of this study, we found no difference in HLA-identical sibling transplantation outcomes between myeloablative TBI and chemotherapy pretransplantation conditioning in persons with CLL.",Journal Article,2236.0,8.0,An allogeneic hematopoietic cell transplantation from an HLA-identical donor after high-dose myeloablative pretransplantation conditioning is an effective therapy for some people with chronic lymphocytic CLL Because CLL is a highly radiosensitive cancer we hypothesized that total body irradiation TBI conditioning regimens may be associated with better outcomes than those without TBI To answer this we analyzed data from 180 subjects with CLL receiving myeloablative doses of TBI n 126 or not n 54 who received transplants from an HLA-identical sibling donor between 1995 and 2007 and reported to the Center for International Blood Marrow Transplant Research At 5 years treatment-related mortality was 48 95 confidence interval CI 39 to 57 versus 50 95 CI 36 to 64 P NS Relapse rates were 17 95 CI 11 to 25 versus 22 95 CI 11 to 35 P NS Five-year progression-free survival and overall survival were 34 95 CI 26 to 43 versus 28 95 CI 15 to 42 P NS and 42 95 CI 33 to 51 versus 33 95 CI 19 to 48 P NS respectively The single most common cause of death in both cohorts was recurrent/progressive CLL No variable tested in the multivariate analysis was found to significantly affect these outcomes including having failed fludarabine Within the limitations of this study we found no difference in HLA-identical sibling transplantation outcomes between myeloablative TBI and chemotherapy pretransplantation conditioning in persons with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[35, 1063, 1007, 31, 497, 29, 35, 1160, 3038, 1488, 50, 64, 61, 3246, 9367, 1933, 16, 35, 323, 36, 9, 476, 3788, 5, 442, 1193, 552, 408, 552, 16, 8, 561, 9478, 12, 21, 1237, 17, 181, 642, 1104, 4889, 1933, 472, 68, 40, 41, 5, 380, 123, 76, 135, 187, 4889, 6, 6634, 26, 21, 311, 74, 29, 3172, 976, 5, 552, 357, 3246, 415, 1, 4889, 78, 3927, 15, 44, 78, 667, 54, 103, 4016, 29, 35, 1160, 3038, 3684, 1488, 59, 2323, 2, 1307, 2, 210, 6, 3, 574, 9, 944, 315, 581, 941, 389, 28, 33, 60, 24, 139, 282, 10, 576, 48, 307, 268, 58, 587, 6, 696, 185, 212, 48, 58, 511, 6, 660, 19, 4044, 429, 151, 11, 269, 48, 58, 175, 6, 243, 185, 350, 48, 58, 175, 6, 465, 19, 4044, 365, 111, 91, 115, 25, 2, 63, 25, 11, 562, 48, 58, 432, 6, 601, 185, 339, 48, 58, 167, 6, 595, 19, 4044, 2, 595, 48, 58, 466, 6, 725, 185, 466, 48, 58, 326, 6, 576, 19, 4044, 106, 3, 226, 96, 186, 708, 1, 273, 4, 110, 736, 10, 387, 1014, 552, 77, 1347, 650, 4, 3, 331, 65, 10, 204, 6, 97, 1158, 46, 123, 141, 1041, 1551, 2027, 262, 3, 1939, 1, 26, 45, 21, 204, 77, 523, 4, 1160, 3038, 3684, 497, 123, 59, 3246, 4889, 2, 56, 9367, 1933, 4, 4327, 5, 552]",1435.0,24321745,453
"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.",The Lancet. Oncology,Lancet Oncol.,2013-12-10,"Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia. In our open-label phase 1b/2 trial, we enrolled previously untreated patients at clinical sites in the USA. Eligible patients were aged at least 65 years, and had symptomatic chronic lymphocytic leukaemia or small lymphocytic lymphoma requiring therapy. Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg. The 840 mg dose was discontinued after enrolment had begun because comparable activity of the doses has been shown. The primary endpoint was the safety of the dose-fixed regimen in terms of frequency and severity of adverse events for all patients who received treatment. This study is registered with ClinicalTrials.gov, number NCT01105247. Between May 20, 2010, and Dec 18, 2012, we enrolled 29 patients with chronic lymphocytic leukaemia and two patients with small lymphocytic lymphoma. Median age was 71 years (range 65-84), and 23 (74%) patients were at least 70 years old. Toxicity was mainly of mild-to-moderate severity (grade 1-2). 21 (68%) patients had diarrhoea (grade 1 in 14 [45%] patients, grade 2 in three [10%] patients, and grade 3 in four [13%] patients). 15 (48%) patients developed nausea (grade 1 in 12 [39%] patients and grade 2 in three [10%] patients). Ten (32%) patients developed fatigue (grade 1 in five [16%] patients, grade 2 in four [13%] patients, and grade 3 in one [3%] patient). Three (10%) patients developed grade 3 infections, although no grade 4 or 5 infections occurred. One patient developed grade 3 neutropenia, and one developed grade 4 thrombocytopenia. After a median follow-up of 22.1 months (IQR 18.4-23.2), 22 (71%) of 31 patients achieved an objective response (95% CI 52.0-85.8); four patients (13%) had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response. The safety and activity of ibrutinib in elderly, previously untreated patients with symptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits further investigation in phase 3 trials. Pharmacyclics, Leukemia and Lymphoma Society, D Warren Brown Foundation, Mr and Mrs Michael Thomas, Harry Mangurian Foundation, P50 CA140158 to Prof J C Byrd MD.","Clinical Trial, Phase I",2233.0,,Chemoimmunotherapy has led to improved numbers of patients achieving disease response and longer overall survival in young patients with chronic lymphocytic leukaemia however its application in elderly patients has been restricted by substantial myelosuppression and infection We aimed to assess safety and activity of ibrutinib an orally administered covalent inhibitor of Bruton tyrosine kinase BTK in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia In our open-label phase 1b/2 trial we enrolled previously untreated patients at clinical sites in the USA Eligible patients were aged at least 65 years and had symptomatic chronic lymphocytic leukaemia or small lymphocytic requiring therapy Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg The 840 mg dose was discontinued after enrolment had begun because comparable activity of the doses has been shown The primary endpoint was the safety of the dose-fixed regimen in terms of frequency and severity of adverse events for all patients who received treatment This study is registered with ClinicalTrials.gov number NCT01105247 Between May 20 2010 and Dec 18 2012 we enrolled 29 patients with chronic lymphocytic leukaemia and two patients with small lymphocytic Median age was 71 years range 65-84 and 23 74 patients were at least 70 years old Toxicity was mainly of mild-to-moderate severity grade 1-2 21 68 patients had diarrhoea grade 1 in 14 45 patients grade 2 in three 10 patients and grade 3 in four 13 patients 15 48 patients developed nausea grade 1 in 12 39 patients and grade 2 in three 10 patients Ten 32 patients developed fatigue grade 1 in five 16 patients grade 2 in four 13 patients and grade 3 in one 3 patient Three 10 patients developed grade 3 infections although no grade 4 or 5 infections occurred One patient developed grade 3 neutropenia and one developed grade 4 thrombocytopenia After a median follow-up of 22.1 months IQR 18.4-23.2 22 71 of 31 patients achieved an objective response 95 CI 52.0-85.8 four patients 13 had a complete response one patient 3 had a nodular partial response and 17 55 patients had a partial response The safety and activity of ibrutinib in elderly previously untreated patients with symptomatic chronic lymphocytic leukaemia or small lymphocytic is encouraging and merits further investigation in phase 3 trials Pharmacyclics and Society D Warren Brown Foundation Mr and Mrs Michael Thomas Harry Mangurian Foundation P50 CA140158 to Prof J C Byrd MD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4438, 71, 836, 6, 231, 1870, 1, 7, 1785, 34, 51, 2, 589, 63, 25, 4, 1169, 7, 5, 442, 1193, 2001, 137, 211, 1581, 4, 1216, 7, 71, 85, 2016, 20, 1281, 2858, 2, 930, 21, 1295, 6, 423, 367, 2, 128, 1, 1795, 35, 1428, 468, 10747, 230, 1, 5796, 564, 216, 3611, 4, 24, 2462, 7, 1032, 556, 60, 2, 434, 5, 442, 1193, 2001, 4, 114, 1020, 1756, 124, 4693, 18, 160, 21, 346, 373, 1278, 7, 28, 38, 633, 4, 3, 2706, 625, 7, 11, 1032, 28, 506, 556, 60, 2, 42, 1704, 442, 1193, 2001, 15, 302, 1193, 1888, 36, 7, 103, 339, 218, 410, 1, 1059, 391, 1795, 5401, 81, 15, 1795, 10752, 81, 3, 10752, 81, 61, 10, 2402, 50, 8206, 42, 6973, 408, 1279, 128, 1, 3, 415, 71, 85, 443, 3, 86, 1138, 10, 3, 367, 1, 3, 61, 1959, 477, 4, 1794, 1, 675, 2, 1702, 1, 290, 281, 9, 62, 7, 54, 103, 24, 26, 45, 16, 1653, 5, 1252, 1239, 207, 27296, 59, 68, 179, 1120, 2, 8702, 203, 1195, 21, 346, 462, 7, 5, 442, 1193, 2001, 2, 100, 7, 5, 302, 1193, 52, 89, 10, 792, 60, 184, 556, 874, 2, 382, 794, 7, 11, 28, 506, 431, 60, 1095, 155, 10, 2615, 1, 1980, 6, 1163, 1702, 88, 14, 18, 239, 806, 7, 42, 4959, 88, 14, 4, 213, 512, 7, 88, 18, 4, 169, 79, 7, 2, 88, 27, 4, 294, 233, 7, 167, 576, 7, 276, 1218, 88, 14, 4, 133, 587, 7, 2, 88, 18, 4, 169, 79, 7, 1618, 531, 7, 276, 613, 88, 14, 4, 365, 245, 7, 88, 18, 4, 294, 233, 7, 2, 88, 27, 4, 104, 27, 69, 169, 79, 7, 276, 88, 27, 1875, 242, 77, 88, 39, 15, 33, 1875, 489, 104, 69, 276, 88, 27, 778, 2, 104, 276, 88, 39, 1340, 50, 8, 52, 166, 126, 1, 350, 14, 53, 2245, 203, 39, 382, 18, 350, 792, 1, 456, 7, 513, 35, 461, 51, 48, 58, 653, 13, 772, 66, 294, 7, 233, 42, 8, 236, 51, 104, 69, 27, 42, 8, 4481, 450, 51, 2, 269, 614, 7, 42, 8, 450, 51, 3, 367, 2, 128, 1, 1795, 4, 1216, 373, 1278, 7, 5, 1704, 442, 1193, 2001, 15, 302, 1193, 16, 2269, 2, 4986, 195, 940, 4, 124, 27, 143, 20013, 2, 1174, 427, 33912, 17305, 3247, 1638, 2, 6087, 20499, 20697, 48102, 63724, 3247, 16197, 63725, 6, 63726, 3543, 256, 33330, 2244]",2528.0,24332241,507
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.,Cancer discovery,Cancer Discov,2013-12-17,"B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge to identify those tumors that are best treated by inhibition of BCL-2. Here, we demonstrate that acute myeloid leukemia (AML) cell lines, primary patient samples, and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist ABT-199. In primary patient cells, the median IC50 was approximately 10 nmol/L, and cell death occurred within 2 hours. Our ex vivo sensitivity results compare favorably with those observed for chronic lymphocytic leukemia, a disease for which ABT-199 has demonstrated consistent activity in clinical trials. Moreover, mitochondrial studies using BH3 profiling demonstrate activity at the mitochondrion that correlates well with cytotoxicity, supporting an on-target mitochondrial mechanism of action. Our protein and BH3 profiling studies provide promising tools that can be tested as predictive biomarkers in any clinical trial of ABT-199 in AML. ",Journal Article,2226.0,240.0,B-cell leukemia/lymphoma 2 BCL-2 prevents commitment to programmed cell death at the mitochondrion It remains a challenge to identify those tumors that are best treated by inhibition of BCL-2 Here we demonstrate that acute myeloid AML cell lines primary patient samples and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist ABT-199 In primary patient cells the median IC50 was approximately 10 nmol/L and cell death occurred within 2 hours Our ex vivo sensitivity results compare favorably with those observed for chronic lymphocytic a disease for which ABT-199 has demonstrated consistent activity in clinical trials Moreover mitochondrial studies using BH3 profiling demonstrate activity at the mitochondrion that correlates well with cytotoxicity supporting an on-target mitochondrial mechanism of action Our protein and BH3 profiling studies provide promising tools that can be tested as predictive biomarkers in any clinical trial of ABT-199 in AML,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 2647, 4763, 18, 1044, 18, 5217, 11082, 6, 1846, 31, 273, 28, 3, 23662, 192, 469, 8, 1745, 6, 255, 135, 57, 17, 32, 824, 73, 20, 297, 1, 1044, 18, 467, 21, 608, 17, 286, 533, 329, 31, 285, 86, 69, 347, 2, 1471, 86, 1348, 32, 923, 745, 6, 24, 5, 3, 1094, 1044, 18, 3137, 3095, 5840, 4, 86, 69, 37, 3, 52, 5211, 10, 705, 79, 4694, 805, 2, 31, 273, 489, 262, 18, 1459, 114, 2581, 386, 485, 99, 932, 5001, 5, 135, 164, 9, 442, 1193, 8, 34, 9, 92, 3095, 5840, 71, 264, 925, 128, 4, 38, 143, 1393, 2019, 94, 75, 5486, 1080, 608, 128, 28, 3, 23662, 17, 1871, 149, 5, 1408, 1912, 35, 23, 283, 2019, 670, 1, 1578, 114, 178, 2, 5486, 1080, 94, 377, 721, 1896, 17, 122, 40, 650, 22, 464, 582, 4, 500, 38, 160, 1, 3095, 5840, 4, 329]",997.0,24346116,139
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.,Cancer discovery,Cancer Discov,2013-12-19,"Although clonal selection by genetic driver aberrations in cancer is well documented, the ability of epigenetic alterations to promote tumor evolution is undefined. We used 450k arrays and next-generation sequencing to evaluate intratumor heterogeneity and evolution of DNA methylation and genetic aberrations in chronic lymphocytic leukemia (CLL). CLL cases exhibit vast interpatient differences in intratumor methylation heterogeneity, with genetically clonal cases maintaining low methylation heterogeneity and up to 10% of total CpGs in a monoallelically methylated state. Increasing methylation heterogeneity correlates with advanced genetic subclonal complexity. Selection of novel DNA methylation patterns is observed only in cases that undergo genetic evolution, and independent genetic evolution is uncommon and is restricted to low-risk alterations. These results reveal that although evolution of DNA methylation occurs in high-risk, clinically progressive cases, positive selection of novel methylation patterns entails coevolution of genetic alteration(s) in CLL. ",Journal Article,2224.0,78.0,Although clonal selection by genetic driver aberrations in cancer is well documented the ability of epigenetic alterations to promote tumor evolution is undefined We used 450k arrays and next-generation sequencing to evaluate intratumor heterogeneity and evolution of DNA methylation and genetic aberrations in chronic lymphocytic CLL CLL cases exhibit vast interpatient differences in intratumor methylation heterogeneity with genetically clonal cases maintaining low methylation heterogeneity and up to 10 of total CpGs in a monoallelically methylated state Increasing methylation heterogeneity correlates with advanced genetic subclonal complexity Selection of novel DNA methylation patterns is observed only in cases that undergo genetic evolution and independent genetic evolution is uncommon and is restricted to low-risk alterations These results reveal that although evolution of DNA methylation occurs in high-risk clinically progressive cases positive selection of novel methylation patterns entails coevolution of genetic alteration s in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 1946, 881, 20, 336, 2228, 2152, 4, 12, 16, 149, 1405, 3, 801, 1, 1418, 593, 6, 1617, 30, 2554, 16, 5425, 21, 95, 25521, 3923, 2, 1305, 914, 615, 6, 376, 7692, 1144, 2, 2554, 1, 261, 569, 2, 336, 2152, 4, 442, 1193, 552, 552, 140, 2239, 4337, 7423, 362, 4, 7692, 569, 1144, 5, 2301, 1946, 140, 3284, 154, 569, 1144, 2, 126, 6, 79, 1, 181, 11432, 4, 8, 44672, 2963, 1309, 602, 569, 1144, 1871, 5, 131, 336, 9210, 3082, 881, 1, 229, 261, 569, 764, 16, 164, 158, 4, 140, 17, 1251, 336, 2554, 2, 306, 336, 2554, 16, 2052, 2, 16, 2016, 6, 154, 43, 593, 46, 99, 2396, 17, 242, 2554, 1, 261, 569, 1780, 4, 64, 43, 505, 1014, 140, 109, 881, 1, 229, 569, 764, 14080, 48112, 1, 336, 2611, 695, 4, 552]",1052.0,24356097,242
"A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.",Blood,Blood,2013-12-31,"Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered intravenously to patients with chronic lymphocytic leukemia (CLL). Otlertuzumab was administered weekly for up to 8 weeks followed by 1 dose per month for 4 months ranging from 0.03 to 20 mg/kg in the dose-escalation phase and 10 to 30 mg/kg in the dose-expansion phase. Responses were determined by using the 1996 National Cancer Institute (NCI-96) and 2008 International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) criteria. Fifty-seven patients were treated in the dose-escalation phase and 26 in the dose-expansion phase. A maximum-tolerated dose was not identified. Response occurred in 19 (23%) of 83 treated patients by NCI-96 criteria. All responses were partial and occurred more commonly in patients with symptomatic untreated CLL (6/7) or 1 to 2 prior therapies (12/28) vs 3 or more therapies (1/48). Twenty percent (12/61) with serial computed tomography scan assessment had a response per IWCLL criteria. The most frequent adverse events were infusion reactions, fatigue, nausea, and diarrhea and were not dose related. Otlertuzumab was well tolerated, and modest clinical activity was observed. Otlertuzumab warrants further evaluation in combination with other agents for the treatment of CLL. This trial was registered at www.clinicaltrials.gov as #NCT00614042. ","Clinical Trial, Phase I",2212.0,50.0,Otlertuzumab is a novel humanized anti-CD37 protein therapeutic This study evaluated the safety of otlertuzumab administered intravenously to patients with chronic lymphocytic CLL Otlertuzumab was administered weekly for up to 8 weeks followed by 1 dose per month for 4 months ranging from 0.03 to 20 mg/kg in the dose-escalation phase and 10 to 30 mg/kg in the dose-expansion phase Responses were determined by using the 1996 National Cancer Institute NCI-96 and 2008 International Workshop on Chronic Lymphocytic Leukaemia IWCLL criteria Fifty-seven patients were treated in the dose-escalation phase and 26 in the dose-expansion phase A maximum-tolerated dose was not identified Response occurred in 19 23 of 83 treated patients by NCI-96 criteria All responses were partial and occurred more commonly in patients with symptomatic untreated CLL 6/7 or 1 to 2 prior therapies 12/28 vs 3 or more therapies 1/48 Twenty percent 12/61 with serial computed tomography scan assessment had a response per IWCLL criteria The most frequent adverse events were infusion reactions fatigue nausea and diarrhea and were not dose related Otlertuzumab was well tolerated and modest clinical activity was observed Otlertuzumab warrants further evaluation in combination with other agents for the treatment of CLL This trial was registered at www.clinicaltrials.gov as NCT00614042,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[20031, 16, 8, 229, 3619, 312, 10006, 178, 189, 26, 45, 194, 3, 367, 1, 20031, 468, 1672, 6, 7, 5, 442, 1193, 552, 20031, 10, 468, 709, 9, 126, 6, 66, 244, 370, 20, 14, 61, 379, 811, 9, 39, 53, 2223, 29, 13, 680, 6, 179, 81, 503, 4, 3, 61, 1125, 124, 2, 79, 6, 201, 81, 503, 4, 3, 61, 1422, 124, 253, 11, 509, 20, 75, 3, 2648, 657, 12, 1377, 2580, 921, 2, 1375, 944, 4014, 23, 442, 1193, 2001, 16575, 371, 1461, 648, 7, 11, 73, 4, 3, 61, 1125, 124, 2, 432, 4, 3, 61, 1422, 124, 8, 689, 421, 61, 10, 44, 108, 51, 489, 4, 326, 382, 1, 852, 73, 7, 20, 2580, 921, 371, 62, 253, 11, 450, 2, 489, 80, 841, 4, 7, 5, 1704, 1278, 552, 49, 67, 15, 14, 6, 18, 324, 235, 133, 339, 105, 27, 15, 80, 235, 14, 576, 737, 714, 133, 713, 5, 2108, 1220, 872, 1657, 455, 42, 8, 51, 379, 16575, 371, 3, 96, 908, 290, 281, 11, 904, 2428, 613, 1218, 2, 1172, 2, 11, 44, 61, 139, 20031, 10, 149, 421, 2, 1721, 38, 128, 10, 164, 20031, 2782, 195, 451, 4, 150, 5, 127, 183, 9, 3, 24, 1, 552, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 63784]",1365.0,24381226,56
How will B-cell-receptor-targeted therapies change future CLL therapy?,Blood,Blood,2014-01-06,"For many years there has been considerable disassociation between the understood biology of chronic lymphocytic leukemia (CLL) and the therapeutics used to treat this disease. With the introduction of the first targeted CD20 antibody rituximab and its addition to chemotherapy came the first observation that minimal residual disease-negative (MRD-negative) complete responses (CRs) could be obtained with dramatically improved progression-free survival and overall survival. This advance was soon to be surpassed by the introduction of therapeutics that target B-cell receptor (BCR) signaling. New data show that BCR-inhibiting agents are very active for the treatment of relapsed CLL, despite the lack of MRD-negative CR, with durability of response being considerably more impressive than previously observed with other agents not producing MRD-negative CRs. This perspective provides a view of where these agents may take us in the future as CLL therapy evolves with this exciting new class of drugs. ",Journal Article,2206.0,44.0,For many years there has been considerable disassociation between the understood biology of chronic lymphocytic CLL and the therapeutics used to treat this disease With the introduction of the first targeted CD20 antibody rituximab and its addition to chemotherapy came the first observation that minimal residual disease-negative MRD-negative complete responses CRs could be obtained with dramatically improved progression-free survival and overall survival This advance was soon to be surpassed by the introduction of therapeutics that target B-cell receptor BCR signaling New data show that BCR-inhibiting agents are very active for the treatment of relapsed CLL despite the lack of MRD-negative CR with durability of response being considerably more impressive than previously observed with other agents not producing MRD-negative CRs This perspective provides a view of where these agents may take us in the future as CLL therapy evolves with this exciting new class of drugs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[9, 445, 60, 125, 71, 85, 2658, 40579, 59, 3, 1784, 891, 1, 442, 1193, 552, 2, 3, 1943, 95, 6, 943, 26, 34, 5, 3, 2456, 1, 3, 157, 238, 2198, 548, 855, 2, 211, 352, 6, 56, 8594, 3, 157, 1664, 17, 1048, 753, 34, 199, 2029, 199, 236, 253, 3115, 359, 40, 683, 5, 2729, 231, 91, 115, 25, 2, 63, 25, 26, 3148, 10, 6176, 6, 40, 17697, 20, 3, 2456, 1, 1943, 17, 283, 132, 31, 153, 1062, 314, 217, 74, 514, 17, 1062, 2062, 183, 32, 923, 544, 9, 3, 24, 1, 591, 552, 550, 3, 926, 1, 2029, 199, 684, 5, 6867, 1, 51, 486, 5597, 80, 5790, 76, 373, 164, 5, 127, 183, 44, 3787, 2029, 199, 3115, 26, 3727, 777, 8, 3811, 1, 1257, 46, 183, 68, 3585, 843, 4, 3, 508, 22, 552, 36, 10413, 5, 26, 4963, 217, 1040, 1, 600]",980.0,24394667,795
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.,Blood,Blood,2014-01-10,"The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing lymphocyte egress from nodal compartments. This resolves within 8 months in the majority of patients, but a subgroup has lymphocytosis lasting >12 months. Here we report a detailed characterization of patients with persistent lymphocytosis during ibrutinib therapy. Signaling evaluation showed that while BTK is inhibited, downstream mediators of B-cell receptor (BCR) signaling are activated in persistent lymphocytes. These cells cannot be stimulated through the BCR and do not show evidence of target gene activation. Flow cytometry for  and  expression, IGHV sequencing, Zap-70 methylation, and targeted gene sequencing in these patients are identical at baseline and later time points, suggesting that persistent lymphocytes do not represent clonal evolution. In vitro treatment with targeted kinase inhibitors shows that they are not addicted to a single survival pathway. Finally, progression-free survival is not inferior for patients with prolonged lymphocytosis vs those with traditional responses. Thus, prolonged lymphocytosis is common following ibrutinib treatment, likely represents the persistence of a quiescent clone, and does not predict a subgroup of patients likely to relapse early. ",Journal Article,2202.0,177.0,The Bruton 's tyrosine kinase BTK inhibitor ibrutinib has outstanding activity in patients with chronic lymphocytic Most patients experience lymphocytosis representing lymphocyte egress from nodal compartments This resolves within 8 months in the majority of patients but a subgroup has lymphocytosis lasting 12 months Here we report a detailed characterization of patients with persistent lymphocytosis during ibrutinib therapy Signaling evaluation showed that while BTK is inhibited downstream mediators of B-cell receptor BCR signaling are activated in persistent lymphocytes These cells can not be stimulated through the BCR and do not show evidence of target gene activation Flow cytometry for  and  expression IGHV sequencing Zap-70 methylation and targeted gene sequencing in these patients are identical at baseline and later time points suggesting that persistent lymphocytes do not represent clonal evolution In vitro treatment with targeted kinase inhibitors shows that they are not addicted to a single survival pathway Finally progression-free survival is not inferior for patients with prolonged lymphocytosis vs those with traditional responses Thus prolonged lymphocytosis is common following ibrutinib treatment likely represents the persistence of a quiescent clone and does not predict a subgroup of patients likely to relapse early,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 5796, 292, 564, 216, 3611, 230, 1795, 71, 14565, 128, 4, 7, 5, 442, 1193, 96, 7, 730, 8125, 2861, 1448, 24404, 29, 779, 6473, 26, 21321, 262, 66, 53, 4, 3, 686, 1, 7, 84, 8, 1363, 71, 8125, 3443, 133, 53, 467, 21, 414, 8, 2455, 2136, 1, 7, 5, 1882, 8125, 190, 1795, 36, 314, 451, 224, 17, 369, 3611, 16, 879, 1489, 4425, 1, 132, 31, 153, 1062, 314, 32, 735, 4, 1882, 1594, 46, 37, 122, 44, 40, 2816, 298, 3, 1062, 2, 1022, 44, 514, 241, 1, 283, 145, 363, 1412, 1914, 9, 4627, 2, 12441, 55, 6220, 615, 6251, 431, 569, 2, 238, 145, 615, 4, 46, 7, 32, 3038, 28, 330, 2, 1559, 98, 862, 802, 17, 1882, 1594, 1022, 44, 1231, 1946, 2554, 4, 439, 24, 5, 238, 216, 222, 1949, 17, 491, 32, 44, 10448, 6, 8, 226, 25, 308, 1368, 91, 115, 25, 16, 44, 1663, 9, 7, 5, 1069, 8125, 105, 135, 5, 1847, 253, 631, 1069, 8125, 16, 186, 366, 1795, 24, 322, 1449, 3, 4108, 1, 8, 6735, 3910, 2, 1097, 44, 678, 8, 1363, 1, 7, 322, 6, 429, 191]",1353.0,24415539,349
How we treat Richter syndrome.,Blood,Blood,2014-01-13,"Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RS occurs in approximately 2% to 10% of CLL patients during the course of their disease, with a transformation rate of 0.5% to 1% per year. A combination of germline genetic characteristics, clinical features (eg, advanced Rai stage), biologic (-associated protein-70(+), CD38(+), CD49d(+)) and somatic genetic (del17p13.1 or del11q23.1) characteristics of CLL B cells, and certain CLL therapies are associated with higher risk of RS. Recent studies have also identified the crucial role of CDKN2A loss, TP53 disruption, C-MYC activation, and NOTCH1 mutations in the transformation from CLL to RS. An excisional lymph node biopsy is considered the gold standard for diagnosis of RS; a (18)F-fluorodeoxyglucose positron emission tomography scan can help inform the optimal site for biopsy. Approximately 80% of DLBCL cases in patients with CLL are clonally related to the underlying CLL, and the median survival for these patients is approximately 1 year. In contrast, the remaining 20% of patients have a clonally unrelated DLBCL and have a prognosis similar to that of de novo DLBCL. For patients with clonally related DLBCL, induction therapy with either an anthracycline- or platinum-based regimen is the standard approach. Postremission stem cell transplantation should be considered for appropriate patients. This article summarizes our approach to the clinical management of CLL patients who develop RS. ",Case Reports,2199.0,83.0,Richter syndrome RS is defined as the transformation of chronic lymphocytic CLL into an aggressive most commonly diffuse large B-cell DLBCL RS occurs in approximately 2 to 10 of CLL patients during the course of their disease with a transformation rate of 0.5 to 1 per year A combination of germline genetic characteristics clinical features eg advanced Rai stage biologic -associated protein-70 CD38 CD49d and somatic genetic del17p13.1 or del11q23.1 characteristics of CLL B cells and certain CLL therapies are associated with higher risk of RS Recent studies have also identified the crucial role of CDKN2A loss TP53 disruption C-MYC activation and NOTCH1 mutations in the transformation from CLL to RS An excisional lymph node biopsy is considered the gold standard for diagnosis of RS a 18 F-fluorodeoxyglucose positron emission tomography scan can help inform the optimal site for biopsy Approximately 80 of DLBCL cases in patients with CLL are clonally related to the underlying CLL and the median survival for these patients is approximately 1 year In contrast the remaining 20 of patients have a clonally unrelated DLBCL and have a prognosis similar to that of de novo DLBCL For patients with clonally related DLBCL induction therapy with either an anthracycline- or platinum-based regimen is the standard approach Postremission stem cell transplantation should be considered for appropriate patients This article summarizes our approach to the clinical management of CLL patients who develop RS,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 681, 2250, 16, 395, 22, 3, 1392, 1, 442, 1193, 552, 237, 35, 571, 96, 841, 1388, 375, 132, 31, 1446, 2250, 1780, 4, 705, 18, 6, 79, 1, 552, 7, 190, 3, 906, 1, 136, 34, 5, 8, 1392, 116, 1, 13, 33, 6, 14, 379, 111, 8, 150, 1, 1009, 336, 374, 38, 404, 2887, 131, 4121, 82, 1283, 14668, 41, 178, 431, 4469, 10485, 2, 1119, 336, 48147, 14, 15, 63833, 14, 374, 1, 552, 132, 37, 2, 1840, 552, 235, 32, 41, 5, 142, 43, 1, 2250, 435, 94, 47, 120, 108, 3, 2653, 200, 1, 3175, 407, 1206, 3220, 256, 1371, 363, 2, 4607, 138, 4, 3, 1392, 29, 552, 6, 2250, 35, 6488, 263, 289, 411, 16, 515, 3, 4159, 260, 9, 147, 1, 2250, 8, 203, 1068, 4085, 1900, 1799, 872, 1657, 122, 987, 2295, 3, 665, 606, 9, 411, 705, 493, 1, 1446, 140, 4, 7, 5, 552, 32, 9157, 139, 6, 3, 1181, 552, 2, 3, 52, 25, 9, 46, 7, 16, 705, 14, 111, 4, 748, 3, 1844, 179, 1, 7, 47, 8, 9157, 2092, 1446, 2, 47, 8, 356, 288, 6, 17, 1, 1566, 2018, 1446, 9, 7, 5, 9157, 139, 1446, 504, 36, 5, 361, 35, 2044, 15, 828, 90, 477, 16, 3, 260, 353, 8635, 452, 31, 497, 257, 40, 515, 9, 870, 7, 26, 946, 2869, 114, 353, 6, 3, 38, 284, 1, 552, 7, 54, 690, 2250]",1505.0,24421328,105
"Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.","Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2014-01-15,"Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complement-dependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance, which is not well characterized. To better understand mechanisms of resistance, we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL. As previously reported, OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and serum complement levels. We now show that after administration of the first dose of OFA, there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substantial ongoing loss of CD20 expression by CLL cells. These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro. Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment. In vitro OFA-mediated CDC did not predict clinical responses, and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo. We propose that optimal efficacy of CD20- targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells. ","Clinical Trial, Phase II",2197.0,26.0,Ofatumumab OFA a human CD20-targeting mAb kills B lymphocytes using the innate immune system including complement-dependent cytotoxicity CDC The efficacy of OFA in patients with chronic lymphocytic CLL is limited by drug resistance which is not well characterized To better understand mechanisms of resistance we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL As previously reported OFA therapy rapidly decreased the absolute lymphocyte count CD20 expression by CLL cells and serum complement levels We now show that after administration of the first dose of OFA there was a modest rebound in the absolute lymphocyte count and serum complement levels but substantial ongoing loss of CD20 expression by CLL cells These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment In vitro OFA-mediated CDC did not predict clinical responses and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo We propose that optimal efficacy of CD20- targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5732, 19977, 8, 171, 2198, 529, 2780, 10955, 132, 1594, 75, 3, 3939, 250, 398, 141, 3731, 470, 1408, 9665, 3, 209, 1, 19977, 4, 7, 5, 442, 1193, 552, 16, 383, 20, 234, 251, 92, 16, 44, 149, 765, 6, 380, 1640, 483, 1, 251, 21, 1143, 656, 552, 37, 1355, 29, 315, 347, 786, 348, 2, 50, 4, 386, 645, 6, 3, 388, 61, 1, 19977, 36, 4, 243, 7, 479, 136, 157, 24, 9, 1014, 552, 22, 373, 210, 19977, 36, 1755, 340, 3, 1766, 1448, 1276, 2198, 55, 20, 552, 37, 2, 524, 3731, 148, 21, 1134, 514, 17, 50, 634, 1, 3, 157, 61, 1, 19977, 125, 10, 8, 1721, 12309, 4, 3, 1766, 1448, 1276, 2, 524, 3731, 148, 84, 1281, 942, 407, 1, 2198, 55, 20, 552, 37, 46, 539, 19977, 24, 552, 37, 11, 561, 436, 6, 19977, 517, 9665, 84, 3532, 485, 6, 3579, 517, 9665, 4, 439, 8163, 524, 19977, 148, 438, 2659, 5, 110, 3, 3108, 1, 1194, 1033, 31, 2951, 2198, 2, 5, 3, 775, 4, 26, 549, 366, 24, 4, 439, 19977, 517, 9665, 205, 44, 678, 38, 253, 2, 3, 7, 5, 157, 61, 2428, 6, 19977, 205, 44, 47, 525, 1, 101, 3731, 363, 4, 386, 21, 2548, 17, 665, 209, 1, 2198, 238, 36, 9, 552, 1706, 2196, 35, 2780, 61, 444, 2, 675, 17, 16282, 552, 3003, 187, 5178, 3, 2162, 1, 3, 759, 483, 2, 631, 14527, 407, 1, 2198, 55, 4, 3, 3050, 552, 37]",1631.0,24431228,446
"Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.",Journal of clinical pharmacology,J Clin Pharmacol,2014-01-28,"Ofatumumab is a human monoclonal antibody directed at CD20 approved for treatment of chronic lymphocytic leukemia. The population pharmacokinetics of intravenous ofatumumab were characterized in patients with relapsed/refractory chronic lymphocytic leukemia, relapsed/refractory follicular lymphoma, and rheumatoid arthritis, diseases with widely varying CD20 B-cell counts in blood. Serum concentration data from a total of 477 patients who received ofatumumab doses ranging from 100mg to 2000mg in different dosing regimens were analyzed to determine the pharmacokinetic characteristics of ofatumumab across different patient groups and to identify factors contributing to the pharmacokinetic variability. Ofatumumab pharmacokinetics were well described by a linear two-compartment model component to represent non-specific monoclonal antibody clearance from the central compartment interacting with a model component representing the target-mediated clearance of ofatumumab by binding to CD20 expressed on B cells. The clearance (7.5mL/h) and steady-state volume of distribution (5.3L) for the linear, non-specific component were consistent with results obtained for other monoclonal antibodies. The target-mediated clearance component was related to the disease-specific number of circulating B cells, which will allow simulation of the contribution of target-mediated clearance to ofatumumab pharmacokinetics in untested disease states with data on B-cell counts and turnover.","Clinical Trial, Phase I",2184.0,14.0,Ofatumumab is a human monoclonal antibody directed at CD20 approved for treatment of chronic lymphocytic The population pharmacokinetics of intravenous ofatumumab were characterized in patients with relapsed/refractory chronic lymphocytic relapsed/refractory follicular and rheumatoid arthritis diseases with widely varying CD20 B-cell counts in blood Serum concentration data from a total of 477 patients who received ofatumumab doses ranging from 100 mg to 2000 mg in different dosing regimens were analyzed to determine the pharmacokinetic characteristics of ofatumumab across different patient groups and to identify factors contributing to the pharmacokinetic variability Ofatumumab pharmacokinetics were well described by a linear two-compartment model component to represent non-specific monoclonal antibody clearance from the central compartment interacting with a model component representing the target-mediated clearance of ofatumumab by binding to CD20 expressed on B cells The clearance 7.5 mL/h and steady-state volume of distribution 5.3 L for the linear non-specific component were consistent with results obtained for other monoclonal antibodies The target-mediated clearance component was related to the disease-specific number of circulating B cells which will allow simulation of the contribution of target-mediated clearance to ofatumumab pharmacokinetics in untested disease states with data on B-cell counts and turnover,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5732, 16, 8, 171, 848, 548, 1166, 28, 2198, 850, 9, 24, 1, 442, 1193, 3, 266, 1159, 1, 1262, 5732, 11, 765, 4, 7, 5, 591, 430, 442, 1193, 591, 430, 1974, 2, 12269, 8646, 1342, 5, 1792, 2990, 39589, 132, 31, 1911, 4, 315, 524, 1227, 74, 29, 8, 181, 1, 11810, 7, 54, 103, 5732, 415, 2223, 29, 394, 81, 6, 1081, 81, 4, 338, 1280, 472, 11, 311, 6, 223, 3, 1456, 374, 1, 5732, 716, 338, 69, 271, 2, 6, 255, 130, 3156, 6, 3, 1456, 1982, 5732, 1159, 11, 149, 1027, 20, 8, 1646, 100, 3616, 202, 1249, 6, 1231, 220, 112, 848, 548, 1960, 29, 3, 854, 3616, 5505, 5, 8, 202, 1249, 2861, 3, 283, 517, 1960, 1, 5732, 20, 791, 6, 2198, 570, 23, 132, 37, 3, 1960, 67, 33, 542, 555, 2, 4152, 1309, 433, 1, 1395, 33, 27, 805, 9, 3, 1646, 220, 112, 1249, 11, 925, 5, 99, 683, 9, 127, 848, 890, 3, 283, 517, 1960, 1249, 10, 139, 6, 3, 34, 112, 207, 1, 1033, 132, 37, 92, 303, 1700, 4026, 1, 3, 2925, 1, 283, 517, 1960, 6, 5732, 1159, 4, 17848, 34, 907, 5, 74, 23, 132, 31, 1911, 2, 5445]",1444.0,24443277,19
Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells.,PloS one,PLoS ONE,2014-01-29,"Chronic Lymphocytic Leukemia (CLL) is defined by a perturbed B-cell receptor-mediated signaling machinery. We aimed to model differential signaling behavior between B cells from CLL and healthy individuals to pinpoint modes of dysregulation. We developed an experimental methodology combining immunophenotyping, multiplexed phosphospecific flow cytometry, and multifactorial statistical modeling. Utilizing patterns of signaling network covariance, we modeled BCR signaling in 67 CLL patients using Partial Least Squares Regression (PLSR). Results from multidimensional modeling were validated using an independent test cohort of 38 patients. We identified a dynamic and variable imbalance between proximal (pSYK, pBTK) and distal (pPLC2, pBLNK, ppERK) phosphoresponses. PLSR identified the relationship between upstream tyrosine kinase SYK and its target, PLC2, as maximally predictive and sufficient to distinguish CLL from healthy samples, pointing to this juncture in the signaling pathway as a hallmark of CLL B cells. Specific BCR pathway signaling signatures that correlate with the disease and its degree of aggressiveness were identified. Heterogeneity in the PLSR response variable within the B cell population is both a characteristic mark of healthy samples and predictive of disease aggressiveness. Single-cell multidimensional analysis of BCR signaling permitted focused analysis of the variability and heterogeneity of signaling behavior from patient-to-patient, and from cell-to-cell. Disruption of the pSYK/pPLC2 relationship is uncovered as a robust hallmark of CLL B cell signaling behavior. Together, these observations implicate novel elements of the BCR signal transduction as potential therapeutic targets.",Journal Article,2183.0,8.0,Chronic Lymphocytic CLL is defined by a perturbed B-cell receptor-mediated signaling machinery We aimed to model differential signaling behavior between B cells from CLL and healthy individuals to pinpoint modes of dysregulation We developed an experimental methodology combining immunophenotyping multiplexed phosphospecific flow cytometry and multifactorial statistical modeling Utilizing patterns of signaling network covariance we modeled BCR signaling in 67 CLL patients using Partial Least Squares Regression PLSR Results from multidimensional modeling were validated using an independent test cohort of 38 patients We identified a dynamic and variable imbalance between proximal pSYK pBTK and distal pPLC2 pBLNK ppERK phosphoresponses PLSR identified the relationship between upstream tyrosine kinase SYK and its target PLC2 as maximally predictive and sufficient to distinguish CLL from healthy samples pointing to this juncture in the signaling pathway as a hallmark of CLL B cells Specific BCR pathway signaling signatures that correlate with the disease and its degree of aggressiveness were identified Heterogeneity in the PLSR response variable within the B cell population is both a characteristic mark of healthy samples and predictive of disease aggressiveness Single-cell multidimensional analysis of BCR signaling permitted focused analysis of the variability and heterogeneity of signaling behavior from patient-to-patient and from cell-to-cell Disruption of the pSYK/pPLC2 relationship is uncovered as a robust hallmark of CLL B cell signaling behavior Together these observations implicate novel elements of the BCR signal transduction as potential therapeutic targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 395, 20, 8, 11289, 132, 31, 153, 517, 314, 6415, 21, 1295, 6, 202, 1777, 314, 1710, 59, 132, 37, 29, 552, 2, 1331, 869, 6, 29402, 8256, 1, 3935, 21, 276, 35, 1560, 3209, 1525, 9416, 7734, 45082, 1412, 1914, 2, 7059, 1050, 2057, 2600, 764, 1, 314, 1801, 15208, 21, 4666, 1062, 314, 4, 598, 552, 7, 75, 450, 506, 11938, 320, 35742, 99, 29, 7002, 2057, 11, 938, 75, 35, 306, 412, 180, 1, 519, 7, 21, 108, 8, 2540, 2, 1347, 6088, 59, 2805, 48175, 40600, 2, 2107, 48176, 63898, 63899, 63900, 35742, 108, 3, 858, 59, 3988, 564, 216, 6792, 2, 211, 283, 21785, 22, 6402, 464, 2, 1952, 6, 3081, 552, 29, 1331, 347, 11548, 6, 26, 31283, 4, 3, 314, 308, 22, 8, 4683, 1, 552, 132, 37, 112, 1062, 308, 314, 2210, 17, 1513, 5, 3, 34, 2, 211, 1444, 1, 3908, 11, 108, 1144, 4, 3, 35742, 51, 1347, 262, 3, 132, 31, 266, 16, 110, 8, 2037, 8863, 1, 1331, 347, 2, 464, 1, 34, 3908, 226, 31, 7002, 65, 1, 1062, 314, 5449, 1649, 65, 1, 3, 1982, 2, 1144, 1, 314, 1710, 29, 69, 6, 69, 2, 29, 31, 6, 31, 3220, 1, 3, 48175, 48176, 858, 16, 5601, 22, 8, 1922, 4683, 1, 552, 132, 31, 314, 1710, 1162, 46, 2172, 5545, 229, 2531, 1, 3, 1062, 1235, 2761, 22, 174, 189, 637]",1692.0,24489640,437
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-02-10,"Although CD49d is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL), definitive validation evidence is lacking. A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of CD49d as an overall (OS) and treatment-free survival (TFS) predictor. A training/validation strategy was chosen to find the optimal CD49d cutoff. The hazard ratio (HR) for death and treatment imposed by CD49d was estimated by pooled analysis of 2,972 CLLs; Cox analysis stratified by center and stage was used to adjust for confounding variables. The importance of CD49d over other flow cytometry-based prognosticators (eg, CD38, ZAP-70) was ranked by recursive partitioning. Patients with  30% of neoplastic cells expressing CD49d were considered CD49d+. Decrease in OS at 5 and 10 years among CD49d+ patients was 7% and 23% (decrease in TFS, 26% and 25%, respectively). Pooled HR of CD49d for OS was 2.5 (2.3 for TFS) in univariate analysis. This HR remained significant and of similar magnitude (HR, 2.0) in a Cox model adjusted for clinical and biologic prognosticators. Hierarchic trees including all patients or restricted to those with early-stage disease or those age  65 years always selected CD49d as the most important flow cytometry-based biomarker, with negligible additional prognostic information added by CD38 or ZAP-70. Consistently, by bivariate analysis, CD49d reliably identified patient subsets with poorer outcome independent of CD38 and ZAP-70. In this analysis of approximately 3,000 patients, CD49d emerged as the strongest flow cytometry-based predictor of OS and TFS in CLL.",Journal Article,2171.0,79.0,"Although CD49d is an unfavorable prognostic marker in chronic lymphocytic CLL definitive validation evidence is lacking A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of CD49d as an overall OS and treatment-free survival TFS predictor A training/validation strategy was chosen to find the optimal CD49d cutoff The hazard ratio HR for death and treatment imposed by CD49d was estimated by pooled analysis of 2,972 CLLs Cox analysis stratified by center and stage was used to adjust for confounding variables The importance of CD49d over other flow cytometry-based prognosticators eg CD38 ZAP-70 was ranked by recursive partitioning Patients with  30 of neoplastic cells expressing CD49d were considered CD49d+ Decrease in OS at 5 and 10 years among CD49d+ patients was 7 and 23 decrease in TFS 26 and 25 respectively Pooled HR of CD49d for OS was 2.5 2.3 for TFS in univariate analysis This HR remained significant and of similar magnitude HR 2.0 in a Cox model adjusted for clinical and biologic prognosticators Hierarchic trees including all patients or restricted to those with early-stage disease or those age  65 years always selected CD49d as the most important flow cytometry-based biomarker with negligible additional prognostic information added by CD38 or ZAP-70 Consistently by bivariate analysis CD49d reliably identified patient subsets with poorer outcome independent of CD38 and ZAP-70 In this analysis of approximately 3,000 patients CD49d emerged as the strongest flow cytometry-based predictor of OS and TFS in CLL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 10485, 16, 35, 2483, 177, 952, 4, 442, 1193, 552, 1057, 929, 241, 16, 1941, 8, 2358, 1570, 65, 10, 173, 75, 983, 2, 16010, 552, 988, 6, 376, 3, 345, 1, 10485, 22, 35, 63, 118, 2, 24, 115, 25, 7335, 980, 8, 1741, 929, 692, 10, 4695, 6, 2469, 3, 665, 10485, 2779, 3, 360, 197, 168, 9, 273, 2, 24, 15933, 20, 10485, 10, 661, 20, 1830, 65, 1, 18, 11959, 31974, 418, 65, 1173, 20, 574, 2, 82, 10, 95, 6, 6611, 9, 4339, 682, 3, 1187, 1, 10485, 252, 127, 1412, 1914, 90, 9996, 2887, 4469, 6251, 431, 10, 6441, 20, 4493, 4515, 7, 5, 749, 201, 1, 2000, 37, 1046, 10485, 11, 515, 10485, 775, 4, 118, 28, 33, 2, 79, 60, 107, 10485, 7, 10, 67, 2, 382, 775, 4, 7335, 432, 2, 243, 106, 1830, 168, 1, 10485, 9, 118, 10, 18, 33, 18, 27, 9, 7335, 4, 880, 65, 26, 168, 958, 93, 2, 1, 288, 3131, 168, 18, 13, 4, 8, 418, 202, 586, 9, 38, 2, 1283, 9996, 63941, 17229, 141, 62, 7, 15, 2016, 6, 135, 5, 191, 82, 34, 15, 135, 89, 1552, 556, 60, 3763, 715, 10485, 22, 3, 96, 305, 1412, 1914, 90, 901, 5, 6821, 402, 177, 487, 1953, 20, 4469, 15, 6251, 431, 2433, 20, 7686, 65, 10485, 4092, 108, 69, 1890, 5, 1769, 228, 306, 1, 4469, 2, 6251, 431, 4, 26, 65, 1, 705, 27, 984, 7, 10485, 2054, 22, 3, 3311, 1412, 1914, 90, 980, 1, 118, 2, 7335, 4, 552]",1599.0,24516016,450
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.,Cancer,Cancer,2014-02-27,"Myc-positive B-cell non-Hodgkin lymphoma (NHL) with or without a B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) rearrangement is associated with inferior progression-free survival (PFS) and overall survival (OS). In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University. All patients who had non-Burkitt, aggressive B-cell NHL from 2008 to 2011 were assessed for the t(14;18) translocation and for v-myc avian myelocytomatosis viral oncogene homolog (CMYC) rearrangements at diagnosis, and all myc-positive patients were included in the current analysis. Associations with clinical characteristics were described, and univariable and multivariable models were used to assess correlations between clinical variables and outcomes. Of 49 myc-positive patients, 29 patients also had BCL2 rearrangements (double-hit NHL). No patients underwent autologous stem cell transplantation in first remission. For all myc-positive patients, the median PFS was 16.6 months, and the median OS was 37.7 months. For patients who had double-hit NHL, the median PFS was 8 months, and the median OS was 12.5 months; whereas the median PFS and OS were not reached for myc-positive patients. A complete response (CR) after front-line therapy, the presence of t(14;18), International Prognostic Index (IPI) group, and age were associated with PFS; whereas only the achievement of a CR and age >60 years were associated with OS in the multivariable setting. The median PFS was 3.3 months, and the median and OS was 7.0 months for patients who did not attain a CR; and the medians were not reached for patients who achieved a CR (P < .00001). The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL, even after adjusting for type of initial therapy, histology, age, IPI, or the presence of a concurrent BCL2 translocation.",Journal Article,2154.0,39.0,Myc-positive B-cell NHL with or without a B-cell chronic lymphocytic leukemia/lymphoma 2 BCL2 rearrangement is associated with inferior progression-free survival PFS and overall survival OS In this study the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University All patients who had non-Burkitt aggressive B-cell NHL from 2008 to 2011 were assessed for the t 14 18 translocation and for v-myc avian myelocytomatosis viral oncogene homolog CMYC rearrangements at diagnosis and all myc-positive patients were included in the current analysis Associations with clinical characteristics were described and univariable and multivariable models were used to assess correlations between clinical variables and outcomes Of 49 myc-positive patients 29 patients also had BCL2 rearrangements double-hit NHL No patients underwent autologous stem cell transplantation in first remission For all myc-positive patients the median PFS was 16.6 months and the median OS was 37.7 months For patients who had double-hit NHL the median PFS was 8 months and the median OS was 12.5 months whereas the median PFS and OS were not reached for myc-positive patients A complete response CR after front-line therapy the presence of t 14 18 International Prognostic Index IPI group and age were associated with PFS whereas only the achievement of a CR and age 60 years were associated with OS in the multivariable setting The median PFS was 3.3 months and the median and OS was 7.0 months for patients who did not attain a CR and the medians were not reached for patients who achieved a CR P .00001 The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL even after adjusting for type of initial therapy histology age IPI or the presence of a concurrent BCL2 translocation,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1371, 109, 132, 31, 1176, 5, 15, 187, 8, 132, 31, 442, 1193, 2647, 4763, 18, 3214, 2675, 16, 41, 5, 1663, 91, 115, 25, 300, 2, 63, 25, 118, 4, 26, 45, 3, 738, 446, 3, 123, 1, 7, 5, 1371, 109, 2, 1627, 6519, 1176, 28, 3, 10009, 1309, 1652, 62, 7, 54, 42, 220, 14387, 571, 132, 31, 1176, 29, 1375, 6, 1132, 11, 275, 9, 3, 102, 213, 203, 2006, 2, 9, 603, 1371, 16811, 29107, 1667, 1836, 3412, 16357, 2072, 28, 147, 2, 62, 1371, 109, 7, 11, 159, 4, 3, 291, 65, 685, 5, 38, 374, 11, 1027, 2, 4084, 2, 658, 274, 11, 95, 6, 423, 2553, 59, 38, 682, 2, 123, 1, 739, 1371, 109, 7, 462, 7, 120, 42, 3214, 2072, 1627, 6519, 1176, 77, 7, 208, 1028, 452, 31, 497, 4, 157, 734, 9, 62, 1371, 109, 7, 3, 52, 300, 10, 245, 49, 53, 2, 3, 52, 118, 10, 567, 67, 53, 9, 7, 54, 42, 1627, 6519, 1176, 3, 52, 300, 10, 66, 53, 2, 3, 52, 118, 10, 133, 33, 53, 547, 3, 52, 300, 2, 118, 11, 44, 1300, 9, 1371, 109, 7, 8, 236, 51, 684, 50, 3007, 328, 36, 3, 463, 1, 102, 213, 203, 944, 177, 558, 3753, 87, 2, 89, 11, 41, 5, 300, 547, 158, 3, 5088, 1, 8, 684, 2, 89, 335, 60, 11, 41, 5, 118, 4, 3, 658, 546, 3, 52, 300, 10, 27, 27, 53, 2, 3, 52, 2, 118, 10, 67, 13, 53, 9, 7, 54, 205, 44, 10719, 8, 684, 2, 3, 12325, 11, 44, 1300, 9, 7, 54, 513, 8, 684, 19, 7868, 3, 5088, 1, 8, 684, 5, 3007, 328, 36, 16, 41, 5, 8, 1069, 300, 2, 118, 4, 7, 5, 1371, 109, 1176, 871, 50, 1358, 9, 267, 1, 388, 36, 784, 89, 3753, 15, 3, 463, 1, 8, 750, 3214, 2006]",1865.0,24578014,117
"The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era.",Leukemia & lymphoma,Leuk. Lymphoma,2014-04-03,"To analyze racial, ethnic, sex and age disparities in chronic lymphocytic leukemia (CLL), we examined population-based overall survival (OS) data from Surveillance, Epidemiology, and End Results (SEER)-13 (1992-2009) across various races/ethnicities over two consecutive 9-year periods: era 1 (1992-2000) and era 2 (2001-2009). We analyzed 28 590 patients (whites: 24 438, blacks: 1954, Hispanics: 1389 and Asians/Pacific Islanders [A/PI]: 809). A higher proportion of whites were aged > 80 years (22% vs. 17% [Hispanics], 16% [blacks], 16% [A/PI]; p < 0.001). Higher socioeconomic status (SES) was also identified for A/PI and whites compared with blacks and Hispanics (p < 0.001). OS for all patients improved at 5 years (66% vs. 60%, p < 0.0001) and was significant in all races/ethnicities except A/PI. Patients of higher SES had better outcomes than others independent of era, but both SES classes experienced relative improvement in their OS across eras. The OS of patients with CLL has improved in the modern era but racial/ethnic, gender and SES differences persist, warranting further investigation.",Journal Article,2119.0,19.0,To analyze racial ethnic sex and age disparities in chronic lymphocytic CLL we examined population-based overall survival OS data from Surveillance Epidemiology and End Results SEER -13 1992-2009 across various races/ethnicities over two consecutive 9-year periods era 1 1992-2000 and era 2 2001-2009 We analyzed 28 590 patients whites 24 438 blacks 1954 Hispanics 1389 and Asians/Pacific Islanders A/PI 809 A higher proportion of whites were aged 80 years 22 vs. 17 Hispanics 16 blacks 16 A/PI p 0.001 Higher socioeconomic status SES was also identified for A/PI and whites compared with blacks and Hispanics p 0.001 OS for all patients improved at 5 years 66 vs. 60 p 0.0001 and was significant in all races/ethnicities except A/PI Patients of higher SES had better outcomes than others independent of era but both SES classes experienced relative improvement in their OS across eras The OS of patients with CLL has improved in the modern era but racial/ethnic gender and SES differences persist warranting further investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 1992, 2257, 2871, 1035, 2, 89, 2227, 4, 442, 1193, 552, 21, 409, 266, 90, 63, 25, 118, 74, 29, 617, 1284, 2, 396, 99, 1605, 233, 2846, 1238, 716, 747, 9290, 11896, 252, 100, 935, 83, 111, 3338, 1713, 14, 2846, 1081, 2, 1713, 18, 1758, 1238, 21, 311, 339, 11176, 7, 2556, 259, 11003, 3544, 22190, 3850, 29535, 2, 5108, 7450, 11846, 8, 2928, 14494, 8, 142, 920, 1, 2556, 11, 1032, 493, 60, 350, 105, 269, 3850, 245, 3544, 245, 8, 2928, 19, 13, 144, 142, 3331, 156, 5699, 10, 120, 108, 9, 8, 2928, 2, 2556, 72, 5, 3544, 2, 3850, 19, 13, 144, 118, 9, 62, 7, 231, 28, 33, 60, 700, 105, 335, 19, 13, 488, 2, 10, 93, 4, 62, 9290, 11896, 2187, 8, 2928, 7, 1, 142, 5699, 42, 380, 123, 76, 1749, 306, 1, 1713, 84, 110, 5699, 3211, 592, 580, 767, 4, 136, 118, 716, 7225, 3, 118, 1, 7, 5, 552, 71, 231, 4, 3, 2366, 1713, 84, 2257, 2871, 1632, 2, 5699, 362, 5589, 7643, 195, 940]",1030.0,24588735,521
"Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.",mAbs,MAbs,2014-03-04,"Chronic lymphocytic leukemia (CLL) is common in both developed and developing nations where the need for inexpensive and convenient administration of therapy is apparent. Ocaratuzumab is a novel Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody (mAb) designed for effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous (vs. intravenous) dosing. Here, we report ocaratuzumab's potency against CLL cells. In vitro assessment of ocaratuzumab's direct cytotoxicity (DC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and ADCC was performed on CLL cells. Ocaratuzumab induced DC, CDC, and ADCP similarly to rituximab or ofatumumab (anti-CD20 mAbs). However, ocaratuzumab showed an advantage in NK cell-mediated ADCC over these antibodies. In allogeneic ADCC, [E:T (effector:target) ratios = 25:1, 12:1, 6:1], ocaratuzumab (10 g/mL) improved ADCC by ~3-fold compared with rituximab or ofatumumab (P<0.001 all tested E:T ratios). Notably, the superiority of ocaratuzumab-induced ADCC was observed at low concentrations (0.1-10 ug/ml; P<0.03; allogeneic assays). In extended allogeneic ADCC E:T titration, ocaratuzumab (0.1 g/mL) demonstrated 19.4% more cytotoxicity than rituximab (E:T = 0.38:1; P = 0.0066) and 21.5% more cytotoxicity than ofatumumab (E:T = 1.5:1; P = 0.0015). In autologous ADCC, ocaratuzumab (10 g/mL) demonstrated ~1.5-fold increase in cytotoxicity compared with rituximab or ofatumumab at all E:T ratios tested (E:Ts = 25:1,12:1,6:1; all P<0.001). Obinutuzumab, a glyco-engineered anti-CD20 mAb, showed no improvement in ADCC activity compared with ocaratuzumab. The enhanced ADCC of ocaratuzumab suggests that it may be effective at low concentrations. If supported by clinical investigation, this feature could potentially allow for subcutaneous dosing at low doses that could expand the potential of administering chemoimmunotherapy in developing countries. ",Journal Article,2149.0,27.0,"Chronic lymphocytic CLL is common in both developed and developing nations where the need for inexpensive and convenient administration of therapy is apparent Ocaratuzumab is a novel Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody mAb designed for effective antibody-dependent cell-mediated cytotoxicity ADCC at very low concentrations that may facilitate sub-cutaneous vs. intravenous dosing Here we report ocaratuzumab 's potency against CLL cells In vitro assessment of ocaratuzumab 's direct cytotoxicity DC complement-dependent cytotoxicity CDC antibody-dependent cellular phagocytosis ADCP and ADCC was performed on CLL cells Ocaratuzumab induced DC CDC and ADCP similarly to rituximab or ofatumumab anti-CD20 mAbs However ocaratuzumab showed an advantage in NK cell-mediated ADCC over these antibodies In allogeneic ADCC E T effector target ratios 25:1 12:1 6:1 ocaratuzumab 10 g/mL improved ADCC by ~3-fold compared with rituximab or ofatumumab P 0.001 all tested E T ratios Notably the superiority of ocaratuzumab-induced ADCC was observed at low concentrations 0.1-10 ug/ml P 0.03 allogeneic assays In extended allogeneic ADCC E T titration ocaratuzumab 0.1 g/mL demonstrated 19.4 more cytotoxicity than rituximab E T 0.38:1 P 0.0066 and 21.5 more cytotoxicity than ofatumumab E T 1.5:1 P 0.0015 In autologous ADCC ocaratuzumab 10 g/mL demonstrated ~1.5-fold increase in cytotoxicity compared with rituximab or ofatumumab at all E T ratios tested E Ts 25:1,12:1,6:1 all P 0.001 Obinutuzumab a glyco-engineered anti-CD20 mAb showed no improvement in ADCC activity compared with ocaratuzumab The enhanced ADCC of ocaratuzumab suggests that it may be effective at low concentrations If supported by clinical investigation this feature could potentially allow for subcutaneous dosing at low doses that could expand the potential of administering chemoimmunotherapy in developing countries",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 186, 4, 110, 276, 2, 931, 14456, 1257, 3, 594, 9, 8168, 2, 7048, 634, 1, 36, 16, 2235, 18077, 16, 8, 229, 4127, 2794, 3619, 8019, 312, 2198, 848, 548, 2780, 1114, 9, 323, 548, 470, 31, 517, 1408, 5551, 28, 923, 154, 1003, 17, 68, 1876, 551, 1486, 105, 1262, 1280, 467, 21, 414, 18077, 292, 3593, 480, 552, 37, 4, 439, 455, 1, 18077, 292, 1196, 1408, 2321, 3731, 470, 1408, 9665, 548, 470, 763, 11788, 32245, 2, 5551, 10, 173, 23, 552, 37, 18077, 277, 2321, 9665, 2, 32245, 1813, 6, 855, 15, 5732, 312, 2198, 5207, 137, 18077, 224, 35, 1874, 4, 1765, 31, 517, 5551, 252, 46, 890, 4, 1063, 5551, 563, 102, 2070, 283, 1137, 243, 14, 133, 14, 49, 14, 18077, 79, 7570, 542, 231, 5551, 20, 27, 1116, 72, 5, 855, 15, 5732, 19, 13, 144, 62, 650, 563, 102, 1137, 2552, 3, 5233, 1, 18077, 277, 5551, 10, 164, 28, 154, 1003, 13, 14, 79, 23321, 542, 19, 13, 680, 1063, 1013, 4, 1747, 1063, 5551, 563, 102, 8715, 18077, 13, 14, 7570, 542, 264, 326, 39, 80, 1408, 76, 855, 563, 102, 13, 519, 14, 19, 13, 19243, 2, 239, 33, 80, 1408, 76, 5732, 563, 102, 14, 33, 14, 19, 13, 9490, 4, 1028, 5551, 18077, 79, 7570, 542, 264, 14, 33, 1116, 344, 4, 1408, 72, 5, 855, 15, 5732, 28, 62, 563, 102, 1137, 650, 563, 3527, 243, 14, 133, 14, 49, 14, 62, 19, 13, 144, 10380, 8, 32246, 2794, 312, 2198, 2780, 224, 77, 767, 4, 5551, 128, 72, 5, 18077, 3, 651, 5551, 1, 18077, 844, 17, 192, 68, 40, 323, 28, 154, 1003, 492, 2708, 20, 38, 940, 26, 2705, 359, 751, 1700, 9, 2529, 1280, 28, 154, 415, 17, 359, 4082, 3, 174, 1, 5776, 4438, 4, 931, 2115]",1908.0,24594909,453
"Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.",Cancer genetics,Cancer Genet,2014-01-17,"Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- (and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL. ",Journal Article,2195.0,4.0,"Pretherapy patients with chronic lymphocytic CLL from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies The four CLL-typical anomalies 11q- +12 13q- and 17p- were found at expected frequencies Acquired anomalies in other regions account for 70 of the total detected anomalies and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- and other covariates These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies which analyzed individuals with a variety of medical conditions and healthy controls The percentage of individuals with acquired anomalies is vastly different between the two studies GENEVA 0.8 E2997 80 The composition of the anomalies also differs with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions The four common CLL anomalies are among the most frequent in GENEVA participants some of whom may have CLL-precursor conditions or early stages of CLL However the patients from E2997 and other studies of symptomatic CLL have recurrent acquired anomalies that were not found in GENEVA participants thus identifying genomic changes that may be unique to symptomatic stages of CLL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8857, 7, 5, 442, 1193, 552, 29, 843, 4839, 160, 23577, 11, 311, 5, 226, 1579, 1907, 2774, 6, 1426, 1294, 1860, 7623, 3, 294, 552, 3476, 7623, 7203, 133, 8453, 2, 4135, 11, 204, 28, 1336, 2722, 1294, 7623, 4, 127, 1374, 1967, 9, 431, 1, 3, 181, 530, 7623, 2, 136, 207, 379, 5705, 71, 8, 93, 254, 23, 91, 115, 25, 50, 1358, 9, 3, 176, 1, 4135, 2, 127, 2489, 46, 99, 11, 72, 5, 135, 29, 8, 698, 45, 1, 80, 76, 212, 984, 776, 29, 3, 32249, 2404, 1, 898, 1019, 248, 94, 92, 311, 869, 5, 8, 1362, 1, 484, 1298, 2, 1331, 535, 3, 1150, 1, 869, 5, 1294, 7623, 16, 16759, 338, 59, 3, 100, 94, 32249, 13, 66, 23577, 493, 3, 3761, 1, 3, 7623, 120, 4990, 5, 32249, 1041, 8, 142, 1150, 1, 1294, 17888, 48249, 2, 8, 280, 1150, 1, 2439, 3, 294, 186, 552, 7623, 32, 107, 3, 96, 908, 4, 32249, 776, 476, 1, 953, 68, 47, 552, 2765, 1298, 15, 191, 1153, 1, 552, 137, 3, 7, 29, 23577, 2, 127, 94, 1, 1704, 552, 47, 387, 1294, 7623, 17, 11, 44, 204, 4, 32249, 776, 631, 1386, 572, 400, 17, 68, 40, 991, 6, 1704, 1153, 1, 552]",1393.0,24613276,520
"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110, for relapsed/refractory chronic lymphocytic leukemia.",Blood,Blood,2014-03-10,"In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3K, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5 [range 2-14] prior regimens), treatment-refractory disease (70%), unmutated IGHV (91%), and del17p and/or TP53 mutations (24%). Patients were treated at 6 dose levels of oral idelalisib (range 50-350 mg once or twice daily) and remained on continuous therapy while deriving clinical benefit. Idelalisib-mediated inhibition of PI3K led to abrogation of Akt phosphorylation in patient CLL cells and significantly reduced serum levels of CLL-related chemokines. The most commonly observed grade 3 adverse events were pneumonia (20%), neutropenic fever (11%), and diarrhea (6%). Idelalisib treatment resulted in nodal responses in 81% of patients. The overall response rate was 72%, with 39% of patients meeting the criteria for partial response per IWCLL 2008 and 33% meeting the recently updated criteria of PR with treatment-induced lymphocytosis.(1,2) The median progression-free survival for all patients was 15.8 months. This study demonstrates the clinical utility of inhibiting the PI3K pathway with idelalisib. Our findings support the further development of idelalisib in patients with CLL. These trials were registered at clinicaltrials.gov as #NCT00710528 and #NCT01090414. ","Clinical Trial, Phase I",2143.0,393.0,"In a phase 1 trial idelalisib GS-1101 CAL-101 a selective inhibitor of the lipid kinase PI3K was evaluated in 54 patients with relapsed/refractory chronic lymphocytic CLL with adverse characteristics including bulky lymphadenopathy 80 extensive prior therapy median 5 range 2-14 prior regimens treatment-refractory disease 70 unmutated IGHV 91 and del17p and/or TP53 mutations 24 Patients were treated at 6 dose levels of oral idelalisib range 50-350 mg once or twice daily and remained on continuous therapy while deriving clinical benefit Idelalisib-mediated inhibition of PI3K led to abrogation of Akt phosphorylation in patient CLL cells and significantly reduced serum levels of CLL-related chemokines The most commonly observed grade 3 adverse events were pneumonia 20 neutropenic fever 11 and diarrhea 6 Idelalisib treatment resulted in nodal responses in 81 of patients The overall response rate was 72 with 39 of patients meeting the criteria for partial response per IWCLL 2008 and 33 meeting the recently updated criteria of PR with treatment-induced lymphocytosis 1,2 The median progression-free survival for all patients was 15.8 months This study demonstrates the clinical utility of inhibiting the PI3K pathway with idelalisib Our findings support the further development of idelalisib in patients with CLL These trials were registered at clinicaltrials.gov as NCT00710528 and NCT01090414",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 8, 124, 14, 160, 7083, 3815, 15129, 10368, 2338, 8, 1094, 230, 1, 3, 3121, 216, 11063, 10, 194, 4, 667, 7, 5, 591, 430, 442, 1193, 552, 5, 290, 374, 141, 4112, 4962, 493, 1344, 324, 36, 52, 33, 184, 18, 213, 324, 472, 24, 430, 34, 431, 7216, 6220, 970, 2, 15403, 2, 15, 1206, 138, 259, 7, 11, 73, 28, 49, 61, 148, 1, 518, 7083, 184, 212, 5408, 81, 1059, 15, 936, 391, 2, 958, 23, 1314, 36, 369, 12709, 38, 247, 7083, 517, 297, 1, 11063, 836, 6, 8589, 1, 649, 982, 4, 69, 552, 37, 2, 97, 405, 524, 148, 1, 552, 139, 4906, 3, 96, 841, 164, 88, 2608, 290, 281, 11, 3485, 179, 3659, 2775, 175, 2, 1172, 49, 7083, 24, 627, 4, 779, 253, 4, 865, 1, 7, 3, 63, 51, 116, 10, 720, 5, 587, 1, 7, 2238, 3, 371, 9, 450, 51, 379, 16575, 1375, 2, 466, 2238, 3, 761, 2939, 371, 1, 998, 5, 24, 277, 8125, 14, 18, 3, 52, 91, 115, 25, 9, 62, 7, 10, 167, 66, 53, 26, 45, 1902, 3, 38, 1207, 1, 2062, 3, 11063, 308, 5, 7083, 114, 272, 538, 3, 195, 193, 1, 7083, 4, 7, 5, 552, 46, 143, 11, 1653, 28, 1252, 1239, 22, 40643, 2, 48253]",1407.0,24615777,577
"Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.",Blood,Blood,2014-03-10,"Richter syndrome (RS) is associated with poor outcome. The prognosis of patients with histologically aggressive chronic lymphocytic leukemia (CLL), or HAC, has not been studied. We aimed to correlate 2-deoxy-2-[(18)F]fluoroglucose/positron emission tomography (FDG/PET) data, histological diagnosis, clinical characteristics, and survival in patients with CLL. A total of 332 patients with CLL were histologically classified as: 95 RS, 117 HAC, and 120 histologically indolent CLL (HIC). HAC and RS patients had higher maximum standardized uptake value (SUVmax), more frequent constitutional symptoms, poorer performance status (PS), lower hemoglobin and platelets, and higher lactate dehydrogenase and -2-microglobulin. An SUVmax 10 strongly correlated with mortality (overall survival [OS], 56.7 vs 6.9 months in patients with SUVmax <10 vs 10). Survival of patients with RS and HAC was similar among patients with SUVmax <10 or 10. SUVmax 10, PS 2, bulky disease, and age 65 were independently associated with shorter OS. In patients undergoing both fine-needle aspiration and biopsy, the former proved diagnostically inadequate in 23%, 29%, and 53% of HIC, HAC, and RS, respectively. FDG/PET is a useful diagnostic tool in patients with CLL and suspected transformation. Patients with HAC show different characteristics and worse prognosis compared with those with HIC. Patients with different CLL phases, but similar SUVmax have similar outcome. Tissue biopsy should be preferred for diagnosing RS. ",Journal Article,2143.0,61.0,Richter syndrome RS is associated with poor outcome The prognosis of patients with histologically aggressive chronic lymphocytic CLL or HAC has not been studied We aimed to correlate 2-deoxy-2- 18 F fluoroglucose/positron emission tomography FDG/PET data histological diagnosis clinical characteristics and survival in patients with CLL A total of 332 patients with CLL were histologically classified as 95 RS 117 HAC and 120 histologically indolent CLL HIC HAC and RS patients had higher maximum standardized uptake value SUVmax more frequent constitutional symptoms poorer performance status PS lower hemoglobin and platelets and higher lactate dehydrogenase and -2-microglobulin An SUVmax 10 strongly correlated with mortality overall survival OS 56.7 vs 6.9 months in patients with SUVmax 10 vs 10 Survival of patients with RS and HAC was similar among patients with SUVmax 10 or 10 SUVmax 10 PS 2 bulky disease and age 65 were independently associated with shorter OS In patients undergoing both fine-needle aspiration and biopsy the former proved diagnostically inadequate in 23 29 and 53 of HIC HAC and RS respectively FDG/PET is a useful diagnostic tool in patients with CLL and suspected transformation Patients with HAC show different characteristics and worse prognosis compared with those with HIC Patients with different CLL phases but similar SUVmax have similar outcome Tissue biopsy should be preferred for diagnosing RS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 681, 2250, 16, 41, 5, 334, 228, 3, 356, 1, 7, 5, 2161, 571, 442, 1193, 552, 15, 19946, 71, 44, 85, 656, 21, 1295, 6, 1513, 18, 6149, 18, 203, 1068, 64056, 1900, 1799, 872, 1285, 495, 74, 1831, 147, 38, 374, 2, 25, 4, 7, 5, 552, 8, 181, 1, 10651, 7, 5, 552, 11, 2161, 1373, 22, 48, 2250, 3843, 19946, 2, 2031, 2161, 2316, 552, 13390, 19946, 2, 2250, 7, 42, 142, 689, 1670, 1135, 549, 4996, 80, 908, 5962, 507, 1769, 528, 156, 1511, 280, 2222, 2, 4407, 2, 142, 3330, 2374, 2, 1458, 18, 5371, 35, 4996, 4556, 1327, 438, 5, 282, 63, 25, 118, 664, 67, 105, 49, 83, 53, 4, 7, 5, 4996, 79, 105, 4556, 25, 1, 7, 5, 2250, 2, 19946, 10, 288, 107, 7, 5, 4996, 79, 15, 4556, 4996, 4556, 1511, 3107, 4112, 34, 2, 89, 5827, 11, 1042, 41, 5, 985, 118, 4, 7, 479, 110, 2924, 2177, 3256, 2, 411, 3, 3623, 4328, 13778, 3358, 4, 382, 462, 2, 699, 1, 13390, 19946, 2, 2250, 106, 1285, 495, 16, 8, 999, 752, 1515, 4, 7, 5, 552, 2, 2768, 1392, 7, 5, 19946, 514, 338, 374, 2, 639, 356, 72, 5, 135, 5, 13390, 7, 5, 338, 552, 3523, 84, 288, 4996, 47, 288, 228, 246, 411, 257, 40, 2514, 9, 5798, 2250]",1443.0,24615780,137
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.,Blood,Blood,2014-04-04,"The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab (FCR) begs the question of the value of minimal residual disease (MRD)-negative status as a treatment end point. We report on 237 patients with chronic lymphocytic leukemia who received first-line FCR. MRD was prospectively assessed by 4-color flow cytometry in bone marrow after course 3 and at final response assessment. After course 3 and at final response assessment, 17% and 43% of patients were MRD negative in bone marrow, respectively. A mutated immunoglobulin heavy chain variable gene and trisomy 12 were independently associated with MRD-negative status both after 3 courses of FCR and at final response assessment in multivariable analyses (MVAs). MRD-negative status was independently associated with significantly longer progression-free survival (PFS) and overall survival (OS) in MVA (P = .03 and .02, respectively). This association was confirmed also on landmark MVA at the time of MRD assessment (P = .04 and .05, respectively). MRD-negative patients had comparable PFS and OS, independent of the number of courses received or interim staging. Early MRD eradication may be a desirable goal, prompting consideration of early discontinuation of treatment. This trial was registered at www.clinicaltrials.gov as #NCT00759798.",Clinical Trial,2118.0,83.0,The high complete remission rate with first-line combined fludarabine cyclophosphamide and rituximab FCR begs the question of the value of minimal residual disease MRD -negative status as a treatment end point We report on 237 patients with chronic lymphocytic who received first-line FCR MRD was prospectively assessed by 4-color flow cytometry in marrow after course 3 and at final response assessment After course 3 and at final response assessment 17 and 43 of patients were MRD negative in marrow respectively A mutated immunoglobulin heavy chain variable gene and trisomy 12 were independently associated with MRD-negative status both after 3 courses of FCR and at final response assessment in multivariable analyses MVAs MRD-negative status was independently associated with significantly longer progression-free survival PFS and overall survival OS in MVA P .03 and .02 respectively This association was confirmed also on landmark MVA at the time of MRD assessment P .04 and .05 respectively MRD-negative patients had comparable PFS and OS independent of the number of courses received or interim staging Early MRD eradication may be a desirable goal prompting consideration of early discontinuation of treatment This trial was registered at www.clinicaltrials.gov as NCT00759798,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 64, 236, 734, 116, 5, 157, 328, 397, 2027, 1112, 2, 855, 4953, 64162, 3, 2840, 1, 3, 549, 1, 1048, 753, 34, 2029, 199, 156, 22, 8, 24, 396, 741, 21, 414, 23, 7296, 7, 5, 442, 1193, 54, 103, 157, 328, 4953, 2029, 10, 1143, 275, 20, 39, 6052, 1412, 1914, 4, 581, 50, 906, 27, 2, 28, 1457, 51, 455, 50, 906, 27, 2, 28, 1457, 51, 455, 269, 2, 601, 1, 7, 11, 2029, 199, 4, 581, 106, 8, 1185, 2593, 4013, 1260, 1347, 145, 2, 6317, 133, 11, 1042, 41, 5, 2029, 199, 156, 110, 50, 27, 1993, 1, 4953, 2, 28, 1457, 51, 455, 4, 658, 318, 31593, 2029, 199, 156, 10, 1042, 41, 5, 97, 589, 91, 115, 25, 300, 2, 63, 25, 118, 4, 5320, 19, 680, 2, 588, 106, 26, 248, 10, 557, 120, 23, 3829, 5320, 28, 3, 98, 1, 2029, 455, 19, 755, 2, 474, 106, 2029, 199, 7, 42, 1279, 300, 2, 118, 306, 1, 3, 207, 1, 1993, 103, 15, 2914, 632, 191, 2029, 5173, 68, 40, 8, 7365, 1326, 8499, 2415, 1, 191, 2007, 1, 24, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 64163]",1287.0,24705492,716
Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.,Cancer,Cancer,2014-04-07,"The 1996 National Cancer Institute Working Group (NCI-WG 96) guidelines classified disease in individuals who had a B-cell clone with chronic lymphocytic leukemia (CLL) immunophenotype as CLL if their absolute lymphocyte count was 510(9)/L. The 2008 International Workshop on CLL guidelines (IWCLL 2008) classified disease as CLL if the absolute B-cell count was 510(9)/L or as monoclonal B-cell lymphocytosis (MBL) if the absolute B-cell count was <510(9)/L. The objective of the current study of Olmsted County, Minnesota, was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010. Using diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database, the authors identified all patients with newly diagnosed CLL and high-count MBL from 2000 to 2010. Age-specific and sex-specific incidence rates were determined. According to NCI-WG 96 criteria, there were 115 patients with CLL and 8 patients with MBL during the period studied. Using the IWCLL 2008 classification, there were 79 patients with CLL and 40 patients with MBL. Rai stage distribution (low risk, intermediate risk, and high risk) using NCI-WG 96 criteria was 60.9%, 33.9%, and 5.2%, respectively, compared with 43%, 49.4%, and 7.6%, respectively, using IWCLL 2008 criteria. The age-adjusted and sex-adjusted incidence rates (per 100,000) for CLL and MBL were 10.0 and 0.66, respectively, using NCI-WG 96 criteria versus 6.8 and 3.5, respectively, using IWCLL 2008 criteria. The median time to treatment according to NCI-WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria. Use of the IWCLL 2008 guidelines reduced the incidence of CLL, altered the distribution of initial Rai stage at diagnosis, and shortened the median time to treatment.",Comparative Study,2115.0,21.0,"The 1996 National Cancer Institute Working Group NCI-WG 96 guidelines classified disease in individuals who had a B-cell clone with chronic lymphocytic CLL immunophenotype as CLL if their absolute lymphocyte count was 5 10 9 /L The 2008 International Workshop on CLL guidelines IWCLL 2008 classified disease as CLL if the absolute B-cell count was 5 10 9 /L or as monoclonal B-cell lymphocytosis MBL if the absolute B-cell count was 5 10 9 /L The objective of the current study of Olmsted County Minnesota was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010 Using diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database the authors identified all patients with newly diagnosed CLL and high-count MBL from 2000 to 2010 Age-specific and sex-specific incidence rates were determined According to NCI-WG 96 criteria there were 115 patients with CLL and 8 patients with MBL during the period studied Using the IWCLL 2008 classification there were 79 patients with CLL and 40 patients with MBL Rai stage distribution low risk intermediate risk and high risk using NCI-WG 96 criteria was 60.9 33.9 and 5.2 respectively compared with 43 49.4 and 7.6 respectively using IWCLL 2008 criteria The age-adjusted and sex-adjusted incidence rates per 100,000 for CLL and MBL were 10.0 and 0.66 respectively using NCI-WG 96 criteria versus 6.8 and 3.5 respectively using IWCLL 2008 criteria The median time to treatment according to NCI-WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria Use of the IWCLL 2008 guidelines reduced the incidence of CLL altered the distribution of initial Rai stage at diagnosis and shortened the median time to treatment",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2648, 657, 12, 1377, 2644, 87, 2580, 12906, 921, 677, 1373, 34, 4, 869, 54, 42, 8, 132, 31, 3910, 5, 442, 1193, 552, 5496, 22, 552, 492, 136, 1766, 1448, 1276, 10, 4126, 79, 83, 805, 3, 1375, 944, 4014, 23, 552, 677, 16575, 1375, 1373, 34, 22, 552, 492, 3, 1766, 132, 31, 1276, 10, 4126, 79, 83, 805, 15, 22, 848, 132, 31, 8125, 8992, 492, 3, 1766, 132, 31, 1276, 10, 33, 79, 83, 805, 3, 461, 1, 3, 291, 45, 1, 12374, 5152, 8297, 10, 6, 423, 3, 176, 1, 46, 400, 23, 287, 151, 2, 1031, 29, 1081, 6, 1120, 75, 752, 3824, 390, 298, 3, 5801, 1284, 3105, 2, 3, 2486, 552, 609, 3, 738, 108, 62, 7, 5, 732, 265, 552, 2, 64, 1276, 8992, 29, 1081, 6, 1120, 89, 112, 2, 1035, 112, 287, 151, 11, 509, 768, 6, 2580, 12906, 921, 371, 125, 11, 3670, 7, 5, 552, 2, 66, 7, 5, 8992, 190, 3, 727, 656, 75, 3, 16575, 1375, 947, 125, 11, 842, 7, 5, 552, 2, 327, 7, 5, 8992, 4121, 82, 1395, 154, 43, 919, 43, 2, 64, 43, 75, 2580, 12906, 921, 371, 10, 335, 83, 466, 83, 2, 33, 18, 106, 72, 5, 601, 739, 39, 2, 67, 49, 106, 75, 16575, 1375, 371, 3, 89, 586, 2, 1035, 586, 287, 151, 379, 394, 984, 9, 552, 2, 8992, 11, 79, 13, 2, 13, 700, 106, 75, 2580, 12906, 921, 371, 185, 49, 66, 2, 27, 33, 106, 75, 16575, 1375, 371, 3, 52, 98, 6, 24, 768, 6, 2580, 12906, 921, 371, 10, 83, 18, 60, 185, 49, 33, 60, 5, 16575, 1375, 371, 119, 1, 3, 16575, 1375, 677, 405, 3, 287, 1, 552, 1495, 3, 1395, 1, 388, 4121, 82, 28, 147, 2, 6151, 3, 52, 98, 6, 24]",1743.0,24711224,119
"Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.",American journal of hematology,Am. J. Hematol.,2014-04-26,"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analog refractory disease or TP53 dysfunction still have limited treatment options and poor survival. Alemtuzumab-containing chemoimmunotherapy regimens can be effective but frequently cause serious infections. We report a Phase II trial testing the efficacy and tolerability of a short-duration regimen combining pentostatin, alemtuzumab, and low-dose high-frequency rituximab designed to decrease the risk of treatment-associated infections and to limit the loss of CD20 expression by CLL cells. The study enrolled 39 patients with progressive CLL that was either relapsed/refractory (n=36) or previously untreated with 17p13 deletion (17p13-) (n=3). Thirteen (33%) patients had both 17p13- and TP53 mutations predicted to be dysfunctional, and eight patients had purine analog refractory CLL without TP53 dysfunction. Twenty-six (67%) patients completed therapy, with only five (13%) patients having treatment-limiting toxicity and no treatment-related deaths. Twenty-two (56%) patients responded to treatment, with 11 (28%) complete responses (four with incomplete bone marrow recovery). Median progression-free survival was 7.2 months, time to next treatment was 9.1 months, and overall survival was 34.1 months. The majority of deaths (82%) were caused by progressive disease, including transformed diffuse large B-cell lymphoma (n=6). Correlative studies showed that low-dose rituximab activates complement and natural killer cells without a profound and sustained decrease in expression of CD20 by circulating CLL cells. We conclude that pentostatin, alemtuzumab, and low-dose high-frequency rituximab is a tolerable and effective therapy for CLL and that low-dose rituximab therapy can activate innate immune cytotoxic mechanisms without substantially decreasing CD20 expression.","Clinical Trial, Phase II",2096.0,25.0,Chronic lymphocytic leukemia/small lymphocytic CLL patients with purine analog refractory disease or TP53 dysfunction still have limited treatment options and poor survival Alemtuzumab-containing chemoimmunotherapy regimens can be effective but frequently cause serious infections We report a Phase II trial testing the efficacy and tolerability of a short-duration regimen combining pentostatin alemtuzumab and low-dose high-frequency rituximab designed to decrease the risk of treatment-associated infections and to limit the loss of CD20 expression by CLL cells The study enrolled 39 patients with progressive CLL that was either relapsed/refractory n 36 or previously untreated with 17p13 deletion 17p13- n 3 Thirteen 33 patients had both 17p13- and TP53 mutations predicted to be dysfunctional and eight patients had purine analog refractory CLL without TP53 dysfunction Twenty-six 67 patients completed therapy with only five 13 patients having treatment-limiting toxicity and no treatment-related deaths Twenty-two 56 patients responded to treatment with 11 28 complete responses four with incomplete marrow recovery Median progression-free survival was 7.2 months time to next treatment was 9.1 months and overall survival was 34.1 months The majority of deaths 82 were caused by progressive disease including transformed diffuse large B-cell n 6 Correlative studies showed that low-dose rituximab activates complement and natural killer cells without a profound and sustained decrease in expression of CD20 by circulating CLL cells We conclude that pentostatin alemtuzumab and low-dose high-frequency rituximab is a tolerable and effective therapy for CLL and that low-dose rituximab therapy can activate innate immune cytotoxic mechanisms without substantially decreasing CD20 expression,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 2647, 302, 1193, 552, 7, 5, 5006, 3497, 430, 34, 15, 1206, 1527, 1234, 47, 383, 24, 838, 2, 334, 25, 3579, 1101, 4438, 472, 122, 40, 323, 84, 746, 708, 1762, 1875, 21, 414, 8, 124, 215, 160, 471, 3, 209, 2, 1543, 1, 8, 978, 654, 477, 1525, 7596, 3579, 2, 154, 61, 64, 675, 855, 1114, 6, 775, 3, 43, 1, 24, 41, 1875, 2, 6, 2385, 3, 407, 1, 2198, 55, 20, 552, 37, 3, 45, 346, 587, 7, 5, 1014, 552, 17, 10, 361, 591, 430, 78, 511, 15, 373, 1278, 5, 7526, 1528, 7526, 78, 27, 3170, 466, 7, 42, 110, 7526, 2, 1206, 138, 783, 6, 40, 9666, 2, 659, 7, 42, 5006, 3497, 430, 552, 187, 1206, 1527, 737, 437, 598, 7, 781, 36, 5, 158, 365, 233, 7, 1041, 24, 817, 155, 2, 77, 24, 139, 1043, 737, 100, 664, 7, 2211, 6, 24, 5, 175, 339, 236, 253, 294, 5, 2610, 581, 1602, 52, 91, 115, 25, 10, 67, 18, 53, 98, 6, 1305, 24, 10, 83, 14, 53, 2, 63, 25, 10, 562, 14, 53, 3, 686, 1, 1043, 878, 11, 1546, 20, 1014, 34, 141, 2423, 1388, 375, 132, 31, 78, 49, 3679, 94, 224, 17, 154, 61, 855, 3932, 3731, 2, 1504, 3458, 37, 187, 8, 4399, 2, 2275, 775, 4, 55, 1, 2198, 20, 1033, 552, 37, 21, 2060, 17, 7596, 3579, 2, 154, 61, 64, 675, 855, 16, 8, 2668, 2, 323, 36, 9, 552, 2, 17, 154, 61, 855, 36, 122, 2977, 3939, 250, 759, 483, 187, 2109, 2777, 2198, 55]",1797.0,24723493,187
"Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.",Leukemia & lymphoma,Leuk. Lymphoma,2014-06-25,"The differential diagnosis of rapidly progressive or symptomatic lymphadenopathy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) includes infectious lymphadenitis. We studied 286 (9%) of 3040 patients with CLL seen between 2003 and 2012 at Mayo Clinic Rochester who had 356 diagnostic lymph node biopsies to evaluate rapidly progressive or symptomatic lymphadenopathy. Most (85.4%) biopsies showed progressive CLL, 8.9% a second lymphoid malignancy, 3.9% infectious lymphadenitis, 1.1% reactive adenitis and 0.6% non-hematological malignancies. Of the 12 patients (14 biopsies) with infectious lymphadenitis, five patients had never been treated for their CLL, and seven had a specific microbiological diagnosis (herpes simplex n=3, Cryptococcus neoformans n=1, Mycobacterium n=1, coagulase negative Staphylococcus n=2). We conclude that infectious lymphadenitis is a rare complication of CLL with clinical characteristics similar to progressive CLL and transformation to a more aggressive lymphoma. Early recognition and antimicrobial therapy treatment of infectious lymphadenitis can be highly effective in these patients.",Journal Article,2036.0,4.0,The differential diagnosis of rapidly progressive or symptomatic lymphadenopathy in patients with chronic lymphocytic leukemia/small lymphocytic CLL includes infectious lymphadenitis We studied 286 9 of 3040 patients with CLL seen between 2003 and 2012 at Mayo Clinic Rochester who had 356 diagnostic lymph node biopsies to evaluate rapidly progressive or symptomatic lymphadenopathy Most 85.4 biopsies showed progressive CLL 8.9 a second lymphoid malignancy 3.9 infectious lymphadenitis 1.1 reactive adenitis and 0.6 non-hematological malignancies Of the 12 patients 14 biopsies with infectious lymphadenitis five patients had never been treated for their CLL and seven had a specific microbiological diagnosis herpes simplex n=3 Cryptococcus neoformans n=1 Mycobacterium n=1 coagulase negative Staphylococcus n=2 We conclude that infectious lymphadenitis is a rare complication of CLL with clinical characteristics similar to progressive CLL and transformation to a more aggressive Early recognition and antimicrobial therapy treatment of infectious lymphadenitis can be highly effective in these patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1777, 147, 1, 1755, 1014, 15, 1704, 4962, 4, 7, 5, 442, 1193, 2647, 302, 1193, 552, 1920, 3398, 25375, 21, 656, 8302, 83, 1, 31559, 7, 5, 552, 527, 59, 1522, 2, 1195, 28, 2486, 1188, 5801, 54, 42, 8664, 752, 263, 289, 1154, 6, 376, 1755, 1014, 15, 1704, 4962, 96, 772, 39, 1154, 224, 1014, 552, 66, 83, 8, 419, 2303, 710, 27, 83, 3398, 25375, 14, 14, 2163, 64215, 2, 13, 49, 220, 2890, 441, 1, 3, 133, 7, 213, 1154, 5, 3398, 25375, 365, 7, 42, 1737, 85, 73, 9, 136, 552, 2, 648, 42, 8, 112, 27055, 147, 4716, 7241, 78, 27, 64216, 64217, 78, 14, 28789, 78, 14, 22294, 199, 14739, 78, 18, 21, 2060, 17, 3398, 25375, 16, 8, 622, 1447, 1, 552, 5, 38, 374, 288, 6, 1014, 552, 2, 1392, 6, 8, 80, 571, 191, 2335, 2, 9816, 36, 24, 1, 3398, 25375, 122, 40, 561, 323, 4, 46, 7]",1107.0,24738974,329
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.,Blood,Blood,2014-04-18,"The fludarabine and cyclophosphamide couplet has become the backbone of the chronic lymphocytic leukemia (CLL) standard of care. Although this is an effective treatment, it results in untoward toxicity. Bendamustine is a newly approved and better-tolerated alkylating agent. We hypothesized that similar to cyclophosphamide, bendamustine-induced DNA damage will be inhibited by fludarabine, resulting in increased cytotoxicity. To test this hypothesis and the role of the stromal microenvironment in this process, we treated CLL lymphocytes in vitro with each drug alone and in combination. Simultaneous or prior addition of fludarabine to bendamustine resulted in maximum cytotoxicity assayed by 3,3'-dihexyloxacarbocyanine iodine negativity, annexin positivity, and poly (adenosine 5'-diphosphate-ribose) polymerase cleavage. Cytotoxicity elicited by combination of both agents was similar in these malignant B cells cultured either in suspension or on marrow stroma cells. Cell death was associated with DNA damage response, which was determined by phosphorylation of H2AX and unscheduled DNA synthesis. H2AX activation was maximum with the drug combination, and unscheduled DNA synthesis induced by bendamustine was blocked by fludarabine. In parallel, ATM, Chk2, and p53 were phosphorylated and PUMA was induced. Cell death was caspase independent; however, caspases did decrease levels of Mcl-1 survival protein. These data provide a rationale for combining fludarabine with bendamustine for patients with CLL. ",Journal Article,2104.0,14.0,"The fludarabine and cyclophosphamide couplet has become the backbone of the chronic lymphocytic CLL standard of care Although this is an effective treatment it results in untoward toxicity Bendamustine is a newly approved and better-tolerated alkylating agent We hypothesized that similar to cyclophosphamide bendamustine-induced DNA damage will be inhibited by fludarabine resulting in increased cytotoxicity To test this hypothesis and the role of the stromal microenvironment in this process we treated CLL lymphocytes in vitro with each drug alone and in combination Simultaneous or prior addition of fludarabine to bendamustine resulted in maximum cytotoxicity assayed by 3,3'-dihexyloxacarbocyanine iodine negativity annexin positivity and poly adenosine 5'-diphosphate-ribose polymerase cleavage Cytotoxicity elicited by combination of both agents was similar in these malignant B cells cultured either in suspension or on marrow stroma cells Cell death was associated with DNA damage response which was determined by phosphorylation of H2AX and unscheduled DNA synthesis H2AX activation was maximum with the drug combination and unscheduled DNA synthesis induced by bendamustine was blocked by fludarabine In parallel ATM Chk2 and p53 were phosphorylated and PUMA was induced Cell death was caspase independent however caspases did decrease levels of Mcl-1 survival protein These data provide a rationale for combining fludarabine with bendamustine for patients with CLL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[3, 2027, 2, 1112, 33499, 71, 1417, 3, 7066, 1, 3, 442, 1193, 552, 260, 1, 165, 242, 26, 16, 35, 323, 24, 192, 99, 4, 15514, 155, 4809, 16, 8, 732, 850, 2, 380, 421, 3410, 420, 21, 1237, 17, 288, 6, 1112, 4809, 277, 261, 1350, 303, 40, 879, 20, 2027, 1113, 4, 101, 1408, 6, 412, 26, 1492, 2, 3, 200, 1, 3, 1126, 995, 4, 26, 1129, 21, 73, 552, 1594, 4, 439, 5, 296, 234, 279, 2, 4, 150, 2824, 15, 324, 352, 1, 2027, 6, 4809, 627, 4, 689, 1408, 4499, 20, 27, 5435, 64231, 4287, 6014, 4850, 1887, 2, 2699, 4938, 7344, 8762, 3507, 1451, 3155, 1408, 5179, 20, 150, 1, 110, 183, 10, 288, 4, 46, 393, 132, 37, 3197, 361, 4, 9348, 15, 23, 581, 2477, 37, 31, 273, 10, 41, 5, 261, 1350, 51, 92, 10, 509, 20, 982, 1, 6286, 2, 13774, 261, 2525, 6286, 363, 10, 689, 5, 3, 234, 150, 2, 13774, 261, 2525, 277, 20, 4809, 10, 2582, 20, 2027, 4, 2755, 3552, 14253, 2, 624, 11, 2365, 2, 8691, 10, 277, 31, 273, 10, 1469, 306, 137, 7629, 205, 775, 148, 1, 1308, 14, 25, 178, 46, 74, 377, 8, 1728, 9, 1525, 2027, 5, 4809, 9, 7, 5, 552]",1478.0,24747434,216
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.,Blood,Blood,2014-04-28,"In chronic lymphocytic leukemia (CLL), stimulation of the B-cell receptor (BCR) triggers survival signals. Because in various cells activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway provides cells with survival advantage, we wondered whether BCR stimulation activates the JAK/STAT pathway in CLL cells. To stimulate the BCR we incubated CLL cells with anti-IgM antibodies. Anti-IgM antibodies induced transient tyrosine phosphorylation and nuclear localization of phosphorylated (p) STAT3. Immunoprecipitation studies revealed that anti-JAK2 antibodies coimmunoprecipitated pSTAT3 and pJAK2 in IgM-stimulated but not unstimulated CLL cells, suggesting that activation of the BCR induces activation of JAK2, which phosphorylates STAT3. Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner. Whether ruxolitinib treatment would benefit patients with CLL remains to be determined. ",Journal Article,2094.0,40.0,In chronic lymphocytic CLL stimulation of the B-cell receptor BCR triggers survival signals Because in various cells activation of the Janus kinase JAK /signal transducer and activator of transcription STAT pathway provides cells with survival advantage we wondered whether BCR stimulation activates the JAK/STAT pathway in CLL cells To stimulate the BCR we incubated CLL cells with anti-IgM antibodies Anti-IgM antibodies induced transient tyrosine phosphorylation and nuclear localization of phosphorylated p STAT3 Immunoprecipitation studies revealed that anti-JAK2 antibodies coimmunoprecipitated pSTAT3 and pJAK2 in IgM-stimulated but not unstimulated CLL cells suggesting that activation of the BCR induces activation of JAK2 which phosphorylates STAT3 Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner Whether ruxolitinib treatment would benefit patients with CLL remains to be determined,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 2503, 1, 3, 132, 31, 153, 1062, 5951, 25, 2312, 408, 4, 747, 37, 363, 1, 3, 6191, 216, 4653, 1235, 5182, 2, 3393, 1, 866, 4168, 308, 777, 37, 5, 25, 1874, 21, 40707, 317, 1062, 2503, 3932, 3, 4653, 4168, 308, 4, 552, 37, 6, 4223, 3, 1062, 21, 8303, 552, 37, 5, 312, 2852, 890, 312, 2852, 890, 277, 2473, 564, 982, 2, 928, 2145, 1, 2365, 19, 1439, 4857, 94, 553, 17, 312, 2509, 890, 26574, 6480, 2, 46138, 4, 2852, 2816, 84, 44, 16781, 552, 37, 802, 17, 363, 1, 3, 1062, 1516, 363, 1, 2509, 92, 12528, 1439, 7797, 1, 552, 37, 5, 3, 8075, 18, 230, 4894, 879, 2852, 277, 1439, 982, 2, 277, 351, 1, 2852, 2816, 84, 44, 16781, 552, 37, 4, 8, 61, 2, 98, 470, 1708, 317, 4894, 24, 688, 247, 7, 5, 552, 469, 6, 40, 509]",1059.0,24778152,101
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.,Blood,Blood,2014-05-05,"In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited information on their independent prognostic value, and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice. We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index. A multivariable Cox regression model identified 8 independent predictors of OS: sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum 2-microglobulin, and serum thymidine kinase. Using a weighted grading system, a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7% to 95.2% and having a C-statistic of 0.75. The index stratified OS within all analyzed subgroups, including all Rai/Binet stages. The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic. Using this multistep process including external validation, we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level. The studies were registered as follows: CLL1 trial (NCT00262782, http://clinicaltrials.gov), CLL4 trial (ISRCTN 75653261, http://www.controlled-trials.com), and CLL8 trial (NCT00281918, http://clinicaltrials.gov). ",Journal Article,2087.0,152.0,In addition to clinical staging a number of biomarkers predicting overall survival OS have been identified in chronic lymphocytic CLL The multiplicity of markers limited information on their independent prognostic value and a lack of understanding of how to interpret discordant markers are major barriers to use in routine clinical practice We therefore performed an analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index A multivariable Cox regression model identified 8 independent predictors of OS sex age ECOG status del 17p del 11q IGHV mutation status serum 2-microglobulin and serum thymidine kinase Using a weighted grading system a prognostic index was derived that separated 4 risk categories with 5-year OS ranging from 18.7 to 95.2 and having a C-statistic of 0.75 The index stratified OS within all analyzed subgroups including all Rai/Binet stages The validity of the index was externally confirmed in a series of 676 newly diagnosed CLL patients from Mayo Clinic Using this multistep process including external validation we developed a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level The studies were registered as follows CLL1 trial NCT00262782 http //clinicaltrials.gov CLL4 trial ISRCTN 75653261 http //www.controlled-trials.com and CLL8 trial NCT00281918 http //clinicaltrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 352, 6, 38, 632, 8, 207, 1, 582, 1434, 63, 25, 118, 47, 85, 108, 4, 442, 1193, 552, 3, 8641, 1, 525, 383, 487, 23, 136, 306, 177, 549, 2, 8, 926, 1, 612, 1, 832, 6, 8048, 4570, 525, 32, 458, 2160, 6, 119, 4, 1311, 38, 758, 21, 673, 173, 35, 65, 1, 382, 177, 525, 90, 23, 1143, 786, 74, 29, 24843, 552, 7, 3052, 4, 124, 27, 143, 1, 3, 10842, 552, 45, 87, 6, 690, 8, 949, 177, 558, 8, 658, 418, 320, 202, 108, 66, 306, 674, 1, 118, 1035, 89, 2351, 156, 3084, 4135, 3084, 7203, 6220, 258, 156, 524, 9314, 5371, 2, 524, 6403, 216, 75, 8, 2337, 3452, 398, 8, 177, 558, 10, 526, 17, 4910, 39, 43, 1996, 5, 33, 111, 118, 2223, 29, 203, 67, 6, 48, 18, 2, 1041, 8, 256, 4502, 1, 13, 481, 3, 558, 1173, 118, 262, 62, 311, 1453, 141, 62, 4121, 17129, 1153, 3, 3099, 1, 3, 558, 10, 7753, 557, 4, 8, 988, 1, 11010, 732, 265, 552, 7, 29, 2486, 1188, 75, 26, 9417, 1129, 141, 1455, 929, 21, 276, 8, 949, 177, 558, 5, 64, 7276, 2349, 2, 177, 724, 23, 3, 797, 69, 301, 3, 94, 11, 1653, 22, 2962, 35808, 160, 64315, 5196, 1252, 1239, 64316, 160, 48343, 64317, 5196, 3064, 1149, 143, 8264, 2, 47434, 160, 64318, 5196, 1252, 1239]",1522.0,24797299,193
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.,Leukemia & lymphoma,Leuk. Lymphoma,2014-08-04,"Chronic lymphocytic leukemia (CLL) remains fatal due to the development of resistance to existing therapies. Targeting abnormal glucose metabolism sensitizes various cancer cells to chemotherapy and/or elicits toxicity. Examination of glucose dependency in CLL demonstrated variable sensitivity to glucose deprivation. Further evaluation of metabolic dependencies of CLL cells resistant to glucose deprivation revealed increased engagement of fatty acid oxidation upon glucose withdrawal. Investigation of glucose transporter expression in CLL reveals up-regulation of glucose transporter GLUT4. Treatment of CLL cells with human immunodeficiency (HIV) protease inhibitor ritonavir, which inhibits GLUT4, elicits toxicity similar to that elicited upon glucose deprivation. CLL cells resistant to ritonavir are sensitized by co-treatment with metformin, potentially targeting compensatory mitochondrial complex 1 activity. Ritonavir and metformin have been administered in humans for the treatment of diabetes in patients with HIV, demonstrating the tolerance to this combination in humans. Our studies strongly substantiate further investigation of Food and Drug Administration approved ritonavir and metformin for CLL.",Journal Article,1996.0,16.0,Chronic lymphocytic CLL remains fatal due to the development of resistance to existing therapies Targeting abnormal glucose metabolism sensitizes various cancer cells to chemotherapy and/or elicits toxicity Examination of glucose dependency in CLL demonstrated variable sensitivity to glucose deprivation Further evaluation of metabolic dependencies of CLL cells resistant to glucose deprivation revealed increased engagement of fatty acid oxidation upon glucose withdrawal Investigation of glucose transporter expression in CLL reveals up-regulation of glucose transporter GLUT4 Treatment of CLL cells with human immunodeficiency HIV protease inhibitor ritonavir which inhibits GLUT4 elicits toxicity similar to that elicited upon glucose deprivation CLL cells resistant to ritonavir are sensitized by co-treatment with metformin potentially targeting compensatory mitochondrial complex 1 activity Ritonavir and metformin have been administered in humans for the treatment of diabetes in patients with HIV demonstrating the tolerance to this combination in humans Our studies strongly substantiate further investigation of Food and Drug Administration approved ritonavir and metformin for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 469, 3034, 520, 6, 3, 193, 1, 251, 6, 1692, 235, 529, 1668, 2522, 1600, 6229, 747, 12, 37, 6, 56, 2, 15, 8748, 155, 1385, 1, 2522, 6359, 4, 552, 264, 1347, 485, 6, 2522, 1868, 195, 451, 1, 1436, 11508, 1, 552, 37, 436, 6, 2522, 1868, 553, 101, 5103, 1, 4038, 971, 8740, 1548, 2522, 3683, 940, 1, 2522, 5246, 55, 4, 552, 4054, 126, 863, 1, 2522, 5246, 14609, 24, 1, 552, 37, 5, 171, 5323, 1942, 5125, 230, 13715, 92, 1576, 14609, 8748, 155, 288, 6, 17, 5179, 1548, 2522, 1868, 552, 37, 436, 6, 13715, 32, 4242, 20, 1269, 24, 5, 2791, 751, 529, 7084, 2019, 840, 14, 128, 13715, 2, 2791, 47, 85, 468, 4, 3218, 9, 3, 24, 1, 1978, 4, 7, 5, 1942, 2219, 3, 2614, 6, 26, 150, 4, 3218, 114, 94, 1327, 16249, 195, 940, 1, 1773, 2, 234, 634, 850, 13715, 2, 2791, 9, 552]",1193.0,24828872,24
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.,Blood,Blood,2014-05-14,"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characterize the dynamics of this redistribution phenomenon, we correlated serial lymphocyte counts with volumetric changes in lymph node and spleen sizes during ibrutinib therapy. Kinetic parameters were estimated by applying a mathematical model to the data. We found that during ibrutinib therapy, 1.7%  1.1% of blood CLL cells and 2.7%  0.99% of tissue CLL cells die per day. The fraction of the tissue CLL cells that was redistributed into the blood during therapy was estimated to be 23.3%  17% of the total tissue disease burden. These data indicate that the reduction of tissue disease burden by ibrutinib is due more to CLL cell death and less to egress from nodal compartments.","Clinical Trial, Phase I",2078.0,49.0,The Bruton tyrosine kinase BTK inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic CLL Characteristically ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy To better characterize the dynamics of this redistribution phenomenon we correlated serial lymphocyte counts with volumetric changes in lymph node and spleen sizes during ibrutinib therapy Kinetic parameters were estimated by applying a mathematical model to the data We found that during ibrutinib therapy 1.7  1.1 of blood CLL cells and 2.7  0.99 of tissue CLL cells die per day The fraction of the tissue CLL cells that was redistributed into the blood during therapy was estimated to be 23.3  17 of the total tissue disease burden These data indicate that the reduction of tissue disease burden by ibrutinib is due more to CLL cell death and less to egress from nodal compartments,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 5796, 564, 216, 3611, 230, 1795, 71, 1503, 38, 128, 4, 7, 5, 442, 1193, 552, 14079, 1795, 1626, 552, 31, 12507, 29, 246, 633, 237, 3, 672, 315, 190, 3, 388, 244, 1, 36, 6, 380, 1507, 3, 5193, 1, 26, 12507, 3936, 21, 438, 2108, 1448, 1911, 5, 4083, 400, 4, 263, 289, 2, 4071, 4131, 190, 1795, 36, 7009, 1038, 11, 661, 20, 4798, 8, 7419, 202, 6, 3, 74, 21, 204, 17, 190, 1795, 36, 14, 67, 810, 14, 14, 1, 315, 552, 37, 2, 18, 67, 810, 13, 1058, 1, 246, 552, 37, 3384, 379, 218, 3, 1509, 1, 3, 246, 552, 37, 17, 10, 48357, 237, 3, 315, 190, 36, 10, 661, 6, 40, 382, 27, 810, 269, 1, 3, 181, 246, 34, 892, 46, 74, 1008, 17, 3, 628, 1, 246, 34, 892, 20, 1795, 16, 520, 80, 6, 552, 31, 273, 2, 299, 6, 24404, 29, 779, 6473]",951.0,24829205,2
STAT3-activated GM-CSFR translocates to the nucleus and protects CLL cells from apoptosis.,Molecular cancer research : MCR,Mol. Cancer Res.,2014-05-16,"Here, it was determined that chronic lymphocytic leukemia (CLL) cells express the  subunit, but not the  subunit, of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR/CSF2R). GM-CSFR was detected on the surface, in the cytosol, and in the nucleus of CLL cells via confocal microscopy, cell fractionation, and GM-CSFR antibody epitope mapping. Because STAT3 is frequently activated in CLL and the GM-CSFR promoter harbors putative STAT3 consensus binding sites, MM1 cells were transfected with truncated forms of the GM-CSFR promoter, then stimulated with IL6 to activate STAT3 and to identify STAT3-binding sites. Chromatin immunoprecipitation (ChIP) and an electoromobility shift assay (EMSA) confirmed STAT3 occupancy to those promoter regions in both IL6-stimulated MM1 and CLL cells. Transfection of MM1 cells with STAT3-siRNA or CLL cells with STAT3-shRNA significantly downregulated GM-CSFR mRNA and protein levels. RNA transcripts, involved in regulating cell survival pathways, and the proteins KAP1 (TRIM28) and ISG15 coimmunoprecipitated with GM-CSFR. GM-CSFR-bound KAP1 enhanced the transcriptional activity of STAT3, whereas GM-CSFR-bound ISG15 inhibited the NF-B pathway. Nevertheless, overexpression of GM-CSFR protected MM1 cells from dexamethasone-induced apoptosis, and GM-CSFR knockdown induced apoptosis in CLL cells, suggesting that GM-CSFR provides a ligand-independent survival advantage. Constitutively, activation of STAT3 induces the expression of GM-CSFR that protects CLL cells from apoptosis, suggesting that inhibition of STAT3 or GM-CSFR may benefit patients with CLL.",Journal Article,2076.0,8.0,Here it was determined that chronic lymphocytic CLL cells express the subunit but not the subunit of the granulocyte-macrophage colony-stimulating factor receptor GM-CSFR/CSF2R GM-CSFR was detected on the surface in the cytosol and in the nucleus of CLL cells via confocal microscopy cell fractionation and GM-CSFR antibody epitope mapping Because STAT3 is frequently activated in CLL and the GM-CSFR promoter harbors putative STAT3 consensus binding sites MM1 cells were transfected with truncated forms of the GM-CSFR promoter then stimulated with IL6 to activate STAT3 and to identify STAT3-binding sites Chromatin immunoprecipitation ChIP and an electoromobility shift assay EMSA confirmed STAT3 occupancy to those promoter regions in both IL6-stimulated MM1 and CLL cells Transfection of MM1 cells with STAT3-siRNA or CLL cells with STAT3-shRNA significantly downregulated GM-CSFR mRNA and protein levels RNA transcripts involved in regulating cell survival pathways and the proteins KAP1 TRIM28 and ISG15 coimmunoprecipitated with GM-CSFR GM-CSFR-bound KAP1 enhanced the transcriptional activity of STAT3 whereas GM-CSFR-bound ISG15 inhibited the NF-B pathway Nevertheless overexpression of GM-CSFR protected MM1 cells from dexamethasone-induced apoptosis and GM-CSFR knockdown induced apoptosis in CLL cells suggesting that GM-CSFR provides a ligand-independent survival advantage Constitutively activation of STAT3 induces the expression of GM-CSFR that protects CLL cells from apoptosis suggesting that inhibition of STAT3 or GM-CSFR may benefit patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[467, 192, 10, 509, 17, 442, 1193, 552, 37, 1669, 3, 3350, 84, 44, 3, 3350, 1, 3, 2764, 2674, 1975, 2122, 161, 153, 2147, 28702, 64359, 2147, 20041, 10, 530, 23, 3, 1255, 4, 3, 11107, 2, 4, 3, 4262, 1, 552, 37, 847, 6541, 3804, 31, 3519, 2, 2147, 20041, 548, 4430, 2568, 408, 1439, 16, 746, 735, 4, 552, 2, 3, 2147, 20041, 973, 8475, 2743, 1439, 1391, 791, 633, 12773, 37, 11, 3245, 5, 6502, 2377, 1, 3, 2147, 20041, 973, 818, 2816, 5, 6772, 6, 2977, 1439, 2, 6, 255, 1439, 791, 633, 2287, 4857, 4222, 2, 35, 64360, 3024, 719, 15941, 557, 1439, 8509, 6, 135, 973, 1374, 4, 110, 6772, 2816, 12773, 2, 552, 37, 3789, 1, 12773, 37, 5, 1439, 1919, 15, 552, 37, 5, 1439, 3976, 97, 3315, 2147, 20041, 956, 2, 178, 148, 893, 2680, 646, 4, 2681, 31, 25, 460, 2, 3, 652, 39793, 22840, 2, 34581, 26574, 5, 2147, 20041, 2147, 20041, 2951, 39793, 651, 3, 1431, 128, 1, 1439, 547, 2147, 20041, 2951, 34581, 879, 3, 1365, 2448, 308, 3873, 851, 1, 2147, 20041, 5541, 12773, 37, 29, 1217, 277, 351, 2, 2147, 20041, 1563, 277, 351, 4, 552, 37, 802, 17, 2147, 20041, 777, 8, 1232, 306, 25, 1874, 2818, 363, 1, 1439, 1516, 3, 55, 1, 2147, 20041, 17, 8170, 552, 37, 29, 351, 802, 17, 297, 1, 1439, 15, 2147, 20041, 68, 247, 7, 5, 552]",1586.0,24836891,38
Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.,Cytometry. Part A : the journal of the International Society for Analytical Cytology,Cytometry A,2014-05-20,"The E2997 Phase III trial included preservation of valuable chronic lymphocytic leukemia (CLL) patient specimens and relevant clinical outcome data. Using a novel high-resolution technology on a flow cytometry platform, we assessed 79 E2997 samples for the expression of 27 analytes that reflected the activity of signaling pathways and apoptosis. We found that the expression levels of ZAP70 segregated the samples into two subpopulations with the distribution showing a peak-trough-peak configuration. Although prior assessment of ZAP70 by standard procedures did not reveal any prognostic information, we found by using the trough in the distribution as a cutpoint that ZAP70 expression levels were significantly correlated with both progression-free survival and overall survival. Additionally, the cells expressing high versus low levels of ZAP70 demonstrated distinct molecular organization as indicated by the other analytes assessed. Our analysis demonstrates the value of ZAP70 expression as a prognostic indicator and suggests that the different clinical results may be due to the distinct molecular biology of the ZAP70-low versus the ZAP70-high CLL samples.","Clinical Trial, Phase III",2072.0,1.0,The E2997 Phase III trial included preservation of valuable chronic lymphocytic CLL patient specimens and relevant clinical outcome data Using a novel high-resolution technology on a flow cytometry platform we assessed 79 E2997 samples for the expression of 27 analytes that reflected the activity of signaling pathways and apoptosis We found that the expression levels of ZAP70 segregated the samples into two subpopulations with the distribution showing a peak-trough-peak configuration Although prior assessment of ZAP70 by standard procedures did not reveal any prognostic information we found by using the trough in the distribution as a cutpoint that ZAP70 expression levels were significantly correlated with both progression-free survival and overall survival Additionally the cells expressing high versus low levels of ZAP70 demonstrated distinct molecular organization as indicated by the other analytes assessed Our analysis demonstrates the value of ZAP70 expression as a prognostic indicator and suggests that the different clinical results may be due to the distinct molecular biology of the ZAP70-low versus the ZAP70-high CLL samples,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 23577, 124, 316, 160, 159, 2224, 1, 2926, 442, 1193, 552, 69, 623, 2, 867, 38, 228, 74, 75, 8, 229, 64, 2125, 2033, 23, 8, 1412, 1914, 2243, 21, 275, 842, 23577, 347, 9, 3, 55, 1, 428, 10942, 17, 4686, 3, 128, 1, 314, 460, 2, 351, 21, 204, 17, 3, 55, 148, 1, 12921, 11324, 3, 347, 237, 100, 4847, 5, 3, 1395, 2069, 8, 2944, 6000, 2944, 13796, 242, 324, 455, 1, 12921, 20, 260, 1369, 205, 44, 2396, 500, 177, 487, 21, 204, 20, 75, 3, 6000, 4, 3, 1395, 22, 8, 15340, 17, 12921, 55, 148, 11, 97, 438, 5, 110, 91, 115, 25, 2, 63, 25, 1724, 3, 37, 1046, 64, 185, 154, 148, 1, 12921, 264, 834, 219, 2533, 22, 1103, 20, 3, 127, 10942, 275, 114, 65, 1902, 3, 549, 1, 12921, 55, 22, 8, 177, 3287, 2, 844, 17, 3, 338, 38, 99, 68, 40, 520, 6, 3, 834, 219, 891, 1, 3, 12921, 154, 185, 3, 12921, 64, 552, 347]",1149.0,24845539,688
Chronic lymphocytic leukemia: state of the art and beyond.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-05-01,"In the treatment of chronic lymphocytic leukemia (CLL), select genomic studies can assist in risk stratification of newly diagnosed patients. Chemoimmunotherapy targeting CD20 offers a survival advantage in symptomatic patients both with and without these high-risk genetic features, though patients with del(17p13.1) have poor outcomes and require specific intervention. Obinutuzumab plus chlorambucil is a treatment standard for untreated elderly patients and is superior to rituximab plus chlorambucil. In the setting of relapsed CLL, the new kinase inhibitors have the potential to completely change the treatment paradigm of CLL. ",Editorial,2091.0,1.0,In the treatment of chronic lymphocytic CLL select genomic studies can assist in risk stratification of newly diagnosed patients Chemoimmunotherapy targeting CD20 offers a survival advantage in symptomatic patients both with and without these high-risk genetic features though patients with del 17p13.1 have poor outcomes and require specific intervention Obinutuzumab plus chlorambucil is a treatment standard for untreated elderly patients and is superior to rituximab plus chlorambucil In the setting of relapsed CLL the new kinase inhibitors have the potential to completely change the treatment paradigm of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 3, 24, 1, 442, 1193, 552, 1717, 572, 94, 122, 3425, 4, 43, 1541, 1, 732, 265, 7, 4438, 529, 2198, 2339, 8, 25, 1874, 4, 1704, 7, 110, 5, 2, 187, 46, 64, 43, 336, 404, 2471, 7, 5, 3084, 7526, 14, 47, 334, 123, 2, 1353, 112, 788, 10380, 349, 11585, 16, 8, 24, 260, 9, 1278, 1216, 7, 2, 16, 1123, 6, 855, 349, 11585, 4, 3, 546, 1, 591, 552, 3, 217, 216, 222, 47, 3, 174, 6, 2500, 707, 3, 24, 2431, 1, 552]",615.0,24853221,341
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.,Haematologica,Haematologica,2014-05-23,"Although uncommon in treatment-naive patients with chronic lymphocytic leukemia, deletion 17p is a high-risk disease characteristic. We analyzed and reported outcomes for 63 patients with deletion 17p chronic lymphocytic leukemia who received first-line therapy at our institution; at time of first treatment, 81% had unmutated immunoglobulin heavy chain variable gene and 58% had complex karyotype. Forty-nine patients (76%) received first-line fludarabine, cyclophosphamide, rituximab-based therapy, 6 (11%) received rituximab-based and 8 (13%) received lenalidomide-based treatment. Overall, the complete plus nodular partial remission rate was 33%; on multivariable model, higher complete plus nodular partial remission rate was observed in patients with less than 50% cells positive for deletion 17p, and a higher probability of achieving at least a partial remission was observed with fludarabine, cyclophosphamide, rituximab-based treatment. After a median follow up of 33 months (range 1-89 months), the estimated median progression-free survival was 14 months (95% confidence interval 10-18) and estimated median overall survival was 63 months (95% confidence interval 43-83). In multivariable analysis, factors independently associated with longer progression-free survival were response to treatment and absence of complex karyotype. Achievement of complete plus nodular partial remission rate and mutated immunoglobulin heavy chain variable gene were independently associated with longer overall survival in multivariable model. Complex karyotype was associated with increased risk for Richter's transformation. New first-line strategies and agents must aim at both improving response and maintaining remission in patients with deletion 17p, particularly in the presence of complex karyotype. ",Journal Article,2069.0,42.0,Although uncommon in treatment-naive patients with chronic lymphocytic deletion 17p is a high-risk disease characteristic We analyzed and reported outcomes for 63 patients with deletion 17p chronic lymphocytic who received first-line therapy at our institution at time of first treatment 81 had unmutated immunoglobulin heavy chain variable gene and 58 had complex karyotype Forty-nine patients 76 received first-line fludarabine cyclophosphamide rituximab-based therapy 6 11 received rituximab-based and 8 13 received lenalidomide-based treatment Overall the complete plus nodular partial remission rate was 33 on multivariable model higher complete plus nodular partial remission rate was observed in patients with less than 50 cells positive for deletion 17p and a higher probability of achieving at least a partial remission was observed with fludarabine cyclophosphamide rituximab-based treatment After a median follow up of 33 months range 1-89 months the estimated median progression-free survival was 14 months 95 confidence interval 10-18 and estimated median overall survival was 63 months 95 confidence interval 43-83 In multivariable analysis factors independently associated with longer progression-free survival were response to treatment and absence of complex karyotype Achievement of complete plus nodular partial remission rate and mutated immunoglobulin heavy chain variable gene were independently associated with longer overall survival in multivariable model Complex karyotype was associated with increased risk for Richter 's transformation New first-line strategies and agents must aim at both improving response and maintaining remission in patients with deletion 17p particularly in the presence of complex karyotype,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 2052, 4, 24, 2462, 7, 5, 442, 1193, 1528, 4135, 16, 8, 64, 43, 34, 2037, 21, 311, 2, 210, 123, 9, 676, 7, 5, 1528, 4135, 442, 1193, 54, 103, 157, 328, 36, 28, 114, 731, 28, 98, 1, 157, 24, 865, 42, 7216, 2593, 4013, 1260, 1347, 145, 2, 717, 42, 840, 3385, 1213, 762, 7, 846, 103, 157, 328, 2027, 1112, 855, 90, 36, 49, 175, 103, 855, 90, 2, 66, 233, 103, 1288, 90, 24, 63, 3, 236, 349, 4481, 450, 734, 116, 10, 466, 23, 658, 202, 142, 236, 349, 4481, 450, 734, 116, 10, 164, 4, 7, 5, 299, 76, 212, 37, 109, 9, 1528, 4135, 2, 8, 142, 1320, 1, 1785, 28, 506, 8, 450, 734, 10, 164, 5, 2027, 1112, 855, 90, 24, 50, 8, 52, 166, 126, 1, 466, 53, 184, 14, 887, 53, 3, 661, 52, 91, 115, 25, 10, 213, 53, 48, 307, 268, 79, 203, 2, 661, 52, 63, 25, 10, 676, 53, 48, 307, 268, 601, 852, 4, 658, 65, 130, 1042, 41, 5, 589, 91, 115, 25, 11, 51, 6, 24, 2, 1127, 1, 840, 3385, 5088, 1, 236, 349, 4481, 450, 734, 116, 2, 1185, 2593, 4013, 1260, 1347, 145, 11, 1042, 41, 5, 589, 63, 25, 4, 658, 202, 840, 3385, 10, 41, 5, 101, 43, 9, 8452, 292, 1392, 217, 157, 328, 422, 2, 183, 1642, 1130, 28, 110, 1673, 51, 2, 3284, 734, 4, 7, 5, 1528, 4135, 823, 4, 3, 463, 1, 840, 3385]",1742.0,24859876,725
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-05-27,"Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patients. Lenalidomide was initiated at 2.5 mg/day and was escalated based on treatment tolerability to a maximum of 10 mg/day, for 21 days/cycle, for a maximum of seven cycles. Rituximab was administered at the end of cycle 1 and was continued for seven cycles. Patients received allopurinol and aspirin for prophylaxis. Sixty-nine patients enrolled onto one of two age-specific strata; patients' median age was 56 and 70 years for arms A and B, respectively. Patients in the older-patient stratum more frequently had elevated serum beta-2 microglobulin levels, high-risk Rai stage, and were less likely to complete the maximum planned therapy. Adverse events were similar in the two arms. Nonhematologic toxicity was predominantly at grade 1/2, and neutropenia was the most common hematologic adverse event. The response rate for arm A was 95%, with 20% complete responses (CRs) and 20% nodular partial responses. Of arm B patients, 78% achieved a response, of which 11% were CRs. Median progression-free survival (PFS) was 19 months for the younger cohort and 20 months for the older cohort. Intrapatient dose-escalation was safe. The majority of patients reached the maximum lenalidomide dose and experienced a response to a defined seven-cycle course of lenalidomide and rituximab therapy. Despite differences in baseline characteristics and the response rate between the two strata, the PFS did not differ.",Journal Article,2065.0,48.0,Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic CLL In preclinical models lenalidomide acted synergistically with rituximab The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patients Lenalidomide was initiated at 2.5 mg/day and was escalated based on treatment tolerability to a maximum of 10 mg/day for 21 days/cycle for a maximum of seven cycles Rituximab was administered at the end of cycle 1 and was continued for seven cycles Patients received allopurinol and aspirin for prophylaxis Sixty-nine patients enrolled onto one of two age-specific strata patients median age was 56 and 70 years for arms A and B respectively Patients in the older-patient stratum more frequently had elevated serum beta-2 microglobulin levels high-risk Rai stage and were less likely to complete the maximum planned therapy Adverse events were similar in the two arms Nonhematologic toxicity was predominantly at grade 1/2 and neutropenia was the most common hematologic adverse event The response rate for arm A was 95 with 20 complete responses CRs and 20 nodular partial responses Of arm B patients 78 achieved a response of which 11 were CRs Median progression-free survival PFS was 19 months for the younger cohort and 20 months for the older cohort Intrapatient dose-escalation was safe The majority of patients reached the maximum lenalidomide dose and experienced a response to a defined seven-cycle course of lenalidomide and rituximab therapy Despite differences in baseline characteristics and the response rate between the two strata the PFS did not differ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 16, 35, 2555, 420, 5, 189, 128, 4, 442, 1193, 552, 4, 693, 274, 1288, 12403, 4240, 5, 855, 3, 552, 389, 2404, 1917, 8, 124, 215, 45, 6, 376, 26, 150, 4, 24, 2462, 7, 1288, 10, 1917, 28, 18, 33, 81, 218, 2, 10, 2842, 90, 23, 24, 1543, 6, 8, 689, 1, 79, 81, 218, 9, 239, 162, 417, 9, 8, 689, 1, 648, 410, 855, 10, 468, 28, 3, 396, 1, 417, 14, 2, 10, 1351, 9, 648, 410, 7, 103, 22090, 2, 2085, 9, 2049, 1746, 762, 7, 346, 3301, 104, 1, 100, 89, 112, 5758, 7, 52, 89, 10, 664, 2, 431, 60, 9, 1335, 8, 2, 132, 106, 7, 4, 3, 434, 69, 4897, 80, 746, 42, 804, 524, 1090, 18, 5371, 148, 64, 43, 4121, 82, 2, 11, 299, 322, 6, 236, 3, 689, 1465, 36, 290, 281, 11, 288, 4, 3, 100, 1335, 3534, 155, 10, 2117, 28, 88, 14, 18, 2, 778, 10, 3, 96, 186, 813, 290, 774, 3, 51, 116, 9, 475, 8, 10, 48, 5, 179, 236, 253, 3115, 2, 179, 4481, 450, 253, 1, 475, 132, 7, 833, 513, 8, 51, 1, 92, 175, 11, 3115, 52, 91, 115, 25, 300, 10, 326, 53, 9, 3, 773, 180, 2, 179, 53, 9, 3, 434, 180, 9838, 61, 1125, 10, 1165, 3, 686, 1, 7, 1300, 3, 689, 1288, 61, 2, 592, 8, 51, 6, 8, 395, 648, 417, 906, 1, 1288, 2, 855, 36, 550, 362, 4, 330, 374, 2, 3, 51, 116, 59, 3, 100, 5758, 3, 300, 205, 44, 1505]",1647.0,24868031,314
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.,Blood,Blood,2014-05-27,"ZAP-70 methylation 223 nucleotides downstream of transcription start (CpG+223) predicts outcome in chronic lymphocytic leukemia (CLL), but its impact relative to CD38 and ZAP-70 expression or immunoglobulin heavy chain variable region (IGHV) status is uncertain. Additionally, standardizing ZAP-70 expression analysis has been unsuccessful. CpG+223 methylation was quantitatively determined in 295 untreated CLL cases using MassARRAY. Impact on clinical outcome vs CD38 and ZAP-70 expression and IGHV status was evaluated. Cases with low methylation (<20%) had significantly shortened time to first treatment (TT) and overall survival (OS) (P < .0001). For TT, low methylation defined a large subset of ZAP-70 protein-negative cases with significantly shortened TT (median, 8.0 vs 3.9 years for high vs low methylation; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.25-0.74). Conversely, 16 ZAP-70 protein-positive cases with high methylation had poor outcome (median, 1.1 vs 2.3 years for high vs low methylation; HR = 1.62; 95% CI, 0.87-3.03). For OS, ZAP-70 methylation was the strongest risk factor; CD38 and ZAP-70 expression or IGHV status did not significantly improve OS prediction. A pyrosequencing assay was established that reproduced the MassARRAY data ( coefficient > 0.90). Thus, ZAP-70 CpG+223 methylation represents a superior biomarker for TT and OS that can be feasibly measured, supporting its use in risk-stratifying CLL. ",Journal Article,2065.0,41.0,ZAP-70 methylation 223 nucleotides downstream of transcription start CpG+223 predicts outcome in chronic lymphocytic CLL but its impact relative to CD38 and ZAP-70 expression or immunoglobulin heavy chain variable region IGHV status is uncertain Additionally standardizing ZAP-70 expression analysis has been unsuccessful CpG+223 methylation was quantitatively determined in 295 untreated CLL cases using MassARRAY Impact on clinical outcome vs CD38 and ZAP-70 expression and IGHV status was evaluated Cases with low methylation 20 had significantly shortened time to first treatment TT and overall survival OS P .0001 For TT low methylation defined a large subset of ZAP-70 protein-negative cases with significantly shortened TT median 8.0 vs 3.9 years for high vs low methylation hazard ratio HR 0.43 95 confidence interval CI 0.25-0.74 Conversely 16 ZAP-70 protein-positive cases with high methylation had poor outcome median 1.1 vs 2.3 years for high vs low methylation HR 1.62 95 CI 0.87-3.03 For OS ZAP-70 methylation was the strongest risk factor CD38 and ZAP-70 expression or IGHV status did not significantly improve OS prediction A pyrosequencing assay was established that reproduced the MassARRAY data  coefficient 0.90 Thus ZAP-70 CpG+223 methylation represents a superior biomarker for TT and OS that can be feasibly measured supporting its use in risk-stratifying CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6251, 431, 569, 3907, 11381, 1489, 1, 866, 2435, 2075, 3907, 2623, 228, 4, 442, 1193, 552, 84, 211, 345, 580, 6, 4469, 2, 6251, 431, 55, 15, 2593, 4013, 1260, 1347, 1053, 6220, 156, 16, 2717, 1724, 15343, 6251, 431, 55, 65, 71, 85, 7581, 2075, 3907, 569, 10, 5889, 509, 4, 7051, 1278, 552, 140, 75, 12442, 345, 23, 38, 228, 105, 4469, 2, 6251, 431, 55, 2, 6220, 156, 10, 194, 140, 5, 154, 569, 179, 42, 97, 6151, 98, 6, 157, 24, 3504, 2, 63, 25, 118, 19, 488, 9, 3504, 154, 569, 395, 8, 375, 697, 1, 6251, 431, 178, 199, 140, 5, 97, 6151, 3504, 52, 66, 13, 105, 27, 83, 60, 9, 64, 105, 154, 569, 360, 197, 168, 13, 601, 48, 307, 268, 58, 13, 243, 13, 794, 3154, 245, 6251, 431, 178, 109, 140, 5, 64, 569, 42, 334, 228, 52, 14, 14, 105, 18, 27, 60, 9, 64, 105, 154, 569, 168, 14, 744, 48, 58, 13, 912, 27, 680, 9, 118, 6251, 431, 569, 10, 3, 3311, 43, 161, 4469, 2, 6251, 431, 55, 15, 6220, 156, 205, 44, 97, 401, 118, 1590, 8, 6031, 719, 10, 635, 17, 14538, 3, 12442, 74, 4627, 3200, 13, 424, 631, 6251, 431, 2075, 3907, 569, 1449, 8, 1123, 901, 9, 3504, 2, 118, 17, 122, 40, 21302, 644, 1912, 211, 119, 4, 43, 5035, 552]",1383.0,24868078,74
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.,The New England journal of medicine,N. Engl. J. Med.,2014-05-28,"Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance. We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy. We then performed functional analysis of identified mutations. In addition, we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis. We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLC2 in two patients. Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib. The R665W and L845F mutations in PLC2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity. These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib. Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs. This finding, combined with two additional mutations in PLC2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL. (Funded by the National Cancer Institute and others.).",Journal Article,2064.0,531.0,Ibrutinib is an irreversible inhibitor of Bruton 's tyrosine kinase BTK and is effective in chronic lymphocytic CLL Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized Although only a small proportion of patients have had a relapse during ibrutinib therapy an understanding of resistance mechanisms is important We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy We then performed functional analysis of identified mutations In addition we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLC2 in two patients Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib The R665W and L845F mutations in PLC2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs This finding combined with two additional mutations in PLC2 that are immediately downstream of BTK underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL Funded by the National Cancer Institute and others,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 35, 4422, 230, 1, 5796, 292, 564, 216, 3611, 2, 16, 323, 4, 442, 1193, 552, 251, 6, 4422, 216, 222, 2, 251, 41, 5, 3611, 297, 47, 44, 85, 765, 242, 158, 8, 302, 920, 1, 7, 47, 42, 8, 429, 190, 1795, 36, 35, 612, 1, 251, 483, 16, 305, 21, 194, 7, 5, 591, 34, 6, 255, 138, 17, 68, 3367, 1795, 251, 21, 173, 902, 2865, 615, 28, 330, 2, 3, 98, 1, 429, 23, 347, 29, 437, 7, 5, 1294, 251, 6, 1795, 36, 21, 818, 173, 583, 65, 1, 108, 138, 4, 352, 21, 173, 7714, 20837, 615, 9, 108, 251, 138, 23, 347, 29, 762, 7, 5, 1069, 8125, 21, 108, 8, 6943, 6, 3734, 258, 4, 3611, 28, 3, 791, 606, 1, 1795, 4, 365, 7, 2, 108, 169, 834, 138, 4, 21785, 4, 100, 7, 583, 65, 224, 17, 3, 17045, 258, 1, 3611, 99, 4, 8, 178, 17, 16, 158, 15837, 879, 20, 1795, 3, 40740, 2, 64427, 138, 4, 21785, 32, 110, 751, 1803, 1, 343, 138, 17, 1122, 6, 12369, 132, 31, 153, 128, 46, 138, 11, 44, 204, 4, 500, 1, 3, 7, 5, 1069, 8125, 54, 11, 2727, 1795, 251, 6, 3, 4422, 3611, 230, 1795, 629, 2921, 258, 1, 8, 6943, 7840, 1257, 1795, 791, 1780, 26, 1567, 397, 5, 100, 402, 138, 4, 21785, 17, 32, 3467, 1489, 1, 3611, 6926, 3, 1187, 1, 3, 132, 31, 153, 308, 4, 3, 670, 1, 1578, 1, 1795, 4, 552, 3827, 20, 3, 657, 12, 1377, 2, 1749]",1759.0,24869598,127
Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2014-01-01,"Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed hematologic malignancy in the United States. Although several features can be useful in the diagnosis of CLL, the most important is the immunophenotype.Two staging systems--the Binet system and the Rai classification--are used to assess risk. After diagnosis, the first major therapeutic decision is when to initiate therapy, as a watchful waiting approach is often appropriate for patients with asymptomatic disease. Once a patient has met the criteria for treatment, the choice of therapy is the next major decision. Younger patients (<65 years) often receive more aggressive treatment that typically consists of cytotoxic chemotherapy. There is a great unmet need concerning treatment of older patients with CLL, who often present with more comorbid conditions that can decrease their ability to tolerate particular regimens. The current standard of care for older patients with CLL is rituximab plus chlorambucil. The concept of targeted agents is currently an area of intense interest in CLL. The Brutons tyrosine kinase inhibitor ibrutinib is the targeted agent that is furthest along in clinical development. It is associated with an overall survival rate of 83%. Idelalisib targets the phosphatidyl inositol 3-kinase and is under evaluation in pivotal trials. Targeted agents offer much promise in terms of efficacy, toxicity, and oral availability. They will change the management of patients with CLL.",Journal Article,2211.0,5.0,Chronic lymphocytic CLL is the most frequently diagnosed hematologic malignancy in the United States Although several features can be useful in the diagnosis of CLL the most important is the immunophenotype.Two staging systems -- the Binet system and the Rai classification -- are used to assess risk After diagnosis the first major therapeutic decision is when to initiate therapy as a watchful waiting approach is often appropriate for patients with asymptomatic disease Once a patient has met the criteria for treatment the choice of therapy is the next major decision Younger patients 65 years often receive more aggressive treatment that typically consists of cytotoxic chemotherapy There is a great unmet need concerning treatment of older patients with CLL who often present with more comorbid conditions that can decrease their ability to tolerate particular regimens The current standard of care for older patients with CLL is rituximab plus chlorambucil The concept of targeted agents is currently an area of intense interest in CLL The Bruton s tyrosine kinase inhibitor ibrutinib is the targeted agent that is furthest along in clinical development It is associated with an overall survival rate of 83 Idelalisib targets the phosphatidyl inositol 3-kinase and is under evaluation in pivotal trials Targeted agents offer much promise in terms of efficacy toxicity and oral availability They will change the management of patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 746, 265, 813, 710, 4, 3, 1088, 907, 242, 392, 404, 122, 40, 999, 4, 3, 147, 1, 552, 3, 96, 305, 16, 3, 5496, 100, 632, 1530, 3, 17129, 398, 2, 3, 4121, 947, 32, 95, 6, 423, 43, 50, 147, 3, 157, 458, 189, 948, 16, 198, 6, 4565, 36, 22, 8, 10689, 7598, 353, 16, 629, 870, 9, 7, 5, 2100, 34, 1059, 8, 69, 71, 543, 3, 371, 9, 24, 3, 1866, 1, 36, 16, 3, 1305, 458, 948, 773, 7, 556, 60, 629, 560, 80, 571, 24, 17, 1969, 5132, 1, 759, 56, 125, 16, 8, 2797, 3715, 594, 4243, 24, 1, 434, 7, 5, 552, 54, 629, 364, 5, 80, 3952, 1298, 17, 122, 775, 136, 801, 6, 5010, 1454, 472, 3, 291, 260, 1, 165, 9, 434, 7, 5, 552, 16, 855, 349, 11585, 3, 2545, 1, 238, 183, 16, 694, 35, 965, 1, 3933, 1333, 4, 552, 3, 5796, 695, 564, 216, 230, 1795, 16, 3, 238, 420, 17, 16, 17143, 1510, 4, 38, 193, 192, 16, 41, 5, 35, 63, 25, 116, 1, 852, 7083, 637, 3, 15628, 13816, 27, 216, 2, 16, 669, 451, 4, 3754, 143, 238, 183, 1918, 1802, 1783, 4, 1794, 1, 209, 155, 2, 518, 2550, 491, 303, 707, 3, 284, 1, 7, 5, 552]",1449.0,24870382,154
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-05-28,"Allogeneic hematopoietic cell transplantation (HCT) can cure some chronic lymphocytic leukemia (CLL) subjects. This study compared outcomes of myeloablative (MA) and reduced-intensity conditioning (RIC) transplants from HLA-matched sibling donors (MSD) for CLL. From 1995 to 2007, information regarding 297 CLL subjects was reported to the Center of International Blood and Marrow Transplant Research; of these, 163 underwent MA and 134 underwent RIC MSD HCT. The MA subjects underwent transplantation less often after 2000 and less commonly received antithymocyte globulin (4% versus 13%, P= .004) or prior antibody therapy (14% versus 53%; P < .001). RIC was associated with a greater likelihood of platelet recovery and less grade 2 to 4 acute graft-versus-host disease compared with MA conditioning. One- and 5-year treatment-related mortality (TRM) were 24% (95% confidence intervals [CI], 16% to 33%) versus 37% (95% CI, 30% to 45%; P= .023), and 40% (95% CI, 29% to 51%) versus 54% (95% CI, 46% to 62%; P= .036), respectively, and the relapse/progression rates at 1 and 5years were 21% (95% CI, 14% to 29%) versus 10% (95% CI, 6% to 15%; P=.020), and 35% (95% CI, 26% to 46%) versus 17% (95% CI, 12% to 24%; P= .003), respectively. MA conditioning was associated with better progression-free (PFS) (relative risk, .60; 95% CI, .37 to .97; P= .038) and 3-year survival in transplantations before 2001, but for subsequent years, RIC was associated with better PFS and survival (relative risk, 1.49 [95% CI, .92 to 2.42]; P= .10; and relative risk, 1.86 [95% CI, 1.11 to 3.13]; P=.019). Pretransplantation disease status was the most important predictor of relapse (P= .003) and PFS (P= .0007) for both forms of transplantation conditioning. MA and RIC MSD transplantations are effective for CLL. Future strategies to decrease TRM and reduce relapses are warranted. ",Journal Article,2064.0,11.0,Allogeneic hematopoietic cell transplantation HCT can cure some chronic lymphocytic CLL subjects This study compared outcomes of myeloablative MA and reduced-intensity conditioning RIC transplants from HLA-matched sibling donors MSD for CLL From 1995 to 2007 information regarding 297 CLL subjects was reported to the Center of International Blood and Marrow Transplant Research of these 163 underwent MA and 134 underwent RIC MSD HCT The MA subjects underwent transplantation less often after 2000 and less commonly received antithymocyte globulin 4 versus 13 P .004 or prior antibody therapy 14 versus 53 P .001 RIC was associated with a greater likelihood of platelet recovery and less grade 2 to 4 acute graft-versus-host disease compared with MA conditioning One- and 5-year treatment-related mortality TRM were 24 95 confidence intervals CI 16 to 33 versus 37 95 CI 30 to 45 P .023 and 40 95 CI 29 to 51 versus 54 95 CI 46 to 62 P .036 respectively and the relapse/progression rates at 1 and 5 years were 21 95 CI 14 to 29 versus 10 95 CI 6 to 15 P .020 and 35 95 CI 26 to 46 versus 17 95 CI 12 to 24 P .003 respectively MA conditioning was associated with better progression-free PFS relative risk .60 95 CI .37 to .97 P .038 and 3-year survival in transplantations before 2001 but for subsequent years RIC was associated with better PFS and survival relative risk 1.49 95 CI .92 to 2.42 P .10 and relative risk 1.86 95 CI 1.11 to 3.13 P .019 Pretransplantation disease status was the most important predictor of relapse P .003 and PFS P .0007 for both forms of transplantation conditioning MA and RIC MSD transplantations are effective for CLL Future strategies to decrease TRM and reduce relapses are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 122, 1722, 476, 442, 1193, 552, 976, 26, 45, 72, 123, 1, 3246, 3687, 2, 405, 837, 1933, 3365, 4016, 29, 1160, 655, 3684, 2344, 10751, 9, 552, 29, 2323, 6, 1307, 487, 666, 8526, 552, 976, 10, 210, 6, 3, 574, 1, 944, 315, 2, 581, 941, 389, 1, 46, 5409, 208, 3687, 2, 4842, 208, 3365, 10751, 1085, 3, 3687, 976, 208, 497, 299, 629, 50, 1081, 2, 299, 841, 103, 11016, 7819, 39, 185, 233, 19, 1520, 15, 324, 548, 36, 213, 185, 699, 19, 144, 3365, 10, 41, 5, 8, 378, 1420, 1, 1596, 1602, 2, 299, 88, 18, 6, 39, 286, 1599, 185, 1204, 34, 72, 5, 3687, 1933, 104, 2, 33, 111, 24, 139, 282, 5064, 11, 259, 48, 307, 1582, 58, 245, 6, 466, 185, 567, 48, 58, 201, 6, 512, 19, 4482, 2, 327, 48, 58, 462, 6, 725, 185, 667, 48, 58, 641, 6, 744, 19, 5395, 106, 2, 3, 429, 91, 151, 28, 14, 2, 33, 60, 11, 239, 48, 58, 213, 6, 462, 185, 79, 48, 58, 49, 6, 167, 19, 5743, 2, 465, 48, 58, 432, 6, 641, 185, 269, 48, 58, 133, 6, 259, 19, 1421, 106, 3687, 1933, 10, 41, 5, 380, 91, 115, 300, 580, 43, 335, 48, 58, 567, 6, 1015, 19, 5215, 2, 27, 111, 25, 4, 6779, 348, 1758, 84, 9, 706, 60, 3365, 10, 41, 5, 380, 300, 2, 25, 580, 43, 14, 739, 48, 58, 937, 6, 18, 595, 19, 79, 2, 580, 43, 14, 868, 48, 58, 14, 175, 6, 27, 233, 19, 4049, 9367, 34, 156, 10, 3, 96, 305, 980, 1, 429, 19, 1421, 2, 300, 19, 6626, 9, 110, 2377, 1, 497, 1933, 3687, 2, 3365, 10751, 6779, 32, 323, 9, 552, 508, 422, 6, 775, 5064, 2, 969, 3713, 32, 1197]",1719.0,24880021,544
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.,The New England journal of medicine,N. Engl. J. Med.,2014-05-31,"In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points. At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P=0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group. Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).",Comparative Study,2061.0,835.0,In patients with chronic lymphoid CLL or small lymphocytic SLL a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome We evaluated the efficacy of ibrutinib a covalent inhibitor of Bruton 's tyrosine kinase in patients at risk for a poor outcome In this multicenter open-label phase 3 study we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab The primary end point was the duration of progression-free survival with the duration of overall survival and the overall response rate as secondary end points At a median follow-up of 9.4 months ibrutinib significantly improved progression-free survival the median duration was not reached in the ibrutinib group with a rate of progression-free survival of 88 at 6 months as compared with a median of 8.1 months in the ofatumumab group hazard ratio for progression or death in the ibrutinib group 0.22 P 0.001 Ibrutinib also significantly improved overall survival hazard ratio for death 0.43 P=0.005 At 12 months the overall survival rate was 90 in the ibrutinib group and 81 in the ofatumumab group The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group 42.6 vs. 4.1 P 0.001 An additional 20 of ibrutinib-treated patients had a partial response with lymphocytosis Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues The most frequent nonhematologic adverse events were diarrhea fatigue pyrexia and nausea in the ibrutinib group and fatigue infusion-related reactions and cough in the ofatumumab group Ibrutinib as compared with ofatumumab significantly improved progression-free survival overall survival and response rate among patients with previously treated CLL or SLL Funded by Pharmacyclics and Janssen RESONATE ClinicalTrials.gov number NCT01578707,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 7, 5, 442, 2303, 552, 15, 302, 1193, 5302, 8, 978, 654, 1, 51, 6, 36, 15, 290, 1266, 1171, 32, 41, 5, 8, 334, 228, 21, 194, 3, 209, 1, 1795, 8, 10747, 230, 1, 5796, 292, 564, 216, 4, 7, 28, 43, 9, 8, 334, 228, 4, 26, 1570, 1020, 1756, 124, 27, 45, 21, 1108, 896, 10881, 7, 5, 591, 15, 430, 552, 15, 5302, 6, 560, 391, 1795, 15, 3, 312, 2198, 548, 5732, 3, 86, 396, 741, 10, 3, 654, 1, 91, 115, 25, 5, 3, 654, 1, 63, 25, 2, 3, 63, 51, 116, 22, 568, 396, 862, 28, 8, 52, 166, 126, 1, 83, 39, 53, 1795, 97, 231, 91, 115, 25, 3, 52, 654, 10, 44, 1300, 4, 3, 1795, 87, 5, 8, 116, 1, 91, 115, 25, 1, 889, 28, 49, 53, 22, 72, 5, 8, 52, 1, 66, 14, 53, 4, 3, 5732, 87, 360, 197, 9, 91, 15, 273, 4, 3, 1795, 87, 13, 350, 19, 13, 144, 1795, 120, 97, 231, 63, 25, 360, 197, 9, 273, 13, 601, 19, 13, 1614, 28, 133, 53, 3, 63, 25, 116, 10, 424, 4, 3, 1795, 87, 2, 865, 4, 3, 5732, 87, 3, 63, 51, 116, 10, 97, 142, 4, 3, 1795, 87, 76, 4, 3, 5732, 87, 595, 49, 105, 39, 14, 19, 13, 144, 35, 402, 179, 1, 1795, 73, 7, 42, 8, 450, 51, 5, 8125, 288, 176, 11, 164, 1583, 1, 317, 7, 42, 8, 1170, 7526, 14, 1528, 15, 251, 6, 5006, 4768, 3, 96, 908, 3534, 290, 281, 11, 1172, 613, 8417, 2, 1218, 4, 3, 1795, 87, 2, 613, 904, 139, 2428, 2, 6546, 4, 3, 5732, 87, 1795, 22, 72, 5, 5732, 97, 231, 91, 115, 25, 63, 25, 2, 51, 116, 107, 7, 5, 373, 73, 552, 15, 5302, 3827, 20, 20013, 2, 14643, 32285, 1252, 1239, 207, 32286]",1968.0,24881631,45
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.,Blood,Blood,2014-06-02,"Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. To test this possibility, we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLLs) that underwent whole-exome sequencing (WES). We predicted 22 mutated HLA-binding peptides per leukemia (derived from 16 missense mutations) and experimentally confirmed HLA binding for 55% of such peptides. Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8(+) T-cell responses against predicted or confirmed HLA-binding peptides. Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1, C6ORF89, and FNDC3B presented on tumor cells. Finally, we applied our computational pipeline to WES data (N = 2488 samples) across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors. ",Journal Article,2059.0,174.0,Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers In principle any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells To test this possibility we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles We applied our computational pipeline to 91 chronic lymphocytic leukemias CLLs that underwent whole-exome sequencing WES We predicted 22 mutated HLA-binding peptides per derived from 16 missense mutations and experimentally confirmed HLA binding for 55 of such peptides Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8 T-cell responses against predicted or confirmed HLA-binding peptides Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1 C6ORF89 and FNDC3B presented on tumor cells Finally we applied our computational pipeline to WES data N 2488 samples across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor suggesting that neoantigens are frequent in most tumors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[898, 615, 71, 553, 8, 375, 207, 1, 2664, 2, 3008, 1119, 138, 716, 171, 163, 4, 4968, 500, 336, 2611, 2319, 8, 178, 3097, 1053, 71, 3, 174, 6, 2562, 1185, 2491, 17, 32, 917, 20, 1255, 1160, 1040, 70, 652, 17, 822, 40, 1904, 20, 759, 102, 37, 6, 412, 26, 2526, 21, 3426, 8, 18625, 353, 9, 3, 1590, 2, 929, 1, 225, 6561, 526, 29, 797, 57, 2, 917, 20, 69, 112, 1160, 2558, 21, 1498, 114, 5368, 8471, 6, 970, 442, 1193, 2792, 31974, 17, 208, 902, 2865, 615, 9148, 21, 783, 47883, 1185, 1160, 791, 2491, 379, 526, 29, 48405, 4007, 138, 2, 8593, 557, 1160, 791, 9, 48406, 1, 225, 2491, 100, 552, 7, 17, 513, 319, 337, 734, 366, 1063, 1007, 452, 31, 497, 11, 2909, 9, 968, 102, 31, 253, 480, 783, 15, 557, 1160, 791, 2491, 319, 4813, 759, 102, 31, 253, 11, 530, 480, 2491, 1419, 29, 3008, 30, 138, 4, 64448, 64449, 2, 64450, 917, 23, 30, 37, 1368, 21, 1498, 114, 5368, 8471, 6, 9148, 74, 78, 40749, 347, 716, 233, 338, 12, 630, 2, 661, 23451, 6, 8505, 1, 783, 6561, 379, 797, 30, 802, 17, 6561, 32, 908, 4, 96, 57]",1396.0,24891321,60
Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.,Leukemia & lymphoma,Leuk. Lymphoma,2014-08-04,"Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure. ",Journal Article,1996.0,10.0,Allogeneic stem cell transplant alloSCT can overcome the adverse prognosis of chronic lymphocytic with 17p deletion 17p- CLL However its applicability remains unclear Since 2007 our service has referred patients with 17p- CLL for alloSCT at presentation In this study the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified Of these patients 32 62 did not undergo alloSCT mainly because of treatment- or disease-related complications n 15 The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64 and 25 respectively p 0.001 These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1063, 452, 31, 941, 7253, 122, 1768, 3, 290, 356, 1, 442, 1193, 5, 4135, 1528, 4135, 552, 137, 211, 5412, 469, 1200, 1192, 1307, 114, 3086, 71, 1995, 7, 5, 4135, 552, 9, 7253, 28, 1031, 4, 26, 45, 3, 123, 1, 46, 7, 11, 446, 894, 6, 223, 317, 491, 208, 7253, 2, 5283, 7, 205, 44, 1251, 7253, 1461, 100, 7, 5, 4135, 552, 54, 11, 1995, 6, 3, 941, 3086, 29, 1307, 6, 1120, 11, 108, 1, 46, 7, 531, 744, 205, 44, 1251, 7253, 2615, 408, 1, 24, 15, 34, 139, 521, 78, 167, 3, 18, 111, 539, 2096, 63, 25, 151, 1, 3, 7253, 2, 220, 1988, 271, 11, 660, 2, 243, 106, 19, 13, 144, 46, 272, 309, 17, 369, 7253, 16, 35, 323, 36, 4, 7, 5, 4135, 552, 671, 1988, 521, 68, 6064, 8, 93, 920, 1, 7, 29, 479, 3, 1299]",951.0,24913509,583
Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.,Archives of pathology & laboratory medicine,Arch. Pathol. Lab. Med.,2014-07-01,"The value of assessing CD5 expression in the differential diagnosis of small B-cell neoplasms is well established. Assessment is usually done qualitatively. To assess CD5 expression levels by quantitative flow cytometry immunophenotyping and to determine possible differences among various small B-cell neoplasms. We performed 4-color flow cytometry analysis on specimens of peripheral blood and bone marrow aspirate and quantified CD5 expression in various small B-cell lymphomas and leukemias. We also assessed CD5 levels in peripheral blood samples of healthy blood donors. Cases of chronic lymphocytic leukemia and mantle cell lymphoma had higher levels of CD5 compared with control B cells (P < .001). Cases of marginal zone lymphoma and hairy cell leukemia had CD5 levels similar to control B cells (P = .35 and P = .14, respectively), whereas cases of follicular lymphoma and lymphoplasmacytic lymphoma had significantly lower CD5 levels than control B cells (P < .001 and P = .04, respectively). In B-cell neoplasms, a high level of CD5 expression was correlated with a homogeneous pattern of positive events, whereas lower CD5 levels were correlated with heterogeneous patterns of positive events. Using flow cytometric immunophenotypic analysis to quantify CD5 levels can aid in diagnosis. CD5 expression levels are higher in patients with chronic lymphocytic leukemia and mantle cell lymphoma, and expression is observed in a homogeneous pattern, as compared with other B-cell neoplasms that are either negative for CD5 or express CD5 at lower levels with a heterogeneous pattern. However, there is some overlap in CD5 expression levels between a subset of atypical chronic lymphocytic leukemia and marginal zone lymphoma cases.",Journal Article,2030.0,5.0,The value of assessing CD5 expression in the differential diagnosis of small B-cell neoplasms is well established Assessment is usually done qualitatively To assess CD5 expression levels by quantitative flow cytometry immunophenotyping and to determine possible differences among various small B-cell neoplasms We performed 4-color flow cytometry analysis on specimens of peripheral blood and marrow aspirate and quantified CD5 expression in various small B-cell lymphomas and leukemias We also assessed CD5 levels in peripheral blood samples of healthy blood donors Cases of chronic lymphocytic and mantle cell had higher levels of CD5 compared with control B cells P .001 Cases of marginal zone and hairy cell had CD5 levels similar to control B cells P .35 and P .14 respectively whereas cases of follicular and lymphoplasmacytic had significantly lower CD5 levels than control B cells P .001 and P .04 respectively In B-cell neoplasms a high level of CD5 expression was correlated with a homogeneous pattern of positive events whereas lower CD5 levels were correlated with heterogeneous patterns of positive events Using flow cytometric immunophenotypic analysis to quantify CD5 levels can aid in diagnosis CD5 expression levels are higher in patients with chronic lymphocytic and mantle cell and expression is observed in a homogeneous pattern as compared with other B-cell neoplasms that are either negative for CD5 or express CD5 at lower levels with a heterogeneous pattern However there is some overlap in CD5 expression levels between a subset of atypical chronic lymphocytic and marginal zone cases,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 549, 1, 1977, 6349, 55, 4, 3, 1777, 147, 1, 302, 132, 31, 1179, 16, 149, 635, 455, 16, 2082, 1822, 8040, 6, 423, 6349, 55, 148, 20, 1156, 1412, 1914, 9416, 2, 6, 223, 899, 362, 107, 747, 302, 132, 31, 1179, 21, 173, 39, 6052, 1412, 1914, 65, 23, 623, 1, 672, 315, 2, 581, 8022, 2, 2790, 6349, 55, 4, 747, 302, 132, 31, 1557, 2, 2792, 21, 120, 275, 6349, 148, 4, 672, 315, 347, 1, 1331, 315, 2344, 140, 1, 442, 1193, 2, 2757, 31, 42, 142, 148, 1, 6349, 72, 5, 182, 132, 37, 19, 144, 140, 1, 3450, 3614, 2, 7152, 31, 42, 6349, 148, 288, 6, 182, 132, 37, 19, 465, 2, 19, 213, 106, 547, 140, 1, 1974, 2, 5325, 42, 97, 280, 6349, 148, 76, 182, 132, 37, 19, 144, 2, 19, 755, 106, 4, 132, 31, 1179, 8, 64, 301, 1, 6349, 55, 10, 438, 5, 8, 5642, 1177, 1, 109, 281, 547, 280, 6349, 148, 11, 438, 5, 1564, 764, 1, 109, 281, 75, 1412, 6226, 6599, 65, 6, 3091, 6349, 148, 122, 2427, 4, 147, 6349, 55, 148, 32, 142, 4, 7, 5, 442, 1193, 2, 2757, 31, 2, 55, 16, 164, 4, 8, 5642, 1177, 22, 72, 5, 127, 132, 31, 1179, 17, 32, 361, 199, 9, 6349, 15, 1669, 6349, 28, 280, 148, 5, 8, 1564, 1177, 137, 125, 16, 476, 4526, 4, 6349, 55, 148, 59, 8, 697, 1, 1973, 442, 1193, 2, 3450, 3614, 140]",1609.0,24978916,414
PKC- as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.,Blood,Blood,2014-07-07,"Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C- (PKC-) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in vitro, and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells. Furthermore, AEB071 alters -catenin expression, resulting in decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL. Taken together, our results indicate that targeting PKC- has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor AEB071 as monotherapy in clinical trials of relapsed and refractory CLL patients are warranted.",Journal Article,2024.0,27.0,Targeting B-cell receptor BCR signaling in chronic lymphocytic CLL has been successful with durable remissions observed with several targeted therapeutics Protein kinase C- PKC- is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo We therefore evaluated sotrastaurin AEB071 an orally administered potent PKC inhibitor on CLL cell survival both in vitro and in vivo AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner Additionally AEB071 attenuates BCR-mediated survival pathways inhibits CpG-induced survival and proliferation of CLL cells in vitro and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells Furthermore AEB071 alters -catenin expression resulting in decreased downstream transcriptional genes as c-Myc Cyclin D1 and CD44 Lastly our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL Taken together our results indicate that targeting PKC- has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance Future efforts targeting PKC with the PKC inhibitor AEB071 as monotherapy in clinical trials of relapsed and refractory CLL patients are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[529, 132, 31, 153, 1062, 314, 4, 442, 1193, 552, 71, 85, 1401, 5, 1480, 3166, 164, 5, 392, 238, 1943, 178, 216, 256, 1458, 4644, 1458, 16, 3467, 1489, 1, 1062, 2, 71, 85, 443, 6, 40, 1452, 6, 552, 31, 25, 2, 457, 4, 386, 21, 673, 194, 40004, 19305, 35, 1428, 468, 1157, 4644, 230, 23, 552, 31, 25, 110, 4, 439, 2, 4, 386, 19305, 1949, 1094, 1408, 480, 132, 552, 37, 4, 8, 61, 470, 1708, 1724, 19305, 9100, 1062, 517, 25, 460, 1576, 2075, 277, 25, 2, 457, 1, 552, 37, 4, 439, 2, 1856, 2860, 995, 517, 25, 314, 460, 4, 86, 552, 37, 798, 19305, 6745, 1458, 1778, 55, 1113, 4, 340, 1489, 1431, 214, 22, 256, 1371, 1226, 2146, 2, 3035, 6354, 114, 1676, 4, 386, 94, 1008, 2524, 579, 1571, 1, 19305, 4, 552, 1633, 1162, 114, 99, 1008, 17, 529, 4644, 1458, 71, 3, 174, 6, 6619, 314, 29, 3, 995, 3156, 6, 552, 31, 25, 2, 751, 234, 251, 508, 1413, 529, 4644, 5, 3, 4644, 230, 19305, 22, 1411, 4, 38, 143, 1, 591, 2, 430, 552, 7, 32, 1197]",1304.0,25001469,273
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.,Cancer,Cancer,2014-07-15,"Patients with relapsed chronic lymphocytic leukemia (CLL) often achieve response with chemoimmunotherapy but have short remission durations. Studies have shown that patients with CLL have increased angiogenesis in the microenvironment; levels of proangiogenic growth factors such as VEGF and/or angiopoietin-2 are also elevated. Increased angiogenesis correlates with poor outcome in CLL. Bevacizumab (B) is a humanized monoclonal antibody targeting VEGF-A. In this study, we analyzed whether a combination of bevacizumab with fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy (FCR-B) could improve outcomes in patients with relapsed CLL. Sixty-two patients were enrolled. The median age of the patients was 60 years (range, 31-84 years) and 40% had received >1 prior therapy for CLL. Sixty-one patients were evaluable for toxicity, and 57 were evaluable for response. Six cycles were planned; 36 patients (59%) completed 4-6 cycles of the regimen. The overall response rate was 79%, with 13 (23%) complete remissions (CRs), 8 nodular partial remissions (14%), and 24 partial remissions (43%). The median progression-free survival and overall survival rates were 13.5 and 45 months, respectively. Grade 3 or 4 toxicities included febrile neutropenia (n=40), infections (n=21), thrombocytopenia (n=18) and anemia (n=9). Results with FCR-B were similar to those observed with an historical cohort of relapsed patients treated with FCR.",Journal Article,2016.0,,Patients with relapsed chronic lymphocytic CLL often achieve response with chemoimmunotherapy but have short remission durations Studies have shown that patients with CLL have increased angiogenesis in the microenvironment levels of proangiogenic growth factors such as VEGF and/or angiopoietin-2 are also elevated Increased angiogenesis correlates with poor outcome in CLL Bevacizumab B is a humanized monoclonal antibody targeting VEGF-A In this study we analyzed whether a combination of bevacizumab with fludarabine cyclophosphamide and rituximab chemoimmunotherapy FCR-B could improve outcomes in patients with relapsed CLL Sixty-two patients were enrolled The median age of the patients was 60 years range 31-84 years and 40 had received 1 prior therapy for CLL Sixty-one patients were evaluable for toxicity and 57 were evaluable for response Six cycles were planned 36 patients 59 completed 4-6 cycles of the regimen The overall response rate was 79 with 13 23 complete remissions CRs 8 nodular partial remissions 14 and 24 partial remissions 43 The median progression-free survival and overall survival rates were 13.5 and 45 months respectively Grade 3 or 4 toxicities included febrile neutropenia n 40 infections n 21 thrombocytopenia n 18 and anemia n 9 Results with FCR-B were similar to those observed with an historical cohort of relapsed patients treated with FCR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 591, 442, 1193, 552, 629, 1359, 51, 5, 4438, 84, 47, 978, 734, 4864, 94, 47, 443, 17, 7, 5, 552, 47, 101, 1056, 4, 3, 995, 148, 1, 8571, 129, 130, 225, 22, 618, 2, 15, 7898, 18, 32, 120, 804, 101, 1056, 1871, 5, 334, 228, 4, 552, 599, 132, 16, 8, 3619, 848, 548, 529, 618, 8, 4, 26, 45, 21, 311, 317, 8, 150, 1, 599, 5, 2027, 1112, 2, 855, 4438, 4953, 132, 359, 401, 123, 4, 7, 5, 591, 552, 1746, 100, 7, 11, 346, 3, 52, 89, 1, 3, 7, 10, 335, 60, 184, 456, 874, 60, 2, 327, 42, 103, 14, 324, 36, 9, 552, 1746, 104, 7, 11, 859, 9, 155, 2, 696, 11, 859, 9, 51, 437, 410, 11, 1465, 511, 7, 728, 781, 5915, 49, 410, 1, 3, 477, 3, 63, 51, 116, 10, 842, 5, 233, 382, 236, 3166, 3115, 66, 4481, 450, 3166, 213, 2, 259, 450, 3166, 601, 3, 52, 91, 115, 25, 2, 63, 25, 151, 11, 233, 33, 2, 512, 53, 106, 88, 27, 15, 39, 385, 159, 2498, 778, 78, 327, 1875, 78, 239, 1340, 78, 203, 2, 1545, 78, 83, 99, 5, 4953, 132, 11, 288, 6, 135, 164, 5, 35, 2252, 180, 1, 591, 7, 73, 5, 4953]",1380.0,25043749,260
The B-cell receptor pathway: a critical component of healthy and malignant immune biology.,Seminars in hematology,Semin. Hematol.,2014-05-15,"The pathogenesis and progression of normal B-cell development to malignant transformation of chronic lymphocytic leukemia (CLL) is still poorly understood and has hampered attempts to develop targeted therapeutics for this disease. The dependence of CLL cells on B-cell receptor signaling has fostered a new area of basic and therapeutic research interest. In particular, identification of the dependence of CLL cells on both phosphatidylinositol 3-kinase delta and Bruton's tyrosine kinase signaling for survival and proliferation has come forth through well-performed preclinical studies and subsequent trials demonstrating dramatic efficacy. This review outlines essential components of B-cell receptor signaling and briefly addresses therapeutics that are emerging to target these in patients with CLL and related lymphoid malignancies. ",Journal Article,2077.0,18.0,The pathogenesis and progression of normal B-cell development to malignant transformation of chronic lymphocytic CLL is still poorly understood and has hampered attempts to develop targeted therapeutics for this disease The dependence of CLL cells on B-cell receptor signaling has fostered a new area of basic and therapeutic research interest In particular identification of the dependence of CLL cells on both phosphatidylinositol 3-kinase delta and Bruton 's tyrosine kinase signaling for survival and proliferation has come forth through well-performed preclinical studies and subsequent trials demonstrating dramatic efficacy This review outlines essential components of B-cell receptor signaling and briefly addresses therapeutics that are emerging to target these in patients with CLL and related lymphoid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1384, 2, 91, 1, 295, 132, 31, 193, 6, 393, 1392, 1, 442, 1193, 552, 16, 1234, 1240, 1784, 2, 71, 6786, 4374, 6, 690, 238, 1943, 9, 26, 34, 3, 3721, 1, 552, 37, 23, 132, 31, 153, 314, 71, 18543, 8, 217, 965, 1, 2795, 2, 189, 389, 1333, 4, 1454, 911, 1, 3, 3721, 1, 552, 37, 23, 110, 3415, 27, 216, 4305, 2, 5796, 292, 564, 216, 314, 9, 25, 2, 457, 71, 6235, 13353, 298, 149, 173, 693, 94, 2, 706, 143, 2219, 3079, 209, 26, 206, 6510, 1452, 1628, 1, 132, 31, 153, 314, 2, 6277, 5437, 1943, 17, 32, 1478, 6, 283, 46, 4, 7, 5, 552, 2, 139, 2303, 441]",825.0,25048784,108
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-09-01,"Chemoimmunotherapy has been the standard of care for chronic lymphocytic leukemia (CLL). However, the introduction of B-cell receptor (BCR) kinase inhibitors such as ibrutinib has the potential to eliminate the role of chemotherapy in the treatment of CLL. How to best incorporate old and new therapies for CLL in this landscape is increasingly complex. This article reviews current data available to clinicians and integrates these data to provide a strategy that can be used to approach the treatment of CLL in the era of BCR signaling inhibitors. Current strategies separate patients based on age or functional status as well as genetics [presence or absence of del(17)(p13.1)]. In the era of targeted therapy, this will likely continue based on current available data. Phase III studies support chemoimmunotherapy as the initial standard therapy for patients without del(17)(p13.1). Choice of chemotherapy (fludarabine plus cyclophosphamide, bendamustine, or chlorambucil) and anti-CD20 antibody (rituximab, ofatumumab, or obinutuzumab) varies based on regimen and patient status. For patients with del(17)(p13.1), no standard initial therapy exists, although several options supported by phase II clinical trials (methylprednisolone plus alemtuzumab or ibrutinib) seem better than chemoimmunotherapy. Treatment of relapsed CLL seems to be best supported by ibrutinib-based therapy. Completion of trials with ibrutinib and other new agents in the near future will offer opportunity for chemotherapy-free treatment across all groups of CLL. Therapy for CLL has evolved significantly over the past decade with introduction of targeted therapy for CLL. This has the potential to completely transform how CLL is treated in the future.",Journal Article,1968.0,79.0,Chemoimmunotherapy has been the standard of care for chronic lymphocytic CLL However the introduction of B-cell receptor BCR kinase inhibitors such as ibrutinib has the potential to eliminate the role of chemotherapy in the treatment of CLL How to best incorporate old and new therapies for CLL in this landscape is increasingly complex This article reviews current data available to clinicians and integrates these data to provide a strategy that can be used to approach the treatment of CLL in the era of BCR signaling inhibitors Current strategies separate patients based on age or functional status as well as genetics presence or absence of del 17 p13.1 In the era of targeted therapy this will likely continue based on current available data Phase III studies support chemoimmunotherapy as the initial standard therapy for patients without del 17 p13.1 Choice of chemotherapy fludarabine plus cyclophosphamide bendamustine or chlorambucil and anti-CD20 antibody rituximab ofatumumab or obinutuzumab varies based on regimen and patient status For patients with del 17 p13.1 no standard initial therapy exists although several options supported by phase II clinical trials methylprednisolone plus alemtuzumab or ibrutinib seem better than chemoimmunotherapy Treatment of relapsed CLL seems to be best supported by ibrutinib-based therapy Completion of trials with ibrutinib and other new agents in the near future will offer opportunity for chemotherapy-free treatment across all groups of CLL Therapy for CLL has evolved significantly over the past decade with introduction of targeted therapy for CLL This has the potential to completely transform how CLL is treated in the future,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4438, 71, 85, 3, 260, 1, 165, 9, 442, 1193, 552, 137, 3, 2456, 1, 132, 31, 153, 1062, 216, 222, 225, 22, 1795, 71, 3, 174, 6, 4964, 3, 200, 1, 56, 4, 3, 24, 1, 552, 832, 6, 824, 3360, 1095, 2, 217, 235, 9, 552, 4, 26, 2801, 16, 1635, 840, 26, 946, 2004, 291, 74, 390, 6, 1490, 2, 9735, 46, 74, 6, 377, 8, 692, 17, 122, 40, 95, 6, 353, 3, 24, 1, 552, 4, 3, 1713, 1, 1062, 314, 222, 291, 422, 2282, 7, 90, 23, 89, 15, 583, 156, 22, 149, 22, 2894, 463, 15, 1127, 1, 3084, 269, 7914, 14, 4, 3, 1713, 1, 238, 36, 26, 303, 322, 1906, 90, 23, 291, 390, 74, 124, 316, 94, 538, 4438, 22, 3, 388, 260, 36, 9, 7, 187, 3084, 269, 7914, 14, 1866, 1, 56, 2027, 349, 1112, 4809, 15, 11585, 2, 312, 2198, 548, 855, 5732, 15, 10380, 4037, 90, 23, 477, 2, 69, 156, 9, 7, 5, 3084, 269, 7914, 14, 77, 260, 388, 36, 2481, 242, 392, 838, 2708, 20, 124, 215, 38, 143, 10787, 349, 3579, 15, 1795, 3233, 380, 76, 4438, 24, 1, 591, 552, 2744, 6, 40, 824, 2708, 20, 1795, 90, 36, 1438, 1, 143, 5, 1795, 2, 127, 217, 183, 4, 3, 1829, 508, 303, 1918, 2666, 9, 56, 115, 24, 716, 62, 271, 1, 552, 36, 9, 552, 71, 3937, 97, 252, 3, 1219, 2025, 5, 2456, 1, 238, 36, 9, 552, 26, 71, 3, 174, 6, 2500, 7136, 832, 552, 16, 73, 4, 3, 508]",1686.0,25049322,88
"MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.",Cancer,Cancer,2014-07-24,"Aberrant expression of the v-myc avian myelocytomatosis viral oncogene homolog (MYC) proto-oncogene has known transformative potential in healthy human cells. Chromosomal MYC rearrangements and consequent MYC overexpression is the defining lesion in Burkitt lymphoma (BL), conferring a highly proliferative state. However, abnormalities of MYC are increasingly appreciated in non-BL histologies, including diffuse large B-cell lymphoma (DLBCL) and B-cell lymphomas intermediate between BL and DLBCL, with a particularly aggressive clinical phenotype. Although there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms. Notably, a distinct pattern of gene expression profiling has been noted when MYC is overexpressed in BL compared with other lymphomas, supporting the notion that, although MYC promotes target gene transcription, the target genes vary by disease subtype. The frequency of MYC activity depends on the method of detection and ranges from 5% to 10% using fluorescence in situ hybridization but up to 30% of DLBCL using immunohistochemistry. Standard therapies developed for DLBCL are less effective when the disease is driven by MYC, leading to lower response rates and response durations. An important clinical challenge is to pre-emptively identify MYC-associated lymphomas and to subsequently develop trials specifically for this group of patients. However, the design of such studies is complicated by variable definitions of MYC-associated lymphoid malignancies and the lack of effective therapies to date. The objective if the current review was to evaluate the implications of MYC aberrancy with respect to the B-cell lymphoma double-hit and triple-hit phenotypes and to consider the available data for clinical and practical management.",Journal Article,2007.0,71.0,Aberrant expression of the v-myc avian myelocytomatosis viral oncogene homolog MYC proto-oncogene has known transformative potential in healthy human cells Chromosomal MYC rearrangements and consequent MYC overexpression is the defining lesion in BL conferring a highly proliferative state However abnormalities of MYC are increasingly appreciated in non-BL histologies including diffuse large B-cell DLBCL and B-cell lymphomas intermediate between BL and DLBCL with a particularly aggressive clinical phenotype Although there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 BCL2 or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell DHL or triple-hit if all 3 abnormalities are observed with a particularly poor prognosis and no established treatment paradigms Notably a distinct pattern of gene expression profiling has been noted when MYC is overexpressed in BL compared with other lymphomas supporting the notion that although MYC promotes target gene transcription the target genes vary by disease subtype The frequency of MYC activity depends on the method of detection and ranges from 5 to 10 using fluorescence in situ hybridization but up to 30 of DLBCL using immunohistochemistry Standard therapies developed for DLBCL are less effective when the disease is driven by MYC leading to lower response rates and response durations An important clinical challenge is to pre-emptively identify MYC-associated lymphomas and to subsequently develop trials specifically for this group of patients However the design of such studies is complicated by variable definitions of MYC-associated lymphoid malignancies and the lack of effective therapies to date The objective if the current review was to evaluate the implications of MYC aberrancy with respect to the B-cell double-hit and triple-hit phenotypes and to consider the available data for clinical and practical management,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1898, 55, 1, 3, 603, 1371, 16811, 29107, 1667, 1836, 3412, 1371, 4976, 1836, 71, 440, 16947, 174, 4, 1331, 171, 37, 1860, 1371, 2072, 2, 8436, 1371, 851, 16, 3, 2847, 1180, 4, 6331, 7209, 8, 561, 2441, 1309, 137, 1171, 1, 1371, 32, 1635, 7292, 4, 220, 6331, 3489, 141, 1388, 375, 132, 31, 1446, 2, 132, 31, 1557, 919, 59, 6331, 2, 1446, 5, 8, 823, 571, 38, 1005, 242, 125, 32, 4274, 74, 666, 177, 1268, 1, 1355, 1371, 25193, 4, 46, 220, 27385, 3, 1269, 2291, 1, 1371, 2072, 2, 361, 3, 4176, 145, 132, 31, 442, 1193, 2647, 4763, 18, 3214, 15, 3, 1431, 7434, 8148, 1940, 6, 35, 2983, 4183, 1627, 6519, 132, 31, 7384, 15, 1500, 6519, 492, 62, 27, 1171, 32, 164, 5, 8, 823, 334, 356, 2, 77, 635, 24, 4887, 2552, 8, 834, 1177, 1, 145, 55, 1080, 71, 85, 1051, 198, 1371, 16, 1711, 4, 6331, 72, 5, 127, 1557, 1912, 3, 6691, 17, 242, 1371, 2148, 283, 145, 866, 3, 283, 214, 2825, 20, 34, 875, 3, 675, 1, 1371, 128, 3828, 23, 3, 596, 1, 638, 2, 5632, 29, 33, 6, 79, 75, 1591, 4, 957, 1554, 84, 126, 6, 201, 1, 1446, 75, 888, 260, 235, 276, 9, 1446, 32, 299, 323, 198, 3, 34, 16, 1621, 20, 1371, 1049, 6, 280, 51, 151, 2, 51, 4864, 35, 305, 38, 1745, 16, 6, 671, 40704, 255, 1371, 41, 1557, 2, 6, 1611, 690, 143, 1225, 9, 26, 87, 1, 7, 137, 3, 771, 1, 225, 94, 16, 4286, 20, 1347, 3833, 1, 1371, 41, 2303, 441, 2, 3, 926, 1, 323, 235, 6, 1244, 3, 461, 492, 3, 291, 206, 10, 6, 376, 3, 1268, 1, 1371, 25193, 5, 2184, 6, 3, 132, 31, 1627, 6519, 2, 1500, 6519, 2618, 2, 6, 2419, 3, 390, 74, 9, 38, 2, 3320, 284]",2077.0,25060588,17
"A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.",Leukemia research,Leuk. Res.,2014-05-29,"Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5mg followed by 5.0mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD. ","Clinical Trial, Phase I",2063.0,12.0,Adequate dosing of lenalidomide in Chronic Lymphocytic CLL remains unclear This study determined maximum tolerated dose MTD in relapsed CLL patients Cohort A and patients achieving a partial response PR or better to recent therapy Cohort B Thirty-seven patients were enrolled MTD was 2.5mg followed by 5.0mg continuous In Cohort A tumor flare grade 1-2 occurred in 15 patients 50 and grade 3 in 1 patient 3 Cohort A had 19 of 23 evaluable 83 patients 4 PR 17 and 15 65 stable disease SD Cohort B had 6 of 7 patients 86 with SD Despite overall response rate not being high many patients remained on therapy several months with SD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1658, 1280, 1, 1288, 4, 442, 1193, 552, 469, 1200, 26, 45, 509, 689, 421, 61, 961, 4, 591, 552, 7, 180, 8, 2, 7, 1785, 8, 450, 51, 998, 15, 380, 6, 435, 36, 180, 132, 977, 648, 7, 11, 346, 961, 10, 18, 11356, 370, 20, 33, 48499, 1314, 4, 180, 8, 30, 6915, 88, 14, 18, 489, 4, 167, 7, 212, 2, 88, 27, 4, 14, 69, 27, 180, 8, 42, 326, 1, 382, 859, 852, 7, 39, 998, 269, 2, 167, 556, 585, 34, 1270, 180, 132, 42, 49, 1, 67, 7, 868, 5, 1270, 550, 63, 51, 116, 44, 486, 64, 445, 7, 958, 23, 36, 392, 53, 5, 1270]",628.0,25082342,217
"BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.",Blood,Blood,2014-08-21,"Myelosuppression, graft-versus-host disease (GVHD), and relapse remain major causes of morbidity after stem cell transplantation for relapsed lymphoma. In this phase 1/2 study, we tested the safety and efficacy of escalating doses of bendamustine (70, 90, 110, and 130 mg/m2 per day for 3 days), coupled with our historical fixed doses of fludarabine and rituximab (BFR), as a nonmyeloablative allogeneic conditioning regimen for patients with relapsed lymphoma (n = 41) and chronic lymphocytic leukemia (CLL) (n = 15). Ten patients entered the phase 1 study; none experienced a dose-limiting toxicity. Forty-six additional patients were then treated in the phase 2 study at the maximum dose of 130 mg/m2 per day for 3 days. The proportions of transplants from matched siblings or unrelated donors were 54% and 46%. Remarkably, 55% of patients did not experience severe neutropenia. Forty-nine patients (88%) did not require platelet transfusion. The incidence of acute grade II-IV GVHD was 11%. The 2-year rate of extensive chronic GVHD was 26%. After a median follow-up duration of 26 months (range, 6-50 months), the 2-year overall and progression-free survival rates were 90% and 75%. In conclusion, our new BFR regimen is safe and effective for relapsed CLL and lymphoma patients.","Clinical Trial, Phase I",1979.0,19.0,Myelosuppression graft-versus-host disease GVHD and relapse remain major causes of morbidity after stem cell transplantation for relapsed In this phase 1/2 study we tested the safety and efficacy of escalating doses of bendamustine 70 90 110 and 130 mg/m2 per day for 3 days coupled with our historical fixed doses of fludarabine and rituximab BFR as a nonmyeloablative allogeneic conditioning regimen for patients with relapsed n 41 and chronic lymphocytic CLL n 15 Ten patients entered the phase 1 study none experienced a dose-limiting toxicity Forty-six additional patients were then treated in the phase 2 study at the maximum dose of 130 mg/m2 per day for 3 days The proportions of transplants from matched siblings or unrelated donors were 54 and 46 Remarkably 55 of patients did not experience severe neutropenia Forty-nine patients 88 did not require platelet transfusion The incidence of acute grade II-IV GVHD was 11 The 2-year rate of extensive chronic GVHD was 26 After a median follow-up duration of 26 months range 6-50 months the 2-year overall and progression-free survival rates were 90 and 75 In conclusion our new BFR regimen is safe and effective for relapsed CLL and patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2858, 1599, 185, 1204, 34, 1562, 2, 429, 918, 458, 1626, 1, 787, 50, 452, 31, 497, 9, 591, 4, 26, 124, 14, 18, 45, 21, 650, 3, 367, 2, 209, 1, 2922, 415, 1, 4809, 431, 424, 3129, 2, 3431, 81, 821, 379, 218, 9, 27, 162, 3332, 5, 114, 2252, 1959, 415, 1, 2027, 2, 855, 48536, 22, 8, 6094, 1063, 1933, 477, 9, 7, 5, 591, 78, 605, 2, 442, 1193, 552, 78, 167, 1618, 7, 2836, 3, 124, 14, 45, 1292, 592, 8, 61, 817, 155, 1213, 437, 402, 7, 11, 818, 73, 4, 3, 124, 18, 45, 28, 3, 689, 61, 1, 3431, 81, 821, 379, 218, 9, 27, 162, 3, 4117, 1, 4016, 29, 655, 2758, 15, 2092, 2344, 11, 667, 2, 641, 4856, 614, 1, 7, 205, 44, 730, 905, 778, 1213, 762, 7, 889, 205, 44, 1353, 1596, 2785, 3, 287, 1, 286, 88, 215, 478, 1562, 10, 175, 3, 18, 111, 116, 1, 1344, 442, 1562, 10, 432, 50, 8, 52, 166, 126, 654, 1, 432, 53, 184, 49, 212, 53, 3, 18, 111, 63, 2, 91, 115, 25, 151, 11, 424, 2, 481, 4, 1221, 114, 217, 48536, 477, 16, 1165, 2, 323, 9, 591, 552, 2, 7]",1197.0,25145344,280
"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.",The Lancet. Oncology,Lancet Oncol.,2014-08-20,"Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL. In this single-arm phase 2 study, we enrolled adult patients with high-risk CLL at the MD Anderson Cancer Center (Houston, TX, USA). All enrolled participants had high-risk cytogenetic abnormalities (deletion 17p, TP53 mutation, or deletion 11q) or a short progression-free survival (PFS <36 months) after previous first-line chemoimmunotherapy. Patients with symptomatic disease requiring therapy received 28-day cycles of once-daily ibrutinib 420 mg together with rituximab (375 mg/m(2), intravenously, every week during cycle 1, then once per cycle until cycle 6), followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment. The primary endpoint was progression-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov number NCT01520519, and is no longer accruing patients. Between Feb 28, 2012, and Sept 11, 2012, we enrolled 40 patients with CLL with high-risk disease features, 20 of whom had deletion 17p (del[17p]) or TP53 mutations (16 previously treated, four untreated), 13 had relapsed CLL with deletion 11q (del[11q]), and seven a PFS less than 36 months after first-line chemoimmunotherapy. 18-month PFS in all patients was 780% (95% CI 606-885), whereas in those with a del(17p) or TP53 mutation it was 724% (456-876) Toxicity was mainly mild to moderate in severity (grade 1-2). Diarrhoea occurred in ten (25%) patients (grade 1 in nine patients and grade 2 in one), bleeding events in 14 (33%) patients (eight grade 1 and five grade 2), nausea or vomiting in 15 patients (38%) (ten grade 1 and five grade 2), and fatigue in seven (18%) patients (four grade 1 and three grade 2). Five patients (13%) had grade 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one mucositis), and no grade 4 or 5 infections occurred. One patient had grade 4 neutropenia. The encouraging safety and activity of ibrutinib and rituximab in this population of patients with high-risk CLL merits further investigation of this combination. Pharmacyclics Inc, Cancer Prevention and Research Institute of Texas, Leukemia and Lymphoma Society, National Cancer Institute, MD Anderson Cancer Center.","Clinical Trial, Phase II",1980.0,248.0,Ibrutinib an orally administered covalent inhibitor of Bruton 's tyrosine kinase BTK is an effective treatment for relapsed chronic lymphocytic leukaemia CLL We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL In this single-arm phase 2 study we enrolled adult patients with high-risk CLL at the MD Anderson Cancer Center Houston TX USA All enrolled participants had high-risk cytogenetic abnormalities deletion 17p TP53 mutation or deletion 11q or a short progression-free survival PFS 36 months after previous first-line chemoimmunotherapy Patients with symptomatic disease requiring therapy received 28-day cycles of once-daily ibrutinib 420 mg together with rituximab 375 mg/m 2 intravenously every week during cycle 1 then once per cycle until cycle 6 followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment The primary endpoint was progression-free survival in the intention-to-treat population This study is registered with ClinicalTrials.gov number NCT01520519 and is no longer accruing patients Between Feb 28 2012 and Sept 11 2012 we enrolled 40 patients with CLL with high-risk disease features 20 of whom had deletion 17p del 17p or TP53 mutations 16 previously treated four untreated 13 had relapsed CLL with deletion 11q del 11q and seven a PFS less than 36 months after first-line chemoimmunotherapy 18-month PFS in all patients was 780 95 CI 606-885 whereas in those with a del 17p or TP53 mutation it was 724 456-876 Toxicity was mainly mild to moderate in severity grade 1-2 Diarrhoea occurred in ten 25 patients grade 1 in nine patients and grade 2 in one bleeding events in 14 33 patients eight grade 1 and five grade 2 nausea or vomiting in 15 patients 38 ten grade 1 and five grade 2 and fatigue in seven 18 patients four grade 1 and three grade 2 Five patients 13 had grade 3 infections two infections one upper respiratory tract infection one sepsis and one mucositis and no grade 4 or 5 infections occurred One patient had grade 4 neutropenia The encouraging safety and activity of ibrutinib and rituximab in this population of patients with high-risk CLL merits further investigation of this combination Pharmacyclics Inc Cancer Prevention and Research Institute of Texas and Society National Cancer Institute MD Anderson Cancer Center,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 35, 1428, 468, 10747, 230, 1, 5796, 292, 564, 216, 3611, 16, 35, 323, 24, 9, 591, 442, 1193, 2001, 552, 21, 565, 3, 128, 2, 367, 1, 3, 150, 1, 1795, 5, 3, 848, 548, 855, 4, 7, 5, 64, 43, 552, 4, 26, 226, 475, 124, 18, 45, 21, 346, 780, 7, 5, 64, 43, 552, 28, 3, 2244, 1929, 12, 574, 6212, 6614, 2706, 62, 346, 776, 42, 64, 43, 1266, 1171, 1528, 4135, 1206, 258, 15, 1528, 7203, 15, 8, 978, 91, 115, 25, 300, 511, 53, 50, 698, 157, 328, 4438, 7, 5, 1704, 34, 1888, 36, 103, 339, 218, 410, 1, 1059, 391, 1795, 5401, 81, 1162, 5, 855, 4175, 81, 188, 18, 1672, 454, 647, 190, 417, 14, 818, 1059, 379, 417, 1100, 417, 49, 370, 20, 1314, 391, 226, 420, 1795, 5401, 81, 1100, 34, 91, 15, 1100, 385, 15, 521, 8035, 195, 24, 3, 86, 1138, 10, 91, 115, 25, 4, 3, 3205, 6, 943, 266, 26, 45, 16, 1653, 5, 1252, 1239, 207, 64790, 2, 16, 77, 589, 10900, 7, 59, 10128, 339, 1195, 2, 8708, 175, 1195, 21, 346, 327, 7, 5, 552, 5, 64, 43, 34, 404, 179, 1, 953, 42, 1528, 4135, 3084, 4135, 15, 1206, 138, 245, 373, 73, 294, 1278, 233, 42, 591, 552, 5, 1528, 7203, 3084, 7203, 2, 648, 8, 300, 299, 76, 511, 53, 50, 157, 328, 4438, 203, 811, 300, 4, 62, 7, 10, 64791, 48, 58, 48540, 64792, 547, 4, 135, 5, 8, 3084, 4135, 15, 1206, 258, 192, 10, 47027, 48541, 39843, 155, 10, 2615, 1980, 6, 1163, 4, 1702, 88, 14, 18, 4959, 489, 4, 1618, 243, 7, 88, 14, 4, 762, 7, 2, 88, 18, 4, 104, 2294, 281, 4, 213, 466, 7, 659, 88, 14, 2, 365, 88, 18, 1218, 15, 1966, 4, 167, 7, 519, 1618, 88, 14, 2, 365, 88, 18, 2, 613, 4, 648, 203, 7, 294, 88, 14, 2, 169, 88, 18, 365, 7, 233, 42, 88, 27, 1875, 100, 1875, 104, 1726, 2718, 1696, 930, 104, 4227, 2, 104, 2606, 2, 77, 88, 39, 15, 33, 1875, 489, 104, 69, 42, 88, 39, 778, 3, 2269, 367, 2, 128, 1, 1795, 2, 855, 4, 26, 266, 1, 7, 5, 64, 43, 552, 4986, 195, 940, 1, 26, 150, 20013, 3479, 12, 1070, 2, 389, 1377, 1, 2738, 2, 1174, 657, 12, 1377, 2244, 1929, 12, 574]",2451.0,25150798,328
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-08-25,"T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. We treated 15 patients with advanced B-cell malignancies. Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leukemia. Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single infusion of anti-CD19 CAR T cells. Of 15 patients, eight achieved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two were not evaluable for response. CRs were obtained by four of seven evaluable patients with chemotherapy-refractory DLBCL; three of these four CRs are ongoing, with durations ranging from 9 to 22 months. Acute toxicities including fever, hypotension, delirium, and other neurologic toxicities occurred in some patients after infusion of anti-CD19 CAR T cells; these toxicities resolved within 3 weeks after cell infusion. One patient died suddenly as a result of an unknown cause 16 days after cell infusion. CAR T cells were detected in the blood of patients at peak levels, ranging from nine to 777 CAR-positive T cells/L. This is the first report to our knowledge of successful treatment of DLBCL with anti-CD19 CAR T cells. These results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells. The numerous remissions obtained provide strong support for further development of this approach.",Clinical Trial,1975.0,777.0,T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor CAR We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19 B-cell malignancies We treated 15 patients with advanced B-cell malignancies Nine patients had diffuse large B-cell DLBCL two had indolent lymphomas and four had chronic lymphocytic Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single infusion of anti-CD19 CAR T cells Of 15 patients eight achieved complete remissions CRs four achieved partial remissions one had stable and two were not evaluable for response CRs were obtained by four of seven evaluable patients with chemotherapy-refractory DLBCL three of these four CRs are ongoing with durations ranging from 9 to 22 months Acute toxicities including fever hypotension delirium and other neurologic toxicities occurred in some patients after infusion of anti-CD19 CAR T cells these toxicities resolved within 3 weeks after cell infusion One patient died suddenly as a result of an unknown cause 16 days after cell infusion CAR T cells were detected in the blood of patients at peak levels ranging from nine to 777 CAR-positive T cells/L This is the first report to our knowledge of successful treatment of DLBCL with anti-CD19 CAR T cells These results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells The numerous remissions obtained provide strong support for further development of this approach,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[102, 37, 122, 40, 2301, 1230, 6, 1669, 35, 312, 3158, 2897, 448, 153, 1881, 21, 275, 3, 367, 2, 209, 1, 5776, 1028, 312, 3158, 1881, 102, 37, 6, 7, 5, 131, 3158, 132, 31, 441, 21, 73, 167, 7, 5, 131, 132, 31, 441, 762, 7, 42, 1388, 375, 132, 31, 1446, 100, 42, 2316, 1557, 2, 294, 42, 442, 1193, 7, 103, 8, 1933, 56, 477, 1, 1112, 2, 2027, 370, 20, 8, 226, 904, 1, 312, 3158, 1881, 102, 37, 1, 167, 7, 659, 513, 236, 3166, 3115, 294, 513, 450, 3166, 104, 42, 585, 2, 100, 11, 44, 859, 9, 51, 3115, 11, 683, 20, 294, 1, 648, 859, 7, 5, 56, 430, 1446, 169, 1, 46, 294, 3115, 32, 942, 5, 4864, 2223, 29, 83, 6, 350, 53, 286, 385, 141, 2775, 6577, 3033, 2, 127, 2543, 385, 489, 4, 476, 7, 50, 904, 1, 312, 3158, 1881, 102, 37, 46, 385, 3862, 262, 27, 244, 50, 31, 904, 104, 69, 1016, 30427, 22, 8, 757, 1, 35, 860, 708, 245, 162, 50, 31, 904, 1881, 102, 37, 11, 530, 4, 3, 315, 1, 7, 28, 2944, 148, 2223, 29, 762, 6, 12021, 1881, 109, 102, 37, 5513, 26, 16, 3, 157, 414, 6, 114, 922, 1, 1401, 24, 1, 1446, 5, 312, 3158, 1881, 102, 37, 46, 99, 608, 3, 1437, 2, 1236, 1, 1367, 56, 430, 132, 31, 441, 5, 312, 3158, 1881, 102, 37, 3, 2331, 3166, 683, 377, 1082, 538, 9, 195, 193, 1, 26, 353]",1599.0,25154820,311
"Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.",Journal of the National Cancer Institute. Monographs,J. Natl. Cancer Inst. Monographs,2014-08-01,"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are two subtypes of non-Hodgkin lymphoma. A number of studies have evaluated associations between risk factors and CLL/SLL risk. However, these associations remain inconsistent or lacked confirmation. This may be due, in part, to the inadequate sample size of CLL/SLL cases. We performed a pooled analysis of 2440 CLL/SLL cases and 15186 controls from 13 case-control studies from Europe, North America, and Australia. We evaluated associations of medical history, family history, lifestyle, and occupational risk factors with CLL/SLL risk. Multivariate logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). We confirmed prior inverse associations with any atopic condition and recreational sun exposure. We also confirmed prior elevated associations with usual adult height, hepatitis C virus seropositivity, living or working on a farm, and family history of any hematological malignancy. Novel associations were identified with hairdresser occupation (OR = 1.77, 95% CI = 1.05 to 2.98) and blood transfusion history (OR = 0.79, 95% CI = 0.66 to 0.94). We also found smoking to have modest protective effect (OR = 0.9, 95% CI = 0.81 to 0.99). All exposures showed evidence of independent effects. We have identified or confirmed several independent risk factors for CLL/SLL supporting a role for genetics (through family history), immune function (through allergy and sun), infection (through hepatitis C virus), and height, and other pathways of immune response. Given that CLL/SLL has more than 30 susceptibility loci identified to date, studies evaluating the interaction among genetic and nongenetic factors are warranted.",Journal Article,1999.0,52.0,Chronic lymphocytic CLL and small lymphocytic SLL are two subtypes of A number of studies have evaluated associations between risk factors and CLL/SLL risk However these associations remain inconsistent or lacked confirmation This may be due in part to the inadequate sample size of CLL/SLL cases We performed a pooled analysis of 2440 CLL/SLL cases and 15186 controls from 13 case-control studies from Europe North America and Australia We evaluated associations of medical history family history lifestyle and occupational risk factors with CLL/SLL risk Multivariate logistic regression analyses were used to estimate odds ratios ORs and 95 confidence intervals CIs We confirmed prior inverse associations with any atopic condition and recreational sun exposure We also confirmed prior elevated associations with usual adult height hepatitis C virus seropositivity living or working on a farm and family history of any hematological malignancy Novel associations were identified with hairdresser occupation OR 1.77 95 CI 1.05 to 2.98 and blood transfusion history OR 0.79 95 CI 0.66 to 0.94 We also found smoking to have modest protective effect OR 0.9 95 CI 0.81 to 0.99 All exposures showed evidence of independent effects We have identified or confirmed several independent risk factors for CLL/SLL supporting a role for genetics through family history immune function through allergy and sun infection through hepatitis C virus and height and other pathways of immune response Given that CLL/SLL has more than 30 susceptibility loci identified to date studies evaluating the interaction among genetic and nongenetic factors are warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 302, 1193, 5302, 32, 100, 814, 1, 8, 207, 1, 94, 47, 194, 685, 59, 43, 130, 2, 552, 5302, 43, 137, 46, 685, 918, 4923, 15, 5005, 3551, 26, 68, 40, 520, 4, 760, 6, 3, 3358, 1000, 444, 1, 552, 5302, 140, 21, 173, 8, 1830, 65, 1, 40814, 552, 5302, 140, 2, 64847, 535, 29, 233, 473, 182, 94, 29, 3934, 2669, 4010, 2, 6978, 21, 194, 685, 1, 484, 532, 607, 532, 3487, 2, 10318, 43, 130, 5, 552, 5302, 43, 331, 812, 320, 318, 11, 95, 6, 1191, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 21, 557, 324, 2931, 685, 5, 500, 30429, 2850, 2, 13640, 5479, 645, 21, 120, 557, 324, 804, 685, 5, 3521, 780, 4594, 3002, 256, 1450, 9525, 2798, 15, 2644, 23, 8, 40813, 2, 607, 532, 1, 500, 2890, 710, 229, 685, 11, 108, 5, 48557, 16701, 15, 14, 849, 48, 58, 14, 474, 6, 18, 1096, 2, 315, 2785, 532, 15, 13, 842, 48, 58, 13, 700, 6, 13, 960, 21, 120, 204, 979, 6, 47, 1721, 2864, 254, 15, 13, 83, 48, 58, 13, 865, 6, 13, 1058, 62, 3401, 224, 241, 1, 306, 176, 21, 47, 108, 15, 557, 392, 306, 43, 130, 9, 552, 5302, 1912, 8, 200, 9, 2894, 298, 607, 532, 250, 343, 298, 9842, 2, 5479, 930, 298, 3002, 256, 1450, 2, 4594, 2, 127, 460, 1, 250, 51, 447, 17, 552, 5302, 71, 80, 76, 201, 1432, 2012, 108, 6, 1244, 94, 1435, 3, 915, 107, 336, 2, 25199, 130, 32, 1197]",1643.0,25174025,498
Risk factors for Richter syndrome in chronic lymphocytic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2014-09-01,"Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) to a more aggressive B-cell lymphoma, most commonly diffuse large B-cell lymphoma. Approximately 5-10% of CLL patients develop this complication during long-term follow-up. Traditional risk factors for future RS include clinical (advanced Rai stage), biological (ZAP-70, CD38, CD49d) and genetic (del17p, del11q) characteristics at the time of CLL diagnosis. The impact of CLL therapy (purine-nucleoside analogue and/or alkylator-based chemoimmunotherapy and kinase inhibitor therapy) on the risk of RS remains controversial. Both heritable (germline) and acquired (somatic) genetic mutations contribute to risk of RS. Germline polymorphisms in genes related to CD38, LRF4, and BCL-2 have been implicated in the development of RS. Somatic mutations contributing to the development of RS include TP53 disruption, c-myc activation, CDKN2A loss and NOTCH1 mutations. This review summarizes recent advances in our understanding of the biological and genetic factors contributing to RS in CLL patients.",Journal Article,1968.0,19.0,Richter syndrome RS is defined as the transformation of chronic lymphocytic CLL to a more aggressive B-cell most commonly diffuse large B-cell Approximately 5-10 of CLL patients develop this complication during long-term follow-up Traditional risk factors for future RS include clinical advanced Rai stage biological ZAP-70 CD38 CD49d and genetic del17p del11q characteristics at the time of CLL diagnosis The impact of CLL therapy purine-nucleoside analogue and/or alkylator-based chemoimmunotherapy and kinase inhibitor therapy on the risk of RS remains controversial Both heritable germline and acquired somatic genetic mutations contribute to risk of RS Germline polymorphisms in genes related to CD38 LRF4 and BCL-2 have been implicated in the development of RS Somatic mutations contributing to the development of RS include TP53 disruption c-myc activation CDKN2A loss and NOTCH1 mutations This review summarizes recent advances in our understanding of the biological and genetic factors contributing to RS in CLL patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 681, 2250, 16, 395, 22, 3, 1392, 1, 442, 1193, 552, 6, 8, 80, 571, 132, 31, 96, 841, 1388, 375, 132, 31, 705, 33, 79, 1, 552, 7, 690, 26, 1447, 190, 319, 337, 166, 126, 1847, 43, 130, 9, 508, 2250, 643, 38, 131, 4121, 82, 1037, 6251, 431, 4469, 10485, 2, 336, 15403, 15402, 374, 28, 3, 98, 1, 552, 147, 3, 345, 1, 552, 36, 5006, 4032, 4696, 2, 15, 9346, 90, 4438, 2, 216, 230, 36, 23, 3, 43, 1, 2250, 469, 2010, 110, 6874, 1009, 2, 1294, 1119, 336, 138, 1248, 6, 43, 1, 2250, 1009, 1203, 4, 214, 139, 6, 4469, 64917, 2, 1044, 18, 47, 85, 1771, 4, 3, 193, 1, 2250, 1119, 138, 3156, 6, 3, 193, 1, 2250, 643, 1206, 3220, 256, 1371, 363, 3175, 407, 2, 4607, 138, 26, 206, 2869, 435, 954, 4, 114, 612, 1, 3, 1037, 2, 336, 130, 3156, 6, 2250, 4, 552, 7]",1029.0,25218362,267
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.,American journal of hematology,Am. J. Hematol.,2014-09-26,"The serum immunoglobulin free light chain (FLC) assay quantitates free kappa () and lambda () light chains. FLC elevations in patients with diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and chronic lymphocytic leukemia (CLL) are associated with an inferior survival. These increases in FLC can be monoclonal (as in myeloma) or polyclonal. The goal was to estimate the frequency of these elevations within distinct types of B-cell and T-cell non-Hodgkin lymphoma (NHL) and whether the FLC measurements are associated with event-free survival (EFS). We studied serum for FLC abnormalities using normal laboratory reference ranges to define an elevated  or  FLC. Elevations were further classified as polyclonal or monoclonal. Four hundred ninety-two patients were studied: 453 B-cell and 34 T-cell NHL patients. Twenty-nine % (142/453) of patients had an elevated FLC of which 10% were monoclonal elevations. Within B-cell NHL, FLC abnormalities were most common in lymphoplasmacytic (79%), mantle cell (68%), and lymphomas of mucosa associated lymphoid tissue (31%); they were least common in follicular (15%). The hazard ratio (HR) for EFS in all patients was 1.41 (95% CI; 1.11-1.81); in all B-cell NHL the HR was 1.44 (95% CI 1.11-1.96); in all T-cell NHL the HR was 1.17 (95% CI 0.55-2.49). FLC abnormalities predicted an inferior OS (HR=2.75, 95% CI: 1.93-3.90, P<0.0001). The serum FLC assay is useful for prognosis in both B-cell and T-cell types of NHL. In B-cell NHL further discrimination between a monoclonal and polyclonal elevation may be helpful and should be analyzed in prospective clinical trials.",Journal Article,1943.0,9.0,The serum immunoglobulin free light chain FLC assay quantitates free kappa  and lambda  light chains FLC elevations in patients with diffuse large B-cell DLBCL HL and chronic lymphocytic CLL are associated with an inferior survival These increases in FLC can be monoclonal as in or polyclonal The goal was to estimate the frequency of these elevations within distinct types of B-cell and T-cell NHL and whether the FLC measurements are associated with event-free survival EFS We studied serum for FLC abnormalities using normal laboratory reference ranges to define an elevated  or  FLC Elevations were further classified as polyclonal or monoclonal Four hundred ninety-two patients were studied 453 B-cell and 34 T-cell NHL patients Twenty-nine 142/453 of patients had an elevated FLC of which 10 were monoclonal elevations Within B-cell NHL FLC abnormalities were most common in lymphoplasmacytic 79 mantle cell 68 and lymphomas of mucosa associated lymphoid tissue 31 they were least common in follicular 15 The hazard ratio HR for EFS in all patients was 1.41 95 CI 1.11-1.81 in all B-cell NHL the HR was 1.44 95 CI 1.11-1.96 in all T-cell NHL the HR was 1.17 95 CI 0.55-2.49 FLC abnormalities predicted an inferior OS HR 2.75 95 CI 1.93-3.90 P 0.0001 The serum FLC assay is useful for prognosis in both B-cell and T-cell types of NHL In B-cell NHL further discrimination between a monoclonal and polyclonal elevation may be helpful and should be analyzed in prospective clinical trials,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 524, 2593, 115, 1691, 1260, 4266, 719, 35074, 115, 3096, 4627, 2, 8561, 12441, 1691, 7802, 4266, 4712, 4, 7, 5, 1388, 375, 132, 31, 1446, 1718, 2, 442, 1193, 552, 32, 41, 5, 35, 1663, 25, 46, 1106, 4, 4266, 122, 40, 848, 22, 4, 15, 6350, 3, 1326, 10, 6, 1191, 3, 675, 1, 46, 4712, 262, 834, 630, 1, 132, 31, 2, 102, 31, 1176, 2, 317, 3, 4266, 1685, 32, 41, 5, 774, 115, 25, 1683, 21, 656, 524, 9, 4266, 1171, 75, 295, 1624, 2482, 5632, 6, 1107, 35, 804, 4627, 15, 12441, 4266, 4712, 11, 195, 1373, 22, 6350, 15, 848, 294, 1128, 2493, 100, 7, 11, 656, 9861, 132, 31, 2, 562, 102, 31, 1176, 7, 737, 762, 4785, 9861, 1, 7, 42, 35, 804, 4266, 1, 92, 79, 11, 848, 4712, 262, 132, 31, 1176, 4266, 1171, 11, 96, 186, 4, 5325, 842, 2757, 31, 806, 2, 1557, 1, 2713, 41, 2303, 246, 456, 491, 11, 506, 186, 4, 1974, 167, 3, 360, 197, 168, 9, 1683, 4, 62, 7, 10, 14, 605, 48, 58, 14, 175, 14, 865, 4, 62, 132, 31, 1176, 3, 168, 10, 14, 584, 48, 58, 14, 175, 14, 921, 4, 62, 102, 31, 1176, 3, 168, 10, 14, 269, 48, 58, 13, 614, 18, 739, 4266, 1171, 783, 35, 1663, 118, 168, 18, 481, 48, 58, 14, 966, 27, 424, 19, 13, 488, 3, 524, 4266, 719, 16, 999, 9, 356, 4, 110, 132, 31, 2, 102, 31, 630, 1, 1176, 4, 132, 31, 1176, 195, 3520, 59, 8, 848, 2, 6350, 3292, 68, 40, 3951, 2, 257, 40, 311, 4, 482, 38, 143]",1494.0,25228125,102
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.,Blood,Blood,2014-09-25,"Chronic lymphocytic leukemia (CLL) displays constitutive phosphatidylinositol 3-kinase (PI3K) activation resulting from aberrant regulation of B-cell receptor (BCR) signaling. Previous studies have shown that an oral PI3K p110 inhibitor idelalisib exhibits promising activity in CLL. Here, we demonstrate that a dual PI3K p110 and p110 inhibitor, IPI-145, antagonizes BCR crosslinking activated prosurvival signals in primary CLL cells. IPI-145 causes direct killing in primary CLL cells in a dose- and time-dependent fashion, but does not generate direct cytotoxicity to normal B cells. However, IPI-145 does reduce the viability of normal T and natural killer cells and decrease activated T-cell production of various inflammatory and antiapoptotic cytokines. Furthermore, IPI-145 overcomes the ibrutinib resistance resulting from treatment-induced BTK C481S mutation. Collectively, these studies provide rationale for ongoing clinical evaluation of IPI-145 as a targeted therapy for CLL and related B-cell lymphoproliferative disorders. ",Clinical Trial,1944.0,59.0,Chronic lymphocytic CLL displays constitutive phosphatidylinositol 3-kinase PI3K activation resulting from aberrant regulation of B-cell receptor BCR signaling Previous studies have shown that an oral PI3K p110 inhibitor idelalisib exhibits promising activity in CLL Here we demonstrate that a dual PI3K p110 and p110 inhibitor IPI-145 antagonizes BCR crosslinking activated prosurvival signals in primary CLL cells IPI-145 causes direct killing in primary CLL cells in a dose- and time-dependent fashion but does not generate direct cytotoxicity to normal B cells However IPI-145 does reduce the viability of normal T and natural killer cells and decrease activated T-cell production of various inflammatory and antiapoptotic cytokines Furthermore IPI-145 overcomes the ibrutinib resistance resulting from treatment-induced BTK C481S mutation Collectively these studies provide rationale for ongoing clinical evaluation of IPI-145 as a targeted therapy for CLL and related B-cell lymphoproliferative disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 7196, 3178, 3415, 27, 216, 974, 363, 1113, 29, 1898, 863, 1, 132, 31, 153, 1062, 314, 698, 94, 47, 443, 17, 35, 518, 974, 15762, 230, 7083, 4273, 721, 128, 4, 552, 467, 21, 608, 17, 8, 1828, 974, 15762, 2, 47941, 230, 3753, 4058, 11574, 1062, 12984, 735, 7331, 2312, 4, 86, 552, 37, 3753, 4058, 1626, 1196, 3003, 4, 86, 552, 37, 4, 8, 61, 2, 98, 470, 3240, 84, 1097, 44, 2562, 1196, 1408, 6, 295, 132, 37, 137, 3753, 4058, 1097, 969, 3, 2120, 1, 295, 102, 2, 1504, 3458, 37, 2, 775, 735, 102, 31, 1529, 1, 747, 1291, 2, 4176, 1886, 798, 3753, 4058, 8510, 3, 1795, 251, 1113, 29, 24, 277, 3611, 17045, 258, 2535, 46, 94, 377, 1728, 9, 942, 38, 451, 1, 3753, 4058, 22, 8, 238, 36, 9, 552, 2, 139, 132, 31, 4192, 1997]",1013.0,25258342,43
"Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).",Blood,Blood,2014-10-03,"Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR, we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR. After a median 142 months of follow-up, 156 patients developed progressive CLL, with a median survival of 51 months after disease progression. The duration of first remission (REM1) was a key determinant of survival after disease progression and first salvage. Patients with a short REM1 (<3 years) had a short survival period, irrespective of salvage therapy received; these patients have high unmet medical needs and are good candidates for investigation of novel therapies. In patients with a long REM1 (3 years), salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, FCR rechallenge represents a reasonable standard of care. ",Journal Article,1936.0,61.0,Although fludarabine cyclophosphamide and rituximab FCR together are established as a standard first-line treatment of younger patients with chronic lymphocytic CLL there is little information to guide the management of patients with CLL refractory to or who have relapsed after receiving frontline FCR treatment To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR After a median 142 months of follow-up 156 patients developed progressive CLL with a median survival of 51 months after disease progression The duration of first remission REM1 was a key determinant of survival after disease progression and first salvage Patients with a short REM1 3 years had a short survival period irrespective of salvage therapy received these patients have high unmet medical needs and are good candidates for investigation of novel therapies In patients with a long REM1 3 years salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years for these patients FCR rechallenge represents a reasonable standard of care,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 2027, 1112, 2, 855, 4953, 1162, 32, 635, 22, 8, 260, 157, 328, 24, 1, 773, 7, 5, 442, 1193, 552, 125, 16, 1215, 487, 6, 1597, 3, 284, 1, 7, 5, 552, 430, 6, 15, 54, 47, 591, 50, 357, 3171, 4953, 24, 6, 1107, 665, 992, 692, 2, 255, 7, 12277, 9, 6291, 5, 4953, 21, 409, 3, 25, 2, 24, 228, 1, 2036, 7, 346, 4, 8, 124, 18, 45, 1, 4953, 50, 8, 52, 4785, 53, 1, 166, 126, 5693, 7, 276, 1014, 552, 5, 8, 52, 25, 1, 725, 53, 50, 34, 91, 3, 654, 1, 157, 734, 40866, 10, 8, 825, 4372, 1, 25, 50, 34, 91, 2, 157, 992, 7, 5, 8, 978, 40866, 27, 60, 42, 8, 978, 25, 727, 3500, 1, 992, 36, 103, 46, 7, 47, 64, 3715, 484, 1891, 2, 32, 1178, 1931, 9, 940, 1, 229, 235, 4, 7, 5, 8, 319, 40866, 2608, 60, 992, 24, 5, 361, 2334, 4953, 15, 1288, 90, 36, 99, 4, 706, 52, 25, 5178, 33, 60, 9, 46, 7, 4953, 9423, 1449, 8, 3203, 260, 1, 165]",1209.0,25281606,733
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.,Blood,Blood,2014-10-07,"Aberrant regulation of endogenous survival pathways plays a major role in progression of chronic lymphocytic leukemia (CLL). Signaling via conjugation of surface receptors within the tumor environmental niche activates survival and proliferation pathways in CLL. Of these, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway appears to be pivotal to support CLL pathogenesis, and pharmacologic inhibitors targeting this axis have shown clinical activity. Here we investigate OSU-T315, a compound that disrupts the PI3K/AKT pathway in a novel manner. Dose-dependent selective cytotoxicity by OSU-T315 is noted in both CLL-derived cell lines and primary CLL cells relative to normal lymphocytes. In contrast to the highly successful Bruton's tyrosine kinase and PI3K inhibitors that inhibit B-cell receptor (BCR) signaling pathway at proximal kinases, OSU-T315 directly abrogates AKT activation by preventing translocation of AKT into lipid rafts without altering the activation of receptor-associated kinases. Through this mechanism, the agent triggers caspase-dependent apoptosis in CLL by suppressing BCR, CD49d, CD40, and Toll-like receptor 9-mediated AKT activation in an integrin-linked kinase-independent manner. In vivo, OSU-T315 attains pharmacologically active drug levels and significantly prolongs survival in the TCL1 mouse model. Together, our findings indicate a novel mechanism of action of OSU-T315 with potential therapeutic application in CLL. ",Journal Article,1932.0,13.0,Aberrant regulation of endogenous survival pathways plays a major role in progression of chronic lymphocytic CLL Signaling via conjugation of surface receptors within the tumor environmental niche activates survival and proliferation pathways in CLL Of these the phosphoinositide 3-kinase PI3K /protein kinase B AKT pathway appears to be pivotal to support CLL pathogenesis and pharmacologic inhibitors targeting this axis have shown clinical activity Here we investigate OSU-T315 a compound that disrupts the PI3K/AKT pathway in a novel manner Dose-dependent selective cytotoxicity by OSU-T315 is noted in both CLL-derived cell lines and primary CLL cells relative to normal lymphocytes In contrast to the highly successful Bruton 's tyrosine kinase and PI3K inhibitors that inhibit B-cell receptor BCR signaling pathway at proximal kinases OSU-T315 directly abrogates AKT activation by preventing translocation of AKT into lipid rafts without altering the activation of receptor-associated kinases Through this mechanism the agent triggers caspase-dependent apoptosis in CLL by suppressing BCR CD49d CD40 and Toll-like receptor 9-mediated AKT activation in an integrin-linked kinase-independent manner In vivo OSU-T315 attains pharmacologically active drug levels and significantly prolongs survival in the TCL1 mouse model Together our findings indicate a novel mechanism of action of OSU-T315 with potential therapeutic application in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1898, 863, 1, 2682, 25, 460, 1698, 8, 458, 200, 4, 91, 1, 442, 1193, 552, 314, 847, 9877, 1, 1255, 1186, 262, 3, 30, 3766, 4385, 3932, 25, 2, 457, 460, 4, 552, 1, 46, 3, 4497, 27, 216, 974, 178, 216, 132, 649, 308, 1233, 6, 40, 3754, 6, 538, 552, 1384, 2, 2788, 222, 529, 26, 2310, 47, 443, 38, 128, 467, 21, 963, 5984, 21359, 8, 2823, 17, 7754, 3, 974, 649, 308, 4, 8, 229, 1708, 61, 470, 1094, 1408, 20, 5984, 21359, 16, 1051, 4, 110, 552, 526, 31, 285, 2, 86, 552, 37, 580, 6, 295, 1594, 4, 748, 6, 3, 561, 1401, 5796, 292, 564, 216, 2, 974, 222, 17, 1433, 132, 31, 153, 1062, 314, 308, 28, 2805, 1549, 5984, 21359, 1606, 8044, 649, 363, 20, 3017, 2006, 1, 649, 237, 3121, 12015, 187, 4831, 3, 363, 1, 153, 41, 1549, 298, 26, 670, 3, 420, 5951, 1469, 470, 351, 4, 552, 20, 4669, 1062, 10485, 5040, 2, 7445, 733, 153, 83, 517, 649, 363, 4, 35, 2876, 1199, 216, 306, 1708, 4, 386, 5984, 21359, 33854, 7854, 544, 234, 148, 2, 97, 5613, 25, 4, 3, 8979, 830, 202, 1162, 114, 272, 1008, 8, 229, 670, 1, 1578, 1, 5984, 21359, 5, 174, 189, 1581, 4, 552]",1442.0,25293770,83
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2014-10-07,"Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the surrounding microenvironment influences leukemia cell survival. The complexity of CLL with respect to different chromosomal aberrations, lack of a common aberrant signaling pathway activation, and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid leukemia. The upcoming therapeutic era we are entering with the B-cell receptor (BCR) tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle. Indeed, for the large majority of patients, it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy. Where other very active targeted agents such as ABT-199, therapeutic antibodies, and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer.",Journal Article,1932.0,35.0,Over the past two decades slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic CLL and how the surrounding microenvironment influences cell survival The complexity of CLL with respect to different chromosomal aberrations lack of a common aberrant signaling pathway activation and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid The upcoming therapeutic era we are entering with the B-cell receptor BCR tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle Indeed for the large majority of patients it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy Where other very active targeted agents such as ABT-199 therapeutic antibodies and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 100, 1968, 3645, 84, 22058, 1466, 71, 85, 1229, 4, 612, 3, 2894, 1, 442, 1193, 552, 2, 832, 3, 2976, 995, 3859, 31, 25, 3, 3082, 1, 552, 5, 2184, 6, 338, 1860, 2152, 926, 1, 8, 186, 1898, 314, 308, 363, 2, 41, 250, 1332, 1, 3, 34, 71, 85, 527, 8, 458, 37449, 2381, 9, 931, 8, 226, 238, 36, 288, 6, 577, 95, 4, 442, 533, 3, 11974, 189, 1713, 21, 32, 7653, 5, 3, 132, 31, 153, 1062, 564, 216, 222, 1795, 2, 7083, 1233, 6, 40, 5344, 26, 7414, 4462, 9, 3, 375, 686, 1, 7, 192, 1233, 17, 1581, 1, 1062, 216, 222, 122, 1617, 1480, 3166, 187, 3, 594, 9, 56, 1257, 127, 923, 544, 238, 183, 225, 22, 3095, 5840, 189, 890, 2, 2897, 448, 153, 1230, 102, 37, 303, 40, 95, 4, 552, 120, 1449, 8, 458, 2840, 17, 508, 38, 143, 303, 6634]",1034.0,25294898,228
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.,Blood,Blood,2014-10-09,"CD19 is ubiquitously expressed on chronic lymphocytic leukemia (CLL) cells and is therefore an attractive candidate for antibody targeting. XmAb5574 (aka MOR00208) is a novel humanized CD19 monoclonal antibody with an engineered Fc region to enhance Fc receptor binding affinity. Here we report results of a first in human phase 1 trial of XmAb5574 in patients with relapsed or refractory CLL. Twenty-seven patients were enrolled to 6 escalating dose levels, with expansion at the highest dose level of 12 mg/kg. Nine doses of XmAb5574 were infused over 8 weeks. No maximal tolerated dose was reached, and the drug was generally well tolerated, with infusion reactions of grades 1 and 2 being the most common toxicities. Grade 3 and 4 toxicities occurred in 5 patients and included neutropenia, thrombocytopenia, increased aspartate aminotransferase, febrile neutropenia, and tumor lysis syndrome. XmAb5574 showed preliminary efficacy, with 18 patients (66.7%) responding by physical examination criteria and laboratory studies, and 8 patients (29.6%) responding by computed tomography criteria. Pharmacokinetics showed a half-life of 14 days with clearance that was not dose-dependent. In conclusion, this phase 1 trial demonstrates safety and preliminary efficacy of a novel Fc-engineered CD19 monoclonal antibody XmAb5574 and justifies movement into the phase 2 setting. This trial was registered at www.clinicaltrials.gov as #NCT01161511. ","Clinical Trial, Phase I",1930.0,30.0,CD19 is ubiquitously expressed on chronic lymphocytic CLL cells and is therefore an attractive candidate for antibody targeting XmAb5574 aka MOR00208 is a novel humanized CD19 monoclonal antibody with an engineered Fc region to enhance Fc receptor binding affinity Here we report results of a first in human phase 1 trial of XmAb5574 in patients with relapsed or refractory CLL Twenty-seven patients were enrolled to 6 escalating dose levels with expansion at the highest dose level of 12 mg/kg Nine doses of XmAb5574 were infused over 8 weeks No maximal tolerated dose was reached and the drug was generally well tolerated with infusion reactions of grades 1 and 2 being the most common toxicities Grade 3 and 4 toxicities occurred in 5 patients and included neutropenia thrombocytopenia increased aspartate aminotransferase febrile neutropenia and tumor lysis syndrome XmAb5574 showed preliminary efficacy with 18 patients 66.7 responding by physical examination criteria and laboratory studies and 8 patients 29.6 responding by computed tomography criteria Pharmacokinetics showed a half-life of 14 days with clearance that was not dose-dependent In conclusion this phase 1 trial demonstrates safety and preliminary efficacy of a novel Fc-engineered CD19 monoclonal antibody XmAb5574 and justifies movement into the phase 2 setting This trial was registered at www.clinicaltrials.gov as NCT01161511,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3158, 16, 11156, 570, 23, 442, 1193, 552, 37, 2, 16, 673, 35, 3059, 1609, 9, 548, 529, 20682, 23834, 65049, 16, 8, 229, 3619, 3158, 848, 548, 5, 35, 2794, 4127, 1053, 6, 1304, 19247, 153, 791, 3601, 467, 21, 414, 99, 1, 8, 157, 4, 171, 124, 14, 160, 1, 20682, 4, 7, 5, 591, 15, 430, 552, 737, 648, 7, 11, 346, 6, 49, 2922, 61, 148, 5, 1422, 28, 3, 1076, 61, 301, 1, 133, 81, 503, 762, 415, 1, 20682, 11, 4524, 252, 66, 244, 77, 2725, 421, 61, 10, 1300, 2, 3, 234, 10, 1228, 149, 421, 5, 904, 2428, 1, 2276, 14, 2, 18, 486, 3, 96, 186, 385, 88, 27, 2, 39, 385, 489, 4, 33, 7, 2, 159, 778, 1340, 101, 6308, 4597, 2498, 778, 2, 30, 4783, 681, 20682, 224, 1676, 209, 5, 203, 7, 700, 67, 3261, 20, 900, 1385, 371, 2, 1624, 94, 2, 66, 7, 462, 49, 3261, 20, 1220, 872, 371, 1159, 224, 8, 1303, 358, 1, 213, 162, 5, 1960, 17, 10, 44, 61, 470, 4, 1221, 26, 124, 14, 160, 1902, 367, 2, 1676, 209, 1, 8, 229, 4127, 2794, 3158, 848, 548, 20682, 2, 13299, 7950, 237, 3, 124, 18, 546, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 65050]",1402.0,25301708,114
"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.",Leukemia & lymphoma,Leuk. Lymphoma,2014-11-19,"Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence of second cancers, but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear. We report on the characteristics, incidence, outcomes and factors associated with second cancers in 234 patients receiving fludarabine, cyclophosphamide and rituximab (FCR) based regimens in the frontline setting. The risk of second cancers was 2.38 times higher than the expected risk in the general population. Ninety-three patients (40%) had other cancers before and 66 patients (28%) after FCR. Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5.1%) and Richter transformation (RT) (9%) were high, while solid tumors were not increased. Overall survival of patients with second cancers after frontline FCR was shorter (median of 4.5 years) compared to patients with and without prior cancers. Second cancer risk after frontline FCR is mainly due to high rates of t-AML/MDS and RT, and as speculated the survival of affected patients is shorter. ",Journal Article,1889.0,60.0,Patients with chronic lymphocytic CLL are known to have an increased incidence of second cancers but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear We report on the characteristics incidence outcomes and factors associated with second cancers in 234 patients receiving fludarabine cyclophosphamide and rituximab FCR based regimens in the frontline setting The risk of second cancers was 2.38 times higher than the expected risk in the general population Ninety-three patients 40 had other cancers before and 66 patients 28 after FCR Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome t-AML/MDS 5.1 and Richter transformation RT 9 were high while solid tumors were not increased Overall survival of patients with second cancers after frontline FCR was shorter median of 4.5 years compared to patients with and without prior cancers Second cancer risk after frontline FCR is mainly due to high rates of t-AML/MDS and RT and as speculated the survival of affected patients is shorter,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 32, 440, 6, 47, 35, 101, 287, 1, 419, 163, 84, 3, 2925, 1, 841, 95, 3171, 235, 6, 3, 287, 1, 419, 163, 16, 1200, 21, 414, 23, 3, 374, 287, 123, 2, 130, 41, 5, 419, 163, 4, 8049, 7, 357, 2027, 1112, 2, 855, 4953, 90, 472, 4, 3, 3171, 546, 3, 43, 1, 419, 163, 10, 18, 519, 1072, 142, 76, 3, 1336, 43, 4, 3, 1083, 266, 2493, 169, 7, 327, 42, 127, 163, 348, 2, 700, 7, 339, 50, 4953, 151, 1, 36, 139, 286, 533, 2647, 10589, 681, 102, 329, 1223, 33, 14, 2, 8452, 1392, 240, 83, 11, 64, 369, 537, 57, 11, 44, 101, 63, 25, 1, 7, 5, 419, 163, 50, 3171, 4953, 10, 985, 52, 1, 39, 33, 60, 72, 6, 7, 5, 2, 187, 324, 163, 419, 12, 43, 50, 3171, 4953, 16, 2615, 520, 6, 64, 151, 1, 102, 329, 1223, 2, 240, 2, 22, 17812, 3, 25, 1, 1424, 7, 16, 985]",1055.0,25308294,119
Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2014-07-01,"Infection is the cause of death in 30% to 50% of patients with chronic lymphocytic leukemia (CLL). A major strategy to decrease infection risk is vaccination. However, vaccine response rates in patients with CLL are typically insufficient. Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, also have an increased risk of infection and thus could benefit from vaccines. However, there are no data on vaccine responses in the MBL population. This article reviews the immunodeficiency of CLL and MBL, discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL, and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection. ",Journal Article,2030.0,,Infection is the cause of death in 30 to 50 of patients with chronic lymphocytic CLL A major strategy to decrease infection risk is vaccination However vaccine response rates in patients with CLL are typically insufficient Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis MBL the precursor to CLL also have an increased risk of infection and thus could benefit from vaccines However there are no data on vaccine responses in the MBL population This article reviews the immunodeficiency of CLL and MBL discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[930, 16, 3, 708, 1, 273, 4, 201, 6, 212, 1, 7, 5, 442, 1193, 552, 8, 458, 692, 6, 775, 930, 43, 16, 1915, 137, 1274, 51, 151, 4, 7, 5, 552, 32, 1969, 3027, 435, 94, 47, 264, 17, 869, 5, 38, 848, 132, 31, 8125, 8992, 3, 2765, 6, 552, 120, 47, 35, 101, 43, 1, 930, 2, 631, 359, 247, 29, 1842, 137, 125, 32, 77, 74, 23, 1274, 253, 4, 3, 8992, 266, 26, 946, 2004, 3, 5323, 1, 552, 2, 8992, 2759, 3, 793, 1842, 2, 74, 23, 1274, 4050, 4, 7, 5, 552, 2, 6510, 3, 594, 6, 690, 80, 323, 1274, 422, 4, 26, 266, 1, 7, 28, 64, 43, 9, 930]",763.0,25322324,777
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.,Blood,Blood,2014-11-06,"Recent high-throughput sequencing and microarray studies have characterized the genetic landscape and clonal complexity of chronic lymphocytic leukemia (CLL). Here, we performed a longitudinal study in a homogeneously treated cohort of 12 patients, with sequential samples obtained at comparable stages of disease. We identified clonal competition between 2 or more genetic subclones in 70% of the patients with relapse, and stable clonal dynamics in the remaining 30%. By deep sequencing, we identified a high reservoir of genetic heterogeneity in the form of several driver genes mutated in small subclones underlying the disease course. Furthermore, in 2 patients, we identified convergent evolution, characterized by the combination of genetic lesions affecting the same genes or copy number abnormality in different subclones. The phenomenon affects multiple CLL putative driver abnormalities, including mutations in NOTCH1, SF3B1, DDX3X, and del(11q23). This is the first report documenting convergent evolution as a recurrent event in the CLL genome. Furthermore, this finding suggests the selective advantage of specific combinations of genetic lesions for CLL pathogenesis in a subset of patients. ",Comparative Study,1902.0,35.0,Recent high-throughput sequencing and microarray studies have characterized the genetic landscape and clonal complexity of chronic lymphocytic CLL Here we performed a longitudinal study in a homogeneously treated cohort of 12 patients with sequential samples obtained at comparable stages of disease We identified clonal competition between 2 or more genetic subclones in 70 of the patients with relapse and stable clonal dynamics in the remaining 30 By deep sequencing we identified a high reservoir of genetic heterogeneity in the form of several driver genes mutated in small subclones underlying the disease course Furthermore in 2 patients we identified convergent evolution characterized by the combination of genetic lesions affecting the same genes or copy number abnormality in different subclones The phenomenon affects multiple CLL putative driver abnormalities including mutations in NOTCH1 SF3B1 DDX3X and del 11q23 This is the first report documenting convergent evolution as a recurrent event in the CLL genome Furthermore this finding suggests the selective advantage of specific combinations of genetic lesions for CLL pathogenesis in a subset of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[435, 64, 3643, 615, 2, 1727, 94, 47, 765, 3, 336, 2801, 2, 1946, 3082, 1, 442, 1193, 552, 467, 21, 173, 8, 2380, 45, 4, 8, 16207, 73, 180, 1, 133, 7, 5, 1787, 347, 683, 28, 1279, 1153, 1, 34, 21, 108, 1946, 12809, 59, 18, 15, 80, 336, 8881, 4, 431, 1, 3, 7, 5, 429, 2, 585, 1946, 5193, 4, 3, 1844, 201, 20, 2369, 615, 21, 108, 8, 64, 10470, 1, 336, 1144, 4, 3, 1297, 1, 392, 2228, 214, 1185, 4, 302, 8881, 1181, 3, 34, 906, 798, 4, 18, 7, 21, 108, 12882, 2554, 765, 20, 3, 150, 1, 336, 406, 2319, 3, 827, 214, 15, 1337, 207, 3698, 4, 338, 8881, 3, 3936, 2561, 232, 552, 2743, 2228, 1171, 141, 138, 4, 4607, 10132, 21696, 2, 3084, 7975, 26, 16, 3, 157, 414, 9255, 12882, 2554, 22, 8, 387, 774, 4, 3, 552, 898, 798, 26, 1567, 844, 3, 1094, 1874, 1, 112, 1247, 1, 336, 406, 9, 552, 1384, 4, 8, 697, 1, 7]",1172.0,25377784,313
"Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.",Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2014-11-08,"Ibrutinib is an oral Bruton's tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients with at least one prior therapy. We developed a population pharmacokinetic (PK) model for ibrutinib in patients. Ibrutinib PK data (3,477 observations/245 patients) were available from the following clinical studies: (1) A phase I dose-escalation study in recurrent B cell malignancies (dose levels of 1.25-12.5 mg/kg/day and fixed dose of 560 mg/day); (2) a phase II study in MCL (fixed dose level of 560 mg/day); (3) a phase Ib/II dose-finding study in CLL (fixed dose levels of 420 and 840 mg/day). Different compartmental PK models were explored using nonlinear mixed effects modeling. A two-compartment PK model with sequential zero-first-order absorption and first-order elimination was able to characterize the PK of ibrutinib. The compound was rapidly absorbed, had a high oral plasma clearance (approximately 1,000 L/h) and a high apparent volume of distribution at steady state (approximately 10,000 L). PK parameters were not dependent on dose, study, or clinical indication. The fasting state was characterized by a 67 % relative bioavailability compared with the meal conditions used in the trials and administration after a high-fat meal. Body weight and coadministration of antacids marginally increased volume of distribution and duration of absorption, respectively. The proposed population PK model was able to describe the plasma concentration-time profiles of ibrutinib across various trials. The linear model indicated that the compound's PK was dose independent and time independent.",Clinical Trial,1900.0,37.0,"Ibrutinib is an oral Bruton 's tyrosine kinase inhibitor recently approved for the treatment of mantle cell MCL and chronic lymphocytic CLL patients with at least one prior therapy We developed a population pharmacokinetic PK model for ibrutinib in patients Ibrutinib PK data 3,477 observations/245 patients were available from the following clinical studies 1 A phase I dose-escalation study in recurrent B cell malignancies dose levels of 1.25-12.5 mg/kg/day and fixed dose of 560 mg/day 2 a phase II study in MCL fixed dose level of 560 mg/day 3 a phase Ib/II dose-finding study in CLL fixed dose levels of 420 and 840 mg/day Different compartmental PK models were explored using nonlinear mixed effects modeling A two-compartment PK model with sequential zero-first-order absorption and first-order elimination was able to characterize the PK of ibrutinib The compound was rapidly absorbed had a high oral plasma clearance approximately 1,000 L/h and a high apparent volume of distribution at steady state approximately 10,000 L PK parameters were not dependent on dose study or clinical indication The fasting state was characterized by a 67 relative bioavailability compared with the meal conditions used in the trials and administration after a high-fat meal Body weight and coadministration of antacids marginally increased volume of distribution and duration of absorption respectively The proposed population PK model was able to describe the plasma concentration-time profiles of ibrutinib across various trials The linear model indicated that the compound 's PK was dose independent and time independent",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 35, 518, 5796, 292, 564, 216, 230, 761, 850, 9, 3, 24, 1, 2757, 31, 1308, 2, 442, 1193, 552, 7, 5, 28, 506, 104, 324, 36, 21, 276, 8, 266, 1456, 2395, 202, 9, 1795, 4, 7, 1795, 2395, 74, 27, 11810, 2172, 7373, 7, 11, 390, 29, 3, 366, 38, 94, 14, 8, 124, 70, 61, 1125, 45, 4, 387, 132, 31, 441, 61, 148, 1, 14, 243, 133, 33, 81, 503, 218, 2, 1959, 61, 1, 7356, 81, 218, 18, 8, 124, 215, 45, 4, 1308, 1959, 61, 301, 1, 7356, 81, 218, 27, 8, 124, 3180, 215, 61, 1567, 45, 4, 552, 1959, 61, 148, 1, 5401, 2, 10752, 81, 218, 338, 13522, 2395, 274, 11, 1443, 75, 7488, 1739, 176, 2057, 8, 100, 3616, 2395, 202, 5, 1787, 5115, 157, 1732, 6125, 2, 157, 1732, 3730, 10, 1665, 6, 1507, 3, 2395, 1, 1795, 3, 2823, 10, 1755, 5249, 42, 8, 64, 518, 554, 1960, 705, 14, 984, 805, 555, 2, 8, 64, 2235, 433, 1, 1395, 28, 4152, 1309, 705, 79, 984, 805, 2395, 1038, 11, 44, 470, 23, 61, 45, 15, 38, 3607, 3, 5706, 1309, 10, 765, 20, 8, 598, 580, 5499, 72, 5, 3, 11497, 1298, 95, 4, 3, 143, 2, 634, 50, 8, 64, 2300, 11497, 642, 924, 2, 5777, 1, 37120, 5007, 101, 433, 1, 1395, 2, 654, 1, 6125, 106, 3, 1587, 266, 2395, 202, 10, 1665, 6, 897, 3, 554, 1227, 98, 1241, 1, 1795, 716, 747, 143, 3, 1646, 202, 1103, 17, 3, 2823, 292, 2395, 10, 61, 306, 2, 98, 306]",1615.0,25381051,213
Chronic lymphocytic leukemia: a clinical review.,JAMA,JAMA,2014-12-01,"The most common leukemia is chronic lymphocytic leukemia (CLL). Every year, there are 15000 new diagnoses and 5000 CLL deaths in the United States. Although therapeutic choices were once limited, treatment of this disease has vastly improved in the last decade. Evidence-based review of the diagnosis, staging, and treatment of CLL. PubMed, Cochrane Library, Scopus, and Google Scholar databases were searched through August 28, 2014. English-language peer-reviewed articles published between 2000-2014 were found using the keywords chronic lymphocytic leukemia, upfront therapy, upfront therapies, upfront therapeutic, upfront therapeutics, upfront treatment, front-line treatment, first-line treatment, front-line treatments, first-line treatments, front-line therapy, front-line therapies, randomized, randomized studies, randomized study, clinical trial, clinical trials, phase 3, and phase 3 clinical trial. Abstracts and presentations at scientific meetings were excluded. A total of 277 articles were retrieved, of which 24 met our predefined selection criteria; treatment recommendations were based on subsequent analysis of these 24 articles. The Rai and Binet systems for staging CLL were established in 1975 and 1977, respectively. However, they do not account for new disease categories such as monoclonal B-cell lymphocytosis (peripheral blood clonal lymphocytosis that does not meet other criteria for CLL). Two subsets of CLL are now recognized based on risk stratification involving molecular and cytogenetic analyses. Outcomes are improved by the addition of immunotherapy to combination chemotherapy for initial treatment in all subsets of treated patients. Overall response rates between 75% and 90% and complete responses between 22% and 45% are expected in the current era, with more than 80% of treated patients alive at 3 years. Overall, 5-year survival has increased to 66% from 60% (P<.001) in the past 10 years. Chemoimmunotherapy is the standard first-line option approach for CLL, the most common leukemia observed in adults. Treatment is initiated when the disease becomes symptomatic, and survival is high following treatment.",Journal Article,1877.0,63.0,The most common is chronic lymphocytic CLL Every year there are 15 000 new diagnoses and 5000 CLL deaths in the United States Although therapeutic choices were once limited treatment of this disease has vastly improved in the last decade Evidence-based review of the diagnosis staging and treatment of CLL PubMed Cochrane Library Scopus and Google Scholar databases were searched through August 28 2014 English-language peer-reviewed articles published between 2000-2014 were found using the keywords chronic lymphocytic upfront therapy upfront therapies upfront therapeutic upfront therapeutics upfront treatment front-line treatment first-line treatment front-line treatments first-line treatments front-line therapy front-line therapies randomized randomized studies randomized study clinical trial clinical trials phase 3 and phase 3 clinical trial Abstracts and presentations at scientific meetings were excluded A total of 277 articles were retrieved of which 24 met our predefined selection criteria treatment recommendations were based on subsequent analysis of these 24 articles The Rai and Binet systems for staging CLL were established in 1975 and 1977 respectively However they do not account for new disease categories such as monoclonal B-cell lymphocytosis peripheral blood clonal lymphocytosis that does not meet other criteria for CLL Two subsets of CLL are now recognized based on risk stratification involving molecular and cytogenetic analyses Outcomes are improved by the addition of immunotherapy to combination chemotherapy for initial treatment in all subsets of treated patients Overall response rates between 75 and 90 and complete responses between 22 and 45 are expected in the current era with more than 80 of treated patients alive at 3 years Overall 5-year survival has increased to 66 from 60 P .001 in the past 10 years Chemoimmunotherapy is the standard first-line option approach for CLL the most common observed in adults Treatment is initiated when the disease becomes symptomatic and survival is high following treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 96, 186, 16, 442, 1193, 552, 454, 111, 125, 32, 167, 984, 217, 2403, 2, 10410, 552, 1043, 4, 3, 1088, 907, 242, 189, 5218, 11, 1059, 383, 24, 1, 26, 34, 71, 16759, 231, 4, 3, 1060, 2025, 241, 90, 206, 1, 3, 147, 632, 2, 24, 1, 552, 3161, 4956, 4157, 11347, 2, 11897, 16945, 2348, 11, 3080, 298, 2480, 339, 1409, 4201, 4794, 5084, 446, 2384, 983, 59, 1081, 1409, 11, 204, 75, 3, 11386, 442, 1193, 2941, 36, 2941, 235, 2941, 189, 2941, 1943, 2941, 24, 3007, 328, 24, 157, 328, 24, 3007, 328, 640, 157, 328, 640, 3007, 328, 36, 3007, 328, 235, 384, 384, 94, 384, 45, 38, 160, 38, 143, 124, 27, 2, 124, 27, 38, 160, 5159, 2, 4261, 28, 3138, 6941, 11, 1800, 8, 181, 1, 7996, 2384, 11, 4539, 1, 92, 259, 543, 114, 5944, 881, 371, 24, 883, 11, 90, 23, 706, 65, 1, 46, 259, 2384, 3, 4121, 2, 17129, 1530, 9, 632, 552, 11, 635, 4, 7585, 2, 11792, 106, 137, 491, 1022, 44, 1967, 9, 217, 34, 1996, 225, 22, 848, 132, 31, 8125, 672, 315, 1946, 8125, 17, 1097, 44, 3362, 127, 371, 9, 552, 100, 1890, 1, 552, 32, 1134, 1904, 90, 23, 43, 1541, 1267, 219, 2, 1266, 318, 123, 32, 231, 20, 3, 352, 1, 726, 6, 150, 56, 9, 388, 24, 4, 62, 1890, 1, 73, 7, 63, 51, 151, 59, 481, 2, 424, 2, 236, 253, 59, 350, 2, 512, 32, 1336, 4, 3, 291, 1713, 5, 80, 76, 493, 1, 73, 7, 1701, 28, 27, 60, 63, 33, 111, 25, 71, 101, 6, 700, 29, 335, 19, 144, 4, 3, 1219, 79, 60, 4438, 16, 3, 260, 157, 328, 1501, 353, 9, 552, 3, 96, 186, 164, 4, 857, 24, 16, 1917, 198, 3, 34, 5366, 1704, 2, 25, 16, 64, 366, 24]",2058.0,25461996,500
Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.,Journal of the American Academy of Dermatology,J. Am. Acad. Dermatol.,2014-12-02,"Cutaneous malignancy is associated with worse outcomes in patients with chronic lymphocytic leukemia (CLL). We sought to identify the incidence and recurrence rate of nonmelanoma skin cancer (NMSC) in patients with non-Hodgkin lymphoma (NHL). NMSC incidence was calculated and Cox proportional hazards models were used to evaluate associations with risk of recurrence for patients with NHL between 1976 and 2005 who were in the Rochester Epidemiology Project research infrastructure. We identified 282 patients with CLL or small lymphocytic lymphoma and 435 with non-CLL NHL. The incidence of basal cell carcinoma and squamous cell carcinoma was 1829.3 (95% confidence interval [CI] 1306.7-2491.1) and 2224.9 (95% CI 1645.9-2941.6), respectively, in patients with CLL. The cumulative recurrence rate at 8 years after treatment with Mohs micrographic surgery was 8.3% (95% CI 0.0%-22.7%) for basal cell carcinoma and 13.4% (95% CI 0.0%-25.5%) for squamous cell carcinoma in patients with CLL. This was a retrospective cohort study. After Mohs micrographic surgery and standard excision of NMSC, patients with NHL had a skin cancer recurrence rate that was higher than expected. Careful treatment and monitoring of patients with NHL and NMSC are warranted.",Journal Article,1876.0,30.0,Cutaneous malignancy is associated with worse outcomes in patients with chronic lymphocytic CLL We sought to identify the incidence and recurrence rate of nonmelanoma cancer NMSC in patients with NHL NMSC incidence was calculated and Cox proportional hazards models were used to evaluate associations with risk of recurrence for patients with NHL between 1976 and 2005 who were in the Rochester Epidemiology Project research infrastructure We identified 282 patients with CLL or small lymphocytic and 435 with non-CLL NHL The incidence of basal cell carcinoma and squamous cell carcinoma was 1829.3 95 confidence interval CI 1306.7-2491.1 and 2224.9 95 CI 1645.9-2941.6 respectively in patients with CLL The cumulative recurrence rate at 8 years after treatment with Mohs micrographic surgery was 8.3 95 CI 0.0 -22.7 for basal cell carcinoma and 13.4 95 CI 0.0 -25.5 for squamous cell carcinoma in patients with CLL This was a retrospective cohort study After Mohs micrographic surgery and standard excision of NMSC patients with NHL had a cancer recurrence rate that was higher than expected Careful treatment and monitoring of patients with NHL and NMSC are warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[1486, 710, 16, 41, 5, 639, 123, 4, 7, 5, 442, 1193, 552, 21, 990, 6, 255, 3, 287, 2, 146, 116, 1, 7814, 12, 7118, 4, 7, 5, 1176, 7118, 287, 10, 981, 2, 418, 831, 1017, 274, 11, 95, 6, 376, 685, 5, 43, 1, 146, 9, 7, 5, 1176, 59, 8586, 2, 1242, 54, 11, 4, 3, 5801, 1284, 3105, 389, 6219, 21, 108, 8219, 7, 5, 552, 15, 302, 1193, 2, 9002, 5, 220, 552, 1176, 3, 287, 1, 2135, 31, 134, 2, 691, 31, 134, 10, 44310, 27, 48, 307, 268, 58, 40923, 67, 47130, 14, 2, 34861, 83, 48, 58, 33843, 83, 65305, 49, 106, 4, 7, 5, 552, 3, 967, 146, 116, 28, 66, 60, 50, 24, 5, 12335, 19876, 152, 10, 66, 27, 48, 58, 13, 13, 350, 67, 9, 2135, 31, 134, 2, 233, 39, 48, 58, 13, 13, 243, 33, 9, 691, 31, 134, 4, 7, 5, 552, 26, 10, 8, 459, 180, 45, 50, 12335, 19876, 152, 2, 260, 1366, 1, 7118, 7, 5, 1176, 42, 8, 12, 146, 116, 17, 10, 142, 76, 1336, 3465, 24, 2, 1315, 1, 7, 5, 1176, 2, 7118, 32, 1197]",1169.0,25479909,29
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2014-09-01,"Over the past several years there has been considerable progress in the number and breadth of therapeutic options for patients with chronic lymphocytic leukemia. In particular, cumulative experience with stem cell transplant and immunotherapy has made these modalities more available to a broader range of patients. Advances in genetic engineering and exvivo expansion techniques have sculpted cellular therapy products to optimize the combination of specificity and toxicity. This brief review discusses recent cutting-edge experience with chimeric antigen receptor Tcells as well as developing cellular therapy products at the authors' institution. ",Journal Article,1968.0,3.0,Over the past several years there has been considerable progress in the number and breadth of therapeutic options for patients with chronic lymphocytic In particular cumulative experience with stem cell transplant and immunotherapy has made these modalities more available to a broader range of patients Advances in genetic engineering and ex vivo expansion techniques have sculpted cellular therapy products to optimize the combination of specificity and toxicity This brief review discusses recent cutting-edge experience with chimeric antigen receptor T cells as well as developing cellular therapy products at the authors institution,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[252, 3, 1219, 392, 60, 125, 71, 85, 2658, 1466, 4, 3, 207, 2, 13945, 1, 189, 838, 9, 7, 5, 442, 1193, 4, 1454, 967, 730, 5, 452, 31, 941, 2, 726, 71, 1229, 46, 1558, 80, 390, 6, 8, 5410, 184, 1, 7, 954, 4, 336, 6717, 2, 2581, 386, 1422, 1092, 47, 65318, 763, 36, 2766, 6, 2465, 3, 150, 1, 1121, 2, 155, 26, 3190, 206, 2759, 435, 13360, 7951, 730, 5, 2897, 448, 153, 102, 37, 22, 149, 22, 931, 763, 36, 2766, 28, 3, 738, 731]",637.0,25486950,33
SnapShot: chronic lymphocytic leukemia.,Cancer cell,Cancer Cell,2014-11-10,"Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in western countries. This SnapShot depicts the origins and evolution of this B cell malignancy, describes prognostic factors and CLL animal models, and illustrates therapies in preclinical and clinical development against CLL. ",Journal Article,1898.0,9.0,Chronic lymphocytic CLL is the most common among adults in western countries This SnapShot depicts the origins and evolution of this B cell malignancy describes prognostic factors and CLL animal models and illustrates therapies in preclinical and clinical development against CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 107, 857, 4, 1521, 2115, 26, 12664, 28206, 3, 8598, 2, 2554, 1, 26, 132, 31, 710, 2677, 177, 130, 2, 552, 2026, 274, 2, 6342, 235, 4, 693, 2, 38, 193, 480, 552]",279.0,25517752,68
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.,Blood,Blood,2014-12-23,"Intrinsic and extrinsic apoptotic pathways converge to activate common downstream executioner caspases (caspase-3, -6, and -7), resulting in cell death. In chronic lymphocytic leukemia (CLL), neoplastic B cells evade apoptosis owing to the overexpression of survival proteins. We hypothesized that direct activation of procaspases could bypass the apoptosis resistance induced by the upstream prosurvival proteins. The procaspase-activating compounds (PAC-1), including B-PAC-1 (L14R8), convert inactive executioner procaspases to their active cleaved forms by chelation of labile zinc ions. Both at transcript and protein levels, primary CLL cells express high levels of latent procaspases (3, -7, and -9). B-PAC-1 treatment induced CLL lymphocyte death which was higher than that in normal peripheral blood mononuclear cells or B cells, and was independent of prognostic markers and microenvironmental factors. Mechanistically, B-PAC-1 treatment activated executioner procaspases and not other Zn-dependent enzymes. Exogenous zinc completely, and pancaspase inhibitors partially, reversed B-PAC-1-induced apoptosis, elucidating the zinc-mediated mechanism of action. The cell demise relied on the presence of caspase-3/7 but not caspase-8 or Bax/Bak proteins. B-PAC-1 in combination with an inhibitor of apoptosis protein antagonist (Smac066) synergistically induced apoptosis in CLL samples. Our investigations demonstrated that direct activation of executioner procaspases via B-PAC-1 treatment bypasses apoptosis resistance and is a novel approach for CLL therapeutics. ",Journal Article,1855.0,17.0,Intrinsic and extrinsic apoptotic pathways converge to activate common downstream executioner caspases caspase-3 -6 and -7 resulting in cell death In chronic lymphocytic CLL neoplastic B cells evade apoptosis owing to the overexpression of survival proteins We hypothesized that direct activation of procaspases could bypass the apoptosis resistance induced by the upstream prosurvival proteins The procaspase-activating compounds PAC-1 including B-PAC-1 L14R8 convert inactive executioner procaspases to their active cleaved forms by chelation of labile zinc ions Both at transcript and protein levels primary CLL cells express high levels of latent procaspases 3 -7 and -9 B-PAC-1 treatment induced CLL lymphocyte death which was higher than that in normal peripheral blood mononuclear cells or B cells and was independent of prognostic markers and microenvironmental factors Mechanistically B-PAC-1 treatment activated executioner procaspases and not other Zn-dependent enzymes Exogenous zinc completely and pancaspase inhibitors partially reversed B-PAC-1-induced apoptosis elucidating the zinc-mediated mechanism of action The cell demise relied on the presence of caspase-3/7 but not caspase-8 or Bax/Bak proteins B-PAC-1 in combination with an inhibitor of apoptosis protein antagonist Smac066 synergistically induced apoptosis in CLL samples Our investigations demonstrated that direct activation of executioner procaspases via B-PAC-1 treatment bypasses apoptosis resistance and is a novel approach for CLL therapeutics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2354, 2, 6539, 1631, 460, 14305, 6, 2977, 186, 1489, 28392, 7629, 1469, 27, 49, 2, 67, 1113, 4, 31, 273, 4, 442, 1193, 552, 2000, 132, 37, 6636, 351, 3421, 6, 3, 851, 1, 25, 652, 21, 1237, 17, 1196, 363, 1, 28034, 359, 5481, 3, 351, 251, 277, 20, 3, 3988, 7331, 652, 3, 10153, 1616, 2411, 6100, 14, 141, 132, 6100, 14, 65388, 10402, 5002, 28392, 28034, 6, 136, 544, 5885, 2377, 20, 19709, 1, 19462, 5988, 15491, 110, 28, 3268, 2, 178, 148, 86, 552, 37, 1669, 64, 148, 1, 6011, 28034, 27, 67, 2, 83, 132, 6100, 14, 24, 277, 552, 1448, 273, 92, 10, 142, 76, 17, 4, 295, 672, 315, 3041, 37, 15, 132, 37, 2, 10, 306, 1, 177, 525, 2, 9300, 130, 4187, 132, 6100, 14, 24, 735, 28392, 28034, 2, 44, 127, 19928, 470, 3039, 4181, 5988, 2500, 2, 44837, 222, 2995, 3682, 132, 6100, 14, 277, 351, 7980, 3, 5988, 517, 670, 1, 1578, 3, 31, 19682, 9896, 23, 3, 463, 1, 1469, 27, 67, 84, 44, 1469, 66, 15, 3119, 5599, 652, 132, 6100, 14, 4, 150, 5, 35, 230, 1, 351, 178, 3137, 32366, 4240, 277, 351, 4, 552, 347, 114, 2492, 264, 17, 1196, 363, 1, 28392, 28034, 847, 132, 6100, 14, 24, 18829, 351, 251, 2, 16, 8, 229, 353, 9, 552, 1943]",1528.0,25538042,0
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.,Blood,Blood,2015-01-08,"Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at our center. Thirty-three (26%) patients have discontinued ibrutinib to date. The majority of those patients had high-risk features: 94% with unmutated immunoglobulin heavy chain variable gene rearrangement, 58% with del(17p) by fluorescence in situ hybridization, and 54% with a complex karyotype. Causes of discontinuation were disease transformation (7), progressive CLL (7), stem cell transplantation (3), adverse events (11), serious adverse events/deaths (3), and miscellaneous reasons (2). Twenty five patients (76%) died after discontinuing ibrutinib; the median overall survival was 3.1 months after discontinuation. Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes. ",Journal Article,1839.0,203.0,Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic RR-CLL We describe the characteristics causes of discontinuation and outcomes in patients who discontinued treatment with ibrutinib One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib with or without rituximab at our center Thirty-three 26 patients have discontinued ibrutinib to date The majority of those patients had high-risk features 94 with unmutated immunoglobulin heavy chain variable gene rearrangement 58 with del 17p by fluorescence in situ hybridization and 54 with a complex karyotype Causes of discontinuation were disease transformation 7 progressive CLL 7 stem cell transplantation 3 adverse events 11 serious adverse events/deaths 3 and miscellaneous reasons 2 Twenty five patients 76 died after discontinuing ibrutinib the median overall survival was 3.1 months after discontinuation Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 8, 5796, 564, 216, 230, 850, 9, 3, 24, 1, 7, 5, 591, 430, 442, 1193, 861, 552, 21, 897, 3, 374, 1626, 1, 2007, 2, 123, 4, 7, 54, 2402, 24, 5, 1795, 104, 1128, 737, 648, 7, 11, 346, 4, 747, 38, 143, 1, 1795, 5, 15, 187, 855, 28, 114, 574, 977, 169, 432, 7, 47, 2402, 1795, 6, 1244, 3, 686, 1, 135, 7, 42, 64, 43, 404, 960, 5, 7216, 2593, 4013, 1260, 1347, 145, 2675, 717, 5, 3084, 4135, 20, 1591, 4, 957, 1554, 2, 667, 5, 8, 840, 3385, 1626, 1, 2007, 11, 34, 1392, 67, 1014, 552, 67, 452, 31, 497, 27, 290, 281, 175, 1762, 290, 281, 1043, 27, 2, 15106, 2325, 18, 737, 365, 7, 846, 1016, 50, 7971, 1795, 3, 52, 63, 25, 10, 27, 14, 53, 50, 2007, 96, 7, 5, 861, 552, 54, 2402, 1795, 191, 11, 1740, 6, 943, 2, 42, 334, 123]",1074.0,25573991,673
"Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.",American journal of hematology,Am. J. Hematol.,2015-01-30,"Although transformation to Hodgkin lymphoma (HL) is a recognized complication in patients with chronic lymphocytic leukemia (CLL), its incidence, clinical characteristics and outcomes are not well defined. We used the Mayo Clinic CLL and Lymphoma Databases to identify CLL patients who developed biopsy-proven HL (CLL/HL) on follow-up, as well as cases of de novo HL (i.e., without prior CLL). Among 3887 CLL patients seen at Mayo Clinic from January 1995 through August 2011, 26 (0.7%) developed HL. In a nested cohort of 2,465 newly diagnosed CLL patients followed prospectively, the incidence of HL was 0.05%/year (10 year risk = 0.5%). The median overall survival (OS) from date of HL diagnosis in patients with CLL/HL was 3.9 years compared to not reached for de novo HL patients (n = 709) seen during the same time interval (P < 0.001). The shorter OS of CLL/HL patients persisted after adjusting for differences in age and Ann Arbor stage of disease. The International Prognostic score (IPS) developed for de novo HL stratified prognosis among CLL/HL patients with median survival of not reached, 6.2, 2.4, and 0.3 years (P = 0.006) for those with IPS scores of 2, 3, 4, and 5, respectively. In summary, approximately 1 of every 200 CLL patients will develop HL within 10 years. Survival after HL diagnosis in patients with CLL is shorter than de novo HL patients. The IPS for de novo HL may be useful for stratifying survival in CLL/HL patients.",Comparative Study,1817.0,29.0,"Although transformation to HL is a recognized complication in patients with chronic lymphocytic CLL its incidence clinical characteristics and outcomes are not well defined We used the Mayo Clinic CLL and Databases to identify CLL patients who developed biopsy-proven HL CLL/HL on follow-up as well as cases of de novo HL i.e. without prior CLL Among 3887 CLL patients seen at Mayo Clinic from January 1995 through August 2011 26 0.7 developed HL In a nested cohort of 2,465 newly diagnosed CLL patients followed prospectively the incidence of HL was 0.05 /year 10 year risk 0.5 The median overall survival OS from date of HL diagnosis in patients with CLL/HL was 3.9 years compared to not reached for de novo HL patients n 709 seen during the same time interval P 0.001 The shorter OS of CLL/HL patients persisted after adjusting for differences in age and Ann Arbor stage of disease The International Prognostic score IPS developed for de novo HL stratified prognosis among CLL/HL patients with median survival of not reached 6.2 2.4 and 0.3 years P 0.006 for those with IPS scores of 2 3 4 and 5 respectively In summary approximately 1 of every 200 CLL patients will develop HL within 10 years Survival after HL diagnosis in patients with CLL is shorter than de novo HL patients The IPS for de novo HL may be useful for stratifying survival in CLL/HL patients",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 1392, 6, 1718, 16, 8, 1904, 1447, 4, 7, 5, 442, 1193, 552, 211, 287, 38, 374, 2, 123, 32, 44, 149, 395, 21, 95, 3, 2486, 1188, 552, 2, 2348, 6, 255, 552, 7, 54, 276, 411, 1930, 1718, 552, 1718, 23, 166, 126, 22, 149, 22, 140, 1, 1566, 2018, 1718, 70, 563, 187, 324, 552, 107, 65467, 552, 7, 527, 28, 2486, 1188, 29, 1024, 2323, 298, 2480, 1132, 432, 13, 67, 276, 1718, 4, 8, 4789, 180, 1, 18, 9940, 732, 265, 552, 7, 370, 1143, 3, 287, 1, 1718, 10, 13, 474, 111, 79, 111, 43, 13, 33, 3, 52, 63, 25, 118, 29, 1244, 1, 1718, 147, 4, 7, 5, 552, 1718, 10, 27, 83, 60, 72, 6, 44, 1300, 9, 1566, 2018, 1718, 7, 78, 14408, 527, 190, 3, 827, 98, 268, 19, 13, 144, 3, 985, 118, 1, 552, 1718, 7, 3760, 50, 1358, 9, 362, 4, 89, 2, 7977, 10799, 82, 1, 34, 3, 944, 177, 368, 13343, 276, 9, 1566, 2018, 1718, 1173, 356, 107, 552, 1718, 7, 5, 52, 25, 1, 44, 1300, 49, 18, 18, 39, 2, 13, 27, 60, 19, 13, 1861, 9, 135, 5, 13343, 703, 1, 6006, 27, 39, 2, 4126, 106, 4, 1962, 705, 14, 1, 454, 1250, 552, 7, 303, 690, 1718, 262, 79, 60, 25, 50, 1718, 147, 4, 7, 5, 552, 16, 985, 76, 1566, 2018, 1718, 7, 3, 13343, 9, 1566, 2018, 1718, 68, 40, 999, 9, 5035, 25, 4, 552, 1718, 7]",1364.0,25581025,756
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2015-01-13,"Adoptive cell therapy with genetically modified T cells expressing a chimeric antigen receptor (CAR) is a promising therapy for patients with B-cell acute lymphoblastic leukemia. However, CAR-modified T cells (CAR T cells) have mostly failed in patients with solid tumors or low-grade B-cell malignancies including chronic lymphocytic leukemia with bulky lymph node involvement. Herein, we enhance the antitumor efficacy of CAR T cells through the constitutive expression of CD40 ligand (CD40L, CD154). T cells genetically modified to constitutively express CD40L (CD40L-modified T cells) demonstrated increased proliferation and secretion of proinflammatory TH1 cytokines. Further, CD40L-modified T cells augmented the immunogenicity of CD40(+) tumor cells by the upregulated surface expression of costimulatory molecules (CD80 and CD86), adhesion molecules (CD54, CD58, and CD70), human leukocyte antigen (HLA) molecules (Class I and HLA-DR), and the Fas-death receptor (CD95). Additionally, CD40L-modified T cells induced maturation and secretion of the proinflammatory cytokine interleukin-12 by monocyte-derived dendritic cells. Finally, tumor-targeted CD19-specific CAR/CD40L T cells exhibited increased cytotoxicity against CD40(+) tumors and extended the survival of tumor-bearing mice in a xenotransplant model of CD19(+) systemic lymphoma. This preclinical data supports the clinical application of CAR T cells additionally modified to constitutively express CD40L with anticipated enhanced antitumor efficacy. ",Journal Article,1834.0,93.0,Adoptive cell therapy with genetically modified T cells expressing a chimeric antigen receptor CAR is a promising therapy for patients with B-cell acute lymphoblastic However CAR-modified T cells CAR T cells have mostly failed in patients with solid tumors or low-grade B-cell malignancies including chronic lymphocytic with bulky lymph node involvement Herein we enhance the antitumor efficacy of CAR T cells through the constitutive expression of CD40 ligand CD40L CD154 T cells genetically modified to constitutively express CD40L CD40L-modified T cells demonstrated increased proliferation and secretion of proinflammatory TH1 cytokines Further CD40L-modified T cells augmented the immunogenicity of CD40 tumor cells by the upregulated surface expression of costimulatory molecules CD80 and CD86 adhesion molecules CD54 CD58 and CD70 human leukocyte antigen HLA molecules Class I and HLA-DR and the Fas-death receptor CD95 Additionally CD40L-modified T cells induced maturation and secretion of the proinflammatory cytokine interleukin-12 by monocyte-derived dendritic cells Finally tumor-targeted CD19-specific CAR/CD40L T cells exhibited increased cytotoxicity against CD40 tumors and extended the survival of tumor-bearing mice in a xenotransplant model of CD19 systemic This preclinical data supports the clinical application of CAR T cells additionally modified to constitutively express CD40L with anticipated enhanced antitumor efficacy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3159, 31, 36, 5, 2301, 1230, 102, 37, 1046, 8, 2897, 448, 153, 1881, 16, 8, 721, 36, 9, 7, 5, 132, 31, 286, 1275, 137, 1881, 1230, 102, 37, 1881, 102, 37, 47, 2754, 1551, 4, 7, 5, 537, 57, 15, 154, 88, 132, 31, 441, 141, 442, 1193, 5, 4112, 263, 289, 799, 1986, 21, 1304, 3, 579, 209, 1, 1881, 102, 37, 298, 3, 3178, 55, 1, 5040, 1232, 8285, 18281, 102, 37, 2301, 1230, 6, 2818, 1669, 8285, 8285, 1230, 102, 37, 264, 101, 457, 2, 2935, 1, 5767, 4714, 1886, 195, 8285, 1230, 102, 37, 4277, 3, 4050, 1, 5040, 30, 37, 20, 3, 2684, 1255, 55, 1, 5555, 1598, 9850, 2, 12514, 2128, 1598, 30653, 23366, 2, 10354, 171, 3627, 448, 1160, 1598, 1040, 70, 2, 1160, 3436, 2, 3, 3625, 273, 153, 6550, 1724, 8285, 1230, 102, 37, 277, 4537, 2, 2935, 1, 3, 5767, 1675, 1603, 133, 20, 5231, 526, 2464, 37, 1368, 30, 238, 3158, 112, 1881, 8285, 102, 37, 1416, 101, 1408, 480, 5040, 57, 2, 1747, 3, 25, 1, 30, 1894, 399, 4, 8, 28800, 202, 1, 3158, 403, 26, 693, 74, 2304, 3, 38, 1581, 1, 1881, 102, 37, 1724, 1230, 6, 2818, 1669, 8285, 5, 4078, 651, 579, 209]",1447.0,25582824,433
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.,Oncotarget,Oncotarget,2015-01-01,"Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. We performed systematic database search and identified highly specific MED12 mutations in CLL patients. To study this further, we collected three independent sample series comprising over 700 CLL samples and screened MED12 exons 1 and 2 by direct sequencing. Mutations were identified at significant frequency in all three series with a combined mutation frequency of 5.2% (37/709). Positive mutation status was found to be associated with unmutated IGHV and ZAP70 expression, which are well-known poor prognosis markers in CLL. Our results recognize CLL as the first extrauterine cancer type where 5'terminus of MED12 is mutated at significant frequency. Functional analyses have shown that these mutations lead to dissociation of Cyclin C-CDK8/19 from the core Mediator and to the loss of Mediator-associated CDK kinase activity. Additional studies on the role of MED12 mutation status as a putative prognostic factor as well as mutations' exact tumorigenic mechanism in CLL are warranted. ",Journal Article,1846.0,30.0,Chronic lymphocytic CLL is the most common in adults We performed systematic database search and identified highly specific MED12 mutations in CLL patients To study this further we collected three independent sample series comprising over 700 CLL samples and screened MED12 exons 1 and 2 by direct sequencing Mutations were identified at significant frequency in all three series with a combined mutation frequency of 5.2 37/709 Positive mutation status was found to be associated with unmutated IGHV and ZAP70 expression which are well-known poor prognosis markers in CLL Our results recognize CLL as the first extrauterine cancer type where 5'terminus of MED12 is mutated at significant frequency Functional analyses have shown that these mutations lead to dissociation of Cyclin C-CDK8/19 from the core Mediator and to the loss of Mediator-associated CDK kinase activity Additional studies on the role of MED12 mutation status as a putative prognostic factor as well as mutations exact tumorigenic mechanism in CLL are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 186, 4, 857, 21, 173, 1556, 609, 1901, 2, 108, 561, 112, 16144, 138, 4, 552, 7, 6, 45, 26, 195, 21, 786, 169, 306, 1000, 988, 3538, 252, 5692, 552, 347, 2, 2261, 16144, 3885, 14, 2, 18, 20, 1196, 615, 138, 11, 108, 28, 93, 675, 4, 62, 169, 988, 5, 8, 397, 258, 675, 1, 33, 18, 567, 14408, 109, 258, 156, 10, 204, 6, 40, 41, 5, 7216, 6220, 2, 12921, 55, 92, 32, 149, 440, 334, 356, 525, 4, 552, 114, 99, 4237, 552, 22, 3, 157, 12115, 12, 267, 1257, 65500, 1, 16144, 16, 1185, 28, 93, 675, 583, 318, 47, 443, 17, 46, 138, 1122, 6, 10443, 1, 1226, 256, 15727, 326, 29, 3, 1793, 3810, 2, 6, 3, 407, 1, 3810, 41, 3954, 216, 128, 402, 94, 23, 3, 200, 1, 16144, 258, 156, 22, 8, 2743, 177, 161, 22, 149, 22, 138, 2472, 3795, 670, 4, 552, 32, 1197]",1031.0,25595892,48
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.,Oncotarget,Oncotarget,2015-02-01,"Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases (CDK) known to impair global transcription via inactivation of positive transcription elongation factor b. It has been demonstrated to have significant activity predominantly in chronic lymphocytic leukemia and acute myeloid leukemia in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies. Although flavopiridol is a potent therapeutic agent against blood diseases, some patients still have primary or acquired resistance throughout their clinical course. Considering the limited knowledge of resistance mechanisms of flavopiridol, we investigated the potential mechanisms of resistance to flavopiridol in a cell line system, which gradually acquired resistance to flavopiridol in vitro, and then confirmed the mechanism in patient samples. Herein, we present that this resistant cell line developed resistance through up-regulation of phosphorylation of RNA polymerase II C-terminal domain, activation of CDK9 kinase activity, and prolonged Mcl-1 stability to counter flavopiridol's drug actions. Further analyses suggest MAPK/ERK activation-mediated Mcl-1 stabilization contributes to the resistance and knockdown of Mcl-1 in part restores sensitivity to flavopiridol-induced cytotoxicity. Altogether, these findings demonstrate that CDK9 is the most relevant target of flavopiridol and provide avenues to improve the therapeutic strategies in blood malignancies. ",Journal Article,1815.0,21.0,Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases CDK known to impair global transcription via inactivation of positive transcription elongation factor b It has been demonstrated to have significant activity predominantly in chronic lymphocytic and acute myeloid in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies Although flavopiridol is a potent therapeutic agent against blood diseases some patients still have primary or acquired resistance throughout their clinical course Considering the limited knowledge of resistance mechanisms of flavopiridol we investigated the potential mechanisms of resistance to flavopiridol in a cell line system which gradually acquired resistance to flavopiridol in vitro and then confirmed the mechanism in patient samples Herein we present that this resistant cell line developed resistance through up-regulation of phosphorylation of RNA polymerase II C-terminal domain activation of CDK9 kinase activity and prolonged Mcl-1 stability to counter flavopiridol 's drug actions Further analyses suggest MAPK/ERK activation-mediated Mcl-1 stabilization contributes to the resistance and knockdown of Mcl-1 in part restores sensitivity to flavopiridol-induced cytotoxicity Altogether these findings demonstrate that CDK9 is the most relevant target of flavopiridol and provide avenues to improve the therapeutic strategies in blood malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3030, 16, 8, 302, 1354, 230, 1, 1226, 470, 1549, 3954, 440, 6, 6267, 1648, 866, 847, 2297, 1, 109, 866, 12359, 161, 132, 192, 71, 85, 264, 6, 47, 93, 128, 2117, 4, 442, 1193, 2, 286, 533, 4, 124, 70, 215, 38, 143, 369, 127, 288, 3954, 222, 32, 23573, 486, 5299, 4, 671, 38, 2, 38, 94, 242, 3030, 16, 8, 1157, 189, 420, 480, 315, 1342, 476, 7, 1234, 47, 86, 15, 1294, 251, 2432, 136, 38, 906, 3075, 3, 383, 922, 1, 251, 483, 1, 3030, 21, 565, 3, 174, 483, 1, 251, 6, 3030, 4, 8, 31, 328, 398, 92, 8092, 1294, 251, 6, 3030, 4, 439, 2, 818, 557, 3, 670, 4, 69, 347, 1986, 21, 364, 17, 26, 436, 31, 328, 276, 251, 298, 126, 863, 1, 982, 1, 893, 1451, 215, 256, 2158, 1398, 363, 1, 11333, 216, 128, 2, 1069, 1308, 14, 2769, 6, 10259, 3030, 292, 234, 5592, 195, 318, 309, 1748, 1819, 363, 517, 1308, 14, 3184, 2444, 6, 3, 251, 2, 1563, 1, 1308, 14, 4, 760, 8489, 485, 6, 3030, 277, 1408, 6767, 46, 272, 608, 17, 11333, 16, 3, 96, 867, 283, 1, 3030, 2, 377, 6612, 6, 401, 3, 189, 422, 4, 315, 441]",1478.0,25596730,726
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2015-02-02,"B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia and dysregulation of the T-cell leukemia/lymphoma 1 (TCL1) oncogene is a contributing event in the pathogenesis of the aggressive form of this disease based on transgenic mouse studies. To determine a role of microRNAs on the pathogenesis of the aggressive form of CLL we studied regulation of TCL1 expression in CLL by microRNAs. We identified miR-3676 as a regulator of TCL1 expression. We demonstrated that miR-3676 targets three consecutive 28-bp repeats within 3'UTR of TCL1 and showed that miR-3676 is a powerful inhibitor of TCL1. We further showed that miR-3676 expression is significantly down-regulated in four groups of CLL carrying the 11q deletions, 13q deletions, 17p deletions, or a normal karyotype compared with normal CD19(+) cord blood and peripheral blood B cells. In addition, the sequencing of 539 CLL samples revealed five germ-line mutations in six samples (1%) in miR-3676. Two of these mutations were loss-of-function mutations. Because miR-3676 is located at 17p13, only 500-kb centromeric of tumor protein p53 (Tp53), and is codeleted with Tp53, we propose that loss of miR-3676 causes high levels of TCL1 expression contributing to CLL progression. ",Journal Article,1814.0,28.0,B-cell chronic lymphocytic CLL is the most common human and dysregulation of the T-cell leukemia/lymphoma 1 TCL1 oncogene is a contributing event in the pathogenesis of the aggressive form of this disease based on transgenic mouse studies To determine a role of microRNAs on the pathogenesis of the aggressive form of CLL we studied regulation of TCL1 expression in CLL by microRNAs We identified miR-3676 as a regulator of TCL1 expression We demonstrated that miR-3676 targets three consecutive 28-bp repeats within 3'UTR of TCL1 and showed that miR-3676 is a powerful inhibitor of TCL1 We further showed that miR-3676 expression is significantly down-regulated in four groups of CLL carrying the 11q deletions 13q deletions 17p deletions or a normal karyotype compared with normal CD19 cord blood and peripheral blood B cells In addition the sequencing of 539 CLL samples revealed five germ-line mutations in six samples 1 in miR-3676 Two of these mutations were loss-of-function mutations Because miR-3676 is located at 17p13 only 500-kb centromeric of tumor protein p53 Tp53 and is codeleted with Tp53 we propose that loss of miR-3676 causes high levels of TCL1 expression contributing to CLL progression,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 3, 96, 186, 171, 2, 3935, 1, 3, 102, 31, 2647, 4763, 14, 8979, 1836, 16, 8, 3156, 774, 4, 3, 1384, 1, 3, 571, 1297, 1, 26, 34, 90, 23, 2862, 830, 94, 6, 223, 8, 200, 1, 3515, 23, 3, 1384, 1, 3, 571, 1297, 1, 552, 21, 656, 863, 1, 8979, 55, 4, 552, 20, 3515, 21, 108, 722, 25672, 22, 8, 2452, 1, 8979, 55, 21, 264, 17, 722, 25672, 637, 169, 935, 339, 3044, 7197, 262, 9990, 1, 8979, 2, 224, 17, 722, 25672, 16, 8, 3757, 230, 1, 8979, 21, 195, 224, 17, 722, 25672, 55, 16, 97, 1328, 1065, 4, 294, 271, 1, 552, 2934, 3, 7203, 2439, 8453, 2439, 4135, 2439, 15, 8, 295, 3385, 72, 5, 295, 3158, 1885, 315, 2, 672, 315, 132, 37, 4, 352, 3, 615, 1, 11416, 552, 347, 553, 365, 2280, 328, 138, 4, 437, 347, 14, 4, 722, 25672, 100, 1, 46, 138, 11, 407, 1, 343, 138, 408, 722, 25672, 16, 2308, 28, 7526, 158, 1666, 5116, 15531, 1, 30, 178, 624, 1206, 2, 16, 12330, 5, 1206, 21, 2548, 17, 407, 1, 722, 25672, 1626, 64, 148, 1, 8979, 55, 3156, 6, 552, 91]",1208.0,25646413,64
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.,Expert opinion on biological therapy,Expert Opin Biol Ther,2015-02-09,"Over 20 years ago, chimeric antigen receptors (CARs) were created to endow T cells with new antigen-specificity and create a therapy that could eradicate cancer and provide life-long protection against recurrence. Steady progress has led to significant improvements with CAR design and CAR T-cell production, allowing evaluation of CAR T cells in patients. The initial trials have targeted CD19, which is expressed on normal and malignant B cells. We review data from trials for patients with chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL). In addition, we discuss the on-target toxicities, B-cell aplasia and cytokine release syndrome (CRS), which is uniquely associated with T-cell immunotherapies. We compare the results when targeting the same antigen in CLL or B-ALL and speculate on reasons for outcome differences and future directions to enhance outcomes. Furthermore, the dramatic results targeting B-ALL require further analysis in Phase II trials, and we discuss important components of these future trials. We also suggest a management scheme for CRS. The next several years will be critical and may lead to the first clinical indication of a gene-engineered cell therapy for cancer.",Journal Article,1807.0,5.0,Over 20 years ago chimeric antigen receptors CARs were created to endow T cells with new antigen-specificity and create a therapy that could eradicate cancer and provide life-long protection against recurrence Steady progress has led to significant improvements with CAR design and CAR T-cell production allowing evaluation of CAR T cells in patients The initial trials have targeted CD19 which is expressed on normal and malignant B cells We review data from trials for patients with chronic lymphocytic CLL and B-cell acute lymphoblastic B-ALL In addition we discuss the on-target toxicities B-cell aplasia and cytokine release syndrome CRS which is uniquely associated with T-cell immunotherapies We compare the results when targeting the same antigen in CLL or B-ALL and speculate on reasons for outcome differences and future directions to enhance outcomes Furthermore the dramatic results targeting B-ALL require further analysis in Phase II trials and we discuss important components of these future trials We also suggest a management scheme for CRS The next several years will be critical and may lead to the first clinical indication of a gene-engineered cell therapy for cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[252, 179, 60, 5028, 2897, 448, 1186, 7441, 11, 2466, 6, 20817, 102, 37, 5, 217, 448, 1121, 2, 3736, 8, 36, 17, 359, 5650, 12, 2, 377, 358, 319, 3525, 480, 146, 4152, 1466, 71, 836, 6, 93, 1474, 5, 1881, 771, 2, 1881, 102, 31, 1529, 2952, 451, 1, 1881, 102, 37, 4, 7, 3, 388, 143, 47, 238, 3158, 92, 16, 570, 23, 295, 2, 393, 132, 37, 21, 206, 74, 29, 143, 9, 7, 5, 442, 1193, 552, 2, 132, 31, 286, 1275, 132, 62, 4, 352, 21, 1139, 3, 23, 283, 385, 132, 31, 12307, 2, 1675, 2008, 681, 3115, 92, 16, 7089, 41, 5, 102, 31, 2811, 21, 932, 3, 99, 198, 529, 3, 827, 448, 4, 552, 15, 132, 62, 2, 11778, 23, 2325, 9, 228, 362, 2, 508, 3540, 6, 1304, 123, 798, 3, 3079, 99, 529, 132, 62, 1353, 195, 65, 4, 124, 215, 143, 2, 21, 1139, 305, 1628, 1, 46, 508, 143, 21, 120, 309, 8, 284, 4633, 9, 3115, 3, 1305, 392, 60, 303, 40, 740, 2, 68, 1122, 6, 3, 157, 38, 3607, 1, 8, 145, 2794, 31, 36, 9, 12]",1188.0,25666545,127
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.,Leukemia & lymphoma,Leuk. Lymphoma,2015-03-11,"The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic leukemia (CLL) cell apoptosis in vitro. We conducted a phase I dose-escalation trial to determine the safety and tolerability of carfilzomib in relapsed/refractory CLL or small lymphocytic lymphoma (SLL). Nineteen patients were treated with carfilzomib initially at 20 mg/m(2), then escalated in four cohorts (27, 36, 45 and 56 mg/m(2)) on days 1, 2, 8, 9, 15 and 16 of 28-day cycles. Therapy was generally well tolerated, and no dose limiting toxicities were observed. The most common hematologic toxicities were thrombocytopenia and neutropenia. All patients evaluable for response had stable disease, including patients with del17p13 and fludarabine-resistant disease. This trial shows acceptable tolerability and limited preliminary efficacy of carfilzomib in CLL and SLL. ","Clinical Trial, Phase I",1777.0,10.0,The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic CLL cell apoptosis in vitro We conducted a phase I dose-escalation trial to determine the safety and tolerability of carfilzomib in relapsed/refractory CLL or small lymphocytic SLL Nineteen patients were treated with carfilzomib initially at 20 mg/m 2 then escalated in four cohorts 27 36 45 and 56 mg/m 2 on days 1 2 8 9 15 and 16 of 28-day cycles Therapy was generally well tolerated and no dose limiting toxicities were observed The most common hematologic toxicities were thrombocytopenia and neutropenia All patients evaluable for response had stable disease including patients with del17p13 and fludarabine-resistant disease This trial shows acceptable tolerability and limited preliminary efficacy of carfilzomib in CLL and SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1694, 840, 17833, 652, 646, 4, 8, 1362, 1, 763, 1849, 2, 16, 8, 3757, 189, 283, 4, 392, 441, 3668, 16, 8, 1157, 1694, 230, 92, 1516, 1321, 442, 1193, 552, 31, 351, 4, 439, 21, 426, 8, 124, 70, 61, 1125, 160, 6, 223, 3, 367, 2, 1543, 1, 3668, 4, 591, 430, 552, 15, 302, 1193, 5302, 3498, 7, 11, 73, 5, 3668, 1625, 28, 179, 81, 188, 18, 818, 2842, 4, 294, 736, 428, 511, 512, 2, 664, 81, 188, 18, 23, 162, 14, 18, 66, 83, 167, 2, 245, 1, 339, 218, 410, 36, 10, 1228, 149, 421, 2, 77, 61, 817, 385, 11, 164, 3, 96, 186, 813, 385, 11, 1340, 2, 778, 62, 7, 859, 9, 51, 42, 585, 34, 141, 7, 5, 48147, 2, 2027, 436, 34, 26, 160, 1949, 1595, 1543, 2, 383, 1676, 209, 1, 3668, 4, 552, 2, 5302]",965.0,25669927,74
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-02-11,"B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches. We previously found that Axl receptor tyrosine kinase (RTK) plays a critical role in CLL B-cell survival. Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clinical trial to treat patients with CLL. Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated. Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs). Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells. Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to determine any synergistic/additive effects of the combination. CLL B cells overexpress Tyro3, but not MER. Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells. TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges. Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis. A marked reduction of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition. Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis. Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.",Journal Article,1805.0,30.0,B-cell chronic lymphocytic CLL is an incurable disease despite aggressive therapeutic approaches We previously found that Axl receptor tyrosine kinase RTK plays a critical role in CLL B-cell survival Here we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton 's tyrosine kinase BTK inhibitors for future clinical trial to treat patients with CLL Expression/activation status of other members of the TAM e.g. Tyro3 Axl and MER family of RTKs in CLL B cells was evaluated Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL marrow stromal cells BMSCs Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells Finally cells were exposed to TP-0903 in combination with BTK inhibitors to determine any synergistic/additive effects of the combination CLL B cells overexpress Tyro3 but not MER Of interest Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges Importantly CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis A marked reduction of the antiapoptotic proteins Mcl-1 Bcl-2 and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition Finally combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[132, 31, 442, 1193, 552, 16, 35, 2641, 34, 550, 571, 189, 611, 21, 373, 204, 17, 4197, 153, 564, 216, 5261, 1698, 8, 740, 200, 4, 552, 132, 31, 25, 467, 21, 1443, 3, 2526, 1, 75, 8, 64, 3601, 4197, 230, 22, 8, 226, 420, 15, 4, 150, 5, 5796, 292, 564, 216, 3611, 222, 9, 508, 38, 160, 6, 943, 7, 5, 552, 55, 363, 156, 1, 127, 1684, 1, 3, 4738, 563, 499, 25530, 4197, 2, 10068, 607, 1, 6798, 4, 552, 132, 37, 10, 194, 37, 11, 73, 5, 8, 64, 3601, 1428, 6582, 4197, 230, 5907, 27420, 5, 15, 187, 3, 463, 1, 552, 581, 1126, 37, 12761, 1810, 176, 1, 5907, 27420, 23, 3, 4197, 314, 308, 11, 120, 194, 4, 552, 132, 37, 1368, 37, 11, 2234, 6, 5907, 27420, 4, 150, 5, 3611, 222, 6, 223, 500, 1806, 3396, 176, 1, 3, 150, 552, 132, 37, 5612, 25530, 84, 44, 10068, 1, 1333, 25530, 469, 22, 2818, 2365, 2, 2377, 8, 840, 5, 4197, 4, 552, 132, 37, 5907, 27420, 1516, 7929, 351, 4, 552, 132, 37, 5, 44163, 1030, 1, 7927, 5632, 1859, 552, 12761, 359, 44, 4869, 3, 2015, 132, 37, 29, 5907, 27420, 277, 351, 8, 2003, 628, 1, 3, 4176, 652, 1308, 14, 1044, 18, 2, 5387, 2, 2218, 1, 3, 4118, 178, 3595, 4, 552, 132, 37, 10, 530, 22, 8, 757, 1, 4197, 297, 1368, 150, 1, 5907, 27420, 5, 3611, 222, 8941, 552, 132, 31, 351, 634, 1, 5907, 27420, 361, 22, 8, 226, 420, 15, 4, 150, 5, 3611, 222, 68, 40, 323, 4, 1367, 7, 5, 552]",1624.0,25673699,318
"Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.",Leukemia & lymphoma,Leuk. Lymphoma,2015-03-17,"Poly-[1-6]--glucopyranosyl-[1-3]--glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% confidence interval [CI]: 9.7, 32.1) and eight patients were retreated (median 35.3 months, 95% CI: 17.9, not reached). We conclude that PGG beta glucan, alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate. ","Clinical Trial, Phase I",1771.0,10.0,"Poly- 1-6 --glucopyranosyl- 1-3 --glucopyranose PGG beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic with high-risk biological markers for early initial treatment with alemtuzumab rituximab and PGG beta glucan 1-2-4 mg/kg/dose over 31 days PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study There were three grade 3-4 toxicities at least possibly attributed to treatment Nineteen 95 patients responded to treatment with 13 65 complete responses All patients were alive at a median follow-up of 24.4 months range 9.5-37 Eleven patients had progressive disease median 17.6 months 95 confidence interval CI 9.7 32.1 and eight patients were retreated median 35.3 months 95 CI 17.9 not reached We conclude that PGG beta glucan alemtuzumab and rituximab treatment is tolerable and results in a high complete response rate",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2699, 14, 49, 1458, 48853, 14, 27, 1458, 48854, 21818, 1090, 11245, 16, 8, 30709, 26357, 526, 14, 27, 14, 49, 2522, 5570, 5, 3939, 250, 398, 363, 174, 26, 124, 70, 215, 38, 160, 346, 179, 625, 7, 5, 442, 1193, 5, 64, 43, 1037, 525, 9, 191, 388, 24, 5, 3579, 855, 2, 21818, 1090, 11245, 14, 18, 39, 81, 503, 61, 252, 456, 162, 21818, 1090, 11245, 28, 39, 81, 503, 10, 149, 421, 2, 95, 9, 3, 124, 215, 45, 125, 11, 169, 88, 27, 39, 385, 28, 506, 2150, 3073, 6, 24, 3498, 48, 7, 2211, 6, 24, 5, 233, 556, 236, 253, 62, 7, 11, 1701, 28, 8, 52, 166, 126, 1, 259, 39, 53, 184, 83, 33, 567, 2627, 7, 42, 1014, 34, 52, 269, 49, 53, 48, 307, 268, 58, 83, 67, 531, 14, 2, 659, 7, 11, 11088, 52, 465, 27, 53, 48, 58, 269, 83, 44, 1300, 21, 2060, 17, 21818, 1090, 11245, 3579, 2, 855, 24, 16, 2668, 2, 99, 4, 8, 64, 236, 51, 116]",1002.0,25676035,185
The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2015-03-01,"Chronic lymphocytic leukemia (CLL) patients with high-risk markers such as del(17p) or those who have relapsed after multiple lines of therapy have a poor prognosis and allogeneic hematopoietic cell transplantation (alloHCT) has historically been the best opportunity for achieving long-term disease control. Recently, several new highly efficacious and well-tolerated small molecules targeting the B cell receptor (BCR) pathway and Bcl-2 have been approved or are in the late stages of development. These new agents are altering therapeutic paradigms in CLL, but unlike with alloHCT, information on long-term disease control is lacking. Here, we provide an overview of the data supporting the use of HCT in CLL and the promising results with the novel agents. We discuss the evolving role of alloHCT for CLL in the novel agent era, including identifying the patients most likely to benefit from transplantation and optimal transplantation timing, as well the use of novel agents in the post-transplantation setting. ",Journal Article,1787.0,0.0,Chronic lymphocytic CLL patients with high-risk markers such as del 17p or those who have relapsed after multiple lines of therapy have a poor prognosis and allogeneic hematopoietic cell transplantation alloHCT has historically been the best opportunity for achieving long-term disease control Recently several new highly efficacious and well-tolerated small molecules targeting the B cell receptor BCR pathway and Bcl-2 have been approved or are in the late stages of development These new agents are altering therapeutic paradigms in CLL but unlike with alloHCT information on long-term disease control is lacking Here we provide an overview of the data supporting the use of HCT in CLL and the promising results with the novel agents We discuss the evolving role of alloHCT for CLL in the novel agent era including identifying the patients most likely to benefit from transplantation and optimal transplantation timing as well the use of novel agents in the post-transplantation setting,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 7, 5, 64, 43, 525, 225, 22, 3084, 4135, 15, 135, 54, 47, 591, 50, 232, 285, 1, 36, 47, 8, 334, 356, 2, 1063, 1007, 31, 497, 5514, 71, 3578, 85, 3, 824, 2666, 9, 1785, 319, 337, 34, 182, 761, 392, 217, 561, 3289, 2, 149, 421, 302, 1598, 529, 3, 132, 31, 153, 1062, 308, 2, 1044, 18, 47, 85, 850, 15, 32, 4, 3, 807, 1153, 1, 193, 46, 217, 183, 32, 4831, 189, 4887, 4, 552, 84, 4246, 5, 5514, 487, 23, 319, 337, 34, 182, 16, 1941, 467, 21, 377, 35, 2901, 1, 3, 74, 1912, 3, 119, 1, 1085, 4, 552, 2, 3, 721, 99, 5, 3, 229, 183, 21, 1139, 3, 3276, 200, 1, 5514, 9, 552, 4, 3, 229, 420, 1713, 141, 1386, 3, 7, 96, 322, 6, 247, 29, 497, 2, 665, 497, 1972, 22, 149, 3, 119, 1, 229, 183, 4, 3, 539, 497, 546]",989.0,25682168,105
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.,American journal of hematology,Am. J. Hematol.,2015-03-30,"We have analyzed patients with previously untreated chronic lymphocytic leukemia with del11q fluorescence in situ hybridization (FISH) abnormality (n=196) in this study. Detection of the 11q22.3 used a multicolor FISH technique. Patients with del11q fell into two major FISH subsets-sole del11q (n=64) and del11q with del13q (n=132). FISH subsets were compared using the median del11q FISH% (>58%, high vs. 58%, low). Overall survival (OS) and time to first treatment (TTFT) were estimated using Kaplan-Meier plots (log rank). Multivariate analysis was performed to assess the association between FISH% of del11q and outcomes. Patients with sole del11q were similar to del11q with del13q in terms of TTFT and OS. Patients with high FISH% of del11q had significantly shorter OS and TTFT as compared with patients with low FISH%, particularly in sole del11q; this negative impact of high FISH% of del11q on OS and TTFT was diminished with coexistent del13q. In multivariate analysis, high FISH% of del11q was a significant predictor for shorter OS and TTFT. A comparison of these del11q subsets with a separate cohort of (n=673) previously untreated patients with sole del13q showed that the high FISH% del11q cohort had a significantly shorter TTFT and OS. In addition, bulky disease by physical examination or computed tomography imaging was infrequent at presentation in patients with del11q. High FISH% of del11q can reliably discriminate higher risk patients with chronic lymphocytic leukemia. Presence of coexistent del13q should be accounted for while prognosticating patients with del11q.",Comparative Study,1758.0,5.0,We have analyzed patients with previously untreated chronic lymphocytic with del11q fluorescence in situ hybridization FISH abnormality n 196 in this study Detection of the 11q22.3 used a multicolor FISH technique Patients with del11q fell into two major FISH subsets-sole del11q n 64 and del11q with del13q n 132 FISH subsets were compared using the median del11q FISH 58 high vs. 58 low Overall survival OS and time to first treatment TTFT were estimated using Kaplan-Meier plots log rank Multivariate analysis was performed to assess the association between FISH of del11q and outcomes Patients with sole del11q were similar to del11q with del13q in terms of TTFT and OS Patients with high FISH of del11q had significantly shorter OS and TTFT as compared with patients with low FISH particularly in sole del11q this negative impact of high FISH of del11q on OS and TTFT was diminished with coexistent del13q In multivariate analysis high FISH of del11q was a significant predictor for shorter OS and TTFT A comparison of these del11q subsets with a separate cohort of n 673 previously untreated patients with sole del13q showed that the high FISH del11q cohort had a significantly shorter TTFT and OS In addition bulky disease by physical examination or computed tomography imaging was infrequent at presentation in patients with del11q High FISH of del11q can reliably discriminate higher risk patients with chronic lymphocytic Presence of coexistent del13q should be accounted for while prognosticating patients with del11q,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 47, 311, 7, 5, 373, 1278, 442, 1193, 5, 15402, 1591, 4, 957, 1554, 1277, 3698, 78, 6369, 4, 26, 45, 638, 1, 3, 12647, 27, 95, 8, 11920, 1277, 1312, 7, 5, 15402, 7689, 237, 100, 458, 1277, 1890, 4991, 15402, 78, 660, 2, 15402, 5, 32397, 78, 4255, 1277, 1890, 11, 72, 75, 3, 52, 15402, 1277, 717, 64, 105, 65651, 154, 63, 25, 118, 2, 98, 6, 157, 24, 14035, 11, 661, 75, 876, 882, 8030, 1066, 1026, 331, 65, 10, 173, 6, 423, 3, 248, 59, 1277, 1, 15402, 2, 123, 7, 5, 4991, 15402, 11, 288, 6, 15402, 5, 32397, 4, 1794, 1, 14035, 2, 118, 7, 5, 64, 1277, 1, 15402, 42, 97, 985, 118, 2, 14035, 22, 72, 5, 7, 5, 154, 1277, 823, 4, 4991, 15402, 26, 199, 345, 1, 64, 1277, 1, 15402, 23, 118, 2, 14035, 10, 2849, 5, 12779, 32397, 4, 331, 65, 64, 1277, 1, 15402, 10, 8, 93, 980, 9, 985, 118, 2, 14035, 8, 1155, 1, 46, 15402, 1890, 5, 8, 2282, 180, 1, 78, 14267, 373, 1278, 7, 5, 4991, 32397, 224, 17, 3, 64, 1277, 15402, 180, 42, 8, 97, 985, 14035, 2, 118, 4, 352, 4112, 34, 20, 900, 1385, 15, 1220, 872, 270, 10, 4475, 28, 1031, 4, 7, 5, 15402, 64, 1277, 1, 15402, 122, 4092, 5696, 142, 43, 7, 5, 442, 1193, 463, 1, 12779, 32397, 257, 40, 3688, 9, 369, 22496, 7, 5, 15402]",1529.0,25683856,123
Shifting paradigms in the treatment of chronic lymphocytic leukemia.,"Future oncology (London, England)",Future Oncol,2015-01-01,"The treatment of chronic lymphocytic leukemia (CLL) is evolving rapidly. Insight into the genetics and biology of the disease, including the importance of intracellular signaling pathways and interactions with the microenvironment has led to the development of rational targeted therapies which are having a major impact on the survival of patients with relapsed and high-risk disease. In addition, an exciting array of cellular therapies and immunotherapy options are in various stages of development. We review the current understanding of CLL genetics and biology, current treatment strategies in specific patient groups and opportunities for future treatment combinations which will bring the goal of cure or long-term disease control with minimal toxicity within reach for the majority of patients.",Journal Article,1846.0,3.0,The treatment of chronic lymphocytic CLL is evolving rapidly Insight into the genetics and biology of the disease including the importance of intracellular signaling pathways and interactions with the microenvironment has led to the development of rational targeted therapies which are having a major impact on the survival of patients with relapsed and high-risk disease In addition an exciting array of cellular therapies and immunotherapy options are in various stages of development We review the current understanding of CLL genetics and biology current treatment strategies in specific patient groups and opportunities for future treatment combinations which will bring the goal of cure or long-term disease control with minimal toxicity within reach for the majority of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 24, 1, 442, 1193, 552, 16, 3276, 1755, 2670, 237, 3, 2894, 2, 891, 1, 3, 34, 141, 3, 1187, 1, 2087, 314, 460, 2, 1286, 5, 3, 995, 71, 836, 6, 3, 193, 1, 2696, 238, 235, 92, 32, 1041, 8, 458, 345, 23, 3, 25, 1, 7, 5, 591, 2, 64, 43, 34, 4, 352, 35, 4963, 1926, 1, 763, 235, 2, 726, 838, 32, 4, 747, 1153, 1, 193, 21, 206, 3, 291, 612, 1, 552, 2894, 2, 891, 291, 24, 422, 4, 112, 69, 271, 2, 2605, 9, 508, 24, 1247, 92, 303, 8798, 3, 1326, 1, 1722, 15, 319, 337, 34, 182, 5, 1048, 155, 262, 3690, 9, 3, 686, 1, 7]",785.0,25686119,585
Three-year follow-up of treatment-nave and previously treated patients with CLL and SLL receiving single-agent ibrutinib.,Blood,Blood,2015-02-19,"Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-nave and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse. ",Journal Article,1797.0,428.0,Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor chemokine and integrin-mediated signaling In early-phase studies ibrutinib demonstrated high response rates and prolonged progression-free survival PFS in chronic lymphocytic CLL The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period We report on median 3-year follow-up of 132 patients with symptomatic treatment-nave and relapsed/refractory CLL or small lymphocytic Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias fatigue and infections Progression remains uncommon occurring primarily in some patients with relapsed del 17 p13.1 and/or del 11 q22.3 disease Treatment-related lymphocytosis remains largely asymptomatic even when persisting 1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better Collectively these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 35, 1428, 468, 230, 1, 5796, 564, 216, 17, 11574, 132, 31, 153, 3596, 2, 2876, 517, 314, 4, 191, 124, 94, 1795, 264, 64, 51, 151, 2, 1069, 91, 115, 25, 300, 4, 442, 1193, 552, 3, 1480, 253, 164, 5, 1795, 6509, 4, 760, 6, 8, 1721, 155, 800, 17, 2333, 3, 686, 1, 7, 6, 560, 1314, 36, 9, 35, 1747, 727, 21, 414, 23, 52, 27, 111, 166, 126, 1, 4255, 7, 5, 1704, 24, 2809, 2, 591, 430, 552, 15, 302, 1193, 589, 24, 5, 1795, 10, 41, 5, 767, 4, 51, 372, 252, 98, 2, 1480, 3166, 155, 5, 589, 166, 126, 2849, 5, 2184, 6, 2291, 1, 88, 27, 15, 378, 5635, 613, 2, 1875, 91, 469, 2052, 1821, 1561, 4, 476, 7, 5, 591, 3084, 269, 7914, 14, 2, 15, 3084, 175, 8026, 27, 34, 24, 139, 8125, 469, 1733, 2100, 871, 198, 12099, 14, 111, 2, 1097, 44, 1322, 6, 2688, 589, 337, 300, 2, 63, 25, 72, 5, 7, 5, 450, 51, 15, 380, 2535, 46, 74, 377, 241, 17, 1795, 535, 552, 34, 4282, 2, 16, 149, 421, 9, 35, 1747, 727, 26, 487, 122, 987, 1196, 174, 24, 838, 9, 338, 1453, 6, 8440, 3, 319, 337, 43, 1, 429]",1435.0,25700432,527
Epigenetic silencing of miR-708 enhances NF-B signaling in chronic lymphocytic leukemia.,International journal of cancer,Int. J. Cancer,2015-03-13,"MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression and their deregulation is involved in tumor development. Epigenetic gene silencing in cancer by DNA methylation contributes to the silencing of tumor-suppressor genes, including miRNAs. We have recently shown that the promoter of miR-708 is aberrantly methylated in chronic lymphocytic leukemia (CLL). To characterize the molecular signaling networks that are influenced by miR-708, we performed a luciferase-based screen evaluating the effects of ectopic miR-708 expression on leukemia-relevant signaling pathways. We found that miR-708 strongly repressed NF-B signaling, a pathway known to be deregulated in CLL. Among the predicted miR-708 targets was IKK (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase-/IKBKB), a key kinase facilitating NF-B signaling. We validated the interaction of miR-708 with the 3'-untranslated region of IKK and found that miR-708 overexpression represses endogenous IKK. Phosphorylation of the IKK target IB and expression of known NF-B target genes were impaired by miR-708. Furthermore, we identified an enhancer region downstream of the miR-708 promoter that displays a distinct DNA methylation status in CLL. High enhancer methylation is significantly correlated with lower miR-708 expression and is predominantly found in patients with poor prognosis and shorter time to treatment. These results demonstrate that miR-708 regulates the NF-B pathway by targeting IKK, and that methylation of a key enhancer region contributes to its suppression in CLL. ",Journal Article,1775.0,31.0,MicroRNAs miRNAs are post-transcriptional regulators of gene expression and their deregulation is involved in tumor development Epigenetic gene silencing in cancer by DNA methylation contributes to the silencing of tumor-suppressor genes including miRNAs We have recently shown that the promoter of miR-708 is aberrantly methylated in chronic lymphocytic CLL To characterize the molecular signaling networks that are influenced by miR-708 we performed a luciferase-based screen evaluating the effects of ectopic miR-708 expression on leukemia-relevant signaling pathways We found that miR-708 strongly repressed NF-B signaling a pathway known to be deregulated in CLL Among the predicted miR-708 targets was IKK inhibitor of kappa light polypeptide gene enhancer in B cells kinase-/IKBKB a key kinase facilitating NF-B signaling We validated the interaction of miR-708 with the 3'-untranslated region of IKK and found that miR-708 overexpression represses endogenous IKK Phosphorylation of the IKK target IB and expression of known NF-B target genes were impaired by miR-708 Furthermore we identified an enhancer region downstream of the miR-708 promoter that displays a distinct DNA methylation status in CLL High enhancer methylation is significantly correlated with lower miR-708 expression and is predominantly found in patients with poor prognosis and shorter time to treatment These results demonstrate that miR-708 regulates the NF-B pathway by targeting IKK and that methylation of a key enhancer region contributes to its suppression in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3515, 2028, 32, 539, 1431, 3196, 1, 145, 55, 2, 136, 4765, 16, 646, 4, 30, 193, 1418, 145, 2077, 4, 12, 20, 261, 569, 2444, 6, 3, 2077, 1, 30, 1245, 214, 141, 2028, 21, 47, 761, 443, 17, 3, 973, 1, 722, 9687, 16, 5619, 2963, 4, 442, 1193, 552, 6, 1507, 3, 219, 314, 3991, 17, 32, 2574, 20, 722, 9687, 21, 173, 8, 3864, 90, 2413, 1435, 3, 176, 1, 3647, 722, 9687, 55, 23, 2647, 867, 314, 460, 21, 204, 17, 722, 9687, 1327, 6654, 1365, 2448, 314, 8, 308, 440, 6, 40, 5415, 4, 552, 107, 3, 783, 722, 9687, 637, 10, 11878, 230, 1, 3096, 1691, 8720, 145, 4239, 4, 132, 37, 216, 1458, 28857, 8, 825, 216, 5379, 1365, 2448, 314, 21, 938, 3, 915, 1, 722, 9687, 5, 3, 5435, 7379, 1053, 1, 11878, 2, 204, 17, 722, 9687, 851, 10946, 2682, 11878, 982, 1, 3, 11878, 283, 15032, 2, 55, 1, 440, 1365, 2448, 283, 214, 11, 2364, 20, 722, 9687, 798, 21, 108, 35, 4239, 1053, 1489, 1, 3, 722, 9687, 973, 17, 7196, 8, 834, 261, 569, 156, 4, 552, 64, 4239, 569, 16, 97, 438, 5, 280, 722, 9687, 55, 2, 16, 2117, 204, 4, 7, 5, 334, 356, 2, 985, 98, 6, 24, 46, 99, 608, 17, 722, 9687, 2468, 3, 1365, 2448, 308, 20, 529, 11878, 2, 17, 569, 1, 8, 825, 4239, 1053, 2444, 6, 211, 1332, 4, 552]",1561.0,25704289,48
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.,Leukemia & lymphoma,Leuk. Lymphoma,2015-03-30,"Fludarabine (F) and cyclophosphamide (C) remain backbones of up-front chemotherapy regimens for chronic lymphocytic leukemia (CLL). We report long-term follow-up of a randomized F vs. FC trial in untreated CLL (#) . With median follow-up of 88 months, estimated median progression-free survival (PFS) was 19.3 vs. 48.1 months for F (n = 109) and FC (n = 118), respectively (p < 0.0001), and median overall survival (OS) was 88.0 vs. 79.1 months (p = 0.96). In multivariable analyses, variables associated with inferior PFS and OS respectively were age (p = 0.002, p < 0.001), Rai stage (p = 0.006, p = 0.02) and sex (p = 0.03, PFS only). Del(17)(p13.1) predicted shorter PFS and OS (p < 0.0001 for each), as did del(11q)(22.3) (p < 0.0001, p = 0.005, respectively), trisomy 12 with mutated Notch1 (p = 0.003, p = 0.03, respectively) and unmutated IGHV (p = 0.009, p = 0.002, respectively), all relative to patients without these features. These data confirm results from shorter follow-up and further justify targeted therapies for CLL. ","Clinical Trial, Phase III",1758.0,5.0,Fludarabine F and cyclophosphamide C remain backbones of up-front chemotherapy regimens for chronic lymphocytic CLL We report long-term follow-up of a randomized F vs. FC trial in untreated CLL With median follow-up of 88 months estimated median progression-free survival PFS was 19.3 vs. 48.1 months for F n 109 and FC n 118 respectively p 0.0001 and median overall survival OS was 88.0 vs. 79.1 months p 0.96 In multivariable analyses variables associated with inferior PFS and OS respectively were age p 0.002 p 0.001 Rai stage p 0.006 p 0.02 and sex p 0.03 PFS only Del 17 p13.1 predicted shorter PFS and OS p 0.0001 for each as did del 11q 22.3 p 0.0001 p 0.005 respectively trisomy 12 with mutated Notch1 p 0.003 p 0.03 respectively and unmutated IGHV p 0.009 p 0.002 respectively all relative to patients without these features These data confirm results from shorter follow-up and further justify targeted therapies for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 1068, 2, 1112, 256, 918, 25603, 1, 126, 3007, 56, 472, 9, 442, 1193, 552, 21, 414, 319, 337, 166, 126, 1, 8, 384, 1068, 105, 4127, 160, 4, 1278, 552, 5, 52, 166, 126, 1, 889, 53, 661, 52, 91, 115, 25, 300, 10, 326, 27, 105, 576, 14, 53, 9, 1068, 78, 3486, 2, 4127, 78, 4002, 106, 19, 13, 488, 2, 52, 63, 25, 118, 10, 889, 13, 105, 842, 14, 53, 19, 13, 921, 4, 658, 318, 682, 41, 5, 1663, 300, 2, 118, 106, 11, 89, 19, 13, 1111, 19, 13, 144, 4121, 82, 19, 13, 1861, 19, 13, 588, 2, 1035, 19, 13, 680, 300, 158, 3084, 269, 7914, 14, 783, 985, 300, 2, 118, 19, 13, 488, 9, 296, 22, 205, 3084, 7203, 350, 27, 19, 13, 488, 19, 13, 1614, 106, 6317, 133, 5, 1185, 4607, 19, 13, 1421, 19, 13, 680, 106, 2, 7216, 6220, 19, 13, 2376, 19, 13, 1111, 106, 62, 580, 6, 7, 187, 46, 404, 46, 74, 1843, 99, 29, 985, 166, 126, 2, 195, 6665, 238, 235, 9, 552]",931.0,25721902,783
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2015-02-28,"To assess ibrutinib pharmacokinetics under fasted and fed conditions, impact of food-intake timing, and the safety and tolerability. Three studies were analyzed. Study 1 was a randomized, open-label, single-dose, four-way crossover study in 44 healthy participants. Study 2 was a randomized, repeat-dose crossover study in 16 patients with previously treated chronic lymphocytic leukemia (CLL). Ibrutinib dose was 420mg in both studies. Study 3 was an open-label, sequential study to assess the effect of a standard breakfast on ibrutinib 560mg in eight healthy participants. Administration of single-dose ibrutinib under fasting conditions (study 1) resulted in approximately 60% of exposure compared with drug intake either 30min before, 30min after (fed), or 2h after a high-fat meal. Similar food effect was observed (study 3) when ibrutinib was given 30min before meal. In CLL patients (study 2), the C max and AUC under fasting conditions were 43 and 61%, respectively, relative to fed conditions. When administered once-daily in uncontrolled food-intake conditions (30min before or 2h after), exposures were slightly (30%) lower than in fed condition. When corrected for repeated dosing, pharmacokinetic parameters in healthy participants and patients were comparable. Ibrutinib was generally well tolerated in all settings studied. Ibrutinib administered in fasted condition reduces exposure to approximately 60% as compared with dosing in proximity to food-intake, regardless of timing/type of meal. Because repeated drug intake in fasted condition is unlikely, no food restrictions may be needed to administer ibrutinib.",Journal Article,1788.0,42.0,To assess ibrutinib pharmacokinetics under fasted and fed conditions impact of food-intake timing and the safety and tolerability Three studies were analyzed Study 1 was a randomized open-label single-dose four-way crossover study in 44 healthy participants Study 2 was a randomized repeat-dose crossover study in 16 patients with previously treated chronic lymphocytic CLL Ibrutinib dose was 420 mg in both studies Study 3 was an open-label sequential study to assess the effect of a standard breakfast on ibrutinib 560 mg in eight healthy participants Administration of single-dose ibrutinib under fasting conditions study 1 resulted in approximately 60 of exposure compared with drug intake either 30 min before 30 min after fed or 2 h after a high-fat meal Similar food effect was observed study 3 when ibrutinib was given 30 min before meal In CLL patients study 2 the C max and AUC under fasting conditions were 43 and 61 respectively relative to fed conditions When administered once-daily in uncontrolled food-intake conditions 30 min before or 2 h after exposures were slightly 30 lower than in fed condition When corrected for repeated dosing pharmacokinetic parameters in healthy participants and patients were comparable Ibrutinib was generally well tolerated in all settings studied Ibrutinib administered in fasted condition reduces exposure to approximately 60 as compared with dosing in proximity to food-intake regardless of timing/type of meal Because repeated drug intake in fasted condition is unlikely no food restrictions may be needed to administer ibrutinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 423, 1795, 1159, 669, 15580, 2, 6994, 1298, 345, 1, 1773, 1514, 1972, 2, 3, 367, 2, 1543, 169, 94, 11, 311, 45, 14, 10, 8, 384, 1020, 1756, 226, 61, 294, 2255, 5265, 45, 4, 584, 1331, 776, 45, 18, 10, 8, 384, 2334, 61, 5265, 45, 4, 245, 7, 5, 373, 73, 442, 1193, 552, 1795, 61, 10, 5401, 81, 4, 110, 94, 45, 27, 10, 35, 1020, 1756, 1787, 45, 6, 423, 3, 254, 1, 8, 260, 32404, 23, 1795, 7356, 81, 4, 659, 1331, 776, 634, 1, 226, 61, 1795, 669, 5706, 1298, 45, 14, 627, 4, 705, 335, 1, 645, 72, 5, 234, 1514, 361, 201, 1538, 348, 201, 1538, 50, 6994, 15, 18, 555, 50, 8, 64, 2300, 11497, 288, 1773, 254, 10, 164, 45, 27, 198, 1795, 10, 447, 201, 1538, 348, 11497, 4, 552, 7, 45, 18, 3, 256, 2649, 2, 1376, 669, 5706, 1298, 11, 601, 2, 713, 106, 580, 6, 6994, 1298, 198, 468, 1059, 391, 4, 6180, 1773, 1514, 1298, 7783, 1538, 348, 15, 18, 555, 50, 3401, 11, 3223, 48877, 280, 76, 4, 6994, 2850, 198, 3848, 9, 2113, 1280, 1456, 1038, 4, 1331, 776, 2, 7, 11, 1279, 1795, 10, 1228, 149, 421, 4, 62, 1947, 656, 1795, 468, 4, 15580, 2850, 2389, 645, 6, 705, 335, 22, 72, 5, 1280, 4, 6167, 6, 1773, 1514, 1583, 1, 1972, 267, 1, 11497, 408, 2113, 234, 1514, 4, 15580, 2850, 16, 3568, 77, 1773, 9999, 68, 40, 575, 6, 6888, 1795]",1583.0,25724156,33
"Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.",Molecular cancer research : MCR,Mol. Cancer Res.,2015-03-02,"While reviewing chronic lymphocytic leukemia (CLL) bone marrow slides, we identified cytoplasmic lipid vacuoles in CLL cells but not in normal B cells. Because lipoprotein lipase (LPL), which catalyzes hydrolysis of triglycerides into free fatty acids (FFA), is aberrantly expressed in CLL, we investigated whether LPL regulates the oxidative metabolic capacity of CLL cells. We found that unlike normal B cells, CLL cells metabolize FFAs. Because STAT3 is constitutively activated in CLL cells and because we identified putative STAT3 binding sites in the LPL promoter, we sought to determine whether STAT3 drives the aberrant expression of LPL. Transfection of luciferase reporter gene constructs driven by LPL promoter fragments into MM1 cells revealed that STAT3 activates the LPL promoter. In addition, chromatin immunoprecipitation confirmed that STAT3 binds to the LPL promoter. Furthermore, transfection of CLL cells with STAT3-shRNA downregulated LPL transcripts and protein levels, confirming that STAT3 activates the LPL gene. Finally, transfection of CLL cells with LPL-siRNAs decreased the capacity of CLL cells to oxidize FFAs and reduced cell viability. Our study suggests that CLL cells adopt their metabolism to oxidize FFA. Activated STAT3 induces LPL, which catalyzes the hydrolysis of triglycerides into FFA. Therefore, inhibition of STAT3 is likely to prevent the capacity of CLL cells to utilize FFA.",Journal Article,1786.0,28.0,While reviewing chronic lymphocytic CLL marrow slides we identified cytoplasmic lipid vacuoles in CLL cells but not in normal B cells Because lipoprotein lipase LPL which catalyzes hydrolysis of triglycerides into free fatty acids FFA is aberrantly expressed in CLL we investigated whether LPL regulates the oxidative metabolic capacity of CLL cells We found that unlike normal B cells CLL cells metabolize FFAs Because STAT3 is constitutively activated in CLL cells and because we identified putative STAT3 binding sites in the LPL promoter we sought to determine whether STAT3 drives the aberrant expression of LPL Transfection of luciferase reporter gene constructs driven by LPL promoter fragments into MM1 cells revealed that STAT3 activates the LPL promoter In addition chromatin immunoprecipitation confirmed that STAT3 binds to the LPL promoter Furthermore transfection of CLL cells with STAT3-shRNA downregulated LPL transcripts and protein levels confirming that STAT3 activates the LPL gene Finally transfection of CLL cells with LPL-siRNAs decreased the capacity of CLL cells to oxidize FFAs and reduced cell viability Our study suggests that CLL cells adopt their metabolism to oxidize FFA Activated STAT3 induces LPL which catalyzes the hydrolysis of triglycerides into FFA Therefore inhibition of STAT3 is likely to prevent the capacity of CLL cells to utilize FFA,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[369, 6979, 442, 1193, 552, 581, 3830, 21, 108, 2828, 3121, 22412, 4, 552, 37, 84, 44, 4, 295, 132, 37, 408, 8984, 7272, 8249, 92, 11074, 15205, 1, 15000, 237, 115, 4038, 4562, 20881, 16, 5619, 570, 4, 552, 21, 565, 317, 8249, 2468, 3, 3495, 1436, 2162, 1, 552, 37, 21, 204, 17, 4246, 295, 132, 37, 552, 37, 18746, 29653, 408, 1439, 16, 2818, 735, 4, 552, 37, 2, 408, 21, 108, 2743, 1439, 791, 633, 4, 3, 8249, 973, 21, 990, 6, 223, 317, 1439, 5267, 3, 1898, 55, 1, 8249, 3789, 1, 3864, 3674, 145, 5500, 1621, 20, 8249, 973, 5843, 237, 12773, 37, 553, 17, 1439, 3932, 3, 8249, 973, 4, 352, 2287, 4857, 557, 17, 1439, 3333, 6, 3, 8249, 973, 798, 3789, 1, 552, 37, 5, 1439, 3976, 3315, 8249, 2680, 2, 178, 148, 5030, 17, 1439, 3932, 3, 8249, 145, 1368, 3789, 1, 552, 37, 5, 8249, 8006, 340, 3, 2162, 1, 552, 37, 6, 41009, 29653, 2, 405, 31, 2120, 114, 45, 844, 17, 552, 37, 11462, 136, 1600, 6, 41009, 20881, 735, 1439, 1516, 8249, 92, 11074, 3, 15205, 1, 15000, 237, 20881, 673, 297, 1, 1439, 16, 322, 6, 1682, 3, 2162, 1, 552, 37, 6, 6391, 20881]",1379.0,25733697,275
"Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2015-03-01,"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL. ",Journal Article,1787.0,32.0,Chronic lymphocytic CLL and small lymphocytic SLL are different manifestations of the same disease which are managed in the same way The advent of novel monoclonal antibodies ofatumumab and obinutuzumab led to the development of effective chemoimmunotherapy regimens The recently approved small molecule kinase inhibitors ibrutinib and idelalisib are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens This portion of the NCCN Guidelines for 's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 302, 1193, 5302, 32, 338, 4282, 1, 3, 827, 34, 92, 32, 2231, 4, 3, 827, 2255, 3, 4114, 1, 229, 848, 890, 5732, 2, 10380, 836, 6, 3, 193, 1, 323, 4438, 472, 3, 761, 850, 302, 1354, 216, 222, 1795, 2, 7083, 32, 323, 24, 838, 9, 552, 4, 1216, 7, 5, 340, 2614, 9, 571, 472, 2, 4, 7, 5, 334, 177, 404, 54, 1022, 44, 247, 29, 809, 4438, 472, 26, 3206, 1, 3, 1944, 677, 9, 292, 1557, 2677, 3, 435, 112, 6, 3, 2838, 1, 761, 850, 238, 235, 9, 3, 284, 1, 7, 5, 732, 265, 2, 591, 15, 430, 552, 5302]",797.0,25736010,108
Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.,International journal of dermatology,Int. J. Dermatol.,2015-03-13,"Patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or non-Hodgkin lymphoma (NHL) are at increased risk for the development of skin malignancies. This study was conducted to estimate the incidences of rare skin malignancies in patients with CLL/SLL or NHL. Patients with a diagnosis of CLL/SLL or NHL recorded in the Surveillance, Epidemiology and End Results (SEER) database during 1992-2007 were identified. Diagnoses of specific skin malignancies were identified from SEER files. During 1992-2007, a total of 128,674 patients with first diagnoses of CLL/SLL or NHL were recorded in SEER; 4743 were excluded because follow-up data were unavailable. Among the remaining 123,931 patients, 28,964 had CLL/SLL and 94,967 had NHL. Standardized incidence ratios (SIRs) for invasive malignant melanoma, Merkel cell carcinoma, malignant fibrous histiocytoma, dermatofibrosarcoma protuberans, Kaposi's sarcoma, and sebaceous carcinoma were 2.3, 8.2, 3.6, 2.5, 2.9, and 1.4, respectively, in CLL/SLL patients and 1.6, 3.2, 1.5, 1.3, 17.6, and 0.8, respectively, in NHL patients. When invasive melanoma was stratified by patient age and sex, the highest SIR (17.8) was found in men aged 0-49 years with CLL (P<0.001). Patients with CLL/SLL or NHL have a higher risk for the subsequent development of rare skin cancers. Given the more aggressive nature of these malignancies in this setting, regular monitoring for the development and prompt treatment of cutaneous malignancy is prudent in patients with NHL and particularly in patients with CLL. Regular use of sun protection may decrease the morbidity associated with skin cancer in this immunosuppressed population.",Journal Article,1775.0,19.0,"Patients with chronic lymphocytic CLL small lymphocytic SLL or NHL are at increased risk for the development of malignancies This study was conducted to estimate the incidences of rare malignancies in patients with CLL/SLL or NHL Patients with a diagnosis of CLL/SLL or NHL recorded in the Surveillance Epidemiology and End Results SEER database during 1992-2007 were identified Diagnoses of specific malignancies were identified from SEER files During 1992-2007 a total of 128,674 patients with first diagnoses of CLL/SLL or NHL were recorded in SEER 4743 were excluded because follow-up data were unavailable Among the remaining 123,931 patients 28,964 had CLL/SLL and 94,967 had NHL Standardized incidence ratios SIRs for invasive malignant Merkel cell carcinoma malignant fibrous histiocytoma dermatofibrosarcoma protuberans Kaposi 's and sebaceous carcinoma were 2.3 8.2 3.6 2.5 2.9 and 1.4 respectively in CLL/SLL patients and 1.6 3.2 1.5 1.3 17.6 and 0.8 respectively in NHL patients When invasive was stratified by patient age and sex the highest SIR 17.8 was found in men aged 0-49 years with CLL P 0.001 Patients with CLL/SLL or NHL have a higher risk for the subsequent development of rare cancers Given the more aggressive nature of these malignancies in this setting regular monitoring for the development and prompt treatment of cutaneous malignancy is prudent in patients with NHL and particularly in patients with CLL Regular use of sun protection may decrease the morbidity associated with cancer in this immunosuppressed population",0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 302, 1193, 5302, 15, 1176, 32, 28, 101, 43, 9, 3, 193, 1, 441, 26, 45, 10, 426, 6, 1191, 3, 3981, 1, 622, 441, 4, 7, 5, 552, 5302, 15, 1176, 7, 5, 8, 147, 1, 552, 5302, 15, 1176, 1872, 4, 3, 617, 1284, 2, 396, 99, 1605, 609, 190, 2846, 1307, 11, 108, 2403, 1, 112, 441, 11, 108, 29, 1605, 7530, 190, 2846, 1307, 8, 181, 1, 3990, 12258, 7, 5, 157, 2403, 1, 552, 5302, 15, 1176, 11, 1872, 4, 1605, 65759, 11, 1800, 408, 166, 126, 74, 11, 9098, 107, 3, 1844, 2698, 17435, 7, 339, 14846, 42, 552, 5302, 2, 960, 20511, 42, 1176, 1670, 287, 1137, 7120, 9, 416, 393, 5855, 31, 134, 393, 5870, 9960, 11922, 11923, 7574, 292, 2, 8621, 134, 11, 18, 27, 66, 18, 27, 49, 18, 33, 18, 83, 2, 14, 39, 106, 4, 552, 5302, 7, 2, 14, 49, 27, 18, 14, 33, 14, 27, 269, 49, 2, 13, 66, 106, 4, 1176, 7, 198, 416, 10, 1173, 20, 69, 89, 2, 1035, 3, 1076, 3636, 269, 66, 10, 204, 4, 325, 1032, 13, 739, 60, 5, 552, 19, 13, 144, 7, 5, 552, 5302, 15, 1176, 47, 8, 142, 43, 9, 3, 706, 193, 1, 622, 163, 447, 3, 80, 571, 2202, 1, 46, 441, 4, 26, 546, 3316, 1315, 9, 3, 193, 2, 4776, 24, 1, 1486, 710, 16, 10263, 4, 7, 5, 1176, 2, 823, 4, 7, 5, 552, 3316, 119, 1, 5479, 3525, 68, 775, 3, 787, 41, 5, 12, 4, 26, 12749, 266]",1549.0,25772131,244
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2015-03-01,"The incidence of non-Hodgkin lymphomas is on the rise worldwide. The aggressive non-Hodgkin lymphomas can potentially be cured with front-line therapy, but indolent ones, such as chronic lymphocytic leukemia/small lymphocytic lymphoma, cannot. Relapsed/refractory non-Hodgkin lymphomas have a poor overall outcome, typically with shorter responses after each relapse. Novel therapies are sought to improve outcomes in this patient population. This review discusses the promising new biologic therapies that have emerged over the last 5 years. Some have already achieved US Food and Drug Administration approval, while others are undergoing active investigation in order to ultimately gain approval. Here, in Part 1, we discuss monoclonal antibodies. In Part 2, we will discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. ",Journal Article,1787.0,1.0,The incidence of lymphomas is on the rise worldwide The aggressive lymphomas can potentially be cured with front-line therapy but indolent ones such as chronic lymphocytic leukemia/small lymphocytic can not Relapsed/refractory lymphomas have a poor overall outcome typically with shorter responses after each relapse Novel therapies are sought to improve outcomes in this patient population This review discusses the promising new biologic therapies that have emerged over the last 5 years Some have already achieved US Food and Drug Administration approval while others are undergoing active investigation in order to ultimately gain approval Here in Part 1 we discuss monoclonal antibodies In Part 2 we will discuss adoptive cellular immunotherapies small-molecule inhibitors and immunomodulatory agents,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 287, 1, 1557, 16, 23, 3, 3693, 2358, 3, 571, 1557, 122, 751, 40, 3733, 5, 3007, 328, 36, 84, 2316, 6737, 225, 22, 442, 1193, 2647, 302, 1193, 122, 44, 591, 430, 1557, 47, 8, 334, 63, 228, 1969, 5, 985, 253, 50, 296, 429, 229, 235, 32, 990, 6, 401, 123, 4, 26, 69, 266, 26, 206, 2759, 3, 721, 217, 1283, 235, 17, 47, 2054, 252, 3, 1060, 33, 60, 476, 47, 3298, 513, 843, 1773, 2, 234, 634, 1814, 369, 1749, 32, 479, 544, 940, 4, 1732, 6, 2050, 1803, 1814, 467, 4, 760, 14, 21, 1139, 848, 890, 4, 760, 18, 21, 303, 1139, 3159, 763, 2811, 302, 1354, 222, 2, 2555, 183]",805.0,25772456,221
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2015-03-18,"Immunoglobulins (Ig) are produced by B lymphocytes as secreted antibodies or as part of the B-cell receptor. There is tremendous diversity of potential Ig transcripts (>1  10(12)) as a result of hundreds of germ-line gene segments, random nucleotide incorporation during joining of gene segments into a complete transcript, and the process of somatic hypermutation at individual nucleotides. This recombination and mutation process takes place in the maturing B cell and is responsible for the diversity of potential epitope recognition. Cancers arising from mature B cells are characterized by clonal production of Ig heavy (IGH@) and light chain transcripts, although whether the sequence has undergone somatic hypermutation is dependent on the maturation stage at which the neoplastic clone arose. Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and arises from a mature B cell with either mutated or unmutated IGH@ transcripts, the latter having worse prognosis and the assessment of which is routinely performed in the clinic. Currently, IGHV mutation status is assessed by Sanger sequencing and comparing the transcript to known germ-line genes. In this paper, we demonstrate that complete IGH@ V-D-J sequences can be computed from unselected RNA-seq reads with results equal or superior to the clinical procedure: in the only discordant case, the clinical transcript was out-of-frame. Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL. ",Journal Article,1770.0,20.0,Immunoglobulins Ig are produced by B lymphocytes as secreted antibodies or as part of the B-cell receptor There is tremendous diversity of potential Ig transcripts 1 10 12 as a result of hundreds of germ-line gene segments random nucleotide incorporation during joining of gene segments into a complete transcript and the process of somatic hypermutation at individual nucleotides This recombination and mutation process takes place in the maturing B cell and is responsible for the diversity of potential epitope recognition Cancers arising from mature B cells are characterized by clonal production of Ig heavy IGH and light chain transcripts although whether the sequence has undergone somatic hypermutation is dependent on the maturation stage at which the neoplastic clone arose Chronic lymphocytic CLL is the most common in adults and arises from a mature B cell with either mutated or unmutated IGH transcripts the latter having worse prognosis and the assessment of which is routinely performed in the clinic Currently IGHV mutation status is assessed by Sanger sequencing and comparing the transcript to known germ-line genes In this paper we demonstrate that complete IGH V-D-J sequences can be computed from unselected RNA-seq reads with results equal or superior to the clinical procedure in the only discordant case the clinical transcript was out-of-frame Therefore a single RNA-seq assay can simultaneously yield gene expression profile SNP and mutation information as well as IGHV mutation status and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[13373, 4200, 32, 1687, 20, 132, 1594, 22, 3613, 890, 15, 22, 760, 1, 3, 132, 31, 153, 125, 16, 6678, 3653, 1, 174, 4200, 2680, 14, 79, 133, 22, 8, 757, 1, 9035, 1, 2280, 328, 145, 5138, 2324, 1579, 2838, 190, 10690, 1, 145, 5138, 237, 8, 236, 3268, 2, 3, 1129, 1, 1119, 13521, 28, 797, 11381, 26, 4017, 2, 258, 1129, 8512, 3536, 4, 3, 17724, 132, 31, 2, 16, 2327, 9, 3, 3653, 1, 174, 4430, 2335, 163, 2635, 29, 2908, 132, 37, 32, 765, 20, 1946, 1529, 1, 4200, 4013, 5221, 2, 1691, 1260, 2680, 242, 317, 3, 1532, 71, 1989, 1119, 13521, 16, 470, 23, 3, 4537, 82, 28, 92, 3, 2000, 3910, 7268, 442, 1193, 552, 16, 3, 96, 186, 4, 857, 2, 6053, 29, 8, 2908, 132, 31, 5, 361, 1185, 15, 7216, 5221, 2680, 3, 3286, 1041, 639, 356, 2, 3, 455, 1, 92, 16, 3066, 173, 4, 3, 1188, 694, 6220, 258, 156, 16, 275, 20, 7285, 615, 2, 1430, 3, 3268, 6, 440, 2280, 328, 214, 4, 26, 2817, 21, 608, 17, 236, 5221, 603, 427, 3543, 2866, 122, 40, 1220, 29, 3594, 893, 4185, 11062, 5, 99, 2997, 15, 1123, 6, 3, 38, 1299, 4, 3, 158, 4570, 473, 3, 38, 3268, 10, 1205, 1, 5331, 673, 8, 226, 893, 4185, 719, 122, 3074, 2309, 145, 55, 800, 1845, 2, 258, 487, 22, 149, 22, 6220, 258, 156, 2, 68, 104, 218, 40, 173, 22, 8, 1083, 412, 6, 2891, 7002, 505, 867, 74, 4, 552]",1619.0,25787252,48
Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma.,Annals of diagnostic pathology,Ann Diagn Pathol,2015-03-06,"Granulomatous interstitial nephritis (GIN) is an uncommon pathologic lesion encountered in 0.5% to 5.9% of renal biopsies. Drugs, sarcoidosis, and infections are responsible for most cases of GIN. Malignancy is not an established cause of GIN. Here, we report a series of 5 patients with GIN secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients were mostly elderly white males with an established history of CLL/SLL who presented with severe renal impairment (median peak serum creatinine, 7.3 mg/dL), leukocyturia, and mild proteinuria. One had nephromegaly. In 2 patients, the development and relapse of renal insufficiency closely paralleled the level of lymphocytosis. Kidney biopsy in all patients showed GIN concomitant with CLL/SLL leukemic interstitial infiltration. Granulomas were nonnecrotizing and epithelioid and were associated with giant cells. One biopsy showed granulomatous arteritis. One patient had a granulomatous reaction in lymph nodes and skin. Steroids with/without CLL/SLL-directed chemotherapy led to partial improvement of kidney function in all patients except 1 who had advanced cortical scarring on biopsy. In conclusion, we report an association between CLL/SLL and GIN. Patients typically present with severe renal failure due to both GIN and leukemic interstitial infiltration, which tends to respond to steroids with/without CLL/SLL-directed chemotherapy. The pathogenesis of GIN in this clinical setting is unknown but may represent a local hypersensitivity reaction to the CLL/SLL tumor cells. ",Case Reports,1782.0,4.0,Granulomatous interstitial nephritis GIN is an uncommon pathologic lesion encountered in 0.5 to 5.9 of biopsies Drugs sarcoidosis and infections are responsible for most cases of GIN Malignancy is not an established cause of GIN Here we report a series of 5 patients with GIN secondary to chronic lymphocytic leukemia/small lymphocytic CLL/SLL Patients were mostly elderly white males with an established history of CLL/SLL who presented with severe impairment median peak serum creatinine 7.3 mg/dL leukocyturia and mild proteinuria One had nephromegaly In 2 patients the development and relapse of insufficiency closely paralleled the level of lymphocytosis biopsy in all patients showed GIN concomitant with CLL/SLL leukemic interstitial infiltration Granulomas were nonnecrotizing and epithelioid and were associated with giant cells One biopsy showed granulomatous arteritis One patient had a granulomatous reaction in lymph nodes and Steroids with/without CLL/SLL-directed chemotherapy led to partial improvement of function in all patients except 1 who had advanced cortical scarring on biopsy In conclusion we report an association between CLL/SLL and GIN Patients typically present with severe failure due to both GIN and leukemic interstitial infiltration which tends to respond to steroids with/without CLL/SLL-directed chemotherapy The pathogenesis of GIN in this clinical setting is unknown but may represent a local hypersensitivity reaction to the CLL/SLL tumor cells,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[11186, 4543, 17277, 22883, 16, 35, 2052, 510, 1180, 3903, 4, 13, 33, 6, 33, 83, 1, 1154, 600, 17877, 2, 1875, 32, 2327, 9, 96, 140, 1, 22883, 710, 16, 44, 35, 635, 708, 1, 22883, 467, 21, 414, 8, 988, 1, 33, 7, 5, 22883, 568, 6, 442, 1193, 2647, 302, 1193, 552, 5302, 7, 11, 2754, 1216, 886, 2296, 5, 35, 635, 532, 1, 552, 5302, 54, 917, 5, 905, 2315, 52, 2944, 524, 3177, 67, 27, 81, 1826, 65795, 2, 1980, 5381, 104, 42, 65796, 4, 18, 7, 3, 193, 2, 429, 1, 4360, 3210, 10591, 3, 301, 1, 8125, 411, 4, 62, 7, 224, 22883, 1781, 5, 552, 5302, 2015, 4543, 2084, 22821, 11, 48919, 2, 3838, 2, 11, 41, 5, 6470, 37, 104, 411, 224, 11186, 48367, 104, 69, 42, 8, 11186, 1329, 4, 263, 502, 2, 4580, 5, 187, 552, 5302, 1166, 56, 836, 6, 450, 767, 1, 343, 4, 62, 7, 2187, 14, 54, 42, 131, 4500, 13542, 23, 411, 4, 1221, 21, 414, 35, 248, 59, 552, 5302, 2, 22883, 7, 1969, 364, 5, 905, 496, 520, 6, 110, 22883, 2, 2015, 4543, 2084, 92, 11488, 6, 1892, 6, 4580, 5, 187, 552, 5302, 1166, 56, 3, 1384, 1, 22883, 4, 26, 38, 546, 16, 860, 84, 68, 1231, 8, 293, 4034, 1329, 6, 3, 552, 5302, 30, 37]",1482.0,25795422,43
Secondary mutations as mediators of resistance to targeted therapy in leukemia.,Blood,Blood,2015-03-20,"The advent of small molecule-based targeted therapy has improved the treatment of both acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a common theme. The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain. FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid leukemia (AML). The occurrence of the ATP-binding site and activation loop mutations confers varying degrees of resistance to the individual FLT3 inhibitors. Second-generation FLT3 inhibitors such as crenolanib may overcome the resistance of these mutations. Furthermore, nonmutational mechanisms of resistance such as prosurvival pathways and bone marrow signaling may be upregulated in FLT3 inhibitor-resistant AML with secondary kinase domain mutations. More recently, point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute promyelocytic leukemia, and the BH3-mimetic ABT199 in lymphoma have been identified. In chronic myeloid leukemia, the emergence of tyrosine kinase domain mutations has historically been the dominant mechanism of resistance. The early identification of secondary point mutations and their downstream effects along with the development of second- or third-generation inhibitors and rationally designed small molecule combinations are potential strategies to overcome mutation-mediated resistance. ",Journal Article,1768.0,52.0,The advent of small molecule-based targeted therapy has improved the treatment of both acute and chronic leukemias Resistance to small molecule inhibitors has emerged as a common theme The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid AML The occurrence of the ATP-binding site and activation loop mutations confers varying degrees of resistance to the individual FLT3 inhibitors Second-generation FLT3 inhibitors such as crenolanib may overcome the resistance of these mutations Furthermore nonmutational mechanisms of resistance such as prosurvival pathways and marrow signaling may be upregulated in FLT3 inhibitor-resistant AML with secondary kinase domain mutations More recently point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic arsenic trioxide in acute promyelocytic and the BH3-mimetic ABT199 in have been identified In chronic myeloid the emergence of tyrosine kinase domain mutations has historically been the dominant mechanism of resistance The early identification of secondary point mutations and their downstream effects along with the development of second- or third-generation inhibitors and rationally designed small molecule combinations are potential strategies to overcome mutation-mediated resistance,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4114, 1, 302, 1354, 90, 238, 36, 71, 231, 3, 24, 1, 110, 286, 2, 442, 2792, 251, 6, 302, 1354, 222, 71, 2054, 22, 8, 186, 10293, 3, 96, 908, 4530, 1, 1294, 251, 16, 3, 3405, 1, 741, 138, 4, 3, 216, 1398, 1224, 222, 47, 231, 51, 151, 4, 1224, 1185, 286, 533, 329, 3, 2291, 1, 3, 3918, 791, 606, 2, 363, 4432, 138, 4020, 2990, 4133, 1, 251, 6, 3, 797, 1224, 222, 419, 914, 1224, 222, 225, 22, 15067, 68, 1768, 3, 251, 1, 46, 138, 798, 37067, 483, 1, 251, 225, 22, 7331, 460, 2, 581, 314, 68, 40, 2684, 4, 1224, 230, 436, 329, 5, 568, 216, 1398, 138, 80, 761, 741, 138, 7209, 251, 6, 3, 5796, 564, 216, 230, 1795, 4, 442, 1193, 3217, 4574, 4, 286, 4300, 2, 3, 5486, 7343, 65801, 4, 47, 85, 108, 4, 442, 533, 3, 3397, 1, 564, 216, 1398, 138, 71, 3578, 85, 3, 2156, 670, 1, 251, 3, 191, 911, 1, 568, 741, 138, 2, 136, 1489, 176, 1510, 5, 3, 193, 1, 419, 15, 1282, 914, 222, 2, 6352, 1114, 302, 1354, 1247, 32, 174, 422, 6, 1768, 258, 517, 251]",1414.0,25795921,202
Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-02-11,"Trisomy 12 (+12) is detected by fluorescence in-situ hybridization (FISH) analysis in up to 20% of patients with chronic lymphocytic leukemia (CLL). Patients with +12 are known to have unique features and to carry an intermediate prognosis. In order to better define this large group, we reviewed the characteristics of 250 untreated patients with +12. When compared to 516 untreated patients negative for +12 by FISH, patients with +12 showed a higher incidence of thrombocytopenia, Richter transformation, and second malignant neoplasms (SMN), in addition to the expected increased rate of CD38 positivity and atypical immunophenotype. At a median follow-up of 51 months, 57% of patients needed first-line treatment; median time to first treatment was 38 months, and on multivariate analysis (MVA), it was found to be shorter in patients with advanced Rai stage, palpable splenomegaly, and deletion of 14q by conventional cytogenetic analysis. The overall response rate with first-line treatment was 94%. The median failure-free survival has not been reached, but on MVA, it was found to be shorter in patients whose disease responded in a manner other than complete remission or with FISH negativity for deletion 13q. The median overall survival for the entire group has not been reached, but MVA revealed it to be shorter in patients with an absolute lymphocyte count of > 30  10(9)/L or who developed SMN. Eighteen deaths have been observed so far, and Richter transformation and SMN were the leading causes of death (3 and 6, respectively). Patients with +12 CLL show characteristic clinical and biologic features, and may benefit from increased surveillance for second cancers.",Journal Article,1805.0,23.0,Trisomy 12 +12 is detected by fluorescence in-situ hybridization FISH analysis in up to 20 of patients with chronic lymphocytic CLL Patients with +12 are known to have unique features and to carry an intermediate prognosis In order to better define this large group we reviewed the characteristics of 250 untreated patients with +12 When compared to 516 untreated patients negative for +12 by FISH patients with +12 showed a higher incidence of thrombocytopenia Richter transformation and second malignant neoplasms SMN in addition to the expected increased rate of CD38 positivity and atypical immunophenotype At a median follow-up of 51 months 57 of patients needed first-line treatment median time to first treatment was 38 months and on multivariate analysis MVA it was found to be shorter in patients with advanced Rai stage palpable splenomegaly and deletion of 14q by conventional cytogenetic analysis The overall response rate with first-line treatment was 94 The median failure-free survival has not been reached but on MVA it was found to be shorter in patients whose disease responded in a manner other than complete remission or with FISH negativity for deletion 13q The median overall survival for the entire group has not been reached but MVA revealed it to be shorter in patients with an absolute lymphocyte count of 30 10 9 /L or who developed SMN Eighteen deaths have been observed so far and Richter transformation and SMN were the leading causes of death 3 and 6 respectively Patients with +12 CLL show characteristic clinical and biologic features and may benefit from increased surveillance for second cancers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6317, 133, 133, 16, 530, 20, 1591, 4, 957, 1554, 1277, 65, 4, 126, 6, 179, 1, 7, 5, 442, 1193, 552, 7, 5, 133, 32, 440, 6, 47, 991, 404, 2, 6, 3542, 35, 919, 356, 4, 1732, 6, 380, 1107, 26, 375, 87, 21, 446, 3, 374, 1, 2039, 1278, 7, 5, 133, 198, 72, 6, 11780, 1278, 7, 199, 9, 133, 20, 1277, 7, 5, 133, 224, 8, 142, 287, 1, 1340, 8452, 1392, 2, 419, 393, 1179, 6474, 4, 352, 6, 3, 1336, 101, 116, 1, 4469, 1887, 2, 1973, 5496, 28, 8, 52, 166, 126, 1, 725, 53, 696, 1, 7, 575, 157, 328, 24, 52, 98, 6, 157, 24, 10, 519, 53, 2, 23, 331, 65, 5320, 192, 10, 204, 6, 40, 985, 4, 7, 5, 131, 4121, 82, 4880, 6364, 2, 1528, 1, 13756, 20, 809, 1266, 65, 3, 63, 51, 116, 5, 157, 328, 24, 10, 960, 3, 52, 496, 115, 25, 71, 44, 85, 1300, 84, 23, 5320, 192, 10, 204, 6, 40, 985, 4, 7, 1310, 34, 2211, 4, 8, 1708, 127, 76, 236, 734, 15, 5, 1277, 6014, 9, 1528, 8453, 3, 52, 63, 25, 9, 3, 1797, 87, 71, 44, 85, 1300, 84, 5320, 553, 192, 6, 40, 985, 4, 7, 5, 35, 1766, 1448, 1276, 1, 201, 79, 83, 805, 15, 54, 276, 6474, 3195, 1043, 47, 85, 164, 1743, 3272, 2, 8452, 1392, 2, 6474, 11, 3, 1049, 1626, 1, 273, 27, 2, 49, 106, 7, 5, 133, 552, 514, 2037, 38, 2, 1283, 404, 2, 68, 247, 29, 101, 617, 9, 419, 163]",1630.0,25800543,647
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.,Journal of oncology practice,J Oncol Pract,2015-03-24,"To evaluate the impact of approval of ibrutinib and idelalisib on pharmaceutical costs in the treatment of chronic lymphocytic leukemia (CLL) at the societal level and assess individual out-of-pocket costs under Medicare Part D. Average wholesale price of commonly used CLL treatment regimens was ascertained from national registries. Using the population of Olmsted County, Minnesota, we identified the proportion of patients with newly diagnosed CLL who experience progression to the point of requiring treatment. Using these data, total pharmaceutical cost over a 10-year period after diagnosis was estimated for a hypothetic cohort of 100 newly diagnosed patients under three scenarios: before approval of ibrutinib and idelalisib (historical scenario), after approval of ibrutinib and idelalisib as salvage therapy (current scenarios A and B), and assuming use of ibrutinib as first-line treatment (potential future scenario). Estimated 10-year pharmaceutical costs for 100 newly diagnosed patients were as follows: $4,565,929 (approximately $45,659 per newly diagnosed patient and $157,446 per treated patient) for the historical scenario, $7,794,843 (approximately $77,948 per newly diagnosed patient and $268,788 per treated patient) for current scenario A, $6,309,162 (approximately $63,092 per newly diagnosed patient and $217,557 per treated patient) for current scenario B, and $16,414,055 (approximately $164,141 per newly diagnosed patient and $566,002 per treated patient) for the potential future scenario. Total out-of-pocket cost for 100 patients with newly diagnosed CLL under Medicare Part D increased from $9,426 under the historical scenario (approximately $325 per treated patient) to $363,830 and $255,051 under current scenarios A and B (approximately $8,800 to $12,500 per treated patient) and to $1,031,367 (approximately $35,564 per treated patient) under the future scenario. Although ibrutinib and idelalisib are profound treatment advances, they will dramatically increase individual out-of-pocket and societal costs of caring for patients with CLL. These cost considerations may undermine the potential promise of these agents by limiting access and reducing adherence.",Journal Article,1764.0,50.0,"To evaluate the impact of approval of ibrutinib and idelalisib on pharmaceutical costs in the treatment of chronic lymphocytic CLL at the societal level and assess individual out-of-pocket costs under Medicare Part D. Average wholesale price of commonly used CLL treatment regimens was ascertained from national registries Using the population of Olmsted County Minnesota we identified the proportion of patients with newly diagnosed CLL who experience progression to the point of requiring treatment Using these data total pharmaceutical cost over a 10-year period after diagnosis was estimated for a hypothetic cohort of 100 newly diagnosed patients under three scenarios before approval of ibrutinib and idelalisib historical scenario after approval of ibrutinib and idelalisib as salvage therapy current scenarios A and B and assuming use of ibrutinib as first-line treatment potential future scenario Estimated 10-year pharmaceutical costs for 100 newly diagnosed patients were as follows 4,565,929 approximately 45,659 per newly diagnosed patient and 157,446 per treated patient for the historical scenario 7,794,843 approximately 77,948 per newly diagnosed patient and 268,788 per treated patient for current scenario A 6,309,162 approximately 63,092 per newly diagnosed patient and 217,557 per treated patient for current scenario B and 16,414,055 approximately 164,141 per newly diagnosed patient and 566,002 per treated patient for the potential future scenario Total out-of-pocket cost for 100 patients with newly diagnosed CLL under Medicare Part D increased from 9,426 under the historical scenario approximately 325 per treated patient to 363,830 and 255,051 under current scenarios A and B approximately 8,800 to 12,500 per treated patient and to 1,031,367 approximately 35,564 per treated patient under the future scenario Although ibrutinib and idelalisib are profound treatment advances they will dramatically increase individual out-of-pocket and societal costs of caring for patients with CLL These cost considerations may undermine the potential promise of these agents by limiting access and reducing adherence",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 376, 3, 345, 1, 1814, 1, 1795, 2, 7083, 23, 6278, 1201, 4, 3, 24, 1, 442, 1193, 552, 28, 3, 9378, 301, 2, 423, 797, 1205, 1, 6575, 1201, 669, 1378, 760, 427, 1011, 35988, 8816, 1, 841, 95, 552, 24, 472, 10, 5240, 29, 657, 3768, 75, 3, 266, 1, 12374, 5152, 8297, 21, 108, 3, 920, 1, 7, 5, 732, 265, 552, 54, 730, 91, 6, 3, 741, 1, 1888, 24, 75, 46, 74, 181, 6278, 835, 252, 8, 79, 111, 727, 50, 147, 10, 661, 9, 8, 39127, 180, 1, 394, 732, 265, 7, 669, 169, 3964, 348, 1814, 1, 1795, 2, 7083, 2252, 5456, 50, 1814, 1, 1795, 2, 7083, 22, 992, 36, 291, 3964, 8, 2, 132, 2, 7242, 119, 1, 1795, 22, 157, 328, 24, 174, 508, 5456, 661, 79, 111, 6278, 1201, 9, 394, 732, 265, 7, 11, 22, 2962, 39, 10852, 12825, 705, 512, 14568, 379, 732, 265, 69, 2, 5311, 9849, 379, 73, 69, 9, 3, 2252, 5456, 67, 13085, 11766, 705, 849, 19199, 379, 732, 265, 69, 2, 8410, 13907, 379, 73, 69, 9, 291, 5456, 8, 49, 9440, 5441, 705, 676, 14874, 379, 732, 265, 69, 2, 6499, 12495, 379, 73, 69, 9, 291, 5456, 132, 2, 245, 9469, 9186, 705, 5279, 4379, 379, 732, 265, 69, 2, 14539, 1111, 379, 73, 69, 9, 3, 174, 508, 5456, 181, 1205, 1, 6575, 835, 9, 394, 7, 5, 732, 265, 552, 669, 1378, 760, 427, 101, 29, 83, 12114, 669, 3, 2252, 5456, 705, 7139, 379, 73, 69, 6, 9517, 12400, 2, 7826, 9891, 669, 291, 3964, 8, 2, 132, 705, 66, 2796, 6, 133, 1666, 379, 73, 69, 2, 6, 14, 5304, 10720, 705, 465, 11090, 379, 73, 69, 669, 3, 508, 5456, 242, 1795, 2, 7083, 32, 4399, 24, 954, 491, 303, 2729, 344, 797, 1205, 1, 6575, 2, 9378, 1201, 1, 6571, 9, 7, 5, 552, 46, 835, 3891, 68, 26672, 3, 174, 1783, 1, 46, 183, 20, 817, 1655, 2, 1818, 2149]",2132.0,25804983,751
"Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-02-19,"Three agents have received Food and Drug Administration (FDA) approval for treatment of chronic lymphocytic leukemia (CLL) within the past year. Ibrutinib and idelalisib block B-cell receptor signaling through inhibition of Bruton tyrosine kinase and phosphatidylinositol 3-kinase  molecules respectively, interfering with several pathways required for leukemia cell survival. Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab. Ibrutinib has been studied in patients with relapsed CLL and as frontline therapy. In the relapsed setting, these agents produce durable remissions, and might be preferable to re-treatment with chemoimmunotherapy for many patients. Ibrutinib is also effective treatment for patients with deletion 17p and is approved by the FDA as frontline therapy in this patient group, although it does not appear to completely abrogate this adverse prognostic factor. These agents have a unique side effect profile and longer follow-up is required to further understand tolerability and rare adverse effects. Obinutuzumab is a type-2 monoclonal anti-CD20 antibody which results in direct and antibody-dependent cell-mediated cytotoxicity of leukemia cells. It is approved by the FDA for use in combination with chlorambucil, and has shown efficacy in the frontline setting in patients unfit for more intensive chemoimmunotherapy. It produces increased response rates and minimal residual disease negativity compared with chlorambucil/rituximab and is associated with an advantage in progression-free survival but not yet overall survival. These agents underscore our advancement in the understanding of the biology of CLL and will improve outcomes for many patients with CLL. ",Journal Article,1797.0,23.0,Three agents have received Food and Drug Administration FDA approval for treatment of chronic lymphocytic CLL within the past year Ibrutinib and idelalisib block B-cell receptor signaling through inhibition of Bruton tyrosine kinase and phosphatidylinositol 3-kinase  molecules respectively interfering with several pathways required for cell survival Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab Ibrutinib has been studied in patients with relapsed CLL and as frontline therapy In the relapsed setting these agents produce durable remissions and might be preferable to re-treatment with chemoimmunotherapy for many patients Ibrutinib is also effective treatment for patients with deletion 17p and is approved by the FDA as frontline therapy in this patient group although it does not appear to completely abrogate this adverse prognostic factor These agents have a unique side effect profile and longer follow-up is required to further understand tolerability and rare adverse effects Obinutuzumab is a type-2 monoclonal anti-CD20 antibody which results in direct and antibody-dependent cell-mediated cytotoxicity of cells It is approved by the FDA for use in combination with chlorambucil and has shown efficacy in the frontline setting in patients unfit for more intensive chemoimmunotherapy It produces increased response rates and minimal residual disease negativity compared with chlorambucil/rituximab and is associated with an advantage in progression-free survival but not yet overall survival These agents underscore our advancement in the understanding of the biology of CLL and will improve outcomes for many patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[169, 183, 47, 103, 1773, 2, 234, 634, 2078, 1814, 9, 24, 1, 442, 1193, 552, 262, 3, 1219, 111, 1795, 2, 7083, 2381, 132, 31, 153, 314, 298, 297, 1, 5796, 564, 216, 2, 3415, 27, 216, 7339, 1598, 106, 3449, 5, 392, 460, 616, 9, 31, 25, 7083, 71, 443, 209, 4, 3, 591, 546, 2, 16, 694, 850, 20, 3, 2078, 9, 119, 4, 150, 5, 855, 1795, 71, 85, 656, 4, 7, 5, 591, 552, 2, 22, 3171, 36, 4, 3, 591, 546, 46, 183, 2410, 1480, 3166, 2, 822, 40, 7474, 6, 1491, 24, 5, 4438, 9, 445, 7, 1795, 16, 120, 323, 24, 9, 7, 5, 1528, 4135, 2, 16, 850, 20, 3, 2078, 22, 3171, 36, 4, 26, 69, 87, 242, 192, 1097, 44, 1322, 6, 2500, 8581, 26, 290, 177, 161, 46, 183, 47, 8, 991, 1152, 254, 800, 2, 589, 166, 126, 16, 616, 6, 195, 1640, 1543, 2, 622, 290, 176, 10380, 16, 8, 267, 18, 848, 312, 2198, 548, 92, 99, 4, 1196, 2, 548, 470, 31, 517, 1408, 1, 37, 192, 16, 850, 20, 3, 2078, 9, 119, 4, 150, 5, 11585, 2, 71, 443, 209, 4, 3, 3171, 546, 4, 7, 9681, 9, 80, 1686, 4438, 192, 4042, 101, 51, 151, 2, 1048, 753, 34, 6014, 72, 5, 11585, 855, 2, 16, 41, 5, 35, 1874, 4, 91, 115, 25, 84, 44, 1145, 63, 25, 46, 183, 5531, 114, 7496, 4, 3, 612, 1, 3, 891, 1, 552, 2, 303, 401, 123, 9, 445, 7, 5, 552]",1723.0,25817936,444
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-03-31,"Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase domain. Though ibrutinib results in impressive clinical activity in chronic lymphocytic leukemia (CLL), most patients achieve only partial remission due to residual disease. We performed a pharmacologic profiling of residual circulating CLL cells from patients receiving ibrutinib to identify optimal agents that could induce cell death of these lymphocytes. Ex vivo serial samples of CLL cells from patients on ibrutinib were obtained prior and after (weeks 2, 4, and 12) the start of treatment. These cells were incubated with PI3K inhibitors (idelalisib or IPI-145), bendamustine, additional ibrutinib, or BCL-2 antagonists (ABT-737 or ABT-199), and cell death was measured. In vitro investigations complemented ex vivo studies. Immunoblots for BTK signaling pathway and antiapoptotic proteins were performed. The BCL-2 antagonists, especially ABT-199, induced high cell death during ex vivo incubations. In concert with the ex vivo data, in vitro combinations also resulted in high cytotoxicity. Serial samples of CLL cells obtained before and 2, 4, 12, or 36 weeks after the start of ibrutinib showed inhibition of BTK activity and sensitivity to ABTs. Among the three BCL-2 family antiapoptotic proteins that are overexpressed in CLL, levels of MCL-1 and BCL-XL were decreased after ibrutinib while ABT-199 selectively antagonizes BCL-2. Our biologic and molecular results suggest that ibrutinib and ABT-199 combination should be tested clinically against CLL.",Journal Article,1757.0,106.0,Bruton 's tyrosine kinase BTK is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase domain Though ibrutinib results in impressive clinical activity in chronic lymphocytic CLL most patients achieve only partial remission due to residual disease We performed a pharmacologic profiling of residual circulating CLL cells from patients receiving ibrutinib to identify optimal agents that could induce cell death of these lymphocytes Ex vivo serial samples of CLL cells from patients on ibrutinib were obtained prior and after weeks 2 4 and 12 the start of treatment These cells were incubated with PI3K inhibitors idelalisib or IPI-145 bendamustine additional ibrutinib or BCL-2 antagonists ABT-737 or ABT-199 and cell death was measured In vitro investigations complemented ex vivo studies Immunoblots for BTK signaling pathway and antiapoptotic proteins were performed The BCL-2 antagonists especially ABT-199 induced high cell death during ex vivo incubations In concert with the ex vivo data in vitro combinations also resulted in high cytotoxicity Serial samples of CLL cells obtained before and 2 4 12 or 36 weeks after the start of ibrutinib showed inhibition of BTK activity and sensitivity to ABTs Among the three BCL-2 family antiapoptotic proteins that are overexpressed in CLL levels of MCL-1 and BCL-XL were decreased after ibrutinib while ABT-199 selectively antagonizes BCL-2 Our biologic and molecular results suggest that ibrutinib and ABT-199 combination should be tested clinically against CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5796, 292, 564, 216, 3611, 16, 8, 740, 1644, 4, 3, 132, 31, 153, 308, 2, 16, 879, 20, 1795, 520, 6, 10747, 791, 6, 3, 216, 1398, 2471, 1795, 99, 4, 5790, 38, 128, 4, 442, 1193, 552, 96, 7, 1359, 158, 450, 734, 520, 6, 753, 34, 21, 173, 8, 2788, 1080, 1, 753, 1033, 552, 37, 29, 7, 357, 1795, 6, 255, 665, 183, 17, 359, 1290, 31, 273, 1, 46, 1594, 2581, 386, 2108, 347, 1, 552, 37, 29, 7, 23, 1795, 11, 683, 324, 2, 50, 244, 18, 39, 2, 133, 3, 2435, 1, 24, 46, 37, 11, 8303, 5, 974, 222, 7083, 15, 3753, 4058, 4809, 402, 1795, 15, 1044, 18, 4444, 3095, 4933, 15, 3095, 5840, 2, 31, 273, 10, 644, 4, 439, 2492, 13275, 2581, 386, 94, 13867, 9, 3611, 314, 308, 2, 4176, 652, 11, 173, 3, 1044, 18, 4444, 1093, 3095, 5840, 277, 64, 31, 273, 190, 2581, 386, 30844, 4, 10562, 5, 3, 2581, 386, 74, 4, 439, 1247, 120, 627, 4, 64, 1408, 2108, 347, 1, 552, 37, 683, 348, 2, 18, 39, 133, 15, 511, 244, 50, 3, 2435, 1, 1795, 224, 297, 1, 3611, 128, 2, 485, 6, 65875, 107, 3, 169, 1044, 18, 607, 4176, 652, 17, 32, 1711, 4, 552, 148, 1, 1308, 14, 2, 1044, 3870, 11, 340, 50, 1795, 369, 3095, 5840, 2382, 11574, 1044, 18, 114, 1283, 2, 219, 99, 309, 17, 1795, 2, 3095, 5840, 150, 257, 40, 650, 505, 480, 552]",1573.0,25829398,665
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.,Blood,Blood,2015-04-01,"Multiple studies show that chronic lymphocytic leukemia (CLL) cells are heavily dependent on their microenvironment for survival. Communication between CLL cells and the microenvironment is mediated through direct cell contact, soluble factors, and extracellular vesicles. Exosomes are small particles enclosed with lipids, proteins, and small RNAs that can convey biological materials to surrounding cells. Our data herein demonstrate that CLL cells release significant amounts of exosomes in plasma that exhibit abundant CD37, CD9, and CD63 expression. Our work also pinpoints the regulation of B-cell receptor (BCR) signaling in the release of CLL exosomes: BCR activation by -immunoglobulin (Ig)M induces exosome secretion, whereas BCR inactivation via ibrutinib impedes -IgM-stimulated exosome release. Moreover, analysis of serial plasma samples collected from CLL patients on an ibrutinib clinical trial revealed that exosome plasma concentration was significantly decreased following ibrutinib therapy. Furthermore, microRNA (miR) profiling of plasma-derived exosomes identified a distinct exosome microRNA signature, including miR-29 family, miR-150, miR-155, and miR-223 that have been associated with CLL disease. Interestingly, expression of exosome miR-150 and miR-155 increases with BCR activation. In all, this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile. ",Journal Article,1756.0,60.0,Multiple studies show that chronic lymphocytic CLL cells are heavily dependent on their microenvironment for survival Communication between CLL cells and the microenvironment is mediated through direct cell contact soluble factors and extracellular vesicles Exosomes are small particles enclosed with lipids proteins and small RNAs that can convey biological materials to surrounding cells Our data herein demonstrate that CLL cells release significant amounts of exosomes in plasma that exhibit abundant CD37 CD9 and CD63 expression Our work also pinpoints the regulation of B-cell receptor BCR signaling in the release of CLL exosomes BCR activation by -immunoglobulin Ig M induces exosome secretion whereas BCR inactivation via ibrutinib impedes -IgM-stimulated exosome release Moreover analysis of serial plasma samples collected from CLL patients on an ibrutinib clinical trial revealed that exosome plasma concentration was significantly decreased following ibrutinib therapy Furthermore microRNA miR profiling of plasma-derived exosomes identified a distinct exosome microRNA signature including miR-29 family miR-150 miR-155 and miR-223 that have been associated with CLL disease Interestingly expression of exosome miR-150 and miR-155 increases with BCR activation In all this study successfully characterized CLL exosomes demonstrated the control of BCR signaling in the release of CLL exosomes and uncovered a disease-relevant exosome microRNA profile,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[232, 94, 514, 17, 442, 1193, 552, 37, 32, 2447, 470, 23, 136, 995, 9, 25, 2063, 59, 552, 37, 2, 3, 995, 16, 517, 298, 1196, 31, 4393, 2968, 130, 2, 1976, 7634, 5290, 32, 302, 6095, 23628, 5, 9176, 652, 2, 302, 4550, 17, 122, 11415, 1037, 5102, 6, 2976, 37, 114, 74, 1986, 608, 17, 552, 37, 2008, 93, 4939, 1, 5290, 4, 554, 17, 2239, 4834, 10006, 18004, 2, 27125, 55, 114, 1357, 120, 46667, 3, 863, 1, 132, 31, 153, 1062, 314, 4, 3, 2008, 1, 552, 5290, 1062, 363, 20, 2014, 2593, 4200, 188, 1516, 11771, 2935, 547, 1062, 2297, 847, 1795, 20745, 2014, 2852, 2816, 11771, 2008, 1393, 65, 1, 2108, 554, 347, 786, 29, 552, 7, 23, 35, 1795, 38, 160, 553, 17, 11771, 554, 1227, 10, 97, 340, 366, 1795, 36, 798, 3213, 722, 1080, 1, 554, 526, 5290, 108, 8, 834, 11771, 3213, 1651, 141, 722, 462, 607, 722, 1577, 722, 3735, 2, 722, 3907, 17, 47, 85, 41, 5, 552, 34, 2873, 55, 1, 11771, 722, 1577, 2, 722, 3735, 1106, 5, 1062, 363, 4, 62, 26, 45, 1878, 765, 552, 5290, 264, 3, 182, 1, 1062, 314, 4, 3, 2008, 1, 552, 5290, 2, 5601, 8, 34, 867, 11771, 3213, 800]",1464.0,25833959,388
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.,Blood,Blood,2015-04-02,"Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and acquired resistance to Bruton agammaglobulinemia tyrosine kinase (BTK) inhibition is being observed in an increasing number of patients. Combination regimens that increase frequency of complete remissions, accelerate time to remission, and overcome single agent resistance are of considerable interest. We previously showed that the XPO1 inhibitor selinexor is proapoptotic in CLL cells and disrupts B-cell receptor signaling via BTK depletion. Herein we show the combination of selinexor and ibrutinib elicits a synergistic cytotoxic effect in primary CLL cells and increases overall survival compared with ibrutinib alone in a mouse model of CLL. Selinexor is effective in cells isolated from patients with prolonged lymphocytosis following ibrutinib therapy. Finally, selinexor is effective in ibrutinib-refractory mice and in a cell line harboring the BTK C481S mutation. This is the first report describing the combined activity of ibrutinib and selinexor in CLL, which represents a new treatment paradigm and warrants further evaluation in clinical trials of CLL patients including those with acquired ibrutinib resistance. ",Journal Article,1755.0,46.0,Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic CLL complete responses are infrequent and acquired resistance to Bruton agammaglobulinemia tyrosine kinase BTK inhibition is being observed in an increasing number of patients Combination regimens that increase frequency of complete remissions accelerate time to remission and overcome single agent resistance are of considerable interest We previously showed that the XPO1 inhibitor selinexor is proapoptotic in CLL cells and disrupts B-cell receptor signaling via BTK depletion Herein we show the combination of selinexor and ibrutinib elicits a synergistic cytotoxic effect in primary CLL cells and increases overall survival compared with ibrutinib alone in a mouse model of CLL Selinexor is effective in cells isolated from patients with prolonged lymphocytosis following ibrutinib therapy Finally selinexor is effective in ibrutinib-refractory mice and in a cell line harboring the BTK C481S mutation This is the first report describing the combined activity of ibrutinib and selinexor in CLL which represents a new treatment paradigm and warrants further evaluation in clinical trials of CLL patients including those with acquired ibrutinib resistance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[550, 3, 189, 209, 1, 1795, 4, 442, 1193, 552, 236, 253, 32, 4475, 2, 1294, 251, 6, 5796, 41043, 564, 216, 3611, 297, 16, 486, 164, 4, 35, 602, 207, 1, 7, 150, 472, 17, 344, 675, 1, 236, 3166, 5792, 98, 6, 734, 2, 1768, 226, 420, 251, 32, 1, 2658, 1333, 21, 373, 224, 17, 3, 9933, 230, 7233, 16, 4118, 4, 552, 37, 2, 7754, 132, 31, 153, 314, 847, 3611, 2286, 1986, 21, 514, 3, 150, 1, 7233, 2, 1795, 8748, 8, 1806, 759, 254, 4, 86, 552, 37, 2, 1106, 63, 25, 72, 5, 1795, 279, 4, 8, 830, 202, 1, 552, 7233, 16, 323, 4, 37, 1355, 29, 7, 5, 1069, 8125, 366, 1795, 36, 1368, 7233, 16, 323, 4, 1795, 430, 399, 2, 4, 8, 31, 328, 2105, 3, 3611, 17045, 258, 26, 16, 3, 157, 414, 4950, 3, 397, 128, 1, 1795, 2, 7233, 4, 552, 92, 1449, 8, 217, 24, 2431, 2, 2782, 195, 451, 4, 38, 143, 1, 552, 7, 141, 135, 5, 1294, 1795, 251]",1227.0,25838351,49
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.,The Journal of biological chemistry,J. Biol. Chem.,2015-04-06,"Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Unlike GLUT1 that is highly expressed in cancer and more ubiquitously expressed in normal tissues, GLUT4 exhibits more limited normal expression profiles. We have previously determined that insulin-responsive GLUT4 is constitutively localized on the plasma membrane of myeloma cells. Consequently, suppression of GLUT4 or inhibition of glucose transport with the HIV protease inhibitor ritonavir elicited growth arrest and/or apoptosis in multiple myeloma. GLUT4 inhibition also caused sensitization to metformin in multiple myeloma and chronic lymphocytic leukemia and a number of solid tumors suggesting the broader therapeutic utility of targeting GLUT4. This study sought to identify selective inhibitors of GLUT4 to develop a more potent cancer chemotherapeutic with fewer potential off-target effects. Recently, the crystal structure of GLUT1 in an inward open conformation was reported. Although this is an important achievement, a full understanding of the structural biology of facilitative glucose transport remains elusive. To date, there is no three-dimensional structure for GLUT4. We have generated a homology model for GLUT4 that we utilized to screen for drug-like compounds from a library of 18 million compounds. Despite 68% homology between GLUT1 and GLUT4, our virtual screen identified two potent compounds that were shown to target GLUT4 preferentially over GLUT1 and block glucose transport. Our results strongly bolster the utility of developing GLUT4-selective inhibitors as anti-cancer therapeutics. ",Journal Article,1751.0,29.0,Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints Unlike GLUT1 that is highly expressed in cancer and more ubiquitously expressed in normal tissues GLUT4 exhibits more limited normal expression profiles We have previously determined that insulin-responsive GLUT4 is constitutively localized on the plasma membrane of cells Consequently suppression of GLUT4 or inhibition of glucose transport with the HIV protease inhibitor ritonavir elicited growth arrest and/or apoptosis in multiple GLUT4 inhibition also caused sensitization to metformin in multiple and chronic lymphocytic and a number of solid tumors suggesting the broader therapeutic utility of targeting GLUT4 This study sought to identify selective inhibitors of GLUT4 to develop a more potent cancer chemotherapeutic with fewer potential off-target effects Recently the crystal structure of GLUT1 in an inward open conformation was reported Although this is an important achievement a full understanding of the structural biology of facilitative glucose transport remains elusive To date there is no three-dimensional structure for GLUT4 We have generated a homology model for GLUT4 that we utilized to screen for drug-like compounds from a library of 18 million compounds Despite 68 homology between GLUT1 and GLUT4 our virtual screen identified two potent compounds that were shown to target GLUT4 preferentially over GLUT1 and block glucose transport Our results strongly bolster the utility of developing GLUT4-selective inhibitors as anti-cancer therapeutics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[30, 37, 5533, 23, 804, 2522, 2421, 2, 1600, 9, 25, 2, 457, 2522, 6733, 3941, 2522, 3001, 32, 825, 2805, 116, 817, 4704, 4246, 16887, 17, 16, 561, 570, 4, 12, 2, 80, 11156, 570, 4, 295, 742, 14609, 4273, 80, 383, 295, 55, 1241, 21, 47, 373, 509, 17, 1601, 2443, 14609, 16, 2818, 909, 23, 3, 554, 1905, 1, 37, 3244, 1332, 1, 14609, 15, 297, 1, 2522, 4294, 5, 3, 1942, 5125, 230, 13715, 5179, 129, 1854, 2, 15, 351, 4, 232, 14609, 297, 120, 1546, 6272, 6, 2791, 4, 232, 2, 442, 1193, 2, 8, 207, 1, 537, 57, 802, 3, 5410, 189, 1207, 1, 529, 14609, 26, 45, 990, 6, 255, 1094, 222, 1, 14609, 6, 690, 8, 80, 1157, 12, 1573, 5, 1497, 174, 1889, 283, 176, 761, 3, 9197, 2772, 1, 16887, 4, 35, 35996, 1020, 7788, 10, 210, 242, 26, 16, 35, 305, 5088, 8, 1647, 612, 1, 3, 3281, 891, 1, 32418, 2522, 4294, 469, 5327, 6, 1244, 125, 16, 77, 169, 2201, 2772, 9, 14609, 21, 47, 1419, 8, 7984, 202, 9, 14609, 17, 21, 2080, 6, 2413, 9, 234, 733, 2411, 29, 8, 4157, 1, 203, 3346, 2411, 550, 806, 7984, 59, 16887, 2, 14609, 114, 8455, 2413, 108, 100, 1157, 2411, 17, 11, 443, 6, 283, 14609, 3509, 252, 16887, 2, 2381, 2522, 4294, 114, 99, 1327, 23533, 3, 1207, 1, 931, 14609, 1094, 222, 22, 312, 12, 1943]",1657.0,25847249,119
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-04-06,"Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT). Our purpose was to determine the outcomes of patients whose disease progressed after allogeneic SCT. We retrospectively analyzed the outcomes of 72 patients (52 with CLL and 20 with RT) who underwent allogeneic SCT between 1998 and 2011 and had documented progression after transplantation. Twenty-two (31%) never had a response, and 50 (69%) had a response but experienced relapse after a median of 7 months (range, 2 to 85 months). Forty-eight patients who were receiving or were candidates to receive post-SCT cell-based therapies were not included in this analysis. The median age at time of transplantation was 58 years (range, 30 to 72 years). Sixty-two patients (86%) received more than two treatment regimens and 37 (51%) received more than three treatment regimens before SCT. Sixty-six patients (92%) had active disease at the time of transplantation. The 2- and 5-year survival rates were 67% and 38% (patients with CLL) and 36% and 0% (patients with RT). The patients who developed acute or chronic graft-versus-host disease had a longer overall survival (OS; P = .05). In a multivariable analysis, RT or low hemoglobin at the time of SCT predicted shorter OS. Chronic graft-versus-host disease and an initial response to SCT predicted longer OS. Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.",Journal Article,1751.0,23.0,Allogeneic stem-cell transplantation SCT induces long-term remission in a fraction of patients with high-risk chronic lymphocytic CLL or Richter 's transformation RT Our purpose was to determine the outcomes of patients whose disease progressed after allogeneic SCT We retrospectively analyzed the outcomes of 72 patients 52 with CLL and 20 with RT who underwent allogeneic SCT between 1998 and 2011 and had documented progression after transplantation Twenty-two 31 never had a response and 50 69 had a response but experienced relapse after a median of 7 months range 2 to 85 months Forty-eight patients who were receiving or were candidates to receive post-SCT cell-based therapies were not included in this analysis The median age at time of transplantation was 58 years range 30 to 72 years Sixty-two patients 86 received more than two treatment regimens and 37 51 received more than three treatment regimens before SCT Sixty-six patients 92 had active disease at the time of transplantation The 2- and 5-year survival rates were 67 and 38 patients with CLL and 36 and 0 patients with RT The patients who developed acute or chronic graft-versus-host disease had a longer overall survival OS P .05 In a multivariable analysis RT or low hemoglobin at the time of SCT predicted shorter OS Chronic graft-versus-host disease and an initial response to SCT predicted longer OS Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies and their prognosis is relatively good,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1063, 452, 31, 497, 1988, 1516, 319, 337, 734, 4, 8, 1509, 1, 7, 5, 64, 43, 442, 1193, 552, 15, 8452, 292, 1392, 240, 114, 743, 10, 6, 223, 3, 123, 1, 7, 1310, 34, 1839, 50, 1063, 1988, 21, 894, 311, 3, 123, 1, 720, 7, 653, 5, 552, 2, 179, 5, 240, 54, 208, 1063, 1988, 59, 1850, 2, 1132, 2, 42, 1405, 91, 50, 497, 737, 100, 456, 1737, 42, 8, 51, 2, 212, 790, 42, 8, 51, 84, 592, 429, 50, 8, 52, 1, 67, 53, 184, 18, 6, 772, 53, 1213, 659, 7, 54, 11, 357, 15, 11, 1931, 6, 560, 539, 1988, 31, 90, 235, 11, 44, 159, 4, 26, 65, 3, 52, 89, 28, 98, 1, 497, 10, 717, 60, 184, 201, 6, 720, 60, 1746, 100, 7, 868, 103, 80, 76, 100, 24, 472, 2, 567, 725, 103, 80, 76, 169, 24, 472, 348, 1988, 1746, 437, 7, 937, 42, 544, 34, 28, 3, 98, 1, 497, 3, 18, 2, 33, 111, 25, 151, 11, 598, 2, 519, 7, 5, 552, 2, 511, 2, 13, 7, 5, 240, 3, 7, 54, 276, 286, 15, 442, 1599, 185, 1204, 34, 42, 8, 589, 63, 25, 118, 19, 474, 4, 8, 658, 65, 240, 15, 154, 2222, 28, 3, 98, 1, 1988, 783, 985, 118, 442, 1599, 185, 1204, 34, 2, 35, 388, 51, 6, 1988, 783, 589, 118, 7, 5, 552, 4, 953, 1063, 1988, 7688, 68, 47, 8, 51, 6, 2, 247, 29, 992, 235, 2, 136, 356, 16, 1352, 1178]",1519.0,25847930,546
"Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.","Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2015-04-01,"Globally, the incidence of non-Hodgkin lymphoma is increasing. Aggressive non-Hodgkin lymphomas like diffuse large B-cell lymphoma are treated with curative intent in the frontline setting, but indolent diseases like chronic lymphocytic leukemia/small lymphocytic lymphoma are not considered to be curable in general. Additionally, relapsed/refractory non-Hodgkin lymphomas have a poor overall outcome, with treatment response durations often decreasing with each relapse. Novel therapies are sought to improve outcomes in this patient population. In a two-part review, we describe the promising new biologic therapies that have emerged over the last 5 years, some approved by the US Food and Drug Administration and others undergoing active investigation. In Part 1, we discussed monoclonal antibodies. Here, in Part 2, we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon. ",Journal Article,1756.0,2.0,Globally the incidence of is increasing Aggressive lymphomas like diffuse large B-cell are treated with curative intent in the frontline setting but indolent diseases like chronic lymphocytic leukemia/small lymphocytic are not considered to be curable in general Additionally relapsed/refractory lymphomas have a poor overall outcome with treatment response durations often decreasing with each relapse Novel therapies are sought to improve outcomes in this patient population In a two-part review we describe the promising new biologic therapies that have emerged over the last 5 years some approved by the US Food and Drug Administration and others undergoing active investigation In Part 1 we discussed monoclonal antibodies Here in Part 2 we discuss adoptive cellular immunotherapies small-molecule inhibitors and immunomodulatory agents We also mention other novel therapies on the horizon,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6873, 3, 287, 1, 16, 602, 571, 1557, 733, 1388, 375, 132, 31, 32, 73, 5, 1075, 1697, 4, 3, 3171, 546, 84, 2316, 1342, 733, 442, 1193, 2647, 302, 1193, 32, 44, 515, 6, 40, 4151, 4, 1083, 1724, 591, 430, 1557, 47, 8, 334, 63, 228, 5, 24, 51, 4864, 629, 2777, 5, 296, 429, 229, 235, 32, 990, 6, 401, 123, 4, 26, 69, 266, 4, 8, 100, 760, 206, 21, 897, 3, 721, 217, 1283, 235, 17, 47, 2054, 252, 3, 1060, 33, 60, 476, 850, 20, 3, 843, 1773, 2, 234, 634, 2, 1749, 479, 544, 940, 4, 760, 14, 21, 1588, 848, 890, 467, 4, 760, 18, 21, 1139, 3159, 763, 2811, 302, 1354, 222, 2, 2555, 183, 21, 120, 23337, 127, 229, 235, 23, 3, 8704]",894.0,25920929,88
"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.",Cancer,Cancer,2015-04-30,"Although hypogammaglobulinemia is a well recognized complication in patients with chronic lymphocytic leukemia (CLL), its prevalence at the time of CLL diagnosis, and association with novel prognostic markers and clinical outcome is not well understood. All patients at the Mayo Clinic between January 1999 and July 2013 who had newly diagnosed CLL and had a baseline assessment of serum immunoglobulin G (IgG) were included. The relation between hypogammaglobulinemia at diagnosis and the novel prognostic parameters time to first treatment (TFT) and overall survival (OS) were evaluated. Of 1485 patients who met the eligibility criteria, 382 (26%) had hypogammaglobulinemia (median IgG, 624 mg/dL), whereas the remaining 1103 patients (74%) had normal serum IgG levels (median IgG, 1040 mg/dL). Patients who had hypogammaglobulinemia at diagnosis were more likely to have advanced Rai stage (III-IV; P=.001) and higher expression of CD49d (P<.001) compared with patients who had normal IgG levels. Although the median TFT for patients who had hypogammaglobulinemia was shorter compared with that for patients who had normal IgG levels (3.8 years vs 7.4 years; P<.001), on multivariable analysis, there was no difference in OS between these 2 groups (12.8 years vs 11.3 years, respectively; P=.73). Of 1103 patients who had CLL with normal IgG levels at diagnosis and who did not receive CLL therapy, the risk of acquired hypogammaglobulinemia was 11% at 5 years and 23% at 10 years. Hypogammaglobulinemia is present in 25% of patients with newly diagnosed CLL. Approximately 25% of patients who have CLL with normal IgG levels at diagnosis will subsequently develop hypogammaglobulinemia on long-term follow-up. The presence of hypogammaglobulinemia does not appear to impact overall survival.",Journal Article,1727.0,25.0,Although hypogammaglobulinemia is a well recognized complication in patients with chronic lymphocytic CLL its prevalence at the time of CLL diagnosis and association with novel prognostic markers and clinical outcome is not well understood All patients at the Mayo Clinic between January 1999 and July 2013 who had newly diagnosed CLL and had a baseline assessment of serum immunoglobulin G IgG were included The relation between hypogammaglobulinemia at diagnosis and the novel prognostic parameters time to first treatment TFT and overall survival OS were evaluated Of 1485 patients who met the eligibility criteria 382 26 had hypogammaglobulinemia median IgG 624 mg/dL whereas the remaining 1103 patients 74 had normal serum IgG levels median IgG 1040 mg/dL Patients who had hypogammaglobulinemia at diagnosis were more likely to have advanced Rai stage III-IV P .001 and higher expression of CD49d P .001 compared with patients who had normal IgG levels Although the median TFT for patients who had hypogammaglobulinemia was shorter compared with that for patients who had normal IgG levels 3.8 years vs 7.4 years P .001 on multivariable analysis there was no difference in OS between these 2 groups 12.8 years vs 11.3 years respectively P .73 Of 1103 patients who had CLL with normal IgG levels at diagnosis and who did not receive CLL therapy the risk of acquired hypogammaglobulinemia was 11 at 5 years and 23 at 10 years Hypogammaglobulinemia is present in 25 of patients with newly diagnosed CLL Approximately 25 of patients who have CLL with normal IgG levels at diagnosis will subsequently develop hypogammaglobulinemia on long-term follow-up The presence of hypogammaglobulinemia does not appear to impact overall survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 13242, 16, 8, 149, 1904, 1447, 4, 7, 5, 442, 1193, 552, 211, 1078, 28, 3, 98, 1, 552, 147, 2, 248, 5, 229, 177, 525, 2, 38, 228, 16, 44, 149, 1784, 62, 7, 28, 3, 2486, 1188, 59, 1024, 2043, 2, 2066, 1346, 54, 42, 732, 265, 552, 2, 42, 8, 330, 455, 1, 524, 2593, 499, 3630, 11, 159, 3, 2191, 59, 13242, 28, 147, 2, 3, 229, 177, 1038, 98, 6, 157, 24, 32430, 2, 63, 25, 118, 11, 194, 1, 66061, 7, 54, 543, 3, 2317, 371, 9625, 432, 42, 13242, 52, 3630, 10999, 81, 1826, 547, 3, 1844, 32431, 7, 794, 42, 295, 524, 3630, 148, 52, 3630, 12812, 81, 1826, 7, 54, 42, 13242, 28, 147, 11, 80, 322, 6, 47, 131, 4121, 82, 316, 478, 19, 144, 2, 142, 55, 1, 10485, 19, 144, 72, 5, 7, 54, 42, 295, 3630, 148, 242, 3, 52, 32430, 9, 7, 54, 42, 13242, 10, 985, 72, 5, 17, 9, 7, 54, 42, 295, 3630, 148, 27, 66, 60, 105, 67, 39, 60, 19, 144, 23, 658, 65, 125, 10, 77, 523, 4, 118, 59, 46, 18, 271, 133, 66, 60, 105, 175, 27, 60, 106, 19, 803, 1, 32431, 7, 54, 42, 552, 5, 295, 3630, 148, 28, 147, 2, 54, 205, 44, 560, 552, 36, 3, 43, 1, 1294, 13242, 10, 175, 28, 33, 60, 2, 382, 28, 79, 60, 13242, 16, 364, 4, 243, 1, 7, 5, 732, 265, 552, 705, 243, 1, 7, 54, 47, 552, 5, 295, 3630, 148, 28, 147, 303, 1611, 690, 13242, 23, 319, 337, 166, 126, 3, 463, 1, 13242, 1097, 44, 1322, 6, 345, 63, 25]",1734.0,25931291,663
"Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2015-05-11,"Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported. Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988-2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800890, rs1800896), TNF (rs1800629), LTA (rs909253), and CARD15 (rs2066847) were investigated using unconditional logistic regression. BMI-polymorphism interaction effects were estimated using the relative excess risk due to interaction (RERI). Obesity (BMI  30 kg/m(2)) was associated with DLBCL risk [OR = 1.33; 95% confidence interval (CI), 1.02-1.73], as was TNF-308GA+AA (OR = 1.24; 95% CI, 1.07-1.44). Together, being obese and TNF-308GA+AA increased DLBCL risk almost 2-fold relative to those of normal weight and TNF-308GG (OR = 1.93; 95% CI, 1.27-2.94), with a RERI of 0.41 (95% CI, -0.05-0.84; Pinteraction = 0.13). For FL and CLL/SLL, no associations with obesity or TNF-308GA+AA, either singly or jointly, were observed. No evidence of interactions between obesity and the other polymorphisms were detected. Our results suggest that cytokine polymorphisms do not generally interact with BMI to increase lymphoma risk but obesity and TNF-308GA+AA may interact to increase DLBCL risk. Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma.",Journal Article,1716.0,2.0,"Excess adiposity has been associated with lymphomagenesis possibly mediated by increased cytokine production causing a chronic inflammatory state The relationship between obesity cytokine polymorphisms and selected mature B-cell neoplasms is reported Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium 1988-2008 were pooled For diffuse large B-cell DLBCL follicular FL and chronic lymphocytic leukemia/small lymphocytic CLL/SLL joint associations of body mass index from self-reported height and weight and 12 polymorphisms in cytokines IL1A rs1800587 IL1B rs16944 rs1143627 IL1RN rs454078 IL2 rs2069762 IL6 rs1800795 rs1800797 IL10 rs1800890 rs1800896 TNF rs1800629 LTA rs909253 and CARD15 rs2066847 were investigated using unconditional logistic regression BMI-polymorphism interaction effects were estimated using the relative excess risk due to interaction RERI Obesity BMI  30 kg/m 2 was associated with DLBCL risk OR 1.33 95 confidence interval CI 1.02-1.73 as was TNF-308GA+AA OR 1.24 95 CI 1.07-1.44 Together being obese and TNF-308GA+AA increased DLBCL risk almost 2-fold relative to those of normal weight and TNF-308GG OR 1.93 95 CI 1.27-2.94 with a RERI of 0.41 95 CI -0.05-0.84 Pinteraction 0.13 For FL and CLL/SLL no associations with obesity or TNF-308GA+AA either singly or jointly were observed No evidence of interactions between obesity and the other polymorphisms were detected Our results suggest that cytokine polymorphisms do not generally interact with BMI to increase risk but obesity and TNF-308GA+AA may interact to increase DLBCL risk Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G A in the pathogenesis of",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2612, 8462, 71, 85, 41, 5, 12366, 2150, 517, 20, 101, 1675, 1529, 3440, 8, 442, 1291, 1309, 3, 858, 59, 1661, 1675, 1203, 2, 715, 2908, 132, 31, 1179, 16, 210, 74, 23, 39, 18324, 140, 2, 39, 11611, 535, 29, 762, 597, 1865, 94, 29, 3, 22505, 2404, 3314, 1375, 11, 1830, 9, 1388, 375, 132, 31, 1446, 1974, 2633, 2, 442, 1193, 2647, 302, 1193, 552, 5302, 2093, 685, 1, 642, 782, 558, 29, 1074, 210, 4594, 2, 924, 2, 133, 1203, 4, 1886, 34509, 45201, 16499, 66096, 45798, 24993, 44636, 6866, 44635, 6772, 34682, 38986, 10920, 39110, 39109, 2254, 26730, 28856, 66097, 2, 66098, 40633, 11, 565, 75, 6438, 812, 320, 1140, 1907, 915, 176, 11, 661, 75, 3, 580, 2612, 43, 520, 6, 915, 26514, 1661, 1140, 749, 201, 503, 188, 18, 10, 41, 5, 1446, 43, 15, 14, 466, 48, 307, 268, 58, 14, 588, 14, 803, 22, 10, 2254, 31517, 1519, 15, 14, 259, 48, 58, 14, 1615, 14, 584, 1162, 486, 2209, 2, 2254, 31517, 1519, 101, 1446, 43, 2214, 18, 1116, 580, 6, 135, 1, 295, 924, 2, 2254, 66099, 15, 14, 966, 48, 58, 14, 428, 18, 960, 5, 8, 26514, 1, 13, 605, 48, 58, 13, 474, 13, 874, 8994, 13, 233, 9, 2633, 2, 552, 5302, 77, 685, 5, 1661, 15, 2254, 31517, 1519, 361, 16659, 15, 7609, 11, 164, 77, 241, 1, 1286, 59, 1661, 2, 3, 127, 1203, 11, 530, 114, 99, 309, 17, 1675, 1203, 1022, 44, 1228, 4491, 5, 1140, 6, 344, 43, 84, 1661, 2, 2254, 31517, 1519, 68, 4491, 6, 344, 1446, 43, 94, 75, 380, 1018, 1, 8462, 32, 575, 6, 195, 963, 3, 1286, 59, 1661, 2, 2254, 48724, 8, 4, 3, 1384, 1]",1766.0,25962811,22
"Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.",Blood,Blood,2015-05-13,"Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector phospholipase C, 2 (PLCG2). Although the C481S mutation found in BTK has been shown to disable ibrutinib's capacity to irreversibly bind this primary target, the detailed mechanisms of mutations in PLCG2 have yet to be established. Herein, we characterize the enhanced signaling competence, BTK independence, and surface immunoglobulin dependence of the PLCG2 mutation at R665W, which has been documented in ibrutinib-resistant CLL. Our data demonstrate that this missense alteration elicits BTK-independent activation after B-cell receptor engagement, implying the formation of a novel BTK-bypass pathway. Consistent with previous results, PLCG2(R665W) confers hypermorphic induction of downstream signaling events. Our studies reveal that proximal kinases SYK and LYN are critical for the activation of mutant PLCG2 and that therapeutics targeting SYK and LYN can combat molecular resistance in cell line models and primary CLL cells from ibrutinib-resistant patients. Altogether, our results engender a molecular understanding of the identified aberration at PLCG2 and explore its functional dependency on BTK, SYK, and LYN, suggesting alternative strategies to combat acquired ibrutinib resistance. ",Journal Article,1714.0,67.0,Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic CLL Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase BTK the target of ibrutinib as well as the immediate downstream effector phospholipase C 2 PLCG2 Although the C481S mutation found in BTK has been shown to disable ibrutinib 's capacity to irreversibly bind this primary target the detailed mechanisms of mutations in PLCG2 have yet to be established Herein we characterize the enhanced signaling competence BTK independence and surface immunoglobulin dependence of the PLCG2 mutation at R665W which has been documented in ibrutinib-resistant CLL Our data demonstrate that this missense alteration elicits BTK-independent activation after B-cell receptor engagement implying the formation of a novel BTK-bypass pathway Consistent with previous results PLCG2 R665W confers hypermorphic induction of downstream signaling events Our studies reveal that proximal kinases SYK and LYN are critical for the activation of mutant PLCG2 and that therapeutics targeting SYK and LYN can combat molecular resistance in cell line models and primary CLL cells from ibrutinib-resistant patients Altogether our results engender a molecular understanding of the identified aberration at PLCG2 and explore its functional dependency on BTK SYK and LYN suggesting alternative strategies to combat acquired ibrutinib resistance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 71, 97, 231, 3, 228, 1, 7, 5, 591, 442, 1193, 552, 435, 1198, 13530, 1795, 251, 6, 1294, 138, 4, 5796, 41043, 564, 216, 3611, 3, 283, 1, 1795, 22, 149, 22, 3, 2181, 1489, 2070, 16685, 256, 31713, 15432, 242, 3, 17045, 258, 204, 4, 3611, 71, 85, 443, 6, 28551, 1795, 292, 2162, 6, 12820, 4060, 26, 86, 283, 3, 2455, 483, 1, 138, 4, 15432, 47, 1145, 6, 40, 635, 1986, 21, 1507, 3, 651, 314, 11573, 3611, 5773, 2, 1255, 2593, 3721, 1, 3, 15432, 258, 28, 40740, 92, 71, 85, 1405, 4, 1795, 436, 552, 114, 74, 608, 17, 26, 4007, 2611, 8748, 3611, 306, 363, 50, 132, 31, 153, 5103, 7885, 3, 1264, 1, 8, 229, 3611, 5481, 308, 925, 5, 698, 99, 15432, 40740, 4020, 46310, 504, 1, 1489, 314, 281, 114, 94, 2396, 17, 2805, 1549, 6792, 2, 8309, 32, 740, 9, 3, 363, 1, 620, 15432, 2, 17, 1943, 529, 6792, 2, 8309, 122, 10584, 219, 251, 4, 31, 328, 274, 2, 86, 552, 37, 29, 1795, 436, 7, 6767, 114, 99, 28212, 8, 219, 612, 1, 3, 108, 7794, 28, 15432, 2, 1645, 211, 583, 6359, 23, 3611, 6792, 2, 8309, 802, 1091, 422, 6, 10584, 1294, 1795, 251]",1467.0,25972157,97
Updates to the management of chronic lymphocytic leukemia.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2015-05-01,"The decision of when to start treatment for patients with chronic lymphocytic leukemia (CLL) has not markedly changed; it is triggered by parameters of active disease, such as progressive symptoms or progressive cytopenias related to bone marrow compromise from disease. How to treat patients with CLL has become less complicated, given the growing list of options for CLL, and generally depends on the patient's age, presence of comorbidities, and risk factors (such as chromosome 17 or 11 deletion). During his presentation at the NCCN 20th Annual Conference, Dr. William Wierda focused attention on many of the new kids on the therapeutic block for CLL--the CD20 monoclonal antibodies obinutuzumab and ofatumumab, the BTK inhibitor ibrutinib, the PI3K inhibitor idelalisib, and the BCL-2 inhibitor venetoclax--and reviewed some of the clinical data supporting the use of these agents in different patient populations with CLL.",Journal Article,1726.0,4.0,The decision of when to start treatment for patients with chronic lymphocytic CLL has not markedly changed it is triggered by parameters of active disease such as progressive symptoms or progressive cytopenias related to marrow compromise from disease How to treat patients with CLL has become less complicated given the growing list of options for CLL and generally depends on the patient 's age presence of comorbidities and risk factors such as chromosome 17 or 11 deletion During his presentation at the NCCN 20th Annual Conference Dr. William Wierda focused attention on many of the new kids on the therapeutic block for CLL -- the CD20 monoclonal antibodies obinutuzumab and ofatumumab the BTK inhibitor ibrutinib the PI3K inhibitor idelalisib and the BCL-2 inhibitor venetoclax -- and reviewed some of the clinical data supporting the use of these agents in different patient populations with CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 948, 1, 198, 6, 2435, 24, 9, 7, 5, 442, 1193, 552, 71, 44, 2195, 2368, 192, 16, 4173, 20, 1038, 1, 544, 34, 225, 22, 1014, 507, 15, 1014, 5635, 139, 6, 581, 4665, 29, 34, 832, 6, 943, 7, 5, 552, 71, 1417, 299, 4286, 447, 3, 1921, 4754, 1, 838, 9, 552, 2, 1228, 3828, 23, 3, 69, 292, 89, 463, 1, 1909, 2, 43, 130, 225, 22, 1170, 269, 15, 175, 1528, 190, 3224, 1031, 28, 3, 1944, 17275, 2114, 4180, 3436, 21178, 66159, 1649, 2111, 23, 445, 1, 3, 217, 36033, 23, 3, 189, 2381, 9, 552, 3, 2198, 848, 890, 10380, 2, 5732, 3, 3611, 230, 1795, 3, 974, 230, 7083, 2, 3, 1044, 18, 230, 4454, 2, 446, 476, 1, 3, 38, 74, 1912, 3, 119, 1, 46, 183, 4, 338, 69, 1184, 5, 552]",903.0,25995424,128
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.,Nature medicine,Nat. Med.,2015-05-25,"B cell malignancies frequently colonize the bone marrow. The mechanisms responsible for this preferential homing are incompletely understood. Here we studied multiple myeloma (MM) as a model of a terminally differentiated B cell malignancy that selectively colonizes the bone marrow. We found that extracellular CyPA (eCyPA), secreted by bone marrow endothelial cells (BMECs), promoted the colonization and proliferation of MM cells in an in vivo scaffold system via binding to its receptor, CD147, on MM cells. The expression and secretion of eCyPA by BMECs was enhanced by BCL9, a Wnt--catenin transcriptional coactivator that is selectively expressed by these cells. eCyPA levels were higher in bone marrow serum than in peripheral blood in individuals with MM, and eCyPA-CD147 blockade suppressed MM colonization and tumor growth in the in vivo scaffold system. eCyPA also promoted the migration of chronic lymphocytic leukemia and lymphoplasmacytic lymphoma cells, two other B cell malignancies that colonize the bone marrow and express CD147. These findings suggest that eCyPA-CD147 signaling promotes the bone marrow homing of B cell malignancies and offer a compelling rationale for exploring this axis as a therapeutic target for these malignancies. ",Journal Article,1702.0,34.0,B cell malignancies frequently colonize the marrow The mechanisms responsible for this preferential homing are incompletely understood Here we studied multiple MM as a model of a terminally differentiated B cell malignancy that selectively colonizes the marrow We found that extracellular CyPA eCyPA secreted by marrow endothelial cells BMECs promoted the colonization and proliferation of MM cells in an in vivo scaffold system via binding to its receptor CD147 on MM cells The expression and secretion of eCyPA by BMECs was enhanced by BCL9 a Wnt--catenin transcriptional coactivator that is selectively expressed by these cells eCyPA levels were higher in marrow serum than in peripheral blood in individuals with MM and eCyPA-CD147 blockade suppressed MM colonization and tumor growth in the in vivo scaffold system eCyPA also promoted the migration of chronic lymphocytic and lymphoplasmacytic cells two other B cell malignancies that colonize the marrow and express CD147 These findings suggest that eCyPA-CD147 signaling promotes the marrow homing of B cell malignancies and offer a compelling rationale for exploring this axis as a therapeutic target for these malignancies,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 441, 746, 18968, 3, 581, 3, 483, 2327, 9, 26, 6629, 5515, 32, 5252, 1784, 467, 21, 656, 232, 321, 22, 8, 202, 1, 8, 7166, 1442, 132, 31, 710, 17, 2382, 39082, 3, 581, 21, 204, 17, 1976, 23351, 29679, 3613, 20, 581, 845, 37, 49078, 2992, 3, 7291, 2, 457, 1, 321, 37, 4, 35, 4, 386, 11547, 398, 847, 791, 6, 211, 153, 16632, 23, 321, 37, 3, 55, 2, 2935, 1, 29679, 20, 49078, 10, 651, 20, 36035, 8, 2112, 1458, 1778, 1431, 8777, 17, 16, 2382, 570, 20, 46, 37, 29679, 148, 11, 142, 4, 581, 524, 76, 4, 672, 315, 4, 869, 5, 321, 2, 29679, 16632, 1189, 1908, 321, 7291, 2, 30, 129, 4, 3, 4, 386, 11547, 398, 29679, 120, 2992, 3, 1381, 1, 442, 1193, 2, 5325, 37, 100, 127, 132, 31, 441, 17, 18968, 3, 581, 2, 1669, 16632, 46, 272, 309, 17, 29679, 16632, 314, 2148, 3, 581, 5515, 1, 132, 31, 441, 2, 1918, 8, 6051, 1728, 9, 4378, 26, 2310, 22, 8, 189, 283, 9, 46, 441]",1182.0,26005854,126
"Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.",Leukemia research,Leuk. Res.,2015-05-12,"The co-occurrence of myeloproliferative and lymphoproliferative neoplasms (MPN/LPN) has been reported, mostly in case reports. The aim of this study was to assess the characteristics and clinical course of the coexistent diseases. Among 9866 patients who presented to our institution from 1960 to 2014, 34 (0.3%) were diagnosed with MPN/LPN. LPN was diagnosed first in 16 patients, second in 15, and at the same time in 3. The time to secondary malignancy was longer when LPN was diagnosed first (119 vs 98 months). Myelofibrosis (41%), polycythemia vera (24%), and essential thrombocythemia (18%) were the most common MPNs, and non-Hodgkin lymphoma (50%) and chronic lymphocytic leukemia (32%) were the most common LPNs. Seventy-three percent of patients treated for MPN and 72% of those treated for LPN achieved a complete response. After a median follow-up from MPN diagnosis of 84 months, 16 patients are alive and 18 died (4 related to MPN and 2 LPN). Coexistent MPN/LPN is a rare event that does not appear to predict worse outcomes. Treatment choice is generally oriented towards controlling the prevalent disease; the other malignancy may influence treatment strategies in selected cases. ",Journal Article,1715.0,8.0,The co-occurrence of and lymphoproliferative neoplasms MPN/LPN has been reported mostly in case reports The aim of this study was to assess the characteristics and clinical course of the coexistent diseases Among 9866 patients who presented to our institution from 1960 to 2014 34 0.3 were diagnosed with MPN/LPN LPN was diagnosed first in 16 patients second in 15 and at the same time in 3 The time to secondary malignancy was longer when LPN was diagnosed first 119 vs 98 months Myelofibrosis 41 polycythemia vera 24 and essential thrombocythemia 18 were the most common MPNs and 50 and chronic lymphocytic 32 were the most common LPNs Seventy-three percent of patients treated for MPN and 72 of those treated for LPN achieved a complete response After a median follow-up from MPN diagnosis of 84 months 16 patients are alive and 18 died 4 related to MPN and 2 LPN Coexistent MPN/LPN is a rare event that does not appear to predict worse outcomes Treatment choice is generally oriented towards controlling the prevalent disease the other malignancy may influence treatment strategies in selected cases,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1269, 2291, 1, 2, 4192, 1179, 4125, 15392, 71, 85, 210, 2754, 4, 473, 1198, 3, 1130, 1, 26, 45, 10, 6, 423, 3, 374, 2, 38, 906, 1, 3, 12779, 1342, 107, 66188, 7, 54, 917, 6, 114, 731, 29, 10391, 6, 1409, 562, 13, 27, 11, 265, 5, 4125, 15392, 15392, 10, 265, 157, 4, 245, 7, 419, 4, 167, 2, 28, 3, 827, 98, 4, 27, 3, 98, 6, 568, 710, 10, 589, 198, 15392, 10, 265, 157, 4299, 105, 1096, 53, 4637, 605, 5755, 5756, 259, 2, 1452, 8962, 203, 11, 3, 96, 186, 6880, 2, 212, 2, 442, 1193, 531, 11, 3, 96, 186, 47808, 2073, 169, 714, 1, 7, 73, 9, 4125, 2, 720, 1, 135, 73, 9, 15392, 513, 8, 236, 51, 50, 8, 52, 166, 126, 29, 4125, 147, 1, 874, 53, 245, 7, 32, 1701, 2, 203, 1016, 39, 139, 6, 4125, 2, 18, 15392, 12779, 4125, 15392, 16, 8, 622, 774, 17, 1097, 44, 1322, 6, 678, 639, 123, 24, 1866, 16, 1228, 8095, 3113, 1893, 3, 2485, 34, 3, 127, 710, 68, 1054, 24, 422, 4, 715, 140]",1103.0,26012362,606
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?,Immunotherapy,Immunotherapy,2015-01-01,"Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma. This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic leukemia and the challenges to this therapeutic strategy. We will also discuss application of CAR T-cell therapy to chronic lymphocytic leukemia and other B-cell malignancies including a follicular lymphoma, diffuse large B-cell lymphoma, as well as acute and plasma cell malignancies. ",Journal Article,1846.0,25.0,Chimeric antigen receptor CAR T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic By targeting CD19 a marker expressed most B-cell tumors as well as normal B cells CAR T-cell therapy has been investigated as a treatment strategy for B-cell and This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic and the challenges to this therapeutic strategy We will also discuss application of CAR T-cell therapy to chronic lymphocytic and other B-cell malignancies including a follicular diffuse large B-cell as well as acute and plasma cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[2897, 448, 153, 1881, 102, 31, 36, 71, 761, 6235, 237, 3, 25558, 520, 6, 5790, 99, 4, 7, 5, 132, 31, 286, 1275, 20, 529, 3158, 8, 952, 570, 96, 132, 31, 57, 22, 149, 22, 295, 132, 37, 1881, 102, 31, 36, 71, 85, 565, 22, 8, 24, 692, 9, 132, 31, 2, 26, 206, 303, 1139, 3, 6697, 1, 26, 36, 9, 3, 24, 1, 132, 31, 286, 1275, 2, 3, 1427, 6, 26, 189, 692, 21, 303, 120, 1139, 1581, 1, 1881, 102, 31, 36, 6, 442, 1193, 2, 127, 132, 31, 441, 141, 8, 1974, 1388, 375, 132, 31, 22, 149, 22, 286, 2, 554, 31, 441]",662.0,26065479,19
Initial treatment of CLL: integrating biology and functional status.,Blood,Blood,2015-06-11,"A better understanding of the biology of chronic lymphocytic leukemia (CLL) has led to significant advances in therapeutic strategies for patients with CLL. Chemoimmunotherapy (CIT) has been the standard first-line therapy for CLL. Age and comorbidities can help decide which patients may benefit from a CIT approach. FCR (fludarabine, cyclophosphamide, and rituximab) is the current standard treatment option for younger patients with CLL. For older patients and for patients with renal dysfunction, bendamustine and rituximab may be a better option. For older patients with comorbidities who may not be able to tolerate intensive CIT, the combination treatment of chlorambucil and obinutuzumab or ofatumumab is an option. For patients with del(17p), ibrutinib is the treatment of choice. Several ongoing phase 3 clinical trials with novel therapies will further refine the frontline therapy of CLL. ",Journal Article,1685.0,45.0,A better understanding of the biology of chronic lymphocytic CLL has led to significant advances in therapeutic strategies for patients with CLL Chemoimmunotherapy CIT has been the standard first-line therapy for CLL Age and comorbidities can help decide which patients may benefit from a CIT approach FCR fludarabine cyclophosphamide and rituximab is the current standard treatment option for younger patients with CLL For older patients and for patients with dysfunction bendamustine and rituximab may be a better option For older patients with comorbidities who may not be able to tolerate intensive CIT the combination treatment of chlorambucil and obinutuzumab or ofatumumab is an option For patients with del 17p ibrutinib is the treatment of choice Several ongoing phase 3 clinical trials with novel therapies will further refine the frontline therapy of CLL,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 380, 612, 1, 3, 891, 1, 442, 1193, 552, 71, 836, 6, 93, 954, 4, 189, 422, 9, 7, 5, 552, 4438, 9192, 71, 85, 3, 260, 157, 328, 36, 9, 552, 89, 2, 1909, 122, 987, 11008, 92, 7, 68, 247, 29, 8, 9192, 353, 4953, 2027, 1112, 2, 855, 16, 3, 291, 260, 24, 1501, 9, 773, 7, 5, 552, 9, 434, 7, 2, 9, 7, 5, 1527, 4809, 2, 855, 68, 40, 8, 380, 1501, 9, 434, 7, 5, 1909, 54, 68, 44, 40, 1665, 6, 5010, 1686, 9192, 3, 150, 24, 1, 11585, 2, 10380, 15, 5732, 16, 35, 1501, 9, 7, 5, 3084, 4135, 1795, 16, 3, 24, 1, 1866, 392, 942, 124, 27, 38, 143, 5, 229, 235, 303, 195, 5003, 3, 3171, 36, 1, 552]",865.0,26065656,44
"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.",Blood,Blood,2015-06-11,"Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5  10(9)/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5  10(9)/L. Low-count MBL can be detected in 5% of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5  10(9)/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL. ",Journal Article,1685.0,69.0,Monoclonal B lymphocytosis MBL is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 10 9 /L B-cells and no other signs of a lymphoproliferative disorder The majority of cases of MBL have the immunophenotype of chronic lymphocytic CLL MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 10 9 /L Low-count MBL can be detected in 5 of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays A number of biological and genetic characteristics distinguish low-count from high-count MBL Whereas low-count MBL rarely progresses to CLL high-count MBL progresses to CLL requiring therapy at a rate of 1 to 2 per year High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 10 9 /L Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL This review highlights challenging questions regarding the classification risk stratification management and supportive care of patients with MBL and CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[848, 132, 8125, 8992, 16, 395, 22, 3, 463, 1, 8, 1946, 132, 31, 266, 4, 3, 672, 315, 5, 1497, 76, 33, 79, 83, 805, 132, 37, 2, 77, 127, 3408, 1, 8, 4192, 2645, 3, 686, 1, 140, 1, 8992, 47, 3, 5496, 1, 442, 1193, 552, 8992, 122, 40, 2320, 22, 361, 154, 1276, 15, 64, 1276, 90, 23, 317, 3, 132, 31, 1276, 16, 2090, 15, 2736, 13, 33, 79, 83, 805, 154, 1276, 8992, 122, 40, 530, 4, 29103, 1, 857, 252, 3, 89, 1, 327, 60, 198, 275, 75, 260, 485, 1412, 1914, 1013, 8, 207, 1, 1037, 2, 336, 374, 3081, 154, 1276, 29, 64, 1276, 8992, 547, 154, 1276, 8992, 2416, 6752, 6, 552, 64, 1276, 8992, 6752, 6, 552, 1888, 36, 28, 8, 116, 1, 14, 6, 18, 379, 111, 64, 1276, 8992, 16, 4735, 29, 4121, 13, 552, 90, 23, 317, 3, 132, 31, 1276, 16, 2090, 15, 2736, 33, 79, 83, 805, 242, 869, 5, 110, 64, 1276, 8992, 2, 552, 4121, 82, 13, 32, 28, 101, 43, 1, 1875, 2, 419, 163, 3, 43, 1, 91, 1888, 24, 2, 3, 174, 6, 12648, 358, 3399, 32, 378, 9, 552, 26, 206, 2527, 1950, 1937, 666, 3, 947, 43, 1541, 284, 2, 1877, 165, 1, 7, 5, 8992, 2, 552]",1247.0,26065657,189
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.,Haematologica,Haematologica,2015-06-18,"While the renal complications of plasma cell dyscrasia have been well-described, most information in patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis is derived from case reports. This is a retrospective analysis of patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis who underwent kidney biopsy for renal insufficiency and/or nephrotic syndrome. Between January 1995 and June 2014, 49 of 4,024 (1.2%) patients with chronic lymphocytic leukemia (n=44) or monoclonal B-cell lymphocytosis (n=5) had a renal biopsy: 34 (69%) for renal insufficiency and 15 (31%) for nephrotic syndrome. The most common findings on biopsy were: membranoproliferative glomerulonephritis (n=10, 20%), chronic lymphocytic leukemia interstitial infiltration as primary etiology (n=6, 12%), thrombotic microangiopathy (n=6, 12%), and minimal change disease (n=5, 10%). All five membranoproliferative glomerulonephritis patients treated with rituximab, cyclophosphamide and prednisone-based regimens had recovery of renal function compared to 0/3 patients treated with rituximab with or without steroids. Chronic lymphocytic leukemia infiltration as the primary cause of renal abnormalities was typically observed in relapsed/refractory patients (4/6). Thrombotic microangiopathy primarily occurred as a treatment-related toxicity of pentostatin (4/6 cases), and resolved with drug discontinuation. All cases of minimal change disease resolved with immunosuppressive agents only. Renal biopsy plays an important role in the management of patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis who develop renal failure and/or nephrotic syndrome. ",Clinical Trial,1678.0,25.0,"While the complications of plasma cell dyscrasia have been well-described most information in patients with chronic lymphocytic and monoclonal B-cell lymphocytosis is derived from case reports This is a retrospective analysis of patients with chronic lymphocytic or monoclonal B-cell lymphocytosis who underwent biopsy for insufficiency and/or nephrotic syndrome Between January 1995 and June 2014 49 of 4,024 1.2 patients with chronic lymphocytic n=44 or monoclonal B-cell lymphocytosis n=5 had a biopsy 34 69 for insufficiency and 15 31 for nephrotic syndrome The most common findings on biopsy were membranoproliferative glomerulonephritis n=10 20 chronic lymphocytic interstitial infiltration as primary etiology n=6 12 thrombotic microangiopathy n=6 12 and minimal change disease n=5 10 All five membranoproliferative glomerulonephritis patients treated with rituximab cyclophosphamide and prednisone-based regimens had recovery of function compared to 0/3 patients treated with rituximab with or without steroids Chronic lymphocytic infiltration as the primary cause of abnormalities was typically observed in relapsed/refractory patients 4/6 Thrombotic microangiopathy primarily occurred as a treatment-related toxicity of pentostatin 4/6 cases and resolved with drug discontinuation All cases of minimal change disease resolved with immunosuppressive agents only biopsy plays an important role in the management of patients with chronic lymphocytic or monoclonal B-cell lymphocytosis who develop failure and/or nephrotic syndrome",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[369, 3, 521, 1, 554, 31, 16613, 47, 85, 149, 1027, 96, 487, 4, 7, 5, 442, 1193, 2, 848, 132, 31, 8125, 16, 526, 29, 473, 1198, 26, 16, 8, 459, 65, 1, 7, 5, 442, 1193, 15, 848, 132, 31, 8125, 54, 208, 411, 9, 4360, 2, 15, 17079, 681, 59, 1024, 2323, 2, 1924, 1409, 739, 1, 39, 4247, 14, 18, 7, 5, 442, 1193, 78, 584, 15, 848, 132, 31, 8125, 78, 33, 42, 8, 411, 562, 790, 9, 4360, 2, 167, 456, 9, 17079, 681, 3, 96, 186, 272, 23, 411, 11, 41129, 26106, 78, 79, 179, 442, 1193, 4543, 2084, 22, 86, 2855, 78, 49, 133, 6108, 13864, 78, 49, 133, 2, 1048, 707, 34, 78, 33, 79, 62, 365, 41129, 26106, 7, 73, 5, 855, 1112, 2, 1979, 90, 472, 42, 1602, 1, 343, 72, 6, 13, 27, 7, 73, 5, 855, 5, 15, 187, 4580, 442, 1193, 2084, 22, 3, 86, 708, 1, 1171, 10, 1969, 164, 4, 591, 430, 7, 39, 49, 6108, 13864, 1561, 489, 22, 8, 24, 139, 155, 1, 7596, 39, 49, 140, 2, 3862, 5, 234, 2007, 62, 140, 1, 1048, 707, 34, 3862, 5, 2989, 183, 158, 411, 1698, 35, 305, 200, 4, 3, 284, 1, 7, 5, 442, 1193, 15, 848, 132, 31, 8125, 54, 690, 496, 2, 15, 17079, 681]",1537.0,26088927,108
Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells.,Annals of the New York Academy of Sciences,Ann. N. Y. Acad. Sci.,2015-06-11,"B-1 cells are considered innate immune cells, which produce the majority of natural antibodies. B-1 cell responses to B cell receptor (BCR) and Toll-like receptor ligation are tightly regulated owing to the cross-reactivity to self-antigens. CD5 has been shown to play a major role in downregulation of BCR responses in B-1 cells. Here, we provide evidence for another mechanism by which BCR response is regulated in B-1 cells. B-1 cells, as well as their malignant counterpart, B cell chronic lymphocytic leukemia (B-CLL) cells, produce interleukin-10 (IL-10) constitutively. IL-10 secretion by normal B-1 cells downregulates their proliferation responses to BCR ligation. However, we found that CLL cells appear to be unique in not responding to IL-10-mediated feedback-suppressive effects in comparison to normal B-1 cells. In addition, we describe a novel role of the BCR signaling pathway in constitutive IL-10 secretion by normal and malignant B-1 cells. We found that inhibition of Src family kinases, spleen tyrosine kinase, Syk, or Bruton's tyrosine kinase reduces constitutive IL-10 production by both normal and malignant B-1 cells. ",Journal Article,1685.0,13.0,B-1 cells are considered innate immune cells which produce the majority of natural antibodies B-1 cell responses to B cell receptor BCR and Toll-like receptor ligation are tightly regulated owing to the cross-reactivity to self-antigens CD5 has been shown to play a major role in downregulation of BCR responses in B-1 cells Here we provide evidence for another mechanism by which BCR response is regulated in B-1 cells B-1 cells as well as their malignant counterpart B cell chronic lymphocytic B-CLL cells produce interleukin-10 IL-10 constitutively IL-10 secretion by normal B-1 cells downregulates their proliferation responses to BCR ligation However we found that CLL cells appear to be unique in not responding to IL-10-mediated feedback-suppressive effects in comparison to normal B-1 cells In addition we describe a novel role of the BCR signaling pathway in constitutive IL-10 secretion by normal and malignant B-1 cells We found that inhibition of Src family kinases spleen tyrosine kinase Syk or Bruton 's tyrosine kinase reduces constitutive IL-10 production by both normal and malignant B-1 cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 14, 37, 32, 515, 3939, 250, 37, 92, 2410, 3, 686, 1, 1504, 890, 132, 14, 31, 253, 6, 132, 31, 153, 1062, 2, 7445, 733, 153, 5307, 32, 8507, 1065, 3421, 6, 3, 1383, 4601, 6, 1074, 1575, 6349, 71, 85, 443, 6, 1343, 8, 458, 200, 4, 2475, 1, 1062, 253, 4, 132, 14, 37, 467, 21, 377, 241, 9, 1809, 670, 20, 92, 1062, 51, 16, 1065, 4, 132, 14, 37, 132, 14, 37, 22, 149, 22, 136, 393, 10423, 132, 31, 442, 1193, 132, 552, 37, 2410, 1603, 79, 501, 79, 2818, 501, 79, 2935, 20, 295, 132, 14, 37, 11265, 136, 457, 253, 6, 1062, 5307, 137, 21, 204, 17, 552, 37, 1322, 6, 40, 991, 4, 44, 3261, 6, 501, 79, 517, 3983, 3707, 176, 4, 1155, 6, 295, 132, 14, 37, 4, 352, 21, 897, 8, 229, 200, 1, 3, 1062, 314, 308, 4, 3178, 501, 79, 2935, 20, 295, 2, 393, 132, 14, 37, 21, 204, 17, 297, 1, 2023, 607, 1549, 4071, 564, 216, 6792, 15, 5796, 292, 564, 216, 2389, 3178, 501, 79, 1529, 20, 110, 295, 2, 393, 132, 14, 37]",1110.0,26096907,238
"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.",American journal of hematology,Am. J. Hematol.,2015-07-27,"The World Health Organization classification of non-Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not well-described. We studied the distribution of NHL subtypes in adults diagnosed from 1998 to 2011, evaluated time trends, geo-demographic correlates, and changes in 5-year overall survival (OS). We obtained data prospectively collected by the National Cancer Data Base, which covers 70% of US cancer cases. There were 596,476 patients diagnosed with NHL. The major subtypes were diffuse large B-cell (32.5%), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; 18.6%), follicular (17.1%), marginal zone (8.3%), mantle cell (4.1%), peripheral T-cell not-otherwise-specified (1.7%), Burkitt (1.6%), hairy cell (1.1%), lymphoplasmacytic (1.1%), and NHL not-otherwise-specified (10.8%). Over the study period, the proportion of NHL not-otherwise-specified declined by half, while marginal zone lymphoma doubled. The distribution of major and rare NHL subtypes varied according to demographics but less so geographically or by type of treatment facility. We noted several novel findings among Hispanics (lower proportion of CLL/SLL, but higher Burkitt lymphoma and nasal NK/T-cell lymphoma), Asians (higher enteropathy-associated T-cell and angioimmunoblastic T-cell lymphomas), Blacks (higher hepatosplenic T-cell lymphoma), and Native Americans (similar proportions of CLL/SLL and nasal NK/T-cell lymphoma as Asians). With the exception of peripheral T-cell not-otherwise-specified and hairy cell leukemia, 5-year OS has improved for all the major NHL subtypes.",Journal Article,1639.0,77.0,"The World Health Organization classification of NHL was introduced in 2001 However its incorporation into clinical practice is not well-described We studied the distribution of NHL subtypes in adults diagnosed from 1998 to 2011 evaluated time trends geo-demographic correlates and changes in 5-year overall survival OS We obtained data prospectively collected by the National Cancer Data Base which covers 70 of US cancer cases There were 596,476 patients diagnosed with NHL The major subtypes were diffuse large B-cell 32.5 chronic lymphocytic leukemia/small lymphocytic CLL/SLL 18.6 follicular 17.1 marginal zone 8.3 mantle cell 4.1 peripheral T-cell not-otherwise-specified 1.7 1.6 hairy cell 1.1 lymphoplasmacytic 1.1 and NHL not-otherwise-specified 10.8 Over the study period the proportion of NHL not-otherwise-specified declined by half while marginal zone doubled The distribution of major and rare NHL subtypes varied according to demographics but less so geographically or by type of treatment facility We noted several novel findings among Hispanics lower proportion of CLL/SLL but higher and nasal NK/T-cell Asians higher enteropathy-associated T-cell and angioimmunoblastic T-cell lymphomas Blacks higher hepatosplenic T-cell and Native Americans similar proportions of CLL/SLL and nasal NK/T-cell as Asians With the exception of peripheral T-cell not-otherwise-specified and hairy cell 5-year OS has improved for all the major NHL subtypes",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1956, 341, 2533, 947, 1, 1176, 10, 3955, 4, 1758, 137, 211, 2838, 237, 38, 758, 16, 44, 149, 1027, 21, 656, 3, 1395, 1, 1176, 814, 4, 857, 265, 29, 1850, 6, 1132, 194, 98, 1963, 14789, 1540, 1871, 2, 400, 4, 33, 111, 63, 25, 118, 21, 683, 74, 1143, 786, 20, 3, 657, 12, 74, 1782, 92, 11273, 431, 1, 843, 12, 140, 125, 11, 10897, 10652, 7, 265, 5, 1176, 3, 458, 814, 11, 1388, 375, 132, 31, 531, 33, 442, 1193, 2647, 302, 1193, 552, 5302, 203, 49, 1974, 269, 14, 3450, 3614, 66, 27, 2757, 31, 39, 14, 672, 102, 31, 44, 2632, 3575, 14, 67, 14, 49, 7152, 31, 14, 14, 5325, 14, 14, 2, 1176, 44, 2632, 3575, 79, 66, 252, 3, 45, 727, 3, 920, 1, 1176, 44, 2632, 3575, 3054, 20, 1303, 369, 3450, 3614, 8431, 3, 1395, 1, 458, 2, 622, 1176, 814, 2051, 768, 6, 2221, 84, 299, 1743, 15354, 15, 20, 267, 1, 24, 3483, 21, 1051, 392, 229, 272, 107, 3850, 280, 920, 1, 552, 5302, 84, 142, 2, 6743, 1765, 102, 31, 5108, 142, 20279, 41, 102, 31, 2, 10722, 102, 31, 1557, 3544, 142, 25697, 102, 31, 2, 4646, 2731, 288, 4117, 1, 552, 5302, 2, 6743, 1765, 102, 31, 22, 5108, 5, 3, 4188, 1, 672, 102, 31, 44, 2632, 3575, 2, 7152, 31, 33, 111, 118, 71, 231, 9, 62, 3, 458, 1176, 814]",1453.0,26096944,518
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.,Blood,Blood,2015-06-26,"Ibrutinib represents a therapeutic advance in chronic lymphocytic leukemia (CLL) but as monotherapy produces few complete remissions in previously treated patients. Anti-CD20 antibodies have improved response and progression-free survival (PFS) when combined with chemotherapy. We evaluated the safety and activity of adding ofatumumab to ibrutinib in 3 different administration sequences. Patients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemia, or Richter's transformation who failed 2 prior therapies were enrolled. Patients received ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg in 3 schedules: ibrutinib lead-in (group 1; n = 27), concurrent start (group 2; n = 20), or ofatumumab lead-in (group 3; n = 24). Seventy-one patients were treated; most had high-risk disease including del(17)(p13.1) (44%) or del(11)(q22.3) (31%). The most frequent adverse events (any grade) were diarrhea (70%), infusion-related reaction (45%), and peripheral sensory neuropathy (44%). Overall response rates in CLL/SLL patients (n = 66) were 100%, 79%, and 71% in groups 1, 2, and 3, respectively. Estimated 12-month PFSs for all patients were 89%, 85%, and 75%, respectively. Four patients in group 3 progressed prior to receiving ibrutinib. This study demonstrates the tolerability and clinical activity of this combination with quicker time to best response than single-agent ibrutinib and with durable responses. This trial was registered at www.clinicaltrials.gov as #NCT01217749. ","Clinical Trial, Phase I",1670.0,76.0,Ibrutinib represents a therapeutic advance in chronic lymphocytic CLL but as monotherapy produces few complete remissions in previously treated patients Anti-CD20 antibodies have improved response and progression-free survival PFS when combined with chemotherapy We evaluated the safety and activity of adding ofatumumab to ibrutinib in 3 different administration sequences Patients with CLL/small lymphocytic SLL prolymphocytic or Richter 's transformation who failed 2 prior therapies were enrolled Patients received ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg in 3 schedules ibrutinib lead-in group 1 n 27 concurrent start group 2 n 20 or ofatumumab lead-in group 3 n 24 Seventy-one patients were treated most had high-risk disease including del 17 p13.1 44 or del 11 q22.3 31 The most frequent adverse events any grade were diarrhea 70 infusion-related reaction 45 and peripheral sensory neuropathy 44 Overall response rates in CLL/SLL patients n 66 were 100 79 and 71 in groups 1 2 and 3 respectively Estimated 12-month PFSs for all patients were 89 85 and 75 respectively Four patients in group 3 progressed prior to receiving ibrutinib This study demonstrates the tolerability and clinical activity of this combination with quicker time to best response than single-agent ibrutinib and with durable responses This trial was registered at www.clinicaltrials.gov as NCT01217749,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 1449, 8, 189, 3148, 4, 442, 1193, 552, 84, 22, 1411, 4042, 1021, 236, 3166, 4, 373, 73, 7, 312, 2198, 890, 47, 231, 51, 2, 91, 115, 25, 300, 198, 397, 5, 56, 21, 194, 3, 367, 2, 128, 1, 2726, 5732, 6, 1795, 4, 27, 338, 634, 2866, 7, 5, 552, 302, 1193, 5302, 14779, 15, 8452, 292, 1392, 54, 1551, 3107, 324, 235, 11, 346, 7, 103, 1795, 5401, 81, 391, 2, 133, 415, 1, 5732, 2036, 1081, 81, 4, 27, 2314, 1795, 1122, 4, 87, 14, 78, 428, 750, 2435, 87, 18, 78, 179, 15, 5732, 1122, 4, 87, 27, 78, 259, 2073, 104, 7, 11, 73, 96, 42, 64, 43, 34, 141, 3084, 269, 7914, 14, 584, 15, 3084, 175, 8026, 27, 456, 3, 96, 908, 290, 281, 500, 88, 11, 1172, 431, 904, 139, 1329, 512, 2, 672, 4148, 1751, 584, 63, 51, 151, 4, 552, 5302, 7, 78, 700, 11, 394, 842, 2, 792, 4, 271, 14, 18, 2, 27, 106, 661, 133, 811, 66361, 9, 62, 7, 11, 887, 772, 2, 481, 106, 294, 7, 4, 87, 27, 1839, 324, 6, 357, 1795, 26, 45, 1902, 3, 1543, 2, 38, 128, 1, 26, 150, 5, 20573, 98, 6, 824, 51, 76, 226, 420, 1795, 2, 5, 1480, 253, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 35626]",1401.0,26116658,330
CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-B mediated pathway.,Oncotarget,Oncotarget,2015-06-01,"CpG oligodeoxynucleotides (ODNs) upregulate the interleukin-21 receptor (IL21R) and enhance IL-21-mediated cytotoxicity in chronic lymphocytic leukemia (CLL) B cells. We demonstrate that treatment of CLL B cells with the ODN CpG-685 leads to increased IL21R expression, and that this increased expression enhances the effects of IL-21 treatment as evidenced by increased phosphorylation of JAK1, STAT1, and STAT3, as compared to IL-21 treatment without prior CpG stimulation. Induction of IL21R by CpG-685 also enhanced IL-21-mediated cytotoxicity. The mechanism by which CpG ODNs upregulate IL21R has not been elucidated, although IL21R regulation in T cells has been shown to be linked to T cell receptor-induced Sp1 binding to the IL21R promoter. Here, we demonstrate that luciferase reporter constructs containing the Sp1 binding site have increased basal luciferase activity compared to constructs lacking the Sp1 binding site, but fail to increase luciferase activity with CpG-685 stimulation in CLL B cells. By treating CLL cells with an NF-B inhibitor, we inhibit the CpG ODN-mediated induction of IL21R, thus demonstrating that CpG-685 upregulates IL21R through an NF-B mediated pathway. These findings suggest an alternative mechanism for induction of IL-21 receptor in CLL B cells and provide a basis for creation of future combination therapies.",Journal Article,1695.0,5.0,CpG oligodeoxynucleotides ODNs upregulate the interleukin-21 receptor IL21R and enhance IL-21-mediated cytotoxicity in chronic lymphocytic CLL B cells We demonstrate that treatment of CLL B cells with the ODN CpG-685 leads to increased IL21R expression and that this increased expression enhances the effects of IL-21 treatment as evidenced by increased phosphorylation of JAK1 STAT1 and STAT3 as compared to IL-21 treatment without prior CpG stimulation Induction of IL21R by CpG-685 also enhanced IL-21-mediated cytotoxicity The mechanism by which CpG ODNs upregulate IL21R has not been elucidated although IL21R regulation in T cells has been shown to be linked to T cell receptor-induced Sp1 binding to the IL21R promoter Here we demonstrate that luciferase reporter constructs containing the Sp1 binding site have increased basal luciferase activity compared to constructs lacking the Sp1 binding site but fail to increase luciferase activity with CpG-685 stimulation in CLL B cells By treating CLL cells with an NF-B inhibitor we inhibit the CpG ODN-mediated induction of IL21R thus demonstrating that CpG-685 upregulates IL21R through an NF-B mediated pathway These findings suggest an alternative mechanism for induction of IL-21 receptor in CLL B cells and provide a basis for creation of future combination therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2075, 20155, 22057, 8676, 3, 1603, 239, 153, 22895, 2, 1304, 501, 239, 517, 1408, 4, 442, 1193, 552, 132, 37, 21, 608, 17, 24, 1, 552, 132, 37, 5, 3, 11601, 2075, 13123, 1940, 6, 101, 22895, 55, 2, 17, 26, 101, 55, 2519, 3, 176, 1, 501, 239, 24, 22, 4728, 20, 101, 982, 1, 8075, 5793, 2, 1439, 22, 72, 6, 501, 239, 24, 187, 324, 2075, 2503, 504, 1, 22895, 20, 2075, 13123, 120, 651, 501, 239, 517, 1408, 3, 670, 20, 92, 2075, 22057, 8676, 22895, 71, 44, 85, 3901, 242, 22895, 863, 4, 102, 37, 71, 85, 443, 6, 40, 1199, 6, 102, 31, 153, 277, 5557, 791, 6, 3, 22895, 973, 467, 21, 608, 17, 3864, 3674, 5500, 1101, 3, 5557, 791, 606, 47, 101, 2135, 3864, 128, 72, 6, 5500, 1941, 3, 5557, 791, 606, 84, 4373, 6, 344, 3864, 128, 5, 2075, 13123, 2503, 4, 552, 132, 37, 20, 1367, 552, 37, 5, 35, 1365, 2448, 230, 21, 1433, 3, 2075, 11601, 517, 504, 1, 22895, 631, 2219, 17, 2075, 13123, 9641, 22895, 298, 35, 1365, 2448, 517, 308, 46, 272, 309, 35, 1091, 670, 9, 504, 1, 501, 239, 153, 4, 552, 132, 37, 2, 377, 8, 877, 9, 7560, 1, 508, 150, 235]",1328.0,26158860,27
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.,JAMA oncology,JAMA Oncol,2015-04-01,"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. To determine features associated with discontinuation of ibrutinib therapy and outcomes. A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-""not reached"") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.",Journal Article,1756.0,270.0,The Bruton tyrosine kinase BTK inhibitor ibrutinib is effective in patients with chronic lymphocytic CLL Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up To determine features associated with discontinuation of ibrutinib therapy and outcomes A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included These clinical trials accrued patients included in this analysis from May 2010 until April 2014 and data were locked in June 2014 Patients were evaluated for time to therapy discontinuation reasons for discontinuation and survival following discontinuation For patients who discontinued therapy because of disease progression targeted deep sequencing was performed in samples at baseline and time of relapse With a median follow-up of 20 months 232 patients remained on therapy 31 had discontinued because of disease progression and 45 had discontinued for other reasons Disease progression includes Richter 's transformation RT or progressive CLL Richter 's transformation appeared to occur early and CLL progressions later cumulative incidence at 12 months 4.5 95 CI 2.0 -7.0 and 0.3 95 CI 0 -1.0 respectively Median survival following RT was 3.5 months 95 CI 0.3-6.0 months and 17.6 months 95 CI 4.7 months- '' not reached '' following CLL progression Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK and a lymph node sample showed no mutations in BTK or PLCG2 Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all These mutations were not identified before treatment in any patient This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies for the first time baseline factors associated with ibrutinib therapy discontinuation Outcomes data show poor prognosis after discontinuation especially for those patients with RT Finally sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations while RT is likely not clinicaltrials.gov Identifiers NCT01105247 NCT01217749 NCT01589302 and NCT01578707,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 5796, 564, 216, 3611, 230, 1795, 16, 323, 4, 7, 5, 442, 1193, 552, 2325, 9, 7971, 36, 5, 26, 234, 2, 123, 366, 2007, 47, 44, 85, 194, 2513, 1, 38, 143, 5, 1352, 978, 166, 126, 6, 223, 404, 41, 5, 2007, 1, 1795, 36, 2, 123, 8, 181, 1, 7786, 7, 3052, 4, 39, 1787, 143, 1, 1795, 28, 3, 10009, 1309, 1652, 949, 12, 574, 11, 159, 46, 38, 143, 3198, 7, 159, 4, 26, 65, 29, 68, 1120, 1100, 2292, 1409, 2, 74, 11, 15663, 4, 1924, 1409, 7, 11, 194, 9, 98, 6, 36, 2007, 2325, 9, 2007, 2, 25, 366, 2007, 9, 7, 54, 2402, 36, 408, 1, 34, 91, 238, 2369, 615, 10, 173, 4, 347, 28, 330, 2, 98, 1, 429, 5, 8, 52, 166, 126, 1, 179, 53, 7186, 7, 958, 23, 36, 456, 42, 2402, 408, 1, 34, 91, 2, 512, 42, 2402, 9, 127, 2325, 34, 91, 1920, 8452, 292, 1392, 240, 15, 1014, 552, 8452, 292, 1392, 2121, 6, 1271, 191, 2, 552, 11704, 1559, 967, 287, 28, 133, 53, 39, 33, 48, 58, 18, 13, 67, 13, 2, 13, 27, 48, 58, 13, 14, 13, 106, 52, 25, 366, 240, 10, 27, 33, 53, 48, 58, 13, 27, 49, 13, 53, 2, 269, 49, 53, 48, 58, 39, 67, 53, 522, 44, 1300, 522, 366, 552, 91, 615, 23, 672, 315, 29, 66, 7, 5, 240, 553, 18, 5, 138, 4, 3611, 2, 8, 263, 289, 1000, 224, 77, 138, 4, 3611, 15, 15432, 2369, 615, 23, 175, 7, 5, 552, 91, 553, 3611, 15, 15432, 138, 4, 62, 46, 138, 11, 44, 108, 348, 24, 4, 500, 69, 26, 226, 731, 730, 5, 1795, 5120, 192, 6, 40, 35, 323, 36, 2, 2953, 9, 3, 157, 98, 330, 130, 41, 5, 1795, 36, 2007, 123, 74, 514, 334, 356, 50, 2007, 1093, 9, 135, 7, 5, 240, 1368, 615, 74, 1843, 388, 1198, 12373, 138, 4, 3611, 2, 15432, 5, 91, 2, 2536, 514, 17, 552, 11704, 32, 41, 5, 46, 138, 369, 240, 16, 322, 44, 1252, 1239, 15877, 27296, 35626, 49192, 2, 32286]",2339.0,26182309,217
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.,Cancer,Cancer,2015-07-20,"Ibrutinib is active in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). In patients treated with ibrutinib for R/R CLL, del(17p), identified by interphase fluorescence in situ hybridization (FISH), is associated with inferior progression-free survival despite equivalent initial response rates. Del(17p) is frequently associated with a complex metaphase karyotype (CKT); the prognostic significance of CKT in ibrutinib-treated patients has not been reported. This study reviewed 88 patients treated for R/R CLL at The University of Texas MD Anderson Cancer Center with investigational ibrutinib-based regimens from 2010 to 2013. Pretreatment FISH and lipopolysaccharide-stimulated metaphase cytogenetic analysis were performed on bone marrow. An adequate pretreatment metaphase karyotype was available for 56 of the 88 patients. The karyotype was complex in 21 of the 56 cases; 17 of the 21 had del(17p) according to FISH. The overall response rate, including partial remission with persistent lymphocytosis, was 94%; 18% had complete responses. In a multivariate analysis (MVA), only CKT was significantly associated with event-free survival (EFS; hazard ratio [HR], 6.6 [95% CI 1.7-25.6]; P=.006). Fludarabine-refractory CLL (HR, 6.9 [95% CI 1.8-27.1], P=.005) and CKT (HR 5.9 [95% CI 1.6-22.2], P=.008) were independently associated with inferior overall survival (OS) in MVA. Del(17p) by FISH was not significantly associated with EFS or OS in MVA. CKT is a powerful predictor of outcomes for ibrutinib-treated patients with R/R CLL and may be a stronger predictor of biological behavior than del(17p) by FISH. Because of their relatively poor outcomes, patients with CKT are ideal candidates for studies of consolidative treatment strategies or novel treatment combinations.",Journal Article,1646.0,135.0,Ibrutinib is active in patients with relapsed/refractory R/R chronic lymphocytic CLL In patients treated with ibrutinib for R/R CLL del 17p identified by interphase fluorescence in situ hybridization FISH is associated with inferior progression-free survival despite equivalent initial response rates Del 17p is frequently associated with a complex metaphase karyotype CKT the prognostic significance of CKT in ibrutinib-treated patients has not been reported This study reviewed 88 patients treated for R/R CLL at The University of Texas MD Anderson Cancer Center with investigational ibrutinib-based regimens from 2010 to 2013 Pretreatment FISH and lipopolysaccharide-stimulated metaphase cytogenetic analysis were performed on marrow An adequate pretreatment metaphase karyotype was available for 56 of the 88 patients The karyotype was complex in 21 of the 56 cases 17 of the 21 had del 17p according to FISH The overall response rate including partial remission with persistent lymphocytosis was 94 18 had complete responses In a multivariate analysis MVA only CKT was significantly associated with event-free survival EFS hazard ratio HR 6.6 95 CI 1.7-25.6 P .006 Fludarabine-refractory CLL HR 6.9 95 CI 1.8-27.1 P .005 and CKT HR 5.9 95 CI 1.6-22.2 P .008 were independently associated with inferior overall survival OS in MVA Del 17p by FISH was not significantly associated with EFS or OS in MVA CKT is a powerful predictor of outcomes for ibrutinib-treated patients with R/R CLL and may be a stronger predictor of biological behavior than del 17p by FISH Because of their relatively poor outcomes patients with CKT are ideal candidates for studies of consolidative treatment strategies or novel treatment combinations,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 544, 4, 7, 5, 591, 430, 668, 668, 442, 1193, 552, 4, 7, 73, 5, 1795, 9, 668, 668, 552, 3084, 4135, 108, 20, 8081, 1591, 4, 957, 1554, 1277, 16, 41, 5, 1663, 91, 115, 25, 550, 2017, 388, 51, 151, 3084, 4135, 16, 746, 41, 5, 8, 840, 10569, 3385, 29700, 3, 177, 724, 1, 29700, 4, 1795, 73, 7, 71, 44, 85, 210, 26, 45, 446, 889, 7, 73, 9, 668, 668, 552, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 5, 3093, 1795, 90, 472, 29, 1120, 6, 1346, 1194, 1277, 2, 15082, 2816, 10569, 1266, 65, 11, 173, 23, 581, 35, 1658, 1194, 10569, 3385, 10, 390, 9, 664, 1, 3, 889, 7, 3, 3385, 10, 840, 4, 239, 1, 3, 664, 140, 269, 1, 3, 239, 42, 3084, 4135, 768, 6, 1277, 3, 63, 51, 116, 141, 450, 734, 5, 1882, 8125, 10, 960, 203, 42, 236, 253, 4, 8, 331, 65, 5320, 158, 29700, 10, 97, 41, 5, 774, 115, 25, 1683, 360, 197, 168, 49, 49, 48, 58, 14, 67, 243, 49, 19, 1861, 2027, 430, 552, 168, 49, 83, 48, 58, 14, 66, 428, 14, 19, 1614, 2, 29700, 168, 33, 83, 48, 58, 14, 49, 350, 18, 19, 2155, 11, 1042, 41, 5, 1663, 63, 25, 118, 4, 5320, 3084, 4135, 20, 1277, 10, 44, 97, 41, 5, 1683, 15, 118, 4, 5320, 29700, 16, 8, 3757, 980, 1, 123, 9, 1795, 73, 7, 5, 668, 668, 552, 2, 68, 40, 8, 3355, 980, 1, 1037, 1710, 76, 3084, 4135, 20, 1277, 408, 1, 136, 1352, 334, 123, 7, 5, 29700, 32, 3662, 1931, 9, 94, 1, 6618, 24, 422, 15, 229, 24, 1247]",1727.0,26193999,656
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.,American journal of hematology,Am. J. Hematol.,2015-10-12,"Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially preventing unnecessary use of aggressive therapies.",Journal Article,1562.0,0.0,Little is known about outcomes of patients with chronic lymphocytic CLL with del 17p13.1 karyotype at diagnosis We reviewed 114 de novo del 17p13.1 CLL patients seen at our institution Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival TFS and overall survival OS we developed a simplified risk score for de novo del 17p13.1 CLL patients to predict TFS and OS based on these variables These scores particularly the very highest can be utilized to identify high-risk patients for expedient enrollment on clinical trials Our data support careful observation for low-risk patients potentially preventing unnecessary use of aggressive therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1215, 16, 440, 545, 123, 1, 7, 5, 442, 1193, 552, 5, 3084, 7526, 14, 3385, 28, 147, 21, 446, 3803, 1566, 2018, 3084, 7526, 14, 552, 7, 527, 28, 114, 731, 75, 831, 1017, 274, 6, 255, 1194, 38, 682, 97, 41, 5, 24, 115, 25, 7335, 2, 63, 25, 118, 21, 276, 8, 8087, 43, 368, 9, 1566, 2018, 3084, 7526, 14, 552, 7, 6, 678, 7335, 2, 118, 90, 23, 46, 682, 46, 703, 823, 3, 923, 1076, 122, 40, 2080, 6, 255, 64, 43, 7, 9, 46087, 1798, 23, 38, 143, 114, 74, 538, 3465, 1664, 9, 154, 43, 7, 751, 3017, 4224, 119, 1, 571, 235]",721.0,26202978,22
"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.",Cancer,Cancer,2015-07-28,"Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL. A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR. The overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow-up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myelogenous leukemia (t-AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort). In patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t-MDS/t-AML.","Clinical Trial, Phase II",1638.0,8.0,Fludarabine cyclophosphamide and rituximab FCR result in durable responses in patients with previously untreated chronic lymphocytic CLL Previous reports have suggested that in patients with relapsed CLL a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab FCR3 in 65 patients with previously untreated CLL The results were compared with those for a historical cohort treated with FCR The overall response rate to FCR3 was 97 with 75 of the patients achieving a complete remission Minimal residual disease negativity was achieved for 62 of the patients according to flow cytometry The median time to progression TTP was 81 months and the median overall survival OS was not reached with 58 of the patients still alive at a median survivor follow-up of 9.7 years Grade 3 or 4 neutropenia grade 3 or 4 thrombocytopenia and major infections were observed with 45 5 and 1.9 of the FCR3 courses respectively Therapy-related syndrome t-MDS or therapy-related acute myelogenous t-AML developed in 7 patients 11 P .01 vs the historical FCR cohort In patients with previously untreated CLL FCR3 resulted in response rates TTP and OS similar to those of a historical cohort of patients treated with FCR FCR3 was associated with an increased incidence of t-MDS/t-AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 1112, 2, 855, 4953, 757, 4, 1480, 253, 4, 7, 5, 373, 1278, 442, 1193, 552, 698, 1198, 47, 1148, 17, 4, 7, 5, 591, 552, 8, 61, 7311, 855, 477, 1106, 51, 151, 4, 1155, 5, 260, 61, 855, 192, 16, 860, 317, 855, 5091, 1, 3, 4953, 477, 303, 757, 4, 231, 51, 151, 2, 69, 123, 4, 7, 5, 373, 1278, 552, 8, 226, 475, 45, 10, 426, 6, 376, 3, 367, 2, 209, 1, 8, 1230, 4953, 477, 5, 232, 61, 855, 32471, 4, 556, 7, 5, 373, 1278, 552, 3, 99, 11, 72, 5, 135, 9, 8, 2252, 180, 73, 5, 4953, 3, 63, 51, 116, 6, 32471, 10, 1015, 5, 481, 1, 3, 7, 1785, 8, 236, 734, 1048, 753, 34, 6014, 10, 513, 9, 744, 1, 3, 7, 768, 6, 1412, 1914, 3, 52, 98, 6, 91, 2422, 10, 865, 53, 2, 3, 52, 63, 25, 118, 10, 44, 1300, 5, 717, 1, 3, 7, 1234, 1701, 28, 8, 52, 2628, 166, 126, 1, 83, 67, 60, 88, 27, 15, 39, 778, 88, 27, 15, 39, 1340, 2, 458, 1875, 11, 164, 5, 512, 33, 2, 14, 83, 1, 3, 32471, 1993, 106, 36, 139, 681, 102, 1223, 15, 36, 139, 286, 2194, 102, 329, 276, 4, 67, 7, 175, 19, 355, 105, 3, 2252, 4953, 180, 4, 7, 5, 373, 1278, 552, 32471, 627, 4, 51, 151, 2422, 2, 118, 288, 6, 135, 1, 8, 2252, 180, 1, 7, 73, 5, 4953, 32471, 10, 41, 5, 35, 101, 287, 1, 102, 1223, 102, 329]",1599.0,26218678,617
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.,EBioMedicine,EBioMedicine,2015-04-29,"Although numerous studies highlighted the role of Epstein-Barr Virus (EBV) in B-cell transformation, the involvement of EBV proteins or genome in the development of the most frequent adult leukemia, chronic lymphocytic leukemia (CLL), has not yet been defined. We hypothesized that EBV microRNAs contribute to progression of CLL and demonstrated the presence of EBV miRNAs in B-cells, in paraffin-embedded bone marrow biopsies and in the plasma of patients with CLL by using three different methods (small RNA-sequencing, quantitative reverse transcription PCR [q-RT-PCR] and miRNAs in situ hybridization [miRNA-ISH]). We found that EBV miRNA BHRF1-1 expression levels were significantly higher in the plasma of patients with CLL compared with healthy individuals (p<00001). Notably, BHRF1-1 as well as BART4 expression were detected in the plasma of either seronegative or seropositive (anti-EBNA-1 IgG and EBV DNA tested) patients; similarly, miRNA-ISH stained positive in bone marrow specimens while LMP1 and EBER immunohistochemistry failed to detect viral proteins and RNA. We also found that BHRF1-1 plasma expression levels were positively associated with elevated beta-2-microglobulin levels and advanced Rai stages and observed a correlation between higher BHRF1-1 expression levels and shorter survival in two independent patients' cohorts. Furthermore, in the majority of CLL cases where BHRF1-1 was exogenously induced in primary malignant B cells the levels of TP53 were reduced. Our findings suggest that EBV may have a role in the process of disease progression in CLL and that miRNA RT-PCR and miRNAs ISH could represent additional methods to detect EBV miRNAs in patients with CLL. ",Journal Article,1728.0,23.0,Although numerous studies highlighted the role of Epstein-Barr Virus EBV in B-cell transformation the involvement of EBV proteins or genome in the development of the most frequent adult chronic lymphocytic CLL has not yet been defined We hypothesized that EBV microRNAs contribute to progression of CLL and demonstrated the presence of EBV miRNAs in B-cells in paraffin-embedded marrow biopsies and in the plasma of patients with CLL by using three different methods small RNA-sequencing quantitative reverse transcription PCR q-RT-PCR and miRNAs in situ hybridization miRNA-ISH We found that EBV miRNA BHRF1-1 expression levels were significantly higher in the plasma of patients with CLL compared with healthy individuals p 0  0001 Notably BHRF1-1 as well as BART4 expression were detected in the plasma of either seronegative or seropositive anti-EBNA-1 IgG and EBV DNA tested patients similarly miRNA-ISH stained positive in marrow specimens while LMP1 and EBER immunohistochemistry failed to detect viral proteins and RNA We also found that BHRF1-1 plasma expression levels were positively associated with elevated beta-2-microglobulin levels and advanced Rai stages and observed a correlation between higher BHRF1-1 expression levels and shorter survival in two independent patients cohorts Furthermore in the majority of CLL cases where BHRF1-1 was exogenously induced in primary malignant B cells the levels of TP53 were reduced Our findings suggest that EBV may have a role in the process of disease progression in CLL and that miRNA RT-PCR and miRNAs ISH could represent additional methods to detect EBV miRNAs in patients with CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 2331, 94, 3681, 3, 200, 1, 5212, 5190, 1450, 2672, 4, 132, 31, 1392, 3, 799, 1, 2672, 652, 15, 898, 4, 3, 193, 1, 3, 96, 908, 780, 442, 1193, 552, 71, 44, 1145, 85, 395, 21, 1237, 17, 2672, 3515, 1248, 6, 91, 1, 552, 2, 264, 3, 463, 1, 2672, 2028, 4, 132, 37, 4, 2487, 2505, 581, 1154, 2, 4, 3, 554, 1, 7, 5, 552, 20, 75, 169, 338, 636, 302, 893, 615, 1156, 1772, 866, 604, 4170, 240, 604, 2, 2028, 4, 957, 1554, 2053, 6321, 21, 204, 17, 2672, 2053, 32481, 14, 55, 148, 11, 97, 142, 4, 3, 554, 1, 7, 5, 552, 72, 5, 1331, 869, 19, 13, 12235, 488, 2552, 32481, 14, 22, 149, 22, 66676, 55, 11, 530, 4, 3, 554, 1, 361, 14924, 15, 9909, 312, 32482, 14, 3630, 2, 2672, 261, 650, 7, 1813, 2053, 6321, 3386, 109, 4, 581, 623, 369, 13574, 2, 12345, 888, 1551, 6, 1426, 1667, 652, 2, 893, 21, 120, 204, 17, 32481, 14, 554, 55, 148, 11, 2375, 41, 5, 804, 1090, 18, 5371, 148, 2, 131, 4121, 1153, 2, 164, 8, 816, 59, 142, 32481, 14, 55, 148, 2, 985, 25, 4, 100, 306, 7, 736, 798, 4, 3, 686, 1, 552, 140, 1257, 32481, 14, 10, 15581, 277, 4, 86, 393, 132, 37, 3, 148, 1, 1206, 11, 405, 114, 272, 309, 17, 2672, 68, 47, 8, 200, 4, 3, 1129, 1, 34, 91, 4, 552, 2, 17, 2053, 240, 604, 2, 2028, 6321, 359, 1231, 402, 636, 6, 1426, 2672, 2028, 4, 7, 5, 552]",1642.0,26288818,54
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-08-05,"Alemtuzumab is effective in fludarabine-refractory patients with chronic lymphocytic leukemia. We performed a phase 2 study of alemtuzumab in combination with fludarabine in patients with relapsed disease. Patients received alemtuzumab and fludarabine daily on days 1 to 5 of a 28-day cycle for up to 6 cycles with the primary objective of determining the rate of complete response. Of 60 enrolled patients, 51 had previously received fludarabine, and 60% had received 3 or more prior therapies. Five patients experienced complete response (8.3%) and 12 experienced partial response, yielding an overall response rate of 28.3% for the intention-to-treat population. Among the 41 patients who completed at least 4 cycles of therapy, the complete response rate was 20%. Median progression-free survival was 211 days. Forty-seven percent of patients experienced cytomegalovirus viremia, including 4 patients with symptomatic cytomegalovirus disease. All patients responded to antiviral therapy. Despite some evidence of efficacy in this setting, the primary end point for the study was not met. In the era of targeted agents that are well tolerated, the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies.","Clinical Trial, Phase II",1630.0,1.0,Alemtuzumab is effective in fludarabine-refractory patients with chronic lymphocytic We performed a phase 2 study of alemtuzumab in combination with fludarabine in patients with relapsed disease Patients received alemtuzumab and fludarabine daily on days 1 to 5 of a 28-day cycle for up to 6 cycles with the primary objective of determining the rate of complete response Of 60 enrolled patients 51 had previously received fludarabine and 60 had received 3 or more prior therapies Five patients experienced complete response 8.3 and 12 experienced partial response yielding an overall response rate of 28.3 for the intention-to-treat population Among the 41 patients who completed at least 4 cycles of therapy the complete response rate was 20 Median progression-free survival was 211 days Forty-seven percent of patients experienced cytomegalovirus viremia including 4 patients with symptomatic cytomegalovirus disease All patients responded to antiviral therapy Despite some evidence of efficacy in this setting the primary end point for the study was not met In the era of targeted agents that are well tolerated the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3579, 16, 323, 4, 2027, 430, 7, 5, 442, 1193, 21, 173, 8, 124, 18, 45, 1, 3579, 4, 150, 5, 2027, 4, 7, 5, 591, 34, 7, 103, 3579, 2, 2027, 391, 23, 162, 14, 6, 33, 1, 8, 339, 218, 417, 9, 126, 6, 49, 410, 5, 3, 86, 461, 1, 2196, 3, 116, 1, 236, 51, 1, 335, 346, 7, 725, 42, 373, 103, 2027, 2, 335, 42, 103, 27, 15, 80, 324, 235, 365, 7, 592, 236, 51, 66, 27, 2, 133, 592, 450, 51, 4949, 35, 63, 51, 116, 1, 339, 27, 9, 3, 3205, 6, 943, 266, 107, 3, 605, 7, 54, 781, 28, 506, 39, 410, 1, 36, 3, 236, 51, 116, 10, 179, 52, 91, 115, 25, 10, 5905, 162, 1213, 648, 714, 1, 7, 592, 7314, 10008, 141, 39, 7, 5, 1704, 7314, 34, 62, 7, 2211, 6, 6264, 36, 550, 476, 241, 1, 209, 4, 26, 546, 3, 86, 396, 741, 9, 3, 45, 10, 44, 543, 4, 3, 1713, 1, 238, 183, 17, 32, 149, 421, 3, 150, 1, 2027, 2, 3579, 257, 40, 95, 2416, 9, 8, 1717, 87, 1, 2975, 7, 54, 32, 430, 6, 260, 235]",1259.0,26385641,548
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2015-10-19,"To evaluate the potential of subcutaneous (SC) injections with anti-CD20 antibody veltuzumab in chronic lymphocytic leukemia (CLL), 21 patients received 80, 160, or 320mg injections every 2 weeks4 doses (n=11) or 160 or 320mg twice-weekly16 doses (n=10). Treatment was well tolerated with only occasional, mild-moderate, transient injection reactions. Lymphocytosis decreased in all patients (maximum decrease, 5-91%), with 12 patients obtaining >50% decreases. Of 14 patients with lymphadenopathy on CT imaging, 5 (36%) achieved 14-61% reductions (sum of perpendicular diameters). By NCI-WG criteria, two patients achieved partial responses (10%). SC veltuzumab appeared active in all dose groups, with no obvious exposure-response relationship, despite cumulative doses ranging from 320-5120mg. Overall median progression-free survival was 7.7 months; three patients remained progression-free >1 year (2 ongoing at 2-year study completion). These data suggest further studies of SC veltuzumab in CLL are warranted. ","Clinical Trial, Phase I",1555.0,11.0,To evaluate the potential of subcutaneous SC injections with anti-CD20 antibody veltuzumab in chronic lymphocytic CLL 21 patients received 80 160 or 320 mg injections every 2 weeks 4 doses n 11 or 160 or 320 mg twice-weekly 16 doses n 10 Treatment was well tolerated with only occasional mild-moderate transient injection reactions Lymphocytosis decreased in all patients maximum decrease 5-91 with 12 patients obtaining 50 decreases Of 14 patients with lymphadenopathy on CT imaging 5 36 achieved 14-61 reductions sum of perpendicular diameters By NCI-WG criteria two patients achieved partial responses 10 SC veltuzumab appeared active in all dose groups with no obvious exposure-response relationship despite cumulative doses ranging from 320-5120 mg Overall median progression-free survival was 7.7 months three patients remained progression-free 1 year 2 ongoing at 2-year study completion These data suggest further studies of SC veltuzumab in CLL are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 376, 3, 174, 1, 2529, 2969, 4344, 5, 312, 2198, 548, 15001, 4, 442, 1193, 552, 239, 7, 103, 493, 3457, 15, 5904, 81, 4344, 454, 18, 244, 39, 415, 78, 175, 15, 3457, 15, 5904, 81, 936, 709, 245, 415, 78, 79, 24, 10, 149, 421, 5, 158, 9753, 1980, 1163, 2473, 1754, 2428, 8125, 340, 4, 62, 7, 689, 775, 33, 970, 5, 133, 7, 5244, 212, 2140, 1, 213, 7, 5, 4962, 23, 425, 270, 33, 511, 513, 213, 713, 2153, 3216, 1, 13385, 10390, 20, 2580, 12906, 371, 100, 7, 513, 450, 253, 79, 2969, 15001, 2121, 544, 4, 62, 61, 271, 5, 77, 6228, 645, 51, 858, 550, 967, 415, 2223, 29, 5904, 41217, 81, 63, 52, 91, 115, 25, 10, 67, 67, 53, 169, 7, 958, 91, 115, 14, 111, 18, 942, 28, 18, 111, 45, 1438, 46, 74, 309, 195, 94, 1, 2969, 15001, 4, 552, 32, 1197]",967.0,26389849,519
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.,Leukemia & lymphoma,Leuk. Lymphoma,2015-10-19,"Chronic lymphocytic leukemia (CLL) and myeloproliferative neoplasms (MPN) may occur concomitantly. However, little is known about the pathobiological characteristics and interaction between the neoplastic clones in these rare cases of coinciding malignancies. We retrospectively examined the clinical and biological characteristics of 13 patients with concomitant CLL and MPN--eight primary myelofibrosis (PMF), three essential thrombocytosis (ET), and two polycythemia vera (PV)--who presented to our institution between 1998 and 2014, and tested all patients for MPN-specific aberrations, such as JAK2, MPL and CALR mutations. Along with epidemiological and molecular characterization of this rare condition, we found that JAK2 mutation can be detected 9 years prior to PMF diagnosis, suggesting that PMF clinical phenotype may require several years to develop and CLL/MPN clinical co-occurrence might be sustained by common molecular events. Some features of these patients suggest that pathobiologies of these diseases might be intertwined.",Journal Article,1555.0,9.0,Chronic lymphocytic CLL and neoplasms MPN may occur concomitantly However little is known about the pathobiological characteristics and interaction between the neoplastic clones in these rare cases of coinciding malignancies We retrospectively examined the clinical and biological characteristics of 13 patients with concomitant CLL and MPN -- eight primary myelofibrosis PMF three essential thrombocytosis ET and two polycythemia vera PV -- who presented to our institution between 1998 and 2014 and tested all patients for MPN-specific aberrations such as JAK2 MPL and CALR mutations Along with epidemiological and molecular characterization of this rare condition we found that JAK2 mutation can be detected 9 years prior to PMF diagnosis suggesting that PMF clinical phenotype may require several years to develop and CLL/MPN clinical co-occurrence might be sustained by common molecular events Some features of these patients suggest that pathobiologies of these diseases might be intertwined,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 1179, 4125, 68, 1271, 6485, 137, 1215, 16, 440, 545, 3, 22217, 374, 2, 915, 59, 3, 2000, 2749, 4, 46, 622, 140, 1, 23852, 441, 21, 894, 409, 3, 38, 2, 1037, 374, 1, 233, 7, 5, 1781, 552, 2, 4125, 659, 86, 4637, 7389, 169, 1452, 7589, 2022, 2, 100, 5755, 5756, 3328, 54, 917, 6, 114, 731, 59, 1850, 2, 1409, 2, 650, 62, 7, 9, 4125, 112, 2152, 225, 22, 2509, 16440, 2, 11222, 138, 1510, 5, 4614, 2, 219, 2136, 1, 26, 622, 2850, 21, 204, 17, 2509, 258, 122, 40, 530, 83, 60, 324, 6, 7389, 147, 802, 17, 7389, 38, 1005, 68, 1353, 392, 60, 6, 690, 2, 552, 4125, 38, 1269, 2291, 822, 40, 2275, 20, 186, 219, 281, 476, 404, 1, 46, 7, 309, 17, 66836, 1, 46, 1342, 822, 40, 22377]",997.0,26402369,20
Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements.,PloS one,PLoS ONE,2015-09-30,"Though numerous polymorphisms have been associated with risk of developing lymphoma, how these variants function to promote tumorigenesis is poorly understood. Here, we report that lymphoma risk SNPs, especially in the non-Hodgkin's lymphoma subtype chronic lymphocytic leukemia, are significantly enriched for co-localization with epigenetic marks of active gene regulation. These enrichments were seen in a lymphoid-specific manner for numerous ENCODE datasets, including DNase-hypersensitivity as well as multiple segmentation-defined enhancer regions. Furthermore, we identify putatively functional SNPs that are both in regulatory elements in lymphocytes and are associated with gene expression changes in blood. We developed an algorithm, UES, that uses a Monte Carlo simulation approach to calculate the enrichment of previously identified risk SNPs in various functional elements. This multiscale approach integrating multiple datasets helps disentangle the underlying biology of lymphoma, and more broadly, is generally applicable to GWAS results from other diseases as well. ",Journal Article,1574.0,2.0,Though numerous polymorphisms have been associated with risk of developing how these variants function to promote tumorigenesis is poorly understood Here we report that risk SNPs especially in the 's subtype chronic lymphocytic are significantly enriched for co-localization with epigenetic marks of active gene regulation These enrichments were seen in a lymphoid-specific manner for numerous ENCODE datasets including DNase-hypersensitivity as well as multiple segmentation-defined enhancer regions Furthermore we identify putatively functional SNPs that are both in regulatory elements in lymphocytes and are associated with gene expression changes in blood We developed an algorithm UES that uses a Monte Carlo simulation approach to calculate the enrichment of previously identified risk SNPs in various functional elements This multiscale approach integrating multiple datasets helps disentangle the underlying biology of and more broadly is generally applicable to GWAS results from other diseases as well,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2471, 2331, 1203, 47, 85, 41, 5, 43, 1, 931, 832, 46, 839, 343, 6, 1617, 1565, 16, 1240, 1784, 467, 21, 414, 17, 43, 1109, 1093, 4, 3, 292, 875, 442, 1193, 32, 97, 2220, 9, 1269, 2145, 5, 1418, 8418, 1, 544, 145, 863, 46, 49313, 11, 527, 4, 8, 2303, 112, 1708, 9, 2331, 6924, 3455, 141, 21951, 4034, 22, 149, 22, 232, 5913, 395, 4239, 1374, 798, 21, 255, 12874, 583, 1109, 17, 32, 110, 4, 1253, 2531, 4, 1594, 2, 32, 41, 5, 145, 55, 400, 4, 315, 21, 276, 35, 2124, 25194, 17, 4025, 8, 7990, 7991, 4026, 353, 6, 3232, 3, 3020, 1, 373, 108, 43, 1109, 4, 747, 583, 2531, 26, 32253, 353, 4568, 232, 3455, 6484, 33209, 3, 1181, 891, 1, 2, 80, 5482, 16, 1228, 3801, 6, 3297, 99, 29, 127, 1342, 22, 149]",1012.0,26422229,150
"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-10-12,"RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted. Primary study objectives included determination of the dose and safety profile of RG7112. Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL). Some Stratum A patients were treated at the MTD to assess clinical activity. RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B). All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported. Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure. Antileukemia activity was observed in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response. Exploratory analysis revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients. Two patients with TP53 mutations exhibited clinical activity. p53 target genes were induced only in TP53 wild-type leukemic cells. Baseline expression levels of MDM2 correlated positively with clinical response. RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies.","Clinical Trial, Phase I",1562.0,93.0,RG7112 is a small-molecule MDM2 antagonist MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias Thus a phase I study of RG7112 in patients with hematologic malignancies was conducted Primary study objectives included determination of the dose and safety profile of RG7112 Secondary objectives included evaluation of pharmacokinetics pharmacodynamics such as TP53-mutation status and MDM2 expression and preliminary clinical activity Patients were divided into two cohorts Stratum A relapsed/refractory acute myeloid AML except acute promyelocytic acute lymphoblastic and chronic myelogenous and Stratum B relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic CLL/sCLL Some Stratum A patients were treated at the MTD to assess clinical activity RG7112 was administered to 116 patients 96 patients in Stratum A and 20 patients in Stratum B All patients experienced at least 1 adverse event and 3 dose-limiting toxicities were reported Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure Antileukemia activity was observed in the 30 patients with AML assessed at the MTD including 5 patients who met International Working Group IWG criteria for response Exploratory analysis revealed TP53 mutations in 14 of Stratum A patients and in 40 of Stratum B patients Two patients with TP53 mutations exhibited clinical activity p53 target genes were induced only in TP53 wild-type leukemic cells Baseline expression levels of MDM2 correlated positively with clinical response RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22908, 16, 8, 302, 1354, 3277, 3137, 3277, 16, 8, 199, 2452, 1, 3, 30, 1245, 624, 2, 746, 1711, 4, 2792, 631, 8, 124, 70, 45, 1, 22908, 4, 7, 5, 813, 441, 10, 426, 86, 45, 2409, 159, 3104, 1, 3, 61, 2, 367, 800, 1, 22908, 568, 2409, 159, 451, 1, 1159, 3587, 225, 22, 1206, 258, 156, 2, 3277, 55, 2, 1676, 38, 128, 7, 11, 2176, 237, 100, 736, 4897, 8, 591, 430, 286, 533, 329, 2187, 286, 4300, 286, 1275, 2, 442, 2194, 2, 4897, 132, 591, 430, 442, 1193, 2647, 302, 31, 1193, 552, 49333, 476, 4897, 8, 7, 11, 73, 28, 3, 961, 6, 423, 38, 128, 22908, 10, 468, 6, 3790, 7, 921, 7, 4, 4897, 8, 2, 179, 7, 4, 4897, 132, 62, 7, 592, 28, 506, 14, 290, 774, 2, 27, 61, 817, 385, 11, 210, 1456, 65, 1103, 17, 936, 391, 1280, 651, 391, 645, 9169, 128, 10, 164, 4, 3, 201, 7, 5, 329, 275, 28, 3, 961, 141, 33, 7, 54, 543, 944, 2644, 87, 14620, 371, 9, 51, 2386, 65, 553, 1206, 138, 4, 213, 1, 4897, 8, 7, 2, 4, 327, 1, 4897, 132, 7, 100, 7, 5, 1206, 138, 1416, 38, 128, 624, 283, 214, 11, 277, 158, 4, 1206, 955, 267, 2015, 37, 330, 55, 148, 1, 3277, 438, 2375, 5, 38, 51, 22908, 264, 38, 128, 480, 591, 430, 329, 2, 552, 49333, 3277, 297, 627, 4, 624, 3184, 2, 1431, 363, 1, 624, 283, 214, 21, 377, 3840, 1, 2545, 17, 3277, 297, 8489, 624, 343, 2, 7919, 38, 253, 4, 813, 441]",1871.0,26459177,303
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2015-10-12,"Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites. Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cancers, and the genetic correlation between pairs of cancers. GWAS heritability was statistically significant at nearly all sites, with the estimates of array-based heritability, hl (2), on the liability threshold (LT) scale ranging from 0.05 to 0.38. Estimating the combined heritability of multiple smoking characteristics, we calculate that at least 24% (95% confidence interval [CI] = 14% to 37%) and 7% (95% CI = 4% to 11%) of the heritability for lung and bladder cancer, respectively, can be attributed to genetic determinants of smoking. Most pairs of cancers studied did not show evidence of strong genetic correlation. We found only four pairs of cancers with marginally statistically significant correlations, specifically kidney and testes ( = 0.73, SE = 0.28), diffuse large B-cell lymphoma (DLBCL) and pediatric osteosarcoma ( = 0.53, SE = 0.21), DLBCL and chronic lymphocytic leukemia (CLL) ( = 0.51, SE =0.18), and bladder and lung ( = 0.35, SE = 0.14). Correlation analysis also indicates that the genetic architecture of lung cancer differs between a smoking population of European ancestry and a nonsmoking Asian population, allowing for the possibility that the genetic etiology for the same disease can vary by population and environmental exposures. Our results provide important insights into the genetic architecture of cancers and suggest new avenues for investigation.",Journal Article,1562.0,68.0,Studies of related individuals have consistently demonstrated notable familial aggregation of cancer We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms SNPs for cancer at 13 anatomical sites Between 2007 and 2014 the US National Cancer Institute has generated data from genome-wide association studies GWAS for 49 492 cancer case patients and 34 131 control patients We apply novel mixed model methodology GCTA to this GWAS data to estimate the heritability of individual cancers as well as the proportion of heritability attributable to cigarette smoking in smoking-related cancers and the genetic correlation between pairs of cancers GWAS heritability was statistically significant at nearly all sites with the estimates of array-based heritability hl 2 on the liability threshold LT scale ranging from 0.05 to 0.38 Estimating the combined heritability of multiple smoking characteristics we calculate that at least 24 95 confidence interval CI 14 to 37 and 7 95 CI 4 to 11 of the heritability for and cancer respectively can be attributed to genetic determinants of smoking Most pairs of cancers studied did not show evidence of strong genetic correlation We found only four pairs of cancers with marginally statistically significant correlations specifically and testes  0.73 SE 0.28 diffuse large B-cell DLBCL and pediatric  0.53 SE 0.21 DLBCL and chronic lymphocytic CLL  0.51 SE =0.18 and and  0.35 SE 0.14 Correlation analysis also indicates that the genetic architecture of cancer differs between a smoking population of European ancestry and a nonsmoking Asian population allowing for the possibility that the genetic etiology for the same disease can vary by population and environmental exposures Our results provide important insights into the genetic architecture of cancers and suggest new avenues for investigation,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,"[94, 1, 139, 869, 47, 2433, 264, 4090, 2200, 6598, 1, 12, 21, 1130, 6, 1191, 3, 13160, 2, 336, 816, 2971, 6, 3, 3396, 176, 1, 186, 226, 1579, 1203, 1109, 9, 12, 28, 233, 5024, 633, 59, 1307, 2, 1409, 3, 843, 657, 12, 1377, 71, 1419, 74, 29, 898, 1019, 248, 94, 3297, 9, 739, 11628, 12, 473, 7, 2, 562, 2229, 182, 7, 21, 4930, 229, 1739, 202, 3209, 66961, 6, 26, 3297, 74, 6, 1191, 3, 13160, 1, 797, 163, 22, 149, 22, 3, 920, 1, 13160, 2971, 6, 4870, 979, 4, 979, 139, 163, 2, 3, 336, 816, 59, 2773, 1, 163, 3297, 13160, 10, 712, 93, 28, 1857, 62, 633, 5, 3, 1423, 1, 1926, 90, 13160, 1718, 18, 23, 3, 24602, 2390, 4980, 1124, 2223, 29, 13, 474, 6, 13, 519, 4563, 3, 397, 13160, 1, 232, 979, 374, 21, 3232, 17, 28, 506, 259, 48, 307, 268, 58, 213, 6, 567, 2, 67, 48, 58, 39, 6, 175, 1, 3, 13160, 9, 2, 12, 106, 122, 40, 3073, 6, 336, 3403, 1, 979, 96, 2773, 1, 163, 656, 205, 44, 514, 241, 1, 1082, 336, 816, 21, 204, 158, 294, 2773, 1, 163, 5, 5007, 712, 93, 2553, 1225, 2, 13100, 7128, 13, 803, 3428, 13, 339, 1388, 375, 132, 31, 1446, 2, 815, 7128, 13, 699, 3428, 13, 239, 1446, 2, 442, 1193, 552, 7128, 13, 725, 3428, 13, 203, 2, 2, 7128, 13, 465, 3428, 13, 213, 816, 65, 120, 2640, 17, 3, 336, 4447, 1, 12, 4990, 59, 8, 979, 266, 1, 1865, 3535, 2, 8, 20378, 2399, 266, 2952, 9, 3, 2526, 17, 3, 336, 2855, 9, 3, 827, 34, 122, 2825, 20, 266, 2, 3766, 3401, 114, 99, 377, 305, 1957, 237, 3, 336, 4447, 1, 163, 2, 309, 217, 6612, 9, 940]",1922.0,26464424,135
"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.",Blood,Blood,2015-10-15,"Obinutuzumab is a glycoengineered, type 2 anti-CD20 humanized antibody with single-agent activity in relapsed chronic lymphocytic leukemia (CLL). With other CD20 antibodies, a dose-response relationship has been shown. We therefore performed a randomized phase 2 study in symptomatic, untreated CLL patients to evaluate if an obinutuzumab dose response exists. Obinutuzumab was given at a dose of 1000 mg (100 mg IV day 1, 900 mg day 2, 1000 mg day 8 and day 15 of cycle 1; 1000 mg day 1 of cycles 2-8) or 2000 mg (100 mg IV day 1, 900 mg day 2, 1000 mg day 3, 2000 mg day 8 and day 15 of cycle 1; 2000 mg day 1 of cycles 2-8). The primary end point was overall response rate (ORR). Eighty patients were enrolled with similar demographics: median age 67 years, 41% high-risk Rai disease, and 10% del(17p)(13.1). ORR (67% vs 49%, P = .08) and complete response (CR) or CR with incomplete cytopenia response (20% vs 5%) favored 2000 mg obinutuzumab. Overall, therapy was well tolerated, and infusion events were manageable. This study demonstrates significant efficacy of obinutuzumab monotherapy, for 1000 mg as well as for 2000 mg, in untreated CLL patients with acceptable toxicity. Although exploratory, a dose-response relationship may exist, but its relevance to improving progression-free survival is uncertain and will require further follow-up. This trial was registered at www.clinicaltrials.gov as #NCT01414205. ","Clinical Trial, Phase II",1559.0,38.0,Obinutuzumab is a glycoengineered type 2 anti-CD20 humanized antibody with single-agent activity in relapsed chronic lymphocytic CLL With other CD20 antibodies a dose-response relationship has been shown We therefore performed a randomized phase 2 study in symptomatic untreated CLL patients to evaluate if an obinutuzumab dose response exists Obinutuzumab was given at a dose of 1000 mg 100 mg IV day 1 900 mg day 2 1000 mg day 8 and day 15 of cycle 1 1000 mg day 1 of cycles 2-8 or 2000 mg 100 mg IV day 1 900 mg day 2 1000 mg day 3 2000 mg day 8 and day 15 of cycle 1 2000 mg day 1 of cycles 2-8 The primary end point was overall response rate ORR Eighty patients were enrolled with similar demographics median age 67 years 41 high-risk Rai disease and 10 del 17p 13.1 ORR 67 vs 49 P .08 and complete response CR or CR with incomplete cytopenia response 20 vs 5 favored 2000 mg obinutuzumab Overall therapy was well tolerated and infusion events were manageable This study demonstrates significant efficacy of obinutuzumab monotherapy for 1000 mg as well as for 2000 mg in untreated CLL patients with acceptable toxicity Although exploratory a dose-response relationship may exist but its relevance to improving progression-free survival is uncertain and will require further follow-up This trial was registered at www.clinicaltrials.gov as NCT01414205,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[10380, 16, 8, 49250, 267, 18, 312, 2198, 3619, 548, 5, 226, 420, 128, 4, 591, 442, 1193, 552, 5, 127, 2198, 890, 8, 61, 51, 858, 71, 85, 443, 21, 673, 173, 8, 384, 124, 18, 45, 4, 1704, 1278, 552, 7, 6, 376, 492, 35, 10380, 61, 51, 2481, 10380, 10, 447, 28, 8, 61, 1, 2345, 81, 394, 81, 478, 218, 14, 5310, 81, 218, 18, 2345, 81, 218, 66, 2, 218, 167, 1, 417, 14, 2345, 81, 218, 14, 1, 410, 18, 66, 15, 1081, 81, 394, 81, 478, 218, 14, 5310, 81, 218, 18, 2345, 81, 218, 27, 1081, 81, 218, 66, 2, 218, 167, 1, 417, 14, 1081, 81, 218, 14, 1, 410, 18, 66, 3, 86, 396, 741, 10, 63, 51, 116, 1735, 2207, 7, 11, 346, 5, 288, 2221, 52, 89, 598, 60, 605, 64, 43, 4121, 34, 2, 79, 3084, 4135, 233, 14, 1735, 598, 105, 739, 19, 1592, 2, 236, 51, 684, 15, 684, 5, 2610, 8165, 51, 179, 105, 33, 5269, 1081, 81, 10380, 63, 36, 10, 149, 421, 2, 904, 281, 11, 2808, 26, 45, 1902, 93, 209, 1, 10380, 1411, 9, 2345, 81, 22, 149, 22, 9, 1081, 81, 4, 1278, 552, 7, 5, 1595, 155, 242, 2386, 8, 61, 51, 858, 68, 1923, 84, 211, 2088, 6, 1673, 91, 115, 25, 16, 2717, 2, 303, 1353, 195, 166, 126, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 66970]",1355.0,26472752,489
Outcomes of Haploidentical Stem Cell Transplantation forLymphoma with Melphalan-Based Conditioning.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-10-20,"Haploidentical transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PTCy) is increasingly utilized for the treatment of lymphoma and almost exclusively with the nonmyeloablative fludarabine (Flu)/cyclophosphamide/total body irradiation (TBI) conditioning regimen. We present early results of a reduced-intensity (RIC) regimen utilizing fludarabine and melphalan (FM) for the treatment of advanced lymphoma. All patients with a diagnosis of lymphoma or chronic lymphocytic leukemia (CLL) who received Haplo-SCT at the University of Texas MD Anderson Cancer Center between 2009 and 2014 were reviewed (N = 22). Patients received Flu 160 mg/m(2) and melphalan 100 mg/m(2) to 140 mg/m(2) with thiotepa 5 mg/kg or 2 Gy TBI. Because of concerns of increased treatment-related mortality (TRM) with the melphalan 140 mg/m(2) regimen (FM140), a RIC regimen with melphalan 100 mg/m(2) (FM100) was devised. Rituximab was included for CD20(+) disease. Graft-versus-host disease prophylaxis consisted of PTCy 50 mg/kg on days +3 and + 4, tacrolimus, and mycophenolate mofetil. Sixty-eight percent of all patients were not in complete remission at the time of transplantation. The 2-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 54%, 1-year TRM was 19%, and the cumulative incidence of relapse at 2 years was 27%. Two-year PFS for Hodgkin lymphoma, non-Hodgkin lymphoma, and CLL/small lymphocytic lymphoma were 57%, 51%, and 75%. Patients treated with FM100 compared to FM140 had equivalent PFS (71% versus 37%, P = .246) and OS (71% versus 58%, P = .32). These early results establish Flu and melphalan 100 mg/m(2) with 2 Gy TBI or thiotepa 5 mg/kg as a very promising conditioning regimen for the treatment of advanced lymphoma with Haplo-SCT and PTCy.",Journal Article,1554.0,16.0,Haploidentical transplantation Haplo-SCT with post-transplantation cyclophosphamide PTCy is increasingly utilized for the treatment of and almost exclusively with the nonmyeloablative fludarabine Flu /cyclophosphamide/total body irradiation TBI conditioning regimen We present early results of a reduced-intensity RIC regimen utilizing fludarabine and melphalan FM for the treatment of advanced All patients with a diagnosis of or chronic lymphocytic CLL who received Haplo-SCT at the University of Texas MD Anderson Cancer Center between 2009 and 2014 were reviewed N 22 Patients received Flu 160 mg/m 2 and melphalan 100 mg/m 2 to 140 mg/m 2 with thiotepa 5 mg/kg or 2 Gy TBI Because of concerns of increased treatment-related mortality TRM with the melphalan 140 mg/m 2 regimen FM140 a RIC regimen with melphalan 100 mg/m 2 FM100 was devised Rituximab was included for CD20 disease Graft-versus-host disease prophylaxis consisted of PTCy 50 mg/kg on days +3 and 4 tacrolimus and mycophenolate mofetil Sixty-eight percent of all patients were not in complete remission at the time of transplantation The 2-year progression-free survival PFS and overall survival OS for the entire cohort were 54 1-year TRM was 19 and the cumulative incidence of relapse at 2 years was 27 Two-year PFS for and CLL/small lymphocytic were 57 51 and 75 Patients treated with FM100 compared to FM140 had equivalent PFS 71 versus 37 P .246 and OS 71 versus 58 P .32 These early results establish Flu and melphalan 100 mg/m 2 with 2 Gy TBI or thiotepa 5 mg/kg as a very promising conditioning regimen for the treatment of advanced with Haplo-SCT and PTCy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5802, 497, 6584, 1988, 5, 539, 497, 1112, 10932, 16, 1635, 2080, 9, 3, 24, 1, 2, 2214, 4437, 5, 3, 6094, 2027, 5119, 1112, 181, 642, 1104, 4889, 1933, 477, 21, 364, 191, 99, 1, 8, 405, 837, 3365, 477, 2600, 2027, 2, 2370, 14228, 9, 3, 24, 1, 131, 62, 7, 5, 8, 147, 1, 15, 442, 1193, 552, 54, 103, 6584, 1988, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 59, 1238, 2, 1409, 11, 446, 78, 350, 7, 103, 5119, 3457, 81, 188, 18, 2, 2370, 394, 81, 188, 18, 6, 3304, 81, 188, 18, 5, 8182, 33, 81, 503, 15, 18, 381, 4889, 408, 1, 2061, 1, 101, 24, 139, 282, 5064, 5, 3, 2370, 3304, 81, 188, 18, 477, 25545, 8, 3365, 477, 5, 2370, 394, 81, 188, 18, 25544, 10, 10085, 855, 10, 159, 9, 2198, 34, 1599, 185, 1204, 34, 2049, 1695, 1, 10932, 212, 81, 503, 23, 162, 27, 2, 39, 5643, 2, 11902, 13246, 1746, 659, 714, 1, 62, 7, 11, 44, 4, 236, 734, 28, 3, 98, 1, 497, 3, 18, 111, 91, 115, 25, 300, 2, 63, 25, 118, 9, 3, 1797, 180, 11, 667, 14, 111, 5064, 10, 326, 2, 3, 967, 287, 1, 429, 28, 18, 60, 10, 428, 100, 111, 300, 9, 2, 552, 302, 1193, 11, 696, 725, 2, 481, 7, 73, 5, 25544, 72, 6, 25545, 42, 2017, 300, 792, 185, 567, 19, 6907, 2, 118, 792, 185, 717, 19, 531, 46, 191, 99, 1811, 5119, 2, 2370, 394, 81, 188, 18, 5, 18, 381, 4889, 15, 8182, 33, 81, 503, 22, 8, 923, 721, 1933, 477, 9, 3, 24, 1, 131, 5, 6584, 1988, 2, 10932]",1632.0,26497906,445
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.,Blood,Blood,2015-11-17,"Deep remission and prolonged disease-free survival can be achieved with first-line chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and rituximab, in the majority of patients with chronic lymphocytic leukemia (CLL). More modest results are reported with less intense regimens like obinutuzumab plus chlorambucil. Clinical assessment has limited sensitivity in detecting residual disease responsible for subsequent relapse, even including morphologic bone marrow (BM) evaluation. Multicolor flow cytometry and polymerase chain reaction (PCR)-based methods can detect minimal residual disease (MRD) to a sensitivity of 1:10,000 (10(-4)). Achieving BM MRD-negative complete remission (CR) is associated with superior progression-free survival (PFS) and overall survival; MRD status is the single best posttreatment predictor of long-term outcomes after CIT. Newer oral B-cell receptor signaling pathway inhibitors are highly effective at controlling disease, but best monotherapy responses are typically partial remission, and patients must remain on treatment to maintain disease control. Therapeutic progress is still needed for CLL. We propose that targeting MRD provides opportunity to realize this progress. Achieving BM MRD-negative CR is a prerequisite for long-term unmaintained disease-free survival and potential for cure. We review available methodologies for detecting MRD and correlations with posttreatment outcomes. We discuss the potential utility of MRD to direct individualized therapy. Finally, we discuss the importance of MRD-negative status as a surrogate marker for longer PFS in clinical studies to allow more rapid determination of clinical benefit.",Journal Article,1526.0,62.0,"Deep remission and prolonged disease-free survival can be achieved with first-line chemoimmunotherapy CIT such as combined fludarabine cyclophosphamide and rituximab in the majority of patients with chronic lymphocytic CLL More modest results are reported with less intense regimens like obinutuzumab plus chlorambucil Clinical assessment has limited sensitivity in detecting residual disease responsible for subsequent relapse even including morphologic marrow BM evaluation Multicolor flow cytometry and polymerase chain reaction PCR -based methods can detect minimal residual disease MRD to a sensitivity of 1:10,000 10 -4 Achieving BM MRD-negative complete remission CR is associated with superior progression-free survival PFS and overall survival MRD status is the single best posttreatment predictor of long-term outcomes after CIT Newer oral B-cell receptor signaling pathway inhibitors are highly effective at controlling disease but best monotherapy responses are typically partial remission and patients must remain on treatment to maintain disease control Therapeutic progress is still needed for CLL We propose that targeting MRD provides opportunity to realize this progress Achieving BM MRD-negative CR is a prerequisite for long-term unmaintained disease-free survival and potential for cure We review available methodologies for detecting MRD and correlations with posttreatment outcomes We discuss the potential utility of MRD to direct individualized therapy Finally we discuss the importance of MRD-negative status as a surrogate marker for longer PFS in clinical studies to allow more rapid determination of clinical benefit",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2369, 734, 2, 1069, 34, 115, 25, 122, 40, 513, 5, 157, 328, 4438, 9192, 225, 22, 397, 2027, 1112, 2, 855, 4, 3, 686, 1, 7, 5, 442, 1193, 552, 80, 1721, 99, 32, 210, 5, 299, 3933, 472, 733, 10380, 349, 11585, 38, 455, 71, 383, 485, 4, 2502, 753, 34, 2327, 9, 706, 429, 871, 141, 2815, 581, 1246, 451, 11920, 1412, 1914, 2, 1451, 1260, 1329, 604, 90, 636, 122, 1426, 1048, 753, 34, 2029, 6, 8, 485, 1, 3567, 79, 984, 79, 39, 1785, 1246, 2029, 199, 236, 734, 684, 16, 41, 5, 1123, 91, 115, 25, 300, 2, 63, 25, 2029, 156, 16, 3, 226, 824, 3149, 980, 1, 319, 337, 123, 50, 9192, 2246, 518, 132, 31, 153, 314, 308, 222, 32, 561, 323, 28, 1893, 34, 84, 824, 1411, 253, 32, 1969, 450, 734, 2, 7, 1642, 918, 23, 24, 6, 3040, 34, 182, 189, 1466, 16, 1234, 575, 9, 552, 21, 2548, 17, 529, 2029, 777, 2666, 6, 13020, 26, 1466, 1785, 1246, 2029, 199, 684, 16, 8, 12088, 9, 319, 337, 30712, 34, 115, 25, 2, 174, 9, 1722, 21, 206, 390, 6616, 9, 2502, 2029, 2, 2553, 5, 3149, 123, 21, 1139, 3, 174, 1207, 1, 2029, 6, 1196, 2596, 36, 1368, 21, 1139, 3, 1187, 1, 2029, 199, 156, 22, 8, 2592, 952, 9, 589, 300, 4, 38, 94, 6, 1700, 80, 1321, 3104, 1, 38, 247]",1646.0,26576865,573
2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.,Cancer,Cancer,2015-11-20,"A high pretreatment 2 -microglobulin (B2M) level is associated with inferior survival outcomes in patients with chronic lymphocytic leukemia. However, to the authors' knowledge, the prognostic and predictive significance of changes in B2M during treatment have not been reported to date. The authors analyzed 83 patients treated with ibrutinib-based regimens (66 with recurrent/refractory disease) and 198 treatment-naive patients who were treated with combined fludarabine, cyclophosphamide, and rituximab (FCR) to characterize changes in B2M and their relationship with clinical outcomes. B2M rapidly decreased during treatment with ibrutinib; on multivariable analysis, patients who received FCR (odds ratio, 0.40; 95% confidence interval [95% CI], 0.18-0.90 [P=.027]) were less likely to have normalized B2M at 6 months than patients treated with ibrutinib. On univariable analysis, normalization of B2M was associated with superior progression-free survival (PFS) from the 6-month landmark in patients treated with ibrutinib-based regimens and FCR. On multivariable analysis, failure to achieve normalized B2M at 6 months of treatment was associated with inferior PFS (hazard ratio, 16.9; 95% CI, 1.3-220.0 [P=.031]) for patients treated with ibrutinib, after adjusting for the effects of baseline B2M, stage of disease, fludarabine-refractory disease, and del(17p). In contrast, in patients treated with FCR, negative minimal residual disease status in the bone marrow was the only variable found to be significantly associated with superior PFS (hazard ratio, 0.28; 95% CI, 0.12-0.67 [P=.004]). Normalization of B2M at 6 months in patients treated with ibrutinib was found to be a useful predictor of subsequent PFS and may assist in clinical decision-making.",Comparative Study,1523.0,14.0,A high pretreatment 2 -microglobulin B2M level is associated with inferior survival outcomes in patients with chronic lymphocytic However to the authors knowledge the prognostic and predictive significance of changes in B2M during treatment have not been reported to date The authors analyzed 83 patients treated with ibrutinib-based regimens 66 with recurrent/refractory disease and 198 treatment-naive patients who were treated with combined fludarabine cyclophosphamide and rituximab FCR to characterize changes in B2M and their relationship with clinical outcomes B2M rapidly decreased during treatment with ibrutinib on multivariable analysis patients who received FCR odds ratio 0.40 95 confidence interval 95 CI 0.18-0.90 P .027 were less likely to have normalized B2M at 6 months than patients treated with ibrutinib On univariable analysis normalization of B2M was associated with superior progression-free survival PFS from the 6-month landmark in patients treated with ibrutinib-based regimens and FCR On multivariable analysis failure to achieve normalized B2M at 6 months of treatment was associated with inferior PFS hazard ratio 16.9 95 CI 1.3-220.0 P .031 for patients treated with ibrutinib after adjusting for the effects of baseline B2M stage of disease fludarabine-refractory disease and del 17p In contrast in patients treated with FCR negative minimal residual disease status in the marrow was the only variable found to be significantly associated with superior PFS hazard ratio 0.28 95 CI 0.12-0.67 P .004 Normalization of B2M at 6 months in patients treated with ibrutinib was found to be a useful predictor of subsequent PFS and may assist in clinical decision-making,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 64, 1194, 9314, 5371, 10918, 301, 16, 41, 5, 1663, 25, 123, 4, 7, 5, 442, 1193, 137, 6, 3, 738, 922, 3, 177, 2, 464, 724, 1, 400, 4, 10918, 190, 24, 47, 44, 85, 210, 6, 1244, 3, 738, 311, 852, 7, 73, 5, 1795, 90, 472, 700, 5, 387, 430, 34, 2, 6189, 24, 2462, 7, 54, 11, 73, 5, 397, 2027, 1112, 2, 855, 4953, 6, 1507, 400, 4, 10918, 2, 136, 858, 5, 38, 123, 10918, 1755, 340, 190, 24, 5, 1795, 23, 658, 65, 7, 54, 103, 4953, 610, 197, 13, 327, 48, 307, 268, 48, 58, 13, 203, 13, 424, 19, 4523, 11, 299, 322, 6, 47, 4207, 10918, 28, 49, 53, 76, 7, 73, 5, 1795, 23, 4084, 65, 5924, 1, 10918, 10, 41, 5, 1123, 91, 115, 25, 300, 29, 3, 49, 811, 3829, 4, 7, 73, 5, 1795, 90, 472, 2, 4953, 23, 658, 65, 496, 6, 1359, 4207, 10918, 28, 49, 53, 1, 24, 10, 41, 5, 1663, 300, 360, 197, 245, 83, 48, 58, 14, 27, 6211, 13, 19, 5304, 9, 7, 73, 5, 1795, 50, 1358, 9, 3, 176, 1, 330, 10918, 82, 1, 34, 2027, 430, 34, 2, 3084, 4135, 4, 748, 4, 7, 73, 5, 4953, 199, 1048, 753, 34, 156, 4, 3, 581, 10, 3, 158, 1347, 204, 6, 40, 97, 41, 5, 1123, 300, 360, 197, 13, 339, 48, 58, 13, 133, 13, 598, 19, 1520, 5924, 1, 10918, 28, 49, 53, 4, 7, 73, 5, 1795, 10, 204, 6, 40, 8, 999, 980, 1, 706, 300, 2, 68, 3425, 4, 38, 948, 1079]",1694.0,26588193,59
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc Receptor (FcR) Function.,The Journal of biological chemistry,J. Biol. Chem.,2015-12-01,"The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Fc receptors (FcR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses, but many such responses involve Btk. Here we tested the effects of ibrutinib on FcR-mediated activities in monocytes. We found that ibrutinib did not affect monocyte FcR-mediated phagocytosis, even at concentrations higher than those achieved physiologically, but suppressed FcR-mediated cytokine production. We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective. Because calcium flux is a major event downstream of Btk, we tested whether it was involved in phagocytosis. The results showed that blocking intracellular calcium flux decreased FcR-mediated cytokine production but not phagocytosis. To verify this, we measured activation of the GTPase Rac, which is responsible for actin polymerization. Results showed that ibrutinib did not inhibit Rac activation, nor did the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester). We next asked whether the effect of ibrutinib on monocyte FcR-mediated cytokine production could be rescued by IFN priming because NK cells produce IFN in response to antibody therapy. Pretreatment of monocytes with IFN abrogated the effects of ibrutinib on FcR-mediated cytokine production, suggesting that IFN priming could overcome this Btk inhibition. Furthermore, in monocyte-natural killer cell co-cultures, ibrutinib did not inhibit FcR-mediated cytokine production despite doing so in single cultures. These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function. ",Journal Article,1512.0,22.0,"The irreversible Bruton 's tyrosine kinase Btk inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic and B-cell Fc receptors FcR on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses but many such responses involve Btk Here we tested the effects of ibrutinib on FcR-mediated activities in monocytes We found that ibrutinib did not affect monocyte FcR-mediated phagocytosis even at concentrations higher than those achieved physiologically but suppressed FcR-mediated cytokine production We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective Because calcium flux is a major event downstream of Btk we tested whether it was involved in phagocytosis The results showed that blocking intracellular calcium flux decreased FcR-mediated cytokine production but not phagocytosis To verify this we measured activation of the GTPase Rac which is responsible for actin polymerization Results showed that ibrutinib did not inhibit Rac activation nor did the calcium chelator 1,2-bis 2-aminophenoxy ethane-N N N N'-tetraacetic acid tetrakis acetoxymethyl ester We next asked whether the effect of ibrutinib on monocyte FcR-mediated cytokine production could be rescued by IFN priming because NK cells produce IFN in response to antibody therapy Pretreatment of monocytes with IFN abrogated the effects of ibrutinib on FcR-mediated cytokine production suggesting that IFN priming could overcome this Btk inhibition Furthermore in monocyte-natural killer cell co-cultures ibrutinib did not inhibit FcR-mediated cytokine production despite doing so in single cultures These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic cell killing without affecting macrophage effector function",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 4422, 5796, 292, 564, 216, 3611, 230, 1795, 71, 443, 209, 480, 132, 31, 57, 225, 22, 442, 1193, 2, 132, 31, 19247, 1186, 16125, 23, 250, 37, 225, 22, 2748, 1343, 35, 305, 200, 4, 30, 112, 548, 517, 250, 253, 84, 445, 225, 253, 3882, 3611, 467, 21, 650, 3, 176, 1, 1795, 23, 16125, 517, 2042, 4, 5078, 21, 204, 17, 1795, 205, 44, 1158, 5231, 16125, 517, 11788, 871, 28, 1003, 142, 76, 135, 513, 9634, 84, 1908, 16125, 517, 1675, 1529, 21, 557, 46, 272, 4, 2748, 29, 49437, 399, 4, 92, 3611, 314, 16, 4552, 408, 3299, 9876, 16, 8, 458, 774, 1489, 1, 3611, 21, 650, 317, 192, 10, 646, 4, 11788, 3, 99, 224, 17, 2521, 2087, 3299, 9876, 340, 16125, 517, 1675, 1529, 84, 44, 11788, 6, 6355, 26, 21, 644, 363, 1, 3, 9189, 11173, 92, 16, 2327, 9, 5525, 12273, 99, 224, 17, 1795, 205, 44, 1433, 11173, 363, 2110, 205, 3, 3299, 17613, 14, 18, 7200, 18, 67257, 37065, 78, 78, 78, 25198, 18297, 971, 31359, 45445, 9617, 21, 1305, 3732, 317, 3, 254, 1, 1795, 23, 5231, 16125, 517, 1675, 1529, 359, 40, 7008, 20, 6062, 4903, 408, 1765, 37, 2410, 6062, 4, 51, 6, 548, 36, 1194, 1, 5078, 5, 6062, 3728, 3, 176, 1, 1795, 23, 16125, 517, 1675, 1529, 802, 17, 6062, 4903, 359, 1768, 26, 3611, 297, 798, 4, 5231, 1504, 3458, 31, 1269, 3231, 1795, 205, 44, 1433, 16125, 517, 1675, 1529, 550, 9647, 1743, 4, 226, 3231, 46, 99, 309, 17, 1525, 1795, 5, 848, 548, 36, 359, 1304, 442, 1193, 31, 3003, 187, 2319, 2674, 2070, 343]",1870.0,26627823,169
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.,The New England journal of medicine,N. Engl. J. Med.,2015-12-06,"New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy. In the dose-escalation phase, 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day. In an expansion cohort, 60 additional patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day. The majority of the study patients had received multiple previous treatments, and 89% had poor prognostic clinical or genetic features. Venetoclax was active at all dose levels. Clinical tumor lysis syndrome occurred in 3 of 56 patients in the dose-escalation cohort, with one death. After adjustments to the dose-escalation schedule, clinical tumor lysis syndrome did not occur in any of the 60 patients in the expansion cohort. Other toxic effects included mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%). A maximum tolerated dose was not identified. Among the 116 patients who received venetoclax, 92 (79%) had a response. Response rates ranged from 71 to 79% among patients in subgroups with an adverse prognosis, including those with resistance to fludarabine, those with chromosome 17p deletions (deletion 17p CLL), and those with unmutated IGHV. Complete remissions occurred in 20% of the patients, including 5% who had no minimal residual disease on flow cytometry. The 15-month progression-free survival estimate for the 400-mg dose groups was 69%. Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features. (Funded by AbbVie and Genentech; ClinicalTrials.gov number, NCT01328626.).","Clinical Trial, Phase I",1507.0,691.0,New treatments have improved outcomes for patients with relapsed chronic lymphocytic CLL but complete remissions remain uncommon Venetoclax has a distinct mechanism of action it targets BCL2 a protein central to the survival of CLL cells We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic SLL to assess safety pharmacokinetic profile and efficacy In the dose-escalation phase 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day In an expansion cohort 60 additional patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day The majority of the study patients had received multiple previous treatments and 89 had poor prognostic clinical or genetic features Venetoclax was active at all dose levels Clinical tumor lysis syndrome occurred in 3 of 56 patients in the dose-escalation cohort with one death After adjustments to the dose-escalation schedule clinical tumor lysis syndrome did not occur in any of the 60 patients in the expansion cohort Other toxic effects included mild diarrhea in 52 of the patients upper respiratory tract infection in 48 nausea in 47 and grade 3 or 4 neutropenia in 41 A maximum tolerated dose was not identified Among the 116 patients who received venetoclax 92 79 had a response Response rates ranged from 71 to 79 among patients in subgroups with an adverse prognosis including those with resistance to fludarabine those with chromosome 17p deletions deletion 17p CLL and those with unmutated IGHV Complete remissions occurred in 20 of the patients including 5 who had no minimal residual disease on flow cytometry The 15-month progression-free survival estimate for the 400-mg dose groups was 69 Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL including those with poor prognostic features Funded by AbbVie and Genentech ClinicalTrials.gov number NCT01328626,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[217, 640, 47, 231, 123, 9, 7, 5, 591, 442, 1193, 552, 84, 236, 3166, 918, 2052, 4454, 71, 8, 834, 670, 1, 1578, 192, 637, 3214, 8, 178, 854, 6, 3, 25, 1, 552, 37, 21, 426, 8, 124, 14, 61, 1125, 45, 1, 391, 518, 4454, 4, 7, 5, 591, 15, 430, 552, 15, 302, 1193, 5302, 6, 423, 367, 1456, 800, 2, 209, 4, 3, 61, 1125, 124, 664, 7, 103, 544, 24, 4, 104, 1, 659, 61, 271, 17, 1869, 29, 1577, 6, 6847, 81, 379, 218, 4, 35, 1422, 180, 335, 402, 7, 11, 73, 5, 8, 709, 5497, 20047, 126, 4, 415, 22, 64, 22, 1524, 81, 379, 218, 3, 686, 1, 3, 45, 7, 42, 103, 232, 698, 640, 2, 887, 42, 334, 177, 38, 15, 336, 404, 4454, 10, 544, 28, 62, 61, 148, 38, 30, 4783, 681, 489, 4, 27, 1, 664, 7, 4, 3, 61, 1125, 180, 5, 104, 273, 50, 6017, 6, 3, 61, 1125, 1055, 38, 30, 4783, 681, 205, 44, 1271, 4, 500, 1, 3, 335, 7, 4, 3, 1422, 180, 127, 1812, 176, 159, 1980, 1172, 4, 653, 1, 3, 7, 1726, 2718, 1696, 930, 4, 576, 1218, 4, 662, 2, 88, 27, 15, 39, 778, 4, 605, 8, 689, 421, 61, 10, 44, 108, 107, 3, 3790, 7, 54, 103, 4454, 937, 842, 42, 8, 51, 51, 151, 1869, 29, 792, 6, 842, 107, 7, 4, 1453, 5, 35, 290, 356, 141, 135, 5, 251, 6, 2027, 135, 5, 1170, 4135, 2439, 1528, 4135, 552, 2, 135, 5, 7216, 6220, 236, 3166, 489, 4, 179, 1, 3, 7, 141, 33, 54, 42, 77, 1048, 753, 34, 23, 1412, 1914, 3, 167, 811, 91, 115, 25, 1191, 9, 3, 1524, 81, 61, 271, 10, 790, 1094, 529, 1, 3214, 5, 4454, 42, 8, 2808, 367, 800, 2, 277, 1281, 253, 4, 7, 5, 591, 552, 15, 5302, 141, 135, 5, 334, 177, 404, 3827, 20, 18697, 2, 9010, 1252, 1239, 207, 67275]",2058.0,26639348,342
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.,The New England journal of medicine,N. Engl. J. Med.,2015-12-07,"Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion. The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred. In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).","Clinical Trial, Phase I",1506.0,345.0,Irreversible inhibition of Bruton 's tyrosine kinase BTK by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic CLL However ibrutinib also irreversibly inhibits alternative kinase targets which potentially compromises its therapeutic index Acalabrutinib ACP-196 is a more selective irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors In this uncontrolled phase 1-2 multicenter study we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety efficacy pharmacokinetics and pharmacodynamics of acalabrutinib Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation phase 1 portion of the study and 100 mg twice daily in the expansion phase 2 portion The median age of the patients was 62 years and patients had received a median of three previous therapies for CLL 31 had chromosome 17p13.1 deletion and 75 had unmutated immunoglobulin heavy-chain variable genes No dose-limiting toxic effects occurred during the dose-escalation portion of the study The most common adverse events observed were headache in 43 of the patients diarrhea in 39 and increased weight in 26 Most adverse events were of grade 1 or 2 At a median follow-up of 14.3 months the overall response rate was 95 including 85 with a partial response and 10 with a partial response with lymphocytosis the remaining 5 of patients had stable disease Among patients with chromosome 17p13.1 deletion the overall response rate was 100 No cases of Richter 's transformation CLL that has evolved into large-cell and only one case of CLL progression have occurred In this study the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL including those with chromosome 17p13.1 deletion Funded by the Acerta Pharma and others ClinicalTrials.gov number NCT02029443,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4422, 297, 1, 5796, 292, 564, 216, 3611, 20, 1795, 1449, 35, 305, 189, 3148, 9, 3, 24, 1, 442, 1193, 552, 137, 1795, 120, 12820, 1576, 1091, 216, 637, 92, 751, 17336, 211, 189, 558, 11378, 6953, 6369, 16, 8, 80, 1094, 4422, 3611, 230, 17, 16, 1225, 1114, 6, 401, 23, 3, 367, 2, 209, 1, 157, 914, 3611, 222, 4, 26, 6180, 124, 14, 18, 1570, 45, 21, 468, 518, 11378, 6, 713, 7, 54, 42, 591, 552, 6, 423, 3, 367, 209, 1159, 2, 3587, 1, 11378, 7, 11, 73, 5, 11378, 28, 8, 61, 1, 394, 6, 1524, 81, 1059, 391, 4, 3, 61, 1125, 124, 14, 3206, 1, 3, 45, 2, 394, 81, 936, 391, 4, 3, 1422, 124, 18, 3206, 3, 52, 89, 1, 3, 7, 10, 744, 60, 2, 7, 42, 103, 8, 52, 1, 169, 698, 235, 9, 552, 456, 42, 1170, 7526, 14, 1528, 2, 481, 42, 7216, 2593, 4013, 1260, 1347, 214, 77, 61, 817, 1812, 176, 489, 190, 3, 61, 1125, 3206, 1, 3, 45, 3, 96, 186, 290, 281, 164, 11, 4538, 4, 601, 1, 3, 7, 1172, 4, 587, 2, 101, 924, 4, 432, 96, 290, 281, 11, 1, 88, 14, 15, 18, 28, 8, 52, 166, 126, 1, 213, 27, 53, 3, 63, 51, 116, 10, 48, 141, 772, 5, 8, 450, 51, 2, 79, 5, 8, 450, 51, 5, 8125, 3, 1844, 33, 1, 7, 42, 585, 34, 107, 7, 5, 1170, 7526, 14, 1528, 3, 63, 51, 116, 10, 394, 77, 140, 1, 8452, 292, 1392, 552, 17, 71, 3937, 237, 375, 31, 2, 158, 104, 473, 1, 552, 91, 47, 489, 4, 26, 45, 3, 1094, 3611, 230, 11378, 42, 721, 367, 2, 209, 1241, 4, 7, 5, 591, 552, 141, 135, 5, 1170, 7526, 14, 1528, 3827, 20, 3, 49442, 15246, 2, 1749, 1252, 1239, 207, 49443]",1973.0,26641137,549
A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.,Expert review of hematology,Expert Rev Hematol,2016-02-24,"Chronic lymphocytic leukemia (CLL) is the most prevalent type of adult leukemia encountered in the western world. Patients with CLL are typically older, with a median age in the 70s, and are at risk for certain complications due to the disease itself and due to the therapies imparted for this. Patients with CLL are at a higher risk of infections, partly due to disease and partly due to the immune dysfunction induced by treatment, such as purine analogous-based chemoimmunotherapy, which leads to lymphocyte depletion. Infections are a leading cause of complications and death in CLL patients. Also, CLL patients have been shown to have a higher incidence of other malignancies. Despite this knowledge, there are no definite guidelines as to what is the best approach to manage or prevent these associated complications of CLL. In this review, the authors discuss the data available and outline recommendations as to the best way to approach this issue in daily practice. ",Journal Article,1427.0,4.0,Chronic lymphocytic CLL is the most prevalent type of adult encountered in the western world Patients with CLL are typically older with a median age in the 70s and are at risk for certain complications due to the disease itself and due to the therapies imparted for this Patients with CLL are at a higher risk of infections partly due to disease and partly due to the immune dysfunction induced by treatment such as purine analogous-based chemoimmunotherapy which leads to lymphocyte depletion Infections are a leading cause of complications and death in CLL patients Also CLL patients have been shown to have a higher incidence of other malignancies Despite this knowledge there are no definite guidelines as to what is the best approach to manage or prevent these associated complications of CLL In this review the authors discuss the data available and outline recommendations as to the best way to approach this issue in daily practice,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 2485, 267, 1, 780, 3903, 4, 3, 1521, 1956, 7, 5, 552, 32, 1969, 434, 5, 8, 52, 89, 4, 3, 29569, 2, 32, 28, 43, 9, 1840, 521, 520, 6, 3, 34, 4045, 2, 520, 6, 3, 235, 22341, 9, 26, 7, 5, 552, 32, 28, 8, 142, 43, 1, 1875, 5180, 520, 6, 34, 2, 5180, 520, 6, 3, 250, 1527, 277, 20, 24, 225, 22, 5006, 8579, 90, 4438, 92, 1940, 6, 1448, 2286, 1875, 32, 8, 1049, 708, 1, 521, 2, 273, 4, 552, 7, 120, 552, 7, 47, 85, 443, 6, 47, 8, 142, 287, 1, 127, 441, 550, 26, 922, 125, 32, 77, 8442, 677, 22, 6, 2067, 16, 3, 824, 353, 6, 4001, 15, 1682, 46, 41, 521, 1, 552, 4, 26, 206, 3, 738, 1139, 3, 74, 390, 2, 5277, 883, 22, 6, 3, 824, 2255, 6, 353, 26, 2537, 4, 391, 758]",939.0,26652692,687
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).,American journal of hematology,Am. J. Hematol.,2016-02-09,"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose anti-CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling older ( 65 years) patients (median age 76 years, n=31) with treatment nave progressive CLL. Patients received 8-12 weeks of standard subcutaneous alemtuzumab with either intravenous standard (375 mg/m(2) weekly)(n=16) or low dose (20 mg/m(2) 3x week)(n=15) rituximab. This study was closed before full accrual because the manufacturer withdrew alemtuzumab for treatment of CLL. The overall response rate was 90% with an 45% complete response rate, median progression-free survival of 17.9 months and no significant differences in outcome between the low and standard dose rituximab arms. The major toxicities were cytopenia and infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no other opportunistic infections. Combination mAb therapy was effective and tolerable treatment for older and frailer patients with progressive CLL, achieving a high rate of complete remissions. These data support the role of mAb in therapy for less fit CLL patients and the further study of low dose higher frequency anti-CD20 mAb therapy as a potentially more effective use of anti-CD20 mAb in the treatment of CLL.","Clinical Trial, Phase II",1442.0,7.0,Chronic lymphocytic leukemia/small lymphocytic CLL patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens Shorter duration combination monoclonal antibody mAb therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL Standard dose anti-CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells which can be minimized by decreasing the mAb dose We report a randomized phase II clinical trial enrolling older  65 years patients median age 76 years n 31 with treatment nave progressive CLL Patients received 8-12 weeks of standard subcutaneous alemtuzumab with either intravenous standard 375 mg/m 2 weekly n 16 or low dose 20 mg/m 2 3x week n 15 rituximab This study was closed before full accrual because the manufacturer withdrew alemtuzumab for treatment of CLL The overall response rate was 90 with an 45 complete response rate median progression-free survival of 17.9 months and no significant differences in outcome between the low and standard dose rituximab arms The major toxicities were cytopenia and infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no other opportunistic infections Combination mAb therapy was effective and tolerable treatment for older and frailer patients with progressive CLL achieving a high rate of complete remissions These data support the role of mAb in therapy for less fit CLL patients and the further study of low dose higher frequency anti-CD20 mAb therapy as a potentially more effective use of anti-CD20 mAb in the treatment of CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 2647, 302, 1193, 552, 7, 1888, 388, 36, 32, 629, 434, 2, 29571, 2, 12277, 1931, 9, 260, 4438, 472, 985, 654, 150, 848, 548, 2780, 36, 75, 3579, 2, 855, 71, 85, 443, 6, 40, 323, 2, 2668, 24, 9, 552, 260, 61, 312, 2198, 2780, 36, 1626, 407, 1, 2198, 55, 20, 3050, 552, 37, 92, 122, 40, 9243, 20, 2777, 3, 2780, 61, 21, 414, 8, 384, 124, 215, 38, 160, 6280, 434, 749, 556, 60, 7, 52, 89, 846, 60, 78, 456, 5, 24, 2809, 1014, 552, 7, 103, 66, 133, 244, 1, 260, 2529, 3579, 5, 361, 1262, 260, 4175, 81, 188, 18, 709, 78, 245, 15, 154, 61, 179, 81, 188, 18, 22403, 647, 78, 167, 855, 26, 45, 10, 3745, 348, 1647, 2262, 408, 3, 18245, 7939, 3579, 9, 24, 1, 552, 3, 63, 51, 116, 10, 424, 5, 35, 512, 236, 51, 116, 52, 91, 115, 25, 1, 269, 83, 53, 2, 77, 93, 362, 4, 228, 59, 3, 154, 2, 260, 61, 855, 1335, 3, 458, 385, 11, 8165, 2, 930, 5, 104, 24, 18222, 1546, 20, 1014, 3492, 8744, 84, 77, 127, 10026, 1875, 150, 2780, 36, 10, 323, 2, 2668, 24, 9, 434, 2, 29571, 7, 5, 1014, 552, 1785, 8, 64, 116, 1, 236, 3166, 46, 74, 538, 3, 200, 1, 2780, 4, 36, 9, 299, 2975, 552, 7, 2, 3, 195, 45, 1, 154, 61, 142, 675, 312, 2198, 2780, 36, 22, 8, 751, 80, 323, 119, 1, 312, 2198, 2780, 4, 3, 24, 1, 552]",1653.0,26662208,238
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.,Leukemia & lymphoma,Leuk. Lymphoma,2015-12-24,"Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), and especially those with purine analogue refractory disease or TP53 deletion/mutation, had a poor prognosis prior to the introduction of therapy targeting B cell receptor signaling. The mammalian target of rapamycin (mTOR) inhibitor everolimus has biological activity in CLL and can mobilize CLL cells from the lymphoid tissues into the circulation. In this clinical trial we determined the maximum tolerated dose (MTD) of everolimus together with eight weeks of standard dose subcutaneous alemtuzumab (Phase I) and then evaluated the tolerability and efficacy of therapy of relapsed/refractory CLL with the combination of everolimus and alemtuzumab (Phase II). The maximum tolerated dose of oral everolimus was 2.5mg three times/week. Therapy with everolimus and alemtuzumab was tolerable, but not sufficiently efficacious (33% partial responses, no complete responses) to recommend further development of the regimen.","Clinical Trial, Phase I",1489.0,3.0,Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic CLL and especially those with purine analogue refractory disease or TP53 deletion/mutation had a poor prognosis prior to the introduction of therapy targeting B cell receptor signaling The mammalian target of rapamycin mTOR inhibitor everolimus has biological activity in CLL and can mobilize CLL cells from the lymphoid tissues into the circulation In this clinical trial we determined the maximum tolerated dose MTD of everolimus together with eight weeks of standard dose subcutaneous alemtuzumab Phase I and then evaluated the tolerability and efficacy of therapy of relapsed/refractory CLL with the combination of everolimus and alemtuzumab Phase II The maximum tolerated dose of oral everolimus was 2.5 mg three times/week Therapy with everolimus and alemtuzumab was tolerable but not sufficiently efficacious 33 partial responses no complete responses to recommend further development of the regimen,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 591, 430, 442, 1193, 2647, 302, 1193, 552, 2, 1093, 135, 5, 5006, 4696, 430, 34, 15, 1206, 1528, 258, 42, 8, 334, 356, 324, 6, 3, 2456, 1, 36, 529, 132, 31, 153, 314, 3, 2359, 283, 1, 1620, 873, 230, 1400, 71, 1037, 128, 4, 552, 2, 122, 13788, 552, 37, 29, 3, 2303, 742, 237, 3, 4984, 4, 26, 38, 160, 21, 509, 3, 689, 421, 61, 961, 1, 1400, 1162, 5, 659, 244, 1, 260, 61, 2529, 3579, 124, 70, 2, 818, 194, 3, 1543, 2, 209, 1, 36, 1, 591, 430, 552, 5, 3, 150, 1, 1400, 2, 3579, 124, 215, 3, 689, 421, 61, 1, 518, 1400, 10, 18, 33, 81, 169, 1072, 647, 36, 5, 1400, 2, 3579, 10, 2668, 84, 44, 5938, 3289, 466, 450, 253, 77, 236, 253, 6, 2237, 195, 193, 1, 3, 477]",987.0,26699397,5
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.,Oncotarget,Oncotarget,2016-01-01,"In chronic lymphocytic leukemia (CLL), patients with unmutated immunoglobulin heavy chain variable region gene (UM-CLL) have worse outcomes than mutated CLL (M-CLL) following chemotherapy or chemoimmunotherapy. However, in the era of BCR-targeted therapies, the adverse prognostic impact of unmutated IGHV seems to be diminishing, and there are clinical datasets showing unexpected improved responses in UM-CLL. We investigated the biological differences of BTK activity between these subgroups and further compared the impact of ibrutinib on molecular and cellular behaviors. Immunoblotting analysis revealed that phosphorylated active BTK is significantly higher in UM-CLL. Moreover, UM-CLL, compared to M-CLL, displayed a much higher proliferative capacity that was correlated with higher phospho-BTK and greater sensitivity to ibrutinib. In addition, BTK depletion with siRNA led to a more prominent reduction in the proliferation of UM-CLL, suggesting that elevated BTK activity is responsible for increased cell proliferation. Further, cell signaling activity by multiple measurements was consistently higher in UM-CLL accompanied by a higher sensitivity to ibrutinib. These studies link UM-CLL to elevated BCR signaling, heightened BTK-dependent cell proliferation and increased sensitivity to ibrutinib. The prognostic significance of IGHV mutation should be reevaluated in the era of new therapies targeting BCR signaling.",Journal Article,1481.0,25.0,In chronic lymphocytic CLL patients with unmutated immunoglobulin heavy chain variable region gene UM-CLL have worse outcomes than mutated CLL M-CLL following chemotherapy or chemoimmunotherapy However in the era of BCR-targeted therapies the adverse prognostic impact of unmutated IGHV seems to be diminishing and there are clinical datasets showing unexpected improved responses in UM-CLL We investigated the biological differences of BTK activity between these subgroups and further compared the impact of ibrutinib on molecular and cellular behaviors Immunoblotting analysis revealed that phosphorylated active BTK is significantly higher in UM-CLL Moreover UM-CLL compared to M-CLL displayed a much higher proliferative capacity that was correlated with higher phospho-BTK and greater sensitivity to ibrutinib In addition BTK depletion with siRNA led to a more prominent reduction in the proliferation of UM-CLL suggesting that elevated BTK activity is responsible for increased cell proliferation Further cell signaling activity by multiple measurements was consistently higher in UM-CLL accompanied by a higher sensitivity to ibrutinib These studies link UM-CLL to elevated BCR signaling heightened BTK-dependent cell proliferation and increased sensitivity to ibrutinib The prognostic significance of IGHV mutation should be reevaluated in the era of new therapies targeting BCR signaling,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 7, 5, 7216, 2593, 4013, 1260, 1347, 1053, 145, 5878, 552, 47, 639, 123, 76, 1185, 552, 188, 552, 366, 56, 15, 4438, 137, 4, 3, 1713, 1, 1062, 238, 235, 3, 290, 177, 345, 1, 7216, 6220, 2744, 6, 40, 12497, 2, 125, 32, 38, 3455, 2069, 3792, 231, 253, 4, 5878, 552, 21, 565, 3, 1037, 362, 1, 3611, 128, 59, 46, 1453, 2, 195, 72, 3, 345, 1, 1795, 23, 219, 2, 763, 3704, 5293, 65, 553, 17, 2365, 544, 3611, 16, 97, 142, 4, 5878, 552, 1393, 5878, 552, 72, 6, 188, 552, 2507, 8, 1802, 142, 2441, 2162, 17, 10, 438, 5, 142, 3125, 3611, 2, 378, 485, 6, 1795, 4, 352, 3611, 2286, 5, 1919, 836, 6, 8, 80, 3689, 628, 4, 3, 457, 1, 5878, 552, 802, 17, 804, 3611, 128, 16, 2327, 9, 101, 31, 457, 195, 31, 314, 128, 20, 232, 1685, 10, 2433, 142, 4, 5878, 552, 2756, 20, 8, 142, 485, 6, 1795, 46, 94, 3460, 5878, 552, 6, 804, 1062, 314, 7145, 3611, 470, 31, 457, 2, 101, 485, 6, 1795, 3, 177, 724, 1, 6220, 258, 257, 40, 13874, 4, 3, 1713, 1, 217, 235, 529, 1062, 314]",1396.0,26717038,725
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-01-05,"We evaluated efficacy and tolerability of the combination of ofatumumab and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and explored whether immune system characteristics could influence the response to treatment. Thirty-four patients were enrolled in this phase II study. Ofatumumab was administered at a dose of 300 mg on day 1, 1,000 mg on days 8, 15, and 22 during course 1, 1,000 mg on day 1 during courses 3-6, and once every other course during courses 7-24 (28-day courses). Oral lenalidomide (10 mg daily) was started on day 9 and continued for as long as a clinical benefit was observed. The overall response rate was 71%. Eight patients (24%) achieved a complete remission (CR) or CR with incomplete recovery of blood counts, including 9% with minimal residual disease-negative CR. The median progression-free survival was 16 months, and the estimated 5-year survival was 53%. The most common treatment-related toxicity was neutropenia (grade >2 in 18% of the 574 patient courses). The most frequent infectious complications were pneumonia and neutropenic fever (24% and 9% of patients, respectively). We observed that patients who achieved a CR had at baseline higher numbers and a better preserved function of T cells and natural killer cells compared with non-responders. The combination of ofatumumab and lenalidomide is a well-tolerated regimen that induces durable responses in the majority of patients with relapsed/refractory CLL. Our correlative data suggest a role of competent immune system in supporting the efficacy of this treatment. Clin Cancer Res; 22(10); 2359-67. 2016 AACR.","Clinical Trial, Phase II",1477.0,15.0,"We evaluated efficacy and tolerability of the combination of ofatumumab and lenalidomide in patients with relapsed/refractory chronic lymphocytic CLL and explored whether immune system characteristics could influence the response to treatment Thirty-four patients were enrolled in this phase II study Ofatumumab was administered at a dose of 300 mg on day 1 1,000 mg on days 8 15 and 22 during course 1 1,000 mg on day 1 during courses 3-6 and once every other course during courses 7-24 28-day courses Oral lenalidomide 10 mg daily was started on day 9 and continued for as long as a clinical benefit was observed The overall response rate was 71 Eight patients 24 achieved a complete remission CR or CR with incomplete recovery of blood counts including 9 with minimal residual disease-negative CR The median progression-free survival was 16 months and the estimated 5-year survival was 53 The most common treatment-related toxicity was neutropenia grade 2 in 18 of the 574 patient courses The most frequent infectious complications were pneumonia and neutropenic fever 24 and 9 of patients respectively We observed that patients who achieved a CR had at baseline higher numbers and a better preserved function of T cells and natural killer cells compared with non-responders The combination of ofatumumab and lenalidomide is a well-tolerated regimen that induces durable responses in the majority of patients with relapsed/refractory CLL Our correlative data suggest a role of competent immune system in supporting the efficacy of this treatment Clin Cancer Res 22 10 2359-67 2016 AACR",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 194, 209, 2, 1543, 1, 3, 150, 1, 5732, 2, 1288, 4, 7, 5, 591, 430, 442, 1193, 552, 2, 1443, 317, 250, 398, 374, 359, 1054, 3, 51, 6, 24, 977, 294, 7, 11, 346, 4, 26, 124, 215, 45, 5732, 10, 468, 28, 8, 61, 1, 2036, 81, 23, 218, 14, 14, 984, 81, 23, 162, 66, 167, 2, 350, 190, 906, 14, 14, 984, 81, 23, 218, 14, 190, 1993, 27, 49, 2, 1059, 454, 127, 906, 190, 1993, 67, 259, 339, 218, 1993, 518, 1288, 79, 81, 391, 10, 3461, 23, 218, 83, 2, 1351, 9, 22, 319, 22, 8, 38, 247, 10, 164, 3, 63, 51, 116, 10, 792, 659, 7, 259, 513, 8, 236, 734, 684, 15, 684, 5, 2610, 1602, 1, 315, 1911, 141, 83, 5, 1048, 753, 34, 199, 684, 3, 52, 91, 115, 25, 10, 245, 53, 2, 3, 661, 33, 111, 25, 10, 699, 3, 96, 186, 24, 139, 155, 10, 778, 88, 18, 4, 203, 1, 3, 15297, 69, 1993, 3, 96, 908, 3398, 521, 11, 3485, 2, 3659, 2775, 259, 2, 83, 1, 7, 106, 21, 164, 17, 7, 54, 513, 8, 684, 42, 28, 330, 142, 1870, 2, 8, 380, 5797, 343, 1, 102, 37, 2, 1504, 3458, 37, 72, 5, 220, 1983, 3, 150, 1, 5732, 2, 1288, 16, 8, 149, 421, 477, 17, 1516, 1480, 253, 4, 3, 686, 1, 7, 5, 591, 430, 552, 114, 3679, 74, 309, 8, 200, 1, 6299, 250, 398, 4, 1912, 3, 209, 1, 26, 24, 2459, 12, 1936, 350, 79, 48713, 598, 3456, 1630]",1589.0,26733610,412
Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver.,Cancer cell,Cancer Cell,2016-01-01,"Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic leukemia asthe first targeted agents to enter routine clinical practice. A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2. ",Journal Article,1481.0,3.0,Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic as the first targeted agents to enter routine clinical practice A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax an inhibitor of the antiapoptotic protein BCL2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[222, 1, 132, 31, 153, 314, 2109, 2368, 3, 24, 1, 442, 1193, 22, 3, 157, 238, 183, 6, 7058, 1311, 38, 758, 8, 435, 2817, 20, 67487, 2, 6367, 2677, 35, 402, 189, 283, 20, 1760, 2269, 38, 99, 5, 4454, 35, 230, 1, 3, 4176, 178, 3214]",351.0,26766586,788
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.,Nature genetics,Nat. Genet.,2016-01-18,"Charting differences between tumors and normal tissue is a mainstay of cancer research. However, clonal tumor expansion from complex normal tissue architectures potentially obscures cancer-specific events, including divergent epigenetic patterns. Using whole-genome bisulfite sequencing of normal B cell subsets, we observed broad epigenetic programming of selective transcription factor binding sites coincident with the degree of B cell maturation. By comparing normal B cells to malignant B cells from 268 patients with chronic lymphocytic leukemia (CLL), we showed that tumors derive largely from a continuum of maturation states reflected in normal developmental stages. Epigenetic maturation in CLL was associated with an indolent gene expression pattern and increasingly favorable clinical outcomes. We further uncovered that most previously reported tumor-specific methylation events are normally present in non-malignant B cells. Instead, we identified a potential pathogenic role for transcription factor dysregulation in CLL, where excess programming by EGR and NFAT with reduced EBF and AP-1 programming imbalances the normal B cell epigenetic program. ",Journal Article,1464.0,109.0,Charting differences between tumors and normal tissue is a mainstay of cancer research However clonal tumor expansion from complex normal tissue architectures potentially obscures cancer-specific events including divergent epigenetic patterns Using whole-genome bisulfite sequencing of normal B cell subsets we observed broad epigenetic programming of selective transcription factor binding sites coincident with the degree of B cell maturation By comparing normal B cells to malignant B cells from 268 patients with chronic lymphocytic CLL we showed that tumors derive largely from a continuum of maturation states reflected in normal developmental stages Epigenetic maturation in CLL was associated with an indolent gene expression pattern and increasingly favorable clinical outcomes We further uncovered that most previously reported tumor-specific methylation events are normally present in non-malignant B cells Instead we identified a potential pathogenic role for transcription factor dysregulation in CLL where excess programming by EGR and NFAT with reduced EBF and AP-1 programming imbalances the normal B cell epigenetic program,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[35342, 362, 59, 57, 2, 295, 246, 16, 8, 4041, 1, 12, 389, 137, 1946, 30, 1422, 29, 840, 295, 246, 22583, 751, 49390, 12, 112, 281, 141, 8332, 1418, 764, 75, 902, 898, 6181, 615, 1, 295, 132, 31, 1890, 21, 164, 2094, 1418, 12926, 1, 1094, 866, 161, 791, 633, 9955, 5, 3, 1444, 1, 132, 31, 4537, 20, 1430, 295, 132, 37, 6, 393, 132, 37, 29, 8410, 7, 5, 442, 1193, 552, 21, 224, 17, 57, 3823, 1733, 29, 8, 7382, 1, 4537, 907, 4686, 4, 295, 4566, 1153, 1418, 4537, 4, 552, 10, 41, 5, 35, 2316, 145, 55, 1177, 2, 1635, 913, 38, 123, 21, 195, 5601, 17, 96, 373, 210, 30, 112, 569, 281, 32, 6150, 364, 4, 220, 393, 132, 37, 3496, 21, 108, 8, 174, 2806, 200, 9, 866, 161, 3935, 4, 552, 1257, 2612, 12926, 20, 10164, 2, 19518, 5, 405, 67501, 2, 2517, 14, 12926, 10143, 3, 295, 132, 31, 1418, 1243]",1140.0,26780610,245
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.,Blood,Blood,2016-01-26,"Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib. We found that 5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. In support of these findings, we observed that 3 CLL patients who had been treated with ibrutinib for 1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion, which correlated positively together and with clinical response. Lastly, we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment, tumor clearance, and survival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered concurrently. Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted. Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL. These trials were registered at www.clinicaltrials.gov as #NCT01747486, #NCT01105247, and #NCT01217749. ",Clinical Trial,1456.0,136.0,Anti-CD19 chimeric antigen receptor CAR T-cell therapy is highly promising but requires robust T-cell expansion and engraftment A T-cell defect in chronic lymphocytic CLL due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib We found that 5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells CTL019 in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells In support of these findings we observed that 3 CLL patients who had been treated with ibrutinib for 1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion which correlated positively together and with clinical response Lastly we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment tumor clearance and survival in human xenograft models of resistant acute lymphocytic and CLL when administered concurrently Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL These trials were registered at www.clinicaltrials.gov as NCT01747486 NCT01105247 and NCT01217749,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[312, 3158, 2897, 448, 153, 1881, 102, 31, 36, 16, 561, 721, 84, 1706, 1922, 102, 31, 1422, 2, 2881, 8, 102, 31, 5398, 4, 442, 1193, 552, 520, 6, 34, 2, 15, 36, 8312, 2581, 386, 1422, 2, 51, 6, 1881, 102, 37, 6, 376, 3, 254, 1, 1795, 24, 23, 3, 102, 31, 3616, 4, 552, 22, 192, 9228, 6, 1881, 102, 31, 914, 21, 409, 3, 1005, 2, 343, 1, 102, 37, 4, 8, 180, 1, 552, 7, 190, 136, 906, 1, 24, 5, 1795, 21, 204, 17, 4126, 410, 1, 1795, 36, 231, 3, 1422, 1, 3158, 1166, 1881, 102, 37, 24228, 4, 248, 5, 340, 55, 1, 3, 2989, 1354, 1846, 31, 273, 14, 23, 102, 37, 2, 1, 20730, 23, 132, 552, 37, 4, 538, 1, 46, 272, 21, 164, 17, 27, 552, 7, 54, 42, 85, 73, 5, 1795, 9, 3567, 111, 28, 3, 98, 1, 102, 31, 2442, 42, 231, 2581, 386, 2, 4, 386, 24228, 1422, 92, 438, 2375, 1162, 2, 5, 38, 51, 6354, 21, 514, 17, 1795, 645, 1097, 44, 6267, 1881, 102, 31, 343, 4, 439, 84, 1097, 401, 1881, 102, 31, 2881, 30, 1960, 2, 25, 4, 171, 1330, 274, 1, 436, 286, 1193, 2, 552, 198, 468, 3294, 114, 9549, 272, 1008, 17, 1795, 2519, 1881, 102, 31, 343, 2, 309, 17, 38, 143, 5, 150, 36, 32, 1197, 114, 94, 608, 17, 231, 102, 31, 343, 68, 120, 1248, 6, 3, 209, 1, 1795, 4, 552, 46, 143, 11, 1653, 28, 3064, 1252, 1239, 22, 67549, 27296, 2, 35626]",1602.0,26813675,565
Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.,Haematologica,Haematologica,2016-01-27,"Abroad array of conditions can lead to neurological symptoms in chronic lymphocytic leukemia patients and distinguishing between clinically significant involvement of the central nervous system by chronic lymphocytic leukemia and symptoms due to other etiologies can be challenging. Between January 1999 and November 2014, 172 (4%) of the 4174 patients with chronic lymphocytic leukemia followed at our center had a magnetic resonance imaging of the central nervous system and/or a lumbar puncture to evaluate neurological symptoms. After comprehensive evaluation, the etiology of neurological symptoms was: central nervous system chronic lymphocytic leukemia in 18 patients (10% evaluated by imaging and/or lumbar puncture, 0.4% overall cohort); central nervous system Richter Syndrome in 15 (9% evaluated, 0.3% overall); infection in 40 (23% evaluated, 1% overall); autoimmune/inflammatory conditions in 28 (16% evaluated, 0.7% overall); other cancer in 8 (5% evaluated, 0.2% overall); and another etiology in 63 (37% evaluated, 1.5% overall). Although the sensitivity of cerebrospinal fluid analysis to detect central nervous system disease was 89%, the specificity was only 42% due to the frequent presence of leukemic cells in the cerebrospinal fluid in other conditions. No parameter on cerebrospinal fluid analysis (e.g. total nucleated cells, total lymphocyte count, chronic lymphocytic leukemia cell percentage) were able to offer a reliable discrimination between patients whose neurological symptoms were due to clinically significant central nervous system involvement by chronic lymphocytic leukemia and another etiology. Median overall survival among patients with clinically significant central nervous system chronic lymphocytic leukemia and Richter syndrome was 12 and 11 months, respectively. In conclusion, clinically significant central nervous system involvement by chronic lymphocytic leukemia is a rare condition, and neurological symptoms in patients with chronic lymphocytic leukemia are due to other etiologies in approximately 80% of cases. Analysis of the cerebrospinal fluid has high sensitivity but limited specificity to distinguish clinically significant chronic lymphocytic leukemia involvement from other etiologies. ",Journal Article,1455.0,22.0,Abroad array of conditions can lead to neurological symptoms in chronic lymphocytic patients and distinguishing between clinically significant involvement of the central nervous system by chronic lymphocytic and symptoms due to other etiologies can be challenging Between January 1999 and November 2014 172 4 of the 4174 patients with chronic lymphocytic followed at our center had a magnetic resonance imaging of the central nervous system and/or a lumbar puncture to evaluate neurological symptoms After comprehensive evaluation the etiology of neurological symptoms was central nervous system chronic lymphocytic in 18 patients 10 evaluated by imaging and/or lumbar puncture 0.4 overall cohort central nervous system Richter Syndrome in 15 9 evaluated 0.3 overall infection in 40 23 evaluated 1 overall autoimmune/inflammatory conditions in 28 16 evaluated 0.7 overall other cancer in 8 5 evaluated 0.2 overall and another etiology in 63 37 evaluated 1.5 overall Although the sensitivity of cerebrospinal fluid analysis to detect central nervous system disease was 89 the specificity was only 42 due to the frequent presence of leukemic cells in the cerebrospinal fluid in other conditions No parameter on cerebrospinal fluid analysis e.g total nucleated cells total lymphocyte count chronic lymphocytic cell percentage were able to offer a reliable discrimination between patients whose neurological symptoms were due to clinically significant central nervous system involvement by chronic lymphocytic and another etiology Median overall survival among patients with clinically significant central nervous system chronic lymphocytic and Richter syndrome was 12 and 11 months respectively In conclusion clinically significant central nervous system involvement by chronic lymphocytic is a rare condition and neurological symptoms in patients with chronic lymphocytic are due to other etiologies in approximately 80 of cases Analysis of the cerebrospinal fluid has high sensitivity but limited specificity to distinguish clinically significant chronic lymphocytic involvement from other etiologies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[28170, 1926, 1, 1298, 122, 1122, 6, 3622, 507, 4, 442, 1193, 7, 2, 4508, 59, 505, 93, 799, 1, 3, 854, 1880, 398, 20, 442, 1193, 2, 507, 520, 6, 127, 8523, 122, 40, 1950, 59, 1024, 2043, 2, 2868, 1409, 5312, 39, 1, 3, 67555, 7, 5, 442, 1193, 370, 28, 114, 574, 42, 8, 1484, 1535, 270, 1, 3, 854, 1880, 398, 2, 15, 8, 6187, 12104, 6, 376, 3622, 507, 50, 949, 451, 3, 2855, 1, 3622, 507, 10, 854, 1880, 398, 442, 1193, 4, 203, 7, 79, 194, 20, 270, 2, 15, 6187, 12104, 13, 39, 63, 180, 854, 1880, 398, 8452, 681, 4, 167, 83, 194, 13, 27, 63, 930, 4, 327, 382, 194, 14, 63, 3445, 1291, 1298, 4, 339, 245, 194, 13, 67, 63, 127, 12, 4, 66, 33, 194, 13, 18, 63, 2, 1809, 2855, 4, 676, 567, 194, 14, 33, 63, 242, 3, 485, 1, 5156, 2357, 65, 6, 1426, 854, 1880, 398, 34, 10, 887, 3, 1121, 10, 158, 595, 520, 6, 3, 908, 463, 1, 2015, 37, 4, 3, 5156, 2357, 4, 127, 1298, 77, 4219, 23, 5156, 2357, 65, 563, 499, 181, 9862, 37, 181, 1448, 1276, 442, 1193, 31, 1150, 11, 1665, 6, 1918, 8, 2450, 3520, 59, 7, 1310, 3622, 507, 11, 520, 6, 505, 93, 854, 1880, 398, 799, 20, 442, 1193, 2, 1809, 2855, 52, 63, 25, 107, 7, 5, 505, 93, 854, 1880, 398, 442, 1193, 2, 8452, 681, 10, 133, 2, 175, 53, 106, 4, 1221, 505, 93, 854, 1880, 398, 799, 20, 442, 1193, 16, 8, 622, 2850, 2, 3622, 507, 4, 7, 5, 442, 1193, 32, 520, 6, 127, 8523, 4, 705, 493, 1, 140, 65, 1, 3, 5156, 2357, 71, 64, 485, 84, 383, 1121, 6, 3081, 505, 93, 442, 1193, 799, 29, 127, 8523]",2099.0,26819053,61
Richter Syndrome in Chronic Lymphocytic Leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2016-02-01,"The term Richter syndrome (RS) indicates the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma. RS is a rare complication with an aggressive clinical course, bearing an unfavorable prognosis. In the majority of cases, CLL transforms into RS as diffuse large B cell lymphoma (DLBCL), and a clonal relation between the two processes can be found. However, clonally unrelated RS can occur and transformations to other histologies beside DLBCL have been described. Recent data have shed some light on genetic characteristics that can influence and drive the transformation from CLL to RS. This molecular information has not been translated yet into significant treatment advances, and currently the therapy regimens for RS continue to rely on intensive chemotherapy combinations followed by stem cell transplant in suitable candidates. Based on the rapid pace of discoveries in the field of hematological malignancies and on the recent revolution in the therapeutic landscape for CLL and B cell lymphomas, new therapeutic options for RS might be available in the upcoming years. ",Journal Article,1450.0,7.0,The term Richter syndrome RS indicates the transformation of chronic lymphocytic CLL into an aggressive RS is a rare complication with an aggressive clinical course bearing an unfavorable prognosis In the majority of cases CLL transforms into RS as diffuse large B cell DLBCL and a clonal relation between the two processes can be found However clonally unrelated RS can occur and transformations to other histologies beside DLBCL have been described Recent data have shed some light on genetic characteristics that can influence and drive the transformation from CLL to RS This molecular information has not been translated yet into significant treatment advances and currently the therapy regimens for RS continue to rely on intensive chemotherapy combinations followed by stem cell transplant in suitable candidates Based on the rapid pace of discoveries in the field of hematological malignancies and on the recent revolution in the therapeutic landscape for CLL and B cell lymphomas new therapeutic options for RS might be available in the upcoming years,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 337, 8452, 681, 2250, 2640, 3, 1392, 1, 442, 1193, 552, 237, 35, 571, 2250, 16, 8, 622, 1447, 5, 35, 571, 38, 906, 1894, 35, 2483, 356, 4, 3, 686, 1, 140, 552, 22028, 237, 2250, 22, 1388, 375, 132, 31, 1446, 2, 8, 1946, 2191, 59, 3, 100, 1849, 122, 40, 204, 137, 9157, 2092, 2250, 122, 1271, 2, 18030, 6, 127, 3489, 26703, 1446, 47, 85, 1027, 435, 74, 47, 5816, 476, 1691, 23, 336, 374, 17, 122, 1054, 2, 3279, 3, 1392, 29, 552, 6, 2250, 26, 219, 487, 71, 44, 85, 5136, 1145, 237, 93, 24, 954, 2, 694, 3, 36, 472, 9, 2250, 1906, 6, 5533, 23, 1686, 56, 1247, 370, 20, 452, 31, 941, 4, 2884, 1931, 90, 23, 3, 1321, 7265, 1, 5012, 4, 3, 1067, 1, 2890, 441, 2, 23, 3, 435, 11030, 4, 3, 189, 2801, 9, 552, 2, 132, 31, 1557, 217, 189, 838, 9, 2250, 822, 40, 390, 4, 3, 11974, 60]",1059.0,26830086,415
Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.,Blood,Blood,2016-02-03,"Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binet staging systems described 40 years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.",Journal Article,1448.0,32.0,Since the first description of the natural history of chronic lymphocytic CLL by David Galton in 1966 the considerable heterogeneity in the disease course has been well recognized The Rai and Binet staging systems described 40 years ago have proven to be robust prognostic tools Over the past 2 decades several novel biological genetic and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems In this systematic review we examined the role of immunoglobulin heavy-chain variable region gene IGHV mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization FISH in patients with newly diagnosed CLL The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so In addition to clinical stage these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL This approach will allow the application of powerful recently developed prognostic indices all of which are dependent on IGHV and FISH results to all patients with newly diagnosed CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1192, 3, 157, 5263, 1, 3, 1504, 532, 1, 442, 1193, 552, 20, 26351, 67585, 4, 11556, 3, 2658, 1144, 4, 3, 34, 906, 71, 85, 149, 1904, 3, 4121, 2, 17129, 632, 1530, 1027, 22685, 60, 5028, 47, 1930, 6, 40, 1922, 177, 1896, 252, 3, 1219, 18, 1968, 392, 229, 1037, 336, 2, 219, 525, 47, 85, 443, 6, 40, 999, 13885, 6, 3, 4121, 2, 17129, 632, 1530, 4, 26, 1556, 206, 21, 409, 3, 200, 1, 2593, 4013, 1260, 1347, 1053, 145, 6220, 258, 156, 2, 336, 1171, 509, 20, 8081, 1591, 4, 957, 1554, 1277, 4, 7, 5, 732, 265, 552, 3, 967, 241, 917, 4, 26, 1556, 206, 16, 1952, 6, 2237, 17, 1277, 2, 6220, 40, 173, 22, 260, 38, 895, 9, 62, 7, 5, 732, 265, 552, 4, 135, 2115, 5, 3, 2892, 6, 1022, 1743, 4, 352, 6, 38, 82, 46, 1038, 359, 1231, 3, 1048, 260, 388, 177, 451, 9, 7, 5, 552, 26, 353, 303, 1700, 3, 1581, 1, 3757, 761, 276, 177, 3824, 62, 1, 92, 32, 470, 23, 6220, 2, 1277, 99, 6, 62, 7, 5, 732, 265, 552]",1235.0,26841802,132
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.,Cancer immunology research,Cancer Immunol Res,2016-02-10,"Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate immune cells with Fc receptors to folate receptor-expressing cancer cells. F-IgG bound to human KB and HeLa cells, as well as murine L1210JF, a folate receptor (FR)-overexpressing cancer cell line, as determined by flow cytometry. Recognition of F-IgG by natural killer (NK) cell Fc receptors led to phosphorylation of the ERK transcription factor and increased NK cell expression of CD69. Lysis of KB tumor cells by NK cells increased by about 5-fold after treatment with F-IgG, an effect synergistically enhanced by treatment with IL2, IL12, IL15, or IL21 (P< 0.001). F-IgG also enhanced the lysis of chronic lymphocytic leukemia cells by autologous NK cells. NK cells significantly increased production of IFN, MIP-1, and RANTES in response to F-IgG-coated KB target cells in the presence of the NK cell-activating cytokine IL12, and these coculture supernatants induced significant T-cell chemotaxis (P< 0.001). F-IgG-coated targets also stimulated FcR-mediated monocyte effector functions. Studies in a murine leukemia model confirmed the intratumoral localization and antitumor activity of F-IgG, as well as enhancement of its effects by IL12 (P =0.05). The antitumor effect of this combination was dependent on NK cells and led to decreased tumor cell proliferation in vivo Thus, F-IgG can induce an immune response against FR-positive tumor cells that is mediated by NK cells and can be augmented by cytokine therapy.",Journal Article,1441.0,1.0,Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor Folate conjugated to immunoglobulin F-IgG could direct innate immune cells with Fc receptors to folate receptor-expressing cancer cells F-IgG bound to human KB and HeLa cells as well as murine L1210JF a folate receptor FR -overexpressing cancer cell line as determined by flow cytometry Recognition of F-IgG by natural killer NK cell Fc receptors led to phosphorylation of the ERK transcription factor and increased NK cell expression of CD69 Lysis of KB tumor cells by NK cells increased by about 5-fold after treatment with F-IgG an effect synergistically enhanced by treatment with IL2 IL12 IL15 or IL21 P 0.001 F-IgG also enhanced the lysis of chronic lymphocytic cells by autologous NK cells NK cells significantly increased production of IFN MIP-1 and RANTES in response to F-IgG-coated KB target cells in the presence of the NK cell-activating cytokine IL12 and these coculture supernatants induced significant T-cell chemotaxis P 0.001 F-IgG-coated targets also stimulated FcR-mediated monocyte effector functions Studies in a murine model confirmed the intratumoral localization and antitumor activity of F-IgG as well as enhancement of its effects by IL12 P =0.05 The antitumor effect of this combination was dependent on NK cells and led to decreased tumor cell proliferation in vivo Thus F-IgG can induce an immune response against FR-positive tumor cells that is mediated by NK cells and can be augmented by cytokine therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5074, 323, 579, 235, 688, 44, 158, 2977, 250, 2070, 37, 84, 120, 7430, 1370, 28, 3, 30, 3100, 3868, 6, 2593, 1068, 3630, 359, 1196, 3939, 250, 37, 5, 4127, 1186, 6, 3100, 153, 1046, 12, 37, 1068, 3630, 2951, 6, 171, 5116, 2, 8466, 37, 22, 149, 22, 1471, 67622, 8, 3100, 153, 6413, 2810, 12, 31, 328, 22, 509, 20, 1412, 1914, 2335, 1, 1068, 3630, 20, 1504, 3458, 1765, 31, 4127, 1186, 836, 6, 982, 1, 3, 1819, 866, 161, 2, 101, 1765, 31, 55, 1, 16337, 4783, 1, 5116, 30, 37, 20, 1765, 37, 101, 20, 545, 33, 1116, 50, 24, 5, 1068, 3630, 35, 254, 4240, 651, 20, 24, 5, 6866, 17146, 16940, 15, 20661, 19, 13, 144, 1068, 3630, 120, 651, 3, 4783, 1, 442, 1193, 37, 20, 1028, 1765, 37, 1765, 37, 97, 101, 1529, 1, 6062, 7076, 3305, 2, 16222, 4, 51, 6, 1068, 3630, 8248, 5116, 283, 37, 4, 3, 463, 1, 3, 1765, 31, 1616, 1675, 17146, 2, 46, 7604, 12142, 277, 93, 102, 31, 12561, 19, 13, 144, 1068, 3630, 8248, 637, 120, 2816, 4953, 517, 5231, 2070, 1681, 94, 4, 8, 1471, 202, 557, 3, 2074, 2145, 2, 579, 128, 1, 1068, 3630, 22, 149, 22, 2461, 1, 211, 176, 20, 17146, 19, 13, 474, 3, 579, 254, 1, 26, 150, 10, 470, 23, 1765, 37, 2, 836, 6, 340, 30, 31, 457, 4, 386, 631, 1068, 3630, 122, 1290, 35, 250, 51, 480, 6413, 109, 30, 37, 17, 16, 517, 20, 1765, 37, 2, 122, 40, 4277, 20, 1675, 36]",1559.0,26865456,54
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.,Nature communications,Nat Commun,2016-03-09,"Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy with strong heritability. To further understand the genetic susceptibility for CLL and identify common loci associated with risk, we conducted a meta-analysis of four genome-wide association studies (GWAS) composed of 3,100 cases and 7,667 controls with follow-up replication in 1,958 cases and 5,530 controls. Here we report three new loci at 3p24.1 (rs9880772, EOMES, P=2.55  10(-11)), 6p25.2 (rs73718779, SERPINB6, P=1.97  10(-8)) and 3q28 (rs9815073, LPP, P=3.62  10(-8)), as well as a new independent SNP at the known 2q13 locus (rs9308731, BCL2L11, P=1.00  10(-11)) in the combined analysis. We find suggestive evidence (P<5  10(-7)) for two additional new loci at 4q24 (rs10028805, BANK1, P=7.19  10(-8)) and 3p22.2 (rs1274963, CSRNP1, P=2.12  10(-7)). Pathway analyses of new and known CLL loci consistently show a strong role for apoptosis, providing further evidence for the importance of this biological pathway in CLL susceptibility. ",Journal Article,1413.0,41.0,"Chronic lymphocytic CLL is a common lymphoid malignancy with strong heritability To further understand the genetic susceptibility for CLL and identify common loci associated with risk we conducted a meta-analysis of four genome-wide association studies GWAS composed of 3,100 cases and 7,667 controls with follow-up replication in 1,958 cases and 5,530 controls Here we report three new loci at 3p24.1 rs9880772 EOMES P=2.55 10 -11 6p25.2 rs73718779 SERPINB6 P=1.97 10 -8 and 3q28 rs9815073 LPP P=3.62 10 -8 as well as a new independent SNP at the known 2q13 locus rs9308731 BCL2L11 P=1.00 10 -11 in the combined analysis We find suggestive evidence P 5 10 -7 for two additional new loci at 4q24 rs10028805 BANK1 P=7.19 10 -8 and 3p22.2 rs1274963 CSRNP1 P=2.12 10 -7 Pathway analyses of new and known CLL loci consistently show a strong role for apoptosis providing further evidence for the importance of this biological pathway in CLL susceptibility",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 186, 2303, 710, 5, 1082, 13160, 6, 195, 1640, 3, 336, 1432, 9, 552, 2, 255, 186, 2012, 41, 5, 43, 21, 426, 8, 1742, 65, 1, 294, 898, 1019, 248, 94, 3297, 3317, 1, 27, 394, 140, 2, 67, 10598, 535, 5, 166, 126, 2079, 4, 14, 16493, 140, 2, 33, 12896, 535, 467, 21, 414, 169, 217, 2012, 28, 25177, 14, 67748, 18660, 19, 18, 614, 79, 175, 20717, 18, 67749, 67750, 19, 14, 1015, 79, 66, 2, 30467, 67751, 18916, 19, 27, 744, 79, 66, 22, 149, 22, 8, 217, 306, 1845, 28, 3, 440, 32135, 2474, 67752, 16124, 19, 14, 2038, 79, 175, 4, 3, 397, 65, 21, 2469, 3832, 241, 19, 33, 79, 67, 9, 100, 402, 217, 2012, 28, 31767, 67753, 67754, 19, 67, 326, 79, 66, 2, 16925, 18, 67755, 67756, 19, 18, 133, 79, 67, 308, 318, 1, 217, 2, 440, 552, 2012, 2433, 514, 8, 1082, 200, 9, 351, 1736, 195, 241, 9, 3, 1187, 1, 26, 1037, 308, 4, 552, 1432]",950.0,26956414,584
Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.,Human molecular genetics,Hum. Mol. Genet.,2016-02-09,"Evidence from a small number of studies suggests that longer telomere length measured in peripheral leukocytes is associated with an increased risk of non-Hodgkin lymphoma (NHL). However, these studies may be biased by reverse causation, confounded by unmeasured environmental exposures and might miss time points for which prospective telomere measurement would best reveal a relationship between telomere length and NHL risk. We performed an analysis of genetically inferred telomere length and NHL risk in a study of 10 102 NHL cases of the four most common B-cell histologic types and 9562 controls using a genetic risk score (GRS) comprising nine telomere length-associated single-nucleotide polymorphisms. This approach uses existing genotype data and estimates telomere length by weighing the number of telomere length-associated variant alleles an individual carries with the published change in kb of telomere length. The analysis of the telomere length GRS resulted in an association between longer telomere length and increased NHL risk [four B-cell histologic types combined; odds ratio (OR) = 1.49, 95% CI 1.22-1.82,P-value = 8.5  10(-5)]. Subtype-specific analyses indicated that chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal NHL subtype contributing to this association (OR = 2.60, 95% CI 1.93-3.51,P-value = 4.0  10(-10)). Significant interactions were observed across strata of sex for CLL/SLL and marginal zone lymphoma subtypes as well as age for the follicular lymphoma subtype. Our results indicate that a genetic background that favors longer telomere length may increase NHL risk, particularly risk of CLL/SLL, and are consistent with earlier studies relating longer telomere length with increased NHL risk. ",Journal Article,1442.0,26.0,Evidence from a small number of studies suggests that longer telomere length measured in peripheral leukocytes is associated with an increased risk of NHL However these studies may be biased by reverse causation confounded by unmeasured environmental exposures and might miss time points for which prospective telomere measurement would best reveal a relationship between telomere length and NHL risk We performed an analysis of genetically inferred telomere length and NHL risk in a study of 10 102 NHL cases of the four most common B-cell histologic types and 9562 controls using a genetic risk score GRS comprising nine telomere length-associated single-nucleotide polymorphisms This approach uses existing genotype data and estimates telomere length by weighing the number of telomere length-associated variant alleles an individual carries with the published change in kb of telomere length The analysis of the telomere length GRS resulted in an association between longer telomere length and increased NHL risk four B-cell histologic types combined odds ratio OR 1.49 95 CI 1.22-1.82 P-value 8.5 10 -5 Subtype-specific analyses indicated that chronic lymphocytic or small lymphocytic CLL/SLL was the principal NHL subtype contributing to this association OR 2.60 95 CI 1.93-3.51 P-value 4.0 10 -10 Significant interactions were observed across strata of sex for CLL/SLL and marginal zone subtypes as well as age for the follicular subtype Our results indicate that a genetic background that favors longer telomere length may increase NHL risk particularly risk of CLL/SLL and are consistent with earlier studies relating longer telomere length with increased NHL risk,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[241, 29, 8, 302, 207, 1, 94, 844, 17, 589, 4136, 1318, 644, 4, 672, 6884, 16, 41, 5, 35, 101, 43, 1, 1176, 137, 46, 94, 68, 40, 11627, 20, 1772, 16518, 8927, 20, 20325, 3766, 3401, 2, 822, 11070, 98, 862, 9, 92, 482, 4136, 2204, 688, 824, 2396, 8, 858, 59, 4136, 1318, 2, 1176, 43, 21, 173, 35, 65, 1, 2301, 13782, 4136, 1318, 2, 1176, 43, 4, 8, 45, 1, 79, 2867, 1176, 140, 1, 3, 294, 96, 186, 132, 31, 884, 630, 2, 67860, 535, 75, 8, 336, 43, 368, 14371, 3538, 762, 4136, 1318, 41, 226, 1579, 1203, 26, 353, 4025, 1692, 1183, 74, 2, 1423, 4136, 1318, 20, 14194, 3, 207, 1, 4136, 1318, 41, 1142, 2558, 35, 797, 4942, 5, 3, 983, 707, 4, 5116, 1, 4136, 1318, 3, 65, 1, 3, 4136, 1318, 14371, 627, 4, 35, 248, 59, 589, 4136, 1318, 2, 101, 1176, 43, 294, 132, 31, 884, 630, 397, 610, 197, 15, 14, 739, 48, 58, 14, 350, 14, 878, 19, 549, 66, 33, 79, 33, 875, 112, 318, 1103, 17, 442, 1193, 15, 302, 1193, 552, 5302, 10, 3, 4312, 1176, 875, 3156, 6, 26, 248, 15, 18, 335, 48, 58, 14, 966, 27, 725, 19, 549, 39, 13, 79, 79, 93, 1286, 11, 164, 716, 5758, 1, 1035, 9, 552, 5302, 2, 3450, 3614, 814, 22, 149, 22, 89, 9, 3, 1974, 875, 114, 99, 1008, 17, 8, 336, 2426, 17, 13054, 589, 4136, 1318, 68, 344, 1176, 43, 823, 43, 1, 552, 5302, 2, 32, 925, 5, 1677, 94, 7750, 589, 4136, 1318, 5, 101, 1176, 43]",1673.0,27008888,109
"Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.",American journal of hematology,Am. J. Hematol.,2016-04-24,"The impact of race on outcomes of patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the west, is not well studied. We aimed to understand racial variations in clinical and disease characteristics, treatment patterns, and outcomes in patients with CLL. We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white (NW) compared to white (W) CLL patients. Differences by race in median overall survival (OS) and time-to-first-treatment (TTFT) were investigated. Of the 4215 CLL patients, 4114 (97.6%) were W and 101 (2.4%) were NW. NW patients were younger (median age at diagnosis 59.4 vs. 63.4; P=0.003) and more likely to have an elevated LDH (28.0% vs. 16.2%; P=0.02). No differences in prognostic parameters were noted. No major differences were observed in treatment selection. OS and TTFT were similar between both groups. In the largest analysis of NW-CLL patients in North America, and contrary to historical retrospective reports, W and NW patients appear to have comparable outcomes when treated similarly. These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology. Am. J. Hematol. 91:677-680, 2016.  2016 Wiley Periodicals, Inc.",Journal Article,1367.0,2.0,The impact of race on outcomes of patients with chronic lymphocytic CLL the most common in the west is not well studied We aimed to understand racial variations in clinical and disease characteristics treatment patterns and outcomes in patients with CLL We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white NW compared to white W CLL patients Differences by race in median overall survival OS and time-to-first-treatment TTFT were investigated Of the 4215 CLL patients 4114 97.6 were W and 101 2.4 were NW NW patients were younger median age at diagnosis 59.4 vs. 63.4 P 0.003 and more likely to have an elevated LDH 28.0 vs. 16.2 P 0.02 No differences in prognostic parameters were noted No major differences were observed in treatment selection OS and TTFT were similar between both groups In the largest analysis of NW-CLL patients in North America and contrary to historical retrospective reports W and NW patients appear to have comparable outcomes when treated similarly These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology Am J. Hematol 91:677-680 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 345, 1, 1047, 23, 123, 1, 7, 5, 442, 1193, 552, 3, 96, 186, 4, 3, 7261, 16, 44, 149, 656, 21, 1295, 6, 1640, 2257, 2293, 4, 38, 2, 34, 374, 24, 764, 2, 123, 4, 7, 5, 552, 21, 2080, 3, 2486, 1188, 552, 609, 6, 2715, 35, 65, 1, 46, 374, 2, 1504, 532, 1, 220, 886, 18101, 72, 6, 886, 5444, 552, 7, 362, 20, 1047, 4, 52, 63, 25, 118, 2, 98, 6, 157, 24, 14035, 11, 565, 1, 3, 67867, 552, 7, 49643, 1015, 49, 11, 5444, 2, 2338, 18, 39, 11, 18101, 18101, 7, 11, 773, 52, 89, 28, 147, 728, 39, 105, 676, 39, 19, 13, 1421, 2, 80, 322, 6, 47, 35, 804, 4592, 339, 13, 105, 245, 18, 19, 13, 588, 77, 362, 4, 177, 1038, 11, 1051, 77, 458, 362, 11, 164, 4, 24, 881, 118, 2, 14035, 11, 288, 59, 110, 271, 4, 3, 2166, 65, 1, 18101, 552, 7, 4, 2669, 4010, 2, 7194, 6, 2252, 459, 1198, 5444, 2, 18101, 7, 1322, 6, 47, 1279, 123, 198, 73, 1813, 46, 272, 309, 373, 1051, 228, 362, 68, 40, 520, 6, 2227, 4, 1655, 6, 165, 2, 284, 1832, 76, 362, 4, 34, 891, 5886, 3543, 13175, 970, 13083, 9297, 1390, 2206, 1390, 4692, 5493, 3479]",1266.0,27013143,177
Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-03-29,"Carfilzomib, while active in B-cell neoplasms, displayed heterogeneous response in chronic lymphocytic leukemia (CLL) samples from patients and showed interpatient variability to carfilzomib-induced cell death. To understand this variability and predict patients who would respond to carfilzomib, we investigated the mechanism by which carfilzomib induces CLL cell death. Using CLL patient samples and cell lines, complementary knockdown and knockout cells, and carfilzomib-resistant cell lines, we evaluated changes in intracellular networks to identify molecules responsible for carfilzomib's cytotoxic activity. Lysates from carfilzomib-treated cells were immunoblotted for molecules involved in ubiquitin, apoptotic, and endoplasmic reticulum (ER) stress response pathways and results correlated with carfilzomib cytotoxic activity. Coimmunoprecipitation and pull-down assays were performed to identify complex interactions among MCL-1, Noxa, and Bak. Carfilzomib triggered ER stress and activation of both the intrinsic and extrinsic apoptotic pathways through alteration of the ubiquitin proteasome pathway. Consequently, the transcription factor CCAAT/enhancer-binding protein homology protein (CHOP) accumulated in response to carfilzomib, and CHOP depletion conferred protection against cytotoxicity. Carfilzomib also induced accumulation of MCL-1 and Noxa, whereby MCL-1 preferentially formed a complex with Noxa and consequently relieved MCL-1's protective effect on sequestering Bak. Accordingly, depletion of Noxa or both Bak and Bax conferred protection against carfilzomib-induced cell death. Collectively, carfilzomib induced ER stress culminating in activation of intrinsic and extrinsic caspase pathways, and we identified the CHOP protein level as a biomarker that could predict sensitivity to carfilzomib in CLL. Clin Cancer Res; 22(18); 4712-26. 2016 AACR.",Journal Article,1393.0,9.0,Carfilzomib while active in B-cell neoplasms displayed heterogeneous response in chronic lymphocytic CLL samples from patients and showed interpatient variability to carfilzomib-induced cell death To understand this variability and predict patients who would respond to carfilzomib we investigated the mechanism by which carfilzomib induces CLL cell death Using CLL patient samples and cell lines complementary knockdown and knockout cells and carfilzomib-resistant cell lines we evaluated changes in intracellular networks to identify molecules responsible for carfilzomib 's cytotoxic activity Lysates from carfilzomib-treated cells were immunoblotted for molecules involved in ubiquitin apoptotic and endoplasmic reticulum ER stress response pathways and results correlated with carfilzomib cytotoxic activity Coimmunoprecipitation and pull-down assays were performed to identify complex interactions among MCL-1 Noxa and Bak Carfilzomib triggered ER stress and activation of both the intrinsic and extrinsic apoptotic pathways through alteration of the ubiquitin proteasome pathway Consequently the transcription factor CCAAT/enhancer-binding protein homology protein CHOP accumulated in response to carfilzomib and CHOP depletion conferred protection against cytotoxicity Carfilzomib also induced accumulation of MCL-1 and Noxa whereby MCL-1 preferentially formed a complex with Noxa and consequently relieved MCL-1 's protective effect on sequestering Bak Accordingly depletion of Noxa or both Bak and Bax conferred protection against carfilzomib-induced cell death Collectively carfilzomib induced ER stress culminating in activation of intrinsic and extrinsic caspase pathways and we identified the CHOP protein level as a biomarker that could predict sensitivity to carfilzomib in CLL Clin Cancer Res 22 18 4712-26 2016 AACR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3668, 369, 544, 4, 132, 31, 1179, 2507, 1564, 51, 4, 442, 1193, 552, 347, 29, 7, 2, 224, 7423, 1982, 6, 3668, 277, 31, 273, 6, 1640, 26, 1982, 2, 678, 7, 54, 688, 1892, 6, 3668, 21, 565, 3, 670, 20, 92, 3668, 1516, 552, 31, 273, 75, 552, 69, 347, 2, 31, 285, 3380, 1563, 2, 5687, 37, 2, 3668, 436, 31, 285, 21, 194, 400, 4, 2087, 3991, 6, 255, 1598, 2327, 9, 3668, 292, 759, 128, 8674, 29, 3668, 73, 37, 11, 67892, 9, 1598, 646, 4, 4213, 1631, 2, 6057, 6078, 516, 1531, 51, 460, 2, 99, 438, 5, 3668, 759, 128, 15888, 2, 18171, 1328, 1013, 11, 173, 6, 255, 840, 1286, 107, 1308, 14, 7363, 2, 5599, 3668, 4173, 516, 1531, 2, 363, 1, 110, 3, 2354, 2, 6539, 1631, 460, 298, 2611, 1, 3, 4213, 1694, 308, 3244, 3, 866, 161, 18747, 4239, 791, 178, 7984, 178, 2907, 6664, 4, 51, 6, 3668, 2, 2907, 2286, 3851, 3525, 480, 1408, 3668, 120, 277, 1835, 1, 1308, 14, 2, 7363, 6131, 1308, 14, 3509, 3516, 8, 840, 5, 7363, 2, 3244, 14429, 1308, 14, 292, 2864, 254, 23, 19413, 5599, 4705, 2286, 1, 7363, 15, 110, 5599, 2, 3119, 3851, 3525, 480, 3668, 277, 31, 273, 2535, 3668, 277, 516, 1531, 15305, 4, 363, 1, 2354, 2, 6539, 1469, 460, 2, 21, 108, 3, 2907, 178, 301, 22, 8, 901, 17, 359, 678, 485, 6, 3668, 4, 552, 2459, 12, 1936, 350, 203, 67893, 432, 3456, 1630]",1834.0,27026200,270
Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study.,American journal of hematology,Am. J. Hematol.,2016-04-24,"Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia (CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment, and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL. Am. J. Hematol. 91:687-691, 2016.  2016 Wiley Periodicals, Inc.",Journal Article,1367.0,7.0,"Monocyte-derived cells constituents of the cancer microenvironment support chronic lymphocytic CLL cell survival in vitro via direct cell-cell interaction and secreted factors We hypothesized that circulating absolute monocyte count AMC reflects the monocyte-derived cells in the microenvironment and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes and whether this information adds to currently used prognostic markers We evaluated AMC clinically used prognostic markers and time to event data from 1,168 CLL patients followed at the Mayo Clinic the Duke University Medical Center and the Durham VA Medical Center Elevated AMC was significantly associated with inferior clinical outcomes including time to first therapy TTT and overall survival OS AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT As an elevated AMC at diagnosis is associated with accelerated disease progression and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL Am J. Hematol 91:687-691 2016  2016 Wiley Periodicals Inc",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5231, 526, 37, 16770, 1, 3, 12, 995, 538, 442, 1193, 552, 31, 25, 4, 439, 847, 1196, 31, 31, 915, 2, 3613, 130, 21, 1237, 17, 1033, 1766, 5231, 1276, 8137, 5224, 3, 5231, 526, 37, 4, 3, 995, 2, 17, 142, 8137, 16, 41, 5, 101, 552, 31, 25, 4, 386, 2, 631, 1663, 552, 69, 123, 21, 275, 3, 1039, 6, 92, 8137, 28, 147, 1, 552, 16, 438, 5, 38, 123, 2, 317, 26, 487, 6659, 6, 694, 95, 177, 525, 21, 194, 8137, 505, 95, 177, 525, 2, 98, 6, 774, 74, 29, 14, 5359, 552, 7, 370, 28, 3, 2486, 1188, 3, 11543, 1652, 484, 574, 2, 3, 49656, 7057, 484, 574, 804, 8137, 10, 97, 41, 5, 1663, 38, 123, 141, 98, 6, 157, 36, 10630, 2, 63, 25, 118, 8137, 397, 5, 635, 38, 2, 219, 177, 525, 97, 231, 43, 1541, 1, 552, 7, 9, 10630, 22, 35, 804, 8137, 28, 147, 16, 41, 5, 2241, 34, 91, 2, 5231, 526, 37, 4, 3, 552, 995, 1617, 552, 31, 25, 2, 457, 46, 272, 309, 17, 5078, 2, 5231, 526, 37, 32, 2696, 189, 637, 4, 552, 5886, 3543, 13175, 970, 16445, 11661, 1390, 2206, 1390, 4692, 5493, 3479]",1388.0,27037726,768
Prognostic factors and risk stratification in chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2016-02-08,"There is considerable heterogeneity in the clinical outcome of patients with chronic lymphocytic leukemia (CLL). While some patients live for decades without any therapy, others die within years of diagnosis despite multiple treatments. To better counsel newly diagnosed CLL patients about their disease course, the Rai and Binet staging systems were developed four decades ago. A deeper understanding of the biologic and molecular aberrations contributing to the pathogenesis of CLL led to identification of novel prognostic markers such as immunoglobulin heavy-chain variable gene (IGHV) mutation status, leukemia-cell expression of CD38, ZAP-70, and CD49d, and cytogenetic abnormalities detected by fluorescent in situ hybridization (FISH). The advent of next-generation sequencing has provided unprecedented insights into the subclonal architecture of CLL and its impact on disease progression and survival. More recently, integrated prognostic scoring systems that incorporate clinical, biologic and genetic characteristics into a single risk score have been developed and appear to improve the accuracy of prognostication for individual patients. This review summarizes the state-of-the-art prognostic factors and will guide the practicing clinician in their care of patients with CLL. ",Journal Article,1443.0,35.0,There is considerable heterogeneity in the clinical outcome of patients with chronic lymphocytic CLL While some patients live for decades without any therapy others die within years of diagnosis despite multiple treatments To better counsel newly diagnosed CLL patients about their disease course the Rai and Binet staging systems were developed four decades ago A deeper understanding of the biologic and molecular aberrations contributing to the pathogenesis of CLL led to identification of novel prognostic markers such as immunoglobulin heavy-chain variable gene IGHV mutation status leukemia-cell expression of CD38 ZAP-70 and CD49d and cytogenetic abnormalities detected by fluorescent in situ hybridization FISH The advent of next-generation sequencing has provided unprecedented insights into the subclonal architecture of CLL and its impact on disease progression and survival More recently integrated prognostic scoring systems that incorporate clinical biologic and genetic characteristics into a single risk score have been developed and appear to improve the accuracy of prognostication for individual patients This review summarizes the state-of-the-art prognostic factors and will guide the practicing clinician in their care of patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[125, 16, 2658, 1144, 4, 3, 38, 228, 1, 7, 5, 442, 1193, 552, 369, 476, 7, 3812, 9, 1968, 187, 500, 36, 1749, 3384, 262, 60, 1, 147, 550, 232, 640, 6, 380, 9892, 732, 265, 552, 7, 545, 136, 34, 906, 3, 4121, 2, 17129, 632, 1530, 11, 276, 294, 1968, 5028, 8, 6029, 612, 1, 3, 1283, 2, 219, 2152, 3156, 6, 3, 1384, 1, 552, 836, 6, 911, 1, 229, 177, 525, 225, 22, 2593, 4013, 1260, 1347, 145, 6220, 258, 156, 2647, 31, 55, 1, 4469, 6251, 431, 2, 10485, 2, 1266, 1171, 530, 20, 2910, 4, 957, 1554, 1277, 3, 4114, 1, 1305, 914, 615, 71, 1052, 5934, 1957, 237, 3, 9210, 4447, 1, 552, 2, 211, 345, 23, 34, 91, 2, 25, 80, 761, 2102, 177, 2504, 1530, 17, 3360, 38, 1283, 2, 336, 374, 237, 8, 226, 43, 368, 47, 85, 276, 2, 1322, 6, 401, 3, 1190, 1, 4260, 9, 797, 7, 26, 206, 2869, 3, 1309, 1, 3, 4363, 177, 130, 2, 303, 1597, 3, 6734, 3744, 4, 136, 165, 1, 7, 5, 552]",1261.0,27040701,528
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2016-02-08,"In the last 10 years, oncology has been transformed by the development and broad availability of small molecule therapies for cancer. Compounds have been and are being developed to target nearly every known relevant component of the cell's machinery. One class of compounds, the cyclin-dependent kinase (CDK) inhibitors, was originally conceived as an anticancer therapeutic based on the premise that as cancer is (in part) defined by loss of cell-cycle control, the interruption of cell cycle could arrest cancer growth. While CDKs do play critical roles in cell cycle, including in cancer, the study of CDK inhibitors in the relatively non-proliferative disease chronic lymphocytic leukemia (CLL) revealed alternate mechanisms both for CDKs, as well as for the role of CDK inhibitors in cancer therapy. In this review, we will consider three CDK inhibitors: alvocidib (flavopiridol), dinaciclib, and TG02. We will discuss their preclinical and clinical development for the treatment of CLL, and suggest that CDK inhibitors remain relevant in CLL, with potential utility in several scenarios. ",Journal Article,1443.0,7.0,In the last 10 years oncology has been transformed by the development and broad availability of small molecule therapies for cancer Compounds have been and are being developed to target nearly every known relevant component of the cell 's machinery One class of compounds the cyclin-dependent kinase CDK inhibitors was originally conceived as an anticancer therapeutic based on the premise that as cancer is in part defined by loss of cell-cycle control the interruption of cell cycle could arrest cancer growth While CDKs do play critical roles in cell cycle including in cancer the study of CDK inhibitors in the relatively non-proliferative disease chronic lymphocytic CLL revealed alternate mechanisms both for CDKs as well as for the role of CDK inhibitors in cancer therapy In this review we will consider three CDK inhibitors alvocidib flavopiridol dinaciclib and TG02 We will discuss their preclinical and clinical development for the treatment of CLL and suggest that CDK inhibitors remain relevant in CLL with potential utility in several scenarios,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 3, 1060, 79, 60, 413, 71, 85, 2423, 20, 3, 193, 2, 2094, 2550, 1, 302, 1354, 235, 9, 12, 2411, 47, 85, 2, 32, 486, 276, 6, 283, 1857, 454, 440, 867, 1249, 1, 3, 31, 292, 6415, 104, 1040, 1, 2411, 3, 1226, 470, 216, 3954, 222, 10, 5045, 17168, 22, 35, 1475, 189, 90, 23, 3, 14448, 17, 22, 12, 16, 4, 760, 395, 20, 407, 1, 31, 417, 182, 3, 4823, 1, 31, 417, 359, 1854, 12, 129, 369, 9336, 1022, 1343, 740, 1790, 4, 31, 417, 141, 4, 12, 3, 45, 1, 3954, 222, 4, 3, 1352, 220, 2441, 34, 442, 1193, 552, 553, 4689, 483, 110, 9, 9336, 22, 149, 22, 9, 3, 200, 1, 3954, 222, 4, 12, 36, 4, 26, 206, 21, 303, 2419, 169, 3954, 222, 14030, 3030, 7619, 2, 67913, 21, 303, 1139, 136, 693, 2, 38, 193, 9, 3, 24, 1, 552, 2, 309, 17, 3954, 222, 918, 867, 4, 552, 5, 174, 1207, 4, 392, 3964]",1058.0,27040705,721
"At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.","Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2016-04-13,"In chronic lymphocytic leukemia (CLL), the increment in PBLs is slower than the expected increment calculated from the cells' proliferation rate, suggesting that cellular proliferation and apoptosis are concurrent. Exploring this phenomenon, we found overexpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a higher apoptosis rate in cells from patients with high counts compared with cells from patients with low counts. Although we previously found that STAT3 protects CLL cells from apoptosis, STAT3 levels were significantly higher in cells from patients with high counts than in cells from patients with low counts. Furthermore, overexpression of STAT3 did not protect the cells. Rather, it upregulated caspase-3 and induced apoptosis. Remarkably, putative STAT3 binding sites were identified in the caspase-3 promoter, and a luciferase assay, chromatin immunoprecipitation, and an EMSA revealed that STAT3 activated caspase-3 However, caspase-3 levels increased only when STAT3 levels were sufficiently high. Using chromatin immunoprecipitation and EMSA, we found that STAT3 binds with low affinity to the caspase-3 promoter, suggesting that at high levels, STAT3 activates proapoptotic mechanisms and induces apoptosis in CLL cells.",Journal Article,1378.0,12.0,In chronic lymphocytic CLL the increment in PBLs is slower than the expected increment calculated from the cells proliferation rate suggesting that cellular proliferation and apoptosis are concurrent Exploring this phenomenon we found overexpression of caspase-3 higher cleaved poly ADP-ribose polymerase levels p 0.007 and a higher apoptosis rate in cells from patients with high counts compared with cells from patients with low counts Although we previously found that STAT3 protects CLL cells from apoptosis STAT3 levels were significantly higher in cells from patients with high counts than in cells from patients with low counts Furthermore overexpression of STAT3 did not protect the cells Rather it upregulated caspase-3 and induced apoptosis Remarkably putative STAT3 binding sites were identified in the caspase-3 promoter and a luciferase assay chromatin immunoprecipitation and an EMSA revealed that STAT3 activated caspase-3 However caspase-3 levels increased only when STAT3 levels were sufficiently high Using chromatin immunoprecipitation and EMSA we found that STAT3 binds with low affinity to the caspase-3 promoter suggesting that at high levels STAT3 activates proapoptotic mechanisms and induces apoptosis in CLL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 3, 9705, 4, 11579, 16, 6715, 76, 3, 1336, 9705, 981, 29, 3, 37, 457, 116, 802, 17, 763, 457, 2, 351, 32, 750, 4378, 26, 3936, 21, 204, 851, 1, 1469, 27, 142, 5885, 2699, 3638, 3507, 1451, 148, 19, 13, 1999, 2, 8, 142, 351, 116, 4, 37, 29, 7, 5, 64, 1911, 72, 5, 37, 29, 7, 5, 154, 1911, 242, 21, 373, 204, 17, 1439, 8170, 552, 37, 29, 351, 1439, 148, 11, 97, 142, 4, 37, 29, 7, 5, 64, 1911, 76, 4, 37, 29, 7, 5, 154, 1911, 798, 851, 1, 1439, 205, 44, 4869, 3, 37, 1832, 192, 2684, 1469, 27, 2, 277, 351, 4856, 2743, 1439, 791, 633, 11, 108, 4, 3, 1469, 27, 973, 2, 8, 3864, 719, 2287, 4857, 2, 35, 15941, 553, 17, 1439, 735, 1469, 27, 137, 1469, 27, 148, 101, 158, 198, 1439, 148, 11, 5938, 64, 75, 2287, 4857, 2, 15941, 21, 204, 17, 1439, 3333, 5, 154, 3601, 6, 3, 1469, 27, 973, 802, 17, 28, 64, 148, 1439, 3932, 4118, 483, 2, 1516, 351, 4, 552, 37]",1239.0,27076684,329
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia.,Oncotarget,Oncotarget,2016-05-01,"Epigenetic or transcriptional silencing of important tumor suppressors has been described to contribute to cell survival and tumorigenesis in chronic lymphocytic leukemia (CLL). Using gene expression microarray analysis, we found that thousands of genes are repressed more than 2-fold in CLL compared to normal B cells; however therapeutic approaches to reverse this have been limited in CLL. Following treatment with the Hsp90 inhibitor 17-DMAG, a significant number of these repressed genes were significantly re-expressed. One of the genes significantly repressed in CLL and up-regulated by 17-DMAG was suppressor of cytokine signaling 3, (SOCS3). SOCS3 has been shown to be silenced in solid tumors as well as myeloid leukemia; however little is known about the regulation in CLL. We found that 17-DMAG induces expression of SOCS3 by via the activation of p38 signaling, and subsequently inhibits AKT and STAT3 phosphorylation resulting in downstream effects on cell migration and survival. We therefore suggest that SOCS3 is an important signaling protein in CLL, and Hsp90 inhibitors represent a novel approach to target transcriptional repression in B cell lymphoproliferative disorders which exhibit a substantial degree of gene repression. ",Journal Article,1360.0,8.0,Epigenetic or transcriptional silencing of important tumor suppressors has been described to contribute to cell survival and tumorigenesis in chronic lymphocytic CLL Using gene expression microarray analysis we found that thousands of genes are repressed more than 2-fold in CLL compared to normal B cells however therapeutic approaches to reverse this have been limited in CLL Following treatment with the Hsp90 inhibitor 17-DMAG a significant number of these repressed genes were significantly re-expressed One of the genes significantly repressed in CLL and up-regulated by 17-DMAG was suppressor of cytokine signaling 3 SOCS3 SOCS3 has been shown to be silenced in solid tumors as well as myeloid however little is known about the regulation in CLL We found that 17-DMAG induces expression of SOCS3 by via the activation of p38 signaling and subsequently inhibits AKT and STAT3 phosphorylation resulting in downstream effects on cell migration and survival We therefore suggest that SOCS3 is an important signaling protein in CLL and Hsp90 inhibitors represent a novel approach to target transcriptional repression in B cell lymphoproliferative disorders which exhibit a substantial degree of gene repression,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1418, 15, 1431, 2077, 1, 305, 30, 5704, 71, 85, 1027, 6, 1248, 6, 31, 25, 2, 1565, 4, 442, 1193, 552, 75, 145, 55, 1727, 65, 21, 204, 17, 8505, 1, 214, 32, 6654, 80, 76, 18, 1116, 4, 552, 72, 6, 295, 132, 37, 137, 189, 611, 6, 1772, 26, 47, 85, 383, 4, 552, 366, 24, 5, 3, 2515, 230, 269, 15323, 8, 93, 207, 1, 46, 6654, 214, 11, 97, 1491, 570, 104, 1, 3, 214, 97, 6654, 4, 552, 2, 126, 1065, 20, 269, 15323, 10, 1245, 1, 1675, 314, 27, 17824, 17824, 71, 85, 443, 6, 40, 5442, 4, 537, 57, 22, 149, 22, 533, 137, 1215, 16, 440, 545, 3, 863, 4, 552, 21, 204, 17, 269, 15323, 1516, 55, 1, 17824, 20, 847, 3, 363, 1, 3970, 314, 2, 1611, 1576, 649, 2, 1439, 982, 1113, 4, 1489, 176, 23, 31, 1381, 2, 25, 21, 673, 309, 17, 17824, 16, 35, 305, 314, 178, 4, 552, 2, 2515, 222, 1231, 8, 229, 353, 6, 283, 1431, 5255, 4, 132, 31, 4192, 1997, 92, 2239, 8, 1281, 1444, 1, 145, 5255]",1212.0,27107422,290
A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.,Annals of hematology,Ann. Hematol.,2016-04-27,"Patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval (PFS). Additionally, the majority of patients treated for relapsed disease demonstrate evidence of measurable disease. Eradication of minimal residual disease (MRD) results in improved PFS and overall survival. Maintenance therapy might result in eradication of MRD and improve response duration but might be associated with an increase in incidence of infectious complications. Flavopiridol is a broad cyclin-dependent kinase (CDK) inhibitor with established safety and efficacy in patients with relapsed CLL, particularly patients with high-risk cytogenetic features. A pharmacologically derived schedule was utilized as consolidation therapy in this phase I study to assess the safety and feasibility of outpatient therapy with flavopiridol in patients with low tumor burden. Flavopiridol was administered as a 30-min loading dose of 30mg/m(2) followed by a 4-h infusion of 30mg/m(2) once weekly for 3weeks every 5weeks (1cycle) for planned 2cycles in ten patients. Therapy was extremely well tolerated and no patient developed acute tumor lysis syndrome. The most common toxicities were gastrointestinal. Of the patients, 22% improved their response from a PR to CR. Eighty-eight percent experienced a reduction in tumor burden as measured by extent of bone marrow involvement including patients with del17p and complex karyotype. The study establishes the safety and efficacy of flavopiridol as consolidation therapy after chemoimmunotherapy for patients with CLL. Further evaluation is required in larger trials for the utility of CDK inhibitors as consolidation or maintenance strategies.Registration number at ClinicalTrials.gov: NCT00377104. ",Clinical Trial,1364.0,12.0,Patients with chronic lymphocytic CLL who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval PFS Additionally the majority of patients treated for relapsed disease demonstrate evidence of measurable disease Eradication of minimal residual disease MRD results in improved PFS and overall survival Maintenance therapy might result in eradication of MRD and improve response duration but might be associated with an increase in incidence of infectious complications Flavopiridol is a broad cyclin-dependent kinase CDK inhibitor with established safety and efficacy in patients with relapsed CLL particularly patients with high-risk cytogenetic features A pharmacologically derived schedule was utilized as consolidation therapy in this phase I study to assess the safety and feasibility of outpatient therapy with flavopiridol in patients with low tumor burden Flavopiridol was administered as a 30-min loading dose of 30 mg/m 2 followed by a 4-h infusion of 30 mg/m 2 once weekly for 3 weeks every 5 weeks 1 cycle for planned 2 cycles in ten patients Therapy was extremely well tolerated and no patient developed acute tumor lysis syndrome The most common toxicities were Of the patients 22 improved their response from a PR to CR Eighty-eight percent experienced a reduction in tumor burden as measured by extent of marrow involvement including patients with del17p and complex karyotype The study establishes the safety and efficacy of flavopiridol as consolidation therapy after chemoimmunotherapy for patients with CLL Further evaluation is required in larger trials for the utility of CDK inhibitors as consolidation or maintenance strategies.Registration number at ClinicalTrials.gov NCT00377104,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 54, 560, 4438, 2, 1022, 44, 1359, 236, 734, 730, 97, 6151, 91, 115, 268, 300, 1724, 3, 686, 1, 7, 73, 9, 591, 34, 608, 241, 1, 1884, 34, 5173, 1, 1048, 753, 34, 2029, 99, 4, 231, 300, 2, 63, 25, 1146, 36, 822, 757, 4, 5173, 1, 2029, 2, 401, 51, 654, 84, 822, 40, 41, 5, 35, 344, 4, 287, 1, 3398, 521, 3030, 16, 8, 2094, 1226, 470, 216, 3954, 230, 5, 635, 367, 2, 209, 4, 7, 5, 591, 552, 823, 7, 5, 64, 43, 1266, 404, 8, 7854, 526, 1055, 10, 2080, 22, 2173, 36, 4, 26, 124, 70, 45, 6, 423, 3, 367, 2, 1437, 1, 2379, 36, 5, 3030, 4, 7, 5, 154, 30, 892, 3030, 10, 468, 22, 8, 201, 1538, 4717, 61, 1, 201, 81, 188, 18, 370, 20, 8, 39, 555, 904, 1, 201, 81, 188, 18, 1059, 709, 9, 27, 244, 454, 33, 244, 14, 417, 9, 1465, 18, 410, 4, 1618, 7, 36, 10, 2938, 149, 421, 2, 77, 69, 276, 286, 30, 4783, 681, 3, 96, 186, 385, 11, 1, 3, 7, 350, 231, 136, 51, 29, 8, 998, 6, 684, 2207, 659, 714, 592, 8, 628, 4, 30, 892, 22, 644, 20, 1039, 1, 581, 799, 141, 7, 5, 15403, 2, 840, 3385, 3, 45, 7410, 3, 367, 2, 209, 1, 3030, 22, 2173, 36, 50, 4438, 9, 7, 5, 552, 195, 451, 16, 616, 4, 1077, 143, 9, 3, 1207, 1, 3954, 222, 22, 2173, 15, 1146, 422, 3169, 207, 28, 1252, 1239, 68061]",1774.0,27118540,350
Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.,American journal of hematology,Am. J. Hematol.,2016-06-01,"Human cytomegalovirus (HCMV) is a widely prevalent herpes virus which establishes a state of chronic infection. The establishment of CMV-specific immunity controls viral reactivation and leads to the accumulation of very large numbers of virus-specific T cells which come to dominate the immune repertoire. There is concern that this may reduce the immune response to heterologous infections and HCMV infection has been associated with reduced survival in elderly people. Patients with chronic lymphocytic leukemia (B-CLL) suffer from a state of immune suppression but have a paradoxical increase in the magnitude of the CMV-specific T cell and humoral immune response. As such, there is now considerable interest in how CMV infection impacts on the clinical outcome of patients with B-CLL. Utilizing a large prospective cohort of patients with B-CLL (n=347) we evaluated the relationship between HCMV seropositivity and patient outcome. HCMV seropositive patients had significantly worse overall survival than HCMV negative patients in univariate analysis (HR=2.28, 95% CI: 1.34-3.88; P=0.002). However, CMV seropositive patients were 4 years older than seronegative donors and this survival difference was lost in multivariate modeling adjusted for age and other validated prognostic markers (P=0.34). No significant difference was found in multivariate modeling between HCMV positive and negative patients in relation to the time to first treatment (HR=1.12, 95% CI: 0.68-1.84; P=0.65). These findings in a second independent cohort of 236 B-CLL patients were validated. In conclusion no evidence that HCMV impacts on the clinical outcome of patients with B-CLL was found. Am. J. Hematol. 91:776-781, 2016.  2016 Wiley Periodicals, Inc.",Journal Article,1329.0,7.0,Human cytomegalovirus HCMV is a widely prevalent herpes virus which establishes a state of chronic infection The establishment of CMV-specific immunity controls viral reactivation and leads to the accumulation of very large numbers of virus-specific T cells which come to dominate the immune repertoire There is concern that this may reduce the immune response to heterologous infections and HCMV infection has been associated with reduced survival in elderly people Patients with chronic lymphocytic B-CLL suffer from a state of immune suppression but have a paradoxical increase in the magnitude of the CMV-specific T cell and humoral immune response As such there is now considerable interest in how CMV infection impacts on the clinical outcome of patients with B-CLL Utilizing a large prospective cohort of patients with B-CLL n 347 we evaluated the relationship between HCMV seropositivity and patient outcome HCMV seropositive patients had significantly worse overall survival than HCMV negative patients in univariate analysis HR 2.28 95 CI 1.34-3.88 P 0.002 However CMV seropositive patients were 4 years older than seronegative donors and this survival difference was lost in multivariate modeling adjusted for age and other validated prognostic markers P 0.34 No significant difference was found in multivariate modeling between HCMV positive and negative patients in relation to the time to first treatment HR 1.12 95 CI 0.68-1.84 P 0.65 These findings in a second independent cohort of 236 B-CLL patients were validated In conclusion no evidence that HCMV impacts on the clinical outcome of patients with B-CLL was found Am J. Hematol 91:776-781 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[171, 7314, 15447, 16, 8, 1792, 2485, 4716, 1450, 92, 7410, 8, 1309, 1, 442, 930, 3, 5346, 1, 3879, 112, 1604, 535, 1667, 3834, 2, 1940, 6, 3, 1835, 1, 923, 375, 1870, 1, 1450, 112, 102, 37, 92, 6235, 6, 18953, 3, 250, 5306, 125, 16, 2893, 17, 26, 68, 969, 3, 250, 51, 6, 15488, 1875, 2, 15447, 930, 71, 85, 41, 5, 405, 25, 4, 1216, 3788, 7, 5, 442, 1193, 132, 552, 6506, 29, 8, 1309, 1, 250, 1332, 84, 47, 8, 9330, 344, 4, 3, 3131, 1, 3, 3879, 112, 102, 31, 2, 5498, 250, 51, 22, 225, 125, 16, 1134, 2658, 1333, 4, 832, 3879, 930, 4719, 23, 3, 38, 228, 1, 7, 5, 132, 552, 2600, 8, 375, 482, 180, 1, 7, 5, 132, 552, 78, 10745, 21, 194, 3, 858, 59, 15447, 9525, 2, 69, 228, 15447, 9909, 7, 42, 97, 639, 63, 25, 76, 15447, 199, 7, 4, 880, 65, 168, 18, 339, 48, 58, 14, 562, 27, 889, 19, 13, 1111, 137, 3879, 9909, 7, 11, 39, 60, 434, 76, 14924, 2344, 2, 26, 25, 523, 10, 3009, 4, 331, 2057, 586, 9, 89, 2, 127, 938, 177, 525, 19, 13, 562, 77, 93, 523, 10, 204, 4, 331, 2057, 59, 15447, 109, 2, 199, 7, 4, 2191, 6, 3, 98, 6, 157, 24, 168, 14, 133, 48, 58, 13, 806, 14, 874, 19, 13, 556, 46, 272, 4, 8, 419, 306, 180, 1, 6383, 132, 552, 7, 11, 938, 4, 1221, 77, 241, 17, 15447, 4719, 23, 3, 38, 228, 1, 7, 5, 132, 552, 10, 204, 5886, 3543, 13175, 970, 14414, 11486, 1390, 2206, 1390, 4692, 5493, 3479]",1692.0,27124884,1
"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.",The Lancet. Oncology,Lancet Oncol.,2016-05-10,"Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response. Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia. In this phase 2, single-arm, multicentre study, we recruited patients aged 18 years and older with del(17p) relapsed or refractory chronic lymphocytic leukaemia (as defined by 2008 Modified International Workshop on Chronic Lymphocytic Leukemia guidelines) from 31 centres in the USA, Canada, UK, Germany, Poland, and Australia. Patients started once daily venetoclax with a weekly dose ramp-up schedule (20, 50, 100, 200, 400 mg) over 4-5 weeks. Patients were then given daily 400 mg continuous dosing until disease progression or discontinuation for another reason. The primary endpoint was the proportion of patients achieving an overall response, assessed by an independent review committee. Activity and safety analyses included all patients who received at least one dose of study drug (per protocol). This study is registered with ClinicalTrials.gov, number NCT01889186. Follow-up is ongoing, and patients are still receiving treatment. Between May 27, 2013, and June 27, 2014, 107 patients were enrolled into the study. At a median follow-up of 121 months (IQR 101-142), an overall response by independent review was achieved in 85 (794%; 95% CI 705-866) of 107 patients. The most common grade 3-4 adverse events were neutropenia (43 [40%]), infection (21 [20%]), anaemia (19 [18%]), and thrombocytopenia (16 [15%]). Serious adverse events occurred in 59 (55%) patients, irrespective of their relationship to treatment, with the most common (5% of patients) being pyrexia and autoimmune haemolytic anaemia (seven [7%] each), pneumonia (six [6%]), and febrile neutropenia (five [5%]). 11 patients died in the study within 30 days of the last dose of venetoclax; seven due to disease progression and four from an adverse event (none assessed as treatment related). Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population. Additionally, in view of the distinct mechanism-of-action of venetoclax, combinations or sequencing with other novel targeted agents should be investigated to further advance treatment of del(17p) chronic lymphocytic leukaemia. AbbVie and Genentech.","Clinical Trial, Phase II",1351.0,349.0,Deletion of chromosome 17p del 17p in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis In a previous first-in-human study of venetoclax 77 of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del 17p chronic lymphocytic leukaemia In this phase 2 single-arm multicentre study we recruited patients aged 18 years and older with del 17p relapsed or refractory chronic lymphocytic leukaemia as defined by 2008 Modified International Workshop on Chronic Lymphocytic guidelines from 31 centres in the USA Canada UK Germany Poland and Australia Patients started once daily venetoclax with a weekly dose ramp-up schedule 20 50 100 200 400 mg over 4-5 weeks Patients were then given daily 400 mg continuous dosing until disease progression or discontinuation for another reason The primary endpoint was the proportion of patients achieving an overall response assessed by an independent review committee Activity and safety analyses included all patients who received at least one dose of study drug per protocol This study is registered with ClinicalTrials.gov number NCT01889186 Follow-up is ongoing and patients are still receiving treatment Between May 27 2013 and June 27 2014 107 patients were enrolled into the study At a median follow-up of 121 months IQR 101-142 an overall response by independent review was achieved in 85 794 95 CI 705-866 of 107 patients The most common grade 3-4 adverse events were neutropenia 43 40 infection 21 20 anaemia 19 18 and thrombocytopenia 16 15 Serious adverse events occurred in 59 55 patients irrespective of their relationship to treatment with the most common 5 of patients being pyrexia and autoimmune haemolytic anaemia seven 7 each pneumonia six 6 and febrile neutropenia five 5 11 patients died in the study within 30 days of the last dose of venetoclax seven due to disease progression and four from an adverse event none assessed as treatment related Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del 17p chronic lymphocytic leukaemia providing a new therapeutic option for this very poor prognosis population Additionally in view of the distinct mechanism-of-action of venetoclax combinations or sequencing with other novel targeted agents should be investigated to further advance treatment of del 17p chronic lymphocytic leukaemia AbbVie and Genentech,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1528, 1, 1170, 4135, 3084, 4135, 4, 7, 5, 442, 1193, 2001, 4020, 923, 334, 356, 198, 73, 5, 260, 3341, 726, 4454, 16, 35, 518, 302, 1354, 3214, 230, 17, 1516, 442, 1193, 2001, 31, 351, 4, 8, 698, 157, 4, 171, 45, 1, 4454, 849, 1, 7, 5, 591, 15, 430, 442, 1193, 2001, 513, 35, 63, 51, 467, 21, 1295, 6, 423, 3, 128, 2, 367, 1, 4454, 1411, 4, 7, 5, 591, 15, 430, 3084, 4135, 442, 1193, 2001, 4, 26, 124, 18, 226, 475, 5761, 45, 21, 2619, 7, 1032, 203, 60, 2, 434, 5, 3084, 4135, 591, 15, 430, 442, 1193, 2001, 22, 395, 20, 1375, 1230, 944, 4014, 23, 442, 1193, 677, 29, 456, 4496, 4, 3, 2706, 4740, 6975, 10697, 20388, 2, 6978, 7, 3461, 1059, 391, 4454, 5, 8, 709, 61, 20047, 126, 1055, 179, 212, 394, 1250, 1524, 81, 252, 39, 33, 244, 7, 11, 818, 447, 391, 1524, 81, 1314, 1280, 1100, 34, 91, 15, 2007, 9, 1809, 3852, 3, 86, 1138, 10, 3, 920, 1, 7, 1785, 35, 63, 51, 275, 20, 35, 306, 206, 2002, 128, 2, 367, 318, 159, 62, 7, 54, 103, 28, 506, 104, 61, 1, 45, 234, 379, 1182, 26, 45, 16, 1653, 5, 1252, 1239, 207, 68167, 166, 126, 16, 942, 2, 7, 32, 1234, 357, 24, 59, 68, 428, 1346, 2, 1924, 428, 1409, 3650, 7, 11, 346, 237, 3, 45, 28, 8, 52, 166, 126, 1, 31678, 53, 2245, 24126, 29651, 35, 63, 51, 20, 306, 206, 10, 513, 4, 772, 68168, 48, 58, 68169, 68170, 1, 3650, 7, 3, 96, 186, 88, 27, 39, 290, 281, 11, 778, 601, 327, 930, 239, 179, 5712, 326, 203, 2, 1340, 245, 167, 1762, 290, 281, 489, 4, 728, 614, 7, 3500, 1, 136, 858, 6, 24, 5, 3, 96, 186, 4126, 1, 7, 486, 8417, 2, 3445, 25737, 5712, 648, 67, 296, 3485, 437, 49, 2, 2498, 778, 365, 33, 175, 7, 1016, 4, 3, 45, 262, 201, 162, 1, 3, 1060, 61, 1, 4454, 648, 520, 6, 34, 91, 2, 294, 29, 35, 290, 774, 1292, 275, 22, 24, 139, 99, 1, 26, 160, 514, 17, 4454, 1411, 16, 544, 2, 149, 421, 4, 7, 5, 591, 15, 430, 3084, 4135, 442, 1193, 2001, 1736, 8, 217, 189, 1501, 9, 26, 923, 334, 356, 266, 1724, 4, 3811, 1, 3, 834, 670, 1, 1578, 1, 4454, 1247, 15, 615, 5, 127, 229, 238, 183, 257, 40, 565, 6, 195, 3148, 24, 1, 3084, 4135, 442, 1193, 2001, 18697, 2, 9010]",2723.0,27178240,643
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.,Cancer,Cancer,2016-05-16,"More active therapies are needed for older and unfit patients with chronic lymphocytic leukemia (CLL) who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The phosphyotidylinositol-3-kinase  inhibitor idelalisib is effective in patients with treatment-naive and relapsed/refractory CLL as monotherapy and in combination with rituximab, but it can be associated with treatment-limiting adverse events, particularly diarrhea/colitis. The outcomes for patients who cease treatment for adverse events have not been previously described. The authors analyzed long-term follow-up data from 40 treatment-nave patients aged 65 years who received treatment at The University of Texas MD Anderson Cancer Center on a phase 2 study of idelalisib plus rituximab for CLL. In patients who permanently ceased treatment because of toxicity, the time to subsequent disease progression was analyzed according to baseline characteristics. Fifteen patients permanently ceased therapy (PCT) because of toxicity (PCTTOX ), most commonly diarrhea/colitis (n = 7), at a median of 11 months after commencing treatment. PCTTOX was associated with a higher risk of subsequent disease progression (hazard ratio, 6.61; 95% confidence interval, 1.77-16.15) relative to that observed in patients who remained on therapy. Ten patients subsequently progressed, and 7 required salvage therapy; 5 patients remained progression-free at a median of 23.3 months (range, 8.5-28.6 months). Patients who were positive for -associated protein-70 had more rapid disease progression after treatment cessation (P = .048). There were no CLL-related deaths. PCTTOX is the major determinant of PFS in patients who receive first-line idelalisib-based treatment. However, a subgroup of patients with favorable biologic characteristics has prolonged PFS, even after PCTTOX . The absence of CLL-related deaths indicates that salvage treatment is generally successful after PCTTOX . Cancer 2016;122:2505-11.  2016 American Cancer Society.",Journal Article,1345.0,18.0,More active therapies are needed for older and unfit patients with chronic lymphocytic CLL who are not eligible for chemoimmunotherapy with fludarabine cyclophosphamide and rituximab The phosphyotidylinositol-3-kinase  inhibitor idelalisib is effective in patients with treatment-naive and relapsed/refractory CLL as monotherapy and in combination with rituximab but it can be associated with treatment-limiting adverse events particularly diarrhea/colitis The outcomes for patients who cease treatment for adverse events have not been previously described The authors analyzed long-term follow-up data from 40 treatment-nave patients aged 65 years who received treatment at The University of Texas MD Anderson Cancer Center on a phase 2 study of idelalisib plus rituximab for CLL In patients who permanently ceased treatment because of toxicity the time to subsequent disease progression was analyzed according to baseline characteristics Fifteen patients permanently ceased therapy PCT because of toxicity PCTTOX most commonly diarrhea/colitis n 7 at a median of 11 months after commencing treatment PCTTOX was associated with a higher risk of subsequent disease progression hazard ratio 6.61 95 confidence interval 1.77-16.15 relative to that observed in patients who remained on therapy Ten patients subsequently progressed and 7 required salvage therapy 5 patients remained progression-free at a median of 23.3 months range 8.5-28.6 months Patients who were positive for -associated protein-70 had more rapid disease progression after treatment cessation P .048 There were no CLL-related deaths PCTTOX is the major determinant of PFS in patients who receive first-line idelalisib-based treatment However a subgroup of patients with favorable biologic characteristics has prolonged PFS even after PCTTOX The absence of CLL-related deaths indicates that salvage treatment is generally successful after PCTTOX Cancer 2016 122:2505-11  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[80, 544, 235, 32, 575, 9, 434, 2, 9681, 7, 5, 442, 1193, 552, 54, 32, 44, 625, 9, 4438, 5, 2027, 1112, 2, 855, 3, 68178, 27, 216, 7339, 230, 7083, 16, 323, 4, 7, 5, 24, 2462, 2, 591, 430, 552, 22, 1411, 2, 4, 150, 5, 855, 84, 192, 122, 40, 41, 5, 24, 817, 290, 281, 823, 1172, 4132, 3, 123, 9, 7, 54, 32569, 24, 9, 290, 281, 47, 44, 85, 373, 1027, 3, 738, 311, 319, 337, 166, 126, 74, 29, 327, 24, 2809, 7, 1032, 5827, 60, 54, 103, 24, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 23, 8, 124, 18, 45, 1, 7083, 349, 855, 9, 552, 4, 7, 54, 14470, 17710, 24, 408, 1, 155, 3, 98, 6, 706, 34, 91, 10, 311, 768, 6, 330, 374, 3057, 7, 14470, 17710, 36, 7612, 408, 1, 155, 32599, 96, 841, 1172, 4132, 78, 67, 28, 8, 52, 1, 175, 53, 50, 16385, 24, 32599, 10, 41, 5, 8, 142, 43, 1, 706, 34, 91, 360, 197, 49, 713, 48, 307, 268, 14, 849, 245, 167, 580, 6, 17, 164, 4, 7, 54, 958, 23, 36, 1618, 7, 1611, 1839, 2, 67, 616, 992, 36, 33, 7, 958, 91, 115, 28, 8, 52, 1, 382, 27, 53, 184, 66, 33, 339, 49, 53, 7, 54, 11, 109, 9, 14668, 41, 178, 431, 42, 80, 1321, 34, 91, 50, 24, 3345, 19, 4969, 125, 11, 77, 552, 139, 1043, 32599, 16, 3, 458, 4372, 1, 300, 4, 7, 54, 560, 157, 328, 7083, 90, 24, 137, 8, 1363, 1, 7, 5, 913, 1283, 374, 71, 1069, 300, 871, 50, 32599, 3, 1127, 1, 552, 139, 1043, 2640, 17, 992, 24, 16, 1228, 1401, 50, 32599, 12, 1390, 3285, 39512, 175, 2206, 1390, 597, 12, 1174]",1970.0,27182988,461
Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.,Leukemia & lymphoma,Leuk. Lymphoma,2016-05-17,"Here we tested impact of Tris (dibenzylideneacetone) dipalladium (Tris-DBA) on chronic lymphocytic leukemia (CLL) B-cell survival. Indeed, treatment of CLL B-cells with Tris-DBA induced apoptosis in a dose-dependent manner irrespective of IgVH mutational status. Further analyses suggest that Tris-DBA-induced apoptosis involves reduced expression of the anti-apoptotic proteins Bcl-xL, and XIAP with an upregulation of the pro-apoptotic protein BIM in CLL B-cells. Our findings also indicate that Tris-DBA targets the ribosomal protein (rp)-S6, an essential component of the Akt/mTOR signaling axis in CLL B-cells. Of interest, CLL bone marrow stromal cells were unable to protect the leukemic B cells from Tris-DBA-induced apoptosis in an in vitro co-culture system. Finally, co-administration of Tris-DBA and the purine nucleoside analog fludarabine (F-ara-A) augmented CLL B-cell apoptosis levels in vitro showing synergistic effects. In total, Tris-DBA is effective at inducing apoptosis in CLL B-cells even in the presence of stromal cells likely by targeting directly the signal mediator, rpS6.",Journal Article,1344.0,5.0,Here we tested impact of Tris dibenzylideneacetone dipalladium Tris-DBA on chronic lymphocytic CLL B-cell survival Indeed treatment of CLL B-cells with Tris-DBA induced apoptosis in a dose-dependent manner irrespective of IgVH mutational status Further analyses suggest that Tris-DBA-induced apoptosis involves reduced expression of the anti-apoptotic proteins Bcl-xL and XIAP with an upregulation of the pro-apoptotic protein BIM in CLL B-cells Our findings also indicate that Tris-DBA targets the ribosomal protein rp -S6 an essential component of the Akt/mTOR signaling axis in CLL B-cells Of interest CLL marrow stromal cells were unable to protect the leukemic B cells from Tris-DBA-induced apoptosis in an in vitro co-culture system Finally co-administration of Tris-DBA and the purine nucleoside analog fludarabine F-ara-A augmented CLL B-cell apoptosis levels in vitro showing synergistic effects In total Tris-DBA is effective at inducing apoptosis in CLL B-cells even in the presence of stromal cells likely by targeting directly the signal mediator rpS6,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[467, 21, 650, 345, 1, 19693, 68198, 68199, 19693, 27530, 23, 442, 1193, 552, 132, 31, 25, 4462, 24, 1, 552, 132, 37, 5, 19693, 27530, 277, 351, 4, 8, 61, 470, 1708, 3500, 1, 14484, 1619, 156, 195, 318, 309, 17, 19693, 27530, 277, 351, 2921, 405, 55, 1, 3, 312, 1631, 652, 1044, 3870, 2, 5387, 5, 35, 2218, 1, 3, 1805, 1631, 178, 3595, 4, 552, 132, 37, 114, 272, 120, 1008, 17, 19693, 27530, 637, 3, 8194, 178, 1622, 4977, 35, 1452, 1249, 1, 3, 649, 873, 314, 2310, 4, 552, 132, 37, 1, 1333, 552, 581, 1126, 37, 11, 4253, 6, 4869, 3, 2015, 132, 37, 29, 19693, 27530, 277, 351, 4, 35, 4, 439, 1269, 2099, 398, 1368, 1269, 634, 1, 19693, 27530, 2, 3, 5006, 4032, 3497, 2027, 1068, 3899, 8, 4277, 552, 132, 31, 351, 148, 4, 439, 2069, 1806, 176, 4, 181, 19693, 27530, 16, 323, 28, 1958, 351, 4, 552, 132, 37, 871, 4, 3, 463, 1, 1126, 37, 322, 20, 529, 1606, 3, 1235, 3810, 21527]",1064.0,27189785,415
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.,Oncotarget,Oncotarget,2016-06-01,"Dysfunctional apoptotic machinery is a hallmark feature of chronic lymphocytic leukemia (CLL). Accordingly, targeting apoptosis regulators has been proven a rational approach for CLL treatment. We show that CLL lymphocytes express high levels of XIAP, cIAP1, and cIAP2 compared to normal lymphocytes. Smac mimetic, Smac066, designed to bind to BIR3-domain of IAPs, induce apoptosis in primary CLL cells (n=71; p<0.0001), irrespective of prognostic markers. Apoptosis was mediated by diminished levels of IAPs (XIAP-p=0.02; cIAP-p<0.0001) and increased activation of caspases-8,-9,-3. The caspase-cleavage was in direct association with the levels of apoptosis (r2=0.8 for caspases-8,-9,-3). Correlative analysis revealed a direct relationship between reduction in IAPs and degree of apoptosis (r2=0.6 (XIAP); 0.5 (cIAP2)). There was a strong association between apoptosis, IAP-degradation, and concurrent caspase-activation. Pan-caspase inhibitor Z-Vad-fmk reversed the degradation of Mcl-1, but not IAPs suggesting that smac066 is selective to IAPs, however, Mcl-1 degradation is through caspase-mediated cleavage. Immunoprecipitation experiments revealed physical interaction between caspase-3 and XIAP that was disrupted by smac066. Importantly, XIAP and cIAP2 were markedly induced in bone-marrow and lymph-node microenvironments, providing a basis for IAP antagonists as anti-tumor agents in CLL. Smac066 synergized with ABT-737, revealing a mechanistic rationale to jointly target BH3 and BIR3 domains.",Journal Article,1329.0,6.0,Dysfunctional apoptotic machinery is a hallmark feature of chronic lymphocytic CLL Accordingly targeting apoptosis regulators has been proven a rational approach for CLL treatment We show that CLL lymphocytes express high levels of XIAP cIAP1 and cIAP2 compared to normal lymphocytes Smac mimetic Smac066 designed to bind to BIR3-domain of IAPs induce apoptosis in primary CLL cells n=71 p 0.0001 irrespective of prognostic markers Apoptosis was mediated by diminished levels of IAPs XIAP-p=0.02 cIAP-p 0.0001 and increased activation of caspases-8 -9 -3 The caspase-cleavage was in direct association with the levels of apoptosis r2=0.8 for caspases-8 -9 -3 Correlative analysis revealed a direct relationship between reduction in IAPs and degree of apoptosis r2=0.6 XIAP 0.5 cIAP2 There was a strong association between apoptosis IAP-degradation and concurrent caspase-activation Pan-caspase inhibitor Z-Vad-fmk reversed the degradation of Mcl-1 but not IAPs suggesting that smac066 is selective to IAPs however Mcl-1 degradation is through caspase-mediated cleavage Immunoprecipitation experiments revealed physical interaction between caspase-3 and XIAP that was disrupted by smac066 Importantly XIAP and cIAP2 were markedly induced in bone-marrow and lymph-node microenvironments providing a basis for IAP antagonists as anti-tumor agents in CLL Smac066 synergized with ABT-737 revealing a mechanistic rationale to jointly target BH3 and BIR3 domains,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[9666, 1631, 6415, 16, 8, 4683, 2705, 1, 442, 1193, 552, 4705, 529, 351, 3196, 71, 85, 1930, 8, 2696, 353, 9, 552, 24, 21, 514, 17, 552, 1594, 1669, 64, 148, 1, 5387, 26624, 2, 24427, 72, 6, 295, 1594, 9251, 7343, 32366, 1114, 6, 4060, 6, 35327, 1398, 1, 19245, 1290, 351, 4, 86, 552, 37, 78, 792, 19, 13, 488, 3500, 1, 177, 525, 351, 10, 517, 20, 2849, 148, 1, 19245, 5387, 19, 13, 588, 19432, 19, 13, 488, 2, 101, 363, 1, 7629, 66, 83, 27, 3, 1469, 3155, 10, 4, 1196, 248, 5, 3, 148, 1, 351, 4332, 13, 66, 9, 7629, 66, 83, 27, 3679, 65, 553, 8, 1196, 858, 59, 628, 4, 19245, 2, 1444, 1, 351, 4332, 13, 49, 5387, 13, 33, 24427, 125, 10, 8, 1082, 248, 59, 351, 9262, 2373, 2, 750, 1469, 363, 3055, 1469, 230, 3905, 10167, 10281, 3682, 3, 2373, 1, 1308, 14, 84, 44, 19245, 802, 17, 32366, 16, 1094, 6, 19245, 137, 1308, 14, 2373, 16, 298, 1469, 517, 3155, 4857, 2332, 553, 900, 915, 59, 1469, 27, 2, 5387, 17, 10, 5576, 20, 32366, 1859, 5387, 2, 24427, 11, 2195, 277, 4, 3417, 581, 2, 263, 289, 9912, 1736, 8, 877, 9, 9262, 4444, 22, 312, 30, 183, 4, 552, 32366, 8914, 5, 3095, 4933, 6475, 8, 2716, 1728, 6, 7609, 283, 5486, 2, 35327, 2703]",1455.0,27223062,393
Reprogramming Nurse-like Cells with Interferon  to Interrupt Chronic Lymphocytic Leukemia Cell Survival.,The Journal of biological chemistry,J. Biol. Chem.,2016-05-13,"Nurse-like cells (NLCs) play a central role in chronic lymphocytic leukemia (CLL) because they promote the survival and proliferation of CLL cells. NLCs are derived from the monocyte lineage and are driven toward their phenotype via contact-dependent and -independent signals from CLL cells. Because of the central role of NLCs in promoting disease, new strategies to eliminate or reprogram them are needed. Successful reprogramming may be of extra benefit because NLCs express Fc receptors (FcRs) and thus could act as effector cells within the context of antibody therapy. IFN is known to promote the polarization of macrophages toward an M1-like state that is no longer tumor-supportive. In an effort to reprogram the phenotype of NLCs, we found that IFN up-regulated the M1-related markers CD86 and HLA-DR as well as FcRIa. This corresponded to enhanced FcR-mediated cytokine production as well as rituximab-mediated phagocytosis of CLL cells. In addition, IFN down-regulated the expression of CD31, resulting in withdrawal of the survival advantage on CLL cells. These results suggest that IFN can re-educate NLCs and shift them toward an effector-like state and that therapies promoting local IFN production may be effective adjuvants for antibody therapy in CLL.",Journal Article,1348.0,6.0,Nurse-like cells NLCs play a central role in chronic lymphocytic CLL because they promote the survival and proliferation of CLL cells NLCs are derived from the monocyte lineage and are driven toward their phenotype via contact-dependent and -independent signals from CLL cells Because of the central role of NLCs in promoting disease new strategies to eliminate or reprogram them are needed Successful reprogramming may be of extra benefit because NLCs express Fc receptors FcRs and thus could act as effector cells within the context of antibody therapy IFN is known to promote the polarization of macrophages toward an M1-like state that is no longer tumor-supportive In an effort to reprogram the phenotype of NLCs we found that IFN up-regulated the M1-related markers CD86 and HLA-DR as well as FcRIa This corresponded to enhanced FcR-mediated cytokine production as well as rituximab-mediated phagocytosis of CLL cells In addition IFN down-regulated the expression of CD31 resulting in withdrawal of the survival advantage on CLL cells These results suggest that IFN can re-educate NLCs and shift them toward an effector-like state and that therapies promoting local IFN production may be effective adjuvants for antibody therapy in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6756, 733, 37, 17425, 1343, 8, 854, 200, 4, 442, 1193, 552, 408, 491, 1617, 3, 25, 2, 457, 1, 552, 37, 17425, 32, 526, 29, 3, 5231, 2542, 2, 32, 1621, 1317, 136, 1005, 847, 4393, 470, 2, 306, 2312, 29, 552, 37, 408, 1, 3, 854, 200, 1, 17425, 4, 2388, 34, 217, 422, 6, 4964, 15, 14947, 1370, 32, 575, 1401, 7394, 68, 40, 1, 3420, 247, 408, 17425, 1669, 19247, 1186, 29802, 2, 631, 359, 2559, 22, 2070, 37, 262, 3, 1533, 1, 548, 36, 6062, 16, 440, 6, 1617, 3, 9207, 1, 2748, 1317, 35, 4445, 733, 1309, 17, 16, 77, 589, 30, 1877, 4, 35, 2919, 6, 14947, 3, 1005, 1, 17425, 21, 204, 17, 6062, 126, 1065, 3, 4445, 139, 525, 12514, 2, 1160, 3436, 22, 149, 22, 68269, 26, 7254, 6, 651, 16125, 517, 1675, 1529, 22, 149, 22, 855, 517, 11788, 1, 552, 37, 4, 352, 6062, 1328, 1065, 3, 55, 1, 6019, 1113, 4, 3683, 1, 3, 25, 1874, 23, 552, 37, 46, 99, 309, 17, 6062, 122, 1491, 10407, 17425, 2, 3024, 1370, 1317, 35, 2070, 733, 1309, 2, 17, 235, 2388, 293, 6062, 1529, 68, 40, 323, 8654, 9, 548, 36, 4, 552]",1250.0,27226587,545
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.,Blood,Blood,2016-05-31,"Idelalisib is a small-molecule inhibitor of PI3K with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 months of idelalisib monotherapy followed by 6 months of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab. After a median follow-up period of 14.7 months, hepatotoxicity was found to be a frequent and often severe adverse event. A total of 19 subjects (79%) experienced either grade 1 ALT or AST elevation during the study, and 13 subjects (54%) experienced grade 3 transaminitis. The median time to development of transaminitis was 28 days, occurring before ofatumumab introduction. Younger age and mutated immunoglobulin heavy chain status were significant risk factors for the development of hepatotoxicity. Multiple lines of evidence suggest that this hepatotoxicity was immune mediated. A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transaminitis, and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity. All cases of transaminitis resolved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated. A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy, which is consistent with an immune-mediated mechanism. These results suggest that caution should be taken as drugs within this class are developed for CLL, particularly in younger patients who have not received prior disease-specific therapy. This study was registered at www.clinicaltrials.gov as #NCT02135133.",Clinical Trial,1330.0,127.0,Idelalisib is a small-molecule inhibitor of PI3K with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic CLL To evaluate idelalisib as front-line therapy we enrolled 24 subjects in a phase 2 study consisting of 2 months of idelalisib monotherapy followed by 6 months of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab After a median follow-up period of 14.7 months hepatotoxicity was found to be a frequent and often severe adverse event A total of 19 subjects 79 experienced either grade 1 ALT or AST elevation during the study and 13 subjects 54 experienced grade 3 transaminitis The median time to development of transaminitis was 28 days occurring before ofatumumab introduction Younger age and mutated immunoglobulin heavy chain status were significant risk factors for the development of hepatotoxicity Multiple lines of evidence suggest that this hepatotoxicity was immune mediated A lymphocytic infiltrate was seen on biopsy specimens taken from 2 subjects with transaminitis and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity All cases of transaminitis resolved either by holding the drug initiating immunosuppressants or both and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy which is consistent with an immune-mediated mechanism These results suggest that caution should be taken as drugs within this class are developed for CLL particularly in younger patients who have not received prior disease-specific therapy This study was registered at www.clinicaltrials.gov as NCT02135133,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7083, 16, 8, 302, 1354, 230, 1, 11063, 5, 264, 209, 9, 3, 24, 1, 591, 430, 442, 1193, 552, 6, 376, 7083, 22, 3007, 328, 36, 21, 346, 259, 976, 4, 8, 124, 18, 45, 2273, 1, 18, 53, 1, 7083, 1411, 370, 20, 49, 53, 1, 150, 36, 5, 7083, 2, 3, 312, 2198, 548, 5732, 50, 8, 52, 166, 126, 727, 1, 213, 67, 53, 6667, 10, 204, 6, 40, 8, 908, 2, 629, 905, 290, 774, 8, 181, 1, 326, 976, 842, 592, 361, 88, 3567, 4548, 15, 5759, 3292, 190, 3, 45, 2, 233, 976, 667, 592, 88, 2608, 8181, 3, 52, 98, 6, 193, 1, 8181, 10, 339, 162, 1821, 348, 5732, 2456, 773, 89, 2, 1185, 2593, 4013, 1260, 156, 11, 93, 43, 130, 9, 3, 193, 1, 6667, 232, 285, 1, 241, 309, 17, 26, 6667, 10, 250, 517, 8, 1193, 5172, 10, 527, 23, 411, 623, 1633, 29, 18, 976, 5, 8181, 2, 148, 1, 3, 5767, 1886, 20773, 27, 2, 20773, 39, 11, 142, 4, 976, 2985, 6667, 62, 140, 1, 8181, 3862, 361, 20, 14904, 3, 234, 2637, 28441, 15, 110, 2, 151, 1, 387, 155, 11, 280, 4, 7, 2727, 4580, 198, 7083, 10, 30623, 8, 775, 4, 672, 315, 1253, 102, 37, 10, 527, 4, 7, 2985, 155, 23, 36, 92, 16, 925, 5, 35, 250, 517, 670, 46, 99, 309, 17, 5526, 257, 40, 1633, 22, 600, 262, 26, 1040, 32, 276, 9, 552, 823, 4, 773, 7, 54, 47, 44, 103, 324, 34, 112, 36, 26, 45, 10, 1653, 28, 3064, 1252, 1239, 22, 68298]",1771.0,27247136,131
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.,Leukemia research,Leuk. Res.,2016-05-17,"Chronic lymphocytic leukemia (CLL) is an incurable disease in need of new therapeutic strategies. The immunomodulatory agent, lenalidomide, has shown activity as salvage therapy for CLL. In this phase II trial, we combined lenalidomide with rituximab in 25 patients (range, 41-79) with refractory/relapsed CLL. Lenalidomide was administered orally on escalating doses, with cycle 1 doses of 2.5mg daily on days 1-7, 5mg on days 8-14, and 10mg on days 15-21 followed by 7days off. On cycle 2 and beyond, lenalidomide was administered at 20mg daily on days 1-21. Rituximab was administered at 375mg/m(2) intravenously on a weekly basis for the first cycle starting on day 15 for 4 doses, with each cycle being 28days. Treatment was continued until disease progression or toxicity. Overall response rate was 45.8% on intent-to-treat and 61.1% in evaluable patients (all partial responses). Median time to treatment failure was 14.3 months for evaluable patients, and median overall survival was not reached. The most common grade 3/4 toxicity was neutropenia (72% of patients). The most common nonhematologic toxicity was infection (29% of patients). Lenalidomide combined with rituximab showed activity in heavily treated refractory CLL with an acceptable toxicity profile.","Clinical Trial, Phase II",1344.0,13.0,Chronic lymphocytic CLL is an incurable disease in need of new therapeutic strategies The immunomodulatory agent lenalidomide has shown activity as salvage therapy for CLL In this phase II trial we combined lenalidomide with rituximab in 25 patients range 41-79 with refractory/relapsed CLL Lenalidomide was administered orally on escalating doses with cycle 1 doses of 2.5mg daily on days 1-7 5mg on days 8-14 and 10mg on days 15-21 followed by 7days off On cycle 2 and beyond lenalidomide was administered at 20mg daily on days 1-21 Rituximab was administered at 375mg/m 2 intravenously on a weekly basis for the first cycle starting on day 15 for 4 doses with each cycle being 28days Treatment was continued until disease progression or toxicity Overall response rate was 45.8 on intent-to-treat and 61.1 in evaluable patients all partial responses Median time to treatment failure was 14.3 months for evaluable patients and median overall survival was not reached The most common grade 3/4 toxicity was neutropenia 72 of patients The most common nonhematologic toxicity was infection 29 of patients Lenalidomide combined with rituximab showed activity in heavily treated refractory CLL with an acceptable toxicity profile,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 35, 2641, 34, 4, 594, 1, 217, 189, 422, 3, 2555, 420, 1288, 71, 443, 128, 22, 992, 36, 9, 552, 4, 26, 124, 215, 160, 21, 397, 1288, 5, 855, 4, 243, 7, 184, 605, 842, 5, 430, 591, 552, 1288, 10, 468, 1428, 23, 2922, 415, 5, 417, 14, 415, 1, 18, 11356, 391, 23, 162, 14, 67, 11356, 23, 162, 66, 213, 2, 12176, 23, 162, 167, 239, 370, 20, 28615, 1889, 23, 417, 18, 2, 1654, 1288, 10, 468, 28, 16403, 391, 23, 162, 14, 239, 855, 10, 468, 28, 68387, 188, 18, 1672, 23, 8, 709, 877, 9, 3, 157, 417, 1723, 23, 218, 167, 9, 39, 415, 5, 296, 417, 486, 27430, 24, 10, 1351, 1100, 34, 91, 15, 155, 63, 51, 116, 10, 512, 66, 23, 1697, 6, 943, 2, 713, 14, 4, 859, 7, 62, 450, 253, 52, 98, 6, 24, 496, 10, 213, 27, 53, 9, 859, 7, 2, 52, 63, 25, 10, 44, 1300, 3, 96, 186, 88, 27, 39, 155, 10, 778, 720, 1, 7, 3, 96, 186, 3534, 155, 10, 930, 462, 1, 7, 1288, 397, 5, 855, 224, 128, 4, 2447, 73, 430, 552, 5, 35, 1595, 155, 800]",1225.0,27285853,336
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.,Cancer immunology research,Cancer Immunol Res,2016-06-10,"The immunomodulatory drug lenalidomide has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), despite a lack of direct cytotoxic effects in vitro The mechanism of lenalidomide efficacy in vivo is thought to occur via a combination of enhanced immune activity and an alteration of tumor cell-microenvironment interactions. We demonstrate in whole blood from patients with CLL that lenalidomide significantly depletes malignant B cells. Lenalidomide also induced production of interleukin-21 (IL21) and its mRNA in T cells from patients with CLL. In addition, lenalidomide enhanced upregulation of functional IL21 receptor (IL21R) on the cell surface and increased receptor mRNA in vitro The in vitro combination of IL21 and lenalidomide enhanced IL21-mediated cytotoxicity toward CLL cells through a variety of mechanisms. We show association of cell death with upregulation of Bid by IL21, enhanced upregulation of Bid by the combination therapy, and diminished Lck and downstream BCR signaling activation of Syk and PLCG2. Collectively, we demonstrated an immune cell-tumor cell interaction through lenalidomide-mediated induction of IL21 and IL21R, with enhanced IL21-mediated cytotoxicity, which provides justification for this combination in clinical trials for patients with CLL. Cancer Immunol Res; 4(8); 698-707. 2016 AACR.",Journal Article,1320.0,6.0,The immunomodulatory drug lenalidomide has demonstrated efficacy in patients with chronic lymphocytic CLL despite a lack of direct cytotoxic effects in vitro The mechanism of lenalidomide efficacy in vivo is thought to occur via a combination of enhanced immune activity and an alteration of tumor cell-microenvironment interactions We demonstrate in whole blood from patients with CLL that lenalidomide significantly depletes malignant B cells Lenalidomide also induced production of interleukin-21 IL21 and its mRNA in T cells from patients with CLL In addition lenalidomide enhanced upregulation of functional IL21 receptor IL21R on the cell surface and increased receptor mRNA in vitro The in vitro combination of IL21 and lenalidomide enhanced IL21-mediated cytotoxicity toward CLL cells through a variety of mechanisms We show association of cell death with upregulation of Bid by IL21 enhanced upregulation of Bid by the combination therapy and diminished Lck and downstream BCR signaling activation of Syk and PLCG2 Collectively we demonstrated an immune cell-tumor cell interaction through lenalidomide-mediated induction of IL21 and IL21R with enhanced IL21-mediated cytotoxicity which provides justification for this combination in clinical trials for patients with CLL Cancer Immunol Res 4 8 698-707 2016 AACR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2555, 234, 1288, 71, 264, 209, 4, 7, 5, 442, 1193, 552, 550, 8, 926, 1, 1196, 759, 176, 4, 439, 3, 670, 1, 1288, 209, 4, 386, 16, 2739, 6, 1271, 847, 8, 150, 1, 651, 250, 128, 2, 35, 2611, 1, 30, 31, 995, 1286, 21, 608, 4, 902, 315, 29, 7, 5, 552, 17, 1288, 97, 15243, 393, 132, 37, 1288, 120, 277, 1529, 1, 1603, 239, 20661, 2, 211, 956, 4, 102, 37, 29, 7, 5, 552, 4, 352, 1288, 651, 2218, 1, 583, 20661, 153, 22895, 23, 3, 31, 1255, 2, 101, 153, 956, 4, 439, 3, 4, 439, 150, 1, 20661, 2, 1288, 651, 20661, 517, 1408, 1317, 552, 37, 298, 8, 1362, 1, 483, 21, 514, 248, 1, 31, 273, 5, 2218, 1, 2793, 20, 20661, 651, 2218, 1, 2793, 20, 3, 150, 36, 2, 2849, 15355, 2, 1489, 1062, 314, 363, 1, 6792, 2, 15432, 2535, 21, 264, 35, 250, 31, 30, 31, 915, 298, 1288, 517, 504, 1, 20661, 2, 22895, 5, 651, 20661, 517, 1408, 92, 777, 12611, 9, 26, 150, 4, 38, 143, 9, 7, 5, 552, 12, 8557, 1936, 39, 66, 14072, 13939, 3456, 1630]",1322.0,27287425,318
Richter transformation of CLL.,Expert review of hematology,Expert Rev Hematol,2016-06-28,"Richter transformation (RT) represents an aggressive transformation of chronic lymphocytic leukemia (CLL), most commonly into diffuse large B cell lymphoma (DLBCL). It occurs in around 5% of patients with CLL. This review will focus on the biology and treatment of RT. We also address the management of RT in the era of targeted therapies. Based on clonal relationship of large cell component to CLL, 2 distinct subtypes could be identified: clonally-related RT which carries a worse outcome, and clonally-unrelated RT where the outcomes are similar to de novo DLBCL. Aberrations of TP53, CDKN2A, MYC, and NOTCH1 are common in RT, many of which are acquired at the time of transformation. PET scan remains the imaging modality of choice for patients with suspected RT. It is important to perform a biopsy rather than fine needle aspiration (FNA) of the suspicious lesions, as FNA can lead to false negative results. Chemoimmunotherapy remains the treatment of choice, though the outcomes remain suboptimal. The median survival is less than 1year. Novel therapies are needed for patients with RT. Expert commentary: RT remains an unmet medical need; the role of targeted therapies, including immunotherapy needs to be explored.",Journal Article,1302.0,13.0,Richter transformation RT represents an aggressive transformation of chronic lymphocytic CLL most commonly into diffuse large B cell DLBCL It occurs in around 5 of patients with CLL This review will focus on the biology and treatment of RT We also address the management of RT in the era of targeted therapies Based on clonal relationship of large cell component to CLL 2 distinct subtypes could be identified clonally-related RT which carries a worse outcome and clonally-unrelated RT where the outcomes are similar to de novo DLBCL Aberrations of TP53 CDKN2A MYC and NOTCH1 are common in RT many of which are acquired at the time of transformation PET scan remains the imaging modality of choice for patients with suspected RT It is important to perform a biopsy rather than fine needle aspiration FNA of the suspicious lesions as FNA can lead to false negative results Chemoimmunotherapy remains the treatment of choice though the outcomes remain suboptimal The median survival is less than 1 year Novel therapies are needed for patients with RT Expert commentary RT remains an unmet medical need the role of targeted therapies including immunotherapy needs to be explored,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8452, 1392, 240, 1449, 35, 571, 1392, 1, 442, 1193, 552, 96, 841, 237, 1388, 375, 132, 31, 1446, 192, 1780, 4, 3337, 33, 1, 7, 5, 552, 26, 206, 303, 1222, 23, 3, 891, 2, 24, 1, 240, 21, 120, 1539, 3, 284, 1, 240, 4, 3, 1713, 1, 238, 235, 90, 23, 1946, 858, 1, 375, 31, 1249, 6, 552, 18, 834, 814, 359, 40, 108, 9157, 139, 240, 92, 4942, 8, 639, 228, 2, 9157, 2092, 240, 1257, 3, 123, 32, 288, 6, 1566, 2018, 1446, 2152, 1, 1206, 3175, 1371, 2, 4607, 32, 186, 4, 240, 445, 1, 92, 32, 1294, 28, 3, 98, 1, 1392, 495, 1657, 469, 3, 270, 1396, 1, 1866, 9, 7, 5, 2768, 240, 192, 16, 305, 6, 2715, 8, 411, 1832, 76, 2924, 2177, 3256, 4064, 1, 3, 3230, 406, 22, 4064, 122, 1122, 6, 2133, 199, 99, 4438, 469, 3, 24, 1, 1866, 2471, 3, 123, 918, 3291, 3, 52, 25, 16, 299, 76, 14, 111, 229, 235, 32, 575, 9, 7, 5, 240, 2005, 4662, 240, 469, 35, 3715, 484, 594, 3, 200, 1, 238, 235, 141, 726, 1891, 6, 40, 1443]",1175.0,27351634,48
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.,Hematology/oncology and stem cell therapy,Hematol Oncol Stem Cell Ther,2016-06-23,"Membranoproliferative glomerulonephritis (MPGN) is a common extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with either a frank renal failure or proteinuria. One of its etiologies has been attributed to a paraneoplastic, immune complex phenomenon occurring in CLL. Although there is no standard of care in such patients, use of anti-CD20 monoclonal antibodies like rituximab have been used before in such patients with variable responses. Obinutuzumab is a novel, type II, immunoglobulin-G1 monoclonal antibody with a higher efficacy than rituximab and has an established safely profile in patients with comorbidities and poor renal functions. There are no such reported cases of MPGN in CLL being treated with obinutuzumab. We used the standard doses of obinutuzumab in our elderly patient (78-year-old woman) with high-risk CLL due to an underlying TP53 mutation, along with a MPGN-related acute renal failure. The patient achieved complete remission after six cycles of obinutuzumab; however, she remained positive for minimal residual disease on flow cytometry. Her renal function improved completely, suggesting a complete response of her underlying MPGN. Obinutuzumab has an established safety profile in patients with CLL, but our case is the first reported case of a paraneoplastic, immune complex-mediated MPGN in CLL being treated with obinutuzumab. Obinutuzumab should be explored as a potential option in patients with CLL and MPGN.",Case Reports,1307.0,2.0,Membranoproliferative glomerulonephritis MPGN is a common extramedullary presentation in chronic lymphocytic CLL and can present with either a frank failure or proteinuria One of its etiologies has been attributed to a paraneoplastic immune complex phenomenon occurring in CLL Although there is no standard of care in such patients use of anti-CD20 monoclonal antibodies like rituximab have been used before in such patients with variable responses Obinutuzumab is a novel type II immunoglobulin-G1 monoclonal antibody with a higher efficacy than rituximab and has an established safely profile in patients with comorbidities and poor functions There are no such reported cases of MPGN in CLL being treated with obinutuzumab We used the standard doses of obinutuzumab in our elderly patient 78-year-old woman with high-risk CLL due to an underlying TP53 mutation along with a MPGN-related acute failure The patient achieved complete remission after six cycles of obinutuzumab however she remained positive for minimal residual disease on flow cytometry Her function improved completely suggesting a complete response of her underlying MPGN Obinutuzumab has an established safety profile in patients with CLL but our case is the first reported case of a paraneoplastic immune complex-mediated MPGN in CLL being treated with obinutuzumab Obinutuzumab should be explored as a potential option in patients with CLL and MPGN,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[41129, 26106, 27404, 16, 8, 186, 5508, 1031, 4, 442, 1193, 552, 2, 122, 364, 5, 361, 8, 15252, 496, 15, 5381, 104, 1, 211, 8523, 71, 85, 3073, 6, 8, 6544, 250, 840, 3936, 1821, 4, 552, 242, 125, 16, 77, 260, 1, 165, 4, 225, 7, 119, 1, 312, 2198, 848, 890, 733, 855, 47, 85, 95, 348, 4, 225, 7, 5, 1347, 253, 10380, 16, 8, 229, 267, 215, 2593, 3344, 848, 548, 5, 8, 142, 209, 76, 855, 2, 71, 35, 635, 2268, 800, 4, 7, 5, 1909, 2, 334, 1681, 125, 32, 77, 225, 210, 140, 1, 27404, 4, 552, 486, 73, 5, 10380, 21, 95, 3, 260, 415, 1, 10380, 4, 114, 1216, 69, 833, 111, 1095, 2854, 5, 64, 43, 552, 520, 6, 35, 1181, 1206, 258, 1510, 5, 8, 27404, 139, 286, 496, 3, 69, 513, 236, 734, 50, 437, 410, 1, 10380, 137, 3109, 958, 109, 9, 1048, 753, 34, 23, 1412, 1914, 1084, 343, 231, 2500, 802, 8, 236, 51, 1, 1084, 1181, 27404, 10380, 71, 35, 635, 367, 800, 4, 7, 5, 552, 84, 114, 473, 16, 3, 157, 210, 473, 1, 8, 6544, 250, 840, 517, 27404, 4, 552, 486, 73, 5, 10380, 10380, 257, 40, 1443, 22, 8, 174, 1501, 4, 7, 5, 552, 2, 27404]",1419.0,27352257,101
At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.,Journal of leukocyte biology,J. Leukoc. Biol.,2016-06-27,"T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR. Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor (CAR) into T cells. CARs are composed of an antigen-binding domain and an intracellular T cell activation domain. Early human trials evaluating CD19-targeted CAR T cells for chronic lymphocytic leukemia (CLL) showed limited responses until CARs included a costimulation domain, and conditioning chemotherapy was given before T cell infusion. Clinical trials evaluating CD19-targeted CAR T cells for B cell acute lymphoblastic leukemia (B-ALL) are demonstrating response rates up to 90%. However, these clinical outcomes are associated with a cytokine release syndrome (CRS), which is caused by T cell activation and manifests as high-grade fever, hypotension, and other cardiovascular complications. It is currently managed conservatively but can be treated with cytokine-directed therapy or with high-dose steroids. Current efforts are dedicated to confirming the clinical efficacy and managing toxicities in multicenter Phase II trials. We present a thorough overview of the preclinical and clinical development of CAR T cell therapy that will highlight important areas for the basic researcher to investigate in the laboratory and contribute to this exciting field.",Journal Article,1303.0,15.0,T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor CAR into T cells CARs are composed of an antigen-binding domain and an intracellular T cell activation domain Early human trials evaluating CD19-targeted CAR T cells for chronic lymphocytic CLL showed limited responses until CARs included a costimulation domain and conditioning chemotherapy was given before T cell infusion Clinical trials evaluating CD19-targeted CAR T cells for B cell acute lymphoblastic B-ALL are demonstrating response rates up to 90 However these clinical outcomes are associated with a cytokine release syndrome CRS which is caused by T cell activation and manifests as high-grade fever hypotension and other cardiovascular complications It is currently managed conservatively but can be treated with cytokine-directed therapy or with high-dose steroids Current efforts are dedicated to confirming the clinical efficacy and managing toxicities in multicenter Phase II trials We present a thorough overview of the preclinical and clinical development of CAR T cell therapy that will highlight important areas for the basic researcher to investigate in the laboratory and contribute to this exciting field,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[102, 37, 5097, 9138, 3369, 2, 393, 37, 20, 638, 1, 49855, 1575, 5, 3, 4134, 30, 4601, 122, 40, 4587, 2301, 20, 11165, 8, 2897, 448, 153, 1881, 237, 102, 37, 7441, 32, 3317, 1, 35, 448, 791, 1398, 2, 35, 2087, 102, 31, 363, 1398, 191, 171, 143, 1435, 3158, 238, 1881, 102, 37, 9, 442, 1193, 552, 224, 383, 253, 1100, 7441, 159, 8, 8085, 1398, 2, 1933, 56, 10, 447, 348, 102, 31, 904, 38, 143, 1435, 3158, 238, 1881, 102, 37, 9, 132, 31, 286, 1275, 132, 62, 32, 2219, 51, 151, 126, 6, 424, 137, 46, 38, 123, 32, 41, 5, 8, 1675, 2008, 681, 3115, 92, 16, 1546, 20, 102, 31, 363, 2, 15096, 22, 64, 88, 2775, 6577, 2, 127, 2179, 521, 192, 16, 694, 2231, 10296, 84, 122, 40, 73, 5, 1675, 1166, 36, 15, 5, 64, 61, 4580, 291, 1413, 32, 4827, 6, 5030, 3, 38, 209, 2, 3969, 385, 4, 1570, 124, 215, 143, 21, 364, 8, 5506, 2901, 1, 3, 693, 2, 38, 193, 1, 1881, 102, 31, 36, 17, 303, 1817, 305, 1361, 9, 3, 2795, 24904, 6, 963, 4, 3, 1624, 2, 1248, 6, 26, 4963, 1067]",1313.0,27354412,18
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.,Leukemia & lymphoma,Leuk. Lymphoma,2016-07-07,"Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000mg ofatumumab (Cycle 1; 300mg) plus FC every 4 weeks for six cycles. Median C<sub>max</sub> and C<sub>trough</sub> values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C<sub>max</sub> and C<sub>trough</sub> values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas ofatumumab pharmacokinetics were not associated with an objective response (OR) on the basis of univariate analyses. Multivariate analyses indicated that baseline patient/disease factors were predominantly associated with CR (17p status) or OR (bulky lymphadenopathy, gender, and serum thymidine kinase), rather than ofatumumab pharmacokinetics. www.clinicaltrials.gov (NCT00410163).","Clinical Trial, Phase II",1293.0,1.0,Relationships between patient characteristics ofatumumab pharmacokinetics and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide FC in untreated chronic lymphocytic Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab Cycle 1 300 mg plus FC every 4 weeks for six cycles Median C sub max /sub and C sub trough /sub values were similar at Cycle 1 regardless of the ultimate clinical outcome At later doses these values were higher for patients with complete response CR than for other patients Higher C sub max /sub and C sub trough /sub values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR whereas ofatumumab pharmacokinetics were not associated with an objective response OR on the basis of univariate analyses Multivariate analyses indicated that baseline patient/disease factors were predominantly associated with CR 17p status or OR bulky lymphadenopathy gender and serum thymidine kinase rather than ofatumumab pharmacokinetics www.clinicaltrials.gov NCT00410163,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2467, 59, 69, 374, 5732, 1159, 2, 24, 123, 11, 565, 4, 26, 124, 18, 160, 1, 5732, 349, 2027, 2, 1112, 4127, 4, 1278, 442, 1193, 7, 11, 384, 14, 14, 6, 560, 1666, 15, 2345, 81, 5732, 417, 14, 2036, 81, 349, 4127, 454, 39, 244, 9, 437, 410, 52, 256, 551, 2649, 551, 2, 256, 551, 6000, 551, 1030, 11, 288, 28, 417, 14, 1583, 1, 3, 5768, 38, 228, 28, 1559, 415, 46, 1030, 11, 142, 9, 7, 5, 236, 51, 684, 76, 9, 127, 7, 142, 256, 551, 2649, 551, 2, 256, 551, 6000, 551, 1030, 28, 410, 27, 2, 49, 11, 97, 41, 5, 35, 101, 1420, 1, 684, 547, 5732, 1159, 11, 44, 41, 5, 35, 461, 51, 15, 23, 3, 877, 1, 880, 318, 331, 318, 1103, 17, 330, 69, 34, 130, 11, 2117, 41, 5, 684, 4135, 156, 15, 15, 4112, 4962, 1632, 2, 524, 6403, 216, 1832, 76, 5732, 1159, 3064, 1252, 1239, 46538]",1076.0,27389174,75
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.,American journal of hematology,Am. J. Hematol.,2016-08-08,"The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum 2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (P<0.0001.; C-statistic:c=0.72; 95% CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090-1095, 2016.  2016 Wiley Periodicals, Inc.",Clinical Trial,1261.0,27.0,The chronic lymphocytic International Prognostic Index CLL-IPI combines 5 parameters age clinical stage TP53 status normal vs. del 17p and/or TP53 mutation IGHV mutational status serum 2-microglobulin to predict survival and time-to-first-treatment TTFT in CLL patients We performed an observational study in 337 prospectively collected Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome Since the CLL-IPI was originally developed to predict survival we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients Recursive partitioning analysis identified three subsets with scores of 0 n 139 1 n 90 and  2 n 108 The probability of remaining free from therapy 5 years after diagnosis was 85 67 and 46 in these three categories P 0.0001. C-statistic c 0.72 95 CI:0.58-0.81 This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic n 525 The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint 2011 MDACC score and O-CLL1 score Although originally developed to predict suvival the CLL-IPI is useful for predicting TTFT in early stage CLL patients Am J. Hematol 91:1090-1095 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 442, 1193, 944, 177, 558, 552, 3753, 6705, 33, 1038, 89, 38, 82, 1206, 156, 295, 105, 3084, 4135, 2, 15, 1206, 258, 6220, 1619, 156, 524, 9314, 5371, 6, 678, 25, 2, 98, 6, 157, 24, 14035, 4, 552, 7, 21, 173, 35, 2495, 45, 4, 8275, 1143, 786, 17129, 82, 8, 7, 6, 2183, 3, 801, 1, 3, 552, 3753, 6, 678, 14035, 4, 35, 306, 180, 1, 191, 82, 552, 7, 3, 552, 3753, 368, 1173, 17129, 82, 8, 7, 237, 169, 1453, 5, 338, 228, 1192, 3, 552, 3753, 10, 5045, 276, 6, 678, 25, 21, 1305, 565, 3, 665, 3554, 1889, 368, 6, 678, 14035, 4, 17129, 82, 8, 7, 4493, 4515, 65, 108, 169, 1890, 5, 703, 1, 13, 78, 4929, 14, 78, 424, 2, 749, 18, 78, 3590, 3, 1320, 1, 1844, 115, 29, 36, 33, 60, 50, 147, 10, 772, 598, 2, 641, 4, 46, 169, 1996, 19, 13, 488, 256, 4502, 256, 13, 720, 48, 58, 13, 717, 13, 865, 26, 4039, 552, 3753, 2504, 9, 14035, 10, 1611, 938, 4, 35, 306, 180, 1, 17129, 8, 7, 29, 3, 2486, 1188, 78, 10223, 3, 801, 1, 361, 2279, 15, 4039, 552, 3753, 6, 678, 14035, 10, 2017, 6, 127, 177, 274, 1225, 1114, 9, 26, 1138, 1132, 7412, 368, 2, 1990, 35808, 368, 242, 5045, 276, 6, 678, 68663, 3, 552, 3753, 16, 999, 9, 1434, 14035, 4, 191, 82, 552, 7, 5886, 3543, 13175, 970, 27380, 23513, 1390, 2206, 1390, 4692, 5493, 3479]",1479.0,27465919,79
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2016-08-17,"BCR signaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL). Most CLL cells express BCRs of IgM and IgD isotypes, but the contribution of these isotypes to functional responses remains incompletely defined. We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells and in CLL cells cultured with nurselike cells, a model that mimics the lymph node microenvironment. IgM signaling induced prolonged activation of ERK kinases and promoted CLL cell survival, CCL3 and CCL4 chemokine secretion, and downregulation of BCL6, the transcriptional repressor of CCL3 In contrast, IgD signaling induced activation of the cytoskeletal protein HS1, along with F-actin polymerization, which resulted in rapid receptor internalization and failure to support downstream responses, including CLL cell survival and chemokine secretion. IgM and IgD receptor downmodulation, HS1 and ERK activation, chemokine secretion, and BCL6 downregulation were also observed when CLL cells were cocultured with nurselike cells. The Bruton's tyrosine kinase inhibitor ibrutinib effectively inhibited both IgM and IgD isotype signaling. In conclusion, through a variety of functional readouts, we demonstrate very distinct outcomes of IgM and IgD isotype activation in CLL cells, providing novel insight into the regulation of BCR signaling in CLL.",Journal Article,1252.0,13.0,BCR signaling is a central pathogenetic pathway in chronic lymphocytic CLL Most CLL cells express BCRs of IgM and IgD isotypes but the contribution of these isotypes to functional responses remains incompletely defined We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells and in CLL cells cultured with nurselike cells a model that mimics the lymph node microenvironment IgM signaling induced prolonged activation of ERK kinases and promoted CLL cell survival CCL3 and CCL4 chemokine secretion and downregulation of BCL6 the transcriptional repressor of CCL3 In contrast IgD signaling induced activation of the cytoskeletal protein HS1 along with F-actin polymerization which resulted in rapid receptor internalization and failure to support downstream responses including CLL cell survival and chemokine secretion IgM and IgD receptor downmodulation HS1 and ERK activation chemokine secretion and BCL6 downregulation were also observed when CLL cells were cocultured with nurselike cells The Bruton 's tyrosine kinase inhibitor ibrutinib effectively inhibited both IgM and IgD isotype signaling In conclusion through a variety of functional readouts we demonstrate very distinct outcomes of IgM and IgD isotype activation in CLL cells providing novel insight into the regulation of BCR signaling in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1062, 314, 16, 8, 854, 10781, 308, 4, 442, 1193, 552, 96, 552, 37, 1669, 34371, 1, 2852, 2, 16730, 19010, 84, 3, 2925, 1, 46, 19010, 6, 583, 253, 469, 5252, 395, 21, 673, 565, 362, 59, 2852, 2, 16730, 314, 4, 9957, 1355, 672, 315, 552, 37, 2, 4, 552, 37, 3197, 5, 28698, 37, 8, 202, 17, 7557, 3, 263, 289, 995, 2852, 314, 277, 1069, 363, 1, 1819, 1549, 2, 2992, 552, 31, 25, 9711, 2, 12660, 3596, 2935, 2, 2475, 1, 8148, 3, 1431, 7434, 1, 9711, 4, 748, 16730, 314, 277, 363, 1, 3, 10055, 178, 41532, 1510, 5, 1068, 5525, 12273, 92, 627, 4, 1321, 153, 7520, 2, 496, 6, 538, 1489, 253, 141, 552, 31, 25, 2, 3596, 2935, 2852, 2, 16730, 153, 23081, 41532, 2, 1819, 363, 3596, 2935, 2, 8148, 2475, 11, 120, 164, 198, 552, 37, 11, 11444, 5, 28698, 37, 3, 5796, 292, 564, 216, 230, 1795, 1856, 879, 110, 2852, 2, 16730, 11420, 314, 4, 1221, 298, 8, 1362, 1, 583, 19040, 21, 608, 923, 834, 123, 1, 2852, 2, 16730, 11420, 363, 4, 552, 37, 1736, 229, 2670, 237, 3, 863, 1, 1062, 314, 4, 552]",1365.0,27534555,498
Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.,Annals of hematology,Ann. Hematol.,2016-08-19,"Chronic lymphocytic leukemia (CLL) is an incurable illness, with some patients requiring no treatment until disease progression. Burden from physical symptoms has been associated with depression, anxiety, and stress in cancer patients. Additionally, patient factors, i.e., individual differences, have been associated with worse psychological outcomes. There are few psychological studies of CLL, with no examination of individual differences. A cross-sectional design studied the covariation of symptom burden with depressive and anxiety symptoms and cancer-specific stress, and tested patients' individual differences as predictors and as moderators. CLL patients (N=112) receiving active surveillance participated. They were Caucasian (100%) and predominately male (55%) with a mean age of 61; most (62.5%) had stage 0 disease. A composite measure of physical symptom burden (CLL symptoms, fatigue, pain, impaired functional status) was tested as a predictor of psychological responses. Individual differences in psychiatric history and social support were tested as moderators. Using multiple linear regression, greater symptom burden covaried with higher levels of depressive and anxiety symptoms and cancer stress (ps<.05). Those with a psychiatric history, low social support, and low relationship satisfaction with one's partner reported greater symptom burden and more psychological symptoms and stress (ps<.05). Findings suggest that CLL patients in surveillance with a psychiatric history and/or low social support are at risk for greater distress when coping with high symptom burden. These new data clarify the experience of CLL surveillance and identify characteristics of patients with heightened risk for symptom burden, stress, and anxiety or depressive symptoms.",Journal Article,1250.0,8.0,Chronic lymphocytic CLL is an incurable illness with some patients requiring no treatment until disease progression Burden from physical symptoms has been associated with depression anxiety and stress in cancer patients Additionally patient factors i.e. individual differences have been associated with worse psychological outcomes There are few psychological studies of CLL with no examination of individual differences A cross-sectional design studied the covariation of symptom burden with depressive and anxiety symptoms and cancer-specific stress and tested patients individual differences as predictors and as moderators CLL patients N 112 receiving active surveillance participated They were Caucasian 100 and predominately male 55 with a mean age of 61 most 62.5 had stage 0 disease A composite measure of physical symptom burden CLL symptoms fatigue pain impaired functional status was tested as a predictor of psychological responses Individual differences in psychiatric history and social support were tested as moderators Using multiple linear regression greater symptom burden covaried with higher levels of depressive and anxiety symptoms and cancer stress ps .05 Those with a psychiatric history low social support and low relationship satisfaction with one 's partner reported greater symptom burden and more psychological symptoms and stress ps .05 Findings suggest that CLL patients in surveillance with a psychiatric history and/or low social support are at risk for greater distress when coping with high symptom burden These new data clarify the experience of CLL surveillance and identify characteristics of patients with heightened risk for symptom burden stress and anxiety or depressive symptoms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 35, 2641, 2973, 5, 476, 7, 1888, 77, 24, 1100, 34, 91, 892, 29, 900, 507, 71, 85, 41, 5, 1774, 2021, 2, 1531, 4, 12, 7, 1724, 69, 130, 70, 563, 797, 362, 47, 85, 41, 5, 639, 2624, 123, 125, 32, 1021, 2624, 94, 1, 552, 5, 77, 1385, 1, 797, 362, 8, 1383, 2832, 771, 656, 3, 41533, 1, 934, 892, 5, 4945, 2, 2021, 507, 2, 12, 112, 1531, 2, 650, 7, 797, 362, 22, 674, 2, 22, 19964, 552, 7, 78, 3726, 357, 544, 617, 3025, 491, 11, 3229, 394, 2, 11583, 1045, 614, 5, 8, 313, 89, 1, 713, 96, 744, 33, 42, 82, 13, 34, 8, 3308, 1463, 1, 900, 934, 892, 552, 507, 613, 559, 2364, 583, 156, 10, 650, 22, 8, 980, 1, 2624, 253, 797, 362, 4, 6563, 532, 2, 2032, 538, 11, 650, 22, 19964, 75, 232, 1646, 320, 378, 934, 892, 68823, 5, 142, 148, 1, 4945, 2, 2021, 507, 2, 12, 1531, 1511, 474, 135, 5, 8, 6563, 532, 154, 2032, 538, 2, 154, 858, 2885, 5, 104, 292, 4852, 210, 378, 934, 892, 2, 80, 2624, 507, 2, 1531, 1511, 474, 272, 309, 17, 552, 7, 4, 617, 5, 8, 6563, 532, 2, 15, 154, 2032, 538, 32, 28, 43, 9, 378, 1462, 198, 4276, 5, 64, 934, 892, 46, 217, 74, 3968, 3, 730, 1, 552, 617, 2, 255, 374, 1, 7, 5, 7145, 43, 9, 934, 892, 1531, 2, 2021, 15, 4945, 507]",1721.0,27539615,537
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.,Cytotherapy,Cytotherapy,2016-08-31,"The past several years have been marked by extraordinary advances in clinical applications of immunotherapy. In particular, adoptive cellular therapy utilizing chimeric antigen receptor (CAR)-modified T cells targeted to CD19 has demonstrated substantial clinical efficacy in children and adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and durable clinical benefit in a smaller subset of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or B-cell non-Hodgkin lymphoma (B-NHL). Early-phase clinical trials are currently assessing CAR T-cell safety and efficacy in additional malignancies. Here, we discuss clinical results from the largest series to date investigating CD19-targeted CAR T cells in B-ALL, CLL, and B-NHL, including discussion of differences in CAR T-cell design and production and treatment approach, as well as clinical efficacy, nature of severe cytokine release syndrome and neurologic toxicities, and CAR T-cell expansion and persistence. We additionally review the current and forthcoming use of CAR T cells in multiple myeloma and several solid tumors and highlight challenges and opportunities afforded by the current state of CAR T-cell therapies, including strategies to overcome inhibitory aspects of the tumor microenvironment and enhance antitumor efficacy.",Journal Article,1238.0,55.0,The past several years have been marked by extraordinary advances in clinical applications of immunotherapy In particular adoptive cellular therapy utilizing chimeric antigen receptor CAR -modified T cells targeted to CD19 has demonstrated substantial clinical efficacy in children and adults with relapsed or refractory B-cell acute lymphoblastic B-ALL and durable clinical benefit in a smaller subset of patients with relapsed or refractory chronic lymphocytic CLL or B-cell B-NHL Early-phase clinical trials are currently assessing CAR T-cell safety and efficacy in additional malignancies Here we discuss clinical results from the largest series to date investigating CD19-targeted CAR T cells in B-ALL CLL and B-NHL including discussion of differences in CAR T-cell design and production and treatment approach as well as clinical efficacy nature of severe cytokine release syndrome and neurologic toxicities and CAR T-cell expansion and persistence We additionally review the current and forthcoming use of CAR T cells in multiple and several solid tumors and highlight challenges and opportunities afforded by the current state of CAR T-cell therapies including strategies to overcome inhibitory aspects of the tumor microenvironment and enhance antitumor efficacy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 1219, 392, 60, 47, 85, 2003, 20, 17915, 954, 4, 38, 2911, 1, 726, 4, 1454, 3159, 763, 36, 2600, 2897, 448, 153, 1881, 1230, 102, 37, 238, 6, 3158, 71, 264, 1281, 38, 209, 4, 541, 2, 857, 5, 591, 15, 430, 132, 31, 286, 1275, 132, 62, 2, 1480, 38, 247, 4, 8, 2170, 697, 1, 7, 5, 591, 15, 430, 442, 1193, 552, 15, 132, 31, 132, 1176, 191, 124, 38, 143, 32, 694, 1977, 1881, 102, 31, 367, 2, 209, 4, 402, 441, 467, 21, 1139, 38, 99, 29, 3, 2166, 988, 6, 1244, 3103, 3158, 238, 1881, 102, 37, 4, 132, 62, 552, 2, 132, 1176, 141, 2488, 1, 362, 4, 1881, 102, 31, 771, 2, 1529, 2, 24, 353, 22, 149, 22, 38, 209, 2202, 1, 905, 1675, 2008, 681, 2, 2543, 385, 2, 1881, 102, 31, 1422, 2, 4108, 21, 1724, 206, 3, 291, 2, 16039, 119, 1, 1881, 102, 37, 4, 232, 2, 392, 537, 57, 2, 1817, 1427, 2, 2605, 9150, 20, 3, 291, 1309, 1, 1881, 102, 31, 235, 141, 422, 6, 1768, 1810, 2695, 1, 3, 30, 995, 2, 1304, 579, 209]",1271.0,27592405,466
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.,Oncotarget,Oncotarget,2016-10-01,"Ibrutinib (ibr), a first-in-class Bruton tyrosine kinase (BTK) inhibitor, has demonstrated high response rates in both relapsed/refractory and treatment nave chronic lymphocytic leukemia (CLL). However, about 25% of patients discontinue ibrutinib therapy at a median follow-up of 20 months and many patients discontinue the treatment due to leukemia progression or Richter transformation. Mutations affecting the C481 residue of BTK disrupt ibrutinib binding and have been characterized by us and others as the most common mechanism of ibrutinib resistance. Thus far, all described BTK mutations are located in its kinase domain and mutations outside this domain have never been described. Herein, we report a patient whose CLL progressed, was salvaged with ibrutinib and then relapsed. Serial analysis of samples throughout patient's clinical course identified a structurally novel mutation (BTKT316A) in the SH2 domain, but not kinase domain, of Bruton tyrosine kinase which was associated with disease relapse. Functionally, cells carrying BTKT316A show resistance to ibrutinib at both cellular and molecular levels to a similar extent as BTKC481S. Our study lends further insight into the diverse mechanisms of ibrutinib resistance that has important implications for the development of next-generation BTK inhibitors as well as mutation detection in relapsed patients.",Case Reports,1207.0,26.0,Ibrutinib ibr a first-in-class Bruton tyrosine kinase BTK inhibitor has demonstrated high response rates in both relapsed/refractory and treatment nave chronic lymphocytic CLL However about 25 of patients discontinue ibrutinib therapy at a median follow-up of 20 months and many patients discontinue the treatment due to progression or Richter transformation Mutations affecting the C481 residue of BTK disrupt ibrutinib binding and have been characterized by us and others as the most common mechanism of ibrutinib resistance Thus far all described BTK mutations are located in its kinase domain and mutations outside this domain have never been described Herein we report a patient whose CLL progressed was salvaged with ibrutinib and then relapsed Serial analysis of samples throughout patient 's clinical course identified a structurally novel mutation BTKT316A in the SH2 domain but not kinase domain of Bruton tyrosine kinase which was associated with disease relapse Functionally cells carrying BTKT316A show resistance to ibrutinib at both cellular and molecular levels to a similar extent as BTKC481S Our study lends further insight into the diverse mechanisms of ibrutinib resistance that has important implications for the development of next-generation BTK inhibitors as well as mutation detection in relapsed patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 7905, 8, 157, 4, 1040, 5796, 564, 216, 3611, 230, 71, 264, 64, 51, 151, 4, 110, 591, 430, 2, 24, 2809, 442, 1193, 552, 137, 545, 243, 1, 7, 7934, 1795, 36, 28, 8, 52, 166, 126, 1, 179, 53, 2, 445, 7, 7934, 3, 24, 520, 6, 91, 15, 8452, 1392, 138, 2319, 3, 36300, 7840, 1, 3611, 6619, 1795, 791, 2, 47, 85, 765, 20, 843, 2, 1749, 22, 3, 96, 186, 670, 1, 1795, 251, 631, 3272, 62, 1027, 3611, 138, 32, 2308, 4, 211, 216, 1398, 2, 138, 2513, 26, 1398, 47, 1737, 85, 1027, 1986, 21, 414, 8, 69, 1310, 552, 1839, 10, 9459, 5, 1795, 2, 818, 591, 2108, 65, 1, 347, 2432, 69, 292, 38, 906, 108, 8, 8533, 229, 258, 50007, 4, 3, 16745, 1398, 84, 44, 216, 1398, 1, 5796, 564, 216, 92, 10, 41, 5, 34, 429, 3772, 37, 2934, 50007, 514, 251, 6, 1795, 28, 110, 763, 2, 219, 148, 6, 8, 288, 1039, 22, 68987, 114, 45, 18458, 195, 2670, 237, 3, 1867, 483, 1, 1795, 251, 17, 71, 305, 1268, 9, 3, 193, 1, 1305, 914, 3611, 222, 22, 149, 22, 258, 638, 4, 591, 7]",1331.0,27626698,617
Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL.,Anticancer research,Anticancer Res.,2016-09-01,"Chronic lymphocytic leukemia (CLL) is characterized by a clonal accumulation of neoplastic lymphocytes, indicating disruption of apoptosis. Differential methylation hybridization analysis was performed to identify novel target genes silenced by CpG island methylation in patients with CLL. Patched (PTCH), a tumor-suppressor gene, was found to be frequently methylated in CLL samples compared to samples derived from healthy individuals. De novo methylation of a CpG island region located upstream of PTCH exon 1 was confirmed by pyrosequencing in 17/37 (46%) of peripheral blood mononuclear cells of patients with CLL, but in none isolated from seven healthy individuals. No association was found between PTCH hypermethylation and currently used prognostic CLL factors. Our investigation suggests that epigenetic silencing of PTCH is a mechanism contributing to CLL tumorigenesis.",Journal Article,1237.0,1.0,Chronic lymphocytic CLL is characterized by a clonal accumulation of neoplastic lymphocytes indicating disruption of apoptosis Differential methylation hybridization analysis was performed to identify novel target genes silenced by CpG island methylation in patients with CLL Patched PTCH a tumor-suppressor gene was found to be frequently methylated in CLL samples compared to samples derived from healthy individuals De novo methylation of a CpG island region located upstream of PTCH exon 1 was confirmed by pyrosequencing in 17/37 46 of peripheral blood mononuclear cells of patients with CLL but in none isolated from seven healthy individuals No association was found between PTCH hypermethylation and currently used prognostic CLL factors Our investigation suggests that epigenetic silencing of PTCH is a mechanism contributing to CLL tumorigenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 765, 20, 8, 1946, 1835, 1, 2000, 1594, 1716, 3220, 1, 351, 1777, 569, 1554, 65, 10, 173, 6, 255, 229, 283, 214, 5442, 20, 2075, 3454, 569, 4, 7, 5, 552, 28884, 22582, 8, 30, 1245, 145, 10, 204, 6, 40, 746, 2963, 4, 552, 347, 72, 6, 347, 526, 29, 1331, 869, 1566, 2018, 569, 1, 8, 2075, 3454, 1053, 2308, 3988, 1, 22582, 1725, 14, 10, 557, 20, 6031, 4, 269, 567, 641, 1, 672, 315, 3041, 37, 1, 7, 5, 552, 84, 4, 1292, 1355, 29, 648, 1331, 869, 77, 248, 10, 204, 59, 22582, 2575, 2, 694, 95, 177, 552, 130, 114, 940, 844, 17, 1418, 2077, 1, 22582, 16, 8, 670, 3156, 6, 552, 1565]",855.0,27630290,113
"A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.",Oncotarget,Oncotarget,2017-03-01,"Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on the preclinical work demonstrating that bendamustine combined with fludarabine resulted in increased DNA damage, we designed a phase I-II clinical trial with fludarabine, bendamustine, and rituximab (FBR) for patients with relapsed/refractory CLL. Treatment consisted of fludarabine 20 mg/m2 daily x 3 days and rituximab 375-500 mg/m2 x 1 day. Phase I included bendamustine at increasing doses of 20, 30, 40, or 50 mg/m2 daily x 3 days; phase II was with FR, and B at the selected dose. DNA damage response (H2AX phosphorylation) was evaluated in a subset of patients. Fifty-one patients were enrolled. The median age was 62 years; median number of prior therapies was 2; 40% had del(11q); and 41 patients had received prior FCR-based therapies. Hematologic toxicity was more common in 40 mg/m2 dose cohorts. Maximum tolerated dose (MTD) was not identified. Bendamustine-elicited H2AX phosphorylation was not dose-dependent, but markedly increased after fludarabine. We identified bendamustine 30 mg/m2 as the safe dose for phase II. The overall response rate (ORR) was 67% with 36% complete response (CR) / CR with incomplete count recovery (CRi). Younger patients (<65 years) had significantly higher ORR (81% vs. 50%; p=0.038). The median progression-free survival was 19 months, and the median overall survival was 52.5 months. FBR is an effective and tolerable CIT regimen for patients with relapsed CLL.","Clinical Trial, Phase I",1056.0,,Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic CLL For young fit patients the standard of care is combination of fludarabine cyclophosphamide and rituximab FCR Based on the preclinical work demonstrating that bendamustine combined with fludarabine resulted in increased DNA damage we designed a phase I-II clinical trial with fludarabine bendamustine and rituximab FBR for patients with relapsed/refractory CLL Treatment consisted of fludarabine 20 mg/m2 daily x 3 days and rituximab 375-500 mg/m2 x 1 day Phase I included bendamustine at increasing doses of 20 30 40 or 50 mg/m2 daily x 3 days phase II was with FR and B at the selected dose DNA damage response H2AX phosphorylation was evaluated in a subset of patients Fifty-one patients were enrolled The median age was 62 years median number of prior therapies was 2 40 had del 11q and 41 patients had received prior FCR-based therapies Hematologic toxicity was more common in 40 mg/m2 dose cohorts Maximum tolerated dose MTD was not identified Bendamustine-elicited H2AX phosphorylation was not dose-dependent but markedly increased after fludarabine We identified bendamustine 30 mg/m2 as the safe dose for phase II The overall response rate ORR was 67 with 36 complete response CR CR with incomplete count recovery CRi Younger patients 65 years had significantly higher ORR 81 vs. 50 p=0.038 The median progression-free survival was 19 months and the median overall survival was 52.5 months FBR is an effective and tolerable CIT regimen for patients with relapsed CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4438, 472, 47, 85, 3, 260, 157, 328, 36, 9, 7, 5, 442, 1193, 552, 9, 1169, 2975, 7, 3, 260, 1, 165, 16, 150, 1, 2027, 1112, 2, 855, 4953, 90, 23, 3, 693, 1357, 2219, 17, 4809, 397, 5, 2027, 627, 4, 101, 261, 1350, 21, 1114, 8, 124, 70, 215, 38, 160, 5, 2027, 4809, 2, 855, 33642, 9, 7, 5, 591, 430, 552, 24, 1695, 1, 2027, 179, 81, 821, 391, 1006, 27, 162, 2, 855, 4175, 1666, 81, 821, 1006, 14, 218, 124, 70, 159, 4809, 28, 602, 415, 1, 179, 201, 327, 15, 212, 81, 821, 391, 1006, 27, 162, 124, 215, 10, 5, 6413, 2, 132, 28, 3, 715, 61, 261, 1350, 51, 6286, 982, 10, 194, 4, 8, 697, 1, 7, 1461, 104, 7, 11, 346, 3, 52, 89, 10, 744, 60, 52, 207, 1, 324, 235, 10, 18, 327, 42, 3084, 7203, 2, 605, 7, 42, 103, 324, 4953, 90, 235, 813, 155, 10, 80, 186, 4, 8483, 81, 821, 61, 736, 689, 421, 61, 961, 10, 44, 108, 4809, 5179, 6286, 982, 10, 44, 61, 470, 84, 2195, 101, 50, 2027, 21, 108, 4809, 201, 81, 821, 22, 3, 1165, 61, 9, 124, 215, 3, 63, 51, 116, 1735, 10, 598, 5, 511, 236, 51, 684, 684, 5, 2610, 1276, 1602, 6341, 773, 7, 556, 60, 42, 97, 142, 1735, 865, 105, 212, 19, 13, 5215, 3, 52, 91, 115, 25, 10, 326, 53, 2, 3, 52, 63, 25, 10, 653, 33, 53, 33642, 16, 35, 323, 2, 2668, 9192, 477, 9, 7, 5, 591, 552]",1587.0,27655665,579
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-09-19,"We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.",Journal Article,1219.0,32.0,We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation allo-HCT for patients with chronic lymphocytic CLL in an era of highly active targeted therapies We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages In the absence of such data we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations We followed the Grading of Recommendations Assessment Development and Evaluation methodology For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor BCR inhibitors For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors regardless of whether an objective response is achieved For Richter transformation we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy A reduced-intensity conditioning regimen is recommended whenever indicated These recommendations highlight the rapidly changing treatment landscape of CLL Newer therapies have disrupted prior paradigms and allo-HCT is now relegated to later stages of relapsed or refractory CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 990, 6, 1811, 38, 758, 883, 6, 17335, 3, 200, 1, 1063, 1007, 31, 497, 2564, 1085, 9, 7, 5, 442, 1193, 552, 4, 35, 1713, 1, 561, 544, 238, 235, 21, 173, 8, 1556, 206, 6, 255, 482, 384, 1149, 143, 1430, 2564, 1085, 480, 229, 235, 9, 24, 1, 552, 28, 747, 34, 1153, 4, 3, 1127, 1, 225, 74, 21, 7594, 1261, 5, 4935, 4, 2564, 1085, 2, 15, 552, 6, 3506, 4, 931, 46, 883, 21, 370, 3, 3452, 1, 883, 455, 193, 2, 451, 3209, 9, 260, 43, 552, 21, 2237, 2564, 1085, 4, 3, 1127, 1, 51, 15, 492, 125, 16, 241, 1, 34, 91, 50, 132, 31, 153, 1062, 222, 9, 64, 43, 552, 35, 2564, 1085, 16, 793, 50, 7928, 18, 285, 1, 36, 2, 2069, 35, 461, 51, 6, 1062, 222, 15, 6, 8, 38, 160, 192, 16, 120, 793, 9, 7, 54, 4373, 6, 514, 35, 461, 51, 15, 1466, 50, 1062, 222, 2, 560, 1044, 18, 222, 1583, 1, 317, 35, 461, 51, 16, 513, 9, 8452, 1392, 21, 2237, 2564, 1085, 1548, 6533, 1, 35, 461, 51, 6, 2044, 90, 56, 8, 405, 837, 1933, 477, 16, 793, 8395, 1103, 46, 883, 1817, 3, 1755, 3600, 24, 2801, 1, 552, 2246, 235, 47, 5576, 324, 4887, 2, 2564, 1085, 16, 1134, 30600, 6, 1559, 1153, 1, 591, 15, 430, 552]",1539.0,27660167,440
A New Role for Lyn in the CLL Microenvironment.,Cancer cell,Cancer Cell,2016-10-01,"The role of Lyn, both a positive and a negative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well characterized. In this issue of Cancer Cell, Nguyen etal. demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy.",Journal Article,1207.0,0.0,The role of Lyn both a positive and a negative regulator of B and myeloid cells in chronic lymphocytic CLL has not been well characterized In this issue of Cancer Cell Nguyen et al demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 200, 1, 8309, 110, 8, 109, 2, 8, 199, 2452, 1, 132, 2, 533, 37, 4, 442, 1193, 552, 71, 44, 85, 149, 765, 4, 26, 2537, 1, 12, 31, 39368, 2022, 2171, 264, 17, 8309, 4, 2748, 1832, 76, 4, 552, 37, 16, 740, 9, 3, 710]",273.0,27728800,568
Targeting BTK through microRNA in chronic lymphocytic leukemia.,Blood,Blood,2016-10-17,"Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need, and therapies that target BTK via alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs (miRs) that target BTK in primary CLL cells and show that the histone deacetylase (HDAC) repressor complex is recruited to these miR promoters to silence their expression. Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death. We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK. This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling.",Journal Article,1191.0,15.0,Bruton 's tyrosine kinase BTK is a critical mediator of survival in B-cell neoplasms Although BTK inhibitors have transformed therapy in chronic lymphocytic CLL patients with high-risk genetics are at risk for relapse and have a poor prognosis Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need and therapies that target BTK via alternative mechanisms may fill this niche Herein we identify a set of microRNAs miRs that target BTK in primary CLL cells and show that the histone deacetylase HDAC repressor complex is recruited to these miR promoters to silence their expression Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor HDACi in CLL and mantle cell restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[5796, 292, 564, 216, 3611, 16, 8, 740, 3810, 1, 25, 4, 132, 31, 1179, 242, 3611, 222, 47, 2423, 36, 4, 442, 1193, 552, 7, 5, 64, 43, 2894, 32, 28, 43, 9, 429, 2, 47, 8, 334, 356, 911, 1, 229, 189, 422, 9, 26, 87, 1, 7, 16, 35, 5013, 3715, 38, 594, 2, 235, 17, 283, 3611, 847, 1091, 483, 68, 11476, 26, 4385, 1986, 21, 255, 8, 916, 1, 3515, 7569, 17, 283, 3611, 4, 86, 552, 37, 2, 514, 17, 3, 1508, 2732, 2654, 7434, 840, 16, 2619, 6, 46, 722, 4347, 6, 13557, 136, 55, 529, 3, 7803, 20, 75, 361, 893, 3182, 480, 14241, 4, 552, 15, 8, 302, 1354, 230, 4265, 4, 552, 2, 2757, 31, 4138, 3, 55, 1, 3, 3611, 529, 7569, 5, 407, 1, 3611, 178, 2, 1489, 314, 2, 8436, 31, 273, 21, 47, 120, 1229, 3, 229, 2, 505, 867, 1574, 17, 297, 1, 2654, 1516, 3, 3611, 529, 7569, 4, 1795, 745, 2, 436, 552, 6, 1856, 969, 110, 955, 267, 2, 17045, 620, 3611, 26, 1567, 2953, 8, 229, 692, 17, 68, 40, 721, 22, 8, 189, 1396, 6, 4964, 3, 17045, 620, 3611, 3910, 17, 5267, 251, 6, 1795, 2, 777, 3, 1728, 9, 8, 150, 692, 17, 1920, 1795, 6, 11409, 283, 3611, 6, 3134, 211, 7331, 314]",1409.0,27756747,595
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-10-19,"<b>Background:</b> Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients with del17p or with <i>TP53</i> mutations. Ibrutinib is broadly indicated for the treatment of patients with CLL and specifically including those with 17p deletion. The optimal use of ibrutinib in combination with other agents remains controversial.<b>Experimental Design:</b> We report the long-term outcome [median follow-up of 47 months (range, 36-51 months)] of 40 patients with high-risk CLL, treated on the first ibrutinib combination trial with rituximab (IR). The majority of patients (36/40) were previously treated.<b>Results:</b> Median age was 65 years, and 21 patients (52%) had 17p deletion. Median duration on treatment was 41 months (range, 2-51 months), and median number of treatment cycles was 42 (range, 2-49). Overall response rate was 95%, and 9 patients (23%) attained a complete remission. Twenty-one patients discontinued treatment, 10 due to disease progression, 9 for other causes, and 2 due to stem cell transplantation; the remaining 19 patients continue on ibrutinib. Median progression-free survival for all patients was 45 months, which was significantly shorter in the subgroup of patients with del17p (<i>n</i> = 21, 32.3 months, <i>P</i> = 0.02). Fourteen patients (35%) died, five from progressive disease, five from infections, and four from other causes. Median overall survival has not been reached.<b>Conclusions:</b> IR combination therapy leads to durable remissions in high-risk CLL; the possible benefit from the addition of rituximab is currently explored in a randomized trial. <i>Clin Cancer Res; 23(9); 2154-8. 2016 AACR</i>.","Clinical Trial, Phase II",1189.0,25.0,b Background /b Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic CLL including high-risk patients with del17p or with i TP53 /i mutations Ibrutinib is broadly indicated for the treatment of patients with CLL and specifically including those with 17p deletion The optimal use of ibrutinib in combination with other agents remains controversial. b Experimental Design /b We report the long-term outcome median follow-up of 47 months range 36-51 months of 40 patients with high-risk CLL treated on the first ibrutinib combination trial with rituximab IR The majority of patients 36/40 were previously treated. b Results /b Median age was 65 years and 21 patients 52 had 17p deletion Median duration on treatment was 41 months range 2-51 months and median number of treatment cycles was 42 range 2-49 Overall response rate was 95 and 9 patients 23 attained a complete remission Twenty-one patients discontinued treatment 10 due to disease progression 9 for other causes and 2 due to stem cell transplantation the remaining 19 patients continue on ibrutinib Median progression-free survival for all patients was 45 months which was significantly shorter in the subgroup of patients with del17p i n /i 21 32.3 months i P /i 0.02 Fourteen patients 35 died five from progressive disease five from infections and four from other causes Median overall survival has not been reached. b Conclusions /b IR combination therapy leads to durable remissions in high-risk CLL the possible benefit from the addition of rituximab is currently explored in a randomized trial i Clin Cancer Res 23 9 2154-8 2016 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 2426, 132, 1795, 16, 35, 544, 36, 5, 35, 1595, 367, 800, 9, 7, 5, 442, 1193, 552, 141, 64, 43, 7, 5, 15403, 15, 5, 70, 1206, 70, 138, 1795, 16, 5482, 1103, 9, 3, 24, 1, 7, 5, 552, 2, 1225, 141, 135, 5, 4135, 1528, 3, 665, 119, 1, 1795, 4, 150, 5, 127, 183, 469, 2010, 132, 1560, 771, 132, 21, 414, 3, 319, 337, 228, 52, 166, 126, 1, 662, 53, 184, 511, 725, 53, 1, 327, 7, 5, 64, 43, 552, 73, 23, 3, 157, 1795, 150, 160, 5, 855, 2123, 3, 686, 1, 7, 511, 327, 11, 373, 73, 132, 99, 132, 52, 89, 10, 556, 60, 2, 239, 7, 653, 42, 4135, 1528, 52, 654, 23, 24, 10, 605, 53, 184, 18, 725, 53, 2, 52, 207, 1, 24, 410, 10, 595, 184, 18, 739, 63, 51, 116, 10, 48, 2, 83, 7, 382, 5105, 8, 236, 734, 737, 104, 7, 2402, 24, 79, 520, 6, 34, 91, 83, 9, 127, 1626, 2, 18, 520, 6, 452, 31, 497, 3, 1844, 326, 7, 1906, 23, 1795, 52, 91, 115, 25, 9, 62, 7, 10, 512, 53, 92, 10, 97, 985, 4, 3, 1363, 1, 7, 5, 15403, 70, 78, 70, 239, 531, 27, 53, 70, 19, 70, 13, 588, 3225, 7, 465, 1016, 365, 29, 1014, 34, 365, 29, 1875, 2, 294, 29, 127, 1626, 52, 63, 25, 71, 44, 85, 1300, 132, 2130, 132, 2123, 150, 36, 1940, 6, 1480, 3166, 4, 64, 43, 552, 3, 899, 247, 29, 3, 352, 1, 855, 16, 694, 1443, 4, 8, 384, 160, 70, 2459, 12, 1936, 382, 83, 44105, 66, 3456, 1630, 70]",1651.0,27797975,193
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.,Blood,Blood,2016-11-01,"Ibrutinib, a potent and irreversible small-molecule inhibitor of both Bruton's tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of progression-free and overall survival. Here, we present 27 patients with relapsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently received ibrutinib salvage therapy. Sixteen of these patients were part of multi-institutional clinical trials and achieved an overall response rate of 87.5%. An additional 11 patients were treated at Stanford University following US Food and Drug Administration approval of ibrutinib; 7 (64%) achieved a complete response, and 3 (27%) achieved a partial response. Of the 9 patients treated at Stanford who had mixed chimerism-associated CLL relapse, 4 (44%) converted to full donor chimerism following ibrutinib initiation, in association with disease response. Four of 11 (36%) patients evaluated by ClonoSeq achieved minimal residual disease negativity with CLL <1/10000 white blood cells, which persisted even after ibrutinib was discontinued, in 1 case even after 26 months. None of the 27 patients developed graft-versus-host-disease (GVHD) following ibrutinib initiation. We postulate that ibrutinib augments the graft-versus-leukemia (GVL) benefit through a T-cell-mediated effect, most likely due to ITK inhibition. To investigate the immune modulatory effects of ibrutinib, we completed comprehensive immune phenotype characterization of peripheral B and T cells from treated patients. Our results show that ibrutinib selectively targets pre-germinal B cells and depletes Th2 helper cells. Furthermore, these effects persisted after drug discontinuation. In total, our results provide evidence that ibrutinib effectively augments GVL without causing GVHD.",Clinical Trial,1176.0,32.0,Ibrutinib a potent and irreversible small-molecule inhibitor of both Bruton 's tyrosine kinase and interleukin-2 inducible kinase ITK has been used to treat relapsed/refractory chronic lymphocytic CLL with prolongation of progression-free and overall survival Here we present 27 patients with relapsed CLL following allogeneic hematopoietic cell transplant HCT who subsequently received ibrutinib salvage therapy Sixteen of these patients were part of multi-institutional clinical trials and achieved an overall response rate of 87.5 An additional 11 patients were treated at Stanford University following US Food and Drug Administration approval of ibrutinib 7 64 achieved a complete response and 3 27 achieved a partial response Of the 9 patients treated at Stanford who had mixed chimerism-associated CLL relapse 4 44 converted to full donor chimerism following ibrutinib initiation in association with disease response Four of 11 36 patients evaluated by ClonoSeq achieved minimal residual disease negativity with CLL 1/10 000 white blood cells which persisted even after ibrutinib was discontinued in 1 case even after 26 months None of the 27 patients developed graft-versus-host-disease GVHD following ibrutinib initiation We postulate that ibrutinib augments the graft-versus-leukemia GVL benefit through a T-cell-mediated effect most likely due to ITK inhibition To investigate the immune modulatory effects of ibrutinib we completed comprehensive immune phenotype characterization of peripheral B and T cells from treated patients Our results show that ibrutinib selectively targets pre-germinal B cells and depletes Th2 helper cells Furthermore these effects persisted after drug discontinuation In total our results provide evidence that ibrutinib effectively augments GVL without causing GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 8, 1157, 2, 4422, 302, 1354, 230, 1, 110, 5796, 292, 564, 216, 2, 1603, 18, 2877, 216, 15430, 71, 85, 95, 6, 943, 591, 430, 442, 1193, 552, 5, 4464, 1, 91, 115, 2, 63, 25, 467, 21, 364, 428, 7, 5, 591, 552, 366, 1063, 1007, 31, 941, 1085, 54, 1611, 103, 1795, 992, 36, 3228, 1, 46, 7, 11, 760, 1, 1414, 1115, 38, 143, 2, 513, 35, 63, 51, 116, 1, 912, 33, 35, 402, 175, 7, 11, 73, 28, 13558, 1652, 366, 843, 1773, 2, 234, 634, 1814, 1, 1795, 67, 660, 513, 8, 236, 51, 2, 27, 428, 513, 8, 450, 51, 1, 3, 83, 7, 73, 28, 13558, 54, 42, 1739, 6047, 41, 552, 429, 39, 584, 4764, 6, 1647, 1488, 6047, 366, 1795, 1118, 4, 248, 5, 34, 51, 294, 1, 175, 511, 7, 194, 20, 50071, 513, 1048, 753, 34, 6014, 5, 552, 14, 79, 984, 886, 315, 37, 92, 3760, 871, 50, 1795, 10, 2402, 4, 14, 473, 871, 50, 432, 53, 1292, 1, 3, 428, 7, 276, 1599, 185, 1204, 34, 1562, 366, 1795, 1118, 21, 12071, 17, 1795, 8941, 3, 1599, 185, 2647, 8149, 247, 298, 8, 102, 31, 517, 254, 96, 322, 520, 6, 15430, 297, 6, 963, 3, 250, 11424, 176, 1, 1795, 21, 781, 949, 250, 1005, 2136, 1, 672, 132, 2, 102, 37, 29, 73, 7, 114, 99, 514, 17, 1795, 2382, 637, 671, 6312, 132, 37, 2, 15243, 8358, 5539, 37, 798, 46, 176, 3760, 50, 234, 2007, 4, 181, 114, 99, 377, 241, 17, 1795, 1856, 8941, 8149, 187, 3440, 1562]",1805.0,27802969,744
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.,Blood,Blood,2016-11-04,"ROR1 is an oncoembryonic orphan receptor found on chronic lymphocytic leukemia (CLL) B cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex with TCL1, a coactivator of AKT that is able to promote development of CLL. We found the CLL cells of a few patients expressed negligible ROR1 (ROR1<sup>Neg</sup>), but expressed TCL1A at levels comparable to those of samples that expressed ROR1 (ROR1<sup>Pos</sup>). Transcriptome analyses revealed that ROR1<sup>Neg</sup> cases generally could be distinguished from those that were ROR1<sup>Pos</sup> in unsupervised gene-expression clustering analysis. Gene-set enrichment analyses demonstrated that ROR1<sup>Neg</sup> CLL had lower expression and activation of AKT signaling pathways relative to ROR1<sup>Pos</sup> CLL, similar to what was noted for leukemia that respectively developed in TCL1 vs ROR1xTCL1 transgenic mice. In contrast to its effect on ROR1<sup>Pos</sup> CLL, Wnt5a did not enhance the proliferation, chemotaxis, or survival of ROR1<sup>Neg</sup> CLL. We examined the CLL cells from 1568 patients, which we randomly assigned to a training or validation set of 797 or 771 cases, respectively. Using recursive partitioning, we defined a threshold for ROR1 surface expression that could segregate samples of the training set into ROR1-Hi vs ROR1-Lo subgroups that differed significantly in their median treatment-free survival (TFS). Using this threshold, we found that ROR1-Hi cases had a significantly shorter median TFS and overall survival than ROR1-Lo cases in the validation set. These data demonstrate that expression of ROR1 may promote leukemia-cell activation and survival and enhance disease progression in patients with CLL.",Journal Article,1173.0,33.0,ROR1 is an oncoembryonic orphan receptor found on chronic lymphocytic CLL B cells but not on normal postpartum tissues ROR1 is a receptor for Wnt5a that may complex with TCL1 a coactivator of AKT that is able to promote development of CLL We found the CLL cells of a few patients expressed negligible ROR1 ROR1 sup Neg /sup but expressed TCL1A at levels comparable to those of samples that expressed ROR1 ROR1 sup Pos /sup Transcriptome analyses revealed that ROR1 sup Neg /sup cases generally could be distinguished from those that were ROR1 sup Pos /sup in unsupervised gene-expression clustering analysis Gene-set enrichment analyses demonstrated that ROR1 sup Neg /sup CLL had lower expression and activation of AKT signaling pathways relative to ROR1 sup Pos /sup CLL similar to what was noted for that respectively developed in TCL1 vs ROR1xTCL1 transgenic mice In contrast to its effect on ROR1 sup Pos /sup CLL Wnt5a did not enhance the proliferation chemotaxis or survival of ROR1 sup Neg /sup CLL We examined the CLL cells from 1568 patients which we randomly assigned to a training or validation set of 797 or 771 cases respectively Using recursive partitioning we defined a threshold for ROR1 surface expression that could segregate samples of the training set into ROR1-Hi vs ROR1-Lo subgroups that differed significantly in their median treatment-free survival TFS Using this threshold we found that ROR1-Hi cases had a significantly shorter median TFS and overall survival than ROR1-Lo cases in the validation set These data demonstrate that expression of ROR1 may promote leukemia-cell activation and survival and enhance disease progression in patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[9826, 16, 35, 69302, 9814, 153, 204, 23, 442, 1193, 552, 132, 37, 84, 44, 23, 295, 7830, 742, 9826, 16, 8, 153, 9, 8123, 17, 68, 840, 5, 8979, 8, 8777, 1, 649, 17, 16, 1665, 6, 1617, 193, 1, 552, 21, 204, 3, 552, 37, 1, 8, 1021, 7, 570, 6821, 9826, 9826, 172, 8696, 172, 84, 570, 34985, 28, 148, 1279, 6, 135, 1, 347, 17, 570, 9826, 9826, 172, 7833, 172, 3917, 318, 553, 17, 9826, 172, 8696, 172, 140, 1228, 359, 40, 4735, 29, 135, 17, 11, 9826, 172, 7833, 172, 4, 6512, 145, 55, 3147, 65, 145, 916, 3020, 318, 264, 17, 9826, 172, 8696, 172, 552, 42, 280, 55, 2, 363, 1, 649, 314, 460, 580, 6, 9826, 172, 7833, 172, 552, 288, 6, 2067, 10, 1051, 9, 17, 106, 276, 4, 8979, 105, 69303, 2862, 399, 4, 748, 6, 211, 254, 23, 9826, 172, 7833, 172, 552, 8123, 205, 44, 1304, 3, 457, 12561, 15, 25, 1, 9826, 172, 8696, 172, 552, 21, 409, 3, 552, 37, 29, 50082, 7, 92, 21, 1108, 896, 6, 8, 1741, 15, 929, 916, 1, 13379, 15, 15186, 140, 106, 75, 4493, 4515, 21, 395, 8, 2390, 9, 9826, 1255, 55, 17, 359, 13258, 347, 1, 3, 1741, 916, 237, 9826, 5910, 105, 9826, 10364, 1453, 17, 2512, 97, 4, 136, 52, 24, 115, 25, 7335, 75, 26, 2390, 21, 204, 17, 9826, 5910, 140, 42, 8, 97, 985, 52, 7335, 2, 63, 25, 76, 9826, 10364, 140, 4, 3, 929, 916, 46, 74, 608, 17, 55, 1, 9826, 68, 1617, 2647, 31, 363, 2, 25, 2, 1304, 34, 91, 4, 7, 5, 552]",1678.0,27815263,427
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.,Cancer cell,Cancer Cell,2016-11-03,"Mutations in SF3B1, which encodes a spliceosome component, are associated with poor outcome in chronic lymphocytic leukemia (CLL), but how these contribute to CLL progression remains poorly understood. We undertook a transcriptomic characterization of primary human CLL cells to identify transcripts and pathways affected by SF3B1 mutation. Splicing alterations, identified in the analysis of bulk cells, were confirmed in single SF3B1-mutated CLL cells and also found in cell lines ectopically expressing mutant SF3B1. SF3B1 mutation was found to dysregulate multiple cellular functions including DNA damage response, telomere maintenance, and Notch signaling (mediated through KLF8 upregulation, increased TERC and TERT expression, or altered splicing of DVL2 transcript, respectively). SF3B1 mutation leads to diverse changes in CLL-related pathways.",Journal Article,1174.0,58.0,Mutations in SF3B1 which encodes a spliceosome component are associated with poor outcome in chronic lymphocytic CLL but how these contribute to CLL progression remains poorly understood We undertook a transcriptomic characterization of primary human CLL cells to identify transcripts and pathways affected by SF3B1 mutation Splicing alterations identified in the analysis of bulk cells were confirmed in single SF3B1-mutated CLL cells and also found in cell lines ectopically expressing mutant SF3B1 SF3B1 mutation was found to dysregulate multiple cellular functions including DNA damage response telomere maintenance and Notch signaling mediated through KLF8 upregulation increased TERC and TERT expression or altered splicing of DVL2 transcript respectively SF3B1 mutation leads to diverse changes in CLL-related pathways,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[138, 4, 10132, 92, 4322, 8, 13443, 1249, 32, 41, 5, 334, 228, 4, 442, 1193, 552, 84, 832, 46, 1248, 6, 552, 91, 469, 1240, 1784, 21, 5418, 8, 5983, 2136, 1, 86, 171, 552, 37, 6, 255, 2680, 2, 460, 1424, 20, 10132, 258, 3895, 593, 108, 4, 3, 65, 1, 5821, 37, 11, 557, 4, 226, 10132, 1185, 552, 37, 2, 120, 204, 4, 31, 285, 11744, 1046, 620, 10132, 10132, 258, 10, 204, 6, 31563, 232, 763, 1681, 141, 261, 1350, 51, 4136, 1146, 2, 3193, 314, 517, 298, 69307, 2218, 101, 18432, 2, 3846, 55, 15, 1495, 3895, 1, 31148, 3268, 106, 10132, 258, 1940, 6, 1867, 400, 4, 552, 139, 460]",825.0,27818134,740
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.,Leukemia & lymphoma,Leuk. Lymphoma,2016-11-08,"Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%) patients were on medications that could increase ibrutinib toxicity and 4 (3%) were on drugs that could decrease ibrutinib efficacy. Nineteen (16%) patients were on concomitant CYP3A inhibitors (11 moderate, 8 strong), and 4 (3%) were on CYP3A inducers (two patients were on both CYP3A inhibitors and inducers). Although the ibrutinib starting dose was changed in 18 patients on CYP3A interacting medications, no difference in 18-month progression-free survival or rate of ibrutinib discontinuation was observed in patients who were not. In routine clinical practice, 2 of 3 CLL patients commencing ibrutinib are on a concomitant medication with potential to influence ibrutinib metabolism. Formal medication review by a pharmacist should be considered in all patients initiating ibrutinib.",Journal Article,1169.0,15.0,Due to Cytochrome P450 3A CYP3A metabolism clinical trials of ibrutinib-treated chronic lymphocytic CLL patients prohibited concurrent medications metabolized by CYP3A We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials Seventy-five 64 patients were on medications that could increase ibrutinib toxicity and 4 3 were on drugs that could decrease ibrutinib efficacy Nineteen 16 patients were on concomitant CYP3A inhibitors 11 moderate 8 strong and 4 3 were on CYP3A inducers two patients were on both CYP3A inhibitors and inducers Although the ibrutinib starting dose was changed in 18 patients on CYP3A interacting medications no difference in 18-month progression-free survival or rate of ibrutinib discontinuation was observed in patients who were not In routine clinical practice 2 of 3 CLL patients commencing ibrutinib are on a concomitant medication with potential to influence ibrutinib metabolism Formal medication review by a pharmacist should be considered in all patients initiating ibrutinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[520, 6, 4155, 6965, 6981, 12768, 1600, 38, 143, 1, 1795, 73, 442, 1193, 552, 7, 19105, 750, 2679, 10523, 20, 12768, 21, 194, 1781, 3012, 119, 4, 4002, 1795, 73, 552, 7, 2513, 3, 1533, 1, 38, 143, 2073, 365, 660, 7, 11, 23, 2679, 17, 359, 344, 1795, 155, 2, 39, 27, 11, 23, 600, 17, 359, 775, 1795, 209, 3498, 245, 7, 11, 23, 1781, 12768, 222, 175, 1163, 66, 1082, 2, 39, 27, 11, 23, 12768, 12780, 100, 7, 11, 23, 110, 12768, 222, 2, 12780, 242, 3, 1795, 1723, 61, 10, 2368, 4, 203, 7, 23, 12768, 5505, 2679, 77, 523, 4, 203, 811, 91, 115, 25, 15, 116, 1, 1795, 2007, 10, 164, 4, 7, 54, 11, 44, 4, 1311, 38, 758, 18, 1, 27, 552, 7, 16385, 1795, 32, 23, 8, 1781, 3012, 5, 174, 6, 1054, 1795, 1600, 5057, 3012, 206, 20, 8, 30531, 257, 40, 515, 4, 62, 7, 2637, 1795]",1069.0,27820970,469
Prognostic factors and indications for treatment of Waldenstrm's Macroglobulinemia.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2016-08-23,"Waldenstrm's Macroglobulinemia (WM) is characterized by the presence of an IgM monoclonal protein regardless of its size, 10% or more bone marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation. These cells usually have the following markers: IgM+, CD5<sup>-</sup>, CD10<sup>-</sup>, CD19<sup>+</sup>, CD20<sup>+</sup> and CD23<sup>-</sup>. Chronic lymphocytic leukemia as well as other lymphoproliferative disorders such as mantle cell, marginal zone and mucosa-associated lymphoid tissue (MALT) lymphoma must be excluded. Weakness or fatigue from anemia, fever, night sweats, or weight loss represent the most common symptoms. Hepatosplenomegaly may be a major feature. Anemia, thrombocytopenia, hyperviscosity or peripheral neuropathy may be prominent features. Systemic amyloidosis, renal insufficiency and cryoglobulinemia may also be seen. WM must be differentiated from smoldering Waldenstrm's Macroglobulinemia (SWM) which is an intermediate disease state characterized by an IgM protein 3g/dL and/or a bone marrow containing 10% bone marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia, constitutional symptoms, hyperviscosity, symptomatic hepatosplenomegaly or lymphadenopathy.",Journal Article,1246.0,0.0,Waldenstrm 's Macroglobulinemia WM is characterized by the presence of an IgM monoclonal protein regardless of its size 10 or more marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation These cells usually have the following markers IgM+ CD5 sup /sup CD10 sup /sup CD19 sup /sup CD20 sup /sup and CD23 sup /sup Chronic lymphocytic as well as other lymphoproliferative disorders such as mantle cell marginal zone and mucosa-associated lymphoid tissue MALT must be excluded Weakness or fatigue from anemia fever night sweats or weight loss represent the most common symptoms Hepatosplenomegaly may be a major feature Anemia thrombocytopenia hyperviscosity or peripheral neuropathy may be prominent features Systemic amyloidosis insufficiency and cryoglobulinemia may also be seen WM must be differentiated from smoldering Waldenstrm 's Macroglobulinemia SWM which is an intermediate disease state characterized by an IgM protein 3 g/dL and/or a marrow containing 10 marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia constitutional symptoms hyperviscosity symptomatic hepatosplenomegaly or lymphadenopathy,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3700, 292, 3389, 1518, 16, 765, 20, 3, 463, 1, 35, 2852, 848, 178, 1583, 1, 211, 444, 79, 15, 80, 581, 2084, 20, 302, 1594, 5, 8, 7978, 15, 554, 31, 910, 46, 37, 2082, 47, 3, 366, 525, 2852, 6349, 172, 172, 6289, 172, 172, 3158, 172, 172, 2198, 172, 172, 2, 9937, 172, 172, 442, 1193, 22, 149, 22, 127, 4192, 1997, 225, 22, 2757, 31, 3450, 3614, 2, 2713, 41, 2303, 246, 8273, 1642, 40, 1800, 6408, 15, 613, 29, 1545, 2775, 8955, 13298, 15, 924, 407, 1231, 3, 96, 186, 507, 15144, 68, 40, 8, 458, 2705, 1545, 1340, 8218, 15, 672, 1751, 68, 40, 3689, 404, 403, 3919, 4360, 2, 16729, 68, 120, 40, 527, 1518, 1642, 40, 1442, 29, 7091, 3700, 292, 3389, 25340, 92, 16, 35, 919, 34, 1309, 765, 20, 35, 2852, 178, 2608, 499, 1826, 2, 15, 8, 581, 1101, 4556, 581, 5325, 2084, 84, 77, 396, 1259, 1350, 225, 22, 1704, 1545, 5962, 507, 8218, 1704, 15144, 15, 4962]",1182.0,27825464,6
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.,Oncotarget,Oncotarget,2016-11-01,"Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label, randomized phase II trial comparing the combination of pentostatin, cyclophosphamide and rituximab (PCR) either without or with bevacizumab (PCR-B) in previously untreated CLL patients. A total of 65 evaluable patients were enrolled, 32 receiving PCR and 33 PCR-B. A higher rate of grade 3-4 cardiovascular toxicity was observed with PCR-B (33% vs. 3%, p < 0.003). Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09). No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab. A significant post-treatment increase in VEGF levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL); in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of CR (p = 0.01). In conclusion, the addition of bevacizumab to chemoimmunotherapy in CLL is generally well-tolerated and appears to prolong PFS and TFS.","Clinical Trial, Phase II",1176.0,4.0,Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor VEGF with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic CLL cells As monotherapy in patients with CLL it has no clinical activity Here we report the results of an open-label randomized phase II trial comparing the combination of pentostatin cyclophosphamide and rituximab PCR either without or with bevacizumab PCR-B in previously untreated CLL patients A total of 65 evaluable patients were enrolled 32 receiving PCR and 33 PCR-B A higher rate of grade 3-4 cardiovascular toxicity was observed with PCR-B 33 vs. 3 p 0.003 Patients treated with PCR-B had a trend for a higher complete remission CR rate 54.5 vs 31.3 p 0.08 longer progression-free survival PFS p 0.06 and treatment-free survival TFS p 0.09 No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab A significant post-treatment increase in VEGF levels was observed in the PCR-B arm 29.77 to 57.05 pg/mL in the PCR-B arm lower baseline CCL-3 levels were significantly associated with achievement of CR p 0.01 In conclusion the addition of bevacizumab to chemoimmunotherapy in CLL is generally well-tolerated and appears to prolong PFS and TFS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[599, 16, 8, 848, 548, 529, 756, 845, 129, 161, 618, 5, 4, 439, 1805, 1631, 2, 2168, 176, 23, 442, 1193, 552, 37, 22, 1411, 4, 7, 5, 552, 192, 71, 77, 38, 128, 467, 21, 414, 3, 99, 1, 35, 1020, 1756, 384, 124, 215, 160, 1430, 3, 150, 1, 7596, 1112, 2, 855, 604, 361, 187, 15, 5, 599, 604, 132, 4, 373, 1278, 552, 7, 8, 181, 1, 556, 859, 7, 11, 346, 531, 357, 604, 2, 466, 604, 132, 8, 142, 116, 1, 88, 27, 39, 2179, 155, 10, 164, 5, 604, 132, 466, 105, 27, 19, 13, 1421, 7, 73, 5, 604, 132, 42, 8, 853, 9, 8, 142, 236, 734, 684, 116, 667, 33, 105, 456, 27, 19, 13, 1592, 589, 91, 115, 25, 300, 19, 13, 1460, 2, 24, 115, 25, 7335, 19, 13, 1730, 77, 362, 4, 300, 2, 7335, 20, 6220, 1619, 156, 11, 164, 5, 3, 352, 1, 599, 8, 93, 539, 24, 344, 4, 618, 148, 10, 164, 4, 3, 604, 132, 475, 462, 849, 6, 696, 474, 3234, 542, 4, 3, 604, 132, 475, 280, 330, 20773, 27, 148, 11, 97, 41, 5, 5088, 1, 684, 19, 13, 355, 4, 1221, 3, 352, 1, 599, 6, 4438, 4, 552, 16, 1228, 149, 421, 2, 1233, 6, 3615, 300, 2, 7335]",1260.0,27861157,573
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-11-21,"Purpose Oral targeted therapies represent a significant advance for the treatment of patients with chronic lymphocytic leukemia (CLL); however, their high cost has raised concerns about affordability and the economic impact on society. Our objective was to project the future prevalence and cost burden of CLL in the era of oral targeted therapies in the United States. Methods We developed a simulation model that evaluated the evolving management of CLL from 2011 to 2025: chemoimmunotherapy (CIT) as the standard of care before 2014, oral targeted therapies for patients with del(17p) and relapsed CLL from 2014, and for first-line treatment from 2016 onward. A comparator scenario also was simulated where CIT remained the standard of care throughout. Disease progression and survival parameters for each therapy were based on published clinical trials. Results The number of people living with CLL in the United States is projected to increase from 128,000 in 2011 to 199,000 by 2025 (55% increase) due to improved survival; meanwhile, the annual cost of CLL management will increase from $0.74 billion to $5.13 billion (590% increase). The per-patient lifetime cost of CLL treatment will increase from $147,000 to $604,000 (310% increase) as oral targeted therapies become the first-line treatment. For patients enrolled in Medicare, the corresponding total out-of-pocket cost will increase from $9,200 to $57,000 (520% increase). Compared with the CIT scenario, oral targeted therapies resulted in an incremental cost-effectiveness ratio of $189,000 per quality-adjusted life-year. Conclusion The increased benefit and cost of oral targeted therapies is projected to enhance CLL survivorship but can impose a substantial financial burden on both patients and payers. More sustainable pricing strategies for targeted therapies are needed to avoid financial toxicity to patients.",Journal Article,1156.0,57.0,"Purpose Oral targeted therapies represent a significant advance for the treatment of patients with chronic lymphocytic CLL however their high cost has raised concerns about affordability and the economic impact on society Our objective was to project the future prevalence and cost burden of CLL in the era of oral targeted therapies in the United States Methods We developed a simulation model that evaluated the evolving management of CLL from 2011 to 2025 chemoimmunotherapy CIT as the standard of care before 2014 oral targeted therapies for patients with del 17p and relapsed CLL from 2014 and for first-line treatment from 2016 onward A comparator scenario also was simulated where CIT remained the standard of care throughout Disease progression and survival parameters for each therapy were based on published clinical trials Results The number of people living with CLL in the United States is projected to increase from 128,000 in 2011 to 199,000 by 2025 55 increase due to improved survival meanwhile the annual cost of CLL management will increase from 0.74 billion to 5.13 billion 590 increase The per-patient lifetime cost of CLL treatment will increase from 147,000 to 604,000 310 increase as oral targeted therapies become the first-line treatment For patients enrolled in Medicare the corresponding total out-of-pocket cost will increase from 9,200 to 57,000 520 increase Compared with the CIT scenario oral targeted therapies resulted in an incremental cost-effectiveness ratio of 189,000 per quality-adjusted life-year Conclusion The increased benefit and cost of oral targeted therapies is projected to enhance CLL survivorship but can impose a substantial financial burden on both patients and payers More sustainable pricing strategies for targeted therapies are needed to avoid financial toxicity to patients",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[743, 518, 238, 235, 1231, 8, 93, 3148, 9, 3, 24, 1, 7, 5, 442, 1193, 552, 137, 136, 64, 835, 71, 5673, 2061, 545, 13211, 2, 3, 3875, 345, 23, 1174, 114, 461, 10, 6, 3105, 3, 508, 1078, 2, 835, 892, 1, 552, 4, 3, 1713, 1, 518, 238, 235, 4, 3, 1088, 907, 636, 21, 276, 8, 4026, 202, 17, 194, 3, 3276, 284, 1, 552, 29, 1132, 6, 18457, 4438, 9192, 22, 3, 260, 1, 165, 348, 1409, 518, 238, 235, 9, 7, 5, 3084, 4135, 2, 591, 552, 29, 1409, 2, 9, 157, 328, 24, 29, 1390, 15088, 8, 8944, 5456, 120, 10, 5872, 1257, 9192, 958, 3, 260, 1, 165, 2432, 34, 91, 2, 25, 1038, 9, 296, 36, 11, 90, 23, 983, 38, 143, 99, 3, 207, 1, 3788, 2798, 5, 552, 4, 3, 1088, 907, 16, 5633, 6, 344, 29, 3990, 984, 4, 1132, 6, 5840, 984, 20, 18457, 614, 344, 520, 6, 231, 25, 8197, 3, 2114, 835, 1, 552, 284, 303, 344, 29, 13, 794, 10243, 6, 33, 233, 10243, 11176, 344, 3, 379, 69, 2898, 835, 1, 552, 24, 303, 344, 29, 4961, 984, 6, 12100, 984, 8292, 344, 22, 518, 238, 235, 1417, 3, 157, 328, 24, 9, 7, 346, 4, 1378, 3, 1734, 181, 1205, 1, 6575, 835, 303, 344, 29, 83, 1250, 6, 696, 984, 9158, 344, 72, 5, 3, 9192, 5456, 518, 238, 235, 627, 4, 35, 3648, 835, 1236, 197, 1, 5899, 984, 379, 372, 586, 358, 111, 1221, 3, 101, 247, 2, 835, 1, 518, 238, 235, 16, 5633, 6, 1304, 552, 2560, 84, 122, 15099, 8, 1281, 3021, 892, 23, 110, 7, 2, 9361, 80, 13226, 25326, 422, 9, 238, 235, 32, 575, 6, 3085, 3021, 155, 6, 7]",1831.0,27870563,356
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).,Leukemia & lymphoma,Leuk. Lymphoma,2016-11-25,"Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p<.0001), male sex (p=.01), valvular heart disease (p=.001), and hypertension (p=.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p<.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.",Journal Article,1152.0,38.0,Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation AF the incidence of AF in a general cohort of chronic lymphocytic CLL patients is unknown We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL A prior history of AF was present at CLL diagnosis in 148 6.1 Among the 2292 patients without history of AF 139 6.1 developed incident AF during follow-up incidence approximately 1 /year Older age p .0001 male sex p .01 valvular disease p .001 and hypertension p .04 were associated with risk of incident AF on multivariate analysis A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4 to 33 p .0001 This information provides context for interpreting rates of AF in CLL patients treated with novel therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"[242, 1676, 74, 844, 17, 1795, 68, 344, 43, 1, 7658, 9380, 8794, 3, 287, 1, 8794, 4, 8, 1083, 180, 1, 442, 1193, 552, 7, 16, 860, 21, 194, 3, 1078, 1, 8794, 28, 552, 147, 2, 287, 1, 8794, 190, 166, 126, 4, 50112, 7, 5, 732, 265, 552, 8, 324, 532, 1, 8794, 10, 364, 28, 552, 147, 4, 4647, 49, 14, 107, 3, 69390, 7, 187, 532, 1, 8794, 4929, 49, 14, 276, 2631, 8794, 190, 166, 126, 287, 705, 14, 111, 434, 89, 19, 488, 1045, 1035, 19, 355, 15633, 34, 19, 144, 2, 1824, 19, 755, 11, 41, 5, 43, 1, 2631, 8794, 23, 331, 65, 8, 464, 202, 9, 931, 2631, 8794, 2776, 29, 46, 130, 1173, 7, 237, 39, 271, 5, 79, 111, 151, 1, 2631, 8794, 2223, 29, 39, 6, 466, 19, 488, 26, 487, 777, 1533, 9, 8876, 151, 1, 8794, 4, 552, 7, 73, 5, 229, 235]",925.0,27885886,539
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-11-30,"<b>Purpose:</b> The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood. The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors.<b>Experimental Design:</b> We performed <i>in vitro</i> studies on cell lines to investigate the role of miR-155 in therapy resistance. To assess the effects of miR-155 inhibition on chemoresistance, we used an <i>in vivo</i> orthotopic lung cancer model of athymic nude mice, which we treated with anti-miR-155 alone or in combination with chemotherapy. To analyze the association of miR-155 expression and the combination of miR-155 and <i>TP53</i> expression with cancer survival, we studied 956 patients with lung cancer, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.<b>Results:</b> We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents <i>in vitro</i>, and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy <i>in vivo</i> We show that anti-miR-155-DOPC can be considered non-toxic <i>in vivo</i> We further demonstrate that miR-155 and <i>TP53</i> are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of <i>TP53</i> is significantly associated with shorter survival in lung cancer.<b>Conclusions:</b> Our findings support the existence of an miR-155/TP53 feedback loop, which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance, an important cause of cancer-related death. <i>Clin Cancer Res; 23(11); 2891-904. 2016 AACR</i>.",Journal Article,1147.0,49.0,b Purpose /b The oncogenic miR-155 is upregulated in many human cancers and its expression is increased in more aggressive and therapy-resistant tumors but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors. b Experimental Design /b We performed i in vitro /i studies on cell lines to investigate the role of miR-155 in therapy resistance To assess the effects of miR-155 inhibition on chemoresistance we used an i in vivo /i orthotopic cancer model of athymic nude mice which we treated with anti-miR-155 alone or in combination with chemotherapy To analyze the association of miR-155 expression and the combination of miR-155 and i TP53 /i expression with cancer survival we studied 956 patients with cancer chronic lymphocytic and acute lymphoblastic leukemia. b Results /b We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents i in vitro /i and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy i in vivo /i We show that anti-miR-155-DOPC can be considered non-toxic i in vivo /i We further demonstrate that miR-155 and i TP53 /i are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of i TP53 /i is significantly associated with shorter survival in cancer. b Conclusions /b Our findings support the existence of an miR-155/TP53 feedback loop which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance an important cause of cancer-related death i Clin Cancer Res 23 11 2891-904 2016 AACR /i,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[132, 743, 132, 3, 1302, 722, 3735, 16, 2684, 4, 445, 171, 163, 2, 211, 55, 16, 101, 4, 80, 571, 2, 36, 436, 57, 84, 3, 219, 483, 1181, 722, 3735, 277, 36, 251, 32, 44, 1910, 1784, 3, 1895, 2409, 1, 26, 45, 11, 6, 223, 3, 200, 1, 722, 3735, 4, 251, 6, 56, 2, 6, 376, 312, 722, 3735, 24, 6, 39955, 57, 132, 1560, 771, 132, 21, 173, 70, 4, 439, 70, 94, 23, 31, 285, 6, 963, 3, 200, 1, 722, 3735, 4, 36, 251, 6, 423, 3, 176, 1, 722, 3735, 297, 23, 3782, 21, 95, 35, 70, 4, 386, 70, 2157, 12, 202, 1, 6396, 2598, 399, 92, 21, 73, 5, 312, 722, 3735, 279, 15, 4, 150, 5, 56, 6, 1992, 3, 248, 1, 722, 3735, 55, 2, 3, 150, 1, 722, 3735, 2, 70, 1206, 70, 55, 5, 12, 25, 21, 656, 14137, 7, 5, 12, 442, 1193, 2, 286, 1275, 2647, 132, 99, 132, 21, 608, 17, 722, 3735, 1516, 251, 6, 232, 1573, 183, 70, 4, 439, 70, 2, 17, 2475, 1, 722, 3735, 1878, 32683, 57, 6, 56, 70, 4, 386, 70, 21, 514, 17, 312, 722, 3735, 8476, 122, 40, 515, 220, 1812, 70, 4, 386, 70, 21, 195, 608, 17, 722, 3735, 2, 70, 1206, 70, 32, 1199, 4, 8, 199, 3983, 670, 2, 17, 8, 150, 1, 64, 55, 1, 722, 3735, 2, 154, 55, 1, 70, 1206, 70, 16, 97, 41, 5, 985, 25, 4, 12, 132, 2130, 132, 114, 272, 538, 3, 5335, 1, 35, 722, 3735, 1206, 3983, 4432, 92, 16, 646, 4, 251, 6, 56, 2, 92, 122, 40, 1225, 238, 6, 1768, 234, 251, 35, 305, 708, 1, 12, 139, 273, 70, 2459, 12, 1936, 382, 175, 23972, 13145, 3456, 1630, 70]",1783.0,27903673,416
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-11-30,"<b>Purpose:</b> Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL).<b>Experimental Design:</b> Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from E-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model. Mice received either vehicle or acalabrutinib formulated into the drinking water.<b>Results:</b> Utilizing biochemical assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib. In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLC2, ERK, and significant inhibition of CLL cell proliferation. Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice. Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLC2, and S6 was observed. Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle.<b>Conclusions:</b> Treatment with acalabrutinib potently inhibits BTK <i>in vivo</i>, leading to on-target decreases in the activation of key signaling molecules (including BTK, PLC2, S6, and ERK). In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment. Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy <i>in vivo</i> on par with ibrutinib. <i>Clin Cancer Res; 23(11); 2831-41. 2016 AACR</i>.",Journal Article,1147.0,35.0,b Purpose /b Acalabrutinib ACP-196 is a novel potent and highly selective Bruton tyrosine kinase BTK inhibitor which binds covalently to Cys481 in the ATP-binding pocket of BTK We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic CLL b Experimental Design /b Two distinct mouse models were used the TCL1 adoptive transfer model where leukemic cells from E-TCL1 transgenic mice are transplanted into C57BL/6 mice and the human NSG primary CLL xenograft model Mice received either vehicle or acalabrutinib formulated into the drinking water. b Results /b Utilizing biochemical assays we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib In the human CLL NSG xenograft model treatment with acalabrutinib demonstrated on-target effects including decreased phosphorylation of PLC2 ERK and significant inhibition of CLL cell proliferation Furthermore tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice Similarly in the TCL1 adoptive transfer model decreased phosphorylation of BTK PLC2 and S6 was observed Most notably treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle. b Conclusions /b Treatment with acalabrutinib potently inhibits BTK i in vivo /i leading to on-target decreases in the activation of key signaling molecules including BTK PLC2 S6 and ERK In two complementary mouse models of CLL acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment Overall acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy i in vivo /i on par with ibrutinib i Clin Cancer Res 23 11 2831-41 2016 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 743, 132, 11378, 6953, 6369, 16, 8, 229, 1157, 2, 561, 1094, 5796, 564, 216, 3611, 230, 92, 3333, 10732, 6, 25598, 4, 3, 3918, 791, 6575, 1, 3611, 21, 990, 6, 376, 3, 579, 176, 1, 11378, 24, 4, 100, 635, 830, 274, 1, 442, 1193, 552, 132, 1560, 771, 132, 100, 834, 830, 274, 11, 95, 3, 8979, 3159, 2602, 202, 1257, 2015, 37, 29, 17467, 8979, 2862, 399, 32, 4600, 237, 7049, 49, 399, 2, 3, 171, 13446, 86, 552, 1330, 202, 399, 103, 361, 4974, 15, 11378, 7495, 237, 3, 7485, 4388, 132, 99, 132, 2600, 1487, 1013, 21, 608, 17, 11378, 16, 8, 561, 1094, 3611, 230, 22, 72, 5, 1795, 4, 3, 171, 552, 13446, 1330, 202, 24, 5, 11378, 264, 23, 283, 176, 141, 340, 982, 1, 21785, 1819, 2, 93, 297, 1, 552, 31, 457, 798, 30, 892, 4, 3, 4071, 1, 3, 399, 73, 5, 11378, 10, 97, 340, 72, 5, 4974, 73, 399, 1813, 4, 3, 8979, 3159, 2602, 202, 340, 982, 1, 3611, 21785, 2, 4977, 10, 164, 96, 2552, 24, 5, 11378, 627, 4, 8, 93, 344, 4, 25, 72, 5, 399, 357, 4974, 132, 2130, 132, 24, 5, 11378, 4684, 1576, 3611, 70, 4, 386, 70, 1049, 6, 23, 283, 2140, 4, 3, 363, 1, 825, 314, 1598, 141, 3611, 21785, 4977, 2, 1819, 4, 100, 3380, 830, 274, 1, 552, 11378, 97, 405, 30, 892, 2, 101, 25, 72, 5, 4974, 24, 63, 11378, 224, 101, 3611, 6072, 72, 5, 1795, 369, 2219, 93, 579, 209, 70, 4, 386, 70, 23, 7112, 5, 1795, 70, 2459, 12, 1936, 382, 175, 41614, 605, 3456, 1630, 70]",1868.0,27903679,648
First-line therapy for young patients with CLL.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2016-12-01,"A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV You are asked by the hematology fellow you are supervising about the best treatment of this patient.",Case Reports,1146.0,0.0,A 61-year-old man with a history of chronic lymphocytic CLL presents with complaints of worsening fatigue and night sweats He was diagnosed with CLL 3 years ago on routine blood count testing He has no major medical comorbidities On examination he has several 2- to 3-cm lymph nodes in the and axillary area Spleen is palpable 5 cm below the costal margin Blood counts show lymphocytosis with thrombocytopenia and anemia Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV You are asked by the hematology fellow you are supervising about the best treatment of this patient,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[8, 713, 111, 1095, 3628, 5, 8, 532, 1, 442, 1193, 552, 2740, 5, 6938, 1, 4323, 613, 2, 8955, 13298, 3174, 10, 265, 5, 552, 27, 60, 5028, 23, 1311, 315, 1276, 471, 3174, 71, 77, 458, 484, 1909, 23, 1385, 3174, 71, 392, 18, 6, 27, 494, 263, 502, 4, 3, 2, 1210, 965, 4071, 16, 4880, 33, 494, 2736, 3, 50133, 959, 315, 1911, 514, 8125, 5, 1340, 2, 1545, 177, 525, 643, 1528, 8453, 20, 1591, 4, 957, 1554, 65, 2, 1185, 6220, 10342, 32, 3732, 20, 3, 6216, 10526, 10342, 32, 69438, 545, 3, 824, 24, 1, 26, 69]",624.0,27913473,151
"Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-12-29,"<b>Purpose:</b> Ibrutinib inhibits Bruton tyrosine kinase (BTK) by irreversibly binding to the Cys-481 residue in the enzyme. However, ibrutinib also inhibits several other enzymes that contain cysteine residues homologous to Cys-481 in BTK. Patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) demonstrate a high overall response rate to ibrutinib with prolonged survival. Acalabrutinib, a selective BTK inhibitor developed to minimize off-target activity, has shown promising overall response rates in patients with relapsed/refractory CLL. A head-to-head comparison of ibrutinib and acalabrutinib in CLL cell cultures and healthy T cells is needed to understand preclinical biologic and molecular effects.<b>Experimental Design:</b> Using samples from patients with CLL, we compared the effects of both BTK inhibitors on biologic activity, chemokine production, cell migration, BTK phosphorylation, and downstream signaling in primary CLL lymphocytes and on normal T-cell signaling to determine the effects on other kinases.<b>Results:</b> Both BTK inhibitors induced modest cell death accompanied by cleavage of PARP and caspase-3. Production of CCL3 and CCL4 chemokines and pseudoemperipolesis were inhibited by both drugs to a similar degree. These drugs also showed similar inhibitory effects on the phosphorylation of BTK and downstream S6 and ERK kinases. In contrast, off-target effects on SRC-family kinases were more pronounced with ibrutinib than acalabrutinib in healthy T lymphocytes.<b>Conclusions:</b> Both BTK inhibitors show similar biological and molecular profile in primary CLL cells but appear different on their effect on normal T cells. <i>Clin Cancer Res; 23(14); 3734-43. 2016 AACR</i>.",Journal Article,1118.0,34.0,b Purpose /b Ibrutinib inhibits Bruton tyrosine kinase BTK by irreversibly binding to the Cys-481 residue in the enzyme However ibrutinib also inhibits several other enzymes that contain cysteine residues homologous to Cys-481 in BTK Patients with relapsed/refractory or previously untreated chronic lymphocytic CLL demonstrate a high overall response rate to ibrutinib with prolonged survival Acalabrutinib a selective BTK inhibitor developed to minimize off-target activity has shown promising overall response rates in patients with relapsed/refractory CLL A head-to-head comparison of ibrutinib and acalabrutinib in CLL cell cultures and healthy T cells is needed to understand preclinical biologic and molecular effects. b Experimental Design /b Using samples from patients with CLL we compared the effects of both BTK inhibitors on biologic activity chemokine production cell migration BTK phosphorylation and downstream signaling in primary CLL lymphocytes and on normal T-cell signaling to determine the effects on other kinases. b Results /b Both BTK inhibitors induced modest cell death accompanied by cleavage of PARP and caspase-3 Production of CCL3 and CCL4 chemokines and pseudoemperipolesis were inhibited by both drugs to a similar degree These drugs also showed similar inhibitory effects on the phosphorylation of BTK and downstream S6 and ERK kinases In contrast off-target effects on SRC-family kinases were more pronounced with ibrutinib than acalabrutinib in healthy T lymphocytes. b Conclusions /b Both BTK inhibitors show similar biological and molecular profile in primary CLL cells but appear different on their effect on normal T cells i Clin Cancer Res 23 14 3734-43 2016 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 743, 132, 1795, 1576, 5796, 564, 216, 3611, 20, 12820, 791, 6, 3, 19760, 12178, 7840, 4, 3, 1644, 137, 1795, 120, 1576, 392, 127, 3039, 17, 3725, 6943, 6418, 3894, 6, 19760, 12178, 4, 3611, 7, 5, 591, 430, 15, 373, 1278, 442, 1193, 552, 608, 8, 64, 63, 51, 116, 6, 1795, 5, 1069, 25, 11378, 8, 1094, 3611, 230, 276, 6, 3241, 1889, 283, 128, 71, 443, 721, 63, 51, 151, 4, 7, 5, 591, 430, 552, 8, 718, 6, 718, 1155, 1, 1795, 2, 11378, 4, 552, 31, 3231, 2, 1331, 102, 37, 16, 575, 6, 1640, 693, 1283, 2, 219, 176, 132, 1560, 771, 132, 75, 347, 29, 7, 5, 552, 21, 72, 3, 176, 1, 110, 3611, 222, 23, 1283, 128, 3596, 1529, 31, 1381, 3611, 982, 2, 1489, 314, 4, 86, 552, 1594, 2, 23, 295, 102, 31, 314, 6, 223, 3, 176, 23, 127, 1549, 132, 99, 132, 110, 3611, 222, 277, 1721, 31, 273, 2756, 20, 3155, 1, 2041, 2, 1469, 27, 1529, 1, 9711, 2, 12660, 4906, 2, 38950, 11, 879, 20, 110, 600, 6, 8, 288, 1444, 46, 600, 120, 224, 288, 1810, 176, 23, 3, 982, 1, 3611, 2, 1489, 4977, 2, 1819, 1549, 4, 748, 1889, 283, 176, 23, 2023, 607, 1549, 11, 80, 3517, 5, 1795, 76, 11378, 4, 1331, 102, 1594, 132, 2130, 132, 110, 3611, 222, 514, 288, 1037, 2, 219, 800, 4, 86, 552, 37, 84, 1322, 338, 23, 136, 254, 23, 295, 102, 37, 70, 2459, 12, 1936, 382, 213, 49934, 601, 3456, 1630, 70]",1708.0,28034907,109
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2017-01-10,"<b>Purpose:</b> Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treatment-nave (TN) or had relapsed/refractory (R/R) CLL after 1 prior therapy in a phase Ib/II study (PCYC-1102). Subsequently, the ibrutinib 420 mg dose was approved in CLL.<b>Experimental Design:</b> We report data with 44 months of follow-up on 94 patients with TN and R/R CLL/SLL receiving ibrutinib 420 mg once-daily in PCYC-1102 and the long-term extension study PCYC-1103.<b>Results:</b> Ninety-four CLL/SLL patients (27 TN, 67 R/R) were treated with ibrutinib (420 mg/day). Patients with R/R disease had received a median of four prior therapies (range, 1-12). Responses were rapid and durable and median duration of response was not reached. Best overall response was 91% [85% TN (complete response, CR 26%) and 94% R/R (9% CR)]. Median progression-free survival (PFS) was not reached in either group. The 30-month PFS rate was 96% and 76% for TN and R/R patients, respectively. Ibrutinib was well tolerated with extended follow-up; rates of grade 3 cytopenias and fatigue, as well as discontinuations due to toxicities decreased over time.<b>Conclusions:</b> Single-agent ibrutinib at 420 mg once-daily resulted in durable responses and was well tolerated with up to 44 months follow-up in patients with TN and R/R CLL/SLL. Currently, 66% of patients continue on ibrutinib. <i>Clin Cancer Res; 23(5); 1149-55. 2017 AACR</i>.","Clinical Trial, Phase I",1106.0,29.0,b Purpose /b Ibrutinib a first-in-class once-daily oral inhibitor of Bruton tyrosine kinase promotes apoptosis and inhibits B-cell proliferation adhesion and migration Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic CLL/SLL who were treatment-nave TN or had relapsed/refractory R/R CLL after 1 prior therapy in a phase Ib/II study PCYC-1102 Subsequently the ibrutinib 420 mg dose was approved in CLL. b Experimental Design /b We report data with 44 months of follow-up on 94 patients with TN and R/R CLL/SLL receiving ibrutinib 420 mg once-daily in PCYC-1102 and the long-term extension study PCYC-1103. b Results /b Ninety-four CLL/SLL patients 27 TN 67 R/R were treated with ibrutinib 420 mg/day Patients with R/R disease had received a median of four prior therapies range 1-12 Responses were rapid and durable and median duration of response was not reached Best overall response was 91 85 TN complete response CR 26 and 94 R/R 9 CR Median progression-free survival PFS was not reached in either group The 30-month PFS rate was 96 and 76 for TN and R/R patients respectively Ibrutinib was well tolerated with extended follow-up rates of grade 3 cytopenias and fatigue as well as discontinuations due to toxicities decreased over time. b Conclusions /b Single-agent ibrutinib at 420 mg once-daily resulted in durable responses and was well tolerated with up to 44 months follow-up in patients with TN and R/R CLL/SLL Currently 66 of patients continue on ibrutinib i Clin Cancer Res 23 5 1149-55 2017 AACR /i,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 743, 132, 1795, 8, 157, 4, 1040, 1059, 391, 518, 230, 1, 5796, 564, 216, 2148, 351, 2, 1576, 132, 31, 457, 2128, 2, 1381, 1795, 71, 264, 226, 420, 209, 2, 1595, 1543, 28, 415, 1, 5401, 2, 10752, 81, 4, 7, 5, 442, 1193, 2647, 302, 1193, 552, 5302, 54, 11, 24, 2809, 3814, 15, 42, 591, 430, 668, 668, 552, 50, 3567, 324, 36, 4, 8, 124, 3180, 215, 45, 27575, 22475, 1611, 3, 1795, 5401, 81, 61, 10, 850, 4, 552, 132, 1560, 771, 132, 21, 414, 74, 5, 584, 53, 1, 166, 126, 23, 960, 7, 5, 3814, 2, 668, 668, 552, 5302, 357, 1795, 5401, 81, 1059, 391, 4, 27575, 22475, 2, 3, 319, 337, 2401, 45, 27575, 32431, 132, 99, 132, 2493, 294, 552, 5302, 7, 428, 3814, 598, 668, 668, 11, 73, 5, 1795, 5401, 81, 218, 7, 5, 668, 668, 34, 42, 103, 8, 52, 1, 294, 324, 235, 184, 14, 133, 253, 11, 1321, 2, 1480, 2, 52, 654, 1, 51, 10, 44, 1300, 824, 63, 51, 10, 970, 772, 3814, 236, 51, 684, 432, 2, 960, 668, 668, 83, 684, 52, 91, 115, 25, 300, 10, 44, 1300, 4, 361, 87, 3, 201, 811, 300, 116, 10, 921, 2, 846, 9, 3814, 2, 668, 668, 7, 106, 1795, 10, 149, 421, 5, 1747, 166, 126, 151, 1, 88, 2608, 5635, 2, 613, 22, 149, 22, 8692, 520, 6, 385, 340, 252, 98, 132, 2130, 132, 226, 420, 1795, 28, 5401, 81, 1059, 391, 627, 4, 1480, 253, 2, 10, 149, 421, 5, 126, 6, 584, 53, 166, 126, 4, 7, 5, 3814, 2, 668, 668, 552, 5302, 694, 700, 1, 7, 1906, 23, 1795, 70, 2459, 12, 1936, 382, 33, 41613, 614, 3194, 1630, 70]",1634.0,28073846,152
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2017-01-11,"The Bruton's tyrosine kinase inhibitor ibrutinib is a highly effective, new targeted therapy for chronic lymphocytic leukemia (CLL) that thwarts leukemia cell survival, growth, and tissue homing. The effects of ibrutinib treatment on the T cell compartment, which is clonally expanded and thought to support the growth of malignant B cells in CLL, are not fully characterized. Using next-generation sequencing technology, we characterized the diversity of TCR-chains in peripheral blood T cells from 15 CLL patients before and after 1 y of ibrutinib therapy. We noted elevated CD4<sup>+</sup> and CD8<sup>+</sup> T cell numbers and a restricted TCR repertoire in all pretreatment samples. After 1 y of ibrutinib therapy, elevated peripheral blood T cell numbers and T cell-related cytokine levels had normalized, and T cell repertoire diversity increased significantly. Dominant TCR clones in pretreatment samples declined or became undetectable, and the number of productive unique clones increased significantly during ibrutinib therapy, with the emergence of large numbers of low-frequency TCR clones. Importantly, broader TCR repertoire diversity was associated with clinical efficacy and lower rates of infections during ibrutinib therapy. These data demonstrate that ibrutinib therapy increases diversification of the T cell compartment in CLL patients, which contributes to cellular immune reconstitution.",Journal Article,1105.0,29.0,The Bruton 's tyrosine kinase inhibitor ibrutinib is a highly effective new targeted therapy for chronic lymphocytic CLL that thwarts cell survival growth and tissue homing The effects of ibrutinib treatment on the T cell compartment which is clonally expanded and thought to support the growth of malignant B cells in CLL are not fully characterized Using next-generation sequencing technology we characterized the diversity of TCR-chains in peripheral blood T cells from 15 CLL patients before and after 1 y of ibrutinib therapy We noted elevated CD4 sup /sup and CD8 sup /sup T cell numbers and a restricted TCR repertoire in all pretreatment samples After 1 y of ibrutinib therapy elevated peripheral blood T cell numbers and T cell-related cytokine levels had normalized and T cell repertoire diversity increased significantly Dominant TCR clones in pretreatment samples declined or became undetectable and the number of productive unique clones increased significantly during ibrutinib therapy with the emergence of large numbers of low-frequency TCR clones Importantly broader TCR repertoire diversity was associated with clinical efficacy and lower rates of infections during ibrutinib therapy These data demonstrate that ibrutinib therapy increases diversification of the T cell compartment in CLL patients which contributes to cellular immune reconstitution,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 5796, 292, 564, 216, 230, 1795, 16, 8, 561, 323, 217, 238, 36, 9, 442, 1193, 552, 17, 69643, 31, 25, 129, 2, 246, 5515, 3, 176, 1, 1795, 24, 23, 3, 102, 31, 3616, 92, 16, 9157, 2064, 2, 2739, 6, 538, 3, 129, 1, 393, 132, 37, 4, 552, 32, 44, 1910, 765, 75, 1305, 914, 615, 2033, 21, 765, 3, 3653, 1, 32609, 7802, 4, 672, 315, 102, 37, 29, 167, 552, 7, 348, 2, 50, 14, 2055, 1, 1795, 36, 21, 1051, 804, 1440, 172, 172, 2, 968, 172, 172, 102, 31, 1870, 2, 8, 2016, 32609, 5306, 4, 62, 1194, 347, 50, 14, 2055, 1, 1795, 36, 804, 672, 315, 102, 31, 1870, 2, 102, 31, 139, 1675, 148, 42, 4207, 2, 102, 31, 5306, 3653, 101, 97, 2156, 32609, 2749, 4, 1194, 347, 3054, 15, 3451, 3920, 2, 3, 207, 1, 10110, 991, 2749, 101, 97, 190, 1795, 36, 5, 3, 3397, 1, 375, 1870, 1, 154, 675, 32609, 2749, 1859, 5410, 4134, 5306, 3653, 10, 41, 5, 38, 209, 2, 280, 151, 1, 1875, 190, 1795, 36, 46, 74, 608, 17, 1795, 36, 1106, 21584, 1, 3, 102, 31, 3616, 4, 552, 7, 92, 2444, 6, 763, 250, 5616]",1371.0,28077600,105
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-01-17,"Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. Patients and Methods A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts. Treatment commenced with a 3-week dose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expansion. Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia (Richter transformation; n = 7), Waldenstrm macroglobulinemia (n = 4), and marginal zone lymphoma (n = 3). Venetoclax was generally well tolerated. Clinical tumor lysis syndrome was not observed, whereas laboratory tumor lysis syndrome was documented in three patients. Treatment-emergent adverse events were reported in 103 patients (97%), a majority of which were grade 1 to 2 in severity. Grade 3 to 4 events were reported in 59 patients (56%), and the most common were hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%). Overall response rate was 44% (MCL, 75%; FL, 38%; DLBCL, 18%). Estimated median progression-free survival was 6 months (MCL, 14 months; FL, 11 months; DLBCL, 1 month). Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes. We determined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable response in MCL. Additional investigations including combination therapy to augment response rates and durability are ongoing.",Journal Article,1099.0,201.0,"Purpose B-cell leukemia/lymphoma-2 BCL-2 overexpression is common in many NHL subtypes A phase I trial in patients with NHL was conducted to determine safety pharmacokinetics and efficacy of venetoclax a selective potent orally bioavailable BCL-2 inhibitor Patients and Methods A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts Treatment commenced with a 3-week dose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expansion Results NHL subtypes included mantle cell MCL n 28 follicular FL n 29 diffuse large B-cell DLBCL n 34 DLBCL arising from chronic lymphocytic Richter transformation n 7 Waldenstrm macroglobulinemia n 4 and marginal zone n 3 Venetoclax was generally well tolerated Clinical tumor lysis syndrome was not observed whereas laboratory tumor lysis syndrome was documented in three patients Treatment-emergent adverse events were reported in 103 patients 97 a majority of which were grade 1 to 2 in severity Grade 3 to 4 events were reported in 59 patients 56 and the most common were hematologic including anemia 15 neutropenia 11 and thrombocytopenia 9 Overall response rate was 44 MCL 75 FL 38 DLBCL 18 Estimated median progression-free survival was 6 months MCL 14 months FL 11 months DLBCL 1 month Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated and single-agent activity varied among NHL subtypes We determined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL with 800 mg being sufficient to consistently achieve durable response in MCL Additional investigations including combination therapy to augment response rates and durability are ongoing",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[743, 132, 31, 2647, 4763, 18, 1044, 18, 851, 16, 186, 4, 445, 1176, 814, 8, 124, 70, 160, 4, 7, 5, 1176, 10, 426, 6, 223, 367, 1159, 2, 209, 1, 4454, 8, 1094, 1157, 1428, 6582, 1044, 18, 230, 7, 2, 636, 8, 181, 1, 3251, 7, 5, 591, 15, 430, 1176, 103, 4454, 1059, 391, 1100, 1014, 34, 15, 3215, 155, 28, 283, 415, 29, 1250, 6, 14, 1250, 81, 4, 61, 1125, 2, 367, 1422, 736, 24, 14843, 5, 8, 27, 647, 61, 20047, 126, 727, 9, 96, 7, 4, 61, 1125, 736, 2, 9, 62, 7, 4, 367, 1422, 99, 1176, 814, 159, 2757, 31, 1308, 78, 339, 1974, 2633, 78, 462, 1388, 375, 132, 31, 1446, 78, 562, 1446, 2635, 29, 442, 1193, 8452, 1392, 78, 67, 3700, 3389, 78, 39, 2, 3450, 3614, 78, 27, 4454, 10, 1228, 149, 421, 38, 30, 4783, 681, 10, 44, 164, 547, 1624, 30, 4783, 681, 10, 1405, 4, 169, 7, 24, 4348, 290, 281, 11, 210, 4, 3283, 7, 1015, 8, 686, 1, 92, 11, 88, 14, 6, 18, 4, 1702, 88, 27, 6, 39, 281, 11, 210, 4, 728, 7, 664, 2, 3, 96, 186, 11, 813, 141, 1545, 167, 778, 175, 2, 1340, 83, 63, 51, 116, 10, 584, 1308, 481, 2633, 519, 1446, 203, 661, 52, 91, 115, 25, 10, 49, 53, 1308, 213, 53, 2633, 175, 53, 1446, 14, 811, 1221, 1094, 529, 1, 1044, 18, 5, 4454, 10, 149, 421, 2, 226, 420, 128, 2051, 107, 1176, 814, 21, 509, 14, 1250, 81, 6, 40, 3, 793, 226, 420, 61, 9, 508, 94, 4, 2633, 2, 1446, 5, 2796, 81, 486, 1952, 6, 2433, 1359, 1480, 51, 4, 1308, 402, 2492, 141, 150, 36, 6, 4369, 51, 151, 2, 6867, 32, 942]",1847.0,28095146,109
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.,Molecular cancer research : MCR,Mol. Cancer Res.,2017-01-27,"In chronic lymphocytic leukemia (CLL), STAT3 is constitutively phosphorylated on serine 727 and plays a role in the pathobiology of CLL. However, what induces constitutive phosphorylation of STAT3 is currently unknown. Mass spectrometry was used to identify casein kinase 2 (CK2), a serine/threonine kinase that coimmunoprecipitated with serine phosphorylated STAT3 (pSTAT3). Furthermore, activated CK2 incubated with recombinant STAT3 induced phosphorylation of STAT3 on serine 727. Although STAT3 and CK2 are present in normal B- and T cells, STAT3 is not constitutively phosphorylated in these cells. Further study found that CD5 and BLNK coexpressed in CLL, but not in normal B- or T cells, are required for STAT3 phosphorylation. To elucidate the relationship of CD5 and BLNK to CK2 and STAT3, STAT3 was immunoprecipitated from CLL cells, and CK2, CD5, and BLNK were detected in the immunoprecipitate. Conversely, STAT3, CD5, and BLNK were in the immunoprecipitate of CLL cells immunoprecipitated with CK2 antibodies. Furthermore, siRNA knockdown of CD5 or BLNK, or treatment with CD5-neutralizing antibodies significantly reduced the levels of serine pSTAT3 in CLL cells. Finally, confocal microscopy determined that CD5 is cell membrane bound, and fractionation studies revealed that the CK2/CD5/BLNK/STAT3 complex remains in the cytoplasm, whereas serine pSTAT3 is shuttled to the nucleus.<b>Implications:</b> These data show that the cellular proteins CK2, CD5, and BLNK are required for constitutive phosphorylation of STAT3 in CLL. Whether this protein complex phosphorylates other proteins or inhibiting its activity would have clinical benefit in patients has yet to be determined. <i>Mol Cancer Res; 15(5); 610-8. 2017 AACR</i>.",Journal Article,1089.0,7.0,In chronic lymphocytic CLL STAT3 is constitutively phosphorylated on serine 727 and plays a role in the pathobiology of CLL However what induces constitutive phosphorylation of STAT3 is currently unknown Mass spectrometry was used to identify casein kinase 2 CK2 a serine/threonine kinase that coimmunoprecipitated with serine phosphorylated STAT3 pSTAT3 Furthermore activated CK2 incubated with recombinant STAT3 induced phosphorylation of STAT3 on serine 727 Although STAT3 and CK2 are present in normal B- and T cells STAT3 is not constitutively phosphorylated in these cells Further study found that CD5 and BLNK coexpressed in CLL but not in normal B- or T cells are required for STAT3 phosphorylation To elucidate the relationship of CD5 and BLNK to CK2 and STAT3 STAT3 was immunoprecipitated from CLL cells and CK2 CD5 and BLNK were detected in the immunoprecipitate Conversely STAT3 CD5 and BLNK were in the immunoprecipitate of CLL cells immunoprecipitated with CK2 antibodies Furthermore siRNA knockdown of CD5 or BLNK or treatment with CD5-neutralizing antibodies significantly reduced the levels of serine pSTAT3 in CLL cells Finally confocal microscopy determined that CD5 is cell membrane bound and fractionation studies revealed that the CK2/CD5/BLNK/STAT3 complex remains in the cytoplasm whereas serine pSTAT3 is shuttled to the nucleus. b Implications /b These data show that the cellular proteins CK2 CD5 and BLNK are required for constitutive phosphorylation of STAT3 in CLL Whether this protein complex phosphorylates other proteins or inhibiting its activity would have clinical benefit in patients has yet to be determined i Mol Cancer Res 15 5 610-8 2017 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 1439, 16, 2818, 2365, 23, 3734, 14093, 2, 1698, 8, 200, 4, 3, 8465, 1, 552, 137, 2067, 1516, 3178, 982, 1, 1439, 16, 694, 860, 782, 3680, 10, 95, 6, 255, 18145, 216, 18, 15036, 8, 3734, 5131, 216, 17, 26574, 5, 3734, 2365, 1439, 6480, 798, 735, 15036, 8303, 5, 2835, 1439, 277, 982, 1, 1439, 23, 3734, 14093, 242, 1439, 2, 15036, 32, 364, 4, 295, 132, 2, 102, 37, 1439, 16, 44, 2818, 2365, 4, 46, 37, 195, 45, 204, 17, 6349, 2, 23645, 10185, 4, 552, 84, 44, 4, 295, 132, 15, 102, 37, 32, 616, 9, 1439, 982, 6, 3061, 3, 858, 1, 6349, 2, 23645, 6, 15036, 2, 1439, 1439, 10, 22170, 29, 552, 37, 2, 15036, 6349, 2, 23645, 11, 530, 4, 3, 38884, 3154, 1439, 6349, 2, 23645, 11, 4, 3, 38884, 1, 552, 37, 22170, 5, 15036, 890, 798, 1919, 1563, 1, 6349, 15, 23645, 15, 24, 5, 6349, 5788, 890, 97, 405, 3, 148, 1, 3734, 6480, 4, 552, 37, 1368, 6541, 3804, 509, 17, 6349, 16, 31, 1905, 2951, 2, 3519, 94, 553, 17, 3, 15036, 6349, 23645, 1439, 840, 469, 4, 3, 4558, 547, 3734, 6480, 16, 69739, 6, 3, 4262, 132, 1268, 132, 46, 74, 514, 17, 3, 763, 652, 15036, 6349, 2, 23645, 32, 616, 9, 3178, 982, 1, 1439, 4, 552, 317, 26, 178, 840, 12528, 127, 652, 15, 2062, 211, 128, 688, 47, 38, 247, 4, 7, 71, 1145, 6, 40, 509, 70, 5824, 12, 1936, 167, 33, 11302, 66, 3194, 1630, 70]",1687.0,28130399,661
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.,JCI insight,JCI Insight,2017-01-26,"<b>BACKGROUND.</b> Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton's tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. <b>METHODS.</b> We used stable isotopic labeling with deuterated water (<sup>2</sup>H<sub>2</sub>O) to measure directly the effects of ibrutinib on leukemia cell proliferation and death in 30 patients with CLL. <b>RESULTS.</b> The measured average CLL cell proliferation (""birth"") rate before ibrutinib therapy was 0.39% of the clone per day (range 0.17%-1.04%); this decreased to 0.05% per day (range 0%-0.36%) with treatment. Death rates of blood CLL cells increased from 0.18% per day (average, range 0%-0.7%) prior to treatment to 1.5% per day (range 0%-3.0%) during ibrutinib therapy, and they were even higher in tissue compartments. <b>CONCLUSIONS.</b> This study provides the first direct in vivo measurements to our knowledge of ibrutinib's antileukemia actions, demonstrating profound and immediate inhibition of CLL cell proliferation and promotion of high rates of CLL cell death. <b>TRIAL REGISTRATION.</b> This trial was registered at clinicaltrials.gov (NCT01752426). <b>FUNDING.</b> This study was supported by a Cancer Center Support Grant (National Cancer Institute grant P30 CA016672), an NIH grant (CA081554) from the National Cancer Institute, MD Anderson's Moon Shots Program in CLL, and Pharmacyclics, an AbbVie company.",Journal Article,1090.0,,b BACKGROUND. /b Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic CLL that inhibits Bruton 's tyrosine kinase BTK a kinase involved in B cell receptor signaling b METHODS. /b We used stable isotopic labeling with deuterated water sup 2 /sup H sub 2 /sub O to measure directly the effects of ibrutinib on cell proliferation and death in 30 patients with CLL b RESULTS. /b The measured average CLL cell proliferation `` birth '' rate before ibrutinib therapy was 0.39 of the clone per day range 0.17 -1.04 this decreased to 0.05 per day range 0 -0.36 with treatment Death rates of blood CLL cells increased from 0.18 per day average range 0 -0.7 prior to treatment to 1.5 per day range 0 -3.0 during ibrutinib therapy and they were even higher in tissue compartments b CONCLUSIONS. /b This study provides the first direct in vivo measurements to our knowledge of ibrutinib 's antileukemia actions demonstrating profound and immediate inhibition of CLL cell proliferation and promotion of high rates of CLL cell death b TRIAL REGISTRATION. /b This trial was registered at clinicaltrials.gov NCT01752426 b FUNDING. /b This study was supported by a Cancer Center Support Grant National Cancer Institute grant P30 CA016672 an NIH grant CA081554 from the National Cancer Institute MD Anderson 's Moon Shots Program in CLL and Pharmacyclics an AbbVie company,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 2426, 132, 1795, 16, 35, 323, 238, 36, 9, 7, 5, 442, 1193, 552, 17, 1576, 5796, 292, 564, 216, 3611, 8, 216, 646, 4, 132, 31, 153, 314, 132, 636, 132, 21, 95, 585, 37435, 3383, 5, 69762, 4388, 172, 18, 172, 555, 551, 18, 551, 1990, 6, 1463, 1606, 3, 176, 1, 1795, 23, 31, 457, 2, 273, 4, 201, 7, 5, 552, 132, 99, 132, 3, 644, 1011, 552, 31, 457, 3809, 522, 116, 348, 1795, 36, 10, 13, 587, 1, 3, 3910, 379, 218, 184, 13, 269, 14, 755, 26, 340, 6, 13, 474, 379, 218, 184, 13, 13, 511, 5, 24, 273, 151, 1, 315, 552, 37, 101, 29, 13, 203, 379, 218, 1011, 184, 13, 13, 67, 324, 6, 24, 6, 14, 33, 379, 218, 184, 13, 27, 13, 190, 1795, 36, 2, 491, 11, 871, 142, 4, 246, 6473, 132, 2130, 132, 26, 45, 777, 3, 157, 1196, 4, 386, 1685, 6, 114, 922, 1, 1795, 292, 9169, 5592, 2219, 4399, 2, 2181, 297, 1, 552, 31, 457, 2, 5478, 1, 64, 151, 1, 552, 31, 273, 132, 160, 3169, 132, 26, 160, 10, 1653, 28, 1252, 1239, 69763, 132, 5468, 132, 26, 45, 10, 2708, 20, 8, 12, 574, 538, 11041, 657, 12, 1377, 11041, 25023, 41660, 35, 6833, 11041, 69764, 29, 3, 657, 12, 1377, 2244, 1929, 292, 36327, 36342, 1243, 4, 552, 2, 20013, 35, 18697, 12588]",1382.0,28138560,273
Pathways and mechanisms of venetoclax resistance.,Leukemia & lymphoma,Leuk. Lymphoma,2017-01-31,"The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor types. However, resistance to BCL-2 inhibitor monotherapy may rapidly ensue. Several studies have shown that the other two major anti-apoptotic BCL-2 family proteins, BCL-X<sub>L</sub> and MCL-1, are the main determinants of resistance to venetoclax. This opens up possibilities for rationally combining venetoclax with other targeted agents to circumvent resistance. Here, we summarize the most promising combinations, and highlight those already in clinical trials. There is also increasing recognition that different tumors display different degrees of addiction to individual BCL-2 family proteins, and of the need to refine current 'BH3 profiling' techniques. Finally, the successful clinical development of potent and selective antagonists of BCL-X<sub>L</sub> and MCL-1 is eagerly awaited.",Journal Article,1085.0,29.0,The approval of venetoclax a 'BH3-mimetic antagonist of the BCL-2 anti-apoptotic protein for chronic lymphocytic represents a major milestone in translational apoptosis research Venetoclax has already received 'breakthrough designation for acute myeloid and is being studied in many other tumor types However resistance to BCL-2 inhibitor monotherapy may rapidly ensue Several studies have shown that the other two major anti-apoptotic BCL-2 family proteins BCL-X sub L /sub and MCL-1 are the main determinants of resistance to venetoclax This opens up possibilities for rationally combining venetoclax with other targeted agents to circumvent resistance Here we summarize the most promising combinations and highlight those already in clinical trials There is also increasing recognition that different tumors display different degrees of addiction to individual BCL-2 family proteins and of the need to refine current 'BH3 profiling techniques Finally the successful clinical development of potent and selective antagonists of BCL-X sub L /sub and MCL-1 is eagerly awaited,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1814, 1, 4454, 8, 50211, 7343, 3137, 1, 3, 1044, 18, 312, 1631, 178, 9, 442, 1193, 1449, 8, 458, 12821, 4, 2460, 351, 389, 4454, 71, 3298, 103, 40059, 8402, 9, 286, 533, 2, 16, 486, 656, 4, 445, 127, 30, 630, 137, 251, 6, 1044, 18, 230, 1411, 68, 1755, 26393, 392, 94, 47, 443, 17, 3, 127, 100, 458, 312, 1631, 1044, 18, 607, 652, 1044, 1006, 551, 805, 551, 2, 1308, 14, 32, 3, 1895, 3403, 1, 251, 6, 4454, 26, 12701, 126, 10433, 9, 6352, 1525, 4454, 5, 127, 238, 183, 6, 8602, 251, 467, 21, 2479, 3, 96, 721, 1247, 2, 1817, 135, 3298, 4, 38, 143, 125, 16, 120, 602, 2335, 17, 338, 57, 3640, 338, 4133, 1, 8053, 6, 797, 1044, 18, 607, 652, 2, 1, 3, 594, 6, 5003, 291, 50211, 1080, 1092, 1368, 3, 1401, 38, 193, 1, 1157, 2, 1094, 4444, 1, 1044, 1006, 551, 805, 551, 2, 1308, 14, 16, 16238, 9958]",1074.0,28140720,281
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.,Cancer,Cancer,2017-02-07,"Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported. Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed. Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed. Ninety of 320 patients (28%) who were treated on ibrutinib-based regimens discontinued ibrutinib. Of these, 80 had relapsed/refractory disease, and 10 were treatment-naive. The median time to discontinuation was 15 months (range, 1.2-54 months). After a median follow-up of 38 months after starting ibrutinib, 40 patients (44%) remained alive. Major reasons for ibrutinib discontinuation were intolerance (n = 29; 32%), miscellaneous (n = 28; 31%), progression (n = 19; 21%), and Richter transformation (RT) (n = 9; 10%). The median survival according to the reason for discontinuation was 33 months for ibrutinib intolerance, 11 months for miscellaneous causes, 16 months for progressive CLL, and 2 months for RT. Among the 19 patients who had progressive CLL, 42% responded to subsequent therapy. Ibrutinib discontinuation was observed during therapy. Patients with CLL who had disease transformation had especially poor outcomes, whereas those who developed progressive disease during ibrutinib therapy had a median survival of <1.5 years. Survival was associated with the reason for discontinuation; patients who had progressive CLL had better survival compared with those who had disease transformation. Effective salvage strategies for patients with CLL who progress on ibrutinib therapy is of critical importance. Cancer 2017;123:2268-2273.  2017 American Cancer Society.",Journal Article,1078.0,40.0,Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic CLL in frontline and relapsed/refractory settings The authors previously reported poor outcomes for patients who discontinued ibrutinib however long-term outcomes were not reported Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed Ninety of 320 patients 28 who were treated on ibrutinib-based regimens discontinued ibrutinib Of these 80 had relapsed/refractory disease and 10 were treatment-naive The median time to discontinuation was 15 months range 1.2-54 months After a median follow-up of 38 months after starting ibrutinib 40 patients 44 remained alive Major reasons for ibrutinib discontinuation were intolerance n 29 32 miscellaneous n 28 31 progression n 19 21 and Richter transformation RT n 9 10 The median survival according to the reason for discontinuation was 33 months for ibrutinib intolerance 11 months for miscellaneous causes 16 months for progressive CLL and 2 months for RT Among the 19 patients who had progressive CLL 42 responded to subsequent therapy Ibrutinib discontinuation was observed during therapy Patients with CLL who had disease transformation had especially poor outcomes whereas those who developed progressive disease during ibrutinib therapy had a median survival of 1.5 years Survival was associated with the reason for discontinuation patients who had progressive CLL had better survival compared with those who had disease transformation Effective salvage strategies for patients with CLL who progress on ibrutinib therapy is of critical importance Cancer 2017 123:2268-2273  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 8, 5796, 564, 216, 230, 2, 16, 850, 9, 3, 24, 1, 7, 5, 442, 1193, 552, 4, 3171, 2, 591, 430, 1947, 3, 738, 373, 210, 334, 123, 9, 7, 54, 2402, 1795, 137, 319, 337, 123, 11, 44, 210, 74, 29, 5904, 7, 54, 103, 1795, 23, 38, 94, 59, 1120, 2, 1483, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 11, 894, 311, 319, 337, 123, 107, 7, 5, 552, 50, 491, 2402, 1795, 11, 311, 2493, 1, 5904, 7, 339, 54, 11, 73, 23, 1795, 90, 472, 2402, 1795, 1, 46, 493, 42, 591, 430, 34, 2, 79, 11, 24, 2462, 3, 52, 98, 6, 2007, 10, 167, 53, 184, 14, 18, 667, 53, 50, 8, 52, 166, 126, 1, 519, 53, 50, 1723, 1795, 327, 7, 584, 958, 1701, 458, 2325, 9, 1795, 2007, 11, 5266, 78, 462, 531, 15106, 78, 339, 456, 91, 78, 326, 239, 2, 8452, 1392, 240, 78, 83, 79, 3, 52, 25, 768, 6, 3, 3852, 9, 2007, 10, 466, 53, 9, 1795, 5266, 175, 53, 9, 15106, 1626, 245, 53, 9, 1014, 552, 2, 18, 53, 9, 240, 107, 3, 326, 7, 54, 42, 1014, 552, 595, 2211, 6, 706, 36, 1795, 2007, 10, 164, 190, 36, 7, 5, 552, 54, 42, 34, 1392, 42, 1093, 334, 123, 547, 135, 54, 276, 1014, 34, 190, 1795, 36, 42, 8, 52, 25, 1, 14, 33, 60, 25, 10, 41, 5, 3, 3852, 9, 2007, 7, 54, 42, 1014, 552, 42, 380, 25, 72, 5, 135, 54, 42, 34, 1392, 323, 992, 422, 9, 7, 5, 552, 54, 1466, 23, 1795, 36, 16, 1, 740, 1187, 12, 1759, 2698, 69834, 69835, 2206, 1759, 597, 12, 1174]",1879.0,28171709,565
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.,Oncotarget,Oncotarget,2017-03-01,"Idelalisib is a targeted agent that potently inhibits PI3K which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL). Both these agents are FDA-approved for CLL. To increase the potency of idelalisib and bendamustine, we tested their combination in primary CLL lymphocytes. While each compound alone produced a moderate response, combination at several concentrations resulted in synergistic cytotoxicity. Idelalisib enhanced the bendamustine-mediated DNA damage/repair response, indicated by the phosphorylation of ATM, Chk2, and p53. Each drug alone activated H2AX but combination treatment further increased the expression of this DNA damage marker. Compared with the control, idelalisib treatment decreased global RNA synthesis, resulting in a decline of early-response and short-lived MCL1 transcripts. In concert, there was a decline in total Mcl-1 protein in CLL lymphocytes. Isogenic mouse embryonic fibroblasts lacking MCL1 had higher sensitivity to bendamustine alone or in combination compared to MCL1 proficient cells. Collectively, these data indicate that bendamustine and idelalisib combination therapy should be investigated for treating patients with CLL.",Journal Article,1056.0,4.0,Idelalisib is a targeted agent that potently inhibits PI3K which is exclusively expressed in hematological cells Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic CLL Both these agents are FDA-approved for CLL To increase the potency of idelalisib and bendamustine we tested their combination in primary CLL lymphocytes While each compound alone produced a moderate response combination at several concentrations resulted in synergistic cytotoxicity Idelalisib enhanced the bendamustine-mediated DNA damage/repair response indicated by the phosphorylation of ATM Chk2 and p53 Each drug alone activated H2AX but combination treatment further increased the expression of this DNA damage marker Compared with the control idelalisib treatment decreased global RNA synthesis resulting in a decline of early-response and short-lived MCL1 transcripts In concert there was a decline in total Mcl-1 protein in CLL lymphocytes Isogenic mouse embryonic fibroblasts lacking MCL1 had higher sensitivity to bendamustine alone or in combination compared to MCL1 proficient cells Collectively these data indicate that bendamustine and idelalisib combination therapy should be investigated for treating patients with CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7083, 16, 8, 238, 420, 17, 4684, 1576, 11063, 92, 16, 4437, 570, 4, 2890, 37, 4809, 16, 8, 149, 421, 759, 3410, 420, 92, 71, 85, 3576, 95, 9, 24, 1, 442, 1193, 552, 110, 46, 183, 32, 2078, 850, 9, 552, 6, 344, 3, 3593, 1, 7083, 2, 4809, 21, 650, 136, 150, 4, 86, 552, 1594, 369, 296, 2823, 279, 1687, 8, 1163, 51, 150, 28, 392, 1003, 627, 4, 1806, 1408, 7083, 651, 3, 4809, 517, 261, 1350, 972, 51, 1103, 20, 3, 982, 1, 3552, 14253, 2, 624, 296, 234, 279, 735, 11363, 84, 150, 24, 195, 101, 3, 55, 1, 26, 261, 1350, 952, 72, 5, 3, 182, 7083, 24, 340, 1648, 893, 2525, 1113, 4, 8, 1858, 1, 191, 51, 2, 978, 4813, 8132, 2680, 4, 10562, 125, 10, 8, 1858, 4, 181, 1308, 14, 178, 4, 552, 1594, 7208, 830, 5390, 3921, 1941, 8132, 42, 142, 485, 6, 4809, 279, 15, 4, 150, 72, 6, 8132, 5550, 37, 2535, 46, 74, 1008, 17, 4809, 2, 7083, 150, 36, 257, 40, 565, 9, 1367, 7, 5, 552]",1284.0,28187444,118
"NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-03-01,"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.",Journal Article,1056.0,29.0,Chronic lymphocytic CLL and small lymphocytic SLL are different manifestations of the same disease and managed in much the same way The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens More recently small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 2, 302, 1193, 5302, 32, 338, 4282, 1, 3, 827, 34, 2, 2231, 4, 1802, 3, 827, 2255, 3, 4114, 1, 229, 2198, 848, 890, 836, 6, 3, 193, 1, 323, 4438, 472, 80, 761, 302, 1354, 222, 529, 1549, 646, 4, 8, 207, 1, 740, 314, 460, 2, 8, 302, 1354, 230, 1, 3, 1044, 18, 607, 1, 652, 47, 264, 128, 9, 3, 24, 1, 7, 5, 552, 5302, 46, 1944, 677, 1957, 1817, 305, 5454, 6, 3, 1944, 38, 758, 677, 4, 413, 1944, 677, 9, 552, 5302, 9, 3, 24, 1, 7, 5, 732, 265, 15, 591, 430, 552, 5302]",707.0,28275031,8
"The regulation of tumor-suppressive microRNA, miR-126, inchronic lymphocytic leukemia.",Cancer medicine,Cancer Med,2017-03-15,"The introduction of miR profiling of chronic lymphocytic leukemia (CLL) patients with different cytogenetic profiles and responses to therapy has allowed incorporation of important miR-mRNA interactions into the understanding of disease biology. In this study, we performed miR expression analysis using NanoString nCounter to discover differentially regulated miRs after therapy with the Bruton tyrosine kinase inhibitor ibrutinib. Of the differentially regulated miRs in the discovery set, miR-29c and miR-126 were confirmed using real-time PCR to be upregulated in CLL patient cells with ibrutinib therapy. In the validation set, an inverse correlation was observed between miR-126 levels and expression of its putative target p85, an isoform of the phosphoinositide 3-kinase p85 regulatory subunit. We found that mRNA for the host gene EGFL7, primary unprocessed miR-126, and mature miR-126 are all downregulated in CLL cells compared to normal B cells. Patients in later stages of disease have a greater decrease in miR-126 expression compared to treatment-naive patients, indicating that lower miR-126 levels may associate with disease progression. Overexpression of miR-126 in leukemia cell lines significantly downregulates p85 expression and decreases activation of prosurvival mitogen-activated protein kinase (MAPK) signaling. These results implicate miR-126 in the pathology of CLL.",Journal Article,1042.0,9.0,The introduction of miR profiling of chronic lymphocytic CLL patients with different cytogenetic profiles and responses to therapy has allowed incorporation of important miR-mRNA interactions into the understanding of disease biology In this study we performed miR expression analysis using NanoString nCounter to discover differentially regulated miRs after therapy with the Bruton tyrosine kinase inhibitor ibrutinib Of the differentially regulated miRs in the discovery set miR-29c and miR-126 were confirmed using real-time PCR to be upregulated in CLL patient cells with ibrutinib therapy In the validation set an inverse correlation was observed between miR-126 levels and expression of its putative target p85 an isoform of the phosphoinositide 3-kinase p85 regulatory subunit We found that mRNA for the host gene EGFL7 primary unprocessed miR-126 and mature miR-126 are all downregulated in CLL cells compared to normal B cells Patients in later stages of disease have a greater decrease in miR-126 expression compared to treatment-naive patients indicating that lower miR-126 levels may associate with disease progression Overexpression of miR-126 in cell lines significantly downregulates p85 expression and decreases activation of prosurvival mitogen-activated protein kinase MAPK signaling These results implicate miR-126 in the pathology of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2456, 1, 722, 1080, 1, 442, 1193, 552, 7, 5, 338, 1266, 1241, 2, 253, 6, 36, 71, 2313, 2838, 1, 305, 722, 956, 1286, 237, 3, 612, 1, 34, 891, 4, 26, 45, 21, 173, 722, 55, 65, 75, 9220, 17520, 6, 6134, 2478, 1065, 7569, 50, 36, 5, 3, 5796, 564, 216, 230, 1795, 1, 3, 2478, 1065, 7569, 4, 3, 1574, 916, 722, 14352, 2, 722, 3927, 11, 557, 75, 1589, 98, 604, 6, 40, 2684, 4, 552, 69, 37, 5, 1795, 36, 4, 3, 929, 916, 35, 2931, 816, 10, 164, 59, 722, 3927, 148, 2, 55, 1, 211, 2743, 283, 50282, 35, 3995, 1, 3, 4497, 27, 216, 11727, 1253, 3350, 21, 204, 17, 956, 9, 3, 1204, 145, 18111, 86, 24062, 722, 3927, 2, 2908, 722, 3927, 32, 62, 3315, 4, 552, 37, 72, 6, 295, 132, 37, 7, 4, 1559, 1153, 1, 34, 47, 8, 378, 775, 4, 722, 3927, 55, 72, 6, 24, 2462, 7, 1716, 17, 280, 722, 3927, 148, 68, 6446, 5, 34, 91, 851, 1, 722, 3927, 4, 31, 285, 97, 11265, 50282, 55, 2, 2140, 363, 1, 7331, 2625, 735, 178, 216, 1748, 314, 46, 99, 5545, 722, 3927, 4, 3, 1117, 1, 552]",1359.0,28299881,165
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.,Blood,Blood,2017-04-03,"Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical outcomes. We therefore evaluated the effect of ibrutinib dose adherence on patient outcomes in the phase 3 RESONATE trial. The overall mean dose intensity (DI) was 95% with median treatment duration of 9 months. Pharmacokinetic assessment of ibrutinib exposure at 420-mg dose suggested similar exposure regardless of patient weight or age. As assessed by independent review committee, patients with higher DI experienced longer median progression-free survival (PFS) compared with those with lower DI regardless of del17p and/or <i>TP53</i> status. Of 79 patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a missed-dose event was 18.7 days (range, 8-56). Patients missing 8 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL. The trial was registered at www.clinicaltrials.gov as #NCT01578707.","Clinical Trial, Phase III",1023.0,47.0,Ibrutinib an oral inhibitor of Bruton 's tyrosine kinase BTK at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic CLL /small lymphocytic SLL that was maintained at 24 hours It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical outcomes We therefore evaluated the effect of ibrutinib dose adherence on patient outcomes in the phase 3 RESONATE trial The overall mean dose intensity DI was 95 with median treatment duration of 9 months Pharmacokinetic assessment of ibrutinib exposure at 420-mg dose suggested similar exposure regardless of patient weight or age As assessed by independent review committee patients with higher DI experienced longer median progression-free survival PFS compared with those with lower DI regardless of del17p and/or i TP53 /i status Of 79 patients requiring a drug hold treatment was restarted at the original dose in 73 92 patients Mean duration of a missed-dose event was 18.7 days range 8-56 Patients missing 8 consecutive days of ibrutinib had a shorter median PFS vs those missing 8 days 10.9 months vs not reached These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL The trial was registered at www.clinicaltrials.gov as NCT01578707,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 35, 518, 230, 1, 5796, 292, 564, 216, 3611, 28, 8, 1059, 391, 61, 1, 5401, 81, 513, 3611, 544, 606, 8509, 4, 7, 5, 442, 1193, 552, 302, 1193, 5302, 17, 10, 1955, 28, 259, 1459, 192, 16, 860, 492, 4102, 4823, 1, 1795, 36, 2444, 6, 1495, 38, 123, 21, 673, 194, 3, 254, 1, 1795, 61, 2149, 23, 69, 123, 4, 3, 124, 27, 32285, 160, 3, 63, 313, 61, 837, 6641, 10, 48, 5, 52, 24, 654, 1, 29414, 53, 1456, 455, 1, 1795, 645, 28, 5401, 81, 61, 1148, 288, 645, 1583, 1, 69, 924, 15, 89, 22, 275, 20, 306, 206, 2002, 7, 5, 142, 6641, 592, 589, 52, 91, 115, 25, 300, 72, 5, 135, 5, 280, 6641, 1583, 1, 15403, 2, 15, 70, 1206, 70, 156, 1, 842, 7, 1888, 8, 234, 4164, 24, 10, 18266, 28, 3, 2279, 61, 4, 803, 937, 7, 313, 654, 1, 8, 5149, 61, 774, 10, 203, 67, 162, 184, 66, 664, 7, 4593, 10772, 935, 162, 1, 1795, 42, 8, 985, 52, 300, 105, 135, 4593, 66, 162, 79, 83, 53, 105, 44, 1300, 46, 99, 538, 2275, 2149, 6, 1059, 391, 1795, 1280, 28, 5401, 81, 22, 505, 1313, 6, 1359, 665, 123, 4, 7, 5, 373, 73, 552, 3, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 32286]",1383.0,28373262,265
Duvelisib: a phosphoinositide-3 kinase / inhibitor for chronic lymphocytic leukemia.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2017-04-13,"Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targeted therapies is on the rise. PI3K is a major player in the B-cell receptor (BCR) signaling axis, which is critical for the survival and maintenance of B cells. Duvelisib, a PI3K / dual isoform specific inhibitor that induces apoptosis and reduces cytokine and chemokine levels in vitro, holds promise for CLL. Areas covered: Herein, we review PI3K isoforms and their inhibitors in general, and duvelisib in particular; examine literature on preclinical investigations, pharmacokinetics and clinical studies of duvelisib either as single agent or in combination, for patients with CLL and other lymphoid malignancies. Expert opinion: Duvelisib targets the PI3K  isoform, which is necessary for cell proliferation and survival, and  isoform, which is critical for cytokine signaling and pro-inflammatory responses from the microenvironment. In phase I clinical trials, duvelisib as a single agent showed promise for CLL and other lymphoid malignancies. Phase II and III trials of duvelisib alone or in combination with other agents are ongoing.",Journal Article,1013.0,19.0,Frontline chemotherapy is successful against chronic lymphocytic CLL but results in untoward toxicity Further prognostic factors cytogenetic anomalies and compensatory cellular signaling lead to therapy resistance or disease relapse Therefore for the past few years development of targeted therapies is on the rise PI3K is a major player in the B-cell receptor BCR signaling axis which is critical for the survival and maintenance of B cells Duvelisib a PI3K / dual isoform specific inhibitor that induces apoptosis and reduces cytokine and chemokine levels in vitro holds promise for CLL Areas covered Herein we review PI3K isoforms and their inhibitors in general and duvelisib in particular examine literature on preclinical investigations pharmacokinetics and clinical studies of duvelisib either as single agent or in combination for patients with CLL and other lymphoid malignancies Expert opinion Duvelisib targets the PI3K  isoform which is necessary for cell proliferation and survival and  isoform which is critical for cytokine signaling and pro-inflammatory responses from the microenvironment In phase I clinical trials duvelisib as a single agent showed promise for CLL and other lymphoid malignancies Phase II and III trials of duvelisib alone or in combination with other agents are ongoing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3171, 56, 16, 1401, 480, 442, 1193, 552, 84, 99, 4, 15514, 155, 195, 177, 130, 1266, 7623, 2, 7084, 763, 314, 1122, 6, 36, 251, 15, 34, 429, 673, 9, 3, 1219, 1021, 60, 193, 1, 238, 235, 16, 23, 3, 3693, 974, 16, 8, 458, 17987, 4, 3, 132, 31, 153, 1062, 314, 2310, 92, 16, 740, 9, 3, 25, 2, 1146, 1, 132, 37, 15080, 8, 974, 7339, 2655, 1828, 3995, 112, 230, 17, 1516, 351, 2, 2389, 1675, 2, 3596, 148, 4, 439, 5253, 1783, 9, 552, 1361, 4306, 1986, 21, 206, 974, 3913, 2, 136, 222, 4, 1083, 2, 15080, 4, 1454, 1004, 789, 23, 693, 2492, 1159, 2, 38, 94, 1, 15080, 361, 22, 226, 420, 15, 4, 150, 9, 7, 5, 552, 2, 127, 2303, 441, 2005, 3564, 15080, 637, 3, 974, 7339, 3995, 92, 16, 1493, 9, 31, 457, 2, 25, 2, 2655, 3995, 92, 16, 740, 9, 1675, 314, 2, 1805, 1291, 253, 29, 3, 995, 4, 124, 70, 38, 143, 15080, 22, 8, 226, 420, 224, 1783, 9, 552, 2, 127, 2303, 441, 124, 215, 2, 316, 143, 1, 15080, 279, 15, 4, 150, 5, 127, 183, 32, 942]",1310.0,28388280,52
"The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.",Oncotarget,Oncotarget,2017-04-01,"The study of long noncoding RNAs (lncRNAs) is an emerging area of cancer research, in part due to their ability to serve as disease biomarkers. However, few studies have investigated lncRNAs in chronic lymphocytic leukemia (CLL). We have identified one particular lncRNA, treRNA, which is overexpressed in CLL B-cells. We measured transcript expression in 144 CLL patient samples and separated samples into high or low expression of treRNA relative to the overall median. We found that high expression of treRNA is significantly associated with shorter time to treatment. High treRNA also correlates with poor prognostic indicators such as unmutated IGHV and high ZAP70 protein expression. We validated these initial findings in samples collected in a clinical trial comparing the nucleoside analog fludarabine alone or in combination with the alkylating agent cyclophosphamide in untreated CLL samples collected prior to starting therapy (E2997). High expression of treRNA was independently prognostic for shorter progression free survival in patients receiving fludarabine plus cyclophosphamide. Given these results, in order to study the role of treRNA in DNA damage response we generated a model cell line system where treRNA was over-expressed in the human B-CLL cell line OSU-CLL. Relative to the vector control line, there was less cell death in OSU-CLL over-expressing treRNA after exposure to fludarabine and mafosfamide, due in part to a reduction in DNA damage. Therefore, we suggest that treRNA is a novel biomarker in CLL associated with aggressive disease and poor response to chemotherapy through enhanced protection against cytotoxic mediated DNA damage.",Journal Article,1025.0,,The study of long noncoding RNAs lncRNAs is an emerging area of cancer research in part due to their ability to serve as disease biomarkers However few studies have investigated lncRNAs in chronic lymphocytic CLL We have identified one particular lncRNA treRNA which is overexpressed in CLL B-cells We measured transcript expression in 144 CLL patient samples and separated samples into high or low expression of treRNA relative to the overall median We found that high expression of treRNA is significantly associated with shorter time to treatment High treRNA also correlates with poor prognostic indicators such as unmutated IGHV and high ZAP70 protein expression We validated these initial findings in samples collected in a clinical trial comparing the nucleoside analog fludarabine alone or in combination with the alkylating agent cyclophosphamide in untreated CLL samples collected prior to starting therapy E2997 High expression of treRNA was independently prognostic for shorter progression free survival in patients receiving fludarabine plus cyclophosphamide Given these results in order to study the role of treRNA in DNA damage response we generated a model cell line system where treRNA was over-expressed in the human B-CLL cell line OSU-CLL Relative to the vector control line there was less cell death in OSU-CLL over-expressing treRNA after exposure to fludarabine and mafosfamide due in part to a reduction in DNA damage Therefore we suggest that treRNA is a novel biomarker in CLL associated with aggressive disease and poor response to chemotherapy through enhanced protection against cytotoxic mediated DNA damage,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 45, 1, 319, 6420, 4550, 6651, 16, 35, 1478, 965, 1, 12, 389, 4, 760, 520, 6, 136, 801, 6, 1833, 22, 34, 582, 137, 1021, 94, 47, 565, 6651, 4, 442, 1193, 552, 21, 47, 108, 104, 1454, 6381, 24291, 92, 16, 1711, 4, 552, 132, 37, 21, 644, 3268, 55, 4, 4415, 552, 69, 347, 2, 4910, 347, 237, 64, 15, 154, 55, 1, 24291, 580, 6, 3, 63, 52, 21, 204, 17, 64, 55, 1, 24291, 16, 97, 41, 5, 985, 98, 6, 24, 64, 24291, 120, 1871, 5, 334, 177, 3539, 225, 22, 7216, 6220, 2, 64, 12921, 178, 55, 21, 938, 46, 388, 272, 4, 347, 786, 4, 8, 38, 160, 1430, 3, 4032, 3497, 2027, 279, 15, 4, 150, 5, 3, 3410, 420, 1112, 4, 1278, 552, 347, 786, 324, 6, 1723, 36, 23577, 64, 55, 1, 24291, 10, 1042, 177, 9, 985, 91, 115, 25, 4, 7, 357, 2027, 349, 1112, 447, 46, 99, 4, 1732, 6, 45, 3, 200, 1, 24291, 4, 261, 1350, 51, 21, 1419, 8, 202, 31, 328, 398, 1257, 24291, 10, 252, 570, 4, 3, 171, 132, 552, 31, 328, 5984, 552, 580, 6, 3, 3374, 182, 328, 125, 10, 299, 31, 273, 4, 5984, 552, 252, 1046, 24291, 50, 645, 6, 2027, 2, 29883, 520, 4, 760, 6, 8, 628, 4, 261, 1350, 673, 21, 309, 17, 24291, 16, 8, 229, 901, 4, 552, 41, 5, 571, 34, 2, 334, 51, 6, 56, 298, 651, 3525, 480, 759, 517, 261, 1350]",1636.0,28412730,481
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-02-13,"Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistance mutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.","Clinical Trial, Phase I",1072.0,89.0,Purpose Therapeutic targeting of Bruton tyrosine kinase BTK with ibrutinib in chronic lymphocytic has led to a paradigm shift in therapy and relapse has been uncommon with current follow-up Acquired mutations in BTK and PLCG2 can cause relapse but data regarding the prevalence and natural history of these mutations are limited Patients and Methods Patients accrued to four sequential studies of ibrutinib were included in these analyses Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population Results With a median follow-up time of 3.4 years the estimated cumulative incidence of progression at 4 years is 19 95 CI 14 to 24 Baseline karyotypic complexity presence of del 17 p13.1 and age less than 65 years were risk factors for progression Among patients who experienced relapse acquired mutations of BTK or PLCG2 were found in 85 95 CI 71 to 94 and these mutations were detected an estimated median of 9.3 months 95 CI 7.6 to 11.7 months before relapse Of a group of 112 patients examined prospectively eight patients have experienced relapse and all of these patients had acquired resistance mutations before relapse A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse Conclusion Relapse of chronic lymphocytic after ibrutinib is an issue of increasing clinical significance We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse suggesting an opportunity for intervention,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[743, 189, 529, 1, 5796, 564, 216, 3611, 5, 1795, 4, 442, 1193, 71, 836, 6, 8, 2431, 3024, 4, 36, 2, 429, 71, 85, 2052, 5, 291, 166, 126, 1294, 138, 4, 3611, 2, 15432, 122, 708, 429, 84, 74, 666, 3, 1078, 2, 1504, 532, 1, 46, 138, 32, 383, 7, 2, 636, 7, 3198, 6, 294, 1787, 94, 1, 1795, 11, 159, 4, 46, 318, 2369, 615, 9, 3611, 2, 15432, 10, 173, 894, 23, 7, 54, 592, 429, 2, 1143, 23, 8, 453, 266, 99, 5, 8, 52, 166, 126, 98, 1, 27, 39, 60, 3, 661, 967, 287, 1, 91, 28, 39, 60, 16, 326, 48, 58, 213, 6, 259, 330, 9465, 3082, 463, 1, 3084, 269, 7914, 14, 2, 89, 299, 76, 556, 60, 11, 43, 130, 9, 91, 107, 7, 54, 592, 429, 1294, 138, 1, 3611, 15, 15432, 11, 204, 4, 772, 48, 58, 792, 6, 960, 2, 46, 138, 11, 530, 35, 661, 52, 1, 83, 27, 53, 48, 58, 67, 49, 6, 175, 67, 53, 348, 429, 1, 8, 87, 1, 3726, 7, 409, 1143, 659, 7, 47, 592, 429, 2, 62, 1, 46, 7, 42, 1294, 251, 138, 348, 429, 8, 251, 258, 10, 530, 4, 35, 402, 659, 7, 54, 47, 44, 1145, 543, 371, 9, 38, 429, 1221, 429, 1, 442, 1193, 50, 1795, 16, 35, 2537, 1, 602, 38, 724, 21, 514, 17, 138, 4, 3611, 2, 15432, 1322, 191, 2, 47, 3, 174, 6, 40, 95, 22, 8, 901, 9, 508, 429, 802, 35, 2666, 9, 788]",1598.0,28418267,98
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.,Blood,Blood,2017-04-19,"Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was designed to test the efficacy and safety of pembrolizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transformed CLL. Twenty-five patients including 16 relapsed CLL and 9 RT (all proven diffuse large cell lymphoma) patients were enrolled, and 60% received prior ibrutinib. Objective responses were observed in 4 out of 9 RT patients (44%) and in 0 out of 16 CLL patients (0%). All responses were observed in RT patients who had progression after prior therapy with ibrutinib. After a median follow-up time of 11 months, the median overall survival in the RT cohort was 10.7 months, but was not reached in RT patients who progressed after prior ibrutinib. Treatment-related grade 3 or above adverse events were reported in 15 (60%) patients and were manageable. Analyses of pretreatment tumor specimens from available patients revealed increased expression of PD-ligand 1 (PD-L1) and a trend of increased expression in PD-1 in the tumor microenvironment in patients who had confirmed responses. Overall, pembrolizumab exhibited selective efficacy in CLL patients with RT. The results of this study are the first to demonstrate the benefit of PD-1 blockade in CLL patients with RT, and could change the landscape of therapy for RT patients if further validated. This trial was registered at www.clinicaltrials.gov as #NCT02332980.",Clinical Trial,1007.0,96.0,Chronic lymphocytic CLL patients progressed early on ibrutinib often develop Richter transformation RT with a short survival of about 4 months Preclinical studies suggest that programmed death 1 PD-1 pathway is critical to inhibit immune surveillance in CLL This phase 2 study was designed to test the efficacy and safety of pembrolizumab a humanized PD-1-blocking antibody at a dose of 200 mg every 3 weeks in relapsed and transformed CLL Twenty-five patients including 16 relapsed CLL and 9 RT all proven diffuse large cell patients were enrolled and 60 received prior ibrutinib Objective responses were observed in 4 out of 9 RT patients 44 and in 0 out of 16 CLL patients 0 All responses were observed in RT patients who had progression after prior therapy with ibrutinib After a median follow-up time of 11 months the median overall survival in the RT cohort was 10.7 months but was not reached in RT patients who progressed after prior ibrutinib Treatment-related grade 3 or above adverse events were reported in 15 60 patients and were manageable Analyses of pretreatment tumor specimens from available patients revealed increased expression of PD-ligand 1 PD-L1 and a trend of increased expression in PD-1 in the tumor microenvironment in patients who had confirmed responses Overall pembrolizumab exhibited selective efficacy in CLL patients with RT The results of this study are the first to demonstrate the benefit of PD-1 blockade in CLL patients with RT and could change the landscape of therapy for RT patients if further validated This trial was registered at www.clinicaltrials.gov as NCT02332980,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 7, 1839, 191, 23, 1795, 629, 690, 8452, 1392, 240, 5, 8, 978, 25, 1, 545, 39, 53, 693, 94, 309, 17, 1846, 273, 14, 333, 14, 308, 16, 740, 6, 1433, 250, 617, 4, 552, 26, 124, 18, 45, 10, 1114, 6, 412, 3, 209, 2, 367, 1, 2233, 8, 3619, 333, 14, 2521, 548, 28, 8, 61, 1, 1250, 81, 454, 27, 244, 4, 591, 2, 2423, 552, 737, 365, 7, 141, 245, 591, 552, 2, 83, 240, 62, 1930, 1388, 375, 31, 7, 11, 346, 2, 335, 103, 324, 1795, 461, 253, 11, 164, 4, 39, 1205, 1, 83, 240, 7, 584, 2, 4, 13, 1205, 1, 245, 552, 7, 13, 62, 253, 11, 164, 4, 240, 7, 54, 42, 91, 50, 324, 36, 5, 1795, 50, 8, 52, 166, 126, 98, 1, 175, 53, 3, 52, 63, 25, 4, 3, 240, 180, 10, 79, 67, 53, 84, 10, 44, 1300, 4, 240, 7, 54, 1839, 50, 324, 1795, 24, 139, 88, 27, 15, 2090, 290, 281, 11, 210, 4, 167, 335, 7, 2, 11, 2808, 318, 1, 1194, 30, 623, 29, 390, 7, 553, 101, 55, 1, 333, 1232, 14, 333, 729, 2, 8, 853, 1, 101, 55, 4, 333, 14, 4, 3, 30, 995, 4, 7, 54, 42, 557, 253, 63, 2233, 1416, 1094, 209, 4, 552, 7, 5, 240, 3, 99, 1, 26, 45, 32, 3, 157, 6, 608, 3, 247, 1, 333, 14, 1189, 4, 552, 7, 5, 240, 2, 359, 707, 3, 2801, 1, 36, 9, 240, 7, 492, 195, 938, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 70213]",1612.0,28424162,680
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.,Blood,Blood,2017-05-03,"Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled. In the dose-escalation phase, patients received 3 to 80 mg/m<sup>2</sup> of selinexor in 3- or 4-week cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity. In the dose-expansion phase, patients were treated with selinexor at 35 or 60 mg/m<sup>2</sup> The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%). Tumor biopsies showed decreases in cell-signaling pathways (Bcl-2, Bcl-6, c-Myc), reduced proliferation (Ki67), nuclear localization of XPO1 cargos (p53, PTEN), and increased apoptosis after treatment. Twenty-two (31%) of the 70 evaluable patients had an objective responses, including 4 complete responses and 18 partial responses, which were observed across a spectrum of NHL subtypes. A dose of 35 mg/m<sup>2</sup> (60 mg) was identified as the RP2D. These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg/m<sup>2</sup> is a safe therapy with encouraging and durable anticancer activity in patients with R/R NHL. The trial was registered at www.clinicaltrials.gov as #NCT01607892.","Clinical Trial, Phase I",993.0,35.0,Patients with relapsed or refractory R/R NHL have a poor prognosis and limited treatment options We evaluated selinexor an orally bioavailable first-in-class inhibitor of the nuclear export protein XPO1 in this phase 1 trial to assess safety and determine a recommended phase 2 dose RP2D Seventy-nine patients with various NHL histologies including diffuse large B-cell Richter 's transformation mantle cell follicular and chronic lymphocytic were enrolled In the dose-escalation phase patients received 3 to 80 mg/m sup 2 /sup of selinexor in 3- or 4-week cycles and were assessed for toxicities pharmacokinetics and antitumor activity In the dose-expansion phase patients were treated with selinexor at 35 or 60 mg/m sup 2 /sup The most common grade 3 to 4 drug-related adverse events were thrombocytopenia 47 neutropenia 32 anemia 27 leukopenia 16 fatigue 11 and hyponatremia 10 Tumor biopsies showed decreases in cell-signaling pathways Bcl-2 Bcl-6 c-Myc reduced proliferation Ki67 nuclear localization of XPO1 cargos p53 PTEN and increased apoptosis after treatment Twenty-two 31 of the 70 evaluable patients had an objective responses including 4 complete responses and 18 partial responses which were observed across a spectrum of NHL subtypes A dose of 35 mg/m sup 2 /sup 60 mg was identified as the RP2D These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg/m sup 2 /sup is a safe therapy with encouraging and durable anticancer activity in patients with R/R NHL The trial was registered at www.clinicaltrials.gov as NCT01607892,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 591, 15, 430, 668, 668, 1176, 47, 8, 334, 356, 2, 383, 24, 838, 21, 194, 7233, 35, 1428, 6582, 157, 4, 1040, 230, 1, 3, 928, 8202, 178, 9933, 4, 26, 124, 14, 160, 6, 423, 367, 2, 223, 8, 793, 124, 18, 61, 3977, 2073, 762, 7, 5, 747, 1176, 3489, 141, 1388, 375, 132, 31, 8452, 292, 1392, 2757, 31, 1974, 2, 442, 1193, 11, 346, 4, 3, 61, 1125, 124, 7, 103, 27, 6, 493, 81, 188, 172, 18, 172, 1, 7233, 4, 27, 15, 39, 647, 410, 2, 11, 275, 9, 385, 1159, 2, 579, 128, 4, 3, 61, 1422, 124, 7, 11, 73, 5, 7233, 28, 465, 15, 335, 81, 188, 172, 18, 172, 3, 96, 186, 88, 27, 6, 39, 234, 139, 290, 281, 11, 1340, 662, 778, 531, 1545, 428, 3904, 245, 613, 175, 2, 6672, 79, 30, 1154, 224, 2140, 4, 31, 314, 460, 1044, 18, 1044, 49, 256, 1371, 405, 457, 3654, 928, 2145, 1, 9933, 41752, 624, 820, 2, 101, 351, 50, 24, 737, 100, 456, 1, 3, 431, 859, 7, 42, 35, 461, 253, 141, 39, 236, 253, 2, 203, 450, 253, 92, 11, 164, 716, 8, 1873, 1, 1176, 814, 8, 61, 1, 465, 81, 188, 172, 18, 172, 335, 81, 10, 108, 22, 3, 3977, 46, 272, 309, 17, 297, 1, 9933, 5, 518, 7233, 28, 465, 81, 188, 172, 18, 172, 16, 8, 1165, 36, 5, 2269, 2, 1480, 1475, 128, 4, 7, 5, 668, 668, 1176, 3, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 50355]",1559.0,28468797,387
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-05-08,"In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes. In an effort to improve these outcomes, patients with persistent CLL who were 90 to 100 days beyond alloSCT with no evidence of graft-versus-host-disease (GVHD) were randomized to receive lenalidomide or standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion). Lenalidomide was initiated at 5mg every other day and increased to 10mg daily, if tolerated, in each patient. Of 38 patients enrolled, 17 (45%) met the eligibility criteria for randomization. Of these 17 patients, 8 were randomized to undergo lenalidomide therapy. Five (62%) patients had to stop taking the drug because of toxicity. The main reason for drug discontinuation was acute GVHD in 43% of patients. This incidence was 11% in the patients who were randomized to not receive lenalidomide. With a median follow-up of 2.6 years, the median survival was 3.4 years for those receiving lenalidomide. This was not reached in patients randomized to not receive lenalidomide and in patients in complete remission who were not randomized. These results suggested that treatments other than lenalidomide are needed for persistent CLL after alloSCT.",Journal Article,988.0,2.0,In patients with chronic lymphocytic CLL persistence of disease after allogeneic stem cell transplantation alloSCT can result in poor outcomes In an effort to improve these outcomes patients with persistent CLL who were 90 to 100 days beyond alloSCT with no evidence of graft-versus-host-disease GVHD were randomized to receive lenalidomide or standard care withdrawal of immunosuppression followed by donor lymphocyte infusion Lenalidomide was initiated at 5 mg every other day and increased to 10 mg daily if tolerated in each patient Of 38 patients enrolled 17 45 met the eligibility criteria for randomization Of these 17 patients 8 were randomized to undergo lenalidomide therapy Five 62 patients had to stop taking the drug because of toxicity The main reason for drug discontinuation was acute GVHD in 43 of patients This incidence was 11 in the patients who were randomized to not receive lenalidomide With a median follow-up of 2.6 years the median survival was 3.4 years for those receiving lenalidomide This was not reached in patients randomized to not receive lenalidomide and in patients in complete remission who were not randomized These results suggested that treatments other than lenalidomide are needed for persistent CLL after alloSCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 7, 5, 442, 1193, 552, 4108, 1, 34, 50, 1063, 452, 31, 497, 7253, 122, 757, 4, 334, 123, 4, 35, 2919, 6, 401, 46, 123, 7, 5, 1882, 552, 54, 11, 424, 6, 394, 162, 1654, 7253, 5, 77, 241, 1, 1599, 185, 1204, 34, 1562, 11, 384, 6, 560, 1288, 15, 260, 165, 3683, 1, 3646, 370, 20, 1488, 1448, 904, 1288, 10, 1917, 28, 33, 81, 454, 127, 218, 2, 101, 6, 79, 81, 391, 492, 421, 4, 296, 69, 1, 519, 7, 346, 269, 512, 543, 3, 2317, 371, 9, 3644, 1, 46, 269, 7, 66, 11, 384, 6, 1251, 1288, 36, 365, 744, 7, 42, 6, 7142, 2727, 3, 234, 408, 1, 155, 3, 1895, 3852, 9, 234, 2007, 10, 286, 1562, 4, 601, 1, 7, 26, 287, 10, 175, 4, 3, 7, 54, 11, 384, 6, 44, 560, 1288, 5, 8, 52, 166, 126, 1, 18, 49, 60, 3, 52, 25, 10, 27, 39, 60, 9, 135, 357, 1288, 26, 10, 44, 1300, 4, 7, 384, 6, 44, 560, 1288, 2, 4, 7, 4, 236, 734, 54, 11, 44, 384, 46, 99, 1148, 17, 640, 127, 76, 1288, 32, 575, 9, 1882, 552, 50, 7253]",1255.0,28495642,347
"N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.",Genome biology,Genome Biol.,2017-05-24,"Non-coding RNAs have been drawing increasing attention in recent years as functional data suggest that they play important roles in key cellular processes. N-BLR is a primate-specific long non-coding RNA that modulates the epithelial-to-mesenchymal transition, facilitates cell migration, and increases colorectal cancer invasion. We performed multivariate analyses of data from two independent cohorts of colorectal cancer patients and show that the abundance of N-BLR is associated with tumor stage, invasion potential, and overall patient survival. Through in vitro and in vivo experiments we found that N-BLR facilitates migration primarily via crosstalk with E-cadherin and ZEB1. We showed that this crosstalk is mediated by a pyknon, a short ~20 nucleotide-long DNA motif contained in the N-BLR transcript and is targeted by members of the miR-200 family. In light of these findings, we used a microarray to investigate the expression patterns of other pyknon-containing genomic loci. We found multiple such loci that are differentially transcribed between healthy and diseased tissues in colorectal cancer and chronic lymphocytic leukemia. Moreover, we identified several new loci whose expression correlates with the colorectal cancer patients' overall survival. The primate-specific N-BLR is a novel molecular contributor to the complex mechanisms that underlie metastasis in colorectal cancer and a potential novel biomarker for this disease. The presence of a functional pyknon within N-BLR and the related finding that many more pyknon-containing genomic loci in the human genome exhibit tissue-specific and disease-specific expression suggests the possibility of an alternative class of biomarkers and therapeutic targets that are primate-specific.",Journal Article,972.0,31.0,Non-coding RNAs have been drawing increasing attention in recent years as functional data suggest that they play important roles in key cellular processes N-BLR is a primate-specific long non-coding RNA that modulates the epithelial-to-mesenchymal transition facilitates cell migration and increases cancer invasion We performed multivariate analyses of data from two independent cohorts of cancer patients and show that the abundance of N-BLR is associated with tumor stage invasion potential and overall patient survival Through in vitro and in vivo experiments we found that N-BLR facilitates migration primarily via crosstalk with E-cadherin and ZEB1 We showed that this crosstalk is mediated by a pyknon a short ~20 nucleotide-long DNA motif contained in the N-BLR transcript and is targeted by members of the miR-200 family In light of these findings we used a microarray to investigate the expression patterns of other pyknon-containing genomic loci We found multiple such loci that are differentially transcribed between healthy and diseased tissues in cancer and chronic lymphocytic Moreover we identified several new loci whose expression correlates with the cancer patients overall survival The primate-specific N-BLR is a novel molecular contributor to the complex mechanisms that underlie metastasis in cancer and a potential novel biomarker for this disease The presence of a functional pyknon within N-BLR and the related finding that many more pyknon-containing genomic loci in the human genome exhibit tissue-specific and disease-specific expression suggests the possibility of an alternative class of biomarkers and therapeutic targets that are primate-specific,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[220, 3097, 4550, 47, 85, 15177, 602, 2111, 4, 435, 60, 22, 583, 74, 309, 17, 491, 1343, 305, 1790, 4, 825, 763, 1849, 78, 29894, 16, 8, 25233, 112, 319, 220, 3097, 893, 17, 5259, 3, 701, 6, 1569, 1970, 4936, 31, 1381, 2, 1106, 12, 578, 21, 173, 331, 318, 1, 74, 29, 100, 306, 736, 1, 12, 7, 2, 514, 17, 3, 4778, 1, 78, 29894, 16, 41, 5, 30, 82, 578, 174, 2, 63, 69, 25, 298, 4, 439, 2, 4, 386, 2332, 21, 204, 17, 78, 29894, 4936, 1381, 1561, 847, 8119, 5, 563, 2154, 2, 8420, 21, 224, 17, 26, 8119, 16, 517, 20, 8, 36428, 8, 978, 179, 1579, 319, 261, 5298, 3070, 4, 3, 78, 29894, 3268, 2, 16, 238, 20, 1684, 1, 3, 722, 1250, 607, 4, 1691, 1, 46, 272, 21, 95, 8, 1727, 6, 963, 3, 55, 764, 1, 127, 36428, 1101, 572, 2012, 21, 204, 232, 225, 2012, 17, 32, 2478, 10088, 59, 1331, 2, 10486, 742, 4, 12, 2, 442, 1193, 1393, 21, 108, 392, 217, 2012, 1310, 55, 1871, 5, 3, 12, 7, 63, 25, 3, 25233, 112, 78, 29894, 16, 8, 229, 219, 8039, 6, 3, 840, 483, 17, 5875, 278, 4, 12, 2, 8, 174, 229, 901, 9, 26, 34, 3, 463, 1, 8, 583, 36428, 262, 78, 29894, 2, 3, 139, 1567, 17, 445, 80, 36428, 1101, 572, 2012, 4, 3, 171, 898, 2239, 246, 112, 2, 34, 112, 55, 844, 3, 2526, 1, 35, 1091, 1040, 1, 582, 2, 189, 637, 17, 32, 25233, 112]",1679.0,28535802,28
Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment.,Practical radiation oncology,Pract Radiat Oncol,2017-05-10,"Craniospinal irradiation (CSI) improves local control of leukemia/lymphoma with central nervous system (CNS) involvement; however, for adult patients anticipating stem cell transplant (SCT), cumulative treatment toxicity is a major concern. We evaluated toxicities and outcomes for patients receiving proton or photon CSI before SCT. We identified 37 consecutive leukemia/lymphoma patients with CNS involvement who received CSI before SCT at our institution. Photon versus proton toxicities during CSI, transplant, and through 100 days posttransplant were compared using Fisher exact and Wilcoxon rank sum tests. Long-term neurotoxicity, disease response, and overall survival were analyzed. Thirty-seven patients (23 photon, 14 proton) underwent CSI for CNS involvement of acute lymphoblastic leukemia (49%), acute myeloblastic leukemia (22%), chronic lymphocytic leukemia (3%), chronic myelocytic leukemia (14%), lymphoma (11%), and myeloma (3%). CSI was used for consolidation (30 patients, 81%) and gross disease treatment (7 patients, 19%). Median radiation dose (interquartile range) was 24 Gy (23.4-24) for photons and 21.8 Gy (21.3-23.6) for protons (P = .03). Proton CSI was associated with lower rates of Radiation Therapy Oncology Group grade 1-3 mucositis during CSI (7% vs 44%, P = .03): 1 grade 3 with protons versus 5 grade 1, 3 grade 2, and 2 grade 3 with photons. During CSI, other toxicities (infection, gastrointestinal symptoms) did not differ. Allogeneic stem cell transplant (SCT) was used in 95% of patients, with 53% of patients in remission before SCT. Myeloablative conditioning was used for 76%. During SCT admission and 100 days post-SCT, toxicities did not differ by CSI technique. Successful engraftment occurred in 95% of patients (P = .67). Progression or death occurred for 47% of patients, with only 1 CNS relapse. In our cohort, CSI offered excellent local control for CNS-involved hematologic malignancies in the pre-SCT setting. Acute mucositis occurred less frequently with proton CSI with comparable peritransplant/long-term toxicity profile, suggesting the need to further explore the benefit/toxicity profile of this technique.",Clinical Trial,986.0,5.0,Craniospinal irradiation CSI improves local control of leukemia/lymphoma with central nervous system CNS involvement however for adult patients anticipating stem cell transplant SCT cumulative treatment toxicity is a major concern We evaluated toxicities and outcomes for patients receiving proton or photon CSI before SCT We identified 37 consecutive leukemia/lymphoma patients with CNS involvement who received CSI before SCT at our institution Photon versus proton toxicities during CSI transplant and through 100 days posttransplant were compared using Fisher exact and Wilcoxon rank sum tests Long-term neurotoxicity disease response and overall survival were analyzed Thirty-seven patients 23 photon 14 proton underwent CSI for CNS involvement of acute lymphoblastic 49 acute myeloblastic 22 chronic lymphocytic 3 chronic myelocytic 14 11 and 3 CSI was used for consolidation 30 patients 81 and gross disease treatment 7 patients 19 Median radiation dose interquartile range was 24 Gy 23.4-24 for photons and 21.8 Gy 21.3-23.6 for protons P .03 Proton CSI was associated with lower rates of Radiation Therapy Oncology Group grade 1-3 mucositis during CSI 7 vs 44 P .03 1 grade 3 with protons versus 5 grade 1 3 grade 2 and 2 grade 3 with photons During CSI other toxicities infection symptoms did not differ Allogeneic stem cell transplant SCT was used in 95 of patients with 53 of patients in remission before SCT Myeloablative conditioning was used for 76 During SCT admission and 100 days post-SCT toxicities did not differ by CSI technique Successful engraftment occurred in 95 of patients P .67 Progression or death occurred for 47 of patients with only 1 CNS relapse In our cohort CSI offered excellent local control for CNS-involved hematologic malignancies in the pre-SCT setting Acute mucositis occurred less frequently with proton CSI with comparable peritransplant/long-term toxicity profile suggesting the need to further explore the benefit/toxicity profile of this technique,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[5748, 1104, 4293, 1804, 293, 182, 1, 2647, 4763, 5, 854, 1880, 398, 1025, 799, 137, 9, 780, 7, 23574, 452, 31, 941, 1988, 967, 24, 155, 16, 8, 458, 2893, 21, 194, 385, 2, 123, 9, 7, 357, 2095, 15, 4216, 4293, 348, 1988, 21, 108, 567, 935, 2647, 4763, 7, 5, 1025, 799, 54, 103, 4293, 348, 1988, 28, 114, 731, 4216, 185, 2095, 385, 190, 4293, 941, 2, 298, 394, 162, 7346, 11, 72, 75, 3135, 2472, 2, 3896, 1026, 3216, 895, 319, 337, 3561, 34, 51, 2, 63, 25, 11, 311, 977, 648, 7, 382, 4216, 213, 2095, 208, 4293, 9, 1025, 799, 1, 286, 1275, 739, 286, 21049, 350, 442, 1193, 27, 442, 19446, 213, 175, 2, 27, 4293, 10, 95, 9, 2173, 201, 7, 865, 2, 1789, 34, 24, 67, 7, 326, 52, 121, 61, 2899, 184, 10, 259, 381, 382, 39, 259, 9, 7862, 2, 239, 66, 381, 239, 27, 382, 49, 9, 6684, 19, 680, 2095, 4293, 10, 41, 5, 280, 151, 1, 121, 36, 413, 87, 88, 14, 27, 2606, 190, 4293, 67, 105, 584, 19, 680, 14, 88, 27, 5, 6684, 185, 33, 88, 14, 27, 88, 18, 2, 18, 88, 27, 5, 7862, 190, 4293, 127, 385, 930, 507, 205, 44, 1505, 1063, 452, 31, 941, 1988, 10, 95, 4, 48, 1, 7, 5, 699, 1, 7, 4, 734, 348, 1988, 3246, 1933, 10, 95, 9, 846, 190, 1988, 3411, 2, 394, 162, 539, 1988, 385, 205, 44, 1505, 20, 4293, 1312, 1401, 2881, 489, 4, 48, 1, 7, 19, 598, 91, 15, 273, 489, 9, 662, 1, 7, 5, 158, 14, 1025, 429, 4, 114, 180, 4293, 2216, 1503, 293, 182, 9, 1025, 646, 813, 441, 4, 3, 671, 1988, 546, 286, 2606, 489, 299, 746, 5, 2095, 4293, 5, 1279, 21203, 319, 337, 155, 800, 802, 3, 594, 6, 195, 1645, 3, 247, 155, 800, 1, 26, 1312]",1994.0,28666906,298
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.,International journal of dermatology,Int. J. Dermatol.,2017-07-07,"Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B-cell lymphoma. Although cutaneous T-cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non-Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program. We searched the SEER 13 registries for patients with a diagnosis of CLL and NHL between 1992 and 2008. Among patients identified, we evaluated the incidence of CTCL. Among 31,286 patients with CLL, the incidence of CTCL was not significantly higher in men than women: 104.2 (95% CI, 50.0-191.8) and 28.1 (95% CI, 3.4-101.3) per 1,000,000 person-years, respectively (P=0.06). Among 97,691 patients with NHL, the incidence of CTCL was similar in men and women (97.9 [95% CI, 62.0-146.9] and 92.0 [95% CI, 56.2-142.1] per 1,000,000 person-years, respectively; P=0.84). The incidence of CTCL among males with CLL (standardized incidence ratio [SIR], 3.0 [95% CI, 1.4-5.5]), males with NHL (SIR, 3.7 [95% CI, 2.3-5.5]), and females with NHL (SIR, 5.9 [95% CI, 3.6-9.1]) was significantly higher than expected in the general population (all P<0.001). The risk of CTCL is greater in men with CLL than in the general population. In patients with NHL, both men and women are at greater risk for CTCL than in the general population.",Journal Article,928.0,1.0,"Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic CLL are well documented and include therapy-related acute myeloid leukemia/myelodysplastic syndromes and transformation to diffuse large B-cell Although cutaneous T-cell CTCL has been reported in patients with CLL the incidence and comparison to expected rates are unknown We evaluated the incidence of CTCL among patients with CLL or other NHL subtypes using data from the Surveillance Epidemiology and End Results SEER Program We searched the SEER 13 registries for patients with a diagnosis of CLL and NHL between 1992 and 2008 Among patients identified we evaluated the incidence of CTCL Among 31,286 patients with CLL the incidence of CTCL was not significantly higher in men than women 104.2 95 CI 50.0-191.8 and 28.1 95 CI 3.4-101.3 per 1,000,000 person-years respectively P 0.06 Among 97,691 patients with NHL the incidence of CTCL was similar in men and women 97.9 95 CI 62.0-146.9 and 92.0 95 CI 56.2-142.1 per 1,000,000 person-years respectively P 0.84 The incidence of CTCL among males with CLL standardized incidence ratio SIR 3.0 95 CI 1.4-5.5 males with NHL SIR 3.7 95 CI 2.3-5.5 and females with NHL SIR 5.9 95 CI 3.6-9.1 was significantly higher than expected in the general population all P 0.001 The risk of CTCL is greater in men with CLL than in the general population In patients with NHL both men and women are at greater risk for CTCL than in the general population",0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[419, 813, 163, 4, 7, 5, 442, 1193, 2647, 302, 1193, 552, 32, 149, 1405, 2, 643, 36, 139, 286, 533, 2647, 10589, 2040, 2, 1392, 6, 1388, 375, 132, 31, 242, 1486, 102, 31, 4742, 71, 85, 210, 4, 7, 5, 552, 3, 287, 2, 1155, 6, 1336, 151, 32, 860, 21, 194, 3, 287, 1, 4742, 107, 7, 5, 552, 15, 127, 1176, 814, 75, 74, 29, 3, 617, 1284, 2, 396, 99, 1605, 1243, 21, 3080, 3, 1605, 233, 3768, 9, 7, 5, 8, 147, 1, 552, 2, 1176, 59, 2846, 2, 1375, 107, 7, 108, 21, 194, 3, 287, 1, 4742, 107, 456, 8302, 7, 5, 552, 3, 287, 1, 4742, 10, 44, 97, 142, 4, 325, 76, 117, 3407, 18, 48, 58, 212, 13, 6130, 66, 2, 339, 14, 48, 58, 27, 39, 2338, 27, 379, 14, 984, 984, 2719, 60, 106, 19, 13, 1460, 107, 1015, 11661, 7, 5, 1176, 3, 287, 1, 4742, 10, 288, 4, 325, 2, 117, 1015, 83, 48, 58, 744, 13, 4909, 83, 2, 937, 13, 48, 58, 664, 18, 4785, 14, 379, 14, 984, 984, 2719, 60, 106, 19, 13, 874, 3, 287, 1, 4742, 107, 2296, 5, 552, 1670, 287, 197, 3636, 27, 13, 48, 58, 14, 39, 33, 33, 2296, 5, 1176, 3636, 27, 67, 48, 58, 18, 27, 33, 33, 2, 2451, 5, 1176, 3636, 33, 83, 48, 58, 27, 49, 83, 14, 10, 97, 142, 76, 1336, 4, 3, 1083, 266, 62, 19, 13, 144, 3, 43, 1, 4742, 16, 378, 4, 325, 5, 552, 76, 4, 3, 1083, 266, 4, 7, 5, 1176, 110, 325, 2, 117, 32, 28, 378, 43, 9, 4742, 76, 4, 3, 1083, 266]",1480.0,28685851,22
Ibrutinib treatment improves T cell number and function in CLL patients.,The Journal of clinical investigation,J. Clin. Invest.,2017-07-17,"Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated. Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers. ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025. The National Cancer Institute.","Clinical Trial, Phase I",918.0,64.0,Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton 's tyrosine kinase BTK and IL-2-inducible T cell kinase ITK The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies Peripheral blood mononuclear cells from chronic lymphocytic CLL patients on clinical trials of ibrutinib BTK/ITK inhibitor n 19 or acalabrutinib selective BTK inhibitor n 13 were collected serially T cell phenotype immune function and CLL cell immunosuppressive capacity were evaluated Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents While the number of Treg cells remained unchanged the ratio of these to conventional CD4+ T cells was reduced with ibrutinib but not acalabrutinib Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells Ibrutinib treatment increased the in vivo persistence of activated T cells decreased the Treg/CD4+ T cell ratio and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers ClinicalTrials.gov NCT01589302 and NCT02029443 Samples described here were collected per OSU-0025 The National Cancer Institute,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 71, 85, 443, 6, 47, 2555, 176, 20, 2062, 5796, 292, 564, 216, 3611, 2, 501, 18, 2877, 102, 31, 216, 15430, 3, 580, 1187, 1, 2062, 46, 18, 1549, 71, 44, 85, 409, 550, 211, 2088, 6, 250, 90, 235, 672, 315, 3041, 37, 29, 442, 1193, 552, 7, 23, 38, 143, 1, 1795, 3611, 15430, 230, 78, 326, 15, 11378, 1094, 3611, 230, 78, 233, 11, 786, 6754, 102, 31, 1005, 250, 343, 2, 552, 31, 2989, 2162, 11, 194, 1795, 2195, 101, 1440, 2, 968, 102, 31, 1870, 4, 552, 7, 26, 254, 10, 80, 3689, 4, 2070, 2070, 2407, 1890, 2, 10, 44, 164, 5, 11378, 2581, 386, 94, 264, 17, 26, 68, 40, 520, 6, 2849, 363, 277, 31, 273, 298, 15430, 297, 333, 14, 2, 2127, 39, 55, 10, 97, 2195, 405, 4, 102, 37, 20, 110, 183, 369, 3, 207, 1, 3960, 37, 958, 4639, 3, 197, 1, 46, 6, 809, 1440, 102, 37, 10, 405, 5, 1795, 84, 44, 11378, 110, 183, 405, 55, 1, 3, 2989, 1598, 20730, 2, 11879, 22, 149, 22, 501, 79, 1529, 20, 552, 37, 1795, 24, 101, 3, 4, 386, 4108, 1, 735, 102, 37, 340, 3, 3960, 1440, 102, 31, 197, 2, 2849, 3, 250, 3707, 1571, 1, 552, 37, 298, 3611, 470, 2, 306, 483, 46, 404, 377, 8, 1082, 1728, 9, 150, 726, 611, 5, 1795, 4, 552, 2, 127, 163, 1252, 1239, 49192, 2, 49443, 347, 1027, 467, 11, 786, 379, 5984, 12615, 3, 657, 12, 1377]",1678.0,28714866,276
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-07-17,"Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD19 CAR-T cells at one of three dose levels (2  10<sup>5</sup>, 2  10<sup>6</sup>, or 2  10<sup>7</sup> CAR-T cells/kg). Nineteen patients experienced disease progression while receiving ibrutinib, three were ibrutinib intolerant, and two did not experience progression while receiving ibrutinib. Six patients were venetoclax refractory, and 23 had a complex karyotype and/or 17p deletion. Results Four weeks after CAR-T cell infusion, the overall response rate (complete response [CR] and/or partial response [PR]) by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria was 71% (17 of 24). Twenty patients (83%) developed cytokine release syndrome, and eight (33%) developed neurotoxicity, which was reversible in all but one patient with a fatal outcome. Twenty of 24 patients received cyclophosphamide and fludarabine lymphodepletion and CD19 CAR-T cells at or below the maximum tolerated dose ( 2  10<sup>6</sup> CAR-T cells/kg). In 19 of these patients who were restaged, the overall response rate by IWCLL imaging criteria 4 weeks after infusion was 74% (CR, 4/19, 21%; PR, 10/19, 53%), and 15/17 patients (88%) with marrow disease before CAR-T cells had no disease by flow cytometry after CAR-T cells. Twelve of these patients underwent deep IGH sequencing, and seven (58%) had no malignant IGH sequences detected in marrow. Absence of the malignant IGH clone in marrow of patients with CLL who responded by IWCLL criteria was associated with 100% progression-free survival and overall survival (median 6.6 months follow-up) after CAR-T cell immunotherapy. The progression-free survival was similar in patients with lymph node PR or CR by IWCLL criteria. Conclusion CD19 CAR-T cells are highly effective in high-risk patients with CLL after they experience treatment failure with ibrutinib therapy.","Clinical Trial, Phase I",918.0,153.0,Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T CAR-T cell therapy in patients with chronic lymphocytic CLL who had previously received ibrutinib Methods Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD19 CAR-T cells at one of three dose levels 2 10 sup 5 /sup 2 10 sup 6 /sup or 2 10 sup 7 /sup CAR-T cells/kg Nineteen patients experienced disease progression while receiving ibrutinib three were ibrutinib intolerant and two did not experience progression while receiving ibrutinib Six patients were venetoclax refractory and 23 had a complex karyotype and/or 17p deletion Results Four weeks after CAR-T cell infusion the overall response rate complete response CR and/or partial response PR by International Workshop on Chronic Lymphocytic IWCLL criteria was 71 17 of 24 Twenty patients 83 developed cytokine release syndrome and eight 33 developed neurotoxicity which was reversible in all but one patient with a fatal outcome Twenty of 24 patients received cyclophosphamide and fludarabine lymphodepletion and CD19 CAR-T cells at or below the maximum tolerated dose  2 10 sup 6 /sup CAR-T cells/kg In 19 of these patients who were restaged the overall response rate by IWCLL imaging criteria 4 weeks after infusion was 74 CR 4/19 21 PR 10/19 53 and 15/17 patients 88 with marrow disease before CAR-T cells had no disease by flow cytometry after CAR-T cells Twelve of these patients underwent deep IGH sequencing and seven 58 had no malignant IGH sequences detected in marrow Absence of the malignant IGH clone in marrow of patients with CLL who responded by IWCLL criteria was associated with 100 progression-free survival and overall survival median 6.6 months follow-up after CAR-T cell immunotherapy The progression-free survival was similar in patients with lymph node PR or CR by IWCLL criteria Conclusion CD19 CAR-T cells are highly effective in high-risk patients with CLL after they experience treatment failure with ibrutinib therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[743, 21, 194, 3, 367, 2, 1437, 1, 312, 3158, 2897, 448, 153, 1230, 102, 1881, 102, 31, 36, 4, 7, 5, 442, 1193, 552, 54, 42, 373, 103, 1795, 636, 737, 294, 7, 5, 552, 103, 36459, 56, 2, 312, 3158, 1881, 102, 37, 28, 104, 1, 169, 61, 148, 18, 79, 172, 33, 172, 18, 79, 172, 49, 172, 15, 18, 79, 172, 67, 172, 1881, 102, 37, 503, 3498, 7, 592, 34, 91, 369, 357, 1795, 169, 11, 1795, 4944, 2, 100, 205, 44, 730, 91, 369, 357, 1795, 437, 7, 11, 4454, 430, 2, 382, 42, 8, 840, 3385, 2, 15, 4135, 1528, 99, 294, 244, 50, 1881, 102, 31, 904, 3, 63, 51, 116, 236, 51, 684, 2, 15, 450, 51, 998, 20, 944, 4014, 23, 442, 1193, 16575, 371, 10, 792, 269, 1, 259, 737, 7, 852, 276, 1675, 2008, 681, 2, 659, 466, 276, 3561, 92, 10, 2786, 4, 62, 84, 104, 69, 5, 8, 3034, 228, 737, 1, 259, 7, 103, 1112, 2, 2027, 16876, 2, 3158, 1881, 102, 37, 28, 15, 2736, 3, 689, 421, 61, 1552, 18, 79, 172, 49, 172, 1881, 102, 37, 503, 4, 326, 1, 46, 7, 54, 11, 15090, 3, 63, 51, 116, 20, 16575, 270, 371, 39, 244, 50, 904, 10, 794, 684, 39, 326, 239, 998, 79, 326, 699, 2, 167, 269, 7, 889, 5, 581, 34, 348, 1881, 102, 37, 42, 77, 34, 20, 1412, 1914, 50, 1881, 102, 37, 2544, 1, 46, 7, 208, 2369, 5221, 615, 2, 648, 717, 42, 77, 393, 5221, 2866, 530, 4, 581, 1127, 1, 3, 393, 5221, 3910, 4, 581, 1, 7, 5, 552, 54, 2211, 20, 16575, 371, 10, 41, 5, 394, 91, 115, 25, 2, 63, 25, 52, 49, 49, 53, 166, 126, 50, 1881, 102, 31, 726, 3, 91, 115, 25, 10, 288, 4, 7, 5, 263, 289, 998, 15, 684, 20, 16575, 371, 1221, 3158, 1881, 102, 37, 32, 561, 323, 4, 64, 43, 7, 5, 552, 50, 491, 730, 24, 496, 5, 1795, 36]",2029.0,28715249,560
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.,Leukemia & lymphoma,Leuk. Lymphoma,2017-07-18,"We hypothesized that the length of treatment-free survival following (a) initial diagnosis and (b) first-line treatment would be associated with improved subsequent five-year relative survival (RS5) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 19,879 patients incident CLL/SLL cases (median age=76 years) were identified from SEER-Medicare. RS5 improved from 0.73 (95% CI: 0.72, 0.74) at diagnosis to 0.81 (95% CI: 0.80, 0.82) at year 1 and 0.89 (95% CI: 0.83, 0.96) at year 10 among those who had not received treatment. In our analysis of survival patterns following first-line treatment, RS5 improved from 0.55 (95% CI: 0.53, 0.57) at initiation of first-line treatment to 0.84 (95% CI: 0.75, 0.92) among patients who had not been retreated at year 5 following first-line therapy. Longer periods of treatment-free survival following initial diagnosis and first-line treatment were both predictive of meaningfully improved prognosis in CLL/SLL patients.",Journal Article,917.0,2.0,"We hypothesized that the length of treatment-free survival following a initial diagnosis and b first-line treatment would be associated with improved subsequent five-year relative survival RS5 in patients with chronic lymphocytic or small lymphocytic CLL/SLL 19,879 patients incident CLL/SLL cases median age 76 years were identified from SEER-Medicare RS5 improved from 0.73 95 CI 0.72 0.74 at diagnosis to 0.81 95 CI 0.80 0.82 at year 1 and 0.89 95 CI 0.83 0.96 at year 10 among those who had not received treatment In our analysis of survival patterns following first-line treatment RS5 improved from 0.55 95 CI 0.53 0.57 at initiation of first-line treatment to 0.84 95 CI 0.75 0.92 among patients who had not been retreated at year 5 following first-line therapy Longer periods of treatment-free survival following initial diagnosis and first-line treatment were both predictive of meaningfully improved prognosis in CLL/SLL patients",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 1237, 17, 3, 1318, 1, 24, 115, 25, 366, 8, 388, 147, 2, 132, 157, 328, 24, 688, 40, 41, 5, 231, 706, 365, 111, 580, 25, 29911, 4, 7, 5, 442, 1193, 15, 302, 1193, 552, 5302, 326, 15896, 7, 2631, 552, 5302, 140, 52, 89, 846, 60, 11, 108, 29, 1605, 1378, 29911, 231, 29, 13, 803, 48, 58, 13, 720, 13, 794, 28, 147, 6, 13, 865, 48, 58, 13, 493, 13, 878, 28, 111, 14, 2, 13, 887, 48, 58, 13, 852, 13, 921, 28, 111, 79, 107, 135, 54, 42, 44, 103, 24, 4, 114, 65, 1, 25, 764, 366, 157, 328, 24, 29911, 231, 29, 13, 614, 48, 58, 13, 699, 13, 696, 28, 1118, 1, 157, 328, 24, 6, 13, 874, 48, 58, 13, 481, 13, 937, 107, 7, 54, 42, 44, 85, 11088, 28, 111, 33, 366, 157, 328, 36, 589, 3338, 1, 24, 115, 25, 366, 388, 147, 2, 157, 328, 24, 11, 110, 464, 1, 14625, 231, 356, 4, 552, 5302, 7]",938.0,28718694,10
Activation of the B-cell receptor successively activates NF-B and STAT3 in chronic lymphocytic leukemia cells.,International journal of cancer,Int. J. Cancer,2017-08-04,"In chronic lymphocytic leukemia (CLL) cells, both interleukin-6 (IL-6) and the B-cell receptor (BCR) activate Janus kinase 2 (JAK2) and induce the phosphorylation of signal transduction and activator of transcription 3 (STAT3) on tyrosine 705 residues. However, whereas IL-6 phosphorylates STAT3 within 15 min, stimulation of the BCR with anti-immunoglobulin M (IgM) antibodies phosphorylates STAT3 in 2-4 hr. Here, we show that this process takes longer because it requires transcriptional activity of NF-B. Using an electromobility shift assay, we found that incubation with IgM antibodies for 4 or 18 hr, but not 15 min, increased NF-B DNA-binding of CLL cells and increased binding was translated to increased transcriptional activity. Hence, 42% of the 83 NF-B target genes were constitutively expressed in all CLL cells prior to any inducible stimuli. However, activation of the BCR increased the number of NF-B target genes with detectable expression by 23%. Remarkably, prolonged incubation with anti-IgM antibodies induced a time-dependent transcription, production and secretion of IL-6 protein. The IgM-induced production of IL-6 prompted the phosphorylation of STAT3 on tyrosine residues. This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib. Taken together, these results suggest that in CLL cells, constitutive tonic activation of NF-B can be further enhanced by the BCR and that the BCR-induced activation of the JAK/STAT3 pathway depends on the NF-B induced production of IL-6.",Journal Article,900.0,7.0,In chronic lymphocytic CLL cells both interleukin-6 IL-6 and the B-cell receptor BCR activate Janus kinase 2 JAK2 and induce the phosphorylation of signal transduction and activator of transcription 3 STAT3 on tyrosine 705 residues However whereas IL-6 phosphorylates STAT3 within 15 min stimulation of the BCR with anti-immunoglobulin M IgM antibodies phosphorylates STAT3 in 2-4 hr Here we show that this process takes longer because it requires transcriptional activity of NF-B Using an electromobility shift assay we found that incubation with IgM antibodies for 4 or 18 hr but not 15 min increased NF-B DNA-binding of CLL cells and increased binding was translated to increased transcriptional activity Hence 42 of the 83 NF-B target genes were constitutively expressed in all CLL cells prior to any inducible stimuli However activation of the BCR increased the number of NF-B target genes with detectable expression by 23 Remarkably prolonged incubation with anti-IgM antibodies induced a time-dependent transcription production and secretion of IL-6 protein The IgM-induced production of IL-6 prompted the phosphorylation of STAT3 on tyrosine residues This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib Taken together these results suggest that in CLL cells constitutive tonic activation of NF-B can be further enhanced by the BCR and that the BCR-induced activation of the JAK/STAT3 pathway depends on the NF-B induced production of IL-6,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 442, 1193, 552, 37, 110, 1603, 49, 501, 49, 2, 3, 132, 31, 153, 1062, 2977, 6191, 216, 18, 2509, 2, 1290, 3, 982, 1, 1235, 2761, 2, 3393, 1, 866, 27, 1439, 23, 564, 11303, 6418, 137, 547, 501, 49, 12528, 1439, 262, 167, 1538, 2503, 1, 3, 1062, 5, 312, 2593, 188, 2852, 890, 12528, 1439, 4, 18, 39, 168, 467, 21, 514, 17, 26, 1129, 8512, 589, 408, 192, 1706, 1431, 128, 1, 1365, 2448, 75, 35, 28011, 3024, 719, 21, 204, 17, 7797, 5, 2852, 890, 9, 39, 15, 203, 168, 84, 44, 167, 1538, 101, 1365, 2448, 261, 791, 1, 552, 37, 2, 101, 791, 10, 5136, 6, 101, 1431, 128, 3665, 595, 1, 3, 852, 1365, 2448, 283, 214, 11, 2818, 570, 4, 62, 552, 37, 324, 6, 500, 2877, 7478, 137, 363, 1, 3, 1062, 101, 3, 207, 1, 1365, 2448, 283, 214, 5, 2083, 55, 20, 382, 4856, 1069, 7797, 5, 312, 2852, 890, 277, 8, 98, 470, 866, 1529, 2, 2935, 1, 501, 49, 178, 3, 2852, 277, 1529, 1, 501, 49, 4140, 3, 982, 1, 1439, 23, 564, 6418, 26, 254, 10, 879, 20, 3, 8075, 18, 230, 1, 3, 4653, 1439, 308, 4894, 1633, 1162, 46, 99, 309, 17, 4, 552, 37, 3178, 26644, 363, 1, 1365, 2448, 122, 40, 195, 651, 20, 3, 1062, 2, 17, 3, 1062, 277, 363, 1, 3, 4653, 1439, 308, 3828, 23, 3, 1365, 2448, 277, 1529, 1, 501, 49]",1487.0,28722170,576
Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2017-07-19,"Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). However, there is disagreement over how widely these therapies should be used in place of standard chemo-immunotherapy (CIT). We investigated whether stratification on the length of the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival, and for whom CIT could be an acceptable treatment choice. Patients with relapsed CLL/SLL who received T2 were identified from the SEER-Medicare Linked Database. Five-year relative survival (RS5; ie, the ratio of observed survival to expected survival based on population life tables) was assessed after stratifying patients on the interval between T1 and T2. We then validated our findings in the Mayo Clinic CLL Database. Among 1974 SEER-Medicare patients (median age= 77 years) who received T2 for relapsed CLL/SLL, longer time-to-retreatment was associated with a modestly improved prognosis (P= .01). However, even among those retreated 3 years after T1, survival was poor compared with the general population (RS5= 0.50 or lower in SEER-Medicare). Similar patterns were observed in the younger Mayo validation cohort, although prognosis was better overall among the Mayo patients, and patients with favorable fluorescence in situ hybridization retreated 3 years after T1 had close to normal expected survival (RS5= 0.87). Further research is needed to quantify the degree to which targeted therapies provide meaningful improvements over CIT in long-term outcomes for older patients with relapsed CLL/SLL.",Journal Article,916.0,2.0,Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic and small lymphocytic CLL/SLL However there is disagreement over how widely these therapies should be used in place of standard chemo-immunotherapy CIT We investigated whether stratification on the length of the interval between first-line T1 and second-line T2 treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival and for whom CIT could be an acceptable treatment choice Patients with relapsed CLL/SLL who received T2 were identified from the SEER-Medicare Linked Database Five-year relative survival RS5 ie the ratio of observed survival to expected survival based on population life tables was assessed after stratifying patients on the interval between T1 and T2 We then validated our findings in the Mayo Clinic CLL Database Among 1974 SEER-Medicare patients median age 77 years who received T2 for relapsed CLL/SLL longer time-to-retreatment was associated with a modestly improved prognosis P .01 However even among those retreated  3 years after T1 survival was poor compared with the general population RS5 0.50 or lower in SEER-Medicare Similar patterns were observed in the younger Mayo validation cohort although prognosis was better overall among the Mayo patients and patients with favorable fluorescence in situ hybridization retreated  3 years after T1 had close to normal expected survival RS5 0.87 Further research is needed to quantify the degree to which targeted therapies provide meaningful improvements over CIT in long-term outcomes for older patients with relapsed CLL/SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[229, 238, 235, 1918, 1503, 978, 337, 123, 4, 7, 5, 442, 1193, 2, 302, 1193, 552, 5302, 137, 125, 16, 10212, 252, 832, 1792, 46, 235, 257, 40, 95, 4, 3536, 1, 260, 3341, 726, 9192, 21, 565, 317, 1541, 23, 3, 1318, 1, 3, 268, 59, 157, 328, 1534, 2, 419, 328, 1786, 640, 359, 255, 8, 1363, 1, 434, 7, 5, 591, 552, 5302, 5, 35, 9988, 1, 295, 63, 25, 2, 9, 953, 9192, 359, 40, 35, 1595, 24, 1866, 7, 5, 591, 552, 5302, 54, 103, 1786, 11, 108, 29, 3, 1605, 1378, 1199, 609, 365, 111, 580, 25, 29911, 2523, 3, 197, 1, 164, 25, 6, 1336, 25, 90, 23, 266, 358, 9941, 10, 275, 50, 5035, 7, 23, 3, 268, 59, 1534, 2, 1786, 21, 818, 938, 114, 272, 4, 3, 2486, 1188, 552, 609, 107, 10201, 1605, 1378, 7, 52, 89, 849, 60, 54, 103, 1786, 9, 591, 552, 5302, 589, 98, 6, 6291, 10, 41, 5, 8, 5588, 231, 356, 19, 355, 137, 871, 107, 135, 11088, 749, 27, 60, 50, 1534, 25, 10, 334, 72, 5, 3, 1083, 266, 29911, 13, 212, 15, 280, 4, 1605, 1378, 288, 764, 11, 164, 4, 3, 773, 2486, 929, 180, 242, 356, 10, 380, 63, 107, 3, 2486, 7, 2, 7, 5, 913, 1591, 4, 957, 1554, 11088, 749, 27, 60, 50, 1534, 42, 2336, 6, 295, 1336, 25, 29911, 13, 912, 195, 389, 16, 575, 6, 3091, 3, 1444, 6, 92, 238, 235, 377, 2538, 1474, 252, 9192, 4, 319, 337, 123, 9, 434, 7, 5, 591, 552, 5302]",1668.0,28802891,74
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.,Molecular cancer research : MCR,Mol. Cancer Res.,2017-08-23,"Peripheral blood chronic lymphocytic leukemia (CLL) cells are quiescent but have active transcription and translation processes, suggesting that these lymphocytes are metabolically active. Based on this premise, the metabolic phenotype of CLL lymphocytes was investigated by evaluating the two intracellular ATP-generating pathways. Metabolic flux was assessed by measuring glycolysis as extracellular acidification rate (ECAR) and mitochondrial oxidative phosphorylation as oxygen consumption rate (OCR) and then correlated with prognostic factors. Further, the impact of B-cell receptor signaling (BCR) on metabolism was determined by genetic ablation and pharmacological inhibitors. Compared with proliferative B-cell lines, metabolic fluxes of oxygen and lactate were low in CLL cells. ECAR was consistently low, but OCR varied considerably in human patient samples (<i>n</i> = 45). Higher OCR was associated with poor prognostic factors such as ZAP 70 positivity, unmutated IGHV, high 2M levels, and higher Rai stage. Consistent with the association of ZAP 70 and IGHV unmutated status with active BCR signaling, genetic ablation of BCR mitigated OCR in malignant B cells. Similarly, knocking out PI3K, a critical component of the BCR pathway, decreased OCR and ECAR. In concert, PI3K pathway inhibitors dramatically reduced OCR and ECAR. In harmony with a decline in metabolic activity, the ribonucleotide pools in CLL cells were reduced with duvelisib treatment. Collectively, these data demonstrate that CLL metabolism, especially OCR, is linked to prognostic factors and is curbed by BCR and PI3K pathway inhibition.<b>Implications:</b> This study identifies a relationship between oxidative phosphorylation in CLL and prognostic factors providing a rationale to therapeutically target these processes. <i>Mol Cancer Res; 15(12); 1692-703. 2017 AACR</i>.",Journal Article,881.0,10.0,Peripheral blood chronic lymphocytic CLL cells are quiescent but have active transcription and translation processes suggesting that these lymphocytes are metabolically active Based on this premise the metabolic phenotype of CLL lymphocytes was investigated by evaluating the two intracellular ATP-generating pathways Metabolic flux was assessed by measuring glycolysis as extracellular acidification rate ECAR and mitochondrial oxidative phosphorylation as oxygen consumption rate OCR and then correlated with prognostic factors Further the impact of B-cell receptor signaling BCR on metabolism was determined by genetic ablation and pharmacological inhibitors Compared with proliferative B-cell lines metabolic fluxes of oxygen and lactate were low in CLL cells ECAR was consistently low but OCR varied considerably in human patient samples i n /i 45 Higher OCR was associated with poor prognostic factors such as ZAP 70 positivity unmutated IGHV high 2M levels and higher Rai stage Consistent with the association of ZAP 70 and IGHV unmutated status with active BCR signaling genetic ablation of BCR mitigated OCR in malignant B cells Similarly knocking out PI3K a critical component of the BCR pathway decreased OCR and ECAR In concert PI3K pathway inhibitors dramatically reduced OCR and ECAR In harmony with a decline in metabolic activity the ribonucleotide pools in CLL cells were reduced with duvelisib treatment Collectively these data demonstrate that CLL metabolism especially OCR is linked to prognostic factors and is curbed by BCR and PI3K pathway inhibition. b Implications /b This study identifies a relationship between oxidative phosphorylation in CLL and prognostic factors providing a rationale to therapeutically target these processes i Mol Cancer Res 15 12 1692-703 2017 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[672, 315, 442, 1193, 552, 37, 32, 6735, 84, 47, 544, 866, 2, 2691, 1849, 802, 17, 46, 1594, 32, 10392, 544, 90, 23, 26, 14448, 3, 1436, 1005, 1, 552, 1594, 10, 565, 20, 1435, 3, 100, 2087, 3918, 3997, 460, 1436, 9876, 10, 275, 20, 2978, 4484, 22, 1976, 18340, 116, 36469, 2, 2019, 3495, 982, 22, 2848, 2421, 116, 20885, 2, 818, 438, 5, 177, 130, 195, 3, 345, 1, 132, 31, 153, 314, 1062, 23, 1600, 10, 509, 20, 336, 1650, 2, 3419, 222, 72, 5, 2441, 132, 31, 285, 1436, 37580, 1, 2848, 2, 3330, 11, 154, 4, 552, 37, 36469, 10, 2433, 154, 84, 20885, 2051, 5597, 4, 171, 69, 347, 70, 78, 70, 512, 142, 20885, 10, 41, 5, 334, 177, 130, 225, 22, 6251, 431, 1887, 7216, 6220, 64, 27019, 148, 2, 142, 4121, 82, 925, 5, 3, 248, 1, 6251, 431, 2, 6220, 7216, 156, 5, 544, 1062, 314, 336, 1650, 1, 1062, 10042, 20885, 4, 393, 132, 37, 1813, 12875, 1205, 11063, 8, 740, 1249, 1, 3, 1062, 308, 340, 20885, 2, 36469, 4, 10562, 974, 308, 222, 2729, 405, 20885, 2, 36469, 4, 48060, 5, 8, 1858, 4, 1436, 128, 3, 7050, 9090, 4, 552, 37, 11, 405, 5, 15080, 24, 2535, 46, 74, 608, 17, 552, 1600, 1093, 20885, 16, 1199, 6, 177, 130, 2, 16, 34389, 20, 1062, 2, 974, 308, 297, 132, 1268, 132, 26, 45, 2953, 8, 858, 59, 3495, 982, 4, 552, 2, 177, 130, 1736, 8, 1728, 6, 4602, 283, 46, 1849, 70, 5824, 12, 1936, 167, 133, 71074, 15273, 3194, 1630, 70]",1805.0,28835371,473
The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.,"Neoplasia (New York, N.Y.)",Neoplasia,2017-08-30,"Peripheral blood chronic lymphocytic leukemia (CLL) cells are replicationally quiescent mature B-cells. In short-term cultures, supporting stromal cells provide a survival advantage to CLL cells by inducing transcription and translation without promoting proliferation. We hypothesized that the stromal microenvironment augments malignant B cells' metabolism to enable the cells to cope with their energy demands for transcription and translation. We used extracellular flux analysis to assess the two major energy-generating pathways, mitochondrial oxidative phosphorylation (OxPhos) and glycolysis, in primary CLL cells in the presence of three different stromal cell lines. OxPhos, measured as the basal oxygen consumption rate (OCR) and maximum respiration capacity, was significantly higher in 28 patients' CLL cells cocultured with bone marrow-derived NK.Tert stromal cells than in CLL cells cultured alone (P = .004 and <.0001, respectively). Similar OCR induction was observed in CLL cells cocultured with M2-10B4 and HS-5 stromal lines. In contrast, heterogeneous changes in the extracellular acidification rate (a measure of glycolysis) were observed in CLL cells cocultured with stromal cells. Ingenuity Pathway Analysis of CLL cells' metabolomics profile indicated stroma-mediated stimulation of nucleotide synthesis. Quantitation of ribonucleotide pools showed a significant two-fold increase in CLL cells cocultured with stromal cells, indicating that the stroma may induce CLL cellular bioenergy and the RNA building blocks necessary for the transcriptional requirement of a prosurvival phenotype. The stroma did not impact the proliferation index (Ki-67 staining) of CLL cells. Collectively, these data suggest that short-term interaction (24 hours) with stroma increases OxPhos and bioenergy in replicationally quiescent CLL cells.",Journal Article,874.0,11.0,Peripheral blood chronic lymphocytic CLL cells are replicationally quiescent mature B-cells In short-term cultures supporting stromal cells provide a survival advantage to CLL cells by inducing transcription and translation without promoting proliferation We hypothesized that the stromal microenvironment augments malignant B cells metabolism to enable the cells to cope with their energy demands for transcription and translation We used extracellular flux analysis to assess the two major energy-generating pathways mitochondrial oxidative phosphorylation OxPhos and glycolysis in primary CLL cells in the presence of three different stromal cell lines OxPhos measured as the basal oxygen consumption rate OCR and maximum respiration capacity was significantly higher in 28 patients CLL cells cocultured with marrow-derived NK.Tert stromal cells than in CLL cells cultured alone P .004 and .0001 respectively Similar OCR induction was observed in CLL cells cocultured with M2-10B4 and HS-5 stromal lines In contrast heterogeneous changes in the extracellular acidification rate a measure of glycolysis were observed in CLL cells cocultured with stromal cells Ingenuity Pathway Analysis of CLL cells metabolomics profile indicated stroma-mediated stimulation of nucleotide synthesis Quantitation of ribonucleotide pools showed a significant two-fold increase in CLL cells cocultured with stromal cells indicating that the stroma may induce CLL cellular bioenergy and the RNA building blocks necessary for the transcriptional requirement of a prosurvival phenotype The stroma did not impact the proliferation index Ki-67 staining of CLL cells Collectively these data suggest that short-term interaction 24 hours with stroma increases OxPhos and bioenergy in replicationally quiescent CLL cells,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[672, 315, 442, 1193, 552, 37, 32, 38754, 6735, 2908, 132, 37, 4, 978, 337, 3231, 1912, 1126, 37, 377, 8, 25, 1874, 6, 552, 37, 20, 1958, 866, 2, 2691, 187, 2388, 457, 21, 1237, 17, 3, 1126, 995, 8941, 393, 132, 37, 1600, 6, 3047, 3, 37, 6, 11103, 5, 136, 2803, 8988, 9, 866, 2, 2691, 21, 95, 1976, 9876, 65, 6, 423, 3, 100, 458, 2803, 3997, 460, 2019, 3495, 982, 12680, 2, 4484, 4, 86, 552, 37, 4, 3, 463, 1, 169, 338, 1126, 31, 285, 12680, 644, 22, 3, 2135, 2848, 2421, 116, 20885, 2, 689, 7725, 2162, 10, 97, 142, 4, 339, 7, 552, 37, 11444, 5, 581, 526, 1765, 3846, 1126, 37, 76, 4, 552, 37, 3197, 279, 19, 1520, 2, 488, 106, 288, 20885, 504, 10, 164, 4, 552, 37, 11444, 5, 821, 71133, 2, 5871, 33, 1126, 285, 4, 748, 1564, 400, 4, 3, 1976, 18340, 116, 8, 1463, 1, 4484, 11, 164, 4, 552, 37, 11444, 5, 1126, 37, 12609, 308, 65, 1, 552, 37, 11364, 800, 1103, 2477, 517, 2503, 1, 1579, 2525, 7887, 1, 7050, 9090, 224, 8, 93, 100, 1116, 344, 4, 552, 37, 11444, 5, 1126, 37, 1716, 17, 3, 2477, 68, 1290, 552, 763, 28358, 2, 3, 893, 5808, 2860, 1493, 9, 3, 1431, 4701, 1, 8, 7331, 1005, 3, 2477, 205, 44, 345, 3, 457, 558, 2311, 598, 1029, 1, 552, 37, 2535, 46, 74, 309, 17, 978, 337, 915, 27042, 1459, 5, 2477, 1106, 12680, 2, 28358, 4, 38754, 6735, 552, 37]",1795.0,28863345,617
"Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.",American journal of hematology,Am. J. Hematol.,2017-10-19,"The prevalence of liver dysfunction and its association with outcomes in patients with previously untreated chronic lymphocytic leukemia (CLL) is unknown. Newly diagnosed (<12months) previously untreated CLL patients seen at Mayo Clinic, Rochester, MN between 9/1993 and 4/2016 who had baseline assessment of at least one liver function test (LFT) were included in this analysis. The prevalence of liver dysfunction at baseline, proportion of patients who acquired LFT abnormalities, time to first therapy (TTFT) and overall survival (OS) were assessed. An abnormal LFT was present in 82/2336 (3.5%) patients at diagnosis and was associated with advanced Rai stage (Rai III-IV) (21% vs. 6%; P<.001), lower hemoglobin (13.1g/dL vs. 13.9g/dL; P<.001), and lower platelet count (187109/L vs. 200109/L; P=.03). Additionally, 236 patients with normal LFTs at diagnosis developed acquired liver dysfunction during follow-up. Patients with abnormal LFTs at diagnosis had a shorter OS compared to those with normal LFTs (HR 1.80 95%CI 1.13-2.87; P=.014, adjusted for age, sex, Rai stage, and treatment), although TTFT was not different. Of 52 patients who underwent a liver biopsy, CLL was present in liver tissue in 39/52 (73%) patients, with the portal tracts the most common region involved. Histopathology findings of liver involvement by CLL had limited correlation with choice of CLL therapy. In conclusion, approximately 1 of 25 newly diagnosed CLL patients has abnormal LFTs at diagnosis. Although the TTFT was not different among patients with abnormal LFTs, these patients have a shorter OS compared to those with normal LFTs.",Journal Article,824.0,3.0,The prevalence of dysfunction and its association with outcomes in patients with previously untreated chronic lymphocytic CLL is unknown Newly diagnosed 12 months previously untreated CLL patients seen at Mayo Clinic Rochester MN between 9/1993 and 4/2016 who had baseline assessment of at least one function test LFT were included in this analysis The prevalence of dysfunction at baseline proportion of patients who acquired LFT abnormalities time to first therapy TTFT and overall survival OS were assessed An abnormal LFT was present in 82/2336 3.5 patients at diagnosis and was associated with advanced Rai stage Rai III-IV 21 vs. 6 P .001 lower hemoglobin 13.1 g/dL vs. 13.9 g/dL P .001 and lower platelet count 187 109/L vs. 200 109/L P .03 Additionally 236 patients with normal LFTs at diagnosis developed acquired dysfunction during follow-up Patients with abnormal LFTs at diagnosis had a shorter OS compared to those with normal LFTs HR 1.80 95 CI 1.13-2.87 P .014 adjusted for age sex Rai stage and treatment although TTFT was not different Of 52 patients who underwent a biopsy CLL was present in tissue in 39/52 73 patients with the portal tracts the most common region involved Histopathology findings of involvement by CLL had limited correlation with choice of CLL therapy In conclusion approximately 1 of 25 newly diagnosed CLL patients has abnormal LFTs at diagnosis Although the TTFT was not different among patients with abnormal LFTs these patients have a shorter OS compared to those with normal LFTs,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1078, 1, 1527, 2, 211, 248, 5, 123, 4, 7, 5, 373, 1278, 442, 1193, 552, 16, 860, 732, 265, 133, 53, 373, 1278, 552, 7, 527, 28, 2486, 1188, 5801, 4691, 59, 83, 3343, 2, 39, 1390, 54, 42, 330, 455, 1, 28, 506, 104, 343, 412, 28715, 11, 159, 4, 26, 65, 3, 1078, 1, 1527, 28, 330, 920, 1, 7, 54, 1294, 28715, 1171, 98, 6, 157, 36, 14035, 2, 63, 25, 118, 11, 275, 35, 1668, 28715, 10, 364, 4, 878, 37754, 27, 33, 7, 28, 147, 2, 10, 41, 5, 131, 4121, 82, 4121, 316, 478, 239, 105, 49, 19, 144, 280, 2222, 233, 14, 499, 1826, 105, 233, 83, 499, 1826, 19, 144, 2, 280, 1596, 1276, 5568, 3486, 805, 105, 1250, 3486, 805, 19, 680, 1724, 6383, 7, 5, 295, 22446, 28, 147, 276, 1294, 1527, 190, 166, 126, 7, 5, 1668, 22446, 28, 147, 42, 8, 985, 118, 72, 6, 135, 5, 295, 22446, 168, 14, 493, 48, 58, 14, 233, 18, 912, 19, 3618, 586, 9, 89, 1035, 4121, 82, 2, 24, 242, 14035, 10, 44, 338, 1, 653, 7, 54, 208, 8, 411, 552, 10, 364, 4, 246, 4, 587, 653, 803, 7, 5, 3, 3307, 10950, 3, 96, 186, 1053, 646, 3831, 272, 1, 799, 20, 552, 42, 383, 816, 5, 1866, 1, 552, 36, 4, 1221, 705, 14, 1, 243, 732, 265, 552, 7, 71, 1668, 22446, 28, 147, 242, 3, 14035, 10, 44, 338, 107, 7, 5, 1668, 22446, 46, 7, 47, 8, 985, 118, 72, 6, 135, 5, 295, 22446]",1523.0,28940587,59
Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.,Leukemia & lymphoma,Leuk. Lymphoma,2017-10-03,"Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy in which cells reside in bone marrow, lymph nodes, and peripheral blood, each of which provides a unique microenvironment. Although the levels of certain proteins are reported to induce, changes in the CLL cell proteome in the presence of bone marrow stromal cells have not been elucidated. Reverse-phase protein array analysis of CLL cells before and 24h after stromal cell interaction revealed changed levels of proteins that regulate cell cycle, gene transcription, and protein translation. The most hit with respect to both the extent of change in expression level and statistical significance was caveolin-1, which was confirmed with immunoblotting. Caveolin-1 mRNA levels were also upregulated in CLL cells after stromal cell interaction. The induction of caveolin-1 levels was rapid and occurred as early as 1h. Studies to determine the significance of upregulated caveolin-1 levels in CLL lymphocytes are warranted.",Journal Article,840.0,1.0,Chronic lymphocytic CLL is an indolent B-cell malignancy in which cells reside in marrow lymph nodes and peripheral blood each of which provides a unique microenvironment Although the levels of certain proteins are reported to induce changes in the CLL cell proteome in the presence of marrow stromal cells have not been elucidated Reverse-phase protein array analysis of CLL cells before and 24 h after stromal cell interaction revealed changed levels of proteins that regulate cell cycle gene transcription and protein translation The most hit with respect to both the extent of change in expression level and statistical significance was caveolin-1 which was confirmed with immunoblotting Caveolin-1 mRNA levels were also upregulated in CLL cells after stromal cell interaction The induction of caveolin-1 levels was rapid and occurred as early as 1 h. Studies to determine the significance of upregulated caveolin-1 levels in CLL lymphocytes are warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 35, 2316, 132, 31, 710, 4, 92, 37, 10114, 4, 581, 263, 502, 2, 672, 315, 296, 1, 92, 777, 8, 991, 995, 242, 3, 148, 1, 1840, 652, 32, 210, 6, 1290, 400, 4, 3, 552, 31, 9895, 4, 3, 463, 1, 581, 1126, 37, 47, 44, 85, 3901, 1772, 124, 178, 1926, 65, 1, 552, 37, 348, 2, 259, 555, 50, 1126, 31, 915, 553, 2368, 148, 1, 652, 17, 2288, 31, 417, 145, 866, 2, 178, 2691, 3, 96, 6519, 5, 2184, 6, 110, 3, 1039, 1, 707, 4, 55, 301, 2, 1050, 724, 10, 8528, 14, 92, 10, 557, 5, 5293, 8528, 14, 956, 148, 11, 120, 2684, 4, 552, 37, 50, 1126, 31, 915, 3, 504, 1, 8528, 14, 148, 10, 1321, 2, 489, 22, 191, 22, 14, 555, 94, 6, 223, 3, 724, 1, 2684, 8528, 14, 148, 4, 552, 1594, 32, 1197]",959.0,28971726,707
"CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2017-10-06,"CD200, a marker currently utilized in the diagnosis of B-cell lymphoma, is uniformly positive in chronic lymphocytic leukemia/chronic lymphocytic leukemia, and is usually absent in mantle cell lymphoma. Over a 6 year-period, of 668 mantle cell lymphoma assessed by flow cytometry, CD200 expression was detected in 25 patients (~4%). All 25 patients had bone marrow involvement; however, 11 (44%) patients had no nodal or extranodal disease and belonged to non-nodal leukemic variant mantle cell lymphoma. Morphologically, bone marrow showed an unusual interstitial infiltrative pattern in 14/25 (56%) and small round cells resembling chronic lymphocytic leukemia in 9/25 (36%). CD23 was positive in 19/25 (76%) patients; and SOX11 was only positive in 5/21(24%). All 4 patients tested showed IGHV mutations. With a median follow-up of 23 months, 12/24 (50%) patients were not treated. These clinicopathological features were significantly different from 154 randomly chosen CD200-negative mantle cell lymphoma patients, in SOX11 positivity (24% versus 74%, P<0.0001), CD23 expression (76% versus 8%, P<0.0001), a non-nodal leukemic presentation (44% versus 2%, P<0.001), and therapy requirement (50% versus 92%, P<0.0001). This is the first study to show that CD200 expression in mantle cell lymphoma, though uncommon, identifies a subgroup of mantle cell lymphoma patients with characteristic pathological features, frequent non-nodal leukemic variant, and an indolent clinical course.",Journal Article,837.0,17.0,CD200 a marker currently utilized in the diagnosis of B-cell is uniformly positive in chronic lymphocytic leukemia/chronic lymphocytic and is usually absent in mantle cell Over a 6 year-period of 668 mantle cell assessed by flow cytometry CD200 expression was detected in 25 patients ~4 All 25 patients had marrow involvement however 11 44 patients had no nodal or extranodal disease and belonged to non-nodal leukemic variant mantle cell Morphologically marrow showed an unusual interstitial infiltrative pattern in 14/25 56 and small round cells resembling chronic lymphocytic in 9/25 36 CD23 was positive in 19/25 76 patients and SOX11 was only positive in 5/21 24 All 4 patients tested showed IGHV mutations With a median follow-up of 23 months 12/24 50 patients were not treated These clinicopathological features were significantly different from 154 randomly chosen CD200-negative mantle cell patients in SOX11 positivity 24 versus 74 P 0.0001 CD23 expression 76 versus 8 P 0.0001 a non-nodal leukemic presentation 44 versus 2 P 0.001 and therapy requirement 50 versus 92 P 0.0001 This is the first study to show that CD200 expression in mantle cell though uncommon identifies a subgroup of mantle cell patients with characteristic pathological features frequent non-nodal leukemic variant and an indolent clinical course,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[20730, 8, 952, 694, 2080, 4, 3, 147, 1, 132, 31, 16, 4254, 109, 4, 442, 1193, 2647, 442, 1193, 2, 16, 2082, 3269, 4, 2757, 31, 252, 8, 49, 111, 727, 1, 13642, 2757, 31, 275, 20, 1412, 1914, 20730, 55, 10, 530, 4, 243, 7, 39, 62, 243, 7, 42, 581, 799, 137, 175, 584, 7, 42, 77, 779, 15, 4093, 34, 2, 18983, 6, 220, 779, 2015, 1142, 2757, 31, 6204, 581, 224, 35, 4015, 4543, 6010, 1177, 4, 213, 243, 664, 2, 302, 4436, 37, 8855, 442, 1193, 4, 83, 243, 511, 9937, 10, 109, 4, 326, 243, 846, 7, 2, 13428, 10, 158, 109, 4, 33, 239, 259, 62, 39, 7, 650, 224, 6220, 138, 5, 8, 52, 166, 126, 1, 382, 53, 133, 259, 212, 7, 11, 44, 73, 46, 2721, 404, 11, 97, 338, 29, 4838, 1108, 4695, 20730, 199, 2757, 31, 7, 4, 13428, 1887, 259, 185, 794, 19, 13, 488, 9937, 55, 846, 185, 66, 19, 13, 488, 8, 220, 779, 2015, 1031, 584, 185, 18, 19, 13, 144, 2, 36, 4701, 212, 185, 937, 19, 13, 488, 26, 16, 3, 157, 45, 6, 514, 17, 20730, 55, 4, 2757, 31, 2471, 2052, 2953, 8, 1363, 1, 2757, 31, 7, 5, 2037, 1301, 404, 908, 220, 779, 2015, 1142, 2, 35, 2316, 38, 906]",1328.0,28984300,516
"Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-10-13,"Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor (CAR) therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The toxicities of this treatment include B cell aplasia, cytokine release syndrome (CRS), and neurotoxicity. Although reversible in most instances, these toxicities may require specific medical interventions, including transfer to intensive care to treat severe CRS. Guidelines for managing these toxicities are emerging. The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome. Finally, new engineering modalities, based on the use of targeted nucleases like CRISPR, may further enhance the efficacy and safety of CAR T cells.",Journal Article,830.0,14.0,Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor CAR therapy CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced CARs targeting CD19 a cell surface molecule found in most leukemias and lymphomas have yielded high remission rates in patients with chemorefractory relapsed disease including acute lymphoblastic chronic lymphocytic and The toxicities of this treatment include B cell aplasia cytokine release syndrome CRS and neurotoxicity Although reversible in most instances these toxicities may require specific medical interventions including transfer to intensive care to treat severe CRS Guidelines for managing these toxicities are emerging The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome Finally new engineering modalities based on the use of targeted nucleases like CRISPR may further enhance the efficacy and safety of CAR T cells,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[189, 102, 31, 6717, 71, 761, 21476, 3029, 1333, 408, 1, 3, 1825, 1, 3158, 2897, 448, 153, 1881, 36, 7441, 32, 3273, 1186, 9, 448, 17, 14744, 3, 1121, 2, 14947, 3, 343, 1, 3, 102, 37, 4, 92, 491, 32, 2301, 3955, 7441, 529, 3158, 8, 31, 1255, 1354, 204, 4, 96, 2792, 2, 1557, 47, 2178, 64, 734, 151, 4, 7, 5, 8923, 591, 34, 141, 286, 1275, 442, 1193, 2, 3, 385, 1, 26, 24, 643, 132, 31, 12307, 1675, 2008, 681, 3115, 2, 3561, 242, 2786, 4, 96, 5342, 46, 385, 68, 1353, 112, 484, 1151, 141, 2602, 6, 1686, 165, 6, 943, 905, 3115, 677, 9, 3969, 46, 385, 32, 1478, 3, 435, 414, 1, 8, 23273, 25233, 202, 9, 3115, 16, 13970, 6, 987, 3148, 3, 284, 1, 26, 681, 1368, 217, 6717, 1558, 90, 23, 3, 119, 1, 238, 36375, 733, 7736, 68, 195, 1304, 3, 209, 2, 367, 1, 1881, 102, 37]",1085.0,29032264,29
Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-10-12,"Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the only known curative treatment for CLL. The potential benefit of transplantation is most likely due to the presence of alloreactive donor T cells that mediate the graft-versus-leukemia (GVL) effect. The recognition of potentially tumor-specific antigens in the context of class I and II major histocompatibility complex on malignant B lymphocytes by donor T cells may be influenced by subtle differences in the highly polymorphic HLA locus. Given previous reports of specific HLA alleles impacting the incidence of CLL and the clinical outcomes of allo-HCT for CLL, we sought to study the overall survival and progression-free survival of a large cohort of patients with CLL who underwent allo-HCT from fully HLA-matched related and unrelated donors at Center for International Blood and Marrow Transplant Research transplantation centers. We found no statistically significant association of allo-HCT outcomes in CLL based on previously reported HLA combinations. Additional study is needed to further define the immunologic features that portend a more favorable GVL effect after allo-HCT for CLL.",Journal Article,831.0,1.0,Chronic lymphocytic CLL is a common hematologic malignancy with many highly effective therapies Chemorefractory disease often characterized by deletion of chromosome 17p has historically been associated with very poor outcomes leading to the application of allogeneic hematopoietic stem cell transplantation allo-HCT for medically fit patients Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL there remains significant interest in understanding factors that may influence the efficacy of allo-HCT the only known curative treatment for CLL The potential benefit of transplantation is most likely due to the presence of alloreactive donor T cells that mediate the graft-versus-leukemia GVL effect The recognition of potentially tumor-specific antigens in the context of class I and II major histocompatibility complex on malignant B lymphocytes by donor T cells may be influenced by subtle differences in the highly polymorphic HLA locus Given previous reports of specific HLA alleles impacting the incidence of CLL and the clinical outcomes of allo-HCT for CLL we sought to study the overall survival and progression-free survival of a large cohort of patients with CLL who underwent allo-HCT from fully HLA-matched related and unrelated donors at Center for International Blood and Marrow Transplant Research transplantation centers We found no statistically significant association of allo-HCT outcomes in CLL based on previously reported HLA combinations Additional study is needed to further define the immunologic features that portend a more favorable GVL effect after allo-HCT for CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 8, 186, 813, 710, 5, 445, 561, 323, 235, 8923, 34, 629, 765, 20, 1528, 1, 1170, 4135, 71, 3578, 85, 41, 5, 923, 334, 123, 1049, 6, 3, 1581, 1, 1063, 1007, 452, 31, 497, 2564, 1085, 9, 4381, 2975, 7, 242, 3, 119, 1, 2564, 1085, 71, 3054, 1192, 3, 2456, 1, 229, 238, 36, 9, 3, 24, 1, 552, 125, 469, 93, 1333, 4, 612, 130, 17, 68, 1054, 3, 209, 1, 2564, 1085, 3, 158, 440, 1075, 24, 9, 552, 3, 174, 247, 1, 497, 16, 96, 322, 520, 6, 3, 463, 1, 13831, 1488, 102, 37, 17, 3367, 3, 1599, 185, 2647, 8149, 254, 3, 2335, 1, 751, 30, 112, 1575, 4, 3, 1533, 1, 1040, 70, 2, 215, 458, 6537, 840, 23, 393, 132, 1594, 20, 1488, 102, 37, 68, 40, 2574, 20, 7543, 362, 4, 3, 561, 7087, 1160, 2474, 447, 698, 1198, 1, 112, 1160, 2558, 8661, 3, 287, 1, 552, 2, 3, 38, 123, 1, 2564, 1085, 9, 552, 21, 990, 6, 45, 3, 63, 25, 2, 91, 115, 25, 1, 8, 375, 180, 1, 7, 5, 552, 54, 208, 2564, 1085, 29, 1910, 1160, 655, 139, 2, 2092, 2344, 28, 574, 9, 944, 315, 2, 581, 941, 389, 497, 1168, 21, 204, 77, 712, 93, 248, 1, 2564, 1085, 123, 4, 552, 90, 23, 373, 210, 1160, 1247, 402, 45, 16, 575, 6, 195, 1107, 3, 3042, 404, 17, 11293, 8, 80, 913, 8149, 254, 50, 2564, 1085, 9, 552]",1657.0,29032274,427
Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2017-10-12,"Recent studies have shown dismal outcomes when chronic lymphocytic leukemia progresses to Richter syndrome after patients receive ibrutinib, with a median overall survival ranging from 2.6 to 3.5 months. Published data on efficacy of allogeneic hematopoietic cell transplantation in Richter syndrome are limited to single-center case series and registry data. We evaluated the efficacy of allogeneic transplantation in 10 patients, median age of 63 (range, 50-74) years, allografted at a median of 5 (range, 4-25) months from diagnosis of Richter syndrome. All showed an objective response to therapy before transplantation (first complete remission= 7 [70%], first partial response= 2 [20%], second partial response= 1 [10%]). Most received a myeloablative conditioning regimen (n = 7, 70%). Filgrastim-mobilized peripheral blood stem cells was the preferred cell source (n = 10, 100%). Median follow-up of surviving patients was 46 (range, 15-82) months. The 4-year overall survival was 50% (95% confidence interval [CI], 19%-81%). Nonrelapse mortality at 1 year and 4 years post-transplantation were 40% (95% CI, 19%-85%) for both time points. The 4-year incidence of relapse/progression was 10% (95% CI, 2%-64%). Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome who show an objective response before allografting. Patients must be referred to transplant centers as soon as the diagnosis is confirmed to evaluate candidacy for the procedure and identify a suitable donor in a timely manner.",Journal Article,831.0,3.0,Recent studies have shown dismal outcomes when chronic lymphocytic progresses to Richter syndrome after patients receive ibrutinib with a median overall survival ranging from 2.6 to 3.5 months Published data on efficacy of allogeneic hematopoietic cell transplantation in Richter syndrome are limited to single-center case series and registry data We evaluated the efficacy of allogeneic transplantation in 10 patients median age of 63 range 50-74 years allografted at a median of 5 range 4-25 months from diagnosis of Richter syndrome All showed an objective response to therapy before transplantation first complete remission 7 70 first partial response 2 20 second partial response 1 10 Most received a myeloablative conditioning regimen n 7 70 Filgrastim-mobilized peripheral blood stem cells was the preferred cell source n 10 100 Median follow-up of surviving patients was 46 range 15-82 months The 4-year overall survival was 50 95 confidence interval CI 19 -81 Nonrelapse mortality at 1 year and 4 years post-transplantation were 40 95 CI 19 -85 for both time points The 4-year incidence of relapse/progression was 10 95 CI 2 -64 Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome who show an objective response before allografting Patients must be referred to transplant centers as soon as the diagnosis is confirmed to evaluate candidacy for the procedure and identify a suitable donor in a timely manner,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[435, 94, 47, 443, 3929, 123, 198, 442, 1193, 6752, 6, 8452, 681, 50, 7, 560, 1795, 5, 8, 52, 63, 25, 2223, 29, 18, 49, 6, 27, 33, 53, 983, 74, 23, 209, 1, 1063, 1007, 31, 497, 4, 8452, 681, 32, 383, 6, 226, 574, 473, 988, 2, 1608, 74, 21, 194, 3, 209, 1, 1063, 497, 4, 79, 7, 52, 89, 1, 676, 184, 212, 794, 60, 41899, 28, 8, 52, 1, 33, 184, 39, 243, 53, 29, 147, 1, 8452, 681, 62, 224, 35, 461, 51, 6, 36, 348, 497, 157, 236, 734, 67, 431, 157, 450, 51, 18, 179, 419, 450, 51, 14, 79, 96, 103, 8, 3246, 1933, 477, 78, 67, 431, 5552, 7695, 672, 315, 452, 37, 10, 3, 2514, 31, 2353, 78, 79, 394, 52, 166, 126, 1, 3050, 7, 10, 641, 184, 167, 878, 53, 3, 39, 111, 63, 25, 10, 212, 48, 307, 268, 58, 326, 865, 4640, 282, 28, 14, 111, 2, 39, 60, 539, 497, 11, 327, 48, 58, 326, 772, 9, 110, 98, 862, 3, 39, 111, 287, 1, 429, 91, 10, 79, 48, 58, 18, 660, 1063, 1007, 31, 497, 16, 35, 323, 24, 9, 7, 5, 8452, 681, 54, 514, 35, 461, 51, 348, 16181, 7, 1642, 40, 1995, 6, 941, 1168, 22, 6176, 22, 3, 147, 16, 557, 6, 376, 18394, 9, 3, 1299, 2, 255, 8, 2884, 1488, 4, 8, 4225, 1708]",1470.0,29126867,491
Frailty and the management of hematologic malignancies.,Blood,Blood,2017-11-15,"The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematologist, we propose elements of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frailty screening, development of disease-specific measures, and inclusion of functional and patient-reported outcomes alongside survival.",Journal Article,797.0,33.0,The majority of blood cancers occur in the elderly This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists In this review we first define frailty and its relevance for patients with hematologic malignancy Next we review current data regarding the effect of domains of frailty on outcomes for blood cancers including syndromes acute lymphomas such as chronic lymphocytic and multiple Finally after presenting assessment and treatment options for the practicing hematologist we propose elements of a new research agenda for geriatric hematology the exchange of age limits for rigorous frailty screening development of disease-specific measures and inclusion of functional and patient-reported outcomes alongside survival,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 686, 1, 315, 163, 1271, 4, 3, 1216, 26, 1991, 71574, 5, 35, 4220, 266, 4, 445, 2115, 6, 2378, 6496, 455, 9, 5289, 1635, 305, 9, 813, 1339, 4, 26, 206, 21, 157, 1107, 5289, 2, 211, 2088, 9, 7, 5, 813, 710, 1305, 21, 206, 291, 74, 666, 3, 254, 1, 2703, 1, 5289, 23, 123, 9, 315, 163, 141, 2040, 286, 1557, 225, 22, 442, 1193, 2, 232, 1368, 50, 1656, 455, 2, 24, 838, 9, 3, 6734, 15278, 21, 2548, 2531, 1, 8, 217, 389, 12402, 9, 3914, 6216, 3, 6695, 1, 89, 3526, 9, 6496, 5289, 453, 193, 1, 34, 112, 1018, 2, 1680, 1, 583, 2, 69, 210, 123, 10150, 25]",816.0,29141942,73
"Duvelisib, a novel oral dual inhibitor of PI3K-,, is clinically active in advanced hematologic malignancies.",Blood,Blood,2017-11-30,"Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase- (PI3K-) and PI3K- in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210 patients with advanced hematologic malignancies. In the dose escalation phase (n = 31), duvelisib 8 to 100 mg twice daily was administered, with MTD determined as 75 mg twice daily. In the expansion phase (n = 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma (TCL) were treated with 25 or 75 mg duvelisib twice daily continuously. Single-dose duvelisib was rapidly absorbed (time to maximum concentration, 1-2 hours), with a half-life of 5.2 to 10.9 hours. PD results showed inhibition of phospho-AKT (S473) in CLL tumor cells following a single dose and near-complete inhibition of CLL proliferation (Ki-67) by cycle 2. Clinical responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n = 55) with 1 CR; peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19). Median time to response was 1.8 months. Severe (grade 3) adverse events occurred in 84% of patients: neutropenia (32%), alanine transaminase increase (20%), aspartate transaminase increase (15%), anemia and thrombocytopenia (each 14%), diarrhea (11%), and pneumonia (10%). These data support further investigation of duvelisib in phase 2 and 3 studies. This trial was registered at clinicaltrials.gov as #NCT01476657.","Clinical Trial, Phase I",782.0,48.0,Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase- PI3K- and PI3K- in late-stage clinical development for hematologic malignancy treatment This phase 1 study evaluated maximum tolerated dose MTD pharmacokinetics pharmacodynamics PD efficacy and safety of duvelisib in 210 patients with advanced hematologic malignancies In the dose escalation phase n 31 duvelisib 8 to 100 mg twice daily was administered with MTD determined as 75 mg twice daily In the expansion phase n 179 patients with indolent iNHL chronic lymphocytic CLL or T-cell TCL were treated with 25 or 75 mg duvelisib twice daily continuously Single-dose duvelisib was rapidly absorbed time to maximum concentration 1-2 hours with a half-life of 5.2 to 10.9 hours PD results showed inhibition of phospho-AKT S473 in CLL tumor cells following a single dose and near-complete inhibition of CLL proliferation Ki-67 by cycle 2 Clinical responses were seen across a range of doses and disease subtypes iNHL overall response rate 58 n 31 with 6 complete responses CRs relapsed/refractory CLL 56 n 55 with 1 CR peripheral TCL 50 n 16 with 3 CR and cutaneous TCL 32 n 19 Median time to response was 1.8 months Severe grade 3 adverse events occurred in 84 of patients neutropenia 32 alanine transaminase increase 20 aspartate transaminase increase 15 anemia and thrombocytopenia each 14 diarrhea 11 and pneumonia 10 These data support further investigation of duvelisib in phase 2 and 3 studies This trial was registered at clinicaltrials.gov as NCT01476657,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[15080, 16, 35, 518, 1828, 230, 1, 4497, 27, 216, 7339, 974, 7339, 2, 974, 2655, 4, 807, 82, 38, 193, 9, 813, 710, 24, 26, 124, 14, 45, 194, 689, 421, 61, 961, 1159, 3587, 333, 209, 2, 367, 1, 15080, 4, 5376, 7, 5, 131, 813, 441, 4, 3, 61, 1125, 124, 78, 456, 15080, 66, 6, 394, 81, 936, 391, 10, 468, 5, 961, 509, 22, 481, 81, 936, 391, 4, 3, 1422, 124, 78, 5977, 7, 5, 2316, 27353, 442, 1193, 552, 15, 102, 31, 8885, 11, 73, 5, 243, 15, 481, 81, 15080, 936, 391, 4285, 226, 61, 15080, 10, 1755, 5249, 98, 6, 689, 1227, 14, 18, 1459, 5, 8, 1303, 358, 1, 33, 18, 6, 79, 83, 1459, 333, 99, 224, 297, 1, 3125, 649, 17019, 4, 552, 30, 37, 366, 8, 226, 61, 2, 1829, 236, 297, 1, 552, 457, 2311, 598, 20, 417, 18, 38, 253, 11, 527, 716, 8, 184, 1, 415, 2, 34, 814, 27353, 63, 51, 116, 717, 78, 456, 5, 49, 236, 253, 3115, 591, 430, 552, 664, 78, 614, 5, 14, 684, 672, 8885, 212, 78, 245, 5, 27, 684, 2, 1486, 8885, 531, 78, 326, 52, 98, 6, 51, 10, 22785, 66, 53, 905, 88, 2608, 290, 281, 489, 4, 874, 1, 7, 778, 531, 5411, 6997, 344, 179, 6308, 6997, 344, 167, 1545, 2, 1340, 296, 213, 1172, 175, 2, 3485, 79, 46, 74, 538, 195, 940, 1, 15080, 4, 124, 18, 2, 27, 94, 26, 160, 10, 1653, 28, 1252, 1239, 22, 50734]",1531.0,29191916,444
"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.",The Lancet. Oncology,Lancet Oncol.,2017-12-12,"Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy. In this interim analysis of a multicentre, open-label, non-randomised, phase 2 trial, we enrolled patients aged 18 years or older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance score of 2 or lower. All patients had relapsed or refractory disease after previous treatment with a BCR signalling pathway inhibitor. All patients were screened for Richter's transformation and cases confirmed by biopsy were excluded. Eligible patients received oral venetoclax, starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day. Patients with rapidly progressing disease received an accelerated dosing schedule (to 400 mg per day by week 3). The primary endpoint was overall response, defined as the proportion of patients with an overall response per investigator's assessment according to IWCLL criteria. All patients who received at least one dose of venetoclax were included in the activity and safety analyses. This study is ongoing; data for this interim analysis were collected per regulatory agencies' request as of June 30, 2017. This trial is registered with ClinicalTrials.gov, number NCT02141282. Between September, 2014, and November, 2016, 127 previously treated patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled from 15 sites across the USA. 91 patients had received ibrutinib as the last BCR inhibitor therapy before enrolment, 43 of whom were enrolled in the main cohort and 48 in the expansion cohort recruited later after a protocol amendment. At the time of analysis, the median follow-up was 14 months (IQR 8-18) for all 91 patients, 19 months (9-27) for the main cohort, and 12 months (8-15) for the expansion cohort. 59 (65%, 95% CI 53-74) of 91 patients had an overall response, including 30 (70%, 54-83) of 43 patients in the main cohort and 29 (60%, 43-72) of 48 patients in the expansion cohort. The most common treatment-emergent grade 3 or 4 adverse events were neutropenia (46 [51%] of 91 patients), thrombocytopenia (26 [29%]), anaemia (26 [29%]), decreased white blood cell count (17 [19%]), and decreased lymphocyte count (14 [15%]). 17 (19%) of 91 patients died, including seven because of disease progression. No treatment-related deaths occurred. The results of this interim analysis show that venetoclax has durable clinical activity and favourable tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or after discontinutation of ibrutinib therapy. The durability of response to venetoclax will be assessed in the final analysis in 2019. AbbVie, Genentech.","Clinical Trial, Phase II",770.0,80.0,Therapy targeting Bruton 's tyrosine kinase BTK with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia However patients who are refractory to or relapse after ibrutinib therapy have poor outcomes Venetoclax is a selective orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia In this study we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy In this interim analysis of a multicentre open-label non-randomised phase 2 trial we enrolled patients aged 18 years or older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 International Workshop on Chronic Lymphocytic IWCLL criteria and an Eastern Cooperative Oncology Group performance score of 2 or lower All patients had relapsed or refractory disease after previous treatment with a BCR signalling pathway inhibitor All patients were screened for Richter 's transformation and cases confirmed by biopsy were excluded Eligible patients received oral venetoclax starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day Patients with rapidly progressing disease received an accelerated dosing schedule to 400 mg per day by week 3 The primary endpoint was overall response defined as the proportion of patients with an overall response per investigator 's assessment according to IWCLL criteria All patients who received at least one dose of venetoclax were included in the activity and safety analyses This study is ongoing data for this interim analysis were collected per regulatory agencies request as of June 30 2017 This trial is registered with ClinicalTrials.gov number NCT02141282 Between September 2014 and November 2016 127 previously treated patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled from 15 sites across the USA 91 patients had received ibrutinib as the last BCR inhibitor therapy before enrolment 43 of whom were enrolled in the main cohort and 48 in the expansion cohort recruited later after a protocol amendment At the time of analysis the median follow-up was 14 months IQR 8-18 for all 91 patients 19 months 9-27 for the main cohort and 12 months 8-15 for the expansion cohort 59 65 95 CI 53-74 of 91 patients had an overall response including 30 70 54-83 of 43 patients in the main cohort and 29 60 43-72 of 48 patients in the expansion cohort The most common treatment-emergent grade 3 or 4 adverse events were neutropenia 46 51 of 91 patients thrombocytopenia 26 29 anaemia 26 29 decreased white blood cell count 17 19 and decreased lymphocyte count 14 15 17 19 of 91 patients died including seven because of disease progression No treatment-related deaths occurred The results of this interim analysis show that venetoclax has durable clinical activity and favourable tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or after discontinutation of ibrutinib therapy The durability of response to venetoclax will be assessed in the final analysis in 2019 AbbVie Genentech,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[36, 529, 5796, 292, 564, 216, 3611, 5, 1795, 71, 2423, 3, 24, 1, 442, 1193, 2001, 137, 7, 54, 32, 430, 6, 15, 429, 50, 1795, 36, 47, 334, 123, 4454, 16, 8, 1094, 1428, 6582, 230, 1, 1044, 18, 544, 4, 373, 73, 7, 5, 591, 15, 430, 442, 1193, 2001, 4, 26, 45, 21, 275, 3, 128, 2, 367, 1, 4454, 4, 7, 5, 442, 1193, 2001, 54, 32, 430, 6, 15, 429, 190, 15, 50, 1795, 36, 4, 26, 2914, 65, 1, 8, 5761, 1020, 1756, 220, 2827, 124, 18, 160, 21, 346, 7, 1032, 203, 60, 15, 434, 5, 8, 1405, 147, 1, 442, 1193, 2001, 768, 6, 3, 1375, 944, 4014, 23, 442, 1193, 16575, 371, 2, 35, 2118, 1690, 413, 87, 528, 368, 1, 18, 15, 280, 62, 7, 42, 591, 15, 430, 34, 50, 698, 24, 5, 8, 1062, 3128, 308, 230, 62, 7, 11, 2261, 9, 8452, 292, 1392, 2, 140, 557, 20, 411, 11, 1800, 625, 7, 103, 518, 4454, 1723, 28, 179, 81, 379, 218, 5, 5497, 61, 20047, 126, 252, 33, 244, 6, 1524, 81, 379, 218, 7, 5, 1755, 4527, 34, 103, 35, 2241, 1280, 1055, 6, 1524, 81, 379, 218, 20, 647, 27, 3, 86, 1138, 10, 63, 51, 395, 22, 3, 920, 1, 7, 5, 35, 63, 51, 379, 3464, 292, 455, 768, 6, 16575, 371, 62, 7, 54, 103, 28, 506, 104, 61, 1, 4454, 11, 159, 4, 3, 128, 2, 367, 318, 26, 45, 16, 942, 74, 9, 26, 2914, 65, 11, 786, 379, 1253, 8968, 11660, 22, 1, 1924, 201, 1759, 26, 160, 16, 1653, 5, 1252, 1239, 207, 50773, 59, 2636, 1409, 2, 2868, 1390, 4080, 373, 73, 7, 5, 591, 15, 430, 442, 1193, 2001, 11, 346, 29, 167, 633, 716, 3, 2706, 970, 7, 42, 103, 1795, 22, 3, 1060, 1062, 230, 36, 348, 8206, 601, 1, 953, 11, 346, 4, 3, 1895, 180, 2, 576, 4, 3, 1422, 180, 2619, 1559, 50, 8, 1182, 11013, 28, 3, 98, 1, 65, 3, 52, 166, 126, 10, 213, 53, 2245, 66, 203, 9, 62, 970, 7, 326, 53, 83, 428, 9, 3, 1895, 180, 2, 133, 53, 66, 167, 9, 3, 1422, 180, 728, 556, 48, 58, 699, 794, 1, 970, 7, 42, 35, 63, 51, 141, 201, 431, 667, 852, 1, 601, 7, 4, 3, 1895, 180, 2, 462, 335, 601, 720, 1, 576, 7, 4, 3, 1422, 180, 3, 96, 186, 24, 4348, 88, 27, 15, 39, 290, 281, 11, 778, 641, 725, 1, 970, 7, 1340, 432, 462, 5712, 432, 462, 340, 886, 315, 31, 1276, 269, 326, 2, 340, 1448, 1276, 213, 167, 269, 326, 1, 970, 7, 1016, 141, 648, 408, 1, 34, 91, 77, 24, 139, 1043, 489, 3, 99, 1, 26, 2914, 65, 514, 17, 4454, 71, 1480, 38, 128, 2, 6816, 1543, 4, 7, 5, 591, 15, 430, 442, 1193, 2001, 1310, 34, 1839, 190, 15, 50, 50774, 1, 1795, 36, 3, 6867, 1, 51, 6, 4454, 303, 40, 275, 4, 3, 1457, 65, 4, 20629, 18697, 9010]",3218.0,29246803,391
Cytokine release syndrome after radiation therapy: case report and review of the literature.,Journal for immunotherapy of cancer,J Immunother Cancer,2018-01-03,"Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not been reported before. The development of unusual clinical signs and symptoms after RT led us to investigate the possibility of CRS after RT and review the medical literature on this topic. A 65year-old man with untreated chronic lymphocytic leukemia and recurrent, metastatic Merkel cell carcinoma undergoing anti-programmed death 1 (PD1) immunotherapy was referred for palliative RT to sites of progressing metastases. Within hours of each weekly dose of RT, he experienced fever, tachycardia, hypotension, rash, dyspnea, and rigors. Based on clinical suspicion for CRS, blood cytokine measurements were performed 1 h after the second and third dose of RT and demonstrated tumor necrosis factor alpha (TNF-) and interleukin-6 (IL-6) levels approximately ten-fold higher than normal. These were near normal immediately prior to the third dose of RT, and resolved to normal levels 3weeks after RT. He experienced rapid regression of irradiated tumors, with development of new sites of metastases soon thereafter. A literature review revealed no clinical cases of CRS after RT for cancer. RT during anti-PD1 immunotherapy in a patient with underlying immune dysfunction appeared to be the putative mediator of an immune process which yielded significant increases in pro-inflammatory cytokines, and produced the clinical symptoms meeting the definition of grade 3 CRS. This case demonstrates the capability of RT to elicit immune-related adverse events.",Case Reports,748.0,3.0,Cytokine release syndrome CRS has been reported after immunologic manipulations most often through therapeutic monoclonal antibodies To our knowledge CRS after radiation therapy RT for cancer has not been reported before The development of unusual clinical signs and symptoms after RT led us to investigate the possibility of CRS after RT and review the medical literature on this topic A 65 year-old man with untreated chronic lymphocytic and recurrent metastatic Merkel cell carcinoma undergoing anti-programmed death 1 PD1 immunotherapy was referred for palliative RT to sites of progressing metastases Within hours of each weekly dose of RT he experienced fever tachycardia hypotension rash dyspnea and rigors Based on clinical suspicion for CRS blood cytokine measurements were performed 1 h after the second and third dose of RT and demonstrated tumor necrosis factor alpha TNF- and interleukin-6 IL-6 levels approximately ten-fold higher than normal These were near normal immediately prior to the third dose of RT and resolved to normal levels 3 weeks after RT He experienced rapid regression of irradiated tumors with development of new sites of metastases soon thereafter A literature review revealed no clinical cases of CRS after RT for cancer RT during anti-PD1 immunotherapy in a patient with underlying immune dysfunction appeared to be the putative mediator of an immune process which yielded significant increases in pro-inflammatory cytokines and produced the clinical symptoms meeting the definition of grade 3 CRS This case demonstrates the capability of RT to elicit immune-related adverse events,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1675, 2008, 681, 3115, 71, 85, 210, 50, 3042, 13775, 96, 629, 298, 189, 848, 890, 6, 114, 922, 3115, 50, 121, 36, 240, 9, 12, 71, 44, 85, 210, 348, 3, 193, 1, 4015, 38, 3408, 2, 507, 50, 240, 836, 843, 6, 963, 3, 2526, 1, 3115, 50, 240, 2, 206, 3, 484, 789, 23, 26, 5463, 8, 556, 111, 1095, 3628, 5, 1278, 442, 1193, 2, 387, 113, 5855, 31, 134, 479, 312, 1846, 273, 14, 4893, 726, 10, 1995, 9, 994, 240, 6, 633, 1, 4527, 196, 262, 1459, 1, 296, 709, 61, 1, 240, 3174, 592, 2775, 12177, 6577, 1641, 2923, 2, 16755, 90, 23, 38, 5782, 9, 3115, 315, 1675, 1685, 11, 173, 14, 555, 50, 3, 419, 2, 1282, 61, 1, 240, 2, 264, 30, 1523, 161, 950, 2254, 2014, 2, 1603, 49, 501, 49, 148, 705, 1618, 1116, 142, 76, 295, 46, 11, 1829, 295, 3467, 324, 6, 3, 1282, 61, 1, 240, 2, 3862, 6, 295, 148, 27, 244, 50, 240, 3174, 592, 1321, 320, 1, 2398, 57, 5, 193, 1, 217, 633, 1, 196, 6176, 3972, 8, 789, 206, 553, 77, 38, 140, 1, 3115, 50, 240, 9, 12, 240, 190, 312, 4893, 726, 4, 8, 69, 5, 1181, 250, 1527, 2121, 6, 40, 3, 2743, 3810, 1, 35, 250, 1129, 92, 2178, 93, 1106, 4, 1805, 1291, 1886, 2, 1687, 3, 38, 507, 2238, 3, 2470, 1, 88, 27, 3115, 26, 473, 1902, 3, 6188, 1, 240, 6, 5487, 250, 139, 290, 281]",1618.0,29298730,400
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.,The Journal of experimental medicine,J. Exp. Med.,2018-01-04,"The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating to retain the tumor cells in nodal compartments. Here, we show that the VLA-4 integrin, as expressed by CD49d-positive CLL, can be inside-out activated upon BCR triggering, thus reinforcing the adhesive capacities of CLL cells. In vitro and in vivo ibrutinib treatment, although reducing the constitutive VLA-4 activation and cell adhesion, can be overcome by exogenous BCR triggering in a BTK-independent manner involving PI3K. Clinically, in three independent ibrutinib-treated CLL cohorts, CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival, suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4. Evaluation of CD49d expression should be incorporated in the characterization of CLL undergoing therapy with BCR inhibitors.",Journal Article,747.0,10.0,The Bruton 's tyrosine kinase BTK inhibitor ibrutinib which antagonizes B cell receptor BCR signals demonstrates remarkable clinical activity in chronic lymphocytic CLL The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating to retain the tumor cells in nodal compartments Here we show that the VLA-4 integrin as expressed by CD49d-positive CLL can be inside-out activated upon BCR triggering thus reinforcing the adhesive capacities of CLL cells In vitro and in vivo ibrutinib treatment although reducing the constitutive VLA-4 activation and cell adhesion can be overcome by exogenous BCR triggering in a BTK-independent manner involving PI3K Clinically in three independent ibrutinib-treated CLL cohorts CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4 Evaluation of CD49d expression should be incorporated in the characterization of CLL undergoing therapy with BCR inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 5796, 292, 564, 216, 3611, 230, 1795, 92, 11574, 132, 31, 153, 1062, 2312, 1902, 3813, 38, 128, 4, 442, 1193, 552, 3, 8125, 592, 20, 96, 7, 669, 1795, 71, 373, 85, 3073, 6, 297, 1, 3611, 470, 2876, 2, 3596, 15209, 2584, 6, 6630, 3, 30, 37, 4, 779, 6473, 467, 21, 514, 17, 3, 25319, 39, 2876, 22, 570, 20, 10485, 109, 552, 122, 40, 8133, 1205, 735, 1548, 1062, 8867, 631, 18356, 3, 18897, 14866, 1, 552, 37, 4, 439, 2, 4, 386, 1795, 24, 242, 1818, 3, 3178, 25319, 39, 363, 2, 31, 2128, 122, 40, 1768, 20, 4181, 1062, 8867, 4, 8, 3611, 306, 1708, 1267, 974, 505, 4, 169, 306, 1795, 73, 552, 736, 10485, 55, 2953, 140, 5, 405, 8125, 2, 1663, 779, 51, 2, 16771, 22, 306, 980, 1, 985, 91, 115, 25, 802, 3, 3947, 1, 10485, 1046, 552, 37, 4, 246, 633, 847, 735, 25319, 39, 451, 1, 10485, 55, 257, 40, 2449, 4, 3, 2136, 1, 552, 479, 36, 5, 1062, 222]",1191.0,29301866,31
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.,Blood,Blood,2018-01-05,"B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib; here we report on patients who received idelalisib as the last BCRi before enrollment. Venetoclax was initiated at 20 mg daily, followed by intrapatient ramp-up to 400 mg daily. Primary objectives included efficacy (objective response rate [ORR]) and safety of venetoclax. The study enrolled 36 patients who previously received idelalisib (ORR, 67% [24/36]); 2 patients achieved complete remission, and 1 had complete remission with incomplete bone marrow recovery. Median progression-free survival (PFS) has not yet been reached; estimated 12-month PFS was 79%. The most common adverse events (AEs; all grades) were neutropenia (56%), diarrhea (42%), upper respiratory tract infection (39%), thrombocytopenia (36%), nausea (31%), fatigue (28%), cough (22%), rash (22%), and anemia (22%). Grade 3 or 4 AEs were primarily hematologic (neutropenia [50%], thrombocytopenia [25%], and anemia [17%]). No patients experienced tumor lysis syndrome. Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy. This trial was registered at www.clinicaltrials.gov as #NCT02141282.","Clinical Trial, Phase II",746.0,36.0,B-cell receptor pathway inhibitors BCRis have transformed treatment of chronic lymphocytic CLL however the efficacy of therapies for patients whose disease is refractory to/relapses after R/R BCRis is unknown Venetoclax is a selective orally bioavailable BCL-2 inhibitor with activity in patients with CLL including those who are heavily pretreated or have 17p deletion This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib here we report on patients who received idelalisib as the last BCRi before enrollment Venetoclax was initiated at 20 mg daily followed by intrapatient ramp-up to 400 mg daily Primary objectives included efficacy objective response rate ORR and safety of venetoclax The study enrolled 36 patients who previously received idelalisib ORR 67 24/36 2 patients achieved complete remission and 1 had complete remission with incomplete marrow recovery Median progression-free survival PFS has not yet been reached estimated 12-month PFS was 79 The most common adverse events AEs all grades were neutropenia 56 diarrhea 42 upper respiratory tract infection 39 thrombocytopenia 36 nausea 31 fatigue 28 cough 22 rash 22 and anemia 22 Grade 3 or 4 AEs were primarily hematologic neutropenia 50 thrombocytopenia 25 and anemia 17 No patients experienced tumor lysis syndrome Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy This trial was registered at www.clinicaltrials.gov as NCT02141282,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[132, 31, 153, 308, 222, 50802, 47, 2423, 24, 1, 442, 1193, 552, 137, 3, 209, 1, 235, 9, 7, 1310, 34, 16, 430, 6, 3713, 50, 668, 668, 50802, 16, 860, 4454, 16, 8, 1094, 1428, 6582, 1044, 18, 230, 5, 128, 4, 7, 5, 552, 141, 135, 54, 32, 2447, 2193, 15, 47, 4135, 1528, 26, 124, 18, 45, 1143, 194, 4454, 4, 7, 5, 668, 668, 552, 50, 1795, 15, 7083, 467, 21, 414, 23, 7, 54, 103, 7083, 22, 3, 1060, 41950, 348, 1798, 4454, 10, 1917, 28, 179, 81, 391, 370, 20, 9838, 20047, 126, 6, 1524, 81, 391, 86, 2409, 159, 209, 461, 51, 116, 1735, 2, 367, 1, 4454, 3, 45, 346, 511, 7, 54, 373, 103, 7083, 1735, 598, 259, 511, 18, 7, 513, 236, 734, 2, 14, 42, 236, 734, 5, 2610, 581, 1602, 52, 91, 115, 25, 300, 71, 44, 1145, 85, 1300, 661, 133, 811, 300, 10, 842, 3, 96, 186, 290, 281, 1477, 62, 2276, 11, 778, 664, 1172, 595, 1726, 2718, 1696, 930, 587, 1340, 511, 1218, 456, 613, 339, 6546, 350, 1641, 350, 2, 1545, 350, 88, 27, 15, 39, 1477, 11, 1561, 813, 778, 212, 1340, 243, 2, 1545, 269, 77, 7, 592, 30, 4783, 681, 4454, 264, 721, 38, 128, 2, 913, 1543, 4, 7, 5, 552, 1310, 34, 1839, 190, 15, 50, 7083, 36, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 50773]",1566.0,29305552,512
Useful information provided by graphic displays of automated cell counter in hematological malignancies.,Journal of clinical laboratory analysis,J. Clin. Lab. Anal.,2018-01-21,"Automated cell counters have become more and more sophisticated with passing years. The numerical and graphic data both provide useful clues for suspecting a diagnosis especially when the workload is very high. We present our experience of useful information provided by graphic displays of an automated cell counter in hematological malignancies in a cancer hospital where a large number of complete blood count (CBC) requests are received either before or during chemotherapy. This study was conducted to assess the usefulness of hematology cell counter, viz. WBC-Diff (WBC differential), WBC/BASO (WBC basophil) and IMI (immature myeloid information) channel scatter plots, and the flaggings generated in various hematological malignancies. The graphic displays have been compiled over a period of 1 year (October 2015-September 2016) from blood samples of various solid and hematological malignancies (approximately 400 per day) received for routine CBC in the laboratory. Approximately 50000 scattergrams have been analyzed during the study period. The findings were confirmed by peripheral blood smear examination. The scattergram analysis on XE-2100 is very sensitive as well as specific for diagnosing acute leukemia, viz. acute myeloid leukemia, acute lymphoblastic leukemia; chronic myeloproliferative disorders, viz. chronic myeloid leukemia; and chronic lymphoproliferative disorder especially chronic lymphocytic leukemia. It is suggested that the laboratories using the hematology analyzers be aware of graphic display patterns in addition to flaggings generated which provide additional information and give clue toward the diagnosis even before peripheral smear examination.",Journal Article,730.0,0.0,Automated cell counters have become more and more sophisticated with passing years The numerical and graphic data both provide useful clues for suspecting a diagnosis especially when the workload is very high We present our experience of useful information provided by graphic displays of an automated cell counter in hematological malignancies in a cancer hospital where a large number of complete blood count CBC requests are received either before or during chemotherapy This study was conducted to assess the usefulness of hematology cell counter viz WBC-Diff WBC differential WBC/BASO WBC basophil and IMI immature myeloid information channel scatter plots and the flaggings generated in various hematological malignancies The graphic displays have been compiled over a period of 1 year October 2015-September 2016 from blood samples of various solid and hematological malignancies approximately 400 per day received for routine CBC in the laboratory Approximately 50 000 scattergrams have been analyzed during the study period The findings were confirmed by peripheral blood smear examination The scattergram analysis on XE-2100 is very sensitive as well as specific for diagnosing acute viz acute myeloid acute lymphoblastic chronic disorders viz chronic myeloid and chronic lymphoproliferative disorder especially chronic lymphocytic It is suggested that the laboratories using the hematology analyzers be aware of graphic display patterns in addition to flaggings generated which provide additional information and give clue toward the diagnosis even before peripheral smear examination,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3235, 31, 33941, 47, 1417, 80, 2, 80, 8023, 5, 15589, 60, 3, 8736, 2, 25039, 74, 110, 377, 999, 10045, 9, 39945, 8, 147, 1093, 198, 3, 26852, 16, 923, 64, 21, 364, 114, 730, 1, 999, 487, 1052, 20, 25039, 7196, 1, 35, 3235, 31, 10259, 4, 2890, 441, 4, 8, 12, 702, 1257, 8, 375, 207, 1, 236, 315, 1276, 5711, 12948, 32, 103, 361, 348, 15, 190, 56, 26, 45, 10, 426, 6, 423, 3, 5235, 1, 6216, 31, 10259, 31121, 4685, 29104, 4685, 1777, 4685, 71992, 4685, 33203, 2, 15242, 5733, 533, 487, 8240, 9411, 8030, 2, 3, 50824, 1419, 4, 747, 2890, 441, 3, 25039, 7196, 47, 85, 8535, 252, 8, 727, 1, 14, 111, 2551, 1483, 2636, 1390, 29, 315, 347, 1, 747, 537, 2, 2890, 441, 705, 1524, 379, 218, 103, 9, 1311, 5711, 4, 3, 1624, 705, 212, 984, 71993, 47, 85, 311, 190, 3, 45, 727, 3, 272, 11, 557, 20, 672, 315, 8379, 1385, 3, 43987, 65, 23, 71994, 21341, 16, 923, 745, 22, 149, 22, 112, 9, 5798, 286, 31121, 286, 533, 286, 1275, 442, 1997, 31121, 442, 533, 2, 442, 4192, 2645, 1093, 442, 1193, 192, 16, 1148, 17, 3, 4884, 75, 3, 6216, 32835, 40, 4749, 1, 25039, 3640, 764, 4, 352, 6, 50824, 1419, 92, 377, 402, 487, 2, 4978, 12360, 1317, 3, 147, 871, 348, 672, 8379, 1385]",1595.0,29356090,158
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.,Blood,Blood,2018-01-22,"Lenalidomide is clinically active in chronic lymphocytic leukemia (CLL), but its effectiveness in the context of the CLL mutational landscape is unknown. We performed targeted capture sequencing of 295 cancer genes in specimens from 102 CLL patients with treatment-nave disease (TN patients) and 186 CLL patients with relapsed/refractory disease (R/R patients) who received lenalidomide-based therapy at our institution. The most frequently mutated gene was <i>SF3B1</i> (15%), followed by <i>NOTCH1</i> (14%) and <i>TP53</i> (14%), with R/R patients having significantly more <i>TP53</i> mutations than did TN patients. Among all lenalidomide-treated patients, del(17p) (<i>P</i>  .001), del(11q) (<i>P</i> = .032), and complex karyotype (<i>P</i> = .022), along with mutations in <i>TP53</i> (<i>P</i>  .001), <i>KRAS</i> (<i>P</i> = .034), and <i>DDX3X</i> (<i>P</i>  .001), were associated with worse overall response (OR). R/R patients with <i>SF3B1</i> and <i>MGA</i> mutations had significantly worse OR (<i>P</i> = .025 and .035, respectively). TN and R/R patients with del(17p) and <i>TP53</i> mutations had worse overall survival (OS) and progression-free survival (PFS). In R/R patients, complex karyotype and <i>SF3B1</i> mutations were associated with worse OS and PFS; <i>DDX3X</i> mutations were associated with worse PFS only. Weibull regression multivariate analysis revealed that <i>TP53</i> aberrations (del(17p), <i>TP53</i> mutation, or both), along with complex karyotype and <i>SF3B1</i> mutations, were associated with worse OS in the R/R cohort. Taken together, cancer gene mutations in CLL contribute to the already comprehensive risk stratification and add to prognosis and response to treatment. The related trials were registered at www.clinicaltrials.gov as #NCT00267059, #NCT00535873, #NCT00759603, #NCT01446133, and #NCT01002755.",Clinical Trial,729.0,15.0,Lenalidomide is clinically active in chronic lymphocytic CLL but its effectiveness in the context of the CLL mutational landscape is unknown We performed targeted capture sequencing of 295 cancer genes in specimens from 102 CLL patients with treatment-nave disease TN patients and 186 CLL patients with relapsed/refractory disease R/R patients who received lenalidomide-based therapy at our institution The most frequently mutated gene was i SF3B1 /i 15 followed by i NOTCH1 /i 14 and i TP53 /i 14 with R/R patients having significantly more i TP53 /i mutations than did TN patients Among all lenalidomide-treated patients del 17p i P /i  .001 del 11q i P /i .032 and complex karyotype i P /i .022 along with mutations in i TP53 /i i P /i  .001 i KRAS /i i P /i .034 and i DDX3X /i i P /i  .001 were associated with worse overall response OR R/R patients with i SF3B1 /i and i MGA /i mutations had significantly worse OR i P /i .025 and .035 respectively TN and R/R patients with del 17p and i TP53 /i mutations had worse overall survival OS and progression-free survival PFS In R/R patients complex karyotype and i SF3B1 /i mutations were associated with worse OS and PFS i DDX3X /i mutations were associated with worse PFS only Weibull regression multivariate analysis revealed that i TP53 /i aberrations del 17p i TP53 /i mutation or both along with complex karyotype and i SF3B1 /i mutations were associated with worse OS in the R/R cohort Taken together cancer gene mutations in CLL contribute to the already comprehensive risk stratification and add to prognosis and response to treatment The related trials were registered at www.clinicaltrials.gov as NCT00267059 NCT00535873 NCT00759603 NCT01446133 and NCT01002755,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1288, 16, 505, 544, 4, 442, 1193, 552, 84, 211, 1236, 4, 3, 1533, 1, 3, 552, 1619, 2801, 16, 860, 21, 173, 238, 2891, 615, 1, 7051, 12, 214, 4, 623, 29, 2867, 552, 7, 5, 24, 2809, 34, 3814, 7, 2, 5869, 552, 7, 5, 591, 430, 34, 668, 668, 7, 54, 103, 1288, 90, 36, 28, 114, 731, 3, 96, 746, 1185, 145, 10, 70, 10132, 70, 167, 370, 20, 70, 4607, 70, 213, 2, 70, 1206, 70, 213, 5, 668, 668, 7, 1041, 97, 80, 70, 1206, 70, 138, 76, 205, 3814, 7, 107, 62, 1288, 73, 7, 3084, 4135, 70, 19, 70, 1552, 144, 3084, 7203, 70, 19, 70, 4708, 2, 840, 3385, 70, 19, 70, 4773, 1510, 5, 138, 4, 70, 1206, 70, 70, 19, 70, 1552, 144, 70, 723, 70, 70, 19, 70, 5337, 2, 70, 21696, 70, 70, 19, 70, 1552, 144, 11, 41, 5, 639, 63, 51, 15, 668, 668, 7, 5, 70, 10132, 70, 2, 70, 22763, 70, 138, 42, 97, 639, 15, 70, 19, 70, 4067, 2, 4514, 106, 3814, 2, 668, 668, 7, 5, 3084, 4135, 2, 70, 1206, 70, 138, 42, 639, 63, 25, 118, 2, 91, 115, 25, 300, 4, 668, 668, 7, 840, 3385, 2, 70, 10132, 70, 138, 11, 41, 5, 639, 118, 2, 300, 70, 21696, 70, 138, 11, 41, 5, 639, 300, 158, 30575, 320, 331, 65, 553, 17, 70, 1206, 70, 2152, 3084, 4135, 70, 1206, 70, 258, 15, 110, 1510, 5, 840, 3385, 2, 70, 10132, 70, 138, 11, 41, 5, 639, 118, 4, 3, 668, 668, 180, 1633, 1162, 12, 145, 138, 4, 552, 1248, 6, 3, 3298, 949, 43, 1541, 2, 4178, 6, 356, 2, 51, 6, 24, 3, 139, 143, 11, 1653, 28, 3064, 1252, 1239, 22, 71998, 46654, 71999, 72000, 2, 72001]",1726.0,29358183,442
"BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.",Cancer discovery,Cancer Discov,2018-01-31,"Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or <i>de novo</i> expressed in CLL with known functions in disease pathogenesis and progression. These genes, including key members of the B-cell receptor (BCR) signaling pathway, provide a rationale for this therapeutic approach to identify new targets in alternative types of cancer. Additionally, we describe PLX51107, a structurally distinct BET inhibitor with novel <i>in vitro</i> and <i>in vivo</i> pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL. Herein, the discovery of the involvement of BRD4 in the core CLL transcriptional program provides a compelling rationale for clinical investigation of PLX51107 as epigenetic therapy in CLL and application of BRD4 profiling in other cancers.<b>Significance:</b> To date, functional studies of BRD4 in CLL are lacking. Through integrated genomic, functional, and pharmacologic analyses, we uncover the existence of BRD4-regulated core CLL transcriptional programs and present preclinical proof-of-concept studies validating BET inhibition as an epigenetic approach to target BCR signaling in CLL. <i>Cancer Discov; 8(4); 458-77. 2018 AACR.</i><i>This article is highlighted in the In This Issue feature, p. 371</i>.",Journal Article,720.0,22.0,Bromodomain and extra-terminal BET family proteins are key regulators of gene expression in cancer Herein we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic CLL BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or i de novo /i expressed in CLL with known functions in disease pathogenesis and progression These genes including key members of the B-cell receptor BCR signaling pathway provide a rationale for this therapeutic approach to identify new targets in alternative types of cancer Additionally we describe PLX51107 a structurally distinct BET inhibitor with novel i in vitro /i and i in vivo /i pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL Herein the discovery of the involvement of BRD4 in the core CLL transcriptional program provides a compelling rationale for clinical investigation of PLX51107 as epigenetic therapy in CLL and application of BRD4 profiling in other cancers. b Significance /b To date functional studies of BRD4 in CLL are lacking Through integrated genomic functional and pharmacologic analyses we uncover the existence of BRD4-regulated core CLL transcriptional programs and present preclinical proof-of-concept studies validating BET inhibition as an epigenetic approach to target BCR signaling in CLL i Cancer Discov 8 4 458-77 2018 AACR. /i i This article is highlighted in the In This Issue feature p. 371 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7904, 2, 3420, 2158, 4661, 607, 652, 32, 825, 3196, 1, 145, 55, 4, 12, 1986, 21, 6391, 8141, 1080, 6, 255, 740, 460, 646, 4, 1384, 1, 442, 1193, 552, 8141, 16, 1711, 4, 552, 2, 16, 2220, 2805, 6, 214, 2684, 15, 70, 1566, 2018, 70, 570, 4, 552, 5, 440, 1681, 4, 34, 1384, 2, 91, 46, 214, 141, 825, 1684, 1, 3, 132, 31, 153, 1062, 314, 308, 377, 8, 1728, 9, 26, 189, 353, 6, 255, 217, 637, 4, 1091, 630, 1, 12, 1724, 21, 897, 50845, 8, 8533, 834, 4661, 230, 5, 229, 70, 4, 439, 70, 2, 70, 4, 386, 70, 2788, 1571, 17, 50846, 15, 9956, 3, 209, 1, 1062, 314, 183, 4, 693, 274, 1, 552, 1986, 3, 1574, 1, 3, 799, 1, 8141, 4, 3, 1793, 552, 1431, 1243, 777, 8, 6051, 1728, 9, 38, 940, 1, 50845, 22, 1418, 36, 4, 552, 2, 1581, 1, 8141, 1080, 4, 127, 163, 132, 724, 132, 6, 1244, 583, 94, 1, 8141, 4, 552, 32, 1941, 298, 2102, 572, 583, 2, 2788, 318, 21, 6281, 3, 5335, 1, 8141, 1065, 1793, 552, 1431, 2251, 2, 364, 693, 3840, 1, 2545, 94, 6897, 4661, 297, 22, 35, 1418, 353, 6, 283, 1062, 314, 4, 552, 70, 12, 7183, 66, 39, 12072, 849, 4281, 1630, 70, 70, 26, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 9196, 70]",1493.0,29386193,221
Single-agent ibrutinib in treatment-nave and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.,Blood,Blood,2018-02-02,"We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-nave (TN) older patients (65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term efficacy and safety with median follow-up of 5 years in this patient population with TN (N = 31) and R/R (N = 101) CLL/SLL. With the current 5-year follow-up, ibrutinib continues to yield a high overall response rate of 89%, with complete response rates increasing over time to 29% in TN patients and 10% in R/R patients. The median progression-free survival (PFS) was not reached in TN patients. The 5-year PFS rate was 92% in TN patients and 44% in R/R patients. Median PFS in R/R patients was 51 months; in those with del(11q), del(17p), and unmutated <i>IGHV</i>, it was 51, 26, and 43 months, respectively, demonstrating long-term efficacy of ibrutinib in some high-risk subgroups. Survival outcomes were less robust for R/R patients with del(17p) and those who received more prior therapies. The onset of grade 3 cytopenias, such as neutropenia and thrombocytopenia, decreased over time. Treatment--limiting adverse events were more frequent during the first year compared with subsequent periods. These results demonstrate sustained efficacy and acceptable tolerability of ibrutinib over an extended time, providing the longest experience for Bruton tyrosine kinase inhibitor treatment in patients with CLL/SLL. These trials were registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01109069.",Clinical Trial,718.0,115.0,We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-nave TN older patients 65 years of age and relapsed/refractory R/R patients with chronic lymphocytic leukemia/small lymphocytic CLL/SLL We now report on long-term efficacy and safety with median follow-up of 5 years in this patient population with TN N 31 and R/R N 101 CLL/SLL With the current 5-year follow-up ibrutinib continues to yield a high overall response rate of 89 with complete response rates increasing over time to 29 in TN patients and 10 in R/R patients The median progression-free survival PFS was not reached in TN patients The 5-year PFS rate was 92 in TN patients and 44 in R/R patients Median PFS in R/R patients was 51 months in those with del 11q del 17p and unmutated i IGHV /i it was 51 26 and 43 months respectively demonstrating long-term efficacy of ibrutinib in some high-risk subgroups Survival outcomes were less robust for R/R patients with del 17p and those who received more prior therapies The onset of grade 3 cytopenias such as neutropenia and thrombocytopenia decreased over time Treatment -- limiting adverse events were more frequent during the first year compared with subsequent periods These results demonstrate sustained efficacy and acceptable tolerability of ibrutinib over an extended time providing the longest experience for Bruton tyrosine kinase inhibitor treatment in patients with CLL/SLL These trials were registered at www.clinicaltrials.gov as NCT01105247 and NCT01109069,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 373, 210, 1480, 253, 2, 2808, 367, 1, 1795, 29, 8, 27, 111, 166, 126, 1, 24, 2809, 3814, 434, 7, 5827, 60, 1, 89, 2, 591, 430, 668, 668, 7, 5, 442, 1193, 2647, 302, 1193, 552, 5302, 21, 1134, 414, 23, 319, 337, 209, 2, 367, 5, 52, 166, 126, 1, 33, 60, 4, 26, 69, 266, 5, 3814, 78, 456, 2, 668, 668, 78, 2338, 552, 5302, 5, 3, 291, 33, 111, 166, 126, 1795, 2274, 6, 2309, 8, 64, 63, 51, 116, 1, 887, 5, 236, 51, 151, 602, 252, 98, 6, 462, 4, 3814, 7, 2, 79, 4, 668, 668, 7, 3, 52, 91, 115, 25, 300, 10, 44, 1300, 4, 3814, 7, 3, 33, 111, 300, 116, 10, 937, 4, 3814, 7, 2, 584, 4, 668, 668, 7, 52, 300, 4, 668, 668, 7, 10, 725, 53, 4, 135, 5, 3084, 7203, 3084, 4135, 2, 7216, 70, 6220, 70, 192, 10, 725, 432, 2, 601, 53, 106, 2219, 319, 337, 209, 1, 1795, 4, 476, 64, 43, 1453, 25, 123, 11, 299, 1922, 9, 668, 668, 7, 5, 3084, 4135, 2, 135, 54, 103, 80, 324, 235, 3, 1707, 1, 88, 2608, 5635, 225, 22, 778, 2, 1340, 340, 252, 98, 24, 817, 290, 281, 11, 80, 908, 190, 3, 157, 111, 72, 5, 706, 3338, 46, 99, 608, 2275, 209, 2, 1595, 1543, 1, 1795, 252, 35, 1747, 98, 1736, 3, 5683, 730, 9, 5796, 564, 216, 230, 24, 4, 7, 5, 552, 5302, 46, 143, 11, 1653, 28, 3064, 1252, 1239, 22, 27296, 2, 72164]",1543.0,29437592,93
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2018-02-21,"Unlike normal B-cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B-cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein levels and inhibited FFA metabolism <i>in vitro</i>. Likewise, in CLL cells from ibrutinib-treated patients, FFA metabolism was reduced and eventually stopped. Because ibrutinib disrupts CLL cells' ability to use FFAs for energy production, and because various BCR-dependent cellular functions rely on a continuous supply of chemical energy, ibrutinib interrupts several pathways imperative for cellular function in CLL cells.",Journal Article,699.0,3.0,Unlike normal B-cells and similar to fat cells chronic lymphocytic CLL cells aberrantly express lipoprotein lipase LPL which contributes to free fatty acids FFAs metabolism Here we show that in CLL cells the B-cell receptor BCR inhibitor ibrutinib reduced LPL mRNA and protein levels and inhibited FFA metabolism i in vitro /i Likewise in CLL cells from ibrutinib-treated patients FFA metabolism was reduced and eventually stopped Because ibrutinib disrupts CLL cells ability to use FFAs for energy production and because various BCR-dependent cellular functions rely on a continuous supply of chemical energy ibrutinib interrupts several pathways imperative for cellular function in CLL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4246, 295, 132, 37, 2, 288, 6, 2300, 37, 442, 1193, 552, 37, 5619, 1669, 8984, 7272, 8249, 92, 2444, 6, 115, 4038, 4562, 29653, 1600, 467, 21, 514, 17, 4, 552, 37, 3, 132, 31, 153, 1062, 230, 1795, 405, 8249, 956, 2, 178, 148, 2, 879, 20881, 1600, 70, 4, 439, 70, 6269, 4, 552, 37, 29, 1795, 73, 7, 20881, 1600, 10, 405, 2, 3124, 4403, 408, 1795, 7754, 552, 37, 801, 6, 119, 29653, 9, 2803, 1529, 2, 408, 747, 1062, 470, 763, 1681, 5533, 23, 8, 1314, 6296, 1, 3743, 2803, 1795, 30880, 392, 460, 6305, 9, 763, 343, 4, 552, 37]",693.0,29465264,362
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.,JAMA oncology,JAMA Oncol,2018-05-01,"Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated increased complete response (CR) rates over time. To analyze baseline factors that predict CR in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with ibrutinib. Univariate and multivariate analyses of pooled data from 2 clinical trials were used to assess the prognostic value of baseline factors associated with CR in 327 patients from the PCYC-1102 and PCYC-1112 studies treated with single-agent ibrutinib. Participants were followed up in academic and community medical centers in the United States, the United Kingdom, Australia, France, Italy, Ireland, Poland, Spain, and Austria. Odds ratio (OR) of CR rate. The 327 patients included in this analysis had a median age of 67 years (range, 30-86 years) and 227 (69.4%) were male. At baseline, 185 patients (56.6%) had bulky disease (lymph node 5 cm), 184 (56.3%) had advanced-stage disease, and 182 (55.7%) had an Eastern Cooperative Oncology Group performance status of 1 or higher. Thirty-one patients (9.5%) were in the first-line setting; 38 (11.6%) had undergone 1 previous therapy, 81 (24.8%) had undergone 2, and 177 (54.1%) had undergone 3 or more; patients with relapsed/refractory disease had undergone a median of 3 (range, 0-12) previous therapies. Median time on study was 26.4 months (range, 0.3-55.6 months). Thirty-two of the 327 patients (9.8%) treated with ibrutinib had a CR (PCYC-1102: relapsed/refractory, 12 of 101 [11.9%]; treatment-naive, 8 of 31 [25.8%]; and PCYC-1112: 12 of 195 [6.2%]). The median time to CR for these patients was 14.7 months (range, 4.6-47.1 months). Univariate analysis of baseline factors showed that bulky disease, clinical stage, number of previous therapies, and 2-microglobulin concentration had a significant effect on the odds of CR. The final multivariate model showed that patients with no previous therapy vs patients with at least 1 previous therapy (OR, 2.65; 95% CI, 1.01-6.95; P=.047) and patients without bulky disease (lymph node <5 cm) vs those with bulky disease (lymph node 5 cm [OR, 4.97; 95% CI, 1.91-12.91; P=.001]) had an increased likelihood of CR. Patients receiving ibrutinib as a first-line therapy for chronic lymphocytic leukemia and those without bulky disease had a better likelihood of CR to treatment. The CR rate with continued longer-term ibrutinib treatment was higher than in previous reports. clinicaltrials.gov Identifiers: NCT01105247 and NCT01578707.",Clinical Trial,630.0,6.0,Ibrutinib a first-in-class Bruton tyrosine kinase inhibitor taken once daily is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic and allows for treatment without chemotherapy Extended treatment with ibrutinib has demonstrated increased complete response CR rates over time To analyze baseline factors that predict CR in patients with chronic lymphocytic leukemia/small lymphocytic treated with ibrutinib Univariate and multivariate analyses of pooled data from 2 clinical trials were used to assess the prognostic value of baseline factors associated with CR in 327 patients from the PCYC-1102 and PCYC-1112 studies treated with single-agent ibrutinib Participants were followed up in academic and community medical centers in the United States the United Kingdom Australia France Italy Ireland Poland Spain and Austria Odds ratio OR of CR rate The 327 patients included in this analysis had a median age of 67 years range 30-86 years and 227 69.4 were male At baseline 185 patients 56.6 had bulky disease lymph node 5 cm 184 56.3 had advanced-stage disease and 182 55.7 had an Eastern Cooperative Oncology Group performance status of 1 or higher Thirty-one patients 9.5 were in the first-line setting 38 11.6 had undergone 1 previous therapy 81 24.8 had undergone 2 and 177 54.1 had undergone 3 or more patients with relapsed/refractory disease had undergone a median of 3 range 0-12 previous therapies Median time on study was 26.4 months range 0.3-55.6 months Thirty-two of the 327 patients 9.8 treated with ibrutinib had a CR PCYC-1102 relapsed/refractory 12 of 101 11.9 treatment-naive 8 of 31 25.8 and PCYC-1112 12 of 195 6.2 The median time to CR for these patients was 14.7 months range 4.6-47.1 months Univariate analysis of baseline factors showed that bulky disease clinical stage number of previous therapies and 2-microglobulin concentration had a significant effect on the odds of CR The final multivariate model showed that patients with no previous therapy vs patients with at least 1 previous therapy OR 2.65 95 CI 1.01-6.95 P .047 and patients without bulky disease lymph node 5 cm vs those with bulky disease lymph node 5 cm OR 4.97 95 CI 1.91-12.91 P .001 had an increased likelihood of CR Patients receiving ibrutinib as a first-line therapy for chronic lymphocytic and those without bulky disease had a better likelihood of CR to treatment The CR rate with continued longer-term ibrutinib treatment was higher than in previous reports clinicaltrials.gov Identifiers NCT01105247 and NCT01578707,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 8, 157, 4, 1040, 5796, 564, 216, 230, 1633, 1059, 391, 16, 850, 4, 3, 1088, 907, 9, 7, 5, 442, 1193, 2647, 302, 1193, 2, 2333, 9, 24, 187, 56, 1747, 24, 5, 1795, 71, 264, 101, 236, 51, 684, 151, 252, 98, 6, 1992, 330, 130, 17, 678, 684, 4, 7, 5, 442, 1193, 2647, 302, 1193, 73, 5, 1795, 880, 2, 331, 318, 1, 1830, 74, 29, 18, 38, 143, 11, 95, 6, 423, 3, 177, 549, 1, 330, 130, 41, 5, 684, 4, 7749, 7, 29, 3, 27575, 22475, 2, 27575, 20805, 94, 73, 5, 226, 420, 1795, 776, 11, 370, 126, 4, 1916, 2, 1714, 484, 1168, 4, 3, 1088, 907, 3, 1088, 10782, 6978, 9670, 11300, 14697, 20388, 13629, 2, 34821, 610, 197, 15, 1, 684, 116, 3, 7749, 7, 159, 4, 26, 65, 42, 8, 52, 89, 1, 598, 60, 184, 201, 868, 60, 2, 7132, 790, 39, 11, 1045, 28, 330, 5805, 7, 664, 49, 42, 4112, 34, 263, 289, 4126, 494, 5894, 664, 27, 42, 131, 82, 34, 2, 5160, 614, 67, 42, 35, 2118, 1690, 413, 87, 528, 156, 1, 14, 15, 142, 977, 104, 7, 83, 33, 11, 4, 3, 157, 328, 546, 519, 175, 49, 42, 1989, 14, 698, 36, 865, 259, 66, 42, 1989, 18, 2, 4699, 667, 14, 42, 1989, 27, 15, 80, 7, 5, 591, 430, 34, 42, 1989, 8, 52, 1, 27, 184, 13, 133, 698, 235, 52, 98, 23, 45, 10, 432, 39, 53, 184, 13, 27, 614, 49, 53, 977, 100, 1, 3, 7749, 7, 83, 66, 73, 5, 1795, 42, 8, 684, 27575, 22475, 591, 430, 133, 1, 2338, 175, 83, 24, 2462, 66, 1, 456, 243, 66, 2, 27575, 20805, 133, 1, 5786, 49, 18, 3, 52, 98, 6, 684, 9, 46, 7, 10, 213, 67, 53, 184, 39, 49, 662, 14, 53, 880, 65, 1, 330, 130, 224, 17, 4112, 34, 38, 82, 207, 1, 698, 235, 2, 9314, 5371, 1227, 42, 8, 93, 254, 23, 3, 610, 1, 684, 3, 1457, 331, 202, 224, 17, 7, 5, 77, 698, 36, 105, 7, 5, 28, 506, 14, 698, 36, 15, 18, 556, 48, 58, 14, 355, 49, 48, 19, 5296, 2, 7, 187, 4112, 34, 263, 289, 33, 494, 105, 135, 5, 4112, 34, 263, 289, 4126, 494, 15, 39, 1015, 48, 58, 14, 970, 133, 970, 19, 144, 42, 35, 101, 1420, 1, 684, 7, 357, 1795, 22, 8, 157, 328, 36, 9, 442, 1193, 2, 135, 187, 4112, 34, 42, 8, 380, 1420, 1, 684, 6, 24, 3, 684, 116, 5, 1351, 589, 337, 1795, 24, 10, 142, 76, 4, 698, 1198, 1252, 1239, 15877, 27296, 2, 32286]",2564.0,29470582,266
Prognostic Factors in the Era of Targeted Therapies in CLL.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2018-04-01,"Chronic lymphocytic leukemia is heterogeneous disease characterized by a variable clinical course that is greatly influenced by various patient and disease characteristics. Over the last two decades, advent of new diagnostic methodologies has led to the identification of several factors of prognostic and predictive relevance. Furthermore, recent advances in next-generation sequencing techniques has identified recurrent novel mutations in NOTCH1, SF3B1, BIRC3, and ATM genes whose role as prognostic and predictive markers is currently being investigated. These biologic markers carry new prognostic information and their incorporation into prognostic scoring systems will likely lead to refined multi-parameter risk models. While the prognostic impact of many of the most commonly used markers on clinical outcomes in patients treated with chemo-immunotherapy is well documented, it is important to review their predictive and prognostic role in the era of novel targeted therapies. This article will discuss the currently available information on the clinical relevance of prognostic markers in patients treated with novel targeted therapies.",Journal Article,660.0,3.0,Chronic lymphocytic is heterogeneous disease characterized by a variable clinical course that is greatly influenced by various patient and disease characteristics Over the last two decades advent of new diagnostic methodologies has led to the identification of several factors of prognostic and predictive relevance Furthermore recent advances in next-generation sequencing techniques has identified recurrent novel mutations in NOTCH1 SF3B1 BIRC3 and ATM genes whose role as prognostic and predictive markers is currently being investigated These biologic markers carry new prognostic information and their incorporation into prognostic scoring systems will likely lead to refined multi-parameter risk models While the prognostic impact of many of the most commonly used markers on clinical outcomes in patients treated with chemo-immunotherapy is well documented it is important to review their predictive and prognostic role in the era of novel targeted therapies This article will discuss the currently available information on the clinical relevance of prognostic markers in patients treated with novel targeted therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 16, 1564, 34, 765, 20, 8, 1347, 38, 906, 17, 16, 3510, 2574, 20, 747, 69, 2, 34, 374, 252, 3, 1060, 100, 1968, 4114, 1, 217, 752, 6616, 71, 836, 6, 3, 911, 1, 392, 130, 1, 177, 2, 464, 2088, 798, 435, 954, 4, 1305, 914, 615, 1092, 71, 108, 387, 229, 138, 4, 4607, 10132, 31246, 2, 3552, 214, 1310, 200, 22, 177, 2, 464, 525, 16, 694, 486, 565, 46, 1283, 525, 3542, 217, 177, 487, 2, 136, 2838, 237, 177, 2504, 1530, 303, 322, 1122, 6, 5332, 1414, 4219, 43, 274, 369, 3, 177, 345, 1, 445, 1, 3, 96, 841, 95, 525, 23, 38, 123, 4, 7, 73, 5, 3341, 726, 16, 149, 1405, 192, 16, 305, 6, 206, 136, 464, 2, 177, 200, 4, 3, 1713, 1, 229, 238, 235, 26, 946, 303, 1139, 3, 694, 390, 487, 23, 3, 38, 2088, 1, 177, 525, 4, 7, 73, 5, 229, 238, 235]",1126.0,29473123,647
"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.",Blood,Blood,2018-03-14,"The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.",Journal Article,678.0,131.0,The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic iwCLL published in 2008 has found broad acceptance by physicians and investigators caring for patients with CLL Recent advances including the discovery of the genomic landscape of the disease the development of genetic tests with prognostic relevance and the detection of minimal residual disease MRD coupled with the increased availability of novel targeted agents with impressive efficacy prompted an international panel to provide updated evidence- and expert opinion-based recommendations These recommendations include a revised version of the iwCLL response criteria an update on the use of MRD status for clinical evaluation and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 698, 3580, 1, 3, 1391, 677, 1, 3, 944, 4014, 23, 442, 1193, 16575, 983, 4, 1375, 71, 204, 2094, 5080, 20, 1261, 2, 2394, 6571, 9, 7, 5, 552, 435, 954, 141, 3, 1574, 1, 3, 572, 2801, 1, 3, 34, 3, 193, 1, 336, 895, 5, 177, 2088, 2, 3, 638, 1, 1048, 753, 34, 2029, 3332, 5, 3, 101, 2550, 1, 229, 238, 183, 5, 5790, 209, 4140, 35, 944, 993, 6, 377, 2939, 241, 2, 2005, 3564, 90, 883, 46, 883, 643, 8, 4218, 2256, 1, 3, 16575, 51, 371, 35, 2991, 23, 3, 119, 1, 2029, 156, 9, 38, 451, 2, 883, 666, 3, 455, 2, 2049, 1, 1667, 1342, 190, 284, 1, 552]",836.0,29540348,709
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.,"Future oncology (London, England)",Future Oncol,2018-03-29,"Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several hematologic malignancies. Preclinical studies have demonstrated venetoclax activity in pediatric patient-derived xenograft models and cell lines; however, clinical studies in pediatric patients have yet to be conducted. The prognosis is poor for children with most relapsed/refractory malignancies, and limited treatment options result in unmet clinical need. Herein, we describe the rationale and design of the first study of venetoclax in pediatric patients with relapsed/refractory malignancies: a Phase I trial investigating the safety and pharmacokinetics of venetoclax monotherapy followed by the addition of chemotherapy (Trial registration: EudraCT 2017-000439-14; NCT03236857).","Clinical Trial, Phase I",663.0,8.0,Venetoclax is a highly selective potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic and has shown promising activity in adult studies across several hematologic malignancies Preclinical studies have demonstrated venetoclax activity in pediatric patient-derived xenograft models and cell lines however clinical studies in pediatric patients have yet to be conducted The prognosis is poor for children with most relapsed/refractory malignancies and limited treatment options result in unmet clinical need Herein we describe the rationale and design of the first study of venetoclax in pediatric patients with relapsed/refractory malignancies a Phase I trial investigating the safety and pharmacokinetics of venetoclax monotherapy followed by the addition of chemotherapy Trial registration EudraCT 2017-000439-14 NCT03236857,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4454, 16, 8, 561, 1094, 1157, 1044, 18, 230, 17, 16, 850, 9, 476, 7, 373, 73, 9, 442, 1193, 2, 71, 443, 721, 128, 4, 780, 94, 716, 392, 813, 441, 693, 94, 47, 264, 4454, 128, 4, 815, 69, 526, 1330, 274, 2, 31, 285, 137, 38, 94, 4, 815, 7, 47, 1145, 6, 40, 426, 3, 356, 16, 334, 9, 541, 5, 96, 591, 430, 441, 2, 383, 24, 838, 757, 4, 3715, 38, 594, 1986, 21, 897, 3, 1728, 2, 771, 1, 3, 157, 45, 1, 4454, 4, 815, 7, 5, 591, 430, 441, 8, 124, 70, 160, 3103, 3, 367, 2, 1159, 1, 4454, 1411, 370, 20, 3, 352, 1, 56, 160, 3169, 14681, 1759, 72461, 213, 72462]",872.0,29595064,42
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).,Journal of geriatric oncology,J Geriatr Oncol,2018-04-17,"Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014. Toxicity was assessed per the NCI-CTCAE (version 3-5). Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression. 1199 patients (409 age65; 790 age<65) were analyzed; 438 received only biologic therapy (145 age65; 293 age<65), and 761 received biologic+chemotherapy (264 age65; 497 age<65). The odds of grade three or four hematologic [odds ratio (OR) 1.70; p=0.009: 95% CI (1.57-1.84)] and non-hematologic toxicities [OR 1.47; p=0.022; 95% CI (1.39-1.55)] were increased in older patients with CLL, as well as odds of grade three or four non-hematologic toxicities [OR 1.89; p=0.017; 95% CI (1.64-2.17)] in older patients with NHL. Grade three or four hematologic toxicities were associated with inferior OS and PFS in older patients with NHL [HR 3.14; p=0.006; 95% CI (2.25-4.39) for OS and 3.06; p=0.011; 95% CI (2.10-4.45) for PFS], though not in CLL. A prognostic model predicting grade three or four toxicities was also developed. CLL and NHL patients65 year encounter more toxicities than younger patients even when treated with novel biologic agents. Development of grade three or four hematologic toxicities lead to inferior PFS and OS in NHL but not in CLL.",Journal Article,644.0,4.0,Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients As novel agents are being used more commonly in chronic lymphocytic CLL and NHL toxicities of these agents in older patients have not been well studied Further impact of these toxicities on outcomes in the elderly is unknown This study aimed to answer both questions We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014 Toxicity was assessed per the NCI-CTCAE version 3-5 Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression 1199 patients 409 age  65 790 age 65 were analyzed 438 received only biologic therapy 145 age  65 293 age 65 and 761 received biologic chemotherapy 264 age  65 497 age 65 The odds of grade three or four hematologic odds ratio OR 1.70 p 0.009 95 CI 1.57-1.84 and non-hematologic toxicities OR 1.47 p 0.022 95 CI 1.39-1.55 were increased in older patients with CLL as well as odds of grade three or four non-hematologic toxicities OR 1.89 p 0.017 95 CI 1.64-2.17 in older patients with NHL Grade three or four hematologic toxicities were associated with inferior OS and PFS in older patients with NHL HR 3.14 p 0.006 95 CI 2.25-4.39 for OS and 3.06 p 0.011 95 CI 2.10-4.45 for PFS though not in CLL A prognostic model predicting grade three or four toxicities was also developed CLL and NHL patients  65 year encounter more toxicities than younger patients even when treated with novel biologic agents Development of grade three or four hematologic toxicities lead to inferior PFS and OS in NHL but not in CLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[434, 7, 5, 12, 6506, 29, 56, 139, 385, 80, 746, 76, 773, 7, 22, 229, 183, 32, 486, 95, 80, 841, 4, 442, 1193, 552, 2, 1176, 385, 1, 46, 183, 4, 434, 7, 47, 44, 85, 149, 656, 195, 345, 1, 46, 385, 23, 123, 4, 3, 1216, 16, 860, 26, 45, 1295, 6, 6634, 110, 1937, 21, 446, 213, 7127, 9, 38, 143, 4, 413, 143, 17, 346, 552, 2, 15, 1176, 7, 59, 1131, 1409, 155, 10, 275, 379, 3, 2580, 3898, 2256, 27, 33, 3518, 1, 2985, 88, 169, 15, 294, 813, 2, 220, 813, 385, 11, 4666, 22, 8, 343, 1, 38, 2, 34, 139, 130, 75, 812, 320, 20790, 7, 10052, 89, 749, 556, 11125, 89, 556, 11, 311, 11003, 103, 158, 1283, 36, 4058, 89, 749, 556, 7541, 89, 556, 2, 15692, 103, 1283, 56, 6528, 89, 749, 556, 11178, 89, 556, 3, 610, 1, 88, 169, 15, 294, 813, 610, 197, 15, 14, 431, 19, 13, 2376, 48, 58, 14, 696, 14, 874, 2, 220, 813, 385, 15, 14, 662, 19, 13, 4773, 48, 58, 14, 587, 14, 614, 11, 101, 4, 434, 7, 5, 552, 22, 149, 22, 610, 1, 88, 169, 15, 294, 220, 813, 385, 15, 14, 887, 19, 13, 3825, 48, 58, 14, 660, 18, 269, 4, 434, 7, 5, 1176, 88, 169, 15, 294, 813, 385, 11, 41, 5, 1663, 118, 2, 300, 4, 434, 7, 5, 1176, 168, 27, 213, 19, 13, 1861, 48, 58, 18, 243, 39, 587, 9, 118, 2, 27, 1460, 19, 13, 3651, 48, 58, 18, 79, 39, 512, 9, 300, 2471, 44, 4, 552, 8, 177, 202, 1434, 88, 169, 15, 294, 385, 10, 120, 276, 552, 2, 1176, 7, 749, 556, 111, 8650, 80, 385, 76, 773, 7, 871, 198, 73, 5, 229, 1283, 183, 193, 1, 88, 169, 15, 294, 813, 385, 1122, 6, 1663, 300, 2, 118, 4, 1176, 84, 44, 4, 552]",1744.0,29673807,420
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.,Blood,Blood,2018-04-19,"Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the InterLymph Consortium. For validation, we used data from 1267 controls from Mayo Clinic and 201 CLL, 95 MBL, and 144 controls with a FH of CLL from the Genetic Epidemiology of CLL Consortium. We used odds ratios (ORs) to estimate disease associations with PRS and c-statistics to assess discriminatory accuracy. In InterLymph, the continuous PRS was strongly associated with CLL risk (OR, 2.49; <i>P</i> = 4.4  10<sup>-94</sup>). We replicated these findings in the Genetic Epidemiology of CLL Consortium and Mayo controls (OR, 3.02; <i>P</i> = 7.8  10<sup>-30</sup>) and observed high discrimination (c-statistic = 0.78). When jointly modeled with FH, PRS retained its significance, along with FH status. Finally, we found a highly significant association of the continuous PRS with MBL risk (OR, 2.81; <i>P</i> = 9.8  10<sup>-16</sup>). In conclusion, our validated PRS was strongly associated with CLL risk, adding information beyond FH. The PRS provides a means of identifying those individuals at greater risk for CLL as well as those at increased risk of MBL, a condition that has potential clinical impact beyond CLL.",Journal Article,642.0,3.0,Inherited loci have been found to be associated with risk of chronic lymphocytic CLL A combined polygenic risk score PRS of representative single nucleotide polymorphisms SNPs from these loci may improve risk prediction over individual SNPs Herein we evaluated the association of a PRS with CLL risk and its precursor monoclonal B-cell lymphocytosis MBL We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history FH of hematological cancers For discovery we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the InterLymph Consortium For validation we used data from 1267 controls from Mayo Clinic and 201 CLL 95 MBL and 144 controls with a FH of CLL from the Genetic Epidemiology of CLL Consortium We used odds ratios ORs to estimate disease associations with PRS and c-statistics to assess discriminatory accuracy In InterLymph the continuous PRS was strongly associated with CLL risk OR 2.49 i P /i 4.4 10 sup -94 /sup We replicated these findings in the Genetic Epidemiology of CLL Consortium and Mayo controls OR 3.02 i P /i 7.8 10 sup -30 /sup and observed high discrimination c-statistic 0.78 When jointly modeled with FH PRS retained its significance along with FH status Finally we found a highly significant association of the continuous PRS with MBL risk OR 2.81 i P /i 9.8 10 sup -16 /sup In conclusion our validated PRS was strongly associated with CLL risk adding information beyond FH The PRS provides a means of identifying those individuals at greater risk for CLL as well as those at increased risk of MBL a condition that has potential clinical impact beyond CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2986, 2012, 47, 85, 204, 6, 40, 41, 5, 43, 1, 442, 1193, 552, 8, 397, 11709, 43, 368, 4018, 1, 3724, 226, 1579, 1203, 1109, 29, 46, 2012, 68, 401, 43, 1590, 252, 797, 1109, 1986, 21, 194, 3, 248, 1, 8, 4018, 5, 552, 43, 2, 211, 2765, 848, 132, 31, 8125, 8992, 21, 275, 211, 3099, 2, 12001, 801, 4, 35, 306, 1000, 2, 194, 254, 2437, 2, 4339, 20, 607, 532, 5348, 1, 2890, 163, 9, 1574, 21, 1830, 1183, 74, 23, 605, 3724, 1109, 29, 43197, 552, 2, 38766, 535, 29, 3, 22505, 2404, 9, 929, 21, 95, 74, 29, 26637, 535, 29, 2486, 1188, 2, 4766, 552, 48, 8992, 2, 4415, 535, 5, 8, 5348, 1, 552, 29, 3, 336, 1284, 1, 552, 2404, 21, 95, 610, 1137, 3694, 6, 1191, 34, 685, 5, 4018, 2, 256, 3065, 6, 423, 7276, 1190, 4, 22505, 3, 1314, 4018, 10, 1327, 41, 5, 552, 43, 15, 18, 739, 70, 19, 70, 39, 39, 79, 172, 960, 172, 21, 6714, 46, 272, 4, 3, 336, 1284, 1, 552, 2404, 2, 2486, 535, 15, 27, 588, 70, 19, 70, 67, 66, 79, 172, 201, 172, 2, 164, 64, 3520, 256, 4502, 13, 833, 198, 7609, 4666, 5, 5348, 4018, 3532, 211, 724, 1510, 5, 5348, 156, 1368, 21, 204, 8, 561, 93, 248, 1, 3, 1314, 4018, 5, 8992, 43, 15, 18, 865, 70, 19, 70, 83, 66, 79, 172, 245, 172, 4, 1221, 114, 938, 4018, 10, 1327, 41, 5, 552, 43, 2726, 487, 1654, 5348, 3, 4018, 777, 8, 2263, 1, 1386, 135, 869, 28, 378, 43, 9, 552, 22, 149, 22, 135, 28, 101, 43, 1, 8992, 8, 2850, 17, 71, 174, 38, 345, 1654, 552]",1701.0,29674426,286
Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.,Blood,Blood,2018-04-25,"Prostate apoptosis response-4 (Par-4), a proapoptotic tumor suppressor protein, is downregulated in many cancers including renal cell carcinoma, glioblastoma, endometrial, and breast cancer. Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells. We found that chronic lymphocytic leukemia (CLL) cells from human patients and from E-Tcl1 mice constitutively express Par-4 in greater amounts than normal B-1 or B-2 cells. Interestingly, knockdown of Par-4 in human CLL-derived Mec-1 cells results in a robust increase in p21/WAF1 expression and decreased growth due to delayed G1-to-S cell-cycle transition. Lack of Par-4 also increased the expression of p21 and delayed CLL growth in E-Tcl1 mice. Par-4 expression in CLL cells required constitutively active B-cell receptor (BCR) signaling, as inhibition of BCR signaling with US Food and Drug Administration (FDA)-approved drugs caused a decrease in Par-4 messenger RNA and protein, and an increase in apoptosis. In particular, activities of Lyn, a Src family kinase, spleen tyrosine kinase, and Bruton tyrosine kinase are required for Par-4 expression in CLL cells, suggesting a novel regulation of Par-4 through BCR signaling. Together, these results suggest that Par-4 may play a novel progrowth rather than proapoptotic role in CLL and could be targeted to enhance the therapeutic effects of BCR-signaling inhibitors.",Journal Article,636.0,3.0,apoptosis response-4 Par-4 a proapoptotic tumor suppressor protein is downregulated in many cancers including cell carcinoma glioblastoma and cancer Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells We found that chronic lymphocytic CLL cells from human patients and from E-Tcl1 mice constitutively express Par-4 in greater amounts than normal B-1 or B-2 cells Interestingly knockdown of Par-4 in human CLL-derived Mec-1 cells results in a robust increase in p21/WAF1 expression and decreased growth due to delayed G1-to-S cell-cycle transition Lack of Par-4 also increased the expression of p21 and delayed CLL growth in E-Tcl1 mice Par-4 expression in CLL cells required constitutively active B-cell receptor BCR signaling as inhibition of BCR signaling with US Food and Drug Administration FDA -approved drugs caused a decrease in Par-4 messenger RNA and protein and an increase in apoptosis In particular activities of Lyn a Src family kinase spleen tyrosine kinase and Bruton tyrosine kinase are required for Par-4 expression in CLL cells suggesting a novel regulation of Par-4 through BCR signaling Together these results suggest that Par-4 may play a novel progrowth rather than proapoptotic role in CLL and could be targeted to enhance the therapeutic effects of BCR-signaling inhibitors,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,"[351, 51, 39, 7112, 39, 8, 4118, 30, 1245, 178, 16, 3315, 4, 445, 163, 141, 31, 134, 996, 2, 12, 7112, 39, 1516, 351, 2382, 4, 747, 630, 1, 12, 37, 84, 44, 295, 37, 21, 204, 17, 442, 1193, 552, 37, 29, 171, 7, 2, 29, 32069, 8979, 399, 2818, 1669, 7112, 39, 4, 378, 4939, 76, 295, 132, 14, 15, 132, 18, 37, 2873, 1563, 1, 7112, 39, 4, 171, 552, 526, 7391, 14, 37, 99, 4, 8, 1922, 344, 4, 2657, 7858, 55, 2, 340, 129, 520, 6, 1612, 3344, 6, 695, 31, 417, 1970, 926, 1, 7112, 39, 120, 101, 3, 55, 1, 2657, 2, 1612, 552, 129, 4, 17467, 8979, 399, 7112, 39, 55, 4, 552, 37, 616, 2818, 544, 132, 31, 153, 1062, 314, 22, 297, 1, 1062, 314, 5, 843, 1773, 2, 234, 634, 2078, 850, 600, 1546, 8, 775, 4, 7112, 39, 5992, 893, 2, 178, 2, 35, 344, 4, 351, 4, 1454, 2042, 1, 8309, 8, 2023, 607, 216, 4071, 564, 216, 2, 5796, 564, 216, 32, 616, 9, 7112, 39, 55, 4, 552, 37, 802, 8, 229, 863, 1, 7112, 39, 298, 1062, 314, 1162, 46, 99, 309, 17, 7112, 39, 68, 1343, 8, 229, 32251, 1832, 76, 4118, 200, 4, 552, 2, 359, 40, 238, 6, 1304, 3, 189, 176, 1, 1062, 314, 222]",1337.0,29695515,75
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.,Nature medicine,Nat. Med.,2018-04-30,"Tolerance to self-antigens prevents the elimination of cancer by the immune system<sup>1,2</sup>. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27<sup>+</sup>CD45RO<sup>-</sup>CD8<sup>+</sup> T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27<sup>+</sup>PD-1<sup>-</sup>CD8<sup>+</sup> CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.",Journal Article,631.0,145.0,"Tolerance to self-antigens prevents the elimination of cancer by the immune system sup 1,2 /sup We used synthetic chimeric antigen receptors CARs to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic CLL Remission was induced in a subset of subjects but most did not respond Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored We performed genomic phenotypic and functional evaluations to identify determinants of response Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes including IL-6/STAT3 signatures whereas T cells from nonresponders upregulated programs involved in effector differentiation glycolysis exhaustion and apoptosis Sustained remission was associated with an elevated frequency of CD27 sup /sup CD45RO sup /sup CD8 sup /sup T cells before CAR T cell generation and these lymphocytes possessed memory-like characteristics Highly functional CAR T cells from patients produced STAT3-related cytokines and serum IL-6 correlated with CAR T cell expansion IL-6/STAT3 blockade diminished CAR T cell proliferation Furthermore a mechanistically relevant population of CD27 sup /sup PD-1 sup /sup CD8 sup /sup CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2614, 6, 1074, 1575, 5217, 3, 3730, 1, 12, 20, 3, 250, 398, 172, 14, 18, 172, 21, 95, 3273, 2897, 448, 1186, 7441, 6, 1768, 5073, 2614, 2, 3367, 30, 4772, 4, 7, 5, 442, 1193, 552, 734, 10, 277, 4, 8, 697, 1, 976, 84, 96, 205, 44, 1892, 949, 455, 1, 69, 526, 1881, 102, 37, 6, 255, 483, 1, 189, 1825, 2, 496, 71, 44, 85, 1443, 21, 173, 572, 3290, 2, 583, 3816, 6, 255, 3403, 1, 51, 5983, 1080, 553, 17, 1881, 102, 37, 29, 236, 3261, 7, 5, 552, 11, 2220, 4, 2407, 139, 214, 141, 501, 49, 1439, 2210, 547, 102, 37, 29, 4498, 2684, 2251, 646, 4, 2070, 910, 4484, 7960, 2, 351, 2275, 734, 10, 41, 5, 35, 804, 675, 1, 8608, 172, 172, 11469, 172, 172, 968, 172, 172, 102, 37, 348, 1881, 102, 31, 914, 2, 46, 1594, 10966, 2407, 733, 374, 561, 583, 1881, 102, 37, 29, 7, 1687, 1439, 139, 1886, 2, 524, 501, 49, 438, 5, 1881, 102, 31, 1422, 501, 49, 1439, 1189, 2849, 1881, 102, 31, 457, 798, 8, 4187, 867, 266, 1, 8608, 172, 172, 333, 14, 172, 172, 968, 172, 172, 1881, 102, 37, 1046, 64, 148, 1, 3, 501, 49, 153, 2623, 189, 51, 2, 16, 2327, 9, 30, 182, 46, 272, 6281, 217, 404, 1, 1881, 102, 31, 891, 2, 5531, 3, 174, 1, 75, 1194, 582, 1, 51, 6, 3148, 2811]",1612.0,29713085,148
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-05-01,"Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on results from 107 patients. An additional 51 patients were enrolled in a safety expansion cohort. Extended analysis of all enrolled patients, including the effect of minimal residual disease (MRD) negativity on outcome, is now reported. Patients and Methods Overall, 158 patients with relapsed/refractory or previously untreated (n = 5) del(17p) CLL received venetoclax 400 mg per day after an initial dose ramp up. Responses were based on 2008 International Workshop on Chronic Lymphocytic Leukemia criteria, with monthly physical exams and blood counts. Computed tomography scan was mandatory at week 36, after which assessment made was by clinical evaluation. Marrow biopsy was performed when complete remission was suspected. MRD was assessed by flow cytometry. Results Patients had a median of two prior therapies (range, zero to 10 therapies), 71% had TP53 mutation, and 48% had nodes that were  5 cm. Median time on venetoclax was 23.1 months (range, 0 to 44.2 months) and median time on study was 26.6 months (range, 0 to 44.2 months). For all patients, investigator-assessed objective response rate was 77% (122 of 158 patients; 20% complete remission) and estimated progression-free survival at 24 months was 54% (95% CI, 45% to 62%). For 16 patients who received prior kinase inhibitors, objective response rate was 63% (10 of 16 patients) and 24-month progression-free survival estimate was 50% (95% CI, 25% to 71%). By intent-to-treat analysis, 48 (30%) of 158 patients achieved MRD below the cutoff of 10<sup>-4</sup> in blood. Common grade 3 and 4 adverse events were hematologic and managed with supportive care and/or dose adjustments. Conclusion Venetoclax achieves durable responses and was well tolerated in patients with del(17p) CLL. A high rate of blood MRD < 10<sup>-4</sup> was achieved in this high-risk population.","Clinical Trial, Phase II",630.0,57.0,Purpose Venetoclax is an orally bioavailable B-cell 2 inhibitor US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic del 17p CLL was based on results from 107 patients An additional 51 patients were enrolled in a safety expansion cohort Extended analysis of all enrolled patients including the effect of minimal residual disease MRD negativity on outcome is now reported Patients and Methods Overall 158 patients with relapsed/refractory or previously untreated n 5 del 17p CLL received venetoclax 400 mg per day after an initial dose ramp up Responses were based on 2008 International Workshop on Chronic Lymphocytic criteria with monthly physical exams and blood counts Computed tomography scan was mandatory at week 36 after which assessment made was by clinical evaluation Marrow biopsy was performed when complete remission was suspected MRD was assessed by flow cytometry Results Patients had a median of two prior therapies range zero to 10 therapies 71 had TP53 mutation and 48 had nodes that were  5 cm Median time on venetoclax was 23.1 months range 0 to 44.2 months and median time on study was 26.6 months range 0 to 44.2 months For all patients investigator-assessed objective response rate was 77 122 of 158 patients 20 complete remission and estimated progression-free survival at 24 months was 54 95 CI 45 to 62 For 16 patients who received prior kinase inhibitors objective response rate was 63 10 of 16 patients and 24-month progression-free survival estimate was 50 95 CI 25 to 71 By intent-to-treat analysis 48 30 of 158 patients achieved MRD below the cutoff of 10 sup -4 /sup in blood Common grade 3 and 4 adverse events were hematologic and managed with supportive care and/or dose adjustments Conclusion Venetoclax achieves durable responses and was well tolerated in patients with del 17p CLL A high rate of blood MRD 10 sup -4 /sup was achieved in this high-risk population,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[743, 4454, 16, 35, 1428, 6582, 132, 31, 18, 230, 843, 1773, 2, 234, 634, 2, 1865, 11478, 8613, 1814, 9, 7, 5, 4135, 4389, 591, 430, 442, 1193, 3084, 4135, 552, 10, 90, 23, 99, 29, 3650, 7, 35, 402, 725, 7, 11, 346, 4, 8, 367, 1422, 180, 1747, 65, 1, 62, 346, 7, 141, 3, 254, 1, 1048, 753, 34, 2029, 6014, 23, 228, 16, 1134, 210, 7, 2, 636, 63, 5162, 7, 5, 591, 430, 15, 373, 1278, 78, 33, 3084, 4135, 552, 103, 4454, 1524, 81, 379, 218, 50, 35, 388, 61, 20047, 126, 253, 11, 90, 23, 1375, 944, 4014, 23, 442, 1193, 371, 5, 3889, 900, 12318, 2, 315, 1911, 1220, 872, 1657, 10, 7322, 28, 647, 511, 50, 92, 455, 1229, 10, 20, 38, 451, 581, 411, 10, 173, 198, 236, 734, 10, 2768, 2029, 10, 275, 20, 1412, 1914, 99, 7, 42, 8, 52, 1, 100, 324, 235, 184, 5115, 6, 79, 235, 792, 42, 1206, 258, 2, 576, 42, 502, 17, 11, 749, 33, 494, 52, 98, 23, 4454, 10, 382, 14, 53, 184, 13, 6, 584, 18, 53, 2, 52, 98, 23, 45, 10, 432, 49, 53, 184, 13, 6, 584, 18, 53, 9, 62, 7, 3464, 275, 461, 51, 116, 10, 849, 3285, 1, 5162, 7, 179, 236, 734, 2, 661, 91, 115, 25, 28, 259, 53, 10, 667, 48, 58, 512, 6, 744, 9, 245, 7, 54, 103, 324, 216, 222, 461, 51, 116, 10, 676, 79, 1, 245, 7, 2, 259, 811, 91, 115, 25, 1191, 10, 212, 48, 58, 243, 6, 792, 20, 1697, 6, 943, 65, 576, 201, 1, 5162, 7, 513, 2029, 2736, 3, 2779, 1, 79, 172, 39, 172, 4, 315, 186, 88, 27, 2, 39, 290, 281, 11, 813, 2, 2231, 5, 1877, 165, 2, 15, 61, 6017, 1221, 4454, 6358, 1480, 253, 2, 10, 149, 421, 4, 7, 5, 3084, 4135, 552, 8, 64, 116, 1, 315, 2029, 79, 172, 39, 172, 10, 513, 4, 26, 64, 43, 266]",1988.0,29715056,271
Chronic Lymphocytic Leukemia: Diagnosis and Treatment.,Mayo Clinic proceedings,Mayo Clin. Proc.,2018-05-01,"The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib, idelalisib, and venetoclax, as well as increasingly potent anti-CD20 monoclonal antibodies. In addition, the identification of molecular predictive markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease have allowed optimization of the use of chemoimmunotherapy and targeted therapies and may become standard of care in the future. This review summarizes the diagnosis, prognostication, and treatment of patients with chronic lymphocytic leukemia with emphasis on new prognostic and predictive factors and novel treatment strategies.",Journal Article,630.0,4.0,The complexity of the treatment of patients with chronic lymphocytic has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib idelalisib and venetoclax as well as increasingly potent anti-CD20 monoclonal antibodies In addition the identification of molecular predictive markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease have allowed optimization of the use of chemoimmunotherapy and targeted therapies and may become standard of care in the future This review summarizes the diagnosis prognostication and treatment of patients with chronic lymphocytic with emphasis on new prognostic and predictive factors and novel treatment strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 3082, 1, 3, 24, 1, 7, 5, 442, 1193, 71, 101, 2109, 252, 3, 1219, 392, 60, 22, 8, 4177, 1, 3, 4114, 1, 229, 1037, 183, 225, 22, 1795, 7083, 2, 4454, 22, 149, 22, 1635, 1157, 312, 2198, 848, 890, 4, 352, 3, 911, 1, 219, 464, 525, 2, 3, 2456, 1, 80, 745, 2, 8023, 1092, 6, 423, 1048, 753, 34, 47, 2313, 3980, 1, 3, 119, 1, 4438, 2, 238, 235, 2, 68, 1417, 260, 1, 165, 4, 3, 508, 26, 206, 2869, 3, 147, 4260, 2, 24, 1, 7, 5, 442, 1193, 5, 3136, 23, 217, 177, 2, 464, 130, 2, 229, 24, 422]",773.0,29728204,597
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.,Cancer research,Cancer Res.,2018-05-07,"A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of ""heterozygote advantage"" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (<i>P</i> trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.<b>Significance:</b> HLA gene diversity reduces risk for non-Hodgkin lymphoma. <i>Cancer Res; 78(14); 4086-96. 2018 AACR</i>.",Journal Article,624.0,3.0,"A growing number of loci within the human leukocyte antigen HLA region have been implicated in NHL etiology Here we test a complementary hypothesis of `` heterozygote advantage '' regarding the role of HLA and NHL whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk HLA alleles at class I and II loci were imputed from genome-wide association studies GWAS using SNP2HLA for 3,617 diffuse large B-cell lymphomas DLBCL 2,686 follicular lymphomas FL 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas CLL/SLL 741 marginal zone lymphomas MZL and 8,753 controls of European descent Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci OR DLBCL 1.31 95 CI 1.06-1.60 OR MZL 1.45 95 CI 1.12-1.89 and class II HLA-DRB1 locus OR DLBCL 2.10 95 CI 1.24-3.55 OR MZL 2.10 95 CI 0.99-4.45 Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci i P /i trend 0.0001 FDR 0.0005 These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. b Significance /b HLA gene diversity reduces risk for i Cancer Res 78 14 4086-96 2018 AACR /i",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 1921, 207, 1, 2012, 262, 3, 171, 3627, 448, 1160, 1053, 47, 85, 1771, 4, 1176, 2855, 467, 21, 412, 8, 3380, 1492, 1, 18921, 1874, 522, 666, 3, 200, 1, 1160, 2, 1176, 6131, 1160, 3653, 16, 2524, 2, 3189, 1160, 2012, 32, 41, 5, 101, 34, 43, 1160, 2558, 28, 1040, 70, 2, 215, 2012, 11, 9902, 29, 898, 1019, 248, 94, 3297, 75, 72718, 9, 27, 12379, 1388, 375, 132, 31, 1557, 1446, 18, 12324, 1974, 1557, 2633, 18, 16040, 442, 1193, 2647, 302, 1193, 1557, 552, 5302, 17393, 3450, 3614, 1557, 8277, 2, 66, 13401, 535, 1, 1865, 9171, 110, 1446, 2, 8277, 43, 11, 804, 5, 12656, 28, 1040, 70, 1160, 132, 2, 256, 2012, 15, 1446, 14, 456, 48, 58, 14, 1460, 14, 335, 15, 8277, 14, 512, 48, 58, 14, 133, 14, 887, 2, 1040, 215, 1160, 8147, 2474, 15, 1446, 18, 79, 48, 58, 14, 259, 27, 614, 15, 8277, 18, 79, 48, 58, 13, 1058, 39, 512, 101, 2633, 43, 10, 164, 5, 3, 63, 344, 4, 207, 1, 3189, 1160, 1040, 215, 2012, 70, 19, 70, 853, 13, 488, 5929, 13, 4252, 46, 99, 538, 8, 200, 9, 1160, 30849, 4, 1176, 2855, 2, 844, 17, 834, 250, 460, 68, 51044, 3, 2855, 1, 3, 338, 1176, 814, 132, 724, 132, 1160, 145, 3653, 2389, 43, 9, 70, 12, 1936, 833, 213, 44241, 921, 4281, 1630, 70]",1254.0,29735552,594
Update on signal inhibitors in chronic lymphocytic leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2018-04-01,"The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new therapeutic targets. As a result, researchers have developed novel targeted therapies, several of which are already approved and many of which are in advanced stages of clinical development. These new agents are much less toxic than chemoimmunotherapy and may be preferred for their superior efficacy in patients with certain high-risk features, such as del(17p). The place of these therapies in CLL management is becoming better defined, and they are gradually replacing traditional forms of chemoimmunotherapy. This review provides an update on the clinical data regarding various signal transduction inhibitors in CLL.",Journal Article,660.0,1.0,The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic CLL and the identification of potential new therapeutic targets As a result researchers have developed novel targeted therapies several of which are already approved and many of which are in advanced stages of clinical development These new agents are much less toxic than chemoimmunotherapy and may be preferred for their superior efficacy in patients with certain high-risk features such as del 17p The place of these therapies in CLL management is becoming better defined and they are gradually replacing traditional forms of chemoimmunotherapy This review provides an update on the clinical data regarding various signal transduction inhibitors in CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1060, 2025, 71, 527, 458, 1466, 4, 114, 612, 1, 3, 8465, 1, 442, 1193, 552, 2, 3, 911, 1, 174, 217, 189, 637, 22, 8, 757, 4211, 47, 276, 229, 238, 235, 392, 1, 92, 32, 3298, 850, 2, 445, 1, 92, 32, 4, 131, 1153, 1, 38, 193, 46, 217, 183, 32, 1802, 299, 1812, 76, 4438, 2, 68, 40, 2514, 9, 136, 1123, 209, 4, 7, 5, 1840, 64, 43, 404, 225, 22, 3084, 4135, 3, 3536, 1, 46, 235, 4, 552, 284, 16, 4009, 380, 395, 2, 491, 32, 8092, 9574, 1847, 2377, 1, 4438, 26, 206, 777, 35, 2991, 23, 3, 38, 74, 666, 747, 1235, 2761, 222, 4, 552]",759.0,29742083,606
"Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.",Haematologica,Haematologica,2018-05-10,"Chronic lymphocytic leukemia is an extremely heterogeneous disease and prognostic factors such as chromosomal abnormalities are important predictors of time to first treatment and survival. Trisomy 12 is the second most frequent aberration detected by fluorescence <i>in situ</i> hybridization at the time of diagnosis (10-25%), and it confers an intermediate prognostic risk, with a median time to first treatment of 33 months and a median overall survival of 114 months. Here, we review the unique morphological, immunophenotypic, and genetic characteristics of patients with chronic lymphocytic leukemia and trisomy 12. These patients carry a significantly higher expression of CD19, CD22, CD20, CD79b, CD24, CD27, CD38, CD49d, sIgM, sIgk, and sIg and lower expression of CD43 compared with patients with normal karyotype. Circulating cells show increased expression of the integrins CD11b, CD18, CD29, and ITGB7, and of the adhesion molecule CD323. Patients with chronic lymphocytic leukemia and trisomy 12 frequently have unmutated <i>IGHV</i>, ZAP-70 positivity, and closely homologous stereotyped B-cell receptors. They rarely show <i>TP53</i> mutations but frequently have <i>NOTCH1</i> mutations, which can be identified in up to 40% of those with a rapidly progressive clinical course.",Journal Article,621.0,2.0,Chronic lymphocytic is an extremely heterogeneous disease and prognostic factors such as chromosomal abnormalities are important predictors of time to first treatment and survival Trisomy 12 is the second most frequent aberration detected by fluorescence i in situ /i hybridization at the time of diagnosis 10-25 and it confers an intermediate prognostic risk with a median time to first treatment of 33 months and a median overall survival of 114 months Here we review the unique morphological immunophenotypic and genetic characteristics of patients with chronic lymphocytic and trisomy 12 These patients carry a significantly higher expression of CD19 CD22 CD20 CD79b CD24 CD27 CD38 CD49d sIgM sIgk and sIg and lower expression of CD43 compared with patients with normal karyotype Circulating cells show increased expression of the integrins CD11b CD18 CD29 and ITGB7 and of the adhesion molecule CD323 Patients with chronic lymphocytic and trisomy 12 frequently have unmutated i IGHV /i ZAP-70 positivity and closely homologous stereotyped B-cell receptors They rarely show i TP53 /i mutations but frequently have i NOTCH1 /i mutations which can be identified in up to 40 of those with a rapidly progressive clinical course,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 16, 35, 2938, 1564, 34, 2, 177, 130, 225, 22, 1860, 1171, 32, 305, 674, 1, 98, 6, 157, 24, 2, 25, 6317, 133, 16, 3, 419, 96, 908, 7794, 530, 20, 1591, 70, 4, 957, 70, 1554, 28, 3, 98, 1, 147, 79, 243, 2, 192, 4020, 35, 919, 177, 43, 5, 8, 52, 98, 6, 157, 24, 1, 466, 53, 2, 8, 52, 63, 25, 1, 3803, 53, 467, 21, 206, 3, 991, 4268, 6599, 2, 336, 374, 1, 7, 5, 442, 1193, 2, 6317, 133, 46, 7, 3542, 8, 97, 142, 55, 1, 3158, 7599, 2198, 21656, 6879, 8608, 4469, 10485, 22187, 72737, 2, 72738, 2, 280, 55, 1, 32356, 72, 5, 7, 5, 295, 3385, 1033, 37, 514, 101, 55, 1, 3, 6593, 6861, 20384, 24405, 2, 39617, 2, 1, 3, 2128, 1354, 72739, 7, 5, 442, 1193, 2, 6317, 133, 746, 47, 7216, 70, 6220, 70, 6251, 431, 1887, 2, 3210, 3894, 30389, 132, 31, 1186, 491, 2416, 514, 70, 1206, 70, 138, 84, 746, 47, 70, 4607, 70, 138, 92, 122, 40, 108, 4, 126, 6, 327, 1, 135, 5, 8, 1755, 1014, 38, 906]",1228.0,29748447,463
"Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.",Cancer,Cancer,2018-05-14,"Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with profound disease-related cellular, humoral, and innate immune suppression. The objective of this study was to study the correlations between stress and disease-specific, negative prognostic cellular, cytokine, and chemokine markers in patients with CLL. A single-group, observational design was used. Patients with relapsed/refractory CLL (N=96) who were entering a phase 2 trial of an experimental therapy (ibrutinib) were studied. Before the first dose, a validated self-report measure of stress (the Impact of Event Scale) was completed, and blood was drawn for absolute lymphocyte counts (ALCs) and for cytokine and chemokine enzyme-linked immunosorbent assays. Multiple linear regression models tested stress as a concurrent predictor of ALCs; of cytokines (tumor necrosis factor  [TNF], a proliferation-inducing ligand [APRIL], B-cell activating factor [BAFF], interleukin 6 [IL-6], IL-10, IL-16, and vascular endothelial growth factor [VEGF]); and of the chemokine (C-C motif) ligand 3 (CCL3). Controlling for relevant demographic variables, comorbidities, CLL genetic risk (deletion of the short arm of chromosome 17 [del17p]), and correlates of inflammation, stress predicted higher ALCs (P<.05), and higher levels of TNF (P<.05), IL-16 (P<.01), and CCL3 (P<.05). Stress was not associated with APRIL, BAFF, IL-6, IL-10, or VEGF. Novel biobehavioral data from patients with relapsed/refractory CLL demonstrate that stress is related to heightened levels of cellular, cytokine, and chemokine markers associated previously with progressive disease in CLL. The current results indicate that stress is related to immune and inflammatory processes that contribute to cancer cell proliferation and survival. These data provide a first look into these processes. Cancer 2018.  2018 American Cancer Society.","Clinical Trial, Phase II",617.0,7.0,Chronic lymphocytic CLL is the most prevalent adult with profound disease-related cellular humoral and innate immune suppression The objective of this study was to study the correlations between stress and disease-specific negative prognostic cellular cytokine and chemokine markers in patients with CLL A single-group observational design was used Patients with relapsed/refractory CLL N 96 who were entering a phase 2 trial of an experimental therapy ibrutinib were studied Before the first dose a validated self-report measure of stress the Impact of Event Scale was completed and blood was drawn for absolute lymphocyte counts ALCs and for cytokine and chemokine enzyme-linked immunosorbent assays Multiple linear regression models tested stress as a concurrent predictor of ALCs of cytokines tumor necrosis factor TNF a proliferation-inducing ligand APRIL B-cell activating factor BAFF interleukin 6 IL-6 IL-10 IL-16 and vascular endothelial growth factor VEGF and of the chemokine C-C motif ligand 3 CCL3 Controlling for relevant demographic variables comorbidities CLL genetic risk deletion of the short arm of chromosome 17 del17p and correlates of inflammation stress predicted higher ALCs P .05 and higher levels of TNF P .05 IL-16 P .01 and CCL3 P .05 Stress was not associated with APRIL BAFF IL-6 IL-10 or VEGF Novel biobehavioral data from patients with relapsed/refractory CLL demonstrate that stress is related to heightened levels of cellular cytokine and chemokine markers associated previously with progressive disease in CLL The current results indicate that stress is related to immune and inflammatory processes that contribute to cancer cell proliferation and survival These data provide a first look into these processes Cancer 2018  2018 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 3, 96, 2485, 780, 5, 4399, 34, 139, 763, 5498, 2, 3939, 250, 1332, 3, 461, 1, 26, 45, 10, 6, 45, 3, 2553, 59, 1531, 2, 34, 112, 199, 177, 763, 1675, 2, 3596, 525, 4, 7, 5, 552, 8, 226, 87, 2495, 771, 10, 95, 7, 5, 591, 430, 552, 78, 921, 54, 11, 7653, 8, 124, 18, 160, 1, 35, 1560, 36, 1795, 11, 656, 348, 3, 157, 61, 8, 938, 1074, 414, 1463, 1, 1531, 3, 345, 1, 774, 1124, 10, 781, 2, 315, 10, 5694, 9, 1766, 1448, 1911, 34536, 2, 9, 1675, 2, 3596, 1644, 1199, 5339, 1013, 232, 1646, 320, 274, 650, 1531, 22, 8, 750, 980, 1, 34536, 1, 1886, 30, 1523, 161, 8713, 8, 457, 1958, 1232, 2292, 132, 31, 1616, 161, 6587, 1603, 49, 501, 49, 501, 79, 501, 245, 2, 756, 845, 129, 161, 618, 2, 1, 3, 3596, 256, 256, 5298, 1232, 27, 9711, 1893, 9, 867, 1540, 682, 1909, 552, 336, 43, 1528, 1, 3, 978, 475, 1, 1170, 269, 15403, 2, 1871, 1, 1815, 1531, 783, 142, 34536, 19, 474, 2, 142, 148, 1, 8713, 19, 474, 501, 245, 19, 355, 2, 9711, 19, 474, 1531, 10, 44, 41, 5, 2292, 6587, 501, 49, 501, 79, 15, 618, 229, 21332, 74, 29, 7, 5, 591, 430, 552, 608, 17, 1531, 16, 139, 6, 7145, 148, 1, 763, 1675, 2, 3596, 525, 41, 373, 5, 1014, 34, 4, 552, 3, 291, 99, 1008, 17, 1531, 16, 139, 6, 250, 2, 1291, 1849, 17, 1248, 6, 12, 31, 457, 2, 25, 46, 74, 377, 8, 157, 5316, 237, 46, 1849, 12, 2982, 2206, 2982, 597, 12, 1174]",1789.0,29757455,213
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2018-07-01,"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell neoplasm and 2% to 9% patients develop an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (Richter transformation, DLBCL-RT). Programmed death-1 (PD-1) pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy. PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy; however, it has not been well documented in CLL/SLL and DLBCL-RT. We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL/SLL, 15 DLBCL-RT, and 26 other DLBCL. In CLL/SLL, neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes/paraimmunoblasts within proliferation centers (PCs) and accentuated PCs of all sizes. Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT, but in contrast was only rarely seen in other DLBCL (12/15 vs. 1/26; P<0.0001). An excellent correlation (90% concordance) was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL/SLL clonal relatedness in DLBCL-RT. PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases (1/15 vs. 1/26; P>0.05) as well as background histiocytes and dendritic cells. Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL (median, 16.9 vs. 106.1mo; P=0.002). Our findings suggest a biological continuum from prolymphocytes/paraimmunoblasts in CLL/SLL PCs to the neoplastic B-cells in DLBCL-RT. The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL/SLL, which may have important prognostic and therapeutic implications.",Journal Article,569.0,5.0,Chronic lymphocytic leukemia/small lymphocytic CLL/SLL is a low-grade B-cell neoplasm and 2 to 9 patients develop an aggressive most commonly diffuse large B-cell Richter transformation DLBCL-RT Programmed death-1 PD-1 pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy however it has not been well documented in CLL/SLL and DLBCL-RT We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL/SLL 15 DLBCL-RT and 26 other DLBCL In CLL/SLL neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes/paraimmunoblasts within proliferation centers PCs and accentuated PCs of all sizes Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT but in contrast was only rarely seen in other DLBCL 12/15 vs. 1/26 P 0.0001 An excellent correlation 90 concordance was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL/SLL clonal relatedness in DLBCL-RT PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases 1/15 vs. 1/26 P 0.05 as well as background histiocytes and dendritic cells Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL median 16.9 vs. 106.1 mo P=0.002 Our findings suggest a biological continuum from prolymphocytes/paraimmunoblasts in CLL/SLL PCs to the neoplastic B-cells in DLBCL-RT The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL/SLL which may have important prognostic and therapeutic implications,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 2647, 302, 1193, 552, 5302, 16, 8, 154, 88, 132, 31, 2131, 2, 25335, 6, 83, 7, 690, 35, 571, 96, 841, 1388, 375, 132, 31, 8452, 1392, 1446, 240, 1846, 273, 14, 333, 14, 308, 1698, 8, 2653, 200, 4, 30, 1204, 1604, 5351, 2, 211, 1189, 71, 2054, 22, 35, 323, 312, 12, 726, 333, 729, 2, 333, 14, 55, 71, 443, 464, 549, 4, 312, 333, 12, 726, 137, 192, 71, 44, 85, 149, 1405, 4, 552, 5302, 2, 1446, 240, 21, 194, 333, 14, 2, 333, 729, 55, 20, 888, 4, 587, 552, 5302, 167, 1446, 240, 2, 432, 127, 1446, 4, 552, 5302, 2000, 132, 31, 333, 14, 55, 10, 4241, 2, 2016, 6, 33784, 51063, 262, 457, 1168, 4270, 2, 25356, 4270, 1, 62, 4131, 2000, 132, 31, 333, 14, 55, 10, 561, 2485, 2, 264, 101, 837, 4, 1446, 240, 84, 4, 748, 10, 158, 2416, 527, 4, 127, 1446, 133, 167, 105, 14, 432, 19, 13, 488, 35, 1503, 816, 424, 1827, 10, 164, 59, 2000, 132, 31, 333, 14, 888, 1887, 2, 2372, 395, 552, 5302, 1946, 22542, 4, 1446, 240, 333, 729, 55, 10, 164, 23, 3, 2000, 132, 37, 4, 622, 1446, 240, 2, 127, 1446, 140, 14, 167, 105, 14, 432, 19, 13, 474, 22, 149, 22, 2426, 16734, 2, 2464, 37, 63, 25, 1, 1446, 240, 10, 97, 1663, 6, 17, 1, 3, 127, 1446, 52, 245, 83, 105, 3251, 14, 2035, 19, 13, 1111, 114, 272, 309, 8, 1037, 7382, 29, 33784, 51063, 4, 552, 5302, 4270, 6, 3, 2000, 132, 37, 4, 1446, 240, 3, 2037, 333, 14, 55, 4, 1446, 240, 4677, 192, 8, 174, 2592, 952, 9, 2196, 1946, 22542, 6, 552, 5302, 92, 68, 47, 305, 177, 2, 189, 1268]",1752.0,29762141,425
Biomarkers for checkpoint inhibition in hematologic malignancies.,Seminars in cancer biology,Semin. Cancer Biol.,2018-06-18,"In the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4. Recent results indicate that checkpoint inhibition also represents a very promising approach for certain types of hematologic malignancies. Unfortunately, treatment with checkpoint inhibitors is also associated with substantial toxicities and high costs and only a subset of patients appears to derive clinical benefit from these treatments. This demonstrates the urgent need for biomarkers for the identification of patient populations that are likely to respond to this type of therapy and/or have fewer side effects. Here, we have reviewed available information on the prognostic and predictive value of biomarkers for anti-CTLA-4 and anti-PD-1/PD-L1 as the most commonly used checkpoint inhibitors. There are currently no reliable biomarkers capable of predicting responses to anti-CTLA-4 agents, such as ipilimumab, in hematologic malignancies. Certain polymorphisms in the CTLA-4 gene, however, seem to have an impact on the patients' outcome, especially in the case of chronic lymphocytic leukemia (CLL). There is now sufficient data supporting PD-L1 expression levels in the tumor tissue as an independent prognostic factor in B cell lymphomas such as diffuse large B-cell lymphoma (DLBCL). Overexpression of PD-L1 in the tumor tissue and elevated serum levels of soluble PD-L1 may also represent adverse prognostic factors in certain subtypes of T cell lymphomas. Finally, expression levels of PD-L1 also seem to predict responses to anti-PD-1/PD-L1 approaches in patients with Hodgkin lymphoma. Future studies will have to further delineate the prognostic/predictive role of PD-L1 expression as a biomarker in hematologic malignancies and may be able to identify confounding variables, which will hopefully to some extent be generalizable to other types of anti-tumor immunotherapies.",Journal Article,582.0,6.0,In the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4 Recent results indicate that checkpoint inhibition also represents a very promising approach for certain types of hematologic malignancies Unfortunately treatment with checkpoint inhibitors is also associated with substantial toxicities and high costs and only a subset of patients appears to derive clinical benefit from these treatments This demonstrates the urgent need for biomarkers for the identification of patient populations that are likely to respond to this type of therapy and/or have fewer side effects Here we have reviewed available information on the prognostic and predictive value of biomarkers for anti-CTLA-4 and anti-PD-1/PD-L1 as the most commonly used checkpoint inhibitors There are currently no reliable biomarkers capable of predicting responses to anti-CTLA-4 agents such as ipilimumab in hematologic malignancies Certain polymorphisms in the CTLA-4 gene however seem to have an impact on the patients outcome especially in the case of chronic lymphocytic CLL There is now sufficient data supporting PD-L1 expression levels in the tumor tissue as an independent prognostic factor in B cell lymphomas such as diffuse large B-cell DLBCL Overexpression of PD-L1 in the tumor tissue and elevated serum levels of soluble PD-L1 may also represent adverse prognostic factors in certain subtypes of T cell lymphomas Finally expression levels of PD-L1 also seem to predict responses to anti-PD-1/PD-L1 approaches in patients with Future studies will have to further delineate the prognostic/predictive role of PD-L1 expression as a biomarker in hematologic malignancies and may be able to identify confounding variables which will hopefully to some extent be generalizable to other types of anti-tumor immunotherapies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 3, 1219, 1021, 60, 21, 47, 527, 3813, 2431, 5906, 4, 3, 24, 1, 445, 537, 57, 520, 6, 3, 2456, 1, 222, 529, 250, 4704, 225, 22, 333, 14, 333, 729, 2, 2127, 39, 435, 99, 1008, 17, 986, 297, 120, 1449, 8, 923, 721, 353, 9, 1840, 630, 1, 813, 441, 3869, 24, 5, 986, 222, 16, 120, 41, 5, 1281, 385, 2, 64, 1201, 2, 158, 8, 697, 1, 7, 1233, 6, 3823, 38, 247, 29, 46, 640, 26, 1902, 3, 5013, 594, 9, 582, 9, 3, 911, 1, 69, 1184, 17, 32, 322, 6, 1892, 6, 26, 267, 1, 36, 2, 15, 47, 1497, 1152, 176, 467, 21, 47, 446, 390, 487, 23, 3, 177, 2, 464, 549, 1, 582, 9, 312, 2127, 39, 2, 312, 333, 14, 333, 729, 22, 3, 96, 841, 95, 986, 222, 125, 32, 694, 77, 2450, 582, 2787, 1, 1434, 253, 6, 312, 2127, 39, 183, 225, 22, 1306, 4, 813, 441, 1840, 1203, 4, 3, 2127, 39, 145, 137, 3233, 6, 47, 35, 345, 23, 3, 7, 228, 1093, 4, 3, 473, 1, 442, 1193, 552, 125, 16, 1134, 1952, 74, 1912, 333, 729, 55, 148, 4, 3, 30, 246, 22, 35, 306, 177, 161, 4, 132, 31, 1557, 225, 22, 1388, 375, 132, 31, 1446, 851, 1, 333, 729, 4, 3, 30, 246, 2, 804, 524, 148, 1, 2968, 333, 729, 68, 120, 1231, 290, 177, 130, 4, 1840, 814, 1, 102, 31, 1557, 1368, 55, 148, 1, 333, 729, 120, 3233, 6, 678, 253, 6, 312, 333, 14, 333, 729, 611, 4, 7, 5, 508, 94, 303, 47, 6, 195, 5092, 3, 177, 464, 200, 1, 333, 729, 55, 22, 8, 901, 4, 813, 441, 2, 68, 40, 1665, 6, 255, 4339, 682, 92, 303, 7464, 6, 476, 1039, 40, 12313, 6, 127, 630, 1, 312, 30, 2811]",1932.0,29775689,357
Kidney Involvement of Patients with Waldenstrm Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.,Clinical journal of the American Society of Nephrology : CJASN,Clin J Am Soc Nephrol,2018-05-30,"Kidney involvement in Waldenstrm macroglobulinemia is less well described compared with kidney manifestations in multiple myeloma. Of the 1363 patients seen with Waldenstrm macroglobulinemia and other IgM-secreting B cell lymphoproliferative disorders seen at the Mayo Clinic between 1996 and 2015, 57 kidney biopsies were retrospectively studied. The biopsy findings were correlated with clinical, kidney, and hematologic characteristics. Criteria for inclusion were evidence of a monoclonal IgM protein and availability of a kidney and a bone marrow biopsy for review. Glomerular and tubulointerstitial pathologies were categorized according to whether they were related to the monoclonal IgM. Of the 57 patients identified, monoclonal gammopathy-related kidney lesions were identified in 82% (47 of 57 biopsies), whereas nonmonoclonal gammopathy-related kidney lesions were seen in 18% (ten of 57). Monoclonal gammopathy-related kidney lesions included monoclonal Ig-related amyloidosis (<i>n</i>=19; 33%), nonamyloid glomerulopathy (<i>n</i>=20, 35%), and tubulointerstitial nephropathies (<i>n</i>=8; 14%). The most common monoclonal gammopathy-related kidney lesion was monoclonal Ig-related amyloidosis (<i>n</i>=19; 33%) followed by cryoglobulinemic GN (<i>n</i>=13; 28%). Lymphoma infiltration was the most common tubulointerstitial lesion (<i>n</i>=4; 9%). The hematologic diagnosis was Waldenstrm macroglobulinemia in 74% (<i>n</i>=42), monoclonal gammopathy of renal significance in 16% (<i>n</i>=9), and marginal zone lymphoma (<i>n</i>=2), chronic lymphocytic leukemia (<i>n</i>=2), and low-grade B cell lymphoma (<i>n</i>=2) in 4% each. Our study confirms a diverse variety of kidney lesions in patients with monoclonal IgM gammopathy.",Journal Article,601.0,7.0,involvement in Waldenstrm macroglobulinemia is less well described compared with manifestations in multiple Of the 1363 patients seen with Waldenstrm macroglobulinemia and other IgM-secreting B cell lymphoproliferative disorders seen at the Mayo Clinic between 1996 and 2015 57 biopsies were retrospectively studied The biopsy findings were correlated with clinical and hematologic characteristics Criteria for inclusion were evidence of a monoclonal IgM protein and availability of a and a marrow biopsy for review Glomerular and tubulointerstitial pathologies were categorized according to whether they were related to the monoclonal IgM Of the 57 patients identified monoclonal gammopathy-related lesions were identified in 82 47 of 57 biopsies whereas nonmonoclonal gammopathy-related lesions were seen in 18 ten of 57 Monoclonal gammopathy-related lesions included monoclonal Ig-related amyloidosis i n /i =19 33 nonamyloid glomerulopathy i n /i =20 35 and tubulointerstitial nephropathies i n /i =8 14 The most common monoclonal gammopathy-related lesion was monoclonal Ig-related amyloidosis i n /i =19 33 followed by cryoglobulinemic GN i n /i =13 28 infiltration was the most common tubulointerstitial lesion i n /i =4 9 The hematologic diagnosis was Waldenstrm macroglobulinemia in 74 i n /i =42 monoclonal gammopathy of significance in 16 i n /i =9 and marginal zone i n /i =2 chronic lymphocytic i n /i =2 and low-grade B cell i n /i =2 in 4 each Our study confirms a diverse variety of lesions in patients with monoclonal IgM gammopathy,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[799, 4, 3700, 3389, 16, 299, 149, 1027, 72, 5, 4282, 4, 232, 1, 3, 25144, 7, 527, 5, 3700, 3389, 2, 127, 2852, 5052, 132, 31, 4192, 1997, 527, 28, 3, 2486, 1188, 59, 2648, 2, 1483, 696, 1154, 11, 894, 656, 3, 411, 272, 11, 438, 5, 38, 2, 813, 374, 371, 9, 1680, 11, 241, 1, 8, 848, 2852, 178, 2, 2550, 1, 8, 2, 8, 581, 411, 9, 206, 6080, 2, 20568, 10456, 11, 2320, 768, 6, 317, 491, 11, 139, 6, 3, 848, 2852, 1, 3, 696, 7, 108, 848, 5334, 139, 406, 11, 108, 4, 878, 662, 1, 696, 1154, 547, 72911, 5334, 139, 406, 11, 527, 4, 203, 1618, 1, 696, 848, 5334, 139, 406, 159, 848, 4200, 139, 3919, 70, 78, 70, 326, 466, 72912, 72913, 70, 78, 70, 179, 465, 2, 20568, 72914, 70, 78, 70, 66, 213, 3, 96, 186, 848, 5334, 139, 1180, 10, 848, 4200, 139, 3919, 70, 78, 70, 326, 466, 370, 20, 43785, 26150, 70, 78, 70, 233, 339, 2084, 10, 3, 96, 186, 20568, 1180, 70, 78, 70, 39, 83, 3, 813, 147, 10, 3700, 3389, 4, 794, 70, 78, 70, 595, 848, 5334, 1, 724, 4, 245, 70, 78, 70, 83, 2, 3450, 3614, 70, 78, 70, 18, 442, 1193, 70, 78, 70, 18, 2, 154, 88, 132, 31, 70, 78, 70, 18, 4, 39, 296, 114, 45, 5120, 8, 1867, 1362, 1, 406, 4, 7, 5, 848, 2852, 5334]",1552.0,29848505,739
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.,Biochemistry,Biochemistry,2018-06-14,"Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S). Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist, and these patients have poor outcomes. To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degradation of both wild-type and C481S mutant BTK. We selected a lead PROTAC, MT-802, from several candidates on the basis of its potency to induce BTK knockdown. MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome. MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK. In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot. Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.",Journal Article,586.0,39.0,Inhibition of Bruton 's tyrosine kinase BTK with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic CLL and other B-cell malignancies yet 80 of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib C481S Currently an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist and these patients have poor outcomes To address this we have developed a PROteolysis TArgeting Chimera PROTAC that induces degradation of both wild-type and C481S mutant BTK We selected a lead PROTAC MT-802 from several candidates on the basis of its potency to induce BTK knockdown MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency 99 degradation at nanomolar concentrations against wild-type and C481S BTK In cells isolated from CLL patients with the C481S mutation MT-802 is able to reduce the pool of active phosphorylated BTK whereas ibrutinib can not Collectively these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[297, 1, 5796, 292, 564, 216, 3611, 5, 3, 4422, 230, 1795, 71, 2054, 22, 8, 16947, 24, 1501, 9, 7, 5, 442, 1193, 552, 2, 127, 132, 31, 441, 1145, 493, 1, 552, 7, 690, 251, 520, 6, 8, 6943, 6, 3734, 258, 28, 3, 606, 10732, 2951, 20, 1795, 17045, 694, 35, 323, 24, 1501, 9, 17045, 7, 4801, 429, 6, 1795, 1097, 44, 1923, 2, 46, 7, 47, 334, 123, 6, 1539, 26, 21, 47, 276, 8, 12080, 529, 25992, 42019, 17, 1516, 2373, 1, 110, 955, 267, 2, 17045, 620, 3611, 21, 715, 8, 1122, 42019, 4875, 15135, 29, 392, 1931, 23, 3, 877, 1, 211, 3593, 6, 1290, 3611, 1563, 4875, 15135, 14063, 3611, 6, 3, 20018, 7193, 4213, 5839, 840, 6, 5781, 3611, 8258, 2, 2373, 847, 3, 1694, 4875, 15135, 3333, 1497, 1889, 283, 1549, 76, 1795, 1097, 2, 10785, 35, 2017, 3593, 1058, 2373, 28, 7927, 1003, 480, 955, 267, 2, 17045, 3611, 4, 37, 1355, 29, 552, 7, 5, 3, 17045, 258, 4875, 15135, 16, 1665, 6, 969, 3, 6545, 1, 544, 2365, 3611, 547, 1795, 122, 44, 2535, 46, 74, 377, 8, 877, 9, 195, 693, 45, 1, 3611, 29971, 22, 8, 229, 692, 9, 24, 1, 17045, 620, 552]",1307.0,29851337,535
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2018-06-15,"Patients with residual chronic lymphocytic leukemia (CLL) following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies. We and others have previously described the safety and efficacy of autologous Tcells modified to express anti-CD19 chimeric antigen receptors (CARs) in patients with relapsed or refractory B cell acute lymphoblastic leukemia and CLL. Here we report the use of CD19-targeted CAR Tcells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab. Outpatients received low-dose conditioning therapy with cyclophosphamide (600mg/m<sup>2</sup>), followed by escalating doses of 3 10<sup>6</sup>, 1 10<sup>7</sup>, or 3 10<sup>7</sup> 19-28z CAR Tcells/kg. An objective response was observed in 3 of 8 patients (38%), with a clinically complete response lasting more than 28months observed in two patients. Self-limited fevers were observed post-CAR Tcell infusion in 4 patients, contemporaneous with elevations in interleukin-6 (IL-6), IL-10, IL-2, and TGF-. None developed severe cytokine release syndrome or neurotoxicity. CAR Tcells were detectable post-infusion in 4 patients, with a longest observed persistence of 48days by qPCR. Further strategies to enhance CAR Tcell efficacy in CLL are under investigation.","Clinical Trial, Phase I",585.0,12.0,Patients with residual chronic lymphocytic CLL following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies We and others have previously described the safety and efficacy of autologous T cells modified to express anti-CD19 chimeric antigen receptors CARs in patients with relapsed or refractory B cell acute lymphoblastic and CLL Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 19-28z as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin cyclophosphamide and rituximab Outpatients received low-dose conditioning therapy with cyclophosphamide 600 mg/m sup 2 /sup followed by escalating doses of 3 10 sup 6 /sup 1 10 sup 7 /sup or 3 10 sup 7 /sup 19-28z CAR T cells/kg An objective response was observed in 3 of 8 patients 38 with a clinically complete response lasting more than 28 months observed in two patients Self-limited fevers were observed post-CAR T cell infusion in 4 patients contemporaneous with elevations in interleukin-6 IL-6 IL-10 IL-2 and TGF- None developed severe cytokine release syndrome or neurotoxicity CAR T cells were detectable post-infusion in 4 patients with a longest observed persistence of 48 days by qPCR Further strategies to enhance CAR T cell efficacy in CLL are under investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[7, 5, 753, 442, 1193, 552, 366, 388, 5006, 3497, 90, 4438, 2239, 8, 985, 654, 1, 51, 2, 68, 247, 29, 229, 189, 422, 21, 2, 1749, 47, 373, 1027, 3, 367, 2, 209, 1, 1028, 102, 37, 1230, 6, 1669, 312, 3158, 2897, 448, 1186, 7441, 4, 7, 5, 591, 15, 430, 132, 31, 286, 1275, 2, 552, 467, 21, 414, 3, 119, 1, 3158, 238, 1881, 102, 37, 2570, 3, 2087, 314, 1398, 1, 5603, 326, 19130, 22, 8, 6618, 36, 4, 66, 7, 5, 753, 552, 366, 157, 328, 4438, 5, 7596, 1112, 2, 855, 5698, 103, 154, 61, 1933, 36, 5, 1112, 2383, 81, 188, 172, 18, 172, 370, 20, 2922, 415, 1, 27, 79, 172, 49, 172, 14, 79, 172, 67, 172, 15, 27, 79, 172, 67, 172, 326, 19130, 1881, 102, 37, 503, 35, 461, 51, 10, 164, 4, 27, 1, 66, 7, 519, 5, 8, 505, 236, 51, 3443, 80, 76, 339, 53, 164, 4, 100, 7, 1074, 383, 12488, 11, 164, 539, 1881, 102, 31, 904, 4, 39, 7, 11633, 5, 4712, 4, 1603, 49, 501, 49, 501, 79, 501, 18, 2, 2387, 2014, 1292, 276, 905, 1675, 2008, 681, 15, 3561, 1881, 102, 37, 11, 2083, 539, 904, 4, 39, 7, 5, 8, 5683, 164, 4108, 1, 576, 162, 20, 6162, 195, 422, 6, 1304, 1881, 102, 31, 209, 4, 552, 32, 669, 940]",1427.0,29910179,384
"An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2018-05-23,"Combination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies; however, the available comparative clinical evidence is limited. The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment approach. MEDLINE, Embase, and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only). The data identified from randomized controlled trials or single-arm prospective studies are reported as descriptive study summaries, grouped by anti-CD20 agent and outcome (overall response rate, including complete response and partial response; duration of response; survival, including overall survival and progression-free survival). Of 56 included reports, 32 reported on CLL/small lymphocytic lymphoma, 15 on FL, and 11 on DLBCL. Within the study period, 40, 11, and 7 studies evaluated rituximab, ofatumumab, and obinutuzumab, respectively. Substantially more data were available for rituximab-based combination regimens than for either ofatumumab or obinutuzumab. Moreover, substantial heterogeneity was recorded in the study design and backbone chemotherapy. Thus, the available data are inconclusive regarding any potential similarities or differences in efficacy among these anti-CD20 agents for each respective disease. More importantly, only 1 direct comparison among the anti-CD20 agents was identified, emphasizing the need for head-to-head randomized controlled trials of these drugs to inform clinical decision-making for patients with relapsed or refractory B-cell lymphoproliferative disorders.",Journal Article,608.0,4.0,Combination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies however the available comparative clinical evidence is limited The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic CLL follicular FL or diffuse large B-cell DLBCL using a rapid evidence assessment approach MEDLINE Embase and the Cochrane Library were searched from January 1 1997 to July 14 2017 English language only The data identified from randomized controlled trials or single-arm prospective studies are reported as descriptive study summaries grouped by anti-CD20 agent and outcome overall response rate including complete response and partial response duration of response survival including overall survival and progression-free survival Of 56 included reports 32 reported on CLL/small lymphocytic 15 on FL and 11 on DLBCL Within the study period 40 11 and 7 studies evaluated rituximab ofatumumab and obinutuzumab respectively Substantially more data were available for rituximab-based combination regimens than for either ofatumumab or obinutuzumab Moreover substantial heterogeneity was recorded in the study design and backbone chemotherapy Thus the available data are inconclusive regarding any potential similarities or differences in efficacy among these anti-CD20 agents for each respective disease More importantly only 1 direct comparison among the anti-CD20 agents was identified emphasizing the need for head-to-head randomized controlled trials of these drugs to inform clinical decision-making for patients with relapsed or refractory B-cell lymphoproliferative disorders,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[150, 472, 5, 312, 2198, 183, 822, 401, 3, 123, 1, 7, 5, 591, 15, 430, 132, 31, 441, 137, 3, 390, 2352, 38, 241, 16, 383, 3, 364, 206, 275, 3, 210, 241, 23, 3, 209, 1, 312, 2198, 848, 890, 397, 5, 56, 9, 7, 5, 591, 15, 430, 442, 1193, 552, 1974, 2633, 15, 1388, 375, 132, 31, 1446, 75, 8, 1321, 241, 455, 353, 3388, 4995, 2, 3, 4956, 4157, 11, 3080, 29, 1024, 14, 2341, 6, 2066, 213, 1759, 4201, 4794, 158, 3, 74, 108, 29, 384, 1149, 143, 15, 226, 475, 482, 94, 32, 210, 22, 3778, 45, 15168, 3706, 20, 312, 2198, 420, 2, 228, 63, 51, 116, 141, 236, 51, 2, 450, 51, 654, 1, 51, 25, 141, 63, 25, 2, 91, 115, 25, 1, 664, 159, 1198, 531, 210, 23, 552, 302, 1193, 167, 23, 2633, 2, 175, 23, 1446, 262, 3, 45, 727, 327, 175, 2, 67, 94, 194, 855, 5732, 2, 10380, 106, 2109, 80, 74, 11, 390, 9, 855, 90, 150, 472, 76, 9, 361, 5732, 15, 10380, 1393, 1281, 1144, 10, 1872, 4, 3, 45, 771, 2, 7066, 56, 631, 3, 390, 74, 32, 6791, 666, 500, 174, 6089, 15, 362, 4, 209, 107, 46, 312, 2198, 183, 9, 296, 3847, 34, 80, 1859, 158, 14, 1196, 1155, 107, 3, 312, 2198, 183, 10, 108, 6826, 3, 594, 9, 718, 6, 718, 384, 1149, 143, 1, 46, 600, 6, 2295, 38, 948, 1079, 9, 7, 5, 591, 15, 430, 132, 31, 4192, 1997]",1761.0,29934061,347
Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum.,Human pathology,Hum. Pathol.,2018-06-24,"Large granular lymphocytic leukemia (LGLL) is a chronic proliferation of cytotoxic lymphocytes in which more than 70% of patients develop cytopenia(s) requiring therapy. LGLL includes T-cell LGLL and chronic lymphoproliferative disorder of natural killer (NK) cells. The neoplastic cells in LGLL usually exhibit a single immunophenotype in a patient, with CD8-positive/ T-cell type being the most common, followed by NK-cell,  T-cell, and CD4-positive/ T-cell types. We investigated a total of 220 LGLL cases and identified 12 mixed-phenotype LGLLs (5%): 7 cases with coexistent  T-cell and NK-cell clones and 5 with coexistent  and  T-cell clones. With a median follow-up of 48 months, the clinicopathological characteristics of these patients seemed similar to those of typical LGLL patients. Treatment was instituted in 9 patients, and 5 patients (55%) attained complete hematologic response or partial response. The therapeutic response rate of this cohort is comparable to the reported overall response rate of 40% to 60% in typical LGLL patients. Three patients who did not receive any treatment had progressive or persistent cytopenias. Interestingly, inverted proportions of 2 clones at disease recurrence were identified in 4 patients (36%) and stable clonal proportions in 7 patients (64%). Mixed-phenotype LGLL is rare, and this study underscores the importance of recognizing this rare type of LGLL in patients who may benefit from LGLL treatment.",Journal Article,576.0,1.0,Large granular lymphocytic LGLL is a chronic proliferation of cytotoxic lymphocytes in which more than 70 of patients develop cytopenia s requiring therapy LGLL includes T-cell LGLL and chronic lymphoproliferative disorder of natural killer NK cells The neoplastic cells in LGLL usually exhibit a single immunophenotype in a patient with CD8-positive/ T-cell type being the most common followed by NK-cell  T-cell and CD4-positive/ T-cell types We investigated a total of 220 LGLL cases and identified 12 mixed-phenotype LGLLs 5 7 cases with coexistent  T-cell and NK-cell clones and 5 with coexistent  and  T-cell clones With a median follow-up of 48 months the clinicopathological characteristics of these patients seemed similar to those of typical LGLL patients Treatment was instituted in 9 patients and 5 patients 55 attained complete hematologic response or partial response The therapeutic response rate of this cohort is comparable to the reported overall response rate of 40 to 60 in typical LGLL patients Three patients who did not receive any treatment had progressive or persistent cytopenias Interestingly inverted proportions of 2 clones at disease recurrence were identified in 4 patients 36 and stable clonal proportions in 7 patients 64 Mixed-phenotype LGLL is rare and this study underscores the importance of recognizing this rare type of LGLL in patients who may benefit from LGLL treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[375, 7694, 1193, 13689, 16, 8, 442, 457, 1, 759, 1594, 4, 92, 80, 76, 431, 1, 7, 690, 8165, 695, 1888, 36, 13689, 1920, 102, 31, 13689, 2, 442, 4192, 2645, 1, 1504, 3458, 1765, 37, 3, 2000, 37, 4, 13689, 2082, 2239, 8, 226, 5496, 4, 8, 69, 5, 968, 109, 25691, 102, 31, 267, 486, 3, 96, 186, 370, 20, 1765, 31, 9532, 102, 31, 2, 1440, 109, 25691, 102, 31, 630, 21, 565, 8, 181, 1, 6211, 13689, 140, 2, 108, 133, 1739, 1005, 73124, 33, 67, 140, 5, 12779, 25691, 102, 31, 2, 1765, 31, 2749, 2, 33, 5, 12779, 25691, 2, 9532, 102, 31, 2749, 5, 8, 52, 166, 126, 1, 576, 53, 3, 2721, 374, 1, 46, 7, 5025, 288, 6, 135, 1, 3476, 13689, 7, 24, 10, 12310, 4, 83, 7, 2, 33, 7, 614, 5105, 236, 813, 51, 15, 450, 51, 3, 189, 51, 116, 1, 26, 180, 16, 1279, 6, 3, 210, 63, 51, 116, 1, 327, 6, 335, 4, 3476, 13689, 7, 169, 7, 54, 205, 44, 560, 500, 24, 42, 1014, 15, 1882, 5635, 2873, 20176, 4117, 1, 18, 2749, 28, 34, 146, 11, 108, 4, 39, 7, 511, 2, 585, 1946, 4117, 4, 67, 7, 660, 1739, 1005, 13689, 16, 622, 2, 26, 45, 6926, 3, 1187, 1, 5842, 26, 622, 267, 1, 13689, 4, 7, 54, 68, 247, 29, 13689, 24]",1423.0,29949739,152
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.,Blood,Blood,2018-07-17,"The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib's ability to produce durable remissions in patients, acquired resistance can develop, mostly commonly by mutation of C481 of BTK in the ibrutinib binding site. Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluate its preclinical efficacy in ibrutinib-naive and ibrutinib-resistant CLL. GDC-0853 is unique among reported BTK inhibitors in that it does not rely upon covalent reaction with C481 to stabilize its occupancy within BTK's adenosine triphosphate binding site. As with ibrutinib, GDC-0853 potently reduces B-cell receptor signaling, viability, NF-B-dependent transcription, activation, and migration in treatment nave CLL cells. We found that GDC-0853 also inhibits the most commonly reported ibrutinib-resistant BTK mutant (C481S) both in a biochemical enzyme activity assay and in a stably transfected 293T cell line and maintains cytotoxicity against patient CLL cells harboring C481S BTK mutations. Additionally, GDC-0853 does not inhibit endothelial growth factor receptor or ITK, 2 alternative targets of ibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibody combinations, respectively. Our results using GDC-0853 indicate that noncovalent, selective BTK inhibition may be effective in CLL either as monotherapy or in combination with therapeutic antibodies, especially among the emerging population of patients with acquired resistance to ibrutinib therapy.",Journal Article,553.0,9.0,The clinical success of ibrutinib validates Bruton tyrosine kinase BTK inhibition as an effective strategy for treating hematologic malignancies including chronic lymphocytic CLL Despite ibrutinib 's ability to produce durable remissions in patients acquired resistance can develop mostly commonly by mutation of C481 of BTK in the ibrutinib binding site Here we characterize a novel BTK inhibitor GDC-0853 to evaluate its preclinical efficacy in ibrutinib-naive and ibrutinib-resistant CLL GDC-0853 is unique among reported BTK inhibitors in that it does not rely upon covalent reaction with C481 to stabilize its occupancy within BTK 's adenosine triphosphate binding site As with ibrutinib GDC-0853 potently reduces B-cell receptor signaling viability NF-B-dependent transcription activation and migration in treatment nave CLL cells We found that GDC-0853 also inhibits the most commonly reported ibrutinib-resistant BTK mutant C481S both in a biochemical enzyme activity assay and in a stably transfected 293T cell line and maintains cytotoxicity against patient CLL cells harboring C481S BTK mutations Additionally GDC-0853 does not inhibit endothelial growth factor receptor or ITK 2 alternative targets of ibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibody combinations respectively Our results using GDC-0853 indicate that noncovalent selective BTK inhibition may be effective in CLL either as monotherapy or in combination with therapeutic antibodies especially among the emerging population of patients with acquired resistance to ibrutinib therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 1825, 1, 1795, 11235, 5796, 564, 216, 3611, 297, 22, 35, 323, 692, 9, 1367, 813, 441, 141, 442, 1193, 552, 550, 1795, 292, 801, 6, 2410, 1480, 3166, 4, 7, 1294, 251, 122, 690, 2754, 841, 20, 258, 1, 36300, 1, 3611, 4, 3, 1795, 791, 606, 467, 21, 1507, 8, 229, 3611, 230, 6165, 29988, 6, 376, 211, 693, 209, 4, 1795, 2462, 2, 1795, 436, 552, 6165, 29988, 16, 991, 107, 210, 3611, 222, 4, 17, 192, 1097, 44, 5533, 1548, 10747, 1329, 5, 36300, 6, 10863, 211, 8509, 262, 3611, 292, 4938, 7345, 791, 606, 22, 5, 1795, 6165, 29988, 4684, 2389, 132, 31, 153, 314, 2120, 1365, 2448, 470, 866, 363, 2, 1381, 4, 24, 2809, 552, 37, 21, 204, 17, 6165, 29988, 120, 1576, 3, 96, 841, 210, 1795, 436, 3611, 620, 17045, 110, 4, 8, 1487, 1644, 128, 719, 2, 4, 8, 5834, 3245, 22270, 31, 328, 2, 8107, 1408, 480, 69, 552, 37, 2105, 17045, 3611, 138, 1724, 6165, 29988, 1097, 44, 1433, 845, 129, 161, 153, 15, 15430, 18, 1091, 637, 1, 1795, 17, 32, 322, 2327, 9, 476, 290, 281, 2, 68, 969, 3, 209, 1, 1795, 548, 1247, 106, 114, 99, 75, 6165, 29988, 1008, 17, 33564, 1094, 3611, 297, 68, 40, 323, 4, 552, 361, 22, 1411, 15, 4, 150, 5, 189, 890, 1093, 107, 3, 1478, 266, 1, 7, 5, 1294, 251, 6, 1795, 36]",1622.0,30018078,222
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).,Blood advances,Blood Adv,2018-07-01,"Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to fludarabine plus rituximab (FR; n = 123), FR plus lenalidomide consolidation (FR+L; n = 109), or FR plus cyclophosphamide (FCR; n = 110) and compared 2-year progression-free survival (PFS) rates of each to the historical control rate with FC (60%). Patients with del(11q) in at least 20% of pretreatment cells continued with FCR (n = 27) or were reassigned to FCR+L (n = 31) and excluded from the primary analysis. Among non-del(11q) patients, 2-year PFS rates were 64% (90% confidence interval [CI], 57-71; FR), 72% (90% CI, 65-79; FR+L), and 74% (90% CI, 66-80; FCR); FR+L and FCR had rates significantly greater than historical control. Median PFS was significantly shorter with FR compared with FR+L (<i>P</i> = .04) and FCR (<i>P</i> < .001): 43 (95% CI, 33-50), 61 (95% CI, 45-71), and 97 (95% CI, 61 to not reached) months, respectively. Median follow-up was 73 months and median overall survival (OS) was only reached with FCR (101 months; 95% CI, 96 to not reached). With FR+L, the risk of death decreased over time and was lower than with FR at later time points (<i>P</i> = .01), but not significantly different from FCR (<i>P</i> = .21). Future studies incorporating short courses of lenalidomide into other novel treatment regimens are justified.","Clinical Trial, Phase II",569.0,1.0,Prior to novel targeted agents for chronic lymphocytic CLL the best chemoimmunotherapy regimen in patients with non-del 11q disease was unclear The role of lenalidomide was also not defined This phase 2 study randomized 342 untreated patients with non-del 11q CLL requiring therapy to fludarabine plus rituximab FR n 123 FR plus lenalidomide consolidation FR+L n 109 or FR plus cyclophosphamide FCR n 110 and compared 2-year progression-free survival PFS rates of each to the historical control rate with FC 60 Patients with del 11q in at least 20 of pretreatment cells continued with FCR n 27 or were reassigned to FCR+L n 31 and excluded from the primary analysis Among non-del 11q patients 2-year PFS rates were 64 90 confidence interval CI 57-71 FR 72 90 CI 65-79 FR+L and 74 90 CI 66-80 FCR FR+L and FCR had rates significantly greater than historical control Median PFS was significantly shorter with FR compared with FR+L i P /i .04 and FCR i P /i .001 43 95 CI 33-50 61 95 CI 45-71 and 97 95 CI 61 to not reached months respectively Median follow-up was 73 months and median overall survival OS was only reached with FCR 101 months 95 CI 96 to not reached With FR+L the risk of death decreased over time and was lower than with FR at later time points i P /i .01 but not significantly different from FCR i P /i .21 Future studies incorporating short courses of lenalidomide into other novel treatment regimens are justified,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[324, 6, 229, 238, 183, 9, 442, 1193, 552, 3, 824, 4438, 477, 4, 7, 5, 220, 3084, 7203, 34, 10, 1200, 3, 200, 1, 1288, 10, 120, 44, 395, 26, 124, 18, 45, 384, 8906, 1278, 7, 5, 220, 3084, 7203, 552, 1888, 36, 6, 2027, 349, 855, 6413, 78, 2698, 6413, 349, 1288, 2173, 6413, 805, 78, 3486, 15, 6413, 349, 1112, 4953, 78, 3129, 2, 72, 18, 111, 91, 115, 25, 300, 151, 1, 296, 6, 3, 2252, 182, 116, 5, 4127, 335, 7, 5, 3084, 7203, 4, 28, 506, 179, 1, 1194, 37, 1351, 5, 4953, 78, 428, 15, 11, 31478, 6, 4953, 805, 78, 456, 2, 1800, 29, 3, 86, 65, 107, 220, 3084, 7203, 7, 18, 111, 300, 151, 11, 660, 424, 307, 268, 58, 696, 792, 6413, 720, 424, 58, 556, 842, 6413, 805, 2, 794, 424, 58, 700, 493, 4953, 6413, 805, 2, 4953, 42, 151, 97, 378, 76, 2252, 182, 52, 300, 10, 97, 985, 5, 6413, 72, 5, 6413, 805, 70, 19, 70, 755, 2, 4953, 70, 19, 70, 144, 601, 48, 58, 466, 212, 713, 48, 58, 512, 792, 2, 1015, 48, 58, 713, 6, 44, 1300, 53, 106, 52, 166, 126, 10, 803, 53, 2, 52, 63, 25, 118, 10, 158, 1300, 5, 4953, 2338, 53, 48, 58, 921, 6, 44, 1300, 5, 6413, 805, 3, 43, 1, 273, 340, 252, 98, 2, 10, 280, 76, 5, 6413, 28, 1559, 98, 862, 70, 19, 70, 355, 84, 44, 97, 338, 29, 4953, 70, 19, 70, 239, 508, 94, 2570, 978, 1993, 1, 1288, 237, 127, 229, 24, 472, 32, 6860]",1431.0,30030269,310
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2018-08-01,"Malignant cell growth within patients with B cell chronic lymphocytic leukemia (B-CLL) is largely restricted to lymphoid tissues, particularly lymph nodes. The recent in vitro finding that TLR-9 ligand (oligodeoxynucleotide [ODN]) and IL-15 exhibit strong synergy in promoting B-CLL growth may be particularly relevant to growth in these sites. This study shows IL-15-producing cells are prevalent within B-CLL-infiltrated lymph nodes and, using purified B-CLL cells from blood, investigates the mechanism for ODN and IL-15 synergy in driving B-CLL growth. ODN boosts baseline levels of phospho-RelA(S529) in B-CLL and promotes NF-B-driven increases in <i>IL15RA</i> and <i>IL2RB</i> mRNA, followed by elevated IL-15R and IL-2/IL-15R (CD122) protein. IL-15CD122 signaling during a critical interval, 20 to 36-48 h following initial ODN exposure, is required for optimal induction of the cycling process. Furthermore, experiments with neutralizing anti-IL-15 and anti-CD122 mAbs indicate that clonal expansion requires continued IL-15/CD122 signaling during cycling. The latter is consistent with evidence of heightened <i>IL2RB</i> mRNA in the fraction of recently proliferated B-CLL cells within patient peripheral blood. Compromised ODN+IL-15 growth with limited cell density is consistent with a role for upregulated IL-15R in facilitating homotypic <i>trans</i> IL-15 signaling, although there may be other explanations. Together, the findings show that ODN and IL-15 elicit temporally distinct signals that function in a coordinated manner to drive B-CLL clonal expansion.",Journal Article,538.0,2.0,Malignant cell growth within patients with B cell chronic lymphocytic B-CLL is largely restricted to lymphoid tissues particularly lymph nodes The recent in vitro finding that TLR-9 ligand oligodeoxynucleotide ODN and IL-15 exhibit strong synergy in promoting B-CLL growth may be particularly relevant to growth in these sites This study shows IL-15-producing cells are prevalent within B-CLL-infiltrated lymph nodes and using purified B-CLL cells from blood investigates the mechanism for ODN and IL-15 synergy in driving B-CLL growth ODN boosts baseline levels of phospho-RelA S529 in B-CLL and promotes NF-B-driven increases in i IL15RA /i and i IL2RB /i mRNA followed by elevated IL-15R and IL-2/IL-15R CD122 protein IL-15CD122 signaling during a critical interval 20 to 36-48 h following initial ODN exposure is required for optimal induction of the cycling process Furthermore experiments with neutralizing anti-IL-15 and anti-CD122 mAbs indicate that clonal expansion requires continued IL-15/CD122 signaling during cycling The latter is consistent with evidence of heightened i IL2RB /i mRNA in the fraction of recently proliferated B-CLL cells within patient peripheral blood Compromised ODN+IL-15 growth with limited cell density is consistent with a role for upregulated IL-15R in facilitating homotypic i trans /i IL-15 signaling although there may be other explanations Together the findings show that ODN and IL-15 elicit temporally distinct signals that function in a coordinated manner to drive B-CLL clonal expansion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[393, 31, 129, 262, 7, 5, 132, 31, 442, 1193, 132, 552, 16, 1733, 2016, 6, 2303, 742, 823, 263, 502, 3, 435, 4, 439, 1567, 17, 8701, 83, 1232, 15543, 11601, 2, 501, 167, 2239, 1082, 3439, 4, 2388, 132, 552, 129, 68, 40, 823, 867, 6, 129, 4, 46, 633, 26, 45, 1949, 501, 167, 3787, 37, 32, 2485, 262, 132, 552, 8652, 263, 502, 2, 75, 5963, 132, 552, 37, 29, 315, 7259, 3, 670, 9, 11601, 2, 501, 167, 3439, 4, 4057, 132, 552, 129, 11601, 20239, 330, 148, 1, 3125, 8672, 73356, 4, 132, 552, 2, 2148, 1365, 2448, 1621, 1106, 4, 70, 73357, 70, 2, 70, 36532, 70, 956, 370, 20, 804, 501, 51180, 2, 501, 18, 501, 73358, 30963, 178, 501, 51181, 314, 190, 8, 740, 268, 179, 6, 511, 576, 555, 366, 388, 11601, 645, 16, 616, 9, 665, 504, 1, 3, 9165, 1129, 798, 2332, 5, 5788, 312, 501, 167, 2, 312, 30963, 5207, 1008, 17, 1946, 1422, 1706, 1351, 501, 167, 30963, 314, 190, 9165, 3, 3286, 16, 925, 5, 241, 1, 7145, 70, 36532, 70, 956, 4, 3, 1509, 1, 761, 15535, 132, 552, 37, 262, 69, 672, 315, 4867, 11601, 501, 167, 129, 5, 383, 31, 1263, 16, 925, 5, 8, 200, 9, 2684, 501, 51180, 4, 5379, 19579, 70, 3437, 70, 501, 167, 314, 242, 125, 68, 40, 127, 11616, 1162, 3, 272, 514, 17, 11601, 2, 501, 167, 5487, 11114, 834, 2312, 17, 343, 4, 8, 5725, 1708, 6, 3279, 132, 552, 1946, 1422]",1538.0,30068596,240
Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.,Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,Ann Behav Med,2018-03-01,"Chronic lymphocytic leukemia is the most prevalent adult leukemia. The disease is incurable with a cycling of treatment and relapse common. Little is known about the psychological and physical functioning of patients with relapsed/refractory chronic lymphocytic leukemia. Cancer-specific stress is an important individual difference variable that predicts psychological and physical outcomes. To examine cancer-specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed/refractory chronic lymphocytic leukemia during the first 5 months of treatment. Patients with relapsed/refractory chronic lymphocytic leukemia (N = 152) enrolled in a phase II clinical trial completed self-report measures at treatment initiation (baseline), 1, 2, and 5 months of treatment. Cancer-specific stress at baseline was examined as a predictor of psychological (cognitive-affective depressive symptoms, negative mood, mental health quality of life) and physical functioning (fatigue interference, sleep problems, physical health quality of life), controlling for demographic and treatment variables. Using multilevel modeling, higher baseline cancer-specific stress was related to worse psychological (cognitive-affective depressive symptoms, negative mood, mental health quality of life) and physical functioning (fatigue interference, sleep problems) at baseline and more rapid improvements during the next 5 months. Despite these improvements, higher baseline cancer-specific stress remained associated with poorer 5-month psychological, though not physical, functioning. Findings suggest cancer-specific stress at treatment initiation may be a risk factor for poorer psychological functioning during treatment for patients with relapsed/refractory chronic lymphocytic leukemia.","Clinical Trial, Phase II",691.0,4.0,Chronic lymphocytic is the most prevalent adult The disease is incurable with a cycling of treatment and relapse common Little is known about the psychological and physical functioning of patients with relapsed/refractory chronic lymphocytic Cancer-specific stress is an important individual difference variable that predicts psychological and physical outcomes To examine cancer-specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed/refractory chronic lymphocytic during the first 5 months of treatment Patients with relapsed/refractory chronic lymphocytic N 152 enrolled in a phase II clinical trial completed self-report measures at treatment initiation baseline 1 2 and 5 months of treatment Cancer-specific stress at baseline was examined as a predictor of psychological cognitive-affective depressive symptoms negative mood mental health quality of life and physical functioning fatigue interference sleep problems physical health quality of life controlling for demographic and treatment variables Using multilevel modeling higher baseline cancer-specific stress was related to worse psychological cognitive-affective depressive symptoms negative mood mental health quality of life and physical functioning fatigue interference sleep problems at baseline and more rapid improvements during the next 5 months Despite these improvements higher baseline cancer-specific stress remained associated with poorer 5-month psychological though not physical functioning Findings suggest cancer-specific stress at treatment initiation may be a risk factor for poorer psychological functioning during treatment for patients with relapsed/refractory chronic lymphocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 16, 3, 96, 2485, 780, 3, 34, 16, 2641, 5, 8, 9165, 1, 24, 2, 429, 186, 1215, 16, 440, 545, 3, 2624, 2, 900, 2702, 1, 7, 5, 591, 430, 442, 1193, 12, 112, 1531, 16, 35, 305, 797, 523, 1347, 17, 2623, 2624, 2, 900, 123, 6, 1004, 12, 112, 1531, 28, 24, 1118, 22, 8, 980, 1, 2624, 2, 900, 2702, 8250, 4, 7, 5, 591, 430, 442, 1193, 190, 3, 157, 33, 53, 1, 24, 7, 5, 591, 430, 442, 1193, 78, 5370, 346, 4, 8, 124, 215, 38, 160, 781, 1074, 414, 1018, 28, 24, 1118, 330, 14, 18, 2, 33, 53, 1, 24, 12, 112, 1531, 28, 330, 10, 409, 22, 8, 980, 1, 2624, 1863, 12838, 4945, 507, 199, 5234, 3031, 341, 372, 1, 358, 2, 900, 2702, 613, 3182, 2494, 2408, 900, 341, 372, 1, 358, 1893, 9, 1540, 2, 24, 682, 75, 10913, 2057, 142, 330, 12, 112, 1531, 10, 139, 6, 639, 2624, 1863, 12838, 4945, 507, 199, 5234, 3031, 341, 372, 1, 358, 2, 900, 2702, 613, 3182, 2494, 2408, 28, 330, 2, 80, 1321, 1474, 190, 3, 1305, 33, 53, 550, 46, 1474, 142, 330, 12, 112, 1531, 958, 41, 5, 1769, 33, 811, 2624, 2471, 44, 900, 2702, 272, 309, 12, 112, 1531, 28, 24, 1118, 68, 40, 8, 43, 161, 9, 1769, 2624, 2702, 190, 24, 9, 7, 5, 591, 430, 442, 1193]",1745.0,30084895,209
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.,Cancer discovery,Cancer Discov,2018-08-09,"Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling. We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways, producing more robust responses. <i>In vitro</i> treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-B gene transcription. <i>In vivo</i>, ARQ 531 was found to increase survival over ibrutinib in a murine E-TCL1 engraftment model of CLL and a murine E-MYC/TCL1 engraftment model resembling Richter transformation. Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLC2 mutants, which facilitate clinical resistance to ibrutinib.<b>Significance:</b> This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib. Reversible BTK inhibition is a promising strategy to combat progressive CLL, and multikinase inhibition demonstrates superior efficacy to targeted ibrutinib therapy in the setting of Richter transformation. <i>Cancer Discov; 8(10); 1300-15. 2018 AACR.</i><i>This article is highlighted in the In This Issue feature, p. 1195</i>.",Journal Article,530.0,9.0,Targeted inhibition of Bruton tyrosine kinase BTK with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies including chronic lymphocytic CLL Here we describe preclinical investigations of ARQ 531 a potent reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways producing more robust responses i In vitro /i treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor BCR signaling viability migration CD40 and CD86 expression and NF-B gene transcription i In vivo /i ARQ 531 was found to increase survival over ibrutinib in a murine E-TCL1 engraftment model of CLL and a murine E-MYC/TCL1 engraftment model resembling Richter transformation Additionally ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLC2 mutants which facilitate clinical resistance to ibrutinib. b Significance /b This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib Reversible BTK inhibition is a promising strategy to combat progressive CLL and multikinase inhibition demonstrates superior efficacy to targeted ibrutinib therapy in the setting of Richter transformation i Cancer Discov 8 10 1300-15 2018 AACR. /i i This article is highlighted in the In This Issue feature p. 1195 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[238, 297, 1, 5796, 564, 216, 3611, 5, 3, 4422, 230, 1795, 71, 231, 123, 9, 7, 5, 813, 441, 141, 442, 1193, 552, 467, 21, 897, 693, 2492, 1, 17005, 11308, 8, 1157, 2786, 230, 1, 3611, 5, 402, 128, 480, 2023, 607, 1549, 2, 1549, 139, 6, 1819, 314, 21, 1237, 17, 529, 402, 1549, 688, 401, 1648, 297, 1, 314, 460, 3787, 80, 1922, 253, 70, 4, 439, 70, 24, 1, 69, 552, 37, 5, 17005, 11308, 2140, 3611, 517, 1681, 141, 132, 31, 153, 1062, 314, 2120, 1381, 5040, 2, 12514, 55, 2, 1365, 2448, 145, 866, 70, 4, 386, 70, 17005, 11308, 10, 204, 6, 344, 25, 252, 1795, 4, 8, 1471, 17467, 8979, 2881, 202, 1, 552, 2, 8, 1471, 17467, 1371, 8979, 2881, 202, 8855, 8452, 1392, 1724, 17005, 11308, 1576, 552, 31, 25, 2, 4079, 1062, 517, 363, 1, 17045, 3611, 2, 21785, 3423, 92, 1876, 38, 251, 6, 1795, 132, 724, 132, 26, 45, 9239, 8, 6352, 1114, 216, 230, 5, 209, 4, 274, 17941, 3, 96, 186, 483, 1, 1294, 251, 6, 1795, 2786, 3611, 297, 16, 8, 721, 692, 6, 10584, 1014, 552, 2, 6524, 297, 1902, 1123, 209, 6, 238, 1795, 36, 4, 3, 546, 1, 8452, 1392, 70, 12, 7183, 66, 79, 17088, 167, 4281, 1630, 70, 70, 26, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 19146, 70]",1573.0,30093506,581
"Duvelisib, an oral dual PI3K-, inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.",American journal of hematology,Am. J. Hematol.,2018-10-20,"Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)- and -, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-nave (TN) CLL. Per protocol, TN patients were at least 65years old or had a del(17p)/TP53 mutation. Duvelisib was administered twice daily (BID) in 28-daycycles at doses of 8-75mg in RR patients (n=55) and 25mg in TN patients (n=18.) Diarrhea was the most common nonhematologic AE (TN 78%, RR 47%); transaminase elevations the most frequent lab-abnormality AE (TN 33.3%, RR 30.9%); and neutropenia the most common grade 3 AE (RR 44%, TN 33%). The overall response rates were 56.4% for RR patients (1.8% CR, 54.5% PR) and 83.3% for TN patients (all PRs); median response duration was 21.0 months in RR patients but was not reached for TN patients. Based upon phase 1 efficacy, pharmacodynamics, and safety, duvelisib 25mg BID was selected for further investigation in a phase 3 study in RR CLL/SLL.","Clinical Trial, Phase I",458.0,7.0,Duvelisib IPI-145 an oral dual inhibitor of phosphoinositide-3-kinase PI3K - and - was evaluated in a Phase 1 study in advanced hematologic malignancies which included expansion cohorts in relapsed/refractory RR chronic lymphocytic CLL /small lymphocytic SLL and treatment-nave TN CLL Per protocol TN patients were at least 65 years old or had a del 17p /TP53 mutation Duvelisib was administered twice daily BID in 28-day cycles at doses of 8-75 mg in RR patients n 55 and 25 mg in TN patients n 18 Diarrhea was the most common nonhematologic AE TN 78 RR 47 transaminase elevations the most frequent lab-abnormality AE TN 33.3 RR 30.9 and neutropenia the most common grade 3 AE RR 44 TN 33 The overall response rates were 56.4 for RR patients 1.8 CR 54.5 PR and 83.3 for TN patients all PRs median response duration was 21.0 months in RR patients but was not reached for TN patients Based upon phase 1 efficacy pharmacodynamics and safety duvelisib 25 mg BID was selected for further investigation in a phase 3 study in RR CLL/SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[15080, 3753, 4058, 35, 518, 1828, 230, 1, 4497, 27, 216, 974, 7339, 2, 2655, 10, 194, 4, 8, 124, 14, 45, 4, 131, 813, 441, 92, 159, 1422, 736, 4, 591, 430, 861, 442, 1193, 552, 302, 1193, 5302, 2, 24, 2809, 3814, 552, 379, 1182, 3814, 7, 11, 28, 506, 556, 60, 1095, 15, 42, 8, 3084, 4135, 1206, 258, 15080, 10, 468, 936, 391, 2793, 4, 339, 218, 410, 28, 415, 1, 66, 481, 81, 4, 861, 7, 78, 614, 2, 243, 81, 4, 3814, 7, 78, 203, 1172, 10, 3, 96, 186, 3534, 3633, 3814, 833, 861, 662, 6997, 4712, 3, 96, 908, 14118, 3698, 3633, 3814, 466, 27, 861, 201, 83, 2, 778, 3, 96, 186, 9140, 27, 3633, 861, 584, 3814, 466, 3, 63, 51, 151, 11, 664, 39, 9, 861, 7, 14, 66, 684, 667, 33, 998, 2, 852, 27, 9, 3814, 7, 62, 4018, 52, 51, 654, 10, 239, 13, 53, 4, 861, 7, 84, 10, 44, 1300, 9, 3814, 7, 90, 1548, 124, 14, 209, 3587, 2, 367, 15080, 243, 81, 2793, 10, 715, 9, 195, 940, 4, 8, 124, 27, 45, 4, 861, 552, 5302]",1034.0,30094870,444
"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.",Blood,Blood,2018-08-15,"Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton's tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) and, based on their complementary mechanisms, are ideal for combination. However, combining venetoclax with other active agents raises safety concerns, as it may increase the risk for tumor lysis syndrome. To minimize this risk, we designed and implemented a fixed-duration regimen using sequentially administered obinutuzumab followed by ibrutinib (cycle 2) and venetoclax (cycle 3), for a total of fourteen 28-day cycles. This phase 1b study included 12 patients with relapsed or refractory CLL. We tested 3 dose levels of venetoclax and identified the doses of all 3 agents approved by the US Food and Drug Administration for use in the combination. Adverse events were consistent with known toxicities of the individual agents, with hematologic adverse events being most frequent. No clinically significant tumor lysis syndrome occurred. The overall response rate was 92% (95% confidence interval, 62%-100%), with 42% (5/12) achieving a complete remission or complete remission with incomplete marrow recovery. There were 6 patients with no detectable CLL in both the blood and bone marrow at the end of treatment. We found this regimen to be safe and tolerable in CLL, and capable of inducing deep responses, justifying future study in our ongoing phase 2 cohorts of relapsed or refractory and treatment-naive patients, as well as larger phase 3 trials currently in planning. This trial was registered at www.clinicaltrials.gov as #NCT02427451.","Clinical Trial, Phase I",524.0,34.0,Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab Bruton 's tyrosine kinase inhibitor ibrutinib and B-cell protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic CLL and based on their complementary mechanisms are ideal for combination However combining venetoclax with other active agents raises safety concerns as it may increase the risk for tumor lysis syndrome To minimize this risk we designed and implemented a fixed-duration regimen using sequentially administered obinutuzumab followed by ibrutinib cycle 2 and venetoclax cycle 3 for a total of fourteen 28-day cycles This phase 1b study included 12 patients with relapsed or refractory CLL We tested 3 dose levels of venetoclax and identified the doses of all 3 agents approved by the US Food and Drug Administration for use in the combination Adverse events were consistent with known toxicities of the individual agents with hematologic adverse events being most frequent No clinically significant tumor lysis syndrome occurred The overall response rate was 92 95 confidence interval 62 -100 with 42 5/12 achieving a complete remission or complete remission with incomplete marrow recovery There were 6 patients with no detectable CLL in both the blood and marrow at the end of treatment We found this regimen to be safe and tolerable in CLL and capable of inducing deep responses justifying future study in our ongoing phase 2 cohorts of relapsed or refractory and treatment-naive patients as well as larger phase 3 trials currently in planning This trial was registered at www.clinicaltrials.gov as NCT02427451,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[238, 235, 141, 3, 2794, 50449, 312, 2198, 848, 548, 10380, 5796, 292, 564, 216, 230, 1795, 2, 132, 31, 178, 18, 230, 4454, 47, 264, 93, 38, 128, 4, 442, 1193, 552, 2, 90, 23, 136, 3380, 483, 32, 3662, 9, 150, 137, 1525, 4454, 5, 127, 544, 183, 5789, 367, 2061, 22, 192, 68, 344, 3, 43, 9, 30, 4783, 681, 6, 3241, 26, 43, 21, 1114, 2, 3426, 8, 1959, 654, 477, 75, 5455, 468, 10380, 370, 20, 1795, 417, 18, 2, 4454, 417, 27, 9, 8, 181, 1, 3225, 339, 218, 410, 26, 124, 4693, 45, 159, 133, 7, 5, 591, 15, 430, 552, 21, 650, 27, 61, 148, 1, 4454, 2, 108, 3, 415, 1, 62, 27, 183, 850, 20, 3, 843, 1773, 2, 234, 634, 9, 119, 4, 3, 150, 290, 281, 11, 925, 5, 440, 385, 1, 3, 797, 183, 5, 813, 290, 281, 486, 96, 908, 77, 505, 93, 30, 4783, 681, 489, 3, 63, 51, 116, 10, 937, 48, 307, 268, 744, 394, 5, 595, 33, 133, 1785, 8, 236, 734, 15, 236, 734, 5, 2610, 581, 1602, 125, 11, 49, 7, 5, 77, 2083, 552, 4, 110, 3, 315, 2, 581, 28, 3, 396, 1, 24, 21, 204, 26, 477, 6, 40, 1165, 2, 2668, 4, 552, 2, 2787, 1, 1958, 2369, 253, 13579, 508, 45, 4, 114, 942, 124, 18, 736, 1, 591, 15, 430, 2, 24, 2462, 7, 22, 149, 22, 1077, 124, 27, 143, 694, 4, 1349, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 73419]",1671.0,30111609,234
An update in treating transformed lymphoma.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2018-07-25,"Indolent lymphomas typically have a prolonged course and favorable prognosis. Recent data support survival times that can reach several decades, even if periodic treatment is needed to manage symptoms or stabilize disease. However, all indolent lymphomas have the potential to undergo transformation to an aggressive phenotype, clinically characterized by a rapid progression of adenopathy, new-onset constitutional symptoms, or laboratory abnormalities, and the immediate need for therapeutic intervention. The most common scenario is transformation of follicular lymphoma to either diffuse large B-cell lymphoma or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations; however, other indolent subtypes such as marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, or even nodular lymphocyte predominant Hodgkin lymphoma, can undergo similar histologic transformation. The prognosis of transformed lymphomas has historically been quite poor, but there is ample evidence this is changing in the rituximab era. This article will provide a review of transformed lymphomas with an emphasis on treatment and the nuances of diagnosis and clinical management. Unless otherwise specified, all discussion in this review pertains to transformed follicular lymphoma which is the more common scenario and the subtype with the most robust data. In many cases, this information can be extrapolated and applied to other indolent histologies (i.e. transformed marginal zone lymphoma); however, several other clinical scenarios, such as Richter's transformation and ""double hit"" transformations, warrant a distinct discussion and will be reviewed separately.",Journal Article,545.0,2.0,Indolent lymphomas typically have a prolonged course and favorable prognosis Recent data support survival times that can reach several decades even if periodic treatment is needed to manage symptoms or stabilize disease However all indolent lymphomas have the potential to undergo transformation to an aggressive phenotype clinically characterized by a rapid progression of adenopathy new-onset constitutional symptoms or laboratory abnormalities and the immediate need for therapeutic intervention The most common scenario is transformation of follicular to either diffuse large B-cell or high-grade B-cell with MYC and BCL2 and/or BCL6 translocations however other indolent subtypes such as marginal zone lymphoplasmacytic small lymphocytic lymphoma/chronic lymphocytic or even nodular lymphocyte predominant can undergo similar histologic transformation The prognosis of transformed lymphomas has historically been quite poor but there is ample evidence this is changing in the rituximab era This article will provide a review of transformed lymphomas with an emphasis on treatment and the nuances of diagnosis and clinical management Unless otherwise specified all discussion in this review pertains to transformed follicular which is the more common scenario and the subtype with the most robust data In many cases this information can be extrapolated and applied to other indolent histologies i.e transformed marginal zone however several other clinical scenarios such as Richter 's transformation and `` double hit '' transformations warrant a distinct discussion and will be reviewed separately,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2316, 1557, 1969, 47, 8, 1069, 906, 2, 913, 356, 435, 74, 538, 25, 1072, 17, 122, 3690, 392, 1968, 871, 492, 9086, 24, 16, 575, 6, 4001, 507, 15, 10863, 34, 137, 62, 2316, 1557, 47, 3, 174, 6, 1251, 1392, 6, 35, 571, 1005, 505, 765, 20, 8, 1321, 91, 1, 7741, 217, 1707, 5962, 507, 15, 1624, 1171, 2, 3, 2181, 594, 9, 189, 788, 3, 96, 186, 5456, 16, 1392, 1, 1974, 6, 361, 1388, 375, 132, 31, 15, 64, 88, 132, 31, 5, 1371, 2, 3214, 2, 15, 8148, 3262, 137, 127, 2316, 814, 225, 22, 3450, 3614, 5325, 302, 1193, 4763, 442, 1193, 15, 871, 4481, 1448, 2750, 122, 1251, 288, 884, 1392, 3, 356, 1, 2423, 1557, 71, 3578, 85, 6223, 334, 84, 125, 16, 17814, 241, 26, 16, 3600, 4, 3, 855, 1713, 26, 946, 303, 377, 8, 206, 1, 2423, 1557, 5, 35, 3136, 23, 24, 2, 3, 15967, 1, 147, 2, 38, 284, 6179, 2632, 3575, 62, 2488, 4, 26, 206, 17594, 6, 2423, 1974, 92, 16, 3, 80, 186, 5456, 2, 3, 875, 5, 3, 96, 1922, 74, 4, 445, 140, 26, 487, 122, 40, 10727, 2, 1498, 6, 127, 2316, 3489, 70, 563, 2423, 3450, 3614, 137, 392, 127, 38, 3964, 225, 22, 8452, 292, 1392, 2, 1627, 6519, 522, 18030, 2946, 8, 834, 2488, 2, 303, 40, 446, 3582]",1602.0,30213394,282
Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2018-05-01,"Three small molecule inhibitors have been approved for the treatment of chronic lymphocytic leukemia (CLL) in the last 4 years. Ibrutinib, idelalisib, and venetoclax are oral agents with excellent efficacy and different toxicity profiles. Issues discussed herein include the current role for chemoimmunotherapy in CLL, the use of oral inhibitors in older patients, and the sequencing of these molecules in daily practice.",Journal Article,630.0,5.0,Three small molecule inhibitors have been approved for the treatment of chronic lymphocytic CLL in the last 4 years Ibrutinib idelalisib and venetoclax are oral agents with excellent efficacy and different toxicity profiles Issues discussed herein include the current role for chemoimmunotherapy in CLL the use of oral inhibitors in older patients and the sequencing of these molecules in daily practice,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[169, 302, 1354, 222, 47, 85, 850, 9, 3, 24, 1, 442, 1193, 552, 4, 3, 1060, 39, 60, 1795, 7083, 2, 4454, 32, 518, 183, 5, 1503, 209, 2, 338, 155, 1241, 1553, 1588, 1986, 643, 3, 291, 200, 9, 4438, 4, 552, 3, 119, 1, 518, 222, 4, 434, 7, 2, 3, 615, 1, 46, 1598, 4, 391, 758]",403.0,30231393,192
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2018-08-18,"Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n= 195) or ofatumumab (n= 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization. With up to 24 months' follow-up (median, 16.4 months), 79% of cytopenic patients showed sustained hematologic improvement (82% with improved platelet count, 69% with improved hemoglobin) on ibrutinib versus 43% on ofatumumab (P< .0001). Higher rates of clinically meaningful improvement were demonstrated with ibrutinib versus ofatumumab for FACIT-F and EORTC global health. Greater improvement was observed in disease-related weight loss, fatigue, night sweats, and abdominal discomfort withibrutinib versus ofatumumab. Hospitalizations in the first 30 days occurred less frequently with ibrutinib than ofatumumab (0.087 vs. 0.184 events/patient; P= .0198). New-onset diarrhea was infrequent with ibrutinib after the first 6 months (47% at6 months vs. 5% at 12-18 months). With ibrutinib, grade 3 hypertension occurred in 6%, grade 3 atrial fibrillation in 4%, major hemorrhage in 2%, and tumor lysis syndrome in 1% of patients. Ibrutinib led to significant improvements in hematologic function and disease symptomatology versus ofatumumab, and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.","Clinical Trial, Phase III",521.0,2.0,Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic CLL/SLL Measures of well-being were assessed in RESONATE where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day n 195 or ofatumumab n 196 for up to 24 weeks Endpoints included hematologic function Functional Assessment of Chronic Illness Therapy-Fatigue FACIT-F disease-related symptoms European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 EORTC QLQ-C30 and medical resource utilization With up to 24 months follow-up median 16.4 months 79 of cytopenic patients showed sustained hematologic improvement 82 with improved platelet count 69 with improved hemoglobin on ibrutinib versus 43 on ofatumumab P .0001 Higher rates of clinically meaningful improvement were demonstrated with ibrutinib versus ofatumumab for FACIT-F and EORTC global health Greater improvement was observed in disease-related weight loss fatigue night sweats and abdominal discomfort with ibrutinib versus ofatumumab Hospitalizations in the first 30 days occurred less frequently with ibrutinib than ofatumumab 0.087 vs. 0.184 events/patient P .0198 New-onset diarrhea was infrequent with ibrutinib after the first 6 months 47 at 6 months vs. 5 at 12-18 months With ibrutinib grade  3 hypertension occurred in 6 grade  3 atrial fibrillation in 4 major hemorrhage in 2 and tumor lysis syndrome in 1 of patients Ibrutinib led to significant improvements in hematologic function and disease symptomatology versus ofatumumab and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 72, 5, 5732, 97, 1804, 91, 115, 2, 63, 25, 4, 7, 5, 373, 73, 442, 1193, 2647, 302, 1193, 552, 5302, 1018, 1, 149, 486, 11, 275, 4, 32285, 1257, 373, 73, 7, 5, 552, 5302, 11, 384, 6, 560, 1795, 5401, 81, 218, 78, 5786, 15, 5732, 78, 6369, 9, 126, 6, 259, 244, 1387, 159, 813, 343, 583, 455, 1, 442, 2973, 36, 613, 7230, 1068, 34, 139, 507, 1865, 2533, 9, 389, 2, 24, 1, 12, 372, 1, 358, 2956, 1793, 201, 4359, 5144, 6273, 2, 484, 3069, 1961, 5, 126, 6, 259, 53, 166, 126, 52, 245, 39, 53, 842, 1, 32164, 7, 224, 2275, 813, 767, 878, 5, 231, 1596, 1276, 790, 5, 231, 2222, 23, 1795, 185, 601, 23, 5732, 19, 488, 142, 151, 1, 505, 2538, 767, 11, 264, 5, 1795, 185, 5732, 9, 7230, 1068, 2, 4359, 1648, 341, 378, 767, 10, 164, 4, 34, 139, 924, 407, 613, 8955, 13298, 2, 1467, 7381, 5, 1795, 185, 5732, 4888, 4, 3, 157, 201, 162, 489, 299, 746, 5, 1795, 76, 5732, 13, 11545, 105, 13, 5894, 281, 69, 19, 73656, 217, 1707, 1172, 10, 4475, 5, 1795, 50, 3, 157, 49, 53, 662, 28, 10020, 53, 105, 33, 28, 133, 203, 53, 5, 1795, 88, 749, 27, 1824, 489, 4, 49, 88, 749, 27, 7658, 9380, 4, 39, 458, 3599, 4, 18, 2, 30, 4783, 681, 4, 14, 1, 7, 1795, 836, 6, 93, 1474, 4, 813, 343, 2, 34, 12279, 185, 5732, 2, 122, 6075, 372, 1, 358, 369, 5559, 25, 4, 591, 430, 552, 5302]",1747.0,30249389,15
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.,Blood,Blood,2018-09-25,"Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton's tyrosine kinase (BTK) protein levels in CLL cells after 1 cycle of ibrutinib, suggesting ibrutinib dose could be lowered after the first cycle without loss of biological effect. To test this postulate, a pilot study (NCT02801578) was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles. After an initial cycle of 420 mg/d, the dose was reduced to 280 mg/d in cycle 2, and then to 140 mg/d in cycle 3. Eleven patients began study treatment, and 9 completed the 3 cycles. Plasma and intracellular pharmacokinetics (PK), BTK occupancy, and pharmacodynamic (PD) response at different doses of ibrutinib were compared. Plasma and intracellular levels of ibrutinib were dose-dependent, and even the lowest dose was sufficient to occupy, on average, more than 95% of BTK protein. In concert, BTK downstream signaling inhibition was maintained with 140 mg/d ibrutinib in cycle 3, and there were comparable reductions in total and phospho-BTK (Tyr223) protein levels across 3 cycles. Reductions of plasma chemokine CCL3 and CCL4 levels, considered to be biomarkers of ibrutinib response, were similar during the 3 cycles. These PK/PD data demonstrate that after 1 cycle of ibrutinib at the standard 420 mg/d dose, the dose can be reduced without losing biological activity. Clinical efficacy of lower doses needs to be systematically evaluated. Such dose reductions would lower drug cost, lessen untoward toxicity, and facilitate rationale-based combinations. This trial was registered at www.clinicaltrials.gov as #NCT02801578.",Clinical Trial,483.0,18.0,Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic CLL We previously demonstrated a decline in Bruton 's tyrosine kinase BTK protein levels in CLL cells after 1 cycle of ibrutinib suggesting ibrutinib dose could be lowered after the first cycle without loss of biological effect To test this postulate a pilot study NCT02801578 was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles After an initial cycle of 420 mg/d the dose was reduced to 280 mg/d in cycle 2 and then to 140 mg/d in cycle 3 Eleven patients began study treatment and 9 completed the 3 cycles Plasma and intracellular pharmacokinetics PK BTK occupancy and pharmacodynamic PD response at different doses of ibrutinib were compared Plasma and intracellular levels of ibrutinib were dose-dependent and even the lowest dose was sufficient to occupy on average more than 95 of BTK protein In concert BTK downstream signaling inhibition was maintained with 140 mg/d ibrutinib in cycle 3 and there were comparable reductions in total and phospho-BTK Tyr223 protein levels across 3 cycles Reductions of plasma chemokine CCL3 and CCL4 levels considered to be biomarkers of ibrutinib response were similar during the 3 cycles These PK/PD data demonstrate that after 1 cycle of ibrutinib at the standard 420 mg/d dose the dose can be reduced without losing biological activity Clinical efficacy of lower doses needs to be systematically evaluated Such dose reductions would lower drug cost lessen untoward toxicity and facilitate rationale-based combinations This trial was registered at www.clinicaltrials.gov as NCT02801578,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 16, 561, 3289, 2, 95, 28, 5401, 81, 427, 9, 24, 1, 442, 1193, 552, 21, 373, 264, 8, 1858, 4, 5796, 292, 564, 216, 3611, 178, 148, 4, 552, 37, 50, 14, 417, 1, 1795, 802, 1795, 61, 359, 40, 7238, 50, 3, 157, 417, 187, 407, 1, 1037, 254, 6, 412, 26, 12071, 8, 2281, 45, 51261, 10, 1114, 6, 3390, 969, 1795, 1280, 262, 3, 827, 69, 5, 552, 252, 3, 906, 1, 169, 339, 218, 410, 50, 35, 388, 417, 1, 5401, 81, 427, 3, 61, 10, 405, 6, 5775, 81, 427, 4, 417, 18, 2, 818, 6, 3304, 81, 427, 4, 417, 27, 2627, 7, 4603, 45, 24, 2, 83, 781, 3, 27, 410, 554, 2, 2087, 1159, 2395, 3611, 8509, 2, 2424, 333, 51, 28, 338, 415, 1, 1795, 11, 72, 554, 2, 2087, 148, 1, 1795, 11, 61, 470, 2, 871, 3, 2101, 61, 10, 1952, 6, 18793, 23, 1011, 80, 76, 48, 1, 3611, 178, 4, 10562, 3611, 1489, 314, 297, 10, 1955, 5, 3304, 81, 427, 1795, 4, 417, 27, 2, 125, 11, 1279, 2153, 4, 181, 2, 3125, 3611, 48212, 178, 148, 716, 27, 410, 2153, 1, 554, 3596, 9711, 2, 12660, 148, 515, 6, 40, 582, 1, 1795, 51, 11, 288, 190, 3, 27, 410, 46, 2395, 333, 74, 608, 17, 50, 14, 417, 1, 1795, 28, 3, 260, 5401, 81, 427, 61, 3, 61, 122, 40, 405, 187, 13705, 1037, 128, 38, 209, 1, 280, 415, 1891, 6, 40, 3390, 194, 225, 61, 2153, 688, 280, 234, 835, 13763, 15514, 155, 2, 1876, 1728, 90, 1247, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 51261]",1693.0,30254130,201
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.,JCI insight,JCI Insight,2018-10-04,"The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an E-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases.",Journal Article,474.0,4.0,The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic CLL irrespective of splicing factor mutation status which was associated with sensitivity to the spliceosome modulator E7107 Splicing modulation affected CLL survival pathways including members of the B cell lymphoma-2 BCL2 family of proteins remodeling antiapoptotic dependencies of human and murine CLL cells E7107 treatment decreased myeloid cell leukemia-1 MCL1 dependence and increased BCL2 dependence sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an E-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 911, 1, 3985, 9614, 4, 3, 1533, 1, 189, 251, 16, 8, 825, 1745, 4, 12, 24, 21, 530, 15130, 1898, 3895, 22, 8, 2037, 2705, 1, 442, 1193, 552, 3500, 1, 3895, 161, 258, 156, 92, 10, 41, 5, 485, 6, 3, 13443, 6318, 51279, 3895, 2356, 1424, 552, 25, 460, 141, 1684, 1, 3, 132, 31, 4763, 18, 3214, 607, 1, 652, 4429, 4176, 11508, 1, 171, 2, 1471, 552, 37, 51279, 24, 340, 533, 31, 2647, 14, 8132, 3721, 2, 101, 3214, 3721, 5979, 86, 171, 552, 37, 2, 4454, 436, 552, 733, 37, 29, 35, 17467, 8979, 90, 3159, 2602, 1471, 202, 6, 24, 5, 3, 3214, 230, 4454, 114, 74, 377, 693, 1728, 6, 538, 3, 150, 1, 4454, 5, 3895, 5014, 6, 14947, 1631, 11508, 4, 552, 9, 1367, 4454, 436, 552, 140]",995.0,30282833,558
Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.,Annals of hematology,Ann. Hematol.,2018-10-18,"Prognostic indices combining several clinical and laboratory parameters have been proposed for prognostication in chronic lymphocytic leukemia (CLL). Recently, international consortium on CLL proposed an international prognostic index (CLL-IPI) integrating clinical, molecular, and genetic parameters. The present study was designed to evaluate the reproducibility of CLL-IPI in Indian CLL cohort. The prognostic ability of CLL-IPI in terms of overall survival (OS) and time to first treatment (TTFT) was investigated in treatment-naive CLL patients and also compared with other existing prognostic scores. For assigning scores, clinical and laboratory details were obtained from medical records, and IGHV gene mutation status, 2-microglobulin levels, and copy number variations were determined using c-DNA, ELISA, and multiplex ligation-dependent probe amplification (MLPA), respectively. The scores were generated as per the weighted grades assigned to each variable involved in score categorization. The predictive value of prognostic models was assessed and compared using Harrell's C-index and Akaike's information criterion (AIC). Stratification of patients according to CLL-IPI yielded significant differences in terms of OS and TTFT (p<0.001). Comparative assessment of scores for OS suggested better performance of CLL-IPI (C=0.64, AIC=740) followed by Barcelona-Brno (C=0.61, AIC=754) and MDACC score (C=0.59, AIC=759). Comparison of predictive value of prognostic scores for TTFT illustrated better performance of CLL-IPI (C=0.72, AIC=726) followed by Barcelona-Brno (C=0.68, AIC=743), modified GCLLSG (C=0.66, AIC=744), and O-CLL1 index (C=0.55, AIC=773). The results suggest better performance of CLL-IPI in terms of both OS and TTFT as compared to other available scores in our cohort.",Clinical Trial,460.0,0.0,Prognostic indices combining several clinical and laboratory parameters have been proposed for prognostication in chronic lymphocytic CLL Recently international consortium on CLL proposed an international prognostic index CLL-IPI integrating clinical molecular and genetic parameters The present study was designed to evaluate the reproducibility of CLL-IPI in Indian CLL cohort The prognostic ability of CLL-IPI in terms of overall survival OS and time to first treatment TTFT was investigated in treatment-naive CLL patients and also compared with other existing prognostic scores For assigning scores clinical and laboratory details were obtained from medical records and IGHV gene mutation status 2-microglobulin levels and copy number variations were determined using c-DNA ELISA and multiplex ligation-dependent probe amplification MLPA respectively The scores were generated as per the weighted grades assigned to each variable involved in score categorization The predictive value of prognostic models was assessed and compared using Harrell 's C-index and Akaike 's information criterion AIC Stratification of patients according to CLL-IPI yielded significant differences in terms of OS and TTFT p 0.001 Comparative assessment of scores for OS suggested better performance of CLL-IPI C 0.64 AIC 740 followed by Barcelona-Brno C 0.61 AIC 754 and MDACC score C 0.59 AIC 759 Comparison of predictive value of prognostic scores for TTFT illustrated better performance of CLL-IPI C 0.72 AIC 726 followed by Barcelona-Brno C 0.68 AIC 743 modified GCLLSG C 0.66 AIC 744 and O-CLL1 index C 0.55 AIC 773 The results suggest better performance of CLL-IPI in terms of both OS and TTFT as compared to other available scores in our cohort,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[177, 3824, 1525, 392, 38, 2, 1624, 1038, 47, 85, 1587, 9, 4260, 4, 442, 1193, 552, 761, 944, 2404, 23, 552, 1587, 35, 944, 177, 558, 552, 3753, 4568, 38, 219, 2, 336, 1038, 3, 364, 45, 10, 1114, 6, 376, 3, 4688, 1, 552, 3753, 4, 7968, 552, 180, 3, 177, 801, 1, 552, 3753, 4, 1794, 1, 63, 25, 118, 2, 98, 6, 157, 24, 14035, 10, 565, 4, 24, 2462, 552, 7, 2, 120, 72, 5, 127, 1692, 177, 703, 9, 9648, 703, 38, 2, 1624, 3791, 11, 683, 29, 484, 1064, 2, 6220, 145, 258, 156, 9314, 5371, 148, 2, 1337, 207, 2293, 11, 509, 75, 256, 261, 3664, 2, 4908, 5307, 470, 2888, 1073, 23750, 106, 3, 703, 11, 1419, 22, 379, 3, 2337, 2276, 896, 6, 296, 1347, 646, 4, 368, 8872, 3, 464, 549, 1, 177, 274, 10, 275, 2, 72, 75, 11214, 292, 256, 558, 2, 13429, 292, 487, 4643, 8965, 1541, 1, 7, 768, 6, 552, 3753, 2178, 93, 362, 4, 1794, 1, 118, 2, 14035, 19, 13, 144, 2352, 455, 1, 703, 9, 118, 1148, 380, 528, 1, 552, 3753, 256, 13, 660, 8965, 10880, 370, 20, 11865, 51300, 256, 13, 713, 8965, 14091, 2, 7412, 368, 256, 13, 728, 8965, 13812, 1155, 1, 464, 549, 1, 177, 703, 9, 14035, 8508, 380, 528, 1, 552, 3753, 256, 13, 720, 8965, 13578, 370, 20, 11865, 51300, 256, 13, 806, 8965, 8172, 1230, 73823, 256, 13, 700, 8965, 12614, 2, 1990, 35808, 558, 256, 13, 614, 8965, 13406, 3, 99, 309, 380, 528, 1, 552, 3753, 4, 1794, 1, 110, 118, 2, 14035, 22, 72, 6, 127, 390, 703, 4, 114, 180]",1735.0,30338367,293
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.,Oncogene,Oncogene,2018-10-25,"The dysregulation of PI3K signaling has been implicated as an underlying mechanism associated with resistance to Bruton's tyrosine kinase inhibition by ibrutinib in both chronic lymphocytic leukemia and mantle cell lymphoma (MCL). Ibrutinib resistance has become a major unmet clinical need, and the development of therapeutics to overcome ibrutinib resistance will greatly improve the poor outcomes of ibrutinib-exposed MCL patients. CUDC-907 inhibits both PI3K and HDAC functionality to exert synergistic or additive effects. Therefore, the activity of CUDC-907 was examined in MCL cell lines and patient primary cells, including ibrutinib-resistant MCL cells. The efficacy of CUDC-907 was further examined in an ibrutinib-resistant MCL patient-derived xenograft (PDX) mouse model. The molecular mechanisms by which CUDC-907 dually inhibits PI3K and histone deacetylation were assessed using reverse protein array, immunoblotting, and chromatin immunoprecipitation (ChIP) coupled with sequencing. We showed evidence that CUDC-907 treatment increased histone acetylation in MCL cells. We found that CUDC-907 caused decreased proliferation and increased apoptosis in MCL in vitro and in vivo MCL models. In addition, CUDC-907 was effective in inducing lethality in ibrutinib-resistant MCL cells. Lastly, CUDC-907 treatment increased histone acetylation in MCL cells. Overall, these studies suggest that CUDC-907 may be a promising therapeutic option for relapsed or resistant MCL.",Journal Article,453.0,2.0,The dysregulation of PI3K signaling has been implicated as an underlying mechanism associated with resistance to Bruton 's tyrosine kinase inhibition by ibrutinib in both chronic lymphocytic and mantle cell MCL Ibrutinib resistance has become a major unmet clinical need and the development of therapeutics to overcome ibrutinib resistance will greatly improve the poor outcomes of ibrutinib-exposed MCL patients CUDC-907 inhibits both PI3K and HDAC functionality to exert synergistic or additive effects Therefore the activity of CUDC-907 was examined in MCL cell lines and patient primary cells including ibrutinib-resistant MCL cells The efficacy of CUDC-907 was further examined in an ibrutinib-resistant MCL patient-derived xenograft PDX mouse model The molecular mechanisms by which CUDC-907 dually inhibits PI3K and histone deacetylation were assessed using reverse protein array immunoblotting and chromatin immunoprecipitation ChIP coupled with sequencing We showed evidence that CUDC-907 treatment increased histone acetylation in MCL cells We found that CUDC-907 caused decreased proliferation and increased apoptosis in MCL in vitro and in vivo MCL models In addition CUDC-907 was effective in inducing lethality in ibrutinib-resistant MCL cells Lastly CUDC-907 treatment increased histone acetylation in MCL cells Overall these studies suggest that CUDC-907 may be a promising therapeutic option for relapsed or resistant MCL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 3935, 1, 974, 314, 71, 85, 1771, 22, 35, 1181, 670, 41, 5, 251, 6, 5796, 292, 564, 216, 297, 20, 1795, 4, 110, 442, 1193, 2, 2757, 31, 1308, 1795, 251, 71, 1417, 8, 458, 3715, 38, 594, 2, 3, 193, 1, 1943, 6, 1768, 1795, 251, 303, 3510, 401, 3, 334, 123, 1, 1795, 2234, 1308, 7, 10252, 8878, 1576, 110, 974, 2, 2654, 8592, 6, 5448, 1806, 15, 3396, 176, 673, 3, 128, 1, 10252, 8878, 10, 409, 4, 1308, 31, 285, 2, 69, 86, 37, 141, 1795, 436, 1308, 37, 3, 209, 1, 10252, 8878, 10, 195, 409, 4, 35, 1795, 436, 1308, 69, 526, 1330, 3250, 830, 202, 3, 219, 483, 20, 92, 10252, 8878, 11409, 1576, 974, 2, 1508, 15191, 11, 275, 75, 1772, 178, 1926, 5293, 2, 2287, 4857, 4222, 3332, 5, 615, 21, 224, 241, 17, 10252, 8878, 24, 101, 1508, 4145, 4, 1308, 37, 21, 204, 17, 10252, 8878, 1546, 340, 457, 2, 101, 351, 4, 1308, 4, 439, 2, 4, 386, 1308, 274, 4, 352, 10252, 8878, 10, 323, 4, 1958, 3266, 4, 1795, 436, 1308, 37, 6354, 10252, 8878, 24, 101, 1508, 4145, 4, 1308, 37, 63, 46, 94, 309, 17, 10252, 8878, 68, 40, 8, 721, 189, 1501, 9, 591, 15, 436, 1308]",1438.0,30361685,289
PI3K p110 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.,The Journal of clinical investigation,J. Clin. Invest.,2018-11-19,"Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110 inhibitor idelalisib. Here, we found that genetic inactivation of p110 (p110D910A/D910A) in the E-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110 inactivation led to rectal prolapse in mice resembling autoimmune colitis in patients receiving idelalisib. Moreover, we showed that p110 inactivation in the microenvironment protected against CLL and acute myeloid leukemia. After receiving higher numbers of TCL1 leukemia cells, half of p110D910A/D910A mice spontaneously recovered from high disease burden and resisted leukemia rechallenge. Despite disease resistance, p110D910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response, and depletion of CD4+ or CD8+ T cells restored leukemia. Interestingly, p110D910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance. Reconstitution of p110D910A/D910A mice with p110WT/WT Tregs reversed leukemia resistance. Our findings suggest that p110 inhibitors may have direct antileukemic and indirect immune-activating effects, further supporting that p110 blockade may have a broader immune-modulatory role in types of leukemia that are not sensitive to p110 inhibition.",Journal Article,428.0,4.0,Targeted therapy with small molecules directed at essential survival pathways in represents a major advance including the phosphatidylinositol-3'-kinase PI3K p110 inhibitor idelalisib Here we found that genetic inactivation of p110 p110D910A/D910A in the E-TCL1 murine chronic lymphocytic CLL model impaired B cell receptor signaling and B cell migration and significantly delayed pathogenesis Regardless of TCL1 expression p110 inactivation led to prolapse in mice resembling autoimmune colitis in patients receiving idelalisib Moreover we showed that p110 inactivation in the microenvironment protected against CLL and acute myeloid After receiving higher numbers of TCL1 cells half of p110D910A/D910A mice spontaneously recovered from high disease burden and resisted rechallenge Despite disease resistance p110D910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response and depletion of CD4+ or CD8+ T cells restored Interestingly p110D910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance Reconstitution of p110D910A/D910A mice with p110WT/WT Tregs reversed resistance Our findings suggest that p110 inhibitors may have direct antileukemic and indirect immune-activating effects further supporting that p110 blockade may have a broader immune-modulatory role in types of that are not sensitive to p110 inhibition,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,"[238, 36, 5, 302, 1598, 1166, 28, 1452, 25, 460, 4, 1449, 8, 458, 3148, 141, 3, 3415, 5435, 216, 974, 15762, 230, 7083, 467, 21, 204, 17, 336, 2297, 1, 15762, 32930, 32931, 4, 3, 17467, 8979, 1471, 442, 1193, 552, 202, 2364, 132, 31, 153, 314, 2, 132, 31, 1381, 2, 97, 1612, 1384, 1583, 1, 8979, 55, 15762, 2297, 836, 6, 38025, 4, 399, 8855, 3445, 4132, 4, 7, 357, 7083, 1393, 21, 224, 17, 15762, 2297, 4, 3, 995, 5541, 480, 552, 2, 286, 533, 50, 357, 142, 1870, 1, 8979, 37, 1303, 1, 32930, 32931, 399, 6459, 5784, 29, 64, 34, 892, 2, 21517, 9423, 550, 34, 251, 32930, 32931, 399, 1416, 4867, 1440, 2, 968, 102, 31, 51, 2, 2286, 1, 1440, 15, 968, 102, 37, 4138, 2873, 32930, 32931, 399, 224, 97, 2364, 3960, 1422, 17, 41, 5, 34, 1960, 5616, 1, 32930, 32931, 399, 5, 74054, 1820, 3975, 3682, 251, 114, 272, 309, 17, 15762, 222, 68, 47, 1196, 4512, 2, 6110, 250, 1616, 176, 195, 1912, 17, 15762, 1189, 68, 47, 8, 5410, 250, 11424, 200, 4, 630, 1, 17, 32, 44, 745, 6, 15762, 297]",1386.0,30457982,356
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.,The New England journal of medicine,N. Engl. J. Med.,2018-12-01,"Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. Patients 65 years of age or older who had untreated CLL were randomly assigned to receive bendamustine plus rituximab, ibrutinib, or ibrutinib plus rituximab. The primary end point was progression-free survival. The Alliance Data and Safety Monitoring Board made the decision to release the data after the protocol-specified efficacy threshold had been met. A total of 183 patients were assigned to receive bendamustine plus rituximab, 182 to receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median progression-free survival was reached only with bendamustine plus rituximab. The estimated percentage of patients with progression-free survival at 2 years was 74% with bendamustine plus rituximab and was higher with ibrutinib alone (87%; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 0.58; P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 0.25 to 0.59; P<0.001). There was no significant difference between the ibrutinib-plus-rituximab group and the ibrutinib group with regard to progression-free survival (hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P=0.49). With a median follow-up of 38 months, there was no significant difference among the three treatment groups with regard to overall survival. The rate of grade 3, 4, or 5 hematologic adverse events was higher with bendamustine plus rituximab (61%) than with ibrutinib or ibrutinib plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 nonhematologic adverse events was lower with bendamustine plus rituximab (63%) than with the ibrutinib-containing regimens (74% with each regimen). Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival. There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival. (Funded by the National Cancer Institute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872 .).","Clinical Trial, Phase III",416.0,86.0,Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic CLL since 2016 but has not been compared with chemoimmunotherapy We conducted a phase 3 trial to evaluate the efficacy of ibrutinib either alone or in combination with rituximab relative to chemoimmunotherapy Patients 65 years of age or older who had untreated CLL were randomly assigned to receive bendamustine plus rituximab ibrutinib or ibrutinib plus rituximab The primary end point was progression-free survival The Alliance Data and Safety Monitoring Board made the decision to release the data after the protocol-specified efficacy threshold had been met A total of 183 patients were assigned to receive bendamustine plus rituximab 182 to receive ibrutinib and 182 to receive ibrutinib plus rituximab Median progression-free survival was reached only with bendamustine plus rituximab The estimated percentage of patients with progression-free survival at 2 years was 74 with bendamustine plus rituximab and was higher with ibrutinib alone 87 hazard ratio for disease progression or death 0.39 95 confidence interval CI 0.26 to 0.58 P 0.001 and with ibrutinib plus rituximab 88 hazard ratio 0.38 95 CI 0.25 to 0.59 P 0.001 There was no significant difference between the ibrutinib-plus-rituximab group and the ibrutinib group with regard to progression-free survival hazard ratio 1.00 95 CI 0.62 to 1.62 P=0.49 With a median follow-up of 38 months there was no significant difference among the three treatment groups with regard to overall survival The rate of grade 3 4 or 5 hematologic adverse events was higher with bendamustine plus rituximab 61 than with ibrutinib or ibrutinib plus rituximab 41 and 39 respectively whereas the rate of grade 3 4 or 5 nonhematologic adverse events was lower with bendamustine plus rituximab 63 than with the ibrutinib-containing regimens 74 with each regimen Among older patients with untreated CLL treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival Funded by the National Cancer Institute and Pharmacyclics ClinicalTrials.gov number NCT01886872,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 71, 85, 850, 20, 3, 1773, 2, 234, 634, 9, 3, 24, 1, 7, 5, 1278, 442, 1193, 552, 1192, 1390, 84, 71, 44, 85, 72, 5, 4438, 21, 426, 8, 124, 27, 160, 6, 376, 3, 209, 1, 1795, 361, 279, 15, 4, 150, 5, 855, 580, 6, 4438, 7, 556, 60, 1, 89, 15, 434, 54, 42, 1278, 552, 11, 1108, 896, 6, 560, 4809, 349, 855, 1795, 15, 1795, 349, 855, 3, 86, 396, 741, 10, 91, 115, 25, 3, 7127, 74, 2, 367, 1315, 2620, 1229, 3, 948, 6, 2008, 3, 74, 50, 3, 1182, 3575, 209, 2390, 42, 85, 543, 8, 181, 1, 6348, 7, 11, 896, 6, 560, 4809, 349, 855, 5160, 6, 560, 1795, 2, 5160, 6, 560, 1795, 349, 855, 52, 91, 115, 25, 10, 1300, 158, 5, 4809, 349, 855, 3, 661, 1150, 1, 7, 5, 91, 115, 25, 28, 18, 60, 10, 794, 5, 4809, 349, 855, 2, 10, 142, 5, 1795, 279, 912, 360, 197, 9, 34, 91, 15, 273, 13, 587, 48, 307, 268, 58, 13, 432, 6, 13, 717, 19, 13, 144, 2, 5, 1795, 349, 855, 889, 360, 197, 13, 519, 48, 58, 13, 243, 6, 13, 728, 19, 13, 144, 125, 10, 77, 93, 523, 59, 3, 1795, 349, 855, 87, 2, 3, 1795, 87, 5, 2539, 6, 91, 115, 25, 360, 197, 14, 2038, 48, 58, 13, 744, 6, 14, 744, 19, 13, 739, 5, 8, 52, 166, 126, 1, 519, 53, 125, 10, 77, 93, 523, 107, 3, 169, 24, 271, 5, 2539, 6, 63, 25, 3, 116, 1, 88, 27, 39, 15, 33, 813, 290, 281, 10, 142, 5, 4809, 349, 855, 713, 76, 5, 1795, 15, 1795, 349, 855, 605, 2, 587, 106, 547, 3, 116, 1, 88, 27, 39, 15, 33, 3534, 290, 281, 10, 280, 5, 4809, 349, 855, 676, 76, 5, 3, 1795, 1101, 472, 794, 5, 296, 477, 107, 434, 7, 5, 1278, 552, 24, 5, 1795, 10, 1123, 6, 24, 5, 4809, 349, 855, 5, 2539, 6, 91, 115, 25, 125, 10, 77, 93, 523, 59, 1795, 2, 1795, 349, 855, 5, 2539, 6, 91, 115, 25, 3827, 20, 3, 657, 12, 1377, 2, 20013, 1252, 1239, 207, 74102]",2316.0,30501481,395
Selecting Frontline Therapy for CLL in 2018.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2018-11-01,"The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years. The role of chemoimmunotherapy has declined significantly for patients with CLL. Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if <i>IGHV</i> mutated. For older adults, ibrutinib has been shown to be superior to chlorambucil. Hence, the role of chlorambucil monotherapy in the current era in the management of CLL is limited. The combination of chlorambucil and obinutuzumab is an alternative option for patients with comorbidities. For patients with del(17p), ibrutinib has become the standard treatment in the frontline setting. Several phase 3 trials with novel targeted agents, either as monotherapy or in combination, are either ongoing or have completed accrual. The results of many of these trials are expected in the next 1 to 2 years, and they will further help refine the frontline treatment strategy.",Journal Article,446.0,2.0,The treatment landscape of chronic lymphocytic CLL has changed dramatically in the last few years The role of chemoimmunotherapy has declined significantly for patients with CLL Fludarabine cyclophosphamide rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL especially if i IGHV /i mutated For older adults ibrutinib has been shown to be superior to chlorambucil Hence the role of chlorambucil monotherapy in the current era in the management of CLL is limited The combination of chlorambucil and obinutuzumab is an alternative option for patients with comorbidities For patients with del 17p ibrutinib has become the standard treatment in the frontline setting Several phase 3 trials with novel targeted agents either as monotherapy or in combination are either ongoing or have completed accrual The results of many of these trials are expected in the next 1 to 2 years and they will further help refine the frontline treatment strategy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 24, 2801, 1, 442, 1193, 552, 71, 2368, 2729, 4, 3, 1060, 1021, 60, 3, 200, 1, 4438, 71, 3054, 97, 9, 7, 5, 552, 2027, 1112, 855, 56, 469, 3, 260, 3171, 36, 9, 1169, 2975, 7, 5, 552, 1093, 492, 70, 6220, 70, 1185, 9, 434, 857, 1795, 71, 85, 443, 6, 40, 1123, 6, 11585, 3665, 3, 200, 1, 11585, 1411, 4, 3, 291, 1713, 4, 3, 284, 1, 552, 16, 383, 3, 150, 1, 11585, 2, 10380, 16, 35, 1091, 1501, 9, 7, 5, 1909, 9, 7, 5, 3084, 4135, 1795, 71, 1417, 3, 260, 24, 4, 3, 3171, 546, 392, 124, 27, 143, 5, 229, 238, 183, 361, 22, 1411, 15, 4, 150, 32, 361, 942, 15, 47, 781, 2262, 3, 99, 1, 445, 1, 46, 143, 32, 1336, 4, 3, 1305, 14, 6, 18, 60, 2, 491, 303, 195, 987, 5003, 3, 3171, 24, 692]",980.0,30504317,50
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.,Cancer,Cancer,2018-12-03,"In a proportion of patients with chronic lymphocytic leukemia (CLL), resistance to Bruton tyrosine kinase (BTK) inhibitors (BTKi) is attributed to acquired BTK/phospholipase C gamma 2 (PLCG2) mutations. However, knowledge regarding additional genetic lesions associated with BTK/PLCG2 mutations, and gene mutations in patients lacking BTK/PLCG2 mutations, is limited. Using targeted deep sequencing, mutations in 29 genes associated with CLL and/or the BCR signaling pathway were assessed in patients with CLL who developed resistance to BTK inhibition with ibrutinib/acalabrutinib at a single institution. The study group included 29 patients with BTKi-resistant CLL, 23 patients with disease progression, and 6 patients with Richter transformation (RT). The median times to disease progression and RT were 33.3 months and 13.3 months, respectively. In 11 patients, sequencing was possible at both baseline (prior to treatment with BTKi) and at time of disease progression/RT. Of these patients, 4 demonstrated BTK mutations at the time of disease progression/RT; patients without BTK mutations frequently acquired mutations associated with disease progression/RT in TP53, SF3B1, and CARD11, whereas additional mutations were rare in patients with BTK-mutated CLL. Sequencing of all 29 patients at the time of disease progression/RT identified BTK mutations at a frequency of 66%, including a novel V537I mutation. Among patients with disease progression, BTK mutations were observed in 16 patients (70%). The median time to disease progression was shorter in patients without BTK mutations compared with those with BTK-mutated CLL. Among patients with RT, SF3B1 mutations were more frequent than BTK mutations (67% vs 50%). Following BTKi discontinuation, we sequential mutation analysis was performed in 2 patients with RT and 3 patients with disease progression in the setting of persistent disease. Both patients with RT demonstrated disappearance of BTK and expansion of TP53 mutations. All 3 patients with disease progression received venetoclax and demonstrated suppression of BTK mutations. Longitudinal, targeted, multigene deep sequencing is informative for the clinical monitoring of mutational evolution in patients with CLL who are receiving BTKi.",Journal Article,414.0,7.0,In a proportion of patients with chronic lymphocytic CLL resistance to Bruton tyrosine kinase BTK inhibitors BTKi is attributed to acquired BTK/phospholipase C gamma 2 PLCG2 mutations However knowledge regarding additional genetic lesions associated with BTK/PLCG2 mutations and gene mutations in patients lacking BTK/PLCG2 mutations is limited Using targeted deep sequencing mutations in 29 genes associated with CLL and/or the BCR signaling pathway were assessed in patients with CLL who developed resistance to BTK inhibition with ibrutinib/acalabrutinib at a single institution The study group included 29 patients with BTKi-resistant CLL 23 patients with disease progression and 6 patients with Richter transformation RT The median times to disease progression and RT were 33.3 months and 13.3 months respectively In 11 patients sequencing was possible at both baseline prior to treatment with BTKi and at time of disease progression/RT Of these patients 4 demonstrated BTK mutations at the time of disease progression/RT patients without BTK mutations frequently acquired mutations associated with disease progression/RT in TP53 SF3B1 and CARD11 whereas additional mutations were rare in patients with BTK-mutated CLL Sequencing of all 29 patients at the time of disease progression/RT identified BTK mutations at a frequency of 66 including a novel V537I mutation Among patients with disease progression BTK mutations were observed in 16 patients 70 The median time to disease progression was shorter in patients without BTK mutations compared with those with BTK-mutated CLL Among patients with RT SF3B1 mutations were more frequent than BTK mutations 67 vs 50 Following BTKi discontinuation we sequential mutation analysis was performed in 2 patients with RT and 3 patients with disease progression in the setting of persistent disease Both patients with RT demonstrated disappearance of BTK and expansion of TP53 mutations All 3 patients with disease progression received venetoclax and demonstrated suppression of BTK mutations Longitudinal targeted multigene deep sequencing is informative for the clinical monitoring of mutational evolution in patients with CLL who are receiving BTKi,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 8, 920, 1, 7, 5, 442, 1193, 552, 251, 6, 5796, 564, 216, 3611, 222, 32935, 16, 3073, 6, 1294, 3611, 16685, 256, 1705, 18, 15432, 138, 137, 922, 666, 402, 336, 406, 41, 5, 3611, 15432, 138, 2, 145, 138, 4, 7, 1941, 3611, 15432, 138, 16, 383, 75, 238, 2369, 615, 138, 4, 462, 214, 41, 5, 552, 2, 15, 3, 1062, 314, 308, 11, 275, 4, 7, 5, 552, 54, 276, 251, 6, 3611, 297, 5, 1795, 11378, 28, 8, 226, 731, 3, 45, 87, 159, 462, 7, 5, 32935, 436, 552, 382, 7, 5, 34, 91, 2, 49, 7, 5, 8452, 1392, 240, 3, 52, 1072, 6, 34, 91, 2, 240, 11, 466, 27, 53, 2, 233, 27, 53, 106, 4, 175, 7, 615, 10, 899, 28, 110, 330, 324, 6, 24, 5, 32935, 2, 28, 98, 1, 34, 91, 240, 1, 46, 7, 39, 264, 3611, 138, 28, 3, 98, 1, 34, 91, 240, 7, 187, 3611, 138, 746, 1294, 138, 41, 5, 34, 91, 240, 4, 1206, 10132, 2, 23962, 547, 402, 138, 11, 622, 4, 7, 5, 3611, 1185, 552, 615, 1, 62, 462, 7, 28, 3, 98, 1, 34, 91, 240, 108, 3611, 138, 28, 8, 675, 1, 700, 141, 8, 229, 74111, 258, 107, 7, 5, 34, 91, 3611, 138, 11, 164, 4, 245, 7, 431, 3, 52, 98, 6, 34, 91, 10, 985, 4, 7, 187, 3611, 138, 72, 5, 135, 5, 3611, 1185, 552, 107, 7, 5, 240, 10132, 138, 11, 80, 908, 76, 3611, 138, 598, 105, 212, 366, 32935, 2007, 21, 1787, 258, 65, 10, 173, 4, 18, 7, 5, 240, 2, 27, 7, 5, 34, 91, 4, 3, 546, 1, 1882, 34, 110, 7, 5, 240, 264, 13528, 1, 3611, 2, 1422, 1, 1206, 138, 62, 27, 7, 5, 34, 91, 103, 4454, 2, 264, 1332, 1, 3611, 138, 2380, 238, 6339, 2369, 615, 16, 4189, 9, 3, 38, 1315, 1, 1619, 2554, 4, 7, 5, 552, 54, 32, 357, 32935]",2197.0,30508305,59
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-12-03,"The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and updated outcomes. Patients were randomly assigned to 2 years of venetoclax plus rituximab during the first six cycles, or six cycles of bendamustine-rituximab. Primary end point was PFS. Safety and peripheral blood (PB) MRD status-at cycle 4, 2 to 3 months after end of combination therapy (EOCT), and every 3 to 6 months thereafter-were secondary end points. Of 194 patients, 174 (90%) completed the venetoclax-rituximab phase and 130 (67%) completed 2 years of venetoclax. With a median follow-up of 36 months, PFS and overall survival remain superior to bendamustine-rituximab (hazard ratio, 0.16 [95% CI, 0.12 to 0.23]; and hazard ratio, 0.50 [95% CI, 0.30 to 0.85], respectively). Patients who received venetoclax-rituximab achieved a higher rate of PB undetectable MRD (uMRD; less than 10<sup>-4</sup>) at EOCT (62% v 13%) with superiority sustained through month 24 (end of therapy). Overall, uMRD status at EOCT predicted longer PFS. Among those with detectable MRD, low-level MRD (10<sup>-4</sup> to less than 10<sup>-2</sup>) predicted improved PFS compared with high-level MRD (10<sup>-2</sup> or greater). At a median of 9.9 months (range, 1.4 to 22.5 months) after completing fixed-duration venetoclax-rituximab, overall only 12% (16 of 130) of patients developed disease progression (11 high-level MRD, three low-level MRD). At the end of therapy, 70% and 98% of patients with uMRD remained in uMRD and without disease progression, respectively. With all patients having finished treatment, continued benefit was observed for venetoclax-rituximab compared with bendamustine-rituximab. uMRD rates were durable and predicted longer PFS, which establishes the impact of PB MRD on the benefit of fixed-duration, venetoclax-containing treatment. Low conversion to detectable MRD and sustained PFS after completion of 2 years of venetoclax-rituximab demonstrate the feasibility of this regimen.","Clinical Trial, Phase III",414.0,35.0,The MURANO study demonstrated significant progression-free survival PFS benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic With all patients off treatment we report minimal residual disease MRD kinetics and updated outcomes Patients were randomly assigned to 2 years of venetoclax plus rituximab during the first six cycles or six cycles of bendamustine-rituximab Primary end point was PFS Safety and peripheral blood PB MRD status-at cycle 4 2 to 3 months after end of combination therapy EOCT and every 3 to 6 months thereafter-were secondary end points Of 194 patients 174 90 completed the venetoclax-rituximab phase and 130 67 completed 2 years of venetoclax With a median follow-up of 36 months PFS and overall survival remain superior to bendamustine-rituximab hazard ratio 0.16 95 CI 0.12 to 0.23 and hazard ratio 0.50 95 CI 0.30 to 0.85 respectively Patients who received venetoclax-rituximab achieved a higher rate of PB undetectable MRD uMRD less than 10 sup -4 /sup at EOCT 62 v 13 with superiority sustained through month 24 end of therapy Overall uMRD status at EOCT predicted longer PFS Among those with detectable MRD low-level MRD 10 sup -4 /sup to less than 10 sup -2 /sup predicted improved PFS compared with high-level MRD 10 sup -2 /sup or greater At a median of 9.9 months range 1.4 to 22.5 months after completing fixed-duration venetoclax-rituximab overall only 12 16 of 130 of patients developed disease progression 11 high-level MRD three low-level MRD At the end of therapy 70 and 98 of patients with uMRD remained in uMRD and without disease progression respectively With all patients having finished treatment continued benefit was observed for venetoclax-rituximab compared with bendamustine-rituximab uMRD rates were durable and predicted longer PFS which establishes the impact of PB MRD on the benefit of fixed-duration venetoclax-containing treatment Low conversion to detectable MRD and sustained PFS after completion of 2 years of venetoclax-rituximab demonstrate the feasibility of this regimen,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 74138, 45, 264, 93, 91, 115, 25, 300, 247, 9, 1959, 654, 4454, 855, 72, 5, 4809, 855, 4, 591, 430, 442, 1193, 5, 62, 7, 1889, 24, 21, 414, 1048, 753, 34, 2029, 3839, 2, 2939, 123, 7, 11, 1108, 896, 6, 18, 60, 1, 4454, 349, 855, 190, 3, 157, 437, 410, 15, 437, 410, 1, 4809, 855, 86, 396, 741, 10, 300, 367, 2, 672, 315, 3767, 2029, 156, 28, 417, 39, 18, 6, 27, 53, 50, 396, 1, 150, 36, 42202, 2, 454, 27, 6, 49, 53, 3972, 11, 568, 396, 862, 1, 5434, 7, 5811, 424, 781, 3, 4454, 855, 124, 2, 3431, 598, 781, 18, 60, 1, 4454, 5, 8, 52, 166, 126, 1, 511, 53, 300, 2, 63, 25, 918, 1123, 6, 4809, 855, 360, 197, 13, 245, 48, 58, 13, 133, 6, 13, 382, 2, 360, 197, 13, 212, 48, 58, 13, 201, 6, 13, 772, 106, 7, 54, 103, 4454, 855, 513, 8, 142, 116, 1, 3767, 3920, 2029, 27718, 299, 76, 79, 172, 39, 172, 28, 42202, 744, 603, 233, 5, 5233, 2275, 298, 811, 259, 396, 1, 36, 63, 27718, 156, 28, 42202, 783, 589, 300, 107, 135, 5, 2083, 2029, 154, 301, 2029, 79, 172, 39, 172, 6, 299, 76, 79, 172, 18, 172, 783, 231, 300, 72, 5, 64, 301, 2029, 79, 172, 18, 172, 15, 378, 28, 8, 52, 1, 83, 83, 53, 184, 14, 39, 6, 350, 33, 53, 50, 4144, 1959, 654, 4454, 855, 63, 158, 133, 245, 1, 3431, 1, 7, 276, 34, 91, 175, 64, 301, 2029, 169, 154, 301, 2029, 28, 3, 396, 1, 36, 431, 2, 1096, 1, 7, 5, 27718, 958, 4, 27718, 2, 187, 34, 91, 106, 5, 62, 7, 1041, 20455, 24, 1351, 247, 10, 164, 9, 4454, 855, 72, 5, 4809, 855, 27718, 151, 11, 1480, 2, 783, 589, 300, 92, 7410, 3, 345, 1, 3767, 2029, 23, 3, 247, 1, 1959, 654, 4454, 1101, 24, 154, 3111, 6, 2083, 2029, 2, 2275, 300, 50, 1438, 1, 18, 60, 1, 4454, 855, 608, 3, 1437, 1, 26, 477]",2107.0,30523712,4
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.,Blood,Blood,2018-12-07,"Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28-day cycles of once-daily ibrutinib 420 mg, either as a single agent (n = 104), or together with rituximab (375 mg/m<sup>2</sup>; n = 104), given weekly during cycle 1, then once per cycle until cycle 6. The primary end point was progression-free survival (PFS) in the intention-to-treat population. We enrolled 208 patients with CLL, 181 with relapsed CLL and 27 treatment-naive patients with high-risk disease (17p deletion or <i>TP53</i> mutation). After a median follow-up of 36 months, the Kaplan-Meier estimates of PFS were 86% (95% confidence interval [CI], 76.6-91.9) for patients receiving ibrutinib, and 86.9% (95% CI, 77.3-92.6) for patients receiving ibrutinib plus rituximab. Similarly, response rates were the same in both arms (overall response rate, 92%). However, time to normalization of peripheral blood lymphocyte counts and time to complete remission were shorter, and residual disease levels in the bone marrow were lower, in patients receiving ibrutinib plus rituximab. We conclude that the addition of rituximab to ibrutinib in relapsed and treatment-naive high-risk patients with CLL failed to show improvement in PFS. However, patients treated with ibrutinib plus rituximab reached their remissions faster and achieved significantly lower residual disease levels. Given these results, ibrutinib as single-agent therapy remains current standard-of-care treatment in CLL. This trial was registered at www.clinicaltrials.gov as #NCT02007044.","Clinical Trial, Phase II",410.0,18.0,Ibrutinib an oral covalent inhibitor of Bruton 's tyrosine kinase is an effective therapy for patients with chronic lymphocytic CLL To determine whether rituximab provides added benefit to ibrutinib we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab Patients with CLL requiring therapy were randomized to receive 28-day cycles of once-daily ibrutinib 420 mg either as a single agent n 104 or together with rituximab 375 mg/m sup 2 /sup n 104 given weekly during cycle 1 then once per cycle until cycle 6 The primary end point was progression-free survival PFS in the intention-to-treat population We enrolled 208 patients with CLL 181 with relapsed CLL and 27 treatment-naive patients with high-risk disease 17p deletion or i TP53 /i mutation After a median follow-up of 36 months the Kaplan-Meier estimates of PFS were 86 95 confidence interval CI 76.6-91.9 for patients receiving ibrutinib and 86.9 95 CI 77.3-92.6 for patients receiving ibrutinib plus rituximab Similarly response rates were the same in both arms overall response rate 92 However time to normalization of peripheral blood lymphocyte counts and time to complete remission were shorter and residual disease levels in the marrow were lower in patients receiving ibrutinib plus rituximab We conclude that the addition of rituximab to ibrutinib in relapsed and treatment-naive high-risk patients with CLL failed to show improvement in PFS However patients treated with ibrutinib plus rituximab reached their remissions faster and achieved significantly lower residual disease levels Given these results ibrutinib as single-agent therapy remains current standard-of-care treatment in CLL This trial was registered at www.clinicaltrials.gov as NCT02007044,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 35, 518, 10747, 230, 1, 5796, 292, 564, 216, 16, 35, 323, 36, 9, 7, 5, 442, 1193, 552, 6, 223, 317, 855, 777, 1953, 247, 6, 1795, 21, 426, 8, 384, 226, 574, 160, 1, 1795, 105, 1795, 349, 855, 7, 5, 552, 1888, 36, 11, 384, 6, 560, 339, 218, 410, 1, 1059, 391, 1795, 5401, 81, 361, 22, 8, 226, 420, 78, 3407, 15, 1162, 5, 855, 4175, 81, 188, 172, 18, 172, 78, 3407, 447, 709, 190, 417, 14, 818, 1059, 379, 417, 1100, 417, 49, 3, 86, 396, 741, 10, 91, 115, 25, 300, 4, 3, 3205, 6, 943, 266, 21, 346, 5920, 7, 5, 552, 5540, 5, 591, 552, 2, 428, 24, 2462, 7, 5, 64, 43, 34, 4135, 1528, 15, 70, 1206, 70, 258, 50, 8, 52, 166, 126, 1, 511, 53, 3, 876, 882, 1423, 1, 300, 11, 868, 48, 307, 268, 58, 846, 49, 970, 83, 9, 7, 357, 1795, 2, 868, 83, 48, 58, 849, 27, 937, 49, 9, 7, 357, 1795, 349, 855, 1813, 51, 151, 11, 3, 827, 4, 110, 1335, 63, 51, 116, 937, 137, 98, 6, 5924, 1, 672, 315, 1448, 1911, 2, 98, 6, 236, 734, 11, 985, 2, 753, 34, 148, 4, 3, 581, 11, 280, 4, 7, 357, 1795, 349, 855, 21, 2060, 17, 3, 352, 1, 855, 6, 1795, 4, 591, 2, 24, 2462, 64, 43, 7, 5, 552, 1551, 6, 514, 767, 4, 300, 137, 7, 73, 5, 1795, 349, 855, 1300, 136, 3166, 5308, 2, 513, 97, 280, 753, 34, 148, 447, 46, 99, 1795, 22, 226, 420, 36, 469, 291, 260, 1, 165, 24, 4, 552, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 74151]",1754.0,30530801,203
Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2018-10-01,"Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and treatment of these autoimmune disorders, specifically in the setting of B-cell malignancies. AIHA and ITP are classically associated with chronic lymphocytic leukemia (CLL) but have also been reported in plasmacytic and lymphoproliferative disorders. AIHA includes both warm AIHA and cold agglutinin disease, the latter of which is strongly associated with Waldenstrm macroglobulinemia. The pathogenesis of these cytopenias varies with the underlying disease, but malignant cells serving as antigen-presenting cells to T lymphocytes, with the generation of autoreactive lymphocytes, may be involved. The diagnosis requires the presence of hemolysis and a positive direct antiglobulin test result. In a minority of cases, the direct antiglobulin test result is negative, and more specialized testing may be required. Data on the prognostic effect of these comorbidities are conflicting, and the prognosis may vary depending on when in the B-cell malignant process the cytopenia(s) develops. The treatment of AIHA and ITP in the setting of B-cell lymphoproliferative disorders often involves treatment of the underlying disorder, although in some cases of CLL, treatment of the underlying disorder is not indicated, and management is similar to that for idiopathic AIHA or ITP.",Journal Article,477.0,1.0,Autoimmune hemolytic anemia AIHA and immune thrombocytopenia purpura ITP have been associated with B-cell lymphoproliferative disorders Here we review the epidemiology pathogenesis diagnosis and treatment of these autoimmune disorders specifically in the setting of B-cell malignancies AIHA and ITP are classically associated with chronic lymphocytic CLL but have also been reported in plasmacytic and lymphoproliferative disorders AIHA includes both warm AIHA and cold agglutinin disease the latter of which is strongly associated with Waldenstrm macroglobulinemia The pathogenesis of these cytopenias varies with the underlying disease but malignant cells serving as antigen-presenting cells to T lymphocytes with the generation of autoreactive lymphocytes may be involved The diagnosis requires the presence of hemolysis and a positive direct antiglobulin test result In a minority of cases the direct antiglobulin test result is negative and more specialized testing may be required Data on the prognostic effect of these comorbidities are conflicting and the prognosis may vary depending on when in the B-cell malignant process the cytopenia s develops The treatment of AIHA and ITP in the setting of B-cell lymphoproliferative disorders often involves treatment of the underlying disorder although in some cases of CLL treatment of the underlying disorder is not indicated and management is similar to that for idiopathic AIHA or ITP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3445, 10425, 1545, 13636, 2, 250, 1340, 14174, 14094, 47, 85, 41, 5, 132, 31, 4192, 1997, 467, 21, 206, 3, 1284, 1384, 147, 2, 24, 1, 46, 3445, 1997, 1225, 4, 3, 546, 1, 132, 31, 441, 13636, 2, 14094, 32, 9260, 41, 5, 442, 1193, 552, 84, 47, 120, 85, 210, 4, 22331, 2, 4192, 1997, 13636, 1920, 110, 15609, 13636, 2, 5945, 20553, 34, 3, 3286, 1, 92, 16, 1327, 41, 5, 3700, 3389, 3, 1384, 1, 46, 5635, 4037, 5, 3, 1181, 34, 84, 393, 37, 6823, 22, 448, 1656, 37, 6, 102, 1594, 5, 3, 914, 1, 28526, 1594, 68, 40, 646, 3, 147, 1706, 3, 463, 1, 17966, 2, 8, 109, 1196, 42211, 412, 757, 4, 8, 2652, 1, 140, 3, 1196, 42211, 412, 757, 16, 199, 2, 80, 4791, 471, 68, 40, 616, 74, 23, 3, 177, 254, 1, 46, 1909, 32, 4274, 2, 3, 356, 68, 2825, 3221, 23, 198, 4, 3, 132, 31, 393, 1129, 3, 8165, 695, 4734, 3, 24, 1, 13636, 2, 14094, 4, 3, 546, 1, 132, 31, 4192, 1997, 629, 2921, 24, 1, 3, 1181, 2645, 242, 4, 476, 140, 1, 552, 24, 1, 3, 1181, 2645, 16, 44, 1103, 2, 284, 16, 288, 6, 17, 9, 7540, 13636, 15, 14094]",1440.0,30543597,139
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.,American journal of hematology,Am. J. Hematol.,2019-01-08,"The prevalence, clinicopathologic correlates, and outcomes of previously untreated chronic lymphocytic leukemia (CLL) patients with IGH-BCL2 and IGH-BCL3 translocations are not well known. Using the Mayo Clinic CLL database, we identified patients seen between March 1, 2002 and September 30, 2016 who had FISH testing performed within 3 years of CLL diagnosis. The prognostic profile, time to first therapy (TTT), and overall survival (OS) of patients with IGH-BCL2 and IGH-BCL3 translocation were compared to patients without these abnormalities (non-IGH group). Of 1684 patients who met the inclusion criteria, 38 (2.2%) had IGH-BCL2, and 16 (0.9%) had IGH-BCL3 translocation at diagnosis. Patients with IGH-BCL3 translocation were more likely to have high and very-high CLL-International Prognostic Index, compared to patients with IGH-BCL2 translocation and the non-IGH group. The 5-year probability of requiring therapy was significantly higher for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups (84% vs 33% vs 29%, respectively, P<0.0001). The 5-year OS was significantly shorter for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups (45% vs 89% vs 86%, respectively, P<0.0001). On multivariable analyses, IGH-BCL3 translocation was associated with a shorter TTT (hazard ratio [HR]=2.7; P=0.005) and shorter OS (HR=5.5; P<0.0001); IGH-BCL2 translocation did not impact TTT and OS. In conclusion, approximately 3% of all newly diagnosed CLL patients have either an IGH-BCL2 or IGH-BCL3 translocation. Patients with IGH-BCL3 translocations have a distinct prognostic profile and outcome. These results support the inclusion of an IGH probe during the routine evaluation of FISH abnormalities in newly diagnosed CLL.",Journal Article,378.0,0.0,The prevalence clinicopathologic correlates and outcomes of previously untreated chronic lymphocytic CLL patients with IGH-BCL2 and IGH-BCL3 translocations are not well known Using the Mayo Clinic CLL database we identified patients seen between March 1 2002 and September 30 2016 who had FISH testing performed within 3 years of CLL diagnosis The prognostic profile time to first therapy TTT and overall survival OS of patients with IGH-BCL2 and IGH-BCL3 translocation were compared to patients without these abnormalities non-IGH group Of 1684 patients who met the inclusion criteria 38 2.2 had IGH-BCL2 and 16 0.9 had IGH-BCL3 translocation at diagnosis Patients with IGH-BCL3 translocation were more likely to have high and very-high CLL-International Prognostic Index compared to patients with IGH-BCL2 translocation and the non-IGH group The 5-year probability of requiring therapy was significantly higher for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups 84 vs 33 vs 29 respectively P 0.0001 The 5-year OS was significantly shorter for IGH-BCL3 compared to IGH-BCL2 and non-IGH groups 45 vs 89 vs 86 respectively P 0.0001 On multivariable analyses IGH-BCL3 translocation was associated with a shorter TTT hazard ratio HR 2.7 P 0.005 and shorter OS HR 5.5 P 0.0001 IGH-BCL2 translocation did not impact TTT and OS In conclusion approximately 3 of all newly diagnosed CLL patients have either an IGH-BCL2 or IGH-BCL3 translocation Patients with IGH-BCL3 translocations have a distinct prognostic profile and outcome These results support the inclusion of an IGH probe during the routine evaluation of FISH abnormalities in newly diagnosed CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 1078, 1399, 1871, 2, 123, 1, 373, 1278, 442, 1193, 552, 7, 5, 5221, 3214, 2, 5221, 17938, 3262, 32, 44, 149, 440, 75, 3, 2486, 1188, 552, 609, 21, 108, 7, 527, 59, 2363, 14, 1544, 2, 2636, 201, 1390, 54, 42, 1277, 471, 173, 262, 27, 60, 1, 552, 147, 3, 177, 800, 98, 6, 157, 36, 10630, 2, 63, 25, 118, 1, 7, 5, 5221, 3214, 2, 5221, 17938, 2006, 11, 72, 6, 7, 187, 46, 1171, 220, 5221, 87, 1, 33434, 7, 54, 543, 3, 1680, 371, 519, 18, 18, 42, 5221, 3214, 2, 245, 13, 83, 42, 5221, 17938, 2006, 28, 147, 7, 5, 5221, 17938, 2006, 11, 80, 322, 6, 47, 64, 2, 923, 64, 552, 944, 177, 558, 72, 6, 7, 5, 5221, 3214, 2006, 2, 3, 220, 5221, 87, 3, 33, 111, 1320, 1, 1888, 36, 10, 97, 142, 9, 5221, 17938, 72, 6, 5221, 3214, 2, 220, 5221, 271, 874, 105, 466, 105, 462, 106, 19, 13, 488, 3, 33, 111, 118, 10, 97, 985, 9, 5221, 17938, 72, 6, 5221, 3214, 2, 220, 5221, 271, 512, 105, 887, 105, 868, 106, 19, 13, 488, 23, 658, 318, 5221, 17938, 2006, 10, 41, 5, 8, 985, 10630, 360, 197, 168, 18, 67, 19, 13, 1614, 2, 985, 118, 168, 33, 33, 19, 13, 488, 5221, 3214, 2006, 205, 44, 345, 10630, 2, 118, 4, 1221, 705, 27, 1, 62, 732, 265, 552, 7, 47, 361, 35, 5221, 3214, 15, 5221, 17938, 2006, 7, 5, 5221, 17938, 3262, 47, 8, 834, 177, 800, 2, 228, 46, 99, 538, 3, 1680, 1, 35, 5221, 2888, 190, 3, 1311, 451, 1, 1277, 1171, 4, 732, 265, 552]",1651.0,30575108,535
Synchronous Diagnosis of <i>De Novo</i> Acute Myeloid Leukemia with inv(16)(p13q22) and Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.,Annals of clinical and laboratory science,Ann. Clin. Lab. Sci.,2018-11-01,"The occurrence of <i>de novo</i> acute myeloid leukemia (AML) with chronic lymphocytic leukemia (CLL) is rare. Most cases of hematologic malignancies such as AML occurring in patients with pre-existing CLL are therapy-related. In this report, we describe a 65-year-old male with no past history of a hematolymphoid malignancy, who presented with abdominal pain. He was evaluated for acute diverticulitis, and incidentally found to have 14% circulating blasts upon peripheral blood smear review for anemia and thrombocytopenia. Bone marrow biopsy revealed 30-40% blasts and lymphoid aggregates. In conjunction with cytogenetics studies, a diagnosis of <i>de novo</i> AML with inv(16)(p13q22) CBFB-MYH11, trisomy 8, monosomy 18, and concurrent CLL with trisomy 12 was made. Serial FISH studies were used to demonstrate that the nuclei with (CBFB-MYH11) fusion did not have trisomy 12 and it was concluded that AML and CLL cells arose from separate clones. He died 3 weeks following presentation from complications of diverticulitis. To our knowledge, this is the second reported case of <i>de novo</i> AML with inv(16) and CLL.",Case Reports,446.0,0.0,The occurrence of i de novo /i acute myeloid AML with chronic lymphocytic CLL is rare Most cases of hematologic malignancies such as AML occurring in patients with pre-existing CLL are therapy-related In this report we describe a 65-year-old male with no past history of a hematolymphoid malignancy who presented with abdominal pain He was evaluated for acute diverticulitis and incidentally found to have 14 circulating blasts upon peripheral blood smear review for anemia and thrombocytopenia marrow biopsy revealed 30-40 blasts and lymphoid aggregates In conjunction with cytogenetics studies a diagnosis of i de novo /i AML with inv 16 p13q22 CBFB-MYH11 trisomy 8 monosomy 18 and concurrent CLL with trisomy 12 was made Serial FISH studies were used to demonstrate that the nuclei with CBFB-MYH11 fusion did not have trisomy 12 and it was concluded that AML and CLL cells arose from separate clones He died 3 weeks following presentation from complications of diverticulitis To our knowledge this is the second reported case of i de novo /i AML with inv 16 and CLL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2291, 1, 70, 1566, 2018, 70, 286, 533, 329, 5, 442, 1193, 552, 16, 622, 96, 140, 1, 813, 441, 225, 22, 329, 1821, 4, 7, 5, 671, 1692, 552, 32, 36, 139, 4, 26, 414, 21, 897, 8, 556, 111, 1095, 1045, 5, 77, 1219, 532, 1, 8, 37298, 710, 54, 917, 5, 1467, 559, 3174, 10, 194, 9, 286, 31430, 2, 5925, 204, 6, 47, 213, 1033, 2438, 1548, 672, 315, 8379, 206, 9, 1545, 2, 1340, 581, 411, 553, 201, 327, 2438, 2, 2303, 9586, 4, 3357, 5, 2510, 94, 8, 147, 1, 70, 1566, 2018, 70, 329, 5, 6397, 245, 22197, 14598, 11644, 6317, 66, 7521, 203, 2, 750, 552, 5, 6317, 133, 10, 1229, 2108, 1277, 94, 11, 95, 6, 608, 17, 3, 4725, 5, 14598, 11644, 1212, 205, 44, 47, 6317, 133, 2, 192, 10, 4724, 17, 329, 2, 552, 37, 7268, 29, 2282, 2749, 3174, 1016, 27, 244, 366, 1031, 29, 521, 1, 31430, 6, 114, 922, 26, 16, 3, 419, 210, 473, 1, 70, 1566, 2018, 70, 329, 5, 6397, 245, 2, 552]",1068.0,30610052,317
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.,Blood,Blood,2019-01-14,"Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients. With its widespread use in clinical practice, ibrutinib's common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, and arthralgias have been reported. The management of ibrutinib's adverse events often cannot be generalized but must be individualized to the patient and their long-term risk of additional complications. When ibrutinib was initially developed, there were limited therapeutic alternatives for CLL, which often resulted in treating through the adverse events. At the present time, there are several effective alternative agents available, so transition to an alternative CLL directed therapy may be considered. Given the continued expansion of ibrutinib across many therapeutic areas, investigation of the pathogenesis of adverse events with this agent and also clinical trials examining therapeutic approaches for complications arising during therapy are needed. Herein, we provide strategies we use in real-world CLL clinical practice to address common adverse events associated with ibrutinib.",Case Reports,372.0,8.0,Chronic lymphocytic CLL therapy has changed dramatically with the introduction of several targeted therapeutics Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients With its widespread use in clinical practice ibrutinib 's common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice In particular atrial fibrillation bleeding infections and arthralgias have been reported The management of ibrutinib 's adverse events often can not be generalized but must be individualized to the patient and their long-term risk of additional complications When ibrutinib was initially developed there were limited therapeutic alternatives for CLL which often resulted in treating through the adverse events At the present time there are several effective alternative agents available so transition to an alternative CLL directed therapy may be considered Given the continued expansion of ibrutinib across many therapeutic areas investigation of the pathogenesis of adverse events with this agent and also clinical trials examining therapeutic approaches for complications arising during therapy are needed Herein we provide strategies we use in real-world CLL clinical practice to address common adverse events associated with ibrutinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 36, 71, 2368, 2729, 5, 3, 2456, 1, 392, 238, 1943, 1795, 10, 3, 157, 850, 9, 119, 4, 1409, 2, 1134, 16, 95, 9, 388, 2, 992, 36, 1, 552, 7, 5, 211, 3029, 119, 4, 38, 758, 1795, 292, 186, 2, 2052, 290, 281, 210, 299, 746, 4, 1677, 38, 143, 47, 85, 592, 80, 746, 4, 1589, 1956, 758, 4, 1454, 7658, 9380, 2294, 1875, 2, 13632, 47, 85, 210, 3, 284, 1, 1795, 292, 290, 281, 629, 122, 44, 40, 4169, 84, 1642, 40, 2596, 6, 3, 69, 2, 136, 319, 337, 43, 1, 402, 521, 198, 1795, 10, 1625, 276, 125, 11, 383, 189, 6295, 9, 552, 92, 629, 627, 4, 1367, 298, 3, 290, 281, 28, 3, 364, 98, 125, 32, 392, 323, 1091, 183, 390, 1743, 1970, 6, 35, 1091, 552, 1166, 36, 68, 40, 515, 447, 3, 1351, 1422, 1, 1795, 716, 445, 189, 1361, 940, 1, 3, 1384, 1, 290, 281, 5, 26, 420, 2, 120, 38, 143, 3282, 189, 611, 9, 521, 2635, 190, 36, 32, 575, 1986, 21, 377, 422, 21, 119, 4, 1589, 1956, 552, 38, 758, 6, 1539, 186, 290, 281, 41, 5, 1795]",1370.0,30642919,784
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.,Leukemia,Leukemia,2019-01-30,"The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure-activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.",Journal Article,356.0,1.0,The viability of chronic lymphocytic CLL is critically dependent upon staving off death by apoptosis a hallmark of CLL pathophysiology The recognition that Mcl-1 a major component of the anti-apoptotic response is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach Pateamine A PatA a macrolide marine natural product inhibits cap-dependent translation by binding to the initiation factor eIF4A In this study we demonstrated that a synthetic derivative of PatA des-methyl des-amino PatA DMDAPatA blocked mRNA translation reduced Mcl-1 protein and initiated apoptosis in CLL cells This action was synergistic with the Bcl-2 antagonist ABT-199 However avid binding to human plasma proteins limited DMDAPatA potency precluding further development To address this we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA with greater selectivity towards CLL cells over normal lymphocytes Computer modeling analysis correlated their structure-activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A Thus these novel PatA analogs hold promise for application to cancers within the appropriate biological context such as CLL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 2120, 1, 442, 1193, 552, 16, 4331, 470, 1548, 74357, 1889, 273, 20, 351, 8, 4683, 1, 552, 4320, 3, 2335, 17, 1308, 14, 8, 458, 1249, 1, 3, 312, 1631, 51, 16, 9759, 978, 4813, 2, 1642, 40, 12539, 74358, 1148, 8, 229, 189, 353, 74359, 8, 32949, 8, 28247, 8178, 1504, 2821, 1576, 3204, 470, 2691, 20, 791, 6, 3, 1118, 161, 34836, 4, 26, 45, 21, 264, 17, 8, 3273, 4819, 1, 32949, 8683, 5228, 8683, 3078, 32949, 42251, 2582, 956, 2691, 405, 1308, 14, 178, 2, 1917, 351, 4, 552, 37, 26, 1578, 10, 1806, 5, 3, 1044, 18, 3137, 3095, 5840, 137, 5189, 791, 6, 171, 554, 652, 383, 42251, 3593, 13551, 195, 193, 6, 1539, 26, 21, 5134, 8, 217, 988, 1, 32949, 4063, 2, 108, 169, 217, 1940, 5, 1157, 297, 1, 2691, 491, 1416, 299, 554, 178, 791, 2, 101, 759, 3593, 1317, 552, 37, 76, 42251, 5, 378, 6072, 3113, 552, 37, 252, 295, 1594, 4236, 2057, 65, 438, 136, 2772, 128, 2467, 2, 1148, 17, 46, 2411, 68, 2559, 20, 9116, 3, 3745, 7788, 1, 34836, 631, 46, 229, 32949, 4063, 4164, 1783, 9, 1581, 6, 163, 262, 3, 870, 1037, 1533, 225, 22, 552]",1388.0,30700841,470
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL.,Cancer discovery,Cancer Discov,2019-03-01,"In this issue, Blombery and colleagues show that the chronic lymphocytic leukemia (CLL) cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells. Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL.<i>See related article by Blombery et al., p. 342</i>.",Journal Article,326.0,0.0,In this issue Blombery and colleagues show that the chronic lymphocytic CLL cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL. i See related article by Blombery et al. p. 342 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 26, 2537, 51455, 2, 6367, 514, 17, 3, 442, 1193, 552, 37, 1894, 74506, 258, 2913, 251, 6, 4454, 20, 1818, 3, 3601, 1, 3214, 9, 4454, 20, 3172, 1116, 4, 31, 285, 2, 4, 69, 37, 638, 1, 26, 258, 777, 8, 174, 901, 9, 9975, 34, 91, 2, 35, 2666, 9, 238, 2, 13237, 36, 6, 943, 552, 70, 3764, 139, 946, 20, 51455, 2022, 2171, 19, 8906, 70]",450.0,30824485,487
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.,Blood,Blood,2019-03-06,"Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relapsed patients with CLL, provided support for approval of ibrutinib in the United States and Europe. We describe long-term follow-up of patients treated in RESONATE, where continued superiority of progression-free survival (PFS) (hazard ratio [HR], 0.133; 95% confidence interval [CI], 0.099-0.178) was observed. Overall survival benefit continues (HR, 0.591; 95% CI, 0.378-0.926), although with decreased magnitude relative to that seen before crossover to ibrutinib was implemented for patients on ofatumumab (HR, 0.426; 95% CI, 0.220-0.823). Notably, overall response to ibrutinib increased over time, with 91% of patients attaining a response. The PFS benefit with ibrutinib was independent of baseline risk factors, although patients with 2 prior therapies had shorter PFS than those with <2 prior therapies, and the presence of <i>TP53</i> or <i>SF3B1</i> mutations showed a trend toward shorter PFS vs without these factors. Median duration of ibrutinib was 41 months, with 46% remaining on treatment at a median follow-up of 44 months. Grade 3 adverse events generally decreased over time, causing only a small proportion of patients to cease therapy. Ibrutinib was discontinued due to progressive disease in 27% of patients. This long-term study provides support for sustained efficacy and safety of ibrutinib in relapsed/refractory CLL and consideration of study provisions that allow crossover to investigational therapy when benefit has been clearly demonstrated. This trial was registered at www.clinicaltrials.gov as #NCT01578707.","Clinical Trial, Phase III",321.0,20.0,Ibrutinib a once-daily oral inhibitor of Bruton tyrosine kinase has greatly improved outcomes for patients with chronic lymphocytic CLL The phase 3 RESONATE trial which compared single-agent ibrutinib to ofatumumab in high-risk relapsed patients with CLL provided support for approval of ibrutinib in the United States and Europe We describe long-term follow-up of patients treated in RESONATE where continued superiority of progression-free survival PFS hazard ratio HR 0.133 95 confidence interval CI 0.099-0.178 was observed Overall survival benefit continues HR 0.591 95 CI 0.378-0.926 although with decreased magnitude relative to that seen before crossover to ibrutinib was implemented for patients on ofatumumab HR 0.426 95 CI 0.220-0.823 Notably overall response to ibrutinib increased over time with 91 of patients attaining a response The PFS benefit with ibrutinib was independent of baseline risk factors although patients with 2 prior therapies had shorter PFS than those with 2 prior therapies and the presence of i TP53 /i or i SF3B1 /i mutations showed a trend toward shorter PFS vs without these factors Median duration of ibrutinib was 41 months with 46 remaining on treatment at a median follow-up of 44 months Grade 3 adverse events generally decreased over time causing only a small proportion of patients to cease therapy Ibrutinib was discontinued due to progressive disease in 27 of patients This long-term study provides support for sustained efficacy and safety of ibrutinib in relapsed/refractory CLL and consideration of study provisions that allow crossover to investigational therapy when benefit has been clearly demonstrated This trial was registered at www.clinicaltrials.gov as NCT01578707,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 8, 1059, 391, 518, 230, 1, 5796, 564, 216, 71, 3510, 231, 123, 9, 7, 5, 442, 1193, 552, 3, 124, 27, 32285, 160, 92, 72, 226, 420, 1795, 6, 5732, 4, 64, 43, 591, 7, 5, 552, 1052, 538, 9, 1814, 1, 1795, 4, 3, 1088, 907, 2, 3934, 21, 897, 319, 337, 166, 126, 1, 7, 73, 4, 32285, 1257, 1351, 5233, 1, 91, 115, 25, 300, 360, 197, 168, 13, 5026, 48, 307, 268, 58, 13, 13395, 13, 7046, 10, 164, 63, 25, 247, 2274, 168, 13, 14437, 48, 58, 13, 10084, 13, 10119, 242, 5, 340, 3131, 580, 6, 17, 527, 348, 5265, 6, 1795, 10, 3426, 9, 7, 23, 5732, 168, 13, 12114, 48, 58, 13, 6211, 13, 12613, 2552, 63, 51, 6, 1795, 101, 252, 98, 5, 970, 1, 7, 11437, 8, 51, 3, 300, 247, 5, 1795, 10, 306, 1, 330, 43, 130, 242, 7, 5, 3107, 324, 235, 42, 985, 300, 76, 135, 5, 18, 324, 235, 2, 3, 463, 1, 70, 1206, 70, 15, 70, 10132, 70, 138, 224, 8, 853, 1317, 985, 300, 105, 187, 46, 130, 52, 654, 1, 1795, 10, 605, 53, 5, 641, 1844, 23, 24, 28, 8, 52, 166, 126, 1, 584, 53, 88, 2608, 290, 281, 1228, 340, 252, 98, 3440, 158, 8, 302, 920, 1, 7, 6, 32569, 36, 1795, 10, 2402, 520, 6, 1014, 34, 4, 428, 1, 7, 26, 319, 337, 45, 777, 538, 9, 2275, 209, 2, 367, 1, 1795, 4, 591, 430, 552, 2, 2415, 1, 45, 19536, 17, 1700, 5265, 6, 3093, 36, 198, 247, 71, 85, 2536, 264, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 32286]",1725.0,30842083,246
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.,Blood,Blood,2019-03-12,"This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL). Venetoclax dose initially was escalated (100-400 mg) in a 3+3 design to define MTD combined with standard-dose obinutuzumab. Patients received venetoclax (schedule A) or obinutuzumab (schedule B) first to compare safety and determine dose/schedule for expansion. Venetoclax-obinutuzumab was administered for 6 cycles, followed by venetoclax monotherapy until disease progression (R/R) or fixed duration 1-year treatment (1L). Fifty R/R and 32 1L patients were enrolled. No dose-limiting toxicities were observed. Safety, including incidence of tumor lysis syndrome (TLS), did not differ between schedules (2 laboratory TLSs per schedule). Schedule B and a 400-mg dose of venetoclax were chosen for expansion. The most common grade 3-4 adverse event was neutropenia (R/R, 58% of patients; 1L, 53%). Rates of grade 3-4 infections were 29% (R/R) and 13% (1L); no fatal infections occurred in 1L. All infusion-related reactions were grade 1-2, except for 2 grade 3 events. No clinical TLS was observed. Overall best response rate was 95% in R/R (complete response [CR]/CR with incomplete marrow recovery [CRi], 37%) and 100% in 1L (CR/CRi, 78%) patients. Rate of undetectable (<10<sup>-4</sup>) minimal residual disease (uMRD) in peripheral blood for R/R and 1L patients, respectively, was 64% and 91% 3 months after last obinutuzumab dose. Venetoclax and obinutuzumab therapy had an acceptable safety profile and elicited durable responses and high rates of uMRD. This trial was registered at www.clinicaltrials.gov as #NCT01685892.","Clinical Trial, Phase I",315.0,13.0,This single-arm open-label phase 1b study evaluated the maximum tolerated dose MTD of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory R/R or previously untreated first line 1L chronic lymphocytic CLL Venetoclax dose initially was escalated 100-400 mg in a 3 3 design to define MTD combined with standard-dose obinutuzumab Patients received venetoclax schedule A or obinutuzumab schedule B first to compare safety and determine dose/schedule for expansion Venetoclax-obinutuzumab was administered for 6 cycles followed by venetoclax monotherapy until disease progression R/R or fixed duration 1-year treatment 1L Fifty R/R and 32 1L patients were enrolled No dose-limiting toxicities were observed Safety including incidence of tumor lysis syndrome TLS did not differ between schedules 2 laboratory TLSs per schedule Schedule B and a 400-mg dose of venetoclax were chosen for expansion The most common grade 3-4 adverse event was neutropenia R/R 58 of patients 1L 53 Rates of grade 3-4 infections were 29 R/R and 13 1L no fatal infections occurred in 1L All infusion-related reactions were grade 1-2 except for 2 grade 3 events No clinical TLS was observed Overall best response rate was 95 in R/R complete response CR /CR with incomplete marrow recovery CRi 37 and 100 in 1L CR/CRi 78 patients Rate of undetectable 10 sup -4 /sup minimal residual disease uMRD in peripheral blood for R/R and 1L patients respectively was 64 and 91 3 months after last obinutuzumab dose Venetoclax and obinutuzumab therapy had an acceptable safety profile and elicited durable responses and high rates of uMRD This trial was registered at www.clinicaltrials.gov as NCT01685892,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 226, 475, 1020, 1756, 124, 4693, 45, 194, 3, 689, 421, 61, 961, 1, 4454, 198, 447, 5, 10380, 2, 211, 367, 2, 1543, 4, 7, 5, 591, 430, 668, 668, 15, 373, 1278, 157, 328, 10253, 442, 1193, 552, 4454, 61, 1625, 10, 2842, 394, 1524, 81, 4, 8, 27, 27, 771, 6, 1107, 961, 397, 5, 260, 61, 10380, 7, 103, 4454, 1055, 8, 15, 10380, 1055, 132, 157, 6, 932, 367, 2, 223, 61, 1055, 9, 1422, 4454, 10380, 10, 468, 9, 49, 410, 370, 20, 4454, 1411, 1100, 34, 91, 668, 668, 15, 1959, 654, 14, 111, 24, 10253, 1461, 668, 668, 2, 531, 10253, 7, 11, 346, 77, 61, 817, 385, 11, 164, 367, 141, 287, 1, 30, 4783, 681, 8778, 205, 44, 1505, 59, 2314, 18, 1624, 29711, 379, 1055, 1055, 132, 2, 8, 1524, 81, 61, 1, 4454, 11, 4695, 9, 1422, 3, 96, 186, 88, 27, 39, 290, 774, 10, 778, 668, 668, 717, 1, 7, 10253, 699, 151, 1, 88, 27, 39, 1875, 11, 462, 668, 668, 2, 233, 10253, 77, 3034, 1875, 489, 4, 10253, 62, 904, 139, 2428, 11, 88, 14, 18, 2187, 9, 18, 88, 27, 281, 77, 38, 8778, 10, 164, 63, 824, 51, 116, 10, 48, 4, 668, 668, 236, 51, 684, 684, 5, 2610, 581, 1602, 6341, 567, 2, 394, 4, 10253, 684, 6341, 833, 7, 116, 1, 3920, 79, 172, 39, 172, 1048, 753, 34, 27718, 4, 672, 315, 9, 668, 668, 2, 10253, 7, 106, 10, 660, 2, 970, 2608, 53, 50, 1060, 10380, 61, 4454, 2, 10380, 36, 42, 35, 1595, 367, 800, 2, 5179, 1480, 253, 2, 64, 151, 1, 27718, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 74558]",1720.0,30862645,302
Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2019-03-25,"The clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive role for tumor-expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease model. CLL cells, among other cancer cells, are CTLA-4<sup>+</sup> Coculture with activated human T cells induced surface CTLA-4 on primary human CLL B cells. CTLA-4 on CLL-derived human cell lines decreased CD80 expression on cocultured CD80<sup>+</sup> cells, with restoration upon CTLA-4 blockade. Coculture of CTLA-4<sup>+</sup> CLL cells with CD80-GFP<sup>+</sup> cell lines revealed transfer of CD80-GFP into CLL tumor cells, similar to CTLA-4<sup>+</sup> T cells able to <i>trans</i>-endocytose CD80. Coculture of T cells with CTLA-4<sup>+</sup> CLL cells decreased IL-2 production. Using a human CTLA-4 knock-in mouse lacking FcR function, antitumor efficacy was observed by blocking murine CTLA-4 on tumor cells in isolation of the T cell effect and Fc-mediated depletion. These data implicate tumor CTLA-4 in cancer cell-mediated immunosuppression in vitro and as having a functional role in tumor cells in vivo.",Journal Article,302.0,1.0,The clinical benefit of CTLA-4 blockade on T cells is known yet the impact of its expression on cancer cells remains unaddressed We define an immunosuppressive role for tumor-expressed CTLA-4 using chronic lymphocytic CLL as a disease model CLL cells among other cancer cells are CTLA-4 sup /sup Coculture with activated human T cells induced surface CTLA-4 on primary human CLL B cells CTLA-4 on CLL-derived human cell lines decreased CD80 expression on cocultured CD80 sup /sup cells with restoration upon CTLA-4 blockade Coculture of CTLA-4 sup /sup CLL cells with CD80-GFP sup /sup cell lines revealed transfer of CD80-GFP into CLL tumor cells similar to CTLA-4 sup /sup T cells able to i trans /i -endocytose CD80 Coculture of T cells with CTLA-4 sup /sup CLL cells decreased IL-2 production Using a human CTLA-4 knock-in mouse lacking FcR function antitumor efficacy was observed by blocking murine CTLA-4 on tumor cells in isolation of the T cell effect and Fc-mediated depletion These data implicate tumor CTLA-4 in cancer cell-mediated immunosuppression in vitro and as having a functional role in tumor cells in vivo,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 38, 247, 1, 2127, 39, 1189, 23, 102, 37, 16, 440, 1145, 3, 345, 1, 211, 55, 23, 12, 37, 469, 29248, 21, 1107, 35, 2989, 200, 9, 30, 570, 2127, 39, 75, 442, 1193, 552, 22, 8, 34, 202, 552, 37, 107, 127, 12, 37, 32, 2127, 39, 172, 172, 7604, 5, 735, 171, 102, 37, 277, 1255, 2127, 39, 23, 86, 171, 552, 132, 37, 2127, 39, 23, 552, 526, 171, 31, 285, 340, 9850, 55, 23, 11444, 9850, 172, 172, 37, 5, 5194, 1548, 2127, 39, 1189, 7604, 1, 2127, 39, 172, 172, 552, 37, 5, 9850, 4687, 172, 172, 31, 285, 553, 2602, 1, 9850, 4687, 237, 552, 30, 37, 288, 6, 2127, 39, 172, 172, 102, 37, 1665, 6, 70, 3437, 70, 74607, 9850, 7604, 1, 102, 37, 5, 2127, 39, 172, 172, 552, 37, 340, 501, 18, 1529, 75, 8, 171, 2127, 39, 6252, 4, 830, 1941, 16125, 343, 579, 209, 10, 164, 20, 2521, 1471, 2127, 39, 23, 30, 37, 4, 5019, 1, 3, 102, 31, 254, 2, 4127, 517, 2286, 46, 74, 5545, 30, 2127, 39, 4, 12, 31, 517, 3646, 4, 439, 2, 22, 1041, 8, 583, 200, 4, 30, 37, 4, 386]",1127.0,30910862,235
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2019-04-15,"Clonal expansion of B cell chronic lymphocytic leukemia (B-CLL) occurs within lymphoid tissue pseudofollicles. IL-15, a stromal cell-associated cytokine found within spleens and lymph nodes of B-CLL patients, significantly boosts in vitro cycling of blood-derived B-CLL cells following CpG DNA priming. Both IL-15 and CpG DNA are elevated in microbe-draining lymphatic tissues, and unraveling the basis for IL-15-driven B-CLL growth could illuminate new therapeutic targets. Using CpG DNA-primed human B-CLL clones and approaches involving both immunofluorescent staining and pharmacologic inhibitors, we show that both PI3K/AKT and JAK/STAT5 pathways are activated and functionally important for IL-15CD122/c signaling in ODN-primed cells expressing activated pSTAT3. Furthermore, STAT5 activity must be sustained for continued cycling of CFSE-labeled B-CLL cells. Quantitative RT-PCR experiments with inhibitors of PI3K and STAT5 show that both contribute to IL-15-driven upregulation of mRNA for cyclin D2 and suppression of mRNA for DNA damage response mediators ATM, 53BP1, and MDC1. Furthermore, protein levels of these DNA damage response molecules are reduced by IL-15, as indicated by Western blotting and immunofluorescent staining. Bioinformatics analysis of ENCODE chromatin immunoprecipitation sequencing data from cell lines provides insight into possible mechanisms for STAT5-mediated repression. Finally, pharmacologic inhibitors of JAKs and STAT5 significantly curtailed B-CLL cycling when added either early or late in a growth response. We discuss how the IL-15-induced changes in gene expression lead to rapid cycling and possibly enhanced mutagenesis. STAT5 inhibitors might be an effective modality for blocking B-CLL growth in patients.",Journal Article,281.0,0.0,Clonal expansion of B cell chronic lymphocytic B-CLL occurs within lymphoid tissue pseudofollicles IL-15 a stromal cell-associated cytokine found within spleens and lymph nodes of B-CLL patients significantly boosts in vitro cycling of blood-derived B-CLL cells following CpG DNA priming Both IL-15 and CpG DNA are elevated in microbe-draining lymphatic tissues and unraveling the basis for IL-15-driven B-CLL growth could illuminate new therapeutic targets Using CpG DNA-primed human B-CLL clones and approaches involving both immunofluorescent staining and pharmacologic inhibitors we show that both PI3K/AKT and JAK/STAT5 pathways are activated and functionally important for IL-15CD122/c signaling in ODN-primed cells expressing activated pSTAT3 Furthermore STAT5 activity must be sustained for continued cycling of CFSE-labeled B-CLL cells Quantitative RT-PCR experiments with inhibitors of PI3K and STAT5 show that both contribute to IL-15-driven upregulation of mRNA for cyclin D2 and suppression of mRNA for DNA damage response mediators ATM 53BP1 and MDC1 Furthermore protein levels of these DNA damage response molecules are reduced by IL-15 as indicated by Western blotting and immunofluorescent staining Bioinformatics analysis of ENCODE chromatin immunoprecipitation sequencing data from cell lines provides insight into possible mechanisms for STAT5-mediated repression Finally pharmacologic inhibitors of JAKs and STAT5 significantly curtailed B-CLL cycling when added either early or late in a growth response We discuss how the IL-15-induced changes in gene expression lead to rapid cycling and possibly enhanced mutagenesis STAT5 inhibitors might be an effective modality for blocking B-CLL growth in patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[1946, 1422, 1, 132, 31, 442, 1193, 132, 552, 1780, 262, 2303, 246, 74672, 501, 167, 8, 1126, 31, 41, 1675, 204, 262, 19073, 2, 263, 502, 1, 132, 552, 7, 97, 20239, 4, 439, 9165, 1, 315, 526, 132, 552, 37, 366, 2075, 261, 4903, 110, 501, 167, 2, 2075, 261, 32, 804, 4, 21372, 7535, 2936, 742, 2, 21376, 3, 877, 9, 501, 167, 1621, 132, 552, 129, 359, 12793, 217, 189, 637, 75, 2075, 261, 7239, 171, 132, 552, 2749, 2, 611, 1267, 110, 12502, 1029, 2, 2788, 222, 21, 514, 17, 110, 974, 649, 2, 4653, 5517, 460, 32, 735, 2, 3772, 305, 9, 501, 51181, 74673, 314, 4, 11601, 7239, 37, 1046, 735, 6480, 798, 5517, 128, 1642, 40, 2275, 9, 1351, 9165, 1, 24987, 2841, 132, 552, 37, 1156, 240, 604, 2332, 5, 222, 1, 974, 2, 5517, 514, 17, 110, 1248, 6, 501, 167, 1621, 2218, 1, 956, 9, 1226, 4171, 2, 1332, 1, 956, 9, 261, 1350, 51, 4425, 3552, 11361, 2, 51501, 798, 178, 148, 1, 46, 261, 1350, 51, 1598, 32, 405, 20, 501, 167, 22, 1103, 20, 1521, 3661, 2, 12502, 1029, 6579, 65, 1, 6924, 2287, 4857, 615, 74, 29, 31, 285, 777, 2670, 237, 899, 483, 9, 5517, 517, 5255, 1368, 2788, 222, 1, 28197, 2, 5517, 97, 31387, 132, 552, 9165, 198, 1953, 361, 191, 15, 807, 4, 8, 129, 51, 21, 1139, 832, 3, 501, 167, 277, 400, 4, 145, 55, 1122, 6, 1321, 9165, 2, 2150, 651, 8595, 5517, 222, 822, 40, 35, 323, 1396, 9, 2521, 132, 552, 129, 4, 7]",1729.0,30988120,129
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.,Blood,Blood,2019-04-25,"To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled. Rates of response, complete remission (CR/CRi), and undetectable minimal residual disease (U-MRD) were analyzed for all patients (n = 436) and for those patients who were planned to receive 400 mg/day monotherapy (n = 347). Univariate and multiple regression analyses were performed to identify the pretreatment factors associated with response rates and duration of response (DoR). Objective responses were documented in 75% of all patients, including 22% CR/CRi. Overall, 27% and 16% of the patients achieved U-MRD in blood and marrow, respectively. Estimated median progression-free survival (PFS), DoR, and time to progression were 30.2, 38.4, and 36.9 months, respectively. Similar efficacy outcomes were observed within the 400 mg/day monotherapy subset. For those who achieved CR/CRi, the 3-year PFS estimate was 83%. DoR was superior for patients achieving CR/CRi or U-MRD in landmark analyses. In multiple regression analyses, bulky lymphadenopathy (5 cm) and refractoriness to B-cell receptor inhibitor (BCRi) therapy were significantly associated with lower CR rate and shorter DoR. Fewer prior therapies were associated with higher CR rate, but not DoR. Chromosome 17p deletion and/or <i>TP53</i> mutation and <i>NOTCH1</i> mutation were consistently associated with shorter DoR, but not probability of response. Thus, both pretreatment factors and depth of response correlated with DoR with venetoclax. Patients without bulky lymphadenopathy, BCRi-refractory CLL, or an adverse mutation profile had the most durable benefit.","Clinical Trial, Phase I",271.0,7.0,To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers updated data for previously treated patients with chronic lymphocytic CLL or small lymphocytic SLL enrolled in 4 early-phase trials were pooled Rates of response complete remission CR/CRi and undetectable minimal residual disease U-MRD were analyzed for all patients n 436 and for those patients who were planned to receive 400 mg/day monotherapy n 347 Univariate and multiple regression analyses were performed to identify the pretreatment factors associated with response rates and duration of response DoR Objective responses were documented in 75 of all patients including 22 CR/CRi Overall 27 and 16 of the patients achieved U-MRD in blood and marrow respectively Estimated median progression-free survival PFS DoR and time to progression were 30.2 38.4 and 36.9 months respectively Similar efficacy outcomes were observed within the 400 mg/day monotherapy subset For those who achieved CR/CRi the 3-year PFS estimate was 83 DoR was superior for patients achieving CR/CRi or U-MRD in landmark analyses In multiple regression analyses bulky lymphadenopathy 5 cm and refractoriness to B-cell receptor inhibitor BCRi therapy were significantly associated with lower CR rate and shorter DoR Fewer prior therapies were associated with higher CR rate but not DoR Chromosome 17p deletion and/or i TP53 /i mutation and i NOTCH1 /i mutation were consistently associated with shorter DoR but not probability of response Thus both pretreatment factors and depth of response correlated with DoR with venetoclax Patients without bulky lymphadenopathy BCRi-refractory CLL or an adverse mutation profile had the most durable benefit,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[6, 1107, 3, 209, 1, 4454, 5, 1747, 166, 126, 2, 255, 38, 15, 1037, 24, 254, 5663, 2939, 74, 9, 373, 73, 7, 5, 442, 1193, 552, 15, 302, 1193, 5302, 346, 4, 39, 191, 124, 143, 11, 1830, 151, 1, 51, 236, 734, 684, 6341, 2, 3920, 1048, 753, 34, 1767, 2029, 11, 311, 9, 62, 7, 78, 10601, 2, 9, 135, 7, 54, 11, 1465, 6, 560, 1524, 81, 218, 1411, 78, 10745, 880, 2, 232, 320, 318, 11, 173, 6, 255, 3, 1194, 130, 41, 5, 51, 151, 2, 654, 1, 51, 8619, 461, 253, 11, 1405, 4, 481, 1, 62, 7, 141, 350, 684, 6341, 63, 428, 2, 245, 1, 3, 7, 513, 1767, 2029, 4, 315, 2, 581, 106, 661, 52, 91, 115, 25, 300, 8619, 2, 98, 6, 91, 11, 201, 18, 519, 39, 2, 511, 83, 53, 106, 288, 209, 123, 11, 164, 262, 3, 1524, 81, 218, 1411, 697, 9, 135, 54, 513, 684, 6341, 3, 27, 111, 300, 1191, 10, 852, 8619, 10, 1123, 9, 7, 1785, 684, 6341, 15, 1767, 2029, 4, 3829, 318, 4, 232, 320, 318, 4112, 4962, 4126, 494, 2, 12483, 6, 132, 31, 153, 230, 41950, 36, 11, 97, 41, 5, 280, 684, 116, 2, 985, 8619, 1497, 324, 235, 11, 41, 5, 142, 684, 116, 84, 44, 8619, 1170, 4135, 1528, 2, 15, 70, 1206, 70, 258, 2, 70, 4607, 70, 258, 11, 2433, 41, 5, 985, 8619, 84, 44, 1320, 1, 51, 631, 110, 1194, 130, 2, 2436, 1, 51, 438, 5, 8619, 5, 4454, 7, 187, 4112, 4962, 41950, 430, 552, 15, 35, 290, 258, 800, 42, 3, 96, 1480, 247]",1747.0,31023700,550
Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.,Drugs & aging,Drugs Aging,2019-09-01,"Median age at diagnosis for patients with chronic lymphocytic leukemia (CLL) is 72years, and the number of older individuals affected by this condition is predicted to increase in the future as populations age. Contrary to common assumptions, CLL significantly affects the life expectancy of older individuals, frequently presenting at a more advanced stage and with more unfavorable features than in the younger population. Therefore, identifying the optimal treatment for these patients is a priority. Older patients with CLL are usually classified as fit, non-fit, or frail based on performance status and comorbidities, and several assessment tools can be used to make these evaluations. While supportive care is appropriate for frail patients, the remaining patients should be treated when indication criteria are met. Treatment options include chemoimmunotherapy, monoclonal antibody-based approaches (such as the use of rituximab, ofatumumab, or obinutuzumab) and, more recently, small molecules (such as ibrutinib, idelalisib, and venetoclax). The choice of treatment is guided by the patient's performance status and co-morbidities and by the disease characteristics, such as chromosomal and molecular abnormalities, and in patients with recurrent disease also by the type of prior regimen, their tolerability, and duration of response.",Journal Article,142.0,0.0,Median age at diagnosis for patients with chronic lymphocytic CLL is 72 years and the number of older individuals affected by this condition is predicted to increase in the future as populations age Contrary to common assumptions CLL significantly affects the life expectancy of older individuals frequently presenting at a more advanced stage and with more unfavorable features than in the younger population Therefore identifying the optimal treatment for these patients is a priority Older patients with CLL are usually classified as fit non-fit or frail based on performance status and comorbidities and several assessment tools can be used to make these evaluations While supportive care is appropriate for frail patients the remaining patients should be treated when indication criteria are met Treatment options include chemoimmunotherapy monoclonal antibody-based approaches such as the use of rituximab ofatumumab or obinutuzumab and more recently small molecules such as ibrutinib idelalisib and venetoclax The choice of treatment is guided by the patient 's performance status and co-morbidities and by the disease characteristics such as chromosomal and molecular abnormalities and in patients with recurrent disease also by the type of prior regimen their tolerability and duration of response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[52, 89, 28, 147, 9, 7, 5, 442, 1193, 552, 16, 720, 60, 2, 3, 207, 1, 434, 869, 1424, 20, 26, 2850, 16, 783, 6, 344, 4, 3, 508, 22, 1184, 89, 7194, 6, 186, 8387, 552, 97, 2561, 3, 358, 3399, 1, 434, 869, 746, 1656, 28, 8, 80, 131, 82, 2, 5, 80, 2483, 404, 76, 4, 3, 773, 266, 673, 1386, 3, 665, 24, 9, 46, 7, 16, 8, 4690, 434, 7, 5, 552, 32, 2082, 1373, 22, 2975, 220, 2975, 15, 7226, 90, 23, 528, 156, 2, 1909, 2, 392, 455, 1896, 122, 40, 95, 6, 2378, 46, 3816, 369, 1877, 165, 16, 870, 9, 7226, 7, 3, 1844, 7, 257, 40, 73, 198, 3607, 371, 32, 543, 24, 838, 643, 4438, 848, 548, 90, 611, 225, 22, 3, 119, 1, 855, 5732, 15, 10380, 2, 80, 761, 302, 1598, 225, 22, 1795, 7083, 2, 4454, 3, 1866, 1, 24, 16, 1808, 20, 3, 69, 292, 528, 156, 2, 1269, 5655, 2, 20, 3, 34, 374, 225, 22, 1860, 2, 219, 1171, 2, 4, 7, 5, 387, 34, 120, 20, 3, 267, 1, 324, 477, 136, 1543, 2, 654, 1, 51]",1306.0,31055788,78
Ibrutinib and Venetoclax for First-Line Treatment of CLL.,The New England journal of medicine,N. Engl. J. Med.,2019-05-01,"Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination. We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated <i>TP53</i>, chromosome 11q deletion, unmutated <i>IGHV</i>, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to 400 mg once daily). Combined therapy was administered for 24 cycles. Response assessments were performed according to International Workshop on Chronic Lymphocytic Leukemia 2008 criteria. Minimal residual disease was assessed by means of multicolor flow cytometry in bone marrow (sensitivity, 10<sup>-4</sup>). A total of 80 patients were treated. The median age was 65 years (range, 26 to 83). A total of 30% of the patients were 70 years of age or older. Overall, 92% of the patients had unmutated <i>IGHV</i>, <i>TP53</i> aberration, or chromosome 11q deletion. With combined treatment, the proportions of patients who had complete remission (with or without normal blood count recovery) and remission with undetectable minimal residual disease increased over time. After 12 cycles of combined treatment, 88% of the patients had complete remission or complete remission with incomplete count recovery, and 61% had remission with undetectable minimal residual disease. Responses were noted in older adults and across all high-risk subgroups. Three patients had laboratory evidence of tumor lysis syndrome. The adverse-event profile was similar to what has been reported with ibrutinib and venetoclax. In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).","Clinical Trial, Phase II",265.0,32.0,Ibrutinib an inhibitor of Bruton 's tyrosine kinase and venetoclax an inhibitor of B-cell 2 protein have been approved for patients with chronic lymphocytic CLL Preclinical investigations have indicated potential synergistic interaction of their combination We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL All patients had at least one of the following features chromosome 17p deletion mutated i TP53 /i chromosome 11q deletion unmutated i IGHV /i or an age of 65 years or older Patients received ibrutinib monotherapy 420 mg once daily for 3 cycles followed by the addition of venetoclax weekly dose escalation to 400 mg once daily Combined therapy was administered for 24 cycles Response assessments were performed according to International Workshop on Chronic Lymphocytic 2008 criteria Minimal residual disease was assessed by means of multicolor flow cytometry in marrow sensitivity 10 sup -4 /sup A total of 80 patients were treated The median age was 65 years range 26 to 83 A total of 30 of the patients were 70 years of age or older Overall 92 of the patients had unmutated i IGHV /i i TP53 /i aberration or chromosome 11q deletion With combined treatment the proportions of patients who had complete remission with or without normal blood count recovery and remission with undetectable minimal residual disease increased over time After 12 cycles of combined treatment 88 of the patients had complete remission or complete remission with incomplete count recovery and 61 had remission with undetectable minimal residual disease Responses were noted in older adults and across all high-risk subgroups Three patients had laboratory evidence of tumor lysis syndrome The adverse-event profile was similar to what has been reported with ibrutinib and venetoclax In this study combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL Funded by AbbVie and others ClinicalTrials.gov number NCT02756897,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1795, 35, 230, 1, 5796, 292, 564, 216, 2, 4454, 35, 230, 1, 132, 31, 18, 178, 47, 85, 850, 9, 7, 5, 442, 1193, 552, 693, 2492, 47, 1103, 174, 1806, 915, 1, 136, 150, 21, 426, 35, 3464, 1917, 124, 18, 45, 1, 397, 1795, 2, 4454, 1267, 373, 1278, 64, 43, 2, 434, 7, 5, 552, 62, 7, 42, 28, 506, 104, 1, 3, 366, 404, 1170, 4135, 1528, 1185, 70, 1206, 70, 1170, 7203, 1528, 7216, 70, 6220, 70, 15, 35, 89, 1, 556, 60, 15, 434, 7, 103, 1795, 1411, 5401, 81, 1059, 391, 9, 27, 410, 370, 20, 3, 352, 1, 4454, 709, 61, 1125, 6, 1524, 81, 1059, 391, 397, 36, 10, 468, 9, 259, 410, 51, 2182, 11, 173, 768, 6, 944, 4014, 23, 442, 1193, 1375, 371, 1048, 753, 34, 10, 275, 20, 2263, 1, 11920, 1412, 1914, 4, 581, 485, 79, 172, 39, 172, 8, 181, 1, 493, 7, 11, 73, 3, 52, 89, 10, 556, 60, 184, 432, 6, 852, 8, 181, 1, 201, 1, 3, 7, 11, 431, 60, 1, 89, 15, 434, 63, 937, 1, 3, 7, 42, 7216, 70, 6220, 70, 70, 1206, 70, 7794, 15, 1170, 7203, 1528, 5, 397, 24, 3, 4117, 1, 7, 54, 42, 236, 734, 5, 15, 187, 295, 315, 1276, 1602, 2, 734, 5, 3920, 1048, 753, 34, 101, 252, 98, 50, 133, 410, 1, 397, 24, 889, 1, 3, 7, 42, 236, 734, 15, 236, 734, 5, 2610, 1276, 1602, 2, 713, 42, 734, 5, 3920, 1048, 753, 34, 253, 11, 1051, 4, 434, 857, 2, 716, 62, 64, 43, 1453, 169, 7, 42, 1624, 241, 1, 30, 4783, 681, 3, 290, 774, 800, 10, 288, 6, 2067, 71, 85, 210, 5, 1795, 2, 4454, 4, 26, 45, 397, 4454, 2, 1795, 10, 35, 323, 518, 477, 9, 64, 43, 2, 434, 7, 5, 552, 3827, 20, 18697, 2, 1749, 1252, 1239, 207, 74827]",2063.0,31141631,250
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.,Blood,Blood,2019-05-31,"Chronic lymphocytic leukemia (CLL) occurs in 2 major forms: aggressive and indolent. Low miR-29b expression in aggressive CLL is associated with poor prognosis. Indiscriminate miR-29b overexpression in the B-lineage of mice causes aberrance, thus warranting the need for selective introduction of miR-29b into B-CLL cells for therapeutic benefit. The oncofetal antigen receptor tyrosine kinase orphan receptor 1 (ROR1) is expressed on malignant B-CLL cells, but not normal B cells, encouraging us with ROR1-targeted delivery for therapeutic miRs. Here, we describe targeted delivery of miR-29b to ROR1<sup>+</sup> CLL cells leading to downregulation of DNMT1 and DNMT3A, modulation of global DNA methylation, decreased SP1, and increased p21 expression in cell lines and primary CLL cells in vitro. Furthermore, using an E-TCL1 mouse model expressing human ROR1, we report the therapeutic benefit of enhanced survival via cellular reprograming by downregulation of DNMT1 and DNMT3A in vivo. Gene expression profiling of engrafted murine leukemia identified reprogramming of cell cycle regulators with decreased SP1 and increased p21 expression after targeted miR-29b treatment. This finding was confirmed by protein modulation, leading to cell cycle arrest and survival benefit in vivo. Importantly, SP1 knockdown results in p21-dependent compensation of the miR-29b effect on cell cycle arrest. These studies form a basis for leukemic cell-targeted delivery of miR-29b as a promising therapeutic approach for CLL and other ROR1<sup>+</sup> B-cell malignancies.",Journal Article,235.0,0.0,Chronic lymphocytic CLL occurs in 2 major forms aggressive and indolent Low miR-29b expression in aggressive CLL is associated with poor prognosis Indiscriminate miR-29b overexpression in the B-lineage of mice causes aberrance thus warranting the need for selective introduction of miR-29b into B-CLL cells for therapeutic benefit The oncofetal antigen receptor tyrosine kinase orphan receptor 1 ROR1 is expressed on malignant B-CLL cells but not normal B cells encouraging us with ROR1-targeted delivery for therapeutic miRs Here we describe targeted delivery of miR-29b to ROR1 sup /sup CLL cells leading to downregulation of DNMT1 and DNMT3A modulation of global DNA methylation decreased SP1 and increased p21 expression in cell lines and primary CLL cells in vitro Furthermore using an E-TCL1 mouse model expressing human ROR1 we report the therapeutic benefit of enhanced survival via cellular reprograming by downregulation of DNMT1 and DNMT3A in vivo Gene expression profiling of engrafted murine identified reprogramming of cell cycle regulators with decreased SP1 and increased p21 expression after targeted miR-29b treatment This finding was confirmed by protein modulation leading to cell cycle arrest and survival benefit in vivo Importantly SP1 knockdown results in p21-dependent compensation of the miR-29b effect on cell cycle arrest These studies form a basis for leukemic cell-targeted delivery of miR-29b as a promising therapeutic approach for CLL and other ROR1 sup /sup B-cell malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 1780, 4, 18, 458, 2377, 571, 2, 2316, 154, 722, 9609, 55, 4, 571, 552, 16, 41, 5, 334, 356, 26618, 722, 9609, 851, 4, 3, 132, 2542, 1, 399, 1626, 74842, 631, 7643, 3, 594, 9, 1094, 2456, 1, 722, 9609, 237, 132, 552, 37, 9, 189, 247, 3, 28288, 448, 153, 564, 216, 9814, 153, 14, 9826, 16, 570, 23, 393, 132, 552, 37, 84, 44, 295, 132, 37, 2269, 843, 5, 9826, 238, 989, 9, 189, 7569, 467, 21, 897, 238, 989, 1, 722, 9609, 6, 9826, 172, 172, 552, 37, 1049, 6, 2475, 1, 7328, 2, 6199, 2356, 1, 1648, 261, 569, 340, 5557, 2, 101, 2657, 55, 4, 31, 285, 2, 86, 552, 37, 4, 439, 798, 75, 35, 17467, 8979, 830, 202, 1046, 171, 9826, 21, 414, 3, 189, 247, 1, 651, 25, 847, 763, 42081, 20, 2475, 1, 7328, 2, 6199, 4, 386, 145, 55, 1080, 1, 6914, 1471, 108, 7394, 1, 31, 417, 3196, 5, 340, 5557, 2, 101, 2657, 55, 50, 238, 722, 9609, 24, 26, 1567, 10, 557, 20, 178, 2356, 1049, 6, 31, 417, 1854, 2, 25, 247, 4, 386, 1859, 5557, 1563, 99, 4, 2657, 470, 19095, 1, 3, 722, 9609, 254, 23, 31, 417, 1854, 46, 94, 1297, 8, 877, 9, 2015, 31, 238, 989, 1, 722, 9609, 22, 8, 721, 189, 353, 9, 552, 2, 127, 9826, 172, 172, 132, 31, 441]",1512.0,31151986,403
"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.",The Lancet. Haematology,Lancet Haematol,2019-06-14,"Fludarabine, cyclophosphamide, and rituximab (FCR) can improve disease-free survival for younger (age 65 years) fit patients with chronic lymphocytic leukaemia with mutated IGHV. However, patients with unmutated IGHV rarely have durable responses. Ibrutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation status but requires continuous treatment. We postulated that time-limited ibrutinib plus FCR would induce durable responses in younger fit patients with chronic lymphocytic leukaemia. We did a multicentre, open-label, non-randomised, single-arm phase 2 trial at seven sites in the USA. We enrolled patients aged 65 years or younger with previously untreated chronic lymphocytic leukaemia. Our initial cohort (original cohort) was not restricted by prognostic marker status and included patients who had del(17p) or TP53 aberrations. After a protocol amendment (on March 21, 2017), we enrolled an additional cohort (expansion cohort) that included patients without del(17p). Ibrutinib was given orally (420 mg/day) for 7 days, then up to six 28-day cycles were administered intravenously of fludarabine (25 mg/m<sup>2</sup>, days 1-3), cyclophosphamide (250 mg/m<sup>2</sup>, days 1-3), and rituximab (375 mg/m<sup>2</sup> day 1 of cycle 1; 500 mg/m<sup>2</sup> day 1 of cycles 2-6) with continuous oral ibrutinib (420 mg/day). Responders continued on ibrutinib maintenance for up to 2 years, and patients with undetectable minimal residual disease in bone marrow after 2 years were able to discontinue treatment. The primary endpoint was the proportion of patients who achieved a complete response with undetectable minimal residual disease in bone marrow 2 months after the last cycle of ibrutinib plus FCR. Analyses were done per-protocol in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov (NCT02251548) and is ongoing. Between Oct 23, 2014, and April 23, 2018, 85 patients with chronic lymphocytic leukaemia were enrolled. del(17p) was detected in four (5%) of 83 patients and TP53 mutations were noted in three (4%) of 81 patients; two patients had both del(17p) and TP53 mutations. Median patients' age was 55 years (IQR 50-58). At data cutoff, median follow-up was 165 months (IQR 106-341). A complete response and undetectable minimal residual disease in bone marrow 2 months after the last cycle of ibrutinib plus FCR was achieved by 28 (33%, 95% CI 023-044) of 85 patients (p=00035 compared with a 20% historical value with FCR alone). A best response of undetectable minimal residual disease in bone marrow was achieved by 71 (84%) of 85 patients during the study. One patient had disease progression and one patient died (sudden cardiac death after 17 months of ibrutinib maintenance, assessed as possibly related to ibrutinib). The most common all-grade toxic effects were haematological, including thrombocytopenia in 63 (74%) patients, neutropenia in 53 (62%), and anaemia in 41 (49%). Grade 3 or 4 non-haematological serious adverse events included grade 3 atrial fibrillation in three (4%) patients and grade 3 Pneumocystis jirovecii pneumonia in two (2%). The proportion of patients who achieved undetectable minimal residual disease in bone marrow with ibrutinib plus FCR is, to our knowledge, the highest ever published in patients with chronic lymphocytic leukaemia unrestricted by prognostic marker status. Ibrutinib plus FCR is promising as a time-limited combination regimen for frontline chronic lymphocytic leukaemia treatment in younger fit patients. Pharmacyclics and the Leukemia & Lymphoma Society.","Clinical Trial, Phase II",221.0,5.0,Fludarabine cyclophosphamide and rituximab FCR can improve disease-free survival for younger age 65 years fit patients with chronic lymphocytic leukaemia with mutated IGHV However patients with unmutated IGHV rarely have durable responses Ibrutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation status but requires continuous treatment We postulated that time-limited ibrutinib plus FCR would induce durable responses in younger fit patients with chronic lymphocytic leukaemia We did a multicentre open-label non-randomised single-arm phase 2 trial at seven sites in the USA We enrolled patients aged 65 years or younger with previously untreated chronic lymphocytic leukaemia Our initial cohort original cohort was not restricted by prognostic marker status and included patients who had del 17p or TP53 aberrations After a protocol amendment on March 21 2017 we enrolled an additional cohort expansion cohort that included patients without del 17p Ibrutinib was given orally 420 mg/day for 7 days then up to six 28-day cycles were administered intravenously of fludarabine 25 mg/m sup 2 /sup days 1-3 cyclophosphamide 250 mg/m sup 2 /sup days 1-3 and rituximab 375 mg/m sup 2 /sup day 1 of cycle 1 500 mg/m sup 2 /sup day 1 of cycles 2-6 with continuous oral ibrutinib 420 mg/day Responders continued on ibrutinib maintenance for up to 2 years and patients with undetectable minimal residual disease in marrow after 2 years were able to discontinue treatment The primary endpoint was the proportion of patients who achieved a complete response with undetectable minimal residual disease in marrow 2 months after the last cycle of ibrutinib plus FCR Analyses were done per-protocol in all patients who received at least one dose of study treatment This trial is registered with ClinicalTrials.gov NCT02251548 and is ongoing Between Oct 23 2014 and April 23 2018 85 patients with chronic lymphocytic leukaemia were enrolled del 17p was detected in four 5 of 83 patients and TP53 mutations were noted in three 4 of 81 patients two patients had both del 17p and TP53 mutations Median patients age was 55 years IQR 50-58 At data cutoff median follow-up was 165 months IQR 106-341 A complete response and undetectable minimal residual disease in marrow 2 months after the last cycle of ibrutinib plus FCR was achieved by 28 33 95 CI 023-044 of 85 patients p=00035 compared with a 20 historical value with FCR alone A best response of undetectable minimal residual disease in marrow was achieved by 71 84 of 85 patients during the study One patient had disease progression and one patient died sudden death after 17 months of ibrutinib maintenance assessed as possibly related to ibrutinib The most common all-grade toxic effects were haematological including thrombocytopenia in 63 74 patients neutropenia in 53 62 and anaemia in 41 49 Grade 3 or 4 non-haematological serious adverse events included grade 3 atrial fibrillation in three 4 patients and grade 3 Pneumocystis jirovecii pneumonia in two 2 The proportion of patients who achieved undetectable minimal residual disease in marrow with ibrutinib plus FCR is to our knowledge the highest ever published in patients with chronic lymphocytic leukaemia unrestricted by prognostic marker status Ibrutinib plus FCR is promising as a time-limited combination regimen for frontline chronic lymphocytic leukaemia treatment in younger fit patients Pharmacyclics and the Society,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"[2027, 1112, 2, 855, 4953, 122, 401, 34, 115, 25, 9, 773, 89, 25391, 60, 2975, 7, 5, 442, 1193, 2001, 5, 1185, 6220, 137, 7, 5, 7216, 6220, 2416, 47, 1480, 253, 1795, 16, 544, 9, 7, 5, 442, 1193, 2001, 3500, 1, 6220, 258, 156, 84, 1706, 1314, 24, 21, 6507, 17, 98, 383, 1795, 349, 4953, 688, 1290, 1480, 253, 4, 773, 2975, 7, 5, 442, 1193, 2001, 21, 205, 8, 5761, 1020, 1756, 220, 2827, 226, 475, 124, 18, 160, 28, 648, 633, 4, 3, 2706, 21, 346, 7, 1032, 556, 60, 15, 773, 5, 373, 1278, 442, 1193, 2001, 114, 388, 180, 2279, 180, 10, 44, 2016, 20, 177, 952, 156, 2, 159, 7, 54, 42, 3084, 4135, 15, 1206, 2152, 50, 8, 1182, 11013, 23, 2363, 239, 1759, 21, 346, 35, 402, 180, 1422, 180, 17, 159, 7, 187, 3084, 4135, 1795, 10, 447, 1428, 5401, 81, 218, 9, 67, 162, 818, 126, 6, 437, 339, 218, 410, 11, 468, 1672, 1, 2027, 243, 81, 188, 172, 18, 172, 162, 14, 27, 1112, 2039, 81, 188, 172, 18, 172, 162, 14, 27, 2, 855, 4175, 81, 188, 172, 18, 172, 218, 14, 1, 417, 14, 1666, 81, 188, 172, 18, 172, 218, 14, 1, 410, 18, 49, 5, 1314, 518, 1795, 5401, 81, 218, 1983, 1351, 23, 1795, 1146, 9, 126, 6, 18, 60, 2, 7, 5, 3920, 1048, 753, 34, 4, 581, 50, 18, 60, 11, 1665, 6, 7934, 24, 3, 86, 1138, 10, 3, 920, 1, 7, 54, 513, 8, 236, 51, 5, 3920, 1048, 753, 34, 4, 581, 18, 53, 50, 3, 1060, 417, 1, 1795, 349, 4953, 318, 11, 1822, 379, 1182, 4, 62, 7, 54, 103, 28, 506, 104, 61, 1, 45, 24, 26, 160, 16, 1653, 5, 1252, 1239, 74886, 2, 16, 942, 59, 5137, 382, 1409, 2, 2292, 382, 2982, 772, 7, 5, 442, 1193, 2001, 11, 346, 3084, 4135, 10, 530, 4, 294, 33, 1, 852, 7, 2, 1206, 138, 11, 1051, 4, 169, 39, 1, 865, 7, 100, 7, 42, 110, 3084, 4135, 2, 1206, 138, 52, 7, 89, 10, 614, 60, 2245, 212, 717, 28, 74, 2779, 52, 166, 126, 10, 27393, 53, 2245, 22649, 50392, 8, 236, 51, 2, 3920, 1048, 753, 34, 4, 581, 18, 53, 50, 3, 1060, 417, 1, 1795, 349, 4953, 10, 513, 20, 339, 466, 48, 58, 27115, 21628, 1, 772, 7, 19, 40423, 72, 5, 8, 179, 2252, 549, 5, 4953, 279, 8, 824, 51, 1, 3920, 1048, 753, 34, 4, 581, 10, 513, 20, 792, 874, 1, 772, 7, 190, 3, 45, 104, 69, 42, 34, 91, 2, 104, 69, 1016, 10643, 273, 50, 269, 53, 1, 1795, 1146, 275, 22, 2150, 139, 6, 1795, 3, 96, 186, 62, 88, 1812, 176, 11, 5143, 141, 1340, 4, 676, 794, 7, 778, 4, 699, 744, 2, 5712, 4, 605, 739, 88, 27, 15, 39, 220, 5143, 1762, 290, 281, 159, 88, 27, 7658, 9380, 4, 169, 39, 7, 2, 88, 27, 13243, 36277, 3485, 4, 100, 18, 3, 920, 1, 7, 54, 513, 3920, 1048, 753, 34, 4, 581, 5, 1795, 349, 4953, 16, 6, 114, 922, 3, 1076, 3353, 983, 4, 7, 5, 442, 1193, 2001, 16806, 20, 177, 952, 156, 1795, 349, 4953, 16, 721, 22, 8, 98, 383, 150, 477, 9, 3171, 442, 1193, 2001, 24, 4, 773, 2975, 7, 20013, 2, 3, 1174]",3471.0,31208944,165
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.,Drugs,Drugs,2019-08-01,"Apoptosis, the process of programmed cell death, occurs normally during development and aging. Members of the B-cell lymphoma 2 (BCL2) family of proteins are central regulators of apoptosis, and resistance to apoptosis is one of the hallmarks of cancer. Targeting the apoptotic pathway via BCL2 inhibitors has been considered a promising treatment strategy in the past decade. Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 (navitoclax) pioneered the development of the first-in-class Food and Drug Administration (FDA)-approved oral BCL2 inhibitor, venetoclax. Venetoclax was approved for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia, and is now being studied in a number of hematologic malignancies. Several other inhibitors targeting different BCL2 family members are now in early stages of development.",Journal Article,173.0,1.0,Apoptosis the process of programmed cell death occurs normally during development and aging Members of the B-cell 2 BCL2 family of proteins are central regulators of apoptosis and resistance to apoptosis is one of the hallmarks of cancer Targeting the apoptotic pathway via BCL2 inhibitors has been considered a promising treatment strategy in the past decade Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 navitoclax pioneered the development of the first-in-class Food and Drug Administration FDA -approved oral BCL2 inhibitor venetoclax Venetoclax was approved for the treatment of chronic lymphocytic and acute myeloid and is now being studied in a number of hematologic malignancies Several other inhibitors targeting different BCL2 family members are now in early stages of development,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[351, 3, 1129, 1, 1846, 31, 273, 1780, 6150, 190, 193, 2, 4220, 1684, 1, 3, 132, 31, 18, 3214, 607, 1, 652, 32, 854, 3196, 1, 351, 2, 251, 6, 351, 16, 104, 1, 3, 7693, 1, 12, 529, 3, 1631, 308, 847, 3214, 222, 71, 85, 515, 8, 721, 24, 692, 4, 3, 1219, 2025, 388, 1413, 5, 302, 1354, 5486, 12446, 225, 22, 3095, 4933, 2, 3095, 6098, 9316, 24630, 3, 193, 1, 3, 157, 4, 1040, 1773, 2, 234, 634, 2078, 850, 518, 3214, 230, 4454, 4454, 10, 850, 9, 3, 24, 1, 442, 1193, 2, 286, 533, 2, 16, 1134, 486, 656, 4, 8, 207, 1, 813, 441, 392, 127, 222, 529, 338, 3214, 607, 1684, 32, 1134, 4, 191, 1153, 1, 193]",821.0,31313099,420
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.,The New England journal of medicine,N. Engl. J. Med.,2019-08-01,"Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary end point was progression-free survival, and overall survival was a secondary end point. We report the results of a planned interim analysis. A total of 529 patients underwent randomization (354 patients to the ibrutinib-rituximab group, and 175 to the chemoimmunotherapy group). At a median follow-up of 33.6 months, the results of the analysis of progression-free survival favored ibrutinib-rituximab over chemoimmunotherapy (89.4% vs. 72.9% at 3 years; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.22 to 0.56; P<0.001), and the results met the protocol-defined efficacy threshold for the interim analysis. The results of the analysis of overall survival also favored ibrutinib-rituximab over chemoimmunotherapy (98.8% vs. 91.5% at 3 years; hazard ratio for death, 0.17; 95% CI, 0.05 to 0.54; P<0.001). In a subgroup analysis involving patients without immunoglobulin heavy-chain variable region (<i>IGHV</i>) mutation, ibrutinib-rituximab resulted in better progression-free survival than chemoimmunotherapy (90.7% vs. 62.5% at 3 years; hazard ratio for progression or death, 0.26; 95% CI, 0.14 to 0.50). The 3-year progression-free survival among patients with <i>IGHV</i> mutation was 87.7% in the ibrutinib-rituximab group and 88.0% in the chemoimmunotherapy group (hazard ratio for progression or death, 0.44; 95% CI, 0.14 to 1.36). The incidence of adverse events of grade 3 or higher (regardless of attribution) was similar in the two groups (in 282 of 352 patients [80.1%] who received ibrutinib-rituximab and in 126 of 158 [79.7%] who received chemoimmunotherapy), whereas infectious complications of grade 3 or higher were less common with ibrutinib-rituximab than with chemoimmunotherapy (in 37 patients [10.5%] vs. 32 [20.3%], P<0.001). The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.).","Clinical Trial, Phase III",173.0,14.0,Data regarding the efficacy of treatment with ibrutinib-rituximab as compared with standard chemoimmunotherapy with fludarabine cyclophosphamide and rituximab in patients with previously untreated chronic lymphocytic CLL have been limited In a phase 3 trial we randomly assigned in a 2:1 ratio patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles after a single cycle of ibrutinib alone followed by ibrutinib until disease progression or six cycles of chemoimmunotherapy with fludarabine cyclophosphamide and rituximab The primary end point was progression-free survival and overall survival was a secondary end point We report the results of a planned interim analysis A total of 529 patients underwent randomization 354 patients to the ibrutinib-rituximab group and 175 to the chemoimmunotherapy group At a median follow-up of 33.6 months the results of the analysis of progression-free survival favored ibrutinib-rituximab over chemoimmunotherapy 89.4 vs. 72.9 at 3 years hazard ratio for progression or death 0.35 95 confidence interval CI 0.22 to 0.56 P 0.001 and the results met the protocol-defined efficacy threshold for the interim analysis The results of the analysis of overall survival also favored ibrutinib-rituximab over chemoimmunotherapy 98.8 vs. 91.5 at 3 years hazard ratio for death 0.17 95 CI 0.05 to 0.54 P 0.001 In a subgroup analysis involving patients without immunoglobulin heavy-chain variable region i IGHV /i mutation ibrutinib-rituximab resulted in better progression-free survival than chemoimmunotherapy 90.7 vs. 62.5 at 3 years hazard ratio for progression or death 0.26 95 CI 0.14 to 0.50 The 3-year progression-free survival among patients with i IGHV /i mutation was 87.7 in the ibrutinib-rituximab group and 88.0 in the chemoimmunotherapy group hazard ratio for progression or death 0.44 95 CI 0.14 to 1.36 The incidence of adverse events of grade 3 or higher regardless of attribution was similar in the two groups in 282 of 352 patients 80.1 who received ibrutinib-rituximab and in 126 of 158 79.7 who received chemoimmunotherapy whereas infectious complications of grade 3 or higher were less common with ibrutinib-rituximab than with chemoimmunotherapy in 37 patients 10.5 vs. 32 20.3 P 0.001 The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL Funded by the National Cancer Institute and Pharmacyclics E1912 ClinicalTrials.gov number NCT02048813,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[74, 666, 3, 209, 1, 24, 5, 1795, 855, 22, 72, 5, 260, 4438, 5, 2027, 1112, 2, 855, 4, 7, 5, 373, 1278, 442, 1193, 552, 47, 85, 383, 4, 8, 124, 27, 160, 21, 1108, 896, 4, 8, 18, 14, 197, 7, 431, 60, 1, 89, 15, 773, 5, 373, 1278, 552, 6, 560, 361, 1795, 2, 855, 9, 437, 410, 50, 8, 226, 417, 1, 1795, 279, 370, 20, 1795, 1100, 34, 91, 15, 437, 410, 1, 4438, 5, 2027, 1112, 2, 855, 3, 86, 396, 741, 10, 91, 115, 25, 2, 63, 25, 10, 8, 568, 396, 741, 21, 414, 3, 99, 1, 8, 1465, 2914, 65, 8, 181, 1, 14964, 7, 208, 3644, 10113, 7, 6, 3, 1795, 855, 87, 2, 3300, 6, 3, 4438, 87, 28, 8, 52, 166, 126, 1, 466, 49, 53, 3, 99, 1, 3, 65, 1, 91, 115, 25, 5269, 1795, 855, 252, 4438, 887, 39, 105, 720, 83, 28, 27, 60, 360, 197, 9, 91, 15, 273, 13, 465, 48, 307, 268, 58, 13, 350, 6, 13, 664, 19, 13, 144, 2, 3, 99, 543, 3, 1182, 395, 209, 2390, 9, 3, 2914, 65, 3, 99, 1, 3, 65, 1, 63, 25, 120, 5269, 1795, 855, 252, 4438, 1096, 66, 105, 970, 33, 28, 27, 60, 360, 197, 9, 273, 13, 269, 48, 58, 13, 474, 6, 13, 667, 19, 13, 144, 4, 8, 1363, 65, 1267, 7, 187, 2593, 4013, 1260, 1347, 1053, 70, 6220, 70, 258, 1795, 855, 627, 4, 380, 91, 115, 25, 76, 4438, 424, 67, 105, 744, 33, 28, 27, 60, 360, 197, 9, 91, 15, 273, 13, 432, 48, 58, 13, 213, 6, 13, 212, 3, 27, 111, 91, 115, 25, 107, 7, 5, 70, 6220, 70, 258, 10, 912, 67, 4, 3, 1795, 855, 87, 2, 889, 13, 4, 3, 4438, 87, 360, 197, 9, 91, 15, 273, 13, 584, 48, 58, 13, 213, 6, 14, 511, 3, 287, 1, 290, 281, 1, 88, 27, 15, 142, 1583, 1, 12076, 10, 288, 4, 3, 100, 271, 4, 8219, 1, 9550, 7, 493, 14, 54, 103, 1795, 855, 2, 4, 3927, 1, 5162, 842, 67, 54, 103, 4438, 547, 3398, 521, 1, 88, 27, 15, 142, 11, 299, 186, 5, 1795, 855, 76, 5, 4438, 4, 567, 7, 79, 33, 105, 531, 179, 27, 19, 13, 144, 3, 1795, 855, 477, 627, 4, 91, 115, 25, 2, 63, 25, 17, 11, 1123, 6, 135, 5, 8, 260, 4438, 477, 107, 7, 431, 60, 1, 89, 15, 773, 5, 373, 1278, 552, 3827, 20, 3, 657, 12, 1377, 2, 20013, 74934, 1252, 1239, 207, 74935]",2639.0,31365801,740
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.,Genetic epidemiology,Genet. Epidemiol.,2019-08-13,"Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)""diseasome"", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p=.0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.",Journal Article,161.0,1.0,Epidemiologic studies show an increased risk of NHL in patients with autoimmune disease AD due to a combination of shared environmental factors and/or genetic factors or a causative cascade chronic inflammation/antigen-stimulation in one disease leads to another Here we assess shared genetic risk in genome-wide-association-studies GWAS Secondary analysis of GWAS of NHL subtypes chronic lymphocytic diffuse large B-cell follicular and marginal zone and ADs rheumatoid arthritis systemic lupus erythematosus and multiple sclerosis Shared genetic risk was assessed by a description of regional genetic of overlap b polygenic risk score PRS c '' diseasome '' d meta-analysis Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype The PRS of ADs were not increased in NHL patients nor vice versa In the diseasome NHLs shared more genetic etiology with ADs than solid cancers p .0041 A meta-analysis combing AD with NHL implicated genes of apoptosis and telomere length This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci explaining little total risk This suggests common genetic variation as assessed by GWAS in these sample sizes may not be the primary explanation for the link between these ADs and NHLs,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3609, 94, 514, 35, 101, 43, 1, 1176, 4, 7, 5, 3445, 34, 1985, 520, 6, 8, 150, 1, 2664, 3766, 130, 2, 15, 336, 130, 15, 8, 8088, 4678, 442, 1815, 448, 2503, 4, 104, 34, 1940, 6, 1809, 467, 21, 423, 2664, 336, 43, 4, 898, 1019, 248, 94, 3297, 568, 65, 1, 3297, 1, 1176, 814, 442, 1193, 1388, 375, 132, 31, 1974, 2, 3450, 3614, 2, 14669, 12269, 8646, 403, 15966, 21228, 2, 232, 7426, 2664, 336, 43, 10, 275, 20, 8, 5263, 1, 951, 336, 1, 4526, 132, 11709, 43, 368, 4018, 256, 522, 51561, 522, 427, 1742, 65, 3778, 65, 553, 1021, 2664, 336, 130, 59, 296, 1985, 2, 296, 1176, 875, 3, 4018, 1, 14669, 11, 44, 101, 4, 1176, 7, 2110, 10449, 10313, 4, 3, 51561, 11440, 2664, 80, 336, 2855, 5, 14669, 76, 537, 163, 19, 23290, 8, 1742, 65, 36599, 1985, 5, 1176, 1771, 214, 1, 351, 2, 4136, 1318, 26, 3297, 90, 65, 294, 1176, 814, 2, 169, 14669, 553, 1021, 7348, 41, 2664, 2012, 8290, 1215, 181, 43, 26, 844, 186, 336, 1380, 22, 275, 20, 3297, 4, 46, 1000, 4131, 68, 44, 40, 3, 86, 6603, 9, 3, 3460, 59, 46, 14669, 2, 11440]",1290.0,31407831,617
